<SEC-DOCUMENT>0001493152-15-000811.txt : 20150312
<SEC-HEADER>0001493152-15-000811.hdr.sgml : 20150312
<ACCEPTANCE-DATETIME>20150312160306
ACCESSION NUMBER:		0001493152-15-000811
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150312
DATE AS OF CHANGE:		20150312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Imprimis Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001360214
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450567010
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35814
		FILM NUMBER:		15695920

	BUSINESS ADDRESS:	
		STREET 1:		12264 EL CAMINO REAL
		STREET 2:		SUITE 350
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-704-4042

	MAIL ADDRESS:	
		STREET 1:		12264 EL CAMINO REAL
		STREET 2:		SUITE 350
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSDEL PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20070912

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bywater Resources, Inc
		DATE OF NAME CHANGE:	20060421
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE>Form 10-K</TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 18pt Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 18pt Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 12pt Times New Roman, Times, Serif"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 18pt Times New Roman, Times, Serif"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Mark
One)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>[X]</B></FONT></td>
    <TD STYLE="width: 94%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For
    the fiscal year ended December 31, 2014</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>OR</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>[&nbsp;&nbsp;]</B></FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For
the transition period from ______________ to ______________</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Commission
File Number: 001-35814</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 18pt Times New Roman, Times, Serif"><B>IMPRIMIS
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Delaware</B></FONT></td>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>45-0567010</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State
    or other jurisdiction of</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(IRS
    Employer </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">incorporation
    or organization)</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Identification
    No.)</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>12264
El Camino Real, Suite 350</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>San
Diego, CA 92130</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address
of Principal Executive Offices)(Zip Code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(858)
704-4040</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Registrant&rsquo;s
telephone number, including area code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Securities
registered pursuant to Section 12(b) of the Act:</B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Title
    of Each Class</B></FONT></td>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Name
    of Each Exchange on Which Registered</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common
    Stock, $0.001 par value per share</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    NASDAQ Capital Market</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Securities
registered pursuant to Section 12(g) of the Act: None</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <B>Yes</B> [&nbsp;&nbsp;]
<B>No</B> [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. <B>Yes
</B>[&nbsp;&nbsp;] <B>No</B> [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. <B>Yes</B> [X] <B>No</B> [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect; 229.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <B>Yes</B> [X]
<B>No</B> [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not
be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller
reporting company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Large
    accelerated filer [&nbsp;&nbsp;]</FONT></td>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accelerated
    filer [&nbsp;&nbsp;]</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-accelerated
    filer [&nbsp;&nbsp;]</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Smaller reporting
    company [X]</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Do not check
    if a smaller reporting company)</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). <B>Yes</B> [&nbsp;&nbsp;]
<B>No</B> [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2014, the last business day of the registrant&rsquo;s most recently completed second fiscal quarter, the aggregate
market value of the common stock held by non-affiliates of the registrant was approximately $47 million, based on the closing
price of $6.94 for the registrant&rsquo;s common stock as quoted on The NASDAQ Capital Market on that date. For purposes of this
calculation, it has been assumed that shares of common stock held by each director, each officer and each person who owns 10%
or more of the outstanding common stock are held by affiliates of the registrant. The treatment of these persons as affiliates
for purposes of this calculation is not conclusive as to whether such persons are, in fact, affiliates of the registrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of March 11, 2015, there were 9,342,935 shares of the registrant&rsquo;s common stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Portions
of the registrant&rsquo;s definitive proxy statement for its 2015 Annual Meeting of Stockholders (Proxy Statement) are incorporated
by reference in Part III of this annual report on Form 10-K (Annual Report), to the extent stated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS </B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Page</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
    I</B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="width: 0.7in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item
    1.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Business</FONT></A></td>
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 1A.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk
    Factors</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 1B.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unresolved
    Staff Comments</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 2.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Properties</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 3.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal
    Proceedings</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 4.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_007"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mine
    Safety Disclosures</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_008"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
    II</B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 5.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_009"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Market
    for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">21</FONT></P></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 6.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_010"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Selected
    Financial Data</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">21</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 7.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_011"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Management&rsquo;s
    Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">22</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 7A.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_012"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quantitative
    and Qualitative Disclosure About Market Risk</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 8.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_013"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Financial
    Statements and Supplementary Data</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 9.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_014"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Changes
    in and Disagreements with Accountants on Accounting and Financial Disclosure</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 9A.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_015"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Controls
    and Procedures</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 9B.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_016"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other
    Information</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_017"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
    III</B></FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 10.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_018"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Directors,
    Executive Officers and Corporate Governance</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">33</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 11.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_019"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Executive
    Compensation</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">33</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 12.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_020"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">33</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 13.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_021"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certain
    Relationships and Related Transactions, and Director Independence</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT>3</td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 14.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_022"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal
    Accountant Fees and Services</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">33</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_023"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
    IV</B></FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 15.</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_024"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibits,
    Financial Statement Schedules</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">34</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_025"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SIGNATURES</FONT></A></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Imprimis
Pharmaceuticals, Inc. has issued trademarks and/or pending trademark applications for Imprimis&trade;, Imprimis Pharmaceuticals&trade;,
ImprimisRx&trade;, SSP Technology&trade;, Go Dropless&trade;, LessDrops&trade;, Dropless Cataract Surgery&trade;, Dropless Cataract
Therapy&trade;, Dropless Therapy&trade;, Say Goodbye&trade;, Defeat IC&trade; and Accudel&trade;. All other trademarks, trade
names and service marks included in this Annual Report are the property of their respective owners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>This
Annual Report contains forward-looking statements regarding future events and our future performance. In some cases, you can identify
forward-looking statements by terminology such as &ldquo;will&rdquo;, &ldquo;may&rdquo;, &ldquo;should&rdquo;, &ldquo;expects&rdquo;,
&ldquo;plans&rdquo;, &ldquo;anticipates&rdquo;, &ldquo;believes&rdquo;, &ldquo;estimates&rdquo;, &ldquo;predicts&rdquo;, &ldquo;forecasts&rdquo;,
&ldquo;potential&rdquo; or &ldquo;continue&rdquo; or the negative of these terms or other comparable terminology. All statements
made in this Annual Report other than statements of historical fact are forward-looking statements. These forward-looking statements
involve risks and uncertainties and reflect only our current views, expectations and assumptions with respect to future events
and our future performance. If risks or uncertainties materialize or assumptions prove incorrect, actual results or events could
differ materially from those expressed or implied by such forward-looking statements. Risks that could cause actual results to
differ from those expressed or implied by the forward-looking statements we make include but are not limited to risks related
to: our ability to successfully implement our business plan, develop and commercialize our proprietary formulations in a timely
manner or at all, identify and acquire additional proprietary formulations, manage our pharmacy operations, obtain financing necessary
to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully complete
and realize the benefits of our acquisitions of Pharmacy Creations, LLC (Pharmacy Creations) and South Coast Specialty Compounding,
Inc. D/B/A Park Compounding (Park) and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical
companies, outsourcing facilities and pharmacies; general economic and business conditions; regulatory and legal risks and uncertainties
related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance
of our current and any future formulations and compounding pharmacies generally; our limited operating history; and the other
risks and uncertainties described under the heading &ldquo;Risk Factors&rdquo; in Part I, Item 1A of this Annual Report. You should
not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made and
except as required by law, we undertake no obligation to revise or publicly update any forward-looking statement for any reason.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Unless
otherwise stated, all information regarding share amounts of common stock and prices per share of common stock described in this
Annual Report reflect the reverse stock splits of our authorized, issued and outstanding common stock effected on February 28,
2012 and February 7, 2013. As used in this Annual Report, unless indicated or the context requires otherwise, the terms the &ldquo;Company&rdquo;,
&ldquo;Imprimis&rdquo; &ldquo;we&rdquo;, &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Imprimis Pharmaceuticals, Inc. and its
consolidated subsidiaries.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_001"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_002"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
1.</B> <B>BUSINESS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Overview
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are a pharmaceutical company focused on developing and commercializing innovative and high quality proprietary compounded drug
therapies and making these therapies available to physicians and patients at accessible prices. We own, market and sell a portfolio
of proprietary combination formulations in ophthalmology and urology that we believe may offer competitive advantages and serve
unmet needs in the marketplace. Our ophthalmology formulation portfolio, led by our Dropless Therapy&trade; and LessDrops&trade;
formulations, serves the multi-billion dollar eye drop market and is designed to address patient compliance issues and provide
other medical and economic benefits to physicians and patients. Our recently launched urology business, headed by our Defeat IC&trade;
campaign, currently includes a patented compounded formulation for patients suffering from interstitial cystitis. We are also
developing additional complementary proprietary compounded formulations to add to our ophthalmology and urology formulation portfolios.
We make, dispense and sell our proprietary compounded formulations, as well as other non-proprietary products, through our compounding
pharmacies Pharmacy Creations and Park.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
of our proprietary formulations are born from the clinical experience of a network of inventors, including physician prescribers,
clinical researchers and pharmacist formulators, who develop and prescribe customized medicines for individual patient needs.
Working collaboratively with these inventors, we identify and evaluate intellectual property related to these drug formulations,
assess relevant markets, and seek to validate the clinical experience of a development candidate with the objective of investing
in commercialization activities. We believe our model allows us to meet the realities of the current health care economy by offering
quality pharmaceutical innovation at accessible prices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have incurred recurring operating losses, and have had negative operating cash flows since July 24, 1998 (inception). In addition,
we have an accumulated deficit of approximately $41.9 million at December 31, 2014. Beginning on April 1, 2014, we began generating
revenue from sales of certain of our proprietary ophthalmic drug compounded formulations and other non-proprietary compounded
formulations; however, we expect to incur further losses as we integrate and develop our pharmacy operations, evaluate other programs
and continue the development of our formulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Proprietary
Compounded Formulations </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Ophthalmic
Formulations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Anti-Inflammatory
and Anti-Bacterial Combination Formulations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
2013, we acquired intellectual property related to compounded formulations for ocular injection of anti-inflammatory and anti-bacterial
agents during ocular surgery. With the use of our SSP Technology&trade;, which allows for increased solubility of active pharmaceutical
ingredients and the creation of small, uniform particle sizes, these compounded formulations can be used as an intraoperative
injectable or as a topical eye drop. These compounded formulations have begun to impact the fast-growing global cataract surgery
eye drop market and the LASIK surgery market and may have potential in other ophthalmology markets for procedures where there
is a risk of inflammation and infection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
formulations provide physicians with the ability to address the primary ocular complications of ophthalmic surgery, infection
risk and post-operative inflammation, due to patient non-compliance with traditional multiple bottle eye drop regimens, by reducing
the complexity of, or in many cases altogether avoiding the need for post-operative eye drop regimens. Although our ophthalmology-related
patent applications include other claims, we have focused our ophthalmology development and commercialization efforts to date
on the proprietary compounded formulations described below, which we market as our Dropless Therapy and LessDrops formulations.
The relative strengths of each of the active ingredients included in these formulations can be prescribed by the physician and
tailored to individual patients.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tri-Moxi,
                                         a compounded formulation that is a combination of triamcinolone acetonide and moxifloxacin
                                         hydrochloride, used as an injection during ocular surgery and as an eye drop pre- and
                                         post-ocular surgery</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tri-Moxi-Vanc,
                                         a compounded formulation that is a combination of triamcinolone acetonide, moxifloxacin
                                         hydrochloride and vancomycin, used as an injection during ocular surgery </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pred-Moxi,
                                         a compounded formulation that is a combination of prednisolone and moxifloxacin hydrochloride,
                                         used as an eye drop pre- and post-ocular surgery</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, we intend to utilize our SSP Technology platform to develop and offer various combinations of topical medicines. For
example, we have filed patent claims and are currently evaluating eye drops that include combinations of a nonsteroidal anti-inflammatory
drug and a steroid, with and without an added antibiotic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Dropless
Therapy Formulations</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
cataract surgery market continues to experience significant growth. According to a 2013 Market Scope report, 3.6 million cataract
surgeries were performed in the U.S. and nearly 22 million cataract surgeries were performed globally, with expected annual market
growth of approximately 3%. The National Eye Institute estimated that over 24 million Americans currently have cataracts and that
this number will grow to 38 million by 2030 and to more than 50 million by 2050. According to the Journal of Cataract &amp; Refractive
Surgery, this growth is due in part to the expanding aging population, and also to the lowered age at which patients require cataract
surgery. The ophthalmology drug market is expected to reach an estimated $21.6 billion by 2018 (Transparency Market Research;
January 24, 2014).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
current treatment regimen for the prevention of post-cataract and other intraocular surgery complications is primarily a pre-operative
and post-operative self-administered eye drop regimen, which requires strict patient compliance and careful adherence to a prescribed
dosing schedule. Physicians have reported and studies have shown that eye drop regimens can be confusing to patients, creating
non-compliance and incorrect dosing (Hennessy AL, Ophthalmology, 2010). Large studies conducted in the U.S. and Europe showed
that antibiotics administered into the eye at the time of cataract surgery significantly reduced the risk of developing inflammation
and infection (Shorstein, N.; Friling E, et al.; Rodr&iacute;guez-Caravaca G, et al., 2013; J of Cataract Refract Surg, 2013 and
Endophthalmitis Study Group, 2007).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
Dropless Therapy formulations include Tri-Moxi and Tri-Moxi-Vanc used as an injectable during ocular surgery. Ophthalmologists
have reported that use of our Dropless Therapy formulations has substantially reduced or eliminated the need for patient-administered
eye drops following ocular surgeries they have performed, thereby largely eliminating patient non-compliance and associated errors
with post-operative care regimens. Physicians have also reported spending less time on instructions and follow-up with post-operative
patients, as well as fewer calls from pharmacists seeking to change the physicians&rsquo; prescribed eye drop regimens, which
collectively can reduce the physicians&rsquo; costs of patient care. By reducing reliance on post-operative eye drops, we believe
use of our Dropless Therapy formulations can simplify the post-operative care process, provide safeguards against bacterial infection
and inflammation and decrease overall costs. Since the launch of our associated Go Dropless&trade; educational campaign in April
2014, more than 240 ophthalmologists have started to use our Dropless Therapy formulations, and since their inception, our Dropless
Therapy formulations have been used in over 50,000 ocular surgeries, primarily cataract surgeries. In the future, we aim for our
Dropless Therapy to be initiated at additional high volume cataract surgery practices, hospitals and large ambulatory surgery
centers throughout the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>LessDrops
Formulations</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">According
to the American Academy of Ophthalmology (AAO), over half of Americans require some form of vision correction and it is estimated
that 43 million of these individuals are candidates for refractive surgery. Nearly 96% of the refractive surgery procedures performed
today are LASIK (laser in situ keratomileusis) surgeries, an outpatient surgical procedure used to treat nearsightedness, farsightedness,
and astigmatism (AAO), Demographics of Refractive Surgery Patients and Market Trends. Lombardo, A., et al). As of 2008, the AAO
estimated 700,000 LASIK procedures are being performed annually in the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
Pred-Moxi and Tri-Moxi topical compounded formulations, branded as LessDrops, were introduced during the first quarter of 2015
as combination eye drops for patients following laser refractive surgery, including LASIK and photorefractive keratectomy (PRK),
cataract and other ocular surgeries. Similar to other ocular surgeries, current treatment regimens following LASIK and PRK surgeries
require self-administered eye drops two or more times daily for up to four weeks. We estimate that our LessDrops compounded formulations
can require up to 50% fewer drops to be administered by patients post-surgery and may cost up to 75% less than other currently
available post-surgery drops regimens. Additionally and importantly, these topical compounded drops may be eligible for reimbursement
to patients covered by both public and private insurance plans. We plan to continue to add to our portfolio of LessDrops topical
compounded formulations and deliver additional eye drop choices for our customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Other
Ophthalmic Formulations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Compounding
pharmacies mix different ingredients to create specialized preparations ordered by a physician to treat an individually identified
patient. Often this is because a standard medication approved by the FDA is not appropriate for individual patients. Compounded
formulations can also help alleviate FDA-recognized shortages of drugs, because compounding pharmacies can prepare compounded
alternatives to commercially available drugs when drugs are in short supply. These shortages are becoming more common: according
to the FDA, there are currently over 75 drugs on the FDA&rsquo;s shortage list. Eye surgeons are particularly concerned about
drug shortages, especially for drugs such as epinephrine or phenylephrine, which are commonly used to dilate the pupil prior to
and during intraocular procedures (among other things). In 2013, we acquired intellectual property related to lyophilized (or
freeze-dried), preservative-free, sulfite-free epinephrine, phenylephrine and lidocaine, and we may rely on this intellectual
property to develop mydriatic (pupil dilation) compounded formulations that use various combinations of these ingredients. We
have made and expect to increase sales of multiple ophthalmic compounded formulations per patient or case in one or more kits.
For example, we may sell a compounded formulation of injectable Tri-Moxi along with a mydriatic compounded formulation for the
same individually identified patient, and also include additional non-proprietary ophthalmic compounded formulations, all as a
part of a kit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Urology
Formulations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>HLA
Formulation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
2014, we entered into a license agreement to acquire the U.S. commercialization and distribution rights to a patented urologic
formulation of heparin and alkalinized lidocaine (HLA or Hep-Lido-A), which is delivered directly to the bladder for the treatment
of interstitial cystitis (IC), also known as painful bladder syndrome. It is estimated that five to ten million women and men
in the U.S. are affected by this chronic disease (Journal of Urology, 2008 and as published by the National Institutes of Health
(NIH), RAND IC Epidemiology Study, 2009, and BACH study, 2009), and based on our self-directed survey of over 400 patients, we
believe the total U.S. market opportunity for IC could exceed $4 billion a year. In 2014, physicians wrote more than 80,000 prescriptions
for compounded HLA to treat IC and since the HLA compounded first became available as a compounded drug in 2011, there have been
an estimated 140,000 HLA instillation procedures completed in the U.S. Importantly, based on our internal research, many of these
instillation procedures were partially or fully reimbursed by private and public healthcare providers. Additionally, third-party
studies of the use of heparin and alkalinized lidocaine instillations in patients with IC have indicated alleviation of IC symptoms,
including pain and frequency and urgency of urination, with the use of this combination of ingredients. During the first quarter
of 2015, we commercially launched our HLA compounded formulation and introduced Defeat IC, our national education campaign designed
to increase awareness among medical practitioners about IC and our HLA treatment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Injectable
Pentoxifylline Formulation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
2013, we acquired intellectual property related to an injectable formulation comprised of pentoxifylline for the treatment of
certain fibrotic conditions, including Peyronie&rsquo;s Disease (PD). According to claims data and various studies, 95,000 patients
were diagnosed with PD during 2013, with an estimated 90,000 patients receiving either non-invasive or no treatment for PD. A
researcher-initiated research study using our patent-pending pentoxifylline formulation for the treatment of PD was initiated
in 2014, and we may commercially launch this formulation following the completion of the study and publication of its results,
which is expected in 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Sales
and Marketing</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
our proprietary ophthalmic and urologic formulations, we have developed and plan to continue to build small internal sales and
commercialization teams that are focused on growing sales of these formulations through, among other things, educating doctors,
ambulatory surgery centers, healthcare systems, hospitals throughout the U.S. and other users about our products. Although we
have engaged distributors for certain of our proprietary formulations in non-U.S. markets, we expect to continue to focus our
efforts on our U.S. commercial opportunities during 2015. We also believe that our proprietary drug formulations could have commercial
appeal in other markets, including veterinary and international markets, and we may choose to pursue commercialization of our
proprietary formulations in selected other markets through licensing or collaborative arrangements with strategic partners in
the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Other
Proprietary Formulations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition to our proprietary ophthalmic and urologic formulations, we have also acquired intellectual property assets, including
provisional patent applications, related to topical formulations for wound healing and other formulations for other potential
uses and purposes. We are pursuing additional supporting data with respect to these formulations as part of our product assessment
process, but these formulations are still in the initial stage of their development and validation and we do not expect to focus
on or actively develop or market any of these formulations in the absence of a successful commercial assessment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Compounding
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Compounding
Pharmacies and Expansion of Non-Proprietary Sales</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">One
of our key strategies is the use of compounding pharmacies to formulate our proprietary compounded drug formulations and distribute
them to physicians and patients. Compounding pharmacies work with physicians to develop customized medications for individually
identified patients, and the compounding pharmacy prepares these customized formulations upon receipt of a physician prescription
for an individual patient. Examples of compounded formulations include medications with alternative dosage strengths or unique
dosage forms, such as topical creams or gels, suspensions or solutions with more tolerable drug delivery vehicles. A physician
may also work together with a pharmacist to repurpose or reformulate via the compounding process drugs that have been approved
by the U.S. Food &amp; Drug Association (FDA) to meet a patient&rsquo;s specific medical needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pharmacy
Creations and Park, our wholly owned pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB), make, dispense
and sell our proprietary ophthalmology and urology formulations. Our pharmacies also dispense prescriptions for complementary
compounded formulations within the ophthalmology and urology therapeutic areas, as well as other non-proprietary compounded formulations
in other therapeutic areas for an individually identified patient. We intend to leverage our marketing and sales of proprietary
compounded formulations to provide us competitive advantages with respect to sales of certain non-proprietary products and compounded
formulations. For example, our brand recognition and know-how allows us to market and sell non-proprietary formulations in the
ophthalmology and urology markets, on which our sales efforts have been focused, and also in other areas, such as oncology, hormone
replacement, autism, and other therapeutic markets. During 2015, we plan to expand our marketing and sales efforts of these non-proprietary
products through our pharmacy businesses. Pharmacy Creations, our New Jersey-based pharmacy that we acquired in April 2014, and
Park, our California-based pharmacy that we acquired in January 2015, are collectively licensed to distribute compounded formulations
in 40 states. We are in the process of expanding our prescription fulfillment and distribution capabilities, with the goal of
owning or otherwise having access to multiple facilities licensed in each of the 50 states in the United States. We intend to
achieve this goal by expanding the operations of our current pharmacies, acquiring or building additional pharmacies and developing
a broader network of Company-owned and third-party-owned compounding pharmacies to which we would have access. We are in the process
of developing &ldquo;ImprimisRx&rdquo; as a uniform brand for our drug fulfillment facilities and operations, which we intend
to launch in 2015. We operate our current pharmacy business under the regulatory framework described in the Drug Quality and Security
Act (DQSA) of 2013, Section 503A of the Federal Food Drug and Cosmetic Act (FDCA) and applicable state pharmacy laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Outsourcing
Facilities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
DQSA provides that a pharmacy engaged in preparing sterile compounded drug formulations may voluntarily elect to register as an
&ldquo;outsourcing facility,&rdquo; a new entity governed by Section 503B of the FDCA. Outsourcing facilities must comply with
certain requirements under Section 503B, including satisfying current good manufacturing practice (cGMP) standards, and are permitted
to compound large quantities of drug formulations if the drug formulations appear on the FDA&rsquo;s drug shortage list or the
component bulk drug substances appear on a &ldquo;clinical need&rdquo; list to be established by the FDA. Outsourcing facilities
may prepare drug formulations in advance of a prescription and distribute formulations across state lines without limitation.
In February 2015, we entered into a lease agreement for space in New Jersey and began construction efforts to build an outsourcing
facility, which we expect to be completed in the fourth quarter of 2015 and will replace our current New Jersey based pharmacy
facility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Development
and Commercialization Pathway</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
model for the selection and development of proprietary formulations focuses on assessing new development opportunities using a
four-step proprietary process, which includes the identification, evaluation, validation, and ultimately commercialization of
selected opportunities. Our relationships with inventive physicians and pharmacists provide us with access to numerous formulation
candidates and technologies to evaluate and validate. These compounded drug formulations are initially made for individual patients
and are developed based on the physician&rsquo;s and pharmacist&rsquo;s experience formulating a new therapy to address an unmet
need. As a result of our review process, we focus our commercialization efforts on a select group of promising formulations that
we believe may be patentable and that could have broad appeal to patients and physicians.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: Red"><IMG SRC="logo.jpg" ALT="" STYLE="height: 75; width: 659">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: Red">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Identify</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
innovation model, which serves as our research and development pipeline, relies on our relationships and partnerships with inventors
to identify and secure new development assets. We are strategically attentive to the ideas generated by pharmacists dealing directly
with doctors and their patients to address specific and often unmet patient needs in our identification of formulations to develop
and commercialize. We believe that going forward, our growing group of collaborative relationships with physicians and pharmacists
will bring additional clinically and commercially relevant formulation opportunities to our Company for potential development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Evaluate
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">After
we have identified potential formulations and technology for development, we subject them to our proprietary evaluation process.
We invest heavily in intellectual property review and analysis at this stage, which includes analyzing the patentability of each
formulation and, more generally, trying to understand the surrounding intellectual property landscape. We also evaluate any existing
supportive clinical data, identify one or more appropriate commercialization pathways to make the therapy available to patients
and, for selected candidates, ultimately seek to acquire development rights through ownership or licensing of promising formulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Validate</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Following
the identification and evaluation process and our acquisition of development rights, we seek to validate and support potential
drug formulations through our review of existing clinical data and documented patient experience and through our support of investigator-initiated
studies, which are typically funded by us and conducted by leading physician groups. Any clinical data we obtain may be used to
support clinical confidence for physicians prescribing the formulation in compounded form or, if we decide to pursue FDA approval
for a particular candidate, to support a development program in connection with the pursuit of such approval. The costs associated
with our validation approach may be significantly lower than a traditional FDA approval process because, to the extent we consider
and select a commercialization pathway as a compounded formulation, our approach would not require FDA approval for the marketing
and sale of the formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Commercialize</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Following
successful results in the first three steps of our assessment, we focus on commercialization. As part of the development of potential
formulations, we evaluate and select an appropriate commercialization pathway to make these therapies available to patients. We
consider multiple commercialization pathways, including dispensing formulations through compounding pharmacies and other prescription
dispensing facilities pursuant to a prescription for an individually identified patient and pursuing FDA approval to market and
sell a drug formulation or technology. We are pursuing, and expect to continue to pursue, a compounding commercialization strategy
for our currently available proprietary formulations and the other assets that we currently own or have rights to and that we
may develop in the future, and we do not presently expect to pursue FDA approval for any of these formulations or other assets.
For any non-drug assets we consider, such as drug-delivery vehicles, we may choose to seek partnerships with wholesalers in order
to make these technologies available to pharmacies. Depending on the selected commercialization pathway, we would build, or contract
with a third party to build, appropriately targeted commercialization teams in order to make the therapies available to physicians
and patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Historical
Impracor</B> <B>Program</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Historically,
our business focused on developing, obtaining FDA approval for, and commercializing our former topical pain management product
candidate Impracor. After considering the totality of circumstances surrounding the development of and clinical trial requirements
for Impracor, including certain manufacturing and formulation issues, in November 2013 we announced our discontinuation of the
proposed Phase 3 clinical trial for Impracor. We do not expect to resume a Phase 3 clinical trial for Impracor or otherwise invest
in the commercial development of this asset.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
pharmaceutical and pharmacy industries are highly competitive. We compete against branded drug companies, generic drug companies,
outsourcing facilities and other compounding pharmacies. The drug products available through branded and generic drug companies
with which our formulations compete have been approved for marketing and sale by the FDA, are required to be manufactured in facilities
compliant with cGMP standards, and are permitted to be manufactured, produced and distributed in large bulk quantities. Although
we prepare our compounded formulations in accordance with the standards provided by United States Pharmacopoeia (USP) &lt;795&gt;
and USP &lt;797&gt; and applicable state and federal law, our proprietary compounded formulations are not required to be, and
have not been, approved for marketing and sale by the FDA and, as a result, some physicians may be unwilling to prescribe, and
some patients may be unwilling to use, our formulations. Additionally, formulations compounded in accordance with FDCA Section
503A must be prepared and dispensed in connection with a physician prescription for an individually identified patient and cannot
be prepared in significant quantities without or in advance of such a prescription or manufactured and distributed by wholesalers
in bulk quantities. These facets of our operations may subject our business to limitations our competitors with FDA-approved drugs
may not face.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition to product safety and efficacy considerations, other competitive factors in the pharmacy and pharmaceutical markets include
product quality and price, reputation, service and access to scientific and technical information. The competitive environment
requires an ongoing, extensive search for medical and technological innovations and the ability to develop those innovations into
products and market these products effectively. Developments by our competitors could make our formulations or technologies uncompetitive
or obsolete. In addition, because we are significantly smaller than our primary competitors, we may lack the financial and other
resources and experience needed to identify and acquire rights to, develop, produce, distribute, market and commercialize any
of the formulations we seek to make available or compete for market share in these sectors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
success and ability to compete depends upon our ability to protect our intellectual property. We conduct a comprehensive analysis
of the intellectual property landscape prior to acquiring rights to formulations and filing patent applications. As of December
31, 2014, we owned one issued U.S. patent and one issued Canadian patent, which cover certain technology related to our former
product candidate Impracor. Our existing patents expire in 2016 in the U.S. and 2018 in Canada, and we do not expect the life
of these patents to be extended beyond these dates. In addition, as of March 2, 2015, we owned 12 U.S. patent applications, including
nine utility and three provisional patent applications, and we owned five international patent applications filed under the Patent
Cooperation Treaty. We expect to file additional patent applications in the U.S. and pursue patent protection for certain of our
formulations in other important international jurisdictions in the future. In addition, as of March 2, 2015, we have acquired
rights under one U.S. patent and U.S. patent application pursuant to our current in-license agreements. As of March 2, 2015, we
had 12 pending U.S. trademark applications, including applications for Imprimis, Imprimis Pharmaceuticals, ImprimisRx, SSP Technology,
Go Dropless, LessDrops, Dropless Cataract Surgery, Dropless Cataract Therapy, Dropless Therapy, Say Goodbye, Defeat IC and Accudel.
We may choose to pursue trademark protection in other jurisdictions for one or more of these or other marks in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Governmental
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
business is subject to federal, state and local laws, regulations, and administrative practices, including, without limitation:
federal, state and local licensure and registration requirements concerning the operation of pharmacies and the practice of pharmacy;
the Health Insurance Portability and Accountability Act (HIPAA); the Patient Protection and Affordable Care Act (ACA); statutes
and regulations of the FDA, the U.S. Federal Trade Commission, the U.S. Drug Enforcement Administration and the U.S. Consumer
Product Safety Commission, as well as regulations promulgated by comparable state agencies concerning the sale, advertisement
and promotion of the products we sell.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Among
the various federal and state laws and regulations which may govern or impact our current and planned operations are the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Pharmacy
Regulation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
pharmacy operations are regulated by both individual states and the federal government. Every state has laws and regulations addressing
pharmacy operations, including regulations relating specifically to compounding pharmacy operations. These regulations generally
include licensing requirements for pharmacists and pharmacies, as well as regulations related to compounding processes, safety
protocols, purity, sterility, storage, controlled substances, recordkeeping and regular inspections, among other things. State
rules and regulations are updated periodically, generally under the jurisdiction of individual state boards of pharmacy. Failure
to comply with the state pharmacy regulations of a particular state could result in a pharmacy being prohibited from operating
in that state, financial penalties and/or becoming subject to additional oversight from that state&rsquo;s board of pharmacy.
In addition, many states are considering imposing, or have already begun to impose, more stringent requirements on compounding
pharmacies. If our pharmacy operations become subject to additional licensure requirements, are unable to maintain their required
licenses or if states place burdensome restrictions or limitations on pharmacies, our ability to operate in some states could
be limited, which may have an adverse impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Many
of the states into which we deliver pharmaceuticals have laws and regulations that require out-of-state pharmacies to register
with, or be licensed by, the boards of pharmacy or similar regulatory bodies in those states. These states generally permit the
dispensing pharmacy to follow the laws of the state within which the dispensing pharmacy is located. However, various state pharmacy
boards have enacted laws and/or adopted rules or regulations directed at restricting or prohibiting the operation of out-of-state
pharmacies by, among other things, requiring compliance with all laws of the states into which the out-of-state pharmacy dispenses
medications, whether or not those laws conflict with the laws of the state in which the pharmacy is located, or requiring the
pharmacist-in-charge to be licensed in that state. To the extent that such laws or regulations are found to be applicable to our
operations, we believe we comply with them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Furthermore,
under federal law, Section 503A of the FDCA seeks to limit the amount of compounded products that a pharmacy can dispense interstate.
The interpretation and enforcement of that provision is dependent on the FDA entering into a standard Memorandum of Understanding
(MOU) with each state setting forth limits on interstate compounding. The FDA has stated in guidance issued in February 2015 that
it will not enforce interstate restrictions until after it publishes a final standard MOU and has made it available to the states
for signature for some designated period of time. The FDA has proposed a 180-day period for states to agree to the standard MOU
after the final version is presented to states. Until a final MOU is issued and presented to the states to consider whether to
sign, the extent of such interstate dispensing restrictions imposed by Section 503A is unknown. If the final standard MOU is not
signed by a particular state, then interstate shipments of compounded preparations from a pharmacy located in that state would
be limited to quantities not greater than 5% total prescription orders dispensed or distributed by such pharmacy. The current
draft standard MOU presented by the FDA in February 2015 would limit interstate shipments of compounded drug units to 30% of all
compounded and non-compounded units dispensed or distributed by the pharmacy per month. If the final standard MOU contains a 30%
limit on interstate distribution, or if the FDA applies the 5% limit in Section 503A because a state refuses to sign the MOU,
then those limitations would have an adverse effect on the interstate dispensing or distribution of compounded drug products by
Pharmacy Creations or Park. To the extent that any of the foregoing laws or regulations restrict interstate shipping by Pharmacy
Creations or Park, they could have an adverse effect on our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certain
provisions of the FDCA govern the preparation, handling, storage, marketing and distribution of pharmaceutical products. The DQSA
clarifies and strengthens the federal regulatory framework governing compounding pharmacies. Title 1 of the DQSA, the Compounding
Quality Act, modifies provisions of the Section 503A of the FDCA that were found to be unconstitutional by the U.S. Supreme Court
in 2002. In general, Section 503A provides that pharmacies are exempt from the provisions of the FDCA requiring compliance with
cGMP, labeling with adequate directions for use and FDA approval prior to marketing if the pharmacy complies with certain other
requirements. Among other things, to comply with Section 503A, a compounded drug must be compounded by a licensed pharmacist for
an identified individual patient on the basis of a valid prescription. Pharmacies may only compound in limited quantities before
receipt of a prescription for an individual patient, and Section 503A limits the distribution of compounded drug products outside
of the state in which the pharmacy is located, as described in the previous paragraph. 503A also provides certain requirements
for compounding from bulk substances and prohibits compounding of products that have been withdrawn from the market for reasons
of safety or efficacy and products that are demonstrably difficult to compound.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
DQSA also contained a new Section 503B of the FDCA. Section 503B provides that a facility engaged in preparing sterile compounded
drug formulations may voluntarily elect to register as an &ldquo;outsourcing facility,&rdquo; a new entity permitted to compound
large quantities of drug formulations without a prescription if the drug formulations appear on the FDA&rsquo;s drug shortage
list or the bulk drug substances contained in a formulation appear on a &ldquo;clinical need&rdquo; list to be established by
the FDA, as well as distribute these formulations out of state without limitation. Entities voluntarily registering as outsourcing
facilities are subject to cGMP requirements and regular FDA inspection. Currently, we operate our pharmacy business under Section
503A and applicable state pharmacy laws. However, in February 2015, entered into a lease agreement and began construction efforts
for an outsourcing facility in New Jersey. We expect construction efforts to be completed during the fourth quarter of 2015. The
FDA has issued final guidance addressing key aspects of Section 503A, and has requested comments with respect to key aspects of
Section 503B of the FDCA. The scope of the regulations and guidance ultimately adopted by the FDA could have a significant impact
on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
February 13, 2015, the FDA released new draft documents and guidance related to compounding of human drugs, in particular areas
concerning certain provisions described in the DQSA. Among other things within the February 2015 guidance, the FDA describes that,
in the event a facility is registered as an outsourcing facility, all of the facility&rsquo;s compounded drugs must be compounded
in accordance with Section 503B, and to cGMP requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Confidentiality,
Privacy and HIPAA</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
pharmacy operations involve the receipt, use and disclosure of confidential medical, pharmacy and other health-related information.
In addition, we use aggregated and blinded (anonymous) data for research and analysis purposes. The federal privacy regulations
under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) are designed to protect the medical information
of a healthcare patient or health plan enrollee that could be used to identify the individual. Among other things, HIPAA limits
certain uses and disclosures of protected health information and requires compliance with federal security regulations regarding
the storage, utilization of, access to and transmission of electronic protected health information. In 2009, the Health Information
for Economic and Clinical Health Act modified certain provisions of HIPAA to strengthen its privacy and security provisions. The
requirements imposed by HIPAA are extensive. In addition, most states have enacted privacy and security laws that protect identifiable
patient information that is not health-related. Further, several states have enacted more protective and comprehensive pharmacy-related
privacy legislation that not only applies to patient records but also prohibits the transfer or use for commercial purposes of
pharmacy data that identifies prescribers. These regulations impose substantial requirements on covered entities and their business
associates regarding the storage, utilization of, access to and transmission of personal health and non-health information. Many
of these laws apply to our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Medicare
and Medicaid Reimbursement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Medicare
is a federally funded program that provides health insurance coverage for qualified persons age 65 or older and for some disabled
persons with certain specific conditions. State-funded Medicaid programs provide medical benefits to groups of low-income and
disabled individuals, some of whom may have inadequate or no medical insurance. Currently, most of our commercially available
formulations are sold in cash transactions and our customers may choose to seek available reimbursement opportunities to the extent
that they exist. We are currently in communications with third-party public and private payors regarding potential reimbursement
options for certain of our proprietary formulations and we have begun hiring public and private payor billers in anticipation
of the potential reimbursement opportunities for certain formulations. However, third-party payors, including Medicare, are increasingly
attempting to contain health care costs by limiting coverage and the level of reimbursement for new drugs and by refusing, in
some cases, to provide coverage for uses of approved products for disease indications for which the FDA has not granted labeling
approval. Further, the Patient Protection and Affordable Care Act (PPACA) and the Health Care and Education Reconciliation Act
of 2010, which amended PPACA (collectively, the Health Reform Law), will result in sweeping changes to the existing U.S. system
for the delivery and financing of health care and may have a considerable impact on our business. As a result, we may be unable
to satisfy the requirements of Medicare, Medicaid or other third-party payors and we may never be able to obtain reimbursement
from such payors for any of our formulations. To the extent we obtain third-party reimbursement for our compounded formulations,
we may become subject to Medicare, Medicaid and other publicly financed health benefit plan regulations prohibiting kickbacks,
beneficiary inducement and the submission of false claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>FDA
New Drug Application Process</I> </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
may choose to pursue FDA approval to market and sell one or more of our formulations through the FDA&rsquo;s new drug application
(NDA) process. Since the active pharmaceutical ingredients in all of our formulations have already been approved by the FDA, we
could choose to pursue FDA approval of one or more of our formulations under Section 505(b)(2) of the FDCA. Section 505(b)(2)
permits the submission of an NDA where at least some of the information required for approval comes from studies not conducted
by or for the applicant and for which the applicant has not obtained a right of reference. The applicant may rely upon certain
published nonclinical or clinical studies conducted for an approved product or the FDA&rsquo;s conclusions from prior review of
such studies. The FDA may also require companies to perform additional studies or measurements to support any changes from the
approved product. The FDA may then approve the new product for all or some of the label indications for which the referenced product
has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant. While references to nonclinical
and clinical data not generated by the applicant or for which the applicant does not have a right of reference are allowed, all
development, process, stability, qualification and validation data related to the manufacturing and quality of the new product
must be performed for the new product and included in the NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
the extent that the Section 505(b)(2) applicant is relying on the FDA&rsquo;s conclusions regarding studies conducted for an already
approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the
FDA&rsquo;s Orange Book publication. As a condition of approval, the FDA or other regulatory authorities may require further studies,
including Phase 4 post-marketing studies, to provide additional data. Other post-marketing studies may be required to gain approval
for the use of a product as a treatment for clinical indications other than those for which the product was initially tested and
approved. Also, the FDA or other regulatory authorities require post-marketing reporting to monitor the adverse effects of the
drug. Results of post-marketing programs may limit or expand the further marketing of the products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer
advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving
the Internet. A company can make only those claims relating to safety and efficacy that are approved by the FDA. Failure to comply
with these requirements can result in adverse publicity, warning letters, corrective advertising, fines and potential civil and
criminal penalties. Physicians may prescribe legally available drugs for uses that are not described in the drug&rsquo;s labeling
and that differ from those tested by us and approved by the FDA. Such off-label uses can be common in some medical specialties,
as physicians may believe that such off-label uses are the best treatment for certain patients in varied circumstances. The FDA
does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions
on manufacturers&rsquo; communications regarding off-label use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>International
Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
we pursue commercialization of our proprietary formulations in countries other than the United States, then we would need to obtain
the approvals required by the regulatory authorities of such foreign countries comparable to the FDA and state boards of pharmacy,
and we would be subject to a variety of other foreign statutes and regulations comparable to those described in this section relating
to our U.S. operations. The regulatory framework and requirements vary by country and could involve additional licensing requirements
and product testing and review periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Environmental
and Other Matters</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are or may become subject to environmental laws and regulations governing, among other things, any use and disposal by us of hazardous
or potentially hazardous substances in connection with our research and use of our formulations. In addition, we are subject to
work safety and labor laws that govern certain of our operations and our employee relations. In each of these areas, as above,
the FDA and other government agencies have broad regulatory and enforcement powers, including, among other things, the ability
to levy fines and civil penalties, suspend or delay issuance of approvals, licenses or permits, seize or recall products, and
withdraw approvals, any one or more of which could have a material adverse effect on us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
research and development expenses primarily include expenses related to the development of intellectual property acquired during
the fiscal year ended December 31, 2013 and researcher and investigator-initiated evaluations and research conducted during the
fiscal year ended December 31, 2014 related to our ophthalmic formulations and certain other assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2013, we incurred $1,616,082 in research and development expenses, as compared to $236,660 during
the year ended December 31, 2014. Research and development activities decreased during the 2014 fiscal year as a result of our
shift in business strategy away from our Impracor Phase 3 development program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of March 2, 2015, we employed 64 employees, of which 56 are full-time employees and 8 are part-time employees. Our employees are
engaged in pharmacy operations, sales, marketing, research, development, and general and administrative functions. We expect to
add additional employees in all departmental functions as we carry out our business plan in the next 12 months. We are not party
to any collective bargaining agreements with any of our employees. We have never experienced a work stoppage, and we believe our
employee relations are good. We hire independent contractor labor and consultants on an as-needed basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Company
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
were incorporated in Delaware in January 2006 as Bywater Resources, Inc. in order to conduct mineral exploration activities. We
changed our name to Transdel Pharmaceuticals, Inc. on September 11, 2007. In September 2007, we closed a merger transaction with
Transdel Pharmaceuticals Holdings, Inc., upon completion of which we began our operations as a pharmaceutical company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
June 26, 2011, we suspended our operations and filed a voluntary petition for reorganization relief under Chapter 11 of the United
States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of California (the &ldquo;Bankruptcy Court&rdquo;),
Case No. 11-10497-11 (the &ldquo;Chapter 11 Case&rdquo;). On November 21, 2011, in connection with our entry into a line of credit
agreement and securities purchase agreement with DermaStar International, LLC, we requested that the Bankruptcy Court dismiss
the Chapter 11 Case. On December 8, 2011, the Bankruptcy Court entered an order dismissing the Chapter 11 Case.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
February 28, 2012, we changed our name to Imprimis Pharmaceuticals, Inc. and effected a one-for-eight reverse split of our authorized,
issued and outstanding common stock, and on February 7, 2013 we effected a one-for-five reverse split of our authorized, issued
and outstanding common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
April 1, 2014 and January 1, 2015, we completed our acquisitions of all of the outstanding capital stock of Pharmacy Creations
and Park, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
common stock is currently traded on The NASDAQ Capital Market under the symbol IMMY. Our executive offices are located at 12264
El Camino Real, Suite 350, San Diego, California 92130 and our telephone number at such office is (858) 704-4040. Our website
address is imprimispharma.com. Information contained on our website is not deemed part of this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_003"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
1A. RISK FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>You
should carefully consider the following risk factors in addition to the other information contained in this Annual Report. Our
business, financial condition, results of operations and stock price could be materially adversely affected by any of these risks.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
have incurred losses in every year of our operations, and we may never become profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have incurred losses in every year of our operations, including net losses of $(10,118,103) and $(7,643,124) for the years ended
December 31, 2014 and 2013, respectively. As of December 31, 2014, our accumulated deficit was $(41,865,495). On June 26, 2011,
we suspended our operations and filed the Chapter 11 Case in the Bankruptcy Court. On December 8, 2011, the Bankruptcy Court entered
an order dismissing the Chapter 11 Case following our entry into a line of credit agreement and securities purchase agreement
with DermaStar International, LLC. Since the dismissal of the Chapter 11 Case, we have focused on resuming our operations and
developing and implementing our business plan. We expect to incur increasing operating losses for the foreseeable future as we
continue to incur costs for commercialization activities and research and development. Although we have been generating revenue
from our pharmacy operations following the closing of our acquisitions of Pharmacy Creations on April 1, 2014 and Park on January
1, 2015, our ability to generate significant revenues and achieve profitability will depend on a number of factors, including
our ability, alone or with others, to identify promising development opportunities and select appropriate commercialization strategies,
develop and commercialize our proprietary compounded formulations, interest physicians and health care organizations in our proprietary
formulations, successfully market and sell these formulations, integrate and operate Pharmacy Creations, Park and any other pharmacies
or outsourcing facilities we may build or acquire in the future, establish a network of pharmacies with a broad geographic footprint,
and comply with federal and state laws related to pharmaceutical compounding and, if applicable, FDA regulations for any formulations
for which we pursue FDA approval, as well as the other risk factors described in this Item 1A, many of which are outside of our
direct control. Our ultimate success will depend on many factors, including factors outside of our control. These activities are
costly and susceptible to failure, and we may never be able to achieve or sustain market acceptance of any of our proprietary
formulations or generate sufficient revenue to support our business from our pharmacy operations, or reach the level of sales
and revenues necessary to achieve and sustain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
aim to sell certain of our proprietary formulations primarily through a network of compounding pharmacies, but we may not be successful
in our efforts to establish such a network or integrate these businesses into our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
key aspect of our business strategy is to establish a compounding pharmacy network, whether through acquisitions, establishing
new pharmacies or entering into licensing arrangements with third-party pharmacies, through which we can market and sell our proprietary
formulations and other non-proprietary products in all 50 states. On April 1, 2014, we completed the acquisition of Pharmacy Creations,
a New Jersey-based compounding pharmacy, and on January 1, 2015, we completed the acquisition of Park, a California-based compounding
pharmacy, through which we have rights to dispense formulations in 40 states. Additionally, in February 2015, we entered into
a lease agreement for space in New Jersey and began construction efforts to build an outsourcing facility, which we expect to
be completed during the fourth quarter of 2015. We have limited experience acquiring, building or operating compounding pharmacies
or other prescription dispensing facilities or commercializing our formulations through ownership of or licensing arrangements
with these pharmacies. We expect to expand our operations and personnel in the pharmacy operations area in order to further develop
this compounding pharmacy network, but we may experience difficulties implementing this strategy, including difficulties that
arise as a result of our lack of experience, and we may be unsuccessful. For instance, we may not be successful in our efforts
to integrate, manage or otherwise realize the benefits we expect from our acquisitions of Pharmacy Creations, Park or any additional
pharmacy businesses or outsourcing facilities we seek to acquire or build in the future, we may not be able to satisfy applicable
federal and state licensing and other requirements for any such pharmacy businesses in a timely manner or at all, changes to state
and federal pharmacy regulations may restrict compounding operations or make them more costly, we may be unable to achieve a sufficient
physician and patient customer base to sustain our pharmacy operations, and we may not be able to enter into licensing or other
arrangements with third-party pharmacies or outsourcing facilities when desired, on acceptable terms, or at all. Moreover, all
such efforts to expand out pharmacy operations and establish a pharmacy network will involve significant costs and other resources,
which we may not be able to afford, disrupt our other operations and distract management and our other employees from other aspects
of our operations. Our business could materially suffer if we are unable to further develop this pharmacy network and, even if
we are successful, we may be unable to generate sufficient revenue to recover our costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
are dependent on market acceptance of compounding pharmacies and compounded formulations, and physicians may be unwilling to prescribe,
and patients may be unwilling to use, our proprietary customizable compounded formulations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
currently expect to distribute our proprietary formulations through compounding pharmacies. Formulations prepared and dispensed
by compounding pharmacies contain FDA-approved ingredients, but are not themselves approved by the FDA. As a result, our formulations
have not undergone the FDA approval process and only limited data, if any, may be available with respect to the safety and efficacy
of our formulations for any particular indication. In addition, certain compounding pharmacies have been the subject of widespread
negative media coverage in recent years, and the actions of these pharmacies have resulted in increased scrutiny of compounding
pharmacy activities from the FDA and state governmental agencies. As a result, some physicians may be hesitant to prescribe, and
some patients may be hesitant to purchase and use, these non-FDA approved compounded formulations, particularly when an FDA-approved
alternative is available. Other reasons physicians may be unwilling to prescribe or patients may be unwilling to use our proprietary
customizable compounded formulations could include the following, among others: we are limited in our ability to discuss the efficacy
or safety of our formulations with potential purchasers of our formulations to the extent applicable data is available; our pharmacy
operations are primarily operating on a cash-pay basis and reimbursement may or may not be available from third-party payors,
including the government Medicare and Medicaid programs; and our formulations are not presently being prepared in a manufacturing
facility governed by cGMP requirements. Any failure by physicians, patients and/or third-party payors to accept and embrace compounded
formulations could substantially limit our market and cause our operations to suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
may not receive sufficient revenue through Pharmacy Creations and Park or other compounding pharmacies we may acquire or develop
or with which we may partner to fund our operations and recover our development costs. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
business plan involves the preparation and sale of our proprietary formulations through a network of compounding pharmacies and
outsourcing facilities. We are in the process of establishing an internal sales force to pursue marketing and sales of our proprietary
and other formulations in the states in which Pharmacy Creations and Park are authorized to operate under federal and state pharmacy
laws. We are also pursuing additional strategic transactions to broaden our geographic reach, including our plans to open our
own outsourcing facility in New Jersey, which is currently under construction that we expect to be completed in the fourth quarter
of 2015. Our Company has limited experience operating pharmacies and commercializing compounded formulations and we may be unable
to successfully manage this business or generate sufficient revenue to recover our development costs and operational expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
may have only limited success in marketing and selling our proprietary formulations through any network of compounding pharmacies
we may develop. Because any of our formulations being commercialized through a compounding pharmacy distribution model will not
have obtained FDA approval, only limited data will be available, if any, with respect to the safety and efficacy of our formulations
for any particular indication, and we will be subject to regulatory limitations with respect to the information we can provide
regarding the safety and efficacy of our formulations even if such data is available. As a result, physicians may not be interested
in prescribing our formulations to their patients, and we may not generate significant revenue from sales of our proprietary formulations
and other products. In addition, we are substantially dependent on Pharmacy Creations, Park, any other pharmacies or prescription
dispensing facilities we acquire or develop and any pharmacy partners with which we may contract to compound and sell our formulations
in sufficient volumes to accommodate the number of prescriptions they receive. We may be unable to acquire, build or enter into
agreements with pharmacies or outsourcing facilities of sufficient size, reputation and quality to implement our business plan,
and our pharmacy partners may be unable to compound our formulations successfully. If physicians and healthcare organizations
were to request our formulations in quantities our pharmacies or pharmacy partners are unable to fill, our business would suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
business is significantly impacted by state and federal statutes and regulations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
of our proprietary formulations are comprised of active pharmaceutical ingredients that are components of drugs that have received
marketing approval from the FDA, although our proprietary compounded formulations have not themselves received FDA approval. FDA
approval of a compounded formulation is not required in order to market and sell the compounded formulations, although in select
instances we may choose to pursue FDA approval to market and sell certain potential product candidates. The marketing and sale
of compounded formulations is subject to and must comply with extensive state and federal statutes and regulations governing compounding
pharmacies. These statutes and regulations include, among other things, restrictions on compounding in advance of receiving a
patient-specific prescription, prohibitions on compounding drugs that are essentially copies of FDA-approved drugs, prohibitions
on compounding drug products for office use without a prescription for an individually identified patient, limitations on the
volume of compounded formulations that may be sold across state lines, and prohibitions on wholesaling or reselling. These and
other restrictions on the activities of compounding pharmacies may significantly limit the market available for compounded formulations,
as compared to the market available for FDA-approved drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
pharmacy business is impacted by federal and state laws and regulations governing, among other things: the purchase, distribution,
management, compounding, dispensing, reimbursement, marketing and labeling of prescription drugs and related services; FDA and/or
state regulation affecting the pharmacy and pharmaceutical industries, including state pharmacy licensure, registration or permit
standards; rules and regulations issued pursuant to HIPAA and other state and federal laws related to the use, disclosure and
transmission of health information; state and federal controlled substance laws; and statutes and regulations related to FDA approval
for the sale and marketing of new drugs and medical devices. Our failure to comply with any of these laws and regulations could
severely limit or curtail our pharmacy operations, which would materially harm our business and prospects. Further, our business
could be affected by changes in these or any newly enacted laws and regulations, as well as federal and state agency interpretations
of such statutes and regulations. Such statutory or regulatory changes could require that we make changes to our business model
and operations and/or could require that we incur significantly increased costs in order to comply with such regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
Pharmacy Creations, Park or any other pharmacy or outsourcing facility we acquire or build or with which we partner fails to comply
with the Controlled Substances Act, FDCA, or state statutes and regulations, the pharmacy could be required to cease operations
or become subject to restrictions that could adversely affect our business. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">State
pharmacy laws require pharmacy locations in those states to be licensed as an in-state pharmacy to dispense pharmaceuticals. In
addition, state controlled substance laws require registration and compliance with state pharmacy licensure, registration or permit
standards promulgated by the state&rsquo;s pharmacy licensing authority. Pharmacy and controlled substance laws often address
the qualification of an applicant&rsquo;s personnel, the adequacy of its prescription fulfillment and inventory control practices
and the adequacy of its facilities, and subject pharmacies to oversight by state boards of pharmacy and other regulators that
could impose burdensome requirements or restrictions on operations if a pharmacy is found not to comply with these laws. For example,
on May 14, 2014, Pharmacy Creations entered into a voluntary interim consent order with the Office of the Attorney General of
the State of New Jersey and New Jersey State Board of Pharmacy related to its sterile compounding activities, pursuant to which
Pharmacy Creations has agreed to conduct four additional mandatory third-party inspections by August 2015. Completing these additional
third-party inspections will involve significant additional costs to us and will distract management and Pharmacy Creations employees
from other aspects of our business. This consent order is not a disciplinary action or sanction or an admission of liability on
the part of the pharmacy, and we believe that Pharmacy Creations is in material compliance with applicable regulatory requirements.
However, if Pharmacy Creations or Park fails to comply with such requirements, it could be forced to permanently or temporarily
cease or limit its sterile compounding operations, which would severely limit our ability to market and sell our proprietary formulations
and would materially harm our operations and prospects. Any such noncompliance could also result in complaints or adverse actions
by respective state boards of pharmacy, FDA inspection of the facility to determine compliance with the FDCA, loss of FDCA exemptions
provided under Section 503A, warning letters, injunctions, prosecution, fines, loss of required government licenses, certifications
and approvals, any of which could involve significant costs and could cause us to be unable to realize the expected benefits of
these pharmacies&rsquo; operations. Although we ultimately expect to distribute our proprietary formulations through a network
of compounding pharmacies, we may not be successful in establishing such a network and the loss or limitation of Pharmacy Creation&rsquo;s
or Park&rsquo;s ability to compound sterile formulations would have an immediate adverse impact on our ability to successfully
and timely implement our business plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Many
of the states into which Pharmacy Creations and Park deliver pharmaceuticals have laws and regulations that require out-of-state
pharmacies to register with, or be licensed by, the boards of pharmacy or similar regulatory bodies in those states. These states
generally permit the dispensing pharmacy to follow the laws of the state within which the dispensing pharmacy is located. However,
various state pharmacy boards have enacted laws and/or adopted rules or regulations directed at restricting the operation of out-of-state
pharmacies by, among other things, requiring compliance with all laws of the states into which the out-of-state pharmacy dispenses
medications, whether or not those laws conflict with the laws of the state in which the pharmacy is located, or requiring the
pharmacist-in-charge to be licensed in that state. Further, under federal law Section 503A of the FDCA seeks to limit the amount
of compounded products that a pharmacy can dispense interstate. The interpretation and enforcement of that provision is dependent
on the FDA entering into a MOU with each state setting forth limits on interstate compounding. In February 2015, the FDA presented
a draft MOU that, if adopted, and signed by states would limit the amount of interstate units dispensed from a compounding pharmacy
to 30% of all compounded and non-compounded units dispensed or distributed by the pharmacy per month. This MOU, if adopted and
signed by states, and any other state laws or requirements that may be enacted that prohibit or restrict the interstate operations
of pharmacies could involve significant additional costs to us in order to sell compounded formulations in certain states and
could have an adverse effect on our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>There
are many competitive risks related to the marketing and sale of our proprietary formulations and operating a compounding pharmacy
business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
pharmaceutical and pharmacy industries are highly competitive. We compete against branded drug companies, generic drug companies,
outsourcing facilities and other compounding pharmacies. We are significantly smaller than some of our competitors, and we may
lack the financial and other resources needed to develop, produce, distribute, market and commercialize any of our proprietary
formulations or compete for market share in these sectors. The drug products available through branded and generic drug companies
with which our formulations compete have been approved for marketing and sale by the FDA and are required to be manufactured in
facilities compliant with cGMP standards. Although we prepare our compounded formulations in accordance with the standards provided
by USP &lt;795&gt; and USP &lt;797&gt; and applicable state and federal law, our proprietary compounded formulations are not required
to be, and have not been, approved for marketing and sale by the FDA and, as a result, some physicians may be unwilling to prescribe,
and some patients may be unwilling to use, our formulations. Additionally, under state and federal laws applicable to compounding
pharmacies, we are not permitted to prepare significant amounts of a specific formulation in advance of a prescription, compound
quantities for office use or utilize a wholesaler for distribution of our formulations; instead, our compounded formulations must
be prepared and dispensed in connection with a physician prescription for an individually identified patient. Pharmaceutical companies,
on the other hand, are able to sell their FDA-approved products to large pharmaceutical wholesalers, who can in turn sell to and
supply hospitals and retail pharmacies. As a result, our business may not be scalable on the scope available to our competitors
with FDA-approved drugs, which may limit our potential for profitable operations. These facets of our operations may subject our
business to limitations our competitors with FDA-approved drugs may not face.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Biotechnology
and related pharmaceutical technologies have undergone and continue to be subject to rapid and significant change. Our future
success, if any, will depend in large part on our ability to maintain a competitive position with respect to these technologies.
Products developed by our competitors, including FDA-approved drugs and compounded formulations created by other pharmacies, could
render our products and technologies obsolete or unable to compete. Any products that we develop may become obsolete before we
recover expenses incurred in developing the products, which may require that we seek to raise additional funds to continue our
operations that may or may not be available. The competitive environment requires an ongoing, extensive search for medical and
technological innovations and the ability to develop and market these innovations effectively, and we may not be competitive with
respect to these factors. Other competitive factors that may limit the success of our proprietary formulations include the size
of the market for such products, which could be smaller than we expect, the timing of market entry relative to competitive products,
the availability of alternative compounded formulations or approved drugs, the price of our formulations and services relative
to these alternative products, the availability of third-party reimbursement and the success of our sales and marketing efforts.
If our proprietary formulations are unable to compete with the products of our competitors, we may never gain market share or
achieve profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
a compounded drug formulation provided through our compounding services leads to patient injury or death or results in a product
recall, we may be exposed to significant liabilities or reputational harm.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
success of our business, including our proprietary formulations and pharmacy operations, is highly dependent upon medical and
patient perceptions of us and the safety and quality of our products. We could be adversely affected if we or any other compounding
pharmacies or our formulations and technologies are subject to negative publicity. We could also be adversely affected if any
of our formulations or technologies, any similar products sold by other companies, or any products sold by other compounding pharmacies
prove to be, or are asserted to be, harmful to patients. For instance, to the extent any of the components of approved drugs or
other ingredients used by Pharmacy Creations and Park to produce our compounded formulations have quality or other problems that
adversely affect the finished compounded preparations, our business could be adversely affected. Also, because of our dependence
upon medical and patient perceptions, any adverse publicity associated with illness or other adverse effects resulting from the
use or misuse of our products, any similar products sold by other companies or any products sold by compounding pharmacies could
have a material adverse impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
assure compliance with USP guidelines, we have implemented a policy whereby 100% of all sterile compound batches produced by Pharmacy
Creations and Park are tested both in-house and externally by an independent, FDA registered laboratory that we understand based
on the laboratory&rsquo;s representations operates in compliance with current good laboratory practices prior to their delivery
to patients and physicians. However, we could still become subject to product recalls and termination or suspension of our state
pharmacy licenses if we fail to fully implement this policy, if the laboratory testing does not identify all contaminated products,
or if our products otherwise cause or appear to have caused injury or harm to patients. In addition, such laboratory testing may
produce false positives, which could harm our business and impact our pharmacy operations and licensure even if the impacted formulations
are ultimately found to be sterile and no patients were harmed by them. If adverse events or deaths or a product recall, either
voluntarily or as required by the FDA or a state board of pharmacy, were associated with one of our proprietary formulations or
any compounds prepared by Pharmacy Creations, Park, or any other acquired or developed pharmacy or pharmacy partner, our reputation
may suffer, physicians may be unwilling to prescribe our proprietary formulations or order any prescriptions from such pharmacies,
we may become subject to product and professional liability lawsuits, or our state pharmacy licenses could be terminated or restricted.
If any of these events were to occur, we may be subject to significant litigation or other costs and loss of revenue, and we may
be unable to continue our pharmacy operations and further develop and commercialize our proprietary formulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Although
we have secured product and professional liability insurance for our pharmacy operations and the marketing and sale of our formulations,
our current or future insurance coverage may prove insufficient to cover any liability claims brought against us. Because of the
increasing costs of insurance coverage, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance
coverage that will be adequate to satisfy any liability that may arise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
ability to generate revenues will be diminished if we fail to obtain acceptable prices or an adequate level of reimbursement from
third-party payors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Currently,
Pharmacy Creations and Park operate on mostly a cash-pay basis and do not submit large amounts of claims for reimbursement through
Medicare, Medicaid or other third-party payors, although our customers may choose to seek available reimbursement opportunities
to the extent that they exist. We are currently in communications with third-party public and private payors regarding potential
reimbursement options for certain of our proprietary formulations, but we may be unsuccessful in these efforts. Many third-party
payors have imposed significant restrictions on reimbursement for compounded formulations in recent years. Additionally, even
if we were to pursue and obtain FDA-approval for a particular product candidate, significant uncertainty exists as to the reimbursement
status of newly approved health care products. Moreover, third-party payors, including Medicare, are increasingly attempting to
contain health care costs by limiting coverage and the level of reimbursement for new drugs and by refusing, in some cases, to
provide coverage for uses of approved products for disease indications for which the FDA has not granted labeling approval. As
a result, reimbursement from insurance companies and other third-party payors may never be available for any of our products or,
if available, it may not be sufficient to allow us to sell the products on a competitive basis. If government and other third-party
payors do not provide adequate coverage and reimbursement levels for our formulations, the market acceptance for our formulations
may be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
may not be able to correctly estimate our future operating expenses, which could lead to cash shortfalls.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
estimates of our future operating and capital expenditures are based upon our current business plan, the anticipated expenses
associated with our Pharmacy Creations and Park operations and our current expectations regarding the commercialization of our
proprietary formulations. Our projections have varied significantly in the past as a result of changes to our business model and
strategy, including our discontinuation of our historical Impracor program in November 2013, and our acquisitions of Pharmacy
Creations, Park and product development opportunities. We have limited experience operating a pharmacy and commercializing compounded
formulations, and we may not accurately estimate expenses and potential revenue associated with these activities. Additionally,
our operating expenses may fluctuate significantly as a result of a variety of factors, including those discussed in this Item
1A, some of which are outside of our direct control. If we are unable to correctly estimate the amount of cash necessary to fund
our business, we could spend our available financial resources much faster than we currently expect. If we do not have sufficient
funds to continue to operate and develop our business, we could be required to seek additional financing earlier than we expect,
which may not be available when needed or at all, or be forced to delay, scale back or eliminate some or all of our proposed operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Historically
we have relied on third party relationships to assist in our identification, research, assessment and acquisition of new formulations.
If we do not successfully identify and acquire rights to potential formulations and successfully integrate them into our operations,
our growth opportunities may be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
expect our acquisition of Pharmacy Creations and Park to provide us with limited research and development support and access to
additional novel compounded formulations. However, we have historically relied, and we expect to continue to rely, primarily upon
third parties to provide us with additional opportunities. In 2013, we entered into three asset purchase agreements for development
opportunities as a result of referrals from Professional Compounding Centers of America (PCCA) pursuant to our strategic alliance
agreement with PCCA. Although the term of the strategic alliance agreement currently extends until February 18, 2016 and automatically
extends for successive one year periods unless either party provides notice of non-renewal, we do not expect to obtain additional
referrals and development opportunities through PCCA. In October 2014, we entered into a license agreement with Urigen that provides
us with, in exchange for certain royalty and diligence obligations, development and commercialization rights in the U.S. with
respect to HLA for the prevention and treatment of lower urinary tract disorders. We may seek to enter into similar arrangements
with other third parties and for other formulations in the future, but only if we are able to identify attractive formulations
and negotiate agreements with their owners on terms acceptable to us, which we may not be able to do. If we are unable to utilize
Pharmacy Creations, Park and our current and future relationships with pharmacists, physicians and other inventors to provide
us with additional development opportunities, our growth opportunities may be limited. Moreover, we have limited resources to
acquire additional potential product development assets and integrate them into our business and acquisition opportunities may
involve competition among several potential purchasers, which could include large multi-national pharmaceutical companies and
other competitors that have access to greater financial resources than we do.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
pharmacist, physician and research consultants and advisors also provide us with significant assistance in our evaluation of product
development opportunities. These third parties generally engage in other business activities and may not devote sufficient time
and attention to our research and development activities. If these third parties were to terminate their relationships with us,
we may be unable to find other, equally qualified consultants and advisors on commercially reasonable terms or at all, and we
may have significant difficulty evaluating potential opportunities and developing and commercializing existing or any new product
candidates. As a result, we face financial and operational risks and uncertainties in connection with any future product or technology
acquisitions, and those we do complete may not be beneficial to us in the long term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
may be unable to successfully develop and commercialize our proprietary formulations or any other assets we may acquire. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
future results of operations will depend to a significant extent upon our ability to successfully develop and commercialize in
a timely manner any of the assets we have acquired or to which we will acquire rights in the future. We have entered into three
asset purchase agreements for assets related to compoundable formulations and one license agreement for rights to commercialize
a compounding formulation since May 2013. We are currently pursuing development and commercialization opportunities with respect
to certain of these formulations and we are in the process of assessing certain of our other assets in order to determine whether
to pursue their development or commercialization. In addition, we expect to consider the acquisition of additional intellectual
property rights or other assets in the future. There are numerous difficulties and risks inherent in acquiring, developing and
commercializing new formulations and product candidates, including the risks identified in this Item 1A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Once
we determine to pursue a potential product candidate, we develop a commercialization strategy for the product candidate. These
commercialization strategies could include, among others, marketing and selling the formulation in compounded form through compounding
pharmacies, or pursuing FDA approval of the product candidate. We may incorrectly assess the risks and benefits of our commercialization
options with respect to one or more formulations or technologies, and we may not pursue a successful commercialization strategy.
If we are unable to successfully commercialize one or more of our proprietary formulations, our operating results would be adversely
affected. Even if we are able to successfully sell one or more proprietary formulations, we may never recoup our investment. Our
failure to identify and expend our resources on formulations and technologies with commercial potential and execute an effective
commercialization strategy for each of our formulations would negatively impact the long-term profitability of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
may participate in strategic transactions that could impact our liquidity, increase our expenses and distract our management.
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">From
time to time we consider strategic transactions, such as out-licensing or in-licensing of compounds or technologies, acquisitions
of companies, and asset purchases. Additional potential transactions we may consider include a variety of different business arrangements,
including strategic partnerships, joint ventures, spin-offs, restructurings, divestitures, business combinations and investments.
In addition, another entity may pursue us or certain of our assets or aspects of our operations as an acquisition target. Any
such transactions may require us to incur charges specific to the transaction and not incident to our operations, may increase
our near and long-term expenditures, may pose significant integration challenges, and may require us to hire or otherwise engage
personnel with additional expertise, any of which could harm our operations and financial results. Such transactions may also
entail numerous other operational and financial risks, including, among others, exposure to unknown liabilities, disruption of
our business and diversion of our management&rsquo;s time and attention in order to develop acquired products, product candidates,
technologies or businesses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
part of our efforts to complete any significant transaction, we would need to expend significant resources to conduct business,
legal and financial due diligence, with the goal of identifying and evaluating material risks involved in the transaction. Despite
our efforts, we may be unsuccessful in ascertaining or evaluating all such risks and, as a result, we may not realize the expected
benefits of any such transaction, whether due to unidentified risks, integration difficulties, regulatory setbacks or other events,
and we may incur material liabilities for the past activities of acquired businesses. If any of these events were to occur, we
could be subject to significant costs and damage to our reputation and our business, results of operations and financial condition
could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
may need additional capital in order to continue operating our business, and such additional funds may not be available when needed,
on acceptable terms, or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
only recently started generating cash from operations, but do not yet receive significant revenues from these operations. Although
we believe we have sufficient cash reserves to operate our business for at least the next 12 months, we will need significant
additional capital to execute our business plan and fund our proposed business operations. Additionally, our plans for this period
may change, our estimates of our operating expenses and working capital requirements could be inaccurate, we may pursue acquisitions
of pharmacies or other strategic transactions that involve one-time expenditures or we may experience growth more quickly or on
a larger scale than we expect, any of which may result in the depletion of capital resources more rapidly than anticipated and
could require us to seek additional financing earlier than we expect to support our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have raised $21.5 million in funds through equity financings since April 2012. We may seek to obtain additional capital through
additional equity or debt financings, funding from corporate partnerships or licensing arrangements, sales or assets or other
financing transactions. If additional capital is not available when necessary and on acceptable terms, we may need to forego pursuit
of potentially valuable development or acquisition opportunities, we may not be able to continue to operate our business pursuant
to our business plan or we may be forced to discontinue our operations entirely. If we issue equity or convertible debt securities
to raise additional funds, our existing stockholders may experience substantial dilution, and the newly issued equity or debt
securities may have more favorable terms or rights, preferences and privileges senior to those of our existing stockholders. If
we raise additional funds through collaboration and licensing arrangements or sales of assets, we may be required to relinquish
potentially valuable rights to our product candidates or proprietary technologies, or grant licenses on terms that are not favorable
to us. If we raise funds by incurring debt, we may be required to pay significant interest expenses and our leverage relative
to our earnings or to our equity capitalization may increase. Obtaining commercial loans, assuming those loans would be available,
would increase our liabilities and future cash commitments and may impose restrictions on our activities, such as financial or
operational covenants with which we must comply. Further, we may incur substantial costs in pursuing future capital and/or financing
transactions, including investment banking fees, legal fees, accounting fees, printing and distribution expenses and other costs.
We may also be required to recognize non-cash expenses in connection with certain securities we may issue, such as options, convertible
notes and warrants, which would adversely impact our financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
we are unable to establish, train and maintain an effective sales and marketing infrastructure, we will not be able to commercialize
our product candidates successfully.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have started to build an internal sales and marketing infrastructure to implement our business plan with the development of internal
sales teams and education campaigns to market our proprietary ophthalmology and urology formulations. We will need to expend significant
resources to further establish and grow this internal infrastructure and properly train sales personnel with respect to regulatory
compliance matters. We may also choose to engage third parties to provide sales and marketing services for us, either in place
of or to supplement our internal commercialization infrastructure. We may not be able to secure sales personnel or relationships
with third-party sales organizations that are adequate in number or expertise to successfully market and sell our proprietary
formulations and pharmacy services. Further, any third-party organizations we may seek to engage may not be able to provide sales
and marketing services in accordance with our expectations and standards, may be more expensive than we can afford or may not
be available on otherwise acceptable terms or at all. If we are unable to establish and maintain compliant and adequate sales
and marketing capabilities, through our own internal infrastructure or third-party services, we may be unable to sell our formulations
or services or generate revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
business and operations would suffer in the event of cybersecurity and other system failures. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Despite
the implementation of security measures, our internal computer systems and those of any third parties with which we partner are
vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical
failures. While we have not experienced any such cybersecurity or system failure, accident or breach to date, if such an event
were to occur, it could result in a material disruption of our operations, substantial costs to rectify or correct the failure,
if possible, and potentially violation of HIPAA and other privacy laws applicable to our pharmacy operations. If any disruption
or security breach resulted in a loss of or damage to our data or applications or inappropriate disclosure of confidential or
proprietary information, we could incur liability, further development of our proprietary formulations could be delayed, and our
pharmacies could be disrupted, subject to restriction or forced to terminate their operations, any of which could severely harm
our business and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
may be unable to demonstrate the safety and efficacy or obtain FDA regulatory approval to market and sell any product candidates
for which we seek FDA approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Although
our current business strategy is focused on developing and commercializing product opportunities as compounded formulations, we
may choose to seek FDA regulatory approval to market and sell one or more of our assets as a FDA-approved drug. The process of
obtaining FDA approval to market and sell pharmaceutical products is costly, time consuming, uncertain and subject to unanticipated
delays. If we choose to pursue FDA approval for one or more product candidates, the FDA or other regulatory agencies may not approve
the product candidate on a timely basis or at all. Before we could obtain FDA approval for the sale of any of our potential product
candidates, we would be required to demonstrate through preclinical studies and clinical trials that the product candidate is
safe and effective for each intended use. Preclinical and clinical studies may fail to demonstrate the safety and efficacy of
our potential product candidates. Even promising results from preclinical and early clinical studies do not accurately predict
positive results in later, large-scale trials. A failure to demonstrate safety and efficacy of a product candidate to the FDA&rsquo;s
satisfaction would result in our failure to obtain FDA approval. Moreover, even if the FDA were to grant regulatory approval of
a product candidate, the approval may be limited to specific therapeutic areas or limited with respect to its distribution, which
could limit revenues, and we would be subject to extensive and costly post-approval requirements and oversight with respect to
our commercialization of the product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Delays
in the conduct or completion of, or the termination of, any clinical and non-clinical trials for any product candidates for which
we seek FDA approval could adversely affect our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Clinical
trials are very expensive, time consuming, unpredictable and difficult to design and implement. The results of clinical trials
may be unfavorable, they may continue for several years and may take significantly longer to complete and involve significantly
more costs than expected. Delays in the commencement or completion of clinical testing could significantly affect our product
development costs and business plan with respect to any product candidate for which we seek FDA approval. For example, we experienced
significant difficulties and delays with respect to initiating our now-terminated former Phase 3 trial for Impracor. The commencement
and completion of clinical trials can be delayed and experience difficulties for a number of reasons, including delays and difficulties
caused by circumstances over which we may have no control. For instance, approvals of the scope, design or trial site may not
be obtained from the FDA and other required bodies in a timely manner or at all, agreements with acceptable terms may not be reached
with clinical research organizations (CROs) to conduct the trials, a sufficient number of subjects may not be recruited and enrolled
in the trials, and third-party manufacturers of the materials for use in the trials may encounter delays and problems in the manufacturing
process, including failure to produce materials in sufficient quantities or of an acceptable quality to complete the trials. If
we were to experience delays in the commencement or completion of, or if we were to terminate, any clinical or non-clinical trials
we pursue in the future, the commercial prospects for the applicable product candidates may be limited or eliminated, which may
prevent us from recouping our investment on research and development efforts for the product candidate and would have a material
adverse effect on our business, results of operations, financial condition and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
are dependent on third parties to conduct clinical trials and non-clinical studies of our formulations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
do not employ personnel or possess the facilities necessary to conduct many of the activities associated with our non-clinical
research activities or any clinical programs we may pursue in the future. We have engaged, and expect to continue to engage consultants,
advisors, CROs and others to design, conduct, analyze and interpret the results of studies in connection with the research and
development of our products. In addition, we have in the past provided and expect to continue to provide grants to physicians
and other healthcare organizations to support investigator-initiated studies of our proprietary formulations. We generally have
only very limited contractual rights in connection with the conduct of any such studies. In addition, if we were to participate
in clinical trials conducted under an approved investigator-sponsored NDA, correspondence and communication with the FDA pertaining
to these trials would strictly be between the investigator and the FDA. The communication and information provided by the investigator
may not be appropriate and accurate, which could result in reviews, audits, delays or clinical holds by the FDA that affect the
timelines for these studies and potentially risk the completion of these trials. As a result, many important aspects of any studies
of our proprietary formulations and clinical or non-clinical trials for any drug candidates we determine to pursue are not in
our direct control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
the third parties we engage to perform these activities fail to devote sufficient time and resources to our studies, or if their
performance is substandard, it would delay the introduction of our proprietary formulations to the market or the approval of our
applications to regulatory agencies. Failure of these third parties to meet their obligations could adversely affect development
of our proprietary formations and product candidates and as a result could have a material adverse effect on our business, financial
condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Even
if we successfully develop any product candidate into an FDA-approved drug, failure to comply with continuing federal and state
regulations could result in the loss of approvals to market the drug.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Even
if we successfully develop any product candidate into an FDA-approved drug, we would be subject to extensive continuing regulatory
requirements and review, including review of adverse drug experiences and clinical results from any post-marketing tests or continued
actions required as a condition of approval. The manufacturer and manufacturing facilities we would use to produce any such drug
preparations would be subject to periodic review and inspection by the FDA, and we would be reliant on these third parties to
maintain their manufacturing processes in compliance with FDA and all other applicable regulatory requirements. Any changes to
a product that may have achieved approval, including the way it is manufactured or promoted, would often require FDA approval
before the product, as modified, could be marketed. In addition, we and our contract manufacturers would be subject to ongoing
FDA requirements for submission of safety and other post-market information. If we or our contract manufacturers failed to comply
with these or any other applicable regulatory requirements, a regulatory agency may, among other things, issue warning letters,
impose civil or criminal penalties, suspend or withdraw regulatory approval, impose restrictions on our operations, close the
facilities of our contract manufacturers, seize or detain products or require a product recall.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Regulatory
review also covers a company&rsquo;s activities in the promotion of its FDA-approved drugs, with significant potential penalties
and restrictions for promotion of drugs for an unapproved use. Sales and marketing programs are under scrutiny for compliance
with various mandated requirements, such as illegal promotions to health care professionals. We are also required to submit information
on our open and completed clinical trials to public registries and databases. Failure to comply with these requirements could
expose us to negative publicity, fines and penalties that could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
are not pursuing further development of Impracor, our historical product candidate, and we do not expect to receive any revenue
from Impracor. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Historically,
our business was focused on developing and commercializing our product candidate Impracor under the regulatory pathway provided
by Section 505(b)(2) of the FDCA. In August 2013, our contract manufacturer for the materials to be used in a proposed Phase 3
clinical trial of Impracor notified us that such materials had demonstrated out of specification and decreasing stability test
results, which we believe could likely have resulted in the materials being unusable for the duration of the trial. After considering
the totality of circumstances surrounding Impracor, including these unexpected manufacturing and formulation issues, other strategic
and competitive considerations related to the Impracor program, the optimal use of our capital and other resources and other potential
commercialization opportunities, we have discontinued the previously planned Phase 3 trial for Impracor and terminated all development
programs for Impracor. We do not expect we will identify or pursue a successful commercialization pathway for Impracor. Even if
we were to pursue commercialization of Impracor or sell compounded formulations utilizing the Impracor technology through our
pharmacy operations, we would not expect to achieve sales and revenues necessary to recover our historical costs associated with
the Impracor development program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
we are unable to protect our proprietary rights, we may not be able to prevent others from using our intellectual property, which
may reduce the competitiveness and value of the related assets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
success will depend in part on our ability to obtain and maintain patent protection for our formulations and technologies and
prevent third parties from infringing upon our proprietary rights. We must also operate without infringing upon patents and proprietary
rights of others, including by obtaining appropriate licenses to patents or proprietary rights held by third parties if necessary.
We will only be able to protect our formulations and technologies from unauthorized use by third parties to the extent that valid
and enforceable patents cover them. As of March 2, 2015, we owned 12 U.S. patent applications, including nine utility and three
provisional patent applications, and we owned five international patent applications filed under the Patent Cooperation Treaty.
However, the applications we have filed or may file may never yield patents that protect our inventions and intellectual property
assets. Failure to obtain patents for our formulations and technologies would limit our protection against other compounding pharmacies
and outsourcing facilities, generic drug manufacturers, pharmaceutical companies and other parties who may seek to copy or otherwise
produce products substantially similar to ours or use technologies substantially similar to those we own. We have made, and expect
to continue to make, significant investments in certain of our proprietary formulations prior to the grant of any patents covering
these formulations, and we may not receive a sufficient return on these investments in patents or other appropriate intellectual
property protection in not obtained and their competitiveness and value decreases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
patent and intellectual property positions of pharmacies and pharmaceutical companies, including ours, are uncertain and involve
complex legal and factual questions. There is no guarantee that we have or will develop or obtain the rights to products or processes
that are patentable, that patents will issue from any pending applications or that claims allowed will be sufficient to protect
the technology we develop or have developed or to which we have acquired rights, our contract manufacturing organizations or our
other service providers. In addition, we cannot be certain that patents issued to us will not be challenged, invalidated, infringed
or circumvented, including by our competitors, or that the rights granted thereunder will provide competitive advantages to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
also rely on unpatented trade secrets and know-how and continuing technological innovation in order to develop our formulations,
which we seek to protect, in part, by confidentiality agreements with our employees, consultants, collaborators and others. We
also have invention or patent assignment agreements with our current employees and certain consultants. However, our employees
and consultants may breach these agreements and we may not have adequate remedies for any breach, or our trade secrets may otherwise
become known or be independently discovered by competitors. In addition, inventions relevant to us could be developed by a person
not bound by an invention assignment agreement with us, in which case we may have no rights to use the applicable invention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
may face additional competition outside of the U.S. as a result of a lack of patent coverage in some territories and differences
in patent prosecution and enforcement laws in foreign counties. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filing,
prosecuting, defending and enforcing patents on our proprietary formulations throughout the world is extremely expensive. While
we have filed five international patent applications under the Patent Cooperation Treaty, we do not currently have patent protection
outside of the U.S. that covers any of our proprietary formulations or other assets that we are currently pursuing. Competitors
may use our technologies to develop their own products in jurisdictions where we have not obtained patent protection. These products
may compete with ours and may not be covered by any of our patent claims or other intellectual property rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Even
if we were to file international patent applications for any of our current or future proprietary formulations and patents were
issued or approved, it is likely that the scope of protection provided by such patents would be different from, and possibly less
than, the scope provided by corresponding U.S. patents. The success of our international market opportunity would be dependent
upon the enforcement of patent rights in various other countries. A number of countries in which we could file patent applications
have a history of weak enforcement and/or compulsory licensing of intellectual property rights. Moreover, the legal systems of
certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patents and other intellectual
property protection, particularly those relating to biotechnology and/or pharmaceuticals, which would make it difficult for us
to stop a party from infringing any of our intellectual property rights. Even if we have patents issued in these jurisdictions,
our patent rights may not be sufficient to prevent generic competition or unauthorized use. Moreover, attempting to enforce our
patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects
of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
proprietary formulations and technologies could potentially conflict with the rights of others.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
preparation or sale of our proprietary formulations and use of our technologies may infringe on the patent rights of others. If
our products infringe or conflict with the patent or other intellectual property rights of others, third parties could bring legal
actions against us claiming damages and seeking to enjoin our manufacturing and marketing of affected products. Patent litigation
is costly and time consuming and may divert management&rsquo;s attention and our resources. We may not have sufficient resources
to bring any such actions to a successful conclusion. If we are not successful in defending against these legal actions should
they arise, we may be subject to monetary liability, be forced to alter our products or cease some or all of our operations relating
to the affected products, or seek to obtain a license in order to continue manufacturing and marketing the affected products,
which may not available on acceptable terms or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
are dependent on our CEO, Mark L. Baum, for the continued growth and development of our Company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
CEO, Mark L. Baum, has played a primary role in creating and developing our current business model. Further, Mr. Baum has played
a primary role in securing much of our material intellectual property rights and related assets, as well as the means to make
and distribute our current products. We are highly dependent on Mr. Baum for the implementation of our business plan and the future
development of our assets and our business, and the loss of Mr. Baum&rsquo;s services to and leadership of our Company would likely
materially adversely impact the Company. We presently do not have key man insurance for Mr. Baum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
we are unable to attract and retain key personnel and consultants, we may be unable to maintain or expand our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
terminated all of our employees following our filing of the Chapter 11 Case. Since the dismissal of the Chapter 11 Case in December
2011, we have developed a new business model and have focused on rebuilding our management, pharmacy, research and development,
sales and marketing and other personnel in order to pursue this business model. However, because of our history, we may have significant
difficulty attracting and retaining necessary employees. In addition, because of the specialized nature of our business, our ability
to develop products and to compete will remain highly dependent, in large part, upon our ability to attract and retain qualified
pharmacy, scientific, technical and commercial employees and consultants. The loss of key employees or consultants or the failure
to recruit or engage new employees and consultants could have a material adverse effect on our business. There is intense competition
for qualified personnel in our industry, and we may be unable to continue to attract and retain the qualified personnel necessary
for the development of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
depend upon consultants and outside contractors for key aspects of our business. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are substantially dependent on consultants and other outside contractors and service providers for key aspects of our business,
including our research and development activities. Our agreements with our consultants typically provide that the consultant may
terminate the agreement with advanced notice to us. If any of our consultants terminates their engagement with us, or we are unable
to engage highly qualified replacements as necessary for our business, we may be unable to successfully execute our business plan.
We must effectively manage these consultants to ensure that they successfully carry out their contractual obligations and meet
expected deadlines. However, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of
the services provided by consultants is compromised for any reason, our development activities may be extended, delayed or terminated,
and we may not be able to commercialize our formulations or advance our business. We may not be able to manage our existing consultants
or find other competent outside contractors and service providers on commercially reasonable terms, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Changes
in the healthcare industry that are beyond our control may have an adverse impact on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
healthcare industry is changing rapidly as consumers, governments, medical professionals and the pharmaceutical industry examine
ways to broaden medical coverage while controlling the increase in healthcare costs. Such changes could include changes to make
the government&rsquo;s Medicare and Medicaid reimbursement programs more restrictive, which could limit or curtail the potential
for our proprietary formulations to obtain eligibility for reimbursement from such payors, or changes to expand the reach of HIPAA
or other health privacy laws, which could make compliance with these laws more costly and burdensome. Further, the Health Reform
Law may have a considerable impact on the existing U.S. system for the delivery and financing of health care and conceivably could
have a material effect on our business, although the details for implementation of many of the requirements under the Health Reform
Law will depend on the promulgation of regulations by a number of federal government agencies. It is impossible to predict the
final requirements of the Health Reform Law, any other changes to laws and regulations affecting the healthcare industry, or the
net effect of these requirements or changes on our business, operations or financial performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Because
of their significant stock ownership, some of our existing stockholders are able to exert control over us and our significant
corporate decisions, and sales of common stock by these stockholders from time to time could have an adverse effect on our stock
price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
executive officers and directors own or have the right to acquire within 60 days after March 10, 2015, in the aggregate, approximately
17% of our common stock that would be outstanding following such issuances. In addition, five individual stockholders own, or
have the right to acquire within 60 days after March 10, 2015, an additional approximately 41% of our common stock that would
be outstanding following such issuances. The sale of even a portion of these shares, or the perception that such sales may occur,
would likely have a material adverse effect on our stock price. In addition, these persons, acting together, have the ability
to exercise significant influence over or control the outcome of all matters submitted to our stockholders for approval, including
the election and removal of directors and any significant transaction involving us, and to control our management and affairs.
Additionally, since our Amended and Restated Certificate of Incorporation and Bylaws permit our stockholders to act by written
consent, a limited number of stockholders may approve stockholder actions without holding a meeting of stockholders. This concentration
of ownership may harm the market price of our common stock by, among other things:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 58px; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="width: 10px; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">delaying,
    deferring, or preventing a change in control of our Company or changes to our board of directors;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">impeding
    a merger, consolidation, takeover, or other business combination involving our Company;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">causing
    us to enter into transactions or agreements that are not in the best interests of all stockholders; or</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">discouraging
    a potential acquirer from making a tender offer or otherwise attempting to obtain control of our Company.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
we fail to maintain an effective system of internal controls, we may not be able to accurately report our financial results. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Effective
internal controls are necessary for us to provide reliable financial reports. If we cannot provide reliable financial reports,
our operating results could be misstated, our reputation may be harmed and the trading price of our stock could decline. As we
discuss in Item 9A of this Annual Report, our management concluded that our internal controls over financial reporting were effective
as of December 31, 2014. However, our controls over financial processes and reporting may not continue to be effective, or we
may identify material weaknesses or significant deficiencies in our internal controls in the future. Any failure to remediate
any future material weaknesses or implement required new or improved controls, or difficulties encountered in their implementation,
could harm our operating results, cause us to fail to meet our reporting obligations or result in material misstatements in our
financial statements or other public disclosures. Inferior internal controls could also cause investors to lose confidence in
our reported financial information, which could have a negative effect on the trading price of our stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>A
consistently active trading market for shares of our common stock may not be sustained.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Historically,
trading in our common stock has been sporadic and volatile, and our common stock has been &ldquo;thinly-traded.&rdquo; There have
been, and may in the future continue to be, extended periods when trading activity in our shares is minimal, as compared to a
seasoned issuer with a large and steady volume of trading activity. The market for our common stock is also characterized by significant
price volatility compared to seasoned issuers, and we expect that such volatility will continue. As a result, the trading of relatively
small quantities of shares may disproportionately influence the market price of our common stock. It is possible that a consistently
active and liquid trading market in our securities may never develop or be sustained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
stock price may be volatile.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
market price of our common stock is likely to be highly volatile and could fluctuate widely in response to various factors, many
of which are beyond our control, including the following:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 58px; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&#9679;</FONT></td>
    <TD STYLE="width: 10px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">changes
    in the pharmacy and pharmaceutical industry and markets;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">competitive
    pricing pressures;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
    ability to obtain working capital financing;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">new
    competitors in our market;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">additions
    or departures of key personnel;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">limited
    &ldquo;public float&rdquo; in the hands of a small number of persons whose sales or lack of sales could result in positive
    or negative pricing pressure on the market price for our common stock;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">sales
    of our common stock by us or by stockholders;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
    ability to execute our business plan;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">operating
    results that fall below expectations;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">loss
    of any material strategic relationships;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">industry
    or regulatory developments;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">economic
    and other external factors; and</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&#9679;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    other risk factors affecting our business discussed in this Item 1A.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated
to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market
price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
have the right to issue shares of preferred stock. If we were to issue preferred stock, it would likely have rights, preferences
and privileges superior to those of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are authorized to issue 5,000,000 shares of &ldquo;blank check&rdquo; preferred stock, with such rights, preferences and privileges
as may be determined from time-to-time by our board of directors. Following the conversion of our Series A Preferred Stock on
June 29, 2012, we have no shares of preferred stock issued and outstanding. Our board of directors is empowered, without stockholder
approval, to issue preferred stock in one or more series and to fix the dividend rights, dissolution or liquidation preferences,
redemption prices, conversion rights, voting rights, and other rights, preferences and privileges for any series of our preferred
stock. We have no immediate plans to issue shares of preferred stock. The issuance of shares of preferred stock, depending on
the rights, preferences and privileges attributable to the preferred stock, could adversely reduce the voting rights and powers
of the common stock and the portion of our assets allocated for distribution to common stockholders in a liquidation event, and
could also result in dilution to the book value per share of our common stock. The preferred stock could also be utilized, under
certain circumstances, as a method for raising additional capital or discouraging, delaying or preventing a change in control
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
have not paid dividends in the past and do not expect to pay dividends in the future. Any return on investment may be limited
to the value of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have never paid cash dividends on our common stock and do not anticipate doing so in the foreseeable future. The payment of dividends
on our common stock will depend on earnings, financial condition and other business and economic factors affecting us at such
time as our board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because
a return on your investment will only occur if our stock price appreciates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Offers
or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
sale by our stockholders of substantial amounts of our common stock in the public market or the perception that such sales could
occur upon the expiration of any statutory holding period, such as under Rule 144 under the Securities Act of 1933, as amended
(the &ldquo;Securities Act&rdquo;) upon expiration of any lock-up periods applicable to outstanding shares, or upon our issuance
of shares upon the exercise of outstanding options or warrants, could cause the market price of our common stock to fall. The
availability for sale of a substantial number of shares of our common stock, whether or not sales have occurred or are occurring,
also could make it more difficult for us to raise additional financing through the sale of equity or equity-related securities
in the future at a time and price that we deem reasonable or appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_004"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
1B. UNRESOLVED STAFF COMMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_005"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
2. PROPERTIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
lease approximately 7,565 square feet of office space in San Diego, California, the current lease term for which expires on October
31, 2018. This facility serves as our corporate headquarters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
lease approximately 8,602 square feet of lab, warehouse and office space in Roxbury, New Jersey, the current lease term for which
expires on July 31, 2022. This facility is currently under construction to serve as an outsourcing facility and pharmacy and will
replace our current New Jersey based pharmacy facility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
lease approximately 4,500 square feet of lab and office space in Irvine, California, the current lease term for which expires
on December 31, 2020. This facility is our California-based pharmacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
lease approximately 3,137 square feet of lab and office space in Randolph, New Jersey, the current lease term for which expires
on December 31, 2015. This facility is our current New Jersey-based pharmacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
lease approximately 3,784 square feet of office space in San Diego, California, the current lease term for which expires on September
30, 2016. This space previously served as our corporate headquarters and is currently being subleased through the lease term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
do not believe additional space will be required in the near-term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_006"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
3. LEGAL PROCEEDINGS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are not aware of any pending legal proceedings to which we are a party or of which any of our property is subject the adverse
outcome of which, individually or in the aggregate, is likely to have a material adverse effect on our financial position or results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_007"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
4. MINE SAFETY DISCLOSURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_008"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_009"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
5. MARKET FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS</B> <B>AND ISSUER PURCHASES OF EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Market
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
common stock began trading on The NASDAQ Capital Market on February 8, 2013 under the symbol &ldquo;IMMY&rdquo;. Prior to that,
our common stock was quoted for trading on several different over-the-counter quotation systems, including the OTC Marketplace
QB tier, where it was quoted from February 24, 2012 until February 7, 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth (i) the high and low last-bid prices for our common stock for the periods indicated prior to February
8, 2013, as reported by the OTC Marketplace QB tier, and (ii) the high and low sale prices for our common stock as reported by
The NASDAQ Capital Market for the periods indicated commencing on February 8, 2013. The liquidity of our shares when quoted on
the OTC Marketplace QB tier was extremely limited, and the quotations during those periods reflect inter-dealer prices, without
retail mark-up, mark-down or commission, and may not represent actual transactions.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Fiscal Year 2013</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">First Quarter</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">9.75</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">4.60</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.57</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.59</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Fiscal Year 2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">First Quarter</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">9.62</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">3.30</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.56</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.71</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.65</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.72</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of March 5, 2015 there were approximately 133 stockholders of record (excluding an indeterminable number of stockholders whose
shares are held in street or &ldquo;nominee&rdquo; name) of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have not paid any dividends on our common stock since our inception and do not expect to pay dividends on our common stock in
the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Recent
Sales of Unregistered Securities </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
October 2014, we issued 4,000 restricted shares of common stock, valued at $29,160, to a consultant in consideration for consulting
services provided. The common stock was sold and issued in reliance on the exemption from the registration requirements of the
Securities Act afforded by Section 4(a)(2) thereof in reliance upon the following facts: the shares were issued to one consultant
who represented to us that it was an accredited investor (as that term is defined in Rule 501 of Regulation D under the Securities
Act) and that it was purchasing the securities for its own account and not with a view to distribute them; we did not use general
solicitation or advertising to market the securities; and the shares were issued as restricted securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
November and December 2014, we issued an aggregate of 3,774 shares of common stock upon the exercise of warrants to purchase 9,363
shares of common stock, some of which were exercised for cash for gross proceeds of $373 and others of which were exercised pursuant
to cashless exercise provisions. Certain of the warrants were issued in April 2012 as part of a private placement of securities,
and certain of the warrants were issued in February and March 2013 to the lead underwriter for a registered public offering of
our common stock. Neither the warrants nor the common stock issued upon exercise of the warrants have been registered under the
Securities Act. The securities were sold and issued in reliance on the exemption from the registration requirements of the Securities
Act afforded by Section 4(a)(2) thereof in reliance upon the following facts: we did not use general solicitation or advertising
to market the securities; each warrant holder represented to us that it was an accredited investor (as that term is defined in
Rule 501 of Regulation D under the Securities Act) and that it was purchasing the securities for its own account and not with
a view to distribute them; and the securities were issued as restricted securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_010"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
6. SELECTED FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_011"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
7. MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>The
following discussion and analysis should be read in conjunction with the consolidated financial statements and the related notes
contained in this annual report on Form 10-K (Annual Report). In addition to historical information, the following discussion
contains forward-looking statements based upon our current views, expectations and assumptions that are subject to risks and uncertainties.
Actual results may differ substantially from those expressed or implied by any forward-looking statements due to a number of factors,
including but not limited to the risks described in the section entitled &ldquo;Risk Factors&rdquo; and elsewhere in this Annual
Report.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Unless
otherwise stated, all information regarding share amounts of common stock and prices per share of common stock described in this
Annual Report reflect the reverse stock splits of our authorized, issued and outstanding common stock effected on February 28,
2012 and February 7, 2013. As used in this discussion and analysis, unless indicated or the context requires otherwise, the terms
the &ldquo;Company&rdquo;, &ldquo;Imprimis&rdquo; &ldquo;we&rdquo;, &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Imprimis Pharmaceuticals,
Inc. and its consolidated subsidiaries.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Overview
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are a pharmaceutical company focused on developing and commercializing innovative and high quality proprietary compounded drug
therapies and making these therapies available to physicians and patients at accessible prices. We own, market and sell a portfolio
of proprietary combination formulations in ophthalmology and urology that we believe may offer competitive advantages and serve
unmet needs in the marketplace. Our ophthalmology formulation portfolio, led by our Dropless Therapy&trade; and LessDrops&trade;
formulations, serves the multi-billion dollar eye drop market and is designed to address patient compliance issues and provide
other medical and economic benefits to physicians and patients. Our recently launched urology business, headed by our Defeat IC&trade;
campaign, currently includes a patented compounded formulation for patients suffering from interstitial cystitis. We are also
developing additional complementary proprietary compounded formulations to add to our ophthalmology and urology formulation portfolios.
We make, dispense and sell our proprietary compounded formulations, as well as other non-proprietary products, through our compounding
pharmacies Pharmacy Creations, LLC (Pharmacy Creations) and South Coast Specialty Compounding, Inc. D/B/A Park Compounding (Park).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
of our proprietary compounded formulations are born from the clinical experience of a network of inventors, including physician
prescribers, clinical researchers and pharmacist formulators, who develop and prescribe customized medicines for individual patient
needs. Working collaboratively with these inventors, we identify and evaluate intellectual property related to these drug formulations,
assess relevant markets, and seek to validate the clinical experience of a development candidate with the objective of investing
in commercialization activities. We believe our model allows us to meet the realities of the current health care economy by offering
quality pharmaceutical innovation at accessible prices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have incurred recurring operating losses, and have had negative operating cash flows since July 24, 1998 (inception). In addition,
we have an accumulated deficit of approximately $41.9 million at December 31, 2014. Beginning on April 1, 2014, we began generating
revenue from sales of certain of our proprietary ophthalmic drug formulations and other non-proprietary formulations; however,
we expect to incur further losses as we integrate and develop our pharmacy operations, evaluate other programs and continue the
development of our formulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Operations
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Compounded
Proprietary Formulations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Ophthalmic
Formulations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
currently commercially available ophthalmic formulations include the following, marketed under our Dropless Therapy and LessDrops
campaigns:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT>&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tri-Moxi,
                                         a compounded formulation that is a combination of triamcinolone acetonide and moxifloxacin
                                         hydrochloride, used as an injection during ocular surgery and as an eye drop pre- and
                                         post-ocular surgery</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tri-Moxi-Vanc,
                                         a compounded formulation that is a combination of triamcinolone acetonide, moxifloxacin
                                         hydrochloride and vancomycin, used as an injection during ocular surgery </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pred-Moxi,
                                         a compounded formulation that is a combination of prednisolone and moxifloxacin hydrochloride,
                                         used as an eye drop pre- and post-ocular surgery</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
Dropless Therapy compounded formulations include Tri-Moxi and Tri-Moxi-Vanc used as an injectable during ocular surgery, which
ophthalmologists have reported has substantially reduced or in most cases, eliminated the need for patient-administered eye drops
following ocular surgeries they have performed. Since the launch of our associated Go Dropless&trade; educational campaign in
April 2014, more than 240 ophthalmologists have started to use our Dropless Therapy compounded formulations, and since their inception,
Dropless Therapy compounded formulations have been used in over 50,000 ocular surgeries, primarily cataract surgeries. In the
future, we aim for our Dropless Therapy to be initiated at additional high volume cataract surgery practices, hospitals and large
ambulatory surgery centers throughout the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
Pred-Moxi and Tri-Moxi topical compounded formulations, branded as LessDrops, were introduced during the first quarter of 2015
as combination compounded eye drops for patients following laser refractive surgery, including LASIK and photorefractive keratectomy
(PRK), cataract and other ocular surgeries. We estimate that our LessDrops compounded formulations can require up to 50% fewer
drops to be administered by patients post-surgery and may cost up to 75% less than other currently available post-surgery drops
regimens. We plan to continue to add to our portfolio of LessDrops topical compounded formulations and deliver additional eye
drop choices for our customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have also acquired intellectual property related to lyophilized (or freeze-dried), preservative-free, sulfite-free epinephrine,
phenylephrine and lidocaine, commonly used as mydriatic (pupil dilation) compounded formulations that use various combinations
of these ingredients. We have made and expect to increase sales of multiple ophthalmic compounded formulations per patient or
case in one or more kits. For example, we may sell a compounded formulation of injectable Tri-Moxi along with a mydriatic compounded
formulation for the same individually identified patient, and also include additional non-proprietary ophthalmic compounded formulations,
all as a part of a kit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Urologic
Formulations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
currently commercially available urologic compounded formulation consists of a patented formulation of heparin and alkalinized
lidocaine (HLA or Hep-Lido-A), to which we acquired development and commercialization rights in 2014. HLA is delivered directly
to the bladder for the treatment of interstitial cystitis (IC), also known as painful bladder syndrome. Since the HLA formulation
first became available as a compounded drug in 2011, there have been an estimated 140,000 HLA instillation procedures completed
in the U.S. During the first quarter of 2015, we commercially launched our HLA compounded formulation and introduced Defeat IC,
our national education campaign designed to increase awareness among medical practitioners about IC and our HLA treatment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have also acquired intellectual property related to an injectable compounded formulation comprised of pentoxifylline for the treatment
of certain fibrotic conditions, including Peyronie&rsquo;s Disease (PD). A researcher-initiated study using our patent-pending
pentoxifylline compounded formulation for the treatment of PD was initiated in 2014, and we may commercially launch this compounded
formulation following the completion of the research and release of its results, which is expected in 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Compounding
Pharmacies and Outsourcing Facilities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">One
of our key strategies is the use of compounding pharmacies to formulate our proprietary compounded drug formulations and distribute
them to physicians and patients. Compounding pharmacies work with physicians to develop customized medications for individually
identified patients, and the compounding pharmacy prepares these customized formulations upon receipt of a physician prescription
for an individual patient. Pharmacy Creations and Park, our wholly owned pharmacies accredited by the Pharmacy Compounding Accreditation
Board (PCAB), make, dispense and sell our proprietary ophthalmology and urology compounded formulations, complementary compounded
formulations within the ophthalmology and urology therapeutic areas, and other non-proprietary compounded formulations in other
therapeutic areas. Our pharmacies are collectively licensed to distribute compounded formulations in 40 states. In February 2015,
we entered into a lease agreement for space in New Jersey and began construction efforts to build an outsourcing facility, which
will be required to comply with certain additional requirements, including adherence to current good manufacturing practices (cGMP),
and will be permitted to compound large quantities of certain drug formulations without a prescription and distribute these formulations
out of state without limitation. We expect construction efforts for our New Jersey-based outsourcing facility to be completed
in the fourth quarter of 2015. We are also in the process of developing &ldquo;ImprimisRx&rdquo; as a uniform brand for our drug
fulfillment facilities, pharmacies and operations, which we intend to launch in 2015. We operate our pharmacy business under the
regulatory framework described in the Drug Quality and Security Act (DQSA) of 2013, the Federal Food Drug and Cosmetic Act (FDCA)
and applicable state pharmacy laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Historical
Impracor Program</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Historically,
our business focused on developing, obtaining approval from the U.S. Food and Drug Administration (FDA) for, and commercializing
our former topical pain management product candidate Impracor. After considering the totality of circumstances surrounding the
development of and clinical trial requirements for Impracor, including certain manufacturing and formulation issues, in November
2013 we announced our discontinuation of the proposed Phase 3 clinical trial for Impracor. We do not expect to resume a Phase
3 clinical trial for Impracor or otherwise invest in the commercial development of this asset.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Plan
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
operating plan for the next 12 months is focused on increasing sales of our proprietary ophthalmic and urologic compounded formulations
and certain non-proprietary products, normalization of pricing for our proprietary compounded formulations, and growing our prescription
fulfillment and dispensing capabilities. Additionally, we plan to continue to pursue development and commercialization opportunities
for certain of our ophthalmology, urology and other assets that we have not yet made commercially available as compounded formulations.
All of these activities will require significant costs and other resources, which we may not have or be able to earn from operations
or other sources. See &ldquo;&mdash;Liquidity and Capital Resources&rdquo; below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Although
we have engaged distributors for certain of our proprietary compounded formulations in non-U.S. markets, we expect to continue
to focus our efforts on our U.S. commercial opportunities during 2015. For our proprietary ophthalmic and urologic compounded
formulations, we have developed and plan to continue to build small internal sales and commercialization teams that are focused
on growing sales of these compounded formulations through, among other things, educating doctors, ambulatory surgery centers,
hospitals throughout the U.S. and other users about our products. However, we have limited experience developing and commercializing
compounded formulations and we may not be successful in doing so, whether due to the safety, quality or availability of our proprietary
compounded formulations, the size of the markets for such formulations, which could be smaller than we expect, the timing of market
entry relative to competitive products, the availability of alternative compounded formulations or FDA-approved drugs, the price
of our compounded formulations relative to alternative products or the success of our sales and marketing efforts, which is dependent
on our ability to build and grow a qualified and adequate internal sales function. Further, we are dependent upon market acceptance
of compounded formulations, and some physicians may be hesitant to prescribe, and some patients may be hesitant to purchase and
use, these non-FDA approved formulations, particularly when an FDA-approved alternative is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
currently make, dispense and sell our commercially available proprietary compounded formulations and certain other non-proprietary
products through our wholly-owned subsidiaries, Pharmacy Creations and Park, pursuant to a prescription for an individually identified
patient. Additionally, in February 2015, we entered into a lease agreement for space in New Jersey and commenced construction
efforts to build an outsourcing facility, which we expect to be completed in the fourth quarter of 2015. We plan to develop our
pharmacy operations into a network of pharmacies and other prescription dispensing facilities to deliver our proprietary compounded
formulations to patients. Our efforts to establish a widespread compounding pharmacy network may not be successful, whether due
to difficulties integrating, managing or otherwise realizing the benefits of our acquisitions of Pharmacy Creations, Park or any
additional pharmacy businesses or outsourcing facilities we seek to acquire or build in the future, inability to satisfy applicable
federal and state licensing and other requirements for any such pharmacy businesses in a timely manner or at all, changes to state
and federal pharmacy regulations that restrict compounding operations or make them more costly, failure to achieve a sufficient
physician and patient customer base to sustain our pharmacy operations, and inability to enter into licensing or other arrangements
with third-party pharmacies or outsourcing facilities when desired, on acceptable terms, or at all. Moreover, all such efforts
to expand out pharmacy operations and establish a pharmacy network will involve significant costs and other resources, which we
may not be able to afford, disrupt our other operations and distract management and our other employees from other aspects of
our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
proprietary ophthalmic compounded formulations are currently primarily available on a cash-pay basis. We plan to devote time and
other resources to seek reimbursement opportunities for these and other compounded formulations and normalize the pricing for
our currently available proprietary ophthalmic compounded formulations. We believe there is an economic argument that would allow
for price optimization of Dropless Therapy compounded formulations, manufactured to cGMP guidelines, to be priced at or near $100
per unit. According to our internally conducted research, we believe this potentially could allow for Medicare and other public
payors to save approximately $1 billion a year by substantially eliminating the higher costs of currently available eye drops.
We have been in communications with third-party public and private payors regarding potential reimbursement options for certain
of our proprietary compounded formulations, but we may be unsuccessful in these efforts. Many third-party payors have imposed
significant restrictions on reimbursement for compounded formulations in recent years. Moreover, third-party payors, including
Medicare, are increasingly attempting to contain health care costs by limiting coverage and the level of reimbursement for new
drugs and by refusing, in some cases, to provide coverage for uses of approved products for disease indications for which the
FDA has not granted labeling approval. As a result, reimbursement from insurance companies and other third-party payors may never
be available for any of our products or, if available, it may not be sufficient to allow us to sell the products on a competitive
basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
also plan to pursue the development of additional proprietary compounded formulations in the ophthalmology, urology or other therapeutic
areas, which may include continued activities to develop and commercialize current assets or, if and as opportunities arise, potential
acquisitions of new intellectual property rights and assets. However, we will need to rely on relationships with third parties,
including pharmacists, physicians and other inventors, to assist in the identification, research, development and assessment of
such formulations, which exposes us to risks. Moreover, we may be unable to identify attractive acquisition opportunities and
negotiate agreements with their owners that are acceptable to us, particularly if such assets involve competition among several
purchasers, and we have limited resources to invest in or acquire additional potential product development assets and integrate
them into our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2014
Developments </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Park
Acquisition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
January 1, 2015, we completed the acquisition of all of the outstanding capital stock of Park pursuant to a stock purchase agreement
entered in November 2014. At the closing of the Park acquisition, we paid an aggregate cash purchase price of $3,000,000, net
of fees and expenses, subject to adjustment based on the final calculation of Park&rsquo;s working capital and certain other financial
information, and issued 63,525 shares of our common stock, valued at $500,000 based on the average closing price of our common
stock for the 10 trading days preceding the issuance date. In addition, we are obligated to make 12 quarterly cash payments of
$53,125 each over the three years following January 1, 2015, totaling $637,500. The sellers of Park have the option to receive
the last six of such quarterly payments, totaling up to an aggregate of $318,750, in the form of 6,749 shares of our common stock
for each such payment. In connection with our acquisition of Park, we have entered into an employment agreement with one of the
founders of Park, who now serves as the Senior Director of Corporate Development of Park.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Urigen
License Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
October 24, 2014, we entered into a license agreement with Urigen Pharmaceuticals, Inc. (Urigen), pursuant to which Urigen granted
us a license under certain U.S. patents and patent applications to develop and sell in the U.S. our HLA compounded formulation
for the prevention or treatment of disorders of the lower urinary tract. Such license is non-exclusive; provided that, between
April 24, 2015 and October 24, 2015, we will have the right, at our option, to convert the non-exclusive license to an exclusive
license for the remaining term of the license agreement, subject only to certain specified existing sublicenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
consideration for the license granted by Urigen, we agreed to pay annual tiered royalties based on our sales of HLA, subject to
certain minimum annual royalty payments. The annual tiered royalties consist of the greater of (i) $0.50 per ml, and (ii) 15%
- 20% of our net sales of HLA, with the royalty within this range depending on the our aggregate sales of HLA during the period
to which the royalty payment applies. We are obligated to pay such royalties beginning with our first commercial sale of HLA and
continuing until the expiration of the patents subject to the license agreement. We have also agreed to use commercially reasonable
efforts to develop and commercialize HLA according to the terms of a diligence plan, which efforts will include, without limitation,
our investment of $2,000,000 in commercialization efforts of HLA over the 18-24 months following October 24, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Pharmacy
Creations Acquisition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
April 1, 2014, we acquired all of the outstanding membership interests of Pharmacy Creations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">At
the closing of the acquisition of Pharmacy Creations, we paid an aggregate cash purchase price of $600,000. In addition, the sellers
of Pharmacy Creations are entitled to receive additional contingent consideration upon the satisfaction of certain conditions,
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
                                         contingent cash payment of $50,000, payable if Pharmacy Creations earns revenue of over
                                         $3,500,000 for the 12 month period ending March 31, 2015.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
                                         contingent stock payment of up to an aggregate of 215,190 shares of our common stock,
                                         issuable if the following revenue milestones are met:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="width: 0.1in"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
                                         Pharmacy Creations earns revenue of over $7,500,000 during the 12 month period ending
                                         March 31, 2016, all 215,190 shares;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="width: 0.1in"></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
                                         Pharmacy Creations earns revenue of between $3,500,000 and $7,500,000 during the 12 month
                                         period ending March 31, 2016, an aggregate of that number of shares of our common stock
                                         equal to the amount that such revenue exceeds $3,500,000 divided by 18.5882, rounded
                                         down to the lower whole number (not to exceed 215,190 shares).</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Quality
Assurance Standards</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Beginning
in April 2014 when we commenced our pharmacy operations with the acquisition of Pharmacy Creations, we have been developing and
implementing new internal quality assurance standards and best practice policies that we intend to exceed those required under
the U.S. Pharmacopeia (USP) and state pharmacy laws in certain important respects. These standards and policies include, among
other things, the engagement of a third-party quality assurance and quality control consultant to perform quarterly inspections
of our pharmacy operations, including assessing compliance with USP and state board of pharmacy standards and environmental monitoring.
In light of a voluntary consent order entered into in May 2014 between Pharmacy Creations and New Jersey regulatory agencies related
to Pharmacy Creations&rsquo; sterile compounding activities, we have also implemented a policy to validate through testing at
a third-party FDA-registered laboratory that formulations produced at Pharmacy Creations and Park satisfy USP guidelines and specifications
prior to their delivery to patients and physicians. Although the consent order was not a disciplinary action or an admission of
liability on the part of the pharmacy and we believe that Pharmacy Creations is currently in material compliance with applicable
regulatory requirements, we have incurred and expect to incur in the future expenses related to observing the requirements of
the consent order and further establishing and implementing our quality assurance standards and other best practices. In addition,
we limited the sales of certain pharmacy products and formulations during the month of July 2014 while implementing our quality
assurance practices, and such sales limitations or other events may occur in the future in connection with our further development
and implementation of our quality assurance standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following period-to-period comparisons of our financial results are not necessarily indicative of results for the current period
or any future period. In particular, much of our operational expenses during the year ended December 31, 2013 were incurred in
connection with our development program for Impracor, which we discontinued in November 2013 and do not expect to resume. In addition,
our pharmacy operations activities commenced on April 1, 2014, and this change in the nature of our operations has had and is
expected to continue to have a significant impact on our financial results. For example, our results of operations in the periods
after commencement of our pharmacy operations, including aggregate revenue and expense amounts and the apportionment of expenses
among categories, have changed and are expected to continue to change as we further develop these operations. Further, as a result
of our acquisitions of Pharmacy Creations and Park or other such transactions we may pursue, we may experience infrequent or one-time
expenditures in connection with effecting those transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Comparison
of Years Ended December 31, 2014 and 2013 </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Revenues</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
revenues include amounts recorded from sales of proprietary formulations, which we began to receive following our acquisition
of Pharmacy Creations, and revenues received from royalty payments owed to us pursuant to an out-license arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
table below provides information regarding our revenues.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">For the year ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; font-weight: bold">Sales</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1,652,386</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">1,652,386</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">License revenues</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,860</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,000</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">($</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">2,140</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 10pt">Total revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,660,246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 2.5pt; text-align: right">1,650,246</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Following
the acquisition of Pharmacy Creations on April 1, 2014, we began recognizing revenues from sales of our proprietary ophthalmic
formulations and other non-proprietary pharmacy products and formulations. For the year ended December 31, 2014, we recognized
revenues of approximately $1,652,386, from sales of such products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">License
revenues of $7,860 and $10,000 recorded during the years ended December 31, 2014 and 2013, respectively, were related to royalty
payments associated with an out-license agreement with a third party granting such third party rights to certain drug delivery
technology to be used for anti-cellulite formulations. We do not expect to recognize significant revenue amounts associated with
this license agreement in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Cost
of Sales</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
cost of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical
ingredients, personnel costs, packaging, storage, royalties, shipping and handling costs and the write-off of obsolete inventory.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
table below provides information regarding our cost of sales.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">For the year ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; font-weight: bold">Cost of sales</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 2.5pt double; text-align: right">1,092,839</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="width: 11%; padding-bottom: 2.5pt; text-align: right">1,092,839</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Following
the acquisition of Pharmacy Creations on April 1, 2014, we began selling our proprietary ophthalmic formulations and other non-proprietary
pharmacy products and formulations and recognizing the associated costs of such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Selling
and Marketing Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
selling and marketing expenses consist of costs associated with our marketing activities and sales of our proprietary ophthalmic
compounded formulations and other non-proprietary compounded formulations, which include associated personnel costs, including
wages and stock-based compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
table below provides information regarding our selling and marketing expenses.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">For the year ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; font-weight: bold; text-align: left">Selling and marketing</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 2.5pt double; text-align: right">2,390,180</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 2.5pt double; text-align: right">85,890</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="width: 11%; padding-bottom: 2.5pt; text-align: right">2,304,290</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
began implementing commercialization efforts in the fourth quarter of the year ended December 31, 2013 and, following the acquisition
of Pharmacy Creations on April 1, 2014, we began selling our proprietary ophthalmic formulations and other non-proprietary pharmacy
products and formulations. For the year ended December 31, 2014, there was an increase of $2,304,290 in sales and marketing expenses,
as compared to the prior year. This increase is attributed to the hiring of additional commercialization personnel, attendance
at trade conferences and implementation of other various marketing activities all related to our commercial efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>General
and Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
general and administrative expenses include personnel costs, including wages and stock-based compensation, corporate facility
expenses, and investor relations, consulting, insurance, filing, legal and accounting fees and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
table below provides information regarding general and administrative expenses.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">For the year ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>General
                                         and administrative</B></FONT></P></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 2.5pt double; text-align: right">8,087,316</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 2.5pt double; text-align: right">5,994,907</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">$</TD><TD STYLE="width: 11%; padding-bottom: 2.5pt; text-align: right">2,092,409</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
the year ended December 31, 2014, there was an increase of $2,092,409 in general and administrative expenses as compared to the
prior year. The increase in general and administrative expenses is largely attributable to additional expenses related to the
acquisition of Pharmacy Creations and the commencement and increase of our pharmacy operations, including hiring additional personnel,
obtaining state pharmacy licenses, incurring increased professional fees and other related activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Research
and Development Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
research and development expenses primarily include expenses related to the development of acquired intellectual property and,
through November 2013, our Impracor clinical program, including costs for our contract research organization. Also included are
personnel costs, including wages and stock-based compensation, other costs related to the clinical development of our assets and,
through November 2013, contract manufacturing, consulting and other costs related to the Impracor clinical program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
table below provides information regarding research and development expenses.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">For the year ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Variance</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 55%; text-align: left; padding-bottom: 2.5pt"><P STYLE="margin-top: 0; margin-bottom: 0"></P><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
                                         and development</B></FONT></P> <P STYLE="margin-top: 0; margin-bottom: 0"></P></TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 2.5pt double; text-align: right">236,660</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 2.5pt double; text-align: right">1,616,082</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">($</TD><TD STYLE="width: 11%; padding-bottom: 2.5pt; text-align: right">1,379,422</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
the year ended December 31, 2014, there was a decrease of $1,379,422 in research and development expenses as compared to the prior
year. The decrease was primarily related to the termination of our Impracor clinical program in November 2013, which represented
substantially all of our research and development expenses incurred in 2013. Research and development expenses in 2014 are related
to patent and other development expenses associated with our other intellectual property assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Interest
Income and Expense</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Interest
income was $32,446 and $43,755 for the years ended December 31, 2014 and 2013, respectively. The decrease was primarily due to
a higher average cash balance during fiscal year 2013 as compared fiscal year 2014. Interest expense was $3,800 for the year ended
December 31, 2014, compared to $0 for the prior year. The increase is due to interest expense recognition related to capital leases
entered into during fiscal year 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Net
Loss </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
loss for the year ended December 31, 2014 was $(10,118,103), or $(1.11) basic and diluted net loss per share, compared to a net
loss for the prior year of $(7,643,124), or $(0.88) basic and diluted net loss per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
cash on hand at December 31, 2014 was $8,211,492, as compared to $15,579,309 at December 31, 2013. The decrease in cash on hand
is primarily attributable to use of cash to support our operations and acquire Pharmacy Creations. Since inception through December
31, 2014, we have incurred aggregate losses to common stockholders of $(41,865,495). These losses are primarily due to selling,
general and administrative and research and development expenses incurred in connection with developing and seeking regulatory
approval for our former drug candidate, Impracor, which activities have been discontinued. Historically, our operations have been
financed through capital contributions and debt and equity financings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Net
Cash Flow</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table provides detailed information about our net cash flow for the years ended December 31, 2014 and 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Cash Flow</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">For the</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2013</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-left: 0pt">Net cash used in operating activities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">(7,055,428</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">(4,438,944</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Net cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(910,527</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(70,003</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">598,138</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,052,641</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt">Net change in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,367,817</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,543,694</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Cash and cash equivalents at beginning of the year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15,579,309</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,035,615</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Cash and cash equivalents at end of the year</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">8,211,492</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">15,579,309</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Operating
Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
cash used in operating activities was $(7,055,428) during the year ended December 31, 2014, as compared to $(4,438,944) used in
operating activities during the prior year. The increase in net cash used in operating activities was mainly due to our commencement
of our pharmacy operations and our expansion of our operations generally, including hiring additional personnel, commercialization
and marketing activities related to our ophthalmic formulations, prescription fulfillment activities and other related undertakings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Investing
Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
cash used in investing activities for the years ended December 31, 2014 and 2013 was $(910,527) and $(70,003), respectively. The
increase in cash used in investing activities during the year ended December 31, 2014 was primarily related to our acquisition
of Pharmacy Creations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Financing
Activities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
cash provided by financing activities for the years ended December 31, 2014 and 2013 was $598,138 and $10,052,641, respectively.
The cash provided by financing activities during the year ended December 31, 2014 is primarily attributable to cash exercises
of stock options and warrants. The cash provided by financing activities during the year ended December 31, 2013 is primarily
attributable to aggregate proceeds received in February and March 2013 from our public offering of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Cash
Position and Sources of Capital</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of the date of this Annual Report, we believe that cash and cash equivalents and restricted investments of approximately $8.4
million at December 31, 2014, together with expected revenues and expenses, including our payment of $3,000,000 in cash upon our
acquisition of Park and other expenses incurred in 2015 to date, will be sufficient to sustain our planned level of operations
for at least the next 12 months. However, our plans for this period may change, our estimates of our operating expenses and working
capital requirements could be inaccurate, we may pursue acquisitions of pharmacies or other strategic transactions that involve
one-time expenditures or we may experience growth more quickly or on a larger scale than we expect, any of which may result in
the depletion of capital resources more rapidly than anticipated and could require us to seek additional financing earlier than
we expect to support our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
expect to use our current cash position to pursue our business plan, including the development and commercialization of our current
compounded formulations and technologies and the integration and expansion of our pharmacy operations, to pursue potential future
strategic transactions, including the construction of an outsourcing facility and potential pharmacy and outsourcing facilities
acquisitions, and to otherwise fund our operations. We expect additional funds would be required if we pursue the acquisition
of additional compounding pharmacies or outsourcing facilities, conduct any clinical trials or any other studies that may be required
to obtain FDA regulatory approval to market any potential product candidates, pursue additional development programs or explore
other development opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
could seek additional financing from a variety of sources, including equity or debt financing, funding from a corporate partnership
or licensing arrangement, sales of assets or any other financing transaction. If we issue equity or convertible debt securities
to raise additional funds, our existing stockholders may experience substantial dilution, and the newly issued equity or debt
securities may have more favorable terms or rights, preferences and privileges senior to those of our existing stockholders. If
we raise additional funds through collaboration or licensing arrangements or sales of assets, we may be required to relinquish
potentially valuable rights to our product candidates or proprietary technologies or formulations, or grant licenses on terms
that are not favorable to us. If we raise funds by incurring debt, we may be required to pay significant interest expenses and
our leverage relative to our earnings or to our equity capitalization may increase. Obtaining commercial loans, assuming they
would be available, would increase our liabilities and future cash commitments and may impose restrictions on our activities,
such as financial or operational covenants with which we must comply. Further, we may incur substantial costs in pursuing future
capital and/or financing transactions, including investment banking fees, legal fees, accounting fees, printing and distribution
expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we may
issue, such as convertible notes and warrants, which would adversely impact our financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
may be unable to obtain financing when necessary as a result of, among other things, general economic conditions and conditions
in the pharmaceuticals and pharmacy industries or as a result of our operating history, including our past bankruptcy proceedings.
In addition, the fact that we are not and have never been profitable could further impact the availability or cost to us of future
financings. As a result, sufficient funds may not be available when needed from any source or, if available, such funds may not
be available on terms that are acceptable to us. If we are unable to raise funds to satisfy our capital needs on a timely basis,
then we may be forced to forego pursuit of potentially valuable development or acquisition opportunities, we may not be able to
pursue any or all elements of our business plan and we may be required to cease operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Critical
Accounting Policies </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
rely on the use of estimates and make assumptions that impact our financial condition and results. These estimates and assumptions
are based on historical results and trends as well as our forecasts as to how results and trends might change in the future. Although
we believe that the estimates we use are reasonable, actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
believe that the accounting policies described below are critical to understanding our business, results of operations and financial
condition because they involve the use of more significant judgments and estimates in the preparation of our consolidated financial
statements. An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions
about matters that are highly uncertain at the time the estimate is made, and any changes in the different assumptions that could
have been used in making the accounting estimates that are reasonably likely to occur could materially impact our consolidated
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Revenue
Recognition </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
recognize revenues when all of the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery
has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. We began generating
revenues upon the acquisition of Pharmacy Creations in the second quarter of 2014, which include sales of certain of our proprietary
compounded drug formulations and certain non-proprietary products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Product
Revenues </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Determination
of criteria (3) and (4) is based on management&rsquo;s judgments regarding the fixed nature of the selling prices of the products
delivered and the collectability of those amounts. Estimated returns and allowances and other adjustments are provided for in
the same period during which the related sales are recorded. We will defer any revenues received for a product that has not been
delivered or is subject to refund until such time that we and the customer jointly determine that the product has been delivered
and no refund will be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>License
Revenues </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">License
arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive
license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These
arrangements can be multiple element arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-refundable
fees that are not contingent on any future performance by us and require no consequential continuing involvement on our part are
recognized as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other
deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded
drug preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents
or patent applications for such compounded drug preparations. We defer recognition of non-refundable fees if we have continuing
performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable
fee has no utility to the licensee and that are separate and independent of our performance under the other elements of the arrangement.
In addition, if our continued involvement is required, through research and development services that are related to our proprietary
know-how and expertise of the delivered technology or can only be performed by us, then such non-refundable fees are deferred
and recognized over the period of continuing involvement. Guaranteed minimum annual royalties are recognized on a straight-line
basis over the applicable term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Stock-Based
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units
and restricted stock, are recognized in the consolidated financial statements based upon their estimated fair values. We use the
Black-Scholes-Merton option pricing model and Monte Carlo Simulation to estimate the fair value of stock-based awards. Fair value
is determined at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised,
if necessary, if the actual effect differs from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the Financial
Accounting Standards Board (FASB) guidance. As such, the value of the applicable stock-based compensation is periodically remeasured
and income or expense is recognized during the vesting term of the equity instrument. The measurement date for the fair value
of the equity instruments issued is the earlier of (i) the date at which a commitment for performance by the consultant or vendor
is reached or (ii) the date at which the consultant or vendor&rsquo;s performance is complete. In the case of equity instruments
issued to consultants, the fair value of the equity instrument is primarily recognized over the term of the consulting agreement.
In accordance with FASB guidance, an asset acquired in exchange for the issuance of fully vested, nonforfeitable equity instruments
should not be presented or classified as an offset to equity on the grantor&rsquo;s balance sheet once the equity instrument is
granted for accounting purposes. Accordingly, we record the fair value of nonforfeitable equity instruments issued for future
consulting services as prepaid stock-based consulting expenses in our consolidated balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
part of the process of preparing our consolidated financial statements, we must estimate our actual current tax liabilities and
assess temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result
in deferred tax assets and liabilities, which are included within the balance sheet. We must assess the likelihood that the deferred
tax assets will be recovered from future taxable income and, to the extent we believe that recovery is not likely, a valuation
allowance must be established. To the extent we establish a valuation allowance or increase or decrease this allowance in a period,
the impact will be included in income tax expense in the statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Research
and Development</I> </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
expense all costs related to research and development as they are incurred. Research and development expenses consist of expenses
incurred in performing research and development activities, including salaries and benefits, other overhead expenses, and costs
related to clinical trials, contract services and outsourced contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Intellectual
Property </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and
milestone payments, are charged to research and development expense as incurred in situations where we have not identified an
alternative future use for the acquired rights, and are capitalized in situations where we have identified an alternative future
use for the acquired rights. No costs associated with acquiring intellectual property rights have been capitalized to date, although
we may begin to capitalize certain costs associated with intellectual property rights beginning in the fiscal year 2015. Costs
of maintaining intellectual property rights are expensed as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Impairment
of Long-Lived Assets </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Long-lived
assets, such as furniture and equipment and purchased intangibles subject to amortization, are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows
expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment
charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be
disposed would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or fair
value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale
would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Business
Combinations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
account for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent
consideration at their fair values on the acquisition date. The purchase price allocation process requires management to make
significant estimates and assumptions at the acquisition date, especially with respect to intangible assets, estimated contingent
consideration payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the intangible
assets we have acquired or may acquire in the future include but are not limited to:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT>&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">future
                                         expected cash flows from product sales, support agreements, consulting contracts, other
                                         customer contracts, and acquired developed technologies and patents; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">discount
                                         rates utilized in valuation estimates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unanticipated
events and circumstances may occur that may affect the accuracy or validity of such assumptions, and estimates compared to actual
results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition
date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other
targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related
contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have
a material effect on the consolidated statements of operations, financial position and cash flows in the period of the change
in the estimate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Goodwill
and Intangible Assets </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
review our goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event or a
change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes in circumstances
considered as impairment indicators include but are not limited to the following:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 92%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">significant
    underperformance of our business relative to expected operating results; </FONT></td></tr>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 92%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">significant
    adverse economic and industry trends; </FONT></td></tr>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 92%; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">significant
    decline in our market capitalization for an extended period of time relative to net book value; and </FONT></td></tr>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="vertical-align: top; width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
    <TD STYLE="vertical-align: top; width: 92%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">expectations
    that a reporting unit will be sold or otherwise disposed. </FONT></td></tr>
</table>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
goodwill impairment test consists of a two-step process as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Step
1. </I>We compare the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair value
of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying value of each reporting unit
is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount,
relative revenues, or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its
fair value, an indication exists that the reporting unit&rsquo;s goodwill may be impaired and we then perform the second step
of the impairment test. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Step
2. </I>If further analysis is required, we compare the implied fair value of the reporting unit&rsquo;s goodwill, determined by
allocating the reporting unit&rsquo;s fair value to all of its assets and its liabilities in a manner similar to a purchase price
allocation, to its carrying amount. If the carrying amount of the reporting unit&rsquo;s goodwill exceeds its fair value, an impairment
loss will be recognized in an amount equal to the excess.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Recently
Adopted and Recently Issued Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See
Note 2 to our consolidated financial statements included in this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Since
our inception, except for standard operating leases, we have not engaged in any off-balance sheet arrangements, including the
use of structured finance, special purpose entities or variable interest entities. We have no off-balance sheet arrangements that
have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><A NAME="a_012"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><A NAME="a_013"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
financial statements and supplementary data required by this item are included in this Annual Report beginning on page F-1 immediately
following the signature page hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_014"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
9.</B> <B>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_015"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
9A. CONTROLS AND PROCEDURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Disclosure
Controls and Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer
(CEO), our principal executive officer, and our Chief Financial Officer (CFO), our principal financial and accounting officer,
of the effectiveness of our disclosure controls and procedures as of December 31, 2014, the end of the period covered by this
Annual Report, pursuant to Rules 13a-15(b) and 15d-15(b) under the Securities Exchange Act of 1934, as amended (Exchange Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with that evaluation, our CEO and CFO concluded that, as of December 31, 2014, our disclosure controls and procedures
were effective. For the purpose of this review, disclosure controls and procedures means controls and procedures designed to ensure
that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in the Securities and Exchange Commission&rsquo;s rules and forms. These
disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required
to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to management,
including our principal executive officer, principal financial officer and principal accounting officer, as appropriate to allow
timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management
recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of
achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the
cost-benefit relationship of possible controls and procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Management&rsquo;s
Annual Report on Internal Control over Financial Reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a process designed by, or under the
supervision of, our CEO and CFO and effected by our board of directors, management and other personnel, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles. Our management, under the supervision and with the participation of
our CEO and CFO, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework
in <I>Internal Control &mdash; Integrated Framework (2013)</I> issued by the Committee of Sponsoring Organizations (COSO). Based
on such evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control
over financial reporting. Management&rsquo;s report was not subject to attestation requirements by our independent registered
public accounting firm pursuant to rules of the Securities and Exchange Commission that permit us to provide only management&rsquo;s
report in this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Changes
in Internal Control over Financial Reporting </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
has been no change in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during
our quarter ended December 31, 2014, that has materially affected, or is reasonably likely to materially affect our internal control
over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Inherent
Limitations on Effectiveness of Controls</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
management, including our CEO and CFO, do not expect that our disclosure controls or our internal control over financial reporting
will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable,
not absolute, assurance that the control system&rsquo;s objectives will be met. The design of a control system must reflect the
fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because
of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements
due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent
limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple
error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people,
or by management override of the controls. The design of any system of controls is based in part on certain assumptions about
the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under
all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks.
Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies
or procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_016"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
9B. OTHER INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">None.</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_017"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_018"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
10.</B> <B>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Except
for the information regarding the Company&rsquo;s Code of Business Conduct and Ethics included below, the information required
by this item is incorporated by reference to information contained in the Proxy Statement or an amendment to this Annual Report,
in either case to be filed with the Securities and Exchange Commission on or before the 120<SUP>th</SUP> day after the end of
the fiscal year covered by this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Code
of Business Conduct and Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
board of directors has adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers and employees.
The Code of Business Conduct and Ethics is available for review on our website at www.imprimispharma.com, and is also available
in print, without charge, to any stockholder who requests a copy by writing to us at Imprimis Pharmaceuticals, Inc., 12264 El
Camino Real, Suite 350, San Diego, CA 92130, Attention: Investor Relations. Each of our directors, employees and officers, including
our CEO and CFO and all of our other executive officers, are required to comply with the Code of Business Conduct and Ethics.
There have not been any waivers of the Code of Business Conduct and Ethics relating to any of our executive officers or directors
in the past year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_019"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
11. EXECUTIVE COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
information required by this item is incorporated by reference to information contained in the Proxy Statement or an amendment
to this Annual Report, in either case to be filed with the Securities and Exchange Commission on or before the 120<SUP>th</SUP>
day after the end of the fiscal year covered by this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_020"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
information required by this item is incorporated by reference to information contained in the Proxy Statement or an amendment
to this Annual Report, in either case to be filed with the Securities and Exchange Commission on or before the 120<SUP>th</SUP>
day after the end of the fiscal year covered by this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_021"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
information required by this item is incorporated by reference to information contained in the Proxy Statement or an amendment
to this Annual Report, in either case to be filed with the Securities and Exchange Commission on or before the 120<SUP>th</SUP>
day after the end of the fiscal year covered by this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_022"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
14. PRINCIPAL ACCOUNTANT FEES AND SERVICES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
information required by this item is incorporated by reference to information contained in the Proxy Statement or an amendment
to this Annual Report, in either case to be filed with the Securities and Exchange Commission on or before the 120<SUP>th</SUP>
day after the end of the fiscal year covered by this Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_023"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
IV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_024"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM
15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</B></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font: 10pt/115% Calibri, Helvetica, Sans-Serif">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 10pt/115% Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">List
    of the following documents filed as part of the report:</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See the index to
    our consolidated financial statements on page F-1 for a list of the financial statements being filed in this Annual Report.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All financial statement
    schedules are omitted because they are not applicable or the required information is shown in the consolidated financial statements
    or the notes thereto.</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="line-height: 115%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">See Item 15(b) below
    for all exhibits being filed or incorporated by reference herein.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 0.25in; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Exhibits:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0.5in">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0.5in">The Exhibit Index attached to this Annual Report is incorporated
by reference herein.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_025"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">IMPRIMIS
    PHARMACEUTICALS, INC. </FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 45%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: white 3pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="border-bottom: white 3pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></td>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Mark L. Baum</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name:</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Mark L. Baum</td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title:</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer (Principal Executive Officer)</td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 12, 2015</FONT></td></tr>
</table>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>POWER
OF ATTORNEY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mark L. Baum and Andrew
R. Boll, and each of them individually, as his true and lawful attorneys-in-fact and agents with full power of substitution and
resubstitution, for him and in his name, place and stead, in any and all capacities to any or all amendments to this Annual Report,
and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange
Commission, granting unto said attorneys-in-fact and agents or any of them the full power and authority to do and perform each
and every act and thing requisite and necessary to be done in and about the foregoing, as full to all intents and purposes as
he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or
his substitutes, may lawfully do or cause to be done by virtue thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 38%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Signature</B></FONT></td>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 40%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Title</B></FONT></td>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 18%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Andrew R. Boll </I></FONT></td>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
    Financial Officer</FONT></td>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March
    12, 2015</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Andrew
    R. Boll</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>(Principal
    Accounting and Financial Officer)</I></FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Mark L. Baum </I></FONT></td>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer and Director</FONT></td>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March
    12, 2015</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mark
    L. Baum</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(<I>Principal
    Executive Officer</I>)</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Robert J. Kammer </I></FONT></td>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman
    of the Board of Directors</FONT></td>
    <TD STYLE="vertical-align: top; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March
    12, 2015</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert
    J. Kammer </FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
                                         William H. Nelson </I></FONT></P></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March
    12, 2015</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">William
    H. Nelson </FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
                                         Stephen G. Austin </I></FONT></P></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March
    12, 2015</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stephen
    G. Austin</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
                                         Richard L. Lindstrom</I></FONT></P></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March
    12, 2015</FONT></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Richard
    L. Lindstrom</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
</table>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->






<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Imprimis Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Index to Consolidated
Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 92%; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_026"><FONT STYLE="font-size: 10pt">Report of
    Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_027"><FONT STYLE="font-size: 10pt">Consolidated Balance Sheets
    at December 31, 2014 and 2013</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_028"><FONT STYLE="font-size: 10pt">Consolidated Statements
    of Operations for the Years Ended December 31, 2014 and 2013</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_029"><FONT STYLE="font-size: 10pt">Consolidated Statements
    of Stockholders&rsquo; Equity for the Years Ended December 31, 2014 and 2013</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_030"><FONT STYLE="font-size: 10pt">Consolidated Statements
    of Cash Flows for the Years Ended December 31, 2014 and 2013</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_031"><FONT STYLE="font-size: 10pt">Notes to the Consolidated
    Financial Statements</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt">F-7</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 38; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_026"></A><B>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To the Board of Directors and Stockholders of<BR>
Imprimis Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of Imprimis Pharmaceuticals, Inc. and subsidiary (the &ldquo;Company&rdquo;) as of December&nbsp;31, 2014 and 2013,
and the related consolidated statements of operations, stockholders&rsquo; equity and cash flows for each of the two years in
the period ended December&nbsp;31, 2014. These consolidated financial statements are the responsibility of the Company&rsquo;s
management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with
the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform
the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.
The Company is not required to have, nor were we engaged to perform, an audit on its internal control over financial reporting.
Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that
are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In our opinion, the consolidated financial
statements referred to above present fairly, in all material respects, the consolidated financial position of Imprimis Pharmaceuticals,
Inc. and subsidiary as of December&nbsp;31, 2014 and 2013, and the consolidated results of their operations and their cash flows
for each of the two years in the period ended December&nbsp;31, 2014, in conformity with accounting principles generally accepted
in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><I>/s/
    KMJ Corbin &amp; Company LLP</I></FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Costa Mesa, California</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">March 12, 2015</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_027"></A><B>IMPRIMIS
PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CONSOLIDATED BALANCE
SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="text-align: center; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">December 31, 2014</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">December 31,&nbsp;2013</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; vertical-align: bottom">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">8,211,492</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">15,579,309</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Restricted short-term investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,264</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,097</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81,322</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">372,735</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1.5pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">240,401</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">105,067</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,056,214</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,734,473</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Intangible assets, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">610,994</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">331,621</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Furniture and equipment, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">243,395</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">26,892</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 2.5pt">TOTAL ASSETS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">10,242,224</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">15,761,365</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; vertical-align: bottom">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">786,675</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">311,924</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued payroll and related liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">716,332</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">338,703</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Customer deposits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,683</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Current portion of contingent acquisition obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,466</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1.5pt">Current portion of capital lease obligations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">24,112</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,560,268</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">650,627</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Capital lease obligations, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,968</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued expenses, net of current portion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,658</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Contingent acquisition obligations</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">483,156</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 1.5pt">TOTAL LIABILITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">2,092,050</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">650,627</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Commitments and contingencies</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Common stock, $0.001 par value, 90,000,000 shares authorized, 9,258,231 and
    8,970,364 shares issued and outstanding at December 31, 2014 and 2013, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,258</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,970</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,006,411</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,849,160</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(41,865,495</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(31,747,392</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 1.5pt">TOTAL STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">8,150,174</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">15,110,738</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 2.5pt">TOTAL LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">10,242,224</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">15,761,365</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part
of these consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_028"></A><B>IMPRIMIS
PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CONSOLIDATED STATEMENTS
OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">For the</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">For the</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Year Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Year Ended</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2014</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2013</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-left: 10pt">Sales, net</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">1,652,386</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1.5pt">License revenues</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">7,860</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">10,000</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,660,246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt">Cost of sales</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(1,092,839</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">567,407</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Selling and marketing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,390,180</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85,890</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,087,316</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,994,907</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1.5pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">236,660</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">1,616,082</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">10,714,156</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">7,696,879</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,146,749</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,686,879</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,800</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; padding-bottom: 1.5pt">Interest income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">32,446</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">43,755</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total other income, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">28,646</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">43,755</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(10,118,103</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(7,643,124</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Basic and diluted net loss per share of common stock</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(1.11</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(0.88</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Weighted average number of shares of common stock outstanding, basic and
    diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">9,132,989</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">8,656,822</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">The accompanying notes
are an integral part of these consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_029"></A><B>IMPRIMIS
PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CONSOLIDATED STATEMENTS
OF STOCKHOLDERS&rsquo; EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>For the years ended
December 31, 2014 and 2013</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 1.5pt">Additional</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 1.5pt">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Par</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Paid-in</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Accumulated</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Stockholders&rsquo;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Capital</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%">Balance at December 31, 2012</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,772,066</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,772</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">34,093,933</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(24,104,268</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">9,996,437</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cancelled common stock at $5.25 per share related to reverse stock split, February 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(35</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(191</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(191</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Public Offering of common stock at $5.25 per share, net of costs, in February and March 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,116,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,116</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,454,435</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,456,551</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Exercise of stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of common stock related to consulting agreements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">282,957</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">282,997</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,114</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,018,066</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,018,068</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Issuance of common stock upon vesting of RSUs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(40</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(7,643,124</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(7,643,124</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Balance at December 31, 2013</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,970,364</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,970</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,849,160</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(31,747,392</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15,110,738</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Exercise of stock options, net of tax withholding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">227,216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">227</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">583,584</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">583,811</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of common stock upon vesting of RSUs, net of tax withholding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,954</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,111</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,109</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Exercise of warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,829</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,819</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,867</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance of common stock related to consulting agreements</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,156</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,160</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,469,810</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,469,810</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Common stock issued in settlement of contract dispute</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,868</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,993</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(10,118,103</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(10,118,103</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Balance at December 31, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">9,258,231</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">9,258</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">50,006,411</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(41,865,495</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">8,150,174</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">The accompanying notes
are an integral part of these consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_030"></A><B>IMPRIMIS PHARMACEUTICALS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">For the</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">For the</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Year Ended</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Year Ended</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2014</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2013</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-left: 10pt">Net loss</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(10,118,103</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(7,643,124</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Depreciation and amortization of furniture and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,343</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,659</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Amortization of intangible assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,006</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Stock-based compensation and payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,614,619</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,134,973</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Changes in assets and liabilities, net of effects from acquisitions:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22,902</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt">Inventories</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(159,545</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(131,727</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16,964</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">345,360</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(239,800</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Accrued payroll and related liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">342,154</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">320,312</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 1.5pt">Customer deposits</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(10,633</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">NET CASH USED IN OPERATING ACTIVITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(7,055,428</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(4,438,944</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Purchase of restricted short-term investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(100,167</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Purchase of Pharmacy Creations, LLC, net of cash and advances</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(636,374</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 1.5pt">Purchases of furniture and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(173,986</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(20,003</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">NET CASH USED IN INVESTING ACTIVITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(910,527</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(70,003</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Cancelled common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,109</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(191</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Payments on capital lease obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,431</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Net proceeds from exercise of warrants and stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">621,678</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 1.5pt">Proceeds from issuance of common stock and warrants
    for cash, net of offering costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">10,052,832</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">NET CASH PROVIDED BY FINANCING ACTIVITIES</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">598,138</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">10,052,641</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">NET CHANGE IN CASH AND CASH EQUIVALENTS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(7,367,817</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,543,694</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 1.5pt">CASH AND CASH EQUIVALENTS, beginning of period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">15,579,309</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">10,035,615</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt; padding-bottom: 2.5pt">CASH AND CASH EQUIVALENTS, end of period</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">8,211,492</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">15,579,309</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Cash paid for income taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Cash paid for interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Issuance of and adjustment to common stock and warrants to consulting firms
    for prepaid consulting fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">319,786</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Reclassification of deferred offering costs in connection with equity offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">596,281</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Issuance of common stock for consulting services included in accounts payable
    and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">139,444</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Purchase of furniture and equipment with a capital lease</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">35,350</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying notes are an integral part
of these consolidated financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_031"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>IMPRIMIS
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For
the years ended December 31, 2014 and 2013</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: justify; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
1. ORGANIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: justify; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Imprimis
Pharmaceuticals, Inc. (together with its subsidiaries, unless the context indicates or otherwise requires, the &ldquo;Company&rdquo;
or &ldquo;Imprimis&rdquo;) is a pharmaceutical company focused on developing and commercializing innovative and high quality proprietary
compounded drug therapies and making these therapies available to physicians and patients at accessible prices. The Company owns,
markets and sells a portfolio of proprietary combination formulations in ophthalmology and urology that it believes may offer
competitive advantages and serve unmet needs in the marketplace. The Company&rsquo;s ophthalmology formulation portfolio, led
by its Dropless Therapy&trade; and LessDrops&trade; formulations, serves the multi-billion dollar eye drop market and is designed
to address patient compliance issues and provide other medical and economic benefits to physicians and patients. The Company recently
launched its urology business, headed by its Defeat IC&trade; campaign, which currently includes a patented compounded formulation
for patients suffering from interstitial cystitis. The Company is also developing additional complementary proprietary compounded
formulations to add to its ophthalmology and urology formulation portfolios. The Company makes, dispenses and sells its proprietary
compounded formulations, as well as other non-proprietary products, through its wholly owned compounding pharmacies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
April 1, 2014, the Company acquired Pharmacy Creations, LLC (&ldquo;PC&rdquo;), a New Jersey based compounding pharmacy and on
January 1, 2015, the Company acquired South Coast Specialty Compounding, Inc. D/B/A Park Compounding (&ldquo;Park&rdquo;), a California
based compounding pharmacy (see Note 16). Effective with the acquisition of PC, the Company commenced sales and marketing efforts
for Imprimis&rsquo; portfolio of proprietary and non-proprietary compounded drug formulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Basis
of Presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
February 28, 2012, the Company effected a one-for-eight reverse stock split and on February 7, 2013, the Company effected a one-for-five
reverse stock split. All share and per share amounts in these consolidated financial statements and notes reflect the effects
of these reverse stock splits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Imprimis
has prepared the accompanying consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America (&ldquo;GAAP&rdquo;). The accompanying consolidated financial statements include the accounts of
the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Business
Combinations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company accounts for business combinations by recognizing the assets acquired, liabilities assumed, contractual contingencies,
and contingent consideration at their fair values on the acquisition date. The purchase price allocation process requires management
to make significant estimates and assumptions at the acquisition date, especially with respect to intangible assets, estimated
contingent consideration payments and pre-acquisition contingencies. Examples of critical estimates in valuing certain of the
intangible assets the Company has acquired or may acquire in the future include but are not limited to:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">future
    expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed
    technologies and patents; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">discount
    rates utilized in valuation estimates.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unanticipated
events and circumstances may occur that may affect the accuracy or validity of such assumptions, and estimates compared to actual
results. Additionally, any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition
date, including changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other
targets, will be recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related
contingent consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have
a material effect on the consolidated financial position, statements of operations, or cash flows in the period of the change
in the estimate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Options: NewSection; Value: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company expenses all costs related to research and development as they are incurred. Research and development expenses consist
of expenses incurred in performing research and development activities, including salaries and benefits, other overhead expenses,
and costs related to clinical trials, contract services and outsourced contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Intellectual
Property</B><I> </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
costs of acquiring intellectual property rights to be used in the research and development process, including licensing fees and
milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified
an alternative future use for the acquired rights, and are capitalized in situations where the Company has identified an alternative
future use for the acquired rights. No costs associated with acquiring intellectual property rights have been capitalized to date,
although the Company may begin to capitalize certain costs associated with intellectual property rights beginning in the fiscal
year 2015. Costs of maintaining intellectual property rights are expensed as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Revenue
Recognition and Deferred Revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company recognizes revenues when all of the following criteria have been met: (1) persuasive evidence of an arrangement exists;
(2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. The
Company began generating revenues upon the acquisition of PC in the second quarter of 2014, which include sales of certain of
the Company&rsquo;s proprietary compounded drug formulations and certain non-proprietary formulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Product
Revenues</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Determination
of criteria (3) and (4) is based on management&rsquo;s judgments regarding the fixed nature of the selling prices of the products
delivered and the collectability of those amounts. Estimated returns and allowances and other adjustments are provided for in
the same period during which the related sales are recorded. The Company will defer any revenue received for a product that has
not been delivered or is subject to refund until such time that the Company and the customer jointly determine that the product
has been delivered and no refund will be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>License
Revenues</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">License
arrangements may consist of non-refundable upfront license fees, data transfer fees, research reimbursement payments, exclusive
license rights to patented or patent pending compounds, technology access fees, and various performance or sales milestones. These
arrangements can be multiple element arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-refundable
fees that are not contingent on any future performance by the Company and require no consequential continuing involvement on the
part of the Company, are recognized as revenue when the license term commences and the licensed data, technology, compounded drug
preparation and/or other deliverable is delivered. Such deliverables may include physical quantities of compounded drug preparations,
design of the compounded drug preparations and structure-activity relationships, the conceptual framework and mechanism of action,
and rights to the patents or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable
fees if it has continuing performance obligations without which the technology, right, product or service conveyed in conjunction
with the non-refundable fee has no utility to the licensee and that are separate and independent of the Company&rsquo;s performance
under the other elements of the arrangement. In addition, if the Company&rsquo;s continued involvement is required, through research
and development services that are related to its proprietary know-how and expertise of the delivered technology or can only be
performed by the Company, then such non-refundable fees are deferred and recognized over the period of continuing involvement.
Guaranteed minimum annual royalties are recognized on a straight-line basis over the applicable term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Cost
of Sales</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cost
of sales includes direct and indirect costs to manufacture formulations and other products sold, including active pharmaceutical
ingredients, personnel costs, packaging, storage, royalties (see Note 14), shipping and handling costs and the write-off of obsolete
inventory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Income
Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
part of the process of preparing the Company&rsquo;s consolidated financial statements, the Company must estimate the actual current
tax liabilities and assess temporary differences resulting from differing treatment of items for tax and accounting purposes.
These differences result in deferred tax assets and liabilities, which are included within the balance sheet. The Company must
assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company
believes that recovery is not likely, a valuation allowance must be established. To the extent the Company establishes a valuation
allowance or increase or decrease this allowance in a period, the impact will be included in income tax expense in the statement
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company accounts for income taxes under the provisions of Financial Accounting Standards Board (&ldquo;FASB&rdquo;) Accounting
Standards Codification (&ldquo;ASC&rdquo;) 740, &ldquo;Income Taxes&rdquo;, or ASC 740. As of December 31, 2014, there were no
unrecognized tax benefits included in the consolidated balance sheet that would, if recognized, affect the effective tax rate.
The Company&rsquo;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The
Company had no accrual for interest or penalties in its consolidated balance sheets at December 31, 2014 and 2013, and has not
recognized interest and/or penalties in the consolidated statements of operations for the years ended December 31, 2014 and 2013.
The Company is subject to taxation in the United States and California. The Company&rsquo;s tax years since 2000 are subject to
examination by the federal and state tax authorities due to the carryforward of unutilized net operating losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Cash
and Cash Equivalents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cash
equivalents include short-term, highly liquid investments with maturities of three months or less at the time of acquisition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Concentrations
of Credit Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company places its cash with financial institutions deemed by management to be of high credit quality. The Federal Deposit Insurance
Corporation (&ldquo;FDIC&rdquo;) provides basic deposit coverage with limits up to $250,000 per owner. At December 31, 2014, the
Company had approximately $7.7 million in cash deposits in excess of FDIC limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Accounts
Receivable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
balance in accounts receivable consists of revenue amounts the Company has invoiced and recognized, but for which payment has
not been received. Accounts receivable are presented net of an allowance for doubtful accounts in the amount of $3,957 as of December
31, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Inventories</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Inventories
are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying
value of inventories on a regular basis, based on the price expected to be obtained for products in their respective markets compared
with historical cost. Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company also regularly evaluates its inventories for excess quantities and obsolescence (expiration), taking into account such
factors as historical and anticipated future sales or use in production compared to quantities on hand and the remaining shelf
life of products and active pharmaceutical ingredients on hand. The Company establishes reserves for excess and obsolete inventories
as required based on its analyses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Furniture
and Equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Furniture
and equipment is stated at cost less accumulated depreciation and amortization. Depreciation and amortization is calculated using
the straight-line method over the estimated useful life of the asset. Leasehold improvements and capital lease equipment are amortized
over the estimated useful life or remaining lease term, whichever is shorter. Computer software and hardware and furniture and
equipment are depreciated over three to five years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Goodwill
and Intangible Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company reviews its goodwill and indefinite-lived intangible assets for impairment as of January 1 of each year and when an event
or a change in circumstances indicates the fair value of a reporting unit may be below its carrying amount. Events or changes
in circumstances considered as impairment indicators include but are not limited to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">significant
    underperformance of the Company&rsquo;s business relative to expected operating results;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">significant
    adverse economic and industry trends;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">significant
    decline in the Company&rsquo;s market capitalization for an extended period of time relative to net book value; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">expectations
    that a reporting unit will be sold or otherwise disposed. </FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
goodwill impairment test consists of a two-step process as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Step
1. The Company compares the fair value of each reporting unit to its carrying amount, including the existing goodwill. The fair
value of each reporting unit is determined using a discounted cash flow valuation analysis. The carrying value of each reporting
unit is determined by specifically identifying and allocating the assets and liabilities to each reporting unit based on headcount,
relative revenues, or other methods as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its
fair value, an indication exists that the reporting unit&rsquo;s goodwill may be impaired and the Company then performs the second
step of the impairment test. If the fair value of a reporting unit exceeds its carrying amount, no further analysis is required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Step
2. If further analysis is required, the Company compares the implied fair value of the reporting unit&rsquo;s goodwill, determined
by allocating the reporting unit&rsquo;s fair value to all of its assets and its liabilities in a manner similar to a purchase
price allocation, to its carrying amount. If the carrying amount of the reporting unit&rsquo;s goodwill exceeds its fair value,
an impairment loss will be recognized in an amount equal to the excess.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Impairment
of Long-Lived Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Long-lived
assets, such as furniture and equipment and purchased intangibles subject to amortization, are reviewed for impairment whenever
events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets
to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows
expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment
charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be
disposed of would be separately presented in the consolidated balance sheet and reported at the lower of the carrying amount or
fair value less costs to sell, and are no longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale
would be presented separately in the appropriate asset and liability sections of the consolidated balance sheet, if material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the years ended December 31, 2014 and 2013, the Company did not recognize any impairment of its long-lived assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Deferred
Rent </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company accounts for rent expense related to its operating leases by determining total minimum rent payments on the leases over
their respective periods and recognizing the rent expense on a straight-line basis. The difference between the actual amount paid
and the amount recorded as rent expense in each fiscal year and interim periods within each fiscal year is recorded as an adjustment
to deferred rent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Fair
Value Measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fair
value measurements are determined based on the assumptions that market participants would use in pricing an asset or liability.
GAAP establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes
the use of unobservable inputs by requiring that the most observable inputs be used when available. The established fair value
hierarchy prioritizes the use of inputs used in valuation methodologies into the following three levels:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level
    1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in
    active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure
    fair value whenever available.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level
    2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such
    as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are
    observable or can be corroborated by observable market data.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level
    3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity&rsquo;s
    own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level
    3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">At
December 31, 2014 and 2013, the Company did not have any financial assets or liabilities that are measured on a recurring basis.
At December 31, 2014 and 2013, the Company&rsquo;s financial instruments included cash and cash equivalents, restricted short-term
investments, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, customer deposits,
and capital leases. The carrying amount of these financial instruments, except for the restricted short-term investments and the
capital leases, approximates fair value due to the short-term maturities of these instruments. The Company&rsquo;s restricted
short-term investments are carried at amortized cost, which approximates fair value. Based on borrowing rates currently available
to the Company, the carrying values of the capital leases approximate their respective fair values.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
stock-based payments to employees, directors and consultants, including grants of stock options, warrants, restricted stock units
(&ldquo;RSUs&rdquo;) and restricted stock, are recognized in the consolidated financial statements based upon their fair values.
The Company uses the Black-Scholes-Merton option pricing model and Monte Carlo Simulation to estimate the fair value of stock-based
awards. The estimated fair value is determined at the date of grant. The financial statement effect of forfeitures is estimated
at the time of grant and revised, if necessary, if the actual effect differs from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company&rsquo;s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services
follows the Financial Accounting Standards Board (the &ldquo;FASB&rdquo;) guidance. As such, the value of the applicable stock-based
compensation is periodically remeasured and income or expense is recognized during the vesting terms of the equity instrument.
The measurement date for the estimated fair value of the equity instruments issued is the earlier of (i) the date at which a commitment
for performance by the consultant or vendor is reached or (ii) the date at which the consultant or vendor&rsquo;s performance
is complete. In the case of equity instruments issued to consultants, the estimated fair value of the equity instrument is primarily
recognized over the term of the consulting agreement. In accordance with FASB guidance, an asset acquired in exchange for the
issuance of fully vested, nonforfeitable equity instruments should not be presented or classified as an offset to equity on the
grantor&rsquo;s balance sheet once the equity instrument is granted for accounting purposes. Accordingly, the Company records
the estimated fair value of nonforfeitable equity instruments issued for future consulting services as prepaid expenses in its
consolidated balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Basic
and Diluted Net Loss per Common Share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Basic
net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted
average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss
attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such
as stock options and warrants, outstanding during the period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Basic
and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the
period. Common stock equivalents (using the treasury stock or, &ldquo;if converted&rdquo; method) from stock options, RSUs and
warrants were 3,024,217 and 3,539,800 at December 31, 2014 and 2013, respectively, and are excluded from the calculation of diluted
net loss per share for all periods presented because the effect is anti-dilutive. Common stock equivalents at December 31, 2014
include 27,218 shares of common stock underlying RSUs, awarded to directors that have vested, but the issuance and delivery of
these shares are deferred until the director resigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table shows the computation of basic and diluted net loss per share of common stock for the years ended December 31,
2014 and 2013:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">For the</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">For the</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Year Ended</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Year Ended</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2014</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2013</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-bottom: 2.5pt">Numerator &ndash; net loss</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="width: 18%; text-align: right; border-bottom: Black 2.5pt double">(10,118,103</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="width: 18%; text-align: right; border-bottom: Black 2.5pt double">(7,643,124</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Denominator &ndash; weighted average number of shares outstanding, basic
    and diluted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">9,132,989</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">8,656,822</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss per share, basic and diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(1.11</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(0.88</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Use
of Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the
reported amounts of assets, and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements
and reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management are, among
others, allowance for doubtful accounts, realizability of inventories, valuation of deferred taxes, goodwill and intangible assets,
recoverability of long-lived assets and goodwill, valuation of contingent acquisition obligations, and valuation of stock-based
compensation issued to employees and non-employees. Actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Reclassifications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certain
prior period items and amounts have been reclassified to conform to the classifications used to prepare the consolidated financial
statements for the year ended December 31, 2014. The Company has classified in these financial statements certain expenses as
selling and marketing, whereas in prior periods certain of these expenses were included in an expense line item titled selling,
general and administrative in the consolidated statements of operations. These reclassifications had no material impact on the
Company&rsquo;s financial position, results of operations, or cash flows as previously reported.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Recently
Adopted Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
June 2014, the FASB issued an Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2014-10, &ldquo;Elimination of Certain Financial
Reporting Requirements, Including an Amendment to Variable Interest Entities&rdquo;. The amendments in this update remove the
definition of a development stage entity from ASC Topic 915, &ldquo;Development Stage Entities&rdquo;, thereby removing from GAAP
the distinction between development stage entities and other reporting entities. In addition, the amendments eliminate the requirements
for development stage entities to (1) present inception-to-date information in the statements of operations, cash flows, and stockholder&rsquo;s
equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development
stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development
stage entity that in prior years it had been in the development stage. These amendments are effective for annual reporting periods
beginning after December 15, 2014, with early application of the amendments permitted. The Company&rsquo;s pharmacy operations
commenced on April 1, 2014. This change in the nature of the Company&rsquo;s operations included the recognition of operating
revenues; as a result, the Company is no longer defined as a development stage company for reporting dates beginning April 1,
2014. With the change in the Company&rsquo;s operations, its revenue recognition and its immediate adoption of ASU No. 2014-10,
the Company no longer presents or discloses any information required under ASC Topic 915.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Recently
Issued Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
August 2014, the FASB issued new accounting guidance which defines management&rsquo;s responsibility to assess an entity&rsquo;s
ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. This guidance will
be effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December
15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously
been issued. The Company is currently evaluating the new guidance and has not determined the impact this standard may have on
its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
May 2014, the FASB issued ASU No. 2014-09, &ldquo;Revenue from Contracts with Customers&rdquo; (&ldquo;ASU 2014-09&rdquo;). The
objective of ASU 2014-19 is to establish a single comprehensive model for entities to use in accounting for revenue arising from
contracts with customers and will supersede most of the existing revenue recognition guidance, including industry-specific guidance.
The core principle of ASU 2014-09 is that an entity recognizes revenue to depict the transfer of promised goods or services to
customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods
or services. In applying the new guidance, an entity will (1) identify the contract(s) with a customer; (2) identify the performance
obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the contract&rsquo;s performance
obligations; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 applies to all
contracts with customers except those that are within the scope of other topics in the FASB ASC. The new guidance is effective
for annual reporting periods, including interim periods within those periods, beginning after December 15, 2016 for public companies.
Early adoption is not permitted. The Company is currently evaluating the new guidance and has not determined the impact this standard
may have on its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
3. ACQUISITION &ndash; PHARMACY CREATIONS, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
April 1, 2014, the Company acquired all of the outstanding membership interests of PC (the &ldquo;PC Acquisition&rdquo;) from
J. Scott Karolchyk and Bernard Covalesky (the &ldquo;PC Sellers&rdquo;), such that PC became a wholly-owned subsidiary of the
Company. The acquisition of PC permits the Company to make and distribute its patent-pending proprietary drug formulations and
other pharmaceutical preparations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
transaction has been accounted for as a business combination and the financial results of PC have been included in the Company&rsquo;s
consolidated financial statements for the period subsequent to its acquisition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
estimated acquisition date fair value of consideration transferred, assets acquired and liabilities assumed for PC are presented
below and represent the Company&rsquo;s best estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Fair
Value of Consideration Transferred</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">At
the closing of the PC Acquisition, the Company paid to the PC Sellers an aggregate cash purchase price of $600,000. In addition,
the PC Sellers are entitled to receive additional contingent consideration upon the satisfaction of certain conditions, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
    contingent cash payment of $50,000, payable if PC earns revenues of over $3,500,000 for the 12 month period ending March 31,
    2015.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
    contingent stock payment of up to an aggregate of 215,190 shares of the Company&rsquo;s common stock, issuable only if the
    following revenue milestones are met:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    PC earns revenue of over $7,500,000 during the 12 month period ending March 31, 2016, all 215,190 shares;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">if
    PC earns revenue of between $3,500,000 and $7,500,000 during the 12 month period ending March 31, 2016, an aggregate of that
    number of shares of Imprimis common stock equal to the amount that such revenue exceeds $3,500,000 divided by 18.5882, rounded
    down to the lower whole number (not to exceed 215,190 shares).</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Although
management estimates that certain of the contingent consideration will be paid, it has applied a discount rate to the contingent
consideration amounts in determining fair value to represent the risk of these payments not being made. The total acquisition
date fair value of the consideration transferred and to be transferred is estimated at approximately $1.1 million, as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; text-align: left">Cash payment to the PC Sellers at closing</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">600,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Contingent common stock issuance to the PC Sellers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">483,156</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Contingent cash consideration to the PC Sellers</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">31,466</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total acquisition date fair value</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">1,114,622</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
$514,622 liability was recognized for the estimated acquisition date fair value of the future contingent common stock and cash
payments and is included in the contingent acquisition obligations in the accompanying consolidated balance sheet at December
31, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Allocation
of Consideration Transferred </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
identifiable assets acquired and liabilities assumed were recognized and measured as of the acquisition date based on their estimated
fair values as of April 1, 2014, the acquisition date. The excess of the acquisition date fair value of consideration transferred
over the estimated fair value of the net tangible assets and intangible assets acquired was recorded as goodwill.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the acquisition date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">4,982</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,420</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Prepaid expenses and other assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,256</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">213,190</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Property and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,510</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Intangible assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">659,000</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Total identifiable assets acquired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,010,358</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,049</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">107,308</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total liabilities assumed</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">227,357</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Total identifiable assets less liabilities assumed</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">783,001</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Goodwill</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">331,621</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net assets acquired</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">1,114,622</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
amount of revenues and operating loss of PC included in the Company&rsquo;s consolidated statement of operations from the acquisition
date through the period ended December 31, 2014 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; text-align: left; padding-bottom: 2.5pt">Total revenues</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="width: 18%; text-align: right; border-bottom: Black 2.5pt double">1,652,386</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Operating loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(662,969</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Pro
Forma Financial Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table presents the Company&rsquo;s unaudited pro forma results (including PC) for the years ended December 31, 2014
and 2013 as though the companies had been combined as of the beginning of each of the periods presented. The pro forma information
is presented for informational purposes only and is not indicative of the results of operations that would have been achieved
if the acquisition had taken place at the beginning of each period presented, nor is it indicative of results of operations which
may occur in the future. The unaudited pro forma results presented include amortization charges for intangible assets and eliminations
of intercompany transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For the</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For the</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Year Ended</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Year Ended</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December
    31, 2014</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December
    31, 2013</FONT></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total
    revenues</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 18%; text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,282,681</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 18%; text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,866,575</FONT></TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(10,048,380</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(7,084,014</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Company did not incur material
acquisition expenses related to the PC Acquisition.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Intangible
Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Management
engaged a third-party valuation firm to assist in the determination of the fair value of the acquired intangible assets of PC.
In determining the fair value of the intangible assets, the Company considered, among other factors, the best use of acquired
assets, analyses of historical financial performance of PC and estimates of future performance of PC. The fair values of the identified
intangible assets related to PC&rsquo;s customer relationships, trade name, non-competition covenant, and state pharmacy licenses.
The fair value of customer relationships and the non-competition covenant were calculated using the income approach. The fair
value of the trade name and state pharmacy licenses were calculated using the cost approach. The following table sets forth the
components of identified intangible assets associated with the PC acquisition and their estimated useful lives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Fair Value</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Useful Life</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; text-align: left">Customer relationships</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">596,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: center">10 - 15 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Trade name</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non-competition covenant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">State pharmacy licenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">8,000</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">25 years</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">659,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company determined the useful lives of intangible assets based on the expected future cash flows and contractual lives associated
with the respective asset. Trade names represent the fair value of the brand and name recognition associated with the marketing
of PC&rsquo;s formulations and services. Customer relationships represent the expected benefit from customer contracts that, at
the date of acquisition, were reasonably anticipated to continue given the history and operating practices of PC. The non-competition
covenant represents the contractual period and expected degree of adverse economic impact that would exist in its absence. Licenses
represent eight state pharmacy licenses PC held at the date of acquisition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Goodwill
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Of
the total estimated purchase price, $331,621 was allocated to goodwill and is attributable to expected synergies between the combined
companies, including access for the Company to fulfill prescriptions with its patent-pending proprietary drug formulations through
PC&rsquo;s market channels and assembled workforce. Goodwill represents the excess of the purchase price of the acquired business
over the estimated fair value of the underlying net tangible and intangible assets acquired. Goodwill resulting from the PC Acquisition
will be tested for impairment at least annually and more frequently if certain indicators of impairment are present. In the event
the Company determines that the value of goodwill has become impaired, it will incur an accounting charge for the amount of the
impairment during the fiscal quarter in which the determination is made. None of the goodwill is expected to be deductible for
income tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
4. RESTRICTED SHORT-TERM INVESTMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
restricted short-term investments at December 31, 2014 consist of certificate of deposits, which are classified as held-to-maturity.
At December 31, 2014, the restricted short-term investments were recorded at amortized cost which approximates fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">At
December 31, 2014, the certificate of deposits of $150,264 were classified as a current asset. The certificates of deposit are
required as collateral under the Company&rsquo;s corporate credit card agreement and office lease agreement and automatically
renew every twelve months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
5. INVENTORIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Inventories
are comprised of over-the-counter retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and
active pharmaceutical ingredients. The composition of inventories as of December 31, 2014 was as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2014</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: left">Raw materials</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 24%; text-align: right">146,300</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Work in progress</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">97,801</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Finished goods</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">128,634</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total inventories</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">372,735</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
6. PREPAID EXPENSES AND OTHER CURRENT ASSETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prepaid
expenses and other current assets consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December
    31, 2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December
    31, 2013</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Prepaid stock-based consulting expenses</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">26,649</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prepaid rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,288</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Prepaid insurance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">123,776</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39,166</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses and deposits</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">116,625</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">22,964</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">240,401</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">105,067</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
7. FURNITURE AND EQUIPMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Furniture
and equipment consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December
    31, 2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December
    31, 2013</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Furniture and equipment, net:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%; text-align: left; padding-left: 10pt">Computer software and hardware</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">52,576</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">24,536</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Furniture and equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154,215</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,449</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Lab and pharmacy equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61,868</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Leasehold improvements</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">20,172</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">288,831</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,985</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Accumulated depreciation and amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(45,436</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(8,093</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">243,395</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">26,892</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company recorded depreciation and amortization expense of $37,343 and $5,659 during the years ended December 31, 2014 and 2013,
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
8. INTANGIBLE ASSETS AND GOODWILL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company&rsquo;s intangible assets at December 31, 2014 consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Amortization</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">periods</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Accumulated</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Net</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">(in years)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Cost</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">amortization</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">carrying value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; text-align: left">Customer relationships</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 13%; text-align: center">10-15 years</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">596,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">(36,740</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 13%; text-align: right">559,260</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Trade name</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">5 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(750</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,250</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non-competition covenant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">4 years</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(9,375</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,625</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">State pharmacy licenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">25 years</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">8,000</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(1,141</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">6,859</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">659,000</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(48,006</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">610,994</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amortization
expense for intangible assets for the year ended December 31, 2014 was as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">For the</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Year Ended</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2014</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: left">Customer relationships</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 24%; text-align: right">36,740</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Trade name</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non-competition covenant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,375</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">State pharmacy licenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">1,141</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">48,006</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Estimated
future amortization expense for the Company&rsquo;s intangible assets at December 31, 2014 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">Years ending December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: left">2015</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 24%; text-align: right">67,087</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,087</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">67,087</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">57,712</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53,837</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Thereafter</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">298,184</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">610,994</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
changes in the carrying value of the Company&rsquo;s goodwill during the year ended December 31, 2014 were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Balance at January 1, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 72%; text-align: left; padding-bottom: 1.5pt">PC Acquisition</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="width: 24%; text-align: right; border-bottom: Black 1.5pt solid">331,621</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Balance at December 31, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">331,621</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accounts
payable and accrued expenses consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December
    31, 2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December
    31, 2013</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Accounts payable</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">698,806</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">261,924</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred rent</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,975</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Building lease liability(1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,552</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">39,000</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">(2)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">50,000</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">816,333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">311,924</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: Current portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(786,675</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(311,924</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Non-current total accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">29,658</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">-</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
                                         September 2014, the Company relocated its primary operations to a 7,565 square foot office
                                         facility in San Diego, California. As of December 31, 2014, the Company was marketing
                                         its previous office space (3,874 square feet) as a sublease through its remaining lease
                                         term. The Company recognized a loss of approximately $117,000 during the year ended December
                                         31, 2014, related to the estimated remaining lease liability, net of expected sublease
                                         income. The obligations were discounted based on current prevailing market rates. This
                                         loss is included in rent expense for the year ended December 31, 2014 (see Note 14).</FONT></TD></TR>                                                                                                                                              <TR STYLE="font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         amount consists of a $39,000 stock-based compensation accrual at December 31, 2014 for
                                         stock options to be granted for services performed. The stock-based compensation expense
                                         related to restricted common stock issuances and accruals was $39,000 and $143,553 during
                                         the years ended December 31, 2014 and 2013, respectively.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
10. DEBT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PC
entered into a working capital line of credit agreement with a financial institution on March 21, 2008 and subsequently renewed
the agreement on September 6, 2013. The line of credit agreement allowed PC to borrow up to $75,000 and was secured by a first
security interest on all of PC&rsquo;s business assets. The line of credit agreement was terminated following the Company&rsquo;s
acquisition of PC, and no amounts were borrowed, paid or outstanding during the period ended December 31, 2014 following the Company&rsquo;s
acquisition of PC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
11. STOCKHOLDERS&rsquo; EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Issuances
During the Year Ended December 31, 2013</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
February 7, 2013, after the effectiveness of the registration statement on Form S-1 filed in connection with the Public Offering
(as defined below), the Company effected a one-for-five reverse stock split of its common stock and on February 8, 2013, the Company&rsquo;s
common stock began trading on The NASDAQ Capital Market on a split-adjusted basis. On September 10, 2014, the Company decreased
the number of authorized shares of its capital stock to 95,000,000, and the number of authorized shares of its common stock to
90,000,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
February 13, 2013, the Company closed a public offering of its common stock (the &ldquo;Public Offering&rdquo;) and issued an
aggregate of 1,840,000 shares of its common stock at a per share price to the public of $5.25, and received net proceeds of $8,140,435,
after deducting underwriter fees and commissions and other offering expenses. The underwriters also exercised their option to
purchase an additional 276,000 shares of common stock from the Company at $5.25 per share to cover over-allotments on March 14,
2013. Net cash proceeds from the exercise of the over-allotment option were $1,316,116. As contemplated by the underwriting agreement
entered into with MDB Capital Group, LLC, the lead underwriter for the Public Offering, at the closing of the Public Offering
and the over-allotment exercise, the lead underwriters received warrants (the &ldquo;Underwriter Warrants&rdquo;) to purchase
up to an aggregate of 179,860 shares, or 8.5% of the number of shares sold in the Public Offering (including 8.5% of shares sold
pursuant to the exercise of the over-allotment option). The Underwriter Warrants are exercisable at $5.25 per share (100% of the
price to the public of the common stock sold in the Public Offering), commencing on the closing date of the Public Offering and
expire five years from the closing date of the Public Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
February and March 2013, the Company made payments totaling $191 in connection with cancelled, fractional share amounts of common
stock (35 common stock share equivalents) in connection with the one-for-five reverse stock split effected February 7, 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
June 2013, the Company issued 40,000 shares of common stock to Mark Baum, the Company&rsquo;s Chief Executive Officer and a director,
related to the vesting of RSUs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
September 2013, the Company issued 2,114 restricted shares of common stock to a consultant, valued at $10,750, in consideration
for consulting services provided during the year ended December 31, 2013. The fair value of the shares of common stock issued
was recorded as stock-based compensation during the year ended December 31, 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2013, the Company issued 40,000 restricted shares of common stock to Dr. Robert Kammer, a director
and former consultant, valued at $282,997, in consideration for consulting services provided during the years ended December 31,
2013 and 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2013, the Company issued a total of 219 shares of common stock as a result of stock option exercises.
The Company received no cash proceeds for the issuance of such shares upon the exercise pursuant to cashless exercise provisions
of stock options to purchase 1,030 shares of common stock with an exercise price of $4.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Issuances
During the Year Ended December 31, 2014</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
April 2014, the Company issued 6,868 shares of restricted common stock, valued at $50,000, in connection with the resolution of
a contract dispute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
October 2014, the Company issued 4,000 shares of restricted common stock to a consultant, valued at $29,160 in consideration for
consulting services provided. The fair value of the shares of common stock issued was recorded as stock-based compensation during
the year ended December 31, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2014, the Company issued a total of 227,216 shares of common stock as a result of stock option exercises.
Of these, the Company received net cash proceeds of $583,811 for the issuance of 160,777 shares of common stock upon the exercise
of stock options to purchase the same number of shares of common stock with exercise prices ranging from $3.68 to $4.00 and the
Company received no cash proceeds for the issuance of 66,439 shares of common stock upon the exercise pursuant to cashless exercise
provisions of stock options to purchase 146,652 shares of common stock with exercise prices ranging from $3.60 to $6.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2014, the Company issued 1,954 shares of common stock to employees related to the vesting of RSUs.
In connection with these common stock issuances, the Company withheld 1,518 shares of common stock for payroll tax withholdings
totaling $13,109.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2014, the Company issued a total of 47,829 shares of common stock as a result of warrant exercises.
Of these, the Company received gross cash proceeds of $37,867 for the issuance of 6,391 shares of common stock upon the exercise
of warrants to purchase the same number of shares of common stock with an exercise price of $5.925 and the Company received no
cash proceeds for the issuance of 41,438 shares of common stock upon the exercise pursuant to cashless exercise provisions of
warrants to purchase 123,715 shares of common stock with an exercise price of $5.25 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2014, 27,218 shares of the Company&rsquo;s common stock underlying RSUs issued to directors vested,
but the issuance and delivery of these shares are deferred until the respective director resigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Preferred
Stock </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">At
December 31, 2014 and 2013, the Company had 5,000,000 shares of preferred stock, $0.001 par value, authorized and no shares of
preferred stock issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stock
Option Plan </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
September 17, 2007, the Company&rsquo;s Board of Directors and stockholders adopted the Company&rsquo;s 2007 Incentive Stock and
Awards Plan, which was subsequently amended on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27,
2013 (as amended, the &ldquo;Plan&rdquo;). As of December 31, 2014, the Plan provides for the issuance of a maximum of 5,000,000
shares of the Company&rsquo;s common stock. The purpose of the Plan is to provide an incentive to attract and retain directors,
officers, consultants, advisors and employees whose services are considered valuable, to encourage a sense of proprietorship and
to stimulate an active interest of such persons in the Company&rsquo;s development and financial success. Under the Plan, the
Company is authorized to issue incentive stock options intended to qualify under Section 422 of the Internal Revenue Code, non-qualified
stock options, RSUs and restricted stock. The Plan is administered by the Compensation Committee of the Company&rsquo;s Board
of Directors. The Company had 2,366,369 shares available for future issuances under the Plan at December 31, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stock
Options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
summary of the stock option activity under the Plan for the year ended December 31, 2014 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; vertical-align: top; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Number of shares</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Avg.<BR>
    Exercise Price</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Avg.<BR>
    Remaining<BR>
    Contractual Life</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Aggregate<BR>
    Intrinsic Value</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left; vertical-align: top">Options outstanding - January 1, 2014</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,328,790</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">5.31</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top">Options granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">245,886</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.35</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top">Options exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(307,429</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.90</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top; padding-bottom: 1.5pt">Options cancelled/forfeit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(238,007</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">6.68</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top; padding-bottom: 2.5pt">Options outstanding - December 31, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">1,029,240</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">5.74</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">6.05</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">2,351,174</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: top; padding-bottom: 2.5pt">Options exercisable</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">728,585</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">5.25</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">4.97</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">2,080,594</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top; padding-bottom: 2.5pt">Options vested and expected to vest</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">999,175</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">5.70</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">5.98</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">2,319,475</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
aggregate intrinsic value in the table above represents the total pre-tax amount of the proceeds, net of exercise price, which
would have been received by option holders if all option holders had exercised and immediately sold all options with an exercise
price lower than the market price on December 31, 2014, based on the closing price of the Company&rsquo;s common stock of $7.50
on that date. The aggregate intrinsic value of stock options exercised during the year ended December 31, 2014 was approximately
$1,161,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
fiscal years 2014 and 2013, the Company granted stock options to certain employees, directors and consultants. The stock options
were granted with an exercise price equal to the current market price of the Company&rsquo;s common stock, as reported by the
securities exchange or quotation system on which the common stock was then listed or quoted, at the grant date and have contractual
terms ranging from three to 10 years. Vesting terms for options granted in fiscal years 2014 and 2013 to employees, directors
and consultants typically included one of the following vesting schedules: 25% or 33% of the shares subject to the option vest
and become exercisable on the first anniversary of the grant date and the remaining 75% or 67%, respectively, of the shares subject
to the option vest and become exercisable in equal quarterly installments thereafter over two or three years, respectively; quarterly
vesting over a three year period; or monthly, quarterly or 100% vesting associated with the provision or completion of services
provided under contracts with consultants. Certain option awards provide for accelerated vesting if there is a change in control
(as defined in the Plan) and in the event of certain modifications to the option award agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option pricing model. Prior to
April 1, 2013, expected volatilities were based on historical volatility of the Company&rsquo;s common stock and other factors.
Following April 1, 2013, the expected volatility is based on the historical volatilities of the common stock of comparable publicly
traded companies based on the Company&rsquo;s belief that it has significantly changed its business operations and focus as of
such date and as a result, it has limited relevant historical data regarding the volatility of its stock price on which to base
a meaningful estimate of expected volatility. The expected term of options granted was determined in accordance with the &ldquo;simplified
approach&rdquo; as the Company has limited, relevant, historical data on employee exercises and post-vesting employment termination
behavior. The expected risk-free interest rate is based on the U.S. Treasury yield for a period consistent with the expected term
of the option in effect at the time of the grant. The financial statement effect of forfeitures is estimated at the time of grant
and revised, if necessary, if the actual effect differs from those estimates. For option grants to employees and directors, the
Company assigns a forfeiture factor of 10%. These factors could change in the future, which would affect the determination of
stock-based compensation expense in future periods. Utilizing these assumptions, the fair value is determined at the date of grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following
assumptions used for valuing options granted to employees and directors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2013</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Weighted-average fair value of options granted</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">5.22</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">6.04</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected terms (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.81
                                         - 6.91</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.8
                                         -7 </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">96
                                         - 102</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">102
                                         - 123</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.37
                                         - 1.65</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.86
                                         - 2.05</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
table below illustrates the fair value per share determined using the Black-Scholes-Merton option pricing model with the following
assumptions used for valuing options granted to consultants:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2014</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2013</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Weighted-average fair value of options granted</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">6.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">5.63</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected terms (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.5
                                         - 10</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;2.33
                                         - 10 </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">78
                                         - 97</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;80
                                         - 366</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.10
                                         - 1.68</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;0.30
                                         - 2.45</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table summarizes information about stock options outstanding and exercisable at December 31, 2014:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Options Exercisable</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Weighted</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Average</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Weighted</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Weighted</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Remaining</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Average</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Average</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Number</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Contractual</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Exercise</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Number</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Exercise</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">Range of Exercise Prices</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Outstanding</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Life in Years</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Price</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Exercisable</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Price</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 24%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$2.40 - $3.20</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">4.57</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">2.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 11%; text-align: right">2.80</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$3.60 - $4.51</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">337,723</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.95</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.36</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">270,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4.42</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$5.49 - $7.71</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">190,557</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.70</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.62</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,110</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.26</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$8.06 - $10.75</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">244,160</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7.03</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">141,660</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.01</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$28.00 - $80.00</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">6,800</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">5.13</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">40.86</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">6,800</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">40.86</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">1,029,240</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">6.05</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">5.74</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">728,585</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">5.25</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2014, there was approximately $1,571,000 of total unrecognized compensation expense related to unvested stock
options granted under the Plan. That expense is expected to be recognized over the weighted-average remaining vesting period of
2.1 years. The stock-based compensation for all stock options was $1,137,634 and $1,689,756 during the years ended December 31,
2014 and 2013, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Restricted
Stock Units</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RSU
awards are granted subject to certain vesting requirements and other restrictions, including performance and market based vesting
criteria. The grant-date fair value of the RSUs, which has been determined based upon the market value of the Company&rsquo;s
common stock on the grant date, is expensed over the vesting period of the RSUs. Unvested portions of RSUs issued to consultants
are remeasured on an interim basis until vesting criteria is met. On May 2, 2013, the Board of Directors of the Company amended
and restated the Plan to provide for the issuance of RSUs under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Grants
During the Year Ended December 31, 2013</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
May 2, 2013, the Company granted 1,250,000 RSUs to its Chief Executive Officer, Mark Baum, pursuant to the Plan. Of these RSUs,
200,000 will vest on the third anniversary of the RSU grant date, subject to continued service to the Company and the remaining
1,050,000 RSUs will vest on the third anniversary of the RSU grant date, subject to the satisfaction of certain market-based and
continued service conditions (the &ldquo;Baum Performance Equity Award&rdquo;). The market-based vesting criteria are separated
into five equal tranches and require that the Company achieve and maintain certain stock price targets ranging from $10 per share
to $30 per share during the three year period following the grant date. With certain limited exceptions, Mr. Baum must be employed
with the Company on the third anniversary of the grant date in order for the Baum Performance Equity Award to vest. These market-based
vesting conditions are further described below:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 16%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tranche</FONT></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</FONT></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 16%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Target
    Share Price</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tranche
    1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">19.05%
    of the shares subject to the Baum Performance Equity Award</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$10.00
    or greater</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tranche
    2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">19.05%
    of the shares subject to the Baum Performance Equity Award</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$15.00
    or greater</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tranche
    3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">19.05%
    of the shares subject to the Baum Performance Equity Award</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$20.00
    or greater</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tranche
    4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">19.05%
    of the shares subject to the Baum Performance Equity Award</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$25.00
    or greater</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tranche
    5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.80%
    of the shares subject to the Baum Performance Equity Award</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$30.00
    or greater</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
each respective tranche to vest the following conditions must be met: (i) the Company&rsquo;s common stock must have an official
closing price at or above the Target Share Price for the respective tranche (each such date, a &ldquo;Trigger Date&rdquo;); (ii)
during the period that includes the Trigger Date and the immediately following 19 trading days (the &ldquo;Measurement Period&rdquo;),
the arithmetic mean of the 20 closing prices of the Company&rsquo;s common stock during the Measurement Period must be at or above
the Target Share Price for such tranche; and (iii) with certain limited exceptions, Mr. Baum must be in continuous service with
the Company through the third anniversary of the grant date. Any unvested RSUs under the Baum Performance Equity Award will be
forfeited on the third anniversary of the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
earning and issuance of any shares under the Baum Performance Equity Award that would exceed the number of shares available for
grant and/or the applicable annual per person grant limit for performance-based restricted stock units under the Plan as of the
grant date of the Baum Performance Equity Award were subject to approval by the Board of Directors and the Company&rsquo;s stockholders
of increases tothe number of shares available for grant and the applicable annual per person grant limit for performance-based
restricted stock units under the Plan. On May 2, 2013, the Board of Directors approved an amendment to the Plan to increase the
number of shares available for grant from 2,400,000 to 5,000,000 shares and the applicable annual per person grant limit from
600,000 to 1,250,000 shares and on September 27, 2013, a majority of the Company&rsquo;s stockholders approved the amendment to
the Plan. The 450,000 RSUs subject to the Baum Performance Equity Award that were pending such approval were granted on that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Concurrent
with the issuance of the 450,000 RSUs, Mr. Baum agreed to cancel 120,000 unvested RSUs previously granted to Mr. Baum in July
2012. As a result, the Company has treated the issuance of the 450,000 RSUs as a modification of the RSU grant made to Mr. Baum
in July 2012. The total compensation cost to be recognized by the Company is equal to the original grant date fair value of the
canceled RSUs plus any incremental cost calculated as the excess of the fair value of the 450,000 RSUs over the fair value of
the canceled 120,000 RSUs on the modification date, which is September 27, 2013. The initial fair value of the 450,000 RSUs pursuant
to the Baum Performance Equity Award granted to Mr. Baum was $189,000. No incremental cost was associated with the exchange of
RSUs as the fair value prior to modification was more than after the modification. The 450,000 RSUs pursuant to the Baum Performance
Equity Award were valued using a Monte Carlo Simulation with a three year life, 75% volatility and a risk free interest rate of
0.64%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
initial fair value of the 200,000 RSUs and 600,000 RSUs pursuant to the Baum Performance Equity Award granted to Mr. Baum was
$3,515,090. The 600,000 RSUs pursuant to the Baum Performance Equity Award were valued using a Monte Carlo Simulation with a three
year life, 75% volatility and a risk free interest rate of 0.30%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
May 24, 2013, the Company granted 100,000 RSUs to a consultant that were to vest based on the satisfaction of certain market-based
conditions subject to the consultant&rsquo;s continued service, among other things. These market-based vesting conditions are
further described below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tranche</FONT></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Number
    of Shares</FONT></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Target
    Share Price</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tranche
    1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20,000
    shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$10.00
    or greater</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tranche
    2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20,000
    shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$15.00
    or greater</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tranche
    3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20,000
    shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$20.00
    or greater</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tranche
    4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20,000
    shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$25.00
    or greater</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tranche
    5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20,000
    shares</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$30.00
    or greater</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
each respective tranche to vest the following conditions must have been met: (i) the Company&rsquo;s common stock must have had
an official closing price at or above the Target Share Price for the respective tranche (each such date a &ldquo;Trigger Date&rdquo;);
(ii) during the period that included the Trigger Date and the immediately following 19 trading days (the &ldquo;Measurement Period&rdquo;),
the arithmetic mean of the 20 closing prices during the Measurement Period have been at or above the Target Share Price for such
tranche ((i) and (ii), the &ldquo;Stock Price Conditions&rdquo;); and (iii) with certain limited exceptions, 50% of the RSUs subject
to a tranche would vest on the quarterly anniversary of the grant date following the satisfaction of the Stock Price Conditions
with respect to that tranche, subject to the consultant being in continuous service with the Company on such quarterly anniversary
and the remaining 50% would vest on the second anniversary of the grant date if (a) the Stock Price Conditions had been satisfied
with respect to that tranche prior to the second anniversary of the grant date and (b) the consultant was in continuous service
with the Company on the second anniversary of the grant date. All unvested RSUs would be forfeited on the second anniversary of
the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
initial value of the 100,000 RSUs with market-based vesting conditions granted to the consultant was $288,000, and as of December
31, 2013 the remeasured fair value of those RSUs was $10,080. The 100,000 RSUs were valued using a Monte Carlo Simulation with
a 2 year life (based on the grant date), 75%-85% volatility and risk free interest rates of 0.13%-0.36%. During March 2014, the
Company terminated its agreement with a consultant that provided for the grant of 100,000 RSUs that had vesting criteria based
on the satisfaction of certain market-based conditions subject to the consultant&rsquo;s continued service, among other things.
Upon termination of the agreement, all 100,000 RSUs were forfeited and deemed reconveyed to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
June 2013, the Company granted an aggregate of 34,325 RSUs to its non-employee directors, valued at $271,854. The RSUs vest in
full 13 months after the date of grant subject to the director&rsquo;s continued service, but the issuance and delivery of these
shares are deferred until the director resigns. In September and October 2013, two directors resigned and forfeited all such RSUs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
October 2013, the Company issued 8,947 RSUs to a former director for his service to the Company as a director, valued at $39,814.
The RSUs were to vest in full 13 months after the date of grant subject to the director&rsquo;s continued service, but the issuance
and delivery of these shares are deferred until the director resigns. All such RSUs were forfeited upon the director&rsquo;s resignation
in September 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
November 2013, the Company granted an aggregate of 10,418 RSUs to certain employees, valued at $42,498. The RSUs will vest in
equal annual installments over a three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Grants
During the Year Ended December 31, 2014</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the year ended December 31, 2014, the Company granted an aggregate of 26,492 RSUs to its non-employee directors valued at $200,015.
These RSUs vest in equal quarterly installments over a one year period subject to the director&rsquo;s continued service, but
the issuance and delivery of these shares are deferred until the director resigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
summary of the Company&rsquo;s RSU activity and related information for the year ended December 31, 2014 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Number of RSUs</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Grant Date Fair Value</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">RSUs unvested - January 1, 2014</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1,389,960</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 36%; text-align: right">3.19</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">RSUs granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26,492</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.55</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">RSUs vested</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30,690</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.41</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">RSUs cancelled/forfeit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(108,947</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">3.01</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">RSUs unvested at December 31, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">1,276,815</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">3.20</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2014, the total unrecognized compensation expense related to unvested RSUs was approximately $1,923,000 which
is expected to be recognized over a weighted-average period of 1.32 years, based on estimated vesting schedules. The stock-based
compensation for RSU&rsquo;s was $1,332,176 and $822,137 during the years ended December 31, 2014 and 2013, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">From
time to time, the Company issues warrants to purchase shares of the Company&rsquo;s common stock to investors, note holders, underwriters
and to non-employees for services rendered or to be rendered in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Issuances
During the Year Ended December 31, 2013</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
February 2013, the Company issued a warrant to purchase 30,000 shares of the Company&rsquo;s common stock to a consultant with
an exercise price of $5.25 per share. The warrants expire three years following the issuance date, and vest as follows: 10,000
shares vested immediately upon execution of the consulting agreement, and the remaining shares vested in 4,000 share installments
on each of the five monthly anniversaries of the date of the consulting agreement, provided the consultant continued to provide
services to the Company as of the applicable vesting dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
July 2013, the Company issued a warrant to purchase 60,000 shares of the Company&rsquo;s common stock to a consultant with an
exercise price of $8.50 per share, in consideration for services to be provided over a six month term. The warrants expire five
years following the issuance date, vested immediately, are non-forfeitable, and became exercisable in January 2014. The Company
recorded an initial stock-based prepaid consulting expense for the fair value of the warrants totaling $319,786, which was being
amortized over the length of the consulting service term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Issuances
During the Year Ended December 31, 2014</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company did not issue any warrants during the year ended December 31, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
summary of warrant activity during the year ended December 31, 2014 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Number of Shares Subject to Warrants Outstanding</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Avg.<BR>
    Exercise Price</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Warrants outstanding - January 1, 2014</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">821,050</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">5.94</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(130,106</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Expired</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 1.5pt">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Warrants outstanding and exercisable - December 31, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">690,944</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">$</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">6.05</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Weighted average remaining contractual life of the outstanding warrants
    in years - December 31, 2014</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">0.86</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: right; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
fair value of each warrant is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The table below
illustrates the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions
used for valuing the warrants issued to consultants:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Year
    Ended</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December
    31, 2013</B></FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: left">Weighted-average fair value of warrants granted</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 24%; text-align: right">5.12</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected terms (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.6-5</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">85%-346</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.32%-1.31</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
list of the warrants outstanding as of December 31, 2014 is included in the following table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Warrants Outstanding</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Warrants Exercisable</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Warrants</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Exercise</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Warrants</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Expiration</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Warrant Series</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Issue Date</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Outstanding</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Price</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Exercisable</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Date</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Warrants issued to a former major shareholder</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: center">4/25/2012</TD><TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">48,262</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5.93</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">48,262</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: center">4/25/2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrants issued in April 2012 private placement</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">4/25/2012</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">496,537</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.93</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">496,537</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">4/25/2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Underwriter Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2/7/2013</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">56,145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2/7/2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Warrants issued to investor relations consultant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2/28/2013</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2/28/2016</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrants issued to investor relations consultant</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">7/19/2013</TD><TD STYLE="text-align: left"></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">60,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">60,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">7/19/2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">690,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.05</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">690,944</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
stock-based compensation for warrants issued was $26,649 and $468,777 during the years ended December 31, 2014 and 2013, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company recorded stock-based compensation (including the amortization of stock-based prepaid consulting fees, issuance of common
stock for services and accrual for stock-based compensation) related to equity instruments granted to employees, directors and
consultants as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">For the</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">For the</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Year Ended</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">Year Ended</TD><TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2014</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2013</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Employees - selling and marketing</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">79,278</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">8,298</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Employees - general and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,095,254</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,512,448</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Employees - research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">156,568</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Directors - general and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">399,986</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Consultants - selling and marketing</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88,406</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Consultants - general and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146,799</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">843,301</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Consultants - research and development</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">8,789</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">214,372</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">2,564,619</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">3,134,973</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
12. INCOME TAXES </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company is subject to taxation in the United States and California. The provision for income taxes for the years ended December
31, 2014 and 2013 are summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2014</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2013</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Federal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">State</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="width: 18%; text-align: right; border-bottom: Black 1.5pt solid">2,800</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="width: 18%; text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="width: 1%; text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total current</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">2,800</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Deferred:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Federal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,082,459</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,075,342</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">State</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,100,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,233,726</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(14,183,086</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(10,309,068</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total deferred</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Income tax provision (benefit)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">2,800</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">-</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Income
taxes for the years ended December 31, 2014 and 2013, are recorded in the general and administrative expenses line item in the
accompanying consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
reconciliation of income taxes computed by applying the statutory U.S. income tax rate to the Company&rsquo;s loss before income
taxes to the income tax provision is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2014</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2013</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">U.S. federal statutory tax rate</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">35.00</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">35.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Benefit of lower tax brackets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1.00</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1.00</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">State tax benefit, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.03</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and development credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.43</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Employee stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1.03</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4.72</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss on debt conversion</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.21</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.08</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(32.76</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(29.63</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Effective income tax rate</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">(0.03</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">)%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">0.00</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Deferred
tax assets and liabilities reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities
for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&rsquo;s deferred
tax assets are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2014</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31, 2013</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred tax assets (liabilities):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 56%; text-align: left; padding-left: 10pt">NOL&rsquo;s</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">10,922,914</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">7,364,058</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Depreciation and amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,787</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(340</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">64,806</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">129,191</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Research &amp; development credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">555,945</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">563,485</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Deferred stock compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,646,208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,252,674</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Unrealized gain or loss on investments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">-</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total deferred tax assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">14,183,086</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">10,309,068</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(14,183,086</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(10,309,068</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">-</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">-</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Realization
of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the
net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately $3,900,000
and $3,000,000 in 2014 and 2013, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2014, the Company had net operating loss carryforwards for federal income tax purposes of approximately $27,800,000
which expire beginning in the year 2027 and federal research and development tax credits of approximately $350,000 which expire
beginning in the year 2026. As of December 31, 2014, the Company had net operating loss carryforwards for state income tax purposes
of approximately $24,600,000 which expire beginning in the year 2017 and state research and development tax credits of approximately
$300,00 which do not expire.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
deferred tax asset at December 31, 2014 does not include approximately $30,000 and $30,000 of excess tax benefits from employee
stock option exercises and RSU vests that are a component of the federal and California net operating loss carryover, respectively.
The Company&rsquo;s stockholders&rsquo; equity balance will be increased if and when such excess tax benefits are ultimately realized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Utilization
of the net operating losses may be subject to substantial annual limitation due to federal and state ownership change limitations
provided by the Internal Revenue Code and similar state provisions. Such annual limitations could result in the expiration of
the net operating losses ad credits before their utilization. The Company has not performed an analysis to determine the limitation
of the net operating loss and research development credit carryforwards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company did not have any unrecognized tax benefits of as of December 31, 2014 and 2013, all of which is offset by a full valuation
allowance. These unrecognized tax benefits, if recognized, would not affect the effective tax rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
13. EMPLOYEE SAVINGS PLAN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company has established an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code, effective January 1,
2014. The plan allows participating employees to deposit into tax deferred investment accounts up to 100% of their salary, subject
to annual limits. The Company makes contributions to the plan in an amount not less than 3% of the participants&rsquo; annual
cash compensation, subject to annual limits. The Company contributed approximately $56,000 to the plan during the year ended December
31, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
14. COMMITMENTS AND CONTINGENCIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Capital
Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company leases equipment under capital leases with an interest rate of 4.25% per annum. At December 31, 2014, future payments
under the Company&rsquo;s capital leases were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">Year ending December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: left">2015</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 24%; text-align: right">25,477</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">2016</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">19,321</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total minimum lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,798</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less amount representing interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(1,718</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Present value of future minimum lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,080</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less current portion</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">(24,112</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Capital lease obligations, net of current portion</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">18,968</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The value
of the equipment under capital leases as of December 31, 2014 was $52,687, with related accumulated depreciation of $8,656.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Operating
Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
June 2014, the Company entered into a lease agreement for 7,565 square feet of office space that commenced on September 1, 2014
and continues until October 31, 2018. Monthly rent began on September 1, 2014 in the amount of $20,426, with a 3% increase in
the base rent amount on an annual basis. The lease agreement allows for the monthly rent amount to be abated for two months at
various times during the lease agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
April 2013, the Company entered into a lease agreement for 3,784 square feet of office space that commenced on May 1, 2013 and
continues until September 30, 2016. Monthly rent began on May 1, 2013 in the amount of $10,406, with a 3% increase in the base
rent amount on an annual basis. The lease agreement allows for the monthly rent amount to be abated for five months at various
times during the lease agreement. The Company entered into a sublease agreement in February 2015 to sublet 3,874 square feet of
its previously occupied offices through the remaining term of the lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
January 2010, PC entered into a lease agreement for 3,137 square feet of office and laboratory space that commenced on January
1, 2010 and continues until December 31, 2015. Monthly rent began on January 1, 2010 in the amount of $3,594.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Rent
expense for the years ended December 31, 2014 and 2013 was $306,465 and $103,191, respectively. The following represents future
annual minimum lease payments, including lease payments related to lease agreements entered into in January and February 2015
(see Note 16), and net of expected sublease income, as of December 31, 2014:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">2015</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 32%; text-align: right">492,503</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">468,997</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">481,443</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">495,938</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,039</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Thereafter</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">478,473</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double">2,674,393</TD><TD STYLE="text-align: left; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Legal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
the ordinary course of business, the Company may face various claims brought by third parties and the Company may, from time to
time, make claims or take legal actions to assert the Company&rsquo;s rights, including intellectual property disputes, contractual
disputes and other commercial disputes. Any of these claims could subject the Company to litigation. Management believes the outcomes
of currently pending claims are not likely to have a material effect on the Company&rsquo;s consolidated financial position and
results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Indemnities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition to the indemnification provisions contained in the Company&rsquo;s charter documents, the Company generally enters into
separate indemnification agreements with each of the Company&rsquo;s directors and officers. These agreements require the Company,
among other things, to indemnify the director or officer against specified expenses and liabilities, such as attorneys&rsquo;
fees, judgments, fines and settlements, paid by the individual in connection with any action, suit or proceeding arising out of
the individual&rsquo;s status or service as the Company&rsquo;s director or officer, other than liabilities arising from willful
misconduct or conduct that is knowingly fraudulent or deliberately dishonest, and to advance expenses incurred by the individual
in connection with any proceeding against the individual with respect to which the individual may be entitled to indemnification
by the Company. The Company also indemnifies its lessors in connection with its facility leases for certain claims arising from
the use of the facilities. These indemnities do not provide for any limitation of the maximum potential future payments the Company
could be obligated to make. Historically, the Company has not been obligated nor incurred any payments for these obligations and,
therefore, no liabilities have been recorded for these indemnities in the accompanying consolidated balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Urigen
License</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
October 24, 2014, (the &ldquo;Urigen Effective Date&rdquo;), the Company entered into a license agreement (the &ldquo;Urigen License&rdquo;)
with Urigen Pharmaceuticals, Inc. (&ldquo;Urigen&rdquo;), pursuant to which Urigen granted to the Company a license under certain
U.S. patents and patent applications to develop and sell in the U.S. Urigen&rsquo;s URG101 product (&ldquo;HLA&rdquo;), a heparin
and alkalinized lidocaine compounded formulation, for the prevention or treatment of disorders of the lower urinary tract. Such
license is non-exclusive; provided that, between April 24, 2015 and October 24, 2015, the Company will have the right, at its
option, to convert such non-exclusive license to an exclusive license for the remaining term of the Urigen License, subject only
to certain specified existing sublicenses (the &ldquo;Existing Sublicenses&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
consideration for the license granted under the Urigen License, the Company agreed to pay Urigen annual tiered royalties based
on sales of HLA, subject to certain minimum annual royalty payments. The annual tiered royalties consist of the greater of (i)
$0.50 per dose, and (ii) 15% - 20% of its net sales of HLA, with the royalty amount within such range depending on the Company&rsquo;s
aggregate sales of HLA during the period to which the royalty payment applies. The minimum annual royalty payment consists of
(a) for the 2015 calendar year, the greater of (i) 110% of the aggregate royalties paid to Urigen under the Existing Sublicenses
during the preceding 12 months, on a prorated basis, and (ii) $800,000, less the aggregate royalties paid to Urigen under the
Existing Sublicenses during the 2015 calendar year, and (b) for each calendar year thereafter, 110% of the aggregate amount owed
by the Company to Urigen under the Urigen License during the prior calendar year. The Company is obligated to pay such royalties
beginning with its first commercial sale of HLA and continuing until the expiration of the patents subject to the license granted
under the Urigen License. The Company has also agreed to use commercially reasonable efforts to develop and commercialize HLA
according to the terms of a diligence plan agreed to by the parties, which efforts will include, without limitation, the Company&rsquo;s
investment of $2 million in commercialization efforts of HLA, which investment and timeline can be adjusted dependent on market
circumstances, and is expected to be incurred over 18-24 months following the Urigen Effective Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Subject
to certain conditions and each party&rsquo;s right to terminate the Urigen License earlier under certain circumstances, the Urigen
License will continue in effect until the expiration of the Company&rsquo;s royalty obligations under the Urigen License. The
Urigen License terminates upon the first commercial sale of HLA by Urigen, its affiliates, or a third party after the U.S. Food
and Drug Administration (the &ldquo;FDA&rdquo;) grants Urigen approval to market HLA in the U.S., if market approval is granted.
The Company shall have the option, at its discretion, to become a non-exclusive distributor of HLA following the FDA granting
Urigen such market approval. No royalty amounts have been paid or accrued under the Urigen License during the year ended December
31, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PCCA
License Agreement </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
August 30, 2012, the Company entered into a license agreement with Professional Compounding Centers of America (&ldquo;PCCA&rdquo;),
pursuant to which PCCA has granted to the Company and its affiliates certain exclusive rights under PCCA&rsquo;s proprietary formulations,
other technologies and data, and the Company has agreed to pay to PCCA certain royalties on net sales relating to the sale of
certain potential future FDA-approved products that the Company may produce, which royalties will range from 4.5% to 9% for each
such product, subject to certain minimum royalty payments. PCCA may terminate the license agreement if the Company fails to commence
efforts to research and develop any such products within certain time periods, as set forth in the license agreement. No royalty
amounts have been paid or accrued under this agreement during the years ended December 31, 2014 or 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PCCA
Strategic Alliance Agreement </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
February 18, 2013, the Company entered into a strategic alliance agreement with PCCA. Under this agreement, PCCA has agreed that,
during the term of the agreement, it will not introduce any of PCCA&rsquo;s members or customers meeting certain criteria (the
&ldquo;Member/Customers&rdquo;) to any third party whereby such third party licenses or otherwise acquires the intellectual property
rights of such Member/Customer, without first presenting such an opportunity to the Company. PCCA may, but is not required to,
present such opportunities to the Company, use reasonable efforts to facilitate an introductory meeting between the Member/Customer
and the Company, and to further provide certain key technical assistance with respect to any potential development project the
Company may pursue associated with the Member/Customer&rsquo;s intellectual property rights. In the event the Company and a Member/Customer
introduced to the Company by PCCA enter into a commercial agreement for the license or acquisition of the intellectual property
rights owned by the Member/Customer, PCCA will be entitled to receive certain cash fees up to an aggregate of $100,000, as well
as a commission based on net sales, if any, generated by the Company as a result of the acquired intellectual property rights.
The agreement has a term of one year and is automatically extended for successive one year periods unless either party gives the
other written notice of non-renewal. This agreement automatically renewed for a one-year term on February 18, 2014 and 2015. No
royalty amounts have been paid or accrued under this agreement during the years ended December 31, 2014 or 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Asset
Purchase Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company has acquired intellectual property rights related to certain proprietary innovations from certain inventors (the &ldquo;Inventors&rdquo;)
through multiple asset purchase agreements. The asset purchase agreements provide that the Inventors will cooperate with the Company
in obtaining patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts
to research, develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired
a right of first refusal on additional intellectual property and drug development opportunities presented by these Inventors during
the term of the respective agreements, which remains in effect until expiration of all payment obligations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
consideration for the acquisition of the intellectual property rights, the Company is obligated to make payments to the Inventors
based on the completion of certain milestones, generally consisting of: (1) a payment payable within 30 days after the issuance
of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within
30 days after the Company files the first investigational new drug application (&ldquo;IND&rdquo;) with the U.S. Food and Drug
Administration (&ldquo;FDA&rdquo;) for the first product arising from the acquired intellectual property (if any); (3) for certain
of the Inventors, a payment payable within 30 days after the Company files the first New Drug application with the FDA for the
first product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts
received by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if
any), after deducting (among other things) the Company&rsquo;s development costs associated with such product. If, following five
years after the date of the applicable asset purchase agreement, the Company either (a) for certain of the Inventors, has not
filed an IND or, for the remaining Inventors, has not initiated a study where data is derived, or (b) has failed to generate royalty
payments to the Inventors for any product based on the acquired intellectual property, the Inventors may terminate the applicable
asset purchase agreement and request that the Company re-assign the acquired technology to the Inventors. No royalty amounts have
been paid or accrued under these agreements for the years ended December 31, 2014 or 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Novel
Drug and Eye Care Northwest Asset Purchase Agreement &ndash; Related Party</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
August 8, 2013, the Company acquired intellectual property rights related to certain proprietary innovations from the compounding
pharmacy operations of Novel Drug Solutions, LLC (&ldquo;NDS&rdquo;) and from Eye Care Northwest, Inc. (together referred to as
the &ldquo;Sellers&rdquo;) pursuant to an asset purchase agreement (as amended, the &ldquo;ECN APA&rdquo;). As part of this acquisition,
the Company acquired intellectual property rights that include a provisional patent application related to injectable ophthalmological
compositions having anti-bacterial and anti-inflammatory properties for the prevention of post-ophthalmic surgery complications.
In addition, under the ECN APA, the Company has a right of first refusal on any of the Sellers&rsquo; additional intellectual
property and drug development opportunities during the term of the agreement, which remains in effect until the expiration of
all payment obligations thereunder. The ECN APA provides that the Sellers will cooperate with the Company in obtaining patent
protection for the acquired intellectual property, among other things, and that the Company will use commercially reasonable efforts
to research, develop and commercialize a product based on the acquired intellectual property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
consideration for the acquisition, the Company is obligated to make the following payments to the Sellers: (1) a payment payable
within 30 days after the issuance of the first patent in the United States arising from the acquired intellectual property (if
any); (2) a payment payable within 30 days after the Company files the first IND with the FDA for the first product arising from
the acquired intellectual property (if any); (3) a payment payable within 30 days after the Company files the first new drug application
with the FDA for the first product arising from the acquired intellectual property (if any); and (4) certain royalty payments
based on the net receipts received by the Company in connection with the sale or licensing of any product based on the acquired
intellectual property (if any), after deducting (among other things) the Company&rsquo;s development costs associated with such
product. If, following five years of the date of the ECN APA, the Company either has not filed an IND or has failed to generate
royalty payments to NDS for any product based on the acquired intellectual property, NDS may terminate the ECN APA and request
that the Company re-assign the acquired technology to NDS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NDS
is owned by the former owners of PC. During the years ended December 31, 2014 and 2013, the Company did not make any payments
to NDS or the other Seller, and no amounts were due and payable to NDS or the other Seller at December 31, 2014 and 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
15. SEGMENT INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company operates the business on the basis of a single reportable segment, which is the business of developing proprietary drug
therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services. The Company&rsquo;s
chief operating decision-maker is the Chief Executive Officer, who evaluates the Company as a single operating segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company categorizes revenues by geographic area based on selling location. All operations are currently located in the United
States; therefore, total revenues for 2014 and 2013 are attributed to the United States. All long-lived assets at December 31,
2014 are located in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company sells its compounded formulations to a large number of customers. Less than 10% of the Company&rsquo;s total pharmacy
sales were derived from a single customer for the year ended December 31, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company receives its active pharmaceutical ingredients from three main suppliers. These suppliers collectively accounted for 84%
of drug and chemical purchases during the year ended December 31, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
16. SUBSEQUENT EVENTS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company has performed an evaluation of events occurring subsequent to December 31, 2014 through the filing date of this Annual
Report on Form 10-K (the &ldquo;Annual Report&rdquo;). Based on its evaluation, nothing other than the events described below
needs to be disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">From
January 1, 2015 through the filing date of this Annual Report, the Company issued a total of 12,658 shares of common stock as
a result of warrant exercises. The Company received gross cash proceeds of $74,998 for the issuance of such shares upon the exercise
on a cash basis to purchase the same number of shares of common stock with an exercise price of $5.925.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2015, the Company issued 8,521
shares of its common stock in connection with RSUs which had been awarded to a non-employee director and vested, but were not
issued until the resignation of the director on January 1, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
January 1, 2015, the Company completed the acquisition of all of the outstanding capital stock of Park from the previous owners
(the &ldquo;Park Sellers,&rdquo; and such transaction, the &ldquo;Park Acquisition&rdquo;), pursuant to a Stock Purchase Agreement,
dated November 26, 2014, by and among the Company, the Park Sellers, Park and the Seller Representative (as defined therein) (the
&ldquo;Park Purchase Agreement&rdquo;). Park is a compounding pharmacy accredited by the Pharmacy Compounding Accreditation Board
and is located in Irvine, California. On January 1, 2015 (the &ldquo;Park Closing Date&rdquo;), in connection with the closing
of the Park Acquisition (the &ldquo;Park Closing&rdquo;), the Company paid to the Park Sellers an aggregate cash purchase price
of $3,000,000, net of fees and expenses, subject to adjustment based on the final calculation of Park&rsquo;s working capital
and certain other financial information, and issued to the Park Sellers 63,525 shares of the Company&rsquo;s common stock, valued
at $500,000 based on the average closing price of the common stock for the 10 trading days preceding the Park Closing. In addition,
the Company is obligated to make 12 quarterly cash payments to the Park Sellers collectively of $53,125 each over the three years
following the Park Closing, totaling $637,500. The Park Sellers have the option to receive the last six of such quarterly payments,
totaling up to an aggregate of $318,750, in the form of 6,749 shares of the Company&rsquo;s common stock for each such payment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with the Park Acquisition, one of the Park Sellers, Dennis Saadeh, entered into an employment agreement with the Company,
effective as of January 1, 2015, to act as Senior Director of Corporate Development of Park. In addition, on January 1, 2015,
Park and an entity affiliated with and controlled by the Park Sellers entered into a Commercial Lease Agreement, for the lease
of certain premises to Park of approximately 4,500 square feet of lab and office space. The monthly rent amount is $9,788 and
includes annual increases of approximately 3%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
February 2015, the Company entered into a lease agreement for approximately 8,602 square feet of lab, warehouse and office space
in Roxbury, New Jersey. The current lease term expires on July 31, 2022. The monthly rent amount is $9,548 and includes annual
increases of approximately 3.75%, and the lease allows for the first five months of rent amounts to be abated. This facility is
currently undergoing construction and being built to serve as an outsourcing facility and pharmacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
February 2015, the Company appointed Andrew R. Boll&rsquo;s as its Chief Financial Officer, and entered into an amended and restated
employment agreement (the &ldquo;CFO Employment Agreement&rdquo;) with Mr. Boll, which amends, restates and supersedes in its
entirety Mr. Boll&rsquo;s prior employment agreement with the Company dated February 1, 2012. The CFO Employment Agreement provides
for the following, among other things: (i) a term of three years, (ii) an annual base salary of $200,000; (iii) eligibility to
receive an annual cash bonus in an amount equal to at least 20% of his then-current annual base salary and a target of 50% of
his then-current annual base salary, with the precise amount to be determined at the discretion of the Company&rsquo;s Board of
Directors; (iv) if Mr. Boll is terminated other than for cause, by death or by disability or if he terminates his employment with
the Company for good reason (any such termination, a &ldquo;Qualifying Termination&rdquo;), then Mr. Boll will be entitled to
receive, subject to the satisfaction of certain conditions, continued payments of his then-current annual base salary for six
months following the date of his termination and a lump-sum payment equal to the pro-rated portion of his minimum annual cash
bonus for the then-current year; and (v) in the event of a Qualifying Termination of Mr. Boll on or within 12 months following
a change of control, Mr. Boll will be entitled to receive, subject to the satisfaction of certain conditions, continued payments
of his then-current annual base salary for six months following the date of his termination, a lump-sum payment equal to the pro-rated
portion of his minimum annual cash bonus for the then-current year, and immediate vesting of all of his outstanding equity awards
as of the date of his termination. In connection with Mr. Boll&rsquo;s appointment as the Company&rsquo;s Chief Financial Officer,
the Company&rsquo;s Board of Directors has granted the following equity awards to Mr. Boll, in each case under the Plan: (i) a
performance-based restricted stock unit award of up to 157,500 shares of the Company&rsquo;s common stock, which will vest if
the Company achieves and maintains certain stock price vesting targets during the three-year period following the date of grant
of the award and subject to Mr. Boll&rsquo;s continued employment with the Company on the third anniversary of the date of grant,
subject to certain exceptions, and (ii) a RSU award of up to 30,000 shares of the Company&rsquo;s common stock, which will vest
on the third anniversary of the date of grant, subject to Mr. Boll&rsquo;s continued employment with the Company on such date
and accelerated vesting of all unvested shares thereunder upon the occurrence of a change in control (as defined in the Plan),
and is subject to the Company&rsquo;s standard form of award agreement for RSUs granted under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
February 2015, the Company appointed John P. Saharek as of the Company&rsquo;s Chief Commercial Officer, effective as of February
1, 2015, and entered into an employment agreement (the &ldquo;CCO Employment Agreement&rdquo;) with Mr. Saharek. The CCO Employment
Agreement provides for the following, among other things: (i) a term of three years, (ii) an annual base salary of $220,000; (iii)
eligibility to receive an annual cash bonus in an amount equal to a target of 50% of his then-current annual base salary, with
the precise amount to be determined at the discretion of the Company&rsquo;s Board of Directors; (iv) in the event of a Qualifying
Termination of Mr. Saharek, Mr. Saharek will be entitled to receive, subject to the satisfaction of certain conditions, continued
payments of his then-current annual base salary for six months following the date of his termination; and (v) in the event of
a Qualifying Termination of Mr. Saharek on or within 12 months following a change of control, then Mr. Saharek will be entitled
to receive, subject to the satisfaction of certain conditions, continued payments of his then-current annual base salary for 12
months following the date of his termination and immediate vesting of all of his outstanding equity awards as of the date of his
termination. In connection with Mr. Saharek&rsquo;s appointment as the Company&rsquo;s Chief Commercial Officer, the Company&rsquo;s
Board of Directors has granted the following equity awards to Mr. Saharek, in each case under the Plan: (i) a stock option award
of up to 90,000 shares of the Company&rsquo;s common stock, which has a term of 10 years and an exercise price of $7.37, will
vest in equal quarterly installments over a three-year period, subject to Mr. Saharek&rsquo;s continued employment with the Company
at the end of such period and accelerated vesting of all unvested shares thereunder upon the occurrence of a change in control
(as defined in the Plan), and is subject to the Company&rsquo;s standard form of award agreement for stock options granted under
the Plan, and (ii) a RSU award of up to 30,000 shares of the Company&rsquo;s common stock, which will vest on the third anniversary
of the date of grant, subject to Mr. Saharek&rsquo;s continued employment with the Company on such date and accelerated vesting
of all unvested shares thereunder upon the occurrence of a change in control (as defined in the Plan), and is subject to the Company&rsquo;s
standard form of award agreement for restricted stock units granted under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><B>EXHIBIT INDEX</B></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR>
    <TD STYLE="text-align: left; width: 8%; vertical-align: bottom; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT><BR>
    <FONT STYLE="font-size: 10pt"><B>No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 90%; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Agreement and Plan of Merger, dated as of September 17, 2007,
    by and among Imprimis Pharmaceuticals, Inc., Transdel Pharmaceuticals Holdings, Inc. and Trans-Pharma Acquisition Corp. Incorporation
    (incorporated herein by reference to Exhibit 2.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed
    with the Securities and Exchange Commission on September 21, 2007)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2.2</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Membership Interest Purchase Agreement, dated February 10, 2014,
    among John Scott Karolchyk and Bernard Covalesky and Imprimis Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit
    2.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission
    on February 11, 2014)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2.3</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Stock Purchase Agreement, dated as of November 26, 2014, by
    and between Imprimis Pharmaceuticals, Inc., and Dennis Saadeh and Tina Sulic-Saadeh (incorporated herein by reference to Exhibit
    2.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission
    on December 2, 2014)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">3.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Amended and Restated Certificate of Incorporation, as amended
    by the Certificate of Amendment to Amended and Restated Certificate of Incorporation effective February 28, 2012, as further
    amended by the Certificate of Amendment to Amended and Restated Certificate of Incorporation effective February 7, 2013, and
    as further amended by the Certificate of Amendment to Amended and Restated Certificate of Incorporation effective September
    10, 2014 </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Amended and Restated Bylaws of Imprimis Pharmaceuticals, Inc.
    (incorporated herein by reference to Exhibit 3.2 to the Annual Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed
    with the Securities and Exchange Commission on March 28, 2014)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">3.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certificate of Designation of Series A Convertible Preferred
    Stock of Imprimis Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K
    of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on December 20, 2011) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Directors and Officers Indemnification Agreement (incorporated
    herein by reference to Exhibit 10.8 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities
    and Exchange Commission on September 21, 2007) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.2#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Imprimis Pharmaceuticals, Inc. Amended and Restated 2007 Stock
    Incentive and Awards Plan (incorporated herein by reference to Exhibit 10.3 to the Quarterly Report on Form 10-Q of Imprimis
    Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on May 8, 2013)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.3#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Amendment No. 1 to Imprimis Pharmaceuticals, Inc. Amended and
    Restated 2007 Incentive Stock and Awards Plan (incorporated herein by reference to Exhibit 10.3 to the Quarterly Report on
    Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on November 6, 2013)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10.4#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Incentive Stock Option Agreement (incorporated herein
    by reference to Exhibit 10.12 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities
    and Exchange Commission on September 21, 2007) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10.5#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Non-Qualified Stock Option Agreement (incorporated herein
    by reference to Exhibit 10.13 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities
    and Exchange Commission on September 21, 2007) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10.6#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Restricted Stock Unit Agreement (incorporated herein
    by reference to Exhibit 10.4 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities
    and Exchange Commission on May 8, 2013)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Warrant dated as of April 25, 2012 (incorporated by
    reference to Exhibit 10.2 to the Company&rsquo;s Current Report on 8-K filed with the Securities and Exchange Commission on
    April 27, 2012)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10.8#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Stand-alone Restricted Stock Unit Agreement, dated July 18,
    2012, granted by Imprimis Pharmaceuticals, Inc. to Mark L. Baum (incorporated herein by reference to Exhibit 10.40 to the
    Company&rsquo;s Registration Statement on Form S-1 (File No. 333-182846) filed on July 25, 2012)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">10.9#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Stand-alone Restricted Stock Unit Agreement, dated July 18,
    2012, granted by Imprimis Pharmaceuticals, Inc. to Robert J. Kammer (incorporated herein by reference to Exhibit 10.41 to
    the Company&rsquo;s Registration Statement on Form S-1 (File No. 333-182846) filed on July 25, 2012)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.10</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">License Agreement, dated as of August 30, 2012, by and between
    Imprimis Pharmaceuticals, Inc. and Professional Compounding Centers of America, Inc. (incorporated herein by reference to
    Exhibit 10.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission
    on August 31, 2012)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Form of Underwriter&rsquo;s Warrant (incorporated herein by
    reference to Exhibit 10.41 to the Company&rsquo;s Registration Statement on Form S-1 (File No. 333-182846) filed on October
    26, 2012)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.12</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Strategic Alliance Agreement, dated February 18, 2013, by and
    between Imprimis Pharmaceuticals, Inc. and Professional Compounding Centers of America, Inc. (incorporated herein by reference
    to Exhibit 10.1 to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange
    Commission on February 21, 2013)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.13#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Amended and Restated Employment Agreement, dated May 2, 2013,
    by and between Imprimis Pharmaceuticals, Inc. and Mark L. Baum (incorporated herein by reference to Exhibit 10.2 to the Quarterly
    Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on May 8, 2013)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.14#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Performance Stock Units Agreement, dated May 2, 2013, by and
    between Imprimis Pharmaceuticals, Inc. and Mark L. Baum (incorporated herein by reference to Exhibit 10.4 to the Quarterly
    Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on August 14, 2013)</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 66; Options: NewSection; Value: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%"><FONT STYLE="font-size: 10pt">10.15+</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 90%; text-align: justify"><FONT STYLE="font-size: 10pt">Asset Purchase Agreement, dated June 11, 2013, by
    and between Imprimis Pharmaceuticals, Inc. and Buderer Drug Company, Inc. (incorporated herein by reference to Exhibit 10.5
    to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on
    August 14, 2013) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.16+</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Asset Purchase Agreement, dated August 8, 2013, by and among
    Imprimis Pharmaceuticals, Inc., Novel Drug Solutions, LLC and Eye Care Northwest, PA (incorporated herein by reference to
    Exhibit 10.1 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange
    Commission on November 6, 2013) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.17</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Amendment to Asset Purchase Agreement, dated as of October 14,
    2013, by and among Imprimis Pharmaceuticals, Inc., Novel Drug Solutions, LLC and EyeCare Northwest, PA (incorporated herein
    by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q of Imprimis Pharmaceuticals, Inc. filed with the Securities
    and Exchange Commission on November 6, 2013)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.18+</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Asset Purchase Agreement, dated October 8, 2013, by and between
    Imprimis Pharmaceuticals, Inc. and Novel Drug Solutions, LLC (incorporated herein by reference to Exhibit 10.27 to the Annual
    Report on Form 10-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on March 28, 2014)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.19</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Amendment to Asset Purchase Agreement, dated as of October 21,
    2013, by and between Imprimis Pharmaceuticals, Inc. and Buderer Drug Company, Inc. (incorporated herein by reference to Exhibit
    10.28 to the Annual Report on Form 10-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission
    on March 28, 2014)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.20</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Amendment to Asset Purchase Agreement, dated as of October 21,
    2013, by and between Imprimis Pharmaceuticals, Inc. and Novel Drug Solutions, LLC and EyeCare Northwest, PA (incorporated
    herein by reference to Exhibit 10.29 to the Annual Report on Form 10-K of Imprimis Pharmaceuticals, Inc. filed with the Securities
    and Exchange Commission on March 28, 2014)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.21</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">License Agreement, dated as of October 24, 2014, by and between
    Imprimis Pharmaceuticals, Inc. and Urigen Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.1 to the Current
    Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on October 29, 2014)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.22#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Amended and Restated Employment Agreement, effective as of February
    1, 2015, by and between Imprimis Pharmaceuticals, Inc. and Andrew R. Boll (incorporated herein by reference to Exhibit 10.1
    to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on February
    2, 2015)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.23#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Performance Stock Units Award Agreement, effective as of February
    1, 2015, by and between Imprimis Pharmaceuticals, Inc. and Andrew R. Boll (incorporated herein by reference to Exhibit 10.2
    to the Current Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on February
    2, 2015)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">10.24#</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Employment Agreement, effective as of February 1, 2015, by and
    between Imprimis Pharmaceuticals, Inc. and John P. Saharek (incorporated herein by reference to Exhibit 10.3 to the Current
    Report on Form 8-K of Imprimis Pharmaceuticals, Inc. filed with the Securities and Exchange Commission on February 2, 2015)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">21.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">List of Subsidiaries </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">23.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Consent of Independent Registered Public Accounting Firm</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">24.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Power of Attorney (included on the signature page to this Annual
    Report) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">31.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certification of Mark L. Baum, Chief Executive Officer, pursuant
    to Rule&nbsp;13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as adopted pursuant to Section&nbsp;302 of
    the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">31.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certification of Andrew R. Boll, Chief Financial Officer, pursuant
    to Rule&nbsp;13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as adopted pursuant to Section&nbsp;302 of
    the Sarbanes-Oxley Act of 2002.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">32.1**</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certification pursuant to 18 U.S.C. Section&nbsp;1350, as adopted
    pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, executed by Mark L. Baum, Chief Executive Officer, and Andrew
    R. Boll, Chief Financial Officer.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">101.INS*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Instant Document</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">101.SCH*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Schema Document</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">101.CAL*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase
    Document</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">101.DEF*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase
    Document</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">101.LAB*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase
    Document</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">101.PRE*</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase
    Document</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">#</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify"><FONT STYLE="font-size: 10pt">Management contract or compensatory plan or arrangement.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">**</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Furnished herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">+</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Confidential treatment has been granted with respect to portions
    of this exhibit pursuant to Rule 24b-2 of the Exchange Act and these confidential portions have been redacted from the filing
    that is incorporated herein by reference. A complete copy of this exhibit, including the redacted terms, has been separately
    filed with the Securities and Exchange Commission.</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 67; Value: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->







</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!:`Q<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#WN:40QERK
M,!UVBJO]JP?W9/R'^-7JR;ZQ\O,L0^7^)1VH`L?VK!_=D_(?XT?VK!_=D_(?
MXUCT4`;']JP?W9/R'^-']JP?W9/R'^-8]%`&Q_:L']V3\A_C1_:L']V3\A_C
M6/10!L?VK!_=D_(?XT?VK!_=D_(?XUCT4`;']JP?W9/R'^-']JP?W9/R'^-8
M]%`&Q_:L']V3\A_C1_:L']V3\A_C6/10!L?VK!_=D_(?XT?VK!_=D_(?XUCT
M4`;']JP?W9/R'^-']JP?W9/R'^-8]%`&Q_:L']V3\A_C1_:L']V3\A_C6/10
M!L?VK!_=D_(?XU9@N([E-T9Z=0>HKGJDAF>"0.AY[CL:`.BHJ&VN$N8]Z]>X
M]*FH`R]7UR#10C7-O<M&_`DC4%0?0Y(Q67_PGNE?\\+S_OA?_BJZ.YMH;RW>
MWN(Q)$XPRGO7F/B'P_-HESE=TEHY_=R'M_LGW_G0!U?_``GNE?\`/"\_[X7_
M`.*H_P"$]TK_`)X7G_?"_P#Q5>=44`>B_P#">Z5_SPO/^^%_^*H_X3W2O^>%
MY_WPO_Q5>=44`>B_\)[I7_/"\_[X7_XJC_A/=*_YX7G_`'PO_P`57G5%`'HO
M_">Z5_SPO/\`OA?_`(JC_A/=*_YX7G_?"_\`Q5>=44`>B_\`">Z5_P`\+S_O
MA?\`XJC_`(3W2O\`GA>?]\+_`/%5YU10!Z+_`,)[I7_/"\_[X7_XJC_A/=*_
MYX7G_?"__%5YU10!Z+_PGNE?\\+S_OA?_BJ/^$]TK_GA>?\`?"__`!5>=44`
M>B_\)[I7_/"\_P"^%_\`BJ/^$]TK_GA>?]\+_P#%5YU10!Z+_P`)[I7_`#PO
M/^^%_P#BJ/\`A/=*_P">%Y_WPO\`\57G5%`'HO\`PGNE?\\;S_OA?_BJZ.VN
M8;RW2XMY!)$XRK"O%ZVO#WB";1+C:<R6DA_>1^G^T/?^=`'J=%16US#=V\=Q
M!('BD&58=ZEH`XW4?B3I6DW\ME>Z?J<4\9P5,2<^X._D'UJK_P`+;T#_`)]=
M2_[])_\`%UL^+O"5KXHL-K8BO8@3!.!T_P!EO537A&H:?=:5?S6-[$8KB(X9
M3^A'J#ZT`>O?\+;T#_GUU+_OTG_Q='_"V]`_Y]=2_P"_2?\`Q=>,44`>S_\`
M"V]`_P"?74O^_2?_`!='_"V]`_Y]=2_[])_\77C%%`'L_P#PMO0/^?74O^_2
M?_%T?\+;T#_GUU+_`+])_P#%UXQ10![/_P`+;T#_`)]=2_[])_\`%T?\+;T#
M_GUU+_OTG_Q=>,44`>S_`/"V]`_Y]=2_[])_\71_PMO0/^?74O\`OTG_`,77
MC%%`'L__``MO0/\`GUU+_OTG_P`71_PMO0/^?74O^_2?_%UXQ10![/\`\+;T
M#_GUU+_OTG_Q='_"V]`_Y]=2_P"_2?\`Q=>,44`>S_\`"V]`_P"?74O^_2?_
M`!='_"V]`_Y]=2_[])_\77C%%`'L_P#PMO0/^?74O^_2?_%T?\+;T#_GUU+_
M`+])_P#%UXQ10![GI7Q)T'5M1CLD^TV\DO"-<(JJ6],AC@GWKL*^7*]7\`>/
M?M'E:-K$H\[A+>X8_?\`16]_0]_KU`/3*@O;EK.RFN$MIKEHU+"&``N^.R@D
M`G\:GHH`\P;X[>%T=D>PUE74X96@C!!]"-]-_P"%\^%?^?+5_P#OQ'_\<J+X
MH?"Y=<637=#B"ZFHS/;J,"Y`[C_;_G]:^?2"K%6!5@2"",$$=0:`/H?_`(7S
MX5_Y\M7_`._$?_QRC_A?/A7_`)\M7_[\1_\`QROG>B@#Z(_X7SX5_P"?+5_^
M_$?_`,<H_P"%\^%?^?+5_P#OQ'_\<KYWHH`^B/\`A?/A7_GRU?\`[\1__'*/
M^%\^%?\`GRU?_OQ'_P#'*^=Z*`/HC_A?/A7_`)\M7_[\1_\`QRC_`(7SX5_Y
M\M7_`._$?_QROG>B@#Z(_P"%\^%?^?+5_P#OQ'_\<H_X7SX5_P"?+5_^_$?_
M`,<KYWHH`^B/^%\^%?\`GRU?_OQ'_P#'*/\`A?/A7_GRU?\`[\1__'*^=Z*`
M/HC_`(7SX5_Y\M7_`._$?_QRC_A?/A7_`)\M7_[\1_\`QROG>B@#Z(_X7SX5
M_P"?+5_^_$?_`,<H_P"%\^%?^?+5_P#OQ'_\<KYWHH`^B/\`A?/A7_GRU?\`
M[\1__'*/^%\^%?\`GRU?_OQ'_P#'*^=Z*`/JWPE\1=!\9S3V^GO/#<Q#<8+I
M0CLO]Y<$@CUYR/Q%=97Q=8WUUIE]#>V4[P7,+;HY$/*FOICX=?$2V\9V`@N-
MD&L0)F>$<"0?WT]O;M^M`'<T444`%%%%`!1110`4444`9-]8^7F6(?)U91VK
M/KIJR;ZQ\O,L0^3^)?2@#/HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@"2&9X)`Z'GN/6MRWN$N8]Z=>X]*Y^I(9G@D#H>>X]:`.BJ*YMH;
MRW>WN(Q)$XPRFBWN$N8PZ=>X]*EH`\K\0>'YM$N<C,EHY_=R>G^R??\`G6-7
ML]U:PWML]O<1B2)QAE->8>(-`FT2YXR]JY_=R?T/O0!CT444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110!M>'O$$NB7.UMSV;G]Y'Z?[0]_P"=
M>G6US#=VZ3P2"2)QE6'>O%ZV_#WB&;1)]C9DLW/SQ]U/]X>_\Z`/4JYSQ=X2
MM?%%AM.V*^B!\B?'3_9;U4UOV]Q%=0)/!(LD3C*LO0BI*`/F74-/NM+OI;*]
MA,5Q$<,I_F#W'O5:O?\`Q?X0M?%%B,XBOH@?(GQ_XZWJI_2O";^PNM,OIK*\
MB:*XB;#*?YCU![&@"M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%'6BB@#UCP#X^^T^7H^L3?O_`+MO<N?]9_LL?[WH>_UZ^EU\N5ZSX`\>_:_*
MT;6)1]HX2WN&/^L]%8_WO0]_KU`/2J\G^*7PO&M)+KNA0J-34;KBW7@7(]1_
MM_S^M>L44`?$[*R,592K*<%2,$'T-)7T!\4?A<-9$NO:%#C4@-UQ;(.+@#N!
M_?\`Y_6OG\@@D$$$'!!&"#0`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!5BPOKK3+^"^L9W@NH&WQR(<%3_G@CN#5>B@#ZA^'?Q#M/&=AY$^V#
M5X%_?0=G']]/4>HZ@_@3W%?%UA?W>EW\-]87#V]U"VZ.5#R#_4>U?3?P\^(5
MKXTL#%*$@U>!,SVX/##IO3/\.?RS0!VU%%%`!1110`4444`%%%%`&1?6/EYE
MB'R?Q*.U4*Z:L>_LA"?-CP$)Y'H:`*-%%%`!114UJJO=1*P!!;D&@"&BKTMJ
MC37#;O+BC_NK3Y;-99HDC"J/+W,P'6@#.HJ\VG$/$-Y"N<'(Y%-ELECB:03;
M@K;6PO2@"G16C-;PI>01Q@#/567(/7D\TL44*)<NZHS(V.4R!]!0!FT5<6R#
M/&1(=CH7+;>E4SUXZ4`%%%%`!1110`4444`20S/;R!T//<>M;MO<)<Q[T_$>
ME<]4D,[V\@=#SW'8T`=%4-U:PWML]O<1AXG&&4TZ"9;B$2*"`>QJ2@#RK7]`
MGT2Y[R6KG]W)_0^]8]>SW=I!>VSV]Q&'B<8*FO+=?T1]$OO*WAX9/FB;/./0
MB@#*HHHH`***[W2K+3$\,V=U<6NF^8_#27>%#<GOCD\4`<%1727>DV^I2:G<
M63P(]KLQ!;`-&RX&2I'X]NHI&\,P+JDUG]MF<PQJS>5;%V+'M@<`=.21UH`Y
MRBNRL/#<5AXD@M[D)=036SR!98QP1CJ.1FLM/#Z36=G=?:2GVJ[,&P)P@W$9
MZ\]*`,&BNC7PQ&=1N[4W4[>0RJOE6Q=F)`//91]3VJ]IWABTMO$CV5ZQN%$`
MFB!4@-SSNP>Q'3D'-`''45T5AX9&IBZN89I3:QR%(]L0WN>,\$@`#/K6?K>C
MR:+?"W=Q(K+O1\8R/<>M`&;1110`4444`%%%%`&WX=\0RZ+<;'W26;GYT'53
M_>'O_.O3K>XBNK=)X)%DB<95EZ$5XM6YX=\12Z+/Y<F7LG/SIW7_`&E_P[T`
M>HUS7B_PC;>*+#^&*_B'[B?'_CK>JG]*Z-'62-77.U@",C'%.H`^9+^PNM,O
MI;.\A:*XB.&4_P`QZCWJO7OWB_P?:^*++/RQ7\0_<SX_\=;U'\J\%N()+6YE
MMY@!+$Y1PK!@"#@\CK0!'1110`449QR,9'K7IS>'=/U^?PIJ6GV$$5K<$K>Q
MPQA5ROS'(''4,#^%.PKGF-%>@R>&--\2ZU>S6+26MNMR;:&&QL"R`+P79N$&
M3SUSTI;;PO;:5:>,;2[B@NYK*U#V\[QC*Y0L",_=/3\JF^EQ];'GM%>@3^$#
MJLOAFSA-G;BZM'EDE@M=C!0$Y?YCO//7CK[TE]H.D+X%MFL98II)-3$'VY[8
MK(!D@@@9)&>PSGBG_7XV!._]>5S@**[C4OA^MIH5YJ=O>W3+:X++<V9AWCN5
M#'=Q[@9JSXB\*:4(?#UGHQ9+N^52I=#^]!`)=R22,==HXY.*`//J*[O6?AM-
MIFDWM[#=2R&T&YUEA"+(O<H0QZ>X%<)0`4444`%%%%`!1110!ZUX!\>B[$>C
MZQ+_`*3]VWN&/^L_V6/][T/?Z]?2:^7*]?\`AYXWEU1DT74B\EVJ$PSXSYB@
M=&]QZ]_KU`/1*\E^*7PO_MA9=>T*$#41\US;*,?:!_>7_;_G]>OK5%`'Q.05
M8JP(8'!!&"#25[S\6?AK!>6UUXFTD1P742&6\B+!4F4#EQG@,!^?UZ\?X%T7
M1+3P+K/C+5],357LY?)@M)3B/HN2PZ'._N#C%'1L/(\VHKT6[T?2?'>LZ##X
M=T6;1+J_B=[K=$1:A4ZM'P`V,$94`$D9YS44WPXL[BUAO=&UQ[VT75$TR[,E
MMY;PLSJNY1D[A\P/;M19_P!?<']?U]QY_17K%S\'-/B&J(GBV+S]-"27"R6I
M`BC89RQ!ZX#$`9Z"H%^$<$OBC3],@UXRV=_I[WL-TMOR=I7C;NZ$.#G-`'EU
M%>II\)=)DM=/O%\80FSNIC:F7[*>9L[0B#//S!ADXZ5!8_!^\N=6UNWEO7-M
MIDHB1K>$/+.6"L,*S`#"L,\]>F:/Z_K[P/,Z*]33X,S'Q3+I$FJF.(V/VNWG
M,`RQW;2C#=P02,D$]:RD\!:*^GZIK0\22/H%B4B%W'9Y>:4XR%3(X&X#.>M`
M'`T5Z5X.\,:7<^(=8MM/U#2]8M(M/,R376GM)M.<8VEEVN/4$BH?"'PQ@\3:
M78W!U2^26Y4L3%ISM#$!_>E;:I.>RYH_K\_\@_K^OO/.Z*]-;PQ::=\+M>^T
MV=I)JECK*V@N_*!;`E13@]=I!/'H:D\2>#=.G^(=OH<LJVDL]E"T":1I6U')
M9P2R^8<8`R6ST^G(M79?UI<3=M_ZUL>745Z7:?"F'4O$NJ:=IVM/=6>EH!<S
MQP#>9CG]TB[L$C'))&.E8?CGP'<>##8RF=Y[:\0E#)&$DC8`$JP!(SSV)I7V
M*L<A1113$%6=/U"[TK4(+^QG:"Z@;='(IY!_P[8JM10!]1_#WXA6GC33O*EV
MP:O`O[^WSPW^VGJI_0\>A/;5\7Z=J-YI.H07]A</;W4#!HY$Z@_U'J#P:^H?
MAYXXC\;:(\[0F&]MB([E`#LW$<%3Z''3J/RR`=?1110`4444`%%%,EE2&,NY
MPHH`)94AC+N<**P[FY>YDW-PH^ZOI1=73W,F3PH^ZOI4%`!1110`4^*0Q2K(
M`"5.<&F44`61>/OE)1&63[RGI2_;I?,1]JY5=I&."*JT4`6!=%9$=(8TV<@`
M=?QI&NG:&2/:N)&W$^E044`66O7:2.0HF]._/--^UOLF7:O[TY/M4%%`%W[1
M'%8&%)"[MQ]TC:#UJE110`4444`%%%%`!1110`5;LK(W#;WXB'ZT65D;AM[Y
M$0_6MI5"J%4``=`*`!5"J%4``<`"EHK)UW7;?1+7>^'N''[J+/+>Y]!0`:]K
MT&B6NYL/</\`ZJ('K[GT%>7WEY/?W<ES<N7E<\GT]AZ"B\O+B_NGN;J0R2OU
M/8>P]!4%`!1110`5NVOBB:VTV&Q>PL[B*+[OG*6YYY_6L*B@#8@\0SVNKOJ%
MO;6\1=-C0HN$(^E%KXBNK=[XO%%,EZ<RH^0/P(.>AQ6/10!O#Q7=B[MKG[-;
MAK>$PJH!`(..V?:FV/BB\L;-;9(+>14E,J-(N2I)R0/S//7FL.B@#>;Q7=2+
M=I+:V\D=RP=HVW8!``]>>@ZTC>*KQM7BU$0P"1(3"4&=K+^=85%`&M#KSQ1W
M,!LK62TG?>;=P2JMQR.<]JHWMV;VY:8PPP@\".%`J@?A5>B@`HHHH`****`"
MBBB@`KN/"OA;9Y>HZA'\WWH86'3T8^_H*/"OA;;LU'48_F^]#"PZ?[3#^E=K
M0`445YCX_P#'WE>;HVC3?O>4N;E#]SU13Z]B>WUZ`">/O'WEF71M&E^?[MQ<
MH?N^JJ?7U/;^7E8``P.E%%`!1110`5TN@^-]3\/:1/IUK'"\<K,ZN^=T9(P=
MO/MGZUS5%'D!T>F^,;O3M$BTHV=I<P0R^=$9@V58'(X!`.#SS4MUXYOKJ36'
M:TME.JP+#+C=\@"E<KSUP>]<O10]=P.G3QSJ45SI$\4-NC:9"T*#!(D4@`AN
M?]D=*<_CJ]^SP06UA8VL=O=B[C6)3@-SD')Y!)/YURU%%PL=9>>/+N\MM3@_
MLZRC&HJ!.Z;]Q(&,Y)],#'08JK/XQOI[32X_L]NMSIFP6]T`=X"]B,X(/&>.
MU<[10!OZKXI.J0W(_L?3+>>Z8/-<QPYD8^Q;.,^U8%%%`!1110`4444`%%%6
MM.TZZU:_BL;*$RSRG"J.WJ2>P'K0`:;IMWJ]_%96,)EGD.`.P]R>P'K7O'A/
MPG:>%]/\M,2WD@'GSXY8^@]%%)X2\)6GA>PV)B6\E`\^<CEO8>BBNBH`*BN;
MF"SM9;FYE2*")2[R.<!0.Y-%Q<0VEM+<W,J0P1*7DDD;"JHZDD]!7S;\2OB3
M/XNN3I^G.\6BQ-D#H;AA_$WMZ#\3SC``GQ)^),_B^Z;3[`O%HL3_`"@\&X(_
MB8>F>@_$\\#"\*^-]3\)+<P6L=M=65U_K[2Z3=&YQC/Y?G@5S=%`':7WQ0\0
M7>L:;?VXM;*/3<BVM+>/$*@KM(([Y''MVI+SXD:A/';0VFF:?I]M%?KJ$L-L
MK`3S*P8%R3G&5[?T%<910!V\WQ.U2>XU^9K"R!UN%(9P-^(PJLH*\]?F/6I+
M3XJ:K:7VE7::?9,^FV!L8@=^&0[.3SU^0?F:X2BC;^O7_-A_7]?<CKHOB#J$
M.BZ?I8LK0Q6-_P#;T<[MS/O9]IYZ9:IW^)>HW%YK+WFF:?=V6KE&N+&96,6Y
M0H##G(/RCOUKBJ*/Z_+_`"0?U_7WG9Z=\1[W2M=NM4L]'TF`3VWV46T$'E1H
MN<Y^7!)]SFL[P]XPNM!T:\T9[*TU'2[O#26MVIV[ACY@5((/`KG:*`.SL_B/
M?6&LWFH6VDZ7"MS:_91;PP^7'&G7(VX)/N<U/IWQ3U.PT_1[9],TZY?21MMI
MI@^Y1C'0,!G;QG&>OJ:X6BC^OZ^\#K;WQ_?WVC:IICV5JL6HW_V^1EW;E?>K
MX'/3*_K6HGQ;U--?N-9.D:<UU-:):9/F#8BEC\I#9!.[GZ"O/J*+?U^'Y!_7
MZG76/CR33+FZ^PZ%I<%A>V_D7=AAVBFZX8Y8G/S$<&L?7=<&M30F/2].TZ"!
M`B0V4`0?5F^\QX[FLFB@`HHHH`***Z;P3X*O_&NK_9K<-%9Q8-S=%?EC'H/5
MCV'XT`+X)\$:AXUU86]OF&RB(-S=$<1KZ#U8]A^)KZBT31+#P]I,.FZ;`(;:
M(<#NQ[LQ[D^M-T+0M/\`#FD0Z9ID`AMHA]2Q[LQ[D^M:5`!1110`444R65(8
MR[G"B@`EE2&,NYPHK#NKI[J3)X4?=7THNKI[F3)X0?=7TJ"@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`JW961N6W-D1#OZT6=F;EMS9
M$0ZGUK:50BA5``'0"@`50JA5``'``I:*RM<URWT2TWR8>=_]5$#RQ]?I0`:[
MKL&B6F]\/._$40/+'U/H*\NO;R?4+M[JY<O*_4^@]![47M[<:A=O<W4A>5SU
M[`>@]!4%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!7;
M^%?"V-FHZC'SUAA8=/\`:/\`04GA7PM_J]1U"/\`VH86'Y,P_D*[>@`HHKS/
MQ]X^^S^;HVCS?OON7%RA^YZJI_O>I[?7H`)X^\?>1YFC:/+^]Y6XN5/W/]E3
MZ^I[?R\IHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHJSI
M^GW>JWT5E90M-<2G"J/YD]@.YH`73M.N]5OXK*RA,L\IPJCM[D]@/6O=_"7A
M*U\+Z?L7;+>R`>?/CJ?0>BBD\)>$;3PO8D+MEO90//GQU_V1Z**Z.@`J*XN(
M;2VDN+B5(H8E+N[G`4#J2:6>>&UMY+BXE2*&-2SR.P55`ZDD]!7S=\2_B5-X
MLN&TW37>+18V^AN2.C-_L^@_$\XP`)\2_B5-XMNFT[3F>+18FX[-<L/XF]%]
M!^)]!YY110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1172^"
M_!>H>--8%K:J8K2,@W-T1\L2^@]6/8?CTH`/!?@K4/&NK?9;7,-I&0;FZ*Y$
M0]!ZL>PKZCT+0M/\.:3#INF0"*WB'U+'NS'N3ZTF@Z#I_AK2(=,TR`16\?/J
MSMW9CW)]:TJ`"BBB@`HHHH`9+*D,9=V`45AW5VUU)D\(/NKFM_&:3`]!0!S6
M1ZT9'K72X'H*,#T%`'-9'K1D>M=+@>@HP/04`<UD>M&1ZUTN!Z"C`]!0!S61
MZT9'K72X'H*,#T%`'-9'K1D>M=+@>@HP/04`<UD>M&1ZUTN!Z"C`]!0!S61Z
MT9'K72X'H*,#T%`'-9'K1D>M=+@>@HP/04`<UD>M&1ZUTN!Z"C`]!0!S61ZU
M:L[,W+;FXB'4^OM6W@>@I:`$50BA5``'0"EHHH`RM=UZVT.T\R0AYV'[J+."
MQ_H/>O+KW4)M1NWN;F4/*_OP!Z#VKV4JK')4'ZBD\M/[B_E0!XGO7^\/SHWK
M_>'YU[9Y:?W%_*CRT_N+^5`'B>]?[P_.C>O]X?G7MGEI_<7\J/+3^XOY4`>)
M[U_O#\Z-Z_WA^=>V>6G]Q?RH\M/[B_E0!XGO7^\/SHWK_>'YU[9Y:?W%_*CR
MT_N+^5`'B>]?[P_.C>O]X?G7MGEI_<7\J/+3^XOY4`>)[U_O#\Z-Z_WA^=>V
M>6G]Q?RH\M/[B_E0!XGO7^\/SHWK_>'YU[9Y:?W%_*CRT_N+^5`'B>]?[P_.
MC>O]X?G7MGEI_<7\J/+3^XOY4`>)[U_O#\Z-Z_WA^=>V>6G]Q?RH\M/[B_E0
M!XGO7^\/SKM_"OA;E-1U&/\`VH86'_CS?T%=KY:?W%_*G4`%%%%`'F7C[X@I
M;>9HVCW"^?\`=N+A6_U?JJ_[7J>WUZ>3^8G]]?SKZB\J/_GFG_?(H\F/_GFG
M_?(H`^7?,3^^OYT>8G]]?SKZB\F/_GFG_?(H\F/_`)YI_P!\B@#Y=\Q/[Z_G
M1YB?WU_.OJ+R8_\`GFG_`'R*/)C_`.>:?]\B@#Y=\Q/[Z_G1YB?WU_.OJ+R8
M_P#GFG_?(H\F/_GFG_?(H`^7?,3^^OYT>8G]]?SKZB\F/_GFG_?(H\F/_GFG
M_?(H`^7?,3^^OYT>8G]]?SKZB\F/_GFG_?(H\F/_`)YI_P!\B@#Y=\Q/[Z_G
M1YB?WU_.OJ+R8_\`GFG_`'R*/)C_`.>:?]\B@#Y=\Q/[Z_G1YB?WU_.OJ+R8
M_P#GFG_?(H\F/_GFG_?(H`^7?,3^^OYT>8G]]?SKZB\F/_GFG_?(H\F/_GFG
M_?(H`^7?,3^^OYT>8G]]?SKZB\F/_GFG_?(H\F/_`)YI_P!\B@#YGTZRN-6O
MXK*QC\ZXE.%53^I]`/6O>/"/A&U\+V&`1-?2C]_/CK_LKZ*/UZUT*QHIRJ*#
MZ@4Z@`J*XN(;2VDN+F5(H8E+O([850.I)J6D*A@0P!!Z@T`?-7Q,^*!\5W#:
M9IDWE:+$W)W8:Y8?Q'T7T'XGT'G/FQ_\]%_.OMCR(?\`GE'_`-\BCR(?^>4?
M_?(H`^)_-C_YZ+^='FQ_\]%_.OMCR(?^>4?_`'R*/(A_YY1_]\B@#XG\V/\`
MYZ+^='FQ_P#/1?SK[8\B'_GE'_WR*/(A_P">4?\`WR*`/B?S8_\`GHOYT>;'
M_P`]%_.OMCR(?^>4?_?(H\B'_GE'_P!\B@#XG\V/_GHOYT>;'_ST7\Z^V/(A
M_P">4?\`WR*/(A_YY1_]\B@#XG\V/_GHOYT>;'_ST7\Z^V/(A_YY1_\`?(H\
MB'_GE'_WR*`/B?S8_P#GHOYT>;'_`,]%_.OMCR(?^>4?_?(H\B'_`)Y1_P#?
M(H`^)_-C_P">B_G1YL?_`#T7\Z^V/(A_YY1_]\BCR(?^>4?_`'R*`/B?S8_^
M>B_G1YL?_/1?SK[8\B'_`)Y1_P#?(H\B'_GE'_WR*`/B?S8_^>B_G1YL?_/1
M?SK[8\B'_GE'_P!\BCR(?^>4?_?(H`^3?!7@V_\`&VK?9;(^7:QD&YNB,K$O
M]6/85]1Z!H&G^&M(ATS381'!$.2>6=N[,>Y-:*HB`A%5<^@Q3J`"BBB@`HHH
(H`****`/_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>3
<FILENAME>ex3-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE>Exhibit 3.1</TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AMENDED AND RESTATED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATE OF INCORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>IMPRIMIS PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<HR SIZE="1" NOSHADE ALIGN="CENTER" STYLE="width: 50%; color: black">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-transform: uppercase">Imprimis
Pharmaceuticals, Inc.</FONT>, a corporation organized and existing under and by virtue of the General Corporation Law of the State
of Delaware (the &ldquo;Corporation&rdquo;), does hereby certify as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">The name of the Corporation is Imprimis Pharmaceuticals, Inc. The Corporation was originally incorporated
under the name of Bywater Resources Inc. and changed its name to Imprimis Pharmaceuticals, Inc. pursuant to a Certificate of Amendment
to Certificate of Incorporation filed with the Secretary of State of Delaware on February 13, 2012 and effective on February 28,
2012.</TD></TR>               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">The Corporation&rsquo;s original Certificate of Incorporation was filed with the Secretary of State
of the State of Delaware on January 11, 2006.</TD></TR>                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">The Board of Directors of the Corporation has duly adopted resolutions proposing to amend and restate
the Certificate of Incorporation, and that said amendment and restatement was duly adopted in accordance with the provisions of
Sections 242 and 245 of the General Corporation Law of the State of Delaware. This Amended and Restated Certificate of Incorporation
amends and restates and replaces in its entirety the Corporation&rsquo;s Certificate of Incorporation as in effect immediately
prior to the filing of this Amended and Restated Certificate of Incorporation.</TD></TR>                                                                                        <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">The text of the Corporation&rsquo;s Amended and Restated Certificate of Incorporation is hereby
restated and further amended to read in its entirety as set forth in <U>Exhibit A</U> attached hereto.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
Corporation has caused this Amended and Restated Certificate of Incorporation to be executed on this 10<SUP>th </SUP>day of September,
2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">IMPRIMIS PHARMACEUTICALS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 6%; padding-bottom: 1.5pt"><font style="font-size: 10pt">By: </font></td>
    <TD STYLE="width: 44%; border-bottom: Black 1.5pt solid"><font style="font-size: 10pt"><i>/s/ Mark L. Baum</i></font></td>
    <TD STYLE="width: 50%; padding-bottom: 1.5pt"><font style="font-size: 10pt"><i>&nbsp;</i></font></td></tr>
<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">Name:</font></td>
    <TD><font style="font-size: 10pt">Mark L. Baum</font></td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD><font style="font-size: 10pt">Title:</font></td>
    <TD><font style="font-size: 10pt">Chief Executive Officer</font></td>
    <TD>&nbsp;</td></tr>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">FIRST: The name of this
Corporation is Imprimis Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">SECOND: The address, including
street, number, city and county, of the registered office of the Corporation in the State of Delaware is 615 South DuPont Highway,
Dover, Delaware 19901, County of Kent; and the name of the registered agent of the Corporation in the State of Delaware at such
address is National Corporate Research, Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">THIRD: The nature of the
business and of the purposes to be conducted and promoted by the Corporation is to conduct any lawful business, to promote any
lawful purpose, and to engage in any lawful act or activity for which corporations may be organized under the General Corporation
Law of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">FOURTH:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">A.&#9;The total number
of shares of stock that the Corporation shall have authority to issue is Ninety Five Million (95,000,000). The classes and aggregate
number of shares of each class which the Corporation shall have authority to issue are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Ninety Million (90,000,000) shares of Common Stock, par value $0.001 per share (the &ldquo;Common
Stock&rdquo;); and</TD></TR>                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Five Million (5,000,000) shares of Preferred Stock, par value $0.001 per share (the &ldquo;Preferred
Stock&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">B.&#9;The Corporation
may issue any class of the Preferred Stock in any series. The Board of Directors shall have authority to establish and designate
series, and to fix the number of shares included in each such series and the variations in the relative rights, preferences and
limitations as between series, provided that, if the stated dividends and amounts payable on liquidation are not paid in full,
the shares of all series of the same class shall share ratably in the payment of dividends including accumulations, if any, in
accordance with the sums which would be payable on such shares if all dividends were declared and paid in full, and in any distribution
of assets other than by way of dividends in accordance with the sums which would be payable on such distribution if all sums payable
were discharged in full. Shares of each such series when issued shall be designated to distinguish the shares of each series from
shares of all other series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">FIFTH: Whenever a compromise
or arrangement is proposed between this Corporation and its creditors or any class of them and/or between this Corporation and
its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application
in a summary way of this Corporation or any creditor or stockholder thereof or on the application of any receiver or receivers
appointed for this Corporation under the provisions of Section 291 of Title 8 of the Delaware Code or on the application of trustees
in dissolution or of any receiver or receivers appointed for this Corporation under the provisions of Section 279 of Title 8 of
the Delaware Code order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders,
of this Corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing
three-fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders, of this Corporation,
as the case may be, agree to any compromise or arrangement and to any reorganization of this Corporation as a consequence of such
compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if sanctioned by the court to
which the said application has been made, be binding on all the creditors or class of creditors, and/or on all the stockholders
or class of stockholders, of this Corporation, as the case may be, and also on this Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">SIXTH: The original Bylaws
of the Corporation shall be adopted by the incorporator. Thereafter, the power to make, alter, or repeal the Bylaws, and to adopt
any new Bylaw, shall be vested in the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">SEVENTH: To the fullest
extent that the General Corporation Law of the State of Delaware, as it exists on the date hereof or as it may hereafter be amended,
permits the limitation or elimination of the liability of directors, no director of this Corporation shall be personally liable
to this Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. Notwithstanding the foregoing,
a director shall be liable to the extent provided by applicable law: (1) for any breach of the directors&rsquo; duty of loyalty
to the Corporation or its stockholders; (2) for acts or omissions not in good faith or which involve intentional misconduct or
a knowing violation of law; (3) under section 174 of the General Corporation Law of the State of Delaware; or (4) for any transaction
from which the director derived any improper personal benefit. Neither the amendment nor repeal of this Article, nor the adoption
of any provision of this Certificate of Incorporation inconsistent with this Article, shall adversely affect any right or protection
of a director of the Corporation existing at the time of such amendment or repeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">EIGHTH: The Corporation
shall, to the fullest extent permitted by Section 145 of the General Corporation Law of the State of Delaware, as the same may
be amended and supplemented, indemnify any and all persons whom it shall have power to indemnify under said section from and against
any and all of the expenses, liabilities or other matters referred to in or covered by said section. The Corporation shall advance
expenses to the fullest extent permitted by said section. Such right to indemnification and advancement of expenses shall continue
as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of the heirs, executors
and administrators of such a person. The indemnification and advancement of expenses provided for herein shall not be deemed exclusive
of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any Bylaw, agreement,
vote of stockholders or disinterested directors or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE>Exhibit 21.1</TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>IMPRIMIS PHARMACEUTICALS, INC. SUBSIDIARIES</B><BR>
as of December&nbsp;31, 2014</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 35%; line-height: 115%; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Name of Subsidiary</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 30%; text-align: center; line-height: 115%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 35%; text-align: center; line-height: 115%; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>State of</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Incorporation or</B></FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Organization</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pharmacy Creations, LLC</FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">New Jersey</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE>Exhibit 23.1</TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -10pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
consent to the incorporation by reference in Registration Statement Nos. 333-159159, 333-183488 and 333-198674 on Form&nbsp;S-8
and Registration Statement No. 333-198675 on Form S-3 of our report dated March 12, 2015, relating to the consolidated financial
statements of Imprimis Pharmaceuticals, Inc. and subsidiary, appearing in this Annual Report on Form 10-K of Imprimis Pharmaceuticals,
Inc. for the year ended December 31, 2014.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 53%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ KMJ Corbin &amp;
    Company LLP</I></FONT></TD>
    <TD STYLE="width: 47%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Costa
    Mesa, California</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March
    12, 2015</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE>Exhibit 31.1</TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit 31.1</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION
OF THE PRINCIPAL EXECUTIVE OFFICER UNDER</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SECTION
302 OF THE SARBANES-OXLEY ACT</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">I,
Mark L. Baum, certify that:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have
    reviewed this Form 10-K for the fiscal year ended December 31, 2015 of Imprimis Pharmaceuticals, Inc.;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
    statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
    covered by this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    the financial statements, and other financial information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
    report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s
    other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
    defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the&nbsp;registrant and have:</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness
    of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in the
    report any change in this registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
    March 12, 2015</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Mark L. Baum</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Mark
                                         L. Baum</FONT></P>
        <P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Chief
        Executive Officer</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE>Exhibit 31.2</TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXHIBIT
31.2</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION
OF THE PRINCIPAL FINANCIAL OFFICER UNDER</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SECTION
302 OF THE SARBANES-OXLEY ACT</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">I,
Andrew R. Boll, certify that:</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have
    reviewed this Form 10-K for the fiscal year ended December 31, 2015 of Imprimis Pharmaceuticals, Inc.;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
    statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
    covered by this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    the financial statements, and other financial information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this
    report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The registrant&rsquo;s
    other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
    defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the&nbsp;registrant and have:</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed
    in the report any change in this registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether
    or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal
    control over financial reporting.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
    March 12, 2015</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    Andrew R. Boll</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Andrew
                                         R. Boll</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">Chief
                                         Financial Officer</FONT></P></TD></TR>
</TABLE>





<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE>Exhibit 32.1</TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit&nbsp;32.1 </B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION
REQUIRED BY</B><BR>
<B>SECTION&nbsp;1350 OF TITLE 18 OF THE UNITED STATES CODE </B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, each of the undersigned hereby certifies in his capacity as the specified
officer of Imprimis Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;), that, to the best of his knowledge, the Annual Report of
the Company on Form&nbsp;10-K for the fiscal year ended December 31, 2014 fully complies with the requirements of Section&nbsp;13(a)
or 15(d), as applicable, of the Securities Exchange Act of 1934, and that the information contained in such report fairly presents,
in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods
presented in the financial statements included in such report.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: March 12, 2015</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/ Mark L. Baum</I></FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mark L. Baum</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Chief Executive Officer</I></FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: March 12, 2015</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/&nbsp;Andrew R. Boll</I></FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Andrew R. Boll</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Chief Financial Officer</I></FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
certification accompanies this Report on Form&nbsp;10-K pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 and shall
not be deemed filed by the Company for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of
1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>immy-20141231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: IMMY%2D20141231 10K FY DFN.xfr; Date: 2015%2D03%2D12T19:30:59 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80030000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:IMMY="http://imprimispharma.com/20141231">
    <link:schemaRef xlink:href="immy-20141231.xsd" xlink:type="simple" />
    <xbrli:context id="From2014-01-01to2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-02-01to2013-02-28_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-02-01</xbrli:startDate>
        <xbrli:endDate>2013-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_StockOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:StockOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_OptionsGrantedConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:OptionsGrantedConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30_us-gaap_StockOptionMember_custom_TwoThousandSecenIncentiveStockAndAwardsPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:TwoThousandSecenIncentiveStockAndAwardsPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IMMY:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_OptionsEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:OptionsEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTranche4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:ExecutiveRestrictedStockUnitsTranche4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTranche5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:ExecutiveRestrictedStockUnitsTranche5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_WarrantsIssuedToFormerMajorShareholderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:WarrantsIssuedToFormerMajorShareholderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_UnderwriterWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:UnderwriterWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-29to2013-05-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-29</xbrli:startDate>
        <xbrli:endDate>2013-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-29to2013-05-02_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-29</xbrli:startDate>
        <xbrli:endDate>2013-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-29to2013-05-02_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-29</xbrli:startDate>
        <xbrli:endDate>2013-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-09-26to2013-09-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-09-26</xbrli:startDate>
        <xbrli:endDate>2013-09-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-07-01to2012-07-31_custom_MarkBaumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:MarkBaumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-07-01</xbrli:startDate>
        <xbrli:endDate>2012-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IMMY:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IMMY:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IMMY:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IMMY:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:ExecutiveRestrictedStockUnitsTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:ExecutiveRestrictedStockUnitsTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:ExecutiveRestrictedStockUnitsTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-23to2013-05-24_custom_ConsultantTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:ConsultantTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-23</xbrli:startDate>
        <xbrli:endDate>2013-05-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-23to2013-05-24_custom_ConsultantTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:ConsultantTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-23</xbrli:startDate>
        <xbrli:endDate>2013-05-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-23to2013-05-24_custom_ConsultantTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:ConsultantTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-23</xbrli:startDate>
        <xbrli:endDate>2013-05-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-23to2013-05-24_custom_ConsultantTrancheFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:ConsultantTrancheFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-23</xbrli:startDate>
        <xbrli:endDate>2013-05-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-23to2013-05-24_custom_ConsultantTrancheFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:ConsultantTrancheFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-23</xbrli:startDate>
        <xbrli:endDate>2013-05-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:WarrantsIssuedToInvestorRelationsConsultantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:WarrantsIssuedToInvestorRelationsConsultantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-04-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-02-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-02-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_OptionsGrantedConsultantsMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:OptionsGrantedConsultantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_OptionsGrantedConsultantsMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:OptionsGrantedConsultantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_RangeOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IMMY:RangeOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_RangeTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IMMY:RangeTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_RangeThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IMMY:RangeThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_RangeFourMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IMMY:RangeFourMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_RangeFiveMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">IMMY:RangeFiveMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-11">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_RestrictedStockUnitsRSUOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:RestrictedStockUnitsRSUOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-02-28_custom_WarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IMMY:WarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_OptionsEmployeesMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:OptionsEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_OptionsEmployeesMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:OptionsEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_custom_StockOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:StockOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_TradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_CustomerRelationshipsMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_CustomerRelationshipsMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_CustomerRelationshipsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_TradeNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_NoncompeteAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_LicensingAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-04-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_RestrictedStockUnitsRSUOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:RestrictedStockUnitsRSUOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-06-01to2014-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-06-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2010-01-31_custom_PharmacyCreationsLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:PharmacyCreationsLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2010-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2010-01-01to2010-01-31_custom_PharmacyCreationsLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:PharmacyCreationsLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2010-01-01</xbrli:startDate>
        <xbrli:endDate>2010-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_WarrantsIssuedToFormerMajorShareholderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:WarrantsIssuedToFormerMajorShareholderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_UnderwriterWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:UnderwriterWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:WarrantsIssuedToInvestorRelationsConsultantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:WarrantsIssuedToInvestorRelationsConsultantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMMY:PharmacyCreationsLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember_us-gaap_MinimumMember_custom_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMMY:PharmacyCreationsLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">IMMY:PeriodEndingMarchThirtyFirstTwoThousandSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember_us-gaap_MaximumMember_custom_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMMY:PharmacyCreationsLlcMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreationDateAxis">IMMY:PeriodEndingMarchThirtyFirstTwoThousandSixteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_PharmacyCreationsLlcMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">IMMY:PharmacyCreationsLlcMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-01to2013-04-02_custom_EmployeesAndDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:EmployeesAndDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-01</xbrli:startDate>
        <xbrli:endDate>2013-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_EmployeesMember_custom_SellingAndMarketingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:SellingAndMarketingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_EmployeesMember_custom_SellingAndMarketingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:SellingAndMarketingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_EmployeesMember_custom_GeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:GeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_EmployeesMember_custom_GeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:GeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_EmployeesMember_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_EmployeesMember_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_DirectorMember_custom_GeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:GeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_DirectorMember_custom_GeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:GeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConsultantMember_custom_SellingAndMarketingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:SellingAndMarketingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConsultantMember_custom_SellingAndMarketingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:SellingAndMarketingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConsultantMember_custom_GeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:GeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConsultantMember_custom_GeneralAndAdministrativeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:GeneralAndAdministrativeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConsultantMember_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConsultantMember_custom_ResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:ConsultantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">IMMY:ResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-30to2015-03-11_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-30</xbrli:startDate>
        <xbrli:endDate>2015-03-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-23to2014-10-24_custom_UrigenPharmaceuticalsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:UrigenPharmaceuticalsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-23</xbrli:startDate>
        <xbrli:endDate>2014-10-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_StockOptionPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:StockOptionPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_OptionsEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:OptionsEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_OptionsEmployeesMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:OptionsEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_OptionsEmployeesMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:OptionsEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_OptionsGrantedConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:OptionsGrantedConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_OptionsGrantedConsultantsMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:OptionsGrantedConsultantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_MaximumMember_custom_OptionsGrantedConsultantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:OptionsGrantedConsultantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-02-01to2013-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-02-01</xbrli:startDate>
        <xbrli:endDate>2013-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-02-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-02-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-02-12to2013-02-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-02-12</xbrli:startDate>
        <xbrli:endDate>2013-02-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-01to2013-06-30_custom_MarkBaumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:MarkBaumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-09-01to2013-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-09-01</xbrli:startDate>
        <xbrli:endDate>2013-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_RestrictedStockMember_custom_DrRobertKammerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:DrRobertKammerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2014-10-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2014-10-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:BaumPerformanceEquityAwardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MonteCarloSimulationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:BaumPerformanceEquityAwardMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">IMMY:MonteCarloSimulationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MarkBaumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:BaumPerformanceEquityAwardMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">IMMY:MarkBaumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MonteCarloSimulationOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">IMMY:BaumPerformanceEquityAwardMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">IMMY:MonteCarloSimulationOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-23to2013-05-24_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-23</xbrli:startDate>
        <xbrli:endDate>2013-05-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_ConsultantMember458685886">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_MonteCarloSimulationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">IMMY:MonteCarloSimulationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-03-01to2014-03-31_custom_ConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:ConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-03-01</xbrli:startDate>
        <xbrli:endDate>2014-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-01to2013-06-30_custom_NonEmployeeDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:NonEmployeeDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-01to2013-06-30_custom_NonEmployeeDirectorsMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:NonEmployeeDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2013-10-31_custom_FormerDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:FormerDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2013-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-10-01to2013-10-31_custom_FormerDirectorsMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:FormerDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-10-01</xbrli:startDate>
        <xbrli:endDate>2013-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-11-01to2013-11-30_custom_EmployeesMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:EmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-11-01</xbrli:startDate>
        <xbrli:endDate>2013-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-11-01to2013-11-30_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-11-01</xbrli:startDate>
        <xbrli:endDate>2013-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_NonEmployeeDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:NonEmployeeDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_NonEmployeeDirectorsMember_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:NonEmployeeDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-07-31_custom_WarrantActivityMember463685406">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IMMY:WarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-07-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-03-11_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-03-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-01-02_us-gaap_SubsequentEventMember_custom_ParkSellersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:ParkSellersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-01-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-01-31_us-gaap_SubsequentEventMember_custom_ParkSellersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:ParkSellersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-02-28_us-gaap_SubsequentEventMember_custom_LeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="IMMY:AgreementAxis">IMMY:LeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-27to2015-02-28_us-gaap_SubsequentEventMember_custom_LeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="IMMY:AgreementAxis">IMMY:LeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-27</xbrli:startDate>
        <xbrli:endDate>2015-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-01to2015-02-28_us-gaap_SubsequentEventMember_custom_CFOEmploymentAgreementMember_custom_AndrewRBollsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="IMMY:AgreementAxis">IMMY:CFOEmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:AndrewRBollsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-01</xbrli:startDate>
        <xbrli:endDate>2015-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-02-28_us-gaap_SubsequentEventMember_custom_CFOEmploymentAgreementMember_custom_AndrewRBollsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="IMMY:AgreementAxis">IMMY:CFOEmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:AndrewRBollsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-01to2015-02-28_us-gaap_SubsequentEventMember_custom_RSUMember_custom_AndrewRBollsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IMMY:RSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:AndrewRBollsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-01</xbrli:startDate>
        <xbrli:endDate>2015-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-01to2015-02-28_us-gaap_SubsequentEventMember_custom_CCOEmploymentAgreementMember_custom_JohnPSaharekMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="IMMY:AgreementAxis">IMMY:CCOEmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:JohnPSaharekMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-01</xbrli:startDate>
        <xbrli:endDate>2015-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-02-28_us-gaap_SubsequentEventMember_custom_CCOEmploymentAgreementMember_custom_JohnPSaharekMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="IMMY:AgreementAxis">IMMY:CCOEmploymentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:JohnPSaharekMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-01to2015-02-28_us-gaap_SubsequentEventMember_custom_JohnPSaharekMember_custom_RSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">IMMY:JohnPSaharekMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">IMMY:RSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-01</xbrli:startDate>
        <xbrli:endDate>2015-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-01-31_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_NonCompetitionCovenantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">IMMY:NonCompetitionCovenantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001360214</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percent">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="SquareFeet">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2014-01-01to2014-12-31">Imprimis Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2014-01-01to2014-12-31">0001360214</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2014-01-01to2014-12-31">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2014-01-01to2014-12-31">2014-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2014-01-01to2014-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2014-01-01to2014-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory contextRef="From2014-01-01to2014-12-31">Smaller Reporting Company</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2014-01-01to2014-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 16. SUBSEQUENT EVENTS &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has performed an evaluation of&#13;events occurring subsequent to December 31, 2014 through the filing date of this Annual Report on Form 10-K (the &amp;#147;Annual&#13;Report&amp;#148;). Based on its evaluation, nothing other than the events described below needs to be disclosed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From January 1, 2015 through the filing date&#13;of this Annual Report, the Company issued a total of 12,658 shares of common stock as a result of warrant exercises. The Company&#13;received gross cash proceeds of $74,998 for the issuance of such shares upon the exercise on a cash basis to purchase the same&#13;number of shares of common stock with an exercise price of $5.925.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2015, the Company issued 8,521 shares&#13;of its common stock in connection with RSUs which had been awarded to a non-employee director and vested, but were not issued until&#13;the resignation of the director on January 1, 2015.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 1, 2015, the Company completed the&#13;acquisition of all of the outstanding capital stock of Park from the previous owners (the &amp;#147;Park Sellers,&amp;#148; and such&#13;transaction, the &amp;#147;Park Acquisition&amp;#148;), pursuant to a Stock Purchase Agreement, dated November 26, 2014, by and among&#13;the Company, the Park Sellers, Park and the Seller Representative (as defined therein) (the &amp;#147;Park Purchase Agreement&amp;#148;).&#13;Park is a compounding pharmacy accredited by the Pharmacy Compounding Accreditation Board and is located in Irvine, California.&#13;On January 1, 2015 (the &amp;#147;Park Closing Date&amp;#148;), in connection with the closing of the Park Acquisition (the &amp;#147;Park&#13;Closing&amp;#148;), the Company paid to the Park Sellers an aggregate cash purchase price of $3,000,000, net of fees and expenses,&#13;subject to adjustment based on the final calculation of Park&amp;#146;s working capital and certain other financial information, and&#13;issued to the Park Sellers 63,525 shares of the Company&amp;#146;s common stock, valued at $500,000 based on the average closing price&#13;of the common stock for the 10 trading days preceding the Park Closing. In addition, the Company is obligated to make 12 quarterly&#13;cash payments to the Park Sellers collectively of $53,125 each over the three years following the Park Closing, totaling $637,500.&#13;The Park Sellers have the option to receive the last six of such quarterly payments, totaling up to an aggregate of $318,750, in&#13;the form of 6,749 shares of the Company&amp;#146;s common stock for each such payment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the Park Acquisition, one&#13;of the Park Sellers, Dennis Saadeh, entered into an employment agreement with the Company, effective as of January 1, 2015, to&#13;act as Senior Director of Corporate Development of Park. In addition, on January 1, 2015, Park and an entity affiliated with and&#13;controlled by the Park Sellers entered into a Commercial Lease Agreement, for the lease of certain premises to Park of approximately&#13;4,500 square feet of lab and office space. The monthly rent amount is $9,788 and includes annual increases of approximately 3%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2015, the Company entered into&#13;a lease agreement for approximately 8,602 square feet of lab, warehouse and office space in Roxbury, New Jersey. The current lease&#13;term expires on July 31, 2022. The monthly rent amount is $9,548 and includes annual increases of approximately 3.75%, and the&#13;lease allows for the first five months of rent amounts to be abated. This facility is currently undergoing construction and being&#13;built to serve as an outsourcing facility and pharmacy.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2015, the Company appointed Andrew&#13;R. Boll&amp;#146;s as its Chief Financial Officer, and entered into an amended and restated employment agreement (the &amp;#147;CFO Employment&#13;Agreement&amp;#148;) with Mr. Boll, which amends, restates and supersedes in its entirety Mr. Boll&amp;#146;s prior employment agreement&#13;with the Company dated February 1, 2012. The CFO Employment Agreement provides for the following, among other things: (i) a term&#13;of three years, (ii) an annual base salary of $200,000; (iii) eligibility to receive an annual cash bonus in an amount equal to&#13;at least 20% of his then-current annual base salary and a target of 50% of his then-current annual base salary, with the precise&#13;amount to be determined at the discretion of the Company&amp;#146;s Board of Directors; (iv) if Mr. Boll is terminated other than&#13;for cause, by death or by disability or if he terminates his employment with the Company for good reason (any such termination,&#13;a &amp;#147;Qualifying Termination&amp;#148;), then Mr. Boll will be entitled to receive, subject to the satisfaction of certain conditions,&#13;continued payments of his then-current annual base salary for six months following the date of his termination and a lump-sum payment&#13;equal to the pro-rated portion of his minimum annual cash bonus for the then-current year; and (v) in the event of a Qualifying&#13;Termination of Mr. Boll on or within 12 months following a change of control, Mr. Boll will be entitled to receive, subject to&#13;the satisfaction of certain conditions, continued payments of his then-current annual base salary for six months following the&#13;date of his termination, a lump-sum payment equal to the pro-rated portion of his minimum annual cash bonus for the then-current&#13;year, and immediate vesting of all of his outstanding equity awards as of the date of his termination. In connection with Mr. Boll&amp;#146;s&#13;appointment as the Company&amp;#146;s Chief Financial Officer, the Company&amp;#146;s Board of Directors has granted the following equity&#13;awards to Mr. Boll, in each case under the Plan: (i) a performance-based restricted stock unit award of up to 157,500 shares of&#13;the Company&amp;#146;s common stock, which will vest if the Company achieves and maintains certain stock price vesting targets during&#13;the three-year period following the date of grant of the award and subject to Mr. Boll&amp;#146;s continued employment with the Company&#13;on the third anniversary of the date of grant, subject to certain exceptions, and (ii) a RSU award of up to 30,000 shares of the&#13;Company&amp;#146;s common stock, which will vest on the third anniversary of the date of grant, subject to Mr. Boll&amp;#146;s continued&#13;employment with the Company on such date and accelerated vesting of all unvested shares thereunder upon the occurrence of a change&#13;in control (as defined in the Plan), and is subject to the Company&amp;#146;s standard form of award agreement for RSUs granted under&#13;the Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2015, the Company appointed John&#13;P. Saharek as of the Company&amp;#146;s Chief Commercial Officer, effective as of February 1, 2015, and entered into an employment&#13;agreement (the &amp;#147;CCO Employment Agreement&amp;#148;) with Mr. Saharek. The CCO Employment Agreement provides for the following,&#13;among other things: (i) a term of three years, (ii) an annual base salary of $220,000; (iii) eligibility to receive an annual&#13;cash bonus in an amount equal to a target of 50% of his then-current annual base salary, with the precise amount to be determined&#13;at the discretion of the Company&amp;#146;s Board of Directors; (iv) in the event of a Qualifying Termination of Mr. Saharek, Mr.&#13;Saharek will be entitled to receive, subject to the satisfaction of certain conditions, continued payments of his then-current&#13;annual base salary for six months following the date of his termination; and (v) in the event of a Qualifying Termination of Mr.&#13;Saharek on or within 12 months following a change of control, then Mr. Saharek will be entitled to receive, subject to the satisfaction&#13;of certain conditions, continued payments of his then-current annual base salary for 12 months following the date of his termination&#13;and immediate vesting of all of his outstanding equity awards as of the date of his termination. In connection with Mr. Saharek&amp;#146;s&#13;appointment as the Company&amp;#146;s Chief Commercial Officer, the Company&amp;#146;s Board of Directors has granted the following&#13;equity awards to Mr. Saharek, in each case under the Plan: (i) a stock option award of up to 90,000 shares of the Company&amp;#146;s&#13;common stock, which has a term of 10 years and an exercise price of $7.37, will vest in equal quarterly installments over a three-year&#13;period, subject to Mr. Saharek&amp;#146;s continued employment with the Company at the end of such period and accelerated vesting&#13;of all unvested shares thereunder upon the occurrence of a change in control (as defined in the Plan), and is subject to the Company&amp;#146;s&#13;standard form of award agreement for stock options granted under the Plan, and (ii) a RSU award of up to 30,000 shares of the&#13;Company&amp;#146;s common stock, which will vest on the third anniversary of the date of grant, subject to Mr. Saharek&amp;#146;s continued&#13;employment with the Company on such date and accelerated vesting of all unvested shares thereunder upon the occurrence of a change&#13;in control (as defined in the Plan), and is subject to the Company&amp;#146;s standard form of award agreement for restricted stock&#13;units granted under the Plan.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 14. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Capital Leases&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leases equipment under capital&#13;leases with an interest rate of 4.25% per annum. At December 31, 2014, future payments under the Company&amp;#146;s capital leases&#13;were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year ending December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,477&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19,321&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44,798&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less amount representing interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,718&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Present value of future minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;43,080&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less current portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(24,112&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Capital lease obligations, net of current portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18,968&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The value of the equipment under capital&#13;leases as of December 31, 2014 was $52,687, with related accumulated depreciation of $8,656.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2014, the Company entered into&#13;a lease agreement for 7,565 square feet of office space that commenced on September 1, 2014 and continues until October 31, 2018.&#13;Monthly rent began on September 1, 2014 in the amount of $20,426, with a 3% increase in the base rent amount on an annual basis.&#13;The lease agreement allows for the monthly rent amount to be abated for two months at various times during the lease agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In April 2013, the Company entered into&#13;a lease agreement for 3,784 square feet of office space that commenced on May 1, 2013 and continues until September 30, 2016. Monthly&#13;rent began on May 1, 2013 in the amount of $10,406, with a 3% increase in the base rent amount on an annual basis. The lease agreement&#13;allows for the monthly rent amount to be abated for five months at various times during the lease agreement. The Company entered&#13;into a sublease agreement in February 2015 to sublet 3,874 square feet of its previously occupied offices through the remaining&#13;term of the lease.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2010, PC entered into a lease&#13;agreement for 3,137 square feet of office and laboratory space that commenced on January 1, 2010 and continues until December 31,&#13;2015. Monthly rent began on January 1, 2010 in the amount of $3,594.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Rent expense for the years ended December&#13;31, 2014 and 2013 was $306,465 and $103,191, respectively. The following represents future annual minimum lease payments, including&#13;lease payments related to lease agreements entered into in January and February 2015 (see Note 16), and net of expected sublease&#13;income, as of December 31, 2014:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 65%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 32%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;492,503&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;468,997&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;481,443&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;495,938&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;257,039&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;478,473&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,674,393&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Legal&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the ordinary course of business,&#13;the Company may face various claims brought by third parties and the Company may, from time to time, make claims or take legal&#13;actions to assert the Company&amp;#146;s rights, including intellectual property disputes, contractual disputes and other commercial&#13;disputes. Any of these claims could subject the Company to litigation. Management believes the outcomes of currently pending claims&#13;are not likely to have a material effect on the Company&amp;#146;s consolidated financial position and results of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Indemnities&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In addition to the indemnification provisions&#13;contained in the Company&amp;#146;s charter documents, the Company generally enters into separate indemnification agreements with&#13;each of the Company&amp;#146;s directors and officers. These agreements require the Company, among other things, to indemnify the&#13;director or officer against specified expenses and liabilities, such as attorneys&amp;#146; fees, judgments, fines and settlements,&#13;paid by the individual in connection with any action, suit or proceeding arising out of the individual&amp;#146;s status or service&#13;as the Company&amp;#146;s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly&#13;fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against&#13;the individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies&#13;its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities&#13;do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically,&#13;the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded&#13;for these indemnities in the accompanying consolidated balance sheets.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Urigen License&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;On October&#13;24, 2014, (the &amp;#147;Urigen Effective Date&amp;#148;), the Company entered into a license agreement (the &amp;#147;Urigen License&amp;#148;)&#13;with Urigen Pharmaceuticals, Inc. (&amp;#147;Urigen&amp;#148;), pursuant to which Urigen granted to the Company a license under certain&#13;U.S. patents and patent applications to develop and sell in the U.S. Urigen&amp;#146;s URG101 product (&amp;#147;HLA&amp;#148;), a heparin&#13;and alkalinized lidocaine compounded formulation, for the prevention or treatment of disorders of the lower urinary tract. Such&#13;license is non-exclusive; provided that, between April 24, 2015 and October 24, 2015, the Company will have the right, at its option,&#13;to convert such non-exclusive license to an exclusive license for the remaining term of the Urigen License, subject only to certain&#13;specified existing sublicenses (the &amp;#147;Existing Sublicenses&amp;#148;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;As consideration&#13;for the license granted under the Urigen License, the Company agreed to pay Urigen annual tiered royalties based on sales of HLA,&#13;subject to certain minimum annual royalty payments. The annual tiered royalties consist of the greater of (i) $0.50 per dose, and&#13;(ii) 15% - 20% of its net sales of HLA, with the royalty amount within such range depending on the Company&amp;#146;s aggregate sales&#13;of HLA during the period to which the royalty payment applies. The minimum annual royalty payment consists of (a) for the 2015&#13;calendar year, the greater of (i) 110% of the aggregate royalties paid to Urigen under the Existing Sublicenses during the preceding&#13;12 months, on a prorated basis, and (ii) $800,000, less the aggregate royalties paid to Urigen under the Existing Sublicenses during&#13;the 2015 calendar year, and (b) for each calendar year thereafter, 110% of the aggregate amount owed by the Company to Urigen under&#13;the Urigen License during the prior calendar year. The Company is obligated to pay such royalties beginning with its first commercial&#13;sale of HLA and continuing until the expiration of the patents subject to the license granted under the Urigen License. The Company&#13;has also agreed to use commercially reasonable efforts to develop and commercialize HLA according to the terms of a diligence plan&#13;agreed to by the parties, which efforts will include, without limitation, the Company&amp;#146;s investment of $2 million in commercialization&#13;efforts of HLA, which investment and timeline can be adjusted dependent on market circumstances, and is expected to be incurred&#13;over 18-24 months following the Urigen Effective Date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Subject to certain conditions and each&#13;party&amp;#146;s right to terminate the Urigen License earlier under certain circumstances, the Urigen License will continue in effect&#13;until the expiration of the Company&amp;#146;s royalty obligations under the Urigen License. The Urigen License terminates upon the&#13;first commercial sale of HLA by Urigen, its affiliates, or a third party after the U.S. Food and Drug Administration (the &amp;#147;FDA&amp;#148;)&#13;grants Urigen approval to market HLA in the U.S., if market approval is granted. The Company shall have the option, at its discretion,&#13;to become a non-exclusive distributor of HLA following the FDA granting Urigen such market approval. No royalty amounts have been&#13;paid or accrued under the Urigen License during the year ended December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;PCCA License Agreement &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 30, 2012, the Company entered&#13;into a license agreement with Professional Compounding Centers of America (&amp;#147;PCCA&amp;#148;), pursuant to which PCCA has granted&#13;to the Company and its affiliates certain exclusive rights under PCCA&amp;#146;s proprietary formulations, other technologies and&#13;data, and the Company has agreed to pay to PCCA certain royalties on net sales relating to the sale of certain potential future&#13;FDA-approved products that the Company may produce, which royalties will range from 4.5% to 9% for each such product, subject to&#13;certain minimum royalty payments. PCCA may terminate the license agreement if the Company fails to commence efforts to research&#13;and develop any such products within certain time periods, as set forth in the license agreement. No royalty amounts have been&#13;paid or accrued under this agreement during the years ended December 31, 2014 or 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;PCCA Strategic Alliance Agreement&#13;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 18, 2013, the Company entered&#13;into a strategic alliance agreement with PCCA. Under this agreement, PCCA has agreed that, during the term of the agreement, it&#13;will not introduce any of PCCA&amp;#146;s members or customers meeting certain criteria (the &amp;#147;Member/Customers&amp;#148;) to any&#13;third party whereby such third party licenses or otherwise acquires the intellectual property rights of such Member/Customer, without&#13;first presenting such an opportunity to the Company. PCCA may, but is not required to, present such opportunities to the Company,&#13;use reasonable efforts to facilitate an introductory meeting between the Member/Customer and the Company, and to further provide&#13;certain key technical assistance with respect to any potential development project the Company may pursue associated with the Member/Customer&amp;#146;s&#13;intellectual property rights. In the event the Company and a Member/Customer introduced to the Company by PCCA enter into a commercial&#13;agreement for the license or acquisition of the intellectual property rights owned by the Member/Customer, PCCA will be entitled&#13;to receive certain cash fees up to an aggregate of $100,000, as well as a commission based on net sales, if any, generated by the&#13;Company as a result of the acquired intellectual property rights. The agreement has a term of one year and is automatically extended&#13;for successive one year periods unless either party gives the other written notice of non-renewal. This agreement automatically&#13;renewed for a one-year term on February 18, 2014 and 2015. No royalty amounts have been paid or accrued under this agreement during&#13;the years ended December 31, 2014 or 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Asset Purchase Agreements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has acquired intellectual&#13;property rights related to certain proprietary innovations from certain inventors (the &amp;#147;Inventors&amp;#148;) through multiple&#13;asset purchase agreements. The asset purchase agreements provide that the Inventors will cooperate with the Company in obtaining&#13;patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research,&#13;develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right&#13;of first refusal on additional intellectual property and drug development opportunities presented by these Inventors during the&#13;term of the respective agreements, which remains in effect until expiration of all payment obligations thereunder.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In consideration for the acquisition&#13;of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain&#13;milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United&#13;States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the&#13;first investigational new drug application (&amp;#147;IND&amp;#148;) with the U.S. Food and Drug Administration (&amp;#147;FDA&amp;#148;) for&#13;the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable&#13;within 30 days after the Company files the first New Drug application with the FDA for the first product arising from the acquired&#13;intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection&#13;with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things)&#13;the Company&amp;#146;s development costs associated with such product. If, following five years after the date of the applicable asset&#13;purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors,&#13;has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product&#13;based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that&#13;the Company re-assign the acquired technology to the Inventors. No royalty amounts have been paid or accrued under these agreements&#13;for the years ended December 31, 2014 or 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Novel Drug and Eye Care Northwest&#13;Asset Purchase Agreement &amp;#150; Related Party&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 8, 2013, the Company acquired&#13;intellectual property rights related to certain proprietary innovations from the compounding pharmacy operations of Novel Drug&#13;Solutions, LLC (&amp;#147;NDS&amp;#148;) and from Eye Care Northwest, Inc. (together referred to as the &amp;#147;Sellers&amp;#148;) pursuant&#13;to an asset purchase agreement (as amended, the &amp;#147;ECN APA&amp;#148;). As part of this acquisition, the Company acquired intellectual&#13;property rights that include a provisional patent application related to injectable ophthalmological compositions having anti-bacterial&#13;and anti-inflammatory properties for the prevention of post-ophthalmic surgery complications. In addition, under the ECN APA, the&#13;Company has a right of first refusal on any of the Sellers&amp;#146; additional intellectual property and drug development opportunities&#13;during the term of the agreement, which remains in effect until the expiration of all payment obligations thereunder. The ECN APA&#13;provides that the Sellers will cooperate with the Company in obtaining patent protection for the acquired intellectual property,&#13;among other things, and that the Company will use commercially reasonable efforts to research, develop and commercialize a product&#13;based on the acquired intellectual property.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In consideration for the acquisition,&#13;the Company is obligated to make the following payments to the Sellers: (1) a payment payable within 30 days after the issuance&#13;of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within&#13;30 days after the Company files the first IND with the FDA for the first product arising from the acquired intellectual property&#13;(if any); (3) a payment payable within 30 days after the Company files the first new drug application with the FDA for the first&#13;product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received&#13;by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after&#13;deducting (among other things) the Company&amp;#146;s development costs associated with such product. If, following five years of&#13;the date of the ECN APA, the Company either has not filed an IND or has failed to generate royalty payments to NDS for any product&#13;based on the acquired intellectual property, NDS may terminate the ECN APA and request that the Company re-assign the acquired&#13;technology to NDS.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;NDS is owned by the former owners of&#13;PC. During the years ended December 31, 2014 and 2013, the Company did not make any payments to NDS or the other Seller, and no&#13;amounts were due and payable to NDS or the other Seller at December 31, 2014 and 2013.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 11. STOCKHOLDERS&amp;#146; EQUITY&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Issuances During the Year Ended December&#13;31, 2013&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 7, 2013, after the effectiveness&#13;of the registration statement on Form S-1 filed in connection with the Public Offering (as defined below), the Company effected&#13;a one-for-five reverse stock split of its common stock and on February 8, 2013, the Company&amp;#146;s common stock began trading&#13;on The NASDAQ Capital Market on a split-adjusted basis. On September 10, 2014, the Company decreased the number of authorized shares&#13;of its capital stock to 95,000,000, and the number of authorized shares of its common stock to 90,000,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 13, 2013, the Company closed a&#13;public offering of its common stock (the &amp;#147;Public Offering&amp;#148;) and issued an aggregate of 1,840,000 shares of its common&#13;stock at a per share price to the public of $5.25, and received net proceeds of $8,140,435, after deducting underwriter fees and&#13;commissions and other offering expenses. The underwriters also exercised their option to purchase an additional 276,000 shares&#13;of common stock from the Company at $5.25 per share to cover over-allotments on March 14, 2013. Net cash proceeds from the exercise&#13;of the over-allotment option were $1,316,116. As contemplated by the underwriting agreement entered into with MDB Capital Group,&#13;LLC, the lead underwriter for the Public Offering, at the closing of the Public Offering and the over-allotment exercise, the lead&#13;underwriters received warrants (the &amp;#147;Underwriter Warrants&amp;#148;) to purchase up to an aggregate of 179,860 shares, or 8.5%&#13;of the number of shares sold in the Public Offering (including 8.5% of shares sold pursuant to the exercise of the over-allotment&#13;option). The Underwriter Warrants are exercisable at $5.25 per share (100% of the price to the public of the common stock sold&#13;in the Public Offering), commencing on the closing date of the Public Offering and expire five years from the closing date of the&#13;Public Offering.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February and March 2013, the Company made&#13;payments totaling $191 in connection with cancelled, fractional share amounts of common stock (35 common stock share equivalents)&#13;in connection with the one-for-five reverse stock split effected February 7, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2013, the Company issued 40,000 shares&#13;of common stock to Mark Baum, the Company&amp;#146;s Chief Executive Officer and a director, related to the vesting of RSUs.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In September 2013, the Company issued 2,114&#13;restricted shares of common stock to a consultant, valued at $10,750, in consideration for consulting services provided during&#13;the year ended December 31, 2013. The fair value of the shares of common stock issued was recorded as stock-based compensation&#13;during the year ended December 31, 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2013, the&#13;Company issued 40,000 restricted shares of common stock to Dr. Robert Kammer, a director and former consultant, valued at $282,997,&#13;in consideration for consulting services provided during the years ended December 31, 2013 and 2012.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2013, the&#13;Company issued a total of 219 shares of common stock as a result of stock option exercises. The Company received no cash proceeds&#13;for the issuance of such shares upon the exercise pursuant to cashless exercise provisions of stock options to purchase 1,030 shares&#13;of common stock with an exercise price of $4.00 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Issuances During the Year Ended December&#13;31, 2014&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In April 2014, the Company issued 6,868 shares&#13;of restricted common stock, valued at $50,000, in connection with the resolution of a contract dispute.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2014, the Company issued 4,000 shares&#13;of restricted common stock to a consultant, valued at $29,160 in consideration for consulting services provided. The fair value&#13;of the shares of common stock issued was recorded as stock-based compensation during the year ended December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2014, the&#13;Company issued a total of 227,216 shares of common stock as a result of stock option exercises. Of these, the Company received&#13;net cash proceeds of $583,811 for the issuance of 160,777 shares of common stock upon the exercise of stock options to purchase&#13;the same number of shares of common stock with exercise prices ranging from $3.68 to $4.00 and the Company received no cash proceeds&#13;for the issuance of 66,439 shares of common stock upon the exercise pursuant to cashless exercise provisions of stock options to&#13;purchase 146,652 shares of common stock with exercise prices ranging from $3.60 to $6.00 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2014, the&#13;Company issued 1,954 shares of common stock to employees related to the vesting of RSUs. In connection with these common stock&#13;issuances, the Company withheld 1,518 shares of common stock for payroll tax withholdings totaling $13,109.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2014,&#13;the Company issued a total of 47,829 shares of common stock as a result of warrant exercises. Of these, the Company received gross&#13;cash proceeds of $37,867 for the issuance of 6,391 shares of common stock upon the exercise of warrants to purchase the same number&#13;of shares of common stock with an exercise price of $5.925 and the Company received no cash proceeds for the issuance of 41,438&#13;shares of common stock upon the exercise pursuant to cashless exercise provisions of warrants to purchase 123,715 shares of common&#13;stock with an exercise price of $5.25 per share.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2014,&#13;27,218 shares of the Company&amp;#146;s common stock underlying RSUs issued to directors vested, but the issuance and delivery of&#13;these shares are deferred until the respective director resigns.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Preferred Stock &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2014 and 2013, the Company&#13;had 5,000,000 shares of preferred stock, $0.001 par value, authorized and no shares of preferred stock issued and outstanding.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock Option Plan &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 17, 2007, the Company&amp;#146;s&#13;Board of Directors and stockholders adopted the Company&amp;#146;s 2007 Incentive Stock and Awards Plan, which was subsequently amended&#13;on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the &amp;#147;Plan&amp;#148;).&#13;As of December 31, 2014, the Plan provides for the issuance of a maximum of 5,000,000 shares of the Company&amp;#146;s common stock.&#13;The purpose of the Plan is to provide an incentive to attract and retain directors, officers, consultants, advisors and employees&#13;whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons&#13;in the Company&amp;#146;s development and financial success. Under the Plan, the Company is authorized to issue incentive stock options&#13;intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, RSUs and restricted stock. The&#13;Plan is administered by the Compensation Committee of the Company&amp;#146;s Board of Directors. The Company had 2,366,369 shares&#13;available for future issuances under the Plan at December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock Options&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the stock option activity&#13;under the Plan for the year ended December 31, 2014 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Avg. Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Avg. Remaining Contractual Life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate Intrinsic Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF"&gt;&#13;    &lt;td style="vertical-align: top; width: 44%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options outstanding - January 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,328,790&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.31&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;245,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF"&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(307,429&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.90&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options cancelled/forfeit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(238,007&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF"&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options outstanding - December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,029,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.74&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,351,174&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options exercisable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;728,585&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.97&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,080,594&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF"&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options vested and expected to vest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;999,175&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,319,475&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value in the&#13;table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option&#13;holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price&#13;on December 31, 2014, based on the closing price of the Company&amp;#146;s common stock of $7.50 on that date. The aggregate intrinsic&#13;value of stock options exercised during the year ended December 31, 2014 was approximately $1,161,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During fiscal years 2014 and 2013, the&#13;Company granted stock options to certain employees, directors and consultants. The stock options were granted with an exercise&#13;price equal to the current market price of the Company&amp;#146;s common stock, as reported by the securities exchange or quotation&#13;system on which the common stock was then listed or quoted, at the grant date and have contractual terms ranging from three to&#13;10 years. Vesting terms for options granted in fiscal years 2014 and 2013 to employees, directors and consultants typically included&#13;one of the following vesting schedules: 25% or 33% of the shares subject to the option vest and become exercisable on the first&#13;anniversary of the grant date and the remaining 75% or 67%, respectively, of the shares subject to the option vest and become exercisable&#13;in equal quarterly installments thereafter over two or three years, respectively; quarterly vesting over a three year period; or&#13;monthly, quarterly or 100% vesting associated with the provision or completion of services provided under contracts with consultants.&#13;Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event&#13;of certain modifications to the option award agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of each option award&#13;is estimated on the date of grant using the Black-Scholes-Merton option pricing model. Prior to April 1, 2013, expected volatilities&#13;were based on historical volatility of the Company&amp;#146;s common stock and other factors. Following April 1, 2013, the expected&#13;volatility is based on the historical volatilities of the common stock of comparable publicly traded companies based on the Company&amp;#146;s&#13;belief that it has significantly changed its business operations and focus as of such date and as a result, it has limited relevant&#13;historical data regarding the volatility of its stock price on which to base a meaningful estimate of expected volatility. The&#13;expected term of options granted was determined in accordance with the &amp;#147;simplified approach&amp;#148; as the Company has limited,&#13;relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest&#13;rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of&#13;the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual&#13;effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of 10%.&#13;These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods.&#13;Utilizing these assumptions, the fair value is determined at the date of grant.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below illustrates the fair&#13;value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing&#13;options granted to employees and directors:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-average fair value of options granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected terms (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.81 - 6.91&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.8-7 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;96 - 102%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;102 - 123%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.37 - 1.65%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.86 - 2.05%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below illustrates the fair&#13;value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing&#13;options granted to consultants:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-average fair value of options granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected terms (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.5 - 10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;2.33 - 10 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;78 - 97%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;80 - 366% &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.10 - 1.68%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;0.30 - 2.45% &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes information about stock options&#13;outstanding and exercisable at December 31, 2014:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options Exercisable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Remaining&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contractual&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Range of Exercise Prices&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Life in Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 28%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$2.40 - $3.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.57&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$3.60 - $4.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;337,723&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.36&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;270,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$5.49 - $7.71&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;190,557&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;60,110&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$8.06 - $10.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;244,160&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.99&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;141,660&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$28.00 - $80.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,029,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.74&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;728,585&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2014, there was approximately&#13;$1,571,000 of total unrecognized compensation expense related to unvested stock options granted under the Plan. That expense is&#13;expected to be recognized over the weighted-average remaining vesting period of 2.1 years. The stock-based compensation for all&#13;stock options was $1,137,634 and $1,689,756 during the years ended December 31, 2014 and 2013, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;Restricted Stock Units&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;RSU awards are granted subject to certain&#13;vesting requirements and other restrictions, including performance and market based vesting criteria. The grant-date fair value&#13;of the RSUs, which has been determined based upon the market value of the Company&amp;#146;s common stock on the grant date, is expensed&#13;over the vesting period of the RSUs. Unvested portions of RSUs issued to consultants are remeasured on an interim basis until vesting&#13;criteria is met. On May 2, 2013, the Board of Directors of the Company amended and restated the Plan to provide for the issuance&#13;of RSUs under the Plan.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Grants During the Year Ended December&#13;31, 2013&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 2, 2013, the Company granted&#13;1,250,000 RSUs to its Chief Executive Officer, Mark Baum, pursuant to the Plan. Of these RSUs, 200,000 will vest on the third anniversary&#13;of the RSU grant date, subject to continued service to the Company and the remaining 1,050,000 RSUs will vest on the third anniversary&#13;of the RSU grant date, subject to the satisfaction of certain market-based and continued service conditions (the &amp;#147;Baum Performance&#13;Equity Award&amp;#148;). The market-based vesting criteria are separated into five equal tranches and require that the Company achieve&#13;and maintain certain stock price targets ranging from $10 per share to $30 per share during the three year period following the&#13;grant date. With certain limited exceptions, Mr. Baum must be employed with the Company on the third anniversary of the grant date&#13;in order for the Baum Performance Equity Award to vest. These market-based vesting conditions are further described below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 16%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 66%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Target Share Price&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19.05% of the shares subject to the Baum Performance Equity Award&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$10.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19.05% of the shares subject to the Baum Performance Equity Award&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$15.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19.05% of the shares subject to the Baum Performance Equity Award&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$20.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19.05% of the shares subject to the Baum Performance Equity Award&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$25.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;23.80% of the shares subject to the Baum Performance Equity Award&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$30.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For each respective tranche to vest&#13;the following conditions must be met: (i) the Company&amp;#146;s common stock must have an official closing price at or above the&#13;Target Share Price for the respective tranche (each such date, a &amp;#147;Trigger Date&amp;#148;); (ii) during the period that includes&#13;the Trigger Date and the immediately following 19 trading days (the &amp;#147;Measurement Period&amp;#148;), the arithmetic mean of the&#13;20 closing prices of the Company&amp;#146;s common stock during the Measurement Period must be at or above the Target Share Price&#13;for such tranche; and (iii) with certain limited exceptions, Mr. Baum must be in continuous service with the Company through the&#13;third anniversary of the grant date. Any unvested RSUs under the Baum Performance Equity Award will be forfeited on the third anniversary&#13;of the grant date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The earning and issuance of any shares&#13;under the Baum Performance Equity Award that would exceed the number of shares available for grant and/or the applicable annual&#13;per person grant limit for performance-based restricted stock units under the Plan as of the grant date of the Baum Performance&#13;Equity Award were subject to approval by the Board of Directors and the Company&amp;#146;s stockholders of increases tothe number&#13;of shares available for grant and the applicable annual per person grant limit for performance-based restricted stock units under&#13;the Plan. On May 2, 2013, the Board of Directors approved an amendment to the Plan to increase the number of shares available for&#13;grant from 2,400,000 to 5,000,000 shares and the applicable annual per person grant limit from 600,000 to 1,250,000 shares and&#13;on September 27, 2013, a majority of the Company&amp;#146;s stockholders approved the amendment to the Plan. The 450,000 RSUs subject&#13;to the Baum Performance Equity Award that were pending such approval were granted on that date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Concurrent with the issuance of the&#13;450,000 RSUs, Mr. Baum agreed to cancel 120,000 unvested RSUs previously granted to Mr. Baum in July 2012. As a result, the Company&#13;has treated the issuance of the 450,000 RSUs as a modification of the RSU grant made to Mr. Baum in July 2012. The total compensation&#13;cost to be recognized by the Company is equal to the original grant date fair value of the canceled RSUs plus any incremental cost&#13;calculated as the excess of the fair value of the 450,000 RSUs over the fair value of the canceled 120,000 RSUs on the modification&#13;date, which is September 27, 2013. The initial fair value of the 450,000 RSUs pursuant to the Baum Performance Equity Award granted&#13;to Mr. Baum was $189,000. No incremental cost was associated with the exchange of RSUs as the fair value prior to modification&#13;was more than after the modification. The 450,000 RSUs pursuant to the Baum Performance Equity Award were valued using a Monte&#13;Carlo Simulation with a three year life, 75% volatility and a risk free interest rate of 0.64%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The initial fair value of the 200,000&#13;RSUs and 600,000 RSUs pursuant to the Baum Performance Equity Award granted to Mr. Baum was $3,515,090. The 600,000 RSUs pursuant&#13;to the Baum Performance Equity Award were valued using a Monte Carlo Simulation with a three year life, 75% volatility and a risk&#13;free interest rate of 0.30%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 24, 2013, the Company granted&#13;100,000 RSUs to a consultant that were to vest based on the satisfaction of certain market-based conditions subject to the consultant&amp;#146;s&#13;continued service, among other things. These market-based vesting conditions are further described below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 34%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Target Share Price&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000 shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$10.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000 shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$15.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000 shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$20.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000 shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$25.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000 shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$30.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For each respective tranche to vest&#13;the following conditions must have been met: (i) the Company&amp;#146;s common stock must have had an official closing price at or&#13;above the Target Share Price for the respective tranche (each such date a &amp;#147;Trigger Date&amp;#148;); (ii) during the period that&#13;included the Trigger Date and the immediately following 19 trading days (the &amp;#147;Measurement Period&amp;#148;), the arithmetic&#13;mean of the 20 closing prices during the Measurement Period have been at or above the Target Share Price for such tranche ((i)&#13;and (ii), the &amp;#147;Stock Price Conditions&amp;#148;); and (iii) with certain limited exceptions, 50% of the RSUs subject to a tranche&#13;would vest on the quarterly anniversary of the grant date following the satisfaction of the Stock Price Conditions with respect&#13;to that tranche, subject to the consultant being in continuous service with the Company on such quarterly anniversary and the remaining&#13;50% would vest on the second anniversary of the grant date if (a) the Stock Price Conditions had been satisfied with respect to&#13;that tranche prior to the second anniversary of the grant date and (b) the consultant was in continuous service with the Company&#13;on the second anniversary of the grant date. All unvested RSUs would be forfeited on the second anniversary of the grant date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The initial value of the 100,000 RSUs&#13;with market-based vesting conditions granted to the consultant was $288,000, and as of December 31, 2013 the remeasured fair value&#13;of those RSUs was $10,080. The 100,000 RSUs were valued using a Monte Carlo Simulation with a 2 year life (based on the grant date),&#13;75%-85% volatility and risk free interest rates of 0.13%-0.36%. During March 2014, the Company terminated its agreement with a&#13;consultant that provided for the grant of 100,000 RSUs that had vesting criteria based on the satisfaction of certain market-based&#13;conditions subject to the consultant&amp;#146;s continued service, among other things. Upon termination of the agreement, all 100,000&#13;RSUs were forfeited and deemed reconveyed to the Company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2013, the Company granted an&#13;aggregate of 34,325 RSUs to its non-employee directors, valued at $271,854. The RSUs vest in full 13 months after the date of grant&#13;subject to the director&amp;#146;s continued service, but the issuance and delivery of these shares are deferred until the director&#13;resigns. In September and October 2013, two directors resigned and forfeited all such RSUs.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2013, the Company issued&#13;8,947 RSUs to a former director for his service to the Company as a director, valued at $39,814. The RSUs were to vest in full&#13;13 months after the date of grant subject to the director&amp;#146;s continued service, but the issuance and delivery of these shares&#13;are deferred until the director resigns. All such RSUs were forfeited upon the director&amp;#146;s resignation in September 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2013, the Company granted&#13;an aggregate of 10,418 RSUs to certain employees, valued at $42,498. The RSUs will vest in equal annual installments over a three-year&#13;period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Grants During the Year Ended December&#13;31, 2014&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the year ended December 31, 2014,&#13;the Company granted an aggregate of 26,492 RSUs to its non-employee directors valued at $200,015. These RSUs vest in equal quarterly&#13;installments over a one year period subject to the director&amp;#146;s continued service, but the issuance and delivery of these shares&#13;are deferred until the director resigns.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the Company&amp;#146;s RSU&#13;activity and related information for the year ended December 31, 2014 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of RSUs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 42%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;RSUs unvested - January 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,389,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 36%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;RSUs granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.55&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;RSUs vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(30,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.41&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;RSUs cancelled/forfeit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(108,947&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;RSUs unvested at December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,276,815&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2014, the total unrecognized&#13;compensation expense related to unvested RSUs was approximately $1,923,000 which is expected to be recognized over a weighted-average&#13;period of 1.32 years, based on estimated vesting schedules. The stock-based compensation for RSU&amp;#146;s was $1,332,176 and $822,137&#13;during the years ended December 31, 2014 and 2013, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From time to time, the Company issues&#13;warrants to purchase shares of the Company&amp;#146;s common stock to investors, note holders, underwriters and to non-employees for&#13;services rendered or to be rendered in the future.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Issuances During the Year Ended December&#13;31, 2013&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2013, the Company issued&#13;a warrant to purchase 30,000 shares of the Company&amp;#146;s common stock to a consultant with an exercise price of $5.25 per share.&#13;The warrants expire three years following the issuance date, and vest as follows: 10,000 shares vested immediately upon execution&#13;of the consulting agreement, and the remaining shares vested in 4,000 share installments on each of the five monthly anniversaries&#13;of the date of the consulting agreement, provided the consultant continued to provide services to the Company as of the applicable&#13;vesting dates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In July 2013, the Company issued a warrant&#13;to purchase 60,000 shares of the Company&amp;#146;s common stock to a consultant with an exercise price of $8.50 per share, in consideration&#13;for services to be provided over a six month term. The warrants expire five years following the issuance date, vested immediately,&#13;are non-forfeitable, and became exercisable in January 2014. The Company recorded an initial stock-based prepaid consulting expense&#13;for the fair value of the warrants totaling $319,786, which was being amortized over the length of the consulting service term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Issuances During the Year Ended December&#13;31, 2014&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company did not issue any warrants&#13;during the year ended December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of warrant activity during&#13;the year ended December 31, 2014 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of Shares Subject to Warrants Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Avg.&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants outstanding - January 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;821,050&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.94&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(130,106&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants outstanding and exercisable - December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;690,944&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average remaining contractual life of the outstanding warrants in years - December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of each warrant is estimated&#13;on the date of grant using the Black-Scholes-Merton option pricing model. The table below illustrates the fair value per share&#13;determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing the warrants issued&#13;to consultants:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-average fair value of warrants granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected terms (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.6-5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;85%-346%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.32%-1.31%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A list of the warrants outstanding as&#13;of December 31, 2014 is included in the following table:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants Exercisable&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expiration&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrant Series&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Issue Date&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Date&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 41%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants issued to a former major shareholder&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/25/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;48,262&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.93&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;48,262&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/25/2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants issued in April 2012 private placement&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/25/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;496,537&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.93&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;496,537&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/25/2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Underwriter Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/7/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;56,145&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;56,145&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/7/2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants issued to investor relations consultant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/28/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/28/2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants issued to investor relations consultant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7/19/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;60,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;60,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7/19/2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;690,944&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;690,944&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The stock-based compensation for warrants&#13;issued was $26,649 and $468,777 during the years ended December 31, 2014 and 2013, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recorded stock-based compensation&#13;(including the amortization of stock-based prepaid consulting fees, issuance of common stock for services and accrual for stock-based&#13;compensation) related to equity instruments granted to employees, directors and consultants as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Employees - selling and marketing&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;79,278&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,298&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Employees - general and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,095,254&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,512,448&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Employees - research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;156,568&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Directors - general and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;146,093&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;399,986&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consultants - selling and marketing&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;88,406&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consultants - general and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;146,799&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;843,301&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consultants - research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,789&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;214,372&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,564,619&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,134,973&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts payable and accrued expenses&#13;consisted of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;698,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;261,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred rent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,975&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Building lease liability(1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;73,552&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;39,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total accounts payable and accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;816,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;311,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less: Current portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(786,675&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(311,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-current total accounts payable and accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;29,658&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 24px; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. As of December 31, 2014, the Company was marketing its previous office space (3,874 square feet) as a sublease through its remaining lease term. The Company recognized a loss of approximately $117,000 during the year ended December 31, 2014, related to the estimated remaining lease liability, net of expected sublease income. The obligations were discounted based on current prevailing market rates. This loss is included in rent expense for the year ended December 31, 2014 (see Note 14).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The amount consists of a $39,000 stock-based compensation accrual at December 31, 2014 for stock options to be granted for services performed. The stock-based compensation expense related to restricted common stock issuances and accruals was $39,000 and $143,553 during the years ended December 31, 2014 and 2013, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 4. RESTRICTED SHORT-TERM INVESTMENTS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The restricted short-term investments&#13;at December 31, 2014 consist of certificate of deposits, which are classified as held-to-maturity. At December 31, 2014, the restricted&#13;short-term investments were recorded at amortized cost which approximates fair value.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2014, the certificate&#13;of deposits of $150,264 were classified as a current asset. The certificates of deposit are required as collateral under the Company&amp;#146;s&#13;corporate credit card agreement and office lease agreement and automatically renew every twelve months.&lt;/p&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses all costs related to&#13;research and development as they are incurred. Research and development expenses consist of expenses incurred in performing research&#13;and development activities, including salaries and benefits, other overhead expenses, and costs related to clinical trials, contract&#13;services and outsourced contracts.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:RevenueRecognitionDeferredRevenue contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Revenue Recognition and Deferred Revenue&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes revenues when all of&#13;the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling&#13;price is fixed and determinable; and (4) collectability is reasonably assured. The Company began generating revenues upon the acquisition&#13;of PC in the second quarter of 2014, which include sales of certain of the Company&amp;#146;s proprietary compounded drug formulations&#13;and certain non-proprietary formulations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Product Revenues&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Determination of criteria (3) and (4) is based&#13;on management&amp;#146;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability&#13;of those amounts. Estimated returns and allowances and other adjustments are provided for in the same period during which the related&#13;sales are recorded. The Company will defer any revenue received for a product that has not been delivered or is subject to refund&#13;until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;License Revenues&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;License arrangements may consist of non-refundable&#13;upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending&#13;compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple element arrangements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Non-refundable fees that are not contingent&#13;on any future performance by the Company and require no consequential continuing involvement on the part of the Company, are recognized&#13;as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable&#13;is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug&#13;preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents&#13;or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has&#13;continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable&#13;fee has no utility to the licensee and that are separate and independent of the Company&amp;#146;s performance under the other elements&#13;of the arrangement. In addition, if the Company&amp;#146;s continued involvement is required, through research and development services&#13;that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company,&#13;then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual&#13;royalties are recognized on a straight-line basis over the applicable term.&lt;/p&gt;</us-gaap:RevenueRecognitionDeferredRevenue>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As part of the process of preparing the Company&amp;#146;s&#13;consolidated financial statements, the Company must estimate the actual current tax liabilities and assess temporary differences&#13;resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and&#13;liabilities, which are included within the balance sheet. The Company must assess the likelihood that the deferred tax assets will&#13;be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, a valuation allowance&#13;must be established. To the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period,&#13;the impact will be included in income tax expense in the statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for income taxes under&#13;the provisions of Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) Accounting Standards Codification (&amp;#147;ASC&amp;#148;)&#13;740, &amp;#147;Income Taxes&amp;#148;, or ASC 740. As of December 31, 2014, there were no unrecognized tax benefits included in the&#13;consolidated balance sheet that would, if recognized, affect the effective tax rate. The Company&amp;#146;s practice is to recognize&#13;interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties&#13;in its consolidated balance sheets at December 31, 2014 and 2013, and has not recognized interest and/or penalties in the consolidated&#13;statements of operations for the years ended December 31, 2014 and 2013. The Company is subject to taxation in the United States&#13;and California. The Company&amp;#146;s tax years since 2000 are subject to examination by the federal and state tax authorities due&#13;to the carryforward of unutilized net operating losses.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash equivalents include short-term,&#13;highly liquid investments with maturities of three months or less at the time of acquisition.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Concentrations of Credit Risk&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company places its cash with financial&#13;institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (&amp;#147;FDIC&amp;#148;)&#13;provides basic deposit coverage with limits up to $250,000 per owner. At December 31, 2014, the Company had approximately $7.7&#13;million in cash deposits in excess of FDIC limits.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Furniture and Equipment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Furniture and equipment is stated at&#13;cost less accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method&#13;over the estimated useful life of the asset. Leasehold improvements and capital lease equipment are amortized over the estimated&#13;useful life or remaining lease term, whichever is shorter. Computer software and hardware and furniture and equipment are depreciated&#13;over three to five years.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Deferred Rent &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for rent expense&#13;related to its operating leases by determining total minimum rent payments on the leases over their respective periods and recognizing&#13;the rent expense on a straight-line basis. The difference between the actual amount paid and the amount recorded as rent expense&#13;in each fiscal year and interim periods within each fiscal year is recorded as an adjustment to deferred rent.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value measurements are determined&#13;based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for&#13;inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by&#13;requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs&#13;used in valuation methodologies into the following three levels:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 24px; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity&amp;#146;s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2014 and 2013, the&#13;Company did not have any financial assets or liabilities that are measured on a recurring basis. At December 31, 2014 and 2013,&#13;the Company&amp;#146;s financial instruments included cash and cash equivalents, restricted short-term investments, accounts receivable,&#13;accounts payable and accrued expenses, accrued payroll and related liabilities, customer deposits, and capital leases. The carrying&#13;amount of these financial instruments, except for the restricted short-term investments and the capital leases, approximates fair&#13;value due to the short-term maturities of these instruments. The Company&amp;#146;s restricted short-term investments are carried&#13;at amortized cost, which approximates fair value. Based on borrowing rates currently available to the Company, the carrying values&#13;of the capital leases approximate their respective fair values.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All stock-based payments to employees,&#13;directors and consultants, including grants of stock options, warrants, restricted stock units (&amp;#147;RSUs&amp;#148;) and restricted&#13;stock, are recognized in the consolidated financial statements based upon their fair values. The Company uses the Black-Scholes-Merton&#13;option pricing model and Monte Carlo Simulation to estimate the fair value of stock-based awards. The estimated fair value is determined&#13;at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary,&#13;if the actual effect differs from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#146;s accounting policy&#13;for equity instruments issued to consultants and vendors in exchange for goods and services follows the Financial Accounting Standards&#13;Board (the &amp;#147;FASB&amp;#148;) guidance. As such, the value of the applicable stock-based compensation is periodically remeasured&#13;and income or expense is recognized during the vesting terms of the equity instrument. The measurement date for the estimated&#13;fair value of the equity instruments issued is the earlier of (i) the date at which a commitment for performance by the consultant&#13;or vendor is reached or (ii) the date at which the consultant or vendor&amp;#146;s performance is complete. In the case of equity&#13;instruments issued to consultants, the estimated fair value of the equity instrument is primarily recognized over the term of&#13;the consulting agreement. In accordance with FASB guidance, an asset acquired in exchange for the issuance of fully vested, nonforfeitable&#13;equity instruments should not be presented or classified as an offset to equity on the grantor&amp;#146;s balance sheet once the&#13;equity instrument is granted for accounting purposes. Accordingly, the Company records the estimated fair value of nonforfeitable&#13;equity instruments issued for future consulting services as prepaid expenses in its consolidated balance sheets.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Basic and Diluted Net Loss per Common&#13;Share&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per common share is computed&#13;by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding&#13;during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the&#13;period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during&#13;the period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic and diluted net loss per share&#13;is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents&#13;(using the treasury stock or, &amp;#147;if converted&amp;#148; method) from stock options, RSUs and warrants were 3,024,217 and 3,539,800&#13;at December 31, 2014 and 2013, respectively, and are excluded from the calculation of diluted net loss per share for all periods&#13;presented because the effect is anti-dilutive. Common stock equivalents at December 31, 2014 include 27,218 shares of common stock&#13;underlying RSUs, awarded to directors that have vested, but the issuance and delivery of these shares are deferred until the director&#13;resigns.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows the computation&#13;of basic and diluted net loss per share of common stock for the years ended December 31, 2014 and 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Numerator &amp;#150; net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(10,118,103&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,643,124&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Denominator &amp;#150; weighted average number of shares outstanding, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,132,989&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,656,822&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Net loss per share, basic and diluted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.88&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements&#13;in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, and liabilities&#13;and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and&#13;expenses during the reporting periods. Significant estimates made by management are, among others, allowance for doubtful accounts,&#13;realizability of inventories, valuation of deferred taxes, goodwill and intangible assets, recoverability of long-lived assets&#13;and goodwill, valuation of contingent acquisition obligations, and valuation of stock-based compensation issued to employees and&#13;non-employees. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows the computation&#13;of basic and diluted net loss per share of common stock for the years ended December 31, 2014 and 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Numerator &amp;#150; net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(10,118,103&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,643,124&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Denominator &amp;#150; weighted average number of shares outstanding, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,132,989&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,656,822&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Net loss per share, basic and diluted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.88&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts payable and accrued expenses&#13;consisted of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts payable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;698,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;261,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred rent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,975&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Building lease liability(1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;73,552&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;39,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total accounts payable and accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;816,333&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;311,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less: Current portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(786,675&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(311,924&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-current total accounts payable and accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;29,658&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 24px; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. As of December 31, 2014, the Company was marketing its previous office space (3,874 square feet) as a sublease through its remaining lease term. The Company recognized a loss of approximately $117,000 during the year ended December 31, 2014, related to the estimated remaining lease liability, net of expected sublease income. The obligations were discounted based on current prevailing market rates. This loss is included in rent expense for the year ended December 31, 2014 (see Note 14).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(2)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The amount consists of a $39,000 stock-based compensation accrual at December 31, 2014 for stock options to be granted for services performed. The stock-based compensation expense related to restricted common stock issuances and accruals was $39,000 and $143,553 during the years ended December 31, 2014 and 2013, respectively.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">311924</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">816333</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">261924</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">698806</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the stock option activity&#13;under the Plan for the year ended December 31, 2014 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Avg. Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Avg. Remaining Contractual Life&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Aggregate Intrinsic Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF"&gt;&#13;    &lt;td style="vertical-align: top; width: 44%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options outstanding - January 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,328,790&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.31&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 2%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;245,886&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF"&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(307,429&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.90&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options cancelled/forfeit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(238,007&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.68&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF"&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options outstanding - December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,029,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.74&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,351,174&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: white"&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options exercisable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;728,585&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.97&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,080,594&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="background-color: #CCEEFF"&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options vested and expected to vest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;999,175&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,319,475&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="vertical-align: bottom; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below illustrates the fair&#13;value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing&#13;options granted to employees and directors:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-average fair value of options granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.04&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected terms (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.81 - 6.91&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.8-7 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;96 - 102%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;102 - 123%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.37 - 1.65%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.86 - 2.05%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below illustrates the fair&#13;value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing&#13;options granted to consultants:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-average fair value of options granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.15&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected terms (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.5 - 10&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;2.33 - 10 &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;78 - 97%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;80 - 366% &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.10 - 1.68%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;0.30 - 2.45% &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;The fair value&#13;of each warrant is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The table below illustrates&#13;the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing&#13;the warrants issued to consultants:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted-average fair value of warrants granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected terms (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.6-5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;85%-346%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.32%-1.31%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <IMMY:ScheduleofWarrantsOutstandingAndExercisableTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A list of the warrants outstanding as&#13;of December 31, 2014 is included in the following table:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants Exercisable&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expiration&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrant Series&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Issue Date&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Date&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 41%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants issued to a former major shareholder&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/25/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;48,262&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.93&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;48,262&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 9%; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/25/2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants issued in April 2012 private placement&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/25/2012&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;496,537&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.93&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;496,537&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4/25/2015&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Underwriter Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/7/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;56,145&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;56,145&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/7/2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants issued to investor relations consultant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/28/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2/28/2016&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants issued to investor relations consultant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7/19/2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;60,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;60,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7/19/2018&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;690,944&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;690,944&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;</IMMY:ScheduleofWarrantsOutstandingAndExercisableTableTextBlock>
    <IMMY:MaximumDepositCoverageLimits contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">250000</IMMY:MaximumDepositCoverageLimits>
    <us-gaap:ProceedsFromDepositsFromCustomers contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">7700000</us-gaap:ProceedsFromDepositsFromCustomers>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">1029240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31_custom_RangeOneMember" unitRef="Shares" decimals="INF">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31_custom_RangeTwoMember" unitRef="Shares" decimals="INF">337723</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31_custom_RangeThreeMember" unitRef="Shares" decimals="INF">190557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31_custom_RangeFourMember" unitRef="Shares" decimals="INF">244160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31_custom_RangeFiveMember" unitRef="Shares" decimals="INF">6800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2013-12-31_custom_StockOptionPlanMember" unitRef="Shares" decimals="INF">1328790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31_custom_StockOptionPlanMember" unitRef="Shares" decimals="INF">1029240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">227216</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-01-01to2014-12-31_custom_StockOptionPlanMember" unitRef="Shares" decimals="INF">-307429</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">227216</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-12-31_custom_StockOptionPlanMember" unitRef="USDPShares" decimals="INF">5.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-12-31_custom_StockOptionPlanMember" unitRef="USDPShares" decimals="INF">5.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_custom_StockOptionPlanMember" unitRef="USDPShares" decimals="INF">6.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">3.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">4.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_custom_StockOptionPlanMember" unitRef="USDPShares" decimals="INF">3.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_custom_StockOptionPlanMember" unitRef="USDPShares" decimals="INF">6.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31_custom_StockOptionPlanMember">P6Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31_custom_RangeOneMember">P4Y6M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31_custom_RangeTwoMember">P4Y11M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31_custom_RangeThreeMember">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31_custom_RangeFourMember">P7Y11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31_custom_RangeFiveMember">P5Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2014-01-01to2014-12-31_custom_OptionsGrantedConsultantsMember" unitRef="USDPShares" decimals="INF">6.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2014-01-01to2014-12-31_custom_OptionsEmployeesMember" unitRef="USDPShares" decimals="INF">5.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2014-01-01to2014-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" decimals="INF">7.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2013-01-01to2013-12-31_custom_OptionsEmployeesMember" unitRef="USDPShares" decimals="INF">6.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2013-01-01to2013-12-31_custom_OptionsGrantedConsultantsMember" unitRef="USDPShares" decimals="INF">5.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="USDPShares" decimals="INF">5.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-12-31_custom_OptionsGrantedConsultantsMember_us-gaap_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-12-31_custom_OptionsGrantedConsultantsMember_us-gaap_MinimumMember">P2Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-12-31_custom_OptionsEmployeesMember_us-gaap_MinimumMember">P5Y9M22D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-12-31_custom_OptionsEmployeesMember_us-gaap_MaximumMember">P6Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31_custom_OptionsEmployeesMember_us-gaap_MinimumMember">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31_custom_OptionsEmployeesMember_us-gaap_MaximumMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31_custom_OptionsGrantedConsultantsMember_us-gaap_MinimumMember">P2Y3M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31_us-gaap_MaximumMember_custom_OptionsGrantedConsultantsMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">P2Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MonteCarloSimulationMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MonteCarloSimulationOneMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-12-31_custom_MonteCarloSimulationMember">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2014-01-01to2014-12-31_custom_OptionsGrantedConsultantsMember" unitRef="Percent" decimals="INF">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2014-01-01to2014-12-31_custom_OptionsEmployeesMember" unitRef="Percent" decimals="INF">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2013-01-01to2013-12-31_custom_OptionsEmployeesMember" unitRef="Percent" decimals="INF">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2013-01-01to2013-12-31_custom_OptionsGrantedConsultantsMember" unitRef="Percent" decimals="INF">0.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Percent" decimals="INF">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2014-01-01to2014-12-31_custom_MonteCarloSimulationMember" unitRef="Percent" decimals="INF">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2014-01-01to2014-12-31_custom_OptionsGrantedConsultantsMember" unitRef="Percent" decimals="INF">0.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2014-01-01to2014-12-31_custom_OptionsEmployeesMember" unitRef="Percent" decimals="INF">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2013-01-01to2013-12-31_custom_OptionsEmployeesMember" unitRef="Percent" decimals="INF">1.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2013-01-01to2013-12-31_custom_OptionsGrantedConsultantsMember" unitRef="Percent" decimals="INF">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Percent" decimals="INF">3.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2014-01-01to2014-12-31_custom_MonteCarloSimulationMember" unitRef="Percent" decimals="INF">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2014-01-01to2014-12-31_custom_OptionsGrantedConsultantsMember" unitRef="Percent" decimals="INF">0.0010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2014-01-01to2014-12-31_custom_OptionsEmployeesMember" unitRef="Percent" decimals="INF">0.0137</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2013-01-01to2013-12-31_custom_OptionsEmployeesMember" unitRef="Percent" decimals="INF">0.0086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2013-01-01to2013-12-31_custom_OptionsGrantedConsultantsMember" unitRef="Percent" decimals="INF">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Percent" decimals="INF">0.0032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2014-01-01to2014-12-31_custom_MonteCarloSimulationMember" unitRef="Percent" decimals="INF">0.0013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2014-01-01to2014-12-31_custom_OptionsGrantedConsultantsMember" unitRef="Percent" decimals="INF">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2014-01-01to2014-12-31_custom_OptionsEmployeesMember" unitRef="Percent" decimals="INF">0.0165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2013-01-01to2013-12-31_custom_OptionsEmployeesMember" unitRef="Percent" decimals="INF">0.0205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2013-01-01to2013-12-31_custom_OptionsGrantedConsultantsMember" unitRef="Percent" decimals="INF">0.0245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Percent" decimals="INF">0.0131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2014-01-01to2014-12-31_custom_MonteCarloSimulationMember" unitRef="Percent" decimals="INF">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2014-01-01to2014-12-31_custom_OptionsGrantedConsultantsMember" unitRef="Percent" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2014-01-01to2014-12-31_custom_OptionsEmployeesMember" unitRef="Percent" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-12-31_custom_OptionsEmployeesMember" unitRef="Percent" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-12-31_custom_OptionsGrantedConsultantsMember" unitRef="Percent" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Percent" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2014-01-01to2014-12-31_custom_RangeOneMember" unitRef="USDPShares" decimals="INF">2.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2014-01-01to2014-12-31_custom_RangeTwoMember" unitRef="USDPShares" decimals="INF">3.60</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2014-01-01to2014-12-31_custom_RangeThreeMember" unitRef="USDPShares" decimals="INF">5.49</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2014-01-01to2014-12-31_custom_RangeFourMember" unitRef="USDPShares" decimals="INF">8.06</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="From2014-01-01to2014-12-31_custom_RangeFiveMember" unitRef="USDPShares" decimals="INF">28.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2014-01-01to2014-12-31_custom_RangeOneMember" unitRef="USDPShares" decimals="INF">3.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2014-01-01to2014-12-31_custom_RangeTwoMember" unitRef="USDPShares" decimals="INF">4.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2014-01-01to2014-12-31_custom_RangeThreeMember" unitRef="USDPShares" decimals="INF">7.71</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2014-01-01to2014-12-31_custom_RangeFourMember" unitRef="USDPShares" decimals="INF">10.75</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="From2014-01-01to2014-12-31_custom_RangeFiveMember" unitRef="USDPShares" decimals="INF">80.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" decimals="INF">5.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_custom_RangeOneMember" unitRef="USDPShares" decimals="INF">2.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_custom_RangeTwoMember" unitRef="USDPShares" decimals="INF">4.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_custom_RangeThreeMember" unitRef="USDPShares" decimals="INF">6.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_custom_RangeFourMember" unitRef="USDPShares" decimals="INF">8.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_custom_RangeFiveMember" unitRef="USDPShares" decimals="INF">40.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
    <IMMY:NumberExercisable contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">728585</IMMY:NumberExercisable>
    <IMMY:NumberExercisable contextRef="From2014-01-01to2014-12-31_custom_RangeOneMember" unitRef="Shares" decimals="INF">250000</IMMY:NumberExercisable>
    <IMMY:NumberExercisable contextRef="From2014-01-01to2014-12-31_custom_RangeTwoMember" unitRef="Shares" decimals="INF">270015</IMMY:NumberExercisable>
    <IMMY:NumberExercisable contextRef="From2014-01-01to2014-12-31_custom_RangeThreeMember" unitRef="Shares" decimals="INF">60110</IMMY:NumberExercisable>
    <IMMY:NumberExercisable contextRef="From2014-01-01to2014-12-31_custom_RangeFourMember" unitRef="Shares" decimals="INF">141660</IMMY:NumberExercisable>
    <IMMY:NumberExercisable contextRef="From2014-01-01to2014-12-31_custom_RangeFiveMember" unitRef="Shares" decimals="INF">6800</IMMY:NumberExercisable>
    <IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2 contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" decimals="INF">5.25</IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2>
    <IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2 contextRef="From2014-01-01to2014-12-31_custom_RangeOneMember" unitRef="USDPShares" decimals="INF">2.80</IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2>
    <IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2 contextRef="From2014-01-01to2014-12-31_custom_RangeTwoMember" unitRef="USDPShares" decimals="INF">4.42</IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2>
    <IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2 contextRef="From2014-01-01to2014-12-31_custom_RangeThreeMember" unitRef="USDPShares" decimals="INF">6.26</IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2>
    <IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2 contextRef="From2014-01-01to2014-12-31_custom_RangeFourMember" unitRef="USDPShares" decimals="INF">9.01</IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2>
    <IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2 contextRef="From2014-01-01to2014-12-31_custom_RangeFiveMember" unitRef="USDPShares" decimals="INF">40.86</IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1 contextRef="AsOf2014-12-31_custom_WarrantsIssuedToFormerMajorShareholderMember" unitRef="Shares" decimals="INF">48262</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1 contextRef="AsOf2014-12-31_custom_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember" unitRef="Shares" decimals="INF">496537</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1 contextRef="AsOf2014-12-31_custom_UnderwriterWarrantsMember" unitRef="Shares" decimals="INF">56145</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1 contextRef="AsOf2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantOneMember" unitRef="Shares" decimals="INF">30000</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1 contextRef="AsOf2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantTwoMember" unitRef="Shares" decimals="INF">60000</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1 contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">690944</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1 contextRef="AsOf2014-12-31_custom_WarrantsIssuedToFormerMajorShareholderMember" unitRef="USDPShares" decimals="INF">5.93</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1 contextRef="AsOf2014-12-31_custom_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember" unitRef="USDPShares" decimals="INF">5.93</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1 contextRef="AsOf2014-12-31_custom_UnderwriterWarrantsMember" unitRef="USDPShares" decimals="INF">5.25</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1 contextRef="AsOf2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantOneMember" unitRef="USDPShares" decimals="INF">5.25</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1 contextRef="AsOf2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantTwoMember" unitRef="USDPShares" decimals="INF">8.50</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1 contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">6.05</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1>
    <IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 contextRef="AsOf2014-12-31_custom_WarrantsIssuedToFormerMajorShareholderMember" unitRef="Shares" decimals="INF">48262</IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
    <IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 contextRef="AsOf2014-12-31_custom_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember" unitRef="Shares" decimals="INF">496537</IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
    <IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 contextRef="AsOf2014-12-31_custom_UnderwriterWarrantsMember" unitRef="Shares" decimals="INF">56145</IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
    <IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 contextRef="AsOf2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantOneMember" unitRef="Shares" decimals="INF">30000</IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
    <IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 contextRef="AsOf2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantTwoMember" unitRef="Shares" decimals="INF">60000</IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
    <IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1 contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">690944</IMMY:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1>
    <us-gaap:OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate contextRef="AsOf2014-12-31" unitRef="Percent" decimals="INF">0.03</us-gaap:OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate>
    <us-gaap:OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate contextRef="AsOf2013-04-30" unitRef="Percent" decimals="INF">0.03</us-gaap:OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate>
    <us-gaap:OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate contextRef="AsOf2014-06-30" unitRef="Percent" decimals="INF">0.03</us-gaap:OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate>
    <IMMY:RoyaltiesRangePercentage contextRef="AsOf2014-12-31_us-gaap_MinimumMember" unitRef="Percent" decimals="INF">0.045</IMMY:RoyaltiesRangePercentage>
    <IMMY:RoyaltiesRangePercentage contextRef="AsOf2014-12-31_us-gaap_MaximumMember" unitRef="Percent" decimals="INF">0.09</IMMY:RoyaltiesRangePercentage>
    <IMMY:AggregateValueOfCashFees contextRef="AsOf2013-02-18" unitRef="USD" decimals="0">100000</IMMY:AggregateValueOfCashFees>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain prior period items and amounts&#13;have been reclassified to conform to the classifications used to prepare the consolidated financial statements for the year ended&#13;December 31, 2014. The Company has classified in these financial statements certain expenses as selling and marketing, whereas&#13;in prior periods certain of these expenses were included in an expense line item titled selling, general and administrative in&#13;the consolidated statements of operations. These reclassifications had no material impact on the Company&amp;#146;s financial position,&#13;results of operations, or cash flows as previously reported.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2014, the FASB issued an Accounting&#13;Standards Update (&amp;#147;ASU&amp;#148;) No. 2014-10, &amp;#147;Elimination of Certain Financial Reporting Requirements, Including an&#13;Amendment to Variable Interest Entities&amp;#148;. The amendments in this update remove the definition of a development stage entity&#13;from ASC Topic 915, &amp;#147;Development Stage Entities&amp;#148;, thereby removing from GAAP the distinction between development stage&#13;entities and other reporting entities. In addition, the amendments eliminate the requirements for development stage entities to&#13;(1) present inception-to-date information in the statements of operations, cash flows, and stockholder&amp;#146;s equity, (2) label&#13;the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities&#13;in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity&#13;that in prior years it had been in the development stage. These amendments are effective for annual reporting periods beginning&#13;after December 15, 2014, with early application of the amendments permitted. The Company&amp;#146;s pharmacy operations commenced&#13;on April 1, 2014. This change in the nature of the Company&amp;#146;s operations included the recognition of operating revenues;&#13;as a result, the Company is no longer defined as a development stage company for reporting dates beginning April 1, 2014. With&#13;the change in the Company&amp;#146;s operations, its revenue recognition and its immediate adoption of ASU No. 2014-10, the Company&#13;no longer presents or discloses any information required under ASC Topic 915.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CertificatesOfDepositAtCarryingValue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">150264</us-gaap:CertificatesOfDepositAtCarryingValue>
    <us-gaap:LeaseExpirationDate1 contextRef="From2013-04-01to2013-04-30">2016-09-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1 contextRef="From2014-06-01to2014-06-30">2018-10-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1 contextRef="From2010-01-01to2010-01-31_custom_PharmacyCreationsLlcMember">2015-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1 contextRef="From2015-02-27to2015-02-28_us-gaap_SubsequentEventMember_custom_LeaseAgreementMember">2022-07-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:AreaOfLand contextRef="AsOf2013-04-30" unitRef="SquareFeet" decimals="INF">3874</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand contextRef="AsOf2010-01-31_custom_PharmacyCreationsLlcMember" unitRef="SquareFeet" decimals="INF">3137</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand contextRef="AsOf2014-06-30" unitRef="SquareFeet" decimals="INF">7565</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand contextRef="AsOf2014-09-30" unitRef="SquareFeet" decimals="INF">7565</us-gaap:AreaOfLand>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2013-12-31_WarrantMember" unitRef="Shares" decimals="INF">821050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">690944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-130106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Shares" xsi:nil="true" />
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2013-12-31_WarrantMember" unitRef="USDPShares" decimals="INF">5.94</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">6.05</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <IMMY:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" xsi:nil="true" />
    <IMMY:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">5.28</IMMY:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2015-03-11" unitRef="Shares" decimals="INF">9342935</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">583811</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">227</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">583584</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="From2013-04-01to2013-04-30" unitRef="USD" decimals="0">10406</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="From2014-06-01to2014-06-30" unitRef="USD" decimals="0">20426</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="From2010-01-01to2010-01-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">3594</us-gaap:OperatingLeasesRentExpenseNet>
    <IMMY:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">47829</IMMY:StockIssuedDuringPeriodSharesWarrantsExercised>
    <IMMY:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2015-01-30to2015-03-11_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">12658</IMMY:StockIssuedDuringPeriodSharesWarrantsExercised>
    <IMMY:CommonStockExercisePricePerShare contextRef="From2014-01-01to2014-12-31_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">3.60</IMMY:CommonStockExercisePricePerShare>
    <IMMY:CommonStockExercisePricePerShare contextRef="From2014-01-01to2014-12-31_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">6.00</IMMY:CommonStockExercisePricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2014-09-30_us-gaap_StockOptionMember_custom_TwoThousandSecenIncentiveStockAndAwardsPlanMember" unitRef="Shares" decimals="INF">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <IMMY:OptionsExercisePrice contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" decimals="INF">7.50</IMMY:OptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1161000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <IMMY:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1 contextRef="From2014-01-01to2014-12-31_us-gaap_MinimumMember">P3Y</IMMY:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1>
    <IMMY:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1 contextRef="From2014-01-01to2014-12-31_us-gaap_MaximumMember">P10Y</IMMY:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1>
    <IMMY:StockOptionsGrantedVestingTermsDescription contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Vesting terms for options granted in fiscal years&#13;2014 and 2013 to employees, directors and consultants typically included one of the following vesting schedules: 25% or 33% of&#13;the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75%&#13;or 67%, respectively, of the shares subject to the option vest and become exercisable in equal quarterly installments thereafter&#13;over two or three years, respectively; quarterly vesting over a three year period; or monthly, quarterly or 100% vesting associated&#13;with the provision or completion of services provided under contracts with consultants.&lt;/font&gt;&lt;/p&gt;</IMMY:StockOptionsGrantedVestingTermsDescription>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1571000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2014-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">1923000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2014-01-01to2014-12-31">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2014-01-01to2014-12-31_us-gaap_RestrictedStockUnitsRSUMember">P1Y3M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2014-01-01to2014-12-31_custom_StockOptionPlanMember" unitRef="Shares" decimals="INF">245886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2014-01-01to2014-12-31_custom_StockOptionPlanMember" unitRef="Shares" decimals="INF">-238007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2014-01-01to2014-12-31_custom_StockOptionPlanMember">P4Y11M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="From2014-01-01to2014-12-31_custom_StockOptionPlanMember">P5Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2013-12-31_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">1389960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="AsOf2014-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">1276815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2014-01-01to2014-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">26492</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1 contextRef="From2014-01-01to2014-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">-30690</IMMY:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2014-01-01to2014-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">-108947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2013-12-31_RestrictedStockUnitsRSUMember" unitRef="USDPShares" decimals="INF">3.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2014-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" decimals="INF">3.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="From2014-01-01to2014-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" decimals="INF">7.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="From2014-01-01to2014-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPShares" decimals="INF">3.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <IMMY:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember">P10M10D</IMMY:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <IMMY:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" xsi:nil="true" />
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 13. EMPLOYEE SAVINGS PLAN&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has established an employee&#13;savings plan pursuant to Section 401(k) of the Internal Revenue Code, effective January 1, 2014. The plan allows participating&#13;employees to deposit into tax deferred investment accounts up to 100% of their salary, subject to annual limits. The Company makes&#13;contributions to the plan in an amount not less than 3% of the participants&amp;#146; annual cash compensation, subject to annual&#13;limits. The Company contributed approximately $56,000 to the plan during the year ended December 31, 2014.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <IMMY:PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount contextRef="From2014-01-01to2014-12-31" unitRef="Percent" decimals="INF">1.00</IMMY:PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount>
    <IMMY:DefinedBenefitPlanContributionsByEmployerPercentage contextRef="From2014-01-01to2014-12-31" unitRef="Percent" decimals="INF">0.03</IMMY:DefinedBenefitPlanContributionsByEmployerPercentage>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">56000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:Assets contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15761365</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">10242224</us-gaap:Assets>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">26892</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">243395</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Goodwill contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">331621</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">331621</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">610994</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AssetsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15734473</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">9056214</us-gaap:AssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">105067</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">240401</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InventoryNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">372735</us-gaap:InventoryNet>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">81322</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RestrictedInvestmentsCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">50097</us-gaap:RestrictedInvestmentsCurrent>
    <us-gaap:RestrictedInvestmentsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">150264</us-gaap:RestrictedInvestmentsCurrent>
    <us-gaap:Liabilities contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">650627</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">2092050</us-gaap:Liabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">483156</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">18968</us-gaap:CapitalLeaseObligationsNoncurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">650627</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1560268</us-gaap:LiabilitiesCurrent>
    <us-gaap:CapitalLeaseObligationsCurrent contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CapitalLeaseObligationsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">24112</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:CustomerDepositsCurrent contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CustomerDepositsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1683</us-gaap:CustomerDepositsCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">338703</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">716332</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">311924</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">786675</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15761365</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">10242224</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15110738</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">8150174</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">9996437</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">6772</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">34093933</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-24104268</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">8970</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">46849160</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-31747392</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">9258</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">50006411</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-41865495</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-31747392</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-41865495</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CommonStockValue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">8970</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">9258</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2013-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">90000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">90000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2013-02-08" unitRef="Shares" decimals="INF">90000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">8970364</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">9258231</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2015-01-31_us-gaap_SubsequentEventMember_custom_ParkSellersMember" unitRef="Shares" decimals="INF">63525</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">8970364</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">9258231</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">636374</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:AccountsReceivableNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">3957</us-gaap:AccountsReceivableNet>
    <us-gaap:AssetImpairmentCharges contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">0</us-gaap:AssetImpairmentCharges>
    <IMMY:CommonStockEquivalentsDilutiveInstruments contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">3024217</IMMY:CommonStockEquivalentsDilutiveInstruments>
    <IMMY:CommonStockEquivalentsDilutiveInstruments contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">3539800</IMMY:CommonStockEquivalentsDilutiveInstruments>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">2564619</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3134973</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-12-31_custom_EmployeesMember_custom_SellingAndMarketingMember" unitRef="USD" decimals="0">79278</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-01-01to2013-12-31_custom_EmployeesMember_custom_SellingAndMarketingMember" unitRef="USD" decimals="0">8298</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-12-31_custom_EmployeesMember_custom_GeneralAndAdministrativeMember" unitRef="USD" decimals="0">2095254</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-01-01to2013-12-31_custom_EmployeesMember_custom_GeneralAndAdministrativeMember" unitRef="USD" decimals="0">1512448</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-12-31_custom_EmployeesMember_custom_ResearchAndDevelopmentMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-01-01to2013-12-31_custom_EmployeesMember_custom_ResearchAndDevelopmentMember" unitRef="USD" decimals="0">156568</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-12-31_us-gaap_DirectorMember_custom_GeneralAndAdministrativeMember" unitRef="USD" decimals="0">146093</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-01-01to2013-12-31_us-gaap_DirectorMember_custom_GeneralAndAdministrativeMember" unitRef="USD" decimals="0">399986</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-12-31_custom_ConsultantMember_custom_SellingAndMarketingMember" unitRef="USD" decimals="0">88406</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-01-01to2013-12-31_custom_ConsultantMember_custom_SellingAndMarketingMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-12-31_custom_ConsultantMember_custom_GeneralAndAdministrativeMember" unitRef="USD" decimals="0">146799</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-01-01to2013-12-31_custom_ConsultantMember_custom_GeneralAndAdministrativeMember" unitRef="USD" decimals="0">843301</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-12-31_custom_ConsultantMember_custom_ResearchAndDevelopmentMember" unitRef="USD" decimals="0">8789</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-01-01to2013-12-31_custom_ConsultantMember_custom_ResearchAndDevelopmentMember" unitRef="USD" decimals="0">214372</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-10118103</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-7643124</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The total acquisition date fair value&#13;of the consideration transferred and to be transferred is estimated at approximately $1.1 million, as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash payment to the PC Sellers at closing&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;600,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contingent common stock issuance to the PC Sellers&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;483,156&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contingent cash consideration to the PC Sellers&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,466&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total acquisition date fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,114,622&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the estimated&#13;fair values of the assets acquired and liabilities assumed at the acquisition date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,982&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts receivable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;58,420&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid expenses and other assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,256&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;213,190&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;659,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total identifiable assets acquired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,010,358&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;120,049&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;107,308&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total liabilities assumed&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;227,357&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total identifiable assets less liabilities assumed&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;783,001&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;331,621&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net assets acquired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,114,622&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <IMMY:ScheduleOfResultOfOperationFromAcquisitionTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The amount of revenues and operating&#13;loss of PC included in the Company&amp;#146;s consolidated statement of operations from the acquisition date through the period ended&#13;December 31, 2014 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total revenues&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,652,386&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(662,969&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</IMMY:ScheduleOfResultOfOperationFromAcquisitionTableTextBlock>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The unaudited pro forma results presented&#13;include amortization charges for intangible assets and eliminations of intercompany transactions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total revenues&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,282,681&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,866,575&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(10,048,380&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,084,014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table sets forth the components&#13;of identified intangible assets associated with the PC acquisition and their estimated useful lives.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Useful Life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 60%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Customer relationships&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;596,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10 - 15 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Trade name&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-competition covenant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State pharmacy licenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;659,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">1114622</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">4982</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">58420</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">30256</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">213190</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">44510</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">659000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">1010358</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">120049</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">107308</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">227357</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">1652386</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">-662969</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">2282681</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">2866575</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-10048380</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-7084014</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_TradeNamesMember">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_LicensingAgreementsMember">P25Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_CustomerRelationshipsMember_us-gaap_MinimumMember">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_CustomerRelationshipsMember_us-gaap_MaximumMember">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="From2014-01-01to2014-12-31_custom_NonCompetitionCovenantMember">P4Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <IMMY:ExpectedRevenueDuringAcquisition contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">3500000</IMMY:ExpectedRevenueDuringAcquisition>
    <IMMY:ExpectedRevenueDuringAcquisition contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember_us-gaap_MinimumMember_custom_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember" unitRef="USD" decimals="0">3500000</IMMY:ExpectedRevenueDuringAcquisition>
    <IMMY:ExpectedRevenueDuringAcquisition contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember_us-gaap_MaximumMember_custom_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember" unitRef="USD" decimals="0">7500000</IMMY:ExpectedRevenueDuringAcquisition>
    <IMMY:ExpectedRevenueDate contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember">2015-03-31</IMMY:ExpectedRevenueDate>
    <IMMY:ExpectedRevenueDate contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember_us-gaap_MinimumMember_custom_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember">2016-03-31</IMMY:ExpectedRevenueDate>
    <IMMY:ExpectedRevenueDate contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember_us-gaap_MaximumMember_custom_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember">2016-03-31</IMMY:ExpectedRevenueDate>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The composition of inventories as of&#13;December 31, 2014 was as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Raw materials&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;146,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Work in progress&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;97,801&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finished goods&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;128,634&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total inventories&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;372,735&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">146300</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">128634</us-gaap:InventoryFinishedGoods>
    <IMMY:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expenses and other current assets&#13;consisted of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid stock-based consulting expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,649&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid rent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,288&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;123,776&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;39,166&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other prepaid expenses and deposits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;116,625&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;22,964&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total prepaid expenses and other current assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;240,401&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;105,067&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in"&gt;&amp;#160;&lt;/p&gt;</IMMY:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">22964</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">116625</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidInsurance contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">39166</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">123776</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidRent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">16288</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <IMMY:PrepaidStockbasedConsultingExpenses contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">26649</IMMY:PrepaidStockbasedConsultingExpenses>
    <IMMY:PrepaidStockbasedConsultingExpenses contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 8. INTANGIBLE ASSETS AND GOODWILL&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;The Company&amp;#146;s intangible assets at December 31, 2014&#13;consisted of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;periods&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cost&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;carrying value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 38%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Customer relationships&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10-15 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;596,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(36,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;559,260&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Trade name&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-competition covenant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(9,375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40,625&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State pharmacy licenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,141&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,859&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;659,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(48,006&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;610,994&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Amortization expense for intangible assets for the year ended&#13;December 31, 2014 was as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Customer relationships&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;36,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Trade name&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-competition covenant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State pharmacy licenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,141&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;48,006&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Estimated future amortization expense for the Company&amp;#146;s&#13;intangible assets at December 31, 2014 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Years ending December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;67,087&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;67,087&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;67,087&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;57,712&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;53,837&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;298,184&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;610,994&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The changes in the carrying value of&#13;the Company&amp;#146;s goodwill during the year ended December 31, 2014 were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at January 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;PC Acquisition&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;331,621&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;331,621&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;The Company&amp;#146;s intangible assets at December 31, 2014&#13;consisted of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;periods&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cost&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;carrying value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 38%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Customer relationships&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10-15 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;596,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(36,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 13%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;559,260&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Trade name&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,250&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-competition covenant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(9,375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40,625&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State pharmacy licenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25 years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,141&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,859&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;659,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(48,006&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;610,994&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Amortization expense for intangible assets for the year ended&#13;December 31, 2014 was as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Customer relationships&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;36,740&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Trade name&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;750&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-competition covenant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9,375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State pharmacy licenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,141&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;48,006&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;Estimated future amortization expense for the Company&amp;#146;s&#13;intangible assets at December 31, 2014 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Years ending December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;67,087&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;67,087&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;67,087&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;57,712&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;53,837&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;298,184&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;610,994&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The changes in the carrying value of&#13;the Company&amp;#146;s goodwill during the year ended December 31, 2014 were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at January 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;PC Acquisition&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 24%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;331,621&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;331,621&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">659000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="From2014-01-01to2014-12-31_us-gaap_CustomerRelationshipsMember" unitRef="USD" decimals="0">596000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="From2014-01-01to2014-12-31_us-gaap_TradeNamesMember" unitRef="USD" decimals="0">5000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="From2014-01-01to2014-12-31_us-gaap_LicensingAgreementsMember" unitRef="USD" decimals="0">8000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="From2014-01-01to2014-12-31_custom_NonCompetitionCovenantMember" unitRef="USD" decimals="0">50000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_TradeNamesMember">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_NoncompeteAgreementsMember">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_LicensingAgreementsMember">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_CustomerRelationshipsMember_us-gaap_MinimumMember">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_CustomerRelationshipsMember_us-gaap_MaximumMember">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">659000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31_us-gaap_CustomerRelationshipsMember" unitRef="USD" decimals="0">596000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31_us-gaap_TradeNamesMember" unitRef="USD" decimals="0">5000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31_us-gaap_NoncompeteAgreementsMember" unitRef="USD" decimals="0">50000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31_us-gaap_LicensingAgreementsMember" unitRef="USD" decimals="0">8000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-48006</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31_us-gaap_CustomerRelationshipsMember" unitRef="USD" decimals="0">-36740</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31_us-gaap_TradeNamesMember" unitRef="USD" decimals="0">-750</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31_us-gaap_NoncompeteAgreementsMember" unitRef="USD" decimals="0">-9375</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31_us-gaap_LicensingAgreementsMember" unitRef="USD" decimals="0">-1141</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">610994</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31_us-gaap_CustomerRelationshipsMember" unitRef="USD" decimals="0">559260</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31_us-gaap_TradeNamesMember" unitRef="USD" decimals="0">4250</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31_us-gaap_NoncompeteAgreementsMember" unitRef="USD" decimals="0">40625</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31_us-gaap_LicensingAgreementsMember" unitRef="USD" decimals="0">6859</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">48006</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2014-01-01to2014-12-31_us-gaap_CustomerRelationshipsMember" unitRef="USD" decimals="0">36740</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2014-01-01to2014-12-31_us-gaap_TradeNamesMember" unitRef="USD" decimals="0">750</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2014-01-01to2014-12-31_us-gaap_LicensingAgreementsMember" unitRef="USD" decimals="0">1141</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2014-01-01to2014-12-31_custom_NonCompetitionCovenantMember" unitRef="USD" decimals="0">9375</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">67087</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">67087</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">53837</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <IMMY:AcquisitionOfRelatedPartyGoodwill contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">331621</IMMY:AcquisitionOfRelatedPartyGoodwill>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 10. DEBT&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;PC entered into a working capital line&#13;of credit agreement with a financial institution on March 21, 2008 and subsequently renewed the agreement on September 6, 2013.&#13;The line of credit agreement allowed PC to borrow up to $75,000 and was secured by a first security interest on all of PC&amp;#146;s&#13;business assets. The line of credit agreement was terminated following the Company&amp;#146;s acquisition of PC, and no amounts were&#13;borrowed, paid or outstanding during the period ended December 31, 2014 following the Company&amp;#146;s acquisition of PC.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-04-01to2014-04-30_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">50000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <IMMY:StockIssuedDuringPeriodSharesStockOptionsExercisedOne contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">160777</IMMY:StockIssuedDuringPeriodSharesStockOptionsExercisedOne>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company leases equipment under capital&#13;leases with an interest rate of 4.25% per annum. At December 31, 2014, future payments under the Company&amp;#146;s capital leases&#13;were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year ending December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25,477&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19,321&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44,798&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less amount representing interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1,718&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Present value of future minimum lease payments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;43,080&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Less current portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(24,112&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Capital lease obligations, net of current portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;18,968&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">43080</us-gaap:CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">25477</us-gaap:CapitalLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">19321</us-gaap:CapitalLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">44798</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1718</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
    <IMMY:LeasesEquipmentUnderCapitalLeaseWithInterestRate contextRef="AsOf2014-12-31" unitRef="Percent" decimals="INF">0.0425</IMMY:LeasesEquipmentUnderCapitalLeaseWithInterestRate>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 15. SEGMENT INFORMATION&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company operates the business on the basis&#13;of a single reportable segment, which is the business of developing proprietary drug therapies and providing such therapies through&#13;sterile and non-sterile pharmaceutical compounding services. The Company&amp;#146;s chief operating decision-maker is the Chief Executive&#13;Officer, who evaluates the Company as a single operating segment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company categorizes revenues by geographic&#13;area based on selling location. All operations are currently located in the United States; therefore, total revenues for 2014 and&#13;2013 are attributed to the United States. All long-lived assets at December 31, 2014 are located in the United States.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company sells its compounded formulations&#13;to a large number of customers. Less than 10% of the Company&amp;#146;s total pharmacy sales were derived from a single customer for&#13;the year ended December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company receives its active pharmaceutical&#13;ingredients from three main suppliers. These suppliers collectively accounted for 84% of drug and chemical purchases during the&#13;year ended December 31, 2014.&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-12-31" unitRef="Percent" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">57712</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">67087</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <IMMY:WarrantsIssuanceDate contextRef="From2014-01-01to2014-12-31_custom_WarrantsIssuedToFormerMajorShareholderMember">2012-04-25</IMMY:WarrantsIssuanceDate>
    <IMMY:WarrantsIssuanceDate contextRef="From2014-01-01to2014-12-31_custom_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember">2012-04-25</IMMY:WarrantsIssuanceDate>
    <IMMY:WarrantsIssuanceDate contextRef="From2014-01-01to2014-12-31_custom_UnderwriterWarrantsMember">2013-02-07</IMMY:WarrantsIssuanceDate>
    <IMMY:WarrantsIssuanceDate contextRef="From2014-01-01to2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantOneMember">2013-02-28</IMMY:WarrantsIssuanceDate>
    <IMMY:WarrantsIssuanceDate contextRef="From2014-01-01to2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantTwoMember">2013-07-19</IMMY:WarrantsIssuanceDate>
    <IMMY:WarrantsExpirationDate contextRef="From2014-01-01to2014-12-31_custom_WarrantsIssuedToFormerMajorShareholderMember">2015-04-25</IMMY:WarrantsExpirationDate>
    <IMMY:WarrantsExpirationDate contextRef="From2014-01-01to2014-12-31_custom_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember">2015-04-25</IMMY:WarrantsExpirationDate>
    <IMMY:WarrantsExpirationDate contextRef="From2014-01-01to2014-12-31_custom_UnderwriterWarrantsMember">2018-02-07</IMMY:WarrantsExpirationDate>
    <IMMY:WarrantsExpirationDate contextRef="From2014-01-01to2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantOneMember">2016-02-28</IMMY:WarrantsExpirationDate>
    <IMMY:WarrantsExpirationDate contextRef="From2014-01-01to2014-12-31_custom_WarrantsIssuedToInvestorRelationsConsultantTwoMember">2018-07-19</IMMY:WarrantsExpirationDate>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 3. ACQUISITION &amp;#150; PHARMACY&#13;CREATIONS, LLC&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 1, 2014, the Company acquired&#13;all of the outstanding membership interests of PC (the &amp;#147;PC Acquisition&amp;#148;) from J. Scott Karolchyk and Bernard Covalesky&#13;(the &amp;#147;PC Sellers&amp;#148;), such that PC became a wholly-owned subsidiary of the Company. The acquisition of PC permits the&#13;Company to make and distribute its patent-pending proprietary drug formulations and other pharmaceutical preparations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The transaction has been accounted for&#13;as a business combination and the financial results of PC have been included in the Company&amp;#146;s consolidated financial statements&#13;for the period subsequent to its acquisition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The estimated acquisition date fair&#13;value of consideration transferred, assets acquired and liabilities assumed for PC are presented below and represent the Company&amp;#146;s&#13;best estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Fair Value of Consideration Transferred&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At the closing of the PC Acquisition,&#13;the Company paid to the PC Sellers an aggregate cash purchase price of $600,000. In addition, the PC Sellers are entitled to receive&#13;additional contingent consideration upon the satisfaction of certain conditions, as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 24px; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 24px; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A contingent cash payment of $50,000, payable if PC earns revenues of over $3,500,000 for the 12 month period ending March 31, 2015.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;A contingent stock payment of up to an aggregate of 215,190 shares of the Company&amp;#146;s common stock, issuable only if the following revenue milestones are met:&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;if PC earns revenue of over $7,500,000 during the 12 month period ending March 31, 2016, all 215,190 shares;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;if PC earns revenue of between $3,500,000 and $7,500,000 during the 12 month period ending March 31, 2016, an aggregate of that number of shares of Imprimis common stock equal to the amount that such revenue exceeds $3,500,000 divided by 18.5882, rounded down to the lower whole number (not to exceed 215,190 shares).&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Although management estimates that certain&#13;of the contingent consideration will be paid, it has applied a discount rate to the contingent consideration amounts in determining&#13;fair value to represent the risk of these payments not being made. The total acquisition date fair value of the consideration transferred&#13;and to be transferred is estimated at approximately $1.1 million, as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash payment to the PC Sellers at closing&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;600,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contingent common stock issuance to the PC Sellers&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;483,156&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contingent cash consideration to the PC Sellers&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;31,466&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total acquisition date fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,114,622&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A $514,622 liability was recognized&#13;for the estimated acquisition date fair value of the future contingent common stock and cash payments and is included in the contingent&#13;acquisition obligations in the accompanying consolidated balance sheet at December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Allocation of Consideration Transferred&#13;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The identifiable assets acquired and&#13;liabilities assumed were recognized and measured as of the acquisition date based on their estimated fair values as of April 1,&#13;2014, the acquisition date. The excess of the acquisition date fair value of consideration transferred over the estimated fair&#13;value of the net tangible assets and intangible assets acquired was recorded as goodwill.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes the estimated&#13;fair values of the assets acquired and liabilities assumed at the acquisition date.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4,982&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts receivable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;58,420&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid expenses and other assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;30,256&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;213,190&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Property and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Intangible assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;659,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total identifiable assets acquired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,010,358&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts payable and accrued liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;120,049&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other liabilities&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;107,308&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total liabilities assumed&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;227,357&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total identifiable assets less liabilities assumed&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;783,001&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Goodwill&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;331,621&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net assets acquired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,114,622&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Results of Operations&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The amount of revenues and operating&#13;loss of PC included in the Company&amp;#146;s consolidated statement of operations from the acquisition date through the period ended&#13;December 31, 2014 are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total revenues&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,652,386&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Operating loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(662,969&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Pro Forma Financial Information&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table presents the Company&amp;#146;s&#13;unaudited pro forma results (including PC) for the years ended December 31, 2014 and 2013 as though the companies had been combined&#13;as of the beginning of each of the periods presented. The pro forma information is presented for informational purposes only and&#13;is not indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning&#13;of each period presented, nor is it indicative of results of operations which may occur in the future. The unaudited pro forma&#13;results presented include amortization charges for intangible assets and eliminations of intercompany transactions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total revenues&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,282,681&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,866,575&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(10,048,380&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(7,084,014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company did not incur material acquisition&#13;expenses related to the PC Acquisition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Intangible Assets&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management engaged a third-party valuation&#13;firm to assist in the determination of the fair value of the acquired intangible assets of PC. In determining the fair value of&#13;the intangible assets, the Company considered, among other factors, the best use of acquired assets, analyses of historical financial&#13;performance of PC and estimates of future performance of PC. The fair values of the identified intangible assets related to PC&amp;#146;s&#13;customer relationships, trade name, non-competition covenant, and state pharmacy licenses. The fair value of customer relationships&#13;and the non-competition covenant were calculated using the income approach. The fair value of the trade name and state pharmacy&#13;licenses were calculated using the cost approach. The following table sets forth the components of identified intangible assets&#13;associated with the PC acquisition and their estimated useful lives.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Fair Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Useful Life&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 60%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Customer relationships&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;596,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10 - 15 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Trade name&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Non-competition covenant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State pharmacy licenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;25 years&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;659,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determined the useful lives&#13;of intangible assets based on the expected future cash flows and contractual lives associated with the respective asset. Trade&#13;names represent the fair value of the brand and name recognition associated with the marketing of PC&amp;#146;s formulations and services.&#13;Customer relationships represent the expected benefit from customer contracts that, at the date of acquisition, were reasonably&#13;anticipated to continue given the history and operating practices of PC. The non-competition covenant represents the contractual&#13;period and expected degree of adverse economic impact that would exist in its absence. Licenses represent eight state pharmacy&#13;licenses PC held at the date of acquisition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Goodwill &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Of the total estimated purchase price,&#13;$331,621 was allocated to goodwill and is attributable to expected synergies between the combined companies, including access&#13;for the Company to fulfill prescriptions with its patent-pending proprietary drug formulations through PC&amp;#146;s market channels&#13;and assembled workforce. Goodwill represents the excess of the purchase price of the acquired business over the estimated fair&#13;value of the underlying net tangible and intangible assets acquired. Goodwill resulting from the PC Acquisition will be tested&#13;for impairment at least annually and more frequently if certain indicators of impairment are present. In the event the Company&#13;determines that the value of goodwill has become impaired, it will incur an accounting charge for the amount of the impairment&#13;during the fiscal quarter in which the determination is made. None of the goodwill is expected to be deductible for income tax&#13;purposes.&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 5. INVENTORIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventories are comprised of over-the-counter&#13;retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients.&#13;The composition of inventories as of December 31, 2014 was as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 73%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Raw materials&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 24%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;146,300&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Work in progress&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;97,801&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Finished goods&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;128,634&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total inventories&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;372,735&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <IMMY:PaymentOfCashToContigent contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">50000</IMMY:PaymentOfCashToContigent>
    <IMMY:NumberOfSharesAppliedForContigentStockPayment contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="Shares" decimals="INF">215190</IMMY:NumberOfSharesAppliedForContigentStockPayment>
    <us-gaap:GainContingencyDescription contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember">&lt;p style="margin: 0pt"&gt;if PC earns revenue of over $7,500,000 during the 12 month period ending March 31, 2016, all 215,190 shares;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;if PC earns revenue of between $3,500,000 and $7,500,000 during the 12 month period ending March 31, 2016,&#13;an aggregate of that number of shares of Imprimis common stock equal to the amount that such revenue exceeds $3,500,000 divided&#13;by 18.5882, rounded down to the lower whole number (not to exceed 215,190 shares).&lt;/p&gt;</us-gaap:GainContingencyDescription>
    <IMMY:BusinessAcquisitionPurchasePriceAllocationGoodwill contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">331621</IMMY:BusinessAcquisitionPurchasePriceAllocationGoodwill>
    <IMMY:ContingentCommonStockIssuanceToRelatedParty contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">483156</IMMY:ContingentCommonStockIssuanceToRelatedParty>
    <IMMY:ContingentCashConsiderationToRelatedParty contextRef="From2014-01-01to2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">31466</IMMY:ContingentCashConsiderationToRelatedParty>
    <IMMY:PercentageOfForfeitureFactor contextRef="From2013-04-01to2013-04-02_custom_EmployeesAndDirectorsMember" unitRef="Percent" decimals="INF">0.10</IMMY:PercentageOfForfeitureFactor>
    <IMMY:PercentageOfDrugAndChemicalPurchases contextRef="From2014-01-01to2014-12-31" unitRef="Percent" decimals="INF">0.84</IMMY:PercentageOfDrugAndChemicalPurchases>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Business Combinations&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for business combinations&#13;by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair&#13;values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions&#13;at the acquisition date, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition&#13;contingencies. Examples of critical estimates in valuing certain of the intangible assets we the Company has acquired or may acquire&#13;in the future include but are not limited to:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 24px; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 24px; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;discount rates utilized in valuation estimates.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Unanticipated events and circumstances&#13;may occur that may affect the accuracy or validity of such assumptions, and estimates compared to actual results. Additionally,&#13;any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including&#13;changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be&#13;recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent&#13;consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material&#13;effect on the consolidated financial position, statements of operations, or cash flows in the period of the change in the estimate.&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Cost of Sales&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cost of sales includes direct and indirect&#13;costs to manufacture formulations and other products sold, including active pharmaceutical ingredients, personnel costs, packaging,&#13;storage, royalties (see Note 14), shipping and handling costs and the write-off of obsolete inventory.&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The balance in accounts receivable&#13;consists of revenue amounts the Company has invoiced and recognized, but for which payment has not been received. Accounts receivable&#13;are presented net of an allowance for doubtful accounts in the amount of $3,957 as of December 31, 2014.&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Inventories&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventories are stated at the lower&#13;of cost or market. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on&#13;a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost.&#13;Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company also regularly evaluates&#13;its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated&#13;future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical&#13;ingredients on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Goodwill and Intangible Assets&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviews its goodwill and&#13;indefinite-lived intangible assets for impairment as of January 1 of each year and when an event or a change in circumstances indicates&#13;the fair value of a reporting unit may be below its carrying amount. Events or changes in circumstances considered as impairment&#13;indicators include but are not limited to the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 24px; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 24px; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant underperformance of the Company&amp;#146;s business relative to expected operating results;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant adverse economic and industry trends;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;significant decline in the Company&amp;#146;s market capitalization for an extended period of time relative to net book value; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;expectations that a reporting unit will be sold or otherwise disposed. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The goodwill impairment test consists&#13;of a two-step process as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Step 1. The Company compares the fair&#13;value of each reporting unit to its carrying amount, including the existing goodwill. The fair value of each reporting unit is&#13;determined using a discounted cash flow valuation analysis. The carrying value of each reporting unit is determined by specifically&#13;identifying and allocating the assets and liabilities to each reporting unit based on headcount, relative revenues, or other methods&#13;as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its fair value, an indication exists that&#13;the reporting unit&amp;#146;s goodwill may be impaired and the Company then performs the second step of the impairment test. If the&#13;fair value of a reporting unit exceeds its carrying amount, no further analysis is required.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Step 2. If further analysis is required,&#13;the Company compares the implied fair value of the reporting unit&amp;#146;s goodwill, determined by allocating the reporting unit&amp;#146;s&#13;fair value to all of its assets and its liabilities in a manner similar to a purchase price allocation, to its carrying amount.&#13;If the carrying amount of the reporting unit&amp;#146;s goodwill exceeds its fair value, an impairment loss will be recognized in&#13;an amount equal to the excess.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long-lived assets, such as furniture&#13;and equipment and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances&#13;indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured&#13;by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the&#13;asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount&#13;by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented&#13;in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no&#13;longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in&#13;the appropriate asset and liability sections of the consolidated balance sheet, if material.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ended December 31,&#13;2014 and 2013, the Company did not recognize any impairment of its long-lived assets.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <IMMY:RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2014, the FASB issued new&#13;accounting guidance which defines management&amp;#146;s responsibility to assess an entity&amp;#146;s ability to continue as a going&#13;concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for annual periods&#13;ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted&#13;for annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently&#13;evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2014, the FASB issued ASU No.&#13;2014-09, &amp;#147;Revenue from Contracts with Customers&amp;#148; (&amp;#147;ASU 2014-09&amp;#148;). The objective of ASU 2014-19 is to establish&#13;a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede&#13;most of the existing revenue recognition guidance, including industry-specific guidance. The core principle of ASU 2014-09 is&#13;that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects&#13;the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the new guidance,&#13;an entity will (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine&#13;the transaction price; (4) allocate the transaction price to the contract&amp;#146;s performance obligations; and (5) recognize revenue&#13;when (or as) the entity satisfies a performance obligation. ASU 2014-09 applies to all contracts with customers except those that&#13;are within the scope of other topics in the FASB ASC. The new guidance is effective for annual reporting periods, including interim&#13;periods within those periods, beginning after December 15, 2016 for public companies. Early adoption is not permitted. The Company&#13;is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial&#13;statements.&lt;/p&gt;</IMMY:RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock>
    <IMMY:BusinessAcquisitionContingentAcquiredObligationsLiabilities contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <IMMY:BusinessAcquisitionContingentAcquiredObligationsLiabilities contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">31466</IMMY:BusinessAcquisitionContingentAcquiredObligationsLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">1114622</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">783001</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <IMMY:ExerciseOfCommonStockOptionToPurchaseOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">146652</IMMY:ExerciseOfCommonStockOptionToPurchaseOfCommonStock>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">50000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" id="Foot-00-0" decimals="0">39000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of warrant activity during&#13;the year ended December 31, 2014 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of Shares Subject to Warrants Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Avg.&lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 54%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants outstanding - January 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;821,050&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.94&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(130,106&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Warrants outstanding and exercisable - December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;690,944&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average remaining contractual life of the outstanding warrants in years - December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A summary of the Company&amp;#146;s RSU&#13;activity and related information for the year ended December 31, 2014 is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of RSUs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted Average Grant Date Fair Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 42%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;RSUs unvested - January 1, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,389,960&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 36%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.19&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;RSUs granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,492&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.55&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;RSUs vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(30,690&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.41&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;RSUs cancelled/forfeit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(108,947&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;RSUs unvested at December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,276,815&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15579309</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">8211492</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">10035615</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:HealthCareOrganizationRevenue contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1652386</us-gaap:HealthCareOrganizationRevenue>
    <us-gaap:HealthCareOrganizationRevenue contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LicensesRevenue contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">7860</us-gaap:LicensesRevenue>
    <us-gaap:LicensesRevenue contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">10000</us-gaap:LicensesRevenue>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1660246</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">10000</us-gaap:SalesRevenueNet>
    <us-gaap:HealthCareOrganizationMedicalSuppliesAndDrugsExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">1092839</us-gaap:HealthCareOrganizationMedicalSuppliesAndDrugsExpense>
    <us-gaap:HealthCareOrganizationMedicalSuppliesAndDrugsExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:GrossProfit contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">567407</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">10000</us-gaap:GrossProfit>
    <us-gaap:SellingAndMarketingExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">2390180</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">85890</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">8087316</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">5994907</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">236660</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1616082</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingCostsAndExpenses contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">10714156</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">7696879</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-10146749</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-7686879</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-10118103</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-7643124</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-7643124</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-10118103</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" decimals="INF">-1.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">-0.88</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">9132989</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">8656822</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:Depreciation contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">37343</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">5659</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">2614619</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3134973</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-12-31_custom_RestrictedStockUnitsRSUOneMember" unitRef="USD" decimals="0">822137</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2014-01-01to2014-12-31_custom_RestrictedStockUnitsRSUOneMember" unitRef="USD" decimals="0">1332176</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">1137634</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">1689756</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">22902</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">159545</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">131727</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">16964</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">345360</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-239800</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">342154</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">320312</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInCustomerDeposits contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-10633</us-gaap:IncreaseDecreaseInCustomerDeposits>
    <us-gaap:IncreaseDecreaseInCustomerDeposits contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-7055428</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-4438944</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">173986</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">20003</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-910527</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-70003</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">13109</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">191</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">10431</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">621678</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">10052832</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">598138</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">10052641</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-7367817</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">5543694</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:IncomeTaxesPaidNet contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">800</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1600</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaid contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">3800</us-gaap:InterestPaid>
    <us-gaap:InterestPaid contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">139444</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2013-01-01to2013-12-31_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0">282997</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2013-09-01to2013-09-30_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">10750</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2013-01-01to2013-12-31_us-gaap_RestrictedStockMember_custom_DrRobertKammerMember" unitRef="USD" decimals="0">282997</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2014-10-01to2014-10-30_us-gaap_RestrictedStockMember" unitRef="USD" decimals="0">29160</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <IMMY:IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <IMMY:IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">319786</IMMY:IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees>
    <IMMY:ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <IMMY:ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">596281</IMMY:ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering>
    <IMMY:PurchaseOfFurnitureAndEquipmentWithCapitalLease contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">35350</IMMY:PurchaseOfFurnitureAndEquipmentWithCapitalLease>
    <IMMY:PurchaseOfFurnitureAndEquipmentWithCapitalLease contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <IMMY:BuildingLeaseLiability contextRef="AsOf2013-12-31" unitRef="USD" id="Foot-01-0" xsi:nil="true" />
    <IMMY:BuildingLeaseLiability contextRef="AsOf2014-12-31" unitRef="USD" id="Foot-01-1" decimals="0">73552</IMMY:BuildingLeaseLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">29658</us-gaap:AccountsPayableAndAccruedLiabilitiesNoncurrent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">66439</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">219</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2014-04-01to2014-04-30_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">6868</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-01-01to2015-01-02_us-gaap_SubsequentEventMember_custom_ParkSellersMember" unitRef="Shares" decimals="INF">6749</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <IMMY:WarrantsToPurchaseCommonStockExercisePricePerShare contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" decimals="INF">5.925</IMMY:WarrantsToPurchaseCommonStockExercisePricePerShare>
    <IMMY:StockWarrantsIssuedDuringPeriodValueOfStockExercised contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">37867</IMMY:StockWarrantsIssuedDuringPeriodValueOfStockExercised>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2015-01-30to2015-03-11_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">74998</us-gaap:ProceedsFromIssuanceOfWarrants>
    <IMMY:ExerciseOfWarrantToPurchaseOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">123715</IMMY:ExerciseOfWarrantToPurchaseOfCommonStock>
    <IMMY:WarrantsSharesExercisePricePerShare contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" decimals="INF">5.25</IMMY:WarrantsSharesExercisePricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2013-01-01to2013-12-31_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">40000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2014-01-01to2014-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">27218</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2013-09-01to2013-09-30_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">2114</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2013-01-01to2013-12-31_us-gaap_RestrictedStockMember_custom_DrRobertKammerMember" unitRef="Shares" decimals="INF">40000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2014-10-01to2014-10-30_us-gaap_RestrictedStockMember" unitRef="Shares" decimals="INF">4000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <IMMY:NumberOfWarrantsCommonStockIssued contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">41438</IMMY:NumberOfWarrantsCommonStockIssued>
    <us-gaap:CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">52687</us-gaap:CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet>
    <us-gaap:CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">8656</us-gaap:CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation>
    <IMMY:WarrantsAndSharesIssuedUponExciseOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">6391</IMMY:WarrantsAndSharesIssuedUponExciseOfCommonStock>
    <IMMY:LicenseAgreementCommitmentsDescription contextRef="From2014-10-23to2014-10-24_custom_UrigenPharmaceuticalsIncMember">&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;The&#13;annual tiered royalties consist of the greater of (i) $0.50 per dose, and (ii) 15% - 20% of its net sales of HLA, with the royalty&#13;amount within such range depending on the Company&amp;#146;s aggregate sales of HLA during the period to which the royalty payment&#13;applies. The minimum annual royalty payment consists of (a) for the 2015 calendar year, the greater of (i) 110% of the aggregate&#13;royalties paid to Urigen under the Existing Sublicenses during the preceding 12 months, on a prorated basis, and (ii) $800,000,&#13;less the aggregate royalties paid to Urigen under the Existing Sublicenses during the 2015 calendar year, and (b) for each calendar&#13;year thereafter, 110% of the aggregate amount owed by the Company to Urigen under the Urigen License during the prior calendar&#13;year. The Company is obligated to pay such royalties beginning with its first commercial sale of HLA and continuing until the&#13;expiration of the patents subject to the license granted under the Urigen License. The Company has also agreed to use commercially&#13;reasonable efforts to develop and commercialize HLA according to the terms of a diligence plan agreed to by the parties, which&#13;efforts will include, without limitation, the Company&amp;#146;s investment of $2 million in commercialization efforts of HLA, which&#13;investment and timeline can be adjusted dependent on market circumstances, and is expected to be incurred over 18-24 months following&#13;the Urigen Effective Date.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;</IMMY:LicenseAgreementCommitmentsDescription>
    <us-gaap:PaymentsForRoyalties contextRef="From2014-10-23to2014-10-24_custom_UrigenPharmaceuticalsIncMember" unitRef="USD" decimals="0">800000</us-gaap:PaymentsForRoyalties>
    <IMMY:ValueOfProductDevelopmentInvestment contextRef="From2014-10-23to2014-10-24_custom_UrigenPharmaceuticalsIncMember" unitRef="USD" decimals="0">2000000</IMMY:ValueOfProductDevelopmentInvestment>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">46849160</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">50006411</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:InterestExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">3800</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InvestmentIncomeInterest contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">32446</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">43755</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">28646</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">43755</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">100167</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">50000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 6. PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expenses and other current assets&#13;consisted of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid stock-based consulting expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,649&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid rent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,288&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;123,776&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;39,166&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other prepaid expenses and deposits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;116,625&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;22,964&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total prepaid expenses and other current assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;240,401&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;105,067&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 28, 2012, the Company effected&#13;a one-for-eight reverse stock split and on February 7, 2013, the Company effected a one-for-five reverse stock split. All share&#13;and per share amounts in these consolidated financial statements and notes reflect the effects of these reverse stock splits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Imprimis has prepared the accompanying&#13;consolidated financial statements in accordance with accounting principles generally accepted in the United States of America&#13;(&amp;#147;GAAP&amp;#148;). The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned&#13;subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Intellectual Property&lt;/b&gt;&lt;i&gt; &lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The costs of acquiring intellectual property&#13;rights to be used in the research and development process, including licensing fees and milestone payments, are charged to research&#13;and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired&#13;rights, and are capitalized in situations where the Company has identified an alternative future use for the acquired rights.&#13;No costs associated with acquiring intellectual property rights have been capitalized to date, although the Company may begin&#13;to capitalize certain costs associated with intellectual property rights beginning in the fiscal year 2015. Costs of maintaining&#13;intellectual property rights are expensed as incurred.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes information about stock options&#13;outstanding and exercisable at December 31, 2014:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Options Exercisable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Remaining&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Average&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Contractual&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Range of Exercise Prices&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Life in Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 28%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$2.40 - $3.20&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.57&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;250,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2.80&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$3.60 - $4.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;337,723&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.95&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.36&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;270,015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;4.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$5.49 - $7.71&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;190,557&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.62&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;60,110&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.26&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$8.06 - $10.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;244,160&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8.99&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;141,660&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;9.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$28.00 - $80.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.13&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;40.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,029,240&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;6.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.74&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;728,585&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recorded stock-based compensation&#13;(including the amortization of stock-based prepaid consulting fees, issuance of common stock for services and accrual for stock-based&#13;compensation) related to equity instruments granted to employees, directors and consultants as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Employees - selling and marketing&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;79,278&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,298&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Employees - general and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,095,254&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1,512,448&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Employees - research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;156,568&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Directors - general and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;146,093&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;399,986&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consultants - selling and marketing&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;88,406&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consultants - general and administrative&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;146,799&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;843,301&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Consultants - research and development&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,789&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;214,372&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,564,619&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,134,973&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <IMMY:RestrictedStockIncludedInCommonStockEquivalents contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">27218</IMMY:RestrictedStockIncludedInCommonStockEquivalents>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">298184</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <IMMY:PreviousOfficeSpaceArea contextRef="AsOf2014-12-31" unitRef="SquareFeet" decimals="INF">3874</IMMY:PreviousOfficeSpaceArea>
    <IMMY:RecognizedLeaseLossesRelatedToLeaseLiability contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">117000</IMMY:RecognizedLeaseLossesRelatedToLeaseLiability>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">75000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ShortTermBorrowings contextRef="AsOf2014-12-31_custom_PharmacyCreationsLlcMember" unitRef="USD" decimals="0">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2015-03-11_us-gaap_SubsequentEventMember" unitRef="USDPShares" decimals="INF">5.925</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2015-02-28_us-gaap_SubsequentEventMember_custom_CCOEmploymentAgreementMember_custom_JohnPSaharekMember" unitRef="USDPShares" decimals="INF">7.37</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2014-01-01to2014-12-31_us-gaap_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:EntityVoluntaryFilers contextRef="From2014-01-01to2014-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2014-01-01to2014-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityCurrentReportingStatus contextRef="From2014-01-01to2014-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityPublicFloat contextRef="AsOf2014-06-30" unitRef="USD" decimals="0">47000000</dei:EntityPublicFloat>
    <us-gaap:SharesOutstanding contextRef="AsOf2012-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">6772066</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">8970364</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">9258231</us-gaap:SharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">2469810</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2469810</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">29160</IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne>
    <IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">282997</IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne>
    <IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">40</IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne>
    <IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">282957</IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne>
    <IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true" />
    <IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4</IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne>
    <IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">29156</IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne>
    <IMMY:IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true" />
    <IMMY:IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">40000</IMMY:IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne>
    <IMMY:IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">4000</IMMY:IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3018068</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">26649</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3018066</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="USD" decimals="0">468777</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <IMMY:StockIssuedDuringPeriodSharesStockOptionsExercisedFour contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">219</IMMY:StockIssuedDuringPeriodSharesStockOptionsExercisedFour>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">40</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-40</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <IMMY:CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013 contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-191</IMMY:CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013>
    <IMMY:CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013 contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-191</IMMY:CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013>
    <IMMY:CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013 contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true" />
    <IMMY:CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">-35</IMMY:CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares>
    <IMMY:StockIssuedDuringPeriodValueForPublicOffering contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">9456551</IMMY:StockIssuedDuringPeriodValueForPublicOffering>
    <IMMY:StockIssuedDuringPeriodValueForPublicOffering contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2116</IMMY:StockIssuedDuringPeriodValueForPublicOffering>
    <IMMY:StockIssuedDuringPeriodValueForPublicOffering contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9454435</IMMY:StockIssuedDuringPeriodValueForPublicOffering>
    <IMMY:StockIssuedDuringPeriodValueForPublicOffering contextRef="From2013-01-01to2013-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true" />
    <IMMY:StockIssuedDuringPeriodSharesForPublicOffering contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2116000</IMMY:StockIssuedDuringPeriodSharesForPublicOffering>
    <IMMY:IssuanceOfCommonStockUponVestingOfRsusShares contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">40000</IMMY:IssuanceOfCommonStockUponVestingOfRsusShares>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">2114</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <IMMY:IssuanceOfCommonStockForPublicOfferingPricePerShare contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">5.25</IMMY:IssuanceOfCommonStockForPublicOfferingPricePerShare>
    <IMMY:CancelledCommonStockPricePerShare contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">5.25</IMMY:CancelledCommonStockPricePerShare>
    <IMMY:IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-13109</IMMY:IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding>
    <IMMY:IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">2</IMMY:IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding>
    <IMMY:IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-13111</IMMY:IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding>
    <IMMY:IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true" />
    <IMMY:IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">1954</IMMY:IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares>
    <IMMY:IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1954</IMMY:IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares>
    <IMMY:StockIssuedDuringPeriodForExerciseOfWarrants contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">37867</IMMY:StockIssuedDuringPeriodForExerciseOfWarrants>
    <IMMY:StockIssuedDuringPeriodForExerciseOfWarrants contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">48</IMMY:StockIssuedDuringPeriodForExerciseOfWarrants>
    <IMMY:StockIssuedDuringPeriodForExerciseOfWarrants contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">37819</IMMY:StockIssuedDuringPeriodForExerciseOfWarrants>
    <IMMY:StockIssuedDuringPeriodForExerciseOfWarrants contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true" />
    <IMMY:StockIssuedDuringPeriodSharesForExerciseOfWarrants contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">47829</IMMY:StockIssuedDuringPeriodSharesForExerciseOfWarrants>
    <IMMY:StockSharesIssuedDuingPeriodForSettlementOfContractDispute contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">50000</IMMY:StockSharesIssuedDuingPeriodForSettlementOfContractDispute>
    <IMMY:StockSharesIssuedDuingPeriodForSettlementOfContractDispute contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">7</IMMY:StockSharesIssuedDuingPeriodForSettlementOfContractDispute>
    <IMMY:StockSharesIssuedDuingPeriodForSettlementOfContractDispute contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">49993</IMMY:StockSharesIssuedDuingPeriodForSettlementOfContractDispute>
    <IMMY:StockSharesIssuedDuingPeriodForSettlementOfContractDispute contextRef="From2014-01-01to2014-12-31_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true" />
    <IMMY:StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">6868</IMMY:StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING&#13;POLICIES&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 28, 2012, the Company effected&#13;a one-for-eight reverse stock split and on February 7, 2013, the Company effected a one-for-five reverse stock split. All share&#13;and per share amounts in these consolidated financial statements and notes reflect the effects of these reverse stock splits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Imprimis has prepared the accompanying consolidated&#13;financial statements in accordance with accounting principles generally accepted in the United States of America (&amp;#147;GAAP&amp;#148;).&#13;The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany&#13;accounts and transactions have been eliminated in consolidation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Business Combinations&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for business combinations&#13;by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair&#13;values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions&#13;at the acquisition date, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition&#13;contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company has acquired or may acquire&#13;in the future include but are not limited to:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;discount rates utilized in valuation estimates.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Unanticipated events and circumstances may&#13;occur that may affect the accuracy or validity of such assumptions, and estimates compared to actual results. Additionally, any&#13;change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes&#13;from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized&#13;in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration&#13;or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the&#13;consolidated financial position, statements of operations, or cash flows in the period of the change in the estimate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company expenses all costs related to research&#13;and development as they are incurred. Research and development expenses consist of expenses incurred in performing research and&#13;development activities, including salaries and benefits, other overhead expenses, and costs related to clinical trials, contract&#13;services and outsourced contracts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Intellectual Property&lt;/b&gt;&lt;i&gt; &lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The costs of acquiring intellectual property&#13;rights to be used in the research and development process, including licensing fees and milestone payments, are charged to research&#13;and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired&#13;rights, and are capitalized in situations where the Company has identified an alternative future use for the acquired rights. No&#13;costs associated with acquiring intellectual property rights have been capitalized to date, although the Company may begin to capitalize&#13;certain costs associated with intellectual property rights beginning in the fiscal year 2015. Costs of maintaining intellectual&#13;property rights are expensed as incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Revenue Recognition and Deferred Revenue&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes revenues when all of&#13;the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling&#13;price is fixed and determinable; and (4) collectability is reasonably assured. The Company began generating revenues upon the acquisition&#13;of PC in the second quarter of 2014, which include sales of certain of the Company&amp;#146;s proprietary compounded drug formulations&#13;and certain non-proprietary formulations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Product Revenues&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Determination of criteria (3) and (4) is based&#13;on management&amp;#146;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability&#13;of those amounts. Estimated returns and allowances and other adjustments are provided for in the same period during which the related&#13;sales are recorded. The Company will defer any revenue received for a product that has not been delivered or is subject to refund&#13;until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;License Revenues&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;License arrangements may consist of non-refundable&#13;upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending&#13;compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple element arrangements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Non-refundable fees that are not contingent&#13;on any future performance by the Company and require no consequential continuing involvement on the part of the Company, are recognized&#13;as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable&#13;is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug&#13;preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents&#13;or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing&#13;performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable&#13;fee has no utility to the licensee and that are separate and independent of the Company&amp;#146;s performance under the other elements&#13;of the arrangement. In addition, if the Company&amp;#146;s continued involvement is required, through research and development services&#13;that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company,&#13;then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual&#13;royalties are recognized on a straight-line basis over the applicable term.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Cost of Sales&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cost of sales includes direct and indirect&#13;costs to manufacture formulations and other products sold, including active pharmaceutical ingredients, personnel costs, packaging,&#13;storage, royalties (see Note 14), shipping and handling costs and the write-off of obsolete inventory.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As part of the process of preparing the Company&amp;#146;s&#13;consolidated financial statements, the Company must estimate the actual current tax liabilities and assess temporary differences&#13;resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and&#13;liabilities, which are included within the balance sheet. The Company must assess the likelihood that the deferred tax assets will&#13;be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, a valuation allowance&#13;must be established. To the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period,&#13;the impact will be included in income tax expense in the statement of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for income taxes under&#13;the provisions of Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) Accounting Standards Codification (&amp;#147;ASC&amp;#148;)&#13;740, &amp;#147;Income Taxes&amp;#148;, or ASC 740. As of December 31, 2014, there were no unrecognized tax benefits included in the consolidated&#13;balance sheet that would, if recognized, affect the effective tax rate. The Company&amp;#146;s practice is to recognize interest and/or&#13;penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties in its consolidated&#13;balance sheets at December 31, 2014 and 2013, and has not recognized interest and/or penalties in the consolidated statements of&#13;operations for the years ended December 31, 2014 and 2013. The Company is subject to taxation in the United States and California.&#13;The Company&amp;#146;s tax years since 2000 are subject to examination by the federal and state tax authorities due to the carryforward&#13;of unutilized net operating losses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash equivalents include short-term, highly&#13;liquid investments with maturities of three months or less at the time of acquisition.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Concentrations of Credit Risk&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company places its cash with financial&#13;institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (&amp;#147;FDIC&amp;#148;)&#13;provides basic deposit coverage with limits up to $250,000 per owner. At December 31, 2014, the Company had approximately $7.7&#13;million in cash deposits in excess of FDIC limits.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Accounts Receivable&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The balance in accounts receivable consists&#13;of revenue amounts the Company has invoiced and recognized, but for which payment has not been received. Accounts receivable are&#13;presented net of an allowance for doubtful accounts in the amount of $3,957 as of December 31, 2014.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Inventories&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventories are stated at the lower of cost&#13;or market. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular&#13;basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. Write-downs&#13;of inventories are considered to be permanent reductions in the cost basis of inventories.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company also regularly evaluates its inventories&#13;for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales&#13;or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients&#13;on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Furniture and Equipment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Furniture and equipment is stated at cost less&#13;accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method over the&#13;estimated useful life of the asset. Leasehold improvements and capital lease equipment are amortized over the estimated useful&#13;life or remaining lease term, whichever is shorter. Computer software and hardware and furniture and equipment are depreciated&#13;over three to five years.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Goodwill and Intangible Assets&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reviews its goodwill and indefinite-lived&#13;intangible assets for impairment as of January 1 of each year and when an event or a change in circumstances indicates the fair&#13;value of a reporting unit may be below its carrying amount. Events or changes in circumstances considered as impairment indicators&#13;include but are not limited to the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 24px"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;significant underperformance of the Company&amp;#146;s business relative to expected operating results;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;significant adverse economic and industry trends;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;significant decline in the Company&amp;#146;s market capitalization for an extended period of time relative to net book value; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;expectations that a reporting unit will be sold or otherwise disposed. &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The goodwill impairment test consists of a&#13;two-step process as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Step 1. The Company compares the fair value&#13;of each reporting unit to its carrying amount, including the existing goodwill. The fair value of each reporting unit is determined&#13;using a discounted cash flow valuation analysis. The carrying value of each reporting unit is determined by specifically identifying&#13;and allocating the assets and liabilities to each reporting unit based on headcount, relative revenues, or other methods as deemed&#13;appropriate by management. If the carrying amount of a reporting unit exceeds its fair value, an indication exists that the reporting&#13;unit&amp;#146;s goodwill may be impaired and the Company then performs the second step of the impairment test. If the fair value of&#13;a reporting unit exceeds its carrying amount, no further analysis is required.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Step 2. If further analysis is required, the&#13;Company compares the implied fair value of the reporting unit&amp;#146;s goodwill, determined by allocating the reporting unit&amp;#146;s&#13;fair value to all of its assets and its liabilities in a manner similar to a purchase price allocation, to its carrying amount.&#13;If the carrying amount of the reporting unit&amp;#146;s goodwill exceeds its fair value, an impairment loss will be recognized in&#13;an amount equal to the excess.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long-lived assets, such as furniture and equipment&#13;and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate&#13;that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison&#13;of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying&#13;amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying&#13;amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the consolidated&#13;balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated.&#13;The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset&#13;and liability sections of the consolidated balance sheet, if material.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ended December 31, 2014 and&#13;2013, the Company did not recognize any impairment of its long-lived assets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Deferred Rent &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for rent expense related&#13;to its operating leases by determining total minimum rent payments on the leases over their respective periods and recognizing&#13;the rent expense on a straight-line basis. The difference between the actual amount paid and the amount recorded as rent expense&#13;in each fiscal year and interim periods within each fiscal year is recorded as an adjustment to deferred rent.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Fair value measurements are determined based&#13;on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs&#13;used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring&#13;that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used&#13;in valuation methodologies into the following three levels:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top; width: 24px"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="vertical-align: top"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity&amp;#146;s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At December 31, 2014 and 2013, the Company&#13;did not have any financial assets or liabilities that are measured on a recurring basis. At December 31, 2014 and 2013, the Company&amp;#146;s&#13;financial instruments included cash and cash equivalents, restricted short-term investments, accounts receivable, accounts payable&#13;and accrued expenses, accrued payroll and related liabilities, customer deposits, and capital leases. The carrying amount of these&#13;financial instruments, except for the restricted short-term investments and the capital leases, approximates fair value due to&#13;the short-term maturities of these instruments. The Company&amp;#146;s restricted short-term investments are carried at amortized&#13;cost, which approximates fair value. Based on borrowing rates currently available to the Company, the carrying values of the capital&#13;leases approximate their respective fair values.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;All stock-based payments to employees, directors&#13;and consultants, including grants of stock options, warrants, restricted stock units (&amp;#147;RSUs&amp;#148;) and restricted stock,&#13;are recognized in the consolidated financial statements based upon their fair values. The Company uses the Black-Scholes-Merton&#13;option pricing model and Monte Carlo Simulation to estimate the fair value of stock-based awards. The estimated fair value is determined&#13;at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary,&#13;if the actual effect differs from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&amp;#146;s accounting policy for equity&#13;instruments issued to consultants and vendors in exchange for goods and services follows the Financial Accounting Standards Board&#13;(the &amp;#147;FASB&amp;#148;) guidance. As such, the value of the applicable stock-based compensation is periodically remeasured and&#13;income or expense is recognized during the vesting terms of the equity instrument. The measurement date for the estimated fair&#13;value of the equity instruments issued is the earlier of (i) the date at which a commitment for performance by the consultant or&#13;vendor is reached or (ii) the date at which the consultant or vendor&amp;#146;s performance is complete. In the case of equity instruments&#13;issued to consultants, the estimated fair value of the equity instrument is primarily recognized over the term of the consulting&#13;agreement. In accordance with FASB guidance, an asset acquired in exchange for the issuance of fully vested, nonforfeitable equity&#13;instruments should not be presented or classified as an offset to equity on the grantor&amp;#146;s balance sheet once the equity instrument&#13;is granted for accounting purposes. Accordingly, the Company records the estimated fair value of nonforfeitable equity instruments&#13;issued for future consulting services as prepaid expenses in its consolidated balance sheets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Basic and Diluted Net Loss per Common Share&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per common share is computed&#13;by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding&#13;during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the&#13;period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during&#13;the period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic and diluted net loss per share is computed&#13;using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the&#13;treasury stock or, &amp;#147;if converted&amp;#148; method) from stock options, RSUs and warrants were 3,024,217 and 3,539,800 at December&#13;31, 2014 and 2013, respectively, and are excluded from the calculation of diluted net loss per share for all periods presented&#13;because the effect is anti-dilutive. Common stock equivalents at December 31, 2014 include 27,218 shares of common stock underlying&#13;RSUs, awarded to directors that have vested, but the issuance and delivery of these shares are deferred until the director resigns.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows the computation of&#13;basic and diluted net loss per share of common stock for the years ended December 31, 2014 and 2013:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;For the&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Year Ended&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Numerator &amp;#150; net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(10,118,103&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(7,643,124&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Denominator &amp;#150; weighted average number of shares outstanding, basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,132,989&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8,656,822&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;Net loss per share, basic and diluted&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.88&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in&#13;conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, and liabilities&#13;and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and&#13;expenses during the reporting periods. Significant estimates made by management are, among others, allowance for doubtful accounts,&#13;realizability of inventories, valuation of deferred taxes, goodwill and intangible assets, recoverability of long-lived assets&#13;and goodwill, valuation of contingent acquisition obligations, and valuation of stock-based compensation issued to employees and&#13;non-employees. Actual results could differ from those estimates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Reclassifications&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Certain prior period items and amounts have&#13;been reclassified to conform to the classifications used to prepare the consolidated financial statements for the year ended December&#13;31, 2014. The Company has classified in these financial statements certain expenses as selling and marketing, whereas in prior&#13;periods certain of these expenses were included in an expense line item titled selling, general and administrative in the consolidated&#13;statements of operations. These reclassifications had no material impact on the Company&amp;#146;s financial position, results of&#13;operations, or cash flows as previously reported.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2014, the FASB issued an Accounting&#13;Standards Update (&amp;#147;ASU&amp;#148;) No. 2014-10, &amp;#147;Elimination of Certain Financial Reporting Requirements, Including an&#13;Amendment to Variable Interest Entities&amp;#148;. The amendments in this update remove the definition of a development stage entity&#13;from ASC Topic 915, &amp;#147;Development Stage Entities&amp;#148;, thereby removing from GAAP the distinction between development stage&#13;entities and other reporting entities. In addition, the amendments eliminate the requirements for development stage entities to&#13;(1) present inception-to-date information in the statements of operations, cash flows, and stockholder&amp;#146;s equity, (2) label&#13;the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities&#13;in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity&#13;that in prior years it had been in the development stage. These amendments are effective for annual reporting periods beginning&#13;after December 15, 2014, with early application of the amendments permitted. The Company&amp;#146;s pharmacy operations commenced&#13;on April 1, 2014. This change in the nature of the Company&amp;#146;s operations included the recognition of operating revenues; as&#13;a result, the Company is no longer defined as a development stage company for reporting dates beginning April 1, 2014. With the&#13;change in the Company&amp;#146;s operations, its revenue recognition and its immediate adoption of ASU No. 2014-10, the Company no&#13;longer presents or discloses any information required under ASC Topic 915.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2014, the FASB issued new accounting&#13;guidance which defines management&amp;#146;s responsibility to assess an entity&amp;#146;s ability to continue as a going concern, and&#13;to provide related footnote disclosures in certain circumstances. This guidance will be effective for annual periods ending after&#13;December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for&#13;annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently&#13;evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2014, the FASB issued ASU No. 2014-09,&#13;&amp;#147;Revenue from Contracts with Customers&amp;#148; (&amp;#147;ASU 2014-09&amp;#148;). The objective of ASU 2014-19 is to establish&#13;a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede&#13;most of the existing revenue recognition guidance, including industry-specific guidance. The core principle of ASU 2014-09 is&#13;that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects&#13;the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the new guidance,&#13;an entity will (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine&#13;the transaction price; (4) allocate the transaction price to the contract&amp;#146;s performance obligations; and (5) recognize revenue&#13;when (or as) the entity satisfies a performance obligation. ASU 2014-09 applies to all contracts with customers except those that&#13;are within the scope of other topics in the FASB ASC. The new guidance is effective for annual reporting periods, including interim&#13;periods within those periods, beginning after December 15, 2016 for public companies. Early adoption is not permitted. The Company&#13;is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial&#13;statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">97801</us-gaap:InventoryWorkInProcess>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">39000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:RestrictedStockExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">39000</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">143553</us-gaap:RestrictedStockExpense>
    <us-gaap:DeferredRentCreditCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">4975</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="AsOf2014-12-31_custom_StockOptionPlanMember" unitRef="Shares" decimals="INF">728585</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2014-12-31_custom_StockOptionPlanMember" unitRef="Shares" decimals="INF">999175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="AsOf2014-12-31_custom_StockOptionPlanMember" unitRef="USDPShares" decimals="INF">5.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-12-31_custom_StockOptionPlanMember" unitRef="USDPShares" decimals="INF">5.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2014-12-31_custom_StockOptionPlanMember" unitRef="USD" decimals="0">2351174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2014-12-31_custom_StockOptionPlanMember" unitRef="USD" decimals="0">2080594</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2014-12-31_custom_StockOptionPlanMember" unitRef="USD" decimals="0">2319475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <IMMY:PercentageSharesTiedToTargetOfNumberOfSharesGranted contextRef="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTranche4Member" unitRef="Percent" decimals="INF">0.1905</IMMY:PercentageSharesTiedToTargetOfNumberOfSharesGranted>
    <IMMY:PercentageSharesTiedToTargetOfNumberOfSharesGranted contextRef="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTranche5Member" unitRef="Percent" decimals="INF">0.2380</IMMY:PercentageSharesTiedToTargetOfNumberOfSharesGranted>
    <IMMY:PercentageSharesTiedToTargetOfNumberOfSharesGranted contextRef="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTrancheOneMember" unitRef="Percent" decimals="INF">0.1905</IMMY:PercentageSharesTiedToTargetOfNumberOfSharesGranted>
    <IMMY:PercentageSharesTiedToTargetOfNumberOfSharesGranted contextRef="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTrancheTwoMember" unitRef="Percent" decimals="INF">0.1905</IMMY:PercentageSharesTiedToTargetOfNumberOfSharesGranted>
    <IMMY:PercentageSharesTiedToTargetOfNumberOfSharesGranted contextRef="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTrancheThreeMember" unitRef="Percent" decimals="INF">0.1905</IMMY:PercentageSharesTiedToTargetOfNumberOfSharesGranted>
    <IMMY:NumberOfSharesTiedToTarget contextRef="From2013-05-23to2013-05-24_custom_ConsultantTrancheOneMember" unitRef="Shares" decimals="INF">20000</IMMY:NumberOfSharesTiedToTarget>
    <IMMY:NumberOfSharesTiedToTarget contextRef="From2013-05-23to2013-05-24_custom_ConsultantTrancheTwoMember" unitRef="Shares" decimals="INF">20000</IMMY:NumberOfSharesTiedToTarget>
    <IMMY:NumberOfSharesTiedToTarget contextRef="From2013-05-23to2013-05-24_custom_ConsultantTrancheThreeMember" unitRef="Shares" decimals="INF">20000</IMMY:NumberOfSharesTiedToTarget>
    <IMMY:NumberOfSharesTiedToTarget contextRef="From2013-05-23to2013-05-24_custom_ConsultantTrancheFourMember" unitRef="Shares" decimals="INF">20000</IMMY:NumberOfSharesTiedToTarget>
    <IMMY:NumberOfSharesTiedToTarget contextRef="From2013-05-23to2013-05-24_custom_ConsultantTrancheFiveMember" unitRef="Shares" decimals="INF">20000</IMMY:NumberOfSharesTiedToTarget>
    <IMMY:TargetSharePriceRelatedToRestrictedStockGrant contextRef="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTranche4Member">$25.00 or greater</IMMY:TargetSharePriceRelatedToRestrictedStockGrant>
    <IMMY:TargetSharePriceRelatedToRestrictedStockGrant contextRef="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTranche5Member">$30.00 or greater</IMMY:TargetSharePriceRelatedToRestrictedStockGrant>
    <IMMY:TargetSharePriceRelatedToRestrictedStockGrant contextRef="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTrancheOneMember">$10.00 or greater</IMMY:TargetSharePriceRelatedToRestrictedStockGrant>
    <IMMY:TargetSharePriceRelatedToRestrictedStockGrant contextRef="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTrancheTwoMember">$15.00 or greater</IMMY:TargetSharePriceRelatedToRestrictedStockGrant>
    <IMMY:TargetSharePriceRelatedToRestrictedStockGrant contextRef="From2013-05-01to2013-05-02_custom_ExecutiveRestrictedStockUnitsTrancheThreeMember">$20.00 or greater</IMMY:TargetSharePriceRelatedToRestrictedStockGrant>
    <IMMY:TargetSharePriceRelatedToRestrictedStockGrant contextRef="From2013-05-23to2013-05-24_custom_ConsultantTrancheOneMember">$10.00 or greater</IMMY:TargetSharePriceRelatedToRestrictedStockGrant>
    <IMMY:TargetSharePriceRelatedToRestrictedStockGrant contextRef="From2013-05-23to2013-05-24_custom_ConsultantTrancheTwoMember">$15.00 or greater</IMMY:TargetSharePriceRelatedToRestrictedStockGrant>
    <IMMY:TargetSharePriceRelatedToRestrictedStockGrant contextRef="From2013-05-23to2013-05-24_custom_ConsultantTrancheThreeMember">$20.00 or greater</IMMY:TargetSharePriceRelatedToRestrictedStockGrant>
    <IMMY:TargetSharePriceRelatedToRestrictedStockGrant contextRef="From2013-05-23to2013-05-24_custom_ConsultantTrancheFourMember">$25.00 or greater</IMMY:TargetSharePriceRelatedToRestrictedStockGrant>
    <IMMY:TargetSharePriceRelatedToRestrictedStockGrant contextRef="From2013-05-23to2013-05-24_custom_ConsultantTrancheFiveMember">$30.00 or greater</IMMY:TargetSharePriceRelatedToRestrictedStockGrant>
    <us-gaap:CapitalUnitsAuthorized contextRef="AsOf2013-02-08" unitRef="Shares" decimals="INF">95000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:EquityIssuancePerShareAmount contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">4.00</us-gaap:EquityIssuancePerShareAmount>
    <us-gaap:EquityIssuancePerShareAmount contextRef="From2013-02-12to2013-02-13" unitRef="USDPShares" decimals="INF">5.25</us-gaap:EquityIssuancePerShareAmount>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2012-07-01to2012-07-31_custom_MarkBaumMember" unitRef="Shares" decimals="INF">450000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MonteCarloSimulationMember" unitRef="Shares" decimals="INF">450000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MarkBaumMember" unitRef="Shares" decimals="INF">600000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MonteCarloSimulationOneMember" unitRef="Shares" decimals="INF">600000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2013-05-23to2013-05-24_custom_ConsultantMember" unitRef="Shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2014-01-01to2014-12-31_custom_ConsultantMember" unitRef="Shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2014-01-01to2014-12-31_custom_MonteCarloSimulationMember" unitRef="Shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2014-03-01to2014-03-31_custom_ConsultantMember" unitRef="Shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2013-06-01to2013-06-30_custom_NonEmployeeDirectorsMember" unitRef="Shares" decimals="INF">34325</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2013-10-01to2013-10-31_custom_FormerDirectorsMember" unitRef="Shares" decimals="INF">8947</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2013-11-01to2013-11-30_custom_EmployeesMember" unitRef="Shares" decimals="INF">10418</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2014-01-01to2014-12-31_custom_NonEmployeeDirectorsMember" unitRef="Shares" decimals="INF">26492</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2015-02-01to2015-02-28_us-gaap_SubsequentEventMember_custom_CFOEmploymentAgreementMember_custom_AndrewRBollsMember" unitRef="Shares" decimals="INF">157500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2015-02-01to2015-02-28_us-gaap_SubsequentEventMember_custom_RSUMember_custom_AndrewRBollsMember" unitRef="Shares" decimals="INF">30000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2015-02-01to2015-02-28_us-gaap_SubsequentEventMember_custom_CCOEmploymentAgreementMember_custom_JohnPSaharekMember" unitRef="Shares" decimals="INF">90000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2015-02-01to2015-02-28_us-gaap_SubsequentEventMember_custom_JohnPSaharekMember_custom_RSUMember" unitRef="Shares" decimals="INF">30000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2015-01-01to2015-01-31_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">8521</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-02-28_custom_WarrantActivityMember" unitRef="Shares" decimals="INF">30000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-07-31_custom_WarrantActivityMember463685406" unitRef="Shares" decimals="INF">60000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <IMMY:WarrantsExercisePricePerShare contextRef="AsOf2013-02-28_custom_WarrantActivityMember" unitRef="USDPShares" decimals="INF">5.25</IMMY:WarrantsExercisePricePerShare>
    <IMMY:WarrantsExercisePricePerShare contextRef="AsOf2013-07-31_custom_WarrantActivityMember463685406" unitRef="USDPShares" decimals="INF">8.50</IMMY:WarrantsExercisePricePerShare>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings contextRef="From2013-04-29to2013-05-02_us-gaap_MinimumMember" unitRef="Shares" decimals="INF">2400000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings contextRef="From2013-04-29to2013-05-02_us-gaap_MaximumMember" unitRef="Shares" decimals="INF">5000000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings contextRef="From2013-09-26to2013-09-27" unitRef="Shares" decimals="INF">450000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings contextRef="From2012-07-01to2012-07-31_custom_MarkBaumMember" unitRef="Shares" decimals="INF">450000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <IMMY:RestrictedStockVestedImmediately contextRef="From2013-04-29to2013-05-02" unitRef="Shares" decimals="INF">200000</IMMY:RestrictedStockVestedImmediately>
    <IMMY:CommonStockIssuedSettleCashlessExerciseProvisionShares contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">1030</IMMY:CommonStockIssuedSettleCashlessExerciseProvisionShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="From2013-02-01to2013-03-31" unitRef="USD" decimals="0">191</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="From2013-02-01to2013-03-31" unitRef="Shares" decimals="INF">35</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <IMMY:NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed contextRef="From2013-02-12to2013-02-13" unitRef="Shares" decimals="INF">1840000</IMMY:NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2013-02-12to2013-02-13" unitRef="USD" decimals="0">8140435</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <IMMY:StockIssuedDuringPeriodSharesIssuedToUnderwriters contextRef="From2013-02-12to2013-02-13" unitRef="Shares" decimals="INF">276000</IMMY:StockIssuedDuringPeriodSharesIssuedToUnderwriters>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2013-02-12to2013-02-13" unitRef="USD" decimals="0">1316116</us-gaap:ProceedsFromStockOptionsExercised>
    <IMMY:StockIssuedDuringPeriodValueIssuedToUnderwriters contextRef="From2013-02-01to2013-03-31" unitRef="USD" decimals="0">179860</IMMY:StockIssuedDuringPeriodValueIssuedToUnderwriters>
    <IMMY:StockIssuedDuringPeriodValueIssuedToUnderwriters contextRef="From2013-02-12to2013-02-13" unitRef="USD" decimals="0">179860</IMMY:StockIssuedDuringPeriodValueIssuedToUnderwriters>
    <IMMY:UnderwritingAgreementDescription contextRef="From2013-02-12to2013-02-13">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As contemplated by the underwriting agreement&#13;entered into with MDB Capital Group, LLC, the lead underwriter for the Public Offering, at the closing of the Public Offering and&#13;the over-allotment exercise, the lead underwriters received warrants (the &amp;#147;Underwriter Warrants&amp;#148;) to purchase up to&#13;an aggregate of 179,860 shares, or 8.5% of the number of shares sold in the Public Offering (including 8.5% of shares sold pursuant&#13;to the exercise of the over-allotment option). The Underwriter Warrants are exercisable at $5.25 per share (100% of the price to&#13;the public of the common stock sold in the Public Offering), commencing on the closing date of the Public Offering and expire five&#13;years from the closing date of the Public Offering.&lt;/p&gt;</IMMY:UnderwritingAgreementDescription>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2013-04-29to2013-05-02" unitRef="USD" decimals="0">1250000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember" unitRef="USD" decimals="0">189000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MarkBaumMember" unitRef="USD" decimals="0">3515090</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2014-01-01to2014-12-31_custom_ConsultantMember" unitRef="USD" decimals="0">288000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2013-01-01to2013-12-31_custom_ConsultantMember458685886" unitRef="USD" decimals="0">10080</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2013-06-01to2013-06-30_custom_NonEmployeeDirectorsMember" unitRef="USD" decimals="0">271854</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2013-10-01to2013-10-31_custom_FormerDirectorsMember" unitRef="USD" decimals="0">39814</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2013-11-01to2013-11-30_custom_EmployeesMember" unitRef="USD" decimals="0">42498</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2014-01-01to2014-12-31_custom_NonEmployeeDirectorsMember" unitRef="USD" decimals="0">200015</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <IMMY:RestrictedStockVestInFuture contextRef="From2013-04-29to2013-05-02" unitRef="Shares" decimals="INF">1050000</IMMY:RestrictedStockVestInFuture>
    <IMMY:TargetRangingPrice contextRef="From2013-04-29to2013-05-02_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">10</IMMY:TargetRangingPrice>
    <IMMY:TargetRangingPrice contextRef="From2013-04-29to2013-05-02_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">30</IMMY:TargetRangingPrice>
    <IMMY:RestrictedStockUnitsGrantedDuringPeriodPerPerson contextRef="From2013-04-29to2013-05-02_us-gaap_MinimumMember" unitRef="Shares" decimals="INF">600000</IMMY:RestrictedStockUnitsGrantedDuringPeriodPerPerson>
    <IMMY:RestrictedStockUnitsGrantedDuringPeriodPerPerson contextRef="From2013-04-29to2013-05-02_us-gaap_MaximumMember" unitRef="Shares" decimals="INF">1250000</IMMY:RestrictedStockUnitsGrantedDuringPeriodPerPerson>
    <IMMY:CancellationOfRestrictedStockUnitsDuringPeriod contextRef="From2013-09-26to2013-09-27" unitRef="Shares" decimals="INF">120000</IMMY:CancellationOfRestrictedStockUnitsDuringPeriod>
    <IMMY:CancellationOfRestrictedStockUnitsDuringPeriod contextRef="From2012-07-01to2012-07-31_custom_MarkBaumMember" unitRef="Shares" decimals="INF">120000</IMMY:CancellationOfRestrictedStockUnitsDuringPeriod>
    <us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings contextRef="From2013-09-26to2013-09-27" unitRef="USD" decimals="0">189000</us-gaap:RestrictedStockValueSharesIssuedNetOfTaxWithholdings>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="From2014-03-01to2014-03-31_custom_ConsultantMember" unitRef="Shares" decimals="INF">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <IMMY:WarrantsExpiredDuration contextRef="From2013-02-01to2013-02-28_us-gaap_WarrantMember">P3Y</IMMY:WarrantsExpiredDuration>
    <us-gaap:PaymentsForRent contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">306465</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">103191</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="From2015-01-01to2015-01-02_us-gaap_SubsequentEventMember_custom_ParkSellersMember" unitRef="USD" decimals="0">9788</us-gaap:PaymentsForRent>
    <us-gaap:PaymentsForRent contextRef="From2015-02-27to2015-02-28_us-gaap_SubsequentEventMember_custom_LeaseAgreementMember" unitRef="USD" decimals="0">9548</us-gaap:PaymentsForRent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">492503</us-gaap:OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">468997</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">481443</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">2674393</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">495938</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">257039</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">478473</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">3900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">27800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">24600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <IMMY:FederalNetOperatingLossExpirationDate contextRef="From2014-01-01to2014-12-31">2027</IMMY:FederalNetOperatingLossExpirationDate>
    <IMMY:StateNetOperatingLossExpirationDate contextRef="From2014-01-01to2014-12-31">2017</IMMY:StateNetOperatingLossExpirationDate>
    <IMMY:FederalResearchAndDevelopmentTaxCredits contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">350000</IMMY:FederalResearchAndDevelopmentTaxCredits>
    <IMMY:StateResearchAndDevelopmentTaxCredits contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">30000</IMMY:StateResearchAndDevelopmentTaxCredits>
    <IMMY:FederalResearchAndDevelopmentTaxCreditsExpirationDate contextRef="From2014-01-01to2014-12-31">2026</IMMY:FederalResearchAndDevelopmentTaxCreditsExpirationDate>
    <us-gaap:DeferredTaxAssetsGrossCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">30000</us-gaap:DeferredTaxAssetsGrossCurrent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">30000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">2800</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">2800</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">11082459</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">8075342</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">3100627</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">2233726</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <IMMY:DeferredIncomeChangeInValuationAllowance contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-14183086</IMMY:DeferredIncomeChangeInValuationAllowance>
    <IMMY:DeferredIncomeChangeInValuationAllowance contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-10309068</IMMY:DeferredIncomeChangeInValuationAllowance>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">2800</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2013-01-01to2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2014-01-01to2014-12-31" unitRef="Percent" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2013-01-01to2013-12-31" unitRef="Percent" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <IMMY:EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets contextRef="From2014-01-01to2014-12-31" unitRef="Percent" decimals="INF">-0.0100</IMMY:EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets>
    <IMMY:EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets contextRef="From2013-01-01to2013-12-31" unitRef="Percent" decimals="INF">-0.0100</IMMY:EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2014-01-01to2014-12-31" unitRef="Percent" decimals="INF">-0.0003</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2013-01-01to2013-12-31" unitRef="Percent" decimals="INF">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="From2014-01-01to2014-12-31" unitRef="Percent" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="From2013-01-01to2013-12-31" unitRef="Percent" decimals="INF">0.0043</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends contextRef="From2014-01-01to2014-12-31" unitRef="Percent" decimals="INF">-0.0103</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends contextRef="From2013-01-01to2013-12-31" unitRef="Percent" decimals="INF">-0.0472</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends>
    <IMMY:EffectiveIncomeTaxRateLossOnDebtConversion contextRef="From2014-01-01to2014-12-31" unitRef="Percent" decimals="INF">0.00</IMMY:EffectiveIncomeTaxRateLossOnDebtConversion>
    <IMMY:EffectiveIncomeTaxRateLossOnDebtConversion contextRef="From2013-01-01to2013-12-31" unitRef="Percent" decimals="INF">0.00</IMMY:EffectiveIncomeTaxRateLossOnDebtConversion>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2014-01-01to2014-12-31" unitRef="Percent" decimals="INF">-0.0021</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2013-01-01to2013-12-31" unitRef="Percent" decimals="INF">-0.0008</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2014-01-01to2014-12-31" unitRef="Percent" decimals="INF">-0.3276</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2013-01-01to2013-12-31" unitRef="Percent" decimals="INF">-0.2963</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2014-01-01to2014-12-31" unitRef="Percent" decimals="INF">-0.0003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2013-01-01to2013-12-31" unitRef="Percent" decimals="INF">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <IMMY:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">7364058</IMMY:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards>
    <IMMY:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">10922914</IMMY:DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards>
    <IMMY:DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">-340</IMMY:DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization>
    <IMMY:DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-6787</IMMY:DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">129191</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">64806</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">563485</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">555945</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">2252674</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">2646208</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">10309068</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">14183086</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">10309068</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">14183086</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 12. INCOME TAXES &lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is subject to taxation in&#13;the United States and California. The provision for income taxes for the years ended December 31, 2014 and 2013 are summarized&#13;below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Current:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Federal&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total current&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Federal&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,082,459&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,075,342&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,100,627&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,233,726&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(14,183,086&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(10,309,068&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total deferred&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income tax provision (benefit)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Income taxes for the years ended December&#13;31, 2014 and 2013, are recorded in the general and administrative expenses line item in the accompanying consolidated statements&#13;of operations.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation of income taxes&#13;computed by applying the statutory U.S. income tax rate to the Company&amp;#146;s loss before income taxes to the income tax&#13;provision is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;U.S. federal statutory tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Benefit of lower tax brackets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State tax benefit, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Employee stock based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Loss on debt conversion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(32.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(29.63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Effective income tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax assets and liabilities&#13;reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting&#13;purposes and the amounts used for income tax purposes. Significant components of the Company&amp;#146;s deferred tax assets are as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred tax assets (liabilities):&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 58%; padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;NOL&amp;#146;s&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,922,914&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,364,058&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation and amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,787&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(340&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;129,191&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research &amp;#38; development credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;555,945&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;563,485&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred stock compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,646,208&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,252,674&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Unrealized gain or loss on investments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,183,086&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,309,068&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(14,183,086&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(10,309,068&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Realization of deferred tax assets is&#13;dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets&#13;have been fully offset by a valuation allowance. The valuation allowance increased by approximately $3,900,000 and $3,000,000 in&#13;2014 and 2013, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2014, the Company&#13;had net operating loss carryforwards for federal income tax purposes of approximately $27,800,000 which expire beginning in the&#13;year 2027 and federal research and development tax credits of approximately $350,000 which expire beginning in the year 2026. As&#13;of December 31, 2014, the Company had net operating loss carryforwards for state income tax purposes of approximately $24,600,000&#13;which expire beginning in the year 2017 and state research and development tax credits of approximately $300,00 which do not expire.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The deferred tax asset at December 31,&#13;2014 does not include approximately $30,000 and $30,000 of excess tax benefits from employee stock option exercises and RSU vests&#13;that are a component of the federal and California net operating loss carryover, respectively. The Company&amp;#146;s stockholders&amp;#146;&#13;equity balance will be increased if and when such excess tax benefits are ultimately realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Utilization of the net operating losses&#13;may be subject to substantial annual limitation due to federal and state ownership change limitations provided by the Internal&#13;Revenue Code and similar state provisions. Such annual limitations could result in the expiration of the net operating losses&#13;ad credits before their utilization. The Company has not performed an analysis to determine the limitation of the net operating&#13;loss and research development credit carryforwards.&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company did not have any unrecognized&#13;tax benefits of as of December 31, 2014 and 2013, all of which is offset by a full valuation allowance. These unrecognized tax&#13;benefits, if recognized, would not affect the effective tax rate.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.75in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is subject to taxation in&#13;the United States and California. The provision for income taxes for the years ended December 31, 2014 and 2013 are summarized&#13;below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Current:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Federal&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total current&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Federal&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;11,082,459&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;8,075,342&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;3,100,627&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,233,726&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(14,183,086&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(10,309,068&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total deferred&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Income tax provision (benefit)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,800&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation of income taxes&#13;computed by applying the statutory U.S. income tax rate to the Company&amp;#146;s loss before income taxes to the income tax&#13;provision is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 58%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;U.S. federal statutory tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;35.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Benefit of lower tax brackets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;State tax benefit, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research and development credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Employee stock based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(1.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(4.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Loss on debt conversion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.21&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.08&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(32.76&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(29.63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Effective income tax rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(0.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax assets and liabilities&#13;reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting&#13;purposes and the amounts used for income tax purposes. Significant components of the Company&amp;#146;s deferred tax assets are as&#13;follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;December 31, 2013&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred tax assets (liabilities):&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 58%; padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;NOL&amp;#146;s&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,922,914&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;7,364,058&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation and amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(6,787&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(340&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;64,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;129,191&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Research &amp;#38; development credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;555,945&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;563,485&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred stock compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,646,208&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,252,674&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Unrealized gain or loss on investments&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 20pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;14,183,086&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,309,068&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(14,183,086&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(10,309,068&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Net deferred tax assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <IMMY:NumberOfCommonStockHeldForPayrollTax contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">1518</IMMY:NumberOfCommonStockHeldForPayrollTax>
    <IMMY:NumberOfFutureIssuancesShareUnderPlan contextRef="From2014-01-01to2014-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">2366369</IMMY:NumberOfFutureIssuancesShareUnderPlan>
    <IMMY:FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares contextRef="From2012-07-01to2012-07-31_custom_MarkBaumMember" unitRef="Shares" decimals="INF">450000</IMMY:FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MonteCarloSimulationMember" unitRef="Percent" decimals="INF">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MonteCarloSimulationOneMember" unitRef="Percent" decimals="INF">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MonteCarloSimulationMember" unitRef="Percent" decimals="INF">0.0064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MonteCarloSimulationOneMember" unitRef="Percent" decimals="INF">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <IMMY:InitialFairValueOfRestrictedStockUnitsShares contextRef="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember" unitRef="Shares" decimals="INF">450000</IMMY:InitialFairValueOfRestrictedStockUnitsShares>
    <IMMY:InitialFairValueOfRestrictedStockUnitsShares contextRef="From2014-01-01to2014-12-31_custom_BaumPerformanceEquityAwardMember_custom_MarkBaumMember" unitRef="Shares" decimals="INF">200000</IMMY:InitialFairValueOfRestrictedStockUnitsShares>
    <IMMY:PercentageOfRestrictedStockUnitsVested contextRef="From2014-01-01to2014-12-31_custom_ConsultantMember" unitRef="Percent" decimals="INF">0.50</IMMY:PercentageOfRestrictedStockUnitsVested>
    <IMMY:PercentageOfRemainingRestrictedStockUnitsVested contextRef="From2014-01-01to2014-12-31_custom_ConsultantMember" unitRef="Percent" decimals="INF">0.50</IMMY:PercentageOfRemainingRestrictedStockUnitsVested>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="From2013-06-01to2013-06-30_custom_MarkBaumMember" unitRef="Shares" decimals="INF">40000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2013-06-01to2013-06-30_custom_NonEmployeeDirectorsMember_us-gaap_RestrictedStockUnitsRSUMember">P13M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2013-10-01to2013-10-31_custom_FormerDirectorsMember_us-gaap_RestrictedStockUnitsRSUMember">P13M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2013-11-01to2013-11-30_custom_EmployeesMember_us-gaap_RestrictedStockUnitsRSUMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2014-01-01to2014-12-31_custom_NonEmployeeDirectorsMember_us-gaap_RestrictedStockUnitsRSUMember">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <IMMY:NumberOfWarrantsVestedImmeditely contextRef="From2013-02-01to2013-02-28_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">10000</IMMY:NumberOfWarrantsVestedImmeditely>
    <IMMY:FairValueOfWarrants contextRef="From2013-07-01to2013-07-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">319786</IMMY:FairValueOfWarrants>
    <dei:DocumentFiscalYearFocus contextRef="From2014-01-01to2014-12-31">2014</dei:DocumentFiscalYearFocus>
    <IMMY:AverageClosingPriceOfCommonStock contextRef="From2015-01-01to2015-01-02_us-gaap_SubsequentEventMember_custom_ParkSellersMember" unitRef="USD" decimals="0">500000</IMMY:AverageClosingPriceOfCommonStock>
    <IMMY:QuarterlyCashPayments contextRef="From2015-01-01to2015-01-02_us-gaap_SubsequentEventMember_custom_ParkSellersMember" unitRef="USD" decimals="0">53125</IMMY:QuarterlyCashPayments>
    <IMMY:AmountOfClosingPrice contextRef="From2015-01-01to2015-01-02_us-gaap_SubsequentEventMember_custom_ParkSellersMember" unitRef="USD" decimals="0">637500</IMMY:AmountOfClosingPrice>
    <IMMY:AggregatedAmountOfClosingPrice contextRef="From2015-01-01to2015-01-02_us-gaap_SubsequentEventMember_custom_ParkSellersMember" unitRef="USD" decimals="0">318750</IMMY:AggregatedAmountOfClosingPrice>
    <IMMY:AreaOfSquareFeet contextRef="AsOf2015-01-31_us-gaap_SubsequentEventMember_custom_ParkSellersMember" unitRef="SquareFeet" decimals="INF">4500</IMMY:AreaOfSquareFeet>
    <IMMY:AreaOfSquareFeet contextRef="AsOf2015-02-28_us-gaap_SubsequentEventMember_custom_LeaseAgreementMember" unitRef="SquareFeet" decimals="INF">8602</IMMY:AreaOfSquareFeet>
    <IMMY:EmploymentAgreementTerm contextRef="From2015-02-01to2015-02-28_us-gaap_SubsequentEventMember_custom_CFOEmploymentAgreementMember_custom_AndrewRBollsMember">P3Y</IMMY:EmploymentAgreementTerm>
    <IMMY:EmploymentAgreementTerm contextRef="From2015-02-01to2015-02-28_us-gaap_SubsequentEventMember_custom_CCOEmploymentAgreementMember_custom_JohnPSaharekMember">P3Y</IMMY:EmploymentAgreementTerm>
    <us-gaap:OfficersCompensation contextRef="From2015-02-01to2015-02-28_us-gaap_SubsequentEventMember_custom_CFOEmploymentAgreementMember_custom_AndrewRBollsMember" unitRef="USD" decimals="0">200000</us-gaap:OfficersCompensation>
    <us-gaap:OfficersCompensation contextRef="From2015-02-01to2015-02-28_us-gaap_SubsequentEventMember_custom_CCOEmploymentAgreementMember_custom_JohnPSaharekMember" unitRef="USD" decimals="0">220000</us-gaap:OfficersCompensation>
    <IMMY:PercentageOfCurrentAnnualSalary contextRef="AsOf2015-02-28_us-gaap_SubsequentEventMember_custom_CFOEmploymentAgreementMember_custom_AndrewRBollsMember" unitRef="Percent" decimals="INF">0.20</IMMY:PercentageOfCurrentAnnualSalary>
    <IMMY:PercentageOfCurrentAnnualSalary contextRef="AsOf2015-02-28_us-gaap_SubsequentEventMember_custom_CCOEmploymentAgreementMember_custom_JohnPSaharekMember" unitRef="Percent" decimals="INF">0.50</IMMY:PercentageOfCurrentAnnualSalary>
    <IMMY:PercentageOfIncreasesCurrentAnnualSalary contextRef="AsOf2015-02-28_us-gaap_SubsequentEventMember_custom_CFOEmploymentAgreementMember_custom_AndrewRBollsMember" unitRef="Percent" decimals="INF">0.50</IMMY:PercentageOfIncreasesCurrentAnnualSalary>
    <IMMY:TermOfStockOption contextRef="From2015-02-01to2015-02-28_us-gaap_SubsequentEventMember_custom_CCOEmploymentAgreementMember_custom_JohnPSaharekMember">P10Y</IMMY:TermOfStockOption>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 1. ORGANIZATION&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Imprimis Pharmaceuticals, Inc. (together with&#13;its subsidiaries, unless the context indicates or otherwise requires, the &amp;#147;Company&amp;#148; or &amp;#147;Imprimis&amp;#148;) is a&#13;pharmaceutical company focused on developing and commercializing innovative and high quality proprietary compounded drug therapies&#13;and making these therapies available to physicians and patients at accessible prices. The Company owns, markets and sells a portfolio&#13;of proprietary combination formulations in ophthalmology and urology that it believes may offer competitive advantages and serve&#13;unmet needs in the marketplace. The Company&amp;#146;s ophthalmology formulation portfolio, led by its Dropless Therapy&amp;#153; and&#13;LessDrops&amp;#153; formulations, serves the multi-billion dollar eye drop market and is designed to address patient compliance issues&#13;and provide other medical and economic benefits to physicians and patients. The Company recently launched its urology business,&#13;headed by its Defeat IC&amp;#153; campaign, which currently includes a patented compounded formulation for patients suffering from&#13;interstitial cystitis. The Company is also developing additional complementary proprietary compounded formulations to add to its&#13;ophthalmology and urology formulation portfolios. The Company makes, dispenses and sells its proprietary compounded formulations,&#13;as well as other non-proprietary products, through its wholly owned compounding pharmacies.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 1, 2014, the Company acquired Pharmacy&#13;Creations, LLC (&amp;#147;PC&amp;#148;), a New Jersey based compounding pharmacy and on January 1, 2015, the Company acquired South&#13;Coast Specialty Compounding, Inc. D/B/A Park Compounding (&amp;#147;Park&amp;#148;), a California based compounding pharmacy (see Note&#13;16). Effective with the acquisition of PC, the Company commenced sales and marketing efforts for Imprimis&amp;#146; portfolio of&#13;proprietary and non-proprietary compounded drug formulations.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 7. FURNITURE AND EQUIPMENT&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Furniture and equipment consisted of&#13;the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture and equipment, net:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 62%; padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Computer software and hardware&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;52,576&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;24,536&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Furniture and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;154,215&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;10,449&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Lab and pharmacy equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;61,868&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,172&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;288,831&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;34,985&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Accumulated depreciation and amortization&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(45,436&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;(8,093&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;243,395&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,892&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recorded depreciation and&#13;amortization expense of $37,343 and $5,659 during the years ended December 31, 2014 and 2013, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expenses and other current assets&#13;consisted of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December 31, 2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid stock-based consulting expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;26,649&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid rent&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;-&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;16,288&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;123,776&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;39,166&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Other prepaid expenses and deposits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;116,625&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;22,964&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total prepaid expenses and other current assets&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;240,401&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;105,067&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <IMMY:ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These market-based vesting conditions&#13;are further described below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 16%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 66%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Target Share Price&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19.05% of the shares subject to the Baum Performance Equity Award&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$10.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19.05% of the shares subject to the Baum Performance Equity Award&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$15.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19.05% of the shares subject to the Baum Performance Equity Award&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$20.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;19.05% of the shares subject to the Baum Performance Equity Award&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$25.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;23.80% of the shares subject to the Baum Performance Equity Award&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$30.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These market-based vesting conditions&#13;are further described below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="width: 34%; border-bottom: black 1.5pt solid; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Number of Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: center; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Target Share Price&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 1&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000 shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$10.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 2&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000 shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$15.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000 shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$20.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 4&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000 shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$25.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Tranche 5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;20,000 shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: justify; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$30.00 or greater&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;/p&gt;</IMMY:ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">24536</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">52576</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">10449</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">154215</us-gaap:FurnitureAndFixturesGross>
    <IMMY:LabAndPharmacyEquipmentGross contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <IMMY:LabAndPharmacyEquipmentGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">61868</IMMY:LabAndPharmacyEquipmentGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">20172</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">34985</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">288831</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">8093</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">45436</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <IMMY:NumberOfSharesVestedInInstallments contextRef="From2013-02-01to2013-02-28_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">4000</IMMY:NumberOfSharesVestedInInstallments>
    <us-gaap:PaymentsForPreviousAcquisition contextRef="From2015-01-01to2015-01-02_us-gaap_SubsequentEventMember_custom_ParkSellersMember" unitRef="USD" decimals="0">3000000</us-gaap:PaymentsForPreviousAcquisition>
    <IMMY:PercentageOfAnnualRentIncreases contextRef="AsOf2015-01-31_us-gaap_SubsequentEventMember_custom_ParkSellersMember" unitRef="Percent" decimals="INF">0.03</IMMY:PercentageOfAnnualRentIncreases>
    <IMMY:PercentageOfAnnualRentIncreases contextRef="AsOf2015-02-28_us-gaap_SubsequentEventMember_custom_LeaseAgreementMember" unitRef="Percent" decimals="INF">0.0375</IMMY:PercentageOfAnnualRentIncreases>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">514622</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2014-01-01to2014-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 65%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 32%; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;492,503&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;468,997&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;481,443&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;495,938&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;257,039&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;478,473&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2,674,393&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="line-height: 115%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-02" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-0" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-1" xlink:label="Foot-01_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-01_loc" xlink:to="Footnote-01" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. As of December 31, 2014, the Company was marketing its previous office space (3,874 square feet) as a sublease through its remaining lease term. The Company recognized a loss of approximately $117,000 during the year ended December 31, 2014, related to the estimated remaining lease liability, net of expected sublease income. The obligations were discounted based on current prevailing market rates. This loss is included in rent expense for the year ended December 31, 2014.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">The amount consists of a $39,000 stock-based compensation accrual at December 31, 2014 for stock options to be granted for services performed. The stock-based compensation expense related to restricted common stock issuances and accruals was $39,000 and $143,553 during the years ended December 31, 2014 and 2013, respectively.</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>immy-20141231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: IMMY%2D20141231 10K FY DFN.xfr; Date: 2015%2D03%2D12T19:30:59 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80030000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /aops7xRiXgen8uPanxMWaSHqbOdx5B5SekhvWR2banany4jy1dsTyKBaDTGwe8P -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:IMMY="http://imprimispharma.com/20141231" elementFormDefault="qualified" targetNamespace="http://imprimispharma.com/20141231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://imprimispharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement -  Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StatementsOfStockholdersEquityParenthetical" id="StatementsOfStockholdersEquityParenthetical">
	  <link:definition>00000006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/Organization" id="Organization">
	  <link:definition>00000008 - Disclosure - Organization</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc" id="Acquisition-PharmacyCreationsLlc">
	  <link:definition>00000010 - Disclosure - Acquisition - Pharmacy Creations, LLC</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/RestrictedShort-termInvestment" id="RestrictedShort-termInvestment">
	  <link:definition>00000011 - Disclosure - Restricted Short-Term Investment</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/Inventories" id="Inventories">
	  <link:definition>00000012 - Disclosure - Inventories</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
	  <link:definition>00000013 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/FurnitureAndEquipment" id="FurnitureAndEquipment">
	  <link:definition>00000014 - Disclosure - Furniture and Equipment</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill" id="IntangibleAssetsAndGoodwill">
	  <link:definition>00000015 - Disclosure - Intangible Assets and Goodwill</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
	  <link:definition>00000016 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/Debt" id="Debt">
	  <link:definition>00000017 - Disclosure - Debt</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000018 - Disclosure - Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000019 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/EmployeeSavingsPlan" id="EmployeeSavingsPlan">
	  <link:definition>00000020 - Disclosure - Employee Savings Plan</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000021 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/SegmentInformation" id="SegmentInformation">
	  <link:definition>00000022 - Disclosure - Segment Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000023 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcTables" id="Acquisition-PharmacyCreationsLlcTables">
	  <link:definition>00000026 - Disclosure - Acquisition - Pharmacy Creations, LLC (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/InventoriesTables" id="InventoriesTables">
	  <link:definition>00000027 - Disclosure - Inventories (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
	  <link:definition>00000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/FurnitureAndEquipmentTables" id="FurnitureAndEquipmentTables">
	  <link:definition>00000029 - Disclosure - Furniture and Equipment (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwillTables" id="IntangibleAssetsAndGoodwillTables">
	  <link:definition>00000030 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesTables" id="AccountsPayableAndAccruedExpensesTables">
	  <link:definition>00000031 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000032 - Disclosure - Stockholders' Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000033 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000034 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000035 - Disclosure - Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" id="SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails">
	  <link:definition>00000036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Common Share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcDetailsNarrative" id="Acquisition-PharmacyCreationsLlcDetailsNarrative">
	  <link:definition>00000037 - Disclosure - Acquisition - Pharmacy Creations, LLC (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfAcquisitionDateFairValueOfConsiderationDetails" id="Acquisition-PharmacyCreationsLlc-ScheduleOfAcquisitionDateFairValueOfConsiderationDetails">
	  <link:definition>00000038 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Acquisition Date Fair Value of Consideration (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfEstimatedFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" id="Acquisition-PharmacyCreationsLlc-ScheduleOfEstimatedFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails">
	  <link:definition>00000039 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfResultOfOperationFromAcquisitionDetails" id="Acquisition-PharmacyCreationsLlc-ScheduleOfResultOfOperationFromAcquisitionDetails">
	  <link:definition>00000040 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Result of Operation from Acquisition (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfProFormaFinancialInformationDetails" id="Acquisition-PharmacyCreationsLlc-ScheduleOfProFormaFinancialInformationDetails">
	  <link:definition>00000041 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Pro Forma Financial Information (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfIntangibleAssetsAcquisitionDetails" id="Acquisition-PharmacyCreationsLlc-ScheduleOfIntangibleAssetsAcquisitionDetails">
	  <link:definition>00000042 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Intangible Assets Acquisition (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/RestrictedShort-termInvestmentDetailsNarrative" id="RestrictedShort-termInvestmentDetailsNarrative">
	  <link:definition>00000043 - Disclosure - Restricted Short-Term Investment (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/Inventories-ScheduleOfInventoriesDetails" id="Inventories-ScheduleOfInventoriesDetails">
	  <link:definition>00000044 - Disclosure - Inventories - Schedule of Inventories (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets-ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssets-ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
	  <link:definition>00000045 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/FurnitureAndEquipmentDetailsNarrative" id="FurnitureAndEquipmentDetailsNarrative">
	  <link:definition>00000046 - Disclosure - Furniture and Equipment (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/FurnitureAndEquipment-ScheduleOfFurnitureAndEquipmentDetails" id="FurnitureAndEquipment-ScheduleOfFurnitureAndEquipmentDetails">
	  <link:definition>00000047 - Disclosure - Furniture and Equipment - Schedule of Furniture and Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfIntangibleAssetsDetails" id="IntangibleAssetsAndGoodwill-ScheduleOfIntangibleAssetsDetails">
	  <link:definition>00000048 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" id="IntangibleAssetsAndGoodwill-ScheduleOfAmortizationExpensesForIntangibleAssetsDetails">
	  <link:definition>00000049 - Disclosure - Intangible Assets and Goodwill - Schedule of Amortization Expenses for Intangible Assets (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfEstimatedFutureAmortizationExpenseDetails" id="IntangibleAssetsAndGoodwill-ScheduleOfEstimatedFutureAmortizationExpenseDetails">
	  <link:definition>00000050 - Disclosure - Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfChangesInCarryingValueOfGoodwillDetails" id="IntangibleAssetsAndGoodwill-ScheduleOfChangesInCarryingValueOfGoodwillDetails">
	  <link:definition>00000051 - Disclosure - Intangible Assets and Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesDetailsNarratvie" id="AccountsPayableAndAccruedExpensesDetailsNarratvie">
	  <link:definition>00000052 - Disclosure - Accounts Payable and Accrued Expenses (Details Narratvie)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails" id="AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails">
	  <link:definition>00000053 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
	  <link:definition>00000054 - Disclosure - Debt (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000055 - Disclosure - Stockholders' Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockOptionPlanActivityDetails" id="StockholdersEquity-ScheduleOfStockOptionPlanActivityDetails">
	  <link:definition>00000056 - Disclosure - Stockholders' Equity - Schedule of Stock Option Plan Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfFairValueAssumptionDetails" id="StockholdersEquity-ScheduleOfFairValueAssumptionDetails">
	  <link:definition>00000057 - Disclosure - Stockholders' Equity - Schedule of Fair Value Assumption (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfSharesOutstandingAndExercisableDetails" id="StockholdersEquity-ScheduleOfSharesOutstandingAndExercisableDetails">
	  <link:definition>00000058 - Disclosure - Stockholders' Equity - Schedule of Shares Outstanding and Exercisable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StockholdersEquity-Market-basedVestingConditionsForRestrictedStockUnitsGrantedDetails" id="StockholdersEquity-Market-basedVestingConditionsForRestrictedStockUnitsGrantedDetails">
	  <link:definition>00000059 - Disclosure - Stockholders' Equity - Market-based Vesting Conditions for Restricted Stock Units Granted (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfRestrictedStockUnitsActivityDetails" id="StockholdersEquity-ScheduleOfRestrictedStockUnitsActivityDetails">
	  <link:definition>00000060 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Units Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsActivityDetails" id="StockholdersEquity-ScheduleOfWarrantsActivityDetails">
	  <link:definition>00000061 - Disclosure - Stockholders' Equity - Schedule of Warrants Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" id="StockholdersEquity-ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails">
	  <link:definition>00000062 - Disclosure - Stockholders' Equity - Schedule of Warrants Outstanding and Warrants Exercisable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" id="StockholdersEquity-ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails">
	  <link:definition>00000063 - Disclosure - Stockholders' Equity - Schedule of Stock Based Compensation Granted to Employees Directors Consultants (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000064 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfProvisionForIncomeTaxesDetails" id="IncomeTaxes-ScheduleOfProvisionForIncomeTaxesDetails">
	  <link:definition>00000065 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfIncomeTaxReconciliationDetails" id="IncomeTaxes-ScheduleOfIncomeTaxReconciliationDetails">
	  <link:definition>00000066 - Disclosure - Income Taxes - Schedule of Income Tax Reconciliation (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
	  <link:definition>00000067 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/EmployeeSavingsPlanDetailsNarrative" id="EmployeeSavingsPlanDetailsNarrative">
	  <link:definition>00000068 - Disclosure - Employee Savings Plan (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000069 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfLeaseEquipmentUnderCapitalLeaseDetails" id="CommitmentsAndContingencies-ScheduleOfLeaseEquipmentUnderCapitalLeaseDetails">
	  <link:definition>00000070 - Disclosure - Commitments and Contingencies - Schedule of Lease Equipment Under Capital Lease (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfFuturePaymentsUnderLeasesDetails" id="CommitmentsAndContingencies-ScheduleOfFuturePaymentsUnderLeasesDetails">
	  <link:definition>00000071 - Disclosure - Commitments and Contingencies - Schedule of Future Payments Under Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/SegmentInformationDetailsNarrative" id="SegmentInformationDetailsNarrative">
	  <link:definition>00000072 - Disclosure - Segment Information (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://imprimispharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000073 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="immy-20141231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="immy-20141231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="immy-20141231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="immy-20141231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" name="ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_MaximumDepositCoverageLimits" name="MaximumDepositCoverageLimits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_NumberExercisable" name="NumberExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RoyaltiesRangePercentage" name="RoyaltiesRangePercentage" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_AggregateValueOfCashFees" name="AggregateValueOfCashFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_CommonStockExercisePricePerShare" name="CommonStockExercisePricePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_OptionsExercisePrice" name="OptionsExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockOptionsGrantedVestingTermsDescription" name="StockOptionsGrantedVestingTermsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" name="PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_DefinedBenefitPlanContributionsByEmployerPercentage" name="DefinedBenefitPlanContributionsByEmployerPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_CommonStockEquivalentsDilutiveInstruments" name="CommonStockEquivalentsDilutiveInstruments" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ScheduleOfResultOfOperationFromAcquisitionTableTextBlock" name="ScheduleOfResultOfOperationFromAcquisitionTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ExpectedRevenueDuringAcquisition" name="ExpectedRevenueDuringAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ExpectedRevenueDate" name="ExpectedRevenueDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PrepaidStockbasedConsultingExpenses" name="PrepaidStockbasedConsultingExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_AcquisitionOfRelatedPartyGoodwill" name="AcquisitionOfRelatedPartyGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne" name="StockIssuedDuringPeriodSharesStockOptionsExercisedOne" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate" name="LeasesEquipmentUnderCapitalLeaseWithInterestRate" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_WarrantsIssuanceDate" name="WarrantsIssuanceDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_WarrantsExpirationDate" name="WarrantsExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PaymentOfCashToContigent" name="PaymentOfCashToContigent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_NumberOfSharesAppliedForContigentStockPayment" name="NumberOfSharesAppliedForContigentStockPayment" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill" name="BusinessAcquisitionPurchasePriceAllocationGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ContingentCommonStockIssuanceToRelatedParty" name="ContingentCommonStockIssuanceToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ContingentCashConsiderationToRelatedParty" name="ContingentCashConsiderationToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PercentageOfForfeitureFactor" name="PercentageOfForfeitureFactor" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PercentageOfDrugAndChemicalPurchases" name="PercentageOfDrugAndChemicalPurchases" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock" name="RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities" name="BusinessAcquisitionContingentAcquiredObligationsLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock" name="ExerciseOfCommonStockOptionToPurchaseOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees" name="IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering" name="ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease" name="PurchaseOfFurnitureAndEquipmentWithCapitalLease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_BuildingLeaseLiability" name="BuildingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare" name="WarrantsToPurchaseCommonStockExercisePricePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised" name="StockWarrantsIssuedDuringPeriodValueOfStockExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ExerciseOfWarrantToPurchaseOfCommonStock" name="ExerciseOfWarrantToPurchaseOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_WarrantsSharesExercisePricePerShare" name="WarrantsSharesExercisePricePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_NumberOfWarrantsCommonStockIssued" name="NumberOfWarrantsCommonStockIssued" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock" name="WarrantsAndSharesIssuedUponExciseOfCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_LicenseAgreementCommitmentsDescription" name="LicenseAgreementCommitmentsDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ValueOfProductDevelopmentInvestment" name="ValueOfProductDevelopmentInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RestrictedStockIncludedInCommonStockEquivalents" name="RestrictedStockIncludedInCommonStockEquivalents" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PreviousOfficeSpaceArea" name="PreviousOfficeSpaceArea" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RecognizedLeaseLossesRelatedToLeaseLiability" name="RecognizedLeaseLossesRelatedToLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne" name="IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne" name="IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour" name="StockIssuedDuringPeriodSharesStockOptionsExercisedFour" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013" name="CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares" name="CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockIssuedDuringPeriodValueForPublicOffering" name="StockIssuedDuringPeriodValueForPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockIssuedDuringPeriodSharesForPublicOffering" name="StockIssuedDuringPeriodSharesForPublicOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_IssuanceOfCommonStockUponVestingOfRsusShares" name="IssuanceOfCommonStockUponVestingOfRsusShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare" name="IssuanceOfCommonStockForPublicOfferingPricePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_CancelledCommonStockPricePerShare" name="CancelledCommonStockPricePerShare" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" name="IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" name="IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockIssuedDuringPeriodForExerciseOfWarrants" name="StockIssuedDuringPeriodForExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants" name="StockIssuedDuringPeriodSharesForExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute" name="StockSharesIssuedDuingPeriodForSettlementOfContractDispute" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute" name="StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted" name="PercentageSharesTiedToTargetOfNumberOfSharesGranted" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_NumberOfSharesTiedToTarget" name="NumberOfSharesTiedToTarget" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_TargetSharePriceRelatedToRestrictedStockGrant" name="TargetSharePriceRelatedToRestrictedStockGrant" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_WarrantsExercisePricePerShare" name="WarrantsExercisePricePerShare" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RestrictedStockVestedImmediately" name="RestrictedStockVestedImmediately" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares" name="CommonStockIssuedSettleCashlessExerciseProvisionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed" name="NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters" name="StockIssuedDuringPeriodSharesIssuedToUnderwriters" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters" name="StockIssuedDuringPeriodValueIssuedToUnderwriters" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_UnderwritingAgreementDescription" name="UnderwritingAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RestrictedStockVestInFuture" name="RestrictedStockVestInFuture" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_TargetRangingPrice" name="TargetRangingPrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson" name="RestrictedStockUnitsGrantedDuringPeriodPerPerson" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_CancellationOfRestrictedStockUnitsDuringPeriod" name="CancellationOfRestrictedStockUnitsDuringPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_WarrantsExpiredDuration" name="WarrantsExpiredDuration" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_FederalNetOperatingLossExpirationDate" name="FederalNetOperatingLossExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StateNetOperatingLossExpirationDate" name="StateNetOperatingLossExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_FederalResearchAndDevelopmentTaxCredits" name="FederalResearchAndDevelopmentTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StateResearchAndDevelopmentTaxCredits" name="StateResearchAndDevelopmentTaxCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_FederalResearchAndDevelopmentTaxCreditsExpirationDate" name="FederalResearchAndDevelopmentTaxCreditsExpirationDate" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_DeferredIncomeChangeInValuationAllowance" name="DeferredIncomeChangeInValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets" name="EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_EffectiveIncomeTaxRateLossOnDebtConversion" name="EffectiveIncomeTaxRateLossOnDebtConversion" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" name="DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" name="DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_NumberOfCommonStockHeldForPayrollTax" name="NumberOfCommonStockHeldForPayrollTax" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_NumberOfFutureIssuancesShareUnderPlan" name="NumberOfFutureIssuancesShareUnderPlan" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares" name="FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_InitialFairValueOfRestrictedStockUnitsShares" name="InitialFairValueOfRestrictedStockUnitsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PercentageOfRestrictedStockUnitsVested" name="PercentageOfRestrictedStockUnitsVested" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PercentageOfRemainingRestrictedStockUnitsVested" name="PercentageOfRemainingRestrictedStockUnitsVested" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_NumberOfWarrantsVestedImmeditely" name="NumberOfWarrantsVestedImmeditely" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_FairValueOfWarrants" name="FairValueOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_AverageClosingPriceOfCommonStock" name="AverageClosingPriceOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_QuarterlyCashPayments" name="QuarterlyCashPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_AmountOfClosingPrice" name="AmountOfClosingPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_AggregatedAmountOfClosingPrice" name="AggregatedAmountOfClosingPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_AreaOfSquareFeet" name="AreaOfSquareFeet" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_EmploymentAgreementTerm" name="EmploymentAgreementTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PercentageOfCurrentAnnualSalary" name="PercentageOfCurrentAnnualSalary" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PercentageOfIncreasesCurrentAnnualSalary" name="PercentageOfIncreasesCurrentAnnualSalary" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_TermOfStockOption" name="TermOfStockOption" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock" name="ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_LabAndPharmacyEquipmentGross" name="LabAndPharmacyEquipmentGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_NumberOfSharesVestedInInstallments" name="NumberOfSharesVestedInInstallments" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PercentageOfAnnualRentIncreases" name="PercentageOfAnnualRentIncreases" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockOptionPlanMember" name="StockOptionPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_OptionsGrantedConsultantsMember" name="OptionsGrantedConsultantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember" name="TwoThousandSecenIncentiveStockAndAwardsPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RangeOneMember" name="RangeOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_OptionsEmployeesMember" name="OptionsEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ExecutiveRestrictedStockUnitsTranche4Member" name="ExecutiveRestrictedStockUnitsTranche4Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ExecutiveRestrictedStockUnitsTranche5Member" name="ExecutiveRestrictedStockUnitsTranche5Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_WarrantsIssuedToFormerMajorShareholderMember" name="WarrantsIssuedToFormerMajorShareholderMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember" name="WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_UnderwriterWarrantsMember" name="UnderwriterWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_MarkBaumMember" name="MarkBaumMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RangeTwoMember" name="RangeTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RangeThreeMember" name="RangeThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RangeFourMember" name="RangeFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RangeFiveMember" name="RangeFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember" name="ExecutiveRestrictedStockUnitsTrancheOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember" name="ExecutiveRestrictedStockUnitsTrancheTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember" name="ExecutiveRestrictedStockUnitsTrancheThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ConsultantTrancheOneMember" name="ConsultantTrancheOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ConsultantTrancheTwoMember" name="ConsultantTrancheTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ConsultantTrancheThreeMember" name="ConsultantTrancheThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ConsultantTrancheFourMember" name="ConsultantTrancheFourMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ConsultantTrancheFiveMember" name="ConsultantTrancheFiveMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember" name="WarrantsIssuedToInvestorRelationsConsultantOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember" name="WarrantsIssuedToInvestorRelationsConsultantTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RestrictedStockUnitsRSUOneMember" name="RestrictedStockUnitsRSUOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_WarrantActivityMember" name="WarrantActivityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PharmacyCreationsLlcMember" name="PharmacyCreationsLlcMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember" name="PeriodEndingMarchThirtyFirstTwoThousandSixteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_EmployeesAndDirectorsMember" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_SellingAndMarketingMember" name="SellingAndMarketingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_GeneralAndAdministrativeMember" name="GeneralAndAdministrativeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ConsultantMember" name="ConsultantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_UrigenPharmaceuticalsIncMember" name="UrigenPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_DrRobertKammerMember" name="DrRobertKammerMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_BaumPerformanceEquityAwardMember" name="BaumPerformanceEquityAwardMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_MonteCarloSimulationMember" name="MonteCarloSimulationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_MonteCarloSimulationOneMember" name="MonteCarloSimulationOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_NonEmployeeDirectorsMember" name="NonEmployeeDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_FormerDirectorsMember" name="FormerDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ParkSellersMember" name="ParkSellersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_LeaseAgreementMember" name="LeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_CFOEmploymentAgreementMember" name="CFOEmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_AndrewRBollsMember" name="AndrewRBollsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RSUMember" name="RSUMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_CCOEmploymentAgreementMember" name="CCOEmploymentAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_JohnPSaharekMember" name="JohnPSaharekMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_NonCompetitionCovenantMember" name="NonCompetitionCovenantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_StockIssuedDuringPeriodValueStockOptionsExercisedFour" name="StockIssuedDuringPeriodValueStockOptionsExercisedFour" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_RestrictedShortTermInvestmentDisclosureAbstract" name="RestrictedShortTermInvestmentDisclosureAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_NumberOfDirectorResignedAndForfeited" name="NumberOfDirectorResignedAndForfeited" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_ScheduleOfEquityInstrumentsGrantedToRelatedPartyDetailsAbstract" name="ScheduleOfEquityInstrumentsGrantedToRelatedPartyDetailsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="IMMY_AgreementAxis" name="AgreementAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="IMMY_AgreementDomain" name="AgreementDomain" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>immy-20141231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: IMMY%2D20141231 10K FY DFN.xfr; Date: 2015%2D03%2D12T19:30:59 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80030000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://imprimispharma.com/role/DocumentAndEntityInformation" xlink:href="immy-20141231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/BalanceSheets" xlink:href="immy-20141231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/BalanceSheetsParenthetical" xlink:href="immy-20141231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/ConsolidatedStatementsOfOperations" xlink:href="immy-20141231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StatementsOfStockholdersEquity" xlink:href="immy-20141231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="immy-20141231.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StatementsOfCashFlows" xlink:href="immy-20141231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Organization" xlink:href="immy-20141231.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="immy-20141231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/RestrictedShort-termInvestment" xlink:href="immy-20141231.xsd#RestrictedShort-termInvestment" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Inventories" xlink:href="immy-20141231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="immy-20141231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/FurnitureAndEquipment" xlink:href="immy-20141231.xsd#FurnitureAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses" xlink:href="immy-20141231.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Debt" xlink:href="immy-20141231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity" xlink:href="immy-20141231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxes" xlink:href="immy-20141231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/EmployeeSavingsPlan" xlink:href="immy-20141231.xsd#EmployeeSavingsPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingencies" xlink:href="immy-20141231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SegmentInformation" xlink:href="immy-20141231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SubsequentEvents" xlink:href="immy-20141231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="immy-20141231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="immy-20141231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcTables" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlcTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/InventoriesTables" xlink:href="immy-20141231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="immy-20141231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/FurnitureAndEquipmentTables" xlink:href="immy-20141231.xsd#FurnitureAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="immy-20141231.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityTables" xlink:href="immy-20141231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxesTables" xlink:href="immy-20141231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingenciesTables" xlink:href="immy-20141231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="immy-20141231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:href="immy-20141231.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcDetailsNarrative" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlcDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfAcquisitionDateFairValueOfConsiderationDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfAcquisitionDateFairValueOfConsiderationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfEstimatedFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfEstimatedFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfResultOfOperationFromAcquisitionDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfResultOfOperationFromAcquisitionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfProFormaFinancialInformationDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfProFormaFinancialInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfIntangibleAssetsAcquisitionDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfIntangibleAssetsAcquisitionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/RestrictedShort-termInvestmentDetailsNarrative" xlink:href="immy-20141231.xsd#RestrictedShort-termInvestmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Inventories-ScheduleOfInventoriesDetails" xlink:href="immy-20141231.xsd#Inventories-ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets-ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="immy-20141231.xsd#PrepaidExpensesAndOtherCurrentAssets-ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/FurnitureAndEquipmentDetailsNarrative" xlink:href="immy-20141231.xsd#FurnitureAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/FurnitureAndEquipment-ScheduleOfFurnitureAndEquipmentDetails" xlink:href="immy-20141231.xsd#FurnitureAndEquipment-ScheduleOfFurnitureAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfIntangibleAssetsDetails" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill-ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill-ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill-ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfChangesInCarryingValueOfGoodwillDetails" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill-ScheduleOfChangesInCarryingValueOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesDetailsNarratvie" xlink:href="immy-20141231.xsd#AccountsPayableAndAccruedExpensesDetailsNarratvie" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="immy-20141231.xsd#AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/DebtDetailsNarrative" xlink:href="immy-20141231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="immy-20141231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockOptionPlanActivityDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfStockOptionPlanActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfFairValueAssumptionDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfFairValueAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfSharesOutstandingAndExercisableDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfSharesOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-Market-basedVestingConditionsForRestrictedStockUnitsGrantedDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-Market-basedVestingConditionsForRestrictedStockUnitsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfRestrictedStockUnitsActivityDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsActivityDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="immy-20141231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="immy-20141231.xsd#IncomeTaxes-ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfIncomeTaxReconciliationDetails" xlink:href="immy-20141231.xsd#IncomeTaxes-ScheduleOfIncomeTaxReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="immy-20141231.xsd#IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/EmployeeSavingsPlanDetailsNarrative" xlink:href="immy-20141231.xsd#EmployeeSavingsPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="immy-20141231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfLeaseEquipmentUnderCapitalLeaseDetails" xlink:href="immy-20141231.xsd#CommitmentsAndContingencies-ScheduleOfLeaseEquipmentUnderCapitalLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfFuturePaymentsUnderLeasesDetails" xlink:href="immy-20141231.xsd#CommitmentsAndContingencies-ScheduleOfFuturePaymentsUnderLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SegmentInformationDetailsNarrative" xlink:href="immy-20141231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="immy-20141231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="loc_us-gaapRestrictedInvestmentsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedInvestmentsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerDepositsCurrent" xlink:label="loc_us-gaapCustomerDepositsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapCustomerDepositsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities" xlink:label="loc_IMMYBusinessAcquisitionContingentAcquiredObligationsLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_IMMYBusinessAcquisitionContingentAcquiredObligationsLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapCapitalLeaseObligationsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement -  Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaapLicensesRevenue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapSalesRevenueNet" xlink:to="loc_us-gaapLicensesRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_HealthCareOrganizationRevenue" xlink:label="loc_us-gaapHealthCareOrganizationRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapSalesRevenueNet" xlink:to="loc_us-gaapHealthCareOrganizationRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense" xlink:label="loc_us-gaapHealthCareOrganizationMedicalSuppliesAndDrugsExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapHealthCareOrganizationMedicalSuppliesAndDrugsExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingCostsAndExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders' Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInCustomerDeposits" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInCustomerDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaapPaymentsToAcquireShortTermInvestments" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireShortTermInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Organization" xlink:title="00000008 - Disclosure - Organization" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc" xlink:title="00000010 - Disclosure - Acquisition - Pharmacy Creations, LLC" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/RestrictedShort-termInvestment" xlink:title="00000011 - Disclosure - Restricted Short-Term Investment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Inventories" xlink:title="00000012 - Disclosure - Inventories" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000013 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/FurnitureAndEquipment" xlink:title="00000014 - Disclosure - Furniture and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000015 - Disclosure - Intangible Assets and Goodwill" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses" xlink:title="00000016 - Disclosure - Accounts Payable and Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Debt" xlink:title="00000017 - Disclosure - Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - Stockholders' Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxes" xlink:title="00000019 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/EmployeeSavingsPlan" xlink:title="00000020 - Disclosure - Employee Savings Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SegmentInformation" xlink:title="00000022 - Disclosure - Segment Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcTables" xlink:title="00000026 - Disclosure - Acquisition - Pharmacy Creations, LLC (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/InventoriesTables" xlink:title="00000027 - Disclosure - Inventories (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/FurnitureAndEquipmentTables" xlink:title="00000029 - Disclosure - Furniture and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000030 - Disclosure - Intangible Assets and Goodwill (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="00000031 - Disclosure - Accounts Payable and Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityTables" xlink:title="00000032 - Disclosure - Stockholders' Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxesTables" xlink:title="00000033 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000034 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:title="00000036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Common Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcDetailsNarrative" xlink:title="00000037 - Disclosure - Acquisition - Pharmacy Creations, LLC (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfAcquisitionDateFairValueOfConsiderationDetails" xlink:title="00000038 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Acquisition Date Fair Value of Consideration (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ContingentCommonStockIssuanceToRelatedParty" xlink:label="loc_IMMYContingentCommonStockIssuanceToRelatedParty" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:to="loc_IMMYContingentCommonStockIssuanceToRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ContingentCashConsiderationToRelatedParty" xlink:label="loc_IMMYContingentCashConsiderationToRelatedParty" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:to="loc_IMMYContingentCashConsiderationToRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfEstimatedFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:title="00000039 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfResultOfOperationFromAcquisitionDetails" xlink:title="00000040 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Result of Operation from Acquisition (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfProFormaFinancialInformationDetails" xlink:title="00000041 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Pro Forma Financial Information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfIntangibleAssetsAcquisitionDetails" xlink:title="00000042 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Intangible Assets Acquisition (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/RestrictedShort-termInvestmentDetailsNarrative" xlink:title="00000043 - Disclosure - Restricted Short-Term Investment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Inventories-ScheduleOfInventoriesDetails" xlink:title="00000044 - Disclosure - Inventories - Schedule of Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets-ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000045 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PrepaidStockbasedConsultingExpenses" xlink:label="loc_IMMYPrepaidStockbasedConsultingExpenses" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_IMMYPrepaidStockbasedConsultingExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaapPrepaidRent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidRent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/FurnitureAndEquipmentDetailsNarrative" xlink:title="00000046 - Disclosure - Furniture and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/FurnitureAndEquipment-ScheduleOfFurnitureAndEquipmentDetails" xlink:title="00000047 - Disclosure - Furniture and Equipment - Schedule of Furniture and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_LabAndPharmacyEquipmentGross" xlink:label="loc_IMMYLabAndPharmacyEquipmentGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_IMMYLabAndPharmacyEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfIntangibleAssetsDetails" xlink:title="00000048 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:title="00000049 - Disclosure - Intangible Assets and Goodwill - Schedule of Amortization Expenses for Intangible Assets (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:title="00000050 - Disclosure - Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfChangesInCarryingValueOfGoodwillDetails" xlink:title="00000051 - Disclosure - Intangible Assets and Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesDetailsNarratvie" xlink:title="00000052 - Disclosure - Accounts Payable and Accrued Expenses (Details Narratvie)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="00000053 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_BuildingLeaseLiability" xlink:label="loc_IMMYBuildingLeaseLiability" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_IMMYBuildingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaapDeferredRentCreditCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="loc_us-gaapDeferredRentCreditCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/DebtDetailsNarrative" xlink:title="00000054 - Disclosure - Debt (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000055 - Disclosure - Stockholders' Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockOptionPlanActivityDetails" xlink:title="00000056 - Disclosure - Stockholders' Equity - Schedule of Stock Option Plan Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfFairValueAssumptionDetails" xlink:title="00000057 - Disclosure - Stockholders' Equity - Schedule of Fair Value Assumption (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfSharesOutstandingAndExercisableDetails" xlink:title="00000058 - Disclosure - Stockholders' Equity - Schedule of Shares Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-Market-basedVestingConditionsForRestrictedStockUnitsGrantedDetails" xlink:title="00000059 - Disclosure - Stockholders' Equity - Market-based Vesting Conditions for Restricted Stock Units Granted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfRestrictedStockUnitsActivityDetails" xlink:title="00000060 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Units Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsActivityDetails" xlink:title="00000061 - Disclosure - Stockholders' Equity - Schedule of Warrants Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:title="00000062 - Disclosure - Stockholders' Equity - Schedule of Warrants Outstanding and Warrants Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:title="00000063 - Disclosure - Stockholders' Equity - Schedule of Stock Based Compensation Granted to Employees Directors Consultants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000064 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000065 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DeferredIncomeChangeInValuationAllowance" xlink:label="loc_IMMYDeferredIncomeChangeInValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:to="loc_IMMYDeferredIncomeChangeInValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfIncomeTaxReconciliationDetails" xlink:title="00000066 - Disclosure - Income Taxes - Schedule of Income Tax Reconciliation (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000067 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:label="loc_IMMYDeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_IMMYDeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" xlink:label="loc_IMMYDeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_IMMYDeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" xlink:label="loc_us-gaapDeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/EmployeeSavingsPlanDetailsNarrative" xlink:title="00000068 - Disclosure - Employee Savings Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000069 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfLeaseEquipmentUnderCapitalLeaseDetails" xlink:title="00000070 - Disclosure - Commitments and Contingencies - Schedule of Lease Equipment Under Capital Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalLeaseObligationsNoncurrent" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCapitalLeaseObligationsNoncurrent" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfFuturePaymentsUnderLeasesDetails" xlink:title="00000071 - Disclosure - Commitments and Contingencies - Schedule of Future Payments Under Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SegmentInformationDetailsNarrative" xlink:title="00000072 - Disclosure - Segment Information (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000073 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>immy-20141231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: IMMY%2D20141231 10K FY DFN.xfr; Date: 2015%2D03%2D12T19:30:59 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80030000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://imprimispharma.com/role/DocumentAndEntityInformation" xlink:href="immy-20141231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/BalanceSheets" xlink:href="immy-20141231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/BalanceSheetsParenthetical" xlink:href="immy-20141231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/ConsolidatedStatementsOfOperations" xlink:href="immy-20141231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StatementsOfStockholdersEquity" xlink:href="immy-20141231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="immy-20141231.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StatementsOfCashFlows" xlink:href="immy-20141231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Organization" xlink:href="immy-20141231.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="immy-20141231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/RestrictedShort-termInvestment" xlink:href="immy-20141231.xsd#RestrictedShort-termInvestment" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Inventories" xlink:href="immy-20141231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="immy-20141231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/FurnitureAndEquipment" xlink:href="immy-20141231.xsd#FurnitureAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses" xlink:href="immy-20141231.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Debt" xlink:href="immy-20141231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity" xlink:href="immy-20141231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxes" xlink:href="immy-20141231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/EmployeeSavingsPlan" xlink:href="immy-20141231.xsd#EmployeeSavingsPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingencies" xlink:href="immy-20141231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SegmentInformation" xlink:href="immy-20141231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SubsequentEvents" xlink:href="immy-20141231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="immy-20141231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="immy-20141231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcTables" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlcTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/InventoriesTables" xlink:href="immy-20141231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="immy-20141231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/FurnitureAndEquipmentTables" xlink:href="immy-20141231.xsd#FurnitureAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="immy-20141231.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityTables" xlink:href="immy-20141231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxesTables" xlink:href="immy-20141231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingenciesTables" xlink:href="immy-20141231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="immy-20141231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:href="immy-20141231.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcDetailsNarrative" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlcDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfAcquisitionDateFairValueOfConsiderationDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfAcquisitionDateFairValueOfConsiderationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfEstimatedFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfEstimatedFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfResultOfOperationFromAcquisitionDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfResultOfOperationFromAcquisitionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfProFormaFinancialInformationDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfProFormaFinancialInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfIntangibleAssetsAcquisitionDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfIntangibleAssetsAcquisitionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/RestrictedShort-termInvestmentDetailsNarrative" xlink:href="immy-20141231.xsd#RestrictedShort-termInvestmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Inventories-ScheduleOfInventoriesDetails" xlink:href="immy-20141231.xsd#Inventories-ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets-ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="immy-20141231.xsd#PrepaidExpensesAndOtherCurrentAssets-ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/FurnitureAndEquipmentDetailsNarrative" xlink:href="immy-20141231.xsd#FurnitureAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/FurnitureAndEquipment-ScheduleOfFurnitureAndEquipmentDetails" xlink:href="immy-20141231.xsd#FurnitureAndEquipment-ScheduleOfFurnitureAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfIntangibleAssetsDetails" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill-ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill-ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill-ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfChangesInCarryingValueOfGoodwillDetails" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill-ScheduleOfChangesInCarryingValueOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesDetailsNarratvie" xlink:href="immy-20141231.xsd#AccountsPayableAndAccruedExpensesDetailsNarratvie" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="immy-20141231.xsd#AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/DebtDetailsNarrative" xlink:href="immy-20141231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="immy-20141231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockOptionPlanActivityDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfStockOptionPlanActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfFairValueAssumptionDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfFairValueAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfSharesOutstandingAndExercisableDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfSharesOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-Market-basedVestingConditionsForRestrictedStockUnitsGrantedDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-Market-basedVestingConditionsForRestrictedStockUnitsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfRestrictedStockUnitsActivityDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsActivityDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="immy-20141231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="immy-20141231.xsd#IncomeTaxes-ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfIncomeTaxReconciliationDetails" xlink:href="immy-20141231.xsd#IncomeTaxes-ScheduleOfIncomeTaxReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="immy-20141231.xsd#IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/EmployeeSavingsPlanDetailsNarrative" xlink:href="immy-20141231.xsd#EmployeeSavingsPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="immy-20141231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfLeaseEquipmentUnderCapitalLeaseDetails" xlink:href="immy-20141231.xsd#CommitmentsAndContingencies-ScheduleOfLeaseEquipmentUnderCapitalLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfFuturePaymentsUnderLeasesDetails" xlink:href="immy-20141231.xsd#CommitmentsAndContingencies-ScheduleOfFuturePaymentsUnderLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SegmentInformationDetailsNarrative" xlink:href="immy-20141231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="immy-20141231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement -  Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:label="loc_us-gaapAccumulatedDeficitDuringDevelopmentStageMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedDeficitDuringDevelopmentStageMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne" xlink:label="loc_IMMYIssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne" xlink:label="loc_IMMYIssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodValueStockOptionsExercisedFour" xlink:label="loc_IMMYStockIssuedDuringPeriodValueStockOptionsExercisedFour_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodValueStockOptionsExercisedFour_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesStockOptionsExercisedFour_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesStockOptionsExercisedFour_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013" xlink:label="loc_IMMYCancelledCommonStockValueRelatedToReverseStockSplitFebruary2013_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYCancelledCommonStockValueRelatedToReverseStockSplitFebruary2013_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares" xlink:label="loc_IMMYCancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYCancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodValueForPublicOffering" xlink:label="loc_IMMYStockIssuedDuringPeriodValueForPublicOffering_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodValueForPublicOffering_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesForPublicOffering" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesForPublicOffering_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesForPublicOffering_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" xlink:label="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" xlink:label="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodForExerciseOfWarrants" xlink:label="loc_IMMYStockIssuedDuringPeriodForExerciseOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodForExerciseOfWarrants_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesForExerciseOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesForExerciseOfWarrants_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_50" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockUponVestingOfRsusShares" xlink:label="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusShares_50" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_50" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute" xlink:label="loc_IMMYStockSharesIssuedDuingPeriodForSettlementOfContractDispute_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockSharesIssuedDuingPeriodForSettlementOfContractDispute_50" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute" xlink:label="loc_IMMYStockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute_50" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Organization" xlink:title="00000008 - Disclosure - Organization" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc" xlink:title="00000010 - Disclosure - Acquisition - Pharmacy Creations, LLC" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/RestrictedShort-termInvestment" xlink:title="00000011 - Disclosure - Restricted Short-Term Investment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Inventories" xlink:title="00000012 - Disclosure - Inventories" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000013 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/FurnitureAndEquipment" xlink:title="00000014 - Disclosure - Furniture and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000015 - Disclosure - Intangible Assets and Goodwill" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses" xlink:title="00000016 - Disclosure - Accounts Payable and Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Debt" xlink:title="00000017 - Disclosure - Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - Stockholders' Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxes" xlink:title="00000019 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/EmployeeSavingsPlan" xlink:title="00000020 - Disclosure - Employee Savings Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SegmentInformation" xlink:title="00000022 - Disclosure - Segment Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcTables" xlink:title="00000026 - Disclosure - Acquisition - Pharmacy Creations, LLC (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/InventoriesTables" xlink:title="00000027 - Disclosure - Inventories (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/FurnitureAndEquipmentTables" xlink:title="00000029 - Disclosure - Furniture and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000030 - Disclosure - Intangible Assets and Goodwill (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="00000031 - Disclosure - Accounts Payable and Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityTables" xlink:title="00000032 - Disclosure - Stockholders' Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock" xlink:label="loc_IMMYScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="loc_IMMYScheduleofWarrantsOutstandingAndExercisableTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYScheduleofWarrantsOutstandingAndExercisableTableTextBlock_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxesTables" xlink:title="00000033 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000034 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_MaximumDepositCoverageLimits" xlink:label="loc_IMMYMaximumDepositCoverageLimits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYMaximumDepositCoverageLimits_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromDepositsFromCustomers" xlink:label="loc_us-gaapProceedsFromDepositsFromCustomers_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromDepositsFromCustomers_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsReceivableNet_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CommonStockEquivalentsDilutiveInstruments" xlink:label="loc_IMMYCommonStockEquivalentsDilutiveInstruments_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYCommonStockEquivalentsDilutiveInstruments_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockIncludedInCommonStockEquivalents" xlink:label="loc_IMMYRestrictedStockIncludedInCommonStockEquivalents_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYRestrictedStockIncludedInCommonStockEquivalents_60" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:title="00000036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Common Share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcDetailsNarrative" xlink:title="00000037 - Disclosure - Acquisition - Pharmacy Creations, LLC (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PharmacyCreationsLlcMember" xlink:label="loc_IMMYPharmacyCreationsLlcMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMMYPharmacyCreationsLlcMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="loc_us-gaapCreationDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCreationDateAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember" xlink:label="loc_IMMYPeriodEndingMarchThirtyFirstTwoThousandSixteenMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDefaultFinancialStatementsDateMember" xlink:to="loc_IMMYPeriodEndingMarchThirtyFirstTwoThousandSixteenMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PaymentOfCashToContigent" xlink:label="loc_IMMYPaymentOfCashToContigent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPaymentOfCashToContigent_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExpectedRevenueDuringAcquisition" xlink:label="loc_IMMYExpectedRevenueDuringAcquisition_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYExpectedRevenueDuringAcquisition_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExpectedRevenueDate" xlink:label="loc_IMMYExpectedRevenueDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYExpectedRevenueDate_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfSharesAppliedForContigentStockPayment" xlink:label="loc_IMMYNumberOfSharesAppliedForContigentStockPayment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfSharesAppliedForContigentStockPayment_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainContingencyDescription" xlink:label="loc_us-gaapGainContingencyDescription_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainContingencyDescription_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill" xlink:label="loc_IMMYBusinessAcquisitionPurchasePriceAllocationGoodwill_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYBusinessAcquisitionPurchasePriceAllocationGoodwill_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityCurrent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityCurrent_60" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfAcquisitionDateFairValueOfConsiderationDetails" xlink:title="00000038 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Acquisition Date Fair Value of Consideration (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PharmacyCreationsLlcMember" xlink:label="loc_IMMYPharmacyCreationsLlcMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMMYPharmacyCreationsLlcMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ContingentCommonStockIssuanceToRelatedParty" xlink:label="loc_IMMYContingentCommonStockIssuanceToRelatedParty_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYContingentCommonStockIssuanceToRelatedParty_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ContingentCashConsiderationToRelatedParty" xlink:label="loc_IMMYContingentCashConsiderationToRelatedParty_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYContingentCashConsiderationToRelatedParty_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_20" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfEstimatedFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:title="00000039 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PharmacyCreationsLlcMember" xlink:label="loc_IMMYPharmacyCreationsLlcMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMMYPharmacyCreationsLlcMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_20" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_20" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_20" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_20" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_20" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwill_20" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_20" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfResultOfOperationFromAcquisitionDetails" xlink:title="00000040 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Result of Operation from Acquisition (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PharmacyCreationsLlcMember" xlink:label="loc_IMMYPharmacyCreationsLlcMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMMYPharmacyCreationsLlcMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_20" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfProFormaFinancialInformationDetails" xlink:title="00000041 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Pro Forma Financial Information (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfIntangibleAssetsAcquisitionDetails" xlink:title="00000042 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Intangible Assets Acquisition (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NonCompetitionCovenantMember" xlink:label="loc_IMMYNonCompetitionCovenantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_IMMYNonCompetitionCovenantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicensingAgreementsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_80" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/RestrictedShort-termInvestmentDetailsNarrative" xlink:title="00000043 - Disclosure - Restricted Short-Term Investment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Inventories-ScheduleOfInventoriesDetails" xlink:title="00000044 - Disclosure - Inventories - Schedule of Inventories (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets-ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000045 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/FurnitureAndEquipmentDetailsNarrative" xlink:title="00000046 - Disclosure - Furniture and Equipment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/FurnitureAndEquipment-ScheduleOfFurnitureAndEquipmentDetails" xlink:title="00000047 - Disclosure - Furniture and Equipment - Schedule of Furniture and Equipment (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfIntangibleAssetsDetails" xlink:title="00000048 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaapNoncompeteAgreementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapNoncompeteAgreementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicensingAgreementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:title="00000049 - Disclosure - Intangible Assets and Goodwill - Schedule of Amortization Expenses for Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NonCompetitionCovenantMember" xlink:label="loc_IMMYNonCompetitionCovenantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_IMMYNonCompetitionCovenantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicensingAgreementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:title="00000050 - Disclosure - Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfChangesInCarryingValueOfGoodwillDetails" xlink:title="00000051 - Disclosure - Intangible Assets and Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesDetailsNarratvie" xlink:title="00000052 - Disclosure - Accounts Payable and Accrued Expenses (Details Narratvie)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="00000053 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/DebtDetailsNarrative" xlink:title="00000054 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PharmacyCreationsLlcMember" xlink:label="loc_IMMYPharmacyCreationsLlcMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMMYPharmacyCreationsLlcMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermBorrowings_20" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000055 - Disclosure - Stockholders' Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_MarkBaumMember" xlink:label="loc_IMMYMarkBaumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IMMYMarkBaumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DrRobertKammerMember" xlink:label="loc_IMMYDrRobertKammerMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IMMYDrRobertKammerMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapRestrictedStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember" xlink:label="loc_IMMYTwoThousandSecenIncentiveStockAndAwardsPlanMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYTwoThousandSecenIncentiveStockAndAwardsPlanMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_BaumPerformanceEquityAwardMember" xlink:label="loc_IMMYBaumPerformanceEquityAwardMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYBaumPerformanceEquityAwardMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockUnitsRSUOneMember" xlink:label="loc_IMMYRestrictedStockUnitsRSUOneMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYRestrictedStockUnitsRSUOneMember_400" xlink:type="arc" order="401" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EmployeesAndDirectorsMember" xlink:label="loc_IMMYEmployeesAndDirectorsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYEmployeesAndDirectorsMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantMember" xlink:label="loc_IMMYConsultantMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYConsultantMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NonEmployeeDirectorsMember" xlink:label="loc_IMMYNonEmployeeDirectorsMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYNonEmployeeDirectorsMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FormerDirectorsMember" xlink:label="loc_IMMYFormerDirectorsMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYFormerDirectorsMember_340" xlink:type="arc" order="341" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EmployeesMember" xlink:label="loc_IMMYEmployeesMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYEmployeesMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_MonteCarloSimulationMember" xlink:label="loc_IMMYMonteCarloSimulationMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_IMMYMonteCarloSimulationMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_MonteCarloSimulationOneMember" xlink:label="loc_IMMYMonteCarloSimulationOneMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_IMMYMonteCarloSimulationOneMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantActivityMember" xlink:label="loc_IMMYWarrantActivityMember_430" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IMMYWarrantActivityMember_430" xlink:type="arc" order="431" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_460" xlink:type="arc" order="461" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_480" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_480" xlink:type="arc" order="481" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="loc_us-gaapCapitalUnitsAuthorized_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalUnitsAuthorized_510" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_510" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed" xlink:label="loc_IMMYNumberOfUnderwrittenPublicOfferingCommonStockSharesClosed_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfUnderwrittenPublicOfferingCommonStockSharesClosed_510" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="loc_us-gaapEquityIssuancePerShareAmount_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityIssuancePerShareAmount_510" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_510" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesIssuedToUnderwriters_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesIssuedToUnderwriters_510" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_510" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters" xlink:label="loc_IMMYStockIssuedDuringPeriodValueIssuedToUnderwriters_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodValueIssuedToUnderwriters_510" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_UnderwritingAgreementDescription" xlink:label="loc_IMMYUnderwritingAgreementDescription_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYUnderwritingAgreementDescription_510" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue_510" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares_510" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_510" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_510" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_510" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares" xlink:label="loc_IMMYCommonStockIssuedSettleCashlessExerciseProvisionShares_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYCommonStockIssuedSettleCashlessExerciseProvisionShares_510" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_510" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_510" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_510" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_510" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesStockOptionsExercisedOne_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesStockOptionsExercisedOne_510" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_510" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_510" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock" xlink:label="loc_IMMYExerciseOfCommonStockOptionToPurchaseOfCommonStock_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYExerciseOfCommonStockOptionToPurchaseOfCommonStock_510" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CommonStockExercisePricePerShare" xlink:label="loc_IMMYCommonStockExercisePricePerShare_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYCommonStockExercisePricePerShare_510" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" xlink:label="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares_510" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfCommonStockHeldForPayrollTax" xlink:label="loc_IMMYNumberOfCommonStockHeldForPayrollTax_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfCommonStockHeldForPayrollTax_510" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" xlink:label="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding_510" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesWarrantsExercised_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesWarrantsExercised_510" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised" xlink:label="loc_IMMYStockWarrantsIssuedDuringPeriodValueOfStockExercised_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockWarrantsIssuedDuringPeriodValueOfStockExercised_510" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock" xlink:label="loc_IMMYWarrantsAndSharesIssuedUponExciseOfCommonStock_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsAndSharesIssuedUponExciseOfCommonStock_510" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare" xlink:label="loc_IMMYWarrantsToPurchaseCommonStockExercisePricePerShare_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsToPurchaseCommonStockExercisePricePerShare_510" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_510" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfWarrantsCommonStockIssued" xlink:label="loc_IMMYNumberOfWarrantsCommonStockIssued_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfWarrantsCommonStockIssued_510" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExerciseOfWarrantToPurchaseOfCommonStock" xlink:label="loc_IMMYExerciseOfWarrantToPurchaseOfCommonStock_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYExerciseOfWarrantToPurchaseOfCommonStock_510" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsSharesExercisePricePerShare" xlink:label="loc_IMMYWarrantsSharesExercisePricePerShare_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsSharesExercisePricePerShare_510" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_510" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_510" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_510" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_510" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_510" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfFutureIssuancesShareUnderPlan" xlink:label="loc_IMMYNumberOfFutureIssuancesShareUnderPlan_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfFutureIssuancesShareUnderPlan_510" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_OptionsExercisePrice" xlink:label="loc_IMMYOptionsExercisePrice_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYOptionsExercisePrice_510" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_510" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="loc_IMMYSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_510" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockOptionsGrantedVestingTermsDescription" xlink:label="loc_IMMYStockOptionsGrantedVestingTermsDescription_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockOptionsGrantedVestingTermsDescription_510" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfForfeitureFactor" xlink:label="loc_IMMYPercentageOfForfeitureFactor_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageOfForfeitureFactor_510" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_510" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_510" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_510" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockVestInFuture" xlink:label="loc_IMMYRestrictedStockVestInFuture_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYRestrictedStockVestInFuture_510" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_TargetRangingPrice" xlink:label="loc_IMMYTargetRangingPrice_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYTargetRangingPrice_510" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockVestedImmediately" xlink:label="loc_IMMYRestrictedStockVestedImmediately_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYRestrictedStockVestedImmediately_510" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson" xlink:label="loc_IMMYRestrictedStockUnitsGrantedDuringPeriodPerPerson_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYRestrictedStockUnitsGrantedDuringPeriodPerPerson_510" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_510" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CancellationOfRestrictedStockUnitsDuringPeriod" xlink:label="loc_IMMYCancellationOfRestrictedStockUnitsDuringPeriod_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYCancellationOfRestrictedStockUnitsDuringPeriod_510" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockValueSharesIssuedNetOfTaxWithholdings_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedStockValueSharesIssuedNetOfTaxWithholdings_510" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares" xlink:label="loc_IMMYFairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYFairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares_510" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_510" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_510" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_510" xlink:type="arc" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_510" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_InitialFairValueOfRestrictedStockUnitsShares" xlink:label="loc_IMMYInitialFairValueOfRestrictedStockUnitsShares_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYInitialFairValueOfRestrictedStockUnitsShares_510" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfRestrictedStockUnitsVested" xlink:label="loc_IMMYPercentageOfRestrictedStockUnitsVested_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageOfRestrictedStockUnitsVested_510" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfRemainingRestrictedStockUnitsVested" xlink:label="loc_IMMYPercentageOfRemainingRestrictedStockUnitsVested_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageOfRemainingRestrictedStockUnitsVested_510" xlink:type="arc" order="64" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_510" xlink:type="arc" order="65" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_510" xlink:type="arc" order="66" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_510" xlink:type="arc" order="67" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_510" xlink:type="arc" order="68" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_510" xlink:type="arc" order="69" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_510" xlink:type="arc" order="70" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfDirectorResignedAndForfeited" xlink:label="loc_IMMYNumberOfDirectorResignedAndForfeited_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfDirectorResignedAndForfeited_510" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_510" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_510" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsExercisePricePerShare" xlink:label="loc_IMMYWarrantsExercisePricePerShare_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsExercisePricePerShare_510" xlink:type="arc" order="74" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsExpiredDuration" xlink:label="loc_IMMYWarrantsExpiredDuration_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsExpiredDuration_510" xlink:type="arc" order="75" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfWarrantsVestedImmeditely" xlink:label="loc_IMMYNumberOfWarrantsVestedImmeditely_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfWarrantsVestedImmeditely_510" xlink:type="arc" order="76" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfSharesVestedInInstallments" xlink:label="loc_IMMYNumberOfSharesVestedInInstallments_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfSharesVestedInInstallments_510" xlink:type="arc" order="77" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FairValueOfWarrants" xlink:label="loc_IMMYFairValueOfWarrants_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYFairValueOfWarrants_510" xlink:type="arc" order="78" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_510" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_510" xlink:type="arc" order="79" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockOptionPlanActivityDetails" xlink:title="00000056 - Disclosure - Stockholders' Equity - Schedule of Stock Option Plan Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockOptionPlanMember" xlink:label="loc_IMMYStockOptionPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYStockOptionPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_20" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_20" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_20" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_20" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_20" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_20" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_20" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_20" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_20" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfFairValueAssumptionDetails" xlink:title="00000057 - Disclosure - Stockholders' Equity - Schedule of Fair Value Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_OptionsEmployeesMember" xlink:label="loc_IMMYOptionsEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYOptionsEmployeesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_OptionsGrantedConsultantsMember" xlink:label="loc_IMMYOptionsGrantedConsultantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYOptionsGrantedConsultantsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_160" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfSharesOutstandingAndExercisableDetails" xlink:title="00000058 - Disclosure - Stockholders' Equity - Schedule of Shares Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeOneMember" xlink:label="loc_IMMYRangeOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IMMYRangeOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeTwoMember" xlink:label="loc_IMMYRangeTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IMMYRangeTwoMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeThreeMember" xlink:label="loc_IMMYRangeThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IMMYRangeThreeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeFourMember" xlink:label="loc_IMMYRangeFourMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IMMYRangeFourMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeFiveMember" xlink:label="loc_IMMYRangeFiveMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IMMYRangeFiveMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberExercisable" xlink:label="loc_IMMYNumberExercisable_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberExercisable_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2" xlink:label="loc_IMMYShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2_130" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-Market-basedVestingConditionsForRestrictedStockUnitsGrantedDetails" xlink:title="00000059 - Disclosure - Stockholders' Equity - Market-based Vesting Conditions for Restricted Stock Units Granted (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember" xlink:label="loc_IMMYExecutiveRestrictedStockUnitsTrancheOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYExecutiveRestrictedStockUnitsTrancheOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember" xlink:label="loc_IMMYExecutiveRestrictedStockUnitsTrancheTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYExecutiveRestrictedStockUnitsTrancheTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember" xlink:label="loc_IMMYExecutiveRestrictedStockUnitsTrancheThreeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYExecutiveRestrictedStockUnitsTrancheThreeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTranche4Member" xlink:label="loc_IMMYExecutiveRestrictedStockUnitsTranche4Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYExecutiveRestrictedStockUnitsTranche4Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTranche5Member" xlink:label="loc_IMMYExecutiveRestrictedStockUnitsTranche5Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYExecutiveRestrictedStockUnitsTranche5Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheOneMember" xlink:label="loc_IMMYConsultantTrancheOneMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYConsultantTrancheOneMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheTwoMember" xlink:label="loc_IMMYConsultantTrancheTwoMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYConsultantTrancheTwoMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheThreeMember" xlink:label="loc_IMMYConsultantTrancheThreeMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYConsultantTrancheThreeMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheFourMember" xlink:label="loc_IMMYConsultantTrancheFourMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYConsultantTrancheFourMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheFiveMember" xlink:label="loc_IMMYConsultantTrancheFiveMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYConsultantTrancheFiveMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted" xlink:label="loc_IMMYPercentageSharesTiedToTargetOfNumberOfSharesGranted_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageSharesTiedToTargetOfNumberOfSharesGranted_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfSharesTiedToTarget" xlink:label="loc_IMMYNumberOfSharesTiedToTarget_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfSharesTiedToTarget_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_TargetSharePriceRelatedToRestrictedStockGrant" xlink:label="loc_IMMYTargetSharePriceRelatedToRestrictedStockGrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYTargetSharePriceRelatedToRestrictedStockGrant_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfRestrictedStockUnitsActivityDetails" xlink:title="00000060 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Units Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:label="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_20" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_20" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsActivityDetails" xlink:title="00000061 - Disclosure - Stockholders' Equity - Schedule of Warrants Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_IMMYSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_20" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_20" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_IMMYShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_20" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_IMMYShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_20" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_IMMYShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_20" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:title="00000062 - Disclosure - Stockholders' Equity - Schedule of Warrants Outstanding and Warrants Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuedToFormerMajorShareholderMember" xlink:label="loc_IMMYWarrantsIssuedToFormerMajorShareholderMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYWarrantsIssuedToFormerMajorShareholderMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember" xlink:label="loc_IMMYWarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYWarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_UnderwriterWarrantsMember" xlink:label="loc_IMMYUnderwriterWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYUnderwriterWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember" xlink:label="loc_IMMYWarrantsIssuedToInvestorRelationsConsultantOneMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYWarrantsIssuedToInvestorRelationsConsultantOneMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember" xlink:label="loc_IMMYWarrantsIssuedToInvestorRelationsConsultantTwoMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYWarrantsIssuedToInvestorRelationsConsultantTwoMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuanceDate" xlink:label="loc_IMMYWarrantsIssuanceDate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsIssuanceDate_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:label="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:label="loc_IMMYShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsExpirationDate" xlink:label="loc_IMMYWarrantsExpirationDate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsExpirationDate_120" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:title="00000063 - Disclosure - Stockholders' Equity - Schedule of Stock Based Compensation Granted to Employees Directors Consultants (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EmployeesMember" xlink:label="loc_IMMYEmployeesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IMMYEmployeesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapDirectorMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantMember" xlink:label="loc_IMMYConsultantMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IMMYConsultantMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_SellingAndMarketingMember" xlink:label="loc_IMMYSellingAndMarketingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_IMMYSellingAndMarketingMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_GeneralAndAdministrativeMember" xlink:label="loc_IMMYGeneralAndAdministrativeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_IMMYGeneralAndAdministrativeMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ResearchAndDevelopmentMember" xlink:label="loc_IMMYResearchAndDevelopmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_IMMYResearchAndDevelopmentMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_170" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000064 - Disclosure - Income Taxes (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000065 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfIncomeTaxReconciliationDetails" xlink:title="00000066 - Disclosure - Income Taxes - Schedule of Income Tax Reconciliation (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000067 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/EmployeeSavingsPlanDetailsNarrative" xlink:title="00000068 - Disclosure - Employee Savings Plan (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000069 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PharmacyCreationsLlcMember" xlink:label="loc_IMMYPharmacyCreationsLlcMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYPharmacyCreationsLlcMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_UrigenPharmaceuticalsIncMember" xlink:label="loc_IMMYUrigenPharmaceuticalsIncMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYUrigenPharmaceuticalsIncMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate" xlink:label="loc_IMMYLeasesEquipmentUnderCapitalLeaseWithInterestRate_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYLeasesEquipmentUnderCapitalLeaseWithInterestRate_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapCapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="loc_us-gaapCapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaapOperatingLeasesRentExpenseNet_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesRentExpenseNet_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate" xlink:label="loc_us-gaapOperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_LicenseAgreementCommitmentsDescription" xlink:label="loc_IMMYLicenseAgreementCommitmentsDescription_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYLicenseAgreementCommitmentsDescription_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ValueOfProductDevelopmentInvestment" xlink:label="loc_IMMYValueOfProductDevelopmentInvestment_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYValueOfProductDevelopmentInvestment_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RoyaltiesRangePercentage" xlink:label="loc_IMMYRoyaltiesRangePercentage_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYRoyaltiesRangePercentage_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AggregateValueOfCashFees" xlink:label="loc_IMMYAggregateValueOfCashFees_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYAggregateValueOfCashFees_140" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfLeaseEquipmentUnderCapitalLeaseDetails" xlink:title="00000070 - Disclosure - Commitments and Contingencies - Schedule of Lease Equipment Under Capital Lease (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfFuturePaymentsUnderLeasesDetails" xlink:title="00000071 - Disclosure - Commitments and Contingencies - Schedule of Future Payments Under Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SegmentInformationDetailsNarrative" xlink:title="00000072 - Disclosure - Segment Information (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000073 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ParkSellersMember" xlink:label="loc_IMMYParkSellersMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYParkSellersMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AndrewRBollsMember" xlink:label="loc_IMMYAndrewRBollsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYAndrewRBollsMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_JohnPSaharekMember" xlink:label="loc_IMMYJohnPSaharekMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYJohnPSaharekMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AgreementAxis" xlink:label="loc_IMMYAgreementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_IMMYAgreementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AgreementDomain" xlink:label="loc_IMMYAgreementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_IMMYAgreementAxis" xlink:to="loc_IMMYAgreementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AgreementDomain" xlink:label="loc_IMMYAgreementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_IMMYAgreementAxis" xlink:to="loc_IMMYAgreementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_LeaseAgreementMember" xlink:label="loc_IMMYLeaseAgreementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_IMMYAgreementDomain" xlink:to="loc_IMMYLeaseAgreementMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CFOEmploymentAgreementMember" xlink:label="loc_IMMYCFOEmploymentAgreementMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_IMMYAgreementDomain" xlink:to="loc_IMMYCFOEmploymentAgreementMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CCOEmploymentAgreementMember" xlink:label="loc_IMMYCCOEmploymentAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_IMMYAgreementDomain" xlink:to="loc_IMMYCCOEmploymentAgreementMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RSUMember" xlink:label="loc_IMMYRSUMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IMMYRSUMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesWarrantsExercised_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesWarrantsExercised_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForPreviousAcquisition" xlink:label="loc_us-gaapPaymentsForPreviousAcquisition_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForPreviousAcquisition_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AverageClosingPriceOfCommonStock" xlink:label="loc_IMMYAverageClosingPriceOfCommonStock_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYAverageClosingPriceOfCommonStock_140" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_QuarterlyCashPayments" xlink:label="loc_IMMYQuarterlyCashPayments_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYQuarterlyCashPayments_140" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AmountOfClosingPrice" xlink:label="loc_IMMYAmountOfClosingPrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYAmountOfClosingPrice_140" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AggregatedAmountOfClosingPrice" xlink:label="loc_IMMYAggregatedAmountOfClosingPrice_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYAggregatedAmountOfClosingPrice_140" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_140" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AreaOfSquareFeet" xlink:label="loc_IMMYAreaOfSquareFeet_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYAreaOfSquareFeet_140" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent_140" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfAnnualRentIncreases" xlink:label="loc_IMMYPercentageOfAnnualRentIncreases_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageOfAnnualRentIncreases_140" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1_140" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EmploymentAgreementTerm" xlink:label="loc_IMMYEmploymentAgreementTerm_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYEmploymentAgreementTerm_140" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOfficersCompensation_140" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfCurrentAnnualSalary" xlink:label="loc_IMMYPercentageOfCurrentAnnualSalary_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageOfCurrentAnnualSalary_140" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfIncreasesCurrentAnnualSalary" xlink:label="loc_IMMYPercentageOfIncreasesCurrentAnnualSalary_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageOfIncreasesCurrentAnnualSalary_140" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_TermOfStockOption" xlink:label="loc_IMMYTermOfStockOption_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYTermOfStockOption_140" xlink:type="arc" order="20" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>immy-20141231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: IMMY%2D20141231 10K FY DFN.xfr; Date: 2015%2D03%2D12T19:30:59 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80030000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockOptionPlanMember" xlink:label="IMMY_StockOptionPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockOptionPlanMember" xlink:to="IMMY_StockOptionPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockOptionPlanMember_lbl" xml:lang="en-US">Stock Option Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_OptionsGrantedConsultantsMember" xlink:label="IMMY_OptionsGrantedConsultantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_OptionsGrantedConsultantsMember" xlink:to="IMMY_OptionsGrantedConsultantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_OptionsGrantedConsultantsMember_lbl" xml:lang="en-US">Options Granted To Consultants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember" xlink:label="IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember" xlink:to="IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember_lbl" xml:lang="en-US">2007 Incentive Stock And Awards Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeOneMember" xlink:label="IMMY_RangeOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RangeOneMember" xlink:to="IMMY_RangeOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RangeOneMember_lbl" xml:lang="en-US">Range One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_OptionsEmployeesMember" xlink:label="IMMY_OptionsEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_OptionsEmployeesMember" xlink:to="IMMY_OptionsEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_OptionsEmployeesMember_lbl" xml:lang="en-US">Options Granted To Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTranche4Member" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTranche4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExecutiveRestrictedStockUnitsTranche4Member" xlink:to="IMMY_ExecutiveRestrictedStockUnitsTranche4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTranche4Member_lbl" xml:lang="en-US">Tranche 4 CEO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTranche5Member" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTranche5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExecutiveRestrictedStockUnitsTranche5Member" xlink:to="IMMY_ExecutiveRestrictedStockUnitsTranche5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTranche5Member_lbl" xml:lang="en-US">Tranche 5 CEO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuedToFormerMajorShareholderMember" xlink:label="IMMY_WarrantsIssuedToFormerMajorShareholderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsIssuedToFormerMajorShareholderMember" xlink:to="IMMY_WarrantsIssuedToFormerMajorShareholderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_WarrantsIssuedToFormerMajorShareholderMember_lbl" xml:lang="en-US">Warrants Issued To Former Major Shareholder [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember" xlink:label="IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember" xlink:to="IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember_lbl" xml:lang="en-US">Warrants Issued In April 2012 Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_UnderwriterWarrantsMember" xlink:label="IMMY_UnderwriterWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_UnderwriterWarrantsMember" xlink:to="IMMY_UnderwriterWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_UnderwriterWarrantsMember_lbl" xml:lang="en-US">Underwriter Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_MarkBaumMember" xlink:label="IMMY_MarkBaumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_MarkBaumMember" xlink:to="IMMY_MarkBaumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_MarkBaumMember_lbl" xml:lang="en-US">Mark Baum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeTwoMember" xlink:label="IMMY_RangeTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RangeTwoMember" xlink:to="IMMY_RangeTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RangeTwoMember_lbl" xml:lang="en-US">Range Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeThreeMember" xlink:label="IMMY_RangeThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RangeThreeMember" xlink:to="IMMY_RangeThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RangeThreeMember_lbl" xml:lang="en-US">Range Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeFourMember" xlink:label="IMMY_RangeFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RangeFourMember" xlink:to="IMMY_RangeFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RangeFourMember_lbl" xml:lang="en-US">Range Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeFiveMember" xlink:label="IMMY_RangeFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RangeFiveMember" xlink:to="IMMY_RangeFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RangeFiveMember_lbl" xml:lang="en-US">Range Five [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember" xlink:to="IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember_lbl" xml:lang="en-US">Tranche 1 CEO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember" xlink:to="IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember_lbl" xml:lang="en-US">Tranche 2 CEO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember" xlink:to="IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember_lbl" xml:lang="en-US">Tranche 3 CEO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheOneMember" xlink:label="IMMY_ConsultantTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ConsultantTrancheOneMember" xlink:to="IMMY_ConsultantTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ConsultantTrancheOneMember_lbl" xml:lang="en-US">Consultant Tranche 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheTwoMember" xlink:label="IMMY_ConsultantTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ConsultantTrancheTwoMember" xlink:to="IMMY_ConsultantTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ConsultantTrancheTwoMember_lbl" xml:lang="en-US">Consultant Tranche 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheThreeMember" xlink:label="IMMY_ConsultantTrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ConsultantTrancheThreeMember" xlink:to="IMMY_ConsultantTrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ConsultantTrancheThreeMember_lbl" xml:lang="en-US">Consultant Tranche 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheFourMember" xlink:label="IMMY_ConsultantTrancheFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ConsultantTrancheFourMember" xlink:to="IMMY_ConsultantTrancheFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ConsultantTrancheFourMember_lbl" xml:lang="en-US">Consultant Tranche 4 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheFiveMember" xlink:label="IMMY_ConsultantTrancheFiveMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ConsultantTrancheFiveMember" xlink:to="IMMY_ConsultantTrancheFiveMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ConsultantTrancheFiveMember_lbl" xml:lang="en-US">Consultant Tranche 5 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember" xlink:label="IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember" xlink:to="IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember_lbl" xml:lang="en-US">Warrants Issued To Investor Relations Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember" xlink:label="IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember" xlink:to="IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember_lbl" xml:lang="en-US">Warrants Issued To Investor Relations Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockUnitsRSUOneMember" xlink:label="IMMY_RestrictedStockUnitsRSUOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RestrictedStockUnitsRSUOneMember" xlink:to="IMMY_RestrictedStockUnitsRSUOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RestrictedStockUnitsRSUOneMember_lbl" xml:lang="en-US">Restricted Stock Units One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantActivityMember" xlink:label="IMMY_WarrantActivityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantActivityMember" xlink:to="IMMY_WarrantActivityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="IMMY_WarrantActivityMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="us-gaap_CustomerRelationshipsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerRelationshipsMember" xlink:to="us-gaap_CustomerRelationshipsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerRelationshipsMember_lbl" xml:lang="en-US">Customer Relationships [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="us-gaap_TradeNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeNamesMember" xlink:to="us-gaap_TradeNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeNamesMember_lbl" xml:lang="en-US">Trade Name [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="us-gaap_NoncompeteAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncompeteAgreementsMember" xlink:to="us-gaap_NoncompeteAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncompeteAgreementsMember_lbl" xml:lang="en-US">Non-Compete Covenant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xml:lang="en-US">State Pharmacy Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PharmacyCreationsLlcMember" xlink:label="IMMY_PharmacyCreationsLlcMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PharmacyCreationsLlcMember" xlink:to="IMMY_PharmacyCreationsLlcMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PharmacyCreationsLlcMember_lbl" xml:lang="en-US">Pharmacy Creations, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember" xlink:label="IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember" xlink:to="IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember_lbl" xml:lang="en-US">Period Ending March 31, 2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_CreationDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreationDateAxis_lbl" xml:lang="en-US">Report Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EmployeesAndDirectorsMember" xlink:label="IMMY_EmployeesAndDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_EmployeesAndDirectorsMember" xlink:to="IMMY_EmployeesAndDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">Employees And Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EmployeesMember" xlink:label="IMMY_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_EmployeesMember" xlink:to="IMMY_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_SellingAndMarketingMember" xlink:label="IMMY_SellingAndMarketingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_SellingAndMarketingMember" xlink:to="IMMY_SellingAndMarketingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_SellingAndMarketingMember_lbl" xml:lang="en-US">Selling And Marketing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_GeneralAndAdministrativeMember" xlink:label="IMMY_GeneralAndAdministrativeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_GeneralAndAdministrativeMember" xlink:to="IMMY_GeneralAndAdministrativeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_GeneralAndAdministrativeMember_lbl" xml:lang="en-US">General And Administrative [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ResearchAndDevelopmentMember" xlink:label="IMMY_ResearchAndDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ResearchAndDevelopmentMember" xlink:to="IMMY_ResearchAndDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ResearchAndDevelopmentMember_lbl" xml:lang="en-US">Research And Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectorMember_lbl" xml:lang="en-US">Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantMember" xlink:label="IMMY_ConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ConsultantMember" xlink:to="IMMY_ConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_UrigenPharmaceuticalsIncMember" xlink:label="IMMY_UrigenPharmaceuticalsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_UrigenPharmaceuticalsIncMember" xlink:to="IMMY_UrigenPharmaceuticalsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_UrigenPharmaceuticalsIncMember_lbl" xml:lang="en-US">Urigen Pharmaceuticals, Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:label="us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:to="us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DrRobertKammerMember" xlink:label="IMMY_DrRobertKammerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_DrRobertKammerMember" xlink:to="IMMY_DrRobertKammerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_DrRobertKammerMember_lbl" xml:lang="en-US">Dr. Robert Kammer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_BaumPerformanceEquityAwardMember" xlink:label="IMMY_BaumPerformanceEquityAwardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_BaumPerformanceEquityAwardMember" xlink:to="IMMY_BaumPerformanceEquityAwardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_BaumPerformanceEquityAwardMember_lbl" xml:lang="en-US">Baum Performance Equity Award [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_MonteCarloSimulationMember" xlink:label="IMMY_MonteCarloSimulationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_MonteCarloSimulationMember" xlink:to="IMMY_MonteCarloSimulationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_MonteCarloSimulationMember_lbl" xml:lang="en-US">Monte Carlo Simulation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_MonteCarloSimulationOneMember" xlink:label="IMMY_MonteCarloSimulationOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_MonteCarloSimulationOneMember" xlink:to="IMMY_MonteCarloSimulationOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_MonteCarloSimulationOneMember_lbl" xml:lang="en-US">Monte Carlo Simulation One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NonEmployeeDirectorsMember" xlink:label="IMMY_NonEmployeeDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NonEmployeeDirectorsMember" xlink:to="IMMY_NonEmployeeDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_NonEmployeeDirectorsMember_lbl" xml:lang="en-US">Non-Employee Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FormerDirectorsMember" xlink:label="IMMY_FormerDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_FormerDirectorsMember" xlink:to="IMMY_FormerDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_FormerDirectorsMember_lbl" xml:lang="en-US">Former Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ParkSellersMember" xlink:label="IMMY_ParkSellersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ParkSellersMember" xlink:to="IMMY_ParkSellersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ParkSellersMember_lbl" xml:lang="en-US">Park Sellers [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_LeaseAgreementMember" xlink:label="IMMY_LeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_LeaseAgreementMember" xlink:to="IMMY_LeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_LeaseAgreementMember_lbl" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AgreementAxis" xlink:label="IMMY_AgreementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AgreementAxis" xlink:to="IMMY_AgreementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_AgreementAxis_lbl" xml:lang="en-US">Agreement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CFOEmploymentAgreementMember" xlink:label="IMMY_CFOEmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CFOEmploymentAgreementMember" xlink:to="IMMY_CFOEmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_CFOEmploymentAgreementMember_lbl" xml:lang="en-US">CFO Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AndrewRBollsMember" xlink:label="IMMY_AndrewRBollsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AndrewRBollsMember" xlink:to="IMMY_AndrewRBollsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_AndrewRBollsMember_lbl" xml:lang="en-US">Andrew R. Boll's [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RSUMember" xlink:label="IMMY_RSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RSUMember" xlink:to="IMMY_RSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RSUMember_lbl" xml:lang="en-US">RSU [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CCOEmploymentAgreementMember" xlink:label="IMMY_CCOEmploymentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CCOEmploymentAgreementMember" xlink:to="IMMY_CCOEmploymentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_CCOEmploymentAgreementMember_lbl" xml:lang="en-US">CCO Employment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_JohnPSaharekMember" xlink:label="IMMY_JohnPSaharekMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_JohnPSaharekMember" xlink:to="IMMY_JohnPSaharekMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_JohnPSaharekMember_lbl" xml:lang="en-US">John P. Saharek [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NonCompetitionCovenantMember" xlink:label="IMMY_NonCompetitionCovenantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NonCompetitionCovenantMember" xlink:to="IMMY_NonCompetitionCovenantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_NonCompetitionCovenantMember_lbl" xml:lang="en-US">Non-Competition Covenant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DocumentAndEntityInformationAbstract" xlink:label="IMMY_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_DocumentAndEntityInformationAbstract" xlink:to="IMMY_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-KnownSeasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="us-gaap_RestrictedInvestmentsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsCurrent" xlink:to="us-gaap_RestrictedInvestmentsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedInvestmentsCurrent_lbl" xml:lang="en-US">Restricted short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Furniture and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued payroll and related liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerDepositsCurrent" xlink:label="us-gaap_CustomerDepositsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerDepositsCurrent" xlink:to="us-gaap_CustomerDepositsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerDepositsCurrent_lbl" xml:lang="en-US">Customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities" xlink:label="IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities" xlink:to="IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities_lbl" xml:lang="en-US">Current portion of contingent acquisition obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Current portion of capital lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Capital lease obligations, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued expenses, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Contingent acquisition obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 90,000,000 shares authorized, 9,258,231 and 8,970,364 shares issued and outstanding at December 31, 2014 and 2013, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">TOTAL STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_HealthCareOrganizationRevenue" xlink:label="us-gaap_HealthCareOrganizationRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenue" xlink:to="us-gaap_HealthCareOrganizationRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationRevenue_lbl" xml:lang="en-US">Sales, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US">License revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense" xlink:label="us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense" xlink:to="us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense_lbl" xml:lang="en-US">Cost of sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xml:lang="en-US">Selling and marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingCostsAndExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted net loss per share of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of shares of common stock outstanding, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options, net of tax withholding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of stock options, net of tax withholding, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne" xlink:label="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne" xlink:to="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne_lbl" xml:lang="en-US">Issuance of common stock related to consulting agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne" xlink:label="IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne" xlink:to="IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne_lbl" xml:lang="en-US">Issuance of common stock related to consulting agreements, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodValueStockOptionsExercisedFour" xlink:label="IMMY_StockIssuedDuringPeriodValueStockOptionsExercisedFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodValueStockOptionsExercisedFour" xlink:to="IMMY_StockIssuedDuringPeriodValueStockOptionsExercisedFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockIssuedDuringPeriodValueStockOptionsExercisedFour_lbl" xml:lang="en-US">Exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour" xlink:label="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour" xlink:to="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour_lbl" xml:lang="en-US">Exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013" xlink:label="IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013" xlink:to="IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013_lbl" xml:lang="en-US">Cancelled common stock at $5.25 per share related to reverse stock split, February 2013</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares" xlink:label="IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares" xlink:to="IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares_lbl" xml:lang="en-US">Cancelled common stock at $5.25 per share related to reverse stock split, February 2013, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodValueForPublicOffering" xlink:label="IMMY_StockIssuedDuringPeriodValueForPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodValueForPublicOffering" xlink:to="IMMY_StockIssuedDuringPeriodValueForPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockIssuedDuringPeriodValueForPublicOffering_lbl" xml:lang="en-US">Public offering of common stock at $5.25 per share, net of costs of $596,281, in February and March 2013</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesForPublicOffering" xlink:label="IMMY_StockIssuedDuringPeriodSharesForPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodSharesForPublicOffering" xlink:to="IMMY_StockIssuedDuringPeriodSharesForPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockIssuedDuringPeriodSharesForPublicOffering_lbl" xml:lang="en-US">Public offering of common stock at $5.25 per share, net of costs of $596,281, in February and March 2013, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" xlink:label="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" xlink:to="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding_lbl" xml:lang="en-US">Issuance of common stock upon vesting of RSUs net of tax withholding</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" xlink:label="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" xlink:to="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares_lbl" xml:lang="en-US">Issuance of common stock upon vesting of RSUs net of tax withholding , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodForExerciseOfWarrants" xlink:label="IMMY_StockIssuedDuringPeriodForExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodForExerciseOfWarrants" xlink:to="IMMY_StockIssuedDuringPeriodForExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockIssuedDuringPeriodForExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:label="IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:to="IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants_lbl" xml:lang="en-US">Exercise of warrants , shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Issuance of common stock upon vesting of RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockUponVestingOfRsusShares" xlink:label="IMMY_IssuanceOfCommonStockUponVestingOfRsusShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfCommonStockUponVestingOfRsusShares" xlink:to="IMMY_IssuanceOfCommonStockUponVestingOfRsusShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_IssuanceOfCommonStockUponVestingOfRsusShares_lbl" xml:lang="en-US">Issuance of common stock upon vesting of RSUs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute" xlink:label="IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute" xlink:to="IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute_lbl" xml:lang="en-US">Common stock issued in settlement of contract dispute</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute" xlink:label="IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute" xlink:to="IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute_lbl" xml:lang="en-US">Common stock issued in settlement of contract dispute, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare" xlink:label="IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare" xlink:to="IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare_lbl" xml:lang="en-US">Issuance of common stock for public offering price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CancelledCommonStockPricePerShare" xlink:label="IMMY_CancelledCommonStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CancelledCommonStockPricePerShare" xlink:to="IMMY_CancelledCommonStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_CancelledCommonStockPricePerShare_lbl" xml:lang="en-US">Cancelled common stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation and amortization of furniture and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation and payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities, net of effects from acquisitions:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued payroll and related liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerDeposits" xlink:label="us-gaap_IncreaseDecreaseInCustomerDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInCustomerDeposits" xlink:to="us-gaap_IncreaseDecreaseInCustomerDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInCustomerDeposits_lbl" xml:lang="en-US">Customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US">Purchase of restricted short-term investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Purchase of Pharmacy Creations, LLC, net of cash and advances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of furniture and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US">Cancelled common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_lbl" xml:lang="en-US">Payments on capital lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Net proceeds from exercise of warrants and stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants for cash, net of offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">NET CHANGE IN CASH AND CASH EQUIVALENTS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_3_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees" xlink:label="IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees" xlink:to="IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees_lbl" xml:lang="en-US">Issuance of and adjustment to common stock and warrants to consulting firms for prepaid consulting fees</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering" xlink:label="IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering" xlink:to="IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering_lbl" xml:lang="en-US">Reclassification of deferred offering costs in connection with equity offering</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock for consulting services included in accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease" xlink:label="IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease" xlink:to="IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease_lbl" xml:lang="en-US">Purchase of furniture and equipment with a capital lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Business Combinations [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">Acquisition - Pharmacy Creations, LLC</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedShortTermInvestmentDisclosureAbstract" xlink:label="IMMY_RestrictedShortTermInvestmentDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RestrictedShortTermInvestmentDisclosureAbstract" xlink:to="IMMY_RestrictedShortTermInvestmentDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RestrictedShortTermInvestmentDisclosureAbstract_lbl" xml:lang="en-US">Restricted Short-term Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_lbl" xml:lang="en-US">Restricted Short-Term Investment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Furniture and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Compensation and Retirement Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee Savings Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xml:lang="en-US">Business Combinations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Intellectual Property</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionDeferredRevenue" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue_lbl" xml:lang="en-US">Revenue Recognition and Deferred Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Furniture and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock" xlink:label="IMMY_RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock" xlink:to="IMMY_RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Earnings Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xml:lang="en-US">Schedule of Acquisition Date Fair Value of Consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ScheduleOfResultOfOperationFromAcquisitionTableTextBlock" xlink:label="IMMY_ScheduleOfResultOfOperationFromAcquisitionTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ScheduleOfResultOfOperationFromAcquisitionTableTextBlock" xlink:to="IMMY_ScheduleOfResultOfOperationFromAcquisitionTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ScheduleOfResultOfOperationFromAcquisitionTableTextBlock_lbl" xml:lang="en-US">Schedule of Result of Operation from Acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US">Schedule of Pro Forma Financial Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:label="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:to="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets Acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="IMMY_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="IMMY_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Furniture and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Amortization Expenses for Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Future Amortization Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfGoodwillTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Carrying Value of Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Plan Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumption</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Shares Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock" xlink:label="IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock" xlink:to="IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock_lbl" xml:lang="en-US">Market-based Vesting Conditions for Restricted Stock Units Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrants Outstanding and Warrants Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Stock Based Compensation Granted to Employees Directors Consultants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Provision for Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Income Tax Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Equipment Under Capital Lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Payments Under Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_MaximumDepositCoverageLimits" xlink:label="IMMY_MaximumDepositCoverageLimits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_MaximumDepositCoverageLimits" xlink:to="IMMY_MaximumDepositCoverageLimits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_MaximumDepositCoverageLimits_lbl" xml:lang="en-US">Deposit coverage limits by FDIC, per owner</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromDepositsFromCustomers" xlink:label="us-gaap_ProceedsFromDepositsFromCustomers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDepositsFromCustomers" xlink:to="us-gaap_ProceedsFromDepositsFromCustomers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDepositsFromCustomers_lbl" xml:lang="en-US">Cash deposits in excess of FDIC limits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">furniture and equipment depreciated useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of long-lived assets</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CommonStockEquivalentsDilutiveInstruments" xlink:label="IMMY_CommonStockEquivalentsDilutiveInstruments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CommonStockEquivalentsDilutiveInstruments" xlink:to="IMMY_CommonStockEquivalentsDilutiveInstruments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_CommonStockEquivalentsDilutiveInstruments_lbl" xml:lang="en-US">Common stock equivalents, dilutive instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockIncludedInCommonStockEquivalents" xlink:label="IMMY_RestrictedStockIncludedInCommonStockEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RestrictedStockIncludedInCommonStockEquivalents" xlink:to="IMMY_RestrictedStockIncludedInCommonStockEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RestrictedStockIncludedInCommonStockEquivalents_lbl" xml:lang="en-US">Number of restricted stock included in common stock equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Numerator - net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Denominator - weighted average number of shares outstanding, basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2_lbl" xml:lang="en-US">Cash paid for business acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PaymentOfCashToContigent" xlink:label="IMMY_PaymentOfCashToContigent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PaymentOfCashToContigent" xlink:to="IMMY_PaymentOfCashToContigent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PaymentOfCashToContigent_lbl" xml:lang="en-US">Contingent cash payment</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExpectedRevenueDuringAcquisition" xlink:label="IMMY_ExpectedRevenueDuringAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExpectedRevenueDuringAcquisition" xlink:to="IMMY_ExpectedRevenueDuringAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ExpectedRevenueDuringAcquisition_lbl" xml:lang="en-US">Expected revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExpectedRevenueDate" xlink:label="IMMY_ExpectedRevenueDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExpectedRevenueDate" xlink:to="IMMY_ExpectedRevenueDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ExpectedRevenueDate_lbl" xml:lang="en-US">Expected revenue date</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfSharesAppliedForContigentStockPayment" xlink:label="IMMY_NumberOfSharesAppliedForContigentStockPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfSharesAppliedForContigentStockPayment" xlink:to="IMMY_NumberOfSharesAppliedForContigentStockPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_NumberOfSharesAppliedForContigentStockPayment_lbl" xml:lang="en-US">Maximum number of common stock applied for contingent stock payment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainContingencyDescription" xlink:label="us-gaap_GainContingencyDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingencyDescription" xlink:to="us-gaap_GainContingencyDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainContingencyDescription_lbl" xml:lang="en-US">Condition for contingent stock payment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Business acquisition, total fair value transferred</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill" xlink:label="IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill" xlink:to="IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill_lbl" xml:lang="en-US">Business combination purchase price allocation for good will</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xml:lang="en-US">Fair value of liability for estimated acquisition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3_lbl" xml:lang="en-US">Cash payment to the PC Sellers at closing</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ContingentCommonStockIssuanceToRelatedParty" xlink:label="IMMY_ContingentCommonStockIssuanceToRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ContingentCommonStockIssuanceToRelatedParty" xlink:to="IMMY_ContingentCommonStockIssuanceToRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ContingentCommonStockIssuanceToRelatedParty_lbl" xml:lang="en-US">Contingent common stock issuance to the PC Sellers</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ContingentCashConsiderationToRelatedParty" xlink:label="IMMY_ContingentCashConsiderationToRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ContingentCashConsiderationToRelatedParty" xlink:to="IMMY_ContingentCashConsiderationToRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ContingentCashConsiderationToRelatedParty_lbl" xml:lang="en-US">Contingent cash consideration to the PC Sellers</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_2_lbl" xml:lang="en-US">Total acquisition date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Total identifiable assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US">Total liabilities assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total identifiable assets less liabilities assumed</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Net assets acquired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US">Useful Life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RestrictedShortTermInvestmentDisclosureAbstract" xlink:to="IMMY_RestrictedShortTermInvestmentDisclosureAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="IMMY_RestrictedShortTermInvestmentDisclosureAbstract_2_lbl" xml:lang="en-US">Restricted Short-term Investment Details Narrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CertificatesOfDepositAtCarryingValue" xlink:label="us-gaap_CertificatesOfDepositAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositAtCarryingValue" xlink:to="us-gaap_CertificatesOfDepositAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertificatesOfDepositAtCarryingValue_lbl" xml:lang="en-US">Certificate of deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in progress</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Total inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PrepaidStockbasedConsultingExpenses" xlink:label="IMMY_PrepaidStockbasedConsultingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PrepaidStockbasedConsultingExpenses" xlink:to="IMMY_PrepaidStockbasedConsultingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PrepaidStockbasedConsultingExpenses_lbl" xml:lang="en-US">Prepaid stock-based consulting expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidRent_lbl" xml:lang="en-US">Prepaid rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses and deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xml:lang="en-US">Computer software and hardware</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_LabAndPharmacyEquipmentGross" xlink:label="IMMY_LabAndPharmacyEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_LabAndPharmacyEquipmentGross" xlink:to="IMMY_LabAndPharmacyEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_LabAndPharmacyEquipmentGross_lbl" xml:lang="en-US">Lab and pharmacy equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Furniture and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Furniture and equipment, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Amortization periods (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net Carrying value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2015</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Goodwill_2_lbl" xml:lang="en-US">Goodwill, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AcquisitionOfRelatedPartyGoodwill" xlink:label="IMMY_AcquisitionOfRelatedPartyGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AcquisitionOfRelatedPartyGoodwill" xlink:to="IMMY_AcquisitionOfRelatedPartyGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_AcquisitionOfRelatedPartyGoodwill_lbl" xml:lang="en-US">PC Acquisition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Goodwill_3_lbl" xml:lang="en-US">Goodwill, Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of office space</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PreviousOfficeSpaceArea" xlink:label="IMMY_PreviousOfficeSpaceArea" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PreviousOfficeSpaceArea" xlink:to="IMMY_PreviousOfficeSpaceArea_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PreviousOfficeSpaceArea_lbl" xml:lang="en-US">Area of previous office space</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RecognizedLeaseLossesRelatedToLeaseLiability" xlink:label="IMMY_RecognizedLeaseLossesRelatedToLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RecognizedLeaseLossesRelatedToLeaseLiability" xlink:to="IMMY_RecognizedLeaseLossesRelatedToLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RecognizedLeaseLossesRelatedToLeaseLiability_lbl" xml:lang="en-US">Recognized lease losses related to estimated remaining lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Stock based compensation accrual</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Stock-based compensation expense related to restricted common stock issuances and accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_BuildingLeaseLiability" xlink:label="IMMY_BuildingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_BuildingLeaseLiability" xlink:to="IMMY_BuildingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_BuildingLeaseLiability_lbl" xml:lang="en-US">Building lease liability(1)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Total accounts payable and accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Less: Current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Non-current total accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of credits borrowing limit maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Borrowed term loan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="us-gaap_CapitalUnitsAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xml:lang="en-US">Capital stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed" xlink:label="IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed" xlink:to="IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed_lbl" xml:lang="en-US">Number of underwritten public offering common stock shares closed</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="us-gaap_EquityIssuancePerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityIssuancePerShareAmount" xlink:to="us-gaap_EquityIssuancePerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityIssuancePerShareAmount_lbl" xml:lang="en-US">Common stock price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from public offerings</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters" xlink:label="IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters" xlink:to="IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters_lbl" xml:lang="en-US">Additional shares purchased by underwriters</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Net cash proceeds from the exercise of the over-allotment option</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters" xlink:label="IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters" xlink:to="IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters_lbl" xml:lang="en-US">Stock issued during period value issued to underwriters</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_UnderwritingAgreementDescription" xlink:label="IMMY_UnderwritingAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_UnderwritingAgreementDescription" xlink:to="IMMY_UnderwritingAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_UnderwritingAgreementDescription_lbl" xml:lang="en-US">Underwriting agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xml:lang="en-US">Payment made on cancellation of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xml:lang="en-US">Payment made on cancellation of common stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Number of shares issued for related party vesting of RSUs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Common stock shares issued for services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_2_lbl" xml:lang="en-US">Common stock issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares" xlink:label="IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares" xlink:to="IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares_lbl" xml:lang="en-US">Common stock issued settle cashless exercise provision, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued shares value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Shares issued upon exercise of stock options, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xml:lang="en-US">Shares issued upon exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne" xlink:label="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne" xlink:to="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne_lbl" xml:lang="en-US">Additional shares issued upon exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Stock option purchase of exercise price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock" xlink:label="IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock" xlink:to="IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock_lbl" xml:lang="en-US">Exercise of common stock option to purchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CommonStockExercisePricePerShare" xlink:label="IMMY_CommonStockExercisePricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CommonStockExercisePricePerShare" xlink:to="IMMY_CommonStockExercisePricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_CommonStockExercisePricePerShare_lbl" xml:lang="en-US">Common stock exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfCommonStockHeldForPayrollTax" xlink:label="IMMY_NumberOfCommonStockHeldForPayrollTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfCommonStockHeldForPayrollTax" xlink:to="IMMY_NumberOfCommonStockHeldForPayrollTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_NumberOfCommonStockHeldForPayrollTax_lbl" xml:lang="en-US">Number of common stock held for payroll tax</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Shares issued upon warrants exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised" xlink:label="IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised" xlink:to="IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised_lbl" xml:lang="en-US">Shares issued upon exercise of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock" xlink:label="IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock" xlink:to="IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock_lbl" xml:lang="en-US">Warrants and shares issued upon excise of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare" xlink:label="IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare" xlink:to="IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare_lbl" xml:lang="en-US">Warrants to purchase common stock exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from issuance of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfWarrantsCommonStockIssued" xlink:label="IMMY_NumberOfWarrantsCommonStockIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfWarrantsCommonStockIssued" xlink:to="IMMY_NumberOfWarrantsCommonStockIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_NumberOfWarrantsCommonStockIssued_lbl" xml:lang="en-US">Number of warrants shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExerciseOfWarrantToPurchaseOfCommonStock" xlink:label="IMMY_ExerciseOfWarrantToPurchaseOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExerciseOfWarrantToPurchaseOfCommonStock" xlink:to="IMMY_ExerciseOfWarrantToPurchaseOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ExerciseOfWarrantToPurchaseOfCommonStock_lbl" xml:lang="en-US">Exercise of warrant to purchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsSharesExercisePricePerShare" xlink:label="IMMY_WarrantsSharesExercisePricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsSharesExercisePricePerShare" xlink:to="IMMY_WarrantsSharesExercisePricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_WarrantsSharesExercisePricePerShare_lbl" xml:lang="en-US">Warrants shares exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Maximum number of common stock issuance under the plan</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfFutureIssuancesShareUnderPlan" xlink:label="IMMY_NumberOfFutureIssuancesShareUnderPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfFutureIssuancesShareUnderPlan" xlink:to="IMMY_NumberOfFutureIssuancesShareUnderPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_NumberOfFutureIssuancesShareUnderPlan_lbl" xml:lang="en-US">Number of future issuances share under the plan</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_OptionsExercisePrice" xlink:label="IMMY_OptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_OptionsExercisePrice" xlink:to="IMMY_OptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_OptionsExercisePrice_lbl" xml:lang="en-US">Stock option exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value of stock options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:to="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Contractual term of stock options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockOptionsGrantedVestingTermsDescription" xlink:label="IMMY_StockOptionsGrantedVestingTermsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockOptionsGrantedVestingTermsDescription" xlink:to="IMMY_StockOptionsGrantedVestingTermsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StockOptionsGrantedVestingTermsDescription_lbl" xml:lang="en-US">Stock options granted vesting terms</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfForfeitureFactor" xlink:label="IMMY_PercentageOfForfeitureFactor" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfForfeitureFactor" xlink:to="IMMY_PercentageOfForfeitureFactor_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PercentageOfForfeitureFactor_lbl" xml:lang="en-US">Percentage of forfeiture factor</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation expense related to unvested stock options granted under the Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Expense expected to recognize over the weighted-average remaining vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Restricted stock units issued</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockVestInFuture" xlink:label="IMMY_RestrictedStockVestInFuture" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RestrictedStockVestInFuture" xlink:to="IMMY_RestrictedStockVestInFuture_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RestrictedStockVestInFuture_lbl" xml:lang="en-US">Restricted stock vest in future</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_TargetRangingPrice" xlink:label="IMMY_TargetRangingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_TargetRangingPrice" xlink:to="IMMY_TargetRangingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_TargetRangingPrice_lbl" xml:lang="en-US">Target ranging price</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockVestedImmediately" xlink:label="IMMY_RestrictedStockVestedImmediately" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RestrictedStockVestedImmediately" xlink:to="IMMY_RestrictedStockVestedImmediately_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RestrictedStockVestedImmediately_lbl" xml:lang="en-US">Restricted stock vested immediately</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson" xlink:label="IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson" xlink:to="IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson_lbl" xml:lang="en-US">Granted restricted stock units per person</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US">Granted restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CancellationOfRestrictedStockUnitsDuringPeriod" xlink:label="IMMY_CancellationOfRestrictedStockUnitsDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CancellationOfRestrictedStockUnitsDuringPeriod" xlink:to="IMMY_CancellationOfRestrictedStockUnitsDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_CancellationOfRestrictedStockUnitsDuringPeriod_lbl" xml:lang="en-US">Number of granted restricted stock units unvested agreed to cancel</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:to="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings_lbl" xml:lang="en-US">Fair value of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares" xlink:label="IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares" xlink:to="IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares_lbl" xml:lang="en-US">Fair value of canceled restricted stock units plus incremental cost, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Issuance of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Fair value assumptions, life term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Fair value assumptions, volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Fair value assumptions, risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_InitialFairValueOfRestrictedStockUnitsShares" xlink:label="IMMY_InitialFairValueOfRestrictedStockUnitsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_InitialFairValueOfRestrictedStockUnitsShares" xlink:to="IMMY_InitialFairValueOfRestrictedStockUnitsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_InitialFairValueOfRestrictedStockUnitsShares_lbl" xml:lang="en-US">Initial fair value of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfRestrictedStockUnitsVested" xlink:label="IMMY_PercentageOfRestrictedStockUnitsVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfRestrictedStockUnitsVested" xlink:to="IMMY_PercentageOfRestrictedStockUnitsVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PercentageOfRestrictedStockUnitsVested_lbl" xml:lang="en-US">Percentage of restricted stock units vested</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfRemainingRestrictedStockUnitsVested" xlink:label="IMMY_PercentageOfRemainingRestrictedStockUnitsVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfRemainingRestrictedStockUnitsVested" xlink:to="IMMY_PercentageOfRemainingRestrictedStockUnitsVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PercentageOfRemainingRestrictedStockUnitsVested_lbl" xml:lang="en-US">Percentage of remaining restricted stock units vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Fair value assumption of volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Fair value assumption of volatility, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Fair value assumption of risk free interest rates, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Fair value assumption of risk free interest rates, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">Issuance of restricted stock units were forfeited and deemed, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Restricted stock units vest period</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfDirectorResignedAndForfeited" xlink:label="IMMY_NumberOfDirectorResignedAndForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfDirectorResignedAndForfeited" xlink:to="IMMY_NumberOfDirectorResignedAndForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_NumberOfDirectorResignedAndForfeited_lbl" xml:lang="en-US">Number of director resigned and forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrant issued to purchase number of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsExercisePricePerShare" xlink:label="IMMY_WarrantsExercisePricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsExercisePricePerShare" xlink:to="IMMY_WarrantsExercisePricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_WarrantsExercisePricePerShare_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsExpiredDuration" xlink:label="IMMY_WarrantsExpiredDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsExpiredDuration" xlink:to="IMMY_WarrantsExpiredDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_WarrantsExpiredDuration_lbl" xml:lang="en-US">Warrants expire</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfWarrantsVestedImmeditely" xlink:label="IMMY_NumberOfWarrantsVestedImmeditely" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfWarrantsVestedImmeditely" xlink:to="IMMY_NumberOfWarrantsVestedImmeditely_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_NumberOfWarrantsVestedImmeditely_lbl" xml:lang="en-US">Number of warrants vested immeditely</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfSharesVestedInInstallments" xlink:label="IMMY_NumberOfSharesVestedInInstallments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfSharesVestedInInstallments" xlink:to="IMMY_NumberOfSharesVestedInInstallments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_NumberOfSharesVestedInInstallments_lbl" xml:lang="en-US">Number of shares vested in installments for each five months</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FairValueOfWarrants" xlink:label="IMMY_FairValueOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_FairValueOfWarrants" xlink:to="IMMY_FairValueOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_FairValueOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2_lbl" xml:lang="en-US">Stock based compensation of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares, Options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Number of shares, Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares, Options cancelled/forfeit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number of shares, Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of shares, Options vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Outstanding, Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Options cancelled/forfeit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Exercisable Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Vested and expected to vest - end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Avg. Remaining Contractual Life, Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Avg. Remaining Contractual Life, Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Avg. Remaining Contractual Life, Options vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Options vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average fair value of options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Expected terms (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2_lbl" xml:lang="en-US">Expected volatility, minimum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2_lbl" xml:lang="en-US">Expected volatility, maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of Exercise Prices, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of Exercise Prices, maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of Options Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberExercisable" xlink:label="IMMY_NumberExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberExercisable" xlink:to="IMMY_NumberExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_NumberExercisable_lbl" xml:lang="en-US">Number Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2" xlink:label="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2" xlink:to="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2_lbl" xml:lang="en-US">Weighted Average Exercisable Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted" xlink:label="IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted" xlink:to="IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted_lbl" xml:lang="en-US">Percentage of Number of Shares Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfSharesTiedToTarget" xlink:label="IMMY_NumberOfSharesTiedToTarget" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfSharesTiedToTarget" xlink:to="IMMY_NumberOfSharesTiedToTarget_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_NumberOfSharesTiedToTarget_lbl" xml:lang="en-US">Number of Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_TargetSharePriceRelatedToRestrictedStockGrant" xlink:label="IMMY_TargetSharePriceRelatedToRestrictedStockGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_TargetSharePriceRelatedToRestrictedStockGrant" xlink:to="IMMY_TargetSharePriceRelatedToRestrictedStockGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_TargetSharePriceRelatedToRestrictedStockGrant_lbl" xml:lang="en-US">Target Share Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of RSUs, Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of RSUs granted</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:to="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_lbl" xml:lang="en-US">Number of RSUs vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of RSUs cancelled/forfeit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of RSUs, Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, RSUs granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, RSUs vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, RSUs cancelled/forfeit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Shares Subject to Warrants Outstanding, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Shares Subject to Warrants Outstanding, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of Shares Subject to Warrants Outstanding, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life Of The Outstanding Warrants In Years</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Avg. Exercise Price, Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuanceDate" xlink:label="IMMY_WarrantsIssuanceDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsIssuanceDate" xlink:to="IMMY_WarrantsIssuanceDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_WarrantsIssuanceDate_lbl" xml:lang="en-US">Issue Date</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:to="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_lbl" xml:lang="en-US">Warrants Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:to="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:label="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:to="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_lbl" xml:lang="en-US">Warrants Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsExpirationDate" xlink:label="IMMY_WarrantsExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsExpirationDate" xlink:to="IMMY_WarrantsExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_WarrantsExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock based compensation related to equity instruments granted to related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Deferred tax asset valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FederalNetOperatingLossExpirationDate" xlink:label="IMMY_FederalNetOperatingLossExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_FederalNetOperatingLossExpirationDate" xlink:to="IMMY_FederalNetOperatingLossExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_FederalNetOperatingLossExpirationDate_lbl" xml:lang="en-US">Federal net operating loss expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FederalResearchAndDevelopmentTaxCredits" xlink:label="IMMY_FederalResearchAndDevelopmentTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_FederalResearchAndDevelopmentTaxCredits" xlink:to="IMMY_FederalResearchAndDevelopmentTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_FederalResearchAndDevelopmentTaxCredits_lbl" xml:lang="en-US">Federal research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FederalResearchAndDevelopmentTaxCreditsExpirationDate" xlink:label="IMMY_FederalResearchAndDevelopmentTaxCreditsExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_FederalResearchAndDevelopmentTaxCreditsExpirationDate" xlink:to="IMMY_FederalResearchAndDevelopmentTaxCreditsExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_FederalResearchAndDevelopmentTaxCreditsExpirationDate_lbl" xml:lang="en-US">Federal research and development tax credits expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StateNetOperatingLossExpirationDate" xlink:label="IMMY_StateNetOperatingLossExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StateNetOperatingLossExpirationDate" xlink:to="IMMY_StateNetOperatingLossExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StateNetOperatingLossExpirationDate_lbl" xml:lang="en-US">State net operating loss expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StateResearchAndDevelopmentTaxCredits" xlink:label="IMMY_StateResearchAndDevelopmentTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StateResearchAndDevelopmentTaxCredits" xlink:to="IMMY_StateResearchAndDevelopmentTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_StateResearchAndDevelopmentTaxCredits_lbl" xml:lang="en-US">State research and development tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossCurrent" xlink:to="us-gaap_DeferredTaxAssetsGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossCurrent_lbl" xml:lang="en-US">Deferrerd tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther_lbl" xml:lang="en-US">Deferrerd tax asset excess tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DeferredIncomeChangeInValuationAllowance" xlink:label="IMMY_DeferredIncomeChangeInValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_DeferredIncomeChangeInValuationAllowance" xlink:to="IMMY_DeferredIncomeChangeInValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_DeferredIncomeChangeInValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision (benefit)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets" xlink:label="IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets" xlink:to="IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets_lbl" xml:lang="en-US">Benefit of lower tax brackets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax benefit, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Research and development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl" xml:lang="en-US">Employee stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EffectiveIncomeTaxRateLossOnDebtConversion" xlink:label="IMMY_EffectiveIncomeTaxRateLossOnDebtConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_EffectiveIncomeTaxRateLossOnDebtConversion" xlink:to="IMMY_EffectiveIncomeTaxRateLossOnDebtConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_EffectiveIncomeTaxRateLossOnDebtConversion_lbl" xml:lang="en-US">Loss on debt conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:label="IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:to="IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_lbl" xml:lang="en-US">NOL's</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" xlink:label="IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" xlink:to="IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research &amp; development credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Deferred stock compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross_lbl" xml:lang="en-US">Unrealized gain or loss on investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" xlink:label="IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" xlink:to="IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount_lbl" xml:lang="en-US">Percentage of salary deposits in tax deferred investment account</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DefinedBenefitPlanContributionsByEmployerPercentage" xlink:label="IMMY_DefinedBenefitPlanContributionsByEmployerPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_DefinedBenefitPlanContributionsByEmployerPercentage" xlink:to="IMMY_DefinedBenefitPlanContributionsByEmployerPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_DefinedBenefitPlanContributionsByEmployerPercentage_lbl" xml:lang="en-US">Percentage of contributions made by the company</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US">Contributions by the company</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate" xlink:label="IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate" xlink:to="IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate_lbl" xml:lang="en-US">Leases equipment under capital lease with interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" xlink:label="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" xlink:to="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Equipment under capital leases net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:to="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation_lbl" xml:lang="en-US">Related accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AreaOfLand_2_lbl" xml:lang="en-US">Lease agreement for office space (Square feet)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Operating lease Expiry</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Operating lease, monthly rental</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate" xlink:label="us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate" xlink:to="us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate_lbl" xml:lang="en-US">Operating lease, rent increase percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_LicenseAgreementCommitmentsDescription" xlink:label="IMMY_LicenseAgreementCommitmentsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_LicenseAgreementCommitmentsDescription" xlink:to="IMMY_LicenseAgreementCommitmentsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_LicenseAgreementCommitmentsDescription_lbl" xml:lang="en-US">License agreement commitments description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Minimum royalties to be paid each calendar year</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ValueOfProductDevelopmentInvestment" xlink:label="IMMY_ValueOfProductDevelopmentInvestment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ValueOfProductDevelopmentInvestment" xlink:to="IMMY_ValueOfProductDevelopmentInvestment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ValueOfProductDevelopmentInvestment_lbl" xml:lang="en-US">Value of product development investment</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RoyaltiesRangePercentage" xlink:label="IMMY_RoyaltiesRangePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RoyaltiesRangePercentage" xlink:to="IMMY_RoyaltiesRangePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_RoyaltiesRangePercentage_lbl" xml:lang="en-US">Royalties range percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AggregateValueOfCashFees" xlink:label="IMMY_AggregateValueOfCashFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AggregateValueOfCashFees" xlink:to="IMMY_AggregateValueOfCashFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_AggregateValueOfCashFees_lbl" xml:lang="en-US">Maximum aggregate value of cash fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2015</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xml:lang="en-US">Less amount representing interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_lbl" xml:lang="en-US">Present value of future minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_2_lbl" xml:lang="en-US">Less current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_2_lbl" xml:lang="en-US">Capital lease obligation, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_lbl" xml:lang="en-US">2015</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Maximum percentage of sales derived from single customer</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfDrugAndChemicalPurchases" xlink:label="IMMY_PercentageOfDrugAndChemicalPurchases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfDrugAndChemicalPurchases" xlink:to="IMMY_PercentageOfDrugAndChemicalPurchases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PercentageOfDrugAndChemicalPurchases_lbl" xml:lang="en-US">Percentage of drug and chemical purchases from three main suppliers</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AgreementAxis" xlink:to="IMMY_AgreementAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="IMMY_AgreementAxis_2_lbl" xml:lang="en-US">Consultant Tranche 1 [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised_2_lbl" xml:lang="en-US">Shares issued upon exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants shares exercise price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Stock issued during period resticted common stock issued, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForPreviousAcquisition" xlink:label="us-gaap_PaymentsForPreviousAcquisition" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPreviousAcquisition" xlink:to="us-gaap_PaymentsForPreviousAcquisition_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForPreviousAcquisition_lbl" xml:lang="en-US">Aggregate cash purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock issued shares</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AverageClosingPriceOfCommonStock" xlink:label="IMMY_AverageClosingPriceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AverageClosingPriceOfCommonStock" xlink:to="IMMY_AverageClosingPriceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_AverageClosingPriceOfCommonStock_lbl" xml:lang="en-US">Common stock value based on average closing price</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_QuarterlyCashPayments" xlink:label="IMMY_QuarterlyCashPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_QuarterlyCashPayments" xlink:to="IMMY_QuarterlyCashPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_QuarterlyCashPayments_lbl" xml:lang="en-US">Quarterly cash payments for acquisition</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AmountOfClosingPrice" xlink:label="IMMY_AmountOfClosingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AmountOfClosingPrice" xlink:to="IMMY_AmountOfClosingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_AmountOfClosingPrice_lbl" xml:lang="en-US">Amount of closing price, total</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AggregatedAmountOfClosingPrice" xlink:label="IMMY_AggregatedAmountOfClosingPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AggregatedAmountOfClosingPrice" xlink:to="IMMY_AggregatedAmountOfClosingPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_AggregatedAmountOfClosingPrice_lbl" xml:lang="en-US">Aggregated amount of closing price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of common stock for each payment</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AreaOfSquareFeet" xlink:label="IMMY_AreaOfSquareFeet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AreaOfSquareFeet" xlink:to="IMMY_AreaOfSquareFeet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_AreaOfSquareFeet_lbl" xml:lang="en-US">Number of square feets of lab and office</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsForRent_2_lbl" xml:lang="en-US">Rent amount</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfAnnualRentIncreases" xlink:label="IMMY_PercentageOfAnnualRentIncreases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfAnnualRentIncreases" xlink:to="IMMY_PercentageOfAnnualRentIncreases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PercentageOfAnnualRentIncreases_lbl" xml:lang="en-US">Percentage of annual rent increases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseExpirationDate1_2_lbl" xml:lang="en-US">Expiration of lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EmploymentAgreementTerm" xlink:label="IMMY_EmploymentAgreementTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_EmploymentAgreementTerm" xlink:to="IMMY_EmploymentAgreementTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_EmploymentAgreementTerm_lbl" xml:lang="en-US">Employment agreement term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Annual base salary</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfCurrentAnnualSalary" xlink:label="IMMY_PercentageOfCurrentAnnualSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfCurrentAnnualSalary" xlink:to="IMMY_PercentageOfCurrentAnnualSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PercentageOfCurrentAnnualSalary_lbl" xml:lang="en-US">Percentage of current annual salary</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfIncreasesCurrentAnnualSalary" xlink:label="IMMY_PercentageOfIncreasesCurrentAnnualSalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfIncreasesCurrentAnnualSalary" xlink:to="IMMY_PercentageOfIncreasesCurrentAnnualSalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_PercentageOfIncreasesCurrentAnnualSalary_lbl" xml:lang="en-US">Percentage of target current annual salary</link:label>
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_TermOfStockOption" xlink:label="IMMY_TermOfStockOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_TermOfStockOption" xlink:to="IMMY_TermOfStockOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_TermOfStockOption_lbl" xml:lang="en-US">Term of stock option</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AcquisitionOfRelatedPartyGoodwill" xlink:to="IMMY_AcquisitionOfRelatedPartyGoodwill_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_AcquisitionOfRelatedPartyGoodwill_doc" xml:lang="en-US">Acquisition Of Related Party Goodwill.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AggregateValueOfCashFees" xlink:to="IMMY_AggregateValueOfCashFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_AggregateValueOfCashFees_doc" xml:lang="en-US">Aggregate Value Of Cash Fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AggregatedAmountOfClosingPrice" xlink:to="IMMY_AggregatedAmountOfClosingPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_AggregatedAmountOfClosingPrice_doc" xml:lang="en-US">Aggregated Amount Of Closing Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AgreementAxis" xlink:to="IMMY_AgreementAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_AgreementAxis_doc" xml:lang="en-US">Agreement [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AmountOfClosingPrice" xlink:to="IMMY_AmountOfClosingPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_AmountOfClosingPrice_doc" xml:lang="en-US">Amount Of Closing Price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AndrewRBollsMember" xlink:to="IMMY_AndrewRBollsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_AndrewRBollsMember_doc" xml:lang="en-US">Andrew .R Bolls [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AreaOfSquareFeet" xlink:to="IMMY_AreaOfSquareFeet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_AreaOfSquareFeet_doc" xml:lang="en-US">Area Of Square Feet.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_AverageClosingPriceOfCommonStock" xlink:to="IMMY_AverageClosingPriceOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_AverageClosingPriceOfCommonStock_doc" xml:lang="en-US">Average Closing Price Of Common Stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_BaumPerformanceEquityAwardMember" xlink:to="IMMY_BaumPerformanceEquityAwardMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_BaumPerformanceEquityAwardMember_doc" xml:lang="en-US">Baum Performance Equity Award [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_BuildingLeaseLiability" xlink:to="IMMY_BuildingLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_BuildingLeaseLiability_doc" xml:lang="en-US">Building Lease Liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities" xlink:to="IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities_doc" xml:lang="en-US">Business Acquisition Contingent Acquired Obligations Liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill" xlink:to="IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill_doc" xml:lang="en-US">Business Acquisition Purchase Price Allocation Goodwill.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CCOEmploymentAgreementMember" xlink:to="IMMY_CCOEmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_CCOEmploymentAgreementMember_doc" xml:lang="en-US">CCO Employment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CFOEmploymentAgreementMember" xlink:to="IMMY_CFOEmploymentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_CFOEmploymentAgreementMember_doc" xml:lang="en-US">CFO Employment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CancellationOfRestrictedStockUnitsDuringPeriod" xlink:to="IMMY_CancellationOfRestrictedStockUnitsDuringPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_CancellationOfRestrictedStockUnitsDuringPeriod_doc" xml:lang="en-US">Cancellation Of Restricted Stock Units During Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CancelledCommonStockPricePerShare" xlink:to="IMMY_CancelledCommonStockPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_CancelledCommonStockPricePerShare_doc" xml:lang="en-US">Cancelled Common Stock Price Per Share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares" xlink:to="IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares_doc" xml:lang="en-US">Cancelled Common Stock Shares Related To Reverse Stock Split February 2013 Shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013" xlink:to="IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013_doc" xml:lang="en-US">Cancelled Common Stock Shares Related To Reverse Stock Split February 2013.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CommonStockEquivalentsDilutiveInstruments" xlink:to="IMMY_CommonStockEquivalentsDilutiveInstruments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_CommonStockEquivalentsDilutiveInstruments_doc" xml:lang="en-US">Common Stock Equivalents Dilutive Instruments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CommonStockExercisePricePerShare" xlink:to="IMMY_CommonStockExercisePricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_CommonStockExercisePricePerShare_doc" xml:lang="en-US">Common stock exercise price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares" xlink:to="IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares_doc" xml:lang="en-US">Common stock issued settle cash less exercise provision shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ConsultantMember" xlink:to="IMMY_ConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ConsultantMember_doc" xml:lang="en-US">Consultant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ConsultantTrancheFiveMember" xlink:to="IMMY_ConsultantTrancheFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ConsultantTrancheFiveMember_doc" xml:lang="en-US">Consultant Tranche Five [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ConsultantTrancheFourMember" xlink:to="IMMY_ConsultantTrancheFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ConsultantTrancheFourMember_doc" xml:lang="en-US">Consultant Tranche Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ConsultantTrancheOneMember" xlink:to="IMMY_ConsultantTrancheOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ConsultantTrancheOneMember_doc" xml:lang="en-US">Consultant Tranche One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ConsultantTrancheThreeMember" xlink:to="IMMY_ConsultantTrancheThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ConsultantTrancheThreeMember_doc" xml:lang="en-US">Consultant Tranche Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ConsultantTrancheTwoMember" xlink:to="IMMY_ConsultantTrancheTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ConsultantTrancheTwoMember_doc" xml:lang="en-US">Consultant Tranche Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ContingentCashConsiderationToRelatedParty" xlink:to="IMMY_ContingentCashConsiderationToRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ContingentCashConsiderationToRelatedParty_doc" xml:lang="en-US">Contingent cash consideration to the relatedparty.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ContingentCommonStockIssuanceToRelatedParty" xlink:to="IMMY_ContingentCommonStockIssuanceToRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ContingentCommonStockIssuanceToRelatedParty_doc" xml:lang="en-US">Contingent common stock issuance to the Sellers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_DeferredIncomeChangeInValuationAllowance" xlink:to="IMMY_DeferredIncomeChangeInValuationAllowance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_DeferredIncomeChangeInValuationAllowance_doc" xml:lang="en-US">Deferred Income Change In Valuation Allowance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" xlink:to="IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization_doc" xml:lang="en-US">Deferred Tax Asset Tax Credit carry Forwards Depreciation And Amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:to="IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards_doc" xml:lang="en-US">Deferred Tax Assets Tax Acquired Net Operating Loss And Credit Carry Forwards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_DefinedBenefitPlanContributionsByEmployerPercentage" xlink:to="IMMY_DefinedBenefitPlanContributionsByEmployerPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_DefinedBenefitPlanContributionsByEmployerPercentage_doc" xml:lang="en-US">Percentage of contributions made by the company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_DrRobertKammerMember" xlink:to="IMMY_DrRobertKammerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_DrRobertKammerMember_doc" xml:lang="en-US">Dr Robert Kammer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets" xlink:to="IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets_doc" xml:lang="en-US">Effecticve Income Tax Rate Benefit Of Lower Tax Brackets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_EffectiveIncomeTaxRateLossOnDebtConversion" xlink:to="IMMY_EffectiveIncomeTaxRateLossOnDebtConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_EffectiveIncomeTaxRateLossOnDebtConversion_doc" xml:lang="en-US">Effective Income Tax Rate Loss On Debt Conversion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_EmployeesAndDirectorsMember" xlink:to="IMMY_EmployeesAndDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_EmployeesAndDirectorsMember_doc" xml:lang="en-US">Employees And Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_EmployeesMember" xlink:to="IMMY_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_EmployeesMember_doc" xml:lang="en-US">Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_EmploymentAgreementTerm" xlink:to="IMMY_EmploymentAgreementTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_EmploymentAgreementTerm_doc" xml:lang="en-US">Employment Agreement Term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExecutiveRestrictedStockUnitsTranche4Member" xlink:to="IMMY_ExecutiveRestrictedStockUnitsTranche4Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTranche4Member_doc" xml:lang="en-US">Tranche 4 CEO</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExecutiveRestrictedStockUnitsTranche5Member" xlink:to="IMMY_ExecutiveRestrictedStockUnitsTranche5Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTranche5Member_doc" xml:lang="en-US">Tranche 5 CEO</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember" xlink:to="IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember_doc" xml:lang="en-US">Executive Restricted Stock Units Tranche One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember" xlink:to="IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember_doc" xml:lang="en-US">Executive Restricted Stock Units Tranche Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember" xlink:to="IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember_doc" xml:lang="en-US">Executive Restricted Stock Units Tranche Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock" xlink:to="IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock_doc" xml:lang="en-US">Exercise of common stock option to purchase of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExerciseOfWarrantToPurchaseOfCommonStock" xlink:to="IMMY_ExerciseOfWarrantToPurchaseOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ExerciseOfWarrantToPurchaseOfCommonStock_doc" xml:lang="en-US">Exercise of warrant to purchase of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExpectedRevenueDate" xlink:to="IMMY_ExpectedRevenueDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ExpectedRevenueDate_doc" xml:lang="en-US">Expected revenue date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ExpectedRevenueDuringAcquisition" xlink:to="IMMY_ExpectedRevenueDuringAcquisition_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ExpectedRevenueDuringAcquisition_doc" xml:lang="en-US">Expected revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares" xlink:to="IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares_doc" xml:lang="en-US">Fair value of canceled restricted stock units plus incremental cost shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_FairValueOfWarrants" xlink:to="IMMY_FairValueOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_FairValueOfWarrants_doc" xml:lang="en-US">Fair Value Of Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_FederalNetOperatingLossExpirationDate" xlink:to="IMMY_FederalNetOperatingLossExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_FederalNetOperatingLossExpirationDate_doc" xml:lang="en-US">Federal net operating loss expiration date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_FederalResearchAndDevelopmentTaxCredits" xlink:to="IMMY_FederalResearchAndDevelopmentTaxCredits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_FederalResearchAndDevelopmentTaxCredits_doc" xml:lang="en-US">Federal Research And Development Tax Credits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_FederalResearchAndDevelopmentTaxCreditsExpirationDate" xlink:to="IMMY_FederalResearchAndDevelopmentTaxCreditsExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_FederalResearchAndDevelopmentTaxCreditsExpirationDate_doc" xml:lang="en-US">Federal Research And Development Tax Credits Expiration Date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_FormerDirectorsMember" xlink:to="IMMY_FormerDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_FormerDirectorsMember_doc" xml:lang="en-US">Former Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_GeneralAndAdministrativeMember" xlink:to="IMMY_GeneralAndAdministrativeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_GeneralAndAdministrativeMember_doc" xml:lang="en-US">General And Administrative [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_InitialFairValueOfRestrictedStockUnitsShares" xlink:to="IMMY_InitialFairValueOfRestrictedStockUnitsShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_InitialFairValueOfRestrictedStockUnitsShares_doc" xml:lang="en-US">Initial fair value of restricted stock units shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees" xlink:to="IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees_doc" xml:lang="en-US">Issuance Of And Adjustment To Common Stock And Warrants To Consulting Firms For Prepaid Consulting Fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne" xlink:to="IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne_doc" xml:lang="en-US">Issuance Of Common Stock And Stock Options Shares Related To Consulting Agreements Shares One.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne" xlink:to="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne_doc" xml:lang="en-US">Issuance Of Common Stock And Stock Options Value Related To Consulting Agreements One.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare" xlink:to="IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare_doc" xml:lang="en-US">Issuance of common stock for public offering price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" xlink:to="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding_doc" xml:lang="en-US">Issuance Of Common Stock Upon Vesting Of Rsus Net Of Tax Withholding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" xlink:to="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares_doc" xml:lang="en-US">Issuance Of Common Stock Upon Vesting Of Rsus Net Of Tax Withholding Shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_IssuanceOfCommonStockUponVestingOfRsusShares" xlink:to="IMMY_IssuanceOfCommonStockUponVestingOfRsusShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_IssuanceOfCommonStockUponVestingOfRsusShares_doc" xml:lang="en-US">Issuance Of Common Stock Upon Vesting Of Rsus Shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_JohnPSaharekMember" xlink:to="IMMY_JohnPSaharekMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_JohnPSaharekMember_doc" xml:lang="en-US">John .P Saharek [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_LabAndPharmacyEquipmentGross" xlink:to="IMMY_LabAndPharmacyEquipmentGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_LabAndPharmacyEquipmentGross_doc" xml:lang="en-US">Lab And Pharmacy Equipment Gross.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_LeaseAgreementMember" xlink:to="IMMY_LeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_LeaseAgreementMember_doc" xml:lang="en-US">Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate" xlink:to="IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate_doc" xml:lang="en-US">Leases Equipment Under Capital Lease With Interest Rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_LicenseAgreementCommitmentsDescription" xlink:to="IMMY_LicenseAgreementCommitmentsDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_LicenseAgreementCommitmentsDescription_doc" xml:lang="en-US">License agreement commitments description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_MarkBaumMember" xlink:to="IMMY_MarkBaumMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_MarkBaumMember_doc" xml:lang="en-US">Mark Baum [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_MaximumDepositCoverageLimits" xlink:to="IMMY_MaximumDepositCoverageLimits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_MaximumDepositCoverageLimits_doc" xml:lang="en-US">Maximum deposit coverage limits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_MonteCarloSimulationMember" xlink:to="IMMY_MonteCarloSimulationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_MonteCarloSimulationMember_doc" xml:lang="en-US">Monte Carlo Simulation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_MonteCarloSimulationOneMember" xlink:to="IMMY_MonteCarloSimulationOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_MonteCarloSimulationOneMember_doc" xml:lang="en-US">Monte Carlo Simulation One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NonEmployeeDirectorsMember" xlink:to="IMMY_NonEmployeeDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_NonEmployeeDirectorsMember_doc" xml:lang="en-US">Non Employee Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberExercisable" xlink:to="IMMY_NumberExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_NumberExercisable_doc" xml:lang="en-US">Number Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfCommonStockHeldForPayrollTax" xlink:to="IMMY_NumberOfCommonStockHeldForPayrollTax_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_NumberOfCommonStockHeldForPayrollTax_doc" xml:lang="en-US">Number of common stock held for payroll tax.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfDirectorResignedAndForfeited" xlink:to="IMMY_NumberOfDirectorResignedAndForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_NumberOfDirectorResignedAndForfeited_doc" xml:lang="en-US">Number of director resigned and forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfFutureIssuancesShareUnderPlan" xlink:to="IMMY_NumberOfFutureIssuancesShareUnderPlan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_NumberOfFutureIssuancesShareUnderPlan_doc" xml:lang="en-US">Number of future issuances share under the plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfSharesAppliedForContigentStockPayment" xlink:to="IMMY_NumberOfSharesAppliedForContigentStockPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_NumberOfSharesAppliedForContigentStockPayment_doc" xml:lang="en-US">Number Of Shares Applied For Contigent Stock Payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfSharesTiedToTarget" xlink:to="IMMY_NumberOfSharesTiedToTarget_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_NumberOfSharesTiedToTarget_doc" xml:lang="en-US">Number Of Shares Tied To Target.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfSharesVestedInInstallments" xlink:to="IMMY_NumberOfSharesVestedInInstallments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_NumberOfSharesVestedInInstallments_doc" xml:lang="en-US">Number of Shares Vested in Installments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed" xlink:to="IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed_doc" xml:lang="en-US">Number of underwritten public offering common stock shares closed.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfWarrantsCommonStockIssued" xlink:to="IMMY_NumberOfWarrantsCommonStockIssued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_NumberOfWarrantsCommonStockIssued_doc" xml:lang="en-US">Number of warrants shares issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NumberOfWarrantsVestedImmeditely" xlink:to="IMMY_NumberOfWarrantsVestedImmeditely_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_NumberOfWarrantsVestedImmeditely_doc" xml:lang="en-US">Number of warrants vested immeditely.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_OptionsEmployeesMember" xlink:to="IMMY_OptionsEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_OptionsEmployeesMember_doc" xml:lang="en-US">Options granted to employees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_OptionsExercisePrice" xlink:to="IMMY_OptionsExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_OptionsExercisePrice_doc" xml:lang="en-US">Options exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_OptionsGrantedConsultantsMember" xlink:to="IMMY_OptionsGrantedConsultantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_OptionsGrantedConsultantsMember_doc" xml:lang="en-US">Options granted to consultants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ParkSellersMember" xlink:to="IMMY_ParkSellersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ParkSellersMember_doc" xml:lang="en-US">Park Sellers [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PaymentOfCashToContigent" xlink:to="IMMY_PaymentOfCashToContigent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PaymentOfCashToContigent_doc" xml:lang="en-US">Payment Of Cash To Contigent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfCurrentAnnualSalary" xlink:to="IMMY_PercentageOfCurrentAnnualSalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PercentageOfCurrentAnnualSalary_doc" xml:lang="en-US">Percentage Of Current Annual Salary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfDrugAndChemicalPurchases" xlink:to="IMMY_PercentageOfDrugAndChemicalPurchases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PercentageOfDrugAndChemicalPurchases_doc" xml:lang="en-US">Percentage of drug and chemical purchases from three main suppliers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfForfeitureFactor" xlink:to="IMMY_PercentageOfForfeitureFactor_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PercentageOfForfeitureFactor_doc" xml:lang="en-US">Percentage of forfeiture factor.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfIncreasesCurrentAnnualSalary" xlink:to="IMMY_PercentageOfIncreasesCurrentAnnualSalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PercentageOfIncreasesCurrentAnnualSalary_doc" xml:lang="en-US">Percentage Of Increases Current Annual Salary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfRemainingRestrictedStockUnitsVested" xlink:to="IMMY_PercentageOfRemainingRestrictedStockUnitsVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PercentageOfRemainingRestrictedStockUnitsVested_doc" xml:lang="en-US">Percentage of remaining restricted stock units vested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfRestrictedStockUnitsVested" xlink:to="IMMY_PercentageOfRestrictedStockUnitsVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PercentageOfRestrictedStockUnitsVested_doc" xml:lang="en-US">Percentage of restricted stock units vested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" xlink:to="IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount_doc" xml:lang="en-US">Percentage of salary deposits in tax deferred investment account.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted" xlink:to="IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted_doc" xml:lang="en-US">Percentage Shares Tied To Target Of Number Of Shares Granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember" xlink:to="IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember_doc" xml:lang="en-US">Period Ending March 31, 2016 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PharmacyCreationsLlcMember" xlink:to="IMMY_PharmacyCreationsLlcMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PharmacyCreationsLlcMember_doc" xml:lang="en-US">Pharmacy Creations Llc [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PrepaidStockbasedConsultingExpenses" xlink:to="IMMY_PrepaidStockbasedConsultingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PrepaidStockbasedConsultingExpenses_doc" xml:lang="en-US">Prepaid Stock based Consulting Expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PreviousOfficeSpaceArea" xlink:to="IMMY_PreviousOfficeSpaceArea_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PreviousOfficeSpaceArea_doc" xml:lang="en-US">Previous Office Space Area.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease" xlink:to="IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease_doc" xml:lang="en-US">Purchase Of Furniture And Equipment With Capital Lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_QuarterlyCashPayments" xlink:to="IMMY_QuarterlyCashPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_QuarterlyCashPayments_doc" xml:lang="en-US">Quarterly Cash Payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RSUMember" xlink:to="IMMY_RSUMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RSUMember_doc" xml:lang="en-US">RSU Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RangeFiveMember" xlink:to="IMMY_RangeFiveMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RangeFiveMember_doc" xml:lang="en-US">Range five [member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RangeFourMember" xlink:to="IMMY_RangeFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RangeFourMember_doc" xml:lang="en-US">Range four [member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RangeOneMember" xlink:to="IMMY_RangeOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RangeOneMember_doc" xml:lang="en-US">Range one [member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RangeThreeMember" xlink:to="IMMY_RangeThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RangeThreeMember_doc" xml:lang="en-US">Range three [member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RangeTwoMember" xlink:to="IMMY_RangeTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RangeTwoMember_doc" xml:lang="en-US">Range two [member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock" xlink:to="IMMY_RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock_doc" xml:lang="en-US">Recently Announced Accounting Pronouncements [PolicyTextBlock].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering" xlink:to="IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering_doc" xml:lang="en-US">Reclassification Of Deferred Offering CostsIn Connectionwit Equity Offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RecognizedLeaseLossesRelatedToLeaseLiability" xlink:to="IMMY_RecognizedLeaseLossesRelatedToLeaseLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RecognizedLeaseLossesRelatedToLeaseLiability_doc" xml:lang="en-US">Recognized lease losses related to estimated remaining lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ResearchAndDevelopmentMember" xlink:to="IMMY_ResearchAndDevelopmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ResearchAndDevelopmentMember_doc" xml:lang="en-US">Research And Development [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RestrictedStockIncludedInCommonStockEquivalents" xlink:to="IMMY_RestrictedStockIncludedInCommonStockEquivalents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RestrictedStockIncludedInCommonStockEquivalents_doc" xml:lang="en-US">Number of restricted stock included in common stock equivalents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson" xlink:to="IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson_doc" xml:lang="en-US">Restricted Stock Units Granted During Period Per Person</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RestrictedStockUnitsRSUOneMember" xlink:to="IMMY_RestrictedStockUnitsRSUOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RestrictedStockUnitsRSUOneMember_doc" xml:lang="en-US">Restricted Stock Units RSU One [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RestrictedStockVestInFuture" xlink:to="IMMY_RestrictedStockVestInFuture_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RestrictedStockVestInFuture_doc" xml:lang="en-US">Restricted Stock Vest In Future.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RestrictedStockVestedImmediately" xlink:to="IMMY_RestrictedStockVestedImmediately_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RestrictedStockVestedImmediately_doc" xml:lang="en-US">Restricted Stock Vested Immediately.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_RoyaltiesRangePercentage" xlink:to="IMMY_RoyaltiesRangePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_RoyaltiesRangePercentage_doc" xml:lang="en-US">Royalties Range Percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock" xlink:to="IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock_doc" xml:lang="en-US">Schedule Of Marketbased Vesting Conditions Further [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="IMMY_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [TableTextBlock].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ScheduleOfResultOfOperationFromAcquisitionTableTextBlock" xlink:to="IMMY_ScheduleOfResultOfOperationFromAcquisitionTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ScheduleOfResultOfOperationFromAcquisitionTableTextBlock_doc" xml:lang="en-US">Schedule of Result of Operation from Acquisition [Table Text Block].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" xlink:to="IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock_doc" xml:lang="en-US">Schedule of warrants outstanding and exercisable [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_SellingAndMarketingMember" xlink:to="IMMY_SellingAndMarketingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_SellingAndMarketingMember_doc" xml:lang="en-US">Selling And Marketing [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:to="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1_doc" xml:lang="en-US">Warrants Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:to="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1_doc" xml:lang="en-US">Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:to="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1_doc" xml:lang="en-US">Vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2" xlink:to="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2_doc" xml:lang="en-US">Weighted Average Exercisable Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:to="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1_doc" xml:lang="en-US">Warrants Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:to="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Options Granted Weighted Average Remaining Contractual Term1.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StateNetOperatingLossExpirationDate" xlink:to="IMMY_StateNetOperatingLossExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StateNetOperatingLossExpirationDate_doc" xml:lang="en-US">State net operating loss expiration date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StateResearchAndDevelopmentTaxCredits" xlink:to="IMMY_StateResearchAndDevelopmentTaxCredits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StateResearchAndDevelopmentTaxCredits_doc" xml:lang="en-US">State Research And Development Tax Credits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodForExerciseOfWarrants" xlink:to="IMMY_StockIssuedDuringPeriodForExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockIssuedDuringPeriodForExerciseOfWarrants_doc" xml:lang="en-US">Stock Issued During Period For Exercise Of Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:to="IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants_doc" xml:lang="en-US">Stock Issued During Period Shares For Exercise Of Warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodSharesForPublicOffering" xlink:to="IMMY_StockIssuedDuringPeriodSharesForPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockIssuedDuringPeriodSharesForPublicOffering_doc" xml:lang="en-US">Stock Issued During Period Shares For Public Offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters" xlink:to="IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters_doc" xml:lang="en-US">Stock issued during period shares issued to underwriters.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour" xlink:to="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour_doc" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercised Four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne" xlink:to="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne_doc" xml:lang="en-US">Stock Issued During Period Shares Stock Options Exercised One.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodValueForPublicOffering" xlink:to="IMMY_StockIssuedDuringPeriodValueForPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockIssuedDuringPeriodValueForPublicOffering_doc" xml:lang="en-US">Stock Issued During Period Value For Public Offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters" xlink:to="IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters_doc" xml:lang="en-US">Stock issued during period value issued to underwriters.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockIssuedDuringPeriodValueStockOptionsExercisedFour" xlink:to="IMMY_StockIssuedDuringPeriodValueStockOptionsExercisedFour_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockIssuedDuringPeriodValueStockOptionsExercisedFour_doc" xml:lang="en-US">Stock Issued During Period Value Stock Options Exercised Four.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockOptionPlanMember" xlink:to="IMMY_StockOptionPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockOptionPlanMember_doc" xml:lang="en-US">StockOptionPlanMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockOptionsGrantedVestingTermsDescription" xlink:to="IMMY_StockOptionsGrantedVestingTermsDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockOptionsGrantedVestingTermsDescription_doc" xml:lang="en-US">Stock Options Granted Vesting Terms Description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute" xlink:to="IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute_doc" xml:lang="en-US">Stock Shares Issued Duing Period For Settlement Of Contract Dispute.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute" xlink:to="IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute_doc" xml:lang="en-US">Stock Shares Issued Duing Period Shares For Settlement Of Contract Dispute.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised" xlink:to="IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised_doc" xml:lang="en-US">Shares issued upon exercise of warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_TargetRangingPrice" xlink:to="IMMY_TargetRangingPrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_TargetRangingPrice_doc" xml:lang="en-US">Target Ranging Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_TargetSharePriceRelatedToRestrictedStockGrant" xlink:to="IMMY_TargetSharePriceRelatedToRestrictedStockGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_TargetSharePriceRelatedToRestrictedStockGrant_doc" xml:lang="en-US">Target Share Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_TermOfStockOption" xlink:to="IMMY_TermOfStockOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_TermOfStockOption_doc" xml:lang="en-US">Term Of Stock Option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember" xlink:to="IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember_doc" xml:lang="en-US">2007 Incentive Stock And Awards Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_UnderwriterWarrantsMember" xlink:to="IMMY_UnderwriterWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_UnderwriterWarrantsMember_doc" xml:lang="en-US">Underwriter Warrants [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_UnderwritingAgreementDescription" xlink:to="IMMY_UnderwritingAgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_UnderwritingAgreementDescription_doc" xml:lang="en-US">Underwriting Agreement Description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_UrigenPharmaceuticalsIncMember" xlink:to="IMMY_UrigenPharmaceuticalsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_UrigenPharmaceuticalsIncMember_doc" xml:lang="en-US">Urigen Pharmaceuticals Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ValueOfProductDevelopmentInvestment" xlink:to="IMMY_ValueOfProductDevelopmentInvestment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_ValueOfProductDevelopmentInvestment_doc" xml:lang="en-US">Value of product development investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantActivityMember" xlink:to="IMMY_WarrantActivityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_WarrantActivityMember_doc" xml:lang="en-US">Warrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock" xlink:to="IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock_doc" xml:lang="en-US">Warrants and shares issued upon excise of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsExercisePricePerShare" xlink:to="IMMY_WarrantsExercisePricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_WarrantsExercisePricePerShare_doc" xml:lang="en-US">Warrants Exercise Price Per Share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsExpirationDate" xlink:to="IMMY_WarrantsExpirationDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_WarrantsExpirationDate_doc" xml:lang="en-US">Warrants Expiration Date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsExpiredDuration" xlink:to="IMMY_WarrantsExpiredDuration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_WarrantsExpiredDuration_doc" xml:lang="en-US">Warrants Expired Duration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsIssuanceDate" xlink:to="IMMY_WarrantsIssuanceDate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_WarrantsIssuanceDate_doc" xml:lang="en-US">Warrants Issuance Date.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember" xlink:to="IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember_doc" xml:lang="en-US">Warrants Issued In April Two Thousand Twelve Private Placement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsIssuedToFormerMajorShareholderMember" xlink:to="IMMY_WarrantsIssuedToFormerMajorShareholderMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_WarrantsIssuedToFormerMajorShareholderMember_doc" xml:lang="en-US">Warrants Issued To Former Major Shareholder [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember" xlink:to="IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember_doc" xml:lang="en-US">Warrants Issued To Investor Relations Consultant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember" xlink:to="IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember_doc" xml:lang="en-US">Warrants Issued To Investor Relations Consultant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsSharesExercisePricePerShare" xlink:to="IMMY_WarrantsSharesExercisePricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_WarrantsSharesExercisePricePerShare_doc" xml:lang="en-US">Warrants shares exercise price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare" xlink:to="IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare_doc" xml:lang="en-US">Warrants to purchase common stock exercise price per share.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_PercentageOfAnnualRentIncreases" xlink:to="IMMY_PercentageOfAnnualRentIncreases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_PercentageOfAnnualRentIncreases_doc" xml:lang="en-US">Percentage of annual rent increases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_NonCompetitionCovenantMember" xlink:to="IMMY_NonCompetitionCovenantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="IMMY_NonCompetitionCovenantMember_doc" xml:lang="en-US">Non Competition Covenant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember" xlink:to="IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember_3_lbl" xml:lang="en-US">WarrantsIssuedToInvestorRelationsConsultantTwoMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_WarrantActivityMember" xlink:to="IMMY_WarrantActivityMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_WarrantActivityMember_3_lbl" xml:lang="en-US">WarrantActivityMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_2_lbl" xml:lang="en-US">Revenue, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense" xlink:to="us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense_2_lbl" xml:lang="en-US">Health Care Organization, Medical Supplies and Drugs Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpenses_2_lbl" xml:lang="en-US">Operating Costs and Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInCustomerDeposits" xlink:to="us-gaap_IncreaseDecreaseInCustomerDeposits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInCustomerDeposits_2_lbl" xml:lang="en-US">Increase (Decrease) in Customer Deposits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_2_lbl" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_2_lbl" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_2_lbl" xml:lang="en-US">Repayments of Debt and Capital Lease Obligations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_2_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2_lbl" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_2_lbl" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_2_lbl" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments Due in Two Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments Due</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Interest Included in Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Next Rolling Twelve Months</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Rolling after Year Five</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>immy-20141231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.3c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: IMMY%2D20141231 10K FY DFN.xfr; Date: 2015%2D03%2D12T19:30:59 -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80030000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://imprimispharma.com/role/DocumentAndEntityInformation" xlink:href="immy-20141231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/BalanceSheets" xlink:href="immy-20141231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/BalanceSheetsParenthetical" xlink:href="immy-20141231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/ConsolidatedStatementsOfOperations" xlink:href="immy-20141231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StatementsOfStockholdersEquity" xlink:href="immy-20141231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="immy-20141231.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StatementsOfCashFlows" xlink:href="immy-20141231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Organization" xlink:href="immy-20141231.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="immy-20141231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/RestrictedShort-termInvestment" xlink:href="immy-20141231.xsd#RestrictedShort-termInvestment" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Inventories" xlink:href="immy-20141231.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="immy-20141231.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/FurnitureAndEquipment" xlink:href="immy-20141231.xsd#FurnitureAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses" xlink:href="immy-20141231.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Debt" xlink:href="immy-20141231.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity" xlink:href="immy-20141231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxes" xlink:href="immy-20141231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/EmployeeSavingsPlan" xlink:href="immy-20141231.xsd#EmployeeSavingsPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingencies" xlink:href="immy-20141231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SegmentInformation" xlink:href="immy-20141231.xsd#SegmentInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SubsequentEvents" xlink:href="immy-20141231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="immy-20141231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="immy-20141231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcTables" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlcTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/InventoriesTables" xlink:href="immy-20141231.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="immy-20141231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/FurnitureAndEquipmentTables" xlink:href="immy-20141231.xsd#FurnitureAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="immy-20141231.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityTables" xlink:href="immy-20141231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxesTables" xlink:href="immy-20141231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingenciesTables" xlink:href="immy-20141231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="immy-20141231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:href="immy-20141231.xsd#SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcDetailsNarrative" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlcDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfAcquisitionDateFairValueOfConsiderationDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfAcquisitionDateFairValueOfConsiderationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfEstimatedFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfEstimatedFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfResultOfOperationFromAcquisitionDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfResultOfOperationFromAcquisitionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfProFormaFinancialInformationDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfProFormaFinancialInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfIntangibleAssetsAcquisitionDetails" xlink:href="immy-20141231.xsd#Acquisition-PharmacyCreationsLlc-ScheduleOfIntangibleAssetsAcquisitionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/RestrictedShort-termInvestmentDetailsNarrative" xlink:href="immy-20141231.xsd#RestrictedShort-termInvestmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/Inventories-ScheduleOfInventoriesDetails" xlink:href="immy-20141231.xsd#Inventories-ScheduleOfInventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets-ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="immy-20141231.xsd#PrepaidExpensesAndOtherCurrentAssets-ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/FurnitureAndEquipmentDetailsNarrative" xlink:href="immy-20141231.xsd#FurnitureAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/FurnitureAndEquipment-ScheduleOfFurnitureAndEquipmentDetails" xlink:href="immy-20141231.xsd#FurnitureAndEquipment-ScheduleOfFurnitureAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfIntangibleAssetsDetails" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill-ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill-ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill-ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfChangesInCarryingValueOfGoodwillDetails" xlink:href="immy-20141231.xsd#IntangibleAssetsAndGoodwill-ScheduleOfChangesInCarryingValueOfGoodwillDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesDetailsNarratvie" xlink:href="immy-20141231.xsd#AccountsPayableAndAccruedExpensesDetailsNarratvie" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:href="immy-20141231.xsd#AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/DebtDetailsNarrative" xlink:href="immy-20141231.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="immy-20141231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockOptionPlanActivityDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfStockOptionPlanActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfFairValueAssumptionDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfFairValueAssumptionDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfSharesOutstandingAndExercisableDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfSharesOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-Market-basedVestingConditionsForRestrictedStockUnitsGrantedDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-Market-basedVestingConditionsForRestrictedStockUnitsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfRestrictedStockUnitsActivityDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfRestrictedStockUnitsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsActivityDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:href="immy-20141231.xsd#StockholdersEquity-ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="immy-20141231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfProvisionForIncomeTaxesDetails" xlink:href="immy-20141231.xsd#IncomeTaxes-ScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfIncomeTaxReconciliationDetails" xlink:href="immy-20141231.xsd#IncomeTaxes-ScheduleOfIncomeTaxReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="immy-20141231.xsd#IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/EmployeeSavingsPlanDetailsNarrative" xlink:href="immy-20141231.xsd#EmployeeSavingsPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="immy-20141231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfLeaseEquipmentUnderCapitalLeaseDetails" xlink:href="immy-20141231.xsd#CommitmentsAndContingencies-ScheduleOfLeaseEquipmentUnderCapitalLeaseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfFuturePaymentsUnderLeasesDetails" xlink:href="immy-20141231.xsd#CommitmentsAndContingencies-ScheduleOfFuturePaymentsUnderLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SegmentInformationDetailsNarrative" xlink:href="immy-20141231.xsd#SegmentInformationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://imprimispharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="immy-20141231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DocumentAndEntityInformationAbstract" xlink:label="loc_IMMYDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedInvestmentsCurrent" xlink:label="loc_us-gaapRestrictedInvestmentsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedInvestmentsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerDepositsCurrent" xlink:label="loc_us-gaapCustomerDepositsCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapCustomerDepositsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities" xlink:label="loc_IMMYBusinessAcquisitionContingentAcquiredObligationsLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_IMMYBusinessAcquisitionContingentAcquiredObligationsLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCapitalLeaseObligationsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiability" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement -  Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_HealthCareOrganizationRevenue" xlink:label="loc_us-gaapHealthCareOrganizationRevenue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapHealthCareOrganizationRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaapLicensesRevenue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapLicensesRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenuesAbstract" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense" xlink:label="loc_us-gaapHealthCareOrganizationMedicalSuppliesAndDrugsExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapHealthCareOrganizationMedicalSuppliesAndDrugsExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaapOperatingCostsAndExpensesAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaapSellingAndMarketingExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapSellingAndMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="loc_us-gaapOperatingCostsAndExpenses" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapOperatingCostsAndExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:label="loc_us-gaapAccumulatedDeficitDuringDevelopmentStageMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedDeficitDuringDevelopmentStageMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne" xlink:label="loc_IMMYIssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne" xlink:label="loc_IMMYIssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodValueStockOptionsExercisedFour" xlink:label="loc_IMMYStockIssuedDuringPeriodValueStockOptionsExercisedFour" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodValueStockOptionsExercisedFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesStockOptionsExercisedFour" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesStockOptionsExercisedFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013" xlink:label="loc_IMMYCancelledCommonStockValueRelatedToReverseStockSplitFebruary2013" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYCancelledCommonStockValueRelatedToReverseStockSplitFebruary2013" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares" xlink:label="loc_IMMYCancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYCancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodValueForPublicOffering" xlink:label="loc_IMMYStockIssuedDuringPeriodValueForPublicOffering" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodValueForPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesForPublicOffering" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesForPublicOffering" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesForPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" xlink:label="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" xlink:label="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodForExerciseOfWarrants" xlink:label="loc_IMMYStockIssuedDuringPeriodForExerciseOfWarrants" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodForExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesForExerciseOfWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesForExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockUponVestingOfRsusShares" xlink:label="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute" xlink:label="loc_IMMYStockSharesIssuedDuingPeriodForSettlementOfContractDispute" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockSharesIssuedDuingPeriodForSettlementOfContractDispute" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute" xlink:label="loc_IMMYStockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare" xlink:label="loc_IMMYIssuanceOfCommonStockForPublicOfferingPricePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_IMMYIssuanceOfCommonStockForPublicOfferingPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CancelledCommonStockPricePerShare" xlink:label="loc_IMMYCancelledCommonStockPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_IMMYCancelledCommonStockPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerDeposits" xlink:label="loc_us-gaapIncreaseDecreaseInCustomerDeposits" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingAssetsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInCustomerDeposits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaapPaymentsToAcquireShortTermInvestments" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireShortTermInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaapPaymentsForRepurchaseOfCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForRepurchaseOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees" xlink:label="loc_IMMYIssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_IMMYIssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering" xlink:label="loc_IMMYReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_IMMYReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease" xlink:label="loc_IMMYPurchaseOfFurnitureAndEquipmentWithCapitalLease" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_IMMYPurchaseOfFurnitureAndEquipmentWithCapitalLease" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Organization" xlink:title="00000008 - Disclosure - Organization">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc" xlink:title="00000010 - Disclosure - Acquisition - Pharmacy Creations, LLC">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaapBusinessCombinationDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapBusinessCombinationDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/RestrictedShort-termInvestment" xlink:title="00000011 - Disclosure - Restricted Short-Term Investment">
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedShortTermInvestmentDisclosureAbstract" xlink:label="loc_IMMYRestrictedShortTermInvestmentDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="loc_us-gaapCashCashEquivalentsAndShortTermInvestmentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYRestrictedShortTermInvestmentDisclosureAbstract" xlink:to="loc_us-gaapCashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Inventories" xlink:title="00000012 - Disclosure - Inventories">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000013 - Disclosure - Prepaid Expenses and Other Current Assets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/FurnitureAndEquipment" xlink:title="00000014 - Disclosure - Furniture and Equipment">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill" xlink:title="00000015 - Disclosure - Intangible Assets and Goodwill">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses" xlink:title="00000016 - Disclosure - Accounts Payable and Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Debt" xlink:title="00000017 - Disclosure - Debt">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity" xlink:title="00000018 - Disclosure - Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxes" xlink:title="00000019 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/EmployeeSavingsPlan" xlink:title="00000020 - Disclosure - Employee Savings Plan">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SegmentInformation" xlink:title="00000022 - Disclosure - Segment Information">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaapSegmentReportingDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapSegmentReportingDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaapBusinessCombinationsPolicy" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessCombinationsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="loc_us-gaapRevenueRecognitionDeferredRevenue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaapReceivablesPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaapDeferredChargesPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDeferredChargesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_IMMYRecentlyAnnouncedAccountingPronouncementsPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_IMMYRecentlyAnnouncedAccountingPronouncementsPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcTables" xlink:title="00000026 - Disclosure - Acquisition - Pharmacy Creations, LLC (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ScheduleOfResultOfOperationFromAcquisitionTableTextBlock" xlink:label="loc_IMMYScheduleOfResultOfOperationFromAcquisitionTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_IMMYScheduleOfResultOfOperationFromAcquisitionTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="loc_us-gaapBusinessAcquisitionProFormaInformationTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapBusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:label="loc_us-gaapFiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapFiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/InventoriesTables" xlink:title="00000027 - Disclosure - Inventories (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="loc_IMMYScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_IMMYScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/FurnitureAndEquipmentTables" xlink:title="00000029 - Disclosure - Furniture and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwillTables" xlink:title="00000030 - Disclosure - Intangible Assets and Goodwill (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaapScheduleOfGoodwillTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfGoodwillTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesTables" xlink:title="00000031 - Disclosure - Accounts Payable and Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityTables" xlink:title="00000032 - Disclosure - Stockholders' Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock" xlink:label="loc_IMMYScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock" xlink:label="loc_IMMYScheduleofWarrantsOutstandingAndExercisableTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYScheduleofWarrantsOutstandingAndExercisableTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxesTables" xlink:title="00000033 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000034 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_MaximumDepositCoverageLimits" xlink:label="loc_IMMYMaximumDepositCoverageLimits" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYMaximumDepositCoverageLimits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromDepositsFromCustomers" xlink:label="loc_us-gaapProceedsFromDepositsFromCustomers" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromDepositsFromCustomers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaapAccountsReceivableNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsReceivableNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CommonStockEquivalentsDilutiveInstruments" xlink:label="loc_IMMYCommonStockEquivalentsDilutiveInstruments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYCommonStockEquivalentsDilutiveInstruments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockIncludedInCommonStockEquivalents" xlink:label="loc_IMMYRestrictedStockIncludedInCommonStockEquivalents" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYRestrictedStockIncludedInCommonStockEquivalents" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails" xlink:title="00000036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Common Share (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcDetailsNarrative" xlink:title="00000037 - Disclosure - Acquisition - Pharmacy Creations, LLC (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PharmacyCreationsLlcMember" xlink:label="loc_IMMYPharmacyCreationsLlcMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMMYPharmacyCreationsLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="loc_us-gaapCreationDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapCreationDateAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember" xlink:label="loc_IMMYPeriodEndingMarchThirtyFirstTwoThousandSixteenMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDefaultFinancialStatementsDateMember" xlink:to="loc_IMMYPeriodEndingMarchThirtyFirstTwoThousandSixteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PaymentOfCashToContigent" xlink:label="loc_IMMYPaymentOfCashToContigent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPaymentOfCashToContigent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExpectedRevenueDuringAcquisition" xlink:label="loc_IMMYExpectedRevenueDuringAcquisition" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYExpectedRevenueDuringAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExpectedRevenueDate" xlink:label="loc_IMMYExpectedRevenueDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYExpectedRevenueDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfSharesAppliedForContigentStockPayment" xlink:label="loc_IMMYNumberOfSharesAppliedForContigentStockPayment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfSharesAppliedForContigentStockPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainContingencyDescription" xlink:label="loc_us-gaapGainContingencyDescription" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGainContingencyDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill" xlink:label="loc_IMMYBusinessAcquisitionPurchasePriceAllocationGoodwill" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYBusinessAcquisitionPurchasePriceAllocationGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfAcquisitionDateFairValueOfConsiderationDetails" xlink:title="00000038 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Acquisition Date Fair Value of Consideration (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PharmacyCreationsLlcMember" xlink:label="loc_IMMYPharmacyCreationsLlcMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMMYPharmacyCreationsLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ContingentCommonStockIssuanceToRelatedParty" xlink:label="loc_IMMYContingentCommonStockIssuanceToRelatedParty" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYContingentCommonStockIssuanceToRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ContingentCashConsiderationToRelatedParty" xlink:label="loc_IMMYContingentCashConsiderationToRelatedParty" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYContingentCashConsiderationToRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfEstimatedFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:title="00000039 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PharmacyCreationsLlcMember" xlink:label="loc_IMMYPharmacyCreationsLlcMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMMYPharmacyCreationsLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfResultOfOperationFromAcquisitionDetails" xlink:title="00000040 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Result of Operation from Acquisition (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PharmacyCreationsLlcMember" xlink:label="loc_IMMYPharmacyCreationsLlcMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMMYPharmacyCreationsLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfProFormaFinancialInformationDetails" xlink:title="00000041 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Pro Forma Financial Information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="loc_us-gaapBusinessAcquisitionsProFormaRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapBusinessAcquisitionsProFormaRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="loc_us-gaapBusinessAcquisitionsProFormaNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapBusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfIntangibleAssetsAcquisitionDetails" xlink:title="00000042 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Intangible Assets Acquisition (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaapBusinessCombinationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBusinessCombinationsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NonCompetitionCovenantMember" xlink:label="loc_IMMYNonCompetitionCovenantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_IMMYNonCompetitionCovenantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicensingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/RestrictedShort-termInvestmentDetailsNarrative" xlink:title="00000043 - Disclosure - Restricted Short-Term Investment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedShortTermInvestmentDisclosureAbstract" xlink:label="loc_IMMYRestrictedShortTermInvestmentDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CertificatesOfDepositAtCarryingValue" xlink:label="loc_us-gaapCertificatesOfDepositAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYRestrictedShortTermInvestmentDisclosureAbstract" xlink:to="loc_us-gaapCertificatesOfDepositAtCarryingValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/Inventories-ScheduleOfInventoriesDetails" xlink:title="00000044 - Disclosure - Inventories - Schedule of Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets-ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000045 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PrepaidStockbasedConsultingExpenses" xlink:label="loc_IMMYPrepaidStockbasedConsultingExpenses" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_IMMYPrepaidStockbasedConsultingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidRent" xlink:label="loc_us-gaapPrepaidRent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/FurnitureAndEquipmentDetailsNarrative" xlink:title="00000046 - Disclosure - Furniture and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/FurnitureAndEquipment-ScheduleOfFurnitureAndEquipmentDetails" xlink:title="00000047 - Disclosure - Furniture and Equipment - Schedule of Furniture and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:label="loc_us-gaapCapitalizedComputerSoftwareGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapCapitalizedComputerSoftwareGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_LabAndPharmacyEquipmentGross" xlink:label="loc_IMMYLabAndPharmacyEquipmentGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_IMMYLabAndPharmacyEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfIntangibleAssetsDetails" xlink:title="00000048 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncompeteAgreementsMember" xlink:label="loc_us-gaapNoncompeteAgreementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapNoncompeteAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicensingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfAmortizationExpensesForIntangibleAssetsDetails" xlink:title="00000049 - Disclosure - Intangible Assets and Goodwill - Schedule of Amortization Expenses for Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CustomerRelationshipsMember" xlink:label="loc_us-gaapCustomerRelationshipsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapCustomerRelationshipsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaapTradeNamesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTradeNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NonCompetitionCovenantMember" xlink:label="loc_IMMYNonCompetitionCovenantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_IMMYNonCompetitionCovenantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaapLicensingAgreementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicensingAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:title="00000050 - Disclosure - Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfChangesInCarryingValueOfGoodwillDetails" xlink:title="00000051 - Disclosure - Intangible Assets and Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AcquisitionOfRelatedPartyGoodwill" xlink:label="loc_IMMYAcquisitionOfRelatedPartyGoodwill" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_IMMYAcquisitionOfRelatedPartyGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwill_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesDetailsNarratvie" xlink:title="00000052 - Disclosure - Accounts Payable and Accrued Expenses (Details Narratvie)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PreviousOfficeSpaceArea" xlink:label="loc_IMMYPreviousOfficeSpaceArea" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_IMMYPreviousOfficeSpaceArea" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RecognizedLeaseLossesRelatedToLeaseLiability" xlink:label="loc_IMMYRecognizedLeaseLossesRelatedToLeaseLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_IMMYRecognizedLeaseLossesRelatedToLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails" xlink:title="00000053 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaapDeferredRentCreditCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapDeferredRentCreditCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_BuildingLeaseLiability" xlink:label="loc_IMMYBuildingLeaseLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_IMMYBuildingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/DebtDetailsNarrative" xlink:title="00000054 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PharmacyCreationsLlcMember" xlink:label="loc_IMMYPharmacyCreationsLlcMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_IMMYPharmacyCreationsLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000055 - Disclosure - Stockholders' Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_MarkBaumMember" xlink:label="loc_IMMYMarkBaumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IMMYMarkBaumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DrRobertKammerMember" xlink:label="loc_IMMYDrRobertKammerMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IMMYDrRobertKammerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember" xlink:label="loc_IMMYTwoThousandSecenIncentiveStockAndAwardsPlanMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYTwoThousandSecenIncentiveStockAndAwardsPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_BaumPerformanceEquityAwardMember" xlink:label="loc_IMMYBaumPerformanceEquityAwardMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYBaumPerformanceEquityAwardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockUnitsRSUOneMember" xlink:label="loc_IMMYRestrictedStockUnitsRSUOneMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYRestrictedStockUnitsRSUOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EmployeesAndDirectorsMember" xlink:label="loc_IMMYEmployeesAndDirectorsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYEmployeesAndDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantMember" xlink:label="loc_IMMYConsultantMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NonEmployeeDirectorsMember" xlink:label="loc_IMMYNonEmployeeDirectorsMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYNonEmployeeDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FormerDirectorsMember" xlink:label="loc_IMMYFormerDirectorsMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYFormerDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EmployeesMember" xlink:label="loc_IMMYEmployeesMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_MonteCarloSimulationMember" xlink:label="loc_IMMYMonteCarloSimulationMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_IMMYMonteCarloSimulationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_MonteCarloSimulationOneMember" xlink:label="loc_IMMYMonteCarloSimulationOneMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_IMMYMonteCarloSimulationOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantActivityMember" xlink:label="loc_IMMYWarrantActivityMember" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IMMYWarrantActivityMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_2" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="90" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="loc_us-gaapCapitalUnitsAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalUnitsAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed" xlink:label="loc_IMMYNumberOfUnderwrittenPublicOfferingCommonStockSharesClosed" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfUnderwrittenPublicOfferingCommonStockSharesClosed" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityIssuancePerShareAmount" xlink:label="loc_us-gaapEquityIssuancePerShareAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEquityIssuancePerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesIssuedToUnderwriters" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesIssuedToUnderwriters" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters" xlink:label="loc_IMMYStockIssuedDuringPeriodValueIssuedToUnderwriters" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodValueIssuedToUnderwriters" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_UnderwritingAgreementDescription" xlink:label="loc_IMMYUnderwritingAgreementDescription" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYUnderwritingAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares" xlink:label="loc_IMMYCommonStockIssuedSettleCashlessExerciseProvisionShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYCommonStockIssuedSettleCashlessExerciseProvisionShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesStockOptionsExercisedOne" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesStockOptionsExercisedOne" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock" xlink:label="loc_IMMYExerciseOfCommonStockOptionToPurchaseOfCommonStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYExerciseOfCommonStockOptionToPurchaseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CommonStockExercisePricePerShare" xlink:label="loc_IMMYCommonStockExercisePricePerShare" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYCommonStockExercisePricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" xlink:label="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfCommonStockHeldForPayrollTax" xlink:label="loc_IMMYNumberOfCommonStockHeldForPayrollTax" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfCommonStockHeldForPayrollTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" xlink:label="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYIssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised" xlink:label="loc_IMMYStockWarrantsIssuedDuringPeriodValueOfStockExercised" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockWarrantsIssuedDuringPeriodValueOfStockExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock" xlink:label="loc_IMMYWarrantsAndSharesIssuedUponExciseOfCommonStock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsAndSharesIssuedUponExciseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare" xlink:label="loc_IMMYWarrantsToPurchaseCommonStockExercisePricePerShare" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsToPurchaseCommonStockExercisePricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfWarrantsCommonStockIssued" xlink:label="loc_IMMYNumberOfWarrantsCommonStockIssued" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfWarrantsCommonStockIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExerciseOfWarrantToPurchaseOfCommonStock" xlink:label="loc_IMMYExerciseOfWarrantToPurchaseOfCommonStock" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYExerciseOfWarrantToPurchaseOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsSharesExercisePricePerShare" xlink:label="loc_IMMYWarrantsSharesExercisePricePerShare" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsSharesExercisePricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfFutureIssuancesShareUnderPlan" xlink:label="loc_IMMYNumberOfFutureIssuancesShareUnderPlan" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfFutureIssuancesShareUnderPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_OptionsExercisePrice" xlink:label="loc_IMMYOptionsExercisePrice" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYOptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="loc_IMMYSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockOptionsGrantedVestingTermsDescription" xlink:label="loc_IMMYStockOptionsGrantedVestingTermsDescription" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockOptionsGrantedVestingTermsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfForfeitureFactor" xlink:label="loc_IMMYPercentageOfForfeitureFactor" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageOfForfeitureFactor" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockVestInFuture" xlink:label="loc_IMMYRestrictedStockVestInFuture" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYRestrictedStockVestInFuture" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_TargetRangingPrice" xlink:label="loc_IMMYTargetRangingPrice" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYTargetRangingPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockVestedImmediately" xlink:label="loc_IMMYRestrictedStockVestedImmediately" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYRestrictedStockVestedImmediately" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson" xlink:label="loc_IMMYRestrictedStockUnitsGrantedDuringPeriodPerPerson" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYRestrictedStockUnitsGrantedDuringPeriodPerPerson" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CancellationOfRestrictedStockUnitsDuringPeriod" xlink:label="loc_IMMYCancellationOfRestrictedStockUnitsDuringPeriod" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYCancellationOfRestrictedStockUnitsDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockValueSharesIssuedNetOfTaxWithholdings" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedStockValueSharesIssuedNetOfTaxWithholdings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares" xlink:label="loc_IMMYFairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYFairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_InitialFairValueOfRestrictedStockUnitsShares" xlink:label="loc_IMMYInitialFairValueOfRestrictedStockUnitsShares" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYInitialFairValueOfRestrictedStockUnitsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfRestrictedStockUnitsVested" xlink:label="loc_IMMYPercentageOfRestrictedStockUnitsVested" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageOfRestrictedStockUnitsVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfRemainingRestrictedStockUnitsVested" xlink:label="loc_IMMYPercentageOfRemainingRestrictedStockUnitsVested" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageOfRemainingRestrictedStockUnitsVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="670" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="680" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
      <link:presentationArc order="690" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfDirectorResignedAndForfeited" xlink:label="loc_IMMYNumberOfDirectorResignedAndForfeited" />
      <link:presentationArc order="710" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfDirectorResignedAndForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="720" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="730" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsExercisePricePerShare" xlink:label="loc_IMMYWarrantsExercisePricePerShare" />
      <link:presentationArc order="740" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsExercisePricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsExpiredDuration" xlink:label="loc_IMMYWarrantsExpiredDuration" />
      <link:presentationArc order="750" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsExpiredDuration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfWarrantsVestedImmeditely" xlink:label="loc_IMMYNumberOfWarrantsVestedImmeditely" />
      <link:presentationArc order="760" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfWarrantsVestedImmeditely" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfSharesVestedInInstallments" xlink:label="loc_IMMYNumberOfSharesVestedInInstallments" />
      <link:presentationArc order="770" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfSharesVestedInInstallments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FairValueOfWarrants" xlink:label="loc_IMMYFairValueOfWarrants" />
      <link:presentationArc order="780" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYFairValueOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="790" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockOptionPlanActivityDetails" xlink:title="00000056 - Disclosure - Stockholders' Equity - Schedule of Stock Option Plan Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockOptionPlanMember" xlink:label="loc_IMMYStockOptionPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYStockOptionPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfFairValueAssumptionDetails" xlink:title="00000057 - Disclosure - Stockholders' Equity - Schedule of Fair Value Assumption (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_OptionsEmployeesMember" xlink:label="loc_IMMYOptionsEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYOptionsEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_OptionsGrantedConsultantsMember" xlink:label="loc_IMMYOptionsGrantedConsultantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYOptionsGrantedConsultantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfSharesOutstandingAndExercisableDetails" xlink:title="00000058 - Disclosure - Stockholders' Equity - Schedule of Shares Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeOneMember" xlink:label="loc_IMMYRangeOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IMMYRangeOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeTwoMember" xlink:label="loc_IMMYRangeTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IMMYRangeTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeThreeMember" xlink:label="loc_IMMYRangeThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IMMYRangeThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeFourMember" xlink:label="loc_IMMYRangeFourMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IMMYRangeFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RangeFiveMember" xlink:label="loc_IMMYRangeFiveMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="loc_IMMYRangeFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberExercisable" xlink:label="loc_IMMYNumberExercisable" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2" xlink:label="loc_IMMYShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-Market-basedVestingConditionsForRestrictedStockUnitsGrantedDetails" xlink:title="00000059 - Disclosure - Stockholders' Equity - Market-based Vesting Conditions for Restricted Stock Units Granted (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember" xlink:label="loc_IMMYExecutiveRestrictedStockUnitsTrancheOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYExecutiveRestrictedStockUnitsTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember" xlink:label="loc_IMMYExecutiveRestrictedStockUnitsTrancheTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYExecutiveRestrictedStockUnitsTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember" xlink:label="loc_IMMYExecutiveRestrictedStockUnitsTrancheThreeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYExecutiveRestrictedStockUnitsTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTranche4Member" xlink:label="loc_IMMYExecutiveRestrictedStockUnitsTranche4Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYExecutiveRestrictedStockUnitsTranche4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ExecutiveRestrictedStockUnitsTranche5Member" xlink:label="loc_IMMYExecutiveRestrictedStockUnitsTranche5Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYExecutiveRestrictedStockUnitsTranche5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheOneMember" xlink:label="loc_IMMYConsultantTrancheOneMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYConsultantTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheTwoMember" xlink:label="loc_IMMYConsultantTrancheTwoMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYConsultantTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheThreeMember" xlink:label="loc_IMMYConsultantTrancheThreeMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYConsultantTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheFourMember" xlink:label="loc_IMMYConsultantTrancheFourMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYConsultantTrancheFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantTrancheFiveMember" xlink:label="loc_IMMYConsultantTrancheFiveMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_IMMYConsultantTrancheFiveMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted" xlink:label="loc_IMMYPercentageSharesTiedToTargetOfNumberOfSharesGranted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageSharesTiedToTargetOfNumberOfSharesGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_NumberOfSharesTiedToTarget" xlink:label="loc_IMMYNumberOfSharesTiedToTarget" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYNumberOfSharesTiedToTarget" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_TargetSharePriceRelatedToRestrictedStockGrant" xlink:label="loc_IMMYTargetSharePriceRelatedToRestrictedStockGrant" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYTargetSharePriceRelatedToRestrictedStockGrant" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfRestrictedStockUnitsActivityDetails" xlink:title="00000060 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Units Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:label="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsActivityDetails" xlink:title="00000061 - Disclosure - Stockholders' Equity - Schedule of Warrants Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_IMMYSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYSharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_IMMYShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_IMMYShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_IMMYShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails" xlink:title="00000062 - Disclosure - Stockholders' Equity - Schedule of Warrants Outstanding and Warrants Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuedToFormerMajorShareholderMember" xlink:label="loc_IMMYWarrantsIssuedToFormerMajorShareholderMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYWarrantsIssuedToFormerMajorShareholderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember" xlink:label="loc_IMMYWarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYWarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_UnderwriterWarrantsMember" xlink:label="loc_IMMYUnderwriterWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYUnderwriterWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember" xlink:label="loc_IMMYWarrantsIssuedToInvestorRelationsConsultantOneMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYWarrantsIssuedToInvestorRelationsConsultantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember" xlink:label="loc_IMMYWarrantsIssuedToInvestorRelationsConsultantTwoMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYWarrantsIssuedToInvestorRelationsConsultantTwoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsIssuanceDate" xlink:label="loc_IMMYWarrantsIssuanceDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsIssuanceDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:label="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:label="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:label="loc_IMMYShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_WarrantsExpirationDate" xlink:label="loc_IMMYWarrantsExpirationDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYWarrantsExpirationDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails" xlink:title="00000063 - Disclosure - Stockholders' Equity - Schedule of Stock Based Compensation Granted to Employees Directors Consultants (Details)">
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ScheduleOfEquityInstrumentsGrantedToRelatedPartyDetailsAbstract" xlink:label="loc_IMMYScheduleOfEquityInstrumentsGrantedToRelatedPartyDetailsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYScheduleOfEquityInstrumentsGrantedToRelatedPartyDetailsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EmployeesMember" xlink:label="loc_IMMYEmployeesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IMMYEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ConsultantMember" xlink:label="loc_IMMYConsultantMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_IMMYConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_SellingAndMarketingMember" xlink:label="loc_IMMYSellingAndMarketingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_IMMYSellingAndMarketingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_GeneralAndAdministrativeMember" xlink:label="loc_IMMYGeneralAndAdministrativeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_IMMYGeneralAndAdministrativeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ResearchAndDevelopmentMember" xlink:label="loc_IMMYResearchAndDevelopmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_IMMYResearchAndDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000064 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FederalNetOperatingLossExpirationDate" xlink:label="loc_IMMYFederalNetOperatingLossExpirationDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_IMMYFederalNetOperatingLossExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FederalResearchAndDevelopmentTaxCredits" xlink:label="loc_IMMYFederalResearchAndDevelopmentTaxCredits" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_IMMYFederalResearchAndDevelopmentTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_FederalResearchAndDevelopmentTaxCreditsExpirationDate" xlink:label="loc_IMMYFederalResearchAndDevelopmentTaxCreditsExpirationDate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_IMMYFederalResearchAndDevelopmentTaxCreditsExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StateNetOperatingLossExpirationDate" xlink:label="loc_IMMYStateNetOperatingLossExpirationDate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_IMMYStateNetOperatingLossExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StateResearchAndDevelopmentTaxCredits" xlink:label="loc_IMMYStateResearchAndDevelopmentTaxCredits" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_IMMYStateResearchAndDevelopmentTaxCredits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGrossCurrent" xlink:label="loc_us-gaapDeferredTaxAssetsGrossCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfProvisionForIncomeTaxesDetails" xlink:title="00000065 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentFederalTaxExpenseBenefit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DeferredIncomeChangeInValuationAllowance" xlink:label="loc_IMMYDeferredIncomeChangeInValuationAllowance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_IMMYDeferredIncomeChangeInValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfIncomeTaxReconciliationDetails" xlink:title="00000066 - Disclosure - Income Taxes - Schedule of Income Tax Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets" xlink:label="loc_IMMYEffecticveIncomeTaxRateBenefitOfLowerTaxBrackets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_IMMYEffecticveIncomeTaxRateBenefitOfLowerTaxBrackets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EffectiveIncomeTaxRateLossOnDebtConversion" xlink:label="loc_IMMYEffectiveIncomeTaxRateLossOnDebtConversion" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_IMMYEffectiveIncomeTaxRateLossOnDebtConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="00000067 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:label="loc_IMMYDeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_IMMYDeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" xlink:label="loc_IMMYDeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_IMMYDeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" xlink:label="loc_us-gaapDeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/EmployeeSavingsPlanDetailsNarrative" xlink:title="00000068 - Disclosure - Employee Savings Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" xlink:label="loc_IMMYPercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_IMMYPercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_DefinedBenefitPlanContributionsByEmployerPercentage" xlink:label="loc_IMMYDefinedBenefitPlanContributionsByEmployerPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_IMMYDefinedBenefitPlanContributionsByEmployerPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaapDefinedBenefitPlanContributionsByEmployer" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedBenefitPlanContributionsByEmployer" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000069 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PharmacyCreationsLlcMember" xlink:label="loc_IMMYPharmacyCreationsLlcMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYPharmacyCreationsLlcMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_UrigenPharmaceuticalsIncMember" xlink:label="loc_IMMYUrigenPharmaceuticalsIncMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYUrigenPharmaceuticalsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate" xlink:label="loc_IMMYLeasesEquipmentUnderCapitalLeaseWithInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYLeasesEquipmentUnderCapitalLeaseWithInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapCapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:label="loc_us-gaapCapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaapOperatingLeasesRentExpenseNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesRentExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate" xlink:label="loc_us-gaapOperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_LicenseAgreementCommitmentsDescription" xlink:label="loc_IMMYLicenseAgreementCommitmentsDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYLicenseAgreementCommitmentsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="loc_us-gaapPaymentsForRoyalties" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRoyalties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ValueOfProductDevelopmentInvestment" xlink:label="loc_IMMYValueOfProductDevelopmentInvestment" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYValueOfProductDevelopmentInvestment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RoyaltiesRangePercentage" xlink:label="loc_IMMYRoyaltiesRangePercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYRoyaltiesRangePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AggregateValueOfCashFees" xlink:label="loc_IMMYAggregateValueOfCashFees" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYAggregateValueOfCashFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfLeaseEquipmentUnderCapitalLeaseDetails" xlink:title="00000070 - Disclosure - Commitments and Contingencies - Schedule of Lease Equipment Under Capital Lease (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCapitalLeaseObligationsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfFuturePaymentsUnderLeasesDetails" xlink:title="00000071 - Disclosure - Commitments and Contingencies - Schedule of Future Payments Under Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SegmentInformationDetailsNarrative" xlink:title="00000072 - Disclosure - Segment Information (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaapSegmentReportingAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfDrugAndChemicalPurchases" xlink:label="loc_IMMYPercentageOfDrugAndChemicalPurchases" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentReportingAbstract" xlink:to="loc_IMMYPercentageOfDrugAndChemicalPurchases" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://imprimispharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000073 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_ParkSellersMember" xlink:label="loc_IMMYParkSellersMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYParkSellersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AndrewRBollsMember" xlink:label="loc_IMMYAndrewRBollsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYAndrewRBollsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_JohnPSaharekMember" xlink:label="loc_IMMYJohnPSaharekMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_IMMYJohnPSaharekMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AgreementAxis" xlink:label="loc_IMMYAgreementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_IMMYAgreementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AgreementDomain" xlink:label="loc_IMMYAgreementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYAgreementAxis" xlink:to="loc_IMMYAgreementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_LeaseAgreementMember" xlink:label="loc_IMMYLeaseAgreementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYAgreementDomain" xlink:to="loc_IMMYLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CFOEmploymentAgreementMember" xlink:label="loc_IMMYCFOEmploymentAgreementMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYAgreementDomain" xlink:to="loc_IMMYCFOEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_CCOEmploymentAgreementMember" xlink:label="loc_IMMYCCOEmploymentAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IMMYAgreementDomain" xlink:to="loc_IMMYCCOEmploymentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_RSUMember" xlink:label="loc_IMMYRSUMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_IMMYRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_IMMYStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForPreviousAcquisition" xlink:label="loc_us-gaapPaymentsForPreviousAcquisition" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForPreviousAcquisition" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AverageClosingPriceOfCommonStock" xlink:label="loc_IMMYAverageClosingPriceOfCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYAverageClosingPriceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_QuarterlyCashPayments" xlink:label="loc_IMMYQuarterlyCashPayments" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYQuarterlyCashPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AmountOfClosingPrice" xlink:label="loc_IMMYAmountOfClosingPrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYAmountOfClosingPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AggregatedAmountOfClosingPrice" xlink:label="loc_IMMYAggregatedAmountOfClosingPrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYAggregatedAmountOfClosingPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_AreaOfSquareFeet" xlink:label="loc_IMMYAreaOfSquareFeet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYAreaOfSquareFeet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaapPaymentsForRent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPaymentsForRent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfAnnualRentIncreases" xlink:label="loc_IMMYPercentageOfAnnualRentIncreases" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageOfAnnualRentIncreases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_EmploymentAgreementTerm" xlink:label="loc_IMMYEmploymentAgreementTerm" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYEmploymentAgreementTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfCurrentAnnualSalary" xlink:label="loc_IMMYPercentageOfCurrentAnnualSalary" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageOfCurrentAnnualSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_PercentageOfIncreasesCurrentAnnualSalary" xlink:label="loc_IMMYPercentageOfIncreasesCurrentAnnualSalary" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYPercentageOfIncreasesCurrentAnnualSalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="immy-20141231.xsd#IMMY_TermOfStockOption" xlink:label="loc_IMMYTermOfStockOption" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_IMMYTermOfStockOption" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E4MAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Acquisition - Pharmacy Creations, Llc - Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump"><a title="us-gaap_Goodwill" onclick="toggleNextSibling(this);">$ 331,621</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Goodwill</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember', window );">Pharmacy Creations, LLC [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">4,982</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">58,420</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">30,256</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">213,190</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">44,510</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">659,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total identifiable assets acquired</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">1,010,358</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued liabilities</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">120,049</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">107,308</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">227,357</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable assets less liabilities assumed</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">783,001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump"><a title="us-gaap_Goodwill[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">331,621</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Goodwill<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">$ 1,114,622</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of assets acquired at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of inventory recognized as of the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 37<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities assumed at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 37<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of property, plant, and equipment recognized as of the acquisition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 37<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744172&amp;loc=d3e2207-128464<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Goodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Debt (Details Narrative) (Pharmacy Creations, LLC [Member], USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Pharmacy Creations, LLC [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credits borrowing limit maximum</a></td>
        <td class="nump"><a title="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">$ 75,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Borrowed term loan</a></td>
        <td class="nump"><a title="us-gaap_ShortTermBorrowings[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShortTermBorrowings<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.(a),16(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Subparagraph a(1)<br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 13<br><br> -Subparagraph 2, 3<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EN4AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets and Goodwill - Schedule of Intangible Assets (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsGross" onclick="toggleNextSibling(this);"> 659,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsGross</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" onclick="toggleNextSibling(this);">(48,006)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying value</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet" onclick="toggleNextSibling(this);">610,994</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsGross[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember]" onclick="toggleNextSibling(this);">596,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsGross<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_CustomerRelationshipsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember]" onclick="toggleNextSibling(this);">(36,740)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_CustomerRelationshipsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying value</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember]" onclick="toggleNextSibling(this);">559,260</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_CustomerRelationshipsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
        <td class="text">15 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Name [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsGross[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember]" onclick="toggleNextSibling(this);">5,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsGross<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_TradeNamesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember]" onclick="toggleNextSibling(this);">(750)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_TradeNamesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying value</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember]" onclick="toggleNextSibling(this);">4,250</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_TradeNamesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Non-Compete Covenant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
        <td class="text">4 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsGross[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsGross<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_NoncompeteAgreementsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember]" onclick="toggleNextSibling(this);">(9,375)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_NoncompeteAgreementsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying value</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember]" onclick="toggleNextSibling(this);">40,625</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_NoncompeteAgreementsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">State Pharmacy Licenses [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization periods (in years)</a></td>
        <td class="text">25 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsGross[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember]" onclick="toggleNextSibling(this);">8,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsGross<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_LicensingAgreementsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
        <td class="num"><a title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember]" onclick="toggleNextSibling(this);">(1,141)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_LicensingAgreementsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying value</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember]" onclick="toggleNextSibling(this);"> 6,859</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_LicensingAgreementsMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>18
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0":6O*S90(``)`K```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,VM%NVC`4!N#[27N'R+<3
M,78<TTU`+[KM<JNT[@&\Y$`BDCBRW0[>?DYH454Q$!K2_AL0)#[G)TC?U3^_
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MA3DD2(X,)(<"R9&#Y-`@.68@.6Y`<GP$R2&F*$%01!4HI`H44P4*J@)%58'"
MJD!Q5:#`*E!DE2BR2A19)8JL$D56B2*K1)%5HL@J4625*+)*%%DS%%DS%%DS
M%%DS%%DS%%DS%%DS%%DS%%DS%%DS%%D5BJP*15:%(JM"D56AR*I09%4HLBH4
M616*K`I%UAQ%UAQ%UAQ%UAQ%UAQ%UAQ%UAQ%UAQ%UAQ%UAQ%5HTBJT:15:/(
MJE%DU2BR:A19-8JL&D56C2*K1I%UAB+K#$76&8JLL_\E:XA]0^+CZ[__*>.8
M,X4W'W8-^2N75/9#SVVNC*/R1W"QF7GU`*]GG\E1F*:XJV)%\<H/X3#WU/[8
MF[QWMO>Q0>KH\@`O%='A]*2/@\B%F@XET6-ER\/&V#Z]?.&;MB<-_=:2RB.[
M^=BG7?X!``#__P,`4$L#!!0`!@`(````(0"U53`C]0```$P"```+``@"7W)E
M;',O+G)E;',@H@0"**```@``````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````C)+/3L,P#,;O2+Q#
MY/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1`]_:$`X)*8]O1]N?//UO>[N9I5!\<
M8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+
M&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9J&7<E.4]AK\>4"T\U<%J"`=[!ZH^
M^CSYLK<T36]X+^9]8I=.C$">$SO+=N5#9@NIS]NHFD++28,5\YS3$<G[(F,#
MGB;:7$_T_[8X<2)+B=!(X/,\WXIS0.OK@2Z?:*GXO<X\XJ>$X4UD^&'!Q0]4
M7P```/__`P!02P,$%``&``@````A`!:&`>[9`@``:RL``!H`"`%X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<R"B!`$HH``!````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````+R:2V_:0!S$[Y7Z':R]%[/OI(K)H56E7-OT`ZS,@E'`
M1M[M@V_?%4T,D9KIQ9H+DA>Q_.6=F=_PN+O_?=A7/^.8=D/?"+E8BBKV[;#>
M]=M&?'_\\N%&5"F'?AWV0Q\;<8I)W*_>O[O[&O<AEQ>E;G=,5=FE3XWH<CY^
MK.O4=O$0TF(XQKX\LQG&0\CE<MS6Q]`^A6VLU7+IZO%Z#[%ZM6?UL&[$^+!6
M3E2/IV-YZ_]O/FPVNS9^'MH?A]CG?[Q'_6L8GU(78RZ;AG$;<R.FI52?GU%N
M4686]1OC2/8X$HUC%'D<H^`XGCV.1^,X31[':3A.\1)5RNX&C2/9SI+069+M
M+`F=I0SYL)1!AZ791M?0Z)IM=`V-;@JVJ,XR2W18QK+'L6@<RXY!"V/0LF/0
MPAAT[!AT,`;]K+F32Q&+18S/7>=\69\?8?BQ]0OEZ]A@</#>R%NRN>4M,K><
M52]3&;YH9EIZ[L<2<DJQ.:4@IQ2;4PIR2K,YI2&G--OG&AK=L#EE(*<,FU,&
M<LJR.64AIQP[=QS,'<=.90=3V<^:.VW8MY^ZL.LOJ3PM(3:P!8SUR\:XA1CW
M;%!Y""IV],'DD^Q[(^&]D;.::>HS%S--2R\5!T)<L:FI(#4U73I0.YH=.AJF
MCF%3TT!J6C:F+,248SO+86>QZ[&"]=BPB64@L2R[<5G<N-B0<!`2GJT=#[7C
M9X5$RJ=]^>%M^A[G[S6J?FSI0N6R,QA&L)SU9*;J<#F<:>FE34!\*S:^%<2W
M8N-;07QKMG0TU(YAX]M`?%LVOBW$MV1'L(01K-D9J&$(&C:^#<2W9>/;0GP[
MMG8<U(YC0\)!2'@V)#R$!%W)J.FP(QDFLF0?E(0')=DTEYCF[+/2\+`T6\<:
M)S([`BV,0,N.0(LC<-8FF+HPQO6W/);_.5Y_KKI>1J'#+EZP=WEVT?&PZ+"+
M!>P5BATY:HJ<^M5?9%=_````__\#`%!+`P04``8`"````"$`?%S?]UD%``#9
M%0``#P```'AL+W=O<FMB;V]K+GAM;)2807.C1A"%[ZG*?U!QSPH0(,EE>VO7
MUB8^Q%9%SNZ1&L-(FC(PVF&PK/SZ-&@-#T:>DD]R@WET]WRO&;C\_)IGHQ>N
M2B&+*\?[Y#HC7B0R%<7FROGW\=L?,V=4:E:D+),%OW(.O'0^7__^V^5>JN<G
M*9]')%"45\Y6Z]W%>%PF6YZS\I/<\8+.K*7*F:90;<;E3G&6EEO.=9Z-?=>-
MQCD3A7-4N%#G:,CU6B3\5B95S@M]%%$\8YK2+[=B5SK7EVN1\>_'BD9LM[MG
M.>7]FCFCC)5ZD0K-TRLGI%#N>>^`JG9?*Y'1V?G$G3CCZ[;(I1JE?,VJ3#]2
M>6_JU"\_\/VH_L^Z%=\%WY?=174X>OTABE3NZW^EUA[::$()[)M3/T2JMW3>
M==WVV%]<;+;Z[2#)CT&_Z2#=I_D=%4UY;QV)::7B1:&%/L1WQ;'[0M(2UEV_
MH\H\9Z0N!/VA[E*O3AQ5;JB),A,IHQ;%7UG&BH3'J_K2$B1\D/`_(!$O&:A,
M0*7I];N)K#3E4R]W&<MU_+#CH!*`2F#-I:^RTM@4ZGO;E/!C*M3/MK<1R#10
MG%G2#</V3D%E.DSF06U8(?YK>(<[3[$/L^%%JRK/F3K4W5N)32'(0JS0\9<D
MD56A408;,1_*?$E^5J(4M=7BY9:1L9-#?$.>;LR',M@(SQWJ_$.N4R*I&5MM
MI=*/7.4$ZPL=IE5&'6R%9]!:7U)HJ02-I&X1IC2PVL7T##Z7BN^8((^\TH`J
M>=D8YD%ON8IO*H4Z<]0Q"/U6J4+H2O&CXZ@SNQI1$)B1W[M$##CO"IJJ&_&4
M\?A+69+#&J$_I4SW(J-AU5(UZUG6P//7*I;DK@.KU>H)0`=51?U=H`[ZUC/X
MO.5/O>S1GY[!(?DG>=[*+*4Y&R^H>GW`6R&.GL'C'3U@<AX_LM?>RLV0/L_`
M;Y'O,GG@-)#8"SV=J&":3WA3I(Z&K3';\ES4@/WJ-,TZ33+TL.OS,T/H?`.Z
M%=_4&C!<>SD@?+X!WZIZ*OG/JKY^4;.+W,Z0-]_@S>YAG$)SY,XWN+,+$2,M
M>',$SS\!GFT<]#)"\HZ/2YR,X&-B@A#&MLR10]_@T&[G7A+(I&\P^8Z?3R2$
ME/H&I79;]Q)"7B<&KW9?]X20V(E)K&G5$U4AN!,#7'3LB8L1W8F![HVT."\&
MX&@+!"-S8J)K/KS(P?&2MBQD8A"J-U?MZ*5@,`KL%B#@6@M,>FMDS$S[$Q&]
MY+FT8EU*!L=VI5Y*O94R.+8+D0>ZVGJK9H!L%Z(&MT(!KAH%@V[;A:C!G1#V
M*#!`M@N1"3HA'#B!0;-]`X+6"G#Z4#`H#2?7*MGRM*+G+^VRCL<Q(1P^@0&V
M?8HA1P&23<$@H?>FV"W73."F(D"P*3A3YU@D%H:S)S"PMD_#7F&(=6!@;1="
M?P2(-06#RNQ"Z(\0L:;@0T+HCQ"QIF`@9!_TV"//1:Y#@VN[$C8I1*XI&*14
M[P7C(S-E?,^4HBW^"X=E#Y%G"@;7G]@=@ASJ(,ZA@?,IG<YGJ(,XAP;.=ATT
M?(@\4W!&85U"N%8A\DS!&4)_,_7,]1,K>YU&G$,#9WMEN.01XDS!&0EUE:$O
M(L29@@\)H2\BI)F"#PGA<R-"FBD8"/4V+S:J(Z2:`IM.UYMUO%3R10"-$5)-
MP;DZ3:*H@U1'!M6]NC"?6[[F"G40ZLB`^N2+5>M7U$&F(X-I^SX/7>;1U[5N
M-Q095-N5T&93I)J"0:OM0FB/*5)-P4#HQ&M?VZ%[!CV:(M04#'6&;X"@HG#-
M/!=AG#90CYL-#GWY2UB6T"?)^J?YIA>$T?%-=?SV5?;Z?P```/__`P!02P,$
M%``&``@````A`-!O"'*)!```1Q```!@```!X;"]W;W)K<VAE971S+W-H965T
M-"YX;6R46%UOHS@4?5]I_P/BO0'S84R49-10=7>D'6FUVH]G0IP$%7"$2=/^
M^[WF$L#.3`;ZD`1S.!R?:Q_;77WY*`OKG=<R%]7:)@O7MGB5B7U>'=?V/W^_
M/C';DDU:[=-"5'QM?W)I?]G\^LOJ*NHW>>*\L8"ADFO[U#3GI>/([,3+5"[$
MF5=PYR#J,FW@LCXZ\ESS=-\^5!:.Y[K4*=.\LI%A64_A$(=#GO$7D5U*7C5(
M4O,B;4"_/.5G>6,KLRET95J_7<Y/F2C/0+'+B[SY;$EMJ\R67X^5J--=`?W^
M($&:W;C;BSOZ,L]J(<6A60"=@T+O^QP[L0-,F]4^AQXHVZV:'];V,UDF'K&=
MS:HUZ-^<7^7HMR5/XOI;G>__R"L.;D.=5`5V0KPIZ->]:H*'G;NG7]L*_%E;
M>WY(+T7SE[C^SO/CJ8%RA]`CU;'E_O.%RPP<!9J%%RJF3!0@`#ZM,E=#`QQ)
M/]KO:[YO3FO;IXLP<GT"<&O'9?.:*TK;RBZR$>5_"&I[U)-X'0E\=R3$FTWB
M=R3P/9!X+"0A_;D4![O5NO22-NEF58NK!4,/A,MSJ@8R60+SS1[L3&_8C_P"
MHQ3)LV)9VS!GP`H)17[?T&#EO$-=L@ZRO8<0'9'<$*J<H*Z7"*Z-)7Z_<C<E
M"JR4J$HJ:5ML`.Y>FF>\]SN(J(=H2L"@Z4H4&$;+Z,4T[&E1&T*"7FPR:M!>
M',QYL0*O;>A5WV-*C1<CA+:5(C3T?&8@$D3`9T_B#[YIVF`:3#=%@0UM@]=H
M"D*B5EO$J*M+3\:WB0M__7U-%9VC2H$-5:RG154(056$4M<+3,<TQ(^%17.$
M*;`A+#:$(02%/1$W]IAO0!*$3*FE6O5&:?!XJBFP+BX:BH&N(03%A30*7*/8
MR1CPH)KQ'%T*K$^\R(B:+4)&$V_4H`TC`@O.=$=:M&'),&O0D@Z#GGA^[!)F
MN)9H$!:R>`#HXE1B3BX7P7P=YT+D&X.IPZ`XYK+()^8PUR!A'`?QJ*BZ/!6L
MT^5A#&OR[M80Q-R\HS`/]0XD9(P@E%"7#070U:FLG:X.DUE39Z8Y00RJ(VY$
M`EB:37UC3$1CRJ)AMNKZ5`)/UX=YK>DSWKTEB$%]$!4D@!DYO+T=GHD.BBA[
MH'!6\JM-ESDMC338=IC1O!RWZ/;,"GARG_"1F?`=IK/'9Z.5I;,&2:;D*)F5
M\BW:B`VC+ML.@^I\+[A;?C1`X$?A,#QUXV9E/+D/>3.NMAT&I7F,WDL;I_PC
M:;-BGF!FCX<\,W.^P^!&1PUYPHAKA%ZB@R(:P-Y^2![-/,]8#M1VV8>VQPME
M^Y1>WU$JX;+08>)VV_-$%J1=#=4VHOTS.I;H<'?!AM&L"S:6""4X@)GX$\'W
M2P4S7-MZB,&JQ\3W8F:,676N4U,>(8R&E'EF&..Y#4\D):^//.%%(:U,7-29
MS`,W^M;^O/CLJ0VST;Z%<V1[Z'+Z&W",.Z='_BVMCWDEK8(?@-)=1-#]&@^"
M>-&(<WL.VHD&#G#MSQ,<V#F<'MP%@`]"-+<+=3;I_P6P^1\``/__`P!02P,$
M%``&``@````A`/6-([X/!```>@T``!D```!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&ULG%?;CJ,X$'U?:?\!\=[AED"(DHR:2^^.-"NM5CNSSP2<!#5@A$FG
M^^^W[`K$-IE,9EZ:4#YU.%4NNZK7G][KRG@C'2MILS&=F6T:I,EI43:'C?GU
MWY>GI6FP/FN*K*(-V9@?A)F?MK__MC[3[I4=">D-8&C8QCSV?;NR+)8?29VQ
M&6U)`RM[VM59#Z_=P6)M1[)".-65Y=JV;]59V9C(L.H>X:#[?9F3A.:GFC0]
MDG2DRGK0SXYERP:V.G^$KLZZUU/[E-.Z!8I=697]AR`UC3I??3XTM,MV%<3]
M[LRS?.`6+Q/ZNLP[RNB^GP&=A4*G,8=6:`'3=EV4$`%/N]&1_<9\=E:IXYK6
M=BT2]*TD9R;]-MB1GO_HRN)+V1#(-NP3WX$=I:\<^KG@)G"V)MXO8@?^[HR"
M[+-3U?]#SW^2\G#L8;L7$!$/;%5\)(3ED%&@F;D+SI33"@3`7Z,N>6E`1K)W
M\3R717_<F)X_6P2VYP#<V!'6OY2<TC3R$^MI_1^"G`L5DK@7$GC>(+GCZ%T<
MX7EQ=.#G'8?YQ0&>/_<E"$;$"<^[7[(P/R+=2=9GVW5'SP;4,&2`M1D_$<X*
M2(8\H]8Q\]]+/&2<DSQS%L$%.650+6_;P'?6UAOL<'[!1(B!`SIB7!41#PB^
MG9PV&0R22Z#ZI`.$%Q.$-,8%>R;'=;MN!OD<#!4B2?,6"_5#$6+FHD"XN%@W
M)+HAE0R*-OC0X]HX>&,"U9@V;['4M"'&%XGWP^72]E5`C("K^$3V<'TG=.>J
M1RIY*-JA0A_7SL&Z]E#]4(280&B?AX&6]AB7)>6Z(94,BE*H9EFIJ.R`WQ;?
MN42&8N!^FFC?UD0C!D4'4"MZ)>/Z$HISW+7`UT`)@D#^B/$T2/H#'B5>_Q?C
MY7YZO/K910S&ZX6VK>4CQG4M7D]-6B*3+(!#(TEQ76RU$E@P#<R#AG+_2',G
M/2HMNQ%B,*JEXWN>ICA&@%1\LH?GW#@VDH<2`Y]+I&OVOG8.UK5KTB+$H/:G
M8.G[DY.#"$F\XG)3O>2BJ`]5]?PH_7@'N),>A78O18C!B\L-??UBBW%=BF$P
MW#DS`T3O"`[4S.-[(-`@/Q@O_&AJBJ>F9&I*%9.26(>W+ZDN>&9#T/FS[1>[
MH-PD)M=-)+X%35I%:?=^?$5=NS"RX[@G&G.JH-2(>-/3(O)_(2).HU9/X.MG
M@(<"("4BS]>:8WQ%72,:'0<3'V8O7&/=X'"*TU)-N@.)254Q(Z<G/G@NH&.-
M5AR*(V<%,PSX:_:$#\LW[,^.#0MB$-8\8+-@Y99/Y+C#Y&V-3C#YMMF!_)5U
MA[)A1D7V(-">!=`^.IR=\:6GK9C2=K2'F5?\/,+_.`3&&7L&X#VE_?#"TS#^
MU[3]'P``__\#`%!+`P04``8`"````"$`0X^N6S8"```'!0``&0```'AL+W=O
M<FMS:&5E=',O<VAE970U-"YX;6R,E,N.VC`4AO>5^@Z6]Q,G0,(,(HP&(=J1
M6JFJ>ED;QTDLXCBR#8&W[[$-Z0#5E$T2D_]\_[F1^?-!-FC/M1&JS7$2Q1CQ
MEJE"M%6.?_Y8/SQB9"QM"]JHEN?XR`U^7GS\,.^5WIJ:<XN`T)H<U]9V,T(,
MJ[FD)E(=;^%-J;2D%HZZ(J;3G!8^2#9D%,<9D52T.!!F^AZ&*DO!^$JQG>2M
M#1#-&VHA?U.+SIQIDMV#DU1O=]T#4[(#Q$8TPAX]%"/)9J]5JS3=-%#W(9E0
M=F;[PPU>"J:54:6-`$="HK<U/Y$G`J3%O!!0@6L[TKS,\4LR6TXP6<Q]?WX)
MWILWS\C4JO^D1?%%M!R:#6-R`]@HM772U\+]!,'D)GKM!_!-HX*7=-?8[ZK_
MS$556YAV"@6YNF;%<<4-@X8")AJECL14`PG`%4GA-@,:0@_^WHO"UCD>9U$Z
MC<<)R-&&&[L6#HD1VQFKY.\@2DZH`!F=('`_09)1-'I,DS3[/X6$C'R!*VKI
M8JY5CV!IP--TU*U@,@.RJVP,_?EW95"2BWEQ03X4U`:FL5],LW1.]M!"=M(L
M;S6C04'`?,@`7-]F\+ZS$^<8KG^=DV3@^NR60>/7X<)H?&ET7ZDNZ,HPRZX,
M@R8+C4CC.![>7_A/+OW?+]2)KWVG`S<4&C3!]]HS['(8=4<K_I7J2K0&-;R$
MUL71%!9/ATT.!ZLZ/]*-LK"!_K&&#PZ'><<1B$NE[/G@_BO#)VSQ!P``__\#
M`%!+`P04``8`"````"$`0HLBYA8L``";*0$`&0```'AL+W=O<FMS:&5E=',O
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M_?)5O:_U*?6?V0\__WOWX<M[?4FUF[?+ZWY/[S_]J@]`__O=;Q_[8T-?DG?_
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M]^<?/W_ZYW=Z,-/>OOSQKG]H7/S0[WJZX`Z7Q\=+\'^Z`NO2V^_EO_O=_/1&
M7RI=7+_H<>,??[Z]V?SX_3]TJ7\_KME>6G,W7W,_K>FO[/V.=P[[`?2_Y[_I
M]FJ^EVC:Z+QF,5]QF%9,?\]Q@O,FM[>V43RMF38Z31!L=&.?43*MF39*)P@V
M\K\IF]9,&^4.A4/I4#G4#HU#.\#P8-A_];L`OM<!\WC4Z)HP.VHN/SQ/!T>_
MNC\XIL]F.X!V'C1<S@O=CQLM'PZF]6)U=S-?L+NTD]5\S?[2FO5\3<0U]J$<
M+JRXG>_DR"6WM]?S-?&E-?9)G2ZML;\K&=9LIJ_,>F$G6GII)[8FN[3&#MW\
MPIJ-G6K%I35VWI27UMC7N+JTQFK6E]98S>;2&@O17EIC(;H+:Z[/?]?L9-"#
MY@M.AG[U3V^T^_.QO['"VV'-PVWVPU7PWF'GL'>('`X.1X?8X>20.*0.F4/N
M4#B4#I5#[=`XM`/</EPL[JZO'OZ9GWY=L,TLGVYU7I"O7SW/=V.'^W98$M1S
MV#GL':(!QL]G^'3LS#L\O>3HNXT=3@Z)0^J0.>0.A4/I4#G4#HU#.\"WOB)=
ML,VLL.Y&9X7[>YR5[J>^_:C5;S4O?;NQJ^AV6!.D=M@-,'S8B\VZ3SD_+O>^
M2>1P<#@ZQ`XGA\0A=<@<<H?"H72H'&J'QJ%UZ`*85=23@5G%;]?K5WL]>WS;
M#FN">@Z[`>X>+BO7FCA8.E\?.1P&N!EN8N9;'WUQ['!R2!Q2A\PA=R@<2H?*
MH79H'%J'+H!913TG>T'%?K55O+/S9SNL"2HZ[`88(FST/'"]\I"^2>1P<#@Z
MQ`XGA\0A=<@<<H?"H72H'&J'QJ%UZ`*8U=,3O%F]YUU)^ZV\HC]H#FN"B@Z[
M`88KZ?+VAA=2WR)R.#@<'6*'DT/BD#ID#KE#X5`Z5`ZU0^/0.G0!S")J$/&*
MB/U6'M%NXK?#FB"BPVZ`\>%PM;A9+.S&>^^;1`X'AZ-#['!R2!Q2A\PA=R@<
M2H?*H79H'%J'+H!9Q7X`^8J,#YMY1WNBM1T7!2$ANU'&E+=WFQN[,.^?7!%A
MKP?($1)#3I`$DD(R2`XI("6D@M20!M)"NE#FJ?LQC`_IEHO;M[I5^O9=4#]?
MQEE[?AK[\.1R.RX*:P^;G64WKNG_.#]OO?.'4>PI@AP@1T@,.4$22`K)(#FD
M@)20"E)#&D@+Z4*9%^['#5[XZ:<H_50<>>V"NAT7G6/>0W:0_:/TL]S%G3U<
M1X__>9KI'2!'2`PY01)("LD@.:2`E)`*4D,:2`OI0IEW[8<.K^@ZS"IF0Z([
M'Q+U+]8H?MC598<U^T?IN_I]</3X7\]9?9]'K(DA)T@"22$9)(<4D!)206I(
M`VDA72CSK/VD(<SZQ%5X&$S,<_HHH7_)S7*Z[+!F#XD>Y7RA7ME]VF%<,]V&
MW:W7]IAP?-S+="#$D!,D@:20#))#"D@)J2`UI(&TD"Z4>>1^$!%&?MZ3G?Y%
M4%R3??(P+@K/W6#L,;[RY;+'5A'D,,J8]FIE-V5';!%#3I`$DD(R2`XI("6D
M@M20!M)"]#Z5\PDU#]O/)L*P3YR]PR@C/'LW/L3;]B]5V]GKLL.:/20:9<AW
M<[->V9%S>-RDOWXO%_:?CX__^7S>^L=QPIH$DD(R2`XI("6D@M20!M)"NE#F
M>?OA19CWF>?M,/.89[;;GFW_E@++[++#FCTD&F7(O%S>+OUI\`';'"$QY`1)
M("DD@^20`E)"*D@-:2`MI`MEGK8?:;PB[3`)F:>UQ\1M_SX/2^NRPYH])!IE
M2'N]66T6=A`=L,T1$D-.D`220C)(#BD@):2"U)`&TD*Z4.9I^SG'*](.XY%Y
M6HPS@AG*\'IJ_V:<6>P=9`^)1AD?6V^N;F_MGOR`;8Z0&'*"))`4DD%R2`$I
M(16DAC20%M*%,DO;OW7I%6D?-IM/JC97=I^Z'1<%-U*0'60/B1[E&W?-XYHQ
M_]75]7+C=];'Q_T\/OY"3I`$DD(R2`XI("6D@M20!M)"NE#FN2]-JYZ>9?1O
M/M,I.3^3;<"T'1>%N3&JPIH])!IE3+F^N;FVAX,#MCE"8L@)DD!22`;)(06D
MA%20&M)`6D@7RCRMZN!,7NL^^]MWT,M^LWG:Q95=.K?CHC#ML-E9=EBSAT2C
MC&GO@C?M/%SZ#]CB"(DA)T@"22$9)(<4D!)206I(`VDA72CSL/V4Y^6/OLMA
M.#0_9WW^."XZ9[R'["![2#3*&/;:W_5VP!9'2`PY01)("LD@.:2`E)`*4D,:
M2`OI0IF']4G5\YX,+3FQ6EPAK,^G[L?-SJEWD#TD&F4(^Z?%:G%ESVH/V.8(
MB2$G2`))(1DDAQ20$E)!:D@#:2%=*/.T_7PC/&>?N`@/XY#YN8J+<#`S&>Z4
M^V]XF=\I0_:0:)0AZ?IVLT11W^T1.XDA)T@"22$9)(<4D!)206I(`VDA72CS
MHOVHY@5%A\G.O*B/E9<^_KF'["![2#3*4'1UN[FQ0^>`38Z0&'*"))`4DD%R
M2`$I(16DAC20%M*%,B_ZNEG4\M(LRDZA[;CH?+&]A^P@>T@TRE#V9N4O]1VP
MQ1$20TZ0!))",D@.*2`EI(+4D`;20KI0YF%?-XE:7IA$+6Q$OQT7A6$QB<*:
M/20:97KWXMUR?1?\8Q>*`[8_0F+("9)`4D@&R2$%I(14D!K20%I(%\H\LT^E
MGGB,O3"-\O'?=NFSIWO(#K*'1(_RK9&%_UW'QZW.`PI?<\*:!))",D@.*2`E
MI(+4D`;20KI09E'[6<0+'F8?EL^?O>K[9N?OY=V.BX)S%K*#["'1*..-TV*]
M\M,4FQPA,>0$22`I)(/DD`)20BI(#6D@+:0+95[T=2.GU861T\*'Q^.BL"Q&
M3EBSAT2C#&47R]7MPH9;!VQSA,20$R2!I)`,DD,*2`FI(#6D@;20+I1YVGX(
M%-X3/^\)[*K?S$]:'QZ/B\*TPV9GV6'-'A*-,CW0^K<)'+#%$1)#3I`$DD(R
M2`XI("6D@M20!M)"NE#F87WD].V'UM6%49.?0=MQT3G?/60'V4.B489S]>)W
MDQVPT1$20TZ0!))",D@.*2`EI(+4D`;20KI0YDU]VO1$4TZ9-OY"^':%*1-D
M!]E#HE&&DW2Q_Y-=YP_8X@B)(2=(`DDA&22'%)`24D%J2`-I(5TH\Z#]F":\
M^CX1=)CJS"82"QL4;%<^^KF'["![2/0H_3MA[#G4X?$_3K>Y1T@,.4$22`K)
M(#FD@)20"E)#&D@+Z4*9UWS9?&EU8;[D4_?MN"B\Y/K$:8<U>TCT*!=K^BZ/
MC\NGOC'D!$D@*22#Y)`"4D(J2`UI("VD"V5>TV=+3YR;%V9*_O:Q[6I8%-9T
MV6'-'A*-,EQL]7T*\V=+!VQPA,20$R2!I)`,DD,*2`FI(#6D@;20+I1YS]>-
ME%871DI+NQQNQT5A5XR4L&8/B489G\3HV[?P77@';'2$Q)`3)(&DD`R20PI(
M":D@-:2!M)`NE'G;?L82/H[VSV(6=WJ@?.*D'68SLP?4I;V?;+OR`<X]9`?9
M0Z)1^G>]/WZ/SV9IDXX#MCM"8L@)DD!22`;)(06DA%20&M)`6D@7RJSOVD=*
M?=^GWQCQL)D]2UW:C>EV7!2<NY`=9`^)1AG/W>O;"^<N-CI"8L@)DD!22`;)
M(06DA%20&M)`6D@7RKSMI>'2,]I>&"XM?0*Q]E'2/60'V4.B1PG/7'_4?5PT
MW3,=(3'D!$D@*22#Y)`"4D(J2`UI("VD"V5>MY_XA%?F;U^0U_UR/V/]C1'C
MHO",'3:;AG\/(X7Y/=$.&^TA$>0`.4)BR`F20%)(!LDA!:2$5)`:TD!:2!?*
MO.G+1DOK"Z.EI3]K'1>%38?-QJ97%YL.2\X;[;&;"'*`'"$QY`1)("DD@^20
M`E)"*D@-:2`MI`MEWO1EHZ7UA='2TEY+V8Z+SGGN1QF:ZF?_XO9VAVWVD`AR
M@!PA,>0$22`I)(/DD`)20BI(#6D@+:0+99[T9<.E_B$7EUY_4\2X:`BXOG!.
MWH\KSM%WD#TD@AP@1T@,.4$22`K)(#FD@)20"E)#&D@+Z4*9)_4)T_->K5E?
MF#3Y=RYNQT738RC/S?MQ19C6!T=[K(D@!\@1$D-.D`220C)(#BD@):2"U)`&
MTD*Z4.9I7S9N6E\8-ZW\F>NX:$RZN</E]GY<$2;U@=0>:R+(`7*$Q)`3)(&D
MD`R20PI(":D@-:2!M)`NE'E2GS@]<>][8=+DWP"S7?M<Z1ZR@^PAT2CC(_'-
M8GWCP\K#;,EJL5K?W=ISYR/V&T-.D`220C)(#BD@):2"U)`&TD*Z4.:1+XV>
M^G=2/!'[PN1I95_>[1J3)\@.LH=$D,,H0_[5U6)SY3].^HB-8L@)DD!22`;)
M(06DA%20&M)`6D@7RJSMM8^=OMWT8;D]>5WY2&)<=+[BWD-VD#TD@AP@1T@,
M.4$22`K)(#FD@)20"E)#&D@+Z4*9)_3ITA,)+TR5<`V^QE0)LH/L(=$HX\/S
M8G5[XT?+8;[D9G-W>VW3D"/V&T-.D`220C)(#BD@):2"U)`&TD*Z4.:17S9D
MNN:0Z69CT[SMN"@\3X?-SK+#FCTD@AP@1T@,.4$22`K)(#FD@)20"E)#&D@+
MZ4*9)_29TO.>V5Q?F"WY3UW:CHO.X>XA.\@>$D$.HVQ6#S^`]NJM'T5';!)#
M3I`$DD(R2`XI("6D@M20!M)"NE#F97VR],RR%R9,*[OV;?6KDN;?/74/V4'V
MD`AR&&4LNWJ[MK_ZB$UBR`F20%)(!LDA!:2$5)`:TD!:2!?*O*P/F)Y9]L*@
M:>7SX.MA47C.NNRP9@^)((=1'LL.8\A^W/'PSQ)O73MB'S'D!$D@*22#Y)`"
M4D(J2`UI("VD"V6>^G6#I^M+@R<?$X^+PM0^5MIAS1X200ZCC*D7;_6MK^$_
M>I>BO?I^Q#YBR`F20%)(!LDA!:2$5)`:TD!:2!?*/+4/HIYY5E\:2/D3VFL?
M+MU#=I`])!IEFE[<K&U.?9@M6-]L\*-DCMAI##E!$D@*R2`YI("4D`I20QI(
M"^E"F9=^V7SJFO.I"[?-F$^-FYU/[QUD#XD@!\@1$D-.D`220C)(#BD@):2"
MU)`&TD*Z4.8)??KTQ-/;2U,G.W>VUY@Z07:0/22"'"!'2/PHY[=:Z-=+SE_,
M/STNFMYJD4!22`;)(06DA%20&M)`6D@7RJSJC<^=GG<)?MC,YD]K?ZOBN.A\
M.MY#=I`])((<($=(/,HX\N@?C*TL-DD@*22#Y)`"4D(J2`UI("VD"V5>UL=1
MSRQ[82RU]E=[;C"6@NP@>T@$.4".D'B4H6S_>W@\K']T"?:10C)(#BD@):2"
MU)`&TD*Z4.9A7S:"NN$(:K.VF]'MN"@\53&"PIH])((<(,=1AGRKQ9U^`L4\
M8(QM3I`$DD(R2`XI("6D@M20!M)"NE#F27TD]>W'UAN.HGA[-"X*DPZ;G66'
M-7M(!#E`CI`8<H(DD!2207)(`2DA%:2&-)`6TH4R3_BZV=/-A=G3VNY!MN.B
M<[A[R`ZRAT20`^0XRG!V]K^:QZZN\6S!B@M.V&<"22$9)(<4D!)206I(`VDA
M72CST#Z*>N)<O3""\I_1OKWQ@=,]9`?90R+(`7(<9?B&GHU_0T_\N$'_W5O\
M16FGQ__^>#\,22$9)(<4D!)206I(`VDA72CSNCY]>J+NA:G3VE_?N?$9TSUD
M!]E#(L@!<H3$D!,D@:20#))#"D@)J2`UI(&TD"Z4><+7395N+DR5?!2_'1>%
M5V*?,^VP9@^)1@F>G-AE]H!MCI`8<H(DD!2207)(`2DA%:2&-)`6TH4R3_NR
M,=(-QTB;M8__QT5A4A\L[;!F#XD>Y3Q-V*QM`'UX7#1=/8^0&'*"))`4DD%R
M2`$I(16DAC20%M*%,J_JDZ5G/E.]-&'"M1<3IAN7'60/B49Y?/G5?R7X`9L<
M(3'D!$D@*22#Y)`"4D(J2`UI("VD"V56]O9UTZ6'S6RZA!=DQT7!>0O90?:0
M:)3'LO["^@&;'"$QY`1)("DD@^20`E)"*D@-:2`MI`ME7O9UTZ7;"],EO"`[
M+@K+^D1GAS5[2#3*XVMRR^!GYO7_BI=?#]C'$1)#3I`$DD(R2`XI("6D@M20
M!M)"NE#FJ7W>]+S+\^V%N9/_#+3MN"A,C;D3UNPAT2ACZM7;ZZ=3^]]SQ%YC
MR`F20%)(!LDA!:2$5)`:TD!:2!?*//7+YE"WG$-M_/71[;@H3(PY%-;L(1'D
M`#E"8L@)DD!22`;)(06DA%20&M)`6D@7RCRASZ&^_03V]L+\Z=J>BVS'16'"
M8;.S[+!F#XD@!\@1$D-.HSP^9-O+$PFV2"$9)(<4D!)206I(`VDA72CSH"^;
M-]U>F#==VQ=H.RXZY[N'["![2`0Y0(Z0&'*"))`4DD%R2`$I(16DAC20%M*%
M,D_XLJ'2[86ATM)>(]F.B\*$/F;:8<T>$HTR3"*6&_T^/#O[#[,5>EO3QA8<
ML=,8<H(DD!2207)(`2DA%:2&-)`6TH4R+_RZF=/M<V9.XZ*P-&9.6+.'1*-\
M8^:$;8Z0&'*")*/\Y[\I?7)%AKWFD`)20BI(#6D@+:0+99[>9U+/O#V^,)OR
M7UVTO?5)U#UD!]E#HE$>'S!M2G+`%D=(##E!$D@*R2`YI("4D`I20QI("^E"
MF8=]W5CJ]L)8ZMI?T1L7A><TQE)8LX=$H_SGL+[7(_810TZ0!))",D@.*2`E
MI(+4D`;20KI09F$WKYM*/6QF4RG_G53;<5$0%K*#["$1Y``Y0F+("9)`TE'^
M\^4ZPS8YI("4D`I20QI("^E"F:?UL=2WG_UL+HRCKNWBN!T7A4DQCL*:/22"
M'"!'2`PY01)("LD@.:2`E)`*4D,:2`OI0IDG]''3$PDOC)EPL[SQ8<\]9`?9
M0Z)1QIMEW2K[SZT^8)LC)(:<(`DDA62CC!_-[6+C5Z,<VQ20$E)!:D@#:2%=
M*//$/F9ZWBV3'N7P8V/P"NVX*#Q;,6["FCTD&F7\XNIM__:6N0,V.4)BR`F2
M0%)(-LKPP:S6*_^Y]#DV*2`EI(+4D`;20KI0YJ%?-HS:7!I&^1/?<5$8&,,H
MK-E#(L@!<H3$D!,D@:20#))#"D@)J2`UI(&TD"Z4><*7C9\V%\9/O!P/B\*$
M+KMQ1^<U>T@$.4".D!AR@B20%))!\E'&T_1NL["?R%!@DQ)206I(`VDA72CS
MHCZ->N;5]\)4BE=?GT'=;UQVD#TD@AP@1T@,.4$22`K)(/DH0]G-G;^)I,`6
M):2"U)`&TD*Z4.9A?0CUQ)W3A>'3M;\[9N.CIGO(#K*'1)`#Y`B)(2=(`DDA
M&22'%)`24D%J2`-I(5TH\X0^3'HBX84A$J^V&")M7':0/22"'"!'2`PY01)(
M"LD@.:0893A+U_HE>?;VJQ*;5)`:TD!:2!?*O.CKIDB;"U,D7FU]NG,_;G9^
MU-Q!]I`(<H`<(3'D!$D@*22#Y)!BE*'LXFKMO[RBQ"85I(8TD!;2A3(K>^=C
MI&^?JP_+?7QD!^AV7'3N=P_90?:0"'*`'"$QY`1)("DD@^20`E)"*D@-:2`M
MI`MEGM#'1<^[%;J[-#;R[VT=%X4I,3;"FCTD&F4X])>W2S_T#[,%_;?#^>MS
MV&<,.4$22`K)(#FD@)20"E)#&D@+Z4*9AW[94*G_=0[V`VIO_<%D.RX*`_N8
M:8<U>T@$.8PR)M>OW+ZSV[(CMHDA)T@"22$9)(<4D!)206I(`VDA72CSI*\;
M(MU=&"+=V!FS'1>%:3%$PIH])!IE#+FZN5G=V&7B@(V.D!AR@B20%))!<D@!
M*2$5I(8TD!;2A3)OZW.C_KK<_ZCB)QYB+\R/\$LX[GQ:=`_90?:0:)3QEN1N
MV7\KW/S[6`_8Z`B)(2=(`DDA&22'%)`24D%J2`-I(5TH\[;]J"?\-0W/;#M,
MB'2%#7ZCC<U7MG<^1KJ'["![2/0HP5]V8V^B.CPN>OQ>#D@,.4$22`K)(#FD
M@)20"E)#&D@+Z4*9UWW=<.GNPG#IQB;NVW%1>%7&<`EK]I`(<H`<(3'D!$D@
M*22#Y)`"4D(J2`UI("VD"V6>\F7CI+L+XZ0;?]_#N"A,Z`.F'=;L(=&CA">H
M70T.CXO.)ZC_93'6G"`))(5DCQ)^0/9*<OZX:/J`"D@)J2`UI(&TD"Z4>6@?
M.CWS6="%X=.-OUISYZ.F>\@.LH=$D`/D"(DA)T@"22$9)(<4D!)206I(`VDA
M72CSE#YM>N*&Z<*4B><LIDQW+CO('A)!#I`C)(:<(`DDA620_%&^<<H6CXNF
M4[:$5)`:TD!:2!?*K*K>='OAGNGIG_P^;&<SIQM[+KF=5@479=*.M"=%I`/I
M2(I))U)"2DD9*2<5I))4D6I20VI)W8PLL`^BOGW>+JXN3*!PXDZK9F$Q@^(J
MA?55"NNDL$X*ZZ2P3@KKI+!."NNDL$X*ZZ2P$YU/;/Q<-[6>5DUGMEH[J;63
M6CNIM9-:!V2M?1;UO(?;Q16'4AO_50HZF7T&=4_2R>RKU-Q)S9W4W$G-G=3<
M2<V=U-Q)S9W4W$G-G=3<28&=%-A)@9T4V$F!G10X(`O\NLG4XNK2:,KF10KL
MDR@%=E)@)P5V4F`G!7928"<%=E)@)P5V4F`G!7928"<%=E)@)P5V4F`G!792
M8"<%'F@8\#S\_K%@P&/%+\VKGO/X?&%@=6M3)!7'Q(JDXKY*Q9U4W$G%G53<
M2<6=5-Q)Q9U4W$G%G53<2<6=5-Q)Q9U4W$G%G53<2<4#LL`^M'KJ\?G2M,J?
M&RVN,*XB*:RO4E@GA1UH'$=>^`5<"NU;*;230CLIM)-".RFTDT([*;230CLI
MM)-".RFTDT([*;230@=DH5\WOUI<71A@W=K$4&>RSZMT[792<"<%=U+P@8;@
MEWX_HH+[5@KNI.!."NZDX$X*[J3@3@KNI.!."NZDX$X*[J3@3@KNI.`!67"?
M<CUO'+VXNC#NNO6)Y;1J=@?N,R@%=U)P)P5W4F`G!7928"<%=E)@)P5V4F`G
M!7928"<%=E)@)P5V4F`G!792X(`L\.NF6XNK"^,MO`-G6C4+[",O!7928"<%
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MU'N@L??-VX<W9/5ORAK^6?&'3DV;S`X`W[$.`"<=`$XZ`)QT`#CI`'#2`>"D
M`\!)!X!31=(!X*MT`#CI`'#2`1"0'0#]M,4/@*??$;)8#%.:^0%@K\OI`!A6
MG0OH`'#2`>"D`\!)!X#3@:0SW%<IL),".RFPDP([*;"3`CLIL),".U4D!?95
M"NRDP$X*')`%[J<M'O@Y9_@PI=%^SV<X;],6/MY18"<%=E)@)P4>:+A->_@)
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M&__4[^NSMR[I1/>]Z`!PT@'@I`/`20>`DPX`)QT`3CH`G'0`..D`<-(!X*0#
MP$D'@),.`"<=``'9`="/8<(#X*F+^C"VF8?'G'P1#'>F\$X*[Z3P3@KOI+!.
M"NNDL$X*ZZ2P3@KKI+!."NNDL$X*ZZ2P3@KKI+!."NNDL`%9V'[<\I*PPWAF
M%A:_W7RQ"(8X4U@GA7526">%'6A\`62U6BYN[4!2Z7#-9KG4+T*?OV5;Y7W/
M*N^D\DXJ[Z3R3BKOI/).*N^D\DXJ[Z3R3BKOI/).*A^0E>^'+R\I/PQKPO*W
M5W@E9!&,=*;R3BKOI/).*N^DT$X*ZZ2P3@KKI+!."NNDL$X*ZZ2P3@KKI+!.
M"NNDL$X*ZZ2P`<W#+E\X.WM8[[,S.W^VBW%5^%0:M..J/2F::/A5-:NW_F:7
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MARIAY.>>V,,P9AX;MV'+8&0SQ1[H/X\W%=RW4G`G!7=2<"<%=U)P)P5W4G`G
M!7=2<"<%=U)P)P5W4G`G!7=2<"<%=U+P@"QX/UT)@S_Q%'HY3&-FH9>\@@<S
MFRGT0$/HY?`ZU?RA5Z5],Y5V4FDGE792:2>5=E)I)Y5V4FDGE792:2>5=E)I
M)Y5V4FDGE792:2>5#LA*]V.4L/1S3^UA_#(KOL%;CY;!D&8J[J3`3@KLI,!.
M"NRDP$X*[*3`3@KLI,!."NRDP$X*[*3`3@KLI,!."NRDP$X*')`%[L<I8>"G
M3N5A_#(+RW>B+(,AS13626&=%-9)89T4=J+P+L&&H6H]K9KNO-3:2:V=U-I)
MK9W4VDFMG=3:2:V=U-I)K9W4VDFMG=0Z(&O=#U!>TGH8N(2M;Z\P\EX&8YFI
MM9-:.ZFUDUH[J;63PCHIK)/".BFLD\(Z*:R3PCHIK)/".BFLD\(Z*:R3PCHI
M;$`6MA^@O"3L,'`)PVYN.28)QC)36">%=5)8)X4=:+@]MT-(C7T#-7928R<U
M=E)C)S5V4F,G-7928R<U=E)C)S5V4F,G-792XX#FC?OW&;RD\<-Z?]:,&<FX
MZOP4^7X!VI'VI&BBH3'FVMCM<=K@_)?'I!,I(:6DC)23"E))JD@UJ2&UI&Y&
MUKB?G83G\3/OME;#S&5^/N/^>EQU_G*K=3"L>3C%U=I)K9W4>J+S(_#MTHZN
MPWG5]`BLYM.&$ZFYDYH[J;F3FCNIN9.:.ZFYDYH[J;F3FCNIN9.:.ZEY0-9<
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M'9"5[H<G8>GG/F@/0Y=9\8W=&F\7JV`T,Q5WVG&5`OLJ!7928"<%=E)@)P5V
M4F`G!7928"<%=E)@)P5V4F`G!7928"<%=E+@@"QP/SP)`S]U*@_#EEE8CDA6
MP4AF"NNDL$X*ZZ2P3@H[T?F18[FQFW*UGE8%=V-.:NVDUDYJ[:363FKMI-9.
M:NVDUDYJ[:363FKMI-8!6>M^>/*2UL.P9=;:?SN[3N)@)#.U=E)K)[5V4FLG
MM7926">=Q$X*ZZ2P3@KKI+!."NNDL$X*ZZ2P3@KKI+!."NNDL`%9V'YX$H9]
M[E5Z&+K,`E_SJ54PFID".RFPDP([*;"3`CLIL),".RFPDP([*;"3`CLIL),"
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MKW*LAU7G`U*GLY,Z.ZFSDSH[J;.3.CNILY,Z.ZFSDSH[J;.3.CNILY,Z.ZFS
MD\(Z*:R3PCHI;$`6MI^BA"?P,^_-UL/T1?L-IF,VA-:)',QHIA/928&=%-A)
M@9T4V$F!G13828&=%-A)@9T4>*#S+9;=8ZFW;Z3>3NKMI-Y.ZNVDWD[J[:3>
M`5GO?I82]O[78OWN_0\__WOWX<O[#[\KYM5;O27ESS\^Y/KOQ7J8O<PZ<S8V
MKIJ=R,'0YF%?ZNRDSD[J[*3.3NKLI,Y.ZNRDSD[J[*3.3@KKI+!."NNDL$X*
MZZ2P`XU'UH6AL4+[5@H=D(7N9RIAZ.>>V,,L9A;<7['0B1U,;*83VTG!G13<
M2<&=%-Q)P9T4W$G!G13<2<&=%-Q)P9T4W$G!G13<2<&=%'R@(;C>H(_G:PKN
M6REX0!:\'ZR\)O@PD)D%W^!9]CH8VTS!G13<2<&=%-Q)P9T4W$G!G13<2<&=
M%-Q)P9T4W$G!G13<2<&=%-Q)P0?ZYAGN6REX0!:\'[B\)O@PJ)D%YX]$6`?C
MG"FXDX([*;B3@CLIN).".RFXDX([*;B3@CLIN).".RFXDX([*;B3@CLI^$#?
M#.Y;*7A`%KP?LKPF^#"<F06_LQL77=*#$<X4W$G!G13<2<&=%-Q)P9T4W$G!
MG13<2<&=%-Q)P9T4W$G!G13<2<&=%-Q)EW`G!0[(`O?CE##POYZX.1O&+[.P
M^/V>BW4PI)G".BFLD\(Z*>Q`PR&]NEY<7_F!I-*^F4H[J;232CNIM)-*.ZFT
MDTH[J;232CNIM)-*.ZFTDTH[J71`\]+7/AY[YMW9PW;VO)K7[G%5>#L.VJF=
MCC;]WJPWTPM0>U(TT5#\\H^SP8Z.TU;G?<>D$RDAI:2,E),*4DFJ2#6I(;6D
M;D86O!^MA*?V<X,/(YG9*<X?''L=#&[&4QRDX+Y*P9T4?*`A^,-MJ3U4'*8E
MY[H*[CM2<"<%=U)P)P5W4G`G!7=2<"<%=U)P)P5W4G`G!7=2\(`LN)*]*GB_
MW?]R=F^Y"0)A&(:W0EQ`[9B8ID1)/*3G7G4%M!W15#L&:+K]OL.(3#](FO1.
M7Q&5)RC^&I4]_+KWM:-I6*H36)E>`ER7`EP3X)H`U@2P)H`U`:P)8$T`:P)8
M$\":`-8$L":`-0&L"6!-`&L".$H"[&<L_]FCPVR&]7:3L_ZGFM-H@M/NT9H`
MU@2P)H`U`1S2Z="T_]X3;[T2WIKPUH2W)KPUX:T);TUX:\);$]Z:\-:$MR:\
M->$=)?'VHY;8^X^#LVD8S<3.`Q]DGI;ZM2-',YV&'F=-.&O"61/.(84OGDZ&
M_BJV7:2[!T#KBH#6!+0FH#4!K0EH34!K`EH3T)J`U@2T)J`U`1VE`#VNMM;6
MZ[S.L]G!EH5=V?V^2M[<EQ^+^DUXKDEI-_/1PJ2+B3]ZDKXTZ=H,]!N3W@[U
M.Y/>#_4'DSX.]2>3OC1]?+[A*IL=\\(^YV6Q^ZR2O=TTD]PKID7EKO#'&OZG
M97G*<<?YB->L5U?7[M"<W-K\W?*CII<77+YQKF[/\,#&WZ[\:#9+]@,``/__
M`P!02P,$%``&``@````A`'85$"M2!```;!```!D```!X;"]W;W)K<VAE971S
M+W-H965T-38N>&ULG%A=;^HX$'U?:?]#E/<FMA-(C("K=JON7FFOM%KMQW,(
M!J(F,8I#:?_]CC_RY31LR@L0.)XY<V9\7'?][;W(G3=6B8R7&Q=[R'58F?)]
M5AXW[M]_O3S$KB/JI-PG.2_9QOU@POVV_?FG]957K^+$6.U`A%)LW%-=GU>^
M+](3*Q+A\3,KX9<#KXJDAL?JZ(MSQ9*]6E3D/D%HZ1=)5KHZPJJ:$X,?#EG*
MGGEZ*5A9ZR`5RY,:^(M3=A9-M"*=$ZY(JM?+^2'EQ1E"[+(\JS]44-<ITM7W
M8\FK9)=#W>\X3-(FMGH8A2^RM.*"'VH/POF:Z+AFZE,?(FW7^PPJD+([%3ML
MW$>\>B)+U]^NE4#_9.PJ>I\=<>+77ZML_WM6,E`;^B0[L./\54*_[^57L-@?
MK7Y1'?BC<O;LD%SR^D]^_8UEQU,-[5Y`1;*PU?[CF8D4%(4P'EG(2"G/@0"\
M.D4F1P,42=[5^S7;UZ>-&RR]180"#'!GQT3]DLF0KI->1,V+?S4(FU`Z"#%!
MX-T$(>'_+?8U$577<U(GVW7%KPX,"Z02YT2.'EY!P*8@G;XM<:I"*$T&>911
M-BY,.9`7T):W;4S)VG\#*5.#>=(8>&TQN$7XP*:E!#3ZE#[7MLDLP3*SU%I2
M>=)?]--T1`9I@J^DD>"-"[%;\C$-6OHZL\9$JGQ"(H*7+6"0&)K5KT]*'L`D
MWJY3+K()A&U\34!C-`&,""4A:A$#!C!K7V<@%]D,%FU\S4!C@$=/I@D5ED,.
MMZN78#MW9.76F%#MW_XX1<-$\^26B^R$L9508XS<`8DC.B&W=/_>'KM=J@3;
MF:F566/,I(6+.)[0F'XEL03;B>T1UQB=^"%`44@Z:H,)PS#0_9KGJ:Y6#3E0
MU(FJ9\R`#`D2Q`AUHS`D(2VG)_Q,$MJHAGO=WFI8@TSS;^TU+`VI1^)V]Q7:
M5J#S2:.`]CB=/"+Q(N[VX5``R^-F"C`V.XHZ$S4<^FY'*<71%(>[[`Z/_8XB
M>QH-*%2.N_""3J>A"G?9G3S6K?U`T6@,&L.31][2"Z8TL,QN9A_&KD=1E\'T
MH;$]R2#PIK;C72:(QRY(46<UAH`&Z28LO67GDL,F6"8X4X*Q&]+>;C<,-*@9
M@ZAKTI"!Y88S&8QMD:*N1L-`@QH&I&O2@`&YRQ35*ML2NCYK!@;4,)@P1'*7
M(:I50P(Q[4HT!+0ASCKZB66)\SJA5@UI4&P?#@;4IT'QA"^03]PQA`U]VZ'5
M*IN&[8X&-*31V==P*J35]0Z(F6K(53:-;O)-4S1('Q0D6&`\M3GD]>,.$I]X
M)!Y-A@89$BA&"]KQ'"IQETW"?6^LA.U2!M0H@6DX.J_TI4]?C@I6'=DO+,^%
MD_*+O-!A.&3:;]O+YB-1?VZV/\!=[YP<V8^D.F:E<')V@*7(BT""2M\6]4/-
MS^KJM>,UW/+4QQ/<ZAE<8)`'X`/G=?,@[Z/M_PFV_P$``/__`P!02P,$%``&
M``@````A`/K*+8NR!0``/Q@``!D```!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&ULG%A=;ZLX$'U?:?\#XKV`34(@2G+5I+>[5]J55JO]>*;$25`#1$";]M_O
M^`/P&)+"]J%)S/'X,#,^![SZ]I&=K7=65FF1KVWB>+;%\J38I_EQ;?_]U_-#
M:%M5'>?[^%SD;&U_LLK^MOGYI]6U*%^K$V.U!1'R:FV?ZOJR=-TJ.;$LKISB
MPG*X<BC*+*[A9WETJTO)XKV8E)U=ZGF!F\5I;LL(RW),C.)P2!/V5"1O&<MK
M&:1DY[@&_M4IO51-M"P9$RZ+R]>WRT-29!<(\9*>T_I3!+6M+%G^..9%&;^<
MX;X_R"Q.FMCB1R]\EB9E416'VH%PKB3:O^?(C5R(M%GM4[@#GG:K9(>U_4B6
M.W]NNYN52-`_*;M6VG>K.A777\IT_UN:,\@VU(E7X*4H7CGTQYX/P62W-_M9
M5."/TMJS0_QVKO\LKK^R]'BJH=QSN"-^8\O]YQ.K$L@HA'&HH)$49R``_ZTL
MY:T!&8D_Q.<UW=>GM>T'SGSA^03@U@NKZN>4A[2MY*VJB^Q?"2*<5!N$JB#P
MJ8+0V>C)OIH,G\UD^'I_95?>A4C*4US'FU597"WH-.!976+>MV0)49IL2.YM
M?FZE!VZ)!WGD4=8V;!&X\PIJ^KZ)R&+EOD,=$H79]C$$(W8-@I</Z+4<(4LZ
MQ^%*-50XF%/AZ>;<MG(`8K?<J+'N`*(CCYA`AL8SX>"U#<';A8-PCI?>2LRL
M9;O3!M#*T![ZRKQ./O3^_5SP29C!C)@,)$9C(`<B4<6Y0[ID(3[0ZSJ?^SPX
M&/.(2&AD0F(T'G(@]`41S]%2AX@$4XAPL$DD,HA(C$9$#B@BOC,+V@F(R&(*
M$0XVB%"OC2L;5V(T(G*@)0+&H?_1[P]^&P$QX]:E[?'[M>)@DYFQ4;<2HS&3
M`XH9<7RB$_/(]X<;711-8<;!F-F,FMTL,1HS.=!TT7!^"&PD/4'C-I>8A?F$
M87>?LH8*I!'21U"5")>_T642:+SZC'2=J5:7BJJOWHQTHA2&-]J&<%W4"(U,
MBU137?;"<-8F7A&3()V8-H+3,DES25]T!]*BB:S@LU/30/I:K:9AETU,B`OD
M]+1(6=73$M%>MTB0GA9M!+,P!'AD<?I*W'<$_C0$&ZUQ`)/E#ET/'*\K+F8X
M29G)D#2;'J%`S6YVHJY$JHY(J^$IOLLPYC9)K,F`6A/3-A2HU4!M:<4-R3=Q
MZ*UM-TFNR9!>FTZB0"TW?Z$KLJ*'-#QT@IMV0B:IMD!CH8JH:2@*U!(,YK<-
M1-%%PDX=[\X,5'IJB/U]-Q1HS+YO.@K4M"76NMVMJYB5(?[CMC.5:HY%I6LK
MD:FM`FFBHH]@%ER$-6G[(C=2LO75^UI+)0ADK%76B':*(8LY".JL'7,T_&!D
MIOJ^$%%#/;:TYPOZ"&;!=7E\IJ2*?Y&I1NKU3'7O(2I30Z!.)C''_V41_"W6
M>,R*J"EV"J3WE)PF1C`+PP9&UJMO!WVCHA(DC2IPS%>;';H^=X)N9V"&D\R`
M#IE!5P&UYY#6>\["`.Q4E$8RG.XZIC;)"^B`%_1\2H':E:->BR$C\)V@VR:8
MVR0;H%*O]2T0]=YX%*BQ`=V!5/LCU?<=Y!(>?]&X46/^KCQ^OPHT5OV^9RE0
M0]8)%A'ZZULLGD&=V5C/\@UWN*_+`HW9]SU+@9HV,#SKUE74`#Z7=DT#Q^UL
M,0NSBWSS@46!-'W11S`+PP^^R$W?!_J>Y3<^H"FQ;SRR[`9!-QXW?<,M1F:J
M[QJ1W_6W5!H1>FWKF6HLPCQ&@U-55*\O,M7W@8%,-:K?96I!.RV3FU:LRRD.
M@V0UY7FM/)K,6'ED.W8^5U92O/&S6`J'0.UH>T[\2/FYF3&^A?-C<=CJMA?@
M^/82']GO<7E,\\HZLP.$!%$&\J4\`)8_ZN(B#D1?BAH.;L77$QS4,SA%]!P`
M'XJB;G[PY/*#9W&BNOD/``#__P,`4$L#!!0`!@`(````(0`1AKH+I`4```8:
M```9````>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;)19VV[J.!1]'VG^(<K[
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MV[V`CD1CZ_WG$ZLS8!3".,%"1,KX&0J`1ZO(Q6@`(^F'_'W-]\UI:X=+9Q%[
MH0]PZX75S7,N0MI6]E8WO/@/0;X*A4$"%01^JR!!]-5B%PN1?3VE3;K;5/QJ
MP;!`JOJ2BM'SUQ!0-!0"+9B^:W&L0VA-!'D04;8V3#DLKV%;WG=)&&W<=Z`R
M4YA'Q,!CA_$[A`O5="5!&;<E#7/;9A9@D5EP+4IYQ!=NTP3#:<(Y:01X:T/L
MKO@D7'1Q,3-B8MF^[P5)$'D=PF@0=NNVP9;S^XV*1;2"91<?*T`,/'95KA*-
M,6J`<;NMX7YN`::Y8Y(;,8GL?N'$>O>-M,LY:068IEV1M(A!TN-@M5CI73$2
MQV;B:9R+1;2`A!2`F+;O8"2].`!N9':?;@$F:6]&";<:,9%TJUOQ)',2"3!-
MI$6)B1"#_07.R+;Z8!G3^Y-HFE>K%/,J$"8.'?UO8UM]X2J3B95HDK@G8P7"
MD0H6'OQT6V[F)D8U;:9\-"C32K1(5?,(NE5R$H4C9<PR,G_(R:B6%:C==*TY
MLW]A-].Y1W,R^]:15=\(FL`]\:^)W`\9&16T.,]!%5\U/\O)_`$KB[265/,(
MZFO:)^9UWSTDF@QY1%6M0*VZ]/R9.SS+MOPAW]*Z54TB"!-'SD(79F:>Y6/^
M@)'U=8T@G*TPC.-@1%`!,;-ILR57$=I#S2MVKT"FKD>.C&"6M4DT34]UK4`M
M^>%2F%OW,T:'\*+),@_0N>[+7(&4S&//\\<X(-XV<2N&/([*/$!0RT6D!]48
M1/'6>D;W`R87]88`07V=B\\`,W(-F%E/YS)D:V8+)](LF%W.<K-@R,TT?VK4
M$83\QDX\(O1@EK=)-)UR/3LJ,[XEP^GR$V^QT#HPNR;V-G&Z!FRN+W0$F4(?
M*V.6UP5#7J<C*PH0A.0OG:7>'(,`\4EO^L!)-"6?GN`*A.0O/=\?>?,4$G>;
MQKU<14O0,XW-*U#;?*#U9S8_R]?"`5^+>LTCJ*_LD/C8_1-<HDF7/64K$':Y
M<KRQ+F?Y5SCD7WIX%+\(PLR^Y\1:@";!L^PL'+"SWAFN0.K@B")_.39>Q-`F
MCM>`L?6D'2+(E+:>09."6>X6HG&99R>5M@*U^YZ,92;>]L7$#7E:;[H1I'P5
MN!\EGQC:1/*'C$UWIV;OUM@2QQLY5:)9QB;11&\+/5B868'ZVHZ(D]UG6J))
MKIZV%6@I+U,"O0_&;$6S_$NB:5ZJ;`7"O"O-@)EWEI=%0^_%M&$H;A&D#HW5
MV`?NB'C9M+F2JTCG/5$KD"'JL<\FT2Q?DVB:GHI:@5#4D>>L1MP\(K;VQ:P-
MV9F>)L4]@K[DGCC91.Z''(UJ&B[L]0?NH>;Q.AZOK0M6'=DO['RNK8R_B:MV
M'U32O=I]#?`0R*NQ[A]P"W])C^R/M#KF96V=V0&6BK/+MBJ\Q\<G#;_(2_$7
MWL#]N_SS!-^W,+A:]AP`'SAOVB?BFX+N&YS=_P```/__`P!02P,$%``&``@`
M```A`)*P!VO?!```Y!0``!D```!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL
ME%C;;JLX%'T?:?X!\7["G80HR5&AZLR1YDBCT5R>"7$25,`1IDW[][-]@?I"
M$NA#VSC+V\M[;2_,WGS_J"OK';6DQ,W6]A:N;:&FP(>R.6WM?_Y^^;:R+=+E
MS2&O<(.V]B<B]O?=K[]LKKA])6>$.@LB-&1KG[ONLG8<4IQ1G9,%OJ`&OCGB
MMLX[^-B>'')I47Y@D^K*\5TW=NJ\;&P>8=U.B8&/Q[)`S[AXJU'3\2`MJO(.
M^)-S>2%]M+J8$J[.V]>WR[<"UQ<(L2^KLOMD06VK+M8_3@UN\WT%^_[PPKSH
M8[,/1OBZ+%I,\+%;0#B'$S7WG#B)`Y%VFT,).Z!IMUITW-I/WCH+?-O9;5B"
M_BW1E4C_6^2,K[^UY>&/LD&0;=")*K#'^)5"?QSH$$QVC-DO3($_6^N`COE;
MU?V%K[^C\G3N0.X(=D0WMCY\/B-20$8AS,*/:*0"5T``?EMU24L#,I)_L+_7
M\M"=MW80+Z*E&W@`M_:(="\E#6E;Q1OI</T?!WDB%`_BBR`!L!??1XM5%(7Q
M:ODPBL,9L0T^YUV^V[3X:D'5P)KDDM,:]-80F>XL@/QP'L->;VT5]DB#/-$H
M6QO*':83T.=]ET3^QGF'G!8"DYJ899RHF*S'4#&`X,`2]BZS',][3X:"*1FJ
M`V67B@&?$0N]((FU935`Z*T&@$(#$C2=!@5O;0@MY208XG)F'!,.5#-I0%DY
M5%?N9;J?"#I)9Q!J##AF%;#<N`LO<2,5D7$$XZA0@IJ;G@P*5JF$D29^RC&P
MW)"P,-:**.LQ>H'$<\A0L$HFB;1=IQPC*2,-*&E8JBM/4X9.TAGHRG#,/64X
MPE2&/G:D,WV_2"A8I6(JPS&J,AK=K,?HRB1SR%"P2B:)M,.:<HRDC#2@*..!
MC\EYF"8-FZ5ST#:;"M`]<03$5,?3+/>^/`RMTC'U$2!5("UOV0#2%?*H_4VN
M%X96"2714O6,5(`DD>01527-5">J-.:NADH<=%>E6X;K4=N;GA2*5I,RHA('
MJ2I]/6G8$R%CZV[MD;*9Y;?T=J(12B)MK52`9)5N^:NG&>Q$E<:<UE")@P:5
M_&"9*#]J;66,RFB&-"M^<+!,#QZ1K+=8Z9FT]'1"/<@X6+.,V#.=.#&>D0(D
M2W;+>+U9SLO0>@4;!2-9K2A7/K)DUP=X*W'=(3G**?<U+[ZO#4/K9/3K@@!)
MJ1A&)+6D&X1*:)8+^_QBJESFXJ^MBFLF!\F$I!%U]5F6ZU.TG@Y=&P&25^?3
M'FNC.?`#;4SG-<^-+]DJ+Y1A1-;FRPK4[,SR7M_TWB36SF@J0')V>C?63RU]
M)9ON_`S]4!O)5D4Z^,AC;33??:"-Z;<CVG"0G(I^1-;FZ_J@:C/+9'W39!/I
M1(IS(_FGR(XTHJX^RU%]TU%#XR$H0'(Z^+3'VLPR6)\[I6PA(]H8!BNFW;HT
M*-FA+^[3*Y>AU<I-8N,%E884#UNNC9C&\J6N/LM1`]-136T$2-)&C#S4!KI!
M<U(Q9K#Z\X:%5%/!IRG:2+<#GAW>5.(]EQJU)Y2AJB)6@=]HPXCV)(;1H9GU
MQ'I9VG@*32[6$7*&+Z#'=,E/Z&?>GLJ&6!4Z0DAW0=M!+>]2\0\=OK!.SQYW
MT%UB_YZAFXB@.>(N`'S$N.L_4#L<^I.[_P$``/__`P!02P,$%``&``@````A
M`*9B\#6.`P``60L``!D```!X;"]W;W)K<VAE971S+W-H965T-3(N>&ULE%9=
M;YLP%'V?M/^`>!\?(80F2E(U`;9)FS1-^WAVP$FL`D:VT[3_?M<XH;;I(OH2
MPO&YQ_?<:QLO[Y_KRGG"C!/:K-S0"UP'-P4M27-8N;]_Y9_N7(<+U)2HH@U>
MN2^8N_?KCQ^69\H>^1%CX8!"PU?N48AVX?N\..(:<8^VN(&1/64U$O#*#CYO
M&49E%U17_B0(9GZ-2.,JA04;HT'W>U+@E!:G&C="B3!<(0'Y\R-I^56M+L;(
MU8@]GMI/!:U;D-B1BHB73M1UZF+Q]=!0AG85^'X.IZBX:G<O`_F:%(QRNA<>
MR/DJT:'GN3_W06F]+`DXD&5W&-ZOW(=PD<]=?[WLZO.'X#/7_CO\2,^?&2F_
MD09#L:%-L@$[2A\E]6LI(0CV!]%YUX`?S"GQ'ITJ\9.>OV!R.`KH=@R&I*]%
M^9)B7D!!0<:;Q%*IH!4D`+].3>3*@(*@Y^YY)J4XKMQHYL5)$(5`=W:8BYQ(
M2=<I3ES0^J\BA1<I)3*YB$PA^\OXQ)O<Q6$\>X<*S->E`L]>970*LTLP//M@
M+YP&(Q+P54FZ"J=(H/62T;,#JQ9,\Q;)/1`N0/=:6E6(OMC_JS4468H\2)65
M"]L-RLAA?3RMDWBR])^@J<6%LQER0I.QO3)D!Z5LJ@#5!PED-I!K@`^.>EO0
M+=W6VROEFKTDR^RO\VX4`-J]'<O,]AJB,1+333H42>*IR<F&'(N1#QE)'/<J
MAN?H/9XEV?"L`-US$D?]1%T_MG90.B(H&\');W,,E[#_QG=6DF&W:XV,M.IU
MIC:*,^V[O[6!U`8R&\@UP$@6MOGX9"5YY4+#^U67Q#.S`QO%T9*U@50!R643
MSE[72N<VNSV<Z\/17?*Z&@U;<%",MR7)MBUKKVP41R5M3*O6G1I^=9W:0&8#
MN088J2=FZO*\B^"#=/N`D$&VA3NK,XHSZ^H>ADD0!"9AJPB:"1O(;"#7`,.$
MO-=HA_;MY"793GYNYK91G$O]Y\/<U;B6NPUD-I!K@)'[W,Q=-F`*J^ZV!QED
M>9A9]=THCFI`](8'?3R<PCE@G6ZI(KR:S&P`[C@RC8ZA/*DKB_J@UI@=\!97
M%7<*>I+7D0@60X_V-Z6'2!XU%KX)%_#Y&^+;R0).7<#]/@!N-BTZX.^('4C#
MG0KO8:K`2Z"(3-V-U(N@;?=YWU$!=YKN[Q&NL!B^HX$'Y#VEXOHB)^@OQ>M_
M````__\#`%!+`P04``8`"````"$`Z[BU*8H"```[!@``&0```'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6R45,MNVS`0O!?H/Q"\1]3#DA+#<I#4<!N@!8JB
MCS--41(1411(^I&_[U*T%;N.`_<BB=3LS,[NDK/[G6S1AFLC5%?@*`@QXAU3
MI>CJ`O_ZN;RYQ<A8VI6T51TO\`LW^'[^\<-LJ_2S:3BW"!@Z4^#&VGY*B&$-
ME]0$JN<=_*F4EM3"4M?$])K3<@B2+8G#,".2B@Y[AJF^AD-5E6!\H=A:\LYZ
M$LU;:B%_TXC>'-@DNX9.4OV\[F^8DCU0K$0K[,M`BI%DTZ>Z4YJN6O"]BR:4
M';B'Q1F]%$PKHRH;`!WQB9Y[OB-W!)CFLU*``U=VI'E5X(=H^IAA,I\-]?DM
M^-8<?2/3J.UG+<JOHN-0;&B3:\!*J6<'?2K=%@23L^CET(#O&I6\HNO6_E#;
M+US4C85NIV#(^9J6+PMN&!04:((X=4Q,M9``/)$4;C*@('0WO+>BM$V!DRQ(
M\S")`(Y6W-BE<)08L;6Q2O[QH&A/Y4GB/0F\]R11%DSB-+^]@H7XC`:#"VKI
M?*;5%L'0@*;IJ1O!:`K,SED"]?%YC%XO606/CN3!L108IAW"#;1G,\\G=S.R
M@9JR/>;18^`Y8J(102";,25(XSBEMXM\4'9@I^R*[E)Y]!O',O';,LFIS,'Y
M^W(N""IT9"*)_S7J,9-AHHY]34X%WQ=RX`*#F;%:>1J.1KQ5CX'GB$DN>(4I
MN[ZD#GPJG:2OO%[:8_*AU4D29?&%7F;_(^S`I\)Y^LKKA3TFNRSL#[&?<<EU
MS3_QMC6(J;4[H!$$CKOCW?$0#\T:?\#9[6G-OU%=B\Z@EE<0&@8YN-;^]/N%
M5?UP@E;*PJD=/ANXI#G,81@`N%+*'A;N?AFO_?E?````__\#`%!+`P04``8`
M"````"$`=Z`>1=,"```)"```&0```'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6R4E5UOVR`4AN\G[3\@[NOO^".*4S6INE5:I6G:QS6Q<8QJ&PM(T_[['2#)
M'+OMFIO$^+R\?L[A`(OKY[9!3U1(QKL<^XZ'$>T*7K)NF^-?/^^N4HRD(EU)
M&M[1'+]0B:^7GS\M]EP\RII2A<"ADSFNE>KGKBN+FK9$.KRG'40J+EJB8"BV
MKNP%):69U#9NX'FQVQ+68>LP%Q_QX%7%"GK+BUU+.V5-!&V(`GY9LUX>W=KB
M(W8M$8^[_JK@;0\6&]8P]6),,6J+^?VVXX)L&LC[V8](<?0V@XE]RPK!):^4
M`W:N!9WFG+F9"T[+1<D@`UUV)&B5XQM_OLZPNUR8^OQF="\'STC6?/]%L/(;
MZR@4&Y9)+\"&\T<MO2_U*YCL3F;?F07X+E!)*[)KU`^^_TK9ME:PVC-(2.<U
M+U]NJ2R@H&#C!#/M5/`&`.`7M4QW!A2$/)O_/2M5G>,P=F:)%_H@1QLJU1W3
MEA@5.ZEX^\>*_(.5-0D.)B'0'^*!$Z0S?Q;_W\6U1";!6Z+(<B'X'D'3P#=E
M3W0+^G-PUIE%;V8&*>DY-WJ2F0IJ":OQM$RB=.$^00F+@V8UU03GBO4KBN0D
M<8'O!`FICR%#6,37RW^$U).@T!B=(,,@._F;1%96$YDZZ\S6@Q=G!&`S)'C_
MRUJ<X\`4)O#\V>BC-AR;<)QXZ;^D#=3:Q@W4&4-T"8,6#QCB$8,-)V\RV/B4
M`5KCXW70X@'#*,^5#;_-8.-3AO@2!BT>,(R[U(8MPRQ)_'&/VOB4(;F$08L'
M#.,FM.$#0YB&HSJM;7S*H"^7P=9]OR>U6#,,=D,T!K$:"Q)DJ9]&YUVSMH(I
M278)B1:?DP1Q>/ZAE=4<MHCO9=F8Q`J@2P>;^^1A=XT]S>UAUY,M?2!BRSJ)
M&EK!),])H+^$/<OM0/'>'&H;KN`,-H\U7+D4S@7/`7'%N3H.]&UQNL27?P$`
M`/__`P!02P,$%``&``@````A`#$O']LV!```M0X``!@```!X;"]W;W)K<VAE
M971S+W-H965T,2YX;6R4EUV/JS80AN\K]3\@[A,P^=I$28X6T+9':J6JG]>$
MF`0MX!0[F]U_WQF,C>V<[B&Y2,+P>OPP8[_`]LM[77EOM.4E:W8^F8:^1YN<
M'<OFM//_^O-E\N1[7&3-,:M80W?^!^7^E_V//VQOK'WE9TJ%!QD:OO//0EPV
M0<#S,ZTS/F47VL"9@K5U)N"P/07\TM+LV`VJJR`*PV509V7CRPR;=DP.5A1E
M3E.67VO:")FDI54F@)^?RPM7V>I\3+HZ:U^OETG.Z@ND.)15*3ZZI+Y7YYNO
MIX:UV:&"ZWXG\RQ7N;N#N_1UF;>,LT),(5T@0>^O>1VL`\BTWQY+N`(LN]?2
M8N<_DTU*5GZPWW8%^KND-V[\]_B9W7YJR^,O94.AVM`GD1W^H!7-!3U"YWP/
M.W)@[!6'?H50")/P3H"3\'_5-,\1SA+H:<S_:LJ7KFV_M=Z1%MFU$K^SV\^T
M/)T%S+2`,F`U-L>/E/(<V@!S3:,%9LU9!2G@VZM+7$]0QNQ=TI5'<=[YL^5T
ML0IG!.3>@7+Q4F)*W\NO7+#Z'RDB?2J9).J3P.]-GH^>IO-HL7IZ),NLSP*_
M?182/8PR[Y/`KT[RO>L(9$VZ<J>9R/;;EMT\6.QPU?R2X=8A&TBH:BLKH:O]
M?\6&*F.29\RR\V&70ATY=/QM'VZ#-^AIWBMBJ8!OK2"V(E$*;"`F38U``+0:
M&5I@(G][&2@R%".9RAK+@`D2.2#WBIFM2.\5<ZVP4*'/XU%1#&O3*-%"9^TJ
M$DO%7%],X@92(V"!0&O'@Z!XY\-%ZEXM'1"I@&^M6-F*1"E4W5,C8)'!%AQ/
MAF*;[,F>-Y:*>;<&R6P91F1H35?$1"DTF1&PR):/D*'8)EL[9%)AUHPXFR11
M$HUF!"RTU2-H*+;1B+/W8BE9=%6;PSW1K9D\/RR\U`A88'BC-NSD\[V)8@?,
MV8NQE,BB';YE+(E2Z)H9`0MM_0@:BATTQP1B*;'ZZ99-232;$;#8"-Q)Q]>M
M4SMTKE7TFD_QM$;SF1$;$,UX=&.)M&[308AK(;W&`G1-1&L&0)FY6XDV('KR
M>$#IX!:@ZR1$:M!*BOUD0J+)#+9-@3>W"7$V=Z+%`ZD:#A&;%#UZ/*ET=(O4
MF3PFRO4'.XY<:]&:`5"-N@.$GCP`B&I[,4:NO1"I&?PCN8ND?60I/6@5=A]M
MH78%T;&-"N)#RPQVT.=N@X^,+JAK-[W&!)6C5AW6>C:/UC-GJZ7F()L3[=O@
M_`Z?-'NSTY'K.43=$(Q.NZ:C-4.GU:B[3J.-CP>4IF\!.K6(X>4!BRSOOU%X
M=_/5YP<X-4+#R9<"^91:T_9$$UI5W,O9%1_R"71"1_5;2_\ZH4_`\_\E.]%?
ML_94-MRK:`%#P^D*NMG*-PAY(-BE>P8^,`%/_MW?,[P>4GC^#*<@+A@3Z@`!
M]0OG_C\```#__P,`4$L#!!0`!@`(````(0!HV;7"D`(``(`&```9````>&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;)1576_:,!1]G[3_8/F]<3X@`42H"E6W
M29LT3?MX-HY#K,9Q9)O2_OM=VY0VH=KH"\3QN>>><Z]]L[Q^E"UZX-H(U94X
MB6*,>,=4);I=B7_]O+N:860L[2K:JHZ7^(D;?+WZ^&%Y4/K>-)Q;!`R=*7%C
M;;\@Q+"&2VHBU?,.=FJE);6PU#MB>LUIY8-D2](XSHFDHL.!8:$OX5!U+1B_
M56PO>6<#B>8MM:#?-*(WSVR274(GJ;[?]U=,R1XHMJ(5]LF38B39XLNN4YIN
M6_#]F$PH>^;VBS-Z*9A61M4V`CH2A)Y[GI,Y`:;5LA+@P)4=:5Z7^"99;'),
M5DM?G]^"'\RK9V0:=?BD1?55=!R*#6UR#=@J=>^@7RKW"H+)6?2=;\!WC2I>
MTWUK?ZC#9RYVC85N3\&0\[6HGFZY85!0H(G2J6-BJ@4!\(ND<"<#"D(?_?]!
M5+8I<99'TR+.$H"C+3?V3CA*C-C>6"7_!%!RI`HDZ9$D`_7'_31*9]-DFO^?
MA01%WN`MM72UU.J`X-!`3M-3=P23!3`[9QG4YVUG8,G%W+@@'PIH`]UX6!59
MOB0/4$)VQ*S/,>D0L7D#49P@!/2=1(+UUR+_+<Z!P01&)W'I?'[B]0;6`3/Q
M]76.-J]>##(#S>69';C$0'7*G,4CT^N`R7W1DDF>Q?%0VB8`O+2!DLE[E#CP
M6$DV3+0.F,(KF1>S.!GN;\+^N1`XL9>7Q(''0B;#1.N`"4*2=)9G(\`F`,Z5
MY.]1XL!C)=.1DH`)S<F*M,A&`)@QC@0J\]+AEP:'=H4A$NY83W?\&]4[T1G4
M\AJ"XJ@`-SJ,D+"PJO=W::LL7'W_V,"DYW`LXPC`M5+V>>&&U.G;L?H+``#_
M_P,`4$L#!!0`!@`(````(0#XM/)[N0(``&$'```9````>&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;)2566^C,!2%WT>:_V#YO>Q+$H543:K.5)I*H]$LSPZ8
M8!4PLIVF_?=S;9,$2-7E)<%P[O%WCXU97C\W-7JB0C+>9MAW/(QHF_."M;L,
M__E]=S7#2"K2%J3F+<WP"Y7X>O7UR_+`Q:.L*%4('%J9X4JI;N&Z,J]H0Z3#
M.]K"DY*+AB@8BITK.T%)88J:V@T\+W$;PEIL'1;B(QZ\+%E.;WF^;VBKK(F@
M-5'`+RO6R:-;DW_$KB'B<=]=Y;SIP&++:J9>C"E&3;ZXW[5<D&T-?3_[$<F/
MWF9P8=^P7'#)2^6`G6M!+WN>NW,7G%;+@D$'.G8D:)GA&W^Q2;&[6II\_C)Z
MD(-K)"M^^"98\8.U%,*&9=(+L.7\44OO"WT+BMV+ZCNS`#\%*FA)]K7ZQ0_?
M*=M5"E8[AH9T7XOBY9;*'`(%&R>(M5/.:P"`7]0PO3,@$/)L_@^L4%6&P\2)
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M2SX#IL53L&@\[]IJ>C"8-HC'@LU0$`3SY&PP`DO'8/JU?'_'ZZ(IX&3^M=7T
MFRGR(L^?``X%OA=[R?F=L83VE+2'2$=V](&('6LEJFD)E)Z30O;"GI%VH'AG
M#HLM5W"VF<L*/F44WC?/`7')N3H.]"E\^CBN_@,``/__`P!02P,$%``&``@`
M```A`-ZWW&F$`@``R@4``!D```!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL
MG)1;;]HP&(;O)^T_6+YO3!("+2)4!<16:96F:8=KXSB)11Q'MCG]^WVV(8+2
M;=5N(+9?/WF_4Z:/!]F@'==&J#;'<33`B+=,%:*M<OSC^^KN'B-C:5O01K4\
MQT=N\./LXX?I7NF-J3FW"`BMR7%M;3<AQ+":2VHBU?$63DJE);6PU!4QG>:T
M\)=D0Y+!8$0D%2T.A(E^#T.5I6!\J=A6\M8&B.8-M>#?U*(S9YID[\%)JC?;
M[HXIV0%B+1IACQZ*D623YZI5FJX;B/L0#RD[L_WB!B\%T\JHTD:`(\'H;<P/
MY($`:38M!$3@THXT+W/\%$\60TQF4Y^?GX+OS<4S,K7:?]*B^"):#LF&,KD"
MK)7:..ESX;;@,KFYO?(%^*I1P4NZ;>PWM?_,155;J'8&`;FX)L5QR0V#A`(F
M2C)'8JH!`_"+I'"=`0FA!_^_%X6M<YR.HFP\2&.0HS4W=B4<$B.V-5;)7T$4
MGU`!DIP@*;@_G2=1<I_%V>C?%!(<^0"7U-+95*L]@J:!=YJ.NA:,)T`^1Q9\
M]+'^*52(T4&>'"7'T.T0A8'R[&;C]'Y*=I!3=M+,;S7QM6)Q5KA2@+W>(T1^
MZ?'MK)^M.+&SXJK@O,W#!K![;\FK][ZA&/>2*R>0H4LG+ELI=-/?';E+H+LP
MD,:CGA],!HUO8;^QN-BX<C#\'P?N4HXAS#X%<?(J^?.@&?GBI>-TF%X[A/%R
MC'">C;*'_CC8"[,36DMR7?$%;QJ#F-JZN4@`V^_V(_N4N"J]VI_#*/O&)_T!
MC%)'*_Y"=25:@QI>`G(0C6%V=!C&L+"J\PV]5A:&R#_6\,WDT`6#",2E4O:\
M<#W6?X5GOP$``/__`P!02P,$%``&``@````A`-3<;FG^`@``B0@``!D```!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&ULE)9);]LP$(7O!?H?!-ZCE=H,VT&L
M(&V`%BB*+F=:HBPBDBB03)S\^PY);Y+3Q+DDEOGX],V;D>CY]7/7.D]42,;[
M!0I<'SFT+WG%^LT"_?YU=Y4A1RK25Z3E/5V@%RK1]?+SI_F6BP?94*H<<.CE
M`C5*#3//DV5#.R)=/M`>5FHN.J+@4FP\.0A**K.I:[W0]Q.O(ZQ'UF$F+O'@
M=<U*>LO+QX[VRIH(VA(%_+)A@]R[=>4E=AT1#X_#5<F[`2S6K&7JQ9@BIRMG
M]YN>"[)NH>[G`)-R[VTNSNP[5@HN>:U<L/,LZ'G-N9=[X+2<5PPJT+$[@M8+
M=!/,BAQYR[G)YP^C6WGRV9$-WWX1K/K&>@IA0YMT`]:</VCI?:6_@LW>V>X[
MTX`?PJEH31Y;]9-OOU*V:11T.X:"=%VSZN66RA("!1LWC+53R5L`@+].Q_1D
M0"#DV?S?LDHU"Q0E;ISZ40!R9TVENF/:$CGEHU2\^VM%P<[*FH0[DPCH=^NA
M&V9Q$"?ONWB6R!1X2Q19S@7?.C`T<$\Y$#V"P0R<=67XOY5!27K/C=YDMH):
M0C>>EFF4S[TGB+#<:5;GFG"L*%Y1I`>)!WP'2"A]"AE!$U^/?P^I-T'0R#E`
M1D%R\#>%K*P&FYQU9<7)%R,"L#DE>/O.6KQ`8'6\<^A/[FPUB0DO#N-T0E:<
MKH<XCH[K(R[\$2XMGG(%$RZK20U7$.,PB,>"8B3P,3[V?00&,W1Y8%H\!9M,
MR\IJ+%@29$DVX;+K0'<2^D$R0DL^@J;%4[3HX&NGR&HL6N@'Z02]L.N7H*4?
M0=/B,5J*IV-F-3NT+,NB2;^+4T&$\^S8[E%F^B";O";>?P+UIC%@%.))=E9C
M`:]PC$\&W81;C`29GQ_#'P'F8\"W'U`M'H.E>!+,RFKL`QKB*,J/R5BPD2#)
M\F/7+9@]3>S+=B`;^IV(#>NET](:1M1W4YA88<\2>Z'X8%ZJ:Z[@##`?&SCR
M*;R7?!?$->=J?Z%/J\./B.4_````__\#`%!+`P04``8`"````"$`$M'TLC($
M``"2$```&0```'AL+W=O<FMS:&5E=',O<VAE970T."YX;6R46%V/LC@8O=]D
M_P/A7J'E2XSX9F8GL_LFN\EFLQ_7B%7)`#44QYE_OT_[5!`J\\*-BA[.>;YZ
M:-U\^R@+ZYW5(N=58I.E:UNLRO@^KXZ)_<_?KXN5;8DFK?9IP2N6V)],V-^V
M/_^TN?+Z39P8:RQ@J$1BGYKFO'8<D9U8F8HE/[,*?CGPNDP;N*R/CCC7+-VK
MF\K"H:X;.F6:5S8RK.LI'/QPR#/VPK-+R:H&26I6I`W$+T[Y6=S8RFP*79G6
M;Y?S(N/E&2AV>9$WGXK4MLIL_?U8\3K=%9#W!_'3[,:M+@SZ,L]J+OBA60*=
M@X&:.<=.[`#3=K//(0-9=JMFA\1^(NMGNK*=[485Z-^<7<7=9TN<^/77.M__
MGE<,J@U]DAW8<?XFH=_W\BNXV3'N?E4=^+.V]NR07HKF+W[]C>7'4P/M#B`C
MF=AZ__G"1`85!9HE#213Q@L(`%ZM,I>C`15)/]3[-=\WI\3VPF40N1X!N+5C
MHGG-):5M91?1\/(_!!%-A214D\"[)B'ATJ=!M)K`XF!$*L&7M$FWFYI?+9@:
MT!3G5,X@60.SS,R#^F`<;:YCJ4*.DN1)LB0VC#O<+J`_[]O(IQOG'6J::<PS
M8N"UQ9`6X4`T;4@0QGU(CXM\4Y9@J2R++D-YQB_N9;I`>C+>'!D)3FS@;H/W
MO*@-'Y41$ZGTPR!V7;<%](3].<(2W!>.?*_E16'$H/#"7X$WM(">,,S:],)*
M\%#8;WE1&#$Z8^+&<0?H"8=SA"5X($R[A%`8,;Y:M/>C$\T1DN"^D-E3Q&"&
M01R.]E0Z_=TR^GIF);@O;/84,;JG7ACY(\,4SQ&6X*%PUS(L+6)TQD%,PQ%A
M`BYQG_+-.;Y.7=TU"($.%Y(&F>TETD,FEUFA!UI^,!AA#8(EU*[LB*Y:4&^,
MR<"9)J:,CG3O'1&-6P6LNJ).[`<IS[(I8OI49*:,H%[*WEB7I;=,KS@Z42]5
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MM^V1](FJ_6G[`YP(S^F1_9'6Q[P25L$.<*N[C&`F:CQ3XD7#S^I<MN,-G`75
MQQ.<_1F<;MPE@`^<-[<+>6IM_TW8_@\``/__`P!02P,$%``&``@````A`!]6
M]3@@`P``50D``!D```!X;"]W;W)K<VAE971S+W-H965T-#DN>&ULE%;;;J,P
M$'U?:?\!^;T0+@E-%%(UJ;I;:2NM5GMY=L`$JX"1[33MW^\,3BB&;C=Y2<+X
M<.;,\=B3Y<U+53K/3"HNZH3X[H0XK$Y%QNM=0G[]O+^Z)H[2M,YH*6J6D%>F
MR,WJ\Z?E0<@G53"F'6"H54(*K9N%YZFT8!55KFA8#2NYD!75\"AWGFHDHUG[
M4E5ZP60R\RK*:V(8%O(<#I'G/&5W(MU7K-:&1+*2:M"O"MZH$UN5GD-74?FT
M;ZY2435`L>4EUZ\M*7&J=/&PJX6DVQ+J?O$CFIZXVX<1?<53*93(M0MTGA$Z
MKGGNS3U@6BTS#A6@[8YD>4)N_<7&]XFW6K8&_>;LH'J_'56(PQ?)LV^\9N`V
M[!/NP%:()X0^9!B"E[W1V_?M#GR73L9RNB_U#W'XROBNT+#=4Z@("UMDKW=,
MI>`HT+C!%)E248(`^'0JCJT!CM"7]OO`,UTD))RYTW@2^@!WMDSI>XZ4Q$GW
M2HOJCP&U%74DP9$D!/7']<`-KJ?^=/9_%L\H:@N\HYJNEE(<'.@:R*D:BCWH
M+X`9*PO!'Z.CJ_5?I4*-2'*++`F!=H?7%>S/\RJ.XJ7W#)ZF1\QZC/%MQ.:$
MP*T`>9U&J+RO\7W73U(0C%)P%U#;V@2`N],6#/*^@W@3;RD!A\Y7@N"$`'F7
MV`\&J=<&,VLMBZ[A5`^DF?6HQQ&^45C2`'.^-`3;TN)@D'IM,%%GY*87L#)#
M"Y^?&<%VYK$I!A.WIH2S.)H,3#'KK3)+R.P2(0BVA<3AH"'7!M.SH!>P,L>7
M9$:PG7EL@<%$YBA-AP:<5H<'!>=-[S!_?%`0;,N(>[UESH[!]`SH!2P#YI=D
M1K"=>6R`P9@>F(?Q=-`"9GG<`C[<7>=;T*)M)7$8VJG61U#/A'[$<@%FT"79
MS7WW\0714B;$W!"^'PU:%,<>FMESPDPQ<\E73.[8AI6E<E*QQPD50$MUT6YZ
MW@9XS`?Q-4Y5C'O=`@RUAN[8(Y4[7BNG9#E03MP83J0T8]$\:-&THV4K-(RS
M]F<!?U\8W,<3%\"Y$/KT@`FZ/T2KOP```/__`P!02P,$%``&``@````A`.'/
M&A$S`P``O`D``!D```!X;"]W;W)K<VAE971S+W-H965T-C`N>&ULG%9=;YM`
M$'ROU/^`>`]P@,%8QE'2*&VE5JJJ?CR?X3"G`(?NSG'R[[O'8K!QW-I],0;F
M9F=GU[M>WK[4E?7,I.*B26WB>+;%FDSDO-FD]L\?CS=SVU*:-CFM1,-2^Y4I
M^W;U_MUR)^23*AG3%C`T*K5+K=N%ZZJL9#55CFA9`V\*(6NJX59N7-5*1O/N
M4%VYON=%;DUY8R/#0E["(8J"9^Q!9-N:-1I))*NH!OVJY*W:L]79)70UE4_;
M]B83=0L4:UYQ_=J1VE:=+3YO&B'INH*\7TA(LSUW=W-"7_-,"B4*[0"=BT)/
M<T[<Q`6FU3+GD(&QW9*L2.T[LK@G@>VNEIU!OSC;J8/OEBK%[J/D^1?>,'`;
MZF0JL!;BR4`_Y^81''9/3C]V%?@FK9P5=%OI[V+WB?%-J:'<,\C()+;(7Q^8
MRL!1H''\F6'*1`4"X-.JN6D-<(2^=-<=SW69VD'DS&(O(`"WUDSI1VXH;2O;
M*BWJWP@B/162^#T)7'L2$CFA/XOG%["XJ*A+\(%JNEI*L;.@:R"F:JGI0;(`
M9I-9")I0QY#KN50A1T-R9UA2&]H=CBNHS_,JB<*E^PR>9CWF'C'P.6#(@'!!
MS2`)9!Q*>MOD?60#-I&-Z4;*/3XX#.._'2:X)HP!IS9P#^+GL_G`BY$1$W:=
M=)A/>!S(6!Q`"_X]+W/H.&`2S28!$1-W?I-@GB21-R".'(6"7NZH`4\C1P,O
MIHH8C.Q'87+&XNB:N`8\C1M/XB(&X]X$7I2<23B^)K`!3P-/:XN8/C#QYDDX
M2CNRVHS\R>_IW\4VAZ8*DDGJB.F+[<?1G(SM<*0@^1\%YM!$03QZBT5'3-*U
M6^"04>!1>`*M?;T#W:FI@'$^H(`>A`IB9W;&`&(FS=4UZ$Y-%8Q]W2O`(;97
M$(X*CSV8C+#+?O($1]?AD$GB8-(&/6A?!>^<@LETNU#!Z9A+XI,YCJ"]@M$B
MM`"7*.Z8FLD-^\"J2EF9V)H%2:![AJ?#\K[SNZ$YO(#=V=(-^TKEAC?*JE@!
M1STGAK$C<?OBC19MM\'60L/6[+Z6\"^)P1[P'``70NC]C=GOP_^NU1\```#_
M_P,`4$L#!!0`!@`(````(0`E5IGI2P,``%<*```9````>&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;)Q676^;,!1]G[3_@/Q>P"0$B$*J=E6W2ILT3?MX=L`$
MJX"1[33MO]^UG1`@39KV)0GDW.-SCNUK+ZZ?Z\IYHD(RWJ0(NSYR:)/QG#7K
M%/WY?7\5(T<JTN2DX@U-T0N5Z'KY^=-BR\6C+"E5#C`T,D6E4NW<\V16TII(
ME[>T@7\*+FJBX%&L/=D*2G)35%=>X/LSKR:L099A+B[AX$7!,GK'LTU-&V5)
M!*V(`OVR9*W<L]79)70U$8^;]BKC=0L4*U8Q]6)(D5-G\X=UPP595>#[&4])
MMN<V#T?T-<L$E[Q0+M!Y5NBQY\1+/&!:+G(&#G3LCJ!%BF[P_!9/D;=<F(#^
M,KJ5O=^.+/GVJV#Y=]902!OF2<_`BO-'#7W(]2LH]HZJ[\T,_!1.3@NRJ=0O
MOOU&V;I4,-TA.-+&YOG+'949)`HT;A!JIHQ7(``^G9KII0&)D&?SO66Y*E,T
MF;EAY$\PP)T5E>J>:4KD9!NI>/W/@O".RI($.Q+XWI'@R`WB$(>SMUD\J\@8
MO".*+!>";QU8-3"F;(E>@W@.S-K9!/*Q.CJOIZR"1TURHUE2!,L=RB7,S],R
MB<*%]P299CO,K<7`9X?!'<(#-9TDD-&7]'K(^Y$U6(^L0]=2;NV+_C#!Z\-,
MWC.,!J<(N#OQLWALT&+,,ASXF0X'VD=\WI<N&@X8)W%GQ%JUF,CD'0?8#_T.
M,!``:ZP?Z&4"=-%00!+-.GXKP&)`1I?*Y$38LX](T$5C"=%(@L78#*[PQ,?^
M0>0@A.@C"G316,%X%BSFDA#T<?#*7CN_$'314$*<3$<A6(P-89;XR?0`&&20
M'`N8PAR>%Z"+A@*2*!D)L)A^!DE\8C%BZ"[O3\%4C53XDY&*'2@Q&R)T>S$-
M4L"Z$_7FX;Q]@QZ-'!\ZE]T(.U`_@%,[`8_:VV6[T52-51SVVDZ%[7U[_\%A
MI0[]OZOSX>/6E\1'R>][W]N=`,[I0?H7^M=5(__^N!<8ZA19_S/7/S1HZ]^>
M[_;XJZE8TR^TJJ23\8T^NS$LF^YM=Z^X"<S-H/L#CO66K.D/(M:LD4Y%"RCU
MW0BVD;`7`_N@>&L.UQ57<*";GR5<X"@<4;X+X()SM7_05X_N2KC\#P``__\#
M`%!+`P04``8`"````"$`:4NL/)\$``!B%```&0```'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6R46-N.JD@4?9]D_H'P?H`J+H)13[JGTS,GF4DFD[D\(Y9*
M&BA#T6WWW\^NBPA5HI0/*KIJKWU9+*!6WS_KROD@+2MILW:1%[@.:0JZ*YO#
MVOWG[]=OJ>NP+F]V>44;LG:_"'._;W[^:76F[1L[$M(Y$*%A:_?8=:>E[[/B
M2.J<>?1$&OAG3]LZ[^"P/?CLU))\)Q;5E8^#(/'KO&Q<&6'9SHE!]_NR("^T
M>*])T\D@+:GR#O)GQ_+$+M'J8DZX.F_?WD_?"EJ?(,2VK,KN2P1UG;I8_C@T
MM,VW%=3]B:*\N,06!T;XNBQ:RNB^\R"<+Q,U:\[\S(=(F]6NA`IXVYV6[-?N
M$UH^AXGK;U:B0?^6Y,P&WQUVI.=?VW+W>]D0Z#;,B4]@2^D;A_[8\9]@L6^L
M?A43^+-U=F2?OU?=7_3\&RD/QP[&'4-%O+#E[NN%L`(Z"F$\'/-(!:T@`7AW
MZI)+`SJ2?XK/<[GKCFLW3+QX$80(X,Z6L.ZUY"%=IWAG':W_DR"D0LD@6`6!
M3Q4$)5Z$XT4Z(XHO,Q(%ON1=OEFU].R`:H"3G7*N0;2$R+RR$/HC\^AKG2H5
M:N1!GGB4M0MRA^4,YO.QR=)HY7]`3PN%>988>.\QJ$?XD$V?$J0Q3.EVDR_,
M',R9>=-Y*L_RAR$-ODT3VM!P\-J%V'WR21KW<26SQ$1"2<-Z(ALB#AX3Q2C5
MB"1F(?J<9$$675L]:B1H:WXC.5@C#JYQ9842DTEB+[@V8$2;V-!RL$:+,JU>
MB7E<[V),?-'R?0'Q1>,$,F.R$F-.EOO[X.2Y3\3!8Z(87Z4I&RPQL6APA`)\
M'<"HPYD-+P=KO(:B)$9V.$IQ<LUKQ(O`&>87+-`:LR$I!9*:BKTL[&<_9N;N
M,;O52'K-\'2-#54IT..BN:/,IY;^,Z3.TJ0O2HX929":,T:#W,95:QXU3]'(
M-*LL7>@I3+D5LK(K@=9F;*A:@1[*FE]2+3I]P[$,88N0:U<-.4OB\-J(<:NM
M7`O=L"U3VA+T4-J:;=UW$63ZU0UI2]",JJT<#)D6=D/;(P^[HVTK$T.FBV6I
M?EU4(-.GL95O"?0C32O01=-P)]>?8"-=82OC$FB-VM"T`LGIQ@F*)J[#V,JX
M!%JC-B2M0!=)XREFS;?N2QJ;?F5*6H$>%VUE7]B\W3(5K4!JU"$*K[H;CUJS
MKWENS9\`M.MSENIW0`IT0]E6MH5OV);AU@K4*SN<N"1C*]\2:$U>IK*'OA4&
M\)HXJ:QL"YNV%9O*EJ"'RK9R+6RZU@UE2Y!4]IVB^6/9_*NC0(_[;2I;@=2H
M<80GE!UJ)C9/V6*5GH*N;`4RE1U:N9=`C[G,NVL%NB@[6DS<7H=6]B70&K6A
M;`620TZFE1U:V9=`:]2&LA5(*COU)BP[U,SKOF4+M$8\N(E5S\/2V1[7;.5A
ML,]C^J5^@ZU`%\N&LTHS$KG5(W=":M(>R"^DJIA3T'>^C8/@`:S_M=]B>L+B
MT;[_`W9X3OF!_)&WA[)A3D7VL#3P%E!V*_>(Y$%'3V*?94L[V-L17X^PET=@
MMR+P`+RGM+L<\%VH?G=P\S\```#__P,`4$L#!!0`!@`(````(0#]Z'IT;P(`
M`*\%```9````>&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;)1476^;,!1]G[3_
M8/F]&`A)TRBD:E9UJ[1*T[2/9\=<P`K&R'::]M_OVFY)NE13]@(8CL\Y]_A>
MEM=/JB./8*S4?4FS)*4$>J$KV3<E_?GC[F).B76\KWBG>RCI,UAZO?KX8;G7
M9FM;`$>0H;<E;9T;%HQ9T8+B-M$#]/BEUD9QATO3,#L8X%78I#J6I^F,*2Y[
M&AD6YAP.7==2P*T6.P6]BR0&.N[0OVWE8%_9E#B'3G&SW0T70JL!*3:RD^XY
MD%*BQ.*^Z;7AFP[K?LH*+EZYP^*$7DEAM-6U2Y".1:.G-5^Q*X9,JV4EL0(?
M.S%0E_0F6ZRGE*V6(9]?$O;VZ)G85N\_&UE]E3U@V'A,_@`V6F\]]+[RKW`S
M.]E]%P[@FR$5U'S7N>]Z_P5DTSH\[2D6Y.M:5,^W8`4&BC1)'FP(W:$!O!(E
M?6=@(/PIW/>R<FU))[-D>IE.,H23#5AW)STE)6)GG5:_(RCSID:2_(4$[R\D
MV2PI\NGE_`P6%AV%`F^YXZNET7N"38.:=N"^!;,%,K]?$;KPV!L/+BDV-9JU
M>`J/JRPMTB5[Q.S$"V@=07@]@$8$0]51&N7.E_9@+^T3\5[6\<6Q3/Z^S.1_
M9#P83^?(_"R_&GFC<L04H6..ZRG>"ODFF6"K_3M2OZFD6,PAK;3(_E*,H/DD
M1)XFA\]O\L16.L[S/'V_Z43_D&2L.()&_7DQ^HL&XN#$OE)@&O@$76>)T#L_
M%!G:'M^.\WJ3AP#'#S@O`V_@@9M&]I9T4./6-+E$;1,G+BZ<'D+7;K3#20F/
M+?X8`7LB31!<:^U>%WZFQU_MZ@\```#__P,`4$L#!!0`!@`(````(0#EZT\!
MU0H``%,Y```9````>&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;)R;6V_;.A:%
MWP>8_V#XO;9U\PU)#BI3O`@SP&!PSLRSZRB)T=@*;+=I__TA1<HB]U(2.WVH
MDR][;TM+F^229=[\\6OW//A9'8[;>G\[C$:3X:#:;^K[[?[Q=OC7G_S+?#@X
MGM;[^_5SO:]NA[^KX_"/NW_^X^:U/GP_/E75::`K[(^WPZ?3Z64Y'A\W3]5N
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M5QQ`ZFKH0^YJQ/,LRJZI,G55]&M7Y5HM9JZ(?FV+1*-YEJ73^>QR1?7P;"Z+
M?FVKQ*.K3VCAJNC7MLHGCB7236E[Q'2GN_[9*(VSV?R"+AG;CFL:F*U/Z[N;
M0_TZT+."[JGCR]K,,='2O$?;NK;1SLW\5B_K)C95OIHRMT,ME&[3HQZ`/^^B
M29K<C'_J4;-Q03D&S691&+-J8\P@,959"[S*84K11K0IO`5="KR/:&/:)-D"
M+VFZ"-])M3%M4FF!_O]\VOX[C;7&9Z'U6`R$[I\;6CU-M-&S?:>\!=T[I>'!
MK3!BEF5A#,.8.(PH>B)F80C'$'*A!4;H;B#'*VV0KYT.(@>L>BM-PP,J>X.Z
M2L%ET!/<%9?!1`>7@8(5!8R"@@).@:!`6N!+,\N(QHHFE1X(SEA/R\$9FQ&>
MZ)'^?@.:K-NA5O;<V?KJD$[(;5!Z[M(5!<R"63,CI+-Y3$9401,X!8("28&B
MH/1`H(2>^0,EWE?`1(<*S",R6^4VQA.``M:"3L>$#KDVI!WKG`)!@:1`45!Z
M(-!`+ZM7:&"BB0:323CZ<AOC:4`!L\`VP2+.YG%"="S\B/E"&Y\IF2TX+2HH
MD!0H"DH/!)IHEQ!H<MD(,5FA-GJ$S(DX-L@3AP)F@15G.DT3.D+:!+.FQA'Y
M*V__VO:.H$!2H"@H/1#(8NY.?&OP_G`QT2`'.=S<!GER4,`LL'(DDVDZ[>;Q
MQ@\4?D"D'?*"]!*G)04%D@)%0>F!0!+MX:Z0Q$1323(Z?&Q09F?())V0QE\%
M?X]U@X0=QNS?.TD+"C@%@@))@:*@]$`@B+&,5RC2A(,DY`KF+JH[IQ40!J0`
MPH$((!*(`E+Z)#Q[X__\(7+9S!&9-*H"+*XNRE?!YG6$04P!A#MBAU043S,R
M1PE(D4`4D-(GH2C&COFBO#]OF)M4(@:NLRZH._,5$`:D`,(=L5K,TL4"M+!'
MT[V1A"(*2.F34`MCRGPM+FP0Z^5\]S6/R,201S:H.]05$`:D`,(=630S4#9:
MQ%J6[A\(1-]50D4%I/1)*)#Q:I\0R%H\7Z!HDA%CE4>>$6P6CQ40!J0`PH$(
M1VP?S;.8S&`2,A20TB>A)L:[?4(3:_F()F2YR,W'4GJX^5U#"8.8`@@'(H!(
M(`I(Z9-0!>/6/J&"-7E$!1@[GA5TG4$)BR@I@'`@`HATQ/7*=$*Z5$%&^79&
MJ)`Q;KY"'TRTUN>%RJ34H46>&W3*4,(@I@#"@0@@TA&KS"*CYEE!1NF34`OC
MV*[0PAJ\4`OZ:4D>>3;0:4$)@Y@""`<B@$A'YDDS#2<CLSCY_XHOT#?T6,IK
M:H3J&7MWA7K6#1+UJ+&-/,_HU*.$04P!A`,10*0CSD6GLQF9]A2DE#X)Q(BI
MI;ULS6[2J*G+R$=5N8ORIE\@#$@!A`,10"00!:3T2:@"M;;O3RYQGZ7-Z.=%
M+LH_>["T$%,`X4`$$`E$.6*GFV32_`MOIDH_*91#-_L5(R0VX6$SS.&#$Q?D
MJV'3.L(@I@#"@0A'[)E.DRPF-]$24A20TB>A%I\SM3&:6NW9B+_,750GP0H(
M`U(`X4`$$`E$.6*%RWH[Q/._H2J?<[)QKY.EJ[*+\E6AWI9!3`&$`Q%`)!#E
MB%/%/)2DP\8[F%`4:F4_F$7Z+.R4+BSFD61H88$P(`40#D0`D4"4(^W8FNDN
MH6IXQQ>J81SEY<ML;`UHN,Q.R:U&[J+\UJ#&E4%,`80#$4`D$.6(52.)]--5
M4,,[FE`-:E\O7&=[;2Q,(]2TKF)*&)`""`<B@$@@RA'7(]K*T0[QCB74Q'@Z
MOT,NU,1:P;!3,GK3$U/#N`+"@!1`.!#AB#W?%$:$A`P%I/1)J,EUYC3N,Z?T
M"N0NRA\U8$XAI@#"@0@@$HARQ.JUF,U)]Y9^1J"%>6X7],?[\VD3'MH0O>22
MV3MW49X60!B0`@@'(AQQ-S63T838<@DI"DCIDU`,:E$O&RQ)GU6=DKNKW$7Y
MHH!5A9@""`<B@$@@"DCIDU`%XQFOGS(2:S7)E`$JV"A?!4J8J]3%%$`X$`%$
M`E%`2D?<<F/\V7EF#47ILZBI7I<_&"]]%G5*FC9//`MH;VR!,"`%$`Y$`)%`
M%)#2)Z$*G[.D2:\EA=;P/)]3@1+F*OFM06,XQ`@@$H@"4CIB6R/*`E\6JF+L
MF3]@/N@)Z^;"@4(?3^>)Y_F<&I0PB"F`<"`"B`2B@)1GTGWO0#]5?V.P7&=+
MDUY;"HN*9_N<()0P5\EO#QK#(48`D4`4D-(1VQ[ZZ[%O3QW&FUW1'M;*D?:@
M'_LDGN%S:E#"(*8`PH$((-*1\Z)+!JZ"C/+MC'#@?,Z<)GWF=$H_&G)172^L
M@#`@!1`.1`"1CIP5(KVK(*-\.R-4B%K5"QU)GV6=$E.8)]2@KH`P(`40#D0`
MD4`4D-(G@0HI-:F7J="D@5DEW9N[**]/@#`@!1`.1`"10!20TI$/'4G:9U8_
M=B1-&A6%?B\U=U&^*&!6(:8`PH$((!*(`E+Z)&P-XQ[]R?7"UK"FTY]DY_`\
M/+5!O@B4,(@I@'`@`HATQ#XSGXT2,ILIR"C/Q'R/*\@(!>HSKN8.Z'V3DO89
M5W@>[J)\A:B591!3`.%`!!`)1`$I';%C9_'VDIP:T^AWS0=B6(_I=TNDOTEV
M-C_-`IPW18,'X4`8D`((!R*`2"`*2'DF%S@V,V]<(TBOA26K7MX4#04!"PLQ
M!1`.1`"10!20TA'GV!K+=KZ$X9@QIO&*]K`>D[0'=6PI=:(K(`Q(`80#$4"D
M(V_Z$<@HW\X(E;G.R^HM4O2I5329=;?8;N!0Y[IR>=V\PH`40#@0`40"44#,
MQB[[.,`;.'%GGJP@=NN6W?FRJPZ/U:IZ?CX.-O4/LRU+?SWI[N:,[9XQ$2_U
M%_/U]VH)5_%2?_<>>1DO]5?PD>N]9U_[>!XM5\T&+E*?14N]HP7K\&BI-ZT@
ME]%2[TM!GL?+O.]]5_%RU<=9O&1]O(B7>@L#UN?Q4N]DT'Q\/@&]I>UE_5C]
M>WUXW.Z/@^?J06L[&9D=5P>[*<[^<JI?FHU'W^J3WLS6_/BD-R]6>KO/9*2#
M'^KZU/YBWN"\'?+N;P```/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL`
M`!,```!X;"]T:&5M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*
MV+&;K4T;Q&Z''FF9EEA3HD#227T;VN.``<.Z89<!N^TP;"O0`KMTGR9;AZT#
M^A7V2$JR&,M+T@8;UM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZB,0^'],X
M:'MWAOU+&QZ2"L=CS'A,VMZ<2._:UOOO7<6;*B010;`^EINX[85*)9N5BO1A
M&,O+/"$QS$VXB+""5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[,J$^04--TMO*
MB/<8O,9*Z@&?B8$F39P5!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5
M_+S*UM4*WDP7,;5B;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU
M>[6<G@%@WP=-K2Q%FO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*9;%$
M#<@^UI?P&]5F?7O-P1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0
MVJ']?DH]ATPXVRV%;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG
M9()]B.(NCD:"8LT`;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J
M^9/CA\^.'_YT_.C1\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_Z
MPR>__/QY.1`R:"'1BR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD"!WP"'0S
MAG$E)R-QOA7#$%-G!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_==V0=A&*F
M:`GG&V'D`/<X9QTN2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]60)5,PM*
MQ_;=D#AB[C,<*QR0F"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-,J0C)Y`6
MBW9I!'Z9E^D,KG9LLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5D1SBB!4-
M?A.KL$S(P5SX15Q/*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC
M>1-S7D3N\&DWQ%%2AAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG
M%X([-'!$6@2(GIF)$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>]
M;=C$RI)G]T2Q7H7[#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM
M&Q+;:YO..UK9>$\H8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29#`P<7""P
M68,$5Q]1%0Y"G$#?7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/
MC^WPNA[.CALY&2-58,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9
MF]B<R\'DN6HPF%L3.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQF*0^
MTGHO^ZAFG)3%RI(B6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP
M$E`[F8XL+B8GB]%1VVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/9
M9/G"FZU,,3<):G#[8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2C
MLTFQO@'!\*])`79T74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!
MGS&5<.-A*H)^@>LY;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I2+D,YJT@
M'NA6*KM1[ORJF)2_(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A0@Y5*`FI
MWQ?0.)C:`=$"5[PP#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I4!"R#V7)
M1-\IQ&KIWF5)LI20B:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,[F3\N>]I
M!HT"W>04\\VI9/G>:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9GNV]147T
MQ*+-JF=9`<P*6T$K3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1A/0?V/^H
M\)G]X*$WU"$_@-J*X/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QIT]9)6RW;
MK"^XT\WYGC"VENPL_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<
M8[Z4%3]F\=%]</0.?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#`%!+
M`P04``8`"````"$`NTQZBIL,``"%=@``#0```'AL+W-T>6QE<RYX;6S<76V/
MXL@1_AXI_\'R)M&=E%G`F`'FACDM[#A9:;,YW4Z42+DH,F!F?.L78LSNS)WR
MWU/5?JL&;+=Q0[/)*+=@<-533U5753=N^_;[9]_3/CO1Q@V#B=Y[W=4U)UB$
M2S=XG.A_>["N1KJVB>U@:7MAX$ST%V>C?W_WV]_<;N(7S_GXY#BQ!B*"S41_
MBN/U3:>S63PYOKUY':Z=`#Y9A9%OQ_`V>NQLUI%C+S=XDN]UC&[WNN/;;J`G
M$F[\A8@0WXX^;==7B]!?V[$[=STW?F&R=,U?W+Q[#,+(GGL`];EGVHM,-GNS
M)]YW%U&X"5?Q:Q#7"5<K=^'LHQQWQAV0='<;;'W+CS?:(MP&\40W\D-:\LF[
MY42_UK7$Y%FX!!!_^,\VC+_[7?+/JS^^>M7]][??_?-'9_FOG[[9_^RG;_5.
MIH;(!!]4RWS=K10+'R>2.ZD%=[>K,""&]($F9.OF4Q!^"2S\#((!S,.OW=UN
M?M$^VQX<Z2&\1>B%D1:#E\$^=B2P?2?YQLSVW'GDXM=6MN]Z+\EA`P^PP$B_
MY[O@)CS8232<5\\<T60VC1`&9U,?CU";?##)QH/5-MD_'[")TS6HU]6&/TX7
MLZ+:+FFZ]N-BC\,VNG)?$3W1XWRB6Q;DD%ZWB[12AYU(V7C6!7UG4W8].)ME
M?:MO#:5:QL7BOM]08=^2266-0NO-\.W9Z)2OK,RZ-`V?:P3@@)/+H@M#MV)\
M#RW\.T><G+F@G<9C3"J7]-G0*W+C@^L[&^V#\T7[,?3M`(FE18U]FZO)7.#)
M%\^Y7[[X/+)J1;?K7*"#CM]X[F.0]#N;[1I:ZD7DKF-D.$=!\J#<<&,NVX`O
M7<_+^]/^`#LX.')W"ZUR[$2!!6^T]/7#RQKZMP"Z>H382;Y7\^W'R'[I&:R+
M$3MA$WKN$E$\SEC7F%;MV?6]-;MG>@DR410E0BUK-CR!T/OI>"8?Z6P\EBW4
ML.!/LM`W`_R3+-2"_\VD<9H.)%,6R%R>%KLXR^N^'H['XU'O>C0:C<U^SS09
MR?,THMU@Z3P[./&31M,^@@$@&/='XVL#@'3-$5-U5@1]`#`<#$:#WM@PX?\L
MDYT>@6Q.![IJKQ($BKQ*$"CR*IMH="1D_G2DP)J+XK%*$"CR*D&@R*M#R1EX
MJ-RK!($BKQ($BKS*EL<DCE58RU0\5@D"15XE"!1Y55KSF6;@L7*O$@2*O$H0
MG-NKV;1J=G]OL<62_<Y,6G^<ZL(FOKDN-FN$>>H\C)8P0\Y^2>GU88Z8'+N[
M]9Q5##/2R'U\PG_C<`W_G8=Q##_1W-TN7?LQ#&P/7G:R,[)_*\Z$'['@]ZJ)
M'C^YBT^@C%LC2;A)5)Q*0Y[U3)Q-F$.S.S0'QG4R89.DVG>6[M;?MR[7?3`N
M@4;DMMYPPF&0*TG#H5BGZZ`74O<)GL%<S3PM>`+$1!82@F?(L+%8LQ:UD9PA
M9B,Y0=!&<H:HC3!T#@VNC,EEN(7?3W<=;%FC;C=9'A354RV0`#\0,8=!D'/V
M^:P]Y0"CM><TM17RR][8F!KXQ[KC`Y;6G+%O9\T)!ZRL.4/41CYN,N]RPO.E
M"TS/!Y#L\,U]_3@8H"@YD>`A&3Y-3_BK1?*[A7"VXZW=4[-CB2P]HE80;@':
MH:*85D<HM@O'\SYB^?O'*J^XL(AU=_N\(A<9P)4?^"L\7L.`+V&E.'V95-?D
M#>@J.\DH/4FSUVOOY</6GSN1Q2X'82K845R1+MY-65M0O&=+ZK[#EN'T1,P/
M41@[BYA=KL(6]<OPP#4-!XWHI8)$\+31;Y;H!YZ$^6BC'Y9Y#MH/O"C5#\$E
MK%]F/."%.6E0@PMH4%?AD8D`)O,9`G"""@1X(5'*`82G"@0P2<H00(`6"`!.
M152T&0<]DLT@!@J5H/]4*B''9%9R*D]H95GZ!?T55EI<^FU%,\FW$.@%S?"F
M`D`KE64I5E6*(6Z'D590`&\J*+"@ZLHI>;VRG*^,$))T`4/!"*2!*D;D127)
MN:"S`%#-R%1B'T*"`E.1:@@`1PD$XHB>HOK;HQ@456`:#8I*,(7`U>`SC@GJ
M":Y"*L(`>)2,BJ)/Z'$5XXPT$`BJ,B2)!D-5BJ085.7(PA6&JA1)(*C*D-03
MJE(DQ:`J1Q)7J$J1!`(PHB1#4D^H2I$4@ZH<6;BBKRI%$@BJ,B3Q1/_$*;)#
METV3152R?CHRCUH_U9Y7M0NIO;))$_@].SV9/24S1_`%FTN1J31NW;+Q<F1<
M.]6>PLC]!2:9N(5K`0><2,<M?[&[H$>^1/;ZP7F&J6CR*\_SJGRM%Y!DZQN[
MP<@C+,54Z(>5;%UKHEPZ/RVPM">BUG(VJ:]=F-^)#'YQNS9":D%@2*K&@`M,
MJC&@OU,,TL-0TC"%(IE!%(Y.V>%":8*"*98K+"`6DT^#;/;S=A.[JY>&^0,9
M2E?!`2C7U?#9ZUR(A/UTDG0JFX[:9$*C0[;R%KD<9^`GBXNL[AY+3G]W-E85
MJ19;/ZT=27*PP*;PG>+##QL>S#1=6?VZP=%4S2[0.#X#]7>GN"H=RV'!U6IQ
M,/(<2^H\'9(\4?O@#M<P*;'8UMVD!%[2.)9>_(23'.UIJ8\Y1,>Y6#@.J5.%
M@9^R=!V;CGG28%9<-6B%Z6F"!ED1:JA*^Y<FVGID.'&VPYLJTTN5TTCX/^DH
M<1E=S"5\@CP=1P94?*F(FH2,=.4MVDSI6%J'+T6DI#Z55?SJGK=YP1>*[B/Z
M.8Y`KH>J24E\;UP*KS;4RPBLQG*A!')>WV\"^(3%,RBONI4Q6@.N.:7"D.DP
M/R)&:9NUTTHKFL"54<P%[?[L\G(I+D\#JJ(8NX!LN9*L;IPBR=/PQ%T._(Q8
MP]LD),M[<`EYI^JWA?)`E9-,I0'EW,WE!?E`10=\V9CBX'U-8ZH\&O:MD%(9
M:'B(LDZ&&0T*.#QGRUWI1HK6DY.VTU1^W%]84N+8JL-V5-642Y_\0=X:'U<Y
M+P,?'0]\^%T&/II?+B@"N06RLO6._4$BTAN=;^B4X:[Q_/'3(!"LHMTYHDS0
ML..[\1IR^/E.*54MJYCT);;:&:R0Z_8#_A)*?KDO+Q,O3<E`>_L6Y5CG<LKK
MN!).6TW04"KXZG2B[K().!I7'%7PIG4KF:]S7_Q*9@N`E$'>O344"F996=!.
MT+>U@,8-BA-`:UF;RN%=PI@MZWFDI3?*WC$3!DJ?]*PB%1!N$ZO*<\(5H2UE
M-(UPE'T%"&L2G3"'30I7:8A)XZL)&NF][%'AU(-$>L3<1&1")UBLY,*NK@NJ
M84/4'R2[&G759$)HIE6Q[LV>AU&Y[HU;OE9"5U'P.$N1U0X2;I%!>-.!B&]+
M,1T*PJ)5$2X?6$TS!^-+(=H.`R^%>H@^MB<$=H&0>^KP=]3)]XQH>,M]>$10
M]_?:E?9F@9;E/[-A1IIO70_N@XDKP[B?9P$7,H?^-#F8[L"HDI671@-7]HDL
MB/"FLD!"4F8-W.-%9,$O1DUE@?I$5A^L);+@=D.-9<&^NU06[L`K<)D0JDUQ
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M9_%)F\%]\')!_'C`,BHBZ/YY[=F!'8?1BX:;)7-QO-,'@N+^%(8Y1[P$`]Z*
M`/HS/%`1GM6H`2\)0WP,XR:U)F+RL<#3@W=.:2(&SD[0\/&'$^DF8N#L1`R?
M5+%_$A'S+EAO<P_QN11+MXB(]V[PR5GRD<,S;`!($4D?G&T<V7G\\4/*$"3F
M`]X],9?!IXCD"4?9K1[3_O,#W"PQ(Q';?3)VL(<6`?[7;4QHQ+.($)SJBPAY
M<&.XI6PVB#D1"$M(1`@;F',1.QE%4,;?[2C`T<(-W9T8+;&HV`X.W?_RN;B3
M)N,]QD>.LGMLYO,!(&KIK.RM%S_D'T[TXO5?V,V:(9C2;_W@?@YC)F*B%Z_?
MXUVP813#55.0;MYOX,[*\*^VC=R)_NO]=#A^>V\95Z/N='1E]IW!U7@P?7LU
M,&?3MV^M<=?HSOX+E.'S66_@`9\MGG_*GM,*&\)[YLW&@Z>D1JFQ*?B/Q;&)
M3MXD\-FM;P$V7/F5&='9Y,^/O?L?````__\#`%!+`P04``8`"````"$`%!&V
M6TRA```3'P(`%````'AL+W-H87)E9%-T<FEN9W,N>&ULS)W);EQ)EJ;W#?0[
M7`@"6@)(BJ2&D#(CHN"BQ$AF2B2+I"(17>B%T_V2])1/Z8,DYBH7O>]%+QH%
M5`&%?I1ZE'B2_OYSS.S:'9RBL@8TD`/E?J\-9_S/8.;?_]V7R;CX5"Z6H]GT
MAP=[.[L/BG(ZF`U'T^L?'GRX.-Q^^:!8KOK387\\FY8_/+@MEP_^[L?_^E^^
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MCY=;T&&PTWPZC'D`R1;],8\,RR_%'\K;YG-IJ1>W\]:4>[O;?]CXPFFY&,W$
MBV'QIK]JO=N#6T/CV.&X?]T<)2SOY]EX/5WU%[?%X6B,"#8?.YXU/PDO_K$<
MC[?_,)U]GIZ7_25R.2R.ELMUN=CP_,%ZL8`4Q5DYGRU6B'9QONJOUJT)?RE;
M'\57#T=+R%W\4O87&S<=5F>;*0Z@RO5LT2+Y^:0_9K/96@YFDWE_VGHPC':Z
MOAR/!L7A>-9?;=K>;#)!"<Y7L\''K>(<`2F7Q<EZ97K+;INO):Z'305>'J)D
MK?T?_O*UMXTDG>\>S*;+V7@TA!+#XG5_W)\.2I:'$5ANTMA<)9\V9XZ\Z"^7
M#-'ZMK^\,?LPT!_EG]>C3_TQ7&\]>%:B9Z.!%K6\01ZV5^5B4HRFG_A<(MMZ
MH3<P,[4L%N6@9-3+<;E53,L6._[U7_[U7YJK.F+8Z6JV&+5%ZW11SONC85%^
MP6`N89F,VVQU@W`,@L!V[_1BMD(4[W[F",6:7H]8:N&#=*[XI]EL^'DT'C=7
M?;A>3$>K]8*769-H.1=E.L>X.+GHO2MZY^=O+\Z;XT2.C4?]R]%XM.J@0B+N
MO'\KRMJ,_<%@L88_D33-<7G)ON>=Q6P\MG<6Y=@$[8ZY#M;+U6P"?8<8@N6H
MS>FX7C,3J-3L"@^%NYE>L_NB/X`0O":/,T,KK_OZLR4N78/TYR/Q;(RY*N]Z
MM\[:N[:R:43CD2T\R%#8RR821A+?]SV4^AOIX0+R[JCW^NC=T<71V[:48+]&
MKGK&R43R08>\G%^<'/SA=R?OWKP]._]OQ=N__W!TT3)16%091)@M@_AP=V=W
M=Z^88[FQ"&MT]]7NUNZN_1<+8-:ROUYA"D9_*8=\N[7__.76_M,]6\S+K5??
M[6X]??$L/CJ2IQG:=[/*QA;]58'Q*B>7B%?$%/80X.+I%J9C.2\'J]&G<MRR
M]+WAT(0*`9%!V!Y-BX&SMX-IZ\G:Y7Q87HT&HY81<FK?ATHMOA2]XS?%?=Z\
MT["?0E`P5VGXY/$F0R\'7!I`0,<.1U-\PXC]GTHMI5__T+L4&AJL_D>3!G7F
M)J[>_5B+S?=ZW%E]KT<S46@_G[G!M.^E=/1D7B[<B&RBTUF)_UB7R]\T1SW'
MN2T[#?*[T4#^!)'S5YMONHW9].W!#&#/TI8:O_GJ3XO9<EG,%[.KMN"%O0"N
MHDEIKQG<)O0EIS+I+SXB(VUT\E,YA2ANT_O#R6AJL%B:TUP-CAPX-G"O/V2W
MXYFYJ>9SOF'"$M$Z6U_SN7?:W-5B-BG"LQW&_<3\\X@0:5(6C\).'[=VBOLM
M4?E5I$5SJO2]C]3\.JPXFZN3T\?EJABSZ.;KK_M+(*.H/!R-UP(ZH!5[LH`(
M;LC<MU5VLCG&'\O1]8U>[1,=]J_+8KHVVR;1<)O)7U`A&=HB4X&MXK*YA.;X
M-1M2UPH#LC>S\9"8`!./TR7<VQ#B!6M@KQ3_\-[L;\MD9`;V5`;V:`H\=X^\
M\94!$6>PM&_<TFX<WKC5W%_$N^X74IRYO^&YK<"5KSVN.,=P=)/Z$?ZL9H(L
MR_781+U_O2C-S+9DY&\>**RT->#;+^5B,!*\04+D>=$BPT>;7CC0/HB%AG4Q
M@@(/G^_L/\]$-=N;S-:"27R&Y1Q0N54<EI>+M>)(^=HF@?^#IMFTJQ"OS:ZN
MB)`Q-DT^M;=7(2],K[F%A\]?O=C:?TGR`2B0-B=])BN!O>O:YG_6O)OVO5&>
MUG/<N6*K0(VS\P\MV?FFES>MP&S`-H;')4I!E?G6ID!L>F[3N!LTN25HX;DP
M3`"$2?%;C]^A+[+6R,VJ_Z7X/%K=R!1V.,IO'F#3!K^)^N9*OKZX?X\QBTT+
MSG?^N;]0TJPE4EW/;!PPQY3%R`$^JD>:835.*%5AB1`I3G4YQZLVY>IO&F33
M%C<(72M->;?0M1[_9J_[-Z!YTZ^F^]Z,YS=*"NG=8N[9KV1-28(.RLHSM%C0
M[5*^]E:>IZI#D0/EDLB]?=Z8L3KHG?^N.'QW\L?SXO#LY'UQ<OKVK'=Q=/Q3
MT3NX./JY,^#M#?]$)L)R307^FK32C/"'W$>":7RJORV5M99!0QHK`(L0CCY9
M-J4%/-^4<X8;F>$S!-B?*.7Y%_\`O;WJ3NTT*=EKO#9JYI.:+VRRJK8(\C2=
MF;6#&Y)49+[8G6>I[.DL[9%\8XD_'>`=#9YGB9AV8)022E6VKKG6X[<7A?'M
MP_G;-\71\;V8UF3TT?'/;\^_PNC3->[:4CY7R@!\6]HQ?SED_6^+`PHI`56]
M>W>0R&."(H#0'WZ2#K3,81S,\,4]9:!%IOMLN4FFPZ/CWO'!W?K0#=&:7#L-
M0E2`)T)^Y.L)M6.TB'AU4);#(#QEAE.C\S"Q6^:@M35Y;0RYB$X4+A:D067`
MQ)C$I63&!D)ZS2D2N4_/3GX^>H-DOOZEN`_Y[,7?]8Y_>BM9-@8HDV-_*$'V
M<^_=V^..Y*PL5]>#1&\4HZ;3`-@(&2GU-%>[<9HM"HCDL:]DI3O>._]P>OKN
M[7L61-;XS='YP;N3\P]G;XN30U^P3"G;.#PY>X\9/3EN63@SR98X%WU#)`Y4
M:LM\\TD/R9L;V;"@<ZWH^.1XVS::23Z4[6)*:YVY7W/-C$9?-K\6.=>DIA[`
M78T6$P17KC"4"[+H[JIL;_JL'(RQI2.2@\GFDRHLJ8")*R$J,0&4V66TJ?*2
MZ)2@IN7ZB;;C@TUBY9NJ;<%DO8H[E^7B$YY:EGTP7@_=@9'55VV7!-(WI/JC
MX9)$;;!;OO)^W2@T5WZRN.Y/@Q^\Z[NMHL)(HHIX<XKM)J>9Z%GE*S.TL!GA
M')]<O"WV=HJ3LY]ZQT?_W<2ZN82[Z[O%H]7LNK1TD'&)TD6Q7%\N1\-17Z6E
M+6KGI.N6!8^(I:ORRPK2#R4#,`'IL;K29X7G"Y5SV-"6/?SK7_\)W#JG_OCK
M7_]9#_)!7`N?/`8-%_UB7BLZ2WCU!F))Q5!B-:6B8NDWF0Q13+*A=$!_//J+
M/L.:S#Y!OT]>W[DAMU3\><VWR!KF&8!66B%8(R,C$ICA8GVM)2[(U(3BV*3_
M48/Q(?O(OOK4'XVM=H3NS&]N27Z-^E.OI\V9%-;Q#]5OD,BEU<0,$2YWB@OH
M%?9?4$Z&*)Z7])>7I"=L^T"H*RJ9,S-K]>5>DKLV]4$#+&&DDI`T:S:_6=WT
MQY/9>'9]:T194ZO2WWP,=U98V?$(LBV9,VB<49:LJ!-*KGQ%ZBTN9@'UUM,)
M'FUJ[HQ)($)8\7Q,4T!M0[_^]1]A?6T5V1H+U85L4UMXT6%Q><N2EL4;=F>2
M!&6@_.VO__/_VMK?03E]M]0'V3!03+K.&FTI2CMM4^J#5L@$I3F*+N5M"3-G
M\[!0&PZI&I;+T;5*]S"M/QPBD3(,QBTC`RA0]6*YVD`!!.73:$B"B:D6Q:24
M>'N>6`!Z-B'G>4GRF-PTJ]DH"34:H0TDRU?CVV+<7T]I8`%I\W;DU.5Z.9JR
ML*WBAOZ5C$H85'AX="!J#/IH`UO9*C[?C,C.A,(L8P;C9R*$(J*6IAE1PC,R
MNH6/LKI<1SMM<!?L3<Y+4L%V![?V5T-VI:7CY:RFAE5525KE<:R29!OT+5N-
MD0^>B(HB1UV(I-^10-E+E4`UUH;6RMHH:J[JW*Y:&OP>R]DB.B@^HXSZ?^?^
M=#;=SM_D[^&:`$%6;3%;8UXT]F?"4/B`9F>4EPD)!@W#TNJ=.9D6/<S#N`B-
M06XGHY&PT$.N=`,B+QYA0$\/9#I9=7%<?BY^KX3EK3+BW8MPXX"^_+X_M2QF
M:#K:,/$Y>?8;C%:?ZL(Y-46$`B.J]<EPLCEO"2K>/'G]I%<0OW_,O_3U\6%<
MX0%&&"Y.1_V[5OAH69;%\6Q5%GLO'N\4;RT:DS4W=R35SV(R6<G3@_KR$4$B
MP`$4L,*2&8%4`BJ([K!&CG,J[_./E4@U#:]DL"D"DO+<=V2RV>;R^7K"]#*[
MQ3FZ:W")$G\('B4BIQC\K@)TQR-W5"O-]^_O%.<?WK_OG?TB4'E^]-/QT>'1
M0>_X@AS!P<F'8XLB3T_>'1UT5,=5S$'J(6F&0IKP`:%->>+]E]:7ME]G@`?0
MT+^/NRZW(<ZV57BP@*V,NG$'@4Q#?F<C/OWJB%<2B8X!=XH>RFMU(QN[JD*1
MGEC+/;LOPZUCR:NFH:M4&%[&>K$[PRFBJ'Z<JS'@U5R/[\\(A3@:SFGMJRT&
M4=@*HG1'V-)MEV?)$RA'LO#U1;%^P=O%T)R6:87^S=[,W%`*&(SD6`LZ27"L
MLDI\7\[E$H(?_T#+#?\R2&G[H(F.=%??5/:G7N]4*NO>2T-_T^(,A*=]&<61
M*.WSP`<RME0F<]M-9L*8M\Y!\T1A:MNOC21E5.?B4GDIH9\;:H:XXG):@'"H
MX%I?#KNLR,AC+</[.CA;+2FBJE:0?)$O.<83"',17;6P0WI;J`8//T/!#88:
M8ZU[S.T5S`;]5,U)RD+1:,J'+-62O6!4^QLN8KX,:CN^35TPVA2HQ.OX@IE,
M,EH45WW^Q_I-X*4#M=Q$JBG.>3F/.2+/4B(:LQ"YX=,$6-F!(W8`U!0X:%T3
M>&;YU4(8*AHOU5AHN0UHR;;B%;BP*M]S:+#0`@C5U96"!T$<368Q,6I3,<??
MS/CI:9]`*&;#_F.FS]5\46[GFTYOB9!XD2\@)^D$HCA8`&\$Y^(<9A)$/]._
M<K&B7U@/BH6M9&1-DJ7*R4TC&4+7X=]1U:[6UMP6\!FR0W!`LQM6!6F@%TDV
M8-:*Z'_]/_^K:7?#0.H#L(9"R\-=6;[8H%N`)>[T@,KKN6!W495E3=)BM38*
MW7(KH!S"*V]8R[Z1^*7MA;!+ZRT'-U/%%S%8`DN76-;?BA/-98/%S#852"WT
MIY>8.,TMD4CN`4WB1$M3/]"N`[=&FH(F/74XNED>C!:4S;'52D$:X6?4T1>P
M![TP/AAP,'9AP]:44W#!IB>$LI9W@$;JZ)`>QO*Q=IP6(_VFZ<<X!!U64E"D
MEL`#B:H*_>-;X!<A*NE7-#?Q/2EE%*5,/+=CF3F)*0GXFG++'**+;%<*8L8D
M:PETC7*9,J$-R6T3A$BD*Z#\AC?#QL.2/8:$=M7.D7Z66"HJY`]K[A'Q'!`3
M/I,A0'+4SXGQY0FW>\Y6&F64SXN.-B3G(A7B',/,;(5U0-2,B)55BZ]^$P%9
MK:AF0D&7&.$=>PJD,1D9]$DH1'Z*R,.10J'0E5.GQB*7$CBU'@_=\_01-<BL
M:,E1033`XF9J2*ZPA?6"XI'0SPIEL+"J"PA]]%1NX;H=/+9G.",EZJ(62=I2
MGC/`2>I:>L/F-W4M99XN=E01Y,D=J4T@"BLT$BY,(V9]4(J6(#?6#]N&7*HA
M=+A3U!:0/YYF,:DGO!!S8G-R?%^JQ+X%KB7DF^<&"WB-2ET,PA]Z'/!O"2MS
M#S%8C]9N!F!3G)TFE0K+US3V.Z")S'P%]10[`B&%M<IL2COJ/?4CS7"N*$!\
MH`D`%SI<<D1X31N*FY)3$A4XF]"CR??ZSRG_,WK"J9*_R*-S3&;W`?\:8&U-
MGB><B]G3)XM#%N*/7(PF6$"%?V<SW+:^O>I/1OA9'T$?/+&![1C-;Y9STC<_
M/)B+GJ13'OQ8N,UFYNQ`RP4RX>2`->X$1%7!LK0#7([MH%BH@<M">:P!:I6`
MYD:>!<"1,XP8B*!=DRC9;/Q@%P@W083RN%;6@T](&/*/"9+GW"P509PDF;E`
M@4G<Z2ADIW'.K`0P<"X3+G\NSPS(PNM<C9BB#]H>H^)*O0$U@Q=FCY9'2899
M7L*IX))DJ_3&K^CNOCKSOV76'4+FP"\<V@R@)7\9@@-ANJ\RKT+2H>)EZY9=
M9"@V-:9M6<D.;3G22W[6"CCB1/5:,0@@R@6HN:`[9:BJ!P7+=^7'86ZQ.^I&
M>K[#[-)2Q%('NP36OKHW<2/(`QRM!*+#8KJOH[0A)&_95BDX?7E>UCAS9]A$
M.=*62)3D#64YO2]6HB8Y&D<#3C84Y*9U"XW*@621#&G7WQ2/]A[+^%'\6TKN
M2J4C@Q>32*H3)>#S\@MMJX"O1_N/2<J->9ID@R0Y^+XA7SU];'Q3*DR3.OXG
MUK\:?3$9)P=>L@P%4!R,,"!7/'KV&(DR9?<C%609M24=@^(I;#W(R<Q\OGOX
MQ_H\]+2`--'`NK.2PH38`"Z>'LC0ZXNEDJM#9>L7+$:T@N'/8K+333M/J5U8
M7T8IXT^]'>AON6A9IDV)_CQ9XU8_2&LSRY,_V)(4K+>R@+@X9W%3(MY$>IH,
M:;61T6*&9$KTA:">K"-NJT(NV\*?UL-K,WF0_+J_,)^F;3K+,$<Z,Q.V7N.K
MT49/0@1+5$:I")S65PV^VC`S;%K(D1`PI?AK43)3*'$H8OSLB-O<'D,!C;(6
M$RD:TTI8`7CXK,A9SAE&(#A<FS'R#+86$_%%2-<QA%1HP1#U!+K!32LP0C]%
MVZZK/,Q1J3`?!:3`&`-YT:!;AB`H!T]J85;6^E.(0$GOD-&DY$%XXF$!X:=\
M@P?94;:,;T:_=8B6_C3#!*$+47VR=^)"M(;&_"+>5+[+9JU@M`7?PY:LQ3;[
M3;(6O\^L@H=$J!,9/4-7$FZ?S\I7ZSFQ`@C"G2Y2A<LE<=Y?]3V_8DC8/DLN
M?%&.)I=K$LR6%:@<<OD%R&5&*@Y6P0&/#)WB_C=28*EC1-!SJ$R;`DI%SY:'
M\.6(3)\`<;,U&3,'@I;S@GTN*PD?$)!=6"JN1H(!ENB2JI5*143_I(A\[?E#
M+6(?UPEE6,3D0+(M<""$AQ%5:(;62A(#*,B72#9(<A)]@G82<BMBO/CBT9TB
M!Q_0L@\<#9R-/_DJ0RJ'"-08F`WG("CY&7-I41O,T^C9R`R9=1$;KBE2UDJR
MKS'\\#QG@=($]>SV7.T`,>DT'3Z!_!X(!H4R@4*?DGZ1@U9DG7WMXA@MN!=.
MV3F6'EKJK)[9\\WS2C:MB!<MWAUK]#W2`85YQD:2%K+P0`9C;.F&Y<UH+JDS
M.PA1YA;97RVP49]GU#!$H@DY#HKX2PYH"/[*B#NPJV1;[X?,APQ*$._^?`[E
M?1ZS@!9KW[7<NI$S^R8W6P$05M#07A/*T16%)W/TF0#E,I@='#0D2)02ZH9:
M>J5T'!D3?M]*IE/ZY5T5DLU/5%4-T//WG]93HX4C2PW37EE`T9[J(=$"--2#
M01Z]*I\4:NFBY9_21E#*/)AJ=3CUS`1@K7$]&M=%,:AV\GV9BN]P*%UE7T-S
M!!SM@0/];)>5_AG8<8LL8?%27[*&$I(\H@T$4QB,SY"MB&Z-_3>+CQ\Y4+Y]
M,_MLHB9@2M\DWC=X\Z1'&8\\*T!:<HJSP:8%/K/DNJ4QL::=6/K79@VJP<)2
MCXY;I92[45!L)&5PG;AG.9ED9:9II_@)B(;JTAM0Z-C49#UA*Y0429#-;@D5
M+#-H-*A&APED/1;4KV]6V\!0\O9>;XK3!M71R5P9K99E%N[7HLZ[SHO%+]TQ
M!$N#3:+_!)2FG:I)Q?[A40EL`7&MKY388Z4YV+/'7:Z"$P<LT!F?1ZMF5>!#
MO5T%OP`BMC80U`GXKIZGD$?A@_[@8Y]V-^JFP`<==4+U$KVRPN<S*KJR4G.!
M=:T=6S0TY.YKUT>2_<_"E-MT4(DLLTO6".IDHP`CQK]M4?#(#Y-==+6P]=03
M4;D:-FZ>F('=_FLIFO/`8V7#J(@'<X9C]U66J\IMN94-K^"(82`!O94.;#`1
M'Z&Q?!'^5,<0:C42]DF4H<H$1SCGD(S0QO-T[LU0QW#\R%*?_I6M5,VK!E38
M`$0*G6V:0,1354M@3['0>D%63D6""T,0[>$%8I/.V`BAKL-`V6ICG"(5"_+G
M$7C`P)?A6@*[FZ1N](TP<:-F*S\2R-UP9!XJ!0C:M8(*.0ZDO&BCD2'@$9;J
MKMFYSKYAAQMCFK9D9#-^8E1"BY#-*/_#B!;R"?2,1ZQ(B6XEE4+6/D4#SMA+
M`!:<Y[0Z.Q1TWSA5]1@&J7-`/!`D5*R)5=0A^O#WZ@:K7,T+90'\9JU<TD;D
M<5#W2)?$!A[D;QVD%/]B:B@P)HFK:1'#N?=N:0_R$:4_"I#W$51#`V0JSX0*
M?>(0/SJB@:M.OEXE?.?4+X8$=\OB]8S_L_KK8>_\M?7#=3YWP(4YJ>%2'2"]
M<VL!*;Y[QB4Q:JG+=)QA+)_,,_J>!+LMY4WS]+@1#[']C`P)GZZG`7^H4B.*
MQ?QI)=B!=C4+4)-PE]S/RI6;TZU&1(JJVHRGS97BT#PJ$M54(T3SLK8#U,IR
MC&DD5H.C0)JDTX*E@(?@?'+G6S&>9#TO6&6BXED4A]J\6%P+T3`4G/<;AU@V
MS%:;2:)%.FHS(1#8NP_LRR#%0#7M3?YJT^:Z:)^$V#A<U1-LY=)S)="6A="5
MTEF;K@^H$P%Z4XB*0;+LB64SPOSU+@+MXB!U^-3&,2:*O;X&<KSPDJN9=@V.
M9#.4E&ECDV/`-5?E4$T,9K5MCR8GX1(%PQG#-;+CMF8`[+O%D],7;_!E/4WU
M1COHYKJ-T==1YHZ&+&OC]HTL;^PX,-8.0]GJ#;`'52L/WT>]P&M3=+5K7FCD
M`^F`UL9<-<7=*_+*\22.Y6411C(A,?@!8-+WQ!%GW2&%@)'C,L$1ZRP7@0G)
M"F`MXW3`N1Y6&FR7#`[G-\"\Q=EH^;&9G,HMF75SHA*281U!LK55OGPTQ5^O
M(*/,V%`G?`UR5LDJT1[3SX36:HNAUJRAX];%X##PD!-#NG0!/$[BT"+Y@QG.
M-X26,F:';VAT5"^PV4Y"/L.(`R;V-\TIZ8BXK=(*Z%C<N=;P</^YW[,!DZT-
MCTNU>AV*5X<D4G-PYV+VQ4`)['KXW<YW@%KO*T72C2AA?K,<Y#O$&YET5@M[
MJ>(WJSVK'X/Q7A9GEIZ2(^[B0C293(2I\08E;$"X^\>LBK*[FBU&^+&/29(1
MD97,AP`Z1I+]H(F5'>&(!7&?<G&><0N)FV1Q+#7E4\IKIW5GJQ"B`02J,9WA
M39,01E8<TX$V_'"VOEQ=K5'5N)%@)WS!VL+#IUNOGG^G##S_:!FAEDP?53<:
MN:50S93].7`A%2E.*TC!`[`_;_+S^H!<1<K)80L$%#C@L%QMCPCD_2_%PQ:"
MU(P5J79#.,B>*&PF13A1GYJ81WAM60N-2WZ6X_OT!2F<L?L(6&3,WM@I0@$.
M:]H(NG*IJ@4/B2O(GF=IG5JT\D!I/2Z?&%O$@2Z`<]XPN0<$Z9ZG@9`S>]\I
M_FAQP%!MY2)(OD+Q3KZ)C*S>]P6@(BBP$""?D28QY0[<,FJ&R*PV5(L]N16Q
MEN!`")2HHJ'L2KX>;3EH4);]D<AZ_++$BN$==-_%R`T#L=#*N_'QB#1PNW1Y
MB*OH;89;0Z(RHFBTO&TDX&$/#9E?U3MV&RC/YJ%0U>F1+8MO%'F91DD8%MPZ
MZ.4F(.[X"MV_,I%(/+2'G77SC9&A9$/#-L0.[^;86=D?I1.0P(Q:&KH5XEF<
MK><]3R$1=-D3V6GA&M]VN;GZG5MO>7>N4*EIG^J/:0I[S%+G21--7-Q99?=8
M8"^Q'QO.ANZ@^G=\K?$1[4&X$D.M>AYYUI,'5,ENE*2(V0.<JYEPLOA+\NK<
M@!68(\8IMD)/WBF@T'GA@D`!=&Z)5A&*NGVXI</OS:HV*_W!@.E@JRC[E=FD
MO%%$?"0PW"1$AM0KO.X@C%#BGF2].=U-MFUVM0*S>!8,N1FF?VPZAZ2'$Y&K
MA0E#H"/6'&M@JZ6T\1XVV_11U7C7LYBV*0*YBN-_1B6GDR5:U^$V-QM%:3L`
M@U(1JCX:<JW?"&=RK-B,(V:R.NX`4A.Z;%;9)V-E15YQP^NE-'4JDR';SI$K
M5,;;J^JM7]79(S&ZWC4DVPR^L#B?*S^],>Q2#:,XCP!Y0(P2,'=2%+XT(U:4
M)AR;T%Q^?<;,G,KM5ML*2Y%!`N+J,-J&?C_S+*D&W.K^RSLM+9S$7F,),-E8
M1FBEC0;/;]`Z-:1:U&.QU,RB&O,Y(19@CY@5-:_]MLGE?#Y.]1(A$<JS2SOG
M(G:PL37:1RZ75JKAW0,0JUMR+[B3?)WNS:*JQ9/BLG&`"4M)*#AALR'[:+@W
MWY.@Q^5L]M&=<5>_H2Z*;7>XN/\-27E/T#8E(Z8,E.<3]RW]9Z?8=)J$!!'F
MNDDW:4?2A$P.:'2T,I%J;^:0*:I]GFTO5^5<3L?@(Y+C`M`^5GZNYSC$ERM?
M<%".2>I";IK3D'-L@-0T@1>7[CQ_*1FRS@$)?]R$S_GUX>O@RBUT7\=N#,'"
M0P/-:F#+LSOFCD:>:*N6EG!5US[J$Q$26A.Q\A_J(PX-,ZZ_B*GPJ$HOP5^8
MT7?KGJ7I9!^[IDJN4WUAM@^2LU8Q`H<%[`VZBZ)!A4C^QZ!'"(LLCJ#M`)"J
MK'P5(E&!<*5M\$.ZW#)1`D<Z02[^59P@9Z(4ELZA60CN31^>8Q$KZ_PWJQ"9
MRD*L9.`""G.DT7HGJ*;^3HUV+F"A$<,$-MB;AGBG+55+_.IN&KOGK#J>:KU@
M>AD`8178S7\BFFGY+E,,3KA`S;O>JT=X-<UA%V0Y`=ZM[MP["*C:H]RX0788
MVQ"SCC>SX858O>_'(%F5.=8_<['$7JJ;E'H!>("84A&%7E:"&E>$2?:NG3B[
M"I+=:IYXTR!X=!T="TZR<I?T58Y.Z9.49*U"38%JA85VT$;GNPE06*)DS2%_
MBZ-'U9C(V;O9]'K[G4&(;CAB#SC&<.6F3.(]W!(('/PZ8*@,OR'LD8(Y,JEE
MM@+`,]5"TQC$P8XD!87/9%_`Q'"<(9.[<4)$)I66=C!$]))0F)9.R;0#3T11
MO+!R!NJA#?_0K;9VBBS8-2C+L\0AKM&@7O9'H1V,"QDL2P-JLL!FM"3D"(I\
MUQH8,H/16)MDT$,(E>PZF<1Z3!LZOGQ><=Q6>9<HIIWG,E=-WYK136`E,"@%
M3:!N,%*5,:".(((H:]5FU+'QM$Z33UE=?9)I;Z!9V$O/M=<)'V&!Z&I9;G$C
MEK-Q3O.4,`EK$FQ,Q;*8][%BD%EDUTKHUTQO:$FMM>>G?CQ7J$",]<]8PW@L
M6C$2@HR-Y3K]:XQ*%BZXGP]RI"=S0\1^S)<#>M#?:^K>\R)>]*#E$6HC<W:L
M3Q%UM?EJQQD9(D/F`)_@&VU>6V"<%K^NA$>HE-B&-Q++B@FQZ[YE4-Z04@WN
M_WX)[[JS&)*HE1(FF\8RP1F5T$$<,]RR5+DA:BZD&X>^J=I("6NZX&3TR2F'
M)OL#Z*9NZNWQ_&-L63`XK954Z-[B31*F53.:4<)N\,9W69'>1HJM6S%'%5Z,
ML6T]`^5HW%%4I$JD<&U=6)C.^K[+6E5514U6GW5@SY3/Z[]!7>VJE8A.PF>:
M4ZV`DKO:?`B6P;B\/UCO6MED-`EAA-P41<..9PUH5&/+&J5&1JE1JK=JUB9[
M?SP4@/C94H+OW>`JL&W5">PQ1[C!+MMCIIDYJ(AI&Z-)=2#)/4<(FT@`^DDH
MQ:=N<5(BBQ-22'VRJ,A,4BV:-3C0F95FX27),MP+L$(7:ZC42AJ"/+IY$!I1
M;4,:,+.$%C5-^J3)282XG=3LZ`-)*9)5<E9Q(+'!)*[YZ'K:?AAY=<#G4A6L
MW\1RNJV1,;&V2L\/?`J7<;B(X3I"`JV&[ZJM8G[(FBJ14UM_8_?BEF-L1_CQ
MH)LE'\6?%+?#'>5;."95CMM1W#M]7.S]AB/^PIQFFH/%S=BC+\2"Y*8PV3+;
M?UYS[!CDHO0Q%\*MIRZ<Y?"Q<\P.*!`%N9LU'!(YKB$1>)5,JPRRSE;E8]H3
MC8>8S3IWG3K&`8P-1U;5.IGUGV=289Q>$^U&QJ`X0=!SX4FHJ9]8UC1^3J[]
MOY%<>0;#&W?:@N:?(\=3\H#&FT#>"D3F%'*^1"3>R;G?UDAJ5(\)>T\RP$AY
M$V?%;ZO8,8A<>BA;++(0VE:Q38O9I:IC"`):DCT4+():-UN6R??V]-^!D%W:
M:DN.A^'SV!7K!SRUP),RA,0RGJHL^I>JM/R'F+9#R*6B,=V]6X&K3Z,5<A/I
M[E(&'34KP:_RF8H?+5:@)NYG%27(&;B-IK"6U&@ATI`#:+&@J^QH>$>WZ78#
M#CM]8[W$Z1Z"3I%SCR`+$=2,9!74QH2JATHFU$HWW:7/[C48S^H%W\7:W53(
M8@;2)!HINL),RN$I1T)F\*[?.`&+QH(@JPR5S>Q#X(B9&`W/D[5?X[#'[O/[
M&W0M8X9JO[C!N\;4>?5[&$OW%"TT;=D9O%DG%3B,3DIFOC+#*RG^ZHYM8CU9
M*RI`JZS2G"=WBJR%H6H@("*L-PB4K%#E^,`=WTL`C,;$>RP,P='N[60;ABD5
M-A0]I`8V876OA^>KW"E>1YB"55KX\259)_*,.N]IYR"2@8^!?UB?2WTBO$$B
M4\0VF7(JR6K4\6CE?-HU]W-=J[CMJ]2\FZYE[I&005AXUI-^"1!C)6@S',]N
M_32$M8M:>5&"1$1"]IRZ(HQTQ9"Z7:L/UG9B(X+'+8Z!EM:"W-00N_A1I0B<
M.OT.NJ':^ATDJCG[]!SR`KL$@'6I!$X@Q%*U0+(2V:P#R+<5#UQ!P)QJM;PR
MAL[=_6LN]?JX?3Z@.E8NM]_3D:R4@6W&W*3V.IG1FFS"_9X^%1*(_<5X5IP3
M68P=,8E^H0QG]KZ:5C8W)WE?+3I!'>,K-=@&/,\`<D"%.#R#G$9TE_^._:>C
MV)CYV>*JM+2091:KF<*`L;/&!K2=*?$##K8HD^L*Z?2@Y]3^)4G%DRNI%<YZ
M>U"#CNB'',@&HY]QAK9P7O!ZKJS!*(JN<]W_XU!<II4L3Z;F)#CL5V"@;2:"
MME9*54,O-LE$>7U,8%+9/(_84E=ZJ#485PZ3B^FY8=8:SIN=B-JN.G)B-^(U
M34PJ0.%:E#L;<->H'O'@!NX:>?SP@P!CSNQ!IHO*UWA,&9+X%$QCQDI*@&:I
M3=/\NA2XF>`95@&^^JFT=.5FDRUI$=#%),QAU4>3(M%)2XX,JPE?V$YK+`F1
M,8--V,LH`)&4A/O1R(]8VN!(EP-Z2\"%7QPR_Y%7\L!T&J3BJG;M//6L%B51
MM)X/'XTZ1]_TMCF#?":6*QZH.YR,G(?>H!W3I<V;K$N<L_N;R&6\YK<$.<)%
M0BPS9#'58*P3];*=B*/ITA);K30EO^U((EE$<927]R`(Y41YE/E4N)_K@T87
MXV+]E.X`UB/QD:)S3"*8"8]TVAJ(3]:-#X+REWDG%)RI)\98"LWXRN;*$OI`
MF%'-;Q9FMC#6U)-_:MQS:6K.+/K9>^Q)\IJ;C-2U+AVVTZ%JS]9,P<@8O=59
MK,\VL>WK>P\"K^DC_G5'*#XE\T)R9DX"L_8;<W!!;J[FK6H[;]M(7'?X-9DW
MX==D=*FR_5@.XJR=Z3=@SDG\MIKI_%45B*TXH<<1>?O)&#TN4DH%:+>P8&K(
MC1%#;2&]06OP8D2KG`F!B7[U@S/ABOF$`!E=)>J@P)\W_WY-O@1,5/8C7ID=
M\]'HBMG\"SJ;5B_>_J?LP*"TTU-R[>C?KUD##L4B3`T"F8NJ4-#=FV^F`RI)
M&-Z/*E6;T!WL6$H4S%5$QA@>NWMI4>Q\<]7NE99)O4DT1JCL0B+;1UQ8+SYG
MS1!_2CE('3`OQ(ND<`08:L3:*@0%:R3S;ORG6[O[S[;V]^B:Q#L^W7K^]-76
M2W5.=[2VVB,>8[+-T$/HUQ,16J$$6$6_(CD@%@4#WFBE)CCL\!W$-@,$<'9I
M-7T/#:&7A-7@2#<TWMF/O*H!;]O&(PUEO4ZFC$:>G(B=&XGM,_O?L?670<ZT
MP!K?K#=F;.5_40]7(%2)@J.^?M9+Z,A2%A9?1XNOAEAI3O()(FTX=6<5-KYD
M/T%:1+B4#%ZSJ[&]'"?`SBK[U#9F%\R0Y0K-KN!)Z*#2W&Z,'#:S+Q#[-_^.
M5C)']ZMTM-J,#K'I+*6I>K^0%.G^%>-CT@($?+SVZU__=[([S?<?-C]XM+>[
MM;?W<FMO]VGSJ\?-#QY]M_7BV=.MO?UGS6_>E.I'XMZ#,/T]U+PRM]:56R=P
M<WQYFN0ZC/7W>.G1WL[>7G.D1[L[+U\V/_S@:.MM"(]:E0))B[E0;WJ5K'>$
M-I9CQ*2@C*#*<)/>3\KOAZ8)';1NW=P7O;_;E^IB"<\_5F=QJA)DN"J317@6
M2BBK7B4TE:$^#,E4=#?5M`-UY`%B4KKUCJM=C.*D!IU[U'M=:XE=.+:84`\C
M3*PB`G]);CU8*4ZB=]Y:..FK-R_OT9%]9)?8*'Y(BY4M9$[N[F]7[DNWCL?;
M4:!!UNF\E;4^\4VR()R#T54+J>-"FZ6V4&^8U-#-LK_*N+6:HY$ACM.8#AE1
M;&3,R"Z.RXZ$.TL5OB4C9!ZIXV>MS%"Z64WI$9M<)XS3)SH[8-$Q!E%MAI@X
MH68/DN\7(Y\U?E&@I24'N%(ZL)61P`P$&.;'.T5'KQGFMX)"QC$B['<Y>4`C
MW8G9J?AE/+"/&S/O,1>81:PEHC4`VRFO<HUZTMI7B<D9HWVXH99VT7F-.#=/
MLR/>QT)T#C\(FTX2S\OQQA?MVJL!<%L)/+K\^;I!(B8+8R")/E,:S,[\I40O
M+Q+$Q%JS-W)R>I8C2/P\%3<J^P5"B._&G\X,FZF3+<M-L8+J=)H%Y^R[8E/D
M1#A_%PO]5H,?T`KLT=0!4)YL>2-U;6>$0#*6E#81K$UFS7M9DM^#ED^Z7L3"
MT[G:LMNWKR"4GMOL#<F'080L:W+*)2H<VN$T'8^TI/6(B[;7G'/W6XPD(1:Z
MAI`*.F<C5?F7#W,SD'ZV\X-E!X]G.S;(-IY429FWX:[;@-JB5ARFQ,Y9:GL^
M$]92CL7RED?I>CS-SH=#RXB@&#\3I!M$H2<<&:*D]Q8+HM-IK,!S*-R/X<^;
M?-E1W+6OE?$)Z4T'L'-J!0\KHWZB4IO_6"J(5T>W6(E<ET%0'4R]F,WQS*_V
MGMO6WF3/0Q.>S]9A`>ZBQ'#;C#+T-HQY0-&7IAS,WL"FCWT&&U:@,JFTQ\N"
ME>>PY?&EIQ[2M1$:/2,`=5$#([[IX'R-R(;*[I@36MO=7M"8J=`6U18@U_9J
MMFV,'YEW=Z/LAD&$\Y\PMMBE4A^J'CJR9S=%NCTW$^[AJBF'N+\B,:#+P?CA
M"M*WVDBGF4$=/(>)TFSF&T-Q?Y4ZP_#\D`0&+[G:RA/%;ETZ>&X54#_KR)92
ML3O*`N%".;V&V:1CQ!-=C96F"#2P,UMN8C<,4;4Z;5X^6R3@8`#W((Z<.1@@
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M3,UNP`>MX,1%=)X)72GP8PSAE0F=K:;Z?8A`0\(/#XL"Q*D=U@DR7JT_7%E<
M73N0Z6W45MR<%M*MJB]L71NZS((!B`-58KEA+,X;N<9':4(ADG[G)@61B5-6
MLA^GT18JF]IIW"W_`=448T;$X_;.!*=F2BQ7FBJZX2BG"&+V`<%(U!2'XLT%
M6;5.SZEG$KQF*`'W9;=<6(^SK013U,H-=ZV[)?!'4WZ8V'Y]^9E;DAQ1U?1P
M]Y7AB3/PA`3,<,(!49%N[_6NP.(`^5?+@"".E6,U@/1A>_>5<)=39687(,C$
M8]W2$WNO1";$$Z@$;N+.$TR<TH'4O@:@TT5)I[C=BN=54_$H0@N]1J0A-Y3I
MF)Z(M@<P9JE%6[5BN6S5L='!X8N=6^*R=QW:(J;UOCGW&>EX3QPUMVB1AWDM
M.Q[SVHZG;!*GG1(4&NP4@O_`1(T<NTX.N_LJ*CN[":7KRJBR<_J0:1<Q86);
MT^65%]!0\XDJKZ%Z"3&6?@>94;G:M(C&?_R,0=Z.%/-J?M;9C2G358KA)LB"
M&XD`WUT&-*K0AG$;12/A&R^E9HMQ6(B#MK1C4R-DM"*H,<X(ZL5C2NZ'`C,?
M+1_[86Y*A$$,_0K7VM.P%;$(!_^0LNO@U%FLIHZ2X3>\)@VL:"O<A:Y9&R$/
M`:O"\1''K4;__!D1)1_8447W(L(ML<\?5WQ.\FO]F8\@6Y]M:L!`^R7K7W*O
MLO!`]][((E1*Z$B(IUD6"T_[#?H;":?#"-:AX_C5TUJ(:FC]U?S+`?!%$ANZ
M`!5SA#`F1&4X6I=RN;ZH'=+Q3E?1,L)U/2*$:K<@^^J"T2:YF##+!N=@]C_\
M++%,"O<1VF]9M#R&V?5.5/C_LRGO97FI[4T_<M5,H[Y6R460`GAUJ6PPXKW\
MVH\B/46H#O[^P]$Y/Y%\<FS)Z]/?]<[>]PY^*0[.WMJO))[3/_CNH#G=20,R
MU]%K*CA+-@-0SVM)DW)RB5WF(C=WWK@*"^"X\?B1A))(GC\S.EBP;S;_]V0N
M![/5JOA#GY_RHU';KZ5\K8O(N=OF@)\XI$_GXVT^T#G)&7=FCT-)SC2!*2ZI
MT-!4T<<8<J'S;>LG=^+B`V9U/;#=U:YI1G1UUXDI='A4FFF_#B,H`"#S&BJN
MC<?FP+7I:GL>X!0&'COD/[YHO[@HRQ8ZA]R7N6XV+DZ8HVKA]M'N&DMNQ`1&
M#-8$OVIP45:(O5]&T4&7HN@8EA,K*O#A84KDDZ&5$!B&F"?8WD``LY#W3Q&Z
M]E,PI;4]_;R'B)51NP5Z+F1`0^&`\"C3&TL8U+NLM!9=]A$<8/"PM$7@F\+I
MP]@G(9[E7>-\3X7'>PV0&L6W4#]5^72<5Z_`$/\T%P2CPR6K3"MM<^NP.C2!
MMAS4%GI1+;2IA#T'"THX"(4&1:MK3ETQK1$AN#*>"XHAW]R_YH)&O"B^4YF3
M>#+0/:2&?OABUZX1ZDC_Y"-!&G-I0@Y,!-*AL551X=!R7WWW52R7I^2V,I;$
MMCSN,)8S#.Z7J6..EL=]%)4@U(:N,D3[@$'/W&&<PG;C/Y)@V_#+D'3GI'?7
M4HIF_>IW3F#,DTE4IW4OSW/?MOD<*<3>OE]&%9/L08G?VZ]_/`V_&]B2U-J:
MO,`=FBNU*+^HJ<8%/MTG![+W:C>66_E$\]?5JVK%P,^JDT<M9G87*OLR_34B
M23PBV*WNAC9!UJ7Z3<'JH(F6:=U)#[]+),D*3/>AR@NXAC^H;ZMUY\*&N6/2
M,N.(5.[?MII<[(V\I,"F:_DF;3>4N?F+T[C`%B`/%K)6K$><@S;EN-NZ/B*Y
MA<!T@#);N/78H!^D:_=>[CQ_^9+?">0TH=5'=%=1'!/I9B5R3:2??%F/IH2J
M3.FC-FCYN"UV\<<ILN)G-)AR5^PW*I?MWY%S5)V:=L9[(&1"E`^R^-82<NR$
MO&(X$FLW%<8-H+"QV%97]5B/PF5$<"X1S0RVV8[<G!+X?117$&K"C]29+'I<
MEGI9I4MWT"L[VO<5=R#EJ"\J!EWJE)-LL03BH/Q3@=[*W:SRAFRRDP^I><<+
MTNXT4`>Y30KRD]M0F.(FO:F7!SD],TE,_1JMP>X:0:MH4,"#G&HMS=<OOD;9
MY@N]XN%S?JGBQ?Y^<J@4YS'>*01VKRIN9*2]VY.;7?-S*JR_DK",(N*?.[+P
M^SC&4?B7,K19I!CD/1>8K!ZL`%@S"CE9<4W")KIM.K/<T8#45,SN4["]<$T'
M@2F"#K,SYYC!@,[SL2$Z]E+5??&,E3@S3HAJ5=.QN4'?.<62`'@-6-&4@XZP
M3+ZEB;YB7*7``#=[OY9V=C"2TUG#N=+*HA&^!#/4?"8W#3S2$-L*(G5=1%4M
M*HZNSL!&8X'+1[/=P#&E#$*4V7CD-K87-#G[XP6BTNINLE^Z3><KN^D5=WY/
M+(KI[N)-:SVG"A,XO9WJVF*R!Q0N)DV5/8JW9#>_.(V_:J415#^;JZ[7?(HR
M:;UEH_F`VY"[Y+7Y1L_S[0J<VB>B,IS>?.\$`E4'?LD1-!_PI60C*!(0TN]^
ML&O-=L/;/490%U5#+9N3G(7V$`3AA'#(0_CF0Q*O@#5X+H`,E$U,]9>P3G@/
MTR0,>=/>U>%C9L12*55*DI6T+.KNDC3$SZ_^UY<A?`,,HRNIB!?@\#,#FG<@
M]K#=L/+FEA^]>+&_]>K%J^;GR&-QJ"1@=H7T454P:CXNRC45,P",6N1N`1OG
MBM?$&FR&Z%S8GUF([:QWXI'35&[@],"/'8L$]VLVE%DDWQ5_,,Q=BO)^J=#*
M1T3AS.P&5$-7&3%X8X?[^?^*[%G/J=O2:LUY`0WO%_;+X&P)V;"-*54$D(WW
MO7OX(('BA2GP*MZNY(E^31LI49<4@Y-^N+3*#G!48T2E@<%\Q;EAUY:YP5*7
M+''("KEVD];>;9"NM'J=36#Y>//FZKI7YJEN7??DOX4:/+KW[3O)[F)XFC=J
MDS10%Q]Z*H$**O>M*!ZU6E3=^IEFQJ8(R\E!-*M8!311^]GFEO56B^CNLY=;
M3U_N-N69CM#=E\^VJ,HTO[F`14'/P>5^/@.97>LF6"5@87;.AN098B&Q0I&]
M"HBUEI89^I[YK.8RWE<-EZ&)@3B!NM=BN$WBBCIHU6-'#X.UGF$A295!'Y/N
M&!HXF8/(M[VY[<6/MS1<CTS9*=GKHWJ8(1%N#P-3ZJRKITXBY+!\4=4-R4`#
MW;3J#U_BVJV"Q<1I66[VB0CL*B\$A2^S2UFK#!MB;@JI<R^V<A>>$''8>^&H
M2>M)%^)J4PE(19\E#6QN$#T>(Q`HX0PR><)N[94__TKR&GX3:*'&T"G)4CL7
MM"WA+6E7X@G`&)5$NMJU0SKA5DHBA5RE+OFF28Q:=W.!VF`L4]0GLU'$(C51
M=LWC_?^Q09_E5Z<-D'(=DK/CQ%B>KDDU,C%=V,U=2[YC'KO<M3%+2K3X21D.
M.YE)B&T6$(S?ZPQ'8N_D"O)2^YU*K1A/GJNL",W'->Q-X=1O=Z6;OZ6LARG#
MV-32#_[:.RZ%;7YUT"D,S:?V=HOM8N^Y^[_FEX0M@=+-;S:\<+R!Z<W7GW7/
M=]XM?<VW]S?,?@&ID^6L[K83!W+R2GC;VI1'10:W!]:5$0)51=O^R\5B'M8$
M(?2V8%V7I'"IS76\6;SPVHP(\ISHJ1!ZS@/*HVI]E>YK=?KDDK`(%,%_I;<\
MGK7M=$R6NF7=]I@YD#GZ?]2=VU)<29:F7R4NI!G2#%%$!,>NLC0C@<QB1@(-
MH,I.&YL+$$A))1(,`:G4O,9<]5T_2S_9?/]:OMQ]^]Z!`F76=+=95RN)O;<?
MEJ_SR3N1B`@]4[<RB!S-HB1:#`KGI,6^0UI[W#X^#2BX*PK^X5LQ&Y--5!A/
M!B_)EXQ>+MG$\(_KS^%?&LH29MX#31<?SF/)&@,"13>^%=BM>0PS2#CHS.>R
MF@QC5Q%CP:IU3DJ)1L_;O+C$BV[,N]<N-N=]L$E7DBP-0;+.PAS$/>#[M&).
M#+."I)71S6.L8@W>ZVXN\%IN,.Q]^"%:%[?$<N3HY%ZUR^S_ZH8(EG%PHNYO
M3,9F*N/H5<=1ERUA*]M)H+6U%849?+//-'E\+VTXW+W"8UBZ*\02!A;KK6/*
MN&7D-Y#RI9>#>D$)N.$[937=0B61B9D"Y$^.PH6MD\2DTXKESG&-E9M?HM`/
MN-_Q%7!9'NO1:6:@-HC4]79T01GTFQ6('*#+Y<'E%/ID+S\RR9(R3[I^#A"U
MS[1BDLY29>?H^VS[@6,[117,'2[5SY?]"O95*S@07)W3L'?MYC/E;3(U&C-,
M2DE\<"Q^PQX(UW,R,%23!DW6(_&)3H\O3(G3`2MMR3$]CCK41-#&3!"])=72
MZ##CGD=`02%/P5(]M+FQS:_MVK$",.YJ,!>?J?49L8K1K?&K1591D-1RC?Z>
M=D\OI%V2;&*5KLQ"!>ZO1M[9.C5H7BM/,TV`R'BA+_PZ`D5W#-KEZIXPVUHB
M__:8PTG]9T[L\I53HM2HPBKV&W+<]-['5'CL_<.CT_W1&GTX]T].CP]V3_?W
M1B=_/3H^?7&Z?_QJ='#X-WY_M7]X>M+RDU.VRJ'&XBC]2S?#@)ZQ.#&)`3\"
M_-<,!-!$R.,7/AG\2)[2%2KHX0YRQ6BK0A)L:6O.2"YYZA[SF=R'@2E<C__R
M\K+KU!V"('NG94RLXA93?*!C3`N2^2N9LTT1RK,QL<S)QEK24TLY#YM5\I2U
MGG&GDTNY:BRCM`0S\\[D[%H^?HLJ*T,1(6?,I&:L;B6DVVD`,62$6*=_#9J&
M9)\PR^B=>G\DF7$"%/+.(RXINE%2+RH\C(`&.2060=9W9,9^NN265P^P]I78
M[)FD(CP7V/W/G7-0"9G^OUJ@&H*NPSA`Q</3H^.#_1XJQH@2.88Q2!@"3?`T
MX"MN^P*ZQ`AY4.T'*Z7&"GD2R>2<K=U00K4!<<'+.^YUR$\ON1E(;>C*.V%L
M46V@WF5<0TBV@Q+:-3<,4FH)>T^CQ_=P(H$8J"83BJFBG,>X9?+6VBAVJGWO
MFWS7_-^\>/GQV:?L&.BY2'_4Q:\P,O;!0F:]Y]]3U$*OUI2=V!Z!.UA%UKIW
MD36V+[Q.WNE];^+ID'"_[6Y"X)U!Y\)>=`S=57O795KNW*J=E=H!+8_2J&Z0
M^F@^RA,09V-E]/IX__7.P=YH_Y]?[Q^>[)^,=@[W1D>G?]T_'NV^.3X&J<C)
M.]GO<[C8E9BXC%\G"%")W@LU68K4C*$YPDD&9`]E+R@?@UKV0"Y&M-Y+$E<Q
M5POA%^T/,8X:4\U[1IN=!ZR'MSV3T(%YFTXMYK3]!0=NQW0<&/SD9@`D[>>O
M4]2!4[W&R6!3[4?PX4L);ILKH^_?'!\>G+XYWK?3VR?;[;6D4CO-]W/:9#_A
M@.8,@<-D(,5"R@L]-^9<<;+@ZMK77IZ=&WPRAYH;I7F)@M:_\*4=C\#+@]E_
MX"?'BP4YY^::]L.EM?7EM>E&[^>MY=7M:?OK*6@O<*C@0T:J2=1'IPMD-RDX
MW5R>KDUMW\_6ES?6M^O"Y\6<\E87F=M"]#2I@^(X2VQ$_#I4^W8[\;NMJ/_I
MXJ)K2Z+K=.?PAX/O7H*]QFD,B7\X.MK[\>#ERW;F"I`FI@>T_0&-YRD\:*?R
M>[>SNSW<X_`5#K5?$!-K?R*VXHZ=7@,$\?GV[=H-WS[KMM1KGXY77\QS62U-
M-Y:Y$[3]8FESO?_;]O)T<[WWYGAYO-9O?H`7?W6U1Q(U1#-:NXK?N*.S)?)8
M-;4;W_-E_7XVWY,GN09A9WX)HT253T$FF??SI_^)/#ML&R\CJA65%H:@,KX>
ME00./*EO(-(RNT<MIM`N/EM6E;'V.!CE;7ID(]^E.XNQ4O)M35ZPV*ZW:SJW
M3ZMQ:G!8L4W[+I3D]R"^KL+@_&AM0$.!:C]*[[H*8B]S(]V7Q.:V\L)WC]Y@
MO(U>[_RT8_P'W8<?C]]@YX5"U$Z65S@4J,_*PA-$:CM@.V'6`H>4F>\>KJXO
MI!I9'_>2?T3I23N.JS5G39/5]BW79'C+C^&Q3;:?OD1U_B=\IFZ3J:">R$G[
MTM+FUL;RQ@!#F8['R]O]SB_F*T]#WJ?,K*]8V\''T0FEUI:37U4]%I$<KCSS
MFEG;.@*IL'MS9>!TT64L9(5NK(]F<GU(B25LG`Q`XF->]0AG/\'#LG=U^?Y&
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MA.3`>A+!5$KJ,*=?4%CW+L][NI)^>X+Y.^92]+W][WIV$N(,'$`ZFC-9E"]O
MMU`H]W0F>46(FEQ#Q?5C5[3JMEF"Q>8J43/7=(6RD@E?60K]Q%+H5[=LKZ4<
M)!Q%(AHA378H\6'A7J28"SQ."]:D96@A"DY\8B#V(KRPGLUQ6?+FNN&=CD?'
MQ?4K#]HKJ=KIGES_267<J-?``3\W2V!([3F%![+#7C&!<-S,78[F$=]1U193
M90]`3XNIXF$^F3LX:!2`%O>@T+*1O&](?A!+_(,6ZMJKBD>E"-:\I*TG+*1G
M,IVHG5WJ#OE?[<+P^\^MN),5#QB_X,`;<^'?R>G1[G__Z]'+O?WC$Y31D:SX
MTY_:\>#82LZWJ=MG:@,@?\9LM%>Z8DD;]89N/5+K&:E''T??7Y[#<G#;;3J6
M`7WK62%\S+605H,')NA'"FI4^.4>_RJ_CJ&(JXY.7HPAAE1B"_NCJ[+E4QB=
MZ/O72"PZP!S12N-.%+8$HD0OB'/=U$DYF]X+4>6+`(7.0,E+NXC(+CQ5EB!5
MT(DESG`YFB21_.NP+2$]`,S[W(I]5I,D_V^5:DVZ%F*=;9JNQ?>G+.EPYV1O
MYW^$5TZD_8O$%X3"387,_R*N[8BV_,"WD+&Z^93V"[&]BTM8"FX+YP"E3B/=
M>:]&X*5DPS:7KJYU40"I;QMQB\"=<K2O1<:I>;N&L4(H#=/#>[:1P2<V[<RZ
M@I^E]ML1I0)6U"0_79"F=R*Y&K*+"58.J=.2H-%@32'+>'EKS>]\;P!2;P3)
M:;7&#C0<O'+7LSLM-J^-]/V5":U8-!F^&=5RD4[`4>(/]KH6EOV,%H;,MS;5
MBT82*5P%SEH`X9.NX:9/+MWC;21A'4NW=#A#.N94R4V"1%@*SL:K$?CZ>J;B
M%_G:$R*0`Y,:CK#V'$@51$K)V61SP[4)//<L@25W\#Z'.0/3`(WM6S'^!!X&
MM[YS'A60!+$@&H.%X*+,(0D?_!JI^""`E&>(I6L-`K3%&/)HL1-CX\_&R]/Q
M!@TB\43OF*<8%9U$2<D(Q)&^SJ`1=R@BL2.@C9N\VOLNT^(/NKC,BGJ=>Z`4
MIYXJ<4PIE-ZP'\[6XZYMO6$7-^V`![86.Q^>U`I"'+NB,VZNX'VC@'9:VX_I
M\@"C@/K`ATOHQILTA=V($CKK<T;!U?.`?J']1"=VR2UZKM;?;)]>X[E'6(Q1
M?P7J2<0`HKC8T9$TYAH\Z=1)8VB'%H]*0+.JO@&D)#MT-6]F#@%K*QUL?V2/
MR!.]2B**$`K,MH]3>6EDY0S!1D0,U1)41Z(1Q)))@!?(V_\K$.L5JH\,T>.D
M6*69DVKXI!WV+HJQCI68X@H\RA95$(C%/QMOCQ6W:N4J=PB]53DXVM$[RP2R
MW&<[R*Q%M?QA:;K>@%!\Q$H@5&W.O/2RZ$\E0'U1#F>9G3>;M(LA@$33/`2+
M!@]VE:1`C^5WCAVTE!3FKI('[EVO/C>)ODN6]KO1_F^HNQ:%1.=`'*AQE[2)
M:.G;,UP5KC=4>3=2H^&A-1>IWI>%:>$3F-P:XJ5*"1CDTVR!N#81,])3+-_4
MLCQ8(.P:E0$'K1*#[`T2+)/>)5LP?:.5%K//[_0BL%$4PD<LV613]--MBH3M
M@#MM3;I]CFGPWW.MRT57T2JVE3K[V.H[)QYJ0T*8A0"_=T>FQPV5L>J\H&`W
MXB#CA:$)@.;G@'5[/A.*7+>WP>W??4#SK..IK0(DF_30\/<`B91U<ZW!%";T
M-IISW!QM%(B(X;O&F?22D'PSUV>":HLZA6IA%:%96T@"6#@D=F4CZCK?-'DN
ME(^1I?=DX:.QK"JI/!6JN[;5K,V<=UEI&B^O3D-6:LX.0KOUKEY`2:ZYO.&U
M9VLK^+ZRJM2#_L$3;:^U%L<//J;^?'V;()'9!E*^[H9>H72]">\%+(59"IYK
M\?,X-T/<7,,,D8+LT?B.I9FHTEF1V_XV/XZ.WMZ+1`9LE[1.RC4`5<&A.>N4
M#C&7TTVVE\>H-$^F(\>^?V<&MM8#VV*TB6Y=B:Q@8#5M6D?\C0JV]<&[!QAH
M(SD>H\\CT\IG%#G4LQ5*[2GV0O_U+5S.8VSY`;+EI)8W-S?G+:M/R0Q8,X\N
M@6I1,^5R]Q17/NOLUZBU2ZH((M6W(`--+WLV78%D0#0G7PGZX3TOPITV-K#^
MYC+'_B[_('ZU1KAD?3(/N(O!8-5@L/$X"_L]2$KH9IUXQ+#I"?QSGW`4!;?N
M^%%'T2I7*F-JU5G>P['3.?J0&B1%U0<J:%B>^'AY??[-$<)AE&E:*UU3FO>;
M=0J3&P^TZ2C7W$2PNOV/HN6US>6MR5QL:D1M,A>S7$+*?H&*N;F;A/&NR!4=
MDTBRM;$Y2,8;RU/,B3EGV$=O1LM6+(>9!:S.XPGTBQ.C2\)B73@FMBE?^7WT
MNC:&7FN!V<&@_H:>0J^#.Q]/ILN;9%S,`>$CRH7\3X\H%PM39N_&E(HX^DY-
M\ZR4&U1"X'"880O-\CU9?\BM*<BF*/6)&601#5V@,ER^\9K+9R\)+U^X`[S7
M)&)G*/5'6-0WRU27FSVEU9'=YBE,1%'RL0K;',,PN)Y-"??8!`\4-]_9I8P:
MF]!$.?'F\X"IWJL"%"U3&=[MB5V7<V31/4L,[.T73VPQ/8G/LL]5_G][ZM_=
M*'49NMK#>8'ZAMM""[(-IOB%MS0&L.VW&A&F3(&CV<R^)GV]`PU<S&Q=D8]N
MP:3<W$PU$3@L<)/*RW*(;\B:#N$_94S<[MD9,/&(%@V"_ML#'W%9C,Z+/ZW9
MJSL<;<%EKR"ZG:F%"](LOF^UU2.'TCNX[CP6=-=K<O'J<FME\WAM34@65XCM
MSO.'#_IC"%E:8-4<QE51F`J9S&;=Z&6;DWBS&*;/S,90<P.\_*["(=*D;<.6
MC$U=;QP;SCWW62#WBH^`/ZC$NIK%N19A2ULEYL[N`#ET])D<!YR*T%E>-P"'
MA*;:@G186NX3O5!"K_;,&K&`+H4QZF.H8^=5!?)5,,>K>*")Y^`,*W%"=#N9
M<9A*,Z:2"M]"J>[NK2%+L)0O5>BT,C)GH7THB'4P&I*J*9#UF-U1`='P.D?%
MM3)#0MXD<X.,C,\IX_\DQ:+6:-S#9K7,`X4[U2C@6"4X5-?L<NNI5P/[M[H[
MMS-^=7=79>C8*XX!<>1G%P0_"949Z)-O>Y>,4&#MP3/^L-;N&5GT-.ZYZ).P
MCY[>&8F=39:GZ*C3C:Q5E/MXA=TI&2X0?%;5/=@:L1=[P?B647WK].\\J9\&
MR=%_^*#H80)G#2G'%`5#3>[DP\V4]XAK9\T.?7[*W:$W#F-6Y\2M<?UC7-*W
M\^M[NFZ'=?]:X:#'WSW.N3.[537K4"'Q3FXN"!(1RM257G^3P&@G2,"KY0'%
MQ5_(L(N/4G;'O#%#E;IH7UB:(AC6)MOM[S%N=AG_"531K;GMBTN3J7([-]O?
M8X!*NK&;'B+-^RPM6&QHWBLR$:`Z<8J<%P0MZ^?VDU-(N#1YA/+3.9C@#E;D
MI>L4J,"VFHI%]X(APU_(+O"$@\#E"`9624JUDRC+0+OWJ/0&R78U)'_CHCQ$
M+M6!EE+1_564G(_1=IWO'4`X6F"C?)5*/>'#\0D\VTJ2K*T>I8+.?B%*Q::3
M.XL$-<*<)HVC>XU==^:26GPP@AGI`V>.-3]Z6T=9H;MGFROKJQY-@8\H!N+\
M:?YIB%C]ND3;/Q[/'/&\6,A;34V8S*1;#J;*4L-OA(MO(&J=E.A4ONC!&_G:
M#,1]_3#2J+IK!.^(&-@M5%G*+A?Y;&-5@MEAT!W"XIXQ^AR;@)(&9!"3V5FD
M[,?N&3Y^)&@$\LG[I4812;4\'[^'A=)<O_@#N?"_'_#]F@]P]AE*0]FI2SH[
M!VU9/+2V)\_4:#)]K4`3IZ[%VL;L_`T61@<`Q%0:VQ,Y0(V3AE1%TN?8+$T6
M[%A61G]+(1>$)6]+>#GIE!MQ42OFGZ3I,PM<Y3ZZ_TPG<*A)>4XI`;`J52VY
M0>&EF.E.Y@<<S_\TFBC">C>:3OG'SR(9`:1S_1W%(DXOT;Q&,(B<4_R!<ZOB
M>TXU"BK>V3L?T:?N=/%X#-S`5&`N*92;OHZ-S>?=?#FIBG8B7[TL0.QXJ'Q7
M3L*@1(;/]74*0_Z,*N.I$(K[4M=X(XCX<=I!=E?T9ZE?::``J'VHACE"`5,`
M/%_KSQJ)1*?[GW6#:?F.7RT<'-^3>]9K(V**M2(!&@-@Z^;KY.'.FK"](\O$
M=9'`T,1..Q2\F^@]':3?72_-6':#X2:YCY?TWK:DA5B8=X)"WY:V6MT_8S/=
M7'?2G)**+"6,-%[$7/K!J\`YQF`Y7";AU<"65)+80[VNDA_14]Q.P9JN7]Q[
M;+GPL5UIK2(\-5`RFTV8%N%L1\+2A>8[NEG]\N+D+<+L<O;B%4`2P'TT20WY
M8.WR"TH,[;X^EEOW29PN0P,IR_?7FVL8$!E3*O#T]#Y+@6+$JH=0?BL3QFZE
M('?XE(#H=7>I<]$*V6A*B-2JFE5HD_V5P!%HT!"KT#M#*]%Z$YEUYM>9:6UW
MEM3@B4:0C_+'@*P]4CO_[@2[U6[(?%.LVDK]26137;_<)';ZUEG`V3>H0CY`
MSL2L\M7-KKJA^9`$`<LQF\S.4D\D-^$ABA18?P"-KSO-=.XX:,F8)L>CVC`?
MZOWW6/R"H,#1/0TMP\5<5C%25P!R3X$BT]%S4SGH:M\32*:%#8#>I69^("&@
M-QVYB@B0,(J&`ZP;HE'50GU7O-:)/V!&(P/,/IENT<X(]X"`H!<2V`W&"0:6
M`F!`6.Y!`9P,R1],G(,44+'S[U\$_?L[8I0Y[54\Z/P2B<CME<T6U??W!7TC
M*CM:[*2'@V]63OA2"8*Z;?KSU257;$HZ6HZ;+B47YY)H9EI3+;3!'B#U8Z)4
M\7B[Q"SD-]2?[4\C>5]I9:*C*W@!?/J0DTDFPP,8U>4A22F(09V'"%9D:RJW
M#>1[1Z:=;'[DG?VEQ>%3D*Z0)O`[1'.FC3P:@4!X"KYG^VDS-KSY5N*$_&`J
M]TE]X,@.>1X!7EE_ZG0F=!NO/K>],UUB(D!7=YHFS2DQ:;>JN]K_F8-4DP6"
MNH+%L$8EN;*Y,O]U3'*[,&YI@,:9LL<W8H[_)U&>B(E@\P?7FMTU4C%VV%;,
M*7QWK:S#Q`=%@QM%EG`[HI_,@Z7T<IS:0S5Z#H#7DWR%4"C8^2[SY6I7:D3E
MF"W+31MOB1]I,N>0>S7E8?R_.$-+D8.KVD^?K;0FY7X(*==%Y]=NKJ]LC;%\
M-U:VV[+(8>\N[[_8['ET\W2%O[8KVMY@FO'JY'G[@-_T9#+M/3D>YB^]`5:F
MFQIA96.]-P376FO>R<IJ_]G>E70AR-HX4COJ*2CTGQ"]*B6PAU*3E74[@V:K
MPP?];_\Z69E.[?W><6]N\?OV9@OM>0-MJ0T=3K[GO8%65[Q%'?'N10=;72$1
M1B>ZA@G1[.1;'5HAS=3MKW1XKKJJCO"D/-PWMGSM#1*_K\T=>%+/_="#\%%R
M"AR5:]S;)<8K^^XW&'(A!>FWG^XX)VA_SLZ^]H'[%]M?=XM=VSY*:[IL?S\F
M.\'D:[P@Y1CQU[[WR+;E>Y20^$GII^UW-EK[XR,`>L;I"PE(E)BLMM\I>\(>
MKJVLMSSM6T*T:]OZ<G-EL_]P:V55W(*,Q95^J>>S"8]MX"W%UMII=QX)VF!0
M#3I]UC?-Z2.Y[3Z\AX\XWG0SJ2HFI'!G-WO(V2H1X<%:,O%BUU-C^@2_=OW5
M4@I`X1A&-E,6$=;&JIK8[6)(Z5-R0&<95`SXT!C=\-4.)ERQD!PA(L.Y&H-I
M?N0P=%<M^)!6/R;2OS%=,\V4/S>VMLD=W6@30>?E&?IW[A5#JYO?-N(850P,
MEN%P8MZ\-]S_W$-+\F9'R7!6#"H`6[E*PL0-:'0N518'<7..M=AT,H"59BFG
MC=0#@`<T_*H\O9U\96[`Q9CTQT.(JQA78+5%^*7+787@GH=*]`V=SINJX?2J
M]"H?..<0I.G<S2P<9(C:G`,!RY4JF`%Z;O.;><U&'(E0_]BH^5)X(99=$"-6
MIOB8GO+VK5=9&\EHT0QEU3+H1Y4`LSQ[4,X,!\V!K:2PH\#QP:N3P'*TS#QI
MP$I+X_8<\DW2W9L>=W6ULQ^4,@(LF\\!8-?YK3SLPG9O$2<66?M1M+V(3FD@
MVT]#?"VS^(%\+VS/*D-"?/$)!6]5C+D;9@PD'2]//(O2U\.:9>S.R257S#KG
MG]<))=J;]EP2=Q*.$0NW?$EKT:=##7>@-9'FF'KN0!%3C3PU%2&1U"`43N:5
MO^&%#"-7YZ"E%/8#WZRW]X<L0S/,N]_*22490%H.:-JLF5_HMV8^KJ@-4T+_
MZ'5%Y*FNTI(0/-9_RJ2=P8-^,BJ+]<S\/CD@!/;3/E.QZ^1M5R\H,LV,8R;V
M`ZR2!94!^-9:O=M+JJJW4$`P+V?$[@&Y5[]T$*6;CXB2!CE[E%)G\PP5K/Q0
MQ3UZ'M%:&V.G!0%61C_JFNM80[AQU'PS3,17^!L,@A\>P*]S=NS.<<I_XX;L
MV%]B3G.1K\PK'41MC`@L8X+KR!\]).U6)Q(V]?!1E9/78;U[N&-<[LNVWJ;G
M')H9J#UE\=2/KN4-)2I\8HF)[?-3.Z*1/70]K/>&#SSJ*3CC;=E!P>UFGO=8
M$>(7P='.)$T)G0A(4O2-AZ7?$B8M9=+_<GVQ+Z>]+R<+SME+5G\V67#.]7;.
MR71E:_4/!=ST"YOX'IB:J[OH,78=`;0>.&G86ZR=BO\$P>@".8KC_#K;1"O]
MA#I[VT)>2%?+U%&SQ&XL%7["@CSZ+"SI(V&FIX$%+]E.LC.7L)L<G*=W5^_?
M0R=[((Z8(9?]7K'6BITD'<+]R1[J<M]._:DQ-:VI#C@7L%`8(@>VU*V+L\^S
M7+KXRK4*\W7"HG%9:0TN3+G*^OYG@$<NA/R_03"3U2Y4LA=]+FBKO?3G&\4Q
M+0A<@Q][$;]/%QE?"6#&#9_$2.&!27[=/*B1PMVO"K[WN"K</-^&L@!KI1:6
M-G'9*FGTH,?9;%QA!U-6&H<K>SK41>9MJ?64[U"GK'>,9'6MG:F376)\14=[
M?&V&?M$77)751GB]//]NVI)+'&;_4Q(S^/#I&&"1%6^^;!(4#)\AO/QM$X)&
M1_P<AD'2.<*$8':7UP^R6!HC+T5-!+=*XB7-_O%-6ORJ$@46<L`RB"C\@-(<
M6EF-_;:VR!1A8FP=:PP@_[:6M2C4#,3_/T"VL(G@``'\\`-+W?0HB2<[A%T0
MVUT<0ZS@8[*\EO1IU(U>QF;`>7%PJ+@WW0DK85%L@83Y&A&LZR>FBC-_./L[
M:<(DO`U8A)WCS1#1P0Z"Q$W6M5I3KU!,GSV.E$YYQ.NA%6],9SS0)P8W.TDI
MI@/"2A4UZ`4+=F]TR8[U2,ILKF8+6DN]3BRBT#ZM>!^:5[&-"I1Q5;OMT^5T
MMPH.P4X)F!KMB4U0UQNCP'(M35@IPM8TH$0R-7<HLK+:[TV5<B[SV!H]'EI'
MU^/(BJUE)=CSUW'*U.YY>EL[F^P.%;Y"YZ[<0J2"U4N5]5\G_(`TE#!Q*A7K
MZ;LH'(8`Q\3#+2$;",H2663H8YB@>1"1!-;7;RU;%X)SF=_MR]\?N3Z^XH[H
MOY=7$.=H*TD61`>:PJ1PI[#;/KDX?I,?>R^-J3]59TFM7?TXZ@_AD/O(<(DI
M48S4=.>N-=3,RSB07%(2IY)_(L&T6C+VGR055Z-7Z1KFMK3K`2!%^%YNJE._
M-$#E3]NKD;%YH>+"H+/1*^QKR.+L[OIF=.*)VXI$&_%V,F\(D7-(RB<JL2=3
M"2$PW4L[$)^&L:VN;*P][W$)D</\TPR?A^&+6&BP6$?EJLY79/*5QTO7,>Z6
M7MWF@+6:WS'%OPM4IX2?6W7L*/G@*!2=G[!(?I0YE`R68&%=8PO;@:_;?GAB
MWJ9.CLM"3IO*/&ID$$^44H)'+ME&C6<'H8@;E&`NQRJ7`:;$S$Z'F/8?Z0](
M8L5E=`O$WV\/EN3>IYJ%RNTU*XC&$_]@T_!W6(8N,/^C6(:/6W[E++["]ALM
MR:07`Y*][!8KYO2)!3(LE(8Z$;Y(-ZS3RXL8B^O%SV&T6!$+?#>Y<]P:JOV^
M)=EQP/=;:P0Y<4),LJ5<_3:\#^?\R;<@,64\(:UG61U$Z_350M+H,#+]%[1X
MD3"F80[O1E#4"HL;6L#JPX*,9>#/"?6<X!4@2"%:.G//S)P=B^S.+XG@.)24
M"&;B;PX0E";O$MP@N\@:#"W.?1$5R*1%+`ZP16=#ZR7JUU6:'7:HF3V[?Q$8
M]B3-*8<3\KL3U>I(%P/BEQAWI7]I@PUTB`6KK"3UJ@-<J!1M=L`T<"7"5Y6R
M9::54L*,Q%RO0_X16#:IWUVN[)\G:4<3STF69C1:ZDC*@G_P#72F%UM]O6F.
MUF1[)%]C^OP%*1@;9)GM>;W#*^\-2DU"-Q*%-SCZ9LI347J@)1VN`JG1<DYN
M!A<,=+Y80-4!A[TKTN@%2CH[;3E+^,<ZYRXR32&;N0SD*3K!FUN9$6G?4E?M
MG#&.HR4JJ@0TT-F/J34%_462%[JKQYKZW1`P_>R6I+`P68D]O#^0<4EKU_GJ
ME93W7.G%JJ9KRU.*MT/;T@'IHKU(3BNU(9V^+!/R%;;6N5A*A&;?F@B`5Y`?
MR[ZFZ7J@RE#HY/"U;#I2'.?!^`\IWXY)8-M>LZUF#<66$\"KYC!3D)B*@/A(
MY2CZBC/0B]4Y*8-!%:,"P]"!-&.6TXM8]];R]MIF/@%+YU23IIC9_(`D,V?W
MK,F\C`-N_,?+G5.B/_/6N#ZDCN;\G^VP)#0RH-T(**>04QD"$(9)?F2>N\IV
MRUE#'_TN-V!#KO)>G(!H:K9&KXX@H&`O04"SSHFLX>#;YLZ03#8E7LWZW(N2
MG,)JO)QK5>HZDQ=5G4D/WWY`+X.$$T<6JW@DGZ`7%ZL^LTGPM8'OK3QKV'L(
MR):S4!:_MCW)@)G/64*FH0$_,]-ZS(5@0"BD8K`6!T_1R(8@I/*G"C[_,?A,
M:\+ML*Q.G7'M.`>12JFQ6$TD>M4YBR$9'SLEI;Z@D'@`;-8+.I?HLE"W76)D
M'HY2JN'($,LB=*/OY]Y3;$20%;LO%@7;ZPE]V@78,YW\Y47[B%K@Y8WM7MZ=
M??'E.N`QO1O@M^V@W:6#BCVL;[_8&53V$G'\GBP^6XHY\-K:T&TZM*@YF=>F
MR._Z>.H>C=_;Q+T4294RM3)U_1`6E34F`)[JIT*KRC6#SK7,\3^4_R^49.7&
M=UV/79Y.Z1JYN6$"\]G6A#_(SZ[L86'O[\[@^S%UFVV/YWMK;*IR$,E+_NTJ
MI?*GDRSS*7VME_!5OL7MCC&:^T")@=;$B7.\),+QB5^&27L)]5C`39D"7LL>
MCO-^N)Z1P\NU7N55H2G@*MU"_7/AM6ZW80?E7Y`+6H775/3X/3*K]"'I]5VU
M3:*PQ#8[NX2*A$N+;[;CB7/='9GEV<L$9JQN&[QJNC([VF0X@['J0%OR@X)#
MR3C71G.@PYWNXH`F`"I6AMY<+]VY1"?J;^H`2U.GU*)])T-#,]6*.#-HXF+,
M)Y#$N!]'54M`CKR6RP"`.^Q#O;=T+!!$99^5U5^5V846K`F'EY.MG^H5E;/Q
M=LHS$ZJF\LV,0/RF]Q.NBN^'Q5&BS4'16L.@IAIQ*:F^U6"/8A&]\_XQ6$3_
MYBJW3,FR!C#U?G&%3@RGWC]$DV&7]*79U6]NB)@M-HR)=2_DCDNJ0<3`!OJJ
M7G##WJ4*>Y7D):I.>JAB^OP(/E$E31PTB,-B_:P_>F28]FDZ8)R7@FM^2:W2
M6CV*5'/:VW298X4RD<`=JD#K5%"F^9UK@R:,A/7/IF/2J+G`*$D0\6EWB^'8
MYKHC)9OG_%V:)K\G,2_A435S`KK#M&6[IQ7B7%RIN]2]VSG`Y7-94B,%1G,T
MS1Z_ZZA.:8-%75IPU(4UHQ,7!"?%I_ACP/21"H=*=WK?VT"W<**%7AZ^+D#Y
MHAYENEE?3XJI^@K4&-X_[M]SMV^\N??ZX**$Y8GW&WHOT#,EPR4*V0K'%7-3
MURB539JW*F%=#89TVN:1=,UA@3F%CEW*,'Z=QA(B%(U'+AM>#Q9MBBF5?"&8
MGE`QKEE_3\E8"K`O/&/)V"KI;F>ER+)?CJA]%G@.I=SW[(4XO5P"T@5K'FV.
M/C]9V7C1RZ;$Z?ABNK;15GQ]BU]Q\OP%"NJX]V@'_%"2N1<IY%EK1''AU]/?
M==BY349H587C"XO[FUZ$W..=1&\:J*5KHRP36^V3'_UK?!-#5R\?Z&C,ZFJ_
MVT,$M;^EL>HBBNQ-LF0>5_9<2?W2QT#(.PT@K2;2[GYEQM$M;1,L/:/]_(T4
MV.8"B/:=@?6%`HWV=6WPL4LT4A2V_5YD54M%M/%2%R4YF-$AJ2QFA^"'V*#4
M2PSKV=K&EK7Z;03%[S9"M+*>+)^[U.J6"A%BDKVNU8#8]7<#@E\WM*CDIO0=
M!P[%*NFH1=ITW,)F#Q0:'+#>OG'X(_Y1)/&S^-59U"H]**FD]"S0TT4:TU3*
M>GN(^_$]]74S;GDP;9QENC^>OQ[[X#WWT.O*>]M7:D@G=?#7'BW4T^`&Q-)$
M3==G5?>^=J:]Z%/(TA:?:3=G#<P6W5+WDZ^=:M%M'=`:$67TE)9@BUQL/%R\
M>WATND_"FZX[WCUZM3\ZW?GG_9/!LMN@`]AM'4LY^\T1/'%>U=F!;B?W,D;L
M8.K;)D5/ILQ;'QQA+IQ;FZ"O&:_K!U'.8@X$4]/=XV8:[G`1QJYG!?9$P/>7
MLCBN6URQA;<_GMHM!"F_L'T8]Z#V9MCU5E8`1L$]AQ*>WYM/RC)L1UDBNC:F
MF?GJ5N^:8FZ:69ZNDA2VL=5^Y0OC7C+K/ML^30BBGG$%Z$OGT-J[J_O>/:SE
M[2>?A%M,V=A)J#`?_\V_156ANKO@V`5C/L@.-*9)KQ1K+RG^(>/DYOI*FINR
MHOG'V1;,M/24Z:GB.S`]OM35IYGW=M!,,W"+`.8<UCQV].=0!37%`UU%/X^L
MHTGYB'(IA&37&#>/F%W4>7X)XBHP7:%R>K?\5AT!%/0(([6IWSEVVJ9]13I%
MK:(]Y.?M#]_Y^4J5TE6+4!1?GJ.%TVFOYP]>&@]4.G_3&].HP@?RT:W;8#OS
M$B4OO6J>XSE,.MU1V5M1,'@7E\F#J1.+2NG>K&RA-^O2VLIFKR3II7J/8PU<
MZ#I.,(2*5O&A=L`C\+!7Y\3>)KUR*VVX1Y-_6X#8IY.5S3Z=3[97-GH[V;>F
M+=[+-O!K$!&"#]DQ826HRD^",:ZQE;>*)M+7U@0.)JN;Y(0:WL[&'4LH`3=W
M:O'FS6UHOLM'YY?WGY2E(O+,UWVCW%"9:U_-F4O,O/3G\:9_(C3<L6H]G-RG
MC!E#Y>8J-=&DEU?($<U]IC@[UOG1-)AD,.PZTS":#';8`03T^0C-#<%NJ0+<
M-SWF?GCT4I.UN+-WB69'#IVY)TV;<0>,_="^O,1E]UN]B,72=*T?`PDB^B]G
M'V[_7.LZ\\@H[\BT3H/8/`)Z0T\"^@_+2?2>TE'YJHVM02FNQAO3;1??%3T5
MK-L7=2/?P)&TKQW;&C+#'OA"AM[%I0H%.'GNC&5]J2-1J@62^DSOTH]X\(2K
M!`>$;^D4P%:Q1`^QR,'W`');RTSREJQ!%R_+^:=/11M#*RAI?<J'4`7%.^C,
MY,B0D'?/Y(#TEZRPLIF0076OT.GR=LJ5U=*?66C(G+&<C5R,MB,/9*,JSN^!
ML&/4V;.7NTY@)=IHMTF>`B\[>Z-S*!C+Z\+ULI!(`\0IN%K)1NEW2B/TK;0)
MAWB*#W!AZ159<TR3Y+U%.B>KDTW;54PR3P4V-`-R)/4XZ[E%L2FS3E,ARF)3
M^MV.K/V/`I%I*)4:4%C=`(#6EB/U>Z'5CAU`/L77@L=.))'`A0)7UB\$ZZBG
M0YU"!'T"4-^N'K!&%S<P<XT%:NBV\A874D#*D=G#"L`C57N8<N(Z!7BFV!XR
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M^]=6&IX"SX1WZ&(>;DD5W*K`E8&3F@AU"$A\9ICKVSFXT%"&(B\ZVV&'M1"S
M-+\!@640(X0^=VH3O6591**L*:'@6K4==%U3RJR6+7.FA^-9_S^A(Z5N/E+I
M90L>@2;4&=O9,;7<7E^VD"_D6W=[3&FZ_^KURZ.?]O=')SM_.SC\X63T^N7.
M83M=?1HJX".V@#?X:D;79>%*X5AIR7A3N<*CJA?*5SJLCI=^^2;P9I!@Z#^;
M-?X(+(ZML"9E_-G@YD>`!&E<3,G&+5B-2(UU)*1%RZ9'J_43$;0S.R]*G7R(
MKL;[%;[DK48/!`AF!E-3]\N*C=24.NM2T8>S7^`\6%4T0B*M$[O*EB'&8"N&
MB`&*Z_HF+>R>1-CWQU'I59WW@VDA]IKFL_NBQ-[CS!==5%Z.#JJK*ZS[M=3)
M3K<E-M[CT:+!2[`15NJN"9,U`('ST%6^_19JC[[\%.0%'?#8O3HX?;5_>'HR
MVCG<X^_#4Y!X_W#W8/^D1>+=="/[2]+5^\NJ49Q;J66?R5]\JUUYU@NVWRT"
M@T">/XY,$1",%!=B-^8C@;&L<6O4<RM^U_%]0+T>T!JX`OCA_@&YG:\/?E"D
MP3BLJ!LMWHRY=E+ERC]BR/V$*:!S$SG4FDH+#+=>=//)!SKXV([R2MIW7](&
M-A`W7\R@"6+G[0=+8^[;ZOD%7DL>`$QQ5^NUEP#PA$5$A3-&N@BL-^\$'^*X
MY_;0T>9)18]?.-AY$L2B+NL3>K9QRY&=?J0PPD8>_.H=^>$K"QALX(+ZC?6-
M'IL_0MHZUQK&QX.2\=[DI0)#2ZDRQG:6SB[G_9@/>7-Y?6-]-%-*J;1`F3=X
M#.V*HM'LEDB7JXUP%-#[+;P!4[(D$2=N"_-!DS!25D89]B-]R"+I.]U/0<KO
M*]Y06A")71B"]*+&@!X:+2DQB0$*,)0#KNF.J50N`1<,JS`T'J7O^<#QF3-1
MR`HZY.E58L*.P`4(23R$/SU2EVR-:2@8WSFD=(X,]I:VRHJW%T%V82G%1@^P
M<#+L,+N]$D3(TTS5.U@.+L<7IUU;<X&3XZ:ZK;4GGIQ:I?F930?/K)PLEH@L
M:`R_X5.K1^J?ES+"5__CG%=)2GO:@742E)HC0=0WYRM4K#,1UZ40VVOW(ZY>
MW>P=EBQS.$"T2KB!-=RJLLW)#X2J>LZ41!%(VIJI9PP;PJM0ASA"#O+U+HS^
MBZR`RS))3AUF!2+P:UH>P8CD\Y_'&6):Q['501RK98U0C$SW811K!^NC&07B
MV_TBAF.Q%RP@-"!8VM/B9,:XIZ#N&EQ1FZ:K%W#99D/(I.)`,LPHF299UF&8
MNZQ.ZMBPQ%(J7_2]="3*HCWD!*C3H)<B]-49`HT`D-;91;RE&4Z!0Z7CCC>^
M\7P\L[RJ9OT9?]U+Q4O#UE#/G?L2QMV+!1ZXSYL,/MI>@""ZB0[HP[O/E3Z$
M6M#E;S*[Z<DN:>O,\^WUV147Q9Q;ER5S$WJW(U-S8:O:HS`^*3RRV]&+^@G.
MTJWI3&6#Z>CUY[56;"ER2=.6&YX;XJOQ3(&B:<?/]RRT'([4EFN%`21$,,:1
MQ#2#25=K\Z8IS2EI*WZUI7I]O$G-.ZL3CZ>H>"0!`A<F!T!II6[#9^NAVJ?P
M@&3(]\D8?X6Q_=Y">X@D+I@@)=.V0?(/D_$'(R?5!T$+"9AZEV:1B/^(E7E]
M]0NYF^).;B<#3!!+_@ZWIR256]BPTQ)?++$*,YR47ZSS@4+P0=@:DI^%CP:X
MT\7E!R5X]C5KL.CLPJL0M3JMX0I5E[>IMC<(N"?%+XD7\''"PS`39TBXX<HP
M>8ML"H\;^A:$PV%56XK<!J!@1*6T*":<I=:2O5FSNI"NEZDSGNM9H_3*\=7Y
M^)TK'AQV-4KI3IE1&@I$I^BV5F#1RK!W$'C+F9A"L8<T`0,#!\P*,2B_)2.Q
M/U]'%9V1-2@WDN0@G/SCY6<S'CVAYN\/%^\3K#CA1'0X[>^O/9B\C-Z/@^7<
M%\*RU#1>E`'\.0QN@;!83K)V"!C;WYH2XYKE0D!J&29[`*JWK$+P-A&#MIG&
MLP.4`^P!7,H9SEIT=83VT@`PN#6)MV0=H5Y6.\]3&M.0]U'WF'RXFK'RBX>W
MML#X3_.4XN[YY:/=-P.6O+L[>]"U44@65G0!Z9U+*1<90=D_$V&;W3N?Y<"X
MRM-<G/D08"A*K7@"Z&I0I<--U!`P3U:%R21AB?NHFI?$9E%=6?85AVBI38%-
M05#I-!,6=QT59]>S@GX*BDICD3-"]Y0.'+H>P]5U#]!G%U\>$$G1H^!V<?C.
MOB%RPIF!!>ES)@L_6EJPW2QTX9YX<XOB/9=PQ_KEF+-_UCDK'(U0!^;J+3+0
M7;FM#5VADJ05MX(`J!M<5;!:AY1$R<KHK^1:TLZ)'DP1\4J@RLY0ZTM0OOS(
MHO*!:W59MB==1)OU><SS`^<TWD3`F=0(5=%TT+;$T>0RM`SY,DX-F\0$Y:<:
MS@H)SSN^.`+>`Y[4-PA`?.\O:8"(ZM2:S$<?LTF'\6SAM>7<03)]NI_]<7M`
ML321#)`9LS6&+3)AGS9388SM>&DI&LAMOS3/:[C[!]0'G&<<#+S]X./;E=$2
MG3_\!9^Y=BLZ>:3/4X)NR)A875F0.U@";2W-!,<AJW>&ZO]M"3&)C&!-<G[_
M>GE]XY?L*J]/)"(TL^]C8?\R&[TY_F&L^ZCO;HSQ:-E_?;GC:SX;_2PAQ)>2
MJ&?7OQ!N]A;X)/?<O)6\`UV)WFB)9HV:-P%,0AT"\S2?;`IA/6)9OQ`C,8^;
M2`QF91U_34CK7<][>6!"J6V6@9Y"#7$X\$$KV_H-C76&/_K/+H,UN_@DE7,I
MZ2'9LHX;KCV'#R`AS'I7"%L(R/!;*S'M"QZ*'U8ZA'4^-OD'5R;<A'23Y.HL
M)2.0L$F%6&F)^?>`R+#UE+`A(5EQE-Y\=.THSK\6JW`#R2]ISXZ\I8OJ_F_I
MX4EYJ$/M:4`[GN';K>.QPTCT$/CI:*@G[5+U6T9;=50PW@ZGB3>3_0'7E-RY
MN_E\1M`,#I[+''%9\R<H`>J5K0/(V'68+FDD'Z)P,Y<4\Z;AS'2+57!U5@CY
M2&&Q%KQ<R)XJFRY(;W&Y:?UNQWA#N<]D];G>%!K(:NFNU.2>X8OM"2W#TFN,
M/4`UAB34_+Q74#;TWP%]MG2`J(>OO3>I3!2(%-':`,$Y0!)5Z!+N(AT&F#0D
M@<1@KFXW@9LR@=7B#UT=AZR"_$XE#<S&8X>*MEX67P[65#,6FS"EH,X06G;V
MB5QQI8PD=_=JH4/!?T3GTG&0C'*?5<?T+"4L+)LR8#SG#UW2$$C$#I?HSR.P
MF?K=`9G6`(ZI)]_R:!A4"4_(\\MZ6%#0$-BZ%-<%F'H+=:;OJDT*%-:*A,C2
M\;*084[N,'PVQ<DN#X6WT_G"3$8A9B)0$P8@$+S'[M)ZX+^N#>[]2&\(JFQ-
MNB$5[/Q+O*6[%87P3`LTV\68C)2ULDHX)7"?W7RT$BCL1_SM/6%87B=U2@S'
MHFGI)D)?'@>'^0_5GR&C4,+D;/9H6)DYJ:K))1`5?#&G21,WW6$I`JN,BZ(:
M=F2/60]5=(^)GX']6`62FO"1>LEN><8\O&HL,P6%[1H/"_T(0^4#MD1=JO"E
M4)Y=_/W!;ODHV5B,[XG^H[=7=QBG&#KL-9$7J".KP6YC`2L9(:N25I4XWGHQ
M60O?<_$_B2DDA.VJ8#W9@VR*YF#!Z,&KZ/RC+1AQ"<8>53*Q;)I2]#`RO&O(
M`ZZ%-X+,`8M,Y9&[&ZQ6F60NQX2:E!!;>PT/Q&,(OEO%O((AUPIU87W=13IF
M=W_+'8J0A;F!BE_C6S#`)%!0(DCH0^`G`M.)V%ORM`X0KJ!VG%=W7.HB^%6M
M?TP%_/Z&^QT%XKV[!RXQK8HWP(FX)^/[/=,$O7,LNJ+KY+G-+TB1L$=D!,`,
MJ%PJR7+>Q:/\-NB4Z+U+UI1W`_>L>H6RE70OE$320J0_FOYUCMU!W<%9HWOQ
MEL>OV;;3!+PY;FC5JMB)SRZ%*>W#V&#:0*QR1>U;XR"=2\]\;699F6`3:-^^
MO=.]*/..MV;1EBIW:1IRZV[N^8N'BSU>[^[NA"4TVHF>5;UJCR-".`_O(?%1
M"IA,.FS&O4LL.B)P/8/'V/_KNYMW6-4`_.S:U#II]X+:+FH\646"[PYB`6/#
MC!PM;IZ)8PL7VPY&#\;H-!+5&/YU$3=K?$5_-J*/CNH^V[]8%A-%<)?WLA3@
M\V%X"/.9`4OC\NW/'V^N;]Y+T12>7W#I;/**5"LPF=+165FB+3OX1M%J((RB
M`IIO7&!)6PH!&9_UC'TP\(5C&4>`-B-S2TXD\+P&B;PD_E2"X^<KS(RR`N-0
MKE":OX*;U)YK`=O/BRIB6)W&?U27#BP/EP`W*PO/M``)0(PP7/9:6DCK[#(4
M===KIO3TVN2LL2D)RY!/K$WA\[;:BP-)6D@&A'!/HLYS>TUV*1=!-Y9R:NJV
M=:\]4@&?^$QO55])NK"ELK$J8"JR59A#MF6/;L5>40RGK4A[A'Y/L&?OT;3>
MJMWBE?GD'B7E'$09;PWUYS5B+,0,^TNCPTQ]]+(KIVL.5S=]79@_LMZU8G(<
M?$T*9DM7P!!"B/!UZGE<"1T7FG+DPU4,J7G!@PJ95#]<?L!!">-`484[P;_Y
MXP-^'Y%/''B^5BEDSRO[ZD^[\85XC'!=H]=RC13-NTL$H>%]_2`AB,UK/.$3
M=P3#N4F/`2=M*\,AE<1PV*Z-V2RDJ',NFG%P*#]$>['7T;5N;F_!5%T$P5([
M'*_0&*X*-$*.0;!+'GBIM/BU?4`?K0PE/M8=C+8V;&A8XTVN2Y$P"XJSL7AI
M0#Y<)3K39H]\PUH*FTQ\DU33![]"";*U^^KC]'ZY%-.`X\H%!KG*N$R9M5`L
M&Y(:&:=76&.=8<F0K@R6:8T7F>.,70QT3V]6G?3HH2B9'RG5DJZCF$NJWJ!M
MF.;F79S+<(/.NJ!7W,&(QLA0[\F%6&EIF4B,,0N4P:],>P`'2?(SIY@3U>.8
M2#IOMA.;-2;B-<F`ABY,#.^Z;&GE;,8A63J>HBMHEWX6E?$.MA->MC1OX[>?
MY#.4P66[HKQ9B\T.FRP'3=.#))=3%,LL=!%H)>0U""B@E.!@(4Z$IHH,Q#3C
MM$X9I0#2^).))@V3.\L)5<7-*+<C="C\PPR\_`T'J3BW+'3($IM&[L+R51(M
M*'"6S\C5-E(:7%-^SYO.'UR54!D]PXE249DTN1Q_).5<?CJ[EBY;,]-F(?96
M6L>9IO=V@<Y/JQ2-Q.37#!$]$>&K%-'.4BH&_E72[-L=E:.-7D<CKIU0/7OU
M4SJI4.KLG!8Y8)#B&@9EM!4X"A?(:AT5)S=T.0#Q4HE!O"1;&8I#BH2P.(A?
M7$JD7!64PONK6QP7BK&3*![[R#@U<TMD[F-I8L;GLIJ6)PIKT8/+*B&`T=5H
MCYIR<ZZ8L"1#<M(S'%S2Z%Z(J=>3/)I'"LZ(&QW1B'U!UX>$B=2OY4Y$H'`J
M.4',NV;N_TS@7UZ:,=.(D'<-C0X&Z+H'4AE$-BXPB2T]H"V;6R\%V/EKF`&:
MXBX#M98479EXZ^(R,TA$8CFDB@)J%28))'&$@@M9W;[438P64T2-E=QZ,`]7
MU[LEFS5ISN%@,T0%<'>76$R7=ZUN^"W"!^_"K.]J-QQ87!YT@0W%=QQ\EG02
M.GV(K0*1S@F#!I!'R*$@+SQ/EZAIA)&#JXNEVM(]X'#SCMOKQM\(;\X^F[N)
M?\WGEK1XKJ&T.]W*O21U?PSA5M*=('^BV$FC;WH0I*A\#LQ^@5*6O(90M]5-
MGK2TX%OX3A+;]\5=F3<M9;N`H;#[T85P$2L.8>Z..,7+#@[WC.UD%K"`@X7/
MPKD2G"#420_$]>+2BV]_ZH[I.,XD<S,*(-X7/[=YP#D$&.8YJH&1`2!ORQ^]
M+;&"I;5OLC;3FJ]%.1%^24$Q_><6(SLI0EF%BDV!=V!U)U5$W[HI3S6M.4C$
MO@&AS`[8]U.Y)"$F^U:);W9)#TH)AK\&7>JGV'Q32Q!/*O$PKA&9[E]"T6D4
M83,ZTLK@R>\4>@W/5]5,KY`BCA!38K35='IDC\Z5D5UNDQ2EB!G-QS')`)DV
MHBHY&FE4LH<%6`+#)0Q:869\A=2DYDVZP1G59P\7M*H37S4GCM<3TP#IDEP%
MI*@",?I.7@A7)KR#!;OLX4C2XO.,AJ5?>;0.F#)4WW&R`'1-WY/Y!\?E\!M!
M?W?Y@N.F@KZK*F3?5C8O\RJ^T@F"DE!)PDR[7Z<UJFOW=>(.$.W^9W1#I?L=
MRGWS21O=F:-7<OOH_QT=)ZWPM=S6?_G3_;=_^=/LZMN_Z'_WWQ8?YZ!7Y`M,
M,EGV3]4[12D2E>$)O?6,#U(G,2.2@@J+J/9]<G--.@C"?GGT\N6N^4D/]TY,
M2HB/F4SKPR521^YON.M9]@BJDG6(,6O-31($QXE,ICMRY7"(U&DE$-D\319F
M`^>`B\!^'&\99W_W\/^Q=V[+<23'&7Z5N:!#5`1!`>!QO1&.`$%0ID0N(0)<
MA6/#%T-@2$(",?`,AMQ5^$5\YV?QD_G[,RNKJZN[9WK(E;RR?2,M,5VGK*P\
M'R8'QV:\)1+4L])$ZC"B\+$D>)=)VA1@'(@-E9,#S.7+3\QF-N5NP`KGS(K`
MQ96L`"9,S*\_,,WE1[/BRJY@=^![,J.\J*B28ZF@A9/*@D8%7?L3Y;DOIU3U
M-I,'Y)&;LIB#8$O715S*.T*SEC<[L1XFNN6*=MM8EK5B\'J4!22X1N(U(<\>
M9@)D&TXB26ME7[>2";?RA?Y'GI[3?K%$/"#T9DEWDZ"K+6TM[%H0>@)$J$W"
MV$31TA'_-EH3O+8G>E6HD?<3(L`O0Y6JJ=P83:&-;;U:@"ZR$09JG2!=R?\%
M45ZRQU]5.+V-S/TS2-6]*L9?=>/_+U5_E52==*M2I.YE!DEL#O&V$HJW$5\1
M([Y.:-4$75$U*+?PX>O$4>;O6#ZTIBA4:<>&$:NMCI>JD-AQ?)A;5XEPK9<]
MM4\YX-I4,$HNF`W$Q'JW3YCG1)M(1C>WZSH!A%DP%X'.X>VWKCPJK:&_AV$#
MQ6%@O()$N_[!V%\'%"<S2VM`E!``3'BLJ7]\\GHF-Y*$G!\.*`.B@LS_6G_[
MG=6!)&WMY.BW2BA'S7KVZO7+@]/GK[ZKOST%JL'WDMG29<I(BY))3J"W$#M3
M>B=*C$`Y]#)@)I4M_0`A1'"M-B1E5FE4LM5IXQ*\PDMOMA.^79"//D,V$G3-
MO*H/38MM?HQL0\*5%FAUZ8JN=N+?20)/,=<MX7PY6WQ"<4=:.VW.:[KTV8>+
M6:Y`R)KG)*A()MT1NA`G[R<YM*\H'JQF!1@(7UG^,8KKYP]46_4:&VQ?APY@
MFJ27()54`AW)`=7!@&);!.[A$B:B_R_,:`*I4I;Q+;V?S0F9N,;]/T%SFC:V
MC26RO^!U2?BU%`P$=PR1A1XB1:M)NK+/4(K[+&S?Z@P1Z']CI3+S%B0E\[RR
M.^*>M@&F>Y"-:]F"0,MDYWNY)&]HYU+:N6LCW'3O`V&^=;M;"S9!P1-`)*!W
MP\^Y'OGCJ(-!Z&W3VCY[G^].7N`0XORH3$4H:[I/0Q8'2-;T9!,BW\IL$*"D
M3F=*'.8)?R$Q=TMW'@H?6'NX9*WR\REM"22L\)TE54P+VVGRC'C_#MFM>4DR
M3Z(?V@-`K\]_X)E8_B`38L]--41T$"[[\?U_L*=K]DU>YMF'V4?SY8;3I)5,
M+MH\^FQ$^2UEX,#0>R2_3<=YU/E@F-[UQU<X$20]_.3-DY.C/[P1'3SZGO]=
M7Q%7W!BUT!B1M,9XW3PKP<*<Q#`M,J$7I"18G'T<!/3JTOP@6GH8"L03B<FV
M-JC+@>?_.UD7K7T&!P#_=GZ?_5BM3Z3@WZ5?]9([XFL%2B7ZPPZMPXU:'D>\
MDW!9*Z=MG\^(FR,Q#*,G>2"?,8C.SNU9O,6*1DP=Y>)FYQT\?*8DUDCE]<1I
M,L>+U.^-YVHSY%3XFTA$HR]`=8]"%`\>%VUN>,$H:ZEJF.O,V5><"HBCC2H,
MF>(F+:(.Q30'-_4/%RH1:OYM6(KR^K@W'-J/[M_YYIO'^4F63@AC.(0>X@IJ
M@BUC'?--^7S."[GO>`@&Y"6VE(*PI'E8LG4:D]R%5VG[\+OD0*8ISS?[#SK@
M1^\+X,L'W`O+QW<>[.\5\!-:M%:%!M16;6]A9<%DN7GM5#4"00^CE);)$@7<
M<B*C6+3W6?%H%2-_5QAUT[6NS"\FI`.*6"G=)0(4]*<\"Y<;ATH8U3GWJ\XG
M[:-S/OFIM%MF+DQ3NF5YXM*:9=N!J$!CI=_T`?9$=9T'P37)-;S.*F4D`30\
MR?954HWO\`)-]'#IA,"[9:21:@I,:/;U06,JTY,E@F>U4#5X#+KB0B<J\M[C
M1,<C:Q;NILDA12K$=`$VY!G8NQ5#2QT"`(NRT#]:6_1_Z6O]Y!N?0&+<*\J-
MP#UD_*.,E*4G\]6"SLN_SB3'9CL.UWAV\3OQL1\A7:E*'R8O49S,%14&JZ*.
MHC(>]'$<IE'M..RE!^DSQX\G<Q#/SL?$A0CP'+GMBJ#'0[+,H,E7%].[DRYB
MM/=]"!G3CIX"28=]#_8+,*)W1BP=.>M[ZYW5)]3H!'ZT`5*.N53]K;P%3E.$
MTC@="H@V;SY7!+4JS$))"\;1W2G.7H6U6P&;'J]OKI^6UU89[QA#IY=G*\RF
MB5MI.R:X?)XO_JR3!OYK^NRFT>W#FZZ(S5**?='#T-6@]+#[COB0`A=TIFU(
M70$8%Z\+0M[JLOD@511M'2*:SL3%9#!I6MY[PQ,DGNB/>[M*"30$-.<R*)YR
MA?2K74="A\I06VS4M-`R'<8T17*-FC:6?GN%WIAG3U2!W15B%+=XZP%5.0"-
M)^*3'FC;=9',M=C&")<G2UN%SHDSZL)N/;Q'`:3=U&JZA5Y5<+Q0,/$^6^IR
MBD]%S;78C)&JYC1A]"O6&0C^ND<(TB,*L8:N(+%($U+LF'8=XZ[=.*V!P;:1
M%N^0>]A<S:$R7`IBBG>/!%.VD'\,NHSP137:Y>1D.CV?$=J"5`E5LQ@:*"X,
MUUB9O9QL]6X,@)F8>GB'*"0$DG4J-B68P6QN].O)[$J)5D]32PI]?3BG(+:B
M;MF-Y=K:>OR@JZM0L,L#B=L3/S(RSX85M@?1CP2.U%'>WBZ95@MA7$-C-3"0
ML7UT4:I(V7JA>F]-ND#C>?5:+FPTR`(OB=H#"$*<UW;%;_@NBQ*]]X68=3D>
M:O#8_KWR@]?A<0'-,O<L&PLFZ'85O;Q;ZG;VV,8DUQ"<Q85B_JU`5O;06?O>
M/_0A4`Z/[@I*%4BJTC6&H^W34>IL=[_G=.C\R(>D;LD["ADM#ZIG\GK^X]N5
M2BTJ&N)WJ%RSG_S\20$G(U%7`&Y2'M>:>7$\1)T5H/%*9/MT\#B%>@T#[,']
M[0%VEP[R3L_U<M+Y%1.`MIB(J0>;E+6H@'M19RQ4!2\TIDUR?[F<`O_=V!C,
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MT`>O:\8;DWX[OUH9B/1W3[S&SH!8([)-MB6/[P:!V@P;0E\>P]5./,V>C0CV
M;%]&(PM7?#!Z*-<9X9_04FFJL2&V(H4;W449-2!G\H<V:6TZOYYINBF[61>1
M^2'XS5*0^?1K)=X$"IB],O)TH$W,(<$#6.BVSJ80+5,DSLEVIVWD0A(ZJTX3
M6/D#D[&N[PSDQJ4.D`ITRF<*)-+$[Y4WZ#D'Z!7XL%TW2ALQP\14FM$?N(B+
M=]:BY;3Y,8O45\TYUH2NM\1A`6F)O+N$6H34&QP,<2*EC7H=+%*3@74(/P+Q
M&`30^7*/4F%]Q%%I:;V@/%%S(GNQF!I7'Z]W:&H4:ZI8IV.BQL)*=R0IL"59
M]"&.:4=5FGZ!UO'D&-X@K:3);VW%VT*&PN"C":>3?J#KMXPU6IO.;)YME9/L
MB[.BZH%$V$T9!5@E>]QIAO]]7Q9DZV]X4TFEB@ZU9DH1M]-5N<U"2%G:+$`:
M$P.]?8,+I6MPSX3,6I*.FW:^YTS1)6&C@"TZ,\@/M>AZ@C21]32G=?)Y\UK:
MIX`"QI9,MS#U`$174?+SI"L=4W@[V$>RR"I[*'7&$W/$<*;GX\8<959-S'XE
M6*8:V`],>1JIJ`3_-726B:M.::2+M!>T$U.075V1_$@]*3W1]^$ZJX;K6IUQ
MM.SDQ@(]XX-CD<M80*F\5X.CSJ(_^L%<$,CY\0%"NU4]2Z=PZZ@U+UW3>4H<
M[`X]9[%,#+>S>(O2QBG5\\!*WR"A:#_.Q"?JXE!!/_6*&*<E=H'_Y5O],K@8
MSS*";CR?]"`"ZHP^QV6F-[JR&'`AGEN*@5N*[F^,QNX@L!H1&A7D$^J<R&?+
M_I:(MC!>,<%`%1I0E<<H7Y[RZ*C%8EX:T\<3>D0J#ABUT(TTC[']K+Y8BO[=
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M;/M_]^R_O.PA.>`7+<%M?Z70Q_]M0EROFC-TG1VQ[F1%LH-;T\J6F[A>\<*:
M?G),2UYUMIG<CO_J]!(^;:2[B`]RXU^.$#R;?WRKRC#8,"Q0#6N7=;0R!4C*
MBS)[H!0I_YNB?!=N<;*0/YJD?U0"B@G&6'%D(O$GG+KN.);F/]WHUR)AUA\R
M/8[(]5IX<Q2SJ(O6EE$!$NU=_LM1&ZZK06U2X)P$P#,%@:7:&^J^ELN9H[.:
M8U!!#5;N&S>&M#S5)G<;+>?$XN-@2.2EW@!N*2O6R9JDK\D^R`U''0PIE%?8
M."/Q#@TK%HCN)8"D/G\V:(EN86G<*=?,4-,ETR'K1WJ.*F@-DJ?B*A;-%6N8
MV52QC+JW4/?X4(#L;(VP-_LAR?W&MN*"94Q2-''Z=]BD4H'C2`!2J1.4"$L(
MM")X:%0W\TXU_^=EA?OC5.&^CF)]&CE1:JU0_[C-*SA5..NR\P9."'U3=6W!
MC=@K16`"[*<7)'2QZZ,I@0G6W@QN);8/(3J1@E3OY*`)"IGL3(YS6`2F4\.:
ME!@V8A/E3$]!P,DS(?_WT8[HL'PA]2[TH#WTRBXHY9B;YML\H3`\M-\:OO:K
M94H_$P3<DEW^5=;B]"C,KMUVJMW:N[L710QYUF%.779NO03X49ZO?<@#)RL&
M"CEZM:$7!67A=U&6^OCEU*]S5-DK;#$>-V'10`5\UXT''RU@;SII_$=K@K@%
M^=45A=HM.@9B(T7]8Q1"4?TR<B[-716/!!<&MF'O="@C`FX()[[=!ZGCXR.Q
M&EU&B<%5OB)(SN.$%"@1L4K=I@<E5'AR08=*&#NBU.#0F1HSWTT*!X?<<[14
M_4(;P&MO`AU[.N>_O`E`SR&J1&;1'IK#E(AJ>&==(!M$PZ^A8OF*,.X>+?)@
MC<V->%O%]WV'M=.D1V,@]KHCSLOT;+I!H&K:L@;9CXFD5Q#140KX,4Q^Q=&A
M)BK+#\E/]W![Q/9'SU8?[MD*,G:S@B0+Q$>8G;UCW)A%!\;62W0Q2TO]%O>1
MZ01C5NI,4:]18O)!^7PR>&4=VVJ:@@)Y\YR^>=?MX]"\)\9@R7I>F`<L$^LX
M?CU!$M/HFID*:0A6"IN3&RL?9@S,1LU4+W^B$,74'O=7A@XX7L>L9@,GKUS-
ME$V331-RB!.CLT3!5@O:;H3;AJ\;8!QV.7E%R(#,H1):#&]_A.+)I7G98;\O
MB9&9W20'PO>B'HR!528OH5M-^7/R*_@YE,VPG/P6V@FKK_<#\<-GX>5"T[QA
M+(9QQKR2<J)(6A6"O9;QP9WZ]C(&FG\$R]@Q\>4C0)\_KF&9?R#S90BHY7-S
MB"$@@:#(0=?1XC/`)WGAR&(A5'`L^[%U!ZH$I@W7$$Y;F/S@)<XZN4[_]9_&
M@++H+P)LWJ3/#@%9TG73DM+1]-T,:;(.'[J+15E*>&K@-$\NIV=_WN%$<X3`
MG9?X=61R<T26KJ#O/LYIKN)ZA#,[#Z7'I+'BMDP7T%2%)(5DX:Z"TN6?0F-'
MK]@$$S3,=EKH&W!`3]H(`5Z;2#"`[O`EOP-^R7,)U!W<>WX%;YM-3J<_<CMC
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M1W^W4@E2+838'836YTKBMX)'`6/_(O5T+U-WA2%*!0<HQ"OMUL4KX*WP(*-/
M68Y]UV%>]]RXVEDU]1$:6G4+Y7=G4B+O%FKNY'9"SD&4!-12KT"!':O"1.!]
MYP40OCLWY<6^^CQ3@3AH5L2$-QE[2ZG6F#`:QD],4U;*[>:[G+I0Z-:IWN-?
MF;T5$]N%V=D65F@J]569A"/R;&:$L(%9I>J"1:V98,A@,'3WL%6).'I-%D24
M+$7UOB1*6B!%RO3<]+M%/=4?O4QXV%Q3Z]U@!B#_T#D4)#^VY:]M8%]LWR4H
MXRYC1SV)I.,"D"G0O63*A<VB/DJ>@1.$7;/)].K8#'7]%@`G%::>:].53?Y]
M4M,-_G3LCH@CEVH16RGXG;H4/_R2%2H:L>4*(Y[.Y1F/JJ0>Y9A-]JG-Y*.<
M;<!NUMG!41;Z"LT"6E]:--98C?XZFT*B3Q5OA^U-Y<J;T.?.I%\$^!*`;;!E
ME=OZ^1;MJ.$H+'#&9%[9R%>B$#B"Y*6;4#]<7"\'E84-G_<\QOJUA8^S_ON(
MF:M'6,]`CR7SGM9_/R6]B3)IRBT=HO/?4:X`4>B:HIT2HU&G,$DIU7!HP,F-
M3,89N5Y834-8ZM#WI2+Z`;/>CJ)W,:%(US5A+2YJA'1ZJ)I;UBW5V&"2-NM3
M%S:XBK*4O\2R@W+':%M8M<CX<1NW,&`9R\]I!,B&IFB3W*&OMMQA%DRI\ZH,
MZOIFVLL47W\WZWA>NJ];*EO8NRJ8=S_>N',TCY4U^9"<6)CZZCVS-54;=+N;
M26#U%RV#'OJ16DP0VGCE;[*C8C4O3I%O&UY;]V!KH-#:2#;R]5HL,PH-HO]6
M*Q<,<]C(^3.O.<HNNGG-P*@[DR?1MJR^X.83EZKJW[,2N][8VM8//ET,:^'+
M?WO7>0\GL^N[T8?G?F<'U\2QI"8]]SH_JN`+TDN9;3;T#>IDRF*W*C6>@U=_
M+,L+?NR_\'(\%TPJ&2R@J+H(<4]FLZ8L:_HV>=FZ!EW3Q%'&F!;IN3$`HO`O
M<.S7NS"#83*<MKZ?N2NDW$ZAI/-IH_='`8?D@_>%.F1KW/VV*>JX,1NIU`][
M':OE#_N=/SW'9TQ@M36;2!G_,N&)KRNCAGM1D`)PE2D')<0#.R!5+O?(MC>=
M$.[^D'1L15/)*T=5AH0P.9D.DG:"1?[I!26&VFGU!Q85T'%>H3L5VY`GR\W=
MLH7Z5GJP;7+[WIW'C^[GG=#7A4PO;DA1S8Y#Q'3-5^_IW,-Q:OS":?DQA>KF
MXV=T)5M#A3UX#+5O>>^18FK'MME2@AU"(Q`%=#KC"'S/=BWAIR<?Q'DP&6$\
M]5V7S=Z\/)"Z>*_,L^N/`RDMDLZN>:Y8]LRV;`Z*B5F1-1.V:SLK_U]:I,PC
M&"]$K$&[E_!(Y/0YY^G<82<PZ.GL[4TFJRT))`N%A^V@A!`-AS2.%^K[RYUX
M[0>,C?/%PK("W6@(TEB_ZYH`/+'/=`>2*"_GTZX1N-<-U:;#ZZRANY.7V!L^
M+"?0_:Y9:'_MKWMK?S5JOD\\(]G&'8)-9/O=B4K1]?V(1@^I]WS+SD@R@8=_
MM&GW4YGC&ICT-[X[V:7!VZ8U.[SG=RN*A@WQ'GHD#V^(0B6;1E(^@`UUUK3=
MIC4[/Y:<<BV$]FL@&(1V!R`4IGNS.Q%$ZI9$VL2@U8@7UI,U)N*53/_1].7:
M^B>+MB(I0@=;_"A-JAH6W0DAYPWG<E.2K/$VIEX<A=RK%EE$2K5FE\$U;3/2
M#B+,S6H$Y/V3[U,O)/'8#82M%8TFNN//GK;^+9?"CHSZJ6%WOY?6I(#D<TJ%
MAUVF]O"\PAVU;EMO`N0"<9/XX1[4WH5A83(3*E_$"'MRLN5%VA-A%VT*1%@L
MWLNG3]`3KB\(0,9E.5]=6T"6<T"X5FKM*"S@SH+P'CLRD.-BR$!8TXT1Y"AB
M`E$4Y*K/S%?=`]$H"]6_J%AE*F^5?7N1")/!Q=Z2U]3+@</>`A4&FCSM/?KF
MSN.'U'*P]V`%]!^KBV#:>F/339BUG%^::Z3O7"A--#DW=WS,48YB)[D,DH;'
M>6.M7@2CXMDIW_:=T$((TR06>P3T*:1%Y97\KFA+LKN;#^./+K'\_*C\QLK'
MN>:,Y&CIQ9/=)82"E>L@<=WA6^Z#C?0^^#9I^]3;P3GEX?*Y_-2(*3J</#D7
MX:]8B215R-EV"?K+$"1^7)RI?O?;C`UB6<_1(FCIR>ME+%/%S3'?$QU,>S(C
M0?C=\=<'T2%"SOW+VZSNV%:O>^*D/NW0.NGF90"3.R+<U8_[\.OGJ-<_Z)#G
MK]I*FS=H*G.R;KCPHP!L]5W$.)24HOJD/D_#&4L,HW8`E$'WCT]'!6K(2ONQ
M'MIS%9F8Q9V,&!.?"LO3^'I4D$$CMGZGP7L2!EA9A@U'S;.4X&F=.F]E*XY>
MWEH`H#Y!`^;X(H061Y_Z^_*&TPBI-YG^CSUJ`M;X@T4`]EC)ZCBWL4@CKE%?
M>DUSG2];%UD#8.CKPEM<#SDQ<26%^;1/7'^*00V!3_'?V8_;HAR9='4DR7*1
M)G\C@L6D_73$LHA0LQ_M427ZE%/L4>;?H5DBK3@GD9AMN"X%0/?NF;,$6RDB
M`M'!^N.)"R$F11C0Y.:GZ]0A,2N918VM)MPH-KM,47O+?YSL2TA83.[=R^PU
M74Z5O)R`JQEL?V^]8W<"MO'MQ$:]!E%/9KK':AEWU0'$7ANS`;6-M(^'CRAQ
MA)U(NCG\]9(J3""\/OWB;0%B;-Q`>"!#C<E1E*V+DT27R<WGN7;2JG-3[NC;
M8J(`J`U,66ZNQ[NT_*TE4DA[U4F:#3"_230QGCBP>0H@R>59,NO4'!`KLCY"
M)`C6K&P7-3*,CN42G55/G)+&2DPI4*0C=;RY`IG"?JC9<Z1?F"4*VTJ3+U\\
MM.8-F'1NEZ18T?K%'25#H.8U@PM8G=?V_$#=;X2+[$2X2(,;`26':3W_?GHZ
MI"4(T).'1#?\U'F*A0/,W[NJ341873UEYV-#>[U5LZN/^IQ+R4FNEQTS:XI&
M%:JWXY9L6_4"#0^Q-\34_>-(3=!.^=V4+;.+N3A9S]B.9.F?K1[C!+!K&A[[
M7<'FAP#O2[PRU7#8F5ELO@F@U.R?YA*;55_J#CDJ5Q<?5Q_KS8T;VV_J&AQ+
M3T/5H)U9EA74!!II%L#M=[%FIOX]9='&M9+ZN`WF9.DC88@C)UV5.[C9C$DT
M-T:HXW21VBLAT0)UBWIS]?H%R+B?V$/]53I$2':EN'.50_Q*>6U@@I;B@4N\
M_DQV1`SRT\7E?'("=B0E*RRC]>?/"Z&\_XD,Z1G%L1L,A853.\M+<]5+)2)6
M_[D)M3Z`8S;AUD,[/B;(&Z.(0D8!-Q?TCA8ER@=1<:WYHI[^,,L0@X$#[1G[
MH9"J2=>SUT-5;T?J]E:3;+X#+]^?SBK2!Z3.9S/+2'4$KC<FWV]`=@10GY'A
MA5RP&?HQYS#E>MV0>R=UGILP=)V'A>H?`I!K#29,AAC0.5]^,Y&PF1"9DC12
MHHL239C9.@Q[SR68>\Y/EY/]C1RU[RR$XFP)YP(X2Y,SG$4;[^UG_;[3^O@(
MSB8)K),!!G8\^JJ+O0Y,M1D9]G=W'Q&"HP<K4Y+/HW=^`)T\)VE(B3=#J+$A
M6E-88O:$1C;KN^HG4VK;\4YY/>1)G\TB2<AV,+CV<T0GU9E^U\K9Z'_60Q1R
MW,J*Y]J.9@]1WD8TJ-%E:,0`*ZZ'?^U!7N%U&[KD`2Q;-\2Q*&EKI=%@O5K<
MHC3M3QLS;'UTV(>I&U824=X_>,ZR3T.H!YYZ,4[RF]Z+(9C-I?YFO81LFX(H
M++LY)SW1N"%?#,$Y5(A'0?+Z*5Z\N9@&[-PT<^<&8VQ]W-8%)!H?XI<"SNOO
M<4#^F41VGN_0C!TQKN`<H=MALB$E4!36[.#O)BHY5B]5/!`NV/6)817DFBPJ
M^;I1WR2)J!+$\F:("G1/`4S'O:AZET_QG+Z>DPYR,_D]'4)AV`$8IAQ]#?9\
MZI3)=DR)OS#749Q&1X9>]L</AG/5=W(G)5DV@FO'[-0SI$R;./((\[=3F$57
MX/UCY&`<?'H/>&8A@I4O]P4R:;./-5:VAZ%H/^[5L+MPB0NHKVK#D7($&#DA
MO:?J&9\TQJ0>CU@P#4C.EMGY;Y(`.7YH8?H:/RBI4I)12WN(_EQ/TKZ[HS#\
M'ZO9#/=5(L%&B&V8:SWTQ@T.IM%!X''#-U[$AFE*<&SS)FJXIG^;03/-\Z0?
M"]=OZ'MN-"DC]443-3OC_J&E_5)M>^(QCS;!7INNL>A^/-ID'EM.]K[I?;[;
MK[H%+J?(^,E>WL7^O=Y='+RG`N9[Q;8WAOKOQ?]&4:@1H]>`:L3H+8X\@I,8
M8[73*:=EY86'-C.1HS"D-C+MH*&I_]M^4])KK%@[72O6X-S#W_?/'V:]D.Q.
MRU3R(5XQ:I#4A`VYFX&!WX2(M[_?BX"=[_;ZN=WH?3DLLC!2O\_,5'?SQOH7
M?.0/N1[?LX_&JC-LB!@Y;`1@0W9^.*!TQ^^AE$_V^^G/%CO:`-(1+^_$8PD*
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M'S\8_'@`C\J\XHXJ[B;P/AUZX-/`]:%`]@9+9,W85E5JCXY`C1K#JJ]<+MSP
MT485ISUIM?'12HWS%WL9UD"Q*"Q89%<-Z=8=GC`PD4`[!)RMYN@'W593;`3L
MV-G6PW@$<B=S8%.TJ:%_D]NUK7`S_B8J1R?E/Q$ZH7"@O$`A:]R)XDS#^#=V
MHN#5'26^0<WQ4RE*MC-1YRK6"$*OWEG0<''4YOS/!X0DTKO=^:/&DGU,L]@`
M)K$XL(M0@Y!</R@F67?8GK70S?H@M`V:E:"132FC1]J227(;)=D\ZCE:*$8+
M%+/D"'LY_1-.?KMR-XH.4GX[C,<L/T5]KU&Q7H+K(WODXE)Y)?L"_B?I_'B\
MSLQL/+C,F\@HP+Z;YPR&L&E1SN49[YSI=90;*$J7#:XZXDKL$U66!7[8\IMP
MJM!V>;R-2[#Q)3=<GFSE345X?)%N!`XN=4(96)E%E,^-3;^HFA1D6K_&AS+\
M4^^RAEBSPX`I&J!Z4LH](->D2X3Z5WPP:HK?SJY@2Y<VQ<&Y%`"KM+9.<NW=
M"A(!FA&U5+27LC_GT&X:0,<7'.@+=M-<4S[XUI#IG^-GV\S6L,'U7!2+&Y^/
MEPNY$1E.2BBQ_Q9+ZX\_EPNK\>(9G0^%`E=\/L?PR>=@D25'GBFQ'_O[9[F]
MMQ@W$P'U9155.C1R$4@C"GE>-'75_E.VX]>,]820X7UXK8YMSSTX:L.I?=R7
MG#G=*TV)\L768.GYA--;P76-><LS?T=893VLA6EM;QII$`,%"#>3PS73-C]!
MZ<^*"H7-K%ML,F/\Z6#IPF;>H:)^W[UZ\:L.9(+*D=+]B?>0@CZ"$;3R>OM+
M]K05Y"6N"KH%E`4`=2_G$=M_T11\(9]?^<PU%-KS`3G"4ZGS;N6H+4,I9>1!
M.J[):J^'0^.*`9N^75O=<3Q!HL%S3F_=K7=DN:_[]_LS6#W'=R#5](5W+LX%
M4E+85'1@]R1X"[2^L#S$%/59;^`HUPE<27C!@>[IB39^*7I8CS#91,ZCHCA*
MKC'84V73-EKD5T)*\2Y1H8>H^6LDJLGMDU1/0%G\]6JICI6(L1?+%%7M7&SU
M%58\;IJH=B0*>?DW3*J8?JH97:1VT')\);-./?"UOH/$$8[>(>@1?S'-3J*<
MPV')K^](D^C,-_]I>BE1AXA<M;\<7OG-XH)">U%3:0;.DY:!^0!2DGE^/7NJ
MNU3`GG>12Y:NR7,]Q?*5>M6R.54Q6^2-\NB6R$=R$"HP'H<8S,VJ7*H3[ZW=
MNP]V+?SEG/1D[ZQA'?SVR*#809ZV1`[%MHOC0!`X.C/]\XN#HIVM+T9_!^^O
M*R3&ZFRM5QQ,H-O,(PM25H=D6MZ[-T_*\"^G+ZLV`&6U143@_/SA`G%-YX@U
MR2NSBE->4)"6%H)%L@D'3.IO$TCL)+>GO[;H1\V)]O"`!T7)4)KIF=W5LVXK
MF.WM.50TI$&>!N)6!)+-)A3P=ZJ/CW[D(B2GH(+39D5(V>H$>4TBP\PR97,3
M++6WITH&F1D*`2=SF[J68)%D#[NF6X]WK5$3P<#*E/S9M]0'$EO\K8,M->HL
M0*8]I`R8.YB:^T"5\&3^60?ZR3:=$$)WW`%;^D.\CI1`KJ.B\T&<6C?F"!#3
M42@CU=Y@*>8&6Q)>YO?Q-BH$>9:+4-USCO3V5.4:*5.(F=#>0"]&1F]-725,
M#[U3FRDDJ?36KKDRU=RNDI_2U6=%JD&0]DG;1['>6I=+JKJHJZ.=ANJP2N5)
MNS3J.5W.KTQ-I[,BA=G`B'D(J6GG\3GE#?2,Q1;F"T,Z/M4Y/+V,(TQ5-5=4
M#)JO<,]BY71K2>^+7IVQIM7NASJ3]@U)$3F8KVBUK:K#)M?ZJTIW9#2@D"18
M^-9^]`21]ZHY8?2]B'4R(3*J4,PA#*56$=TO"(?$GJ?VVM/S/ZTLB,*)D1@#
M3^NC5U@YNUA0.8QL!,Z:GI?JA(=K',@P`R=2]P5B+938M?=X9_]^6(>:I#A!
M,%WC$14`+._,#*>=G*GP,3>$PY<Q\M%]5S6S<$\_((`VG*^PYY6Z2`.+>AA0
MSQQ%8#HT5-8EBZNUI6F7!!J)XXU)'%$0P7\-X7(P2"T^=W&@J8232^?DNC?J
M;-(-P-QFP^L*;&\6J4]F[XV5%`U;\J!"=JXA&G)$(PN(5#@O0T+#*D$&]&+^
MD:[A5^^5U@X:HBEWTB>.LQ2C\>>+E?<OP*OUT=HR1?@M]$FS>4:A0O"@+U9-
MM^OCA<\L$3B%ZT?J2M(8A8KS#&D8I1S\H#YT67>F\Z.-3'5G.C\FBV\*'^TD
MWJ.U(S.H9/?2O.KUPC(J6FPY,!)EX`T#SC,2IN`$]FJ21%`/-%'0.4_]TU&C
M^3.K(ZJH8/U=#<Y!0<XM:^F([8(GJ-*(@F+EK=W[MT.''EP8JY$_PP,Q!</>
ML$S5FV]L[E$.#/'=1*#+Z5OC#2[DU^/::)FDS);\W9&2UVWW6)'&L@$2;3T(
MOR9VRLO0K##280OM#^T6@<A8X"*\VS0E.4&IE;X4E300&+JA#7^@.AK7#?\L
MJV)[6Z5I4WVV!LR!2[O"0^Q.D@5L=IC;O$>%R4="$>L?6,^_#HH'5^>+V>?)
MZ[N3)Q15^%4#21`"7]H@8+]TSL-G_4V5!Q=R2X1+YADU^][4P=65`OYU8Z*9
MV!MJ.+01,+A%0L0Q0VX\/V#4R'4`JIM=QTO["IBOF7*P*74L6\/IM"=GHOGF
M-\OES3_]MP````#__P,`4$L#!!0`!@`(````(0"@;-BUAP(``+4&```8````
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULE%5=;YLP%'V?M/]@^;T82"`?"JF:
M=-TJ==(T[>/9,298Q1C93M/^^UW;:19(U[4\`,;G'I]S[[597#[*!CUP;81J
M"YQ$,4:\9:H4[;;`/W_<7$PQ,I:V)6U4RPO\Q`V^7'[\L-@K?6]JSBT"AM84
MN+:VFQ-B6,TE-9'J>`LSE=*26ACJ+3&=YK3T0;(A:1SG1%+1XL`PUV_A4%4E
M&+]6;"=Y:P.)Y@VUH-_4HC//;)*]A4Y2?;_K+IB2'5!L1"/LDR?%2++Y[;95
MFFX:\/V8C"E[YO:#,WHIF%9&538".A*$GGN>D1D!IN6B%.#`I1UI7A7X*IFO
M<TR6"Y^?7X+OS<D[,K7:?]:BO!,MAV1#F5P!-DK=.^AMZ3Y!,#F+OO$%^*91
MR2NZ:^QWM?_"Q;:V4.T,##E?\_+IFAL&"06:*,T<$U,-"(`[DL)U!B2$/OKG
M7I2V+O`HC[))/$H`CC;<V!OA*#%B.V.5_!U`R8$JD*0'DA&H/\RG43K-DBS_
M/PL)BKS!:VKI<J'5'D'3P)JFHZX%DSDP.V<CR,_+SL"2B[ER03X4T`:J\;#,
MI@OR`!ED!\CJ')+V$>L7$),CA("\HT9P_GZ-+@B\8/17X^Q([VVL`F3LL^Q\
MK4\^]`0`RZF`UY/CP`4&JN/">3Q8.$!F/G/)IXM1?WK]S^F>J/%[1#GP0%32
M7W45(!,O:A:'JP]9OPKIB8.V?GO&''@@;M`LJP`YB$NS:3H:R%^?(J8SV%OY
M^*B^)RU_CS0''D@;5&L5(*]).T6\+"V</&%C=G3+OU*]%:U!#:^@B^)H`NYT
M.'?"P*K.;\"-LG!>^-<:?@\<NCB.`%PI99\'[F0[_G"6?P```/__`P!02P,$
M%``&``@````A``XU?<@]!0``=A4``!@```!X;"]W;W)K<VAE971S+W-H965T
M,BYX;6R<F%UOJS@0AN]7VO^`N&_`QGQ%28X.5-T]TJZT6NW'-24D00T0`?TX
M_W['C!OLH3F%O4F;\#!^/6//"]Y\>:O.UDO1=F53;VVV<FVKJ/-F7];'K?WW
M7P]WD6UU?5;OLW-3%UO[>]'97W8__[1Y;=JG[E04O041ZFYKG_K^LG:<+C\5
M5=:MFDM1PY5#TU99#U_;H]-=VB+;#S=59X>[;N!465G;&&'=SHG1'`YE7MPW
M^7-5U#T&:8MSUH/^[E1>NO=H53XG7)6U3\^7N[RI+A#BL3R7_?<AJ&U5^?K;
ML6[:[/$,\WYC(LO?8P]?)N&K,F^;KCGT*PCGH-#IG&,G=B#2;K,O808R[59;
M'+;V5[9./==V=ILA0?^4Q6NG_6]UI^;UE[;<_U;6!60;ZB0K\-@T3Q+]MI<_
MP<W.Y.Z'H0)_M-:^.&3/Y_[/YO77HCR>>BBW#S.2$UOOO]\770X9A3`K[LM(
M>7,&`?!I5:5<&I"1[&WX^UKN^]/6]H*5'[H>`]QZ++K^H90A;2M_[OJF^A<A
MID)A$*Z">*!>7><K'OG,#SZ/XJ"B88+W69_M-FWS:L&J@3&[2R;7(%M#Y(]G
M!%.1[%<)#[>`V`[*\++CP<9Y@<SE"DD^0$PB_8`(KX@#LJ[:8,;SM4D8\FI;
MH[;H&G:0GR`BAJS*^:3:#\;`$&7^P!+>VA!J'#@F`R,2#!F+.&,BYB:1Z@3S
M_3#VW#&(H4TLT29A4YOGFB,GB(2#-N:[/!`FD.J`[[KQC6+!0IZ?,PD37<P<
M-D$$=47,XS1C>!W$7=/NC8B1L6"),@D391Y1A@@J\T(>>KX)I`C,D1::TF1?
M@3[VR2Z4-Q&)I&8)(BB1"U>X)+NI#C#7=X,;594.-KL]2)@((ZE)$$%AL0N=
MBQ'IJ4XP/_2$",<"&'6-EVB3,-%&6Q<BJ"U@;AQ3:0C,J2N#(L[/VT`3<6,]
ML'<I1JTZCT'FR*I3Q"QYR[H^=FR]PWFTM3)DWE><Y\6D\JE)!)'6`HVJ,MF4
M9R^Y@2:I&QNG2AVV>=3&7"XXY[2T*HYB_#!@7C#.P!2XR!T8=G;XO/8I05NP
M8C1CTG\Q!X?RZMF9US&8O,O,DB#+)U$,9B",@B`<YS_D,34(C[%8RZ(I<I$7
MR`<I*F[LY*J$NAN$+/"T7J_$Z83G1?!P==T?IKA%=L"F?B#&P$J<;@@LB,CU
M5,68M3'_ER&PJ2,(LL`3Q6!Y/28"TOU2!<Q225QAYB*<VH,@2RQA>O?G@C&R
M$%(%S%*YR!_8U"`$25&BF/<F$<##$NF#J8$$X*M\;.3&,N3$(>;E<+B+;.1Q
M`%R.BE$JHWBB40%S<LB)4<Q4.34,01*5#)&W-JKD<>`3(%7`+)6++(.C'<#G
MV)&I92@&U8G(@W>L:S?!?J.(6?(6&09'P]#E^=0P%*.2Y\8<GN"H/@R#R`\7
M(DQ!=Y0?OP%R29L+T*=.HI@;J5'IPS@W&'.G+'(3^2H,`G6_]4D3212C^:W^
MBSDX<0NY`4(8XI,L35W#)ZZ0<-TU8CY=__KU*`['`IL"B6-\(FSJ%#YU"HX,
MKAQXX7,#Z,-T=>F,""(1L^"60&(6GPB<FH1/38+K)G$G6!3X8O*X:4(>"^$U
MXM8C)U_D%`--M@#I#HEB,(<1O%;#^#2%:#B(,)\Q-]2>JHT:RU="?8O.Z\+#
M740G]0K%X,G$C4=CD_GXT1A/SO!@Z9(=B]^S]EC6G74N#K!AW)7<,BV>F^&7
MOKD,!TF/30_G7<._)SC?+.!4QET!?&B:_OV+/)F[GICN_@,``/__`P!02P,$
M%``&``@````A`!=Z-G"Z`@``4@<``!D```!X;"]W;W)K<VAE971S+W-H965T
M-S$N>&ULE%7+;MLP$+P7Z#\0O$?OIV$Y2!"D+=`"1=''F98HBX@D"B0=)W_?
M)2E+<MRD\<62S-F9G=W5:GW]U+7HD0K)>%]@W_$PHGW)*];O"OSKY_U5AI%4
MI*](RWM:X&<J\?7FXX?U@8L'V5"J$##TLL"-4L/*=679T(Y(AP^TAY.:BXXH
M>!0[5PZ"DLH$=:T;>%[B=H3UV#*LQ'LX>%VSDM[Q<M_17ED205NB('_9L$$>
MV;KR/70=$0_[X:KDW0`46]8R]6Q(,>K*U9==SP79MN#[R8](>>0V#V?T'2L%
ME[Q6#M"Y-M%SS[F;N\"T65<,'.BR(T'K`M_XJ]L<NYNUJ<]O1@]R<8]DPP^?
M!*N^LIY"L:%-N@%;SA\T]$NE_X)@]RSZWC3@NT`5K<F^53_XX3-ENT9!MV,P
MI'VMJN<[*DLH*-`X0:R92MY"`O"+.J8G`PI"GLSUP"K5%#A,G#CU0A_@:$NE
MNF>:$J-R+Q7O_EB0/U)9DF`D@>M(X@=.D,5^G/R?Q;49&8-W1)'-6O`#@J$!
M33D0/8+^"IBUL^A59V!)Q]SH(!,*:`G=>-SX7IBOW4>H83F";L]!P81P07U*
M`61?IA!"B_Y=W&,*.@C*B-&40IS/_";-6XN)3&N7@A"U%'Q;2(,+'!B7@>?'
MDP>K88\3<QSE0>R%$^#$9'2)I@8O-).)TFK:X]1J)EF>IQ/@1!/Z^'Z?&KS0
MG"FMICT>-3,_BE[QF5RBJ<$+S6RR837M\:B9QWDX`TY\II=H:O!"\^74VF.K
M&>A7=`:<:.K-OGAOWIXA#=::\["&T<QKS5K,:#;-HO25`N>7"&OPJ7`VU]#J
M6H@=X"!)HS!_*6S7HMT:`]G1;T3L6"]12VMX^3PGA=D0=BG:!\4'LQVV7,$R
M,[<-?+LHK`[/`7#-N3H^Z+4[?0TW?P$``/__`P!02P,$%``&``@````A`)BR
MI>;I`@``.P@``!D```!X;"]W;W)K<VAE971S+W-H965T-S`N>&ULE)5=;YLP
M%(;O)^T_(-\7,)\A"JD*5;=*FS1-^[AVP`2K@)'M-.V_WS%.T@!=F]XD(>?U
MRW,^;*^NG]K&>J1",MZE"-LNLFA7\))UVQ3]_G5WM4"65*0K2<,[FJ)G*M'U
M^O.GU9Z+!UE3JBQPZ&2*:J7ZI>/(HJ8MD3;O:0>1BHN6*'@46T?V@I)R6-0V
MCN>ZD=,2UB'CL!27>/"J8@6]Y<6NI9TR)H(V1`&_K%DOCVYM<8E=2\3#KK\J
M>-N#Q88U3#T/ILAJB^7]MN.";!K(^PD'I#AZ#P\S^Y85@DM>*1OL'`,ZSSEQ
M$@><UJN200:Z[):@58IN\#)/D+->#?7YP^A>GOVV9,WW7P0KO[&.0K&A3;H!
M&\X?M/2^U'_!8F>V^FYHP`]AE;0BNT;]Y/NOE&UK!=T.(2&=U[)\OJ6R@(*"
MC>V%VJG@#0#`I]4R/1E0$/(T?.]9J>H4^9$=QJZ/06YMJ%1W3%LBJ]A)Q=N_
M1H0/5L;$.YCX0'^(>[:W"'$8O>_B&*(AP5NBR'HE^-Z"H8%WRI[H$<1+<-:9
M!?_-#%+2:V[THF$IJ"5TXW&-73]>.8]0P^(@RN8B;ZS(7U&\F#@`>**$W*>4
M/G3Q]?H?*?4BJ#2R3I3A8C%&R(PF&`JM4\O/_A@1@,TYP=MOUN(4>4-E/!>'
MDY>:<&3"81"_)#V4-S?Q`6K$$'R$08O/&*()@PG'IGF)[^%Q/#?Q.0/,QN5U
MT&+-<-:!9))L9C0&)`CB9-*AW,3G(-%'0+1X"C)Y468T!N0*QW@2STU\#A*/
M0?0.>G\V]:(Q4.2ZXQ9D1G.HC.\N)O'<Q.=`^M(YV])OCZH63T$FLY`9S:$R
M7H#Q=",;`8S,::?Y+Y+1""=CMLN*I1>-&>&XF;0G,R*SJ?`BB29QN!ZTR9N,
MYOPWQV-/MO0[$5O62:NA%23FVC',HC"GOWE0O!^.P0U7<&H//VNXI"D<)*X-
MXHIS=7S0]\OIVE__`P``__\#`%!+`P04``8`"````"$`=.O+1L0&``#9'0``
M&0```'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6R<F=MNXD@0AN]7VG>P?#_@
MMC$&%#(:XZ.T*ZU6>[AVP`1K,$:V,YEY^ZUV-U!=13+.YB+`Y^JB_^J#?]P/
MG[_71^M;V795<UK;8N+85GG:-KOJ]+RV__XK^;2PK:XO3KOBV)S*M?VC[.S/
MC[_^\O#:M%^[0UGV%F0X=6O[T/?GU73:;0]E7723YER>X,J^:>NBAX_M\[0[
MMV6Q&QK5QZGK./-I750G6V58M6-R-/M]M2VC9OM2EZ=>)6G+8]%#_[M#=>XN
MV>KMF'1UT7Y].7_:-O494CQ5QZK_,22UK7J[RI]/35L\'4'W=S$KMI?<PP>6
MOJZV;=,U^WX"Z::JHUSS<KJ<0J;'AUT%"F39K;;<K^TO8I6[,WOZ^#`4Z)^J
M?.W0>ZL[-*]I6^U^JTXE5!O&28[`4]-\E:'Y3B)H/&6MDV$$_FBM7;DO7H[]
MG\UK5E;/AQZ&VP=%4MAJ]R,JNRU4%-),7%]FVC9'Z`#\M^I*3@VH2/%]>'VM
M=OUA;7OSB1\XGH!PZZGL^J22*6UK^]+U3?VO"A(ZE4KBZB3PJI,(>#NRL:<;
MP^NU\43,G/D'.C#3.:#+MQSNPA?^1[+,=19XO63Q)S/7#Q8?*4:@L\"KSO(_
M*@K+<QB6Y36)<"=C!4W5&`]3)BKZXO&A;5XM6(<PBMVYD*M:K"#S9:ZHD;W.
MGK<F#\P:F>2+S+*VH8<P+SJ8\=\>A2,6#]-O,$VW.BCD04$@S)C-)4;.2IDY
MN@"4V6P27R(N31(%X/^U,^Q[TCLQ\Z69.+O$7!+G"$RA?-<:PL3&-;R_SBZE
MDL&R5)>LH0*XNS.S(QL>$?B^&1-=TMY$NV9$?"<B,$,2_D4PC*0L*<\C'-<Q
M,V4\4^`36?G=1+<)8908=H+Q)9;!1HD5P"4.?,_L\69$3$03QQ0D([*DM%$V
MHE&.&AF%@6T.%T:N7P_N&._/0=EH;4/]KRL$AI#,EU`%#?>I82EN*(@46'C#
M@I_!S<3!?U[\B:2,:8:$@I2"C((<`:,0L,_C0KQ?`!G,"D!F1*B"4`$HB!28
M#_I]=[X@ZRFF#1(*4@HR"G($#+UP1QJO5P8SO60]ABH(Z:4@4B`8]"[F_MQ<
M0C&-3RA(*<@HR!$PY,*M$\L=-\]E(R:;[)RA"E*B`G].+F_P96\1D*)%ZO*M
M:#$%"04I!9D";_4@1_%&2:1?1[?N]V>\#&:E(`,8JB!?K6=OYA"Q&^.Z.Y^1
M%1.IZZ@8%"04I!1D%.0(&/+!K8R7+X.9?+)<0Q6DQL%U9BXISP9?%P[847/^
M1^HZDD]!0D%*049!CH`A7\`NC_6/6Q%#*U8(YM1D;KB#JIW=F3ADH#<ZS9L!
MT<\"8AUP*U;"2,I(QDB.B5D?Z=9&+P^AO!VY)1+K$^JH6Z<WC$2:J%GD.?,9
MW5%B(T+`SZKES?0,=]J$94T9R1C),3%+(9W6^%(H7V:6PB,&+Y2_YF"*X%)0
M$K&8F)&$D921C)%<$U5D,;B.ZUHTI4O?-%ZZ<EE8>N"0P0F%"L+**8E83,Q(
MPDC*2,9(CHFI5!JC\4J5C<)*Y4R\%G&8AZ%`9DMY0$8B3:XN<+8T_A;<!;(<
M"2,I(QDC.29F*:1G&E\*Y;!P*0)ZYPOE\Q,RW2F)6$S,2,)(RDC&2(Z)J53:
MI?%*E;G"2N\-.K)@>M`IB80BM_V?[)2Q#K@MDH21E)&,D1P34[ET1>.5*P^%
ME0>"S79DM+1P2B)!2<Q(PDC*2,9(CHFI5!H@I'3DC5[9)JP8?N,1<QL*9*ZT
M9$HB%A,SDFBB;WK"(\XJ92TR1G),S`)("X0*\+[1%<HP$>'$JH4ZZC8_-XQ$
MC,2,))IHR^QZ]"%2RIIDC.28&,I=XO'>5SY$,V]'AB+444@Y(Q$C,2.))GK(
M_27YK9"R%ADC.2:F\`^9-_>>>?/(PX=01V'AJMV-1"PF9B1A)&4D8R3'Q)0*
M,Q7/;KF\9\YR`COL3X9;-J3#[1&G'KHJZJ9QPTC$2,Q(PDBJB72=Z#&21^9!
MQAKFF)BE(&9MW$[G<M,&=S6ZT^DH7`?FVEA,S$C"2*J)6@@+TXL.>VK&VN28
MF"4@+FYD">ZZ.;KGP9D3\3",1(S$C"2,I)JH!V%PVB?_3"N9L4;R".S:'54#
M=:*ECB?JLGTN-^7QV%G;YD6>5LD"7ZDZ2<O=%3P8A2?IA,,)VY=[/!0K.&'@
M\9%8P3'"'>ZNX)DOY[&[@D>_G*?N"I[N`I]>.P0':^?BN?R]:)^K4V<=RSU(
M<28!N,=6'<VI#WUS'@YCGIH>CM2&MP<X0BWA#,290/"^:?K+!_D%UT/9Q_\`
M``#__P,`4$L#!!0`!@`(````(0#0_"6B[`,``&H-```9````>&PO=V]R:W-H
M965T<R]S:&5E=#8S+GAM;)Q776^K.!!]7VG_`^+]!LPW49*KAJJ[5]HKK5;[
M\4S`25`!(^PT[;_?&4R(;=JF[4L2S)G#F>/Q,%E]?VYJZXGVO&+MVB8+U[9H
M6["R:@]K^Y^_'[XEML5%WI9YS5JZME\HM[]O?OUE=6;](S]2*BQ@:/G:/@K1
M+1V'%T?:Y'S!.MK"G3WKFUS`97]P>-?3O!R"FMKQ7#=RFKQJ;<FP[#_"P?;[
MJJ#WK#@UM!62I*=U+D`_/U8=O[`UQ4?HFKQ_/'7?"M9T0+&KZDJ\#*2VU13+
M'X>6]?FNAKR?29`7%^[A8D;?5$7/.-N+!=`Y4N@\Y]1)'6#:K,H*,D#;K9[N
MU_8=668DMIW-:C#HWXJ>N?+;XD=V_JVORC^JEH+;L$^X`SO&'A'ZH\0E"'9F
MT0_##OS96R7=YZ=:_,7.O]/J<!2PW2%DA(DMRY=[R@MP%&@67HA,!:M!`'Q:
M386E`8[DS\/WN2K%<6W[T2*,79\`W-I1+AXJI+2MXL0%:_Z3(#)221)O)/%!
M_7C?6WA)2,+H-HLC%0T)WN<BWZQZ=K:@:N"9O,NQ!LD2F#&S`#1)'5.N;Z4*
M.2+)';*L;2AW".>P/T^;-'57SA-X6HR8[1Q#=$1V0>!6@+Q)(V2N:GS=]8L4
M!*,4W`74MI4+P#UI\XSGOH*()XBF!!Q2E5S<>E\1!JUM>,@D($V-U+<2$PW6
M>6$41"2=%`QI9"K")WZ0QOZ$T#0&<XT^5/S[&C'(U&C8M)688'(V4Q8T!5`_
MGW<)@TP%IDL2$P\NQ:D7)Y,#TB/U?N*EU]N:O&@N[[9!&&3*NVZ`K#2)40Q2
M%C0%\5P!'KKWMPB#3`6F01(C#?+<-/3"P+!(19"0>$'PADOX[C(:PVV7,,C4
M:"C82HSBDK*@N93.%=QV"8-,!:9+$@/5.QU(WZCU3$*DD=!@P^@-EPB<K,_;
M-$29*D-]I[8C2#%*7=&<(M@YC<VZ;=409:HPO1I!HQ-!Y*9&U6<:PD_3-(FF
M3'25V&<-E;=+BLCNK+?/ZQ/DR1M!JE<R;%C157RIAY./-/$1)+U*DL`U9&8C
MX(W*TV5B<_V\6;(EZV9=WV6C61*DFJ6LZ"JPHQHJ/E!8L@_K*F:%I39K$D1Q
M:K[Q<,*"LSS:&?B^>^7057ZIHY/76OKUF(]>*2U\6,G&L%<*ZTM='<;6VPUK
M!,GQ((F3F5.29!P?2.#'UWXFG9*CK9S\&MH?:$;KFEL%.^'8ZL$;=5J=1NH[
M#U_UQOH61VU<=Z8;,.EV^8'^S/M#U7*KIGN@=!<Q;%\O9V5Y(5@WS)L[)F#&
M'7X>X3\-A2'-70!XSYBX7.`#IG])F_\!``#__P,`4$L#!!0`!@`(````(0#Y
M42+M6P,``-\*```9````>&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;)Q6VVZC
M,!!]7VG_`?%>KB$WA50E57<K[4JKU5Z>'7`2JX"1[33MW^\,!AH,FUY>$K"/
MC\^<&<9>73\5N?5(A62\C&W?\6R+EBG/6+F/[=^_[J[FMB45*3.2\Y+&]C.5
M]O7Z\Z?5B8L'>:!46<!0RM@^*%4M75>F!UH0Z?"*EC"SXZ(@"E[%WI65H"2K
M%Q6Y&WC>U"T(*VW-L!1OX>"['4OI+4^/!2V5)A$T)PKTRP.K9,M6I&^A*XAX
M.%97*2\JH-BRG*GGFM2VBG1YOR^Y(-L<XG[R)R1MN>N7`7W!4L$EWRD'Z%PM
M=!CSPEVXP+1>90PB0-LM07>Q?>,O-WYHN^M5;=`?1D_R[-F2!W[Z(ECVC944
MW(8\80:VG#\@]#[#(5CL#E;?U1GX(:R,[L@Q5S_YZ2ME^X."=$<0$0:VS)YO
MJ4S!4:!Q@@B94IZ#`/BU"H:E`8Z0I_K_Q#)UB.UPZD0S+_0!;FVI5'<,*6TK
M/4K%B[\:Y#=4FB1H2$)0W\P'3C"/_&CZ.HNK%=4!WA)%UBO!3Q94#>PI*X(U
MZ"^!N8U,Z^AB_5^H$".2W"!+;$.Y0Q02\O.X7BP6*_<1/$T;3#+$^'W$ID5@
M*D!>IQ$B/]<X[GHK!<$H!;.`VA(]`-R=ML#8=P0QZR`])>#0VY4@&#)]MG$4
MOO!J<1HSZ=1NS@9Z.T_>LS."8QO"ZD+V/<_K0M);:]"TSE:X@'D3L>DA:L`+
M1T\<%/&Y+5A$(7QDEQ.%BP8BC9)(-&A6BPQF\S&5&E);V!,U_8@H7#009=1+
MHD$3+<H+C)QNVFFSC&<?$82+!H)"(Y4:I%T*HY%,:L#0(SR@C*__]<3AHH&D
MB2%)@SJ/IOWI33MM>K3H"[I<00@>"(GZ.R4:U%309#I601HR=,>'&GZ_/?6J
M@2S#@*1!M0;Y9A%U\Z9#/G;)=^>L7C4096R:-*BFD$;JJ`&,6(4]]$S5Y<3Y
MNN,:#6IN9*Y!75"C:4;48!=]NQK=<PTU@^-+HYI^.>;-H'7K^X0^;@LJ]G1#
M\UQ:*3_B72&`_M&-=O>8FP#/`F,\P?L-CKO=!%PO*K*GWXG8LU):.=T!I>?,
MH!L*?4'1+XI7]2&_Y0HN%O7C`2Z2%$Y&SP'PCG/5ON`&W=5T_0\``/__`P!0
M2P,$%``&``@````A`+CW%$$]`P``$`H``!D```!X;"]W;W)K<VAE971S+W-H
M965T-C4N>&ULE)9=CZ(P%(;O-]G_0+@?H""*1IR,3&9WDMUDL]F/ZPI%F@%*
MVCK._/L]I5JEZJS>J+0O;Y_S`<?Y_5M3.Z^$"\K:U$5>X#JDS5E!VW7J_O[U
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M2NBZDE#N&")2@<V*]T<B<L@HV'AAK)QR5@,`?#H-5:T!&<%O_?>6%K)*W6CL
MQ9,@0B!W5D3()ZHL72??",F:OUK41V1,PIU)!/2[_=`+DQC%X_^[^)JH#_`1
M2[R8<[9UH&O@3-%AU8-H!L[[R#2'B?52J!"C,GE0+JD+[0Y1"*C/ZP(%*)C[
MKY#4?"=:GA$-%=E>H6H!?`820C^&/)_V/8L2*Q95!@6WU`O@;>!"Z]PSBHF1
M#$@@1=>3*#&4^NC@.#KX:CBM&1G:[&AA</+HEI.5.'4A+!-R/$(F(GVRUL"G
MT41V7CZ4#.B@C:_/BQ+;=-;12ZV9]+T4)H'52YG>O@`_(!O?0J;$-EEDY4UK
M+I+I[6O()K>0*;%-9E=4:S090D$2CN+I$#X[EB3!)(Y&A\0/TJ9&U]%[X>-'
M3HEMN(.O;C>MT7`1@OD56H]"=JP(PRB:A&-#/V";WL*FQ#9;;'PUF]9HMCLT
M0DD4)(>S>TTVU`11,`W&B?$9\"$8,-<GKU?;A`=G3;@376@K3?BQ9DBHWK17
MEQ=&ZVD.K<Y:[D3C2T_L;O]"!)I.#V`]GQK"UR0C=2V<G&W4<`W!VJR:P?\0
MJG>GM;Y4?PC4NF\V8!YW>$V^8[ZFK7!J4H)EX$W@3<+U1-<7DG7]5%PQ"9.X
M_UG!/R\"DR3P0%PR)O<7Z@#S7V[Q#P``__\#`%!+`P04``8`"````"$`$Q'0
M2W8#``#O"@``&0```'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6R4EEMOFS`8
MAN\G[3\@[L,QY*20JJ'M5FF3IFF':P=,L`H8V4[3_OM]QD"PVW1)+MH$OW[]
M?`=LKV]>JM)ZQHP36L>V[WBVA>N49J3>Q_;O7P^3A6UQ@>H,E;3&L?V*N7VS
M^?QI?:3LB1<8"PL<:A[;A1#-RG5Y6N`*<8<VN(:1G+(*"?C)]BYO&$99.ZDJ
MW<#S9FZ%2&TKAQ6[Q(/F.4GQ'4T/%:Z%,F&X1`+X>4$:WKM5Z25V%6)/AV:2
MTJH!BQTIB7AM36VK2E>/^YHRM"LA[A=_BM+>N_WQQKXB*:.<YL(!.U>!OHUY
MZ2Y=<-JL,P(1R+1;#.>Q?>NO$C^PW<VZ3=`?@H]\]-WB!3U^823[1FH,V88Z
MR0KL*'V2TL=,/H+)[IO9#VT%?C`KPSDZE.(G/7[%9%\(*'<$$<G`5MGK'>8I
M9!1LG""23BDM`0#^6A61K0$902_M_R/)1!';X<R)YE[H@]S:82X>B+2TK?3`
M!:W^*I'?62F3H#,)@;X;#YQ@$?G1[/\NKB)J`[Q#`FW6C!XMZ!I8DS=(]J"_
M`N<^,L4QQ'HN5(A1FMQ*E]B&=H<H.-3G>>-[OK]VGR&I:2?:OB/2%4FOD+4`
MO@$20A]#OI_VGD6*)8LL@X3;J@?@/<`%QKKO*.:#1".!%%U.(L50ZM'"47CR
M57!*,QUHD]$#;>7I-2M+<6Q#6$/(460$O56:1=B6RW/":(BX)4O.CVM<T,"7
M9T2*3:ZIONY6:3JNB>=X1A\E'P@TLMDU9%)LDIFU4IJ>+'"6^F=^/S%B2;09
MWA"HACF_!E.*3<SEX*M:2FGZPNJ#B38X=<+[23@H-"QY=HTVAH_?.2DVL&:G
M<!66TO39@],2UC9Z,M$U4V?NZRD>S]!HE]?02K%)>\J"HE6:,TD\,Z@1^7#*
M7)[`5FTR&=VT[41]"@/'T[.S'!=3O<3&E(7CZ9_IN&=U?KD97]P`OMJZM1UG
M9KX_G:CGASTGF,^&[NN`NS-`;4OP^@?+63AF/NT&.J[<PR_'53N^ACLW&Q9N
M%+)/>MQ+WG=]RLE0H:K[A3I^*\SV.,%ER:V4'N3=(8"->'@ZW&MNVVN-\7PK
M[SORR'"'`;AN-&B/OR.V)S6W2IR#I>?,8;-DZL*B?@C:M(?^C@JX:+1?"[A8
M8C@H/0?$.:6B_R$7&*ZJFW\```#__P,`4$L#!!0`!@`(````(0`5#X%R,0,`
M`,\)```9````>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;)2676_:,!2&[R?M
M/T2Y)XGS'014A:I;I4V:IGU<F\0A5I,XBDUI__V.;0C$M`QN6D(>OW[/ZY,<
M9G>O36V]D)Y3ULYMY'BV1=J<%;3=S.W?OQXGJ6UQ@=L"UZPE<_N-</MN\?G3
M;,?Z9UX1(BQ0:/G<KH3HIJ[+\XHTF#NL(RW<*5G?8`&7_<;E74]PH18UM>M[
M7NPVF+:V5ICVUVBPLJ0Y>6#YMB&MT"(]J;$`_[RB'3^H-?DU<@WNG[?=)&=-
M!Q)K6E/QID1MJ\FG3YN6]7A=0]VO*,3Y05M=G,DW-.\99Z5P0,[51L]KSMS,
M!:7%K*!0@8S=ZDDYM^_1=(60[2YF*J`_E.SXR6>+5VSWI:?%-]H22!O.29[`
MFK%GB3X5\BM8[)ZM?E0G\*.W"E+B;2U^LMU70C>5@...H")9V+1X>R`\AT1!
MQO$CJ92S&@S`7ZNALC4@$?RJ_N]H(:JY'<1.E'@!`MQ:$RX>J92TK7S+!6O^
M:DA5-(CX>Y$`W._O^XZ?1BB*_Z_B:D>JP`<L\&+6LYT%70-[\@[+'D134):5
MA1]6!B7)-?=RD5H*-(?C>%D@#_DS]P4RS/?0\APRB-4[1#*(N&!P<`FUG[I\
M/_>#.PE#PK8UN(N"HZZJ8*F94)V5+&EU\L5H9Y"Y?F<)SVV0&G:&7(*A)+VU
MAN)];)GO9R@<(ZM3)`GBT(O2@1BY"V]Q)^&QNR@Q=EYJ)E'F)G&2&KFM]/U0
MWP]"[WU;T$#7AR9APU9LVM*,MA6'J1</^ZI,5Z?W$02:H0$8Y17?8DS"AK'$
MR&.I&6TLBJ(LC(:-M;,1$`=A>@1&SI);G$G8=';L$-UFFM'._#B,?<\@5B/"
MC_SXI!M&WN08.WE'7'[Z)&QZR\:A+#4#O30\)X'Y;KB(C-QEM[B3L.$N/3:Q
M3DXS.CD4HC3P4K/?1H@7>)D7'],=N4,P;*X/3]&&O]CLN3VD#4X^<&A`EST:
M0^#R`<.@/<_P^+SI#/?0Q2.^S.@4]4C6$ZO#&_(=]QO:<JLF)?2.YR3PY/=Z
M(.L+P3HUF=9,P"!5'ROXX43@'>\Y`)>,B<.%'/G#3['%/P```/__`P!02P,$
M%``&``@````A``*DE(J5`@``1P8``!D```!X;"]W;W)K<VAE971S+W-H965T
M-C@N>&ULG%5=;]L@%'V?M/^`>*_!2>RD49PJ7=6MTBI-TSZ>"<8VBC$6D*;]
M][N8A"9+5T5[L0V<>\X]EPM>W#RK%CT)8Z7N"IPF%"/1<5W*KB[PSQ_W5S.,
MK&-=R5K=B0*_"(MOEA\_+';:;&PCA$/`T-D"-\[U<T(L;X1B-M&]Z&"ETD8Q
M!T-3$]L;P<HA2+5D1&E.%),=#@QS<PF'KBK)Q9WF6R4Z%TB,:)F#_&TC>WM@
M4_P2.L7,9MM?<:UZH%C+5KJ7@10CQ></=:<-6[?@^SF=,'[@'@9G]$IRHZVN
M7`)T)"1Z[OF:7!-@6BY*"0Y\V9$158%7Z?PVQV2Y&.KS2XJ=/?I&MM&[ST:6
M7V4GH-BP37X#UEIO//2A]%,03,ZB[X<-^&90*2JV;=UWO?LB9-TXV.T,#'E?
M\_+E3E@.!06:9)1Y)JY;2`">2$G?&5`0]CR\=[)T38''>9)-Z3@%.%H+Z^ZE
MI\2(;ZW3ZG<`I7NJ0#+:D\![3Y+FR62436<7L)"0T6#PCCFV7!B]0]`TH&E[
MYELPG0/SP5G((WK]EU7PZ$E6GJ7`T.W@PL+V/"U3FDX6Y`F*RO>@VP""YRLH
M(@BD$W."/(YS>KO*!VD/]M*^ZCZ7VS!Q+#-Z6V9\*N.MCZ$UWI?S08`[,I'-
M9I$_9!`PDZ&ECGU-_D?0!Q483+U6C:;97XH!-!N'TL?%DZI"IQU7]3*[/NA,
M/8\"P6\`[=5I0L=Q_22!_#2!]^OLP6?"TT@<A`,H'UQG.:4TK@?A<*!#ORMA
M:O%)M*U%7&_]84TA+L[&>V0U&O8M+L`Y[EDM'IFI96=1*RH(I<D43)MP$X2!
MT_UPFM;:P0D>/ANXL`6T)$T`7&GM#@-_U\1?P/(/````__\#`%!+`P04``8`
M"````"$`0`MM9W4#``##"P``&0```'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6R45MN.VC`0?:_4?XC\OB0.EP`BK':[VG:E5JJJ7IY-8L#:)(YLL^S^?6=L
M")AP?0$2CL^9,S.9S.3^O2R"-ZZTD%5*:"<B`:\RF8MJD9(_OY_OAB30AE4Y
M*V3%4_+!-;F??OXT64OUJI><FP`8*IV2I3'U.`QUMN0ETQU9\PK^F4M5,@.7
M:A'J6G&6VT-E$<91-`A+)BKB&,;J&@XYGXN,/\EL5?+*.!+%"V8@?KT4M=ZR
ME=DU="53KZOZ+I-E#10S40CS84E)4&;CET4E%9L5X/N=]EBVY;87+?I29$IJ
M.3<=H`M=H&W/HW`4`M-TD@MP@&D/%)^GY(&.'^F0A-.)3=!?P==Z[W>@EW+]
M58G\NZ@X9!OJA!682?F*T)<<;\'AL'7ZV5;@IPIR/F>KPOR2ZV]<+)8&RMT'
M1VALG'\\<9U!1H&F$_>1*9,%!`"?02FP-2`C[-U^KT5NEBGI#CK]).I2@`<S
MKLVS0$H29"MM9/G/@>B&RI'$&Q+XWI#00:<7]Y/A%2RAB\@:?&*&32=*K@/H
M&M#4-<,>I&-@1F==R(^+H_%ZRBIX1)('9$D)M#L<UU"?MVD2]R?A&^0TVV`>
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M<$^B\`II[C8[W$-L$]?\`2M4S1;\!U,+4>F@X',X&G42*+)R2YB[,+*VB\Q,
M&EB>[,\E+,L<UH&H`^"YE&9[@95IUN_I?P```/__`P!02P,$%``&``@````A
M`**;HP<F`@``C`0``!D```!X;"]W;W)K<VAE971S+W-H965T-#,N>&ULC)3;
MCMHP$(;O*_4=+-]OG`0"2Y2P6H1H5VJEJNKAVC@.L8CMR#:GM^_8!HI*U7*3
MQ.2?;V;^F5"]'&6/]MQ8H56-LR3%B"NF&Z$V-?[^;?7TC)%U5#6TUXK7^,0M
M?IF_?U<=M-G:CG.'@*!LC3OGAI(0RSHNJ4WTP!6\:;61U,'1;(@=#*=-")(]
MR=-T0B05"D=":1YAZ+85C"\UVTFN7(08WE,']=M.#/9"D^P1G*1FNQN>F)8#
M(-:B%^X4H!A)5KYME#9TW4/?QVQ,V84=#G=X*9C15K<N`1R)A=[W/",S`J1Y
MU0CHP-N.#&]K_)J5BQ$F\RKX\T/P@[UY1K;3AP]&-)^$XF`VC,D/8*WUUDO?
M&O\3!).[Z%48P!>#&M[27>^^ZL-'+C:=@VD7T)#OJVQ.2VX9&`J8)"\\B>D>
M"H`KDL)O!AA"C^%^$(WK:CR:),4T'64@1VMNW4IX)$9L9YV6/Z,H.Z,B)#]#
MX'Z&9'F2/Q=9,?D_A<2*0H-+ZNB\,OJ`8&D@IQVH7\&L!++O;`3^_+TS:,G'
MO/J@$`IJ"]/8SZ>C<47V8"$[:Q;WFORJ()#\6@%DO:W@WYF]&"K$Z)HYGQ57
M;JAN$37C,-';1!#U>"(OKC&@KHFFHS\31<TD&)`5:3[Y[4'L,"Y4]'N@&_Z9
MFHU0%O6\!6R:3&'Z)JY3/#@]!%_7VL$:A,<.OGH.IJ<)B%NMW>7@%_;Z/S+_
M!0``__\#`%!+`P04``8`"````"$`,AG39'8"``"Y!0``&0```'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6R45%UOFS`4?9^T_V#Y/3B0A'PHI$I7=:NT2=.T
MCV?'7,`JQLAVFO;?[]I.:+IV4OH"&([/.??X7M97CZHE#V"LU%U!TV1,"71"
ME[*K"_KKY^UH08EUO"MYJSLHZ!-8>K7Y^&%]T.;>-@".($-G"]HXUZ\8LZ(!
MQ6VB>^CP2Z6-X@Z7IF:V-\#+L$FU+!N/<Z:X[&AD6)E+.'1520$W6NP5="Z2
M&&BY0_^VD;T]L2EQ"9WBYG[?CX16/5+L9"O=4R"E1(G57=UIPW<MUOV83KDX
M<8?%*WHEA=%65RY!.A:-OJYYR98,F3;K4F(%/G9BH"KH-EU=SRC;K$,^OR4<
M[-DSL8T^?#:R_"H[P+#QF/P![+2^]]"[TK_"S>S5[MMP`-\-*:'B^];]T(<O
M(.O&X6G/L"!?UZI\N@$K,%"D2;)@0^@6#>"5*.D[`P/AC^%^D*5K"CK)D]E\
M/$D13G9@W:WTE)2(O75:_8F@U)L:2+(C"=Z/)&F>3+/9?'$!"XN.0H$WW/'-
MVN@#P:9!3=MSWX+I"IE]95/T%'T,M?ZO5+3G2;:>I:#8[;C=XO$\;.;99,T>
M,%-QQ%Q'#%X'3#H@&+H9+*&-<TMOAWQ2]F"O[)/R5J[CBW.9[&V9R7MD/+B@
MR#V8GZ?/]J-RQ$Q#)YW7,WV/D`>_%,H7@_^H$R%YB#G-9]EDD0^(%T'B.5X>
MI`>_%,[FS\E%Y8B)RJ,\SY;Y\A_E.$*QPQ28&CY!VUHB]-Z/1XJ>A[?#Y&ZS
M$-GP`2>GYS5\XZ:6G24M5+AUG,Q1W<39BPNG^]"_.^UP9L)C@[](P"X8)PBN
MM':GA9_NX:>[^0L``/__`P!02P,$%``&``@````A`"VLMCR:!@``91H``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,30N>&ULK)E=CZ,V%(;O*_4_(.XW"5\)
M04E6$[Y1*U75MKUF")F@"2$"9F?WW_<8VV#[I)F,U)MEYYGC8\[KUQ]X-E]_
MU&?M>]EV57/9ZL9LH6OEI6@.U>5EJ__U+?KBZEK7YY=#?FXNY5;_67;ZU]VO
MOVS>F_:U.Y5EKT&&2[?53WU_]>;SKCB5==[-FFMY@=\<F[;.>_BQ?9EWU[;,
M#T.C^CPW%XOEO,ZKBTXS>.TC.9KCL2K*H"G>ZO+2TR1M><Y[>/_N5%T[GJTN
M'DE7Y^WKV_5+T=172/%<G:O^YY!4U^K"2U\N39L_GZ'N'X:=%SSW\`-*7U=%
MVW3-L9]!NCE]45SS>KZ>0Z;=YE!!!41VK2V/6_W)\#+#U>>[S2#0WU7YW@G_
MU[I3\QZWU>&WZE*"VC!.9`2>F^:5A*8'@J#Q'+6.AA'XH]4.Y3%_._=_-N])
M6;V<>AAN!RHBA7F'GT'9%:`HI)F9#LE4-&=X`?A7JRMB#5`D_S$\WZM#?]KJ
MUG+FK!:6`>':<]GU4452ZEKQUO5-_0\-,E@JFL1D2>!Y(\F=AA9K"$_6T+!G
MKN/82W<%W=]I:;.6\.1=WHV';$.=\.0]+68K8[&V/NAHR1K"DS4T)WWNO."*
MM8,G[_#!TF!J#J\*SX=*6[-X>++X]<QT'<-9DB&\\XH&N(T./K$='=B[Q<VI
M>08O!GF?[S9M\Z[!!`=[=-><+!>&1[)R%]+.1U_^ERW!CR3+$TFSU:%N<%P'
M<^G[SE@O-O/OX/^"Q>QOQ,@1/H\@9B=I`Q6$*HA4$*L@44&J@DP`<Y!EU`8F
MQ?^A#4E#M.%5[3F8Q#(5(7@$;Q*H(%1!I()8!8D*4A5D`I"$@$F.A+#`++>7
M*NX)T@H6)<$3EK&4"]W3&',UBN,C$B`2(A(A$B.2()(BDHE$D@!6*TF"^Z63
M:)A1H.>=^4"#')C\8Y!EK&2!_#%HM`(B(2(1(C$B"2(I(IE()#E@>?J$'"1Z
MD(,7L:>$[6MDJON(!(B$B$2(Q(@DB*2(9"*1"H7-XQ.%DFBY4$I,>9!=99#'
M(*Y/@$B(2(1(C$B"2(I()A*I=M@`/U$[B99KIP1JYV7YB`2(A(A$B,2()(BD
MB&0BD0HE1VJ\"<[(^:(_5<7KOJ$'J1N3WH+-CFZ!)(E</R46/7$-)J?$GO:"
M@!+'&?9,&X[@MNR-<`S@(D8H28Q(,K8B6[%M+*VUG#8=`WC:3$PBJ0/>O:O.
MM^8*=7^T&Y`LLCR,@/V$]4]Y3Y\&6?;HH0"1D!*;'I*)SA&*B1%)$$E1GDR,
MD30A1R5)E!O6@-6->V,(EZMGR(8E=BK?5,Y,/HNREE/]/!>\V]C0-)431,@;
MK@9C.::S4K;>B$=,J6.,DH=Z2WE#VIMI.Y;26\8CAMYD*<GQ2YQ]'TA)3VNP
MMW+G[@V*;-B\1T4LTY`=[[,HT4H8A1S1"6DXMFDX<J*(ATR>C#%*,$HY8KD7
MMJVX/>,10VI9)7(V^X1*]"@GJ4218CC%-SXYL\`\E0R'4,BCZ'@O#7>I;&D1
MCQ#=A?(D."IER('E:!I,0QG,3&HH"T6.<*)0](OFDXNY00^"T,WD,HH4EUFR
M.7S64'(9;6A-JW[(H];#[#07QDH9AXA'B"9C>2:4\*@I=<K0$A:H>_J)N63]
MR)GOGGZ/+?<&/3I*`E(D6,MG40(*,`HY8JN+Z[J6XH>(AXAV0]TE."KEB.:V
M[+6K3/>,1]Q8N<BI\9Y4#YT;R)V/LC-R)&V-IG(R\%F49#6:2[(:1;(?3*7(
MZ%:/IMICC'M,.!(=>+-'M"&PLL4:Q1YE4Y(S*E(:KKO`Y.2`QCWY^&G-(!F5
M'9DBP8P^BQ)0P)`MSJ\;VR_-91MT@MN6M4:2H^YBW%WR4'<ICV+=+=VULIYD
M4FI96W(L1MHZTX+)Q?U@7Z:G:VG"BP?NX9#L&P@%&(4811C%&"48I1AE$I*U
M((=@50O3(3[[[(48/4Y+<E`D?PN:Z@<_7#D38PI?30%&(4811C%&"48I1N3>
M>WH)JA"]QZ9WAW79OI1^>3YW6M&\D3MJV'5VFQ'3"_3]RH-/+M@_56[`+V`,
M;OW&Y7?N2IO`]>!+"+=(7`\^93"'R_NG8>]6\NS)I?Z-^+WIP>T7SK.W/+@3
MPOS)]IY`)/R+O>W!K<D-[GAPR7"#+SWX``<^']\4+OFO^4OY>]Z^5)=..Y='
M$!BNO,&$+?TS`?VA9]]=STT/U_LP!G!["W_.*>$#:$$<>VR:GO]`.AC_0+3[
M%P``__\#`%!+`P04``8`"````"$`SCM\JI@,``""/P``&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6RLFUMSXCH2Q]^W:K\#Q?L)V.9>24Y-?`$;,*ZM
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M5J[O3L_8H%_;DNL;TC=&Z/>W&^+1<-#14>-">]Z_Z?C=_J`,SYF0>%5@Z3]&
M=7"AJ@VG=XJG=_68\&P\U7^JME<CZUS3;0S5.#::P[KQU])CN9P:T?*XO+_=
M[[XW*-]0EP_O2Y6]O)%'4;230M^TFB:_FB4T/9253\K,79,R)4V``TWM;_>!
M/[AM?:/IN#(R#RCC<8G02JBYI\Q&$L02)!*,)9A(D$J023"58";!7()<@H4$
MA0-:Y/PJ`C1R_A\14&94!*SO'BPXA<07[K825B62()8@D6`LP42"5(),@JD$
M,PGF$N02+"0H',#<'=2X.Z"<4;\*V/&MM"C?L_$]Y.Y\T#)^OPI!""0"$@-)
M@(R!3("D0#(@4R`S(',@.9`%D,(ES-V4T=CH/N]F)4V9B&)W)H]HH2[EN9-0
MT.;!""NA:G`#B8$D0,9`)D!2(!F0*9`9D#F0',@"2.$2YGI:$JYPO9(N76\=
M]J")*854.@Z!1$!B(`F0,9`)D!1(!F0*9`9D#B0'L@!2N(0YE9;(*YRJI+E3
M-5$%HS-XY3I8"=E81$!B(`F0,9`)D!1(!F0*9`9D#B0'L@!2N(3YF6K!*_RL
MI+F?-7$'+Y`(2`PD`3(&,@&2`LF`3(',@,R!Y$`60`J7,*>JG:Q;[)U/QDJ:
M.U630.]HRHP`)#):?("+RB,&M423GE\MGF,@$]!*@62@-04R`ZTYD!RT%D`*
M5XOYF9:F*_RLI+F?-7']#"0R6MS/`5\%8U!+-'']#&0"6BF03!.?UGTGCW7X
M[:>5D,UC,S`T!Y)76J[I+C>]J(2LZ<(UQ**AMH8L''J/<Z.VRL>7S>K+PX[Z
M0.5YS70(:"]C=CC*"@]3:9BJ0F<^((H,ZI*^XZH>[T^,BHE5I`7>4>QSQ?%)
MRGIB@K921-E)T34O-FW3DY0U/T-;<T3Y2=$U+VKFQ4G*FB^8+1Y(M85R\Y<,
MY%^[]U\%DE:"*I)Z)T95IKWG@SH"4,&EY:ARM3\0LRDT4D%Y1F4VJ%JQ2S^5
M8M`1Q6B,BDGM'7V1)\=6437^VWUWV&NWA>V)%3DU*D64772[J9'JT@+B]$94
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MS`:Q\3H0BTVHCE?EI-6(3]JA"$^,BHE!G=-8&QOD>^6D'=1$&>Z?HN4,+4\-
MZO%51DS'F9'Z:-)"(W*\X\(@TY?>H"M\61@!G0#YI*6R"H-,CQ8HXZAJRR[2
M5Y1>RJ(HO31R9FRHCL!5=$]S*$(4(TH,\MQ5S\>E6)OO],KH]KK#FOA""U*\
M77;1[:96BN=I,=5F5HJE-YS8T*[<*I[M\\)(V3[34ZJA&'2%$=%>Y^-`[>W/
M378[$#Y8HI49$7R-W,V]2FTDY:`(48PH031&-$&4(LH031'-$,T1Y8@6B`J&
MN/?5(8#K_0^\K,2%ES4BE[J5@JAG0C5KI.,!Q2B5(!HCFB!*$66(IHAFB.:(
M<D0+1`5#W/'J5.`*Q^M#!+:8:>2,Y=`#%"&*$26(QH@FB%)$&:(IHAFB.:(<
MT0)1P1#WLMKM7^%E)2Z&MT;,RX`BM9CRX1TC2A"-$4T0I8@R1%-$,T1S1#FB
M!:*"(>9E7YZ<G$\BI3CWLD&=TW/)$%%D$#M-\CU1<L0G*5O>)\P6;[K:F%\^
M0*C0D0/$(-9T+>6@R$CQIONR@#Q)G9KNVN)-5_LAM^F_527[>E?E)A:#G.:'
MB"*#_$Y9Z'3H)26QYL<GB5-O]-VT:=X;M:LXUYO+R@#E8#&#+:*EO]K*XJ&-
MD7++PEI%6?#%5E%O=()>7Q[K)%8"-SKD/-[I#R:.KLE9K`RB_.-T3M1_87D?
M?@R!*#:(]OSJ%*DO-^`)4^'!4Y6C&[P/^J$+3=8/@WB0Y`9<%1D4718D0+&5
MTA%1;TSQL]#$"M0$1-6';D=^;T[I*I/USR`>)Y&Z0E]+N<=%!CD;R-@@2A8J
M3I[7$2=O"3/#`Z5J+NC?W]ETT7L,,.$T<J(4&BD'15:1A$\C%V>7MF6V%AW:
M+8O*,F&F>6=EB26#>6%*P=++ASHK1!0ABA$EB,:()HA21!FB*:(9HCFB'-$"
M4<$0][XJB=RA]D%.T!44FS,:J=E:C9"@`SFADK*K3.0#BA$EB,:()HA21!FB
M*:(9HCFB'-$"4<$0<[QZ2^D*QY?BO!HSB!QO71HBBA#%B!)$8T031"FB#-$4
MT0S1'%&.:(&H8(A[61:.,KE<=$9)SP1E]C2H1X6,,^K%B7)HI)QGBI%5/!TU
MQH@2ILA[]%$]>5FZ#+"@M$B?B?EM3RS(H1%PEX>3SLD-<-H66T6]U/?Z[8%(
M#XF5P+4^D!7G^015BHMY8HK-8;D04[_$VA0:'7<]1Q1;I)]\U'9"WZCF%)5<
M=M5DQPJRM$#]JH(C/!@:`18<;<9!L94Z$PE7B8\\5<-=OE0$NN1SEPJ+JDC`
M?#%EXNFI5V1TG.#$%IGG:?V^)YYX)5:BM,,[(4O'#X83UHC4DC(95)&0Y:$1
M<-P>(8HMTI'H!H-`1#2Q$C5S0I5;;B1^+ZOIHHT%R"!:F9VL!AW44M0^N_!$
M@49N_6N0J7_]X<`;B*UG8D2T(1ZFVJ+P[U3``=:'!CF!"A%%5I%Z6/FD)L5I
M\V<.UQ-FF_=654+GXGEA3M<%%0LHU%AA`"A"%"-*$(T131"EB#)$4T0S1'-$
M.:(%HH(AYOW.=958*<Y7&(-4L5<-D4!NS,.35#5M$,6($D1C1!-$*:(,T131
M#-$<48YH@:A@B#M>%F?G<W$'JS"#R/'6I2&B"%&,*$$T1C1!E"+*$$T1S1#-
M$>6(%H@*AKB79<'X@9>Q,*2L;E8\=WB+XXS02#G9-*I3Q-1II/A;#YXPGS#S
MO(.R0ORMU;!CJL137?Y@$9_6HM8(C92[&AI$3;;#,C;(K(9!X/5\Z.$ORT?Z
MCK)F??@[JV%I420Q4W12>>,D,?'R26@4692-XOD%TBB:!;+>`5AZZL\_]3=N
MV_7^>1VN7U\/C=7NJ_JTDW8-][<5UM^=/OB#D3KO(,_#E2%=*5.%O!*T1VH3
M6:,3D`XM'357.J1#N:WNBOKTM7R-5-R'-G\CM=M#'?I:]E,Y6H3&`YFJDW_P
MJ2LU=AX":FX-_]09?:((X(T?.M36.MX=T6<3-?*]$;WF7\/[(WI3'3F]]SI2
M;[7B%7IE=:1>2,4K]+;I2+U+BE?HV=)(/3FJNT*NI=E5=\6G*[7.\J@SM*-"
MG0>/ND-/A>NNT/"B)YEU5VBHT-,WO)(,1O3^._)L,*+WV9'G@Q&]GXX\&8[&
M=?:SX8A>SD;Y?#BB-ZN)MZI115]`OR^?U_/E_GGS=FB\KI]H&K7+EZ?W^AMJ
M_<?1O'O[>7>D;Y\I4="WI/2M^YJ^&VJK=W^>=KNC_4/=H/IZ_OY_````__\#
M`%!+`P04``8`"````"$`#&3QEJP&```G&P``&0```'AL+W=O<FMS:&5E=',O
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MS&R/*!7-&08`_VIU14H#',F_;70;.JX._6FC._[,FYN.!>':4]GU444D=:UX
M[?JF_I<&64R*BCA,!#Z9B#US;6^^>$3$92+P^?,C@3$/Z<`G$YG/+-?T'TC&
M9Q+P^?/)P/0:Q@&?3,2:+3S/]1?S^VU=,A'X_-ED+"BH82#D/^-([GR^!JV5
MH?2"O,^WZ[9YTV`^0S5TUYRL#M:*"/.BHR4REN&/JA#*CZA\)C(;'2R"`NM@
MZGS=.IZ[-KY"N1<L9H=C+#EBSR-(;1/90`6A"B(5Q"I(5)"J(!.``;:,WL!$
M^C^\(3+$&Y[5CH/)+%LQ@D?P)H$*0A5$*HA5D*@@54$F`,D(6`PD(VZO2+P6
M2#2L/5(M>'*".QICST=3]H@$B(2(1(C$B"2(I(AD(I%2AR7L@=1)-,PD\/&=
M>4"#/%@*A"!?-F@_!HTE@$B(2(1(C$B"2(I()A+)#ECQ'K"#1`]V\"1VE+#M
MBTSQ/2(!(B$B$2(Q(@DB*2*92*1$8<MX(%$2+2=*B2T_Y+GRD,<@[D^`2(A(
MA$B,2()(BD@F$BGW^4.YDV@Y=TH@=Y[6'I$`D1"1")$8D021%)%,)%*BY.2,
M-[\9V=?[4U6\[!IZ7KJQWCFPR=&MCXC(^5/B3BO^'I&`$L\;]DH73MK*;AF.
M`=S$"(G$B"1C*[(%NY;O+.622\<`+IN)(I([4+OONO.EN4+>'YT,B(IL#R-0
M?L+ZMY#'N:=!CCO64'"CF6TK&V?(FE%;_>5B82H+:X2$8T22>[I*I:YLWUK:
MRB/,1&')67+0DJR]46"P1O(*&\)E#SF"+@03E8>]9U&./[F(4<C1G-;B<JYL
MUA$/F&1BC!*,4H8\*+%IE)9RZLNDAK)/Y&0F3M`/?*('.=A^>7'O+(:D8O--
MI=A8E%AM&(4<T>*:.YZG5%_$(Z:JC3%*,$H9\F"E>L\HF@P=IFP4.;F)1M%C
M_(,K&3FW*'.5(ZG.?.4)[EF45&=4RYV>1<BB;&NH,V=IFLISB'B$.41\4NR-
M<3<)0T(W*1>AW7C0B])-)NG(/I)SH.HCG%+I=G#?@F?1LR1T,E4A0W(5*NGM
M64.I"FE#`84\BE;A`I9XQY'+.>(A8ADBH01'I1Q1;<>ZL:;QD$%;]HX<&E7O
M+._1&J1'3\D]AN0:5)+>6S1*JD&*A.((690/,VF::+ZR<$<L"BY[IBA;7=YC
MW&/"D-!C>KM'98G-6)0EYBCV*#M-3JVJT_9\<IH7ZOV'&'+/I$Y]AN2B5;;3
M/6LH5&C`M<3%#._4+,KUA[EN+WU/.0)$+,(7RYB.2>@MN:NWE$=]L!.)\K+E
MX`*R7"QN;OD'.Q21479RBL2?1!9"`48A1A%&,48)1BE&F81D+\AY6BT_:VF1
M6\D?7%:.)QG25,F?(H=>0PX_"2T6Y=)M0-EM`O9G'WH3YO#TVTH>+#G>BH/]
MX`'1T["T_%`D#9"A:8D/+(K\X8PDCP#FM#2"86\V[6&Z?C`:TE2QBR)I-"R*
MV:5L*P%94XB(O.1-DTT:+%GRI,&^/\`A7!X@0V(]8Q1@%&(4811CE&"48D1N
M[HD-=%PT9WH33Z]#Z[)]+O?E^=QI1?-*;MEAI]NN1TQ?`>SF*_@U"?NZRBU_
M16;,C;_8)G]KH+0)%BOXD8=;)(L5_$K#'%X_?!X*3M'9P6N)8?*HW(:.;^CL
MG!5<=]W0=T%_>$.A"KDKN!#"#7;>"NY/;G#P@DZ#40A>4USSY_*/O'VN+IUV
M+H]@L#G,@):^Z*!?>O:3\JGIX04%/`.XD(874B5<%)DSF._'INGY%^C8&%]Q
M;?\#``#__P,`4$L#!!0`!@`(````(0#^/R@!>P(``!$&```9````>&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;)14R6[;,!2\%^@_$+Q'U.(E%BP'3H.T`5J@
M*+J<:>I)(BR*`DG'R=_W4;15-TY1YR*)U'#FS5NXO'E2+7D$8Z7N"II$,270
M"5W*KB[HC^_W5]>46,>[DK>Z@X(^@Z4WJ_?OEGMMMK8!<`09.EO0QKD^9\R*
M!A2WD>ZAPS^5-HH[7)J:V=X`+X=#JF5I',^8XK*C@2$WEW#HJI("[K38*>A<
M(#'0<H?QVT;V]LBFQ"5TBIOMKK\26O5(L9&M=,\#*25*Y`]UIPW?M.C[*9EP
M<>0>%F?T2@JCK:Y<A'0L!'KN><$6#)E6RU*B`Y]V8J`JZ#K);V>4K99#?GY*
MV-N3;V(;O?]H9/E9=H#)QC+Y`FRTWGKH0^FW\#`[.WT_%."K(254?->Z;WK_
M"63=.*SV%`UY7WGY?`=68$*1)DJGGDGH%@/`)U'2=P8FA#\-[[TL75/0=!)-
MTNG\.D$\V8!U]])S4B)VUFGU*Z"2`U=@20\L^#ZP9+-H.H^S"TA8B&@P>,<=
M7RV-WA-L&I2T/?<MF.1(_+HCM.*Q:P\N*#8UQFJQ"H^K;+98LD=,G3A@;@,&
MGR,F&1$,14=E5+M<V8.]LL^M#^4V;)S*I*_+9&^1\>""XG,,/IO'(V]0#IC)
MT#"G?B9O$?)@3#FZ^*-TELH`FLY.0?-_9!/;Z/)L>O"@/J;SL).=N4+Q4]ZA
M\V?8=O]K%7_N;XG#SFG)LOG+HH41#!VJP-3P`=K6$J%W?KQ2[+EQ=YS\=>JC
M?KD_R=?#C<#&'SB1/:_A"S>U["QIH4+*.)JC%Q-F.BR<[C%R'$OM<!2'SP:O
M7L"VB[WQ2FMW7*`P&R_SU6\```#__P,`4$L#!!0`!@`(````(0`]WR625$4`
M`,BW`0`9````>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;*S=6W/;1KJVX?.O
MZOL/+I\O692H72K)JA42^SVX/?4XRL0UL9VR/9.9?[\>$`VBNV]$$IPU!V/-
M-=U-`GC01+^`J.__^]\??GOUK\?/7]Y_^OC#Z\7%Y>M7CQ_???KY_<>___!Z
MMPW_Z_[UJR]?WW[\^>UOGSX^_O#Z/X]?7O_WC____WW_QZ?/__CRZ^/CUU<:
MX>.7'U[_^O7K[]^]>?/EW:^/']Y^N?CT^^-'_3^_?/K\X>U7_<_/?W_SY??/
MCV]_/G7Z\-N;J\O+VS<?WK[_^+H?X;O/+QGCTR^_O'_WN/[T[I\?'C]^[0?Y
M_/C;VZ]Z_U]^??_[EV&T#^]>,MR'MY__\<_?_^O=IP^_:XB_O?_M_=?_G`9]
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MP71=+%ZT)Q=#CKH?AJYZ`T^]VI":Q1@;O='EU<W=_2E\3_4=<K,8@_/"'=J=
M8OW^&>.R6%XLEI>GT^:I%QWBLACS\M(7'0*S>'%B%D-DNA]F'L<A-(LQ-8N[
ME^U9S7C][NE^F/>R5T-\NA^&KB^+S]40G^X'T_6%N_9JB%'W@^GZLN-Y-82H
M^V%XOT^>*6_Z*?@THZ_??GW[X_>?/_WQ2I^3VN`OO[_M/G47WW6C#7-YGZ;S
M[/YGD[MF]6Z4_^F&^>&UCK>F[2_Z2/K7C]=WU]^_^9<^1=Z9-C^QS<)ML1I:
M=!\9W;!K'P(?0A\B'V(?$A]2'S(?<A\*'TH?*A]J'QH?6A\V/FQ]V/FP]^'@
MP]&"-PK!.0G*[_]%$KIANB0,Q_"G`<9H7'F'?6@Q=%G[$/@0^A#Y$/N0^)#Z
MD/F0^U#X4/I0^5#[T/C0^K#Q8>O#SH>]#P<?CA8XAUUSCW/8IR_BAO.\:_W#
M:_VW=9XOW</Y4]_FZNX<@15D#0D@(22"Q)`$DD(R2`XI("6D@M20!M)"-I`M
M9`?90PZ0HRW.8==4/^.P=ZWU":$,6<?=G]_[1E?NA\"-&X[5N='Y9(<$D!`2
M06)(`DDA&22'%)`24D%J2`-I(1O(%K*#["$'R-$6)PJZFIP1A:[U*0K#`?RI
MEZN'\7R'K"$!)(1$D!B20%)(!LDA!:2$5)`:TD!:R`:RA>P@>\@!<K3%.<BZ
M\)]QD+O6[D'NQ3NY;[V3^]QHR,8:$D!"2`2)(0DDA620'%)`2D@%J2$-I(5L
M(%O(#K*''"!'6YSCKE7;C./>M7:/>R_VR0U90P)("(D@,22!I)`,DD,*2`FI
M(#6D@;20#60+V4'VD`/D:(MSD/61.^,@=ZW=@]S+M=;-UL?[G7=RGQN=3VY(
M``DA$22&))`4DD%R2`$I(16DAC20%K*!;"$[R!YR@!QM<8Z[BB0SCGO7VCWN
MO=@G-V0-"2`A)(+$D`220C)(#BD@):2"U)`&TD(VD"UD!]E##I"C+<Y![LJB
M,X[RJ;E[F`WI.-OG][UW?H^MSB<X*2"%I(@4DQ)22LI(.:D@E:2*5),:4DO:
MD+:D'6E/.I".#KF!Z"HX=LWNZ27[HB_X:/$V'->?#-DG/FE-"D@A*2+%I(24
MDC)23BI():DBU:2&U)(VI"UI1]J3#J2C0^[1[PHY]M'O*K;7]]V=-G//XN5%
MV[XFY"2C)V^J>/"GBG.K(5+KKC:@3Q<K4@$I)$6DF)204E)&RDD%J215I)K4
MD%K2AK0E[4A[TH%T=,@-2U?_L</RS%31EXLTWG!<?^IN<;G'=45:DP)22(I(
M,2DAI:2,E),*4DFJ2#6I(;6D#6E+VI'VI`/IZ)![]+N2SXRCWU>(G*-OBD;.
ME</]I3\=G%L-L5EW=S?=V`2DD!218E)"2DD9*2<5I))4D6I20VI)&]*6M"/M
M20?2T2$W$%UY:$8@^FJ2$PB[P'2Z1[?J;DN[AWI-"D@A*2+%I(24DC)23BI(
M):DBU:2&U)(VI"UI1]J3#J2C0^[1[XI$,XY^7U-RCKXI,[G3`>[BGEN-TP$H
MZ!Y%<&,3DB)23$I(*2DCY:2"5)(J4DUJ2"UI0]J2=J0]Z4`Z.N0&HBLHS0A$
M7W]R`F&7I,QT`%IWCXZXASH@A:2(%),24DK*2#FI()6DBE23&E)+VI"VI!UI
M3SJ0C@ZY1[\K*\TX^GT5RCGZ/;F+A7O_[G[W%)![]->D@!22(E),2D@I*2/E
MI()4DBI236I(+6E#VI)VI#WI0#HZY`:B*T'-"$37W"LT]60M`E?=@US^T0<%
M;!62(E),2D@I*2/EI()4DBI236I(+6E#VI)VI#WI0#HZY!S][JFY&4?_U-P]
M^H:\Z<![2F`UMCI?'9`"4DB*2#$I(:6DC)23"E))JD@UJ2&UI`UI2]J1]J0#
MZ>B0&XAY9<;NT4EO.C!D3P>D-2D@A:2(%),24DK*2#FI()6DBE23&E)+VI"V
MI!UI3SJ0C@ZY1[^KY[W\PZ![^M4_^N>*H'77X=Y[6&QE.EH969,"4DB*2#$I
M(:6DC)23"E))JD@UJ2&UI`UI2]J1]J0#2;\W<CJ._>%P`S&OE-@]T^P'@J5$
MT\HY^F@5L%5(BD@Q*2&EI(R4DPI22:I(-:DAM:0-:4O:D?:D`^GHD'OTNWK>
MC.F@+__9BX7NX7(%PGW(X-Y_/'!L-5X=G#L.%+!52(I(,2DAI:2,E),*4DFJ
M2#6I(;6D#6E+VI'VI`/IZ)`;B'FEQ.[NE#\=H&ZX,JV<Z0"M`K8*21$I)B6D
ME)21<E)!*DD5J28UI):T(6U).]*>="`='7*/?E>\FS$=]+4^9SHXE__LJP/_
M@<*K<ZOAW%^3`E)(BD@Q*2&EI(R4DPI22:I(-:DAM:0-:4O:D?:D`^GHD!N(
MKL0W(Q!]1=`)!(J$*_T*03=I.-,!*&"KD!218E)"2DD9*2<5I))4D6I20VI)
M&]*6M"/M20?2T2'WZ,\K)79/$?L?!N<BH3T=^(\@FHY.(,X=AQDB8*N0%)%B
M4D)*21DI)Q6DDE21:E)#:DD;TI:T(^U)!]+1(3<078EOQG305P2=Z0!%PI4.
M.Z8#4,!6(2DBQ:2$E)(R4DXJ2"6I(M6DAM22-J0M:4?:DPZDHT/.T>^N\9VC
MWSVB='5SH4NYF;]6>AK)K3(:ZEY]?%CYWG^8<6PU3`MK4D`*21$I)B6DE)21
M<E)!*DD5J28UI):T(6U).]*>="`='7*S,J_*>,TJHR$%8CC4*]*:%)!"4D2*
M20DI)66DG%202E)%JDD-J25M2%O2CK0G'4A'A]RC/Z_*>,TJHR%O.O`?6!Q;
M#1E9DP)22(I(,2DAI:2,E),*4DFJ2#6I(;6D#6E+VI'VI`/IZ)`;B'E5QFM6
M&0TYTP%*BFNV"D@A*2+%I(24DC)23BI():DBU:2&U)(VI"UI1]J3#J2C0^[1
MGU=EO&:5T9`['3SX#RR.K<;IH!_+BDW`5B$I(L6DA)22,E).*D@EJ2+5I(;4
MDC:D+6E'VI,.I*-#;B"ZZM_+UQ'7?;'07D<8LH[KBK0F!:20%)%B4D)*21DI
M)Q6DDE21:E)#:DD;TI:T(^U)!]+1(??HSZLR7K/*:,B;#OP'%L=6XW2`PF/`
M5B$I(L6DA)22,E).*D@EJ2+5I(;4DC:D+6E'VI,.I*-#;B"ZZM^,Z:`O%CK3
M`>J'JVO0FA200E)$BDD)*25EI)Q4D$I21:I)#:DE;4A;THZT)QU(1X?<HS^O
MRGC-*J.AKFXUU@X>_`<6QU;C=&"JC./7&@5L%9(B4DQ*2"DI(^6D@E22*E)-
M:D@M:4/:DG:D/>E`.CKD!J*K_LV8#OIBH3,=H'ZXN@:M20$I)$6DF)204E)&
MRDD%J215I)K4D%K2AK0E[4A[TH%T=,@Y^DN_ROCT[[:=FKNE1$/>U8'_P.+8
MZCP=D`)22(I(,2DAI:2,E),*4DFJ2#6I(;6D#6E+VI'VI`/IZ)`;B'FEQ"5+
MB8;LQ0)I30I((2DBQ:2$E)(R4DXJ2"6I(M6DAM22-J0M:4?:DPZDHT/NT9]7
M2ERRE&C(NSKP'U@<6XW303^6.@X4L%5(BD@Q*2&EI(R4DPI22:I(-:DAM:0-
M:4O:D?:D`^GHD!N(>:7$)4N)AISI@*5$M@I((2DBQ:2$E)(R4DXJ2"6I(M6D
MAM22-J0M:4?:DPZDHT/NT?=+B=]\#W+)*J,A[\+!?Y9Q;#5,"VM20`I)$2DF
M):24E)%R4D$J216I)C6DEK0A;4D[TIYT(!T=<K,RK\JX9)71D#-3]*TL6K-5
M0`I)$2DF):24E)%R4D$J216I)C6DEK0A;4D[TIYT(!T=<H_^O"KCDE5&0]Z%
M@_\LX]AJG`Y,E=&^<`"%[!B18E)"2DD9*2<5I))4D6I20VI)&]*6M"/M20?2
MT2$W$/.JC$M6&0U9Y_Z*M"8%I)`4D6)20DI)&2DG%:225)%J4D-J21O2EK0C
M[4D'TM$A]^C/JS(N664TY%T=^,\RCJW&Z<!4&<<G60*V"DD1*28EI)24D7)2
M02I)%:DF-:26M"%M23O2GG0@'1UR`S&ORKADE=&0,QVPRLA6`2DD1:28E)!2
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MTWK*@3-23BH,.2<M]D'%CC6IX5BMT\H]R%-%O<7-W`]C%O2ZSU?]1I)W+GNG
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M\N+!F_)*]JE(M:&G-Z,9.IH+ILO[RYL'+^[MT.9TQ>2&Q*_P_?60L`C8??AW
MGRG.-<#"FP!6II4SE9B.]E32DYE*'AX>%G?><0LY4$2*#3U]"B:FE?[I,JG/
M5S\C_=NQWG3&U\I)A3_P@S>SENQ3D6I#3V]%,W0<)I+%P]+?:^W09F(B\>N`
MW[@29'U09XCW>ZPKTIH4D$)21(I)"2DE9:2<5)!*4D6J20VI)6U(6]*.M"<=
M2$>'W)EC7C'PAL5`0TYU>+GP%M2KL=5P7;DF!:20%)%B4D)*21DI)Q6DDE21
M:E)#:DD;TI:T(^U)!]+1(2<0MWY]<*(.:!6&3LW=0J`ANSI,6I,"4DB*2#$I
M(:6DC)23"E))JD@UJ2&UI`UI2]J1]J0#Z>B0>_2GRH7?]L<X;EDR-.1-%=X5
MW6IL=9XJ2`$I)$6DF)204E)&RDD%J215I)K4D%K2AK0E[4A[TH%T=,@-R[R2
MXRU+CH:<J:)O9=&:K0)22(I(,2DAI:2,E),*4DFJ2#6I(;6D#6E+VI'VI`/I
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MII`=(U),2J:']T]#IZ.[L^;5$.Y80QC(299_%W!E6CG)ZL>R*#"MG&1=^[7L
MD&-%I)B4O&CXU.GH[BQ_R?U,LKBLOL/J>$5:DP)22(I(,2DAI:2,E),*4DFJ
M2#6I(;6D#6E+VI'VI`/IZ)![].>MH>^XAC;DKJ*N_$^LL=5PD;(F!:20%)%B
M4D)*21DI)Q6DDE21:E)#:DD;TI:T(^U)!]+1(3<0\Y;5W1/>W@6S(7L515J3
M`E)(BD@Q*2&EI(R4DPI22:I(-:DAM:0-:4O:D?:D`^GHD'OTN[7M7UY%W76C
M>)=J/=FK*-/*HK4A?;*;M8[WF1^,#89I).0P$2D>._[)*FIL,(R<.L.XNVEJ
ML3ES%77'I>9`SE4'5E&FE76)L9[JR%64:6564;<7_L@A1XY(\8M>+'%?[.;B
MUKLZ3)V1W;WKKU&?N2+A<O3.D'.MN\!G4M_*N=8%!68L[UK77T695M98$2DF
M)=/#^ZLHIZ.[L[H%HWW&/K.SNN;>J6G(31U647TK)W6@X*XGYUIW>>6-%9I6
MUE@1*28ED\-?>XNTU.GH[*S[>4O.4W-W9PVD[;26B?[=9M/*2L.:%!ARD^7_
MUDC(CA$I)B73PWMO-74ZNCMKWI+SGDO.@9QD815E6EEI6),"0TZRN(IBQX@4
MDY(7#9\Z'=V=-6_)><\EIR$]!C-\`*U(:U)`"DD1*28EI)24D7)202I)%:DF
M-:26M"%M23O2GG0@'1URC_Z\-?0]U]"&NC\F-<XKU]YGYFIL-61D30I((2DB
MQ:2$E)(R4DXJ2"6I(M6DAM22-J0M:4?:DPZDHT-N(.8MJ^^YK#;D3`=]*XO6
M;!600E)$BDD)*25EI)Q4D$I21:I)#:DE;4A;THZT)QU(1X?<H^^OH;_I7M0]
ME]:&]/S,</ZO2&M#UL(J((6&NE\ELF8<;\$5C:V&5XQ)"2DE9:2<5)!*4D6J
M#5F;W9#:L:.]V=Z=JLW8:MCL+6E'VI,.I*.A_JVZT>G6R?;EO!^=X1>XGK[,
MO^^&\:Y<>W*R`UJ;CM9.#$BA(945A]T3D6)V3$CIT-'-H;=6R\96PROF'*L@
ME4/'\:U6I)H=&U++CAO2EAUWI#T['DA'IZ,;%+\$\4P@6&VX[\D)!&AM6CF!
MZ%M9%)I6NLLP')Z(%'.LA)0:ZO[,KC4Q>0ON;&PUO&+.L0I2.7:TA_?R5HVM
MAN%KCM606D/6GMB0MNRX(^T->7O">ZN'L=7P5H_.6&YLN@*'/;\\$QM32!F/
MZT_W/3FQ`:U-*RLC`2DT9.VLB!2S8T)*#7D[RRND9&.K86?E'*L@E6-'.S9>
M*JNQU3!\S;$:4FO(VA,;TI8==Z2](6]/>&_U,+8:WNK1&<N-35?7F1&;O@QD
M/UMUWY,3&]#:M')BT[>R*#2MO`WTJDS1V&K8P)C#)Z1T[&@=:O^7DK.QU3!\
MSK$*4CEVM(?W'@6HQE;#\#7':DCMV-$:_MK;.9NQU3#\EF/M2/NQHS7\TGOW
MA['5,/S1&<L)UX-?E?.O>5[TZ-9I%/>2QU!WNV/\)%EZ%;#5V&IXKVM#5N8"
M4FC(O8)>>FOV:&PU#!]SK(24CAWM=^]=H&=CJV'XG&,5I'+L:`_O70A78ZMA
M^)IC-:1V[&@/[WUV;<96P_!;CK4C[<>.]O#>NS^,K8;AC\Y8;@S]>J<?PY==
M>C^P#FK(JG"NAE:Z`K>BZ<W1:W8,2"$I&LC\5N_-I?[C_GIR/#09?X$Z(:6D
MS)"YC;2\N/'>=<X^!:DTY#PRB'M6E?MB5Q?>YWG-@1M22]H,].=[:#LT&??0
MCK0W]/1V'$PKL].P'4=G8#>6\RK+#ZPL&[+N1JR&5OILM>+G[=PU.P:DD!0-
MU#^O>7U]=^<_'!8/3<9O:DI(*2DSI+LFW9U<?8."=]+G[%.02D-/?X-"Y;_8
M]6UW)IW_X\WU-5^G(;6DS4#FFQKN+B_]F[/;H<FXPW:DO:&G-^M@6IWWH?^9
M>'1&=N,XK]3]P%*W(6<V-*W<V="[9EFS8T`*2=%`_;F^>+B\\>>L>&@RGNL)
M*25EALR)?7]QJ^^=L/[C)23G"`6I-/3TG%*Y+WU[<>M=V=0<N2&UI,U`_0Z[
MO5SXW\BQ'5J,^VM'VAMZ>CL.II79A;<7_L-C1V=D-XU=2?SEZY*'OH)NKTL,
M.9.C:>5,CC?>Y^>:'0-22(H&,N?Z<KFX]<:.AR;CN9Z04E)FR)S8=Q?^-^WE
M[%.02D-/SR*5^V+W%P_>"5MSY(;4DC8#];MHH3WD[Z+MT&3<13O2WM#3&W(P
MK<Q>>[BX])8S1V=D-X#_)Z7^!Y;Z#3FSI&GES)(WWGM=LV-`"@<:OT4U&NCA
M],%Z>\\KQO[UK;>4#'W&:2`E98;,"7YSX?\*2\X^!:DT]/1L4KDOMKR\\+\D
MLN;0#:D=:-Q#FX'^;`]MAP;C[MB1]H:>WHZ#:65VVL1V')VAW51VA7U[6CPM
M9?[*M\`]="-ZJ^N>G)D3M#8=K58!*32DWW\8%FJ1(?.57XNI+X:+.5)"2DF9
M(7/&\[O:<O8I2*6AIZ>7RGTQ?5&4MX:O.7)#:@U9^VACZ(FO1=MRH!UI;^CI
M#3F85F:O\6O1CL[(;B*[>P9(I/6EE"]<7/>W'IP/\)[LQXT?0&M20`I)$2DF
M):24E)%R4D$J216I)C6DEK0A;4D[TIYT(!T=<E,Q[V[$`^]&&')_^^#&NQ!>
MC:V&Z65-"D@A*2+%I(24DC)23BI():DBU:2&U)(VI"UI1]J3#J2C0VX@NF*_
M/4T\?7OJH;\WX$P'/3G3`6AM.EJM`E)(BD@Q*2&EI(R4DPI22:I(-:DAM:0-
M:4O:D?:D`^GHD'/T%Y?^G8"G#W_?WKTJ&:S[,K*QM'7CK<-75K/SE#!AP82%
M$Q9-6#QAR82E$Y9-6#YAQ825$U9-6#UAS82U$[:9L.V$[29L/V&'"3NZYB7%
M+]8_EQ16Y1>7O5G/TRD6L/6$*19HIUC`%`N88@%3+&"*!4RQ@"D6,,4"IEC`
M%`N88@%3+&"*!4RQ@"D6,,4"IEC`%`N88F&;%XMYQ7*M*K"L&<R[I/"NV964
MOJOU$:*DP)04F)("4U)@2@I,28$I*3`E!::DP)04F)("4U)@2@I,28$I*3`E
M!::DP)04F)("4U)@2HIM7E+FU;$7ERQD#V9%0+'HVUFF6,`4"YAB`5,L8(H%
M3+&`*18PQ0*F6,`4"YAB`5,L8(H%3+&`*18PQ0*F6,`4"YAB`5,L8(J%;5XL
MYA64%Y>L*`]VK8L9ZPK$NTVEI/1=U<RZ`H$I*3`E!::DP)04F)("4U)@2@I,
M28$I*3`E!::DP)04F)("4U)@2@I,28$I*3`E!::DP)04V[RD^)7?YZY`6.-=
M7/9F31:*!4P3"$RQ@"D6,,4"IEC`%`N88@%3+&"*!4RQ@"D6,,4"IEC`%`N8
M8@%3+&"*!4RQ@"D6,,4"IEC8YL5BJO1Z==/]`8YW__SR]=.'^/']WT_EV,F_
MAJ:+T>'/8RTN67,=3(FQYQ;OL1J%J.]J!4LA@BE$,(4(IA#!%"*80@13B&`*
M$4PA@BE$,(4(IA#!%"*80@13B&`*$4PA@BE$,(4(IA#!%"+;O!#YU=+GYA:6
M11>7I@AJ_3[AA"D6:*=8P!0+F&(!4RQ@B@5,L8`I%C#%`J98P!0+F&(!4RQ@
MB@5,L8`I%C#%`J98P!0+F&(!4RQL\V+AETO])]1>]*#DXI)EU,&Z+UNUKEF\
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MRQ)F."ML"A':*40PA0BF$,$4(IA"!%.(8`H13"&"*40PA0BF$,$4(IA"!%.(
M8`H13"&"*40PA0BF$-GFA:A;5=@A>FYNZ5<A;E+LE<D0"YCF%IAB`5,L8(H%
M3+&`*18PQ0*F6,`4"YAB`5,L8(H%3+&`*18PQ0*F6,`4"YAB`5,L8(H%3+&P
MS8M%MZJP8_$7YI9^@>(FQBQ:=$EK?73R<O+<S)I;8`H13"&"*40PA0BF$,$4
M(IA"!%.(8`H13"&"*40PA0BF$,$4(IA"!%.(8`H13"&"*40PA<@V+T3=<LT.
MT7-S2[^\<Y/2F_51LEHL8)I;8(H%3+&`*18PQ0*F6,`4"YAB`5,L8(H%3+&`
M*18PQ0*F6,`4"YAB`5,L8(H%3+&`*18PQ<(V+Q;=0M:.Q5^86\R:V/I]\T7W
M4*+6<MYUR[AH'#Z@SLVLN06F$,$4(IA"!%.(8`H13"&"*40PA0BF$,$4(IA"
M!%.(8`H13"&"*40PA0BF$,$4(IA"!%.(;'-#=.77-YZ96T[MO16^,6=NH:T7
MM&#"P@F+)BR>L&3"T@G+)BR?L&+"R@FK)JR>L&;"V@G;3-AVPG83MI^PPX0=
M7?-BT95/[+GEN5AT[?U8].9-("C\7)V;C1,(34E!.R4%IJ3`E!28D@)34F!*
M"DQ)@2DI,"4%IJ3`E!28D@)34F!*"DQ)@2DI,"4%IJ3`E!3;O*1T5:<Y23%5
M*ONCYJHW=P*!:0*!*18PQ0*F6,`4"YAB`5,L8(H%3+&`*18PQ0*F6,`4"YAB
M`5,L8(H%3+&`*18PQ0*F6,`4"]N\6'25N3FQ,)4\)Q:]>1/(6,,U5R#=]Y'T
M%RK6!`)34F!*"DQ)@2DI,"4%IJ3`E!28D@)34F!*"DQ)@2DI,"4%IJ3`E!28
MD@)34F!*"DQ)@2DIMGE)Z2J@<Y+25TR=U<T5JJBK!4T3"-HI%C#%`J98P!0+
MF&(!4RQ@B@5,L8`I%C#%`J98P!0+F&(!4RQ@B@5,L8`I%C#%`J98P!0+V[Q8
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M(IA2!%.*8$H13"FRS4N19CXG1<]\^%]W[?VD].;4%$P[RQ0+M%,L8(H%3+&`
M*18PQ0*F6,`4"YAB`5,L8(H%3+&`*18PQ0*F6,`4"YAB`5,L8(H%3+&`*1:V
M>;'H5@O^Y/)MSWCKRU28F/-BQ)Y;^+%[;F;-+3"%"*80P10BF$($4XA@"A%,
M(8(I1#"%"*80P10BF$($4XA@"A%,(8(I1#"%"*80P10BF$)DFQ<B?UWYW-PR
ML8"\[LV:1U8+FN86M%,L8(H%3+&`*18PQ0*F6,`4"YAB`5,L8(H%3+&`*18P
MQ0*F6,`4"YAB`5,L8(H%3+&`*1:V>;'H5J?VW/)<+,QJUJY7ZLMVNDFE6S",
MB^-[[T%&)>7<S)I`8$H*3$F!*2DP)06FI,"4%)B2`E-28$H*3$F!*2DP)06F
MI,"4%)B2`E-28$H*3$F!*2DP)<4V+RG=^GY.4DP]P$E*;^X$`M,$`E,L8(H%
M3+&`*18PQ0*F6,`4"YAB`5,L8(H%3+&`*18PQ0*F6,`4"YAB`5,L8(H%3+&`
M*1:V>;'HRB%S8F'*)TXL>O,FD'$)/JQNSLVL"02FI,"4%)B2`E-28$H*3$F!
M*2DP)06FI,"4%)B2`E-28$H*3$F!*2DP)06FI,"4%)B2`E-2;/.2TA64YB3%
M%*"<I/3F3B`P32`PQ0*F6,`4"YAB`5,L8(H%3+&`*18PQ0*F6,`4"YAB`5,L
M8(H%3+&`*18PQ0*F6,`4"YAB89L;B^7,RN&IO;?H->9-('C6?&PV3B"T8$$+
M)RR:L'C"D@E+)RR;L'S"B@DK)ZR:L'K"F@EK)VPS8=L)VTW8?L(.$W9TS4O*
MS-JKOJ<0BUUCS@1"6^L[8$]]K7:*!4RQ@"D6,,4"IEC`%`N88@%3+&"*!4RQ
M@"D6,,4"IEC`%`N88@%3+&"*!4RQ@"D6,,7"-B\674%MQN?*LB_`.;=8C'7W
M`JPE#&Z9C<VL":0?3ET'4U)@2@I,28$I*3`E!::DP)04F)("4U)@2@I,28$I
M*3`E!::DP)04F)("4U)@2@I,28$I*;9Y2>EJ;'.2TM?DW*38=3IS8;J$:0*!
M*18PQ0*F6,`4"YAB`5,L8(H%3+&`*18PQ0*F6,`4"YAB`5,L8(H%3+&`*18P
MQ0*F6,`4"]N\6'15LSFQZ*ML;BS.E3=[`AGO?@]).3<;)@LE!::DP)04F)("
M4U)@2@I,28$I*3`E!::DP)04F)("4U)@2@I,28$I*3`E!::DP)04F)("4U)L
M\Y+2%=+F)*4OO+E)L8MQ0RQ@B@5,L8`I%C#%`J98P!0+F&(!4RQ@B@5,L8`I
M%C#%`J98P!0+F&(!4RQ@B@5,L8`I%C#%`J98V.;%HJN:S8E%7V5S8W&NO-D3
M"!YF69Z;61,(3$F!*2DP)06FI,"4%)B2`E-28$H*3$F!*2DP)06FI,"4%)B2
M`E-28$H*3$F!*2DP)06FI-CF):4KI,U)2E]X<Y-B%^.&"02F"02F6,`4"YAB
M`5,L8(H%3+&`*18PQ0*F6,`4"YAB`5,L8(H%3+&`*18PQ0*F6,`4"YAB`5,L
M;/-BT57-[%A\VT.?>F23"][>K*>E5@O3SGG"TYC[UP7]OV6A`/7#J=DP_RA`
MO5G#*4`P!>C<UY[BO.?8E*ESL^$EE"E[.&_?=:6EI_;="Y\87?8E*O=4,Z83
MVEH6XK$;TU5W7X=WK+.O[VJ9=IXQ\X>AKN\?'OS'3[4WT5%[$Z:]V5OW2]CG
M]X8_:*>]V3<S?]?C^F+AW=C7OK4'=_=M]]"NLV__O5B^???=S_]9/WYY]_A1
MKWO9?2/0^2OD3NV]VMQ@>I7S^US>>^]BM3#-=`-JW(>TX-S._#FCV^6#5^8+
MSTW&H:()BP?K?DOP_,XF]J!Y%^<_<G3C?2BGPT#]>_?V8%>WL-/YW![LZQQ.
M"F^,V4=Z^8#[JZ:9E;CU@J8]V`^G1(R;O7SP[K9H+TZ\ZM65MZ+1CNV;6:^J
M'3O9U3M.R=#,1//NPO^SKMJQ]N#>CNV6^?:._;8I\Z:O%KC[VYB="\1,B36%
MAC%FVM^]J08QI%C[N[=;;<LY9LL'K[:D_3WQJE/[&Z^J_3W9E?N[;V:"?(V_
M.Z7];0_N[>]N_8S]_5?^QL_BIE^2N_O>F)MU+W7:]WTS*W7:][W=CK.P]GUO
MNB+K_GJCGE&_O??_TJ'V/`93K/^7M'-;CMO6$NBOI,X'.-WLFZ3*I"J2+?DN
M6[Z^9C+.I4[.^)3CF?G]6;M!L@&L;<GMY$$5KPV`C<U%D`#9;#'27-A=(^Y8
M;!YQN_U`ENNVNRS'W%-9KK[]\94GLSB-]T\&CJQ:TB:/]5QW?RU)'L7(HQAI
M$R-M8J1-C$-?C+2(/4G8TX0]2]CSA%TG[$7"7B;L)F&O$O8Z86\2]C9A[Q+V
MOF6=+C$GK76YZ^Q2YK#M$3?/:^OAJ3O'8<I<;!K9,$4,4\0P10Q3Q#!%#%/$
M,$4,4\0P10Q3Q#!%#%/$,$4,4\0P10Q3Q#!%#%/$,$4,4\0PI6:=*0RH1YD2
MY?LKN<+:`40,+<300@PMQ-!"#"W$T$(,+<300@PMQ-!"#"W$T$(,+<300@PM
MQ-!"#"W$T$(,+<300@PM:M9I$7/28P:0,H=M!Y!Q7LL4K;J^.7PA:ERBB.O-
M>$KP\`.'F"*&*6*8(H8I8I@BABEBF"*&*6*8(H8I8I@BABEBF"*&*6*8(H8I
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M[$W"WB;L7<+>MZS3(I9XCAA`8AFE'T!&UCR]L^J_G7^Q/!0[#"!F#Y)RF#*N
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MM]:4>C%N7!K;BC&`B*&%&%J(H8486HBAA1A:B*&%&%J(H8486HBAA1A:B*&%
M&%J(H8486HBAA1A:B*&%&%K4K-,B5LV.T:*LLK5:%-9.84YT%V8[%ZL&$#%,
M$<,4,4P1PQ0Q3!'#%#%,$<,4,4P1PQ0Q3!'#%#%,$<,4,4P1PQ0Q3!'#%#%,
M$<.4FG6FQ$+:,::4A;?6E'$Q[G`1>K'<BC&`B*&%&%J(H8486HBAA1A:B*&%
M&%J(H8486HBAA1A:B*&%&%J(H8486HBAA1A:B*&%&%K4K-,B5LV.T:*LLK5:
MS"MOARN0S4(/"6WG8M4`(H8I8I@BABEBF"*&*6*8(H8I8I@BABEBF"*&*6*8
M(H8I8I@BABEBF"*&*6*8(H8I8IA2L]:4W9&+J/ORW2+JR*I9[,72['["'B3L
M,F%7"7N8L$<)>YRP)PE[FK!G"7N>L.N$O4C8RX3=).Q5PEXG[$W"WB;L7<+>
MMZS3(E;-CAA`=F65K1E`1M:L@6P6W6.!F%*J5O9@BABFB&&*&*:(88H8IHAA
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ME<E6DV]*>*MD-ZW:G7LXL.</4AP=NL]`8DN)TJ4NL3%]JQ/[C:>),@ML\SVR
M5EW=9MB58LUWJ4;6?#-E9''/?<YWIJZ:0UTQDEO8G>J68K<?,&2XWD*;X9-^
M%AP9'G;W8NS]_/L?O_QS.K_L__%U/YBQ;[.;*4^LT7O9#9`7R[%8H_?(N.TT
MG3$?3.7&+Z-L3Q>GZV[LNYS*5&U=)>SAQ.X:;,>/,0ZVVWN+[DSQ>&HH$_DD
MIA&]R.O%O;^3Y3(S::3>;X;,L[]G"S?]`$J62]5&ZI&Q>E%EN93CV[9Q["[N
M]=]A)<=JB1R+D6.Q1Q-CB6;:(BFLRW6FQB5WG\+ZUUPF4^^X%#@IE^YMWNK+
M^7$:-I9K9N=FJ*BZI$6,M(B1%C'2(D9:Q)XD[&G"GB7L><*N$_8B82\3=I.P
M5PE[G;`W"7N;L'<)>]^R3I>8?-2ZW*5%F:RT6HR3FH.A'#MB]Q.&%BJ'%F)H
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MFCV5K,0TS76=BLO'8SI5+C?;3HV7H(<?H:,'8K@F1@_$V`=B5PE[F+!'"7N<
ML"<)>YJP9PE[GK#KA+U(V,N$W23L5<)>)^Q-PMXF[%W"WK>LTR*N%8_1HEQ;
MMEK,UYN'`WBSU"KOZ5QL.OEABABFB&&*&*:(88H8IHAABABFB&&*&*:(88H8
MIHAABABFB&&*&*:(88H8IHAABABFB&%*S3I3XO+Q&%/*Y69KRG@)V@P@8F@A
MAA9B:"&&%F)H(8868F@AAA9B:"&&%F)H(8868F@AAA9B:"&&%F)H(8868F@A
MAA9B:%&S3HNX)J^U^+8+[]-HIK_:*:RY\![+50Q;2KEX/]!\`;%9=K=D$&@N
M-HT_""2&0&(()(9`8@@DAD!B""2&0&((5%C570020Z"Y;IV";OZ!4W.Q*04X
M)8938C@EAE,UZ[R(:<UM7GSERO9IF1ZUPT@]91I7ML=R5:80HY3CD8VINU@@
MA@5J#PO$L&"L6XNV/NTN+1%C+C9M%C'4'&*((<9<][`CU_V+[W!E+C9M`E?4
M'*Z(X<I<M]I$WPM<F8M-F\`5-8<K8K@RUSUL8M//\=%G+L8F.GUB=GB;/E]W
MU^YTG*W6D]^1Q6L;#\/%T-V0OUB.Q5JAQEEM+<"FGZK@V%QL2AV.%58UAV-B
M.#;7/7RZ];J;FN/87&S:!(ZI.1P3P[&Y;KV);FZ"8W.Q:1,XIN9P3`S'YKKU
M)KHC!<?F8M,F<$S-X9@8CLUU#YO8#%VB<&PNQB8ZQV*RWCMV[/+*:9GQM^/3
MR!@=*\.ZQ0(,*\7:R9\8.A7&(P5E86G1OV43NU0-N\2P2PR51C:N6YT,VV[N
MC5FJAEEBF%78[7>=,:L4FQ>'^I==XID:QS,Q/!-#JI%]L3\XIFHX)H9C8@A5
MV+0WAF6U_M+X-2SZ%9_]8PC;>"/N=[<O_I2J[>70S-A^955WV%Y,Q>IUDH0]
MF!B/47S)JJE(U=15PAXF[-',RFUVSI*;53<C?#R7.3Q"]21A3R?6/`&@-<=G
M4S%6?J)'/#G6#0;/IQ)5AZX3]B)A+V?VY0[=S&4.'7J5L-<)>S.Q:7_<YM5Q
MBV[#PHMN,VN'J&Z`1J92M1ZB$H9,I=QT4"Q76N^=BE1-(9.:1R8Q9!I9.:0W
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M7B,K)]AMJI>:0B\Q]"KLSD&K%!L'K9-[W2#)F*6VL4L,NT9VZ`YVC>R+W<$N
M-85=8M@EAEV%33MCQ>$X'XR=7;%&V=NU_#MO&A\6T61_N558-;(P<(EAEAAF
M%58]!8A**H=*8JA46/7,(BH5QH\<QI5-]F0H0Y7:PB4Q7"KLSJ&J%!N'*C\9
MBDQJ')G$D*FPJD/(5-@M'<(FM85-8M@DADV%E1W0Z1-KF=+GZ%>H#XNR)MH.
M4/4Z:5F8FLIQT3_-<7%&Y7!&#&?$<$8,9\1P1@Q'Q'!$#$?$N+H60P$Q%!!#
M`3$4$&.7B['+Q=CE8NQRL;<)>Y>P]RWK=(DESEJ7NV9N4;X?2@IKGZVKSIZ3
M*7.QRA0Q3!'#%#%,$<,4,4P1PQ0Q3!'#%#%,$<,4,4P1PQ0Q3!'#%#%,$<,4
M,4P1PQ0Q3!'#E)IUIL1JYC&FE-7/=@`IK'ZV;EB(,8"(H8486HBAA1A:B*&%
M&%J(H8486HBAA1A:B*&%&%J(H8486HBAA1A:B*&%&%J(H8486M2LTR(6((_1
MHBQ8MEH4U@T@W>V=BV$Q%ZL&$#%,$<,4,4P1PQ0Q3!'#%#%,$<,4,4P1PQ0Q
M3!'#%#%,$<,4,4P1PQ0Q3!'#%#%,$<.4FG6FQ,KB,::4E<C6E,+:`42,`40,
M+<300@PMQ-!"#"W$T$(,+<300@PMQ-!"#"W$T$(,+<300@PMQ-!"#"W$T$(,
M+<30HF:M%LM^&?F.*Y!]^>X*9&35W:>+P>S^Q)KOW@_5`O?^2N5!56P::"XG
M5FWB*F$/)W;[)AY5Q:9-/)Y8V427I%CR.N+8698ELN;8&5G5`Y)4RE6,)!76
M]J"_NTF2YF)3#TB2FB-)8B1IKGM8ZQ_Z39"DN=BT"9)4-]<E*59PZB1]T[,:
M`TG3)>[(JCR1NU*N8N2NL&%=[CJPZMVMN9"WN<C4*?*FILB;&'F;ZY:;&GH&
MFYS-1:;FR5G=5)>S6)>X+6=?]QS#L"SK&VQIVNSYS+BF/-S161W6/<9YP5BU
M6<^:FJNKZI8(N1Q76LI"\^YTV!U6@O>MD]JQR.&;J*16C-2.';AUBZ2WV>+)
M<-IMD&37C7?)CFE[G>R[AKHRS6^3.C(&U"JI_>W]85F*5<L[R"E&!D=6%E49
MIS?#IE.6'*HB.10CAV(DK-D`/VDXK-?.65VQRUG,>X_)69DGMSD;6;UO-ZON
M-C`'="G6BBA&S@J[XVGEJ5C5'%E3<V1-C*R-K(C-3QAMMDY:7:]+&CT]*FE1
MOC^GCJP5K;M#0=)*L58T,9(VLB(:/Q*]Z.]?XIGJD3$Q,B9&QIKV5Z>GI_TW
MGSDTZWI=QF*&<XQF94;4:C8RME(=FMW11,9*L<H+#DTQ,C:RXL#)R7K1W;\D
M8:I&PL1(F!@)*^QVB\E97;7+65SK'Y.S,C=H<S:RUK)N99^<E6*M96+D;&2S
M9;O3;AI)TE2/I(F1-#&2UK1_LF8=OQMZR5A=K\M87`;7&?O&*Y1HIC]<1];*
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M.FDL]@/WY-)8[`=^8"N+;6,_\`M7:2SV`^_XR6+KR-DZS]DZ<K;.W5U'SM9Y
MSM;1=UYRDVXO^LZK6;+8)K97WFRG?;2*>JN\WBIRMLISMHJ<K?*<K2-GC!;9
M9UE'SKA[F<;"P?(>)7_.J%?>0^=8U%OE7J]B/ZSR_;"*O)3SE=N,_<#;V[+/
MN8K]4$8PU5M&7CC!9/6&R`LC<QJ+_@UY7H;HWY#W;XC^L:"2MAG]8\$@BRUB
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M(R2YSL\W<;K)SS8#N<[/-7&J^<*9)@;B?!RF3IEYJS_DFD7+)`?[4TPZANQ/
M,.D8LB37^=F%W9/6H$*Z;TASNF=(<C[J,NBFO2##W`QR_^)6QQE3W2Q?S%N7
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M\-DRFRZ)7*61QT2>I)'G1*[3R`V15VGD+9%W7XALB:1''0?K17JL7A*Y2B./
MB3Q)(\^)7*>1&R*OTLA;(N_2R/T=@PQO+/?>?DCD41HY9S"X2,>"2R+7:>2&
MR+LT<LXP=Y'F[9+(51IY3.1)&GE.Y#J-W!!YE4;N;SAQ\7WK)`=$'J61IT2>
MI9$71%ZFD?M;!NUTQ>TAD4=IY'R[Y/(JO;K8<GF1KR7&4F*^DKAEB"_KB-_/
MEY%__?C#OW_^[<.SGS_]]L=___7=GQ]^94%XL7\;]:<_?HNE^?*/SQ__S0+[
M/[[[SX^?/W_\U_Y_?__P\W]]^!0%N)?YZ\>/GZ=_D,KO_^_CIW_N%YU__'\!
M````__\#`%!+`P04``8`"````"$`G8<UR)4.``#.3```&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6RLG-MNXS@2AN\7V'<P?#^)=;*=(.E!1R=2V`46
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M3_?CS]%MD]V,KS_=M0+]=[WZO@_^/]J_;+_7N_7C/]9O*U*;KI.Y`E^VVZ_&
M5#\:1(VOH7757H%_[4:/JZ?%M]?#O[??U6K]_'*@RYU1CTS';A__+%;[)2E*
M;J[BS'A:;E_I!.C?T69M4H,46?S1?GY?/QY>[L?)Y"J-L]D\(OO1E]7^4*V-
MS_%H^6U_V&[^9ZTBY\MZB9T7^O1>IE?9;)*T3HXT3%Q#^G0-X]E9#5/7D#Y=
MP^PJGF=1-C6G?20B'6T[3)\^(MT+1QI,70/Z=`UNKJ)T<BK.S#6C3Q_GO)[1
MV;0G2)^7]>S&-:1/'_%XSR+*-GOQ3=K9ZWJL;]<V=]I4+!:'Q:>[W?;[B.YO
M2H[]^\*,%M&M<>J3T*K:I>5'64GI:+Q\-F[NQW3.E&][NI5^_Q3-;NZN?Z?T
M7SJ;AP$;;I%["Y/KQFTA02E!)4$M@9)`2]`$X)IDZ;2A6^*OT,:X,=KX7CUX
MT(L5"R&\A6]22%!*4$E02Z`DT!(T`6!"T"W.A!@>H7PN&&L:BX)<R)(9[^"#
MM8EGG2@YD`)(":0"4@-10#20)B2LZS1(7=!U8TUW$NEXY#ZP1C2S]$99,N<"
MY9U1EP)`2B`5D!J(`J*!-"%A<M#0>X$<QKJ5PW?BP1(WG9E;/`=2`"F!5$!J
M(`J(!M*$A'64IHP+.FJL>4<MB?E%%B-BWAEY?0H@)9`*2`U$`=%`FI"POM.\
M=T'?C37ONR74=]^M'$@!I`12`:F!*"`:2!,2UE&:KUA'[>1W-:.L.+RLEU\?
MMK9\&ACO$IKD[-1GG/#^6Y+V(WX.I+`D3MNY,J7*.^4#0-D9>!$K<%(#45TK
M,P6GT301*:<[`^^V"9TP=2AWCZKSV_:=^GVJ,C!>N#R.4/IU@V263GCW<VN4
MI%T.%4!*2U);&YO!I`*;&H@"HL%/$]HP34R)Q$092`T:W7QNM.:\]PZE-,0&
MW8]$]YU5,NW[[WW1N74-XUA4#J6SRNBJ=E9))-Q7Z+Y&I,Z*J,^*V##W7%)3
M?F$)>N%=&-DBCJ9>G]@/#J4TMW=29*D0+'=68:9YU-_`I4<W[?T:SR<B7RMO
MT"=LC4AYU'O6#DTIL;JSA`O6^(:M>RZ?*=I`/EK"D3\SAOF[]/P!S90OXI;U
M*,R]+$UDTMJ&+&DMBL/>#22MLXH^5!<\U^Z4@F#*H>/!M+.:4L(<$SR,R`4W
MM2((GO7YZA4_,338DI/.ID]8BX)4S"-`!:+2H7`D1*L:D4*DT5?#K+@6IE`,
MM3C19UM7LCX[Q#-+3(9Y9*V"BUT@*AV:]H5'A58U(H5(HZ^&67$93!EY@0RV
MZF0R6"3&*C%LYV9WB.[,($$*AZ)P-AVXP5Q#,S/1TCR:S.,T$Z5!A=YK1.JL
M@-HWM`'GDUF6R)&W\38#8YHI32_0TU:R3$^+Q"P+8[^U8FD%J#3:&M5GK7A)
M1+NDL5C/5MZFGZ]K1`J1]L@ZC^,DF<53/JXVWJ9USA//E+:A4#]4P4:V0&;Z
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M3(T;CFDG9+`E<3A@Q1:Q2P^H0*L2486H1J00:40-0[S/LGH_T6>LTF.+Q*67
MI5IOU5_ZKJ%')5I5B&I$"I%&U##$9;BL<*=]*CFV.L0NO;4*4(%6):(*48U(
M(=*(&H9XGTT1'*;[#Q5+YAFEF&8<2NR#U797&U'A$)U?NS<WL.776_@$J=!/
MC4CU#3_:]NLMO.N&^>%"F8+WF%#GK7!C6S>S\<(A-B%G8E[-7<-P0D94.I2Y
MLES4II6/SD.)+8L:_2I$^GBHYE0H+JXID$-Q3PQ`MIYF(CI$4WU7"629J)1S
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MM59!,A?.U[1_^E=Z]U0@!!,\J#X4$56'B`HCZC[BP&S9^*.L;\&@Q-4^M50Z
M;P60X%K)(9I._4(D1U0@*A%5B&I$"I%&U##$M2#%6$ED,B_.S`/6"[\D27<-
M9)Q%IKKHLV0FYN;<-0Q$*Q"5B"I$-2*%2"-J&.(*F>7!^44C/4@!&2P*.I@[
MJP`5B$I$%:(:D4*D$34,\3Z;PC_L\X^-_';Y$-;/].3$J$,S>W^#`"J<U9'-
MA-["^ZG0=8U(]0T_VDSH+;SKAOGA0IGZ^YA09PXEQHVHD1UB(]I,5)EY8JUH
M^/,G6R`J'0J?H*-5C4@ATNBK859,GO2RI4)KSF5PB#_JG(EJ,W=6=!-W,GA?
M)%`W]N"C8]_0;K-$DYLXOHE$R5=YH]Y[C4B=%5#[AC;@+)FFDTQ,FXVW:>-Q
M/2];)Z2X3G"(/_J<B1[GSBI,*T2E0[S(G<DBUUFQO0!\](GN%2(]'%$6N:<B
M<DDO6S=0(2CO5(=XBDY!4E?%]TE4N(9!UI8>V?28IO.)Z%SE+7H_-2*%2'OD
M4IWR_$;,Q(TW&4@\N10XON8WZ27&,X=$XLF:WUFQQ'-%>3_$E=[*?O^"=O1N
M4L@Z:%7[5KTCA4A[Y'Q/DW0N?#?>I'7$D\F4LN%T<$(F5Q_W#[8?3!:1<CR9
M9F*$R)U5D#D%HM(C>\7C:3J-)\)3Y6W"='+U>(\46FF/G/,XBZ=R&&F\S4`^
MG2K!S_IR,DUHD&86F4O4#?N9_+%.[AJR-+,-::KW4TCIK-A7.^"A=(6^:D3*
MH]Z]/LM]XQL.)-M0Z1[]S**1GO6#GA;-PZ\X9G.Y:'0-63[:AC2D]'I:1(]L
M3>T5I=$\F<QA?+-&@:L:O2N'`N_:(>]]DDQN)G(?H&&N^*TKR_R?7H*GN!+P
MB/K89^<4!D';D&6G0WWZE,X7RT[\XM%0Q('9%R(JUS"X'_1P1''VS:F(7/7!
MA<9/Y3`N.NBW"FU:AZ5@-A>37^ZL@L0K'#+U6'>Y!FI(Z][TN[,:&":L5>"^
MQHCJK(C:6QV-V##W7'6S:@BG*;F\.V_5DMK%1[B^<XB>OOJ[/D=4("H158AJ
M1`J11M0PQ+3(Y!+EAS=`6D]\]>(0WP"9RT5<;^5%*Q"5B"I$-2*%2"-J&.(*
M7;;HR'#1X5"PVY$C*A"5B"I$-2*%2"-J&.)]EJL"DQ7)W/Q4_=)]L0Q7#`Z)
MM)"+VMZJ3POK*Q"R1*L*48U((=*(&H:X1*;"#@>1X[5N9@OR<+!P*.A-CJA`
M5"*J$-6(%"*-J&&(]UG6]S\^6&#IGUDDLD*N(WNK/BNZAAZ5:%4AJA$I1!I1
MPQ!7R)31%V2%K;I95EC$L@)0D0$J$56(:D0*D4;4,,3[;$K6L,\_,5C8ZI?I
M89%("[$FS;/.RN=`@:A$5"&J$2E$&E'#$)?(%)BA1"<&"UN/,ADL8FD!J#![
M4;1\#JQ*1!6B&I%"I!$U#/$^FXKO@CZ[*K5?,#V8+R[9WO2592973'EOU5_Z
MKJ%')5I5B&I$"I%&U##$99#%YHE+CT6E>9D`OZ@YH@)1B:A"5"-2B#0B\_J<
M_KQLG^WK<.P[2#:KW?,J7[V^[D?+[3?SJAM:T7VZZ[!]#P]=9'H13[NN@R,W
M_A4]<"2F(VVBP)&$CB2F^H8C*1UI=Q'@2$9'VHH=CDSI2+M[`T=F=*1]P84\
MDI`W>MXX<`8)>;/K'VA#WNAIU$";E#2@XGW@2#:A,VC?022]9>;51NT3)G&$
MWGGT>5`U:C!D_T`R#]J3R$,:?TYO/U-2#)PL:3\L/9WID#TI-2@[Z30H4TQB
MT"\",'(QORV'DDO-;^G7\@/V<79;VN6;$(^^AWNK!X_0\[K;TFX4R#9T1`\>
M>8A)<]JKP3-XB(WJ@[+'I#M]ZWNH#0E,CPOIR'5W"O0VJ??%\^J?B]WS^FT_
M>ET]T2TX:7_)NK/OH[)_'-PO_;]L#_0:*5K`T7N"Z+UA*_K)_<0\!W_:;@_^
M#Q.@>Q/9I_\#``#__P,`4$L#!!0`!@`(````(0#V&+O/=`(``-,%```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;(Q4RV[;,!"\%^@_$+S'E/RV8#EP
M:K@-T`!%T<>9IE82$5$42#J._[Y+T1;D.$A]$<35<&9W=E?+^U=5D1<P5NHZ
MI?$@H@1JH3-9%RG]_6M[-Z?$.EYGO-(UI/0(EMZO/G]:'K1YMB6`(\A0VY26
MSC4)8U:4H+@=Z`9J_))KH[C#HRF8;0SPK+VD*C:,HBE37-8T,"3F%@Z=YU+`
M1HN]@MH%$@,5=YB_+65CSVQ*W$*GN'G>-W="JP8I=K*2[MB24J)$\EC4VO!=
MA76_QF,NSMSMX8I>26&TU;D;(!T+B5[7O&`+ADRK92:Q`F\[,9"G=!TG#U/*
M5LO6GS\2#K;W3FRI#U^-S+[+&M!L;)-OP$[K9P]]S'P(+[.KV]NV`3\,R2#G
M^\K]U(=O((O28;<G6)"O*\F.&[`"#46:P7#BF82N,`%\$B7]9*`A_#6E0Q26
MF2M3.IH.)K-H%".<[,"ZK?24E(B]=5K]#:"X32IPM:EMN..KI=$'@NU&M&VX
M'YXX0>+W<\$D/';MP2G%<409B_Z]K";SV9*]8-'BA'D(&'QVF+A#,!3ME%'M
M=F4/]LK>%9_*0PCT98;ORXPN9;SI(VS=QX7Z2XCK%3&9SSO^D$'`C%MW^W6-
M+P4_%O)@M!ZKZ>RZMO0$PJQ[H$67SH6K.`FWN^K!K7IGZRD29J9?U?22MYW=
M*8[?_YST]RXE3I%^ZR:+Z$TU88G"I"HP!7R!JK)$Z+U?D"'.7A?M=G<]]+UX
M&Q\GZW:G6?<!=ZKA!3QQ4\C:D@IRI(P&,ZS%A*T,!Z<;S!PW2SO<IO:UQ)\G
MX/A%OO!<:W<^H##K?L>K?P```/__`P!02P,$%``&``@````A`'#UX.QC!0``
MA!0``!D```!X;"]W;W)K<VAE971S+W-H965T,3,N>&ULK)A=C^(V%(;O*_4_
M1+E?\AV8"%@-Y%NM5%7;]CH3#$1#,$HR'_OO>QS'(?:AS(S4FV5YYOA-SNMC
M^^#E]_?ZI+V2IJWH>:5;,U/7R+FDN^I\6.E__8B_+72M[8KSKCC1,UGI/TFK
M?U__^LORC3;/[9&03@.%<[O2CUUW"0RC+8^D+MH9O9`S_&5/F[KHX&MS,-I+
M0XI=/Z@^&;9I^D9=5&>=*P3-9S3H?E^5)*3E2TW.'1=IR*GHX/W;8W5IA5I=
M?D:N+IKGE\NWDM87D'BJ3E7WLQ?5M;H,LL.9-L73"?)^M]RB%-K]%R1?5V5#
M6[KO9B!G\!?%.3\8#P8HK9>["C)@MFL-V:_T1RO(+5<WULO>H+\K\M9._J^U
M1_J6--7NM^I,P&V8)S8#3Y0^L]!LQQ`,-M#HN)^!/QIM1_;%RZG[D[ZEI#H<
M.YAN#S)BB06[GR%I2W`49&:VQY1*>H(7@'^UNF*E`8X4[RO=A@=7N^ZXTAU_
MYLU-QX)P[8FT75PQ25TK7]J.UO_P(&N0XB+N(`*?@X@U6WB>ZR_F(')G(/RU
M?SI\#@/G=^.A:OMX^/S:@QZ&@?!Y[T$&=Z<W.RRZ8KULZ)L&%0SYMY>"K0<K
ML&"2A,T\M]'X__(=#&<JCTQFI</;@Z4M%,OKVC']I?$*$UP.,1L<8\D16Q'!
M9I/)ABJ(5!"K(%%!JH),!?D$&&#+Z`V4SO_A#9-AWHBL-@)<S;(5(T2$&!*J
M(%)!K()$!:D*,A7D$R`9X=PPPH%BN;T614VP4;#JI)J8RXEN>(P]'\W9(A(B
M$B$2(Y(@DB*2(9)/B60![`!2+=Q/G47#B@(_[ZP''N3!RIT$+62#MF/06`J(
M1(C$B"2(I(ADB.13(MD!^]H7[&#1O1TBB0TGP\;-EOH6D1"1")$8D021%)$,
MD7Q*I$3]+R7*HN5$.;'E27Y0)GD,$OZ$B$2(Q(@DB*2(9(CD4R+E#D?6%R:9
M1<NY<P*YB[2VB(2(1(C$B"2(I(ADB.13(B7*>D9\",[8&=\=J_)Y0WFG<&/1
M.W#8\2.0B<CY<^)>=_XM(B$GGM>?F2[TF*Y<&]$8($R,D4B"2#J.8D>Q:_F.
M4G+9&"!D\ZF(Y`[4[EUW?M`+Y/W1:<!49'L&`N5WW?\L4TY_RX.<OM'D/<&-
M8;:M'*`1#_)@QB?:2KL1(^T$D?0S3\N&87P2;=]W%;?SJ:[D+6NY)'-OE!CL
MDJ+&^G#918'@$9-4%3^V0Y3CCVLQQ"@:D`>E,-%2;<,#$XQ2C#*!YGVQ6[Z]
M4$Z[7$3TKRD;Q9JTZ1K]P"C>T\$)+.I[8PU(KC='J;<A:EIP&$4"\1FW;&<^
M5[K=6(1<*S?!*,4H$XAK.P^6KTCG(J*7EEUB'=S4)=[.?W$G8WV+LE8%DJM,
MV:NV0Y1495S+O4Y$-$39%B\#R,_VY%F(L5""43J@B78F:]OV@Z^\8R[IR.:Q
MYD\USYY?S1,;W>?/!(OWD_#,:QD.2"Y#Q8#M,%`JPV'@=$_#&]\PT/5[<VW7
M=$VT?KG01#O!CTO%J]]]7"8_SC(]TU=:_%S2E@UG[:5JN.5APS]8Z[Q+E4SF
M:-I?PET%*^H)"C&*,(HQ2C!*,<HP8A<FUY?@7O`+$/Z;O";-@6S)Z=1J)7UA
MEQN0U'HY8G[SLID'T,I`0:G<<L65C/*7<!%`'X%'I(L`&@',X6[GL2]916?#
M[GQNQ&_L`'X[8IV-$\`O*LP?W>`1K,!_V$`&-[D70(M^(]X/H'T%;HQO"G=`
ME^)`?B^:0W5NM1/9@XUF7U,-OT7B7[JA:WFB'=S^]`W,$6[["/P6,6?0^.TI
M[<07]H#Q_G#]+P```/__`P!02P,$%``&``@````A`)9?;'EG!```E0X``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,3(N>&ULK%?;;N,V$'TOT'\0]+ZZ4#=;
ML+VP;NT"6Z`HMNVS+-.V$$DT1"5._KY#4E1$T9MUT;Z$T?',T1S.##G:?'YM
M&^,%][0FW=9T+<<T<%>18]V=M^:?WXI/*].@0]D=RX9T>&N^86I^WOW\T^9&
M^B=ZP7@P@*&C6_,R#-?8MFEUP6U)+7+%'?QR(GU;#O#8GVUZ[7%YY$YM8R/'
M">VVK#M3,,3](QSD=*HKG)'JN<7=($AZW)0#Q$\O]95*MK9ZA*XM^Z?GZZ>*
MM%>@.-1-/;QQ4M-HJ_C+N2-]>6A`]ZOKEY7DY@\:?5M7/:'D-%A`9XM`=<UK
M>VT#TVYSK$$!VW:CQZ>MN7?CPD6FO=OP#?JKQC<Z^]^@%W+[I:^/7^L.PVY#
MGE@&#H0\,=,O1P:!LZUY%SP#O_?&$9_*YV;X@]Q^Q?7Y,D"Z`U#$A,7'MPS3
M"G84:"P4,*:*-!``_#7:FI4&[$CYRM=;?1PN6Q.MK%40^.$J`IH#ID-1,T[3
MJ)[I0-J_A94[<@D6-++`.K)XH15$CN?"2S]R]$9'6*6C:_DHB%8_\O1'3UA'
MS]!"J\`-PA^\$@+BBF$='1%Z*-9P=(3UL5AML=<\=5DYE+M-3VX&]`-L)KV6
MK+O<&-ADSL0&3UG\7A(A>XQDSUBV)C0RI(="Y;WL/&]COT"Q5*-)HINXJD4J
M+5AE,-9L">1+H)@!-@B:5$'R_P=5C(6ID@$E$GB7B18:I(5TR99`O@2*&:!H
M@#J<:[C?13(!S'AKPM\I`6B]5F-+A`V*)CVIAF0:DFM(,4>4B*'^'X^8&4/1
M@?HI9*UFA`U2ZLIQ5%GI9#3MN8;D&E+,$44$].+C(I@Q%R'?G0@$0I9(JB&9
MAN0:4LP1)3YHTGE\K&%18('YOVQ9QJ.&+A"TGF?$63;I9"3U91J2:T@Q1Q0U
MD:KFXR)GQFK(`H&0932IAF0:DFM(,4>4^-ALHAV/%KN.ADM=/24$MA\.H3MQ
M>W`,BL.1<:AA"\03%Q<[ZE(-R002!/PT]6&4\=6ZSR<#J;V8DR@J(*4?J?A&
MKM]3`1>8E,%(5!DC`LE];V%G>2(*(\^?4I3=<4-HX9:/;D*^ZX?>LN^+.;&B
MUH7)92[W3G)FLKBUJDM"\(:9L,6%EHY67OBN3(=R"44\C^MHM>RH0EIP'E4(
MN][^:_6YXHX4@Q\OR$1":N(6]96.5O/,2>C]=,LEM.;Z7+0*O051(4UX":@"
MV=VW%`C3VMA=LBX?;S5VG2R*5$)J,@.UF=+12DFFX/*AFJ8JT.MT=/1=KM^+
M4.0MN-G,S8(2W$*_F*'%(-;B_HQ3W#34J,@SFX^A(G:;"1;#>[:*H>.AU1<X
M#/5[/M,O\(0-^W?L$Q3#Q*'S)%X,%[N.[_UX#P+T'Q(_ADOT#A[$<'G=P<,8
MKH$[>!3#\0NX/2F`CX)K><:_E?VY[JC1X!-LBL-/W5Y\5HB'83RW#F2`KP%^
MA%W@\P_#@>JP(CH1,L@']H+I@W+W#P```/__`P!02P,$%``&``@````A`-V5
M!R2K`@``Y@8``!D```!X;"]W;W)K<VAE971S+W-H965T,3$N>&ULE%7;;IPP
M$'VOU']`?@\&]D)`RT:;1FDKM5)5]?+L-0:L`$:V-YO\?6<PBR`;)=L7+L/Q
M.7/&XV%S\]34WJ/01JHV(Z$?$$^T7.6R+3/R^]?]U37QC&5MSFK5BHP\"T-N
MMA\_;(Y*/YA*".L!0VLR4EG;I90:7HF&&5]UHH4OA=(-L_"J2VHZ+5C>+VIJ
M&@7!FC9,ML0QI/H2#E44DHL[Q0^-:*TCT:)F%O(WE>S,B:WAE]`U3#\<NBNN
MF@XH]K*6]KDG)5[#TZ]EJS3;U^#[*5PR?N+N7\[H&\FU,JJP/M!1E^BYYX0F
M%)BVFUR"`RR[IT61D5V8WEX3NMWT]?DCQ=%,GCU3J>-G+?-OLA50;-@FW("]
M4@\(_9IC"!;3L]7W_0;\T%XN"G:H[4]U_")D65G8[1480E]I_GPG#(>"`HT?
MK9")JQH2@*O72.P,*`A[ZN]'F=LJ(XO0C\,@6<3`LA?&WDND)!X_&*N:OPX4
M#E2.)!I(X'XB6?NK.%B$H/D."74)]?[NF&7;C59'#WH&)$W'L`/#%(A?-P1.
M$+M#<$:@IR%7`YOPN(V2Y88^0N7X@+EU&+B.F'!$4!`=E4'M<F4$HS*6%E.Y
M=8&I3/2ZS.)_9!`,>S-)/DI6(Z]3=IAEWR]3/\NY$+9(M,9V>*>HN`ZJ#X;&
MBIU7=0!!XTY`ZS&S66%!\?+"(KA7'RL[1-R!F!I<SWG18!Q?8!#7S26&R&SW
MDOAU-_%<]>T&1?!<:HCT)VE6)9S,D\9'-PF4]VU^7#3G'R)S*]<OK+BYXLY=
M(W0I/HFZ-AY7!YP9$9RD,3J.LUV$'?8RODQW_2&@XP<8,QTKQ7>F2]D:KQ8%
M4`8^SA7M!I5[L:J#S&%.*`L#IG^LX'\BX#`%/H`+I>SI!83I^(?:_@,``/__
M`P!02P,$%``&``@````A``A/Z73+!@``6QP``!@```!X;"]W;W)K<VAE971S
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MCE7WHS=J+4[;N\]/Y[HI'H_`^[OPBNU@N_\Q,7^JMDW=UOMN!>;6Z.B4<[R.
MUV#IX7Y7`0.Y[8NFW&^LC^(N=X6U?KCO-^C?JGQIC>^+]E"__-94NR_5N83=
MACC)"#S6]5<)_;R3(E!>3[0_]1'XLUGLRGWQ?.S^JE]^+ZNG0P?A]H&1)':W
M^Y&5[19V%,RL'%]:VM9'<`#^+TZ53`W8D>)[__E2[;K#QG*#E1_:K@#XXK%L
MNT^5-&DMML]M5Y_^0U#/:#3B*"/PJ8PXWDIX=O`.&ZZR`9^#(]YL!P#9LX#/
MP8%XMC+P[)7A4RD+>Q7YOA=$X9M[L,;][,.3%5WQ<-_4+PO(>=BQ]E+($R3N
MP(J,BPO1O1X7"(C4^2B5>E5`MY!,WQXB[W[]#>*_59#D"L2GD/0*)*"0[`HD
MI)#\"B0:(6M@.5*%L)M4;U.4X(T%_S7%>#3;[T*"D*#G'X2A0Y=3<]GU[-B-
M79=",A.R=#QA>TZ@G>^ODIN8.(X#S]4[0.A!1LZG)\&47FQ3YQ*$A",].V#1
M21'A]<=5YD7&!;DA(+["`3!]G9=U4HGY+)C/"/%ZGSU&*,5%).1$3NSKC>RW
M.ANT=<Q=%M2<VXBU#4(0CM+["4HE1I!=/T$(<O!L^*,;D.*Z$1(NR`T!\3B@
M'M\^'1+,/&6YG2`$0^$(=G;28556^CYUN"`W!,3/D/HI4\<#3K?]E4K,7UZP
M$*)W+AT$LKPM1<Q2+1N6;R3+`)E8((3DB,,J\-N$I!(CQ,IK@A`,P-)EJ^FP
M.@:`"W)#0/R%CO5^?Z42\Y=5DP0AZG@*P993<SGV?,_CE#)$P`D=2_;D^#(C
M@>_KL!*2`GH@9QF\W1>E%J.I"P1VC=[RQM(\IX=8070N9A-);DJHY[(ALGR:
MT=&QC4*S&3<O9ITH$8AYI;J2U24OOMFX/"1<;DHH`]GRWL\`&R5AP*I.(A#S
M>OE4`'/G445+<A-#_9;=SO#[=DD2V!M-?P4OYXD"J2K*:KU:1#:N+:))A\Y&
M?;WK>%E32<>9TI&];CX=[(R4CCY<*O=)^Q2"U>!4X+K>[&PBR4T)]5=VMOG^
M8A\T_8TF[AJ]LB>0REL6.."F@RC!_5R&,)X)A]'*E=8K&$I"MKWY)+!)FB2$
MS4<&@2"\>A2'?&0@ZW`SX<4B8)B,8):N"+W0C=F%<@(2OA!VZ+Z66[(USJ>)
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M2>Y#FXWJMX)C#@+2BJVG)4J3S0'S[KB<:_,`JVR)`B$3$?NL,*9J70<CFTCR
MUVU0%K)/&U7MC5J`79U6,]W+U`$:A@%Y?^>QU50^4X3T1&YN&/%;X$P!8)_&
MD7M2M+F10.\@9?>NL<&Y-C;HZ"MVYMC@A?"\A)\=!)C!X9)<7:G'4(=EFS7"
M,?/L8',F8>'5-G&&#B[#HO>K9Y6J1540X'D:&R.R4?M65/`*:,0G3V$HR9\:
M&9PK(P,_X8D"H0M!Q)\:IFK=#`Z:U9+<Q%"_V03PQEF9=O[)).WP)IY.))F2
M(*6EL(6`3LK"D[\!(C3D7:^98[=I]&C:3H1@(VZB0/C,-W9\?NC)NLR,P..A
MRPAFZ8DH\+V834HY`47"MV'D'L\?9<D&A#=83@<#(=@F)_`B2)<NR=)QV?"0
M*HC.IFPBD>^3QILE=!E?#^'[ATOQ5/Y1-$_5N5T<RSW40'LEWV,T^'((?W3U
MI7_/\%AW\%*G_WJ`EW@E/&RV5P#>UW4W_(`1?CV^%GSX'P``__\#`%!+`P04
M``8`"````"$`*'<E6',"``#-!0``&````'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;)Q4RV[;,!"\%^@_$+Q'E/Q,#$M!TB!M@!8HBC[.-+62B(BB0-*Q_?==
MDK;BQ$EA]"*)Y.[LS'!7R^NM:LD3&"MUE],L22F!3NA2=G5.?_V\O[BDQ#K>
ME;S5'>1T!Y9>%Q\_+#?:/-H&P!%$Z&Q.&^?Z!6-6-*"X370/'9Y4VBCN<&EJ
M9GL#O`Q)JF6C-)TQQ65'(\+"G(.AJTH*N--BK:!S$<1`RQWRMXWL[0%-B7/@
M%#>/Z_Y":-4CQ$JVTNT"*"5*+![J3AN^:E'W-IMP<<`.BQ-X)8715E<N03@6
MB9YJOF)7#)&*92E1@;>=&*AR>I,M;J>4%<O@SV\)&WOT36RC-Y^-++_*#M!L
MO"9_`2NM'WWH0^FW,)F=9-^'"_AN2`D57[?NA]Y\`5DW#F][BH*\KD6YNP,K
MT%"$24:!AM`M$L`G4=)W!AK"M^&]D:5K<CJ>)=-Y.LXPG*S`NGOI(2D1:^NT
M^A.#,D]J`!GM0?"]!\EFR60TG5^>@<(BHR#PCCM>+(W>$&P:K&E[[ELP6R"R
M5S9&?R*/0>M[4I&>![GQ*#G%;L=TB]?S5&399,F>T%.QC[F-,?A\CADB&+(9
M*"&-8TIOFWRH[(-]9>^4IW(;-X[+C.9OUQF_K'.0_N]Z/@DM.E:130?\2"'&
M3$)+'0N;_$]!GY135/5L6S9[53#&7`7CI]B"P_$+7['5CGT]3Z]/>EW^V<^H
M-\:\6SZ.5>PZ!::&3]"VE@B]]B.3(>MA=YCFFU%P;SC`:>IY#=^XJ65G20L5
MIJ;)'$N;.(]QX70?>GJE'<Y1^&SPMPG8&6F"P976[K#P$S_\B(N_````__\#
M`%!+`P04``8`"````"$`K^3Y"7P&```9&P``&````'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;)Q9VXZC.!!]7VG_`?'>`=M<0M3IT4"K=T?:D5:KO3S3A"1H
M0HB`GI[Y^RU3!NP*2>C,PZ1#CHOC4^53!C]^^E$>K.]YW135<6VSA6M;^3&K
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M,E`4PBRX+R-EU0$(P/]66<C2`$72']WG>[%I]VM;!`L_=`4#N/6:-^U+(4/:
M5O;6M%7Y'X*8"H5!N`H"GRH(XQ\.(E00^!R#\*7/_.`V%0>GU:GTG+;ITV-=
MO5M0>D"\.:6RD-D*(O?RX&0&P2[I!4+)()]EE+4-:P:D:"#)WY\86SXZWR$Q
MF<+$$Q@3D?0(F4^@-W`$V72.TZGKJ4BPI")3*;G%>`%B#]PXN>\$(AP@!A-0
M2&<BU1)0DM<9R4&`TP@P%@WQD21BO(%UHETP&'@F@^MWEN"U#=,;IKYDY,8(
M";J</3`7TL9<86(2`Q,&'M2^-T`,=K`D/JZ/'$3TX>X0'_5!C*:/=L%@$-S#
M0`XR=6*<"H68L!-*A,*C(NF_^X$_)MB@%YKTKJ=/@BDM4KLQ8I"6MX3>8@J7
MX.^0P:$$Q!C"H"8['G&"V[4M!U&*1)D8,4B1!\P+:/4G.D(PX47A&,/@&-W#
M40ZB]376+]878K3ZTBX8#!@L=UVFZQGLT%0?WTQ1K$`HT`/GD3MFJ&.7*,2<
M+#)IHEH:;_!#R]4=0HS2HS1=Q+6MZ#$_\CTR@T1!9O&39JOQFV>A#"W:X$E3
MJ#`]3\%"/KJXTA'#])`@"L8@9I:E_7Z<)9JVSM*C-L(0@Q2$YXN`6%UB(!ZX
MB&!5#Q5CLI3&K+&\D6N)-FO1(X46,\3T[#CS1X&4A`:"RWW0!7*D%]P@AWYN
M2'=6B(CIL^<&M%03N;&#*0+%FV['[FH4W2A30\:)Y<8*I'B&KN][G&R&$A/C
M>6(9>:/49I9)SYBY8M#XH=H&*1A=#S'KNT._64KT*R:+N]H#F^H/1(M8@8:\
MNBPX6[AZAWCP7?AWH>KNZA`,W5ZO/L;'#JY\$$&*9B`"$8X94XNC[QJCZ)>Z
M+?]0'^G0I.[$*`$25*!>QQ"<@Y1F8D+@453;ZQGIYJ2-S"NZ;A2E21U0@13-
MB+D^K<O$A(17:$I#UQQP)DTYBNP(M#PI-1&D;0FX=L44BW2+ZU;'S[L$HTX6
M*U"?2\%<4HZ)0GAJYQZ-,IO<I%]K"MW@ANX.$QU=0Y`JC[G>`N"9`9X'AL6(
MZT`AYOBP?'35^<W,X'F[8(+L2N(N=+]Q"3BX"G&>1"%F\9SH%QZPN*$G/A68
M>I)%&7,$76"A%$4,U@-S8<TLM8HU,WY7O^#8"DRFQ(9C!4(6?K1DXDQ1#*/Q
M#+0MD,GSKH[")SH*91$KD%H]H8#,,S*7Q,!`BQ9!-!:Z2?2NGL(G>HH@BSA6
M("67[X>1.%_H>M^!U`L_8&.I&TSE\]K'%U,WBKBV1YN+`B'3)6?,B\:-']:H
M`6%T,B;1N]J+P*<58T^C51?ZM@)IOJU?,5E(0Y_MC4*BJ4Q$@UB!T)7UC;N2
M"&.H?`>7=C'B0PVE0U-B=/.L0'AG,<$,N](%$S)E`Y`NF[3LVU8HY"C2=+4M
MKTH>@O3D:5=,%A.-8P:+B<9!'V=C@2"X\]`%-;-5F42,TI-%H;;7,GG>U3C$
M1./P:.-0H.L\]<;A1P'7W@":/"?:1G#[W>9$V_"(U<8"0==Y&HU#P-/0!3>&
MPX*SZI/.<[T1=Z/H&B'-*U8@?!DJ?.$3$Y0'%3>?+_$D`M^QEWF]RY/\<&BL
MK'J3IPP<MFO#U>$$Y#.7+W[)]1A.1KIC!&?X`0XF3NDN_YK6N^+86(=\"R'=
M10BU6./1!GYIJU/W9O^U:N%(HOMS#T=0.;P.=Q<`WE95VW^1+]N'0ZVG_P$`
M`/__`P!02P,$%``&``@````A`$10.Z2:`@``H@8``!@```!X;"]W;W)K<VAE
M971S+W-H965T."YX;6R,55MOFS`8?9^T_V#YO1AR:1L44B6KNE5:I6G:Y=DQ
M!JQ@C&RG2?[]/ML)A:;M\H+PQ_$YWSF^,+_;RQH]<VV$:C*<1#%&O&$J%TV9
MX=^_'JYN,3*6-CFM5<,S?.`&WRT^?YKOE-Z8BG.+@*$Q&:ZL;5-"#*NXI"92
M+6_@2Z&TI!:&NB2FU9SF?I*LR2B.KXFDHL&!(=67<*BB$(S?*[:5O+&!1/.:
M6NC?5*(U)S;)+J&35&^V[153L@6*M:B%/7A2C"1+'\M&:;JNP?<^F5!VXO:#
M,WHIF%9&%38".A(:/?<\(S,"3(MY+L"!BQUI7F1XF:2K6TP6<Y_/'\%WIO>.
M3*5V7[7(OXN&0]BP3&X!UDIM'/0Q=R683,YF/_@%^*%1S@NZK>U/M?O&15E9
M6.TI&'*^TOQPSPV#0($F&DT=$U,U-`!/)(7;&1`(W6=X!,(BMU6&Q]?1]"8>
M)P!':V[L@W"4&+&ML4K^#:#$-Q6X?&OWU-+%7*L=@N4&M&FIVSQ)"L1O]P)-
M..S2@3,,VQ%D#.3WO$@FLSEY!M/LB%D%##Q?,!V"@&BG#&J7*SNP4W:IN%96
MH="7&;TM,Q[*N-`G[X9^,NHF0;Q]$].XXP\=!,S$I]OW-1D*?IRH`T/TX.8E
MKK-(CR#8<"^@:=*U,T@5K%V>J@-[]2[68R7LF;ZKZR&OCS&>15#^V*";-Y0X
M5OI+ETS?6;R;H>K'4@X\E#I6SMVX&[6WZ\-)'$<W_]T8;N)0XU@9VAF_6IQP
M)X2#)[DN^1=>UP8QM77G?01'J:MV5]%RY+;6Z_HD7?I30+H/<$6TM.1/5)>B
M,:CF!5#&WHL.ETP86-5"YW!1*`N7@W^MX%_`X33%$1@OE+*G`0B3[N^R^`<`
M`/__`P!02P,$%``&``@````A`"F47HG1'```6JT``!@```!X;"]W;W)K<VAE
M971S+W-H965T.2YX;6RLG5UOVTB6AN\7V/\0^'YB4Y)E.T@RZ(C?V`46B]G=
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M1_/_7SU^N?^]>;C]^!^WW_:26P,5AN#G^_M?0FCW,2!U/D7O^C`$__7PZN/^
MT_6O7Y_^^_[W=G_[^<N3QOM<*87,WGS\L]P_WDA2'>;UZCP<Z>;^JTY`__OJ
M[C;4AB2Y_N/=R48??/OQZ<N[D_7V]?G%V;I0^*N?]X]/]6TXY,FKFU\?G^[O
M_F\(*N*AAH,H\G`0_1L/4FQ?%YNS;3C&,_VVL9_^C?U6KS>K\XO+PX<_T_$B
M=M2_XP>>O[X\/]]L+R^>_T@5_N%4]>_TD3_4\2IVU+_C1VY>7Q1G5^LCGUAH
M3`\?&?[/])G/I7DZC-%AR,OKI^OW;Q_N?W^E"TFC\/C].ER6Q9MPM'&P!Z6F
MX?^KT=>PAZ/\%`[S[D0*:&`?5;._O5>)OCW]365V$V,^9&)\Q&Z,"#45#ENF
MH$I!G8(F!6T*NA3T!IQ*EDF;U;]&FW"8H,V8U8<1S&*M$B'&B+%+F8(J!74*
MFA2T*>A2T!O@A%@G0N3O!&,MA&A=\ZX6SGV"'X:8U<4DR@ZD!*E`:I`&I`7I
M0'I+7.JZB;GKX_G40[2N).GXS'4P!*W\Q;+U`NVFH*D$0"J0&J0!:4$ZD-X2
M)X?NA`OD"-$'.<8D/@QD=36/.T@)4H'4(`U("]*!]):X1#5_+$@T1/M$!Y(,
M\D4RR%/0J$\)4H'4(`U("]*!]):XW#4%+L@]1/O<!V('&:0$J4!JD`:D!>E`
M>DM<HKH$7:)A\EN=OU91+)S^PH&\!@.1!O9.<)F,_Q0TC3](!5*#-"`M2`?2
M6^)DT4D[69Z_YX5HG_M`[/B#E"`52`W2@+0@'4AOB4LT&!Z7Z8L+X'`DKT)$
M20E<)24P1TTU0%01U40-44O4$?4.>86"-[+^\/E:*`8KI0EPS.9#1+8:B$JB
MBJ@F:HA:HHZH=\CG'&S0@IP'U^1R'I"_^V_/TJ&?HD:QRN`<=#&IXX@JHIJH
M(6J).J+>(2]#\$0+9!@LE(XWGOJ'(KHJ,]L3E40544W4$+5$'5'OD,\Y&!^;
M<[@AK"_#<^[2*:$8/)33(]HJW8]F>[@MTK*8HD8ARW@L<PU51#510]02=42]
M0UZB8)FL1$?N"(/#<C(,R&2S"\L+H>[G2BF)*J*:J"%JB3HB+:J8D_`Y!ZMD
M<PYEL=T$HW`D^\%CN>PC6D_7R:Z(2`-OZB)Y)BS'*-UB3=1ZJAY_QL'SV#,^
M<IZ#17+G&9$]SX@.:T_Q`3VBP^*-/X-@+Q:<P>!&W!E$9,\@HB-*Q2BOU+P<
MX<\SN(,%YSF8"7>>UE\<9-D50"511503-40M44?4.^1R7N5\S[GD6FA[#\?Q
MKB<B7<FV2I/'_]T<-=WCB"JBFJ@A:HDZHMXAKT^P,3]>$ZL0GL@P('-#V\4H
M@TJBBJ@F:HA:HHZH=\CG'*S'@IP'IV*O@]5D7NS0IPL;<]0\]%/'$56,JHD:
MHI:H(^H=\C(L<STKNIZ(S#COB$JBBJ@F:HA:HHZH=\CG'!R''?H7/P:M!N_B
MJF)`R0TA70F)'8UH)5%%5!,U1"U11]0[Y!4*UL`J]/QT&NQB>D.PYF*8)&*4
MRQE1%:-JHH:H)>J(>H=\SJGI.9(SK<YJ0,EC4+H(,D>-5W])5!'51`U12]01
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MP>4Y&0;DAAZH7`-51#510]02=42]0R[G36H/7[R&<#B2=XX120X[3Z2+BG/4
M.-XE4454$S5$+5%'U#OD%5KF'#=TCA'9JB`JB2JBFJ@A:HDZHMXAGW/..5Y>
MO>3O:1LZQXB2LD@7'.>HN2R&8QDA*T;51`U12]01]0YYB98YQPV=8T0FFQU1
M2501U40-44O4$?4.^9R7.<<-G6-$R;-DNJHX1\U#/QQ+'4=4,:HF:HA:HHZH
M=\C+L,PY;N@<(W)#/T095#*J(JJ)&J*6J"/J'?(YYYSCB[YSM:%QC$BYVWDB
M77"<H\82*(DJHIJH(6J).J+>(:_0,N.XH7&,R)3`CJ@DJHAJHH:H)>J(>H=\
MSLN,XX;&,:+DAI"N*\Y1\]`/QW(W!*":'1NBEJ@CZAWR,@1#]^/&<3/X/VL<
M(W)#/T095#*J(JJ)&J*6J"/J'7(YG^>,XPO6F@_'\;8Q(G\[N$P7'.>HJ2:(
M*J*:J"%JB3JBWB&OSS+;&)1+_O04D2F`'5%)5!'51`U12]01]0[YG'.V<;M^
M/?\LYH=_F').VQA14A;I@N,<-9<%;2.C:J*&J"7JB'J'O$3+;.,Y;6-$KBR&
M*(-*1E5$-5%#U!)U1+U#/N=EME&_D<.E,+D_8Q`NTP7'V-%,"2511503-40M
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MYZAYZ*,#-*M'C*J)&J*6J"/J'?(R+'.`6SK`B-S0TP$RJB*JB1JBEJ@CZAWR
M.:<.\,5_9=C2'$:4W!#2-<4Y:JZ*Z"KG;W14C*J)&J*6J"/J'?(*+3.'6YK#
MB%Q5#%$&E8RJB&JBAJ@EZHAZAWS.R\SAEN8P(G=#6*?><`Z:1SYZ0WL_`*K9
ML2%JB3JBWB&OPC)ON*4WC,@,\XZH)*J(:J*&J"7JB'J'?,ZI-WSY_8"V<1O=
MGSS2_.V4RW0U>8Z:JV+J.***43510]02=42]0UZA9;9Q2]L8D:L*VD9&540U
M44/4$G5$O4,NYXM_F6T\',G;QH@DAZV*=*%YCAI+H"2JB&JBAJ@EZHAZA[Q"
MRVSC!6UC1+8JB$JBBJ@F:HA:HHZH=\CGO,PV7M`V1N1FB>(J74^>H^:AIVUD
M5$W4$+5$'5'OD)=AF6V\H&V,R`T];2.C*J*:J"%JB3JBWB&?<\XVONQGO1?T
MC1'Y.\)5NIX\1\UE0=_(J)JH(6J).J+>(2_1,M\85N*3/S-$Y,J"OI%1%5%-
MU!"U1!U1[Y#/>9EOO*!OC"BY(Z3KR7/4//1PB16C:J*&J"7JB'J'O`S+C.,%
MC6-$;NB'*(-*1E5$-5%#U!)U1+U#/N=_F7&\H'&,*+DAI(\3<]1<%32.C*J)
M&J*6J"/J'?(*+3..%S2.$9D2V!&51!513=00M40=4>^0R_DR9QS#=QZ?7V$Z
M=/,N<43FM^LCTDU_?IS8)O>*<HR2XYJCKN:U:G^^RVS<)6W<B.QYQBCS*_\Q
MBK_ROTQ-U>$!;'OX@M\1T>BO#@>3CO9D8M01T6*4%VU>RO6B+3-`ES1`([+G
M&:.L:!%E1`OSOOV:1Q#M!\ILL`OVZQZ7$0WOS@RO3-R-Z(AB4T=;9O,*J%=L
MF3>XI#<8D3W/&&45BRBC6#I3_WB9<=*^C,B>3$1'1)LZ6M'F!4(OVK)9]9*S
M:D3ZW?8X0>R(2J**J"9JB%JBCJAWR.><SJI';@&<.B^G&=!*G*ZYS%&C,B51
M1503-40M44?4.^1E6#9U7G+JC,A.G40E4454$S5$+5%'U#OD<K[*39WA&SX+
M7RER.(Z?2R-*[%2ZXC)'335!5!'51`U12]01]0YY?<*L:N_YSU\:5W$2-K^<
MCLC6!%%)5!'51`U12]01]0[YG'/FX&6/W5=T"Q&YLM"KPJ?W(0T_%9JCYK(8
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M<]9/'+MY#/[/+J$59Y,GM`4Q+X6-!3&%F9L'F!0!DR)@4@1,BH!)$3`I8EFB
MR#)769S15H[,#+X*@L8RPY0^XI0^F-('4_I@2A],Z5N6I)\SF"][Y"S.Z#!'
MEMP]YB7`L5A@*'7Y@$DM,*D%)K7`I!:8U`*36I8E:BWSFL49S>;(?+$,<88I
M?3"E#Z;TP90^F-('4_I@2M^R)/W4=H:GD;"$<^PN0O]9G$6F*W/^NTWZUQU=
M1C%,T]\4MCJ;US>3$UQF"+5SU,&X^-M;9/,ZN\XB,BZT%X>M`.P=]0<UB5L(
MN(\>V1%-QC"OR;R^YS4YO+??GN"1P8KO^?<G-K@/O>1\O)?OBC$NITF8?^U'
M!DV*XK!1R+%/'Z9N_^F1'9,EACE9BGE]*Y$E3)+V'(^=V#"I^A.S$VV\D[EW
MY1^8]FI`G#9K`--N#6#:K@%,^S6`:<,&,.W88%F2?I@1;?HO7U@HXKOOO33A
M^(<7U)OKMDA7G,:N[L;G7J5_4%!J38<;"U!J@4DM,*D%)K7`I)9EB5IA`K5J
M'2N68<+UBMA)>"P6,!4+F-('4_I@2A],Z8,I?3"E;UF2?I@1EZ0_S*`^_3BK
MZGX^W\B+=*VIB"_MUY/I.-!29.HZ,BD")D7`I`B8%`&3(F!2Q+)$D3!)+E%D
MF%2](G:B'0L"3.F#*7TPI0^F],&4/IC2!U/ZEB7IAUG9IA_N'B]TC46<X<VZ
M9!&9=XU%NCIEPL;"D%K#X<P=16J!22TPJ04FM<"D%IC4LBQ1:Z$KB?L0^&(9
M'(A)2S,PF-('4_I@2A],Z8,I?3"E#Z;T+?/I'[8-2(OE9>^T*N(6!$Z:>5L"
M>V?!8M8<-A<+F;8/B@M-\X^3M'\0F#80`M,.0F#:0@A,>PA9EJ@5K)95Z\A4
M$S<H\(H,=LT5B]O((/H2,J6/ODH?3.F#*7TPI0^F]"U+TD^MX['T,WYQWJS`
M%@16K.8P4Q##X<ST(T7`I`B8%`&3(F!2!$R*6)8H$DS<DH(83)\O"&L$XU3C
MMC<8"P)Q2A],Z8,I?3"E#Z;TP92^94GZP979]/^)J2;N5^"EF5R?+1:L9KFM
M#D:UIJYC`4DM,*D%)K7`I!:8U`*36I8E:@439]4Z=OD,IL\K8HW@6"Q@VGH-
M3.F#*7TPI0^F],&4/IC2MRQ)/S@VFWXHEA=\J::(VQMX7:(=U$QG'"R6LL:=
M$>;Y0U)-74VE@$DJ,$D%)JG`)!68I+(LD2JX.RO5L4H9W*!7Q#K$L5+`E#Z8
M*@5,Z8,I?3"E#Z;TP92^94GZP:XM27^P=S[]R?+9@IC7ID9%IK!Q\*4(F!0!
MDR)@4@1,BH!)$3`I8EFB2'!P2Q09')]7Q+K`,7TPI0^F],&4/IC2!U/Z8$H?
M3.E;YM,_[&"P(/U#?/)GU9&=3P^ONX),&SA&^Z=9S]Q)Y@6\@W+:U'$*&PM'
MNSH.3`_K(].VCF#:UW'J^\Q':*_'*6P\G#9[M(=+1`K&;8E(@]%S-1*W33`9
M2*08-V<ED:))="*MYN6\4:0I;,Q`(N%P$@E,(DU]C4CI1TBD*6S\"(ED#Y>(
M%+R<%2E,0EK\#+^K>OIR>_/+A_L`LJOFZY-Q4_@B[IW@M1MLHM<.3-I%.[G1
MX7Y[O]&W_)+'(177%#(F)=UP*.D&)MVFOH?#%]MU4KO2;`H9#R_-[*$2S8(!
M?$ZS?]Q__RO-Y`=FT08CZ46+S'PMO(B;-&B!=#P]B3;$:<X<F50"DTHXGE0"
MDTKH*UG`)(OMF\@2G-YSLOQ@*0V&T:L2F1S"?`]:88$V;N.@I;!1%`D5NVIV
M-5V3I3QI%\,TY9BP9!%'<F9/)*E7*3R%C2<BA7_D1"1Z]D22YT&-P_0)]GSG
M$TF&)KC0=&A6%_-5/E;LDDM^<+9^G"+3S&54Q/-)W'I"RS"C/!JGH:L6&T:F
M08FL.-P9KG1-7ETF%Z^&9/K,L:/T!Y/^^`")[3[@<GN^O5PEI2&I[<$278-E
M374MMF'KV(.2+Y%U<,%>UNB,=4LRLL+,Q^TJ?/G'PQTK_QCFRS]QA](ZAND?
M<R)SU1VF.<D_A8U#(ODC>_9$-"(QS)](,N@:D^D3\B>2#%.PUA@F,\F-XW3D
ML2+NC>'')AS;;6XLAP"F^@93?8-)8C#I"28]P20>F)2R+)$E^&LKR['T0WSJ
M(@<6K/I<$>O$^$B1*6RL""D")D7`I`B8%`&3(F!2!$R*6)8H$BSW$D4&B^X+
MPMKV^%CA=M8X,*6/.*4/IO3!E#Z8T@=3^F!*WS*?_F%["YO^2U<DXCX93I=Y
M[PQ;*9C#Y["Y4LBT0WI\&)CG$&V1#J8]TL':#-,NZ8C3-NF6)5(%2VVE.G+M
MQ%TTO"+1JL\I[`JWVT:L%#*EC[Y*'TSI@RE],*4/IO0M2](/[GA)^M%-V[^;
MC;MFZ'(TMXYD^I4B0U?=84Q!@$D1,"D")D7`I`B8%`&3(I8EB@1CO$21:*2=
M(M%PNX(`*PNW]\:A2)0^XI0^F-('4_I@2A],Z5N6I!_\J$W_GUCYCGMJ^&ME
M\+MA3<042^+/52Q3F"D6,*D%)K7`I!:8U`*36F!2R[)$K6`IK5I_%)OKFS<?
M_RSWCS?[;\KP+/S(?GI2C#MN>$6B=W7%`J9B`5/Z8$H?3.F#*7TPI0^F]"U+
MT@_N;4GZT>VY:V5@B?%(K*@*8@HS!0$F1<"D")@4`9,B8%($3(I8EB@27-H2
M1097YPO".KUH/-RF'.-T@CBE#Z;TP90^F-('4_I@2M^R)/U@R6SZAU6H\,WX
MA3\P+N+V&UZ8:/C\O2-YI%:I3&&F5,"D%9BT`I-68-(*3%J!22O+$JV"?[-:
M_7'DWC'X/:_(P'0W'5-5^F"Z=X`I?3"E#Z;TP90^F-('4_J6^?0/>VDL2#_N
MO>'2'_?CD,AF,L$RQ1PVJE069%6&U1G69%B;85V&]9XEB@2;MD21P=9Y1:S5
MB_<.MX-'O'>0*7WT5?I@2A],Z8,I?3"E;UF2?O!D-OV7/K3$[3B\+M'PJ1Y-
MI6#EQ>WD,4HU=1VK1U*!22HP204FJ<`D%9BDLBR1*O@W*]616T?<K,,K8CW@
M6"E@NE#`E#Z8T@=3^F!*'TSI@RE]RY+T@R&SZ8=*>>%WN^(&'EZ:R?#98DD6
MT7;%N/?'?/.56E-74RQ@4@M,:H%)+3"I!2:U+!O4.GW\LM\_E==/U^_?WNT?
M/N]W^Z]?'U_=W/\:?&EX!#+\U</^T[N3#[IAOSG<M77V4Y^Q[?Q,;;IO9MN*
MT';X5C[[K4+;P?.Q;1W:#G\08=LFM!V^_8^V3>BGQYC<N6Q"/YGV;-MY:#O\
MQ8_'W(:VP]\<V'81VB[RQ[P,;8?'6O1;AWY:NLN=RSKTTR)6MBV,@U9X<FV;
M,`Y:TLBVA7'0\WZV+8R#ACW7M@J:Z2L^V;:@F9YBLFU!L^&/5\A]%7+7MR&R
M_4+NPU(`^X7<!TN#MB+TT[=><\<L0K_A;Q'HMPJ:#7^38%O03-\.S!US%333
M]^2R;:$&]26R7-M9R%T_:LJU%:'?\$=`G$L1QD&_"<CV"^,P_!66_<(X#'\P
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M,`]Y[[!2G[QS"$8L[\-6TCKOPE;2.N_!@@7["P>F,_@+#Z(S^`L'HC/X"_\A
MK?/.*QBOO.]:2>N\Z]))9Z]?#77VKJ</SUZ'A3Y;/UO.C$RAS]9/B7,M&K/A
M83#Q4?I#[_J-_K*;&VG]T7;]1G^ES;7]5+SY*5LWX11R9Q"*)L=#F67X3YLW
M/_W%4U*XU#,]/F@8L]>LRBAWQ2KSLY!Y3DEE?A8RS[6I7Q'ZY;)4OR+TR[6I
MWRKTRZF@?JO0[]!V.@W1X_NWWZ\_[__S^N'S[;?'5U_WG_2(>W;X6M3#[>>P
M/##\QU/\0M_/]T]/]W>'[_9]V5]_W.N5O&?ARSZ?[N^?QO]0<9S^?O_PR^$Q
M^OW_"P```/__`P!02P,$%``&``@````A`/$)8?>G$0``66```!D```!X;"]W
M;W)K<VAE971S+W-H965T,3`N>&ULK)W;;N/($8;O`^0=#-^O+9(B)1LSLQB+
MW3P@`8)@DUQK;'DLK&T9DF9G]^U3S:XFN^KGZN#97$29C]7-KJH^_-VDF0\_
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MK%]7%&W*D\O`E\WF5V?:/#A$A:^AM.TR\*_MQ</J<?GM>?_OS?=ZM?[ZM*=T
MY^21<^SVX8]RM;NGB%(U5VGN:KK?/%,#Z+\O7M:N:U!$EK]WO]_7#_NGCY?9
M]&J63&ZR&=7R9;7;V[6K\O+B_MMNOWGYGS=*N"I?2<J5T&^HI+C*9Y,LH7N>
M6DG&E=`O5S*]FJ;Y;-Y5<N#N4RY(O^^_.[6SBP/]<B4IY>+`70LN0+_AKE?I
M/$_RPOE\H.","](O%TQNAH@?*$A#MFLB_88FIJ=%Z(9+TF^XY?PJF4Z.-36A
M$/C>X?HE=X^#7E[[[M7UUG*Y7W[ZL-U\OZ`I@#K0[FWI)I3DUE4;^JGWM^^Y
M?]9QJ<>Z6CZ[:CY>4@2H3^YHM/WV*<UN/ES_1B/DGFWNT":1%HM@X8:#J[;4
MP&A@-:@TJ#5H-&@C<$UAZ6-#P^:OB(VKQL4F>'470!0L%8A@$8J4&A@-K`:5
M!K4&C09M!$0@:.B+0(Q/8J$O.&N:KN*^,)U(!^^\33KK@[(`4@(Q0"R0"D@-
MI`'2QD2X3I/7&:X[:QI)%,<#X\`;I6*P3/50Z(WZ+@#$`+%`*B`UD`9(&Q,1
M#II"SPB'L^["$9RX\R2]&?(.I`1B@%@@%9`:2`.DC8EPE)8/X:B;%]/\BNS/
MG!E=13(&GE`,HDXR3>4`6?1&(70E$`/$`JF`U$`:(&U,1%AH<11A.3P3.&OI
MNR=Q_H&40`P0"Z0"4@-I@+0Q$8[2Z#S#46<M'?5$)3E32>Z-^B0#,4`LD`I(
M#:0!TL9$^$X]\PS?G;7TW9,XR4!*(`:(!5(!J8$T0-J8"$>=X#G#T\Y<NLI(
MY7FJ\CQ8]8E&9!!91!6B&E&#J!5(AL$)H%@$'A[5B==+M,H%;^X8Q2E'5"(R
MB"RB"E&-J$'4"B1]=EKG#)^]-!(^>Z36\5RGOK<*P2J=/*`10P4#,H@LH@I1
MC:A!U`HDP^"$SQEA\#J)Z@M-OTM8.D5+.J(2D4%D$56(:D0-HE8@Z;-3-['/
M[U[;$Z^31#A8.M&<,TC`::%[16\5XEAR7=$0,H@LH@I1C:A!U`HD(^1D41RA
M(Q."5U$B#+&PZO9R"W?ZX;K]T%%*1`:1150AJA$UB%J!I,].\\0^NUZ1)U?N
MN.6(^UXM"?<]ROQQC-O*+A*VHLSW'2,IE.PK@Q5-L;U5.IWUW4<VV:F7N,E'
MVNG%CFBG1Z*=C(8A7B:,,C?J90N<AHA;<'K0O/H0C?%(-(:MC@2-K630YG\2
M-*<&XB8?"9H7#Z*='HEV,HJ#Q@B#Y@ZP1`M<T#(R/]R2KIA4'XSBE@2KPQ$+
M5C)BPX&-2'+JUOO3(]:9JW:Z&LC':#BP519%+*"1B+D5,VZ!BU@R24\8G*E?
M;./\,1*M8:LC46,K$;5\.-J043MO94UQ967$Q\/=)(*H1&006405HAI1@Z@5
M2/I,\8,\O6O7G+J:5"?R2$KM7)^;<,%XE4%D$%E$%:(:48.H%4A&R"V"<4\^
M,N;]FBEZ+RRC"W>PK5961`:1150AJA$UB%J!I,]Z93WB,RZG*2/Z&5;%7*V=
M"[;*IKTX+4<+IJJ@"07S[N"ZF+C_](M')UYL,.GJEMZYQ3'.J)N;TL(]U3DV
MH?ME5227$2T&D:/ZV(".3;OIM(@<!62"U:SS:CK/Z!&(]BHN);UR2RIX1>;[
MI_7]KW<;-_^.^I?1W?PC`;<QTD.8D<RCWBUS09%'7S"+MDS!ZJ9S+TNF!7C'
MA49RYM9F[5U"C\;8OU\V;YU_9SCK5WN12T8REWI_Z*8SMS3&N?1H2C)AZ`38
M:=DJZ?Q/$@J`MK&B<I'?;$R#)'FWH'9>AQ`<'JM=-7*:9A1-P`M$)2*#R"*J
M$-6(&D2M0#(66M]T(_@]9[TD*7279^0R,213#\3%8-7O!Q$91!91A:A&U"!J
M!9(1TOKK2*]`S44ZST5&]`I`)5H91!91A:A&U"!J!9(^GZ??,M1OC-Q$%:5^
MV,OY;?%@-:3>UT4%`S)H91%5B&I$#:)6(!D&+>F.I!YU&\WCD'I`)5H91!91
MA:A&U"!J!9(^.SVEEX=WR=C,*[-X66"D)H1AL\J]PA>,QDLY%!QZ!5A9M*H0
MU8@:1*U`,D).D,41.M(K6+\-F[T[6O"@5P`JT<H@LH@J1#6B!E$KD/39B:4S
M?/;:2J3>(Y7Z8=?-J>^M0I[+#)!!9!%5B&I$#:)6(!D&IZK."(,782(,'D5]
M>T'"3O6&$I%!9!%5B&I$#:)6(.FSTUIG^.REF?"9$77Q82V`S'LCFIB&S(^5
MTSK/N,,C)R+]!F9Z,U<['!L,4`H[E7F&:YVY%'P!41MZU^C5,+G56+`5#:_>
M-T0F(+]GR>?35&_$@D57CTC25,NXPW-29ZX\8?DFDE2H%BRX8)PE1"8@GY)L
MDFK-9X/%2$[.DUM3E%L!Q3E)"WU6PE8B)[ZN")E@Y7.2)EERHT)B@\E(4LY3
M45-440')I*@.OF`KD11?5X1,L.)Q,LT3\"0N)+N7%D+=&62T8SII4SQ%?120
MS)7>\[-5E)B2$04_#"G#B$Y2W2MX17Z#)QFB(NGAF.PY?T\X1<W#R(6_GR+2
M0N_[V2I*6(G(!.1SF$R2298K]62#S<C0<AKC])E\ZLS5),%(I@NF.V\ET@7(
M</6TV+IT)?2*]E2M"3:8C`PM)PIB5][7(;VTB->J*2-J;Y0M=;JR8"N1+5^0
MUM&A0S+RIS3)9)9-(%EL,I(L+34Z#W_DF&:*:H21&Q:1MWJ7QE8BG[XN,?Q8
MQOCAEZ:S+%<565&1''[4HR"?[A#OC/.8J:M#]5>/U-A325AP09%-7S!")ECY
ML3>;9Y.)6E-L,,%LYEIIO*N_=K5(#P.B]O89S%3<%VP4)Y!1G$!&/']F&3V@
MU0Z*BD0"<RU`M(.GG:EUU2@/O3")4K%@JPB5B`PCF@_#B+3"2K9?RP[=_I-6
MN!S5"",UQ-1,MV`KD2%?E]-\?6934+^A^D,GH:)RZ;5;\0]-HR=FS0N'>![-
M/8KW.8A*1`:1150AJA$UB%J!9"RTQCDLH7,4,XSDF==,J:S%8!6Z98G((+*(
M*D0UH@91*Y`,@Q9"1\*`@B?W2*0>4(E6!I%%5"&J$36(6H&DSTZ=Q,/@B,]>
MS(CN[I$\W9BIZ7.1]U9#Z@$9M+*(*D0UH@91*Y`,@Q,C9X3!:Q<1!H]$Z@&5
M.2"#R"*J$-6(&D2M0-+G49EU[LXF1VD5$.6WG[X+K3S82"QD7!7%J"\W,NU[
M*Q+(G7@N\C2;*Y%J1>72::=NXD3_L+;,O5X2?8%1K$S2F=Z[<D&Q\/F"QQ8^
MMA)QFJF=HPWM$HU(A\V7"$MQ3*2=MAIVU4@-PR@>%XA*1`:1150AJA$UB%J!
M9"RTGCL\)19\>C1LQ^\8J=5P"+T_\!VL^BD1D4%D$56(:D0-HE8@&08M"X^$
M`?5?X9%(/:`2K0PBBZA"5"-J$+4"29_'1*%3SN?^\0^JPJ)7A='D-M/G!X/5
MT"?Z@@$9M+*(*D0UH@91*Y",SWE"L4"AR$CT"6\5H1*M#"*+J$)4(VH0M0))
MG\]3A06J0D9T!!`RN$!4,G)OV0VK7Z)V2V:P"G59K*M"5`\%#U3?#%:A^E;4
M)2/C!%R\EAZ9(;S>BQ?*PB,1&4`E6\G(Z"<$9K`*3;=8?86H'@I&D='5-X-5
MJ+X5=<G(.)D71^9=6^K"BT41,(]$P`"57)!>1W02B1ZF3-3:8P:+X(UE%%5=
M(:J'@EW52:'_W+L9+$+5K:A'!FI4@_[(45^!>C0@ZEG]R`(]RD:Q'F7DCK;Z
M<JA'0T%_U)FF\[28J]V/#3;=Z5BW^E>(ZI/NUX2"?+]Y4>1Z&6F##9[&%4X[
M0L_\H8![-2IZ*:,X<#HFBZXE\@TX1D?D;["B?C^D9::W`&R5Q&U((_G+6?`M
MC31X':H_>/C4!"O9"'7ZV!YKA!@+L[]&@W?52`W.*%IA%XA*1`:1150AJA$U
MB%J!9"S.T^`SU.",R.>XE^A=Z&`5)JL2D4%D$56(:D0-HE8@&8;S-/@,-3@C
MD7K4X&AE$%E$%:(:48.H%4CZ[/1N/$,=5A4S+X_CZ8>1VGXI);48K(;4L]0>
MA)I!*XNH0E0C:A"U`LDPG">U9RBU&8G4H]1&*X/((JH0U8@:1*U`TF<MM9UL
M*K+N[>0S=V#NS_?4$S%&<D:8ZS/JP6KH%KZN*)`&K2RB"E&-J$'4"B1#Y.3Q
M&:/#JVDQ.CR*O%G,`)6(#"*+J$)4(VH0M0))GYW"C7U^EYJ>>9TL0N$1O0`=
M<KU@JT@%EXS<<X-!;V@Y8P:K4)?%NBI$=2@H]$;T)I<,Q:A>CLYL3SNGFZ%(
M#HBZ0N2E.E1<L%6LDD<+PL.Z4-`_0LYOW%_;R%?%;#")1#*BFI$[E(G:.>QO
M9+B<O(M[SI&UQ*M!T448"1DQU\<V,V\5R<@2D0F(WW(;B0!44X4RP_MS-2/W
M:#.*P*!_103F6E0>CD!G+L5C0+)C**6[8*NX8R`R`7$OH`CH3A`LHDZ`J&:D
M.L$@[F0(M)9\U_0Q1XD9D.P;6F>P5=PW&,5O(##B-Q#F(X'Q]X^JJ;#FFI'L
M&]%[>S(P6EUV@?F1O>`<!2BCJ&,L$)6AH-A.P23"5OSH9_0U-ZR[0E0SHB?B
M-%G+F&CUJ3O+:1/L'%4IHWC=150B,H@LH@I1C:A!U`HD8Z$EJ(O%.T[#YZA-
M&4DM=J..31:#55A32T0&D454(:H1-8A:@61\M%P],K>B))V#LEP@*A$91!91
MA:A&U"!J!9(^.ZEX^HHZ]\HR7E$9R=W9C7XX.E@-J?=U4<&`#%I91!6B&E&#
MJ!5(AD%+TB.I1^TY]TA,!X!*M#*(+*(*48VH0=0*)'T>TY[OVYW1%WCU[HR1
MFA&T_ARL0A\H$1E$%E&%J$;4('+?#W:M]ZGS(?+?`_9?6'U9;;^N%JOGY]W%
M_>:;^]8O/8K_]*''_D/$=_-Y^!*QOC(K;MUNB#S45^89E>D6+;@RI2N=:((K
M.5WI7@2$*W0?ZN)C]YG1E>XCG;K,;$)MZSZ!#%?HR\ITDC52VRRE*]WC<2A#
M_M`1R%@9\H<."L:ND#^T/QZYDE.KZ767D2L%M9H>^(]=H5;3,_"Q*]1J>E(\
M=H5:3<](QZY0J^E)XLB5C-I&[WN/7:%^X%^=UM')Z3Y>HL`5N@_M1T=JRRDZ
M]+;7V!7*-KT`-7(EHQCX/;"^3T8QH#^5'2M#;:._'AV[0FWS:@]JH[;1WRJ-
ME:&V>66KRR14&WVP:J1,0K719YU&KJ34-GI8.':%:J.G8F-7J#;Z=,/(E8SZ
M#OT1^<@5-X#'^,TM?7IPQ#ZAFNAK?&-7*`/TS;JQ*Y0!OWI"9,A+^M@9EJ$#
MBUMW'(%7Z./GGT>SZ6X_8G]'-Q^U=\D?L?\\O?U,DR/>^([B/AIVUUO'[*D_
MC'95&D5CCM'#\UOW:!SO3,^];]U3;;Q"CY6IS-A=Z(DPE1F[0D]6J<Q8"^C!
M*)7IKESWF:(/N[\MOZ[^N=Q^7;_N+IY7C[083+KCS*W_-+S_QYZ_._%ELZ=/
MNM/VF[['39_P7]'WPR;NXQ2/F\T^_(,<N>[_3P$^_5\`````__\#`%!+`P04
M``8`"````"$`1]W?_ZP"``"A!@``&0```'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6R455UOVR`4?9^T_X!XK[]B.VX4IVI2=:NT2M.TCV>"L8UJC`6D:?_]
M+B:A^>BT],48?#B<>^[E>G[S(CKTS)3FLB]Q'$08L9[*BO=-B7_]O+\J,-*&
M]!7I9,]*_,HTOEE\_C3?2O6D6\8,`H9>E[@U9IB%H:8M$T0'<F`]?*FE$L3`
M5#6A'A0CU;A)=&$217DH".^Q8YBI2SAD77/*[B3="-8;1Z)81PSHURT?])Y-
MT$OH!%%/F^&*2C$`Q9IWW+R.I!@).GMH>JG(NH.X7^*4T#WW.#FC%YPJJ65M
M`J`+G=#SF*_#ZQ"8%O.*0P36=J187>+;>+;*<+B8C_[\YFRK#]Z1;N7VB^+5
M-]XS,!O29!.PEO+)0A\JNP2;P[/=]V,"OBM4L9IL.O-#;K\RWK0&LIU!0#:N
M6?5ZQS0%0X$F2$895'8@`)Y(<%L98`AY&<<MKTQ;XDD>9--H$@,<K9DV]]Q2
M8D0WVDCQQX%B*\J3)#L2&'<D<?)ADLF.!,8WDJ3(XBS_OY30A36Z=$<,6<R5
MW"*H/!"N!V+K.)X!L[5G`B:[8+QA__(+8K0DMY:EQ'!E8+N&'#\OIDDZ#Y\A
M,72'69YCXF/$:H^P^01Y7B/8=JCQ_=3MI5BPE6+]M]J6;@&XO;;DY-QW$%,/
M.5("#EVNQ(+!S<.#T\CS.G$.DWJUJX.%HY/3CYQLP26&L'S(>7%RL(/D8ZZ2
MI$CRXC0;1X@BS[-IYCF.I,$]N-P4"SZ6=GKPTD&<M*LXBM)B4ISX!AW#TNPP
MTZA(H_BMWIPZUQ)<L0NF&K9B7:<1E1M[W1.(W*_Z3G2;V$R<K"^A0XWW.?0?
MH$,,I&&/1#6\UZAC-5!&P11D*==CW,3(8;QB:VF@-XRO+?P*&-1E%`"XEM+L
M)[;J_<]E\1<``/__`P!02P,$%``&``@````A`.DQT/05#0``[$(``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C$N>&ULK)Q=;^.Z$8;O"_0_&+X_L?5I.TAR
ML)'(]@`M4!2G[;7741)C;2NPO1_GW_>E2$J<&:YC!>=FLWDXI&:&%%^2DG+W
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MVY-!J#P3M777`_\Z3IZ:Y_77W?G?[?>_-]N7US.ZNT!$)K#;IS_JYK1!1M',
M3=JYL6EW<`#_3O9;,S20D?6/^VF*"V^?SJ_WTZR\*1;S+('YY'-S.NNM:7(Z
MV7P]G=O]_ZQ18ISJ&\E<(_CI&C&5+U3(707\=!7RFV51Y.42N;I4$:6=N_CI
MKY3<Y&FQ6';^7KADZ6KB9W_)))^7<4]G-DU=UNOU>?UP=VR_3S"4D8C3V]K<
M&,DMFO+IMA?N.^!G^4?.3".?3"OW4]R#2.T)@^;;0[%*[F;?T-$;9_,H;9A%
MY2U,5YAF:PX4!SH`,T34AX7N_Q/",JV8L+Q#CQX,<:8TRLI;^"HU!XH#'0`2
M`T8?CR'#_12_$WQ/F$H8\Z0GF(^/UB9=]'%5@M2"*$%T2(CGN`U"SR][;(PQ
M^I"%"X/'&J5TA&4L][U1GWQ!E"`Z)"0*W)/71V&,NRC\M1\M25=#E@6I!5&"
MZ)`0_W"[7N^?,:;^6<)2FK.4]D8^K%H0)8@."7%Y,<9E8TQ=MB1,J2"U($H0
M'1+BGUE%L-DP+6[0`R/G0],.==T2N!Z.\H)ENS?JLRV($D2'A$2#BX717+X-
MC3%UV9(PVX+4@BA!=$B(?PEFL]!!*SXW1C+/K]O-E\?6*G7$\0PBXZ3'-$(=
M[]J]GY:8GX(II63)=E:9E7ZK-[:M,NWO6>7;&I`F%6E`1H[8^$F*(:#?VS=X
M^MX4GEA1PXSHA\&C1V6GK>D\X2/'&61Y7Z<>Z@Q92%.F!<I7+&S+1;Y8T#QI
M;]$U3<,URG4AW.OZS\H?B=:AE8]6=)TUR,H@6HOR(6G*2`I&1IITS22K+&4+
M#NTL;#LT-*-M%T*[LB>M0I+8',(4&8Q-EO,JL5:D.P52WLKV79XO5DO>=V$E
M&J"1O0L!7M=W5CM)?`[AI@_B8WY5B;4B'6@1Z4"+2MP/05LK'F/DBFDZ"!D-
MVZ@I"QL+(3O?7-FI5I!)T`Z%G5K.Y]31RFQC,!Y)IPJDO)7KU&R^9.UH;Q&Y
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M,E]FG2B,3;Y3]S`$BUCR^3+5',69!>AP!%!+I"32!-&HC'H&4;V3?*NU9-A8
M%/A4I0+5$BF)-$'432-6@9LF^=G2G-B.'OE6]D@(%K'D<RDVJSJ>?(&4M-($
MT:B8T+Z3?"FHYK"%^E1)5$ND)-($43<C@OK!Y$M%-5FW(0S+F7+.%BO58#5,
M^'U%CY2TT@21J,S19SBD+B>_LZ:*ZA#&H'>@DJB62$FD":)NCE)4'#Z8;(:C
MVZ.?;O6=0;C&'.H,G2+7F+ZBVUFLTH*OA+0WD5N+;)3>=M8L+B?!/]W4NSKA
M]D$BY=&BV]3C`<MJQ>Y\[4VZTP':.4R-WQE#4G0SA_K.8=>NG`'I'%LG0,I;
MN9Y8)GG.UJ3:FT1Z8I3^XK)BA#G4]P2_>UT=TA.V3H"4MW(]L2I6&6M(>Y-(
M3QAI#`3BG9ZP0DIN$X?ZGF#'`E5F#>""O]UKB91'MB?PW&V>L8:T-XGT!!/C
M#YU?(J6B@QS"C-EO&;.<^56YBD&7U`Z%VVV'L)`V3^7RQ3)?B*%F+V<;HO>+
M$<R@E[H`\3B5G9=<OZ_.K`*3CG0(3O3!+ME`JEP]TIFN'G[T]2)SGK5R^^JT
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M:8)H3$;K@I@N3XF0#3&V+2*I%ZAV%0,K)9$FB+II).EZ-ZV`A3-W;A$;VTSY
MJL%J2'!?T2,EK31!U',C8]=[;D6/>&Y1D+HJ%ZB62$FD":)N&C4*W#1C>[GZ
MR`%%;G6-A."DCL[<_%#450P"K252$FF"2%3%*-GLK*EL.A3X5$E42Z0DT@11
M-R.RF:R2CV3?G*6R#;1#B"&<UOG!Z&#EQWDMD9)($T3#&J6;A=1-ATCVI6Y*
M*R61)HBZR73SXT._D)KJ$$L^/Q@=K(;D.TT=%FQ*6FF":%2C-+60FNH02;ZU
M"E`MK91$FB#J)M/4R_I32.5TB$WL_!ABL!H2;-L*%RW22A-$/1^EG(543H>"
M;%82U1(IB31!U$VFG-VB98Z[:.2BI9":ZA`;VWRK.E@-J7>:&HYM@32I2&,:
MI:F%U%2'2.JEIDHK)9$FB+II9"_0U'?&MA7)4#?-4T1SM@S7@@4YWVX.5D."
M^XH>*6FE"2*>EZ-TL[.FNNE0F&"):HF41)H@ZN:?IYOF]0NFFP[1X9WR_>9@
MY5-=2Z0DT@31L$;I)E[.$YX+D:R<5=`AM41*(DT0=9/IYN7A;5X^Y`EV$D>&
M-W\GK7(5@WFZEDA)I`FBGH_2QE)JHT-!-BN):HF41)H@ZB;3QH\O3$JIFPZQ
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MF3GA%R4Y2KJGP:*D0$GW`(^7E"C!&B'26EFBI'M`+NHL4-)]I"=*EBCIGCZ(
MDA5*NJ4*+UG,X5OW[2TO*5`'>Z.8;ZB#[4BL!!G%BCY6@HQB$1TK04;1/;$2
M9!3KPDA)@3HX](F5H`[.66(ER#7.,6(ER#6.#F(ER#4VX+$2Y!I[WDA)CCHX
M"(^5H`[.GF,ER#7.;R,E!7*-(]-8"7*-4\=8"7*-@[Y(28XZ>,(7*T$=/%2+
ME2#7>&@5*T&N\9PH5H)<XVE+K`2YQ@..2$F*[-CM#1^)*;)C;W5>DB$[>.DJ
MTEJ&UO`(/%:"UO"(.5*2HS4\U8V4I,@.WN:-E2`[>"DV5H+LX#W46`FR8Y_Q
M\WA29`>O3\;J8%3A%<1("0*-QHDPHU$FJ(#7[B,M):B"=]<C)2DR@]?%8R48
M47B+1);4R?S6?"8G2_"W`CY%<XFF8BT]FN1'VGE$ZF.9_Y3??HI/MV:\QAHR
M,T.,FSDXQM$775?,^O[#WQIX6[\T_UP?7[:'TV37/$-TYMUKQ4?[UPKL+V?W
MJ=_G]HR_,H`E+[ZMQU^5:/`1Q=R\0//<MF?_"S(WZ_].Q</_`0``__\#`%!+
M`P04``8`"````"$``MJIAVT#``#3"P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6R45MMNHS`0?5]I_P'Q7L`)(4T44K5;=;?2KK1:[>79`2=8!8QL
MIVG_?F=L0B&0VTL2)N-S?,;CPRSNWHK<>652<5'&+O$"UV%E(E)>;F+WS^^G
MFUO749J6*<U%R6+WG2GW;OGYTV(GY(O*&-,.()0J=C.MJ[GOJR1C!56>J%@)
M_ZR%+*B&1[GQ52493<VB(O='01#Y!>6E:Q'F\A(,L5[SA#V*9%NP4EL0R7*J
M8?\JXY7:HQ7))7`%E2_;ZB811040*YYS_6Y`7:=(YL^;4DBZRD'W&PEILL<V
M#SWX@B=2*+'6'L#Y=J-]S3-_Y@/2<I%R4(!E=R1;Q^X]F3^,`M=?+DR!_G*V
M4ZW?CLK$[JODZ7=>,J@VG!.>P$J(%TQ]3C$$B_W>ZB=S`C^ED[(UW>;ZE]A]
M8WR3:3CN"2A"8?/T_9&I!"H*,-YH@DB)R&$#\.D4'%L#*D+?S/>.ISJ+W='4
MFTR#,8%T9\64?N((Z3K)5FE1_+-)I(:R(*,:!+YKD'%T*8AO-V3T/5)-EPLI
M=@XT#5"JBF(+DCD`#PL")9A[C\FQ"TT->U5P"J_+:#Q9^*]0N:3.>;`Y\-GD
MD";#!]*&&=@N9\9D9,;2XE8>;*!-,QJF&5]#@\FQ"Y_-YJ-QU.!:9IL3FGYI
MZPFO(<)D*#FH:#$=EK).@FYM)4V;[72J"6UT>34QV;`WY:PCIN$ZN%$7%QM_
M!ALZW2>XJ(M?1]KG%8UOAZ5,NY2GJ3"Y2U5'^E+0C%NM;NXPF7@@_30%KNM2
MU)&NFMFPFEF7]305)G>IZDA?#8%3.)0SG:+]G)%C%G9)]J&.H#`8%D0@JTU\
M6I')/F!#``@-:#KP!#RB,)AYT#UG6&H[&'T8!-XMR]*Z/>$1+R)7N83)/M!D
M76%(TX$OF+:+P+C/:FH\HKFEI`YUS^F(\>'[Z8ISPNP#375HX)P&7(%,QM[T
MO*B^-9`A;PC'1YKO*G,@?7?8AP9$#?C#9<W7-P@RY!!A>$33519!^AZQ#_4U
MP4S4Z8&++Y19V&V'?:C;?!_O+/O:L".4'3$*)C?L"\MSY21BB^/1"(:&)MJ,
M;O?FVA[&P_D]4$+O^\T_,%)5=,-^4+GAI7)RM@;,P+2=M$.9?="B@KW#8"4T
M#%/F9P;#,X/!(<"+MQ9"[Q^0H!G'E_\!``#__P,`4$L#!!0`!@`(````(0!6
MK8'?\@(``(((```9````>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;)16RV[;
M,!"\%^@_"+Q'3S]BP7+@-$@;H`6*HH\S+5$284D42#I._KZ[I"Q(MN,X%]E:
M#V=VELNEEW<O=>4\,ZFX:!(2N#YQ6).*C#=%0O[\?KRY)8[2M,EH)1J6D%>F
MR-WJ\Z?E7LBM*AG3#C`T*B&EUFWL>2HM64V5*UK6P"^YD#75\"H+3[62T<PL
MJBLO]/V95U/>$,L0RVLX1)[SE#V(=%>S1EL2R2JJ(7]5\E8=V.KT&KJ:RNVN
MO4E%W0+%AE=<OQI2XM1I_%0T0M)-!;Y?@@E-#]SFY82^YJD42N3:!3K/)GKJ
M>>$M/&!:+3,.#K#LCF1Y0M9!?!^$Q%LM38'^<K97@^^.*L7^J^39=]XPJ#;L
M$^[`1H@M0I\R#,%B[V3UH]F!G]+)6$YWE?XE]M\8+TH-VST%1V@LSEX?F$JA
MHD#CAE-D2D4%"<#3J3FV!E2$OIC//<]TF9!P[LX#?Q'-@67#E'[D2$F<=*>T
MJ/]94-!169*P(X'/CB2:N=.Y'P6@^0Z)9Q,R_AZHIJNE%'L'F@8D54NQ!8,8
MB,\;`B>(72,X(=#4D*N"77A>S<+;I?<,E4L[S+W%P+/'!#W"`]%>&=2N5T8P
M*F-I,95[&QC*A.=EHH_((#@A\.R3GX6+GM<J6\S$],O0S^0C0@B&DH.+@=)Q
M*2UH.AN"(K]/9U1-Z(#KJXE@H]Z7LXM$)ZY`?,AK&C^8NH"_W"JX;BS1189;
M-HO>Z(WY6/6R%(+'4EW$')]1E7`>#[H=W2Q@&%SFQT5C_BXRMO)&_RW&DI>E
M$#R6ZB*G5@+(^]C+?([CYQT[9N%8Y!`:&XK.=UH`J*'P94<&?:2&!!`ZX^EH
M)N#^7.>I&P?F"K#'%,^651D<L6ARY,E.?#L1:R8+]H55E7)2L<-I'L*,ZZ/]
M3;,V*L?Q2;RV-Y#7_P(W0$L+]H/*@C?*J5@.G+Z+(U_:.\2^:-%".6"$"PVS
MWWPMX:YG,.=\/&FY$/KP@K=4_^]A]1\``/__`P!02P,$%``&``@````A`(!7
M17G?!0``M14``!D```!X;"]W;W)K<VAE971S+W-H965T,S0N>&ULK%A=CZ,V
M%'VOU/^`>-^`S5>(DJPF!-J56JFJ=K?/#'$2-`%'P'S]^UYCF_%')I.I^C*9
MG%P??'SN]35>?GUI3LX3Z?J:MBL7S7S7(6U%=W5[6+D_OA=?YJ[3#V6[*T^T
M)2OWE?3NU_6OORR?:??0'PD9'&!H^Y5['(;SPO/ZZDB:LI_1,VGAESWMFG*`
MK]W!Z\\=*7?CH.;D8=^/O::L6Y<S++I;..A^7U=D2ZO'AK0#)^G(J1Q@_OVQ
M/O>2K:ENH6O*[N'Q_*6BS1DH[NM3/;R.I*[35(MOAY9VY?T)=+^@L*PD]_C%
MHF_JJJ,]W0\SH//X1&W-J9=ZP+1>[FI0P);=Z<A^Y=ZA18%]UULOQP7Z69/G
M7OG?Z8_T^;>NWOU1MP16&WQB#MQ3^L!"O^T8!(,]:W0Q.O!7Y^S(OGP\#7_3
MY]])?3@.8'<$BIBPQ>YU2_H*5A1H9CAB3!4]P03@K]/4+#5@1<J7E8OAP?5N
M.*[<()Y%B1\@"'?N23\4-:-TG>JQ'VCS#P]"@HJ3!(($/@4)]F<H]&/&<65<
M*,;!IQ@'_UV)![9QLO`IXE$RP_,(11\]*18CX5.,#&8ACI+Y*--^I,>7:5SU
M;3F4ZV5'GQU(95B(_ERRPD`+()/+S1DF`]Y;?UAX1G+'6%8NU"`L;0])\[2.
M4[3TGL#H2L1L[!@C(I,1S%5&NS6!W`0*!?!`T20+[/\?9#$6)DM.:".!-YU8
M5YG)"#ED:P*Y"10*H&F`[#,U!%!/ERM!.L$&0<XK3D3SN3['#8_!R:0KLY"M
MA>064JB(-G/(>G/F.)I-M7-S6C$>2$Q8("6OC!7?\""<*D%1&NF2LREH\L5"
M<@LI5$03"%)4@=<M8<&C"OGL#4=@RA+)+&1K(;F%%"JBS0\J69T?K^I9`O'#
ML:X>-I1O@1?F'4#U\IIF'/JT.1*#[9,=41H;*\V#`KZACE4LAN%);6XAA3I*
M4Y)<5_*=GF&.'Q4%(]&E""0>]RKL(S-?^.]!.,UY.XUX$X^QD8NY&!9QVBA,
M$GUU"I57T\G.+]8^_$G'&(<N4R"IE&F:Q7\/XC>9'`D5LSB"T<B!T@`;VW:A
MDFB:H"2O:;K-.T:BBQ((I(R2AL9"9SQ(-=!"<H%PM\(P28V-LE"':,H0[,/7
MI-U48".)+DU"\&!%FS&M3$2IM@E(]4U`,52'PI4:"7GIB1B'4Y0NF[5;(TNA
MC?!-Y38[$>_8L*?+O6\C(=70V/>G*8S;42:B5$=M*)>0\#3PYP9/(2/&TM;5
ML49LJ$/1)VN0-2LC7R6DFAK[1A5E(DHSE7-IIG)(,S7VC6VHN/3$]TUE;=R0
MC9,WV=+7VSL'X@<#F,6;QP)2/0[-FA7C-(O%.)9D\FAI;[MB8,BW<S1/8Z-D
M"HU:=YTU>4.^ZKJ4?Z%7PMN`;):('Q78PD_SC--`S^&-C'JW[8@`;04$L[IR
M%U:`1P4B[U,<^<;#"XU;7P)VCE"6X`.I_-2AN2N@=_L,>X.#JM"2VX)R&96,
MK2:,YVEJI$@A0\:.I8N`!?J$"!9M[+T"FLPQGITA'J"98T&YC!).S%$86DZH
MHW01['QPNQ/\-*$Y(:#)":,0,L0#-"<L*)=1PHDT2@.#J)`A%YQ@!X+;1?#C
M@R9"0),31M/*D#AR*,<S&\HEQ)V`EV,_,(@*&7*A&;#>KXCX3T=HQ`\0FC8!
MJ<T@"(UY96*@YA(?J#4##HFC69C,P\1*-1["B;14@TL<6R!<E1C=_/9=?R34
M2TI"D._3KFB^C68B2"TK.0X2<QIG[WDB2NSZ.$["P-QQV575N/$H!O.K)WX)
MTI#N0#)R.O5.11_9M1(KG`F55U[AX@Z(H)D9OVSC!;S+V#A<DMV-S<^(W\#E
MV?AB9.(8+M4N\&R"!;QD7^"'"4%'LW_8A`MX:;V`1PMX603<FYX,EV;G\D#^
M++M#W?;.B>Q!O3^V_8Y?N_$O@WC#NJ<#7)>!OW!)!->C!.YG?)8M>TH'^84]
M8+IP7?\+``#__P,`4$L#!!0`!@`(````(0#T!HF+60,``$8*```9````>&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;)16RV[;,!"\%^@_"+I'+UM^P7(0*TA;
MH`6*HH\S+5$6$4D42#I._KZ[I*U*5.HX.3B6.!S.SJYWN;Y]KBOGB0K)>).X
MH1>X#FTRGK-FG[B_?C[<+%Q'*M+DI.(-3=P7*MW;S<</ZR,7C[*D5#G`T,C$
M+95J5[XOLY+61'J\I0VL%%S41,&CV/NR%93D>E-=^5$0S/R:L,8U#"MQ#0<O
M"I;1>YX=:MHH0R)H113HER5KY9FMSJZAJXEX/+0W&:];H-BQBJD73>HZ=;;Z
MLF^X(+L*XGX.IR0[<^N'$7W-,L$E+Y0'=+X1.HYYZ2]]8-JL<P81H.V.H$7B
MWH6K-(Q<?[/6!OUF]"A[WQU9\N,GP?*OK*'@-N0),[#C_!&A7W)\!9O]T>X'
MG8'OPLEI00Z5^L&/GRG;EPK2'4-$&-@J?[FG,@-'@<:+8F3*>`4"X-.I&98&
M.$*>]?\CRU69N).9%\^#20AP9T>E>F!(Z3K902I>_S&@\$1E2*(3R034G]8C
M+UK$83Q[F\4WBG2`]T21S5KPHP-5`V?*EF`-ABM@/D=F='2Q_B]4B!%)[I`E
M<:'<(0H)^7G:S);3M?\$GF8GS':,"8>(](S`5("\3B-$WM?XNNMG*0A&*9@%
MU+8U+X"[TQ99Y[Z"F'>0@1)PJ*\$W9I`-5U6A)L2%P[I!,R6<<=O1!K,3%L7
MQ0'\#0&I`4QUF?:]F0X575:"8%O);'C0UF#F6LE\CDIL*08QE@*E_'YS<),M
MZ9_YQAR#,9(FR]A:3LWR6,]LJ.>R-0BV=2PL:PS&),DVY?6U0?',AWJN*Q[<
M9.M:6KH,YN1/$$VCT+9H@(@GRT4OJ0.-.+&L=O!V@>.FH4:H&TNCP1B-T3P*
M+6]3LSY.XG(HZ'(2$6P+L9K,UF#T0;JZTMZ+@14A_+#?[X7>96NP&L[V!((?
M4M<28!@,'4L[D-T.0^R3O21=]D2C;4&CWFQ:;\^5T[9Q0F#.#DZ_KHSU+EO%
MR!;3B/NV1`NK/^&<QR3WA)FQ;:9:3<6>IK2JI)/Q`X[D"#I9][:[+MSIVX+U
M?HO7"-UANP68XBW9TV]$[%DCG8H60!EX<^@YPMP#S(/BK9ZE.ZY@?NNO)=S7
M*`R@P`-PP;DZ/V`^NQO@YB\```#__P,`4$L#!!0`!@`(````(0`V2!6!V0(`
M`%$'```9````>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;)1576^;,!1]G[3_
M@/Q>P"1\)`JIVE3=*JW2-.WCV3$&K`)&MM.T_W[7.'$AZ;HV#S$VQ\?GGGM]
M65T^M8WWR*3BHLL1]D/DL8Z*@G=5CG[]O+W(D*<TZ0K2B([EZ)DI=+G^_&FU
M%_)!U8QI#Q@ZE:-:ZWX9!(K6K"7*%SWKX$TI9$LT3&45J%XR4@R;VB:(PC`)
M6L([9!F6\CT<HBPY93>"[EK6:4LB64,TZ%<U[]61K:7OH6N)?-CU%U2T/5!L
M></U\T"*O)8N[ZI.2+)M(.XG/"?TR#U,SNA;3J50HM0^T`56Z'G,BV`1`--Z
M57"(P-CN25;FZ`HO-PD*UJO!G]^<[=7HV5.UV'^1O/C&.P9F0YI,`K9"/!CH
M76&68'-PMOMV2,!WZ16L)+M&_Q#[KXQ7M89LQQ"0B6M9/-\P1<%0H/&CV#!1
MT8``^/=:;BH##"%/P[CGA:YS-$O\.`UG&.#>EBE]RPTE\NA.:='^L2!\H+(D
MT8$$Q@,)CCY,,CN0P/A"$F4QCI/_2PEL6(-+-T23]4J*O0>5!\)53TP=XR4P
M&WOF$)@-QAGV+[_`*$-R95AR!%<&MBO(\>,Z#>-5\`B)H0?,]3D&3Q&;(\+D
M$^0YC6#;6./KJ3M*,6`CQ:32:+NV"\#MM$4GY[Z"2!UDH@0<>K\2`X9R&1V,
MXU-3+&;NU&Y&"Y.3YQ\YV8!S!&&YD-,P<1%96RPF&9)U@4.,,QS.IIC-!),F
M<RCZN8-,Y$')C(TYEM';J3*;3F6^&&]E6DPZR%S@6;3(%D[!@-B,$5D2)UGT
MDM^)QF2J\6UM!CS5%D6GVBQF<;#0QS@<_TZK>X(._2QS<5B5MH79R]DR6;$-
M:QKE4;$S[2F"4]RJZYQ7D:F<D_5KZ*A#_PG<"^AH/:G8/9$5[Y37L!(H0S\%
M[Z3MB7:B13^TA*W0T,N&QQH^70SN4>@#N!1"'R?FEKJ/X?HO````__\#`%!+
M`P04``8`"````"$`[3\Z73X$``!%#P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970S-RYX;6R45]MNHSH4?1_I_`/B?0+FVD0AHT#5,R/-2$='Y_),P$E0`4>8
M-.W?S[:W0\#07/K0%GNQO/;%RWCY[;TJC3?:\(+5D4EFMFG0.F-Y4>\B\]]_
M7KX^F09OTSI/2U;3R/R@W/RV^N/+\L2:5[ZGM#6`H>:1N6_;P\*R>+:G5<IG
M[$!KF-FRIDI;>&QV%C\T-,WE2U5I.;8=6%5:U"8R+)I[.-AV6V3TF67'BM8M
MDC2T3%O0S_?%@9_9JNP>NBIM7H^'KQFK#D"Q*<JB_9"DIE%EBQ^[FC7IIH2X
MWXF79F=N^3"BKXJL89QMVQG062AT'//<FEO`M%KF!40@TFXT=!N9:[)('&):
MJZ5,T'\%/?'>_P;?L].?39'_+&H*V88ZB0IL&'L5T!^Y&(*7K=';+[("?S5&
M3K?IL6S_9J?OM-CM6RBW#Q&)P!;YQS/E&604:&:.+Y@R5H(`^&U4A6@-R$CZ
M'ID.+%SD[3XRW6#FA[9+`&YL*&]?"D%I&MF1MZSZ'T$RHH[$523P5Y$09^8\
M^<0/;K-8J$@&^)RVZ6K9L),!70-K\D,J>I`L@/D<&>KH8OTL5(A1D*P%2V1"
MNT,4'.KSM@KMIZ7U!CG-%"8>8\@0D9P1HA0@K],(:>MKG,[Z68H`"RFB"D);
MC`/`W6ESM'4G$&$'&2B!#-VO1(!ES;N%0WO>\:(XQ`0R98$;N*$W!"0(\'KJ
MW8O\@3;`]+6)2KK0Z=>S)5[2-!)[*"%&3"@U^L0+G(L`&42"`$]NH7[=H+?[
MBJXK$6!=B=8@,6+D0KAR;V"0B^"1E0586WE4)\1@#@);_`R3E"!@G(/P$24"
MK"DA6K)CQ*AJ3`C!^;$0<1;U-OKU8@BP+L0=1APC!H6X_E1.$#&6,G]$B@#K
M4K1-$B/&EQWJ.?9<FT]P?BR$P/[H)^6^/2/?TB7Y6G84"-/C$)_,]8Y1B`E5
MP@=[I1*J/.CTZR4CZ)X$S.SB-R3092$*=FP'<CS-E!)%Y82C'2W8^])N2%+&
MZES,6!)`.-U(HD:F%M/<5IY-[NU$H&4";W<$D+&+.OZH'@B:$B(,3BO(;6LE
M:(O#>ES.%?1_!<(V(63*715DHD^$^STN"SUS*&MT5B-(;6Z7!(YFQ8GX_(%]
M.:%*\]X[NW?"A(G6ES'IF2SZ?W]D<`"0AWQ7HO4=K?N=`ETS/`692,I#[DNF
M[%?SM%B!SJ;G!:-^_LQ^B>:_=U9HPH@=;<U84@^W]V?>ZVC>>]U*)/I6A10(
MOZ;"R2-)0<85<C33O2$';72XB?0*2<K(_+Q""M`3@S<0_$"O:+.C"2U+;F3L
M*&X7'AQPW6AW\UE+H]/&8[@1R>N#-KXF9+$&.P1KU&;`]>$5.6-U4W").:0[
M^BMM=D7-C9)N088]"V'S-W@-PH>6'>158L-:N+[(?_=P7:7P_6W/`+QEK#T_
MB*_[[@*\^@T``/__`P!02P,$%``&``@````A`(HNQXGP`@``!P@``!D```!X
M;"]W;W)K<VAE971S+W-H965T,S@N>&ULG)5;;YLP&(;O)^T_6+XOQP!I%%(5
MJFZ55FF:=KAVP(!5P,AVFO;?[S-.*(>NJYJ+!,SKU\]WR,?VZJFIT2,5DO$V
MQJ[E8$3;C.>L+6/\Z^?MQ1HCJ4B;DYJW-,;/5.*KW>=/VR,7#[*B5"%P:&6,
M*Z6ZC6W+K*(-D1;O:`M/"BX:HN!6E+;L!"5YOZFI;<]Q0KLAK,7&82/>X\&+
M@F7TAF>'AK;*F`A:$P7\LF*=/+LUV7OL&B(>#MU%QIL.+/:L9NJY-\6HR39W
M9<L%V=<0]Y.[(MG9N[]9V#<L$USR0EE@9QO09<R7]J4-3KMMSB`"G78D:!'C
M:W>3KK&]V_;Y^<WH48ZND:SX\8M@^3?64D@VE$D78,_Y@Y;>Y7H)-MN+W;=]
M`;X+E-."'&KU@Q^_4E96"JH=0$`ZKDW^?$-E!@D%&\L+M%/&:P"`;]0PW1F0
M$/+4_QY9KJH8^Z$51([O@ASMJ52W3%MBE!VDXLT?(W)/5L;$.YGX0']Z[EG>
M.G"#\/\NMB'J`[PABNRV@A\1-`V<*3NB6]#=@+..S(?\&(XAUG^%"C%JDVOM
M$F/H=M@NH3R/N\ASM_8CY#0[:9*E9J9(SPI="L`;&"'R,>/K63^C:+%&T570
M;(E9`.^!S9N2I:\HHD$R(8$,C4G.V7J;2&^*,1SR`A#,$!*C"?O4A7[H1ZL!
MH(\B-8+5R,1_\9@P@F;,^#:;%D_9(G=6EL1H5D-&T]'"Y&3HY?')[\N.WC0E
M\!;9,9K(9,?1GUEVC*!'G!"%'R'2F^9$_O3`Q&@,T6KMPW]P*DB-8$D4?81(
M;YH3S1HD,1I#Y+NK<`YDGB^!]"MJ-`#>;A<MGH,$T\@3HS&M[+I`XKTTJNEE
MHQBAF,%KYE)#14E36M<29?R@AZH'=1]6AWE_[>F&G*TG\![HIZ8]/(`YW)&2
MWA-1LE:BFA9@Z5@1M(PPD]S<*-[UTW#/%4S@_K*"%RZ%$>)8("XX5^<;/:"&
M5_CN+P```/__`P!02P,$%``&``@````A`#CIQ\Z.`P``#`P``!D```!X;"]W
M;W)K<VAE971S+W-H965T,SDN>&ULE);=CJ,X$(7O5]IW0-Q/P.8OB9*,!EJ]
M.]*.M%KMSEP[X"16`T;8W>E^^RV[Z'0P:":Y24)\./ZJ;)=K\_FUJ;T7WBLA
MVZU/%J'O\;:4E6B/6_^_?Q\_+7U/:=96K)8MW_IO7/F?=[__MCG+_DF=.-<>
M.+1JZY^T[M9!H,H3;YA:R(ZW,'*0?<,T//;'0'4]9Y5]J:D#&H9IT##1^NBP
M[F_QD(>#*/F#+)\;WFHTZ7G--/"KD^C4NUM3WF+7L/[IN?M4RJ8#B[VHA7ZS
MIK[7E.NOQU;V;%]#W*\D9N6[MWV8V#>B[*62![T`NP!!IS&O@E4`3KM-)2`"
MDW:OYX>M_X6L"Y+ZP6YC$_1=\+.Z^NVIDSS_T8OJ+]%RR#:LDUF!O91/1OJU
M,G_!R\'D[4>[`G_W7L4/[+G6_\CSGUP<3QJ6.X&(3&#KZNV!JQ(R"C8+FABG
M4M8``)]>(\S6@(RP5_M]%I4^;?TH7219&!&0>WNN]*,PEKY7/BLMFQ\H(H,5
MFM#!)`+Z89PNZ#(A2?IKEP");(`/3+/=II=G#W8-S*DZ9O8@68.SB2R%_,Q'
M!B&9=[Z8E^RKH%:P'"^[C-)-\`(I+`=-/M4XBF)&D5U,`N"[0$+HUY`_AS/B
MK0^?%[CHP];RYRA)+7D4D922R[Q64*`@OO;XH!^A0<YN1S/B,5I&G*ESU,1V
MZ4VRBZL_1C,#W>TS&_%X9KH:QYRC)+-)B5?+CW@Q)3ALN488L(%OQS#B,0:<
M`(<#-<B1+&,:CL<+')^"I/>`&/$8A*;.1#EJ$"0*:9(Z(#@^!<GN`3%B%\3=
M$JA!$$HBLG)("Q1,2<S]<W6X?WYNC-@E<39!CIIAC\0)<4%P?`JRN@?$B%V0
M:)S['#4(DB:K,'1)4#`E(5#<;L^)5;LLL<,RB!"&A"2,DN584@R2&9R9^AO]
MNOYBZ;RN<31USQ%!T8`%'4/LG/AB4,Q0F?IW\\8A6"W'-,YAR0?1>Y*R*)SD
M"&UF:.ZJL61:9&GJ7@"#"&DHS:+$412#8H;&J;OFQKQAQ68*<.ID("?7)3A;
M1F'H5()B4,Q0W56&3>_B'+')'3EH,$6SE^2@F(&YJQ1#X^;"T-39JOD@PBN;
M$!*G;L-A&D#C<X6#_1RV.QT[\F^L/XI6>34_P**%BPS2T&,WAP]:=K:MV4L-
M79C]>8*NF\,U'"Y`?)!2OS^8?O'2Q^_^!P``__\#`%!+`P04``8`"````"$`
MA:O`)[TD``!IS0``&0```'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6RLG=ER
M'#FNAN]/Q'D'A^Z/7/NB:/>$5;G7OM>MVI;;BK8MAZ2>GGG[`Q;!)(&?KBJY
M>R[&ZH\`,@F"3`*YU"__^L_7+V_^??_T_/#X[=U5\[IQ]>;^VX?'CP_??G]W
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M^?C?Y/[Y`[F4S%RWNL;2A\<O=`+T_V^^/IC8()?<_>?=58L._/#QY?.[JW;O
MNMMOM)LD_N:W^^>7[,&8O'KSX<_GE\>O>RO49%/62)N-T+]LI-F^[C<;PW:?
MC)Q0[+`B_?OS1Z=#'+M`_[JCMZX[K6Y_<.S#B</W6)/^=9K]RS3[K$G_LN;P
MNMEI](S33AR0IMWQ5.E?5NM<MP;=9O><XI`5Z5]6;`TNTVQ22!V/:?YPO6SX
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MI!ID&N0:%!J4&E0:C#68:##58*;!7(.%!DL-5AJL-=AHL-5@I\%>@T,`WE(0
MU)%`<?M/1((Q8R+!C>&M`SXT6FK8G813231(-<@TR#4H-"@UJ#08:S#18*K!
M3(.Y!@L-EAJL-%AKL-%@J\%.@[T&AP"(8:?%1PQ[?`OFYKF1IJ6"C`43O2?'
M\]8*M6CAKH7:P[X4&M5"]:@#28%D0'(@!9`22`5D#&0"9`ID!F0.9`%D"60%
M9`UD`V0+9`=D#^00$A$*M/R_(A2,]#$4W`#>6D+C[L@(2`(D!9(!R8$40$H@
M%9`QD`F0*9`9D#F0!9`ED!60-9`-D"V0'9`]D$-(Q"#3UE$,LKW@7YM][LOG
MAP]_W#[:Q"FR#K3IPFXO]\:(''M+VBT_]I9T_)4@L:1+IQ:L"P.Y+J2UD`NB
M#`SE0(I:*S0]E*;+6LB9KL#0&,BDUO*F.XV&-#VMA9SI&1B:`UG46J%IM2E:
MUD+.]"HT),:6]O8GQW;S^)U&[=Q>SEB1@VM)CQ*`>N`Z#7T5MT+M8]7`[MZ`
MI$RZQQUBL]T:](?*DQDHY4`*2TPJ4Y]/JZ7.I[1"W?[Q6-WKMO)K!6;'0"9`
MII9T;%'"[%%G(#,'L@"R!#NK4$:,*KE=C&ID9E("[Z:FD9:C9TDOW)QW&FT9
MP",KU.[5\S<!DC*Q'FUUNH.!NO)GH),#*2PQ:=V)P;-"W<%Q\'K7;95+5&!V
M#&0"9&I)SU^@9B`S![(`L@0[JU!&#!YY_16#9Z3EX%FBIEY'#9X5"J<>D-02
MF@[>[9V&<FMFA=3$4D?+P7815=/SL3X!DQVVK]7B7('5,9`)D*DEX70$F3F0
M!9`EV%F%,F)$*7#%B/[4!=08D0-MB9JE:GZ-K%`X2RWI^.MNRH9HF:_G5Z>A
M=M^9%5*34`\T'*V(JNF!MD+UW.VI*WP%9L=`)D"FEH1S%V3F0!9`EF!G%<J(
MD3:U1QQJ*C23:\U6R5U.+]\W'2W*<6>D9KCRV8BEPBGN%/T%-V74Z=GK:Z,U
M;'7T]14MY8@*1FHET"/-4O4UMJ\BJ$++8T031%-IN7>M5ZH9ZLP1+1B=[L;2
M*=IM2:O=;39U3U9.YNAM&26FH`(EM+\5);9$0UFVV_+=FEHV+1AJ>5!KZ(BE
MPO6!4?]X/^:X+4L9=9K'*.E3)7^@KP-H*$=4,%*K"`2)/75>#[IT0T=>O2JT
M/$8T031EQ)8[U[K&,$.=.:(%H]/=6#I%WOTT!HWN4(7[RLD<=U$R2$SYY9\-
M$EO0$4%BD5Q*FFH!&)GB#8626$I8,5Q*+.*E9#@<-G4]-T-#.:*"T>DI6+*4
M7TETC,!)C_%8$T13;7BH5M89ZLP1+1B=[L72*;J%I#GL:*^MG$QD(3&%&8B1
MKD_-W?7F=`)@[D39O87?`/3Z:@-PRU*B2-=IJH`>>2FW$B6(4D09HAQ1@:A$
M5"$:(YH@FB*:(9HC6B!:(EHA6B/:(-HBVB':(SH()-<74^\)8^=,C-CR$,6B
M&]=;<Q>2PB:LWB%*$*6(,D0YH@)1B:A"-$8T031%-$,T1[1`M$2T0K1&M$&T
M1;1#M$=T$$B.OJD(A:/_4SF)N;UL%PX?%&&IZ;A[&+%46-=CU+<;BE9#+R.I
M%W"6,S23(RJ\HDD:R;(J6Y1>P%FNA!GI)E-BT6YJF8PXW,V?F3FV3"-F#B/Z
MQV=<3;7+&9E+A[[L1A2ACI6R8GUIU(6N#"WGB`I&YI_Z+.%@)4OQP6C?K:X(
ME;`LO6MJ(*%WSSC2EDR$(QE10E:?8J>I<V#S'()Q9%"J0I0RHKUA:$M=!3-4
MS!$5B,JX>;6WJ(2B=)8I+[S"6;8:(9S%*!S/3A,R`BLE-GN`4O-X!KF41CUP
M5DMM'#.6"FSEB`I$9=R\KL<*1>DLDZ&_PEDVH1?.8B0B2T^DD<D`=&0!2EE*
M1E9++4P9VLH1%8C*N'F8AN%Y"6>9IUY>X:RCN*Q(."0B2V=M(Y8*HB%!E#(2
MD=5NJJ'/4#%'5"`J+S)?"47I+)V[GUZS6IB8,PJW38@21"FB#%&.J$!4(JH0
MC1%-$$T1S1#-$2T0+1&M$*T1;1!M$>T0[1$=!)*C;Y+*R]<5\V07+0_ANL)(
M9E$M?<7R4FZ3DB!*$66(<D0%HA)1A6B,:()HBFB&:(YH@6B):(5HC6B#:(MH
MAVB/Z""0#`B=@9]9#NI,VXWKK7F6CV)$+`>`$I1*$66(<D0%HA)1A6B,:()H
MBFB&:(YH@6B):(5HC6B#:(MHAVB/Z""0''V=0_]4%F4>HM2KA$5!RC1BJ0`E
MC'Z<17D!%VX9FLD1%5[Q!UF4%W"6*V%&NBF6;+XRBS(/G&LG,1*[#LBB6%'L
M.B**D-BDK%@G-MIRAI9S1`6C,UF4/%CWNJ=VAY6P++U+_7_--<F(JVL2(['7
MA2RJ9:7"+`I1RDCM=746A8HYH@)1&3>OLRBA*)UE4L%77,`YOPRJ7B9NC?_(
M&T'*J;,HEA)19Q4#E+*4V.MV6LI6AK9R1`6B,FJ^K9*T2BA*9YDD[Q7.LCFA
MV.TP$I$%653+2HG(`I2RE(PL_8Q.AK9R1`6B,FY>W9JJA*)TELFO7N$LFXX)
M9S$2D859E)4*PB@QFTD*R0"EC$1D1;(H4,S15H&HO,A\)12%L]JO2SF/XG+-
M8D3+HKL`C1`EB%)$&:(<48&H1%0A&B.:()HBFB&:(UH@6B):(5HCVB#:(MHA
MVB,Z""1'_W4Y=+O.H?V*V^NK-?^6I<QUTJ_+;749'7DI%S8)HA11ABA'5"`J
M$56(QH@FB*:(9HCFB!:(EHA6B-:(-HBVB':(]H@.`LD8>5VF38\1ZUT-([%"
M6*D`)2B5(LH0Y8@*1"6B"M$8T031%-$,T1S1`M$2T0K1&M$&T1;1#M$>T4$@
M.?HZK?ZIQ*J-V3:CGM_0C1`EC()<*T64,1)/IW?:JNZ:>RFWXA2(2D05HC&B
M":(IHAFB.:(%HZ#;2T0KKQ@NM.KFU=I+N6YO$&T1[1#M$1T8V5.5H7,N)[_L
MF0C:3,&"8I&('4`)*P9.3!%EC/KM>ON2(RI0L414.44ZE^#*ITJ*8R_E!F2"
MMJ:(9D[1G^H<T0(5EXA6J+A&M$'%+:(=*NX1'82B#!13!;A\P][FHH%?.6X9
MB8"P4@%*6$H$A)4*4,92?6\^1U2@K1)1Q<C4K8*`4#GXV$OY@(#SFJ+YF5<,
MS:MXFWLI9WZ!MI:(5HP"3ZP1;5!QBVC'2'E"G>K>2[E3/0A;,FQ,&>0586.K
M)F&>1WFN65J"&!DA2A@%,9(BRA@%SLH1%:A8(JH8*6>I??;82SEG3=#6%-',
M*X9AHZ)R[J6<^07:6B):,0H\L4:T0<4MHATCY0EUJGLOY4[U(&S)L'E=X:F-
MA2=&(FRL5(`2EA)A8Z4"E+&4ZJ`J/.5>RG6P0/,EHLHK!D.MGRL?>REG?H*V
MIHAF7C$TKVX1S[V4,[]`6TM$*Z\8F&\KYZR]E#._05M;1#NO&)COJ+/?>REG
M_B!LR>`RU;)P3?JY[3(7Z_PEZ+9MT?%53_>9ADY'%<5&7LJ=:\(HB+D44<9(
M[J`[*F?/O90S7Z"M$E'E%4-/JPWZV$LY\Q.T-44T\XJA>;41GGLI9WZ!MI:(
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MI3,'85D&X#]2ZN]@J9^16"592JR2776N"2JFB#*'_-=J<H>&]AL4`]@Q.@$_
MYTM$%:(Q(Y[@W6O]5LL$=::(9HQ.KR9S>;!.XUI_M&.!II>(5@YY#ZT=^I&'
M-D[`>VB+:,?H=#_V+,5.B_3C($S+J#2%?4AE_LXKVAU[JR#,:A@%"^`(48(H
M190Q"M[:SAG1VF_V><W8N_T%6BH158C&C'C&X^OV$]29(IHQ.KV\S.7!Z/U6
ME<,OT/(2T8I1X*,U(_91[,WV#1K:(MHQ.MV1/4NQU_#-]H.P+"/2U.8A(E_]
MKB]]^(0OX'[7WNNKZ\XM2YD'>.J]?6^@+K(C+^72H@11BBA#E",J$)6(*D1C
M1!-$4T0S1'-$"T1+1"M$:T0;1%M$.T1[1`>!9.R8.PYA[)Q^2IU>X8=-GD7!
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M6W4OY6(D090BRA#EB`I$):(*T1C1!-$4T0S1'-$"T1+1"M$:T0;1%M$.T1[1
M02`9$#K-.Q,0=3KGQO6V:Y%8#@`E*)4BRA#EB`I$):(*T1C1!-$4T0S1'-$"
MT1+1"M$:T0;1%M$.T1[102`Y^CI1^ZFM>A?S-T9GMNHL1?M-%TT)([-5\?LQ
MV*JC8A97])==V>]S*<IE3PY0J0]V.HQ$C@*[=5845W]6E%=_M45*43%S)R$4
M@SM+LN,Z1SDSW3$=H5K2L<^R@WJ+SE*B@[%T1'_U+47%S!U1=O!'6W2SQ;^\
M]-#EO"%X!LDAV4'8ET,JD3A%<9[805#,HHJ]'^S+>SH'.3V"1W&Y&7=(=E!%
MVHBEPA%TBJ<[B(I95#'XZJX(T1Z9?\4('L55!XT%0K*#?BFP.W!6%!UDQ3,=
MM%*!8N9.0BK^8`=.CT^^JH-UBN%7Q-[`VS[VYO9H5&W+.OJKJ2,O52^XB%)$
M&:(<48&H1%0A&B.:()HBFB&:(UH@6B):(5HCVB#:(MHAVB,Z""0G`<7N:R:!
M$5>3P*)P6V:NQG;K[D<?4(I2&:(<48&H1%0A&B.:()HBFB&:(UH@6B):(5HC
MVB#:(MHAVB,Z""1'7V=I/[4MZV'RQBA8ND:,PCT8(Y,T^#V8OBF;>BD731G:
MRA$57C$TKZX_I9=RYBMA2SI,9S':89?MYWJ8W3A$6]S`%[Z.Q-<2JQC<^T]8
M,4"I0_Q44WLP'.J=8>9D_`WI'%'!Z/0-Z9*E:(-H;LBVK_6W]RIA63I4)P9G
M=AF8`?08T78G<!Q<A*U4<$LZ8<4`I0[Q`SB]SM`7HX\#D#D)_W!)CJA@=/JF
M:<E2M.TT;J.?=%1[OTI8EF[3><49MV'^8#Z-;59R\HMWF_X)FA%+!<&5($H9
MF00AL*5V#EGLB*V6WUX?'9RC^2*NJ$:F]"=AO:G?/*B$9>E-G:SH67W1+T&9
M+]+K:R,C$9LZID:L&`1BPHB>+G*+4LK([``#)ZM\*',G$1XQXF1[7L$1B[@B
M.-DJ<LBVX7FHBLU8R]+))A\)$Z:CD__.DR?T"QC@<$8RJE6,C5A11+55I)7?
M.]PBNO]X?,RDU:?-L)JA&5K*$17N1,.S@B>*2Y:J5U'E^TH8%JZE!S\BKGWU
M(Q1',\?-G8^PWD"=QBU+B;IL5S\7-_)2SI\)HA11ABA'5"`J$56(QH@FB*:(
M9HCFB!:(EHA6B-:(-HBVB':(]H@.`LG8,4EF."U/7TGHFVQZSC$*$P!$":(4
M488H1U0@*A%5B,:()HBFB&:(YH@6B):(5HC6B#:(MHAVB/:(#@+)T7]=B8!>
M0H71MX@R3#?11RP5O+&:,!+O97;U[^:E7LK9RM!6CJCPBG[EZNHGG$LOY<Q7
MPI;TC$E8PWGQ4WL"^@X".,PBX3"+Z&3<B26L2*F10RFBC%&@F",JO&+H'751
M++V4.V(E;$GOG$L<+\N#^I@Y,@HS1T0)H[[?AJ>(,E3,$16H6"*JA*+TA<X)
MSZR@F/N9UU#U7KRK?^=IQ%+AK@51ZI#-_0:M9D._GY`Y$1];.:*"D4@0<-/"
M4KQIZ5[K'P*JA&7I-Y.2A3/LC-^,N"P]T?`?$6W4ZBUQM^'KV39G9JE@LYL@
M2AF9>P"U+?RP'"KFB`I&9]*_BXY8"?/2?Z_+`?N8`SH4[DN[^@?R1BPEXL[:
M"E#*4B('[#94_2*+'1'3$SQB$5=4>]/2GX39LM-CR.KXE;`LO6DRFS`:?VZ]
MM_E1^#!\GY$,4EV?8"D1I%8QS`%92N2`D2"UBH&M',T7L?.*S&]KZ_2TJ(1Y
MZ5:31&FWMOKX2TZ7_W)@W^9EPL>,1"#K-]-&K!A$;<(H3/L8<=K7&S:&'76I
MS-!0CJA@=&X!M:?."RB^;U`)R\*W@UC:1Z^#T-5$/`EZN6N/%N4:ZQ"=9KTN
MTJ\"RD=:1RP5A%S"B#(/MY](&='#KF9ZXOLW&9K)$16(2D:4(KN#54)*^DVG
M/'JJ7[9Y&=2ID/=,;Z`*,K<L)=/EIBI"C[R4._\$48HH0Y0C*A"5B"I$8T03
M1%-$,T1S1`M$2T0K1&M$&T1;1#M$>T0'@63LO"YA&F#"Q"AXO6"$*$&4(LH0
MY8@*1"6B"M$8T031%-$,T1S1`M$2T0K1&M$&T1;1#M$>T4$@.?K_2%(XP*20
M47!S;(0H823NEW6;:H^3>BFWEF2(<D0%HA)1A6B,:()HBFC&*.CV'-'"*_J%
MMJOO,2V]E.OV"M$:T0;15B`9`?],XCO`Q)=1X(L1HH019>:NERFB#!5S1(53
MI'.I+^V=H4J?2B_ECEBAK3&BB5<,S.N[,E,OY<S/T-8<T<(K!N;UV2^]E#._
M0EMK1!NOZ,UW]0^!;;T4F9>!HJL">I-QT3VE`18+&(D'%[LMV)!9Q2":$J<8
M#G=7?[,^]5+.81FCP%:.J/"*WF$=_<VKTDLY\Q7:&B.:>,70O+H?,_52SOP,
M;<T1+;QB:%[-A:67<N97:&N-:.,5O?FN_O+-UDN1>1E-IM*!:93:Z)\NH`RX
M6N*KC+<.B;Q)WY(=L528-R%*&5$J:#;W'7HM6Z=-J)0C*A"5#MF:5F?0"IXZ
M/=9X*B?A2UIC1!-&IS.R*4OYDI;:TL_0\AS1`M'2H1_V8^4D?#_6B#:(MHR<
M]UO-X/HH(TE7C<RZ=-%K=`,L(#DDDD/X90>6$LDA%Y""^BU+4;K[P_@!I1Q-
M%XA*AVS>29>X;ELE8)43\2<T1C1A=+JP-V4IODE.-5$((.C('`^V0+1TZ,<=
M63D1WY$UH@VB+2/G_Q,19$I"X5IT9MFQ%:2P7#-@))<=M=B.6$HL.U8Q0"E+
MN<!OMINJ*)BAG1Q1@:ATR$[7;J_949>;RDGXZ3I&-&%T;MFQ?:N7'3V-9FAY
MCFB!:.G0#_NQ<A*^'VM$&T1;1L[[[6;;9R-RV3%EKC!H+E]V;(%,Q`\CN>RH
M*3T:6"FQ[`!*6<J%?;.M?UHC0SLYH@)1Z9"=K6WS;3A9-JN<A)^L8T031N=6
M'=NW>M7!^('.S_%@"T1+AW[8CY63\/U8(]H@VC)RWF]U@HJ]B)]AK-99O_-^
MT5[Z:$(6-QV2"Y$.))8*5IT$4<K(385F1W_,)4.E'%'AD']7J72(ORX4"20G
MX2?P&-&$T9F%B*5X(1I<JT5OAH;GB!8.^6XL'?IA-U9.PG=CC6B#:,O(.;]-
MDZV>:C*.HK7?O_,4VK`N`[N<X)91L/*,$"6(4D9!&3M#J1Q1P2@HMI>,^`M`
ML?L8%1H:(YHP.K/\L!0O/W@?8X:6YX@6C(*.+!F=Z,@*#:T1;1!M&5F'RT#1
MA5Z=OU]VDV!8%X!]XM<;J,SHEJ7D30+]>WDC+^4B+4&4(LH0Y8@*1"6B"M$8
MT031%-$,T1S1`M$2T0K1&M$&T1;1#M$>T4$@&3NZ3'QZASS$>C"C\)DZ1`FB
M%%&&*$=4("H158C&B":(IHAFB.:(%HB6B%:(UH@VB+:(=HCVB`X"R='7)>(S
MHX^EX*%%0<%MA"AA))ZI:P5I_[$RDGHIMVAD:"M'5'A%OW*!^=)+.?.5L"4]
MHVNB9SR#Q<\AE#5'B!)&TC.Z=IMZ*7?J&=K*$15>,?",-E]Z*6>^$K:D9TQM
M3J='S>`)[LMVN,:*VN%:)$()4#*TB'[I^%A[:34:Z@J5>@G7FXQ18#I'5'A%
M6];IZ1^<*+V$,UT).])1IG1RRE$77I9M!29,*H>,R!7UW9"N_E'9$4N)7""B
M"`_2I$[1)N']84O_T&/F)/SF-T=4,#J]AR^=HCW:H#7T:;DMF#J!X\&DATT=
M(O3PF4G*M9R@JCQD1/EFX$E]AX*E@DUR@BAUR.:>K<:PV^JJV,R<C,\^<T0%
MHM(A:[S9;;8Z^DOWE9,Y&I>.,OGT*QQETV\1<HQDR*GZU6AHI43(`4I9BK(V
M[W1\-`QMY8@*1*5#-J":W5XW>*V>0RH\*>&I9D-G[Z=CRLK+A:QF=)0@JE1I
M=>3$PK"*L+1F//:=7D.7:;-:)@BL""LBK*P9%TWHP^_ZQ=:JEL'8:C9TGGK.
M8YB%6AOD11E>:O:0QZQJ&%\11AYC.5Y3!AW]I"TY#$SE$48.`SERF&6G`YA\
M%JJJ*-,IVSF?U;F9N_#<TETK>PF54:9*(.0S*R:C#!CYC%D=97W]*71R&NB1
MTX"1TX"1TX3]08<*'VJ=)8^%>LIC.E'12>Y%VXYF`Q.8FLG@TS5^)R:#SYJC
MW^-QXT*.9&9K1X/^0#U`2VYDB>#R&6'D1K!.;A366\U.NZ]687)C:%^Y4>_X
MCV[\.T6E9@.S`L?,@XWU"CA0%W8*3:LI0Y,3BE`3MRA.E2LMK6ZOT]/Y!/D9
M[%.X`B,_7W),<CV+V8]YTPV$SK"O%G7R?6A?^5[G%#J$+]L0TFL2QXE/<Z7V
M;4]_UH26!Y;JUZ%)#@>61!B%,,B1,X&1,X&1,X&1YX"1HX"-(VP28=,(FT78
M/,(6$;:,L%6$K2-L$V';"-M%V#["#I*I`*(5ZA7;N&;#R!_W)D&DZ*\O4:18
M,5'2Z^DM``5/+>;6.@H>8!0\P"AX@%'P`*/@`4;!`XR"!Q@%#S`*'F`4/,`H
M>(!1\`"CX`%&P0.,@@<8!0\P"AY@%#S`*'B`4?``H^`)F0H>D_M=G@,T&YPK
M!MF28V&M+\(H+*QN($=A`8S"`AB%!3`*"V`4%L`H+(!16`"CL`!&80&,P@(8
MA04P"@M@%!;`*"R`45@`H[``1F$!C,("&(4%,`J+D*FP>%T.W6Q@$NU84%ZA
MU<+*!8S"PC+S9E-]Y6KI:A1%2BWF%AJ*E-"<ZH%)YL+`UI?5"W>&-B<,D]YF
MP[*@$]0Q8-0QR^BCDC^H'%&G:I&@4Z$IV:FF3D--I^J;R!=N%(Y&5&[J&"T4
M]1AT]6_9C.BWLHZ7#K'9C:E&MF8L5C\=`D^Y2..JWR9G"@?S3&)D/F:MZHA-
MQ\B[=1?IUY?JNZS'&@!UD=,SGS(G$98Z)MXKZS95;IHY,;N959TR:<UK.F73
M(!&*]!_'CH;CUM%;7NJ4%9/C!HPZ99E(8;OPS1`G9LVI3IDDPW6*SNK<0-F<
M1/:)F1@H_9@O]8G3&3%0P*A/EJF!4N-.`Q6JJCZ9S?LK^F3W^K)/S,0XZ0=<
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M+Y=&6KKD`_JB>JRE0RW1L^[2<>@*B3KOF^V;]^VH=ZCE0/,5=6Z;=)QXH+;(
M.ZUH3UODG5;,.[<M.@[=@XL<ITTC%SVW]S0\45MT^/C1Z1"1([RGSML5!`:3
MCAQ1N*6>QQQ,]Q)OS)U"[`3=!KPQ-_FPA6ZGD4YLB.EN&.G$6LP^[N:X2XO8
MHWV.:3N^W*K[0ZFM626BYS&@<Z=W"M`BO:QQ8U[%P!9ZS^+&O$6!+?2*Q(UY
M`0);Z.V&&_/N`K;0/6KR1,RO='N9/!%KH6^RW)@OCT2L]<D:?8<#6^@;'C?F
MHQW80N_,47]BUNBU,CKK6`N]9$5^BUFC5Z;(;[$6>MN)CA-KH1>5R&^Q%GK'
MB,X@UI+TZ`SL2^EJO.FCEC?FDY78TUORVVW4;_1!GIM1M(6^RT,>C?F`/KQS
M8SXO@\>A[^_<F*_,8`M]AH=&(38=Z1,TU!+3N6T/;D:VTJMZFE%+'FVIJ,7\
MNCV>`?UT_8WY87ILH5^=OS&_*8\M](/Q-^;GX+'EMMVG<XM=?S-JR:,M%;6,
MHRTS:IE'6U;4LHZV[*AE'VVY;??HW&(K248M>;2EHI9QM&5&+?-HRXI:UM&6
M';7L?]#2H99HC+:[=-:QE2*CECS:4E'+.-HRHY9YM&5%+>MHRXY:]M&6I$5S
MCIZ`P#@HJ*6,MMRVV]2?6%QGU#*/MJRH91]MN6UWR%KL##)JR:,M%;6,HRTS
M:IE'6U;4LHZV)'3!B(U.09>+&)_0Q2+&%W2IB/&D20=HQEH*:BEMR]MZ(7C^
M]9?O=[_?3^^>?G_X]OSFR_TGVF0WCM\.>7KXW23O]C]>'K_3YOOJS6^/+R^/
M7X]_?KZ_^WC_9`2H(O[I\?'%_0<-[]N_'I_^.&[D?_U_`0```/__`P!02P,$
M%``&``@````A`#S+!#W["P``*SH``!D```!X;"]W;W)K<VAE971S+W-H965T
M,S,N>&ULK%M;;]M*#GY?8/^#X?<36U=?D.0@D74981=8+,[N/KN.DABUK<!V
MF_;?+T?#D8:DXDO3EZKYQ/FH^<3AD))U^^>/[6;PO=H?UO7N;NC=C(>#:K>J
MG]:[E[OA?_[*_I@.!X?C<O>TW-2[ZF[XLSH,_[S_^]]NW^O]U\-K51T'P+`[
MW`U?C\>W^6AT6+U6V^7AIGZK=G#FN=YOET?X<_\R.KSMJ^53,VB[&?GC<3S:
M+M>[H6&8[R_AJ)^?UZMJ4:^^;:O=T9#LJ\WR"-=_>%V_'2S;=G4)W7:Y__KM
M[8]5O7T#BB_KS?KXLR$=#K:KN7K9U?OEEPW,^X<7+E>6N_E#T&_7JWU]J)^/
M-T`W,A<JYSP;S4;`='_[M(89:-D'^^KY;OC@S<O0'X[N;QN!_KNNW@_._P>'
MU_H]WZ^?_K'>5:`VW"=]![[4]5=MJIXT!(-'8G36W(%_[0=/U?/RV^;X[_J]
MJ-8OKT>XW1',2$]L_O1S41U6H"C0W/B19EK5&[@`^'>P7>O0`$66/YKC^_KI
M^'HW#.*;:#(./#`??*D.QVRM*8>#U;?#L=[^SQAY2&5(?"2!8P_)B8$!#H0C
M#O0A,$\,"'$`''%`=!/ZT63:7.Z)@3"99IYP;#UU\SPQ,,:!<,2!LQM_&GE1
MK`4Z,7""`^'8>CPY`&;>7"(<KYO;#`?"L?5TT=P\"#=S]W7<F3M[>G8C$SY-
M-"Z6Q^7][;Y^'\`2AP`YO"UUPO#FFM;&H1&HC<R/`A,B4K,\:)J[(2@`,7>`
MU?3]/IY.;D??806LT.91VGC4(K$6.MPU[8(#*0<R#N0<*#B@.%`ZP`AD:;6!
M9?$[M-$T6AL[JT<+=&+Y3`AK88<L.)!R(.-`SH&"`XH#I0,0(6"9$R'ZDY2-
M!6T-Z<B)A2C@L6!L_$DK2B*0A4!2@60"R052"$0)I'01,G5(6%=,75O#2@(=
MG74PI3?WT1CYL.I;HRB84:.D-6I#0""I0#*!Y`(I!*($4KH(D0-2YQ5R:.M&
M#CN)1X/`W"V2"&0AD%0@F4!R@10"40(I781,%+8-,E&3%V\F,.#XNEY]?:S-
M[MJS%`+(?R8K:A(Z?X.$73)(!+(PB!\V:32$NBRDL9&V!E;$3)#D`BG:43H[
MAU[,0TZU!I:V=$F(.K`WGE3GK_H-YGUNT]`L5!Y$P&^W-,(QG7YBC(*PC:&%
M0%*#A*9RTEM))FQR@10"48*G=&V()K#Y$4UZ(@,J#QL:VIK.W2`A+#UG[GR'
M-$9!W,T=B=QLXOML/TF-402'ECOP&'<FN'.!%`;Q3GI3QNBTM]+E)CH"-]'Q
MEU:>)J'R&B2$1-]*$(5,I\08N:&%2+=@4T1FS?+TIV,6GIG@R`52"%9ED!@J
ML/;RQ!TJ72*BF:[<I&C0$`"=SE9V/5Z>NAI&JJ"%X"K::XS"@*U.M')#%"'?
MG9R,46OE?22L9,XE5%B:D\X46L60H]JY2+T)/15<UXRR;N[V!ZOXZ2S@F=(3
M"@:;<Q\1<F(PD=!"0BE";LZ35KF$"@DIR542*ZJ%+AM=+<[,V5299,X(T<AB
MVUZBRRI8U"2R!)2B5=R5&)D<F$NHD)"27"6QHC+H&O(*&4S)"7S=K3<0RU$L
M32>>L7("9(&0Y^Z;/0L,!^I-Z/N]YXVG?ABQNC.3[+F$BHL<*CO0.)R.)U'`
M,VYI;9K=G.JIB]`K]#0U*]'30&Q+Y3G?,U8DK`246JM)(U[@P=,RGS4UF;7I
M=N=<0H6$E(4,N>\'P<2/:5XMK4U#3H721:PKU"_MF/KA$]LR$6+Q&-$+2]"*
MQ*/A"IQ=$ZW(!A>%;)*9O0@:R"P1Y-)C8:'.H^KWR.Y9><XC55H7Q$+I3VVS
MFI%MLPC19,B:R$2O=9X,#62>6C8-2(I6I[>Y3'+E$BH0<NC51?0EX:)ZZF+Z
M]^IIRG.2!1`"==JM/@I9WDL\MZ['AT\X$`[MP)ZL:JS"^,.R13#GTEF!D#Y\
M[$Q9*RB>6ZN>LL7U2`775;<0/+JZ;#'%N]X+V\N(ITS21\]8T0<=D=C.6BN[
M#RZZ@19*)91)*)=0(2$EH9)`5#%=<[N*G2ENM#E;SP9RGWGH_@FL'&@AH51"
MF81R"1424A(J"43FK`MU,N=?VE`:%BH%0H%Y"Z';\D1""X1./`#I+&R`9)(G
MEU#1#?SH(4AG8:E+PD.%^CU=@"^[``N1I!7QT@6MW*U70BE"$98N;/_.^EVQ
MMBZ7O(6$U&E7Y3E75%Q=VU^^\GS3"KB9WT*PVMHT%46LFDC0RJW_))0B1!YJ
M1)'0$B^">F153B[I"PFIBSR6:*47LS/'SB.55'<`5TAJ&@8B*4(T+EE1E?C8
M:3B/Z"24(@1QZ5XZ*W0RM-)%1.\$F[TZE_2%A%3G42]_]N"F[/?4+00JI6X1
MKI#2=!1$2H3HG6.;:`)9D-=Y$DH1@NCLF5B&9UF,=!-#"86G0GI2S-,-?_Y3
MGG-&5>2MR^G=5;^Y9;NKA4AXQ.S6)FA%$B7V*%V,IFA%`S)F!4O6ZS'J5ARJ
M*>@+>1&JWR-+\^4YCU124.*:P-3F;)=&B`1FS,(E\8T529L"2M'JH\#L\Q0Q
M3[GT5$A(G?14XMD/EP"54-?/5ZQM4VZ3M8T0S*]+6K'8>8P5B4H!I?"25-\A
M%I5BY^GS**-2T!=([UR$ZO?((KQ$JP\3,Y7T7.-QT?LT_2,3'JP(T6`5&Y*Q
M(L%J(*>=39&>=,M1+#:D/H]2:>&Q0'K'H^KWR/:`TDZ;S-'Q2)4&*Q*\3?'^
MF6<4NH'CJB-$XGLBLJZQ<D)K@5RQFW61"P3KUDHD5._SZ&B`65=X+*1'92?4
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M-Y[Y_LQC95!FC9S7)A(J+G*H[$#C<!+$X9AO):6UD6]2`EVT7Z&GJ?'=PJ]A
MN!O25R83-N,$K>!"[!I82"A%B!9^$U[XH14IPWR?><PE?2$AU>^1%W[G/-(0
MA05VC:3:G+8C$'4:HB$J:FFT(B%J!CI0:JU,>,3A=,PFEUD+-Q@%3R&ME(4P
MU"'.9VPG+JU)3^#INOR*P,-BWWEW'!B(!1ZO@]&*!)YH"5)K9=[;PE.N62BB
M3HS*[:@NJ`L)*0LA=QR$4\9=6I.&B`:3+JJOD`DK=5<F`]%@FK!B,X$7ESKD
MX'YUZU-`J;4R=]R/P]@?,Z;,VG1,N80*"2D+(;D?^3%/(Z6UZ8DG70>[0O%]
M\Z)V*S#5-,EO!F)AQAJ6!`>2,#,#X9*MI"E:D5?"XF56)KER"146ZNC51?2E
M'2B#+>PK[;W/-%(-(TUN"$W=7RM%4U;H)VCEQB-"3C.9(@0/V77MY87>-!A/
M>7Z35+F$"LFN&/LX&,_&O#<N"159NB$O\S_=EC:,3$UL#B!A=PU1S),@#G2C
MTT)=^*0(D>B4/UBP%^%ZE+NOI7=2HX4ZCZK?([OZ\IQ'JGIOH_&I&)9-!\1@
MLV?#"N]4G[+-+T$K$L-FH`Z:=J"L(7%@"#M.:R73A*3/)518KI,>E;4ZZ5%_
M'=9M$D9U\[67^;YF6^U?JJ3:;`Z#5?U-?\D%#Q_O;UO8?F8VG3^8SI6=@=?G
M<_U>&M*E.#.#,TVWR\X\!./Y`UQ7SQ@XHYOPOC/PI9OI#CF;!Y?6-P(&-`TF
MLW_TY_`%29\'<-"#/X3S!_A!0\^`$+Z]Z\.C.?Q@7]HOXCG\)E[B13R''[5+
M'-XPSU-XJRO/P`OBN>H]`TWS/(5&M6<,G%'FS*A5!#[5>UN^5/]<[E_6N\-@
M4SU#`(R;WUGLS<=^YH\C_E#^2WV$C_0@1N`++/@HLX)7XV/]$.FYKH_V#W`]
M:C_SO/\_````__\#`%!+`P04``8`"````"$`5H\H>'T+``#T-@``&0```'AL
M+W=O<FMS:&5E=',O<VAE970S,"YX;6RLFUMSXL@.Q]]/U?D.%.\;L`WF4DFV
M@B_<+W5JSSG/#'$2:@).`3.9_?:K=G>;EOY>$F;G99C\D.26U*U6&_OV]Q^[
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M!Z^_"KKUQOUM$:#_;;/WH_/_VO$E?Q\>MH^S[3ZC:%.>5`:^Y/E7)3I^5(B4
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M=F\;WVDY;HS,`&4\+A%9";7VE-E8@D2"5(*A!",)QA),))A*,)-@+L%"@J4$
M*P<T*/AE!FCF_(H,*#,J`S9V`PO.*?%%N*V$58DE2"1()1A*,))@+,%$@JD$
M,PGF$BPD6$JP<@`+=U`1[H!J1O4N8.>WTJ)Z[\SOP._Q<`ZTC-\I4Q`!B8$D
M0%(@0R`C(&,@$R!3(#,@<R`+($L@*Y>P<%-%8[/[<IB5-%4BRIU31V2<M9#:
M<TNA()"EI!0J)S>0!$@*9`AD!&0,9`)D"F0&9`YD`60)9.42%GH*T!6A5])%
MZ&W`!IJ85DB5XPA(#"0!D@(9`AD!&0.9`)D"F0&9`UD`60)9N80%E;;(*X*J
MI'E0-0ET4U@$%4ALM&@,S@07Q3L!M523T"_KSQ#("+3&0":@-04R`ZTYD`5H
M+8&L7"T69^H%KXBSDN9QUL2-,Y#8:/$X![RJ)Z"6:N+&&<@(M,9`)IKX5#J=
M-+?XY:>ED%V6,S`T![(HM5S3;6YZ60I9TRO7$,N&.@)CEWBC#ANGE^WFZR`G
M%ZC!J:CN`76#ND=41GB2-'&3!"36I$T[M!.ED+N2@%IJU*@X.FH=KC8LA6P$
M1F!H#&12:KFF1;,[+86LZ1D8F@-9E%JN:;'_+4LA:WKE&F)YH[/`Q;S]D;_]
M7=ZH[MO$*2L\<8;0ZBVCZW?%RHFT4-`JZU&L29LF2JD6M)H\*0FHI557\T4]
M'!HU->KO]^U>V&P*PR,P/`8R^<REIEJH3:O%<4,T(+-*2V)USV$`BTHUX>O2
MJ!E?VST_%+ZN7,-L1JAS,IL2%4O627TASG-O$5VB=-_OBN(2&:D@/&??H+;;
MW?E=N911,44TM*BCTXW)M@+GZX\131!-#6K3FBK="UHB`S,CY;$@^#*]:'Z!
M:&F1]H5N6<AD6H'"%YY-=:AT"_,'V=1G4.JO;>D8J)L?:G'SI2P*962DW+5L
M$%O,?E>4P0054T1#B\R$IFR*$(RLQ+F8C!%-$$T-$HM5E*J9D>)1P'3J6#E1
M6.`5EQ9I9UK-T!=K8V4E"F=X/M6IU<VGOAUSY4:KSD^B8%O$YFM7["R1D6*+
M5MOBB[8GTI.@8FI0ZSS7A@;Y7K%HNQ59UA=SKC]&RQ.T/#4HI`0YBU8LQYF1
M^FC1PB`6>,6E0<:7L-L6L5P9`>T+3[(Z+$.2Z=XK#5XU4W93_GQGY>GC-UWR
MO*XU<N9J9*0<%"-*$*76O+OA^;`!&ZE66&0W;/<J\@N#&N/E)I^ZW-1*\3HM
MEMK,2K'RA@L;QK6PBA=]7AHIZS/=QN^)2;<R(CKJ?!ZHDSO,@_9YL=N)\$%1
MUS<`U'PKYW[8$2MTH&XM4TV@K?TL%;3$YAN=I>Q$BA$EB%)$0T0C1&-$$T13
M1#-$<T0+1$M$*X9XCBA>+$<?Y$*)BW9)(_<VBKI9KW-QCC*@!*521$-$(T1C
M1!-$4T0S1'-$"T1+1"N&>)35;0!W)7P0924NHJQ1ZWS_.U*;.4DY*#:(';E]
M3U3NY"QETY,R6WSHZLQ\Q="5N!BZ1LXX(P]0;!`?NB]6>7*6.@_=M<6'KHZ-
M[M!_KMG0AT^V]VC$/`(4>QKYK6*_:-&/X:)T)F>)LS>N'>Z-.O)<\N:3U529
M$0DRB.9366#QM*NZ"E)DNVN5HMPW$ZNH^\4@[,@3<6HEL%_TKSO-%>+<.8MH
MJ(YS8AN-C)33F,6($H/HZ*3.X!UYCDF9"DL>M5$\>9<+0"$N_/C4.<8HNDE"
ME%BD,Z)^F>>W*%(K4)$0U3Q>FH6?NE/FZQ;475,6\3R)TA49*98G;<OIPQ,C
M15ZH/'E>2]R[2)D9GBC5*8%__Z1W515-+#B#G"Q%B&*K2/7M/'-A=1DITZ&U
MZ-`A>IZ4F>;._IH&C2J<\?`\T+`C8CXP4J)!DP?QLY0MB3&B!%&*:(AHA&B,
M:()HBFB&:(YH@6B):,40SY%JG-P)^4'ET'T66UG0>D4J"30GG9XM1I0@2A$-
M$8T0C1%-$$T1S1#-$2T0+1&M&.)15KV4&^6?:A5\W9&QX&L44A$H%W'0$G>1
M(J/H_%`0&^3\"I,@2IDB]TBU19<\^ER[0+_V0_4R2)^#_:8G=H_(Z#CE+;9F
M6(N!M4Q;#O2^1&>\KB@/*3/-_56-D^OO!^M$]UDL50;UBEV#_!*%-/*U`-M\
M`"562M_MK'3"5>).J(;J"B=,_^7<%O$-*I,C(A@9`98<K>.@Q$I=R(2KQ)Q0
M#YM<X40ASGL=B\I,R/5B!-Q,($HL,O?0.QU/W.5.K03>>*:E>)43ICMS,E%8
M(+_*3,A>Q@@X88\1)1;I3+2#;B`RFEH);-:"7]*L%59$@DS_1G/`J6K@H)9B
M6<)FS9@WS9K?ZWI=<4Y*C8@VQ.?:+V_7`FS7#'(2%2&*K2+5L#(F<!,Q,5(7
M;JBES#;W]M?T:^1(1;\FUL;`2*E*4/H3R"-/=)8J^S5$":(4T1#1"-$8T031
M%-$,T1S1`M$2T8HAGJ/K^C7:Z^3^:A`%WH8T0A0C2A"EB(:(1HC&B":(IHAF
MB.:(%HB6B%8,\2C+?NWR;D^5`Z)LD-N1!&UQ:(F,(J7;YB*VMES%BG6NS?.?
MY3QA/F7FN8.J%7([@9]J2`/3JKG;DD%\68O%'QE%&M_9;ZWHGK.-E"G=](QB
MZ(.'6DL;XAZJ+@@\_"<G;7JW`K)LD)NLH"U^'8V,(LNR4:3AE]6O(LM:RE3S
MZ@!H$6U;!T"_P*&?4M]EA^<LREY?C[5-_DV]G$'K_OZVQ.;-$;_5?Z!]@9(A
MOJ%C=5^='JN^:=,WQ7L>0N<A4-:*.\GB&RKZ](I*I;6`K-%ZQ.O02:6OCB;X
M#;WO\E#,/'D5>@^F>#Y0<I\&7&%G$-"E*_@#N4&_/N&%!^1%I1/D0Y4+#QY9
MHMLD%9;H&_7K"7Z3=OOT>!7R2;=/ST8A7W3[]&`3<KIGWU=WY*N^Z=`WQ=/6
M(E!T:YF^J;(V\,A%^AT"K:5AGQZ71#X)^_3X(_)%V*?'&9&GG?ZP:DR33I^>
MY4/Y1:=/#^(1;Y1.T#M';^OG;+X^/&_WQ]IK]D33OEG\+'C0;RWI/T[FX:TO
M^8G>-J(.E-[>H+?+,GI2MZE^3'[*\Y/]0UV@?%_M_B\```#__P,`4$L#!!0`
M!@`(````(0"M!JGY+QH``+^7```9````>&PO=V]R:W-H965T<R]S:&5E=#(T
M+GAM;*R=6V_DN':%WP/D/QA^/^U2W<OH[H,J2=0%"1`$)\FSQUW=;4S;U;`]
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M>SH]W_WR`WG_62SO[D/=PS^H^L>'^^?3R^GKZP=4=^,:RCGO;G8WJ.GSQR\/
MR,#*?O5\_/KI>E_<]L6BN+[Y_'%0Z+\?CG^\)/]_]?+]]$?S_/#EWQZ>CI`;
M'66[X)?3Z5<;VGVQ"(5OJ+09NN`_GJ^^'+_>_?;C]3]/?[3'AV_?7]'?*Z1D
M,[O]\L_J^'(/25'-A_G*UG1_^H$&X+]7CP]V;$"2NS\_72]QXH<OK]\_72_6
M'U:;V:)`^-4OQY=7\V"KO+ZZ_^WE]?3X/RYHR&BL!)%#)?CK*RG6'XKE;&WK
M>*/<VI?#7U]N_F$Y7VVVP\G?*+CQ!?$WG'#U8;M:+=?;S=NGQ,`?FHJ_XRG?
M57#G"^)O..7RPZ:8[19GSEB@3X=3VO\9S_E6FC>NCX8NK^Y>[SY_?#[]<86)
MA%YX^7EGIV5Q:VL+G>V4&KO_KWH?W6YKV=MJ/EU#`73L"\;L[Y_7R_7'F]\Q
MS.Y]S(%C"AE1A@@[IFRUE0:U!D:#1H-6@TZ#/@$WD&749O[_HXVMQFH3LCH$
M$,6:*R%"1"A2:5!K8#1H-&@UZ#3H$R"$6"@A\E>",!9L-.9\,A:*U4HF>'`Q
M\\TH2DFD(E(3,40:(BV1CDB?$I$Z+F)B?KR=NHW&3(*.XSPH5AN5NPN:IY.%
M@LHQ:!P"1&HBADA#I"72$>E3(N3`E7""'#9ZD",D<7!DOHO]3J0B4A,Q1!HB
M+9&.2)\2D2C6#Y&HO2[.5Q\0/_'*:"N2&C@"#=)!LI6#I!R#@G05D9J((=(0
M:8ET1/J4"%FP.@I9WIX.-EKF[DC:_T0J(C410Z0ATA+IB/0I$8EB=HI$+^Y_
M6Y'4P!'5_SO5_V/0V/]$:B*&2$.D)=(1Z5,B9,&@%;*\W?\V>L@]&>GKF<ST
MX(+DY5`'E6/0*`>1FH@ATA!IB71$^I0(.:QCFJ#'$"X'@T?IC&!4,:H9&48-
MHY91QZ@72.9L[9*VC(NMO1>8>FTLG//">AFZ]>"1F!WKI5I"RQ@5"E:,:D:&
M4<.H9=0QZ@62$EDCE4KT]C2Q?D%=(SP2P\)%):CBJ)J18=0P:AEUC'J!9,[6
M0J4YVROF>FE7S#/9.^^%FD-?'@J'W$WN<"=0>E3`F41KM5:^N0I1&%=)U&*\
MXL@66Y>3MOA,.YTI$NUT2+33HYA-9=N,[ETL;(*R!=9^3&B!#5>7#X=$"WP4
MSIIH0$KY**G4\B^4LGY@0CN=?1!*I8["]RBAJB!4,S*,&D8MHXY1+Y#L&VL-
MTISM>%Y!KHG^KW`60X@QNHZTA]0M4ND+BOD^%@Q3I>8HPZAAU#+J&/4"27VL
M1TCU.3-[G*6`#&G.M$7@C0?^)&-7197%&!5DJ!C5C`RCAE'+J&/4"R25L79A
M@C+.78@!X@U'<IM4$*H8U8P,HX91RZACU`LD<IYK(W2Q7QYJDA<YCX0G*-;:
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M:D:&4<.H9=0QZ@62$FF[^K8=P\Z[OI7P2`P+\IL51]6,#*.&4<NH8]0+)'.V
M/C`=%F=R=K91=+U#"[B7Z#<WZEZIM!<,>P,W?&SJ/IAB5#,RC!I&+:..42^0
ME&&:W[3C7-U%>B2ZGOTF1]6,#*.&4<NH8]0+)'*V/2:Z_O(KPE"5-)P>V=,G
MPR)N([@;V!@U7A$8U8P,HX91RZACU`LD)9IF.+&%H(>%1Y`A)%@RJAC5C`RC
MAE'+J&/4"R1SGF8E%VPE/;*R)ET?]T5\U[N"B`K*5+%@0#4CPZAAU#+J&/4"
M21FTNWS[PHB=*>IZAT37$ZI\P22J9F08-8Q:1AVC7B"9LW:,%]^!+D8S&7KR
MX)&Z(.@=FQ@5"E:,:D:&4<.H9=0QZ@62"DUSC@MVCAXE_5TRJAC5C`RCAE'+
MJ&/4"R1SSCG'[>Z2#RL6[!P]4L-";U?%J#@L7%V)D#5'&48-HY91QZ@72$HT
MS3DN1N>87B#59LS!1UG3DEQ&5509HZ(RWG(F&Q,<91@UC%I&':->(*F,]7WO
M]Y<+9Q-3?^E1TL\EHXI1S<@P:ABUC#I&O4`R9VTF+[^,LL]<C*8R'15ZNRI&
MQ5$Q%@RHYBC#J&'4,NH8]0()A9;:>KZ]N`[A:B.OV*CMF(./4O-%194Q*LA0
M,:H9&48-HY91QZ@72"HSS7$NV7%ZE,X71A6CFI%AU#!J&76,>H%DSMIQVOER
MP4;>DJVH1W)UV:I-K3)&Q3'AZDI4K#G*,&H8M8PZ1KU`4I]I5G3)5M2C))N2
M4<6H9F08-8Q:1AVC7B"9<\Z*KA<?XK=ZW_V]VB5[48_4L-#;53$J#@M75R)D
MS5&&4<.H9=0QZ@62$DWSHLO1BR8+QU;MTQQ\E+R(ZJ@R1D5E7/4H&%#-4891
MPZAEU#'J!9+*:,=Z9GEA5[HD<UDRJAC5C`RCAE'+J&/4"R1SGF9!EZ,%#=UU
M\$A-"KUC$Z-"P8I1S<@P:ABUC#I&O4!2AFE^<SGZS712J*V*@X]2DT)%E3$J
M*N.J%Y."D.&"#:.64<>H%T@JHUWIF4G!UG-)#K)D5#&J&1E&#:.64<>H%TCD
MO-(^\V(G/M0D=S@]4O-%;VC$J'%4,*H9&48-HY91QZ@72"HTS6]:5Z8_4B^V
MZF[]X*/4?%%198R*RKCJT_G"4891PZAEU#'J!9+*:%?Z]GQ9L?GT*#$+):.*
M4<W(,&H8M8PZ1KU`,F?M-"^?+VQ"5PZI^:+W,V)4'!5CP8!JCC*,&D8MHXY1
M+Y!42/O2,Z-B])YQ?5FH)?6P\J82*\.XT:.#RA@41*@8U8P,HX91RZACU`LD
M=9EF1E>C&0W9'#P2L\5[ROCA2<51-2/#J&'4,NH8]0+)G+7-O'RVL`-=C0XT
M#HIBJ_=Y8E30L6)4,S*,&D8MHXY1+Y!4:)HI7;$I]4B,"A>5H(JC:D:&4<.H
M9=0QZ@62.5N#E^YX7CXJG%5,-T-7WCW"B8V7BF*K][AB5!P58\&`:HXRC!I&
M+:..42^05&B:$UV-3C3)>:?V<`X^2GH.'57&J"!#Q:AF9!@UC%I&':->(*',
M6OO5MU>7(5R:4H^2R5$RJAC5C`RCAE'+J&/4"R1SU@[4SI?+OIBT'MUIZ-V#
M1]`C'3QZIR=&A8(5HYJ18=0P:AEUC'J!I$33K.AZM*)ISGJGQT>I":.BRA@5
ME7'5IR:=HPRCAE'+J&/4"R25T8;US(1A5[HF<UDRJAC5C`RCAE'+J&/4"R1S
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M"%]'#TTO&56,:D:&4<.H9=0QZ@62.=NU<,)`L>%JH#BDEDY]Q[X9HX(R%:.:
MD6'4,&H9=8QZ@:0,TY9.^W&LEH'6R=)'):MIQ:AF9!@UC%I&':->()ES;NFT
M&\,3?Z:ZX;74(S4F]/UZC(ICPM652%9SE&'4,&H9=8QZ@:0^TY;J#2_5'B79
ME(PJ1C4CPZAAU#+J&/4"R9QSYN"RN](-NP6/Q+#`(_K&7XZ[;TC'J#@L7%V)
MD#5'&48-HY91QZ@72$ID3<*$*Z;S%-C-BBO0?*;NQ`\;%R7N2BFJC%%1F;%@
M0#5'&48-HY91QZ@72"BSU2;I;=,QA,NUQ*.DGTM&%:.:D6'4,&H9=8QZ@63.
MUA.EH\':G,N^L+-U]BK=]_1(31B]61&CPABH&-6,#*.&4<NH8]0+)"6R'BR5
MZ,RP\)8MNLS#UB$Q+`A5'%4S,HP:1BVCCE$OD,QYFI7<LI7T2'6]WI&(4;'K
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MD7=HP7YKJ`E#XXP6OJ#4(CH4J87U&^\WOCMG3U+_[Y'0PD5E=EQWVE)8+8IB
M>/+LF:'![F*H[+P<OJ"0HX@W]%(.O?R?:12O\3M:O4M&%:.:D6'4,&H9=8QZ
M@63.>D&__/9P-R[VX;)[\$A>P@NUMU#&J%"P8E0S,HP:1BVCCE$OD)1HVLJ^
M&U?VY&I4J%OB@X^2GD='E3$J*N-=0G*/P%&&4<.H9=0QZ@62RNCU_\R$X35^
M1ZMWR:AB5#,RC!I&+:..42^0R+F8Z17]<M/CZI++?6!JSNC[ZB1L'!H9AD?I
MVN:*)R+A6;K$\#!=8GB:+C$\3I<8GJ>;,J667=3?O\04,QNO%7$L=4`A+F%X
MD##%(7UB2)\8TB>&](DA?6)(/V4J?>TV[&"Y[#?ZQ8RM2&!JL.BMAB0L&2RN
MND1!J$4,:A&#6L2@%C&H10QJI4RII<W2V]>38C:ZI/12JVZI#R%,76M56)F$
M)2*Y,Z!H8!")&$0B!I&(021B$(D81$J9$FF::2MF[-H"2_H>Z;NXA&%&$4/Z
MQ)`^,:1/#.D30_K$D'[*5/HY$WG9!T#%C&UE8&I&Z<V()"P,#*CEJDL4A%K$
MH!8QJ$4,:A&#6L2@5LJ46M,L;3%C3QM8DA8&"QE=I$\,Z1-#^L20/C&D3PSI
M$T/Z*5/IY]SM!9\@%S/VMH&ID:+W)Y*P9*2XZA))(14Q2$4,4A&#5,0@%3%(
ME3(EU3276\Q&FQO2PH76>].X%X.10@PCA1C2)X;TB2%]8DB?&-(GAO13IM*?
M9F7Q(JN,3QG-;+H<Q7T(MV$5BB:=#T7&HD%-*$(,BA"#(L2@"#$H0@R*I$PJ
M,KPE88)S\V]52'<'"O&F!9\^,[S?(#600QQ><$`,;S@@AE<<$,,[#HCA)0?$
M\):#E*GTK:F;DKXS@3)]Q_#;W]"K>+L#,:3OF'UD;-S`*N*F35!D#`O501&J
M#HH0@R)CV3=.`9'&L'`*B)16IT2R7FZ*2,[[29$<DR(1@TB.29'F<2LGB#2&
MA0P@$E4'D8A!I+%L(I(^!40:P\(I(%):G1+)>KE4I&';:S4\,N/U^\/]KX>3
MW0?+;H\N\+ZY(;%]$=[_D'SL')C4SEG'A$$[;R>7P^OKEOA*B[I%P'0;0T)2
MT(VJ@F[$H-M8UKX=;UFL%VKL0K,Q)%0/S=*JE&;6`+ZEV3]./_]*,WRY,8KF
MC"1Z)YP6;V%Q+/VJ;89!-!>'[U^%LE")&%2B^J`2,:A$92$+,<B2EE6R6*?W
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M85=3Y*##8+;&L##B,0N(H6^(H2.(8=`3@^K$(#$QZ)DR)9YUX:EXYT1RKET.
MX-3)#Y8!Z1-#^L20/C&D3PSI$T/ZQ)`^,:2?,IG^\&*1-'UKD"ZY2_=O*!&Z
MQ+>6I`.*UK48%D<*,[R"++UC&&3&.\B(X25DQ/`6,F)X#1DQO(<L94HJZ\53
MJ<Z,%/]F$C6=U"7A4,07F*0BJ;`R"4M$\G<,\1X'(A&#2,0@$C&(1`PB$8-(
M*5,B62\^123GW>6P<2RY24?ZQ/"6.F)(GQC2)X;TB2%]8DB?&-)/F4K?VNHT
M_?_#!U3^+292&F_E,:'C,D//12G$"U"&F0*UQJ)A`$$M8E"+&-0B!K6(02UB
M4"ME2BWKME.USLTHY\[5C%+K,V:4"U,+E`K#D!K#@B`0B1A$(@:1B$$D8A")
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M\KDZ"]L6W.7FCLUM6[)UXE2%/=_PS6'*`<=0+M=.]-'<'AL<%I=;V&.Y.O?X
M:@G.A\V=7#MQ#)\)YLH=\)T,>RP_)F9V3.!K"-DZ[9C`9_398[;?\:%T]IC5
M&I_89H]9K?'99>Y88;7&!WN98SLT!5^%S1U!0_`-4#ZRW]GA`*O'A_`=3A3*
M-G"']N$KA)DR^*Z<;7JV>?@BF3V6[^Z9[>Y\.[;H-?S$C<^VWV*.X\<\?`2_
M44.9;&=NT9?XB52N#.3+UK;?8FYGY<-O>U`F)^QA"_7PTY+<>:`>?E&1.;*#
M>/CR?.;(!OG@Z0FY(\@'SQC('4$^[M,=/8$V:#5^@YXK@U;CI]=\9+_90>M<
M+^"WTRB3S6>+?/#37:[ML,50P"]6<T<P$/"[3CZR7Z$%>%@9'\%#^&[MT^TR
M1]9H`9X!ESN"%F1KVZ_GM_NL!@<<L0\%R]6&,8I'9^6.H.?PR*C<$?0<'JR4
M.;)!;7AD"!_9KW`UQ5-B^0@>?@P-\NJ@U7CV;JX,SI.M;;_"S,*3%'-ED`^>
MQYH[@GSPU-+<$8Q$/*TS=P0C$<^TS!W!2,RV8+]<W>[Q)/9,&1RQC^?/'4$+
M\!#[W!&T(%O;?HE+(YY@G2N#MKD/H/7,6F(DXKG@F3(KC,1L;?OE#/ED%<41
M^\Z63&U+]#;>;)([@MYV'X%1V]#;>/-%K@SZ--^"!<JXG[KHVA8HXSZ>H2/H
M!;S6*W.>!7K!?<JFRNP7N,+BJ6&Y,N@?O.<I=P2]@+<AY8Z@%[*U[:TKS+;@
M8#UAWA+.D4_>$,Z13]8.'N`&[=M/,VV;H]5YNS='J_-FSWJ]O-6S3B]K]`X+
MC`/WNR6MM76`6;-V&/Q?5M'!_67[QWJ_;&U[Z_RR)@WO/D>9[.BUKB]O^N88
MB?G:('56:0B=RV6/923O#Z%_-L7!<F6G88%$\/VA3#<72,3=BBGY#P4&#3X0
MSI5!)MF6X6.MY2T^Q\I=)/`1U?(6GTGECNUM#V3/A!/EN%4_Q^U5(,/WUG]E
M^,%>3W+<KA`Y#DERBB#OPN:=:ROR+FS>N6,H-[?E<KF@W-R6RQU#N84ME\L5
MY1:VW'#L9NS4E\\??]Y]._[[W?.WAZ>7JQ_'K[@EG0U?BWA^^&9OY]T_7OT7
M>GXYO;Z>'H?O]GP_WGTY/ML`;,U^/9U>PS\P-&[^.#W_.MSV?OY?`0```/__
M`P!02P,$%``&``@````A`#_==I%U!0``)!0``!D```!X;"]W;W)K<VAE971S
M+W-H965T,C4N>&ULK%A=C^HV$'VOU/\0Y?T2XGP`$7"U$/*E5JJJV_8Y&PQ$
M2S!*LKOW_ON.XSC$GEW$K?JRV1QFCCW',_;$RZ_?J[/Q1NNF9)>5:4^FID$O
M!=N7E^/*_.M;]&5N&DV;7_;YF5WHROQ!&_/K^M=?EN^L?FE.E+8&,%R:E7EJ
MVVM@64UQHE7>3-B57N"7`ZNKO(77^F@UUYKF^\ZI.EMD.O6M*B\OIF`(ZD<X
MV.%0%C1DQ6M%+ZT@J>DY;V'^S:F\-I*M*AZAJ_+ZY?7ZI6#5%2B>RW/9_NA(
M3:,J@O1X877^?(:XO]MN7DCN[@715V51LX8=V@G066*B..:%M;"`:;W<EQ`!
ME]VHZ6%E/ME!9A/36B\[@?XNZ7LS^M]H3NP]KLO];^6%@MJP3GP%GAE[X:;I
MGD/@;"'OJ%N!/VIC3P_YZ[G]D[TGM#R>6EAN#R+B@07['R%M"E`4:";$XTP%
M.\,$X*]1E3PU0)'\^\HD,'"Y;T\KT_$GWFSJV&!N/-.FC4I.:1K%:].RZA]A
M9/=4@L3I2>#9D]C.Q"7>;-ZQW/%T>T]X]IYD,K.G"V<&H]_Q@U^[:</S-N(C
MCG[O",]A0#+W;,_G\=X9<=8[PO,VXD,Q0JEU<X7G,.0C4UWT?O"4(Y+'5+4A
MC;HA^3_#F/?"M$1:=%D6YFV^7M;LW8#2A85OKCG?".R`L\G\$DH-&?=9PD&F
M<98G3K,R00'(I0:JY&WM>].E]0:97?0V&VQCJQ9;:<'3F-.&.K#3@4@'8AU(
M="#5@6P$6"#+H`W4S/^A#:?AVLBH-A*XB44T(:2%=`EU8*<#D0[$.I#H0*H#
MV0A0A("Z5X3X>/.1N<"M89L9Y8+M>6J`&V%#9H,H6X2$"-DA)$)(C)`$(2E"
MLC&BA`X;EQ(ZKP_B38:]Y.$*X4109"#QJ$2T`M@((P([PF!$[+FJW78P&K(#
M(3N$1`B)$9(@)$5(-D84I4`21:G[2<*M.SED$!N!0.P2V2(D1,@.(1%"8H0D
M"$D1DHT1)5`X6GXB4&ZM!BH0][8A;!$2"H1`6HX28:$FPFXPDHI%B"A&2#)X
MW:%.!R-)G8V)%#G@P/P).;BU*H=`QG(@)!2(*@?1SI?=8"3G'"&B&"')X#62
M0Z=.!R-)G8V)%#EXXXT/U`GO=]I36;QL&*PHG#@?E(<#!Z<X3CF)JI)`QBHA
M)!0(<;OSUX5&W=429C"0842()$9(,GCQ8]VU?4?+PW0PD+39F$11!W:VN^I\
M8]?/U('^3<K#651Y!.*(MI6W#EN$A`*9^<,&LT-(A+QBA"3(*T5(-O92!.`]
MUET%'LJ/CD550$)0I[<M@V@'S+:W<MQ!A%`Z0D:/'+6.9">M8&5'5HZ:8)&T
M4B>AI6&,)Y%(Q[N32*65.@FMM\BDU6>34->#-W]ZO9+9K5YE1CY>O+;H)\57
M85?/&PE!6HS4\U7UMKV5<\O0L(?<[@NSX]KU$+&[,E_8#EG,M8J,,%.,H023
MIRKYW/?\.=%2(5.85#%Y`ZF+:</W)H3-][[_H*5H214M!43&G10A,UU+8:4D
M>L]U-\=VO$/CFXN:8UH/%DFKSW*L6ZJXMQI-(I&.=R>12BMU$MHJ\WN';JJ?
M34*LC;A:$!]]%:V/=$O/Y\8HV"N_-H"[A/5R@,6=1K@(8&N$S5S#DT4`6QW&
MX0[DJ4M0S7[#[T8^L-^0`#XU,,_&":`1Q_B3&SQ!K/B'C1M`/_H![@70OF$\
M]`-HFC">^`%T/!@/9P%T%1A/9@&T!!@/Y\&N:^LT(9)Y`(<DV%O##W!'<\V/
M]/>\/I:7QCC3`RS&M-MV:G'+(U[:_D!\9BW<SL!ZP2<ZW,91..*FO*X.C+7R
MA0\PW.^M_P4``/__`P!02P,$%``&``@````A`/8OCBL8"P``.C,``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C8N>&ULK%M;;RI)#GY?:?\#XGT"77V!H"2C
MT%?0KK1:S>X^<T@G02?0$7!N_W[M+A==MOL`F3/S,)Q\V.[RK?Q5`7>_?]^^
M#;[6^\.FV=T/@YOQ<%#OULW39O=R/_S/'\5OT^'@<%SMGE9OS:Z^'_ZH#\/?
M'_[^M[MOS?[SX;6NCP.PL#O<#U^/Q_?9:'18O];;U>&F>:]W\,YSL]^NCO#G
M_F5T>-_7JZ=6:?LV,N-Q,MJN-KNAM3#;7V.C>7[>K.NL67_9UKNC-;*OWU9'
M6/_A=?-^<-:VZVO,;5?[SU_>?ULWVW<P\6GSMCG^:(T.!]OU;/&R:_:K3V_@
M]_<@6JV=[?8/97Z[6>^;0_-\O`%S([M0[?/MZ'8$EA[NGC;@`89]L*^?[X>/
MP6P91</1PUT;H/]NZF\'[]^#PVOSK=QOGOZQV=40;<@39N!3TWQ&T<430J`\
M4MI%FX%_[0=/]?/JR]OQW\VWJMZ\O!XAW3%XA([-GGYD]6$-$04S-R9&2^OF
M#18`_Q]L-U@:$)'5]_NA@0=OGHZO]\,PN8DGXS``\<&G^G`L-FAR.%A_.1R;
M[?^L4$"FK)&0C,`K&0F@OLXH1*0`K^ZI-Y&))]/VJ6<484WM<N'U]*2;(!HG
MN-HS>@GIP:M[X%GY"<G#Z^DY9Q7`WW9A\$H*9GR=2[>D":_N45X&SO@40+&T
MS\1_G/-J9'/>EE"V.JX>[O;-MP'T)63U\+["+@]F:,05CWWHJ9Q^5DU01FCE
M$<W<#\%S*)0#M,#7AR0V=Z.O4+9KDIEKF8!+I$X":Q3-9A+()5!(H)1`)8&%
M!)8>,(*PG&(##?%7Q`;-8&R<5W,'=,$2H4J=A%/)))!+H)!`*8%*`@L)+#V`
M!0*:F@6B?V=QM8#2L(=XM6"B,<_TW,J8R2DHJ4(RA>0**112*J12R$(A2Q]A
MKL/V]`'741HZ">+H]4$H?+="!IK=$XJX4'H2.I6`0G*%%`HI%5(I9*&0I8^P
M<,`6^X%PH'0;#N?$W"+@NT-2A60*R152**142*60A4*6/L(<A2GQ`4=1FCM*
M"+R<DFSDCIA:H;#E!G;#ZU,S8G?(22VV^^P8_^/54_B&F5LPS)A;N-V;!'G!
M3^B":VI4Y!X2XI>QB46MIU8H3$[YSA22$S)IW8FF81`GPAU?A[D#`T>[`]+'
MU\WZ\[P!YV!O[]FM0GB6'5QH@?M%"(30RYQL3ROD9XZ0;IO/";EM_0J#*)%N
M^4:86Q!3Y58`C(`<^Z-Y;QV[WDLTR+TDA&<OYG%/K9"?/8M$0!2ZX*CZ)*&@
M=3P(P',I4OB6F>O(0;3O\<U$.M^35:ABE];63.MQM]`D%O[-28IMQ2:^%5'H
MI-RFE6DHUU"AH5)#E886&EHRB$<,Z8M/X2Y$QK(=F%'.FWE@(7]7UE"FH5Q#
MA89*#54:6FAHR2#N,S*5#_ALB0WSF2#6YBKS5LAO<YSMV$I,3Y9W3E*AW:*C
MVZG8P@LGT&[]W#6D(A]PS3(7YAI!T&.G)H5#E:QJ*^4W=Z"@W$%V<XZGD9&C
MQDFT6SSW!%G$!SRQI(-Y0A`+=B)6D`96BF5)0;F3LBD)QT9-&2?1DQ.D"1_P
M!,7Y=HOG<83\G)A$G7^L%,N)@G*R%=J<F"`,;D5("B?2DQ2(Y4=<07'A"D$\
M*:+`4VP04&1)45#NI*A/HCA0GOA*O+R0%?A)L4?7;E)<-?\#RRU8U1'$<R69
M#2FR7%G%J-M:<Y(R=A8F\:WF:LP0]Q`)PCD/'1&XL.-;GL%<M%`$#7_:(DPB
M20[>X,@<*BAW4C:'P3@8A_&4;S:%D^EI+60"OH\7?$%Q48\$\72I[<Y*L70I
M*,?^1(]M:P5PD1F)F5`X$=U:YA)UN:H@6RO<0P?QCA-L,B4IO^,<Y)%2!UE6
M&HPGX5@FRXGH9$$9\V2U+?<KQ+2U*+RU;`1N3/W:G/"*2DG1SR=!?OL1!"]X
M)67,)(R%H8(98NUG<-3[I=D>EJ#'6]Y]7>^U-H1_ED&(WA-)2$F195.QD=Q)
MV=Z;3,/Q6,R4PHGT9!/'O?0O\*CV=?5J28._NQB"_(X,1=Q3$F()M'HL@1:B
M!(9AD!CEH!6QAG@"D06<<_#*'%HRP3Q4_"(U"LHTE!,4V7MXO.,LF!1?/\[^
M<^N_+D%$/;JI-,?C/FQSHL7$3I>2%,L0*9X__SGSYPZ`S#CW&B>^]-K$>/I5
ME](?Z41+)""+W;:22`XX-U:*GP@GHN323LJ=H3(-Y1HJ-%1JJ-+00D-+!O$(
M(@_Q(WA^IL(MK)RI!/DG0@UE&LHU5&BHU%"EH86&E@SB/B,Q\7W^4VS06'K#
M6IT@?_@F:K=6M"ASIG!>N,]$C#HHDE24V+L2^-`DG(K!7I",'07<::0KRNE?
MFL>6`+$`$.3OYF8B^3YV##(G[Z:/H`N714Z*Q6DBV'9!4OS\9#K"RL(27B)B
MU^W[K9EV=G<93"1_F),4+O"4YT02X+23.NT8&LHU5&BHU%"EH86&E@SB$9/$
M[OR.$5J*YE<)01`&YV"JH4Q#N88*#94:JC2TT-"20=QG2>\N^&S9%_/90E%'
MK]-001E!R'=.!6(",6SS3LK%K]"V2@U5G>(9\XM.RIE?,EL\,LBH_&WE0F0L
M`6.1L1"+C(*RT$(\,O*"*>^DW-(+@CSSI8:J3M&+C#2_Z*2<^26SQ2-SB5%>
MQ<A@)Y<#ER#/HU1#&4'`&/$X`W=QXVX';#_.R#L)YTVA[90:JCK%UG20A*)"
M%YV$,[UD=GB@D"CZ)?3+)T6X2U5!(^CL:"8]6*I;=D90Y&_9>C0[17M2-F9J
MDJD@@H63Z8R7&JJN>M["*=+SI@G,&G&+L70R^C`'@_>O#KBEPJRM"?(#)V.2
MMBOA3("@"TS`27$F(-D02?V4";1]4.I%5,[\V;/+PDGQ18C#Z_+2(G@O@"W=
M"]XY^THZ@F84'1%=.H>K*Y3B=$1=F7=275.<%!V4:ZE"0Z6&*@TM-+1D$(^8
M)/,7!I!F[:&%&!U14*:E<@T5&BHU5&EHH:$E@[C/2*#5CNE5R76C!:WP^Z;0
M0D"$7&)3@KQIDQ$4PVCJ6(KL[;R3<K8*;:O44.446?-YGXJQ4.`^<384US5,
M:X;'PD'^Q#!3<=A(2<H?&;V*ZC3G%.UU7'R;Z-M^)^)-#`U5!,7`L[UL=,.>
MA^MCY#W2Y-U!_KYNIF+XI"0%>Y]+?J:AW$'TB6%/!.SS/3.ET^DL5P3%P*>]
M"'3#@$<`6;??.^?W"[A@E$WB(%X88MM/28H5AK7E0;F3HBJ`",@/M9R$7P3*
M3D52H@BZJP<>`N32?@C^U/T'7DJ+[<-!O#;$V$E)RDMJ1A!XX<HE)XAN<Z<]
M@;'/]\R4VG)%$*\-[S-0'IA>ROXK=R1X;2J#9"&O"E*2\J#,*<*D[6I:;R+6
M%ET)]7YDJ&V7&JH(BD-,@(V)_0ZY_0+PMMZ_U&G]]G88K)LO^/UPN%%\N#O!
M].7U<#)[!$M@0KP#5&.&,[SOG2F\TYZ*I4X`WX6'KW5HG4>3S![MN)8Z\`Y>
M=FJ=N8$5P)6@?N<Q',\>;15):_`.7H1HG7D(:[-34NC`<)SAZ-,Z\-7^Q[:^
MA<8<W>R1GQM8<!\>PJ-[\,=H]MCWW'D$/RGHD9_',_A*8]\Z(1YPY:[?F0<0
M#_ARD7X'+B[`Z[[5PIW##&\4^G1"T.GS!$[CH-/W#IQJ0:?/&SB4@D[[SN@4
M8/CEPOOJI?[G:O^RV1T&;_4S5.ZX_=1_;W_[8/\XTI?D/C5'^,T"T`#X;CO\
M1J6&CUS&^%G"<],<W1_@R.CTJY>'_P,``/__`P!02P,$%``&``@````A`&)S
M$?$R!@``[1<``!D```!X;"]W;W)K<VAE971S+W-H965T,S$N>&ULK%A=;Z,X
M%'U?:?\#XKWAFR0HR:B!\!'M2JO5[.XS)21!#2$".IWY]W.-;6+[9MJTVI=2
M3JZ/?8^/KXT77[[7)^U;V795<U[JUL34M?)<-+OJ?%CJ_WR-'V:ZUO7Y>9>?
MFG.YU'^4G?YE]?MOB]>F?>Z.9=EKP'#NEOJQ[R^!873%L:SS;M)<RC/\LF_:
M.N_AM3T8W:4M\]W0J#X9MFGZ1IU79YTR!.T]',U^7Q5EU!0O=7GN*4E;GO(>
MQM\=JTO'V>KB'KHZ;Y]?+@]%4U^`XJDZ5?V/@537ZB+(#N>FS9].D/=WR\T+
MSCV\(/JZ*MJF:_;]!.@,.E"<\]R8&\"T6NPJR(#(KK7E?JD_6L'6FNK&:C$(
M]&]5OG;"_UIW;%Z3MMK]49U+4!OFB<S`4],\D]!L1R!H;*#6\3`#?[7:KMSG
M+Z?^[^8U+:O#L8?I]B`CDEBP^Q&570&*`LW$]@A3T9Q@`/!7JRMB#5`D_[[4
M;>BXVO7'I>[X$V]J.A:$:T]EU\<5H=2UXJ7KF_H_&F0Q*DKB,!)X,A)[XMK>
M=/81$I>1P//S(X$Q#^G`DY%,)Y9K^A](QF<4\/Q\,K"\AG'`DY%8DYGGN?YL
M>K^L<T8"S\\F8X&AAH&0?\:1W#F_!O7*8+TH[_/5HFU>-5C/X(;NDI/J8`6$
MF)N.6F2TX:]<"/8C+(^$9JF#1&"P#I;.MY4_=1;&-[![P6+6.,:2(T(>0;Q-
M:",5V*A`K`*)"J0JD*G`5@`,D&74!A;2_Z$-H2':\*S6'+B*92M"\`C>)%*!
MC0K$*I"H0*H"F0IL!4`2`HJ!),3MBL2]0**A]@A><#Q/3G!-8^RAF@Y3'2(D
M0L@&(3%"$H2D",D0LA41*74H81](G43#2@(=A77@*KG3(!M*P1CD>%,Y*!R#
M1@L@9(.0&"$)0E*$9`C9BH@D!U2\#\A!H@<Y>!)KBD#N'`D1$B%D@Y`8(0E"
M4H1D"-F*B)0H;!E2HK0N3DC)[X]5\;QNZ%9Z8RDX4/]H520D<OX4<:_%($1(
M1!'/&\JH"X<PQ4";,8"+&".2!"'IV(I49]?RG;ELN6P,X+1;D4129_J..E^;
M"^3]WJ9!6&1Y&`+]"DMC)H\SI$&..WHHNM',MI6:NF'-J*S^?#8S?9DX1L0)
M0M)[NLJDKFS?FMO*%&Y%8DE9<I@7]^,;_H(#$#<8B9859(A<7)29#FF0XU\5
M1,B&(5/JPOE4J>`Q:I$@)$5(1A$/'M<)MI1CP%9L)HD#67U`'!(MB\,0R5Z^
M*;L@I$&BO1"R80CUTA2V-\5L,6J2("1%2$81#\SQACIB,TD=<GR3Y/E4S1I8
M9-DX!#U?Q^4KLQ:R*-%5#'+MT6@;!MG6X"MG;IJ*_C&/,(>(!T79!'>3XFXR
M3D*[\:`7I9NMQ"/K2,Z#XAHD.L)1A1;^^TJ;1<^4<!+@Q73-(=E]2GHABQ+M
MAZ$-AZ@!9U#,'>6T'?.0:YE,,)1B*.,0Y7:L&]6+APS<LG;D"*EJ9WD?W#?)
M`4I9NAR2/:@D';(HR8.42_(@A7R8(\'/2HF.&9<-JVJ,LM5"GN`>4P8)/68,
M4GI42NJ615EBCF*/LM+DR*HJ;4^O2G.CWG]<L>@I&(9Q-2V#9-,J&V?(&DJF
M90W%6H;W9-;0]8>U;L]]3]GL8Q;ABS:FU$)O*1_YF[UE/.KMW8=%47I9<G(L
M5B47S<TE?WO3MNCI6I*9';CIM0[Y]`U9%&SV?#(B#&TP%&,HP5"*H0Q#6PF2
MM2`G9Z3%W")74[^XL>*'%G*GI:YN"CGT+HKFSZ)<N@THNTW$2'R(&E>GXU^_
MHN3!@GVEP;XS021<V0(I)`V00=?5$ED4\H>#E3P"<.8X`ICL86LV[6&UOC,8
MTE(9#(6DP;`HII:RJT1P;3F0R!7ONM;H6.G-)+T>JLOV4(;EZ=1I1?-";AUA
MPUPM1IA>B49^`%\C8%`%3_T`/B<P#E>HCX->2OR:7*W>B%_;`5Q*8)ZU$\`G
M.\8?W>"17M&J';@!?-3B!FLO@&_`&[@%#<#]\(LQ4L%EZR4_E'_F[:$Z=]JI
MW(,LYC"'+;VNI2\]^_IY:GJX9@7E8+[A6KV$96U.P+#[INGY"^E@O*A?_00`
M`/__`P!02P,$%``&``@````A`$*[4#@/!0``61(``!D```!X;"]W;W)K<VAE
M971S+W-H965T,CDN>&ULK)C;CJLV%(;O*_4=$/<[8$Z9H"1;$\)1K515N^TU
M0YP$3<`1,*>WW\L8&.R53F>DW@R3+\N_[=_+"SOK[Z_517NF35NR>J.3A:EK
MM"[8H:Q/&_VO']&W.UUKN[P^Y!=6TXW^1EO]^_;77]8OK'ELSY1V&BC4[48_
M=]W5-XRV.-,J;Q?L2FOXYLB:*N_@8W,RVFM#\T/?J+H8EFEZ1I67M2X4_.8S
M&NQX+`NZ9\531>M.B#3TDG<P_O9<7MM1K2H^(U?ES>/3]5O!JBM(/)27LGOK
M176M*OST5+,F?[C`O%^)DQ>C=O\!R5=ET;"6';L%R!EBH'C.*V-E@-)V?2AA
M!MQVK:''C7Y/_(Q8NK%=]P;]7=*7=O:_UI[92]R4A]_*FH+;L$Y\!1X8>^2A
MZ8$C:&R@UE&_`G\TVH$>\Z=+]R=[26AY.G>PW"[,B$_,/[SM:5N`HR"SL%RN
M5+`+#`#^:E7)4P,<R5\WN@4=EX?NO-%M;^$N39M`N/9`VRXJN:2N%4]MQZI_
M1!`9I(2(,XC`<Q`ABSO7=;R[)8A\T!"^[7N'Y]!P^6$\9&T?#\^O=;0:&L+S
MHXX,X4YO]C[O\NVZ82\:9##,O[WF?#\0G\`BC3:+N4W&_YOO8#A7N><R&QU&
M#Y:VD"S/6\_SUL8S+'`QQ.QP#)$C@C&"KR:7W:L@5$&D@E@%B0I2%60S8(`M
MDS>0.O^'-UR&>S/.:C>"=[,LQ8@Q8FRR5T&H@D@%L0H2%:0JR&9`,L*^880-
MR7)[+XXYP5O!KIOEA$W4G!`QUG(R)T!DCTB(2(1(C$B"2(I(-B>2!5`!I%SX
M>.H\&G84^#G;#TMYD7<BR(*=.P79YDH."J:@*140"1&)$(D121!)$<GF1+(#
MZMH7[.#1O1WC)':"P-Q'$B"R1R1$)$(D1B1!)$4DFQ-IHIXR45$?%[S\=^>R
M>-PQ\1*YD0\VU$%1';F(/']!G/>B$""R%\1U^W+JP/'#D7,CG`)&$R,D$B.2
M3*UXE7:(9RLIETX!HVPV%Y'<@9>:E`:J.S_8%>;]7X6"J\CV#`3Z?=\:Q)2G
M'X@@VYER:'^CF64IM34402X\9MK*FRA"VC$BB2!D/DC46SHT$XMH>9ZCN)W-
M=25O^4%V_F:^D6%PDAE3C$?+'@Y$*B]$,2,00;;W[B$BH2`N/#XP##6+$4D0
M20>R[%.<>-;=G;S&V;R)Y`Y,ZPON\&C9G8',%\\FMMQ[((+F&89(.!"QP,2R
METOE'1>A-C$B"2*II&NOB'J<RN9-)&OX,4[R1MV5GZI9O8KLV8B@YUDF*%4I
M&*+F.34@I[\N]"4Q')!%Q-+#]"Q7=C_"0C%&"=9.96W+6GG*&#-)1S:/'P;G
MVXZ;9RW?"_Y8TCY?_8DX7XK+4C_[W8CD]%,,"(:H>?Z-#:%J3$N`BDXX1#E>
M;Z[EF(ZI%CBL'6.4?*J[5.Z.F*[I*6>=3-*6#>>'3M5PXF+#/ZY__*RE;/$!
M#;=#?I\(,-IC%&(4811CE&"48L1OS7RH8ES""W$+%A>SBC8G&M#+I=4*]L1O
MN)"MV_6$Q?5[[_GP_H<WM,(3SX<7..9P7;_OMY\2O^/7^!OQ.\N'ZP#6V=D^
M')(QOW?\>Y@8_F+G^'",O,%='TY=-SB!GH62,8T5+O;7_$1_SYM36;?:A1[!
M%K//D4;\-"`^=,-YXX%U<*4'Y^!""S_A4%A[<P%'MB-CW?@!NC:F'X6V/P$`
M`/__`P!02P,$%``&``@````A`-\5YF\/!```X`P``!D```!X;"]W;W)K<VAE
M971S+W-H965T,C<N>&ULK%==K]HX$'U?:?]#E/>2[P`14$$^VDI=:;7JML\A
M,1#=)(YB<[GWW^\XCG/MF-ZB:E\P.<P<S_',.,/FXTM3&\^H)Q5NMZ:SL$T#
MM04NJ_:\-?_]EGU8F0:A>5OF-6[1UGQ%Q/RX^_./S0WW3^2"$#6`H25;\T)I
M%UD6*2ZHR<D"=ZB%7TZX;W(*C_W9(EV/\G)P:FK+M>W0:O*J-3E#U#_"@4^G
MJD`)+JX-:BDGZ5&=4XB?7*J."+:F>(2NR?NG:_>AP$T'%,>JKNCK0&H:31%]
M.;>XSX\UZ'YQ_+P0W,.#1M]418\)/M$%T%D\4%WSVEI;P+3;E!4H8,=N].BT
M-?=.E#FV:>TVPP%]K]"-2-\-<L&W3WU5?JU:!*<->6(9.&+\Q$R_E`P"9TOS
MSH8,_-T;)3KEUYK^@V^?476^4$AW`(J8L*A\31`IX$2!9N$&C*G`-00`GT93
ML=*`$\E?AO56E?2R-=W58A4$?KA:`LT1$9I5C-,TBBNAN/G!K9R1B[.X(PNL
M(XNSEEC>\?1&3UB%I[L(EK;G0+CO;>F/CK"*P!>^&RQ7OW($VD$QK*/C^MV-
MPM$>UH<BM/@)#PE+<IKO-CV^&=`%<(2DRUE/.1&0B4SQPYER][/40<X8R9ZQ
M;$UH7T@*@7I[WH6AL[&>H4:*T>:@V\PL8F'!"H+1)G,@G0.9!%B@:)(%.?\?
M9#$6)DL$=!#`FTY751D+"^&2S(%T#F02H&B`ZI,UW&\>D0%FO#7A<\J`NUZK
ML1VXC;N<],0:DFA(JB&9C"@10]D_'C$SAJH#]5/(83@[S@,W<J$9)"-/U15/
M1M.A:TBJ(9F,*"J@!Q]7P8P'%6+O`T<@9('$&I)H2*HAF8PH\4&;RO'QEEVP
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M-44*\V67G]%?>7^N6F+4Z`0:[>':[/F$RA_H>/$<,87!$K((0Q'\DT!P(]JL
M)DX84_'`-IC^F^S^`P``__\#`%!+`P04``8`"````"$`HL#`X`X%``!9$@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970R."YX;6RLF%V/HS84AN\K]3\@[C=@
MOI*@)*M)PJ=:J:JV[35#G`1-P!$P7_]^CS$PV"=-9Z3>;#;/'+_FO#X^V%E]
M?RLOV@NMFX)5:YW,3%VC5<X.175:ZW_]"+\M=*UIL^J075A%U_H[;?3OFU]_
M6;VR^JDY4]IJH%`U:_W<ME??,)K\3,NLF;$KK>`O1U:760M?ZY/17&N:';I!
MY<6P3-,SRJRH=*'@UY_18,=CD=,]RY]+6K5"I*:7K(7G;\[%M1G4ROPS<F56
M/SU?O^6LO(+$8W$IVO=.5-?*W$].%:NSQPOD_4:<+!^TNR](OBSRFC7LV,Y`
MSA`/BG->&DL#E#:K0P$9<-NUFA[7^@/Q4V+IQF;5&?1W05^;R?^UYLQ>H[HX
M_%94%-R&=>(K\,C8$P]-#AS!8`.-#KL5^*/6#O28/5_:/]EK3(O3N87E=B$C
MGIA_>-_3)@='069FN5PI9Q=X`/A7*PM>&N!(]K;6+9BX.+3GM6Y[,W=NV@3"
MM4?:M&'!)74M?VY:5OXC@D@O)42<7@0^>Q$R6[BNXRWF(')G(/RUFQT^^X'S
MN_%0M5T\?'YMHF4_$#[O360(=SJS]UF;;58U>]6@@B'_YIKQ_4!\`HLTV"QR
M&XW_-]_!<*[RP&76.CP]6-I`L;QL/,]9&2^PP'D?L\4Q1([8#1%\-;GL7@6!
M"D(51"J(59"H()T``VP9O8'2^3^\X3+<FR&K[0`^S+(4(X:(8<A>!8$*0A5$
M*HA5D*@@G0#)"/N&$384R^V].-0$'P6[;E(3MCF7$]V*&&L^FK-#9(](@$B(
M2(1(C$B"2#HED@70`:1:N)\ZCX8=!7Y.]H.KY"Z"+-BY8Y!M+N6@W1@TE@(B
M`2(A(A$B,2()(NF42'9`7_N"'3RZLV-(8BL(Y#Z0'2)[1`)$0D0B1&)$$D32
M*9$2]91$17^<\?;?GHO\:<O$2^1&/=C0!T5WY")R_H(X'TUAA\A>$-?MVJD#
MQP^EH09CP&!BB$0B1.)Q%._2#O%LI>22,6"03:<BDCOP4I/*0'7G![M"WO_5
M*+B*;$]/8-Z/K4%,96N((-L9:VA_8YAE*;TU$$$N?$RTE3=1B+0C1&)!R/0A
MT6Q)/TPLH@4O1<7M=*HK><L/LM,W\XT*@Y/,4&(\6O:P)U)[(8H9.Q%D>Q\>
M(A((XL+''</0L`B1&)&D)_.NQ(EG+1;R&J?3(9([D-87W.'1LCL]F2Z>36QY
M]IT(FE88(D%/Q`(3RY[//5DE1&,B1&)$$DG77A)/D4VG0R1K^#%.\D;=E9_J
M69V*[-F`8.9))2A=:=='36NJ1TYW7>A:8M`CBXBEA_0LY?T88J$(HQAK)[*V
M92W5HV@JZ<CF\</@=-MQ\ZSY1\,?6MKGNS\1YTMQ6>JRWPY(+C_%@%T?-:V_
M82!TC7$)4-,)^BC'Z\RU'-,QU0:'M2.,XD]-E\C3$=,U/>6<ETK:LN'\T*D:
M3EQL^/W^Q\]:RA;O47\[Y/>)'49[C`*,0HPBC&*,$HSXK9D_JG@NX86X!8N+
M64GK$]W1RZ71<O;,;[A0K9O5B,7U>^_Y\/Z'-[3"8\^'%SCF<%U_Z+:?$K_E
MU_@;\5O+A^L`UMG:/AR2,7]P_`=(#/]AZ_APC+S!71].73<X@9F%DC$^*USL
MK]F)_I[5IZ)JM`L]@BUF5R.U^&E`?&G[\\8C:^%*#\[!A19^PJ&P]N8,CFQ'
MQMKA"TQMC#\*;7X"``#__P,`4$L#!!0`!@`(````(0!D4<_'E@```*H````0
M````>&PO8V%L8T-H86EN+GAM;#R.P0H"(11%]T'_(&_?.#.+B%`'"OJ"^@!Q
M7J.@3_%)U-]GFS87#A?.O6IYIRA>6#EDTC`-(P@DE]=`FX;'_78X@>!F:;4Q
M$VKX(,-B]COE;'17;P.);B#6X%LK9RG9>4R6AUR0>O/,-=G6L6Z22T6[LD=L
M*<IY'(\R=0$8Y435<)EF$*&?`!%_*8V2_Q7S!0``__\#`%!+`P04``8`"```
M`"$`]R=(3?D#``#D$```$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0``
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````"<6-N.VS80?2_0?S#TGI7W
MTFRQD!5L;:=9H,D:E9,\$EQI9!,KD0I)*7:^OD,I:TOUB$G\)I-SYGIF2#IZ
MLRN+20/:""5GP>7%-)B`3%4FY&86?%R_??5G,#&6RXP72L(LV(,)WL2__Q:M
MM*I`6P%F@BJDF05;:ZN[,#3I%DIN+G!;XDZN=,DM_M2;4.6Y2&&ATKH$:<.K
MZ?1U"#L+,H/L5750&'0:[QI[KM),I<X_\VF]K]#A.+JOJD*DW&*4\7N1:F54
M;B?+70I%%/8W(_0N@;36PN[C:13V?T9)R@N8H^(XYX6!*#PN1.^`NZ2MN-`F
MCAI[UT!JE9X8\0W3=A5,GK@!Y\XL:+@67%ITRXEU/]KOHC)6QY^5?C9;`&NB
M$`6ZQ?:S+]O_%C?Q[74K@5]#2:>A\P0WACZNA2W`/.8KKBWA\NUUW^?6B\[C
MSJ&7*C+D!EM*B_EB#[*KME!]SP\QS)4TJA`9MY"QOWC!90HL.8GT9^39BO_8
M1&+1DF.:82IGCQ46[*#;I;X+9.#5$)+8GPCD!'+YJV;F?%#I@V>/>L.E^-:R
MEM29U&7)]=Y%EXB-%-A=R"MVGZ:JEI:$W*=?:F&$:P2VVG+LS73/YAI:([0;
M_P*R4J2N:,E6:;L&76*I&US&Y))6W*Y$]N-T(/=7&BHND#<['!(&3$NB1[L%
MS>:U)B%O:RV%K35TA,,H*E=:4O9!XL3:B*<"V+TQV$@MYF^ELJ^BP(8_9/C(
M@N\Y,TBL/7=`1VM<U#6&O20A"WBBS2-MTN>M*C(<JVR)GMH]J>`!!VT);,UW
M(VE:EE6A]H!-PAN<+>@<]@RI:J[*4KAR?(\526T1@:-\K`0);)QXKV=IS4G]
M9.!+[427KJAT0?U,I#O"C[DBX_33E[;3(R/F&FM+A^#G)*UZA)0^,WYNTF;\
MY*0Q!`G];AVYZ)/S$HV1-2-&$U*3K?`H0';2$.]@NR8Q?FJ<0Z=S[-R<X=L?
M9V!>GX&Y)3'^\4Z3J]]2"=[WLAHG)IY"W3IIQM]>='G&VFL!E@MZCH]!.B])
MS_P=27OFQ]#$\6-HXO@Q8\1IC_^1HXR.QS]AZ'C<^<>Z4ACV@6N-=XAFI)]/
M3\0>DJP*-;^.5#L#0C/9;X9.%H5YS_4S6'?'/\,U.K^4F6,&:+[X,31?_!AZ
MT/2O+KU*^C@P@!SCR!F^U!I!9FT4TF[\&F0!.6@20MZR#D&1$/\I2#/-CZ&9
MYL>,T.;T8G<(Y@,GPSFYX_4`>I"TP7/R?P_(?X1\-A^KM5K@L^OEA3Q<C!)\
M<D"&;\>7_>-"]`X?Q[IP2N9;O+Y#]B)SNN'>\Y^Z/RWBRYN+Z?44G^J]M2@\
M_CT1_P<``/__`P!02P,$%``&``@````A`,4(=&\R`0``0`(``!$`"`%D;V-0
M<F]P<R]C;W)E+GAM;""B!`$HH``!````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````)R104_#(!B&[R;^AX9["VV=,:1EB9J=7&+BC(LWA&\KL5`":+=_
M+^NZ.J,GC^1]>7B^CVJ^TVWR"<ZKSM0HSPA*P(A.*K.MT?-JD=Z@Q`=N)&\[
M`S7:@T=S=GE1"4M%Y^#1=19<4."32#*>"ENC)@1+,?:B`<U]%ALFAIO.:1[B
MT6VQY>*=;P$7A%QC#8%+'C@^`%,[$=&(E&)"V@_7#@`I,+2@P02/\RS'W]T`
M3OL_+PS)65.KL+=QIE'WG"W%,9S:.Z^F8M_W65\.&M$_Q^OEP],P:JK,85<"
M$#OLI^4^+.,J-PKD[9[MWER;>-]4^'=623'84>&`!Y!)?(\>[4[)2WEWOUH@
M5I!\EI(RS8M502B9T:O9:X5/K?$^FX!Z%/@W\01@@_?//V=?````__\#`%!+
M`0(M`!0`!@`(````(0":6O*S90(``)`K```3``````````````````````!;
M0V]N=&5N=%]4>7!E<UTN>&UL4$L!`BT`%``&``@````A`+55,"/U````3`(`
M``L`````````````````G@0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A
M`!:&`>[9`@``:RL``!H`````````````````Q`<``'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L!`BT`%``&``@````A`'Q<W_=9!0``V14```\`````
M````````````W0L``'AL+W=O<FMB;V]K+GAM;%!+`0(M`!0`!@`(````(0#0
M;PARB00``$<0```8`````````````````&,1``!X;"]W;W)K<VAE971S+W-H
M965T-"YX;6Q02P$"+0`4``8`"````"$`]8TCO@\$``!Z#0``&0``````````
M```````B%@``>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+`0(M`!0`!@`(
M````(0!#CZY;-@(```<%```9`````````````````&@:``!X;"]W;W)K<VAE
M971S+W-H965T-30N>&UL4$L!`BT`%``&``@````A`$*+(N86+```FRD!`!D`
M````````````````U1P``'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"
M+0`4``8`"````"$`=A40*U($``!L$```&0`````````````````B20``>&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+`0(M`!0`!@`(````(0#ZRBV+L@4`
M`#\8```9`````````````````*M-``!X;"]W;W)K<VAE971S+W-H965T-3<N
M>&UL4$L!`BT`%``&``@````A`!&&N@ND!0``!AH``!D`````````````````
ME%,``'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"+0`4``8`"````"$`
MDK`':]\$``#D%```&0````````````````!O60``>&PO=V]R:W-H965T<R]S
M:&5E=#4Y+GAM;%!+`0(M`!0`!@`(````(0"F8O`UC@,``%D+```9````````
M`````````(5>``!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L!`BT`%``&
M``@````A`.NXM2F*`@``.P8``!D`````````````````2F(``'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"+0`4``8`"````"$`=Z`>1=,"```)"```
M&0`````````````````+90``>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M`0(M`!0`!@`(````(0`Q+Q_;-@0``+4.```8`````````````````!5H``!X
M;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"+0`4``8`"````"$`:-FUPI`"
M``"`!@``&0````````````````"!;```>&PO=V]R:W-H965T<R]S:&5E=#0T
M+GAM;%!+`0(M`!0`!@`(````(0#XM/)[N0(``&$'```9````````````````
M`$AO``!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L!`BT`%``&``@````A
M`-ZWW&F$`@``R@4``!D`````````````````.'(``'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"+0`4``8`"````"$`U-QN:?X"``")"```&0``````
M``````````#S=```>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+`0(M`!0`
M!@`(````(0`2T?2R,@0``)(0```9`````````````````"AX``!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L!`BT`%``&``@````A`!]6]3@@`P``50D`
M`!D`````````````````D7P``'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"+0`4``8`"````"$`X<\:$3,#``"\"0``&0````````````````#H?P``
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+`0(M`!0`!@`(````(0`E5IGI
M2P,``%<*```9`````````````````%*#``!X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L!`BT`%``&``@````A`&E+K#R?!```8A0``!D`````````````
M````U(8``'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"+0`4``8`"```
M`"$`_>AZ=&\"``"O!0``&0````````````````"JBP``>&PO=V]R:W-H965T
M<R]S:&5E=#<R+GAM;%!+`0(M`!0`!@`(````(0#EZT\!U0H``%,Y```9````
M`````````````%".``!X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L!`BT`
M%``&``@````A`/MBI6V4!@``IQL``!,`````````````````7)D``'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"+0`4``8`"````"$`NTQZBIL,``"%=@``#0``
M```````````````AH```>&PO<W1Y;&5S+GAM;%!+`0(M`!0`!@`(````(0`4
M$;9;3*$``!,?`@`4`````````````````.>L``!X;"]S:&%R9613=')I;F=S
M+GAM;%!+`0(M`!0`!@`(````(0"@;-BUAP(``+4&```8````````````````
M`&5.`0!X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"+0`4``8`"````"$`
M#C5]R#T%``!V%0``&``````````````````B40$`>&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L!`BT`%``&``@````A`!=Z-G"Z`@``4@<``!D`````````
M````````E58!`'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"+0`4``8`
M"````"$`F+*EYND"```["```&0````````````````"&60$`>&PO=V]R:W-H
M965T<R]S:&5E=#<P+GAM;%!+`0(M`!0`!@`(````(0!TZ\M&Q`8``-D=```9
M`````````````````*9<`0!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L!
M`BT`%``&``@````A`-#\):+L`P``:@T``!D`````````````````H6,!`'AL
M+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"+0`4``8`"````"$`^5$B[5L#
M``#?"@``&0````````````````#$9P$`>&PO=V]R:W-H965T<R]S:&5E=#8T
M+GAM;%!+`0(M`!0`!@`(````(0"X]Q1!/0,``!`*```9````````````````
M`%9K`0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L!`BT`%``&``@````A
M`!,1T$MV`P``[PH``!D`````````````````RFX!`'AL+W=O<FMS:&5E=',O
M<VAE970V-BYX;6Q02P$"+0`4``8`"````"$`%0^!<C$#``#/"0``&0``````
M``````````!W<@$`>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+`0(M`!0`
M!@`(````(0`"I)2*E0(``$<&```9`````````````````-]U`0!X;"]W;W)K
M<VAE971S+W-H965T-C@N>&UL4$L!`BT`%``&``@````A`$`+;6=U`P``PPL`
M`!D`````````````````JW@!`'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"+0`4``8`"````"$`HINC!R8"``",!```&0````````````````!7?`$`
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+`0(M`!0`!@`(````(0`R&=-D
M=@(``+D%```9`````````````````+1^`0!X;"]W;W)K<VAE971S+W-H965T
M-#`N>&UL4$L!`BT`%``&``@````A`"VLMCR:!@``91H``!D`````````````
M````88$!`'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"+0`4``8`"```
M`"$`SCM\JI@,``""/P``&0`````````````````RB`$`>&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+`0(M`!0`!@`(````(0`,9/&6K`8``"<;```9````
M``````````````&5`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!`BT`
M%``&``@````A`/X_*`%[`@``$08``!D`````````````````Y)L!`'AL+W=O
M<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"+0`4``8`"````"$`/=\EDE1%``#(
MMP$`&0````````````````"6G@$`>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM
M;%!+`0(M`!0`!@`(````(0"=AS7(E0X``,Y,```9`````````````````"'D
M`0!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!`BT`%``&``@````A`/88
MN\]T`@``TP4``!D`````````````````[?(!`'AL+W=O<FMS:&5E=',O<VAE
M970R,"YX;6Q02P$"+0`4``8`"````"$`</7@[&,%``"$%```&0``````````
M``````"8]0$`>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(M`!0`!@`(
M````(0"67VQY9P0``)4.```9`````````````````#+[`0!X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L!`BT`%``&``@````A`-V5!R2K`@``Y@8``!D`
M````````````````T/\!`'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M+0`4``8`"````"$`"$_I=,L&``!;'```&`````````````````"R`@(`>&PO
M=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`BT`%``&``@````A`"AW)5AS`@``
MS04``!@`````````````````LPD"`'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;%!+`0(M`!0`!@`(````(0"OY/D)?`8``!D;```8`````````````````%P,
M`@!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"+0`4``8`"````"$`1%`[
MI)H"``"B!@``&``````````````````.$P(`>&PO=V]R:W-H965T<R]S:&5E
M=#@N>&UL4$L!`BT`%``&``@````A`"F47HG1'```6JT``!@`````````````
M````WA4"`'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+`0(M`!0`!@`(````
M(0#Q"6'WIQ$``%E@```9`````````````````.4R`@!X;"]W;W)K<VAE971S
M+W-H965T,3`N>&UL4$L!`BT`%``&``@````A`$?=W_^L`@``H08``!D`````
M````````````PT0"`'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"+0`4
M``8`"````"$`Z3'0]!4-``#L0@``&0````````````````"F1P(`>&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+`0(M`!0`!@`(````(0`"VJF';0,``-,+
M```9`````````````````/)4`@!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L!`BT`%``&``@````A`%:M@=_R`@``@@@``!D`````````````````EE@"
M`'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"+0`4``8`"````"$`@%=%
M>=\%``"U%0``&0````````````````"_6P(`>&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+`0(M`!0`!@`(````(0#T!HF+60,``$8*```9````````````
M`````-5A`@!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L!`BT`%``&``@`
M```A`#9(%8'9`@``40<``!D`````````````````964"`'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"+0`4``8`"````"$`[3\Z73X$``!%#P``&0``
M``````````````!U:`(`>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+`0(M
M`!0`!@`(````(0"*+L>)\`(```<(```9`````````````````.IL`@!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L!`BT`%``&``@````A`#CIQ\Z.`P``
M#`P``!D`````````````````$7`"`'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"+0`4``8`"````"$`A:O`)[TD``!IS0``&0````````````````#6
M<P(`>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+`0(M`!0`!@`(````(0`\
MRP0]^PL``"LZ```9`````````````````,J8`@!X;"]W;W)K<VAE971S+W-H
M965T,S,N>&UL4$L!`BT`%``&``@````A`%:/*'A]"P``]#8``!D`````````
M````````_*0"`'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"+0`4``8`
M"````"$`K0:I^2\:``"_EP``&0````````````````"PL`(`>&PO=V]R:W-H
M965T<R]S:&5E=#(T+GAM;%!+`0(M`!0`!@`(````(0`_W7:1=04``"04```9
M`````````````````!;+`@!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L!
M`BT`%``&``@````A`/8OCBL8"P``.C,``!D`````````````````PM`"`'AL
M+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"+0`4``8`"````"$`8G,1\3(&
M``#M%P``&0`````````````````1W`(`>&PO=V]R:W-H965T<R]S:&5E=#,Q
M+GAM;%!+`0(M`!0`!@`(````(0!"NU`X#P4``%D2```9````````````````
M`'KB`@!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L!`BT`%``&``@````A
M`-\5YF\/!```X`P``!D`````````````````P.<"`'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"+0`4``8`"````"$`HL#`X`X%``!9$@``&0``````
M```````````&[`(`>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+`0(M`!0`
M!@`(````(0!D4<_'E@```*H````0`````````````````$OQ`@!X;"]C86QC
M0VAA:6XN>&UL4$L!`BT`%``&``@````A`/<G2$WY`P``Y!```!``````````
M````````#_("`&1O8U!R;W!S+V%P<"YX;6Q02P$"+0`4``8`"````"$`Q0AT
M;S(!``!``@``$0`````````````````^]P(`9&]C4')O<',O8V]R92YX;6Q0
52P4&`````%,`4P"N%@``I_D"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6KAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Lease Equipment Under Capital Lease (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent" onclick="toggleNextSibling(this);">$ 25,477</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears" onclick="toggleNextSibling(this);">19,321</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" onclick="toggleNextSibling(this);">44,798</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less amount representing interest</a></td>
        <td class="num"><a title="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" onclick="toggleNextSibling(this);">(1,718)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments', window );">Present value of future minimum lease payments</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments" onclick="toggleNextSibling(this);">43,080</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Less current portion</a></td>
        <td class="num"><a title="us-gaap_CapitalLeaseObligationsCurrent" onclick="toggleNextSibling(this);">(24,112)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsCurrent</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligation, net of current portion</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeaseObligationsNoncurrent" onclick="toggleNextSibling(this);">$ 18,968</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsNoncurrent</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum lease payments for capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum lease payments for capital leases due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of minimum lease payments for capital leases due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDueInTwoYears</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Present value of minimum lease payments for capital leases net of executory costs, including amounts paid by the lessee to the lessor for insurance, maintenance and taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3S2O">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="3">0 Months Ended</th>
        <th class="th" colspan="1">2 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="8">1 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 27, 2013</div>
        </th>
        <th class="th">
          <div>May 02, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 13, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2013</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2013</div>
        </th>
        <th class="th">
          <div>Apr. 02, 2013</div>
        </th>
        <th class="th">
          <div>May 24, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2013</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 30, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012</div>
        </th>
        <th class="th">
          <div>Feb. 08, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Capital stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CapitalUnitsAuthorized" onclick="toggleNextSibling(this);">95,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalUnitsAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">90,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">90,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">90,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed', window );">Number of underwritten public offering common stock shares closed</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed" onclick="toggleNextSibling(this);">1,840,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuancePerShareAmount', window );">Common stock price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EquityIssuancePerShareAmount" onclick="toggleNextSibling(this);">$ 5.25</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityIssuancePerShareAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EquityIssuancePerShareAmount" onclick="toggleNextSibling(this);">$ 4.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EquityIssuancePerShareAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offerings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceInitialPublicOffering" onclick="toggleNextSibling(this);">$ 8,140,435</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters', window );">Additional shares purchased by underwriters</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters" onclick="toggleNextSibling(this);">276,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net cash proceeds from the exercise of the over-allotment option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">1,316,116</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters', window );">Stock issued during period value issued to underwriters</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters" onclick="toggleNextSibling(this);">179,860</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters</span><span></span></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters" onclick="toggleNextSibling(this);">179,860</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_UnderwritingAgreementDescription', window );">Underwriting agreement description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As contemplated by the underwriting agreement
entered into with MDB Capital Group, LLC, the lead underwriter for the Public Offering, at the closing of the Public Offering and
the over-allotment exercise, the lead underwriters received warrants (the &#147;Underwriter Warrants&#148;) to purchase up to
an aggregate of 179,860 shares, or 8.5% of the number of shares sold in the Public Offering (including 8.5% of shares sold pursuant
to the exercise of the over-allotment option). The Underwriter Warrants are exercisable at $5.25 per share (100% of the price to
the public of the common stock sold in the Public Offering), commencing on the closing date of the Public Offering and expire five
years from the closing date of the Public Offering.</p><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Payment made on cancellation of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" onclick="toggleNextSibling(this);">191</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Payment made on cancellation of common stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" onclick="toggleNextSibling(this);">35</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" onclick="toggleNextSibling(this);">139,444</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares', window );">Common stock issued settle cashless exercise provision, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares" onclick="toggleNextSibling(this);">1,030</a><span style="display:none;white-space:normal;text-align:left;">IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">66,439</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">219</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued upon exercise of stock options, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">227,216</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued upon exercise of stock options</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" onclick="toggleNextSibling(this);">583,811</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne', window );">Additional shares issued upon exercise of stock options, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne" onclick="toggleNextSibling(this);">160,777</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">10,052,832</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock', window );">Exercise of common stock option to purchase of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock" onclick="toggleNextSibling(this);">146,652</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares', window );">Issuance of common stock upon vesting of RSUs net of tax withholding , shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" onclick="toggleNextSibling(this);">1,954</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberOfCommonStockHeldForPayrollTax', window );">Number of common stock held for payroll tax</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_NumberOfCommonStockHeldForPayrollTax" onclick="toggleNextSibling(this);">1,518</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberOfCommonStockHeldForPayrollTax</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding', window );">Issuance of common stock upon vesting of RSUs net of tax withholding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" onclick="toggleNextSibling(this);">(13,109)</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Shares issued upon warrants exercise</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised" onclick="toggleNextSibling(this);">47,829</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodSharesWarrantsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised', window );">Shares issued upon exercise of warrant</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised" onclick="toggleNextSibling(this);">37,867</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock', window );">Warrants and shares issued upon excise of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock" onclick="toggleNextSibling(this);">6,391</a><span style="display:none;white-space:normal;text-align:left;">IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare', window );">Warrants to purchase common stock exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare" onclick="toggleNextSibling(this);">$ 5.925</a><span style="display:none;white-space:normal;text-align:left;">IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberOfWarrantsCommonStockIssued', window );">Number of warrants shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_NumberOfWarrantsCommonStockIssued" onclick="toggleNextSibling(this);">41,438</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberOfWarrantsCommonStockIssued</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ExerciseOfWarrantToPurchaseOfCommonStock', window );">Exercise of warrant to purchase of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_ExerciseOfWarrantToPurchaseOfCommonStock" onclick="toggleNextSibling(this);">123,715</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ExerciseOfWarrantToPurchaseOfCommonStock</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsSharesExercisePricePerShare', window );">Warrants shares exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_WarrantsSharesExercisePricePerShare" onclick="toggleNextSibling(this);">$ 5.25</a><span style="display:none;white-space:normal;text-align:left;">IMMY_WarrantsSharesExercisePricePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesAuthorized" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockParOrStatedValuePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesIssued" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesIssued</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PreferredStockSharesOutstanding" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PreferredStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_OptionsExercisePrice', window );">Stock option exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_OptionsExercisePrice" onclick="toggleNextSibling(this);">$ 7.50</a><span style="display:none;white-space:normal;text-align:left;">IMMY_OptionsExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" onclick="toggleNextSibling(this);">1,161,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockOptionsGrantedVestingTermsDescription', window );">Stock options granted vesting terms</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text"><p style="margin: 0pt"><font style="font: 10pt Times New Roman, Times, Serif">Vesting terms for options granted in fiscal years
2014 and 2013 to employees, directors and consultants typically included one of the following vesting schedules: 25% or 33% of
the shares subject to the option vest and become exercisable on the first anniversary of the grant date and the remaining 75%
or 67%, respectively, of the shares subject to the option vest and become exercisable in equal quarterly installments thereafter
over two or three years, respectively; quarterly vesting over a three year period; or monthly, quarterly or 100% vesting associated
with the provision or completion of services provided under contracts with consultants.</font></p><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to unvested stock options granted under the Plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" onclick="toggleNextSibling(this);">1,571,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expense expected to recognize over the weighted-average remaining vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 1 month 6 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock units issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" onclick="toggleNextSibling(this);">1,250,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_RestrictedStockVestInFuture', window );">Restricted stock vest in future</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_RestrictedStockVestInFuture" onclick="toggleNextSibling(this);">1,050,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_RestrictedStockVestInFuture</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_RestrictedStockVestedImmediately', window );">Restricted stock vested immediately</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_RestrictedStockVestedImmediately" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_RestrictedStockVestedImmediately</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Granted restricted stock units</a></td>
        <td class="nump"><a title="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" onclick="toggleNextSibling(this);">450,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_CancellationOfRestrictedStockUnitsDuringPeriod', window );">Number of granted restricted stock units unvested agreed to cancel</a></td>
        <td class="nump"><a title="IMMY_CancellationOfRestrictedStockUnitsDuringPeriod" onclick="toggleNextSibling(this);">120,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_CancellationOfRestrictedStockUnitsDuringPeriod</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings', window );">Fair value of restricted stock units</a></td>
        <td class="nump"><a title="us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings" onclick="toggleNextSibling(this);">189,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">2,614,619</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">3,134,973</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock based compensation of warrants issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" onclick="toggleNextSibling(this);">3,018,068</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">1,137,634</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">1,689,756</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_OptionIndexedToIssuersEquityTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Fair value assumption of volatility, minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">85.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Fair value assumption of volatility, maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">346.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Fair value assumption of risk free interest rates, minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">0.32%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Fair value assumption of risk free interest rates, maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">1.31%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock based compensation of warrants issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">26,649</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">468,777</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsExpiredDuration', window );">Warrants expire</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberOfWarrantsVestedImmeditely', window );">Number of warrants vested immeditely</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_NumberOfWarrantsVestedImmeditely[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">10,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberOfWarrantsVestedImmeditely<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberOfSharesVestedInInstallments', window );">Number of shares vested in installments for each five months</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_NumberOfSharesVestedInInstallments[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">4,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberOfSharesVestedInInstallments<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_FairValueOfWarrants', window );">Fair value of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_FairValueOfWarrants[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">319,786</a><span style="display:none;white-space:normal;text-align:left;">IMMY_FairValueOfWarrants<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=IMMY_WarrantActivityMember', window );">Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued to purchase number of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_StatementEquityComponentsAxis=IMMY_WarrantActivityMember]" onclick="toggleNextSibling(this);">60,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_StatementEquityComponentsAxis<br>= IMMY_WarrantActivityMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_StatementEquityComponentsAxis=IMMY_WarrantActivityMember]" onclick="toggleNextSibling(this);">30,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_StatementEquityComponentsAxis<br>= IMMY_WarrantActivityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsExercisePricePerShare', window );">Warrants exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_WarrantsExercisePricePerShare[us-gaap_StatementEquityComponentsAxis=IMMY_WarrantActivityMember]" onclick="toggleNextSibling(this);">$ 8.50</a><span style="display:none;white-space:normal;text-align:left;">IMMY_WarrantsExercisePricePerShare<br>/ us-gaap_StatementEquityComponentsAxis<br>= IMMY_WarrantActivityMember</span><span></span></td>
        <td class="nump"><a title="IMMY_WarrantsExercisePricePerShare[us-gaap_StatementEquityComponentsAxis=IMMY_WarrantActivityMember]" onclick="toggleNextSibling(this);"> 5.25</a><span style="display:none;white-space:normal;text-align:left;">IMMY_WarrantsExercisePricePerShare<br>/ us-gaap_StatementEquityComponentsAxis<br>= IMMY_WarrantActivityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationMember', window );">Monte Carlo Simulation [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_PlanNameAxis<br>= IMMY_MonteCarloSimulationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, life term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Fair value assumption of volatility, minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum[us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationMember]" onclick="toggleNextSibling(this);">75.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum<br>/ us-gaap_PlanNameAxis<br>= IMMY_MonteCarloSimulationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Fair value assumption of volatility, maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum[us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationMember]" onclick="toggleNextSibling(this);">85.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum<br>/ us-gaap_PlanNameAxis<br>= IMMY_MonteCarloSimulationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Fair value assumption of risk free interest rates, minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum[us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationMember]" onclick="toggleNextSibling(this);">0.13%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum<br>/ us-gaap_PlanNameAxis<br>= IMMY_MonteCarloSimulationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Fair value assumption of risk free interest rates, maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum[us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationMember]" onclick="toggleNextSibling(this);">0.36%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum<br>/ us-gaap_PlanNameAxis<br>= IMMY_MonteCarloSimulationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_EmployeesAndDirectorsMember', window );">Employees And Directors [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageOfForfeitureFactor', window );">Percentage of forfeiture factor</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_PercentageOfForfeitureFactor[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_EmployeesAndDirectorsMember]" onclick="toggleNextSibling(this);">10.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfForfeitureFactor<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_EmployeesAndDirectorsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ConsultantMember', window );">Consultant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock units issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ConsultantMember]" onclick="toggleNextSibling(this);">288,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ConsultantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ConsultantMember]" onclick="toggleNextSibling(this);">10,080</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ConsultantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ConsultantMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ConsultantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ConsultantMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ConsultantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ConsultantMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ConsultantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageOfRestrictedStockUnitsVested', window );">Percentage of restricted stock units vested</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_PercentageOfRestrictedStockUnitsVested[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ConsultantMember]" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfRestrictedStockUnitsVested<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ConsultantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageOfRemainingRestrictedStockUnitsVested', window );">Percentage of remaining restricted stock units vested</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_PercentageOfRemainingRestrictedStockUnitsVested[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ConsultantMember]" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfRemainingRestrictedStockUnitsVested<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ConsultantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Issuance of restricted stock units were forfeited and deemed, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ConsultantMember]" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ConsultantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_NonEmployeeDirectorsMember', window );">Non-Employee Directors [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock units issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_NonEmployeeDirectorsMember]" onclick="toggleNextSibling(this);">200,015</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_NonEmployeeDirectorsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_NonEmployeeDirectorsMember]" onclick="toggleNextSibling(this);">271,854</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_NonEmployeeDirectorsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_NonEmployeeDirectorsMember]" onclick="toggleNextSibling(this);">26,492</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_NonEmployeeDirectorsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_NonEmployeeDirectorsMember]" onclick="toggleNextSibling(this);">34,325</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_NonEmployeeDirectorsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_FormerDirectorsMember', window );">Former Directors [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock units issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_FormerDirectorsMember]" onclick="toggleNextSibling(this);">39,814</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_FormerDirectorsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_FormerDirectorsMember]" onclick="toggleNextSibling(this);">8,947</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_FormerDirectorsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_EmployeesMember', window );">Employees [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock units issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_EmployeesMember]" onclick="toggleNextSibling(this);">42,498</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_EmployeesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_EmployeesMember]" onclick="toggleNextSibling(this);">10,418</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_EmployeesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock shares issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">27,218</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">40,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">282,997</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberOfFutureIssuancesShareUnderPlan', window );">Number of future issuances share under the plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_NumberOfFutureIssuancesShareUnderPlan[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">2,366,369</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberOfFutureIssuancesShareUnderPlan<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to unvested stock options granted under the Plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">1,923,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expense expected to recognize over the weighted-average remaining vesting period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year 3 months 26 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | Non-Employee Directors [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Restricted stock units vest period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">13 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | Former Directors [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Restricted stock units vest period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">13 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member] | Employees [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Restricted stock units vest period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember', window );">2007 Incentive Stock And Awards Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Maximum number of common stock issuance under the plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant[us-gaap_AwardTypeAxis=IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant<br>/ us-gaap_AwardTypeAxis<br>= IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember', window );">Baum Performance Equity Award [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock units issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross[us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember]" onclick="toggleNextSibling(this);">189,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross<br>/ us-gaap_AwardTypeAxis<br>= IMMY_BaumPerformanceEquityAwardMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_InitialFairValueOfRestrictedStockUnitsShares', window );">Initial fair value of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_InitialFairValueOfRestrictedStockUnitsShares[us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember]" onclick="toggleNextSibling(this);">450,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_InitialFairValueOfRestrictedStockUnitsShares<br>/ us-gaap_AwardTypeAxis<br>= IMMY_BaumPerformanceEquityAwardMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember', window );">Baum Performance Equity Award [Member] | Monte Carlo Simulation [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember;us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationMember]" onclick="toggleNextSibling(this);">450,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_AwardTypeAxis<br>= IMMY_BaumPerformanceEquityAwardMember<br>/ us-gaap_PlanNameAxis<br>= IMMY_MonteCarloSimulationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, life term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember;us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationMember]" onclick="toggleNextSibling(this);">75.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= IMMY_BaumPerformanceEquityAwardMember<br>/ us-gaap_PlanNameAxis<br>= IMMY_MonteCarloSimulationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Fair value assumptions, risk free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember;us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationMember]" onclick="toggleNextSibling(this);">0.64%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= IMMY_BaumPerformanceEquityAwardMember<br>/ us-gaap_PlanNameAxis<br>= IMMY_MonteCarloSimulationMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember', window );">Baum Performance Equity Award [Member] | Monte Carlo Simulation One [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember;us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationOneMember]" onclick="toggleNextSibling(this);">600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_AwardTypeAxis<br>= IMMY_BaumPerformanceEquityAwardMember<br>/ us-gaap_PlanNameAxis<br>= IMMY_MonteCarloSimulationOneMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, life term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Fair value assumptions, volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember;us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationOneMember]" onclick="toggleNextSibling(this);">75.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= IMMY_BaumPerformanceEquityAwardMember<br>/ us-gaap_PlanNameAxis<br>= IMMY_MonteCarloSimulationOneMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Fair value assumptions, risk free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember;us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationOneMember]" onclick="toggleNextSibling(this);">0.30%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= IMMY_BaumPerformanceEquityAwardMember<br>/ us-gaap_PlanNameAxis<br>= IMMY_MonteCarloSimulationOneMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_RestrictedStockUnitsRSUOneMember', window );">Restricted Stock Units One [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_AwardTypeAxis=IMMY_RestrictedStockUnitsRSUOneMember]" onclick="toggleNextSibling(this);">1,332,176</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_AwardTypeAxis<br>= IMMY_RestrictedStockUnitsRSUOneMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation[us-gaap_AwardTypeAxis=IMMY_RestrictedStockUnitsRSUOneMember]" onclick="toggleNextSibling(this);">822,137</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation<br>/ us-gaap_AwardTypeAxis<br>= IMMY_RestrictedStockUnitsRSUOneMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option purchase of exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">$ 3.68</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_CommonStockExercisePricePerShare', window );">Common stock exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_CommonStockExercisePricePerShare[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">$ 3.60</a><span style="display:none;white-space:normal;text-align:left;">IMMY_CommonStockExercisePricePerShare<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1', window );">Contractual term of stock options granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_TargetRangingPrice', window );">Target ranging price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_TargetRangingPrice[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">$ 10</a><span style="display:none;white-space:normal;text-align:left;">IMMY_TargetRangingPrice<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson', window );">Granted restricted stock units per person</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">600,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Granted restricted stock units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">2,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, life term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 7 months 6 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option purchase of exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">$ 4.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_CommonStockExercisePricePerShare', window );">Common stock exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_CommonStockExercisePricePerShare[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">$ 6.00</a><span style="display:none;white-space:normal;text-align:left;">IMMY_CommonStockExercisePricePerShare<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1', window );">Contractual term of stock options granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_TargetRangingPrice', window );">Target ranging price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_TargetRangingPrice[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">$ 30</a><span style="display:none;white-space:normal;text-align:left;">IMMY_TargetRangingPrice<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson', window );">Granted restricted stock units per person</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">1,250,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Granted restricted stock units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Fair value assumptions, life term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock shares issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices[us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">4,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices[us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">2,114</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices[us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">29,160</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices[us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">10,750</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">6,868</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued shares value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_RestrictedStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=IMMY_MarkBaumMember', window );">Mark Baum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Number of shares issued for related party vesting of RSUs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures[us-gaap_TitleOfIndividualAxis=IMMY_MarkBaumMember]" onclick="toggleNextSibling(this);">40,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_MarkBaumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Granted restricted stock units</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings[us-gaap_TitleOfIndividualAxis=IMMY_MarkBaumMember]" onclick="toggleNextSibling(this);">450,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_MarkBaumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_CancellationOfRestrictedStockUnitsDuringPeriod', window );">Number of granted restricted stock units unvested agreed to cancel</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_CancellationOfRestrictedStockUnitsDuringPeriod[us-gaap_TitleOfIndividualAxis=IMMY_MarkBaumMember]" onclick="toggleNextSibling(this);">120,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_CancellationOfRestrictedStockUnitsDuringPeriod<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_MarkBaumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares', window );">Fair value of canceled restricted stock units plus incremental cost, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares[us-gaap_TitleOfIndividualAxis=IMMY_MarkBaumMember]" onclick="toggleNextSibling(this);">450,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_MarkBaumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_TitleOfIndividualAxis=IMMY_MarkBaumMember]" onclick="toggleNextSibling(this);">450,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_MarkBaumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=IMMY_MarkBaumMember', window );">Mark Baum [Member] | Baum Performance Equity Award [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock units issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross[us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember;us-gaap_TitleOfIndividualAxis=IMMY_MarkBaumMember]" onclick="toggleNextSibling(this);">3,515,090</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross<br>/ us-gaap_AwardTypeAxis<br>= IMMY_BaumPerformanceEquityAwardMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_MarkBaumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember;us-gaap_TitleOfIndividualAxis=IMMY_MarkBaumMember]" onclick="toggleNextSibling(this);">600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_AwardTypeAxis<br>= IMMY_BaumPerformanceEquityAwardMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_MarkBaumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_InitialFairValueOfRestrictedStockUnitsShares', window );">Initial fair value of restricted stock units, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_InitialFairValueOfRestrictedStockUnitsShares[us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember;us-gaap_TitleOfIndividualAxis=IMMY_MarkBaumMember]" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_InitialFairValueOfRestrictedStockUnitsShares<br>/ us-gaap_AwardTypeAxis<br>= IMMY_BaumPerformanceEquityAwardMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_MarkBaumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=IMMY_DrRobertKammerMember', window );">Dr. Robert Kammer [Member] | Restricted Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock shares issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices[us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=IMMY_DrRobertKammerMember]" onclick="toggleNextSibling(this);">40,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_DrRobertKammerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices[us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember;us-gaap_TitleOfIndividualAxis=IMMY_DrRobertKammerMember]" onclick="toggleNextSibling(this);">$ 282,997</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices<br>/ us-gaap_StatementClassOfStockAxis<br>= us-gaap_RestrictedStockMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_DrRobertKammerMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_CancellationOfRestrictedStockUnitsDuringPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cancellation Of Restricted Stock Units During Period</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_CancellationOfRestrictedStockUnitsDuringPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_CommonStockExercisePricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock exercise price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_CommonStockExercisePricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock issued settle cash less exercise provision shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_CommonStockIssuedSettleCashlessExerciseProvisionShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise of common stock option to purchase of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ExerciseOfCommonStockOptionToPurchaseOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ExerciseOfWarrantToPurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise of warrant to purchase of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ExerciseOfWarrantToPurchaseOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of canceled restricted stock units plus incremental cost shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_FairValueOfCanceledRestrictedStockUnitsPlusIncrementalCostShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_FairValueOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair Value Of Warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_FairValueOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_InitialFairValueOfRestrictedStockUnitsShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial fair value of restricted stock units shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_InitialFairValueOfRestrictedStockUnitsShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock Upon Vesting Of Rsus Net Of Tax Withholding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock Upon Vesting Of Rsus Net Of Tax Withholding Shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_NumberOfCommonStockHeldForPayrollTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common stock held for payroll tax.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_NumberOfCommonStockHeldForPayrollTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_NumberOfFutureIssuancesShareUnderPlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of future issuances share under the plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_NumberOfFutureIssuancesShareUnderPlan</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_NumberOfSharesVestedInInstallments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of Shares Vested in Installments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_NumberOfSharesVestedInInstallments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of underwritten public offering common stock shares closed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_NumberOfUnderwrittenPublicOfferingCommonStockSharesClosed</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_NumberOfWarrantsCommonStockIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants shares issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_NumberOfWarrantsCommonStockIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_NumberOfWarrantsVestedImmeditely">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants vested immeditely.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_NumberOfWarrantsVestedImmeditely</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_OptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options exercise price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_OptionsExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_PercentageOfForfeitureFactor">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of forfeiture factor.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_PercentageOfForfeitureFactor</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_PercentageOfRemainingRestrictedStockUnitsVested">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of remaining restricted stock units vested.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_PercentageOfRemainingRestrictedStockUnitsVested</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_PercentageOfRestrictedStockUnitsVested">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of restricted stock units vested.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_PercentageOfRestrictedStockUnitsVested</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restricted Stock Units Granted During Period Per Person</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_RestrictedStockUnitsGrantedDuringPeriodPerPerson</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_RestrictedStockVestedImmediately">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restricted Stock Vested Immediately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_RestrictedStockVestedImmediately</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_RestrictedStockVestInFuture">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restricted Stock Vest In Future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_RestrictedStockVestInFuture</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based Compensation Arrangement By Share based Payment Award Options Granted Weighted Average Remaining Contractual Term1.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares issued to underwriters.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockIssuedDuringPeriodSharesIssuedToUnderwriters</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period Shares Stock Options Exercised One.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockIssuedDuringPeriodSharesWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period Shares Warrants Exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockIssuedDuringPeriodSharesWarrantsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period value issued to underwriters.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockIssuedDuringPeriodValueIssuedToUnderwriters</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockOptionsGrantedVestingTermsDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Options Granted Vesting Terms Description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockOptionsGrantedVestingTermsDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Shares issued upon exercise of warrant.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockWarrantsIssuedDuringPeriodValueOfStockExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_TargetRangingPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Target Ranging Price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_TargetRangingPrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_UnderwritingAgreementDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Underwriting Agreement Description</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_UnderwritingAgreementDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants and shares issued upon excise of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_WarrantsAndSharesIssuedUponExciseOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_WarrantsExercisePricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Exercise Price Per Share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_WarrantsExercisePricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_WarrantsExpiredDuration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Expired Duration</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_WarrantsExpiredDuration</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_WarrantsSharesExercisePricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants shares exercise price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_WarrantsSharesExercisePricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants to purchase common stock exercise price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_WarrantsToPurchaseCommonStockExercisePricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-04.16(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuancePerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit assigned to the consideration received of equity securities issued for development stage entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 215<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472370&amp;loc=d3e38297-110927<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityIssuancePerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of restricted shares issued as compensation, net of shares for the payment of withholding taxes. This element is to be used only if shares are used in lieu of cash to satisfy all or a portion of withholding taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The value of restricted shares issued as compensation, net of the value of shares for the payment of withholding taxes. This element is to be used only if shares are used in lieu of cash to satisfy all or a portion of withholding taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares related to Restricted Stock Award forfeited during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares that have been repurchased and retired during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_BaumPerformanceEquityAwardMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_RestrictedStockUnitsRSUOneMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_RestrictedStockUnitsRSUOneMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_TwoThousandSecenIncentiveStockAndAwardsPlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PlanNameAxis=IMMY_MonteCarloSimulationMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ConsultantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ConsultantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_EmployeesAndDirectorsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_EmployeesAndDirectorsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_EmployeesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_EmployeesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_FormerDirectorsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_FormerDirectorsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_NonEmployeeDirectorsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_NonEmployeeDirectorsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RestrictedStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=IMMY_WarrantActivityMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=IMMY_WarrantActivityMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=IMMY_DrRobertKammerMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=IMMY_DrRobertKammerMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=IMMY_MarkBaumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=IMMY_MarkBaumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EFH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Furniture and Equipment (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization of furniture and equipment</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 37,343</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 5,659</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to taxation in
the United States and California. The provision for income taxes for the years ended December 31, 2014 and 2013 are summarized
below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2013</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Current:</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Federal</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">State</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,800</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total current</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,800</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Deferred:</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Federal</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">11,082,459</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8,075,342</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">State</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3,100,627</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,233,726</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Change in valuation allowance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(14,183,086</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(10,309,068</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total deferred</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Income tax provision (benefit)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,800</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Income Tax Reconciliation</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of income taxes
computed by applying the statutory U.S. income tax rate to the Company&#146;s loss before income taxes to the income tax
provision is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2013</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">U.S. federal statutory tax rate</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">35.00</font></td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">35.00</font></td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Benefit of lower tax brackets</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">State tax benefit, net</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.03</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Research and development credits</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.43</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Employee stock based compensation</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1.03</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(4.72</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Loss on debt conversion</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.21</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.08</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(32.76</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(29.63</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Effective income tax rate</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.03</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities
reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Significant components of the Company&#146;s deferred tax assets are as
follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2013</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets (liabilities):</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 58%; padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NOL&#146;s</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,922,914</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7,364,058</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation and amortization</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(6,787</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(340</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">64,806</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">129,191</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Research &#38; development credits</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">555,945</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">563,485</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Deferred stock compensation</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,646,208</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,252,674</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Unrealized gain or loss on investments</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total deferred tax assets</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">14,183,086</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,309,068</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(14,183,086</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(10,309,068</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Net deferred tax assets</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EP6BK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Mar. 11, 2015</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2015</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2015

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Jan. 02, 2015</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Shares issued upon exercise of warrants, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised" onclick="toggleNextSibling(this);">47,829</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodSharesWarrantsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">9,258,231</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">8,970,364</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for each payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">66,439</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">219</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsForRent" onclick="toggleNextSibling(this);">306,465</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsForRent" onclick="toggleNextSibling(this);">103,191</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiration of lease term</a></td>
        <td class="text">Oct. 31,  2018<span></span></td>
        <td class="text">Sep. 30,  2016<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Shares issued upon exercise of warrants, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodSharesWarrantsExercised[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">12,658</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodSharesWarrantsExercised<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfWarrants[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">74,998</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfWarrants<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants shares exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 5.925</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period resticted common stock issued, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">8,521</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Lease Agreement [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_AreaOfSquareFeet', window );">Number of square feets of lab and office</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_AreaOfSquareFeet[IMMY_AgreementAxis=IMMY_LeaseAgreementMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">8,602</a><span style="display:none;white-space:normal;text-align:left;">IMMY_AreaOfSquareFeet<br>/ IMMY_AgreementAxis<br>= IMMY_LeaseAgreementMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_AreaOfSquareFeet[IMMY_AgreementAxis=IMMY_LeaseAgreementMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">8,602</a><span style="display:none;white-space:normal;text-align:left;">IMMY_AreaOfSquareFeet<br>/ IMMY_AgreementAxis<br>= IMMY_LeaseAgreementMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsForRent[IMMY_AgreementAxis=IMMY_LeaseAgreementMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">9,548</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRent<br>/ IMMY_AgreementAxis<br>= IMMY_LeaseAgreementMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageOfAnnualRentIncreases', window );">Percentage of annual rent increases</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_PercentageOfAnnualRentIncreases[IMMY_AgreementAxis=IMMY_LeaseAgreementMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">3.75%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfAnnualRentIncreases<br>/ IMMY_AgreementAxis<br>= IMMY_LeaseAgreementMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_PercentageOfAnnualRentIncreases[IMMY_AgreementAxis=IMMY_LeaseAgreementMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">3.75%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfAnnualRentIncreases<br>/ IMMY_AgreementAxis<br>= IMMY_LeaseAgreementMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Expiration of lease term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jul. 31,  2022<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Park Sellers [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForPreviousAcquisition', window );">Aggregate cash purchase price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsForPreviousAcquisition[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ParkSellersMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">3,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForPreviousAcquisition<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ParkSellersMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ParkSellersMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">63,525</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ParkSellersMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_AverageClosingPriceOfCommonStock', window );">Common stock value based on average closing price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_AverageClosingPriceOfCommonStock[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ParkSellersMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">500,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_AverageClosingPriceOfCommonStock<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ParkSellersMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_QuarterlyCashPayments', window );">Quarterly cash payments for acquisition</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_QuarterlyCashPayments[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ParkSellersMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">53,125</a><span style="display:none;white-space:normal;text-align:left;">IMMY_QuarterlyCashPayments<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ParkSellersMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_AmountOfClosingPrice', window );">Amount of closing price, total</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_AmountOfClosingPrice[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ParkSellersMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">637,500</a><span style="display:none;white-space:normal;text-align:left;">IMMY_AmountOfClosingPrice<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ParkSellersMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_AggregatedAmountOfClosingPrice', window );">Aggregated amount of closing price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_AggregatedAmountOfClosingPrice[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ParkSellersMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">318,750</a><span style="display:none;white-space:normal;text-align:left;">IMMY_AggregatedAmountOfClosingPrice<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ParkSellersMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for each payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ParkSellersMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">6,749</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ParkSellersMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_AreaOfSquareFeet', window );">Number of square feets of lab and office</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_AreaOfSquareFeet[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ParkSellersMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">4,500</a><span style="display:none;white-space:normal;text-align:left;">IMMY_AreaOfSquareFeet<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ParkSellersMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsForRent[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ParkSellersMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">9,788</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRent<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ParkSellersMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageOfAnnualRentIncreases', window );">Percentage of annual rent increases</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_PercentageOfAnnualRentIncreases[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_ParkSellersMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">3.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfAnnualRentIncreases<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_ParkSellersMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Andrew R. Boll's [Member] | RSU [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period resticted common stock issued, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_AndrewRBollsMember;us-gaap_StatementEquityComponentsAxis=IMMY_RSUMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">30,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_AndrewRBollsMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= IMMY_RSUMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Andrew R. Boll's [Member] | CFO Employment Agreement [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period resticted common stock issued, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[IMMY_AgreementAxis=IMMY_CFOEmploymentAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_AndrewRBollsMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">157,500</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ IMMY_AgreementAxis<br>= IMMY_CFOEmploymentAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_AndrewRBollsMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_EmploymentAgreementTerm', window );">Employment agreement term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Annual base salary</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_OfficersCompensation[IMMY_AgreementAxis=IMMY_CFOEmploymentAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_AndrewRBollsMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OfficersCompensation<br>/ IMMY_AgreementAxis<br>= IMMY_CFOEmploymentAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_AndrewRBollsMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageOfCurrentAnnualSalary', window );">Percentage of current annual salary</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_PercentageOfCurrentAnnualSalary[IMMY_AgreementAxis=IMMY_CFOEmploymentAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_AndrewRBollsMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">20.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfCurrentAnnualSalary<br>/ IMMY_AgreementAxis<br>= IMMY_CFOEmploymentAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_AndrewRBollsMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_PercentageOfCurrentAnnualSalary[IMMY_AgreementAxis=IMMY_CFOEmploymentAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_AndrewRBollsMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">20.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfCurrentAnnualSalary<br>/ IMMY_AgreementAxis<br>= IMMY_CFOEmploymentAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_AndrewRBollsMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageOfIncreasesCurrentAnnualSalary', window );">Percentage of target current annual salary</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_PercentageOfIncreasesCurrentAnnualSalary[IMMY_AgreementAxis=IMMY_CFOEmploymentAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_AndrewRBollsMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfIncreasesCurrentAnnualSalary<br>/ IMMY_AgreementAxis<br>= IMMY_CFOEmploymentAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_AndrewRBollsMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_PercentageOfIncreasesCurrentAnnualSalary[IMMY_AgreementAxis=IMMY_CFOEmploymentAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_AndrewRBollsMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfIncreasesCurrentAnnualSalary<br>/ IMMY_AgreementAxis<br>= IMMY_CFOEmploymentAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_AndrewRBollsMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | John P. Saharek [Member] | RSU [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period resticted common stock issued, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_JohnPSaharekMember;us-gaap_StatementEquityComponentsAxis=IMMY_RSUMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">30,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_JohnPSaharekMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= IMMY_RSUMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | John P. Saharek [Member] | CCO Employment Agreement [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants shares exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[IMMY_AgreementAxis=IMMY_CCOEmploymentAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_JohnPSaharekMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 7.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ IMMY_AgreementAxis<br>= IMMY_CCOEmploymentAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_JohnPSaharekMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[IMMY_AgreementAxis=IMMY_CCOEmploymentAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_JohnPSaharekMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);"> 7.37</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ IMMY_AgreementAxis<br>= IMMY_CCOEmploymentAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_JohnPSaharekMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period resticted common stock issued, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross[IMMY_AgreementAxis=IMMY_CCOEmploymentAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_JohnPSaharekMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">90,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross<br>/ IMMY_AgreementAxis<br>= IMMY_CCOEmploymentAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_JohnPSaharekMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_EmploymentAgreementTerm', window );">Employment agreement term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Annual base salary</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_OfficersCompensation[IMMY_AgreementAxis=IMMY_CCOEmploymentAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_JohnPSaharekMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);"> 220,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OfficersCompensation<br>/ IMMY_AgreementAxis<br>= IMMY_CCOEmploymentAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_JohnPSaharekMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageOfCurrentAnnualSalary', window );">Percentage of current annual salary</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_PercentageOfCurrentAnnualSalary[IMMY_AgreementAxis=IMMY_CCOEmploymentAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_JohnPSaharekMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfCurrentAnnualSalary<br>/ IMMY_AgreementAxis<br>= IMMY_CCOEmploymentAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_JohnPSaharekMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_PercentageOfCurrentAnnualSalary[IMMY_AgreementAxis=IMMY_CCOEmploymentAgreementMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_JohnPSaharekMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">50.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfCurrentAnnualSalary<br>/ IMMY_AgreementAxis<br>= IMMY_CCOEmploymentAgreementMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_JohnPSaharekMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_TermOfStockOption', window );">Term of stock option</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_AggregatedAmountOfClosingPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregated Amount Of Closing Price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_AggregatedAmountOfClosingPrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_AmountOfClosingPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount Of Closing Price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_AmountOfClosingPrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_AreaOfSquareFeet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Area Of Square Feet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_AreaOfSquareFeet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:areaItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_AverageClosingPriceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average Closing Price Of Common Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_AverageClosingPriceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_EmploymentAgreementTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Employment Agreement Term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_EmploymentAgreementTerm</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_PercentageOfAnnualRentIncreases">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of annual rent increases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_PercentageOfAnnualRentIncreases</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_PercentageOfCurrentAnnualSalary">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage Of Current Annual Salary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_PercentageOfCurrentAnnualSalary</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_PercentageOfIncreasesCurrentAnnualSalary">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage Of Increases Current Annual Salary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_PercentageOfIncreasesCurrentAnnualSalary</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_QuarterlyCashPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Quarterly Cash Payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_QuarterlyCashPayments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockIssuedDuringPeriodSharesWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period Shares Warrants Exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockIssuedDuringPeriodSharesWarrantsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_TermOfStockOption">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Term Of Stock Option.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_TermOfStockOption</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPreviousAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash outflow representing an adjustment to the purchase price of a previous acquisition.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsForPreviousAcquisition</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash payments to lessor's for use of assets under operating leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E4HBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Fair Value Assumption (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 5.12</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">85.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">346.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">0.32%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">1.31%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (in years)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years 7 months 6 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (in years)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember', window );">Options Granted To Employees [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember]" onclick="toggleNextSibling(this);">$ 5.22</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsEmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember]" onclick="toggleNextSibling(this);">$ 6.04</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsEmployeesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum[us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember]" onclick="toggleNextSibling(this);">96.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsEmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum[us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember]" onclick="toggleNextSibling(this);">102.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsEmployeesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum[us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember]" onclick="toggleNextSibling(this);">102.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsEmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum[us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember]" onclick="toggleNextSibling(this);">123.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsEmployeesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum[us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember]" onclick="toggleNextSibling(this);">1.37%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsEmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum[us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember]" onclick="toggleNextSibling(this);">0.86%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsEmployeesMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum[us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember]" onclick="toggleNextSibling(this);">1.65%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsEmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum[us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember]" onclick="toggleNextSibling(this);">2.05%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsEmployeesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsEmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsEmployeesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember', window );">Options Granted To Employees [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (in years)</a></td>
        <td class="text">5 years 9 months 22 days<span></span></td>
        <td class="text">5 years 9 months 18 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember', window );">Options Granted To Employees [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (in years)</a></td>
        <td class="text">6 years 10 months 28 days<span></span></td>
        <td class="text">7 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember', window );">Options Granted To Consultants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of options granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember]" onclick="toggleNextSibling(this);">$ 6.15</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsGrantedConsultantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember]" onclick="toggleNextSibling(this);">$ 5.63</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsGrantedConsultantsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum[us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember]" onclick="toggleNextSibling(this);">78.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsGrantedConsultantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum[us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember]" onclick="toggleNextSibling(this);">80.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsGrantedConsultantsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum[us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember]" onclick="toggleNextSibling(this);">97.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsGrantedConsultantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum[us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember]" onclick="toggleNextSibling(this);">366.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsGrantedConsultantsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum[us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember]" onclick="toggleNextSibling(this);">0.10%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsGrantedConsultantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum[us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember]" onclick="toggleNextSibling(this);">0.30%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsGrantedConsultantsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum[us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember]" onclick="toggleNextSibling(this);">1.68%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsGrantedConsultantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum[us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember]" onclick="toggleNextSibling(this);">2.45%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsGrantedConsultantsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsGrantedConsultantsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= IMMY_OptionsGrantedConsultantsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember', window );">Options Granted To Consultants [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (in years)</a></td>
        <td class="text">2 years 6 months<span></span></td>
        <td class="text">2 years 3 months 29 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember', window );">Options Granted To Consultants [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected terms (in years)</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">10 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_OptionsEmployeesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_OptionsGrantedConsultantsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Payments Under Leases (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths" onclick="toggleNextSibling(this);">$ 492,503</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" onclick="toggleNextSibling(this);">468,997</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree', window );">2017</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree" onclick="toggleNextSibling(this);">481,443</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour', window );">2018</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour" onclick="toggleNextSibling(this);">495,938</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive', window );">2019</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive" onclick="toggleNextSibling(this);">257,039</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive', window );">Thereafter</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive" onclick="toggleNextSibling(this);">478,473</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" onclick="toggleNextSibling(this);">$ 2,674,393</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings Per Common Share</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the computation
of basic and diluted net loss per share of common stock for the years ended December 31, 2014 and 2013:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2013</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Numerator &#150; net loss</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(10,118,103</font></td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(7,643,124</font></td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Denominator &#150; weighted average number of shares outstanding, basic and diluted</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9,132,989</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8,656,822</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Net loss per share, basic and diluted</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1.11</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.88</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZKAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" onclick="toggleNextSibling(this);">$ 67,087</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" onclick="toggleNextSibling(this);">67,087</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2017</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" onclick="toggleNextSibling(this);">67,087</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2018</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" onclick="toggleNextSibling(this);">57,712</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2019</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" onclick="toggleNextSibling(this);">53,837</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" onclick="toggleNextSibling(this);">298,184</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
        <td class="nump"><a title="us-gaap_IntangibleAssetsNetExcludingGoodwill" onclick="toggleNextSibling(this);">$ 610,994</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IntangibleAssetsNetExcludingGoodwill</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph ((a)(1),(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EEQAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition - Pharmacy Creations, Llc - Schedule of Intangible Assets Acquisition (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Fair Value</a></td>
        <td class="nump"><a title="us-gaap_FinitelivedIntangibleAssetsAcquired1" onclick="toggleNextSibling(this);">$ 659,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FinitelivedIntangibleAssetsAcquired1</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Fair Value</a></td>
        <td class="nump"><a title="us-gaap_FinitelivedIntangibleAssetsAcquired1[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember]" onclick="toggleNextSibling(this);">596,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FinitelivedIntangibleAssetsAcquired1<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_CustomerRelationshipsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful Life</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful Life</a></td>
        <td class="text">15 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Name [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Fair Value</a></td>
        <td class="nump"><a title="us-gaap_FinitelivedIntangibleAssetsAcquired1[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember]" onclick="toggleNextSibling(this);">5,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FinitelivedIntangibleAssetsAcquired1<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_TradeNamesMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful Life</a></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=IMMY_NonCompetitionCovenantMember', window );">Non-Competition Covenant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Fair Value</a></td>
        <td class="nump"><a title="us-gaap_FinitelivedIntangibleAssetsAcquired1[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=IMMY_NonCompetitionCovenantMember]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FinitelivedIntangibleAssetsAcquired1<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= IMMY_NonCompetitionCovenantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful Life</a></td>
        <td class="text">4 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">State Pharmacy Licenses [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Fair Value</a></td>
        <td class="nump"><a title="us-gaap_FinitelivedIntangibleAssetsAcquired1[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember]" onclick="toggleNextSibling(this);">$ 8,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FinitelivedIntangibleAssetsAcquired1<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_LicensingAgreementsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful Life</a></td>
        <td class="text">25 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, resulting from a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=IMMY_NonCompetitionCovenantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=IMMY_NonCompetitionCovenantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EMZAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition - Pharmacy Creations, LLC (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for business acquisition</a></td>
        <td class="nump"><a title="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" onclick="toggleNextSibling(this);">$ 636,374</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Fair value of liability for estimated acquisition</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" onclick="toggleNextSibling(this);">514,622</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember', window );">Pharmacy Creations, LLC [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for business acquisition</a></td>
        <td class="nump"><a title="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PaymentOfCashToContigent', window );">Contingent cash payment</a></td>
        <td class="nump"><a title="IMMY_PaymentOfCashToContigent[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PaymentOfCashToContigent<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ExpectedRevenueDuringAcquisition', window );">Expected revenue</a></td>
        <td class="nump"><a title="IMMY_ExpectedRevenueDuringAcquisition[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">3,500,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ExpectedRevenueDuringAcquisition<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ExpectedRevenueDate', window );">Expected revenue date</a></td>
        <td class="text">Mar. 31,  2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberOfSharesAppliedForContigentStockPayment', window );">Maximum number of common stock applied for contingent stock payment</a></td>
        <td class="nump"><a title="IMMY_NumberOfSharesAppliedForContigentStockPayment[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">215,190</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberOfSharesAppliedForContigentStockPayment<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyDescription', window );">Condition for contingent stock payment</a></td>
        <td class="text"><p style="margin: 0pt">if PC earns revenue of over $7,500,000 during the 12 month period ending March 31, 2016, all 215,190 shares;</p>

<p style="margin: 0pt">&#160;</p>

<p style="margin: 0pt">if PC earns revenue of between $3,500,000 and $7,500,000 during the 12 month period ending March 31, 2016,
an aggregate of that number of shares of Imprimis common stock equal to the amount that such revenue exceeds $3,500,000 divided
by 18.5882, rounded down to the lower whole number (not to exceed 215,190 shares).</p><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business acquisition, total fair value transferred</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationConsiderationTransferred1[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">1,114,622</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationConsiderationTransferred1<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill', window );">Business combination purchase price allocation for good will</a></td>
        <td class="nump"><a title="IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">331,621</a><span style="display:none;white-space:normal;text-align:left;">IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember', window );">Pharmacy Creations, LLC [Member] | Minimum [Member] | Period Ending March 31, 2016</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ExpectedRevenueDuringAcquisition', window );">Expected revenue</a></td>
        <td class="nump"><a title="IMMY_ExpectedRevenueDuringAcquisition[us-gaap_CreationDateAxis=IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember;dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember;us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">3,500,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ExpectedRevenueDuringAcquisition<br>/ us-gaap_CreationDateAxis<br>= IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ExpectedRevenueDate', window );">Expected revenue date</a></td>
        <td class="text">Mar. 31,  2016<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember', window );">Pharmacy Creations, LLC [Member] | Maximum [Member] | Period Ending March 31, 2016</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ExpectedRevenueDuringAcquisition', window );">Expected revenue</a></td>
        <td class="nump"><a title="IMMY_ExpectedRevenueDuringAcquisition[us-gaap_CreationDateAxis=IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember;dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember;us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">$ 7,500,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ExpectedRevenueDuringAcquisition<br>/ us-gaap_CreationDateAxis<br>= IMMY_PeriodEndingMarchThirtyFirstTwoThousandSixteenMember<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ExpectedRevenueDate', window );">Expected revenue date</a></td>
        <td class="text">Mar. 31,  2016<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business Acquisition Purchase Price Allocation Goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_BusinessAcquisitionPurchasePriceAllocationGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ExpectedRevenueDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected revenue date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ExpectedRevenueDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ExpectedRevenueDuringAcquisition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected revenue.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ExpectedRevenueDuringAcquisition</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_NumberOfSharesAppliedForContigentStockPayment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number Of Shares Applied For Contigent Stock Payment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_NumberOfSharesAppliedForContigentStockPayment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_PaymentOfCashToContigent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payment Of Cash To Contigent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_PaymentOfCashToContigent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 25<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 35<br><br> -Paragraph 1<br><br> -Subparagraph b<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes an existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible gain to the entity that will ultimately be realized when one or more future events occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GainContingencyDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details Narratvie) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2013

</div>
          <div>sqft</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of office space</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AreaOfLand" onclick="toggleNextSibling(this);">7,565</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AreaOfLand</span><span></span></td>
        <td class="nump"><a title="us-gaap_AreaOfLand" onclick="toggleNextSibling(this);">7,565</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AreaOfLand</span><span></span></td>
        <td class="nump"><a title="us-gaap_AreaOfLand" onclick="toggleNextSibling(this);">3,874</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AreaOfLand</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PreviousOfficeSpaceArea', window );">Area of previous office space</a></td>
        <td class="nump"><a title="IMMY_PreviousOfficeSpaceArea" onclick="toggleNextSibling(this);">3,874</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PreviousOfficeSpaceArea</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_RecognizedLeaseLossesRelatedToLeaseLiability', window );">Recognized lease losses related to estimated remaining lease liability</a></td>
        <td class="nump"><a title="IMMY_RecognizedLeaseLossesRelatedToLeaseLiability" onclick="toggleNextSibling(this);">$ 117,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_RecognizedLeaseLossesRelatedToLeaseLiability</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Stock based compensation accrual</a></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" onclick="toggleNextSibling(this);">39,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Stock-based compensation expense related to restricted common stock issuances and accruals</a></td>
        <td class="nump"><a title="us-gaap_RestrictedStockExpense" onclick="toggleNextSibling(this);">$ 39,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedStockExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedStockExpense" onclick="toggleNextSibling(this);">$ 143,553</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedStockExpense</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_PreviousOfficeSpaceArea">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Previous Office Space Area.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_PreviousOfficeSpaceArea</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:areaItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_RecognizedLeaseLossesRelatedToLeaseLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Recognized lease losses related to estimated remaining lease liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_RecognizedLeaseLossesRelatedToLeaseLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Area of land held.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:areaItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1OAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards', window );">NOL's</a></td>
        <td class="nump"><a title="IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" onclick="toggleNextSibling(this);">$ 10,922,914</a><span style="display:none;white-space:normal;text-align:left;">IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards</span><span></span></td>
        <td class="nump"><a title="IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards" onclick="toggleNextSibling(this);">$ 7,364,058</a><span style="display:none;white-space:normal;text-align:left;">IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="num"><a title="IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" onclick="toggleNextSibling(this);">(6,787)</a><span style="display:none;white-space:normal;text-align:left;">IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization</span><span></span></td>
        <td class="num"><a title="IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization" onclick="toggleNextSibling(this);">(340)</a><span style="display:none;white-space:normal;text-align:left;">IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Other</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" onclick="toggleNextSibling(this);">64,806</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" onclick="toggleNextSibling(this);">129,191</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research &amp; development credits</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" onclick="toggleNextSibling(this);">555,945</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" onclick="toggleNextSibling(this);">563,485</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Deferred stock compensation</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="toggleNextSibling(this);">2,646,208</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" onclick="toggleNextSibling(this);">2,252,674</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross', window );">Unrealized gain or loss on investments</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">14,183,086</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGross" onclick="toggleNextSibling(this);">10,309,068</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(14,183,086)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(10,309,068)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred Tax Assets Tax Acquired Net Operating Loss And Credit Carry Forwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_DeferredTaxAssetsTaxAcquiredNetOperatingLossAndCreditCarryForwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred Tax Asset Tax Credit carry Forwards Depreciation And Amortization.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_DeferredTaxAssetTAxCreditXarryForwardsDepreciationAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to other deductible tax credit carryforwards not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Warrants Activity (Details) (Warrant [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares, Outstanding, Beginning balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">821,050</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares Subject to Warrants Outstanding, Granted</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares Subject to Warrants Outstanding, Exercised</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">(130,106)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares Subject to Warrants Outstanding, Expired</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares, Outstanding, Ending balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">690,944</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life Of The Outstanding Warrants In Years</a></td>
        <td class="text">10 months 10 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Outstanding, Beginning balance</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 5.94</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Granted</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Exercised</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 5.28</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Expired</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Outstanding, Ending balance</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 6.05</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercisable Weighted Average Remaining Contractual Term</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of non-option equity instruments exercised by participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of non-option equity instruments granted to participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2KAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Furniture and Equipment - Schedule of Furniture and Equipment (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Computer software and hardware</a></td>
        <td class="nump"><a title="us-gaap_CapitalizedComputerSoftwareGross" onclick="toggleNextSibling(this);">$ 52,576</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalizedComputerSoftwareGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_CapitalizedComputerSoftwareGross" onclick="toggleNextSibling(this);">$ 24,536</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalizedComputerSoftwareGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and equipment</a></td>
        <td class="nump"><a title="us-gaap_FurnitureAndFixturesGross" onclick="toggleNextSibling(this);">154,215</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FurnitureAndFixturesGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_FurnitureAndFixturesGross" onclick="toggleNextSibling(this);">10,449</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FurnitureAndFixturesGross</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_LabAndPharmacyEquipmentGross', window );">Lab and pharmacy equipment</a></td>
        <td class="nump"><a title="IMMY_LabAndPharmacyEquipmentGross" onclick="toggleNextSibling(this);">61,868</a><span style="display:none;white-space:normal;text-align:left;">IMMY_LabAndPharmacyEquipmentGross</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
        <td class="nump"><a title="us-gaap_LeaseholdImprovementsGross" onclick="toggleNextSibling(this);">20,172</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LeaseholdImprovementsGross</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furniture and equipment, gross</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">288,831</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">34,985</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(45,436)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(8,093)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and equipment, Net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">$ 243,395</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">$ 26,892</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_LabAndPharmacyEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Lab And Pharmacy Equipment Gross.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_LabAndPharmacyEquipmentGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 28, 2012, the Company effected
a one-for-eight reverse stock split and on February 7, 2013, the Company effected a one-for-five reverse stock split. All share
and per share amounts in these consolidated financial statements and notes reflect the effects of these reverse stock splits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Imprimis has prepared the accompanying consolidated
financial statements in accordance with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;).
The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany
accounts and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Business Combinations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for business combinations
by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair
values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions
at the acquisition date, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition
contingencies. Examples of critical estimates in valuing certain of the intangible assets the Company has acquired or may acquire
in the future include but are not limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and</font></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">discount rates utilized in valuation estimates.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Unanticipated events and circumstances may
occur that may affect the accuracy or validity of such assumptions, and estimates compared to actual results. Additionally, any
change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including changes
from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be recognized
in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent consideration
or the occurrence of events that cause results to differ from our estimates or assumptions could have a material effect on the
consolidated financial position, statements of operations, or cash flows in the period of the change in the estimate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses all costs related to research
and development as they are incurred. Research and development expenses consist of expenses incurred in performing research and
development activities, including salaries and benefits, other overhead expenses, and costs related to clinical trials, contract
services and outsourced contracts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Intellectual Property</b><i> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The costs of acquiring intellectual property
rights to be used in the research and development process, including licensing fees and milestone payments, are charged to research
and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired
rights, and are capitalized in situations where the Company has identified an alternative future use for the acquired rights. No
costs associated with acquiring intellectual property rights have been capitalized to date, although the Company may begin to capitalize
certain costs associated with intellectual property rights beginning in the fiscal year 2015. Costs of maintaining intellectual
property rights are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Revenue Recognition and Deferred Revenue</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenues when all of
the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling
price is fixed and determinable; and (4) collectability is reasonably assured. The Company began generating revenues upon the acquisition
of PC in the second quarter of 2014, which include sales of certain of the Company&#146;s proprietary compounded drug formulations
and certain non-proprietary formulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Product Revenues</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Determination of criteria (3) and (4) is based
on management&#146;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability
of those amounts. Estimated returns and allowances and other adjustments are provided for in the same period during which the related
sales are recorded. The Company will defer any revenue received for a product that has not been delivered or is subject to refund
until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>License Revenues</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">License arrangements may consist of non-refundable
upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending
compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple element arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Non-refundable fees that are not contingent
on any future performance by the Company and require no consequential continuing involvement on the part of the Company, are recognized
as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable
is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug
preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents
or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has continuing
performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable
fee has no utility to the licensee and that are separate and independent of the Company&#146;s performance under the other elements
of the arrangement. In addition, if the Company&#146;s continued involvement is required, through research and development services
that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company,
then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual
royalties are recognized on a straight-line basis over the applicable term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cost of Sales</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of sales includes direct and indirect
costs to manufacture formulations and other products sold, including active pharmaceutical ingredients, personnel costs, packaging,
storage, royalties (see Note 14), shipping and handling costs and the write-off of obsolete inventory.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of the process of preparing the Company&#146;s
consolidated financial statements, the Company must estimate the actual current tax liabilities and assess temporary differences
resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and
liabilities, which are included within the balance sheet. The Company must assess the likelihood that the deferred tax assets will
be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, a valuation allowance
must be established. To the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period,
the impact will be included in income tax expense in the statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes under
the provisions of Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;)
740, &#147;Income Taxes&#148;, or ASC 740. As of December 31, 2014, there were no unrecognized tax benefits included in the consolidated
balance sheet that would, if recognized, affect the effective tax rate. The Company&#146;s practice is to recognize interest and/or
penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties in its consolidated
balance sheets at December 31, 2014 and 2013, and has not recognized interest and/or penalties in the consolidated statements of
operations for the years ended December 31, 2014 and 2013. The Company is subject to taxation in the United States and California.
The Company&#146;s tax years since 2000 are subject to examination by the federal and state tax authorities due to the carryforward
of unutilized net operating losses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cash and Cash Equivalents</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash equivalents include short-term, highly
liquid investments with maturities of three months or less at the time of acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentrations of Credit Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company places its cash with financial
institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (&#147;FDIC&#148;)
provides basic deposit coverage with limits up to $250,000 per owner. At December 31, 2014, the Company had approximately $7.7
million in cash deposits in excess of FDIC limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Accounts Receivable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The balance in accounts receivable consists
of revenue amounts the Company has invoiced and recognized, but for which payment has not been received. Accounts receivable are
presented net of an allowance for doubtful accounts in the amount of $3,957 as of December 31, 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Inventories</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost
or market. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on a regular
basis, based on the price expected to be obtained for products in their respective markets compared with historical cost. Write-downs
of inventories are considered to be permanent reductions in the cost basis of inventories.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also regularly evaluates its inventories
for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated future sales
or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical ingredients
on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Furniture and Equipment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Furniture and equipment is stated at cost less
accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method over the
estimated useful life of the asset. Leasehold improvements and capital lease equipment are amortized over the estimated useful
life or remaining lease term, whichever is shorter. Computer software and hardware and furniture and equipment are depreciated
over three to five years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Goodwill and Intangible Assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews its goodwill and indefinite-lived
intangible assets for impairment as of January 1 of each year and when an event or a change in circumstances indicates the fair
value of a reporting unit may be below its carrying amount. Events or changes in circumstances considered as impairment indicators
include but are not limited to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">significant underperformance of the Company&#146;s business relative to expected operating results;</font></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">significant adverse economic and industry trends;</font></td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">significant decline in the Company&#146;s market capitalization for an extended period of time relative to net book value; and</font></td></tr>
<tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr>
    <td style="text-align: justify">&#160;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">expectations that a reporting unit will be sold or otherwise disposed. </font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The goodwill impairment test consists of a
two-step process as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Step 1. The Company compares the fair value
of each reporting unit to its carrying amount, including the existing goodwill. The fair value of each reporting unit is determined
using a discounted cash flow valuation analysis. The carrying value of each reporting unit is determined by specifically identifying
and allocating the assets and liabilities to each reporting unit based on headcount, relative revenues, or other methods as deemed
appropriate by management. If the carrying amount of a reporting unit exceeds its fair value, an indication exists that the reporting
unit&#146;s goodwill may be impaired and the Company then performs the second step of the impairment test. If the fair value of
a reporting unit exceeds its carrying amount, no further analysis is required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Step 2. If further analysis is required, the
Company compares the implied fair value of the reporting unit&#146;s goodwill, determined by allocating the reporting unit&#146;s
fair value to all of its assets and its liabilities in a manner similar to a purchase price allocation, to its carrying amount.
If the carrying amount of the reporting unit&#146;s goodwill exceeds its fair value, an impairment loss will be recognized in
an amount equal to the excess.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Impairment of Long-Lived Assets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets, such as furniture and equipment
and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying
amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying
amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the consolidated
balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated.
The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in the appropriate asset
and liability sections of the consolidated balance sheet, if material.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended December 31, 2014 and
2013, the Company did not recognize any impairment of its long-lived assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Deferred Rent </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for rent expense related
to its operating leases by determining total minimum rent payments on the leases over their respective periods and recognizing
the rent expense on a straight-line basis. The difference between the actual amount paid and the amount recorded as rent expense
in each fiscal year and interim periods within each fiscal year is recorded as an adjustment to deferred rent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value Measurements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value measurements are determined based
on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for inputs
used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring
that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs used
in valuation methodologies into the following three levels:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 24px"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.</font></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</font></td></tr>
<tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt">&#9679;</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity&#146;s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2014 and 2013, the Company
did not have any financial assets or liabilities that are measured on a recurring basis. At December 31, 2014 and 2013, the Company&#146;s
financial instruments included cash and cash equivalents, restricted short-term investments, accounts receivable, accounts payable
and accrued expenses, accrued payroll and related liabilities, customer deposits, and capital leases. The carrying amount of these
financial instruments, except for the restricted short-term investments and the capital leases, approximates fair value due to
the short-term maturities of these instruments. The Company&#146;s restricted short-term investments are carried at amortized
cost, which approximates fair value. Based on borrowing rates currently available to the Company, the carrying values of the capital
leases approximate their respective fair values.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock-Based Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All stock-based payments to employees, directors
and consultants, including grants of stock options, warrants, restricted stock units (&#147;RSUs&#148;) and restricted stock,
are recognized in the consolidated financial statements based upon their fair values. The Company uses the Black-Scholes-Merton
option pricing model and Monte Carlo Simulation to estimate the fair value of stock-based awards. The estimated fair value is determined
at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary,
if the actual effect differs from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#146;s accounting policy for equity
instruments issued to consultants and vendors in exchange for goods and services follows the Financial Accounting Standards Board
(the &#147;FASB&#148;) guidance. As such, the value of the applicable stock-based compensation is periodically remeasured and
income or expense is recognized during the vesting terms of the equity instrument. The measurement date for the estimated fair
value of the equity instruments issued is the earlier of (i) the date at which a commitment for performance by the consultant or
vendor is reached or (ii) the date at which the consultant or vendor&#146;s performance is complete. In the case of equity instruments
issued to consultants, the estimated fair value of the equity instrument is primarily recognized over the term of the consulting
agreement. In accordance with FASB guidance, an asset acquired in exchange for the issuance of fully vested, nonforfeitable equity
instruments should not be presented or classified as an offset to equity on the grantor&#146;s balance sheet once the equity instrument
is granted for accounting purposes. Accordingly, the Company records the estimated fair value of nonforfeitable equity instruments
issued for future consulting services as prepaid expenses in its consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basic and Diluted Net Loss per Common Share</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is computed
by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding
during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the
period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during
the period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic and diluted net loss per share is computed
using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the
treasury stock or, &#147;if converted&#148; method) from stock options, RSUs and warrants were 3,024,217 and 3,539,800 at December
31, 2014 and 2013, respectively, and are excluded from the calculation of diluted net loss per share for all periods presented
because the effect is anti-dilutive. Common stock equivalents at December 31, 2014 include 27,218 shares of common stock underlying
RSUs, awarded to directors that have vested, but the issuance and delivery of these shares are deferred until the director resigns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the computation of
basic and diluted net loss per share of common stock for the years ended December 31, 2014 and 2013:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">For the</font></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">For the</font></td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Year Ended</font></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Year Ended</font></td>
    <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31, 2014</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31, 2013</font></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; padding-bottom: 2.5pt"><font style="font-size: 10pt">Numerator &#150; net loss</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="width: 18%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(10,118,103</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="width: 18%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(7,643,124</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Denominator &#150; weighted average number of shares outstanding, basic and diluted</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">9,132,989</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">8,656,822</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt"><b>Net loss per share, basic and diluted</b></font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(1.11</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.88</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in
conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and
expenses during the reporting periods. Significant estimates made by management are, among others, allowance for doubtful accounts,
realizability of inventories, valuation of deferred taxes, goodwill and intangible assets, recoverability of long-lived assets
and goodwill, valuation of contingent acquisition obligations, and valuation of stock-based compensation issued to employees and
non-employees. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reclassifications</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior period items and amounts have
been reclassified to conform to the classifications used to prepare the consolidated financial statements for the year ended December
31, 2014. The Company has classified in these financial statements certain expenses as selling and marketing, whereas in prior
periods certain of these expenses were included in an expense line item titled selling, general and administrative in the consolidated
statements of operations. These reclassifications had no material impact on the Company&#146;s financial position, results of
operations, or cash flows as previously reported.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2014, the FASB issued an Accounting
Standards Update (&#147;ASU&#148;) No. 2014-10, &#147;Elimination of Certain Financial Reporting Requirements, Including an
Amendment to Variable Interest Entities&#148;. The amendments in this update remove the definition of a development stage entity
from ASC Topic 915, &#147;Development Stage Entities&#148;, thereby removing from GAAP the distinction between development stage
entities and other reporting entities. In addition, the amendments eliminate the requirements for development stage entities to
(1) present inception-to-date information in the statements of operations, cash flows, and stockholder&#146;s equity, (2) label
the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities
in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity
that in prior years it had been in the development stage. These amendments are effective for annual reporting periods beginning
after December 15, 2014, with early application of the amendments permitted. The Company&#146;s pharmacy operations commenced
on April 1, 2014. This change in the nature of the Company&#146;s operations included the recognition of operating revenues; as
a result, the Company is no longer defined as a development stage company for reporting dates beginning April 1, 2014. With the
change in the Company&#146;s operations, its revenue recognition and its immediate adoption of ASU No. 2014-10, the Company no
longer presents or discloses any information required under ASC Topic 915.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2014, the FASB issued new accounting
guidance which defines management&#146;s responsibility to assess an entity&#146;s ability to continue as a going concern, and
to provide related footnote disclosures in certain circumstances. This guidance will be effective for annual periods ending after
December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for
annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently
evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued ASU No. 2014-09,
&#147;Revenue from Contracts with Customers&#148; (&#147;ASU 2014-09&#148;). The objective of ASU 2014-19 is to establish
a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede
most of the existing revenue recognition guidance, including industry-specific guidance. The core principle of ASU 2014-09 is
that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects
the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the new guidance,
an entity will (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine
the transaction price; (4) allocate the transaction price to the contract&#146;s performance obligations; and (5) recognize revenue
when (or as) the entity satisfies a performance obligation. ASU 2014-09 applies to all contracts with customers except those that
are within the scope of other topics in the FASB ASC. The new guidance is effective for annual reporting periods, including interim
periods within those periods, beginning after December 15, 2016 for public companies. Early adoption is not permitted. The Company
is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial
statements.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1SAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Warrants Outstanding and Warrants Exercisable (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1', window );">Warrants Outstanding</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">690,944</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1', window );">Exercise Price</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">$ 6.05</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Warrants Exercisable</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1[us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">690,944</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToFormerMajorShareholderMember', window );">Warrants Issued To Former Major Shareholder [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsIssuanceDate', window );">Issue Date</a></td>
        <td class="text">Apr. 25,  2012<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1', window );">Warrants Outstanding</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToFormerMajorShareholderMember]" onclick="toggleNextSibling(this);">48,262</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_WarrantsIssuedToFormerMajorShareholderMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1', window );">Exercise Price</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToFormerMajorShareholderMember]" onclick="toggleNextSibling(this);">$ 5.93</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_WarrantsIssuedToFormerMajorShareholderMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Warrants Exercisable</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToFormerMajorShareholderMember]" onclick="toggleNextSibling(this);">48,262</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_WarrantsIssuedToFormerMajorShareholderMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsExpirationDate', window );">Expiration Date</a></td>
        <td class="text">Apr. 25,  2015<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember', window );">Warrants Issued In April 2012 Private Placement [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsIssuanceDate', window );">Issue Date</a></td>
        <td class="text">Apr. 25,  2012<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1', window );">Warrants Outstanding</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember]" onclick="toggleNextSibling(this);">496,537</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1', window );">Exercise Price</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember]" onclick="toggleNextSibling(this);">$ 5.93</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Warrants Exercisable</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember]" onclick="toggleNextSibling(this);">496,537</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsExpirationDate', window );">Expiration Date</a></td>
        <td class="text">Apr. 25,  2015<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_UnderwriterWarrantsMember', window );">Underwriter Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsIssuanceDate', window );">Issue Date</a></td>
        <td class="text">Feb.  07,  2013<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1', window );">Warrants Outstanding</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_UnderwriterWarrantsMember]" onclick="toggleNextSibling(this);">56,145</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_UnderwriterWarrantsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1', window );">Exercise Price</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_UnderwriterWarrantsMember]" onclick="toggleNextSibling(this);">$ 5.25</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_UnderwriterWarrantsMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Warrants Exercisable</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_UnderwriterWarrantsMember]" onclick="toggleNextSibling(this);">56,145</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_UnderwriterWarrantsMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsExpirationDate', window );">Expiration Date</a></td>
        <td class="text">Feb.  07,  2018<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember', window );">Warrants Issued To Investor Relations Consultant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsIssuanceDate', window );">Issue Date</a></td>
        <td class="text">Feb. 28,  2013<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1', window );">Warrants Outstanding</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember]" onclick="toggleNextSibling(this);">30,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1', window );">Exercise Price</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember]" onclick="toggleNextSibling(this);">$ 5.25</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Warrants Exercisable</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember]" onclick="toggleNextSibling(this);">30,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsExpirationDate', window );">Expiration Date</a></td>
        <td class="text">Feb. 28,  2016<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember', window );">Warrants Issued To Investor Relations Consultant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsIssuanceDate', window );">Issue Date</a></td>
        <td class="text">Jul. 19,  2013<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1', window );">Warrants Outstanding</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember]" onclick="toggleNextSibling(this);">60,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1', window );">Exercise Price</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember]" onclick="toggleNextSibling(this);">$ 8.50</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1', window );">Warrants Exercisable</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember]" onclick="toggleNextSibling(this);">60,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_WarrantsExpirationDate', window );">Expiration Date</a></td>
        <td class="text">Jul. 19,  2018<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Outstanding</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise Price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Exercisable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_WarrantsExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Expiration Date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_WarrantsExpirationDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_WarrantsIssuanceDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Issuance Date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_WarrantsIssuanceDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_UnderwriterWarrantsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_UnderwriterWarrantsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedInAprilTwoThousandTwelvePrivatePlacementMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToFormerMajorShareholderMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToFormerMajorShareholderMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToInvestorRelationsConsultantOneMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_WarrantsIssuedToInvestorRelationsConsultantTwoMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>37
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?4W1O/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?4W1O,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-BYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A
M<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970P-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]R9V%N
M:7IA=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P
M.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C<75I<VET:6]N7U!H87)M86-Y
M7T-R96%T:6]N<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E)E<W1R:6-T961?4VAO<G1497)M7TEN=F5S=&UE;CPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=F5N=&]R:65S/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#$R+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')E<&%I9%]%>'!E
M;G-E<U]A;F1?3W1H97)?0W5R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$S+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^1G5R;FET=7)E7V%N9%]%<75I<&UE;G0\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,30N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);G1A;F=I8FQE7T%S<V5T
M<U]A;F1?1V]O9'=I;&P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y!8V-O=6YT<U]087EA8FQE7V%N9%]!8V-R=65D7T4\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y$96)T/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#$W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q
M=6ET>3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970Q."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN
M8V]M95]487AE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q.2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/D5M<&QO>65E7U-A=FEN9W-?4&QA;CPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC
M:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#(Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4V5G
M;65N=%]);F9O<FUA=&EO;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,BYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-U8G-E<75E;G1?179E;G1S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(S+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!
M8V-O=6YT,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#(\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,C4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!8W%U:7-I=&EO;E]0:&%R;6%C
M>5]#<F5A=&EO;G,Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(V+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^26YV96YT;W)I97-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(W+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4')E<&%I9%]%>'!E;G-E<U]A;F1?3W1H97)?
M0W5R,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D9U
M<FYI='5R95]A;F1?17%U:7!M96YT7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R.2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=&%N9VEB;&5?07-S971S7V%N9%]'
M;V]D=VEL;#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,S`N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y!8V-O=6YT<U]087EA8FQE7V%N9%]!8V-R=65D7T4Q/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#,Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET
M>5]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,S(N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y);F-O;65?5&%X97-?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,S+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I97-?
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#,T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4VEG;FEF
M:6-A;G1?06-C;W5N=&EN9U]0;VQI8VEE/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,U+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O
M=6YT,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970S-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C
M<75I<VET:6]N7U!H87)M86-Y7T-R96%T:6]N<S(\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S<N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!8W%U:7-I=&EO;E]0:&%R;6%C>5]#
M<F5A=&EO;G,S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#,X+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^06-Q=6ES:71I;VY?4&AA<FUA8WE?0W)E871I;VYS-#PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D%C<75I<VET:6]N7U!H87)M
M86-Y7T-R96%T:6]N<S4\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#`N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y!8W%U:7-I=&EO;E]0:&%R;6%C>5]#<F5A=&EO;G,V/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#0Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^06-Q=6ES:71I;VY?
M4&AA<FUA8WE?0W)E871I;VYS-SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,BYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/E)E<W1R:6-T961?4VAO<G1497)M7TEN=F5S=&UE;C$\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-#,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);G9E;G1O
M<FEE<U]38VAE9'5L95]O9E]);G9E;G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#0N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y0<F5P86ED7T5X<&5N<V5S7V%N9%]/=&AE<E]#
M=7(R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#0U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1G5R
M;FET=7)E7V%N9%]%<75I<&UE;G1?1&5T86EL/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^1G5R;FET=7)E7V%N9%]%<75I<&UE;G1?
M4V-H961U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#0W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M26YT86YG:6)L95]!<W-E='-?86YD7T=O;V1W:6QL,CPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T
M."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN=&%N9VEB;&5?07-S971S7V%N
M9%]';V]D=VEL;#,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T-#DN:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y);G1A;F=I8FQE7T%S<V5T<U]A;F1?1V]O9'=I;&PT/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#4P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YT86YG:6)L95]!<W-E
M='-?86YD7T=O;V1W:6QL-3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U,2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/D%C8V]U;G1S7U!A>6%B;&5?86YD7T%C8W)U961?13(\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T-3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y!8V-O=6YT<U]0
M87EA8FQE7V%N9%]!8V-R=65D7T4S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4S+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^1&5B=%]$971A:6QS7TYA<G)A=&EV93PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970U-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%
M<75I='E?1&5T86EL<U].83PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970U-2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='E?4V-H961U;&5?;SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970U-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R
M<U]%<75I='E?4V-H961U;&5?;S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-3<N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U:71Y7U-C:&5D=6QE7V\R
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#4X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W1O8VMH
M;VQD97)S7T5Q=6ET>5]-87)K971B87-E/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#4Y+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET>5]38VAE9'5L
M95]O,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970V,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T
M;V-K:&]L9&5R<U]%<75I='E?4V-H961U;&5?;S0\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-C$N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U:71Y7U-C
M:&5D=6QE7V\U/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#8R+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4W1O8VMH;VQD97)S7T5Q=6ET>5]38VAE9'5L95]O-CPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970V,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<U]$971A
M:6QS7TYA<G)A=&EV93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970V-"YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DEN8V]M95]487AE<U]38VAE9'5L95]O9E]0<F]V:3PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970V-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<U]3
M8VAE9'5L95]O9E]);F-O;3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970V-BYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DEN8V]M95]487AE<U]38VAE9'5L95]O9E]$969E<CPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970V-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5M<&QO>65E7U-A
M=FEN9W-?4&QA;E]$971A:6QS7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970V."YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7S$\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-CDN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M
M96YT<U]A;F1?0V]N=&EN9V5N8VEE<U\R/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#<P+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD7T-O;G1I;F=E;F-I
M97-?,SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970W,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-E
M9VUE;G1?26YF;W)M871I;VY?1&5T86EL<U].83PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970W,BYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E;G1?179E;G1S7T1E=&%I
M;'-?3F%R<CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970W,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@(#QX.E-T>6QE
M<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B+SX-"B`@/'@Z
M06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T
M<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*("`\>#I0<F]T
M96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-"B`\+W@Z17AC
M96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\
M8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@
M36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$W8V9C8F8U7V)D-&9?-#<Y
M,%]A-SDY7S@U-#%D9#0X9&%A-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]A-V-F8V)F-5]B9#1F7S0W.3!?83<Y.5\X-30Q9&0T.&1A838O5V]R
M:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5E)!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN9F]R;6%T:6]N
M("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`Q
M,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN
M(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D1O8W5M96YT($%N9"!%;G1I='D@26YF;W)M871I;VX\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y
M(%)E9VES=')A;G0@3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^26UP<FEM:7,@4&AA<FUA8V5U=&EC86QS+"!);F,N/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N
M=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C`P,#$S-C`R,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C$P+4L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1&5C(#,Q+`T*"0DR,#$T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5N=&ET>2!6;VQU;G1A<GD@1FEL97)S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#Y.;SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%=E;&PM2VYO=VY396%S
M;VYE9"!)<W-U97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%;G1I='D@0W5R<F5N="!297!O<G1I;F<@4W1A='5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#Y997,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@1FES8V%L(%EE87(@
M16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/BTM,3(M
M,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N=&ET>2!&:6QE<B!#871E9V]R>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^4VUA;&QE<B!297!O<G1I;F<@0V]M<&%N>3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y
M(%!U8FQI8R!&;&]A=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`T-RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;G1I='D@0V]M;6]N(%-T;V-K+"!3:&%R97,@3W5T
M<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,S0R
M+#DS-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^1&]C=6UE;G0@1FES8V%L(%!E<FEO9"!&;V-U<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^1ED\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R
M($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15%'04<^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N<V]L:61A=&5D($)A;&%N8V4@
M4VAE971S("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@87-S971S/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@
M86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@."PR,3$L-#DR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q-2PU-SDL,S`Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D('-H
M;W)T+71E<FT@:6YV97-T;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$U,"PR-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,"PP.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I=F%B;&4L(&YE
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#$L,S(R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G9E;G1O<FEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S<R+#<S-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A
M;F0@;W1H97(@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(T,"PT,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,#4L,#8W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!A<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,#4V+#(Q-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U
M+#<S-"PT-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEN=&%N9VEB;&4@87-S971S+"!N970\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8Q,"PY.30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O;V1W
M:6QL/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,S$L-C(Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y&=7)N:71U<F4@86YD(&5Q=6EP;65N="P@;F5T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#,L,SDU/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L.#DR/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5$]4
M04P@05-31513/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PR
M-#(L,C(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,34L-S8Q+#,V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&QI86)I;&ET:65S
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C
M8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<X-BPV-S4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3$L.3(T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D
M('!A>7)O;&P@86YD(')E;&%T960@;&EA8FEL:71I97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<Q-BPS,S(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,S@L-S`S/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7-T;VUE<B!D
M97!O<VET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV.#,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-U<G)E;G0@<&]R=&EO;B!O9B!C;VYT:6YG96YT(&%C
M<75I<VET:6]N(&]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,2PT-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@<&]R=&EO;B!O
M9B!C87!I=&%L(&QE87-E(&]B;&EG871I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-"PQ,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R
M96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#4V,"PR-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV-3`L-C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#87!I=&%L(&QE87-E(&]B;&EG871I;VYS
M+"!N970@;V8@8W5R<F5N="!P;W)T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ."PY-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@97AP96YS
M97,L(&YE="!O9B!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(Y+#8U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=&EN9V5N="!A
M8W%U:7-I=&EO;B!O8FQI9V%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#@S+#$U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1/5$%,($Q)04))3$E4
M2453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`Y,BPP-3`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M-3`L-C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@8V]N=&EN9V5N8VEE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-43T-+2$],1$524R<@15%52519/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@
M)#`N,#`Q('!A<B!V86QU92P@.3`L,#`P+#`P,"!S:&%R97,@875T:&]R:7IE
M9"P@.2PR-3@L,C,Q(&%N9"`X+#DW,"PS-C0@<VAA<F5S(&ES<W5E9"!A;F0@
M;W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P,30@86YD(#(P,3,L(')E
M<W!E8W1I=F5L>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PR
M-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+#DW,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^061D:71I;VYA;"!P86ED+6EN(&-A<&ET86P\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P-BPT,3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPX-#DL,38P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M8V-U;75L871E9"!D969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@T,2PX-C4L-#DU*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#,Q+#<T-RPS.3(I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5$]404P@4U1/0TM(3TQ$
M15)3)R!%455)5%D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L
M,34P+#$W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$U+#$Q,"PW,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y43U1!3"!,24%"24Q)5$E%4R!!3D0@4U1/
M0TM(3TQ$15)3)R!%455)5%D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3`L,C0R+#(R-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,34L-S8Q+#,V-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?8F0T9E\T-SDP7V$W
M.3E?.#4T,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V$W8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X9&%A-B]7;W)K<VAE
M971S+U-H965T,#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5924%#/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H4&%R96YT
M:&5T:6-A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1A=&5M96YT(&]F($9I
M;F%N8VEA;"!0;W-I=&EO;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3`L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP+#`P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.2PR-3@L,C,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PY-S`L,S8T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O
M8VLL('-H87)E<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^.2PR-3@L,C,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^."PY-S`L,S8T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14]3044^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@3W!E<F%T:6]N
M<R`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4F5V96YU97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-A;&5S+"!N970\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,2PV-3(L,S@V/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,
M:6-E;G-E(')E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW+#@V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E=F5N=65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#8V,"PR-#8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O<W0@;V8@<V%L
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,#DR+#@S.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y'<F]S<R!P<F]F:70\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4V-RPT,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG
M(&5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y396QL:6YG(&%N9"!M87)K971I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,SDP+#$X,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@U+#@Y,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@
M861M:6YI<W1R871I=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@L,#@W+#,Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4L.3DT+#DP-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L;W!M96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,S8L-C8P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,38L
M,#@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@;W!E<F%T:6YG(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,"PW,30L,34V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPV.38L.#<Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!F
M<F]M(&]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$P+#$T-BPW-#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-RPV.#8L.#<Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B!I;F-O;64@
M*&5X<&5N<V4I.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G1E<F5S="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@S+#@P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&EN8V]M
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(L-#0V/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,L-S4U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&]T86P@;W1H97(@:6YC;VUE+"!N970\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(X+#8T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0S+#<U-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$P+#$Q."PQ,#,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@W+#8T,RPQ
M,C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y"87-I8R!A;F0@9&EL=71E9"!N970@;&]S<R!P97(@<VAA<F4@;V8@
M8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#$N,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@P+C@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!N=6UB97(@;V8@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:R!O=71S=&%N9&EN9RP@8F%S:6,@86YD(&1I
M;'5T960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,3,R+#DX
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@L-C4V+#@R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?83=C9F-B9C5?8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W8V9C8F8U7V)D-&9?-#<Y
M,%]A-SDY7S@U-#%D9#0X9&%A-B]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$53-$%)/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED
M871E9"!3=&%T96UE;G1S(&]F(%-T;V-K:&]L9&5R<R<@17%U:71Y("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M0V]M;6]N(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D%D9&ET:6]N86P@4&%I9"U);B!#87!I=&%L(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%C8W5M=6QA=&5D
M($1E9FEC:70@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^5&]T86P\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D)A;&%N8V4@870@1&5C+B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V+#<W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S0L,#DS+#DS,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C0L,3`T+#(V
M."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#DL.3DV+#0S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0F%L86YC92P@<VAA<F4@870@1&5C+B`S,2P@,C`Q
M,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW-S(L,#8V/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@<F5L871E9"!T;R!C;VYS=6QT:6YG
M(&%G<F5E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C@R+#DU-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(X,BPY.3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO
M;B!S=&]C:R!R96QA=&5D('1O(&-O;G-U;'1I;F<@86=R965M96YT<RP@<VAA
M<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M97)C:7-E(&]F('-T;V-K(&]P=&EO;G,L('-H87)E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#86YC96QL960@8V]M;6]N('-T;V-K
M(&%T("0U+C(U('!E<B!S:&%R92!R96QA=&5D('1O(')E=F5R<V4@<W1O8VL@
M<W!L:70L($9E8G)U87)Y(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$Y,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.3$I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#86YC96QL960@8V]M;6]N
M('-T;V-K(&%T("0U+C(U('!E<B!S:&%R92!R96QA=&5D('1O(')E=F5R<V4@
M<W1O8VL@<W!L:70L($9E8G)U87)Y(#(P,3,L('-H87)E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0=6)L:6,@;V9F97)I;F<@;V8@
M8V]M;6]N('-T;V-K(&%T("0U+C(U('!E<B!S:&%R92P@;F5T(&]F(&-O<W1S
M(&]F("0U.38L,C@Q+"!I;B!&96)R=6%R>2!A;F0@36%R8V@@,C`Q,SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ,38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#0U-"PT,S4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY+#0U-BPU-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!U8FQI8R!O9F9E<FEN9R!O9B!C;VUM;VX@
M<W1O8VL@870@)#4N,C4@<&5R('-H87)E+"!N970@;V8@8V]S=',@;V8@)#4Y
M-BPR.#$L(&EN($9E8G)U87)Y(&%N9"!-87)C:"`R,#$S+"!S:&%R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,3$V+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N
M8V4@;V8@8V]M;6]N('-T;V-K('5P;VX@=F5S=&EN9R!O9B!24U5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@
M8V]M;6]N('-T;V-K('5P;VX@=F5S=&EN9R!O9B!24U5S+"!S:&%R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S
M960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPP,3@L,#8V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPP,3@L,#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I
M;VXL('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ
M,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W
M+#8T,RPQ,C0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-RPV-#,L,3(T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q+"`R,#$S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#DW,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0V+#@T.2PQ
M-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S,2PW-#<L,SDR*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$U+#$Q,"PW,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4L('-H87)E(&%T($1E
M8RX@,S$L(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L
M.3<P+#,V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<RP@;F5T(&]F('1A
M>"!W:71H:&]L9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-3@S+#4X-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4X,RPX,3$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E(&]F('-T
M;V-K(&]P=&EO;G,L(&YE="!O9B!T87@@=VET:&AO;&1I;F<L('-H87)E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(W+#(Q-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R-RPR,38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPT-CDL.#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPT-CDL.#$P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C
M;VUM;VX@<W1O8VL@<F5L871E9"!T;R!C;VYS=6QT:6YG(&%G<F5E;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PQ-38\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR.2PQ-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!R96QA=&5D
M('1O(&-O;G-U;'1I;F<@86=R965M96YT<RP@<VAA<F5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N
M('-T;V-K('5P;VX@=F5S=&EN9R!O9B!24U5S(&YE="!O9B!T87@@=VET:&AO
M;&1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,RPQ,3$I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,3,L,3`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K
M('5P;VX@=F5S=&EN9R!O9B!24U5S(&YE="!O9B!T87@@=VET:&AO;&1I;F<@
M+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.34T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PY-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X97)C:7-E(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,W+#@Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,W+#@V-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE
M<F-I<V4@;V8@=V%R<F%N=',@+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0W+#@R.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!I;B!S
M971T;&5M96YT(&]F(&-O;G1R86-T(&1I<W!U=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT.2PY.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S=&]C:R!I<W-U960@:6X@<V5T=&QE;65N="!O9B!C;VYT<F%C="!D
M:7-P=71E+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8L.#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3`L,3$X+#$P,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q,"PQ,3@L,3`S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC92!A="!$96,N(#,Q
M+"`R,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DL,C4X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`U,"PP,#8L-#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XD("@T,2PX-C4L-#DU*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@."PQ-3`L,3<T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E
M+"!S:&%R92!A="!$96,N(#,Q+"`R,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY+#(U."PR,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7V$W8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D
M9#0X9&%A-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A-V-F8V)F
M-5]B9#1F7S0W.3!?83<Y.5\X-30Q9&0T.&1A838O5V]R:W-H965T<R]3:&5E
M=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%2D<^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M0V]N<V]L:61A=&5D(%-T871E;65N=',@;V8@4W1O8VMH;VQD97)S)R!%<75I
M='D@*%!A<F5N=&AE=&EC86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1A=&5M96YT(&]F(%-T
M;V-K:&]L9&5R<R<@17%U:71Y(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N
M('-T;V-K(&9O<B!P=6)L:6,@;V9F97)I;F<@<')I8V4@<&5R('-H87)E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4N,C4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A;F-E;&QE
M9"!C;VUM;VX@<W1O8VL@<')I8V4@<&5R('-H87)E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#4N,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V$W8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U
M-#%D9#0X9&%A-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A-V-F
M8V)F-5]B9#1F7S0W.3!?83<Y.5\X-30Q9&0T.&1A838O5V]R:W-H965T<R]3
M:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%3%-!1SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#05-(($9,3U=3($923TT@3U!%4D%424Y'($%#5$E6251)
M15,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3`L
M,3$X+#$P,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#<L-C0S+#$R-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@
M<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H('5S960@:6X@;W!E<F%T
M:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N(&]F
M(&9U<FYI='5R92!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS-RPS-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#8U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&EN=&%N
M9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M."PP,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!A
M;F0@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M-C$T+#8Q.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,3,T+#DW,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&%S<V5T<R!A
M;F0@;&EA8FEL:71I97,L(&YE="!O9B!E9F9E8W1S(&9R;VT@86-Q=6ES:71I
M;VYS.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-O=6YT<R!R96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R,BPY,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G9E;G1O<FEE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,34Y+#4T-2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,S$L-S(W*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$V+#DV
M-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T-2PS-C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,SDL.#`P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C<G5E9"!P87ER;VQL(&%N9"!R96QA=&5D(&QI86)I;&ET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-#(L,34T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(P+#,Q,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0W5S
M=&]M97(@9&5P;W-I=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$P+#8S,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.150@0T%32"!54T5$($E.($]015)!
M5$E.1R!!0U1)5DE42453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@W+#`U-2PT,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-"PT,S@L.30T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#05-(($9,3U=3($92
M3TT@24Y615-424Y'($%#5$E6251)15,\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@;V8@<F5S=')I8W1E9"!S
M:&]R="UT97)M(&EN=F5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q,#`L,38W*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#4P+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E(&]F(%!H87)M86-Y
M($-R96%T:6]N<RP@3$Q#+"!N970@;V8@8V%S:"!A;F0@861V86YC97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8S-BPS-S0I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0=7)C:&%S97,@;V8@9G5R;FET=7)E(&%N9"!E<75I<&UE;G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W,RPY.#8I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C`L,#`S*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DY%5"!#05-((%53140@24X@24Y615-424Y'($%#5$E6251)15,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#DQ,"PU,C<I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-S`L,#`S*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#05-(($9,3U=3($923TT@1DE.04Y#24Y'($%#5$E6251)15,\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%N8V5L
M;&5D(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3,L,3`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$Y,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!A>6UE;G1S(&]N(&-A<&ET86P@;&5A<V4@;V)L
M:6=A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P+#0S
M,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYE="!P<F]C965D<R!F<F]M(&5X97)C:7-E(&]F
M('=A<G)A;G1S(&%N9"!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV,C$L-C<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F
M<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!A;F0@=V%R<F%N=',@9F]R
M(&-A<V@L(&YE="!O9B!O9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#4R+#@S,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY%5"!#
M05-((%!23U9)1$5$($)9($9)3D%.0TE.1R!!0U1)5DE42453/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.3@L,3,X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#4R+#8T,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DY%
M5"!#2$%.1T4@24X@0T%32"!!3D0@0T%32"!%455)5D%,14Y44SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-RPS-C<L.#$W*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-30S+#8Y-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0T%32"!!3D0@0T%32"!%455)5D%,14Y44RP@8F5G:6YN:6YG(&]F('!E<FEO
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34L-3<Y+#,P.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P
M+#`S-2PV,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-!4T@@04Y$($-!4T@@15%5259!3$5.5%,L(&5N9"!O9B!P
M97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,C$Q+#0Y
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$U+#4W.2PS,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4U504$Q%345.5$%,($1)4T-,3U-54D4@
M3T8@0T%32"!&3$]7($E.1D]234%424]..CPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!A:60@9F]R(&EN8V]M92!T
M87AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-A<V@@<&%I9"!F;W(@:6YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L.#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-54%!,14U%
M3E1!3"!$25-#3$]355)%4R!/1B!.3TXM0T%32"!)3E9%4U1)3D<@04Y$($9)
M3D%.0TE.1R!!0U1)5DE42453.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!A;F0@861J=7-T;65N="!T
M;R!C;VUM;VX@<W1O8VL@86YD('=A<G)A;G1S('1O(&-O;G-U;'1I;F<@9FER
M;7,@9F]R('!R97!A:60@8V]N<W5L=&EN9R!F965S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3DL-S@V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-L87-S
M:69I8V%T:6]N(&]F(&1E9F5R<F5D(&]F9F5R:6YG(&-O<W1S(&EN(&-O;FYE
M8W1I;VX@=VET:"!E<75I='D@;V9F97)I;F<\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Y-BPR.#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F
M(&-O;6UO;B!S=&]C:R!F;W(@8V]N<W5L=&EN9R!S97)V:6-E<R!I;F-L=61E
M9"!I;B!A8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,SDL
M-#0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0=7)C:&%S92!O9B!F=7)N:71U<F4@86YD(&5Q=6EP;65N="!W:71H
M(&$@8V%P:71A;"!L96%S93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`S-2PS-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V$W8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U
M-#%D9#0X9&%A-@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A-V-F
M8V)F-5]B9#1F7S0W.3!?83<Y.5\X-30Q9&0T.&1A838O5V]R:W-H965T<R]3
M:&5E=#`X+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^3W)G86YI>F%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D]R9V%N:7IA=&EO;BP@0V]N<V]L:61A=&EO
M;B!A;F0@4')E<V5N=&%T:6]N(&]F($9I;F%N8VEA;"!3=&%T96UE;G1S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W)G86YI>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/DY/5$4@,2X@
M3U)'04Y)6D%424]./"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY);7!R:6UI<R!0:&%R;6%C975T:6-A;',L($EN8RX@*'1O9V5T:&5R
M('=I=&@-"FET<R!S=6)S:61I87)I97,L('5N;&5S<R!T:&4@8V]N=&5X="!I
M;F1I8V%T97,@;W(@;W1H97)W:7-E(')E<75I<F5S+"!T:&4@)B,Q-#<[0V]M
M<&%N>28C,30X.R!O<B`F(S$T-SM);7!R:6UI<R8C,30X.RD@:7,@80T*<&AA
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M<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@07!R:6P@
M,2P@,C`Q-"P@=&AE($-O;7!A;GD@86-Q=6ER960@4&AA<FUA8WD-"D-R96%T
M:6]N<RP@3$Q#("@F(S$T-SM00R8C,30X.RDL(&$@3F5W($IE<G-E>2!B87-E
M9"!C;VUP;W5N9&EN9R!P:&%R;6%C>2!A;F0@;VX@2F%N=6%R>2`Q+"`R,#$U
M+"!T:&4@0V]M<&%N>2!A8W%U:7)E9"!3;W5T:`T*0V]A<W0@4W!E8VEA;'1Y
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M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?8F0T9E\T
M-SDP7V$W.3E?.#4T,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V$W8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X9&%A-B]7
M;W)K<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I
M;F<@4&]L:6-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U
M;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN
M.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SX\8CY.3U1%(#(N(%-534U!4ED@3T8@4TE'3DE&24-!3E0@
M04-#3U5.5$E.1PT*4$],24-)15,\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQB/D)A<VES(&]F(%!R97-E;G1A=&EO;CPO8CX\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@1F5B<G5A<GD@,C@L
M(#(P,3(L('1H92!#;VUP86YY(&5F9F5C=&5D#0IA(&]N92UF;W(M96EG:'0@
M<F5V97)S92!S=&]C:R!S<&QI="!A;F0@;VX@1F5B<G5A<GD@-RP@,C`Q,RP@
M=&AE($-O;7!A;GD@969F96-T960@82!O;F4M9F]R+69I=F4@<F5V97)S92!S
M=&]C:R!S<&QI="X@06QL('-H87)E#0IA;F0@<&5R('-H87)E(&%M;W5N=',@
M:6X@=&AE<V4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N
M9"!N;W1E<R!R969L96-T('1H92!E9F9E8W1S(&]F('1H97-E(')E=F5R<V4@
M<W1O8VL@<W!L:71S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SY);7!R:6UI<R!H87,@<')E<&%R960@=&AE(&%C8V]M<&%N>6EN9R!C;VYS
M;VQI9&%T960-"F9I;F%N8VEA;"!S=&%T96UE;G1S(&EN(&%C8V]R9&%N8V4@
M=VET:"!A8V-O=6YT:6YG('!R:6YC:7!L97,@9V5N97)A;&QY(&%C8V5P=&5D
M(&EN('1H92!5;FET960@4W1A=&5S(&]F($%M97)I8V$@*"8C,30W.T=!05`F
M(S$T.#LI+@T*5&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI9&%T960@9FEN86YC
M:6%L('-T871E;65N=',@:6YC;'5D92!T:&4@86-C;W5N=',@;V8@=&AE($-O
M;7!A;GD@86YD(&ET<R!W:&]L;'DM;W=N960@<W5B<VED:6%R>2X@06QL(&EN
M=&5R8V]M<&%N>0T*86-C;W5N=',@86YD('1R86YS86-T:6]N<R!H879E(&)E
M96X@96QI;6EN871E9"!I;B!C;VYS;VQI9&%T:6]N+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY"=7-I;F5S<R!#;VUB:6YA=&EO;G,\
M+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#;VUP
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M(&EN8VQU9&4@8G5T(&%R92!N;W0@;&EM:71E9"!T;SH\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M
M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#(T<'@G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[('=I9'1H.B`R-'!X)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0G/B8C.38W.3L\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T)SYF=71U<F4@97AP96-T960@8V%S:"!F;&]W
M<R!F<F]M('!R;V1U8W0@<V%L97,L('-U<'!O<G0@86=R965M96YT<RP@8V]N
M<W5L=&EN9R!C;VYT<F%C=',L(&]T:&5R(&-U<W1O;65R(&-O;G1R86-T<RP@
M86YD(&%C<75I<F5D(&1E=F5L;W!E9"!T96-H;F]L;V=I97,@86YD('!A=&5N
M=',[(&%N9#PO9F]N=#X\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU
M<W1I9GDG/B8C,38P.SPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(SDV-SD[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GDG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^9&ES8V]U;G0@<F%T
M97,@=71I;&EZ960@:6X@=F%L=6%T:6]N(&5S=&EM871E<RX\+V9O;G0^/"]T
M9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
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M97-T:6UA=&4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB
M/E)E<V5A<F-H(&%N9"!$979E;&]P;65N=#PO8CX\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
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M=',N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/DEN=&5L
M;&5C='5A;"!0<F]P97)T>3PO8CX\:3X@/"]I/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SY4:&4@8V]S=',@;V8@86-Q=6ER:6YG(&EN=&5L
M;&5C='5A;"!P<F]P97)T>0T*<FEG:'1S('1O(&)E('5S960@:6X@=&AE(')E
M<V5A<F-H(&%N9"!D979E;&]P;65N="!P<F]C97-S+"!I;F-L=61I;F<@;&EC
M96YS:6YG(&9E97,@86YD(&UI;&5S=&]N92!P87EM96YT<RP@87)E(&-H87)G
M960@=&\@<F5S96%R8V@-"F%N9"!D979E;&]P;65N="!E>'!E;G-E(&%S(&EN
M8W5R<F5D(&EN('-I='5A=&EO;G,@=VAE<F4@=&AE($-O;7!A;GD@:&%S(&YO
M="!I9&5N=&EF:65D(&%N(&%L=&5R;F%T:79E(&9U='5R92!U<V4@9F]R('1H
M92!A8W%U:7)E9`T*<FEG:'1S+"!A;F0@87)E(&-A<&ET86QI>F5D(&EN('-I
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M86P@>65A<B`R,#$U+B!#;W-T<R!O9B!M86EN=&%I;FEN9R!I;G1E;&QE8W1U
M86P-"G!R;W!E<G1Y(')I9VAT<R!A<F4@97AP96YS960@87,@:6YC=7)R960N
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/E)E=F5N=64@
M4F5C;V=N:71I;VX@86YD($1E9F5R<F5D(%)E=F5N=64\+V(^/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#;VUP86YY(')E8V]G;FEZ
M97,@<F5V96YU97,@=VAE;B!A;&P@;V8-"G1H92!F;VQL;W=I;F<@8W)I=&5R
M:6$@:&%V92!B965N(&UE=#H@*#$I('!E<G-U87-I=F4@979I9&5N8V4@;V8@
M86X@87)R86YG96UE;G0@97AI<W1S.R`H,BD@9&5L:79E<GD@:&%S(&]C8W5R
M<F5D.R`H,RD@=&AE('-E;&QI;F<-"G!R:6-E(&ES(&9I>&5D(&%N9"!D971E
M<FUI;F%B;&4[(&%N9"`H-"D@8V]L;&5C=&%B:6QI='D@:7,@<F5A<V]N86)L
M>2!A<W-U<F5D+B!4:&4@0V]M<&%N>2!B96=A;B!G96YE<F%T:6YG(')E=F5N
M=65S('5P;VX@=&AE(&%C<75I<VET:6]N#0IO9B!00R!I;B!T:&4@<V5C;VYD
M('%U87)T97(@;V8@,C`Q-"P@=VAI8V@@:6YC;'5D92!S86QE<R!O9B!C97)T
M86EN(&]F('1H92!#;VUP86YY)B,Q-#8[<R!P<F]P<FEE=&%R>2!C;VUP;W5N
M9&5D(&1R=6<@9F]R;75L871I;VYS#0IA;F0@8V5R=&%I;B!N;VXM<')O<')I
M971A<GD@9F]R;75L871I;VYS+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\:3Y0<F]D=6-T(%)E=F5N=65S/"]I/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
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M:&EC:"!T:&4@<F5L871E9`T*<V%L97,@87)E(')E8V]R9&5D+B!4:&4@0V]M
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M;"!B92!R97%U:7)E9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^/&D^3&EC96YS92!2979E;G5E<SPO:3X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
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M96UE;G0@87)R86YG96UE;G1S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
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M9"!M:6YI;75M(&%N;G5A;`T*<F]Y86QT:65S(&%R92!R96-O9VYI>F5D(&]N
M(&$@<W1R86EG:'0M;&EN92!B87-I<R!O=F5R('1H92!A<'!L:6-A8FQE('1E
M<FTN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/D-O<W0@
M;V8@4V%L97,\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/D-O<W0@;V8@<V%L97,@:6YC;'5D97,@9&ER96-T(&%N9"!I;F1I<F5C=`T*
M8V]S=',@=&\@;6%N=69A8W1U<F4@9F]R;75L871I;VYS(&%N9"!O=&AE<B!P
M<F]D=6-T<R!S;VQD+"!I;F-L=61I;F<@86-T:79E('!H87)M86-E=71I8V%L
M(&EN9W)E9&EE;G1S+"!P97)S;VYN96P@8V]S=',L('!A8VMA9VEN9RP-"G-T
M;W)A9V4L(')O>6%L=&EE<R`H<V5E($YO=&4@,30I+"!S:&EP<&EN9R!A;F0@
M:&%N9&QI;F<@8V]S=',@86YD('1H92!W<FET92UO9F8@;V8@;V)S;VQE=&4@
M:6YV96YT;W)Y+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\
M8CY);F-O;64@5&%X97,\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
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M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!A8V-O=6YT
M<R!F;W(@:6YC;VUE('1A>&5S('5N9&5R#0IT:&4@<')O=FES:6]N<R!O9B!&
M:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A<F0@*"8C,30W.T9!
M4T(F(S$T.#LI($%C8V]U;G1I;F<@4W1A;F1A<F1S($-O9&EF:6-A=&EO;B`H
M)B,Q-#<[05-#)B,Q-#@[*0T*-S0P+"`F(S$T-SM);F-O;64@5&%X97,F(S$T
M.#LL(&]R($%30R`W-#`N($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T+"!T:&5R
M92!W97)E(&YO('5N<F5C;V=N:7IE9"!T87@@8F5N969I=',@:6YC;'5D960@
M:6X@=&AE(&-O;G-O;&ED871E9`T*8F%L86YC92!S:&5E="!T:&%T('=O=6QD
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M:6X@:71S(&-O;G-O;&ED871E9`T*8F%L86YC92!S:&5E=',@870@1&5C96UB
M97(@,S$L(#(P,30@86YD(#(P,3,L(&%N9"!H87,@;F]T(')E8V]G;FEZ960@
M:6YT97)E<W0@86YD+V]R('!E;F%L=&EE<R!I;B!T:&4@8V]N<V]L:61A=&5D
M('-T871E;65N=',@;V8-"F]P97)A=&EO;G,@9F]R('1H92!Y96%R<R!E;F1E
M9"!$96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q,RX@5&AE($-O;7!A;GD@:7,@
M<W5B:F5C="!T;R!T87AA=&EO;B!I;B!T:&4@56YI=&5D(%-T871E<R!A;F0@
M0V%L:69O<FYI82X-"E1H92!#;VUP86YY)B,Q-#8[<R!T87@@>65A<G,@<VEN
M8V4@,C`P,"!A<F4@<W5B:F5C="!T;R!E>&%M:6YA=&EO;B!B>2!T:&4@9F5D
M97)A;"!A;F0@<W1A=&4@=&%X(&%U=&AO<FET:65S(&1U92!T;R!T:&4@8V%R
M<GEF;W)W87)D#0IO9B!U;G5T:6QI>F5D(&YE="!O<&5R871I;F<@;&]S<V5S
M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY#87-H(&%N
M9"!#87-H($5Q=6EV86QE;G1S/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY#87-H(&5Q=6EV86QE;G1S(&EN8VQU9&4@<VAO<G0M=&5R
M;2P@:&EG:&QY#0IL:7%U:60@:6YV97-T;65N=',@=VET:"!M871U<FET:65S
M(&]F('1H<F5E(&UO;G1H<R!O<B!L97-S(&%T('1H92!T:6UE(&]F(&%C<75I
M<VET:6]N+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY#
M;VYC96YT<F%T:6]N<R!O9B!#<F5D:70@4FES:SPO8CX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
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M=&@@;&EM:71S('5P('1O("0R-3`L,#`P('!E<B!O=VYE<BX@070@1&5C96UB
M97(@,S$L(#(P,30L('1H92!#;VUP86YY(&AA9"!A<'!R;WAI;6%T96QY("0W
M+C<-"FUI;&QI;VX@:6X@8V%S:"!D97!O<VET<R!I;B!E>&-E<W,@;V8@1D1)
M0R!L:6UI=',N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB
M/D%C8V]U;G1S(%)E8V5I=F%B;&4\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
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M8G1F=6P@86-C;W5N=',@:6X@=&AE(&%M;W5N="!O9B`D,RPY-3<@87,@;V8@
M1&5C96UB97(@,S$L(#(P,30N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/CQB/DEN=F5N=&]R:65S/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
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M;G9E;G1O<FEE<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
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M(&)A<V5D(&]N(&ET<R!A;F%L>7-E<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^/&(^1G5R;FET=7)E(&%N9"!%<75I<&UE;G0\+V(^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D9U<FYI='5R92!A;F0@
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M9&5P<F5C:6%T960-"F]V97(@=&AR964@=&\@9FEV92!Y96%R<RX\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^1V]O9'=I;&P@86YD($EN
M=&%N9VEB;&4@07-S971S/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY4:&4@0V]M<&%N>2!R979I97=S(&ET<R!G;V]D=VEL;"!A;F0@
M:6YD969I;FET92UL:79E9`T*:6YT86YG:6)L92!A<W-E=',@9F]R(&EM<&%I
M<FUE;G0@87,@;V8@2F%N=6%R>2`Q(&]F(&5A8V@@>65A<B!A;F0@=VAE;B!A
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M;VQL;W=I;F<Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\
M='(^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R-'!X)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W:61T
M:#H@,C1P>"<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(SDV
M-SD[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GDG/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^<VEG
M;FEF:6-A;G0@=6YD97)P97)F;W)M86YC92!O9B!T:&4@0V]M<&%N>28C,30V
M.W,@8G5S:6YE<W,@<F5L871I=F4@=&\@97AP96-T960@;W!E<F%T:6YG(')E
M<W5L=',[/"]F;VYT/CPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S
M=&EF>2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C.38W.3L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SYS:6=N:69I8V%N="!A
M9'9E<G-E(&5C;VYO;6EC(&%N9"!I;F1U<W1R>2!T<F5N9',[/"]F;VYT/CPO
M=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J
M=7-T:69Y)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@=&]P)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G
M/B8C.38W.3L\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M)SYS:6=N:69I8V%N="!D96-L:6YE(&EN('1H92!#;VUP86YY)B,Q-#8[<R!M
M87)K970@8V%P:71A;&EZ871I;VX@9F]R(&%N(&5X=&5N9&5D('!E<FEO9"!O
M9B!T:6UE(')E;&%T:79E('1O(&YE="!B;V]K('9A;'5E.R!A;F0\+V9O;G0^
M/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@=&]P)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y)SXF(S$V,#L\+W1D/CPO='(^#0H\='(^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`G
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^)B,Y-C<Y.SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/F5X<&5C=&%T:6]N
M<R!T:&%T(&$@<F5P;W)T:6YG('5N:70@=VEL;"!B92!S;VQD(&]R(&]T:&5R
M=VES92!D:7-P;W-E9"X@/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE(&=O;V1W:6QL(&EM<&%I<FUE
M;G0@=&5S="!C;VYS:7-T<R!O9B!A#0IT=V\M<W1E<"!P<F]C97-S(&%S(&9O
M;&QO=W,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E-T97`@
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M;B!P97)F;W)M<R!T:&4@<V5C;VYD('-T97`@;V8@=&AE(&EM<&%I<FUE;G0@
M=&5S="X@268@=&AE(&9A:7(@=F%L=64@;V8-"F$@<F5P;W)T:6YG('5N:70@
M97AC965D<R!I=',@8V%R<GEI;F<@86UO=6YT+"!N;R!F=7)T:&5R(&%N86QY
M<VES(&ES(')E<75I<F5D+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
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M=6%L('1O('1H92!E>&-E<W,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/CQB/DEM<&%I<FUE;G0@;V8@3&]N9RU,:79E9"!!<W-E=',\+V(^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DQO;F<M;&EV960@
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M86)I;&ET:65S(&]F(&$@9&ES<&]S86P@9W)O=7`@8VQA<W-I9FEE9"!A<R!H
M96QD+69O<BUS86QE('=O=6QD(&)E('!R97-E;G1E9"!S97!A<F%T96QY(&EN
M('1H92!A<'!R;W!R:6%T92!A<W-E=`T*86YD(&QI86)I;&ET>2!S96-T:6]N
M<R!O9B!T:&4@8V]N<V]L:61A=&5D(&)A;&%N8V4@<VAE970L(&EF(&UA=&5R
M:6%L+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$=7)I;F<@
M=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&%N9`T*,C`Q,RP@
M=&AE($-O;7!A;GD@9&ED(&YO="!R96-O9VYI>F4@86YY(&EM<&%I<FUE;G0@
M;V8@:71S(&QO;F<M;&EV960@87-S971S+CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SX\8CY$969E<G)E9"!296YT(#PO8CX\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
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M87,@86X@861J=7-T;65N="!T;R!D969E<G)E9"!R96YT+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY&86ER(%9A;'5E($UE87-U<F5M
M96YT<SPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
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M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P
M)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('=I9'1H.B`R-'!X)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B8C.38W.3L\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SY,979E;"`Q.B!!<'!L
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M8FQE+CPO9F]N=#X\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!T;W`G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GDG/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXF(SDV-SD[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GDG
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M='(^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GDG/B8C,38P.SPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<"<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T)SXF(SDV-SD[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
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M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP
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M8F5R(#,Q+"`R,#$T(&%N9"`R,#$S+"!T:&4@0V]M<&%N>28C,30V.W,-"F9I
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M;'5E<R!O9B!T:&4@8V%P:71A;`T*;&5A<V5S(&%P<')O>&EM871E('1H96ER
M(')E<W!E8W1I=F4@9F%I<B!V86QU97,N/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQB/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO8CX\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
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M(S$T.#LI(&%N9"!R97-T<FEC=&5D('-T;V-K+`T*87)E(')E8V]G;FEZ960@
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M(&9A:7(@=F%L=64@:7,@9&5T97)M:6YE9`T*870@=&AE(&1A=&4@;V8@9W)A
M;G0N(%1H92!F:6YA;F-I86P@<W1A=&5M96YT(&5F9F5C="!O9B!F;W)F96ET
M=7)E<R!I<R!E<W1I;6%T960@870@=&AE('1I;64@;V8@9W)A;G0@86YD(')E
M=FES960L(&EF(&YE8V5S<V%R>2P-"FEF('1H92!A8W1U86P@969F96-T(&1I
M9F9E<G,@9G)O;2!T:&]S92!E<W1I;6%T97,N/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
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M;W(@:7,@<F5A8VAE9"!O<B`H:6DI('1H92!D871E(&%T('=H:6-H('1H92!C
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M92!S:&5E="!O;F-E('1H92!E<75I='D@:6YS=')U;65N=`T*:7,@9W)A;G1E
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M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/D)A<VEC(&%N9"!$:6QU=&5D
M($YE="!,;W-S('!E<B!#;VUM;VX@4VAA<F4\+V(^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
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M(&1U<FEN9PT*=&AE('!E<FEO9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
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M9R!T:&4-"G1R96%S=7)Y('-T;V-K(&]R+"`F(S$T-SMI9B!C;VYV97)T960F
M(S$T.#L@;65T:&]D*2!F<F]M('-T;V-K(&]P=&EO;G,L(%)357,@86YD('=A
M<G)A;G1S('=E<F4@,RPP,C0L,C$W(&%N9"`S+#4S.2PX,#`@870@1&5C96UB
M97(-"C,Q+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T:79E;'DL(&%N9"!A<F4@
M97AC;'5D960@9G)O;2!T:&4@8V%L8W5L871I;VX@;V8@9&EL=71E9"!N970@
M;&]S<R!P97(@<VAA<F4@9F]R(&%L;"!P97)I;V1S('!R97-E;G1E9`T*8F5C
M875S92!T:&4@969F96-T(&ES(&%N=&DM9&EL=71I=F4N($-O;6UO;B!S=&]C
M:R!E<75I=F%L96YT<R!A="!$96-E;6)E<B`S,2P@,C`Q-"!I;F-L=61E(#(W
M+#(Q."!S:&%R97,@;V8@8V]M;6]N('-T;V-K('5N9&5R;'EI;F<-"E)357,L
M(&%W87)D960@=&\@9&ER96-T;W)S('1H870@:&%V92!V97-T960L(&)U="!T
M:&4@:7-S=6%N8V4@86YD(&1E;&EV97)Y(&]F('1H97-E('-H87)E<R!A<F4@
M9&5F97)R960@=6YT:6P@=&AE(&1I<F5C=&]R(')E<VEG;G,N/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!F;VQL;W=I;F<@=&%B;&4@
M<VAO=W,@=&AE(&-O;7!U=&%T:6]N(&]F#0IB87-I8R!A;F0@9&EL=71E9"!N
M970@;&]S<R!P97(@<VAA<F4@;V8@8V]M;6]N('-T;V-K(&9O<B!T:&4@>65A
M<G,@96YD960@1&5C96UB97(@,S$L(#(P,30@86YD(#(P,3,Z/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!W:61T:#H@,3`P)3L@8F]R
M9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P="<^1F]R('1H93PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/D9O
M<B!T:&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^665A<B!%;F1E9#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97(G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<B<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0G/EEE87(@16YD960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@=&5X="UA;&EG;CH@8V5N=&5R
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<B<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T)SY$96-E;6)E<B`S,2P@,C`Q-#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU
M<'0[('1E>'0M86QI9VXZ(&-E;G1E<B<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!T97AT+6%L:6=N.B!C
M96YT97(G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97(G/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^
M1&5C96UB97(@,S$L(#(P,3,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!T97AT+6%L:6=N.B!C96YT97(G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M)SX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@-3@E.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^3G5M97)A=&]R("8C,34P.R!N970@
M;&]S<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0G/B0\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$X)3L@8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@
M<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^*#$P+#$Q
M."PQ,#,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!P861D:6YG+6)O='1O;3H@,BXU<'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P="<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE)SX\9F]N="!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$X)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P
M="<^*#<L-C0S+#$R-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[('!A9&1I;F<M8F]T=&]M.B`R+C5P="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T)SXI/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P="<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SY$96YO
M;6EN871O<B`F(S$U,#L@=V5I9VAT960@879E<F%G92!N=6UB97(@;V8@<VAA
M<F5S(&]U='-T86YD:6YG+"!B87-I8R!A;F0@9&EL=71E9#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0G/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P="<^.2PQ
M,S(L.3@Y/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9"<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-I>F4Z(#$P<'0G/C@L-C4V+#@R,CPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0G/CQB/DYE="!L;W-S('!E<B!S:&%R92P@8F%S:6,@
M86YD(&1I;'5T960\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L92<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXD/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0G/B@Q+C$Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T)SXI/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M92<^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T)SXD/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0G/B@P+C@X/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P="<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US:7IE.B`Q,'!T)SXI/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B
M;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/E5S92!O9B!%<W1I
M;6%T97,\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H
M92!P<F5P87)A=&EO;B!O9B!F:6YA;F-I86P@<W1A=&5M96YT<R!I;@T*8V]N
M9F]R;6ET>2!W:71H($=!05`@<F5Q=6ER97,@;6%N86=E;65N="!T;R!M86ME
M(&5S=&EM871E<R!A;F0@:G5D9VUE;G1S('1H870@869F96-T('1H92!R97!O
M<G1E9"!A;6]U;G1S(&]F(&%S<V5T<RP@86YD(&QI86)I;&ET:65S#0IA;F0@
M9&ES8VQO<W5R92!O9B!C;VYT:6YG96YT(&%S<V5T<R!A;F0@;&EA8FEL:71I
M97,@870@=&AE(&1A=&4@;V8@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N
M9"!R97!O<G1E9"!A;6]U;G1S(&]F(')E=F5N=65S(&%N9`T*97AP96YS97,@
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M97-U;'1S(&-O=6QD(&1I9F9E<B!F<F]M('1H;W-E(&5S=&EM871E<RX\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^4F5C;&%S<VEF:6-A
M=&EO;G,\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D-E
M<G1A:6X@<')I;W(@<&5R:6]D(&ET96US(&%N9"!A;6]U;G1S(&AA=F4-"F)E
M96X@<F5C;&%S<VEF:65D('1O(&-O;F9O<FT@=&\@=&AE(&-L87-S:69I8V%T
M:6]N<R!U<V5D('1O('!R97!A<F4@=&AE(&-O;G-O;&ED871E9"!F:6YA;F-I
M86P@<W1A=&5M96YT<R!F;W(@=&AE('EE87(@96YD960@1&5C96UB97(-"C,Q
M+"`R,#$T+B!4:&4@0V]M<&%N>2!H87,@8VQA<W-I9FEE9"!I;B!T:&5S92!F
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M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/E)E8V5N=&QY($%D;W!T960@06-C
M;W5N=&EN9R!0<F]N;W5N8V5M96YT<SPO8CX\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^26X@2G5N92`R,#$T+"!T:&4@1D%30B!I<W-U960@
M86X@06-C;W5N=&EN9PT*4W1A;F1A<F1S(%5P9&%T92`H)B,Q-#<[05-5)B,Q
M-#@[*2!.;RX@,C`Q-"TQ,"P@)B,Q-#<[16QI;6EN871I;VX@;V8@0V5R=&%I
M;B!&:6YA;F-I86P@4F5P;W)T:6YG(%)E<75I<F5M96YT<RP@26YC;'5D:6YG
M(&%N#0I!;65N9&UE;G0@=&\@5F%R:6%B;&4@26YT97)E<W0@16YT:71I97,F
M(S$T.#LN(%1H92!A;65N9&UE;G1S(&EN('1H:7,@=7!D871E(')E;6]V92!T
M:&4@9&5F:6YI=&EO;B!O9B!A(&1E=F5L;W!M96YT('-T86=E(&5N=&ET>0T*
M9G)O;2!!4T,@5&]P:6,@.3$U+"`F(S$T-SM$979E;&]P;65N="!3=&%G92!%
M;G1I=&EE<R8C,30X.RP@=&AE<F5B>2!R96UO=FEN9R!F<F]M($=!05`@=&AE
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M<B8C,30V.W,@97%U:71Y+"`H,BD@;&%B96P-"G1H92!F:6YA;F-I86P@<W1A
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M96=I;FYI;F<@07!R:6P@,2P@,C`Q-"X@5VET:"!T:&4-"F-H86YG92!I;B!T
M:&4@0V]M<&%N>28C,30V.W,@;W!E<F%T:6]N<RP@:71S(')E=F5N=64@<F5C
M;V=N:71I;VX@86YD(&ET<R!I;6UE9&EA=&4@861O<'1I;VX@;V8@05-5($YO
M+B`R,#$T+3$P+"!T:&4@0V]M<&%N>2!N;PT*;&]N9V5R('!R97-E;G1S(&]R
M(&1I<V-L;W-E<R!A;GD@:6YF;W)M871I;VX@<F5Q=6ER960@=6YD97(@05-#
M(%1O<&EC(#DQ-2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&(^4F5C96YT;'D@27-S=65D($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\
M+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($%U9W5S
M="`R,#$T+"!T:&4@1D%30B!I<W-U960@;F5W(&%C8V]U;G1I;F<-"F=U:61A
M;F-E('=H:6-H(&1E9FEN97,@;6%N86=E;65N="8C,30V.W,@<F5S<&]N<VEB
M:6QI='D@=&\@87-S97-S(&%N(&5N=&ET>28C,30V.W,@86)I;&ET>2!T;R!C
M;VYT:6YU92!A<R!A(&=O:6YG(&-O;F-E<FXL(&%N9`T*=&\@<')O=FED92!R
M96QA=&5D(&9O;W1N;W1E(&1I<V-L;W-U<F5S(&EN(&-E<G1A:6X@8VER8W5M
M<W1A;F-E<RX@5&AI<R!G=6ED86YC92!W:6QL(&)E(&5F9F5C=&EV92!F;W(@
M86YN=6%L('!E<FEO9',@96YD:6YG(&%F=&5R#0I$96-E;6)E<B`Q-2P@,C`Q
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M=&5M96YT<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@
M36%Y(#(P,30L('1H92!&05-"(&ES<W5E9"!!4U4@3F\N(#(P,30M,#DL#0HF
M(S$T-SM2979E;G5E(&9R;VT@0V]N=')A8W1S('=I=&@@0W5S=&]M97)S)B,Q
M-#@[("@F(S$T-SM!4U4@,C`Q-"TP.28C,30X.RDN(%1H92!O8FIE8W1I=F4@
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M8V]N=')A8W0H<RD@=VET:"!A(&-U<W1O;65R.R`H,BD@:61E;G1I9GD@=&AE
M('!E<F9O<FUA;F-E(&]B;&EG871I;VYS(&EN('1H92!C;VYT<F%C=#L@*#,I
M(&1E=&5R;6EN90T*=&AE('1R86YS86-T:6]N('!R:6-E.R`H-"D@86QL;V-A
M=&4@=&AE('1R86YS86-T:6]N('!R:6-E('1O('1H92!C;VYT<F%C="8C,30V
M.W,@<&5R9F]R;6%N8V4@;V)L:6=A=&EO;G,[(&%N9"`H-2D@<F5C;V=N:7IE
M(')E=F5N=64-"G=H96X@*&]R(&%S*2!T:&4@96YT:71Y('-A=&ES9FEE<R!A
M('!E<F9O<FUA;F-E(&]B;&EG871I;VXN($%352`R,#$T+3`Y(&%P<&QI97,@
M=&\@86QL(&-O;G1R86-T<R!W:71H(&-U<W1O;65R<R!E>&-E<'0@=&AO<V4@
M=&AA=`T*87)E('=I=&AI;B!T:&4@<V-O<&4@;V8@;W1H97(@=&]P:6-S(&EN
M('1H92!&05-"($%30RX@5&AE(&YE=R!G=6ED86YC92!I<R!E9F9E8W1I=F4@
M9F]R(&%N;G5A;"!R97!O<G1I;F<@<&5R:6]D<RP@:6YC;'5D:6YG(&EN=&5R
M:6T-"G!E<FEO9',@=VET:&EN('1H;W-E('!E<FEO9',L(&)E9VEN;FEN9R!A
M9G1E<B!$96-E;6)E<B`Q-2P@,C`Q-B!F;W(@<'5B;&EC(&-O;7!A;FEE<RX@
M16%R;'D@861O<'1I;VX@:7,@;F]T('!E<FUI='1E9"X@5&AE($-O;7!A;GD-
M"FES(&-U<G)E;G1L>2!E=F%L=6%T:6YG('1H92!N97<@9W5I9&%N8V4@86YD
M(&AA<R!N;W0@9&5T97)M:6YE9"!T:&4@:6UP86-T('1H:7,@<W1A;F1A<F0@
M;6%Y(&AA=F4@;VX@:71S(&-O;G-O;&ED871E9"!F:6YA;F-I86P-"G-T871E
M;65N=',N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?83=C9F-B9C5?8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W8V9C8F8U7V)D-&9?-#<Y
M,%]A-SDY7S@U-#%D9#0X9&%A-B]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY!8W%U:7-I=&EO
M;B`M(%!H87)M86-Y($-R96%T:6]N<RP@3$Q#/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D)U<VEN97-S($-O;6)I
M;F%T:6]N<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C<75I<VET:6]N("T@4&AA<FUA8WD@0W)E871I
M;VYS+"!,3$,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T
M>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/DY/5$4@,RX@04-1
M54E3251)3TX@)B,Q-3`[(%!(05)-04-9#0I#4D5!5$E/3E,L($Q,0SPO8CX\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SY/;B!!<')I;"`Q+"`R,#$T+"!T:&4@0V]M<&%N>2!A8W%U:7)E9`T*86QL
M(&]F('1H92!O=71S=&%N9&EN9R!M96UB97)S:&EP(&EN=&5R97-T<R!O9B!0
M0R`H=&AE("8C,30W.U!#($%C<75I<VET:6]N)B,Q-#@[*2!F<F]M($HN(%-C
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M<F5P87)A=&EO;G,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
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M=6ES:71I;VXN/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@
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M.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^1F%I<B!686QU92!O9B!#;VYS
M:61E<F%T:6]N(%1R86YS9F5R<F5D/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D%T('1H92!C;&]S:6YG(&]F
M('1H92!00R!!8W%U:7-I=&EO;BP-"G1H92!#;VUP86YY('!A:60@=&\@=&AE
M(%!#(%-E;&QE<G,@86X@86=G<F5G871E(&-A<V@@<'5R8VAA<V4@<')I8V4@
M;V8@)#8P,"PP,#`N($EN(&%D9&ET:6]N+"!T:&4@4$,@4V5L;&5R<R!A<F4@
M96YT:71L960@=&\@<F5C96EV90T*861D:71I;VYA;"!C;VYT:6YG96YT(&-O
M;G-I9&5R871I;VX@=7!O;B!T:&4@<V%T:7-F86-T:6]N(&]F(&-E<G1A:6X@
M8V]N9&ET:6]N<RP@87,@9F]L;&]W<SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T($-A;&EB<FDL
M($AE;'9E=&EC82P@4V%N<RU397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,C1P>#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('=I9'1H.B`R
M-'!X.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Y-C<Y.SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^02!C;VYT:6YG
M96YT(&-A<V@@<&%Y;65N="!O9B`D-3`L,#`P+"!P87EA8FQE(&EF(%!#(&5A
M<FYS(')E=F5N=65S(&]F(&]V97(@)#,L-3`P+#`P,"!F;W(@=&AE(#$R(&UO
M;G1H('!E<FEO9"!E;F1I;F<@36%R8V@@,S$L(#(P,34N/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!T;W`[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C.38W.3L\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/D$@8V]N=&EN9V5N="!S=&]C:R!P87EM96YT(&]F
M('5P('1O(&%N(&%G9W)E9V%T92!O9B`R,34L,3DP('-H87)E<R!O9B!T:&4@
M0V]M<&%N>28C,30V.W,@8V]M;6]N('-T;V-K+"!I<W-U86)L92!O;FQY(&EF
M('1H92!F;VQL;W=I;F<@<F5V96YU92!M:6QE<W1O;F5S(&%R92!M970Z/"]F
M;VYT/CPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C.38W.3L\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/FEF(%!#(&5A<FYS(')E=F5N=64@
M;V8@;W9E<B`D-RPU,#`L,#`P(&1U<FEN9R!T:&4@,3(@;6]N=&@@<&5R:6]D
M(&5N9&EN9R!-87)C:"`S,2P@,C`Q-BP@86QL(#(Q-2PQ.3`@<VAA<F5S.SPO
M9F]N=#X\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@=&]P.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<CX-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(SDV-SD[/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SYI9B!00R!E87)N<R!R979E;G5E
M(&]F(&)E='=E96X@)#,L-3`P+#`P,"!A;F0@)#<L-3`P+#`P,"!D=7)I;F<@
M=&AE(#$R(&UO;G1H('!E<FEO9"!E;F1I;F<@36%R8V@@,S$L(#(P,38L(&%N
M(&%G9W)E9V%T92!O9B!T:&%T(&YU;6)E<B!O9B!S:&%R97,@;V8@26UP<FEM
M:7,@8V]M;6]N('-T;V-K(&5Q=6%L('1O('1H92!A;6]U;G0@=&AA="!S=6-H
M(')E=F5N=64@97AC965D<R`D,RPU,#`L,#`P(&1I=FED960@8GD@,3@N-3@X
M,BP@<F]U;F1E9"!D;W=N('1O('1H92!L;W=E<B!W:&]L92!N=6UB97(@*&YO
M="!T;R!E>&-E960@,C$U+#$Y,"!S:&%R97,I+CPO9F]N=#X\+W1D/CPO='(^
M#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D%L=&AO=6=H(&UA;F%G
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M:6QL:6]N+"!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L
M=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`W.24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY#87-H('!A>6UE;G0@=&\@=&AE(%!#(%-E;&QE<G,@870@8VQO
M<VEN9SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[
M('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^-C`P+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^0V]N=&EN9V5N="!C;VUM;VX@<W1O
M8VL@:7-S=6%N8V4@=&\@=&AE(%!#(%-E;&QE<G,\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0X,RPQ-38\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D-O;G1I;F=E
M;G0@8V%S:"!C;VYS:61E<F%T:6]N('1O('1H92!00R!396QL97)S/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N
M-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C,Q+#0V-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1O=&%L(&%C<75I<VET:6]N(&1A=&4@
M9F%I<B!V86QU93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXQ+#$Q-"PV,C(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^02`D
M-3$T+#8R,B!L:6%B:6QI='D@=V%S(')E8V]G;FEZ960-"F9O<B!T:&4@97-T
M:6UA=&5D(&%C<75I<VET:6]N(&1A=&4@9F%I<B!V86QU92!O9B!T:&4@9G5T
M=7)E(&-O;G1I;F=E;G0@8V]M;6]N('-T;V-K(&%N9"!C87-H('!A>6UE;G1S
M(&%N9"!I<R!I;F-L=61E9"!I;B!T:&4@8V]N=&EN9V5N=`T*86-Q=6ES:71I
M;VX@;V)L:6=A=&EO;G,@:6X@=&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI9&%T
M960@8F%L86YC92!S:&5E="!A="!$96-E;6)E<B`S,2P@,C`Q-"X\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY!
M;&QO8V%T:6]N(&]F($-O;G-I9&5R871I;VX@5')A;G-F97)R960-"CPO8CX\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
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M('=A<R!R96-O<F1E9"!A<R!G;V]D=VEL;"X\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@9F]L;&]W:6YG('1A
M8FQE('-U;6UA<FEZ97,@=&AE(&5S=&EM871E9`T*9F%I<B!V86QU97,@;V8@
M=&AE(&%S<V5T<R!A8W%U:7)E9"!A;F0@;&EA8FEL:71I97,@87-S=6UE9"!A
M="!T:&4@86-Q=6ES:71I;VX@9&%T92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T($-A;&EB<FDL
M($AE;'9E=&EC82P@4V%N<RU397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@-SDE.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[('1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-"PY.#(\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/D%C8V]U;G1S(')E8V5I=F%B;&4\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4X+#0R,#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4')E<&%I9"!E
M>'!E;G-E<R!A;F0@;W1H97(@87-S971S/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS,"PR-38\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY);G9E;G1O<GD\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(Q,RPQ.3`\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0T+#4Q,#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DEN=&%N9VEB;&4@87-S971S
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8U.2PP,#`\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUL969T.B`Q,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^5&]T86P@:61E;G1I9FEA8FQE(&%S<V5T<R!A8W%U:7)E9#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PP,3`L
M,S4X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^06-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE<SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,3(P
M+#`T.3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^3W1H97(@;&EA8FEL:71I97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,3`W+#,P.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&]T86P@;&EA8FEL:71I97,@
M87-S=6UE9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,C<L,S4W/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/E1O=&%L(&ED96YT:69I86)L92!A<W-E=',@;&5S<R!L
M:6%B:6QI=&EE<R!A<W-U;65D/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXW.#,L,#`Q/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^1V]O9'=I;&P\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N
M-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L
M:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,S,Q+#8R,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY.970@87-S971S(&%C<75I<F5D/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$L,3$T+#8R,CPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SX\8CY297-U;'1S(&]F($]P97)A=&EO;G,\+V(^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
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M(#,Q+"`R,#$T(&%R92!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R
M:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`W,R4[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY4;W1A;"!R979E;G5E<SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`R-"4[(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,2PV-3(L,S@V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/<&5R871I;F<@;&]S
M<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH-C8R
M+#DV.3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/CPO='(^#0H\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/CQB/E!R;R!&;W)M82!&:6YA;F-I86P@26YF;W)M871I;VX\+V(^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE
M(&9O;&QO=VEN9R!T86)L92!P<F5S96YT<R!T:&4@0V]M<&%N>28C,30V.W,-
M"G5N875D:71E9"!P<F\@9F]R;6$@<F5S=6QT<R`H:6YC;'5D:6YG(%!#*2!F
M;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"`R,#$S
M(&%S('1H;W5G:"!T:&4@8V]M<&%N:65S(&AA9"!B965N(&-O;6)I;F5D#0IA
M<R!O9B!T:&4@8F5G:6YN:6YG(&]F(&5A8V@@;V8@=&AE('!E<FEO9',@<')E
M<V5N=&5D+B!4:&4@<')O(&9O<FUA(&EN9F]R;6%T:6]N(&ES('!R97-E;G1E
M9"!F;W(@:6YF;W)M871I;VYA;"!P=7)P;W-E<R!O;FQY(&%N9`T*:7,@;F]T
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M8W1I;VYS+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\
M+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS
M+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S
M92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D9O<B!T:&4\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^1F]R('1H93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/EEE
M87(@16YD960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^665A<B!%;F1E9#PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$
M96-E;6)E<B`S,2P@,C`Q-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S
M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^1&5C96UB97(@,S$L(#(P,3,\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-3@E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^5&]T86P@<F5V96YU97,\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$X)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,BPR.#(L-C@Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q."4[(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N
M-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C(L.#8V+#4W-3PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3F5T(&QO<W,\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#$P+#`T
M."PS.#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^*#<L,#@T+#`Q-#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*3PO9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY4:&4@0V]M<&%N>2!D:60@;F]T(&EN8W5R(&UA=&5R:6%L(&%C<75I
M<VET:6]N#0IE>'!E;G-E<R!R96QA=&5D('1O('1H92!00R!!8W%U:7-I=&EO
M;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SX\8CY);G1A;F=I8FQE($%S<V5T<SPO8CX\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY-86YA9V5M96YT(&5N
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M(&%N9"!T:&5I<B!E<W1I;6%T960@=7-E9G5L(&QI=F5S+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P
M)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1F%I<B!686QU93PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^57-E9G5L($QI9F4\+V9O;G0^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@-C`E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^0W5S=&]M97(@<F5L871I;VYS:&EP<SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q."4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-3DV+#`P,#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,3@E.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ,"`M(#$U('EE87)S/"]F;VYT/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4<F%D92!N86UE/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+#`P
M,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C4@>65A<G,\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^3F]N+6-O;7!E=&ET:6]N(&-O=F5N86YT/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU,"PP,#`\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT('EE87)S/"]F
M;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY3=&%T92!P
M:&%R;6%C>2!L:6-E;G-E<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXX+#`P,#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(U
M('EE87)S/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8U.2PP,#`\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\
M+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
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M9&%T92!O9B!A8W%U:7-I=&EO;BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY';V]D=VEL;"`\+V(^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
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M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$W
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4F5S=')I8W1E9"!3:&]R="U4
M97)M($EN=F5S=&UE;G0\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4F5S=')I8W1E9"!3:&]R="UT97)M($EN=F5S
M=&UE;G0\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5S=')I8W1E9"!3:&]R="U497)M($EN=F5S=&UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T
M)SX\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/CQB/DY/5$4@-"X@4D535%))0U1%1"!32$]25"U415)-($E.5D535$U%3E13
M/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\8CXF(S$V,#L\
M+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY4:&4@<F5S=')I8W1E9"!S:&]R="UT97)M(&EN=F5S
M=&UE;G1S#0IA="!$96-E;6)E<B`S,2P@,C`Q-"!C;VYS:7-T(&]F(&-E<G1I
M9FEC871E(&]F(&1E<&]S:71S+"!W:&EC:"!A<F4@8VQA<W-I9FEE9"!A<R!H
M96QD+71O+6UA='5R:71Y+B!!="!$96-E;6)E<B`S,2P@,C`Q-"P@=&AE(')E
M<W1R:6-T960-"G-H;W)T+71E<FT@:6YV97-T;65N=',@=V5R92!R96-O<F1E
M9"!A="!A;6]R=&EZ960@8V]S="!W:&EC:"!A<'!R;WAI;6%T97,@9F%I<B!V
M86QU92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY!="!$96-E;6)E<B`S,2P@,C`Q-"P@=&AE(&-E<G1I9FEC871E
M#0IO9B!D97!O<VET<R!O9B`D,34P+#(V-"!W97)E(&-L87-S:69I960@87,@
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M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?8F0T9E\T-SDP7V$W.3E?
M.#4T,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W
M8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X9&%A-B]7;W)K<VAE971S
M+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY);G9E;G1O<FEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY);G9E;G1O<GD@1&ES8VQO<W5R92!;06)S
M=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN=F5N=&]R:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS
M1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY.3U1%(#4N($E.5D5.5$]2
M2453/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\8CXF(S$V
M,#L\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
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M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H
M.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&(^1&5C96UB97(@,S$L(#(P,30\+V(^/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`W,R4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY287<@;6%T97)I86QS/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#(T)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ-#8L,S`P/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY7
M;W)K(&EN('!R;V=R97-S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXY-RPX,#$\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/D9I;FES:&5D(&=O;V1S/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C$R."PV,S0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY4;W1A;"!I;G9E;G1O<FEE<SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS-S(L-S,U/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\+W`^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,CX\<W1R;VYG/E!R97!A:60@17AP96YS97,@86YD($]T:&5R($-U<G)E
M;G0@07-S971S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D1E9F5R<F5D($-O<W1S+"!#87!I=&%L:7IE9"P@4')E
M<&%I9"P@86YD($]T:&5R($%S<V5T<R!$:7-C;&]S=7)E(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E
M<&%I9"!%>'!E;G-E<R!A;F0@3W1H97(@0W5R<F5N="!!<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@
M,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQB/DY/5$4@-BX@4%)%4$%)
M1"!%6%!%3E-%4R!!3D0@3U1(15(@0U524D5.5"!!4U-%5%,\+V(^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H
M97(@8W5R<F5N="!A<W-E=',-"F-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG
M.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF
M.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY$96-E;6)E<B`S,2P@,C`Q-#PO8CX\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/D1E
M8V5M8F5R(#,Q+"`R,#$S/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`V,B4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY0<F5P86ED('-T;V-K+6)A<V5D(&-O;G-U;'1I;F<@97AP96YS
M97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,38E.R!T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,38E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(V+#8T.3PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4')E<&%I
M9"!R96YT/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,38L,C@X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY0<F5P86ED(&EN<W5R86YC93PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,3(S+#<W-CPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,Y
M+#$V-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/D]T:&5R('!R97!A:60@97AP96YS97,@86YD(&1E<&]S:71S/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N
M-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C$Q-BPV,C4\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S
M;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C(R+#DV-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^5&]T86P@<')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@
M8W5R<F5N="!A<W-E=',\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,C0P+#0P,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,3`U+#`V-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD
M96YT.B`M,"XW-6EN)SXF(S$V,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/D9U<FYI='5R92!A;F0@17%U:7!M96YT/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N
M="!A;F0@17%U:7!M96YT(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1G5R;FET=7)E(&%N9"!%<75I<&UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$
M)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T
M)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQB/DY/5$4@
M-RX@1E523DE455)%($%.1"!%455)4$U%3E0\+V(^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^1G5R;FET=7)E(&%N9"!E<75I<&UE;G0@8V]N<VES=&5D
M(&]F#0IT:&4@9F]L;&]W:6YG.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L
M=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^/&(^1&5C96UB97(@,S$L(#(P,30\+V(^/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY$96-E
M;6)E<B`S,2P@,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1G5R;FET
M=7)E(&%N9"!E<75I<&UE;G0L(&YE=#H\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`V,B4[('!A9&1I;F<M;&5F=#H@,3!P=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D-O;7!U=&5R('-O9G1W
M87)E(&%N9"!H87)D=V%R93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-B4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^-3(L-3<V/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$V)3L@=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR-"PU
M,S8\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY&=7)N:71U<F4@
M86YD(&5Q=6EP;65N=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,34T+#(Q-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$P+#0T.3PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.B`Q,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^3&%B(&%N9"!P:&%R;6%C>2!E<75I<&UE;G0\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8Q+#@V.#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BT\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^3&5A<V5H;VQD(&EM<')O=F5M96YT<SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P
M="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXR,"PQ-S(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI
M9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C@X+#@S,3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,T
M+#DX-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^06-C=6UU;&%T960@9&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I
M;VX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^*#0U+#0S-CPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH."PP.3,\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/BD\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(T,RPS.34\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(V+#@Y,CPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!R96-O<F1E9"!D
M97!R96-I871I;VX@86YD#0IA;6]R=&EZ871I;VX@97AP96YS92!O9B`D,S<L
M,S0S(&%N9"`D-2PV-3D@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q-"!A;F0@,C`Q,RP@<F5S<&5C=&EV96QY+CPO<#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^26YT86YG:6)L92!!<W-E=',@86YD($=O;V1W
M:6QL/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D=O;V1W:6QL(&%N9"!);G1A;F=I8FQE($%S<V5T<R!$:7-C;&]S
M=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YT86YG:6)L92!!<W-E=',@86YD($=O;V1W:6QL/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G
M:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\8CY.3U1%(#@N($E.
M5$%.1TE"3$4@05-31513($%.1"!'3T]$5TE,3#PO8CX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SY4:&4@0V]M
M<&%N>28C,30V.W,@:6YT86YG:6)L92!A<W-E=',@870@1&5C96UB97(@,S$L
M(#(P,30-"F-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG.CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A
M+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C
M;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^06UO<G1I>F%T
M:6]N/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SYP97)I;V1S/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS
M<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!8V-U;75L871E9#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/DYE=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH:6X@
M>65A<G,I/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^0V]S=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SYA;6]R=&EZ871I;VX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^8V%R<GEI;F<@=F%L=64\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#,X)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/D-U<W1O;65R(')E;&%T:6]N<VAI<',\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,3`M,34@>65A<G,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C4Y-BPP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@S-BPW-#`\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-34Y+#(V,#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^5')A9&4@;F%M93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^-2!Y96%R<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^-2PP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH-S4P/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT
M+#(U,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^3F]N+6-O;7!E=&ET:6]N(&-O=F5N86YT/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT('EE87)S/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU,"PP,#`\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH.2PS
M-S4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C0P+#8R-3PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E-T871E('!H87)M86-Y(&QI8V5N
M<V5S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR
M-2!Y96%R<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXX+#`P,#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*#$L,30Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N
M-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C8L.#4Y/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C8U.2PP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B@T."PP,#8\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-C$P+#DY
M-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SY!;6]R=&EZ871I;VX@
M97AP96YS92!F;W(@:6YT86YG:6)L92!A<W-E=',@9F]R('1H92!Y96%R(&5N
M9&5D#0I$96-E;6)E<B`S,2P@,C`Q-"!W87,@87,@9F]L;&]W<SH\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E
M.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^1F]R('1H93PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/EEE87(@16YD960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5C96UB
M97(@,S$L(#(P,30\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@-S,E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M0W5S=&]M97(@<F5L871I;VYS:&EP<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`R-"4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,S8L-S0P/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4<F%D
M92!N86UE/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXW-3`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/DYO;BUC;VUP971I=&EO;B!C;W9E;F%N=#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^.2PS-S4\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY3=&%T92!P
M:&%R;6%C>2!L:6-E;G-E<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#$T,3PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-#@L,#`V/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`G/D5S=&EM871E9"!F=71U<F4@86UO<G1I>F%T
M:6]N(&5X<&5N<V4@9F]R('1H92!#;VUP86YY)B,Q-#8[<PT*:6YT86YG:6)L
M92!A<W-E=',@870@1&5C96UB97(@,S$L(#(P,30@:7,@87,@9F]L;&]W<SH\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT
M.B`M,"XW-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R
M:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^665A<G,@96YD:6YG($1E8V5M8F5R(#,Q+#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`W,R4[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$U/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#(T)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV-RPP.#<\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C(P,38\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C8W+#`X-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,C`Q-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^-C<L,#@W/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^,C`Q.#PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^-3<L-S$R/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$Y/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU,RPX,S<\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4:&5R
M96%F=&5R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(Y."PQ.#0\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C8Q,"PY.30\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T
M<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE(&-H86YG97,@
M:6X@=&AE(&-A<G)Y:6YG('9A;'5E(&]F#0IT:&4@0V]M<&%N>28C,30V.W,@
M9V]O9'=I;&P@9'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R
M,#$T('=E<F4@87,@9F]L;&]W<SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T($-A;&EB<FDL($AE
M;'9E=&EC82P@4V%N<RU397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL
M87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^0F%L
M86YC92!A="!*86YU87)Y(#$L(#(P,30\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^+3PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#<S)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/E!#($%C<75I<VET:6]N/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,C0E.R!B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS,S$L-C(Q/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/D)A;&%N8V4@870@1&5C96UB97(@,S$L(#(P,30\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,S,Q+#8R,3PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#`N-6EN)SX\
M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%C8V]U;G1S(%!A>6%B;&4@
M86YD($%C8W)U960@17AP96YS97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4&%Y86)L97,@86YD($%C8W)U86QS
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C;W5N=',@4&%Y86)L92!A;F0@06-C<G5E9"!%>'!E;G-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G
M;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&(^3D]412`Y
M+B!!0T-/54Y44R!005E!0DQ%($%.1"!!0T-2545$($584$5.4T53/"]B/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D%C8V]U;G1S('!A>6%B;&4@86YD
M(&%C8W)U960@97AP96YS97,-"F-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG
M.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF
M.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY$96-E;6)E<B`S,2P@,C`Q-#PO8CX\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/D1E
M8V5M8F5R(#,Q+"`R,#$S/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`U."4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY!8V-O=6YT<R!P87EA8FQE/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$X)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV.3@L.#`V/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$X)3L@
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXR-C$L.3(T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$969E<G)E9"!R96YT/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT+#DW-3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BT\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D)U:6QD:6YG(&QE87-E(&QI86)I;&ET>2@Q*3PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-S,L-34R/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^+3PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]T:&5R(&%C
M8W)U960@97AP96YS97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,SDL,#`P/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^*#(I/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4P+#`P,#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&]T86P@86-C
M;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!E>'!E;G-E<SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^.#$V+#,S,SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,Q
M,2PY,C0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY,97-S.B!#=7)R96YT('!O<G1I;VX\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O
M;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^*#<X-BPV-S4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@S,3$L
M.3(T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/DYO;BUC=7)R96YT('1O=&%L(&%C8V]U;G1S
M('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,CDL-C4X/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\
M+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R
M:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)2<^#0H\='(^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R-'!X)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!W:61T:#H@
M,C1P>#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q*3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^26X@4V5P=&5M8F5R(#(P,30L('1H92!#;VUP86YY(')E;&]C
M871E9"!I=',@<')I;6%R>2!O<&5R871I;VYS('1O(&$@-RPU-C4@<W%U87)E
M(&9O;W0@;V9F:6-E(&9A8VEL:71Y(&EN(%-A;B!$:65G;RP@0V%L:69O<FYI
M82X@07,@;V8@1&5C96UB97(@,S$L(#(P,30L('1H92!#;VUP86YY('=A<R!M
M87)K971I;F<@:71S('!R979I;W5S(&]F9FEC92!S<&%C92`H,RPX-S0@<W%U
M87)E(&9E970I(&%S(&$@<W5B;&5A<V4@=&AR;W5G:"!I=',@<F5M86EN:6YG
M(&QE87-E('1E<FTN(%1H92!#;VUP86YY(')E8V]G;FEZ960@82!L;W-S(&]F
M(&%P<')O>&EM871E;'D@)#$Q-RPP,#`@9'5R:6YG('1H92!Y96%R(&5N9&5D
M($1E8V5M8F5R(#,Q+"`R,#$T+"!R96QA=&5D('1O('1H92!E<W1I;6%T960@
M<F5M86EN:6YG(&QE87-E(&QI86)I;&ET>2P@;F5T(&]F(&5X<&5C=&5D('-U
M8FQE87-E(&EN8V]M92X@5&AE(&]B;&EG871I;VYS('=E<F4@9&ES8V]U;G1E
M9"!B87-E9"!O;B!C=7)R96YT('!R979A:6QI;F<@;6%R:V5T(')A=&5S+B!4
M:&ES(&QO<W,@:7,@:6YC;'5D960@:6X@<F5N="!E>'!E;G-E(&9O<B!T:&4@
M>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"`H<V5E($YO=&4@,30I+CPO
M9F]N=#X\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@=&]P.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B@R*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^5&AE(&%M;W5N="!C;VYS:7-T<R!O9B!A("0S.2PP
M,#`@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&%C8W)U86P@870@1&5C96UB
M97(@,S$L(#(P,30@9F]R('-T;V-K(&]P=&EO;G,@=&\@8F4@9W)A;G1E9"!F
M;W(@<V5R=FEC97,@<&5R9F]R;65D+B!4:&4@<W1O8VLM8F%S960@8V]M<&5N
M<V%T:6]N(&5X<&5N<V4@<F5L871E9"!T;R!R97-T<FEC=&5D(&-O;6UO;B!S
M=&]C:R!I<W-U86YC97,@86YD(&%C8W)U86QS('=A<R`D,SDL,#`P(&%N9"`D
M,30S+#4U,R!D=7)I;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R
M,#$T(&%N9"`R,#$S+"!R97-P96-T:79E;'DN/"]F;VYT/CPO=&0^/"]T<CX-
M"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN
M9&5N=#H@+3`N-S5I;B<^)B,Q-C`[/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?8F0T9E\T-SDP7V$W.3E?
M.#4T,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W
M8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X9&%A-B]7;W)K<VAE971S
M+U-H965T,3<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5,13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY$96)T/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D1E8G0@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I
M;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`G/CQB/DY/5$4@,3`N($1%
M0E0\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^4$,@96YT97)E9"!I
M;G1O(&$@=V]R:VEN9R!C87!I=&%L(&QI;F4-"F]F(&-R961I="!A9W)E96UE
M;G0@=VET:"!A(&9I;F%N8VEA;"!I;G-T:71U=&EO;B!O;B!-87)C:"`R,2P@
M,C`P."!A;F0@<W5B<V5Q=65N=&QY(')E;F5W960@=&AE(&%G<F5E;65N="!O
M;B!397!T96UB97(@-BP@,C`Q,RX-"E1H92!L:6YE(&]F(&-R961I="!A9W)E
M96UE;G0@86QL;W=E9"!00R!T;R!B;W)R;W<@=7`@=&\@)#<U+#`P,"!A;F0@
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M:6YG('1H92!#;VUP86YY)B,Q-#8[<R!A8W%U:7-I=&EO;B!O9B!00RX\+W`^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D5Q=6ET>2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K:&]L9&5R<R<@17%U:71Y/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ
M(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB
M/DY/5$4@,3$N(%-43T-+2$],1$524R8C,30V.R!%455)5%D\+V(^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/D-O;6UO;B!3=&]C:SPO
M8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^27-S=6%N
M8V5S($1U<FEN9R!T:&4@665A<B!%;F1E9"!$96-E;6)E<@T*,S$L(#(P,3,\
M+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N($9E8G)U
M87)Y(#<L(#(P,3,L(&%F=&5R('1H92!E9F9E8W1I=F5N97-S#0IO9B!T:&4@
M<F5G:7-T<F%T:6]N('-T871E;65N="!O;B!&;W)M(%,M,2!F:6QE9"!I;B!C
M;VYN96-T:6]N('=I=&@@=&AE(%!U8FQI8R!/9F9E<FEN9R`H87,@9&5F:6YE
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M97(@,3`L(#(P,30L('1H92!#;VUP86YY(&1E8W)E87-E9"!T:&4@;G5M8F5R
M(&]F(&%U=&AO<FEZ960@<VAA<F5S#0IO9B!I=',@8V%P:71A;"!S=&]C:R!T
M;R`Y-2PP,#`L,#`P+"!A;F0@=&AE(&YU;6)E<B!O9B!A=71H;W)I>F5D('-H
M87)E<R!O9B!I=',@8V]M;6]N('-T;V-K('1O(#DP+#`P,"PP,#`N/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N($9E8G)U87)Y(#$S+"`R
M,#$S+"!T:&4@0V]M<&%N>2!C;&]S960@80T*<'5B;&EC(&]F9F5R:6YG(&]F
M(&ET<R!C;VUM;VX@<W1O8VL@*'1H92`F(S$T-SM0=6)L:6,@3V9F97)I;F<F
M(S$T.#LI(&%N9"!I<W-U960@86X@86=G<F5G871E(&]F(#$L.#0P+#`P,"!S
M:&%R97,@;V8@:71S(&-O;6UO;@T*<W1O8VL@870@82!P97(@<VAA<F4@<')I
M8V4@=&\@=&AE('!U8FQI8R!O9B`D-2XR-2P@86YD(')E8V5I=F5D(&YE="!P
M<F]C965D<R!O9B`D."PQ-#`L-#,U+"!A9G1E<B!D961U8W1I;F<@=6YD97)W
M<FET97(@9F5E<R!A;F0-"F-O;6UI<W-I;VYS(&%N9"!O=&AE<B!O9F9E<FEN
M9R!E>'!E;G-E<RX@5&AE('5N9&5R=W)I=&5R<R!A;'-O(&5X97)C:7-E9"!T
M:&5I<B!O<'1I;VX@=&\@<'5R8VAA<V4@86X@861D:71I;VYA;"`R-S8L,#`P
M('-H87)E<PT*;V8@8V]M;6]N('-T;V-K(&9R;VT@=&AE($-O;7!A;GD@870@
M)#4N,C4@<&5R('-H87)E('1O(&-O=F5R(&]V97(M86QL;W1M96YT<R!O;B!-
M87)C:"`Q-"P@,C`Q,RX@3F5T(&-A<V@@<')O8V5E9',@9G)O;2!T:&4@97AE
M<F-I<V4-"F]F('1H92!O=F5R+6%L;&]T;65N="!O<'1I;VX@=V5R92`D,2PS
M,38L,3$V+B!!<R!C;VYT96UP;&%T960@8GD@=&AE('5N9&5R=W)I=&EN9R!A
M9W)E96UE;G0@96YT97)E9"!I;G1O('=I=&@@341"($-A<&ET86P@1W)O=7`L
M#0I,3$,L('1H92!L96%D('5N9&5R=W)I=&5R(&9O<B!T:&4@4'5B;&EC($]F
M9F5R:6YG+"!A="!T:&4@8VQO<VEN9R!O9B!T:&4@4'5B;&EC($]F9F5R:6YG
M(&%N9"!T:&4@;W9E<BUA;&QO=&UE;G0@97AE<F-I<V4L('1H92!L96%D#0IU
M;F1E<G=R:71E<G,@<F5C96EV960@=V%R<F%N=',@*'1H92`F(S$T-SM5;F1E
M<G=R:71E<B!787)R86YT<R8C,30X.RD@=&\@<'5R8VAA<V4@=7`@=&\@86X@
M86=G<F5G871E(&]F(#$W.2PX-C`@<VAA<F5S+"!O<B`X+C4E#0IO9B!T:&4@
M;G5M8F5R(&]F('-H87)E<R!S;VQD(&EN('1H92!0=6)L:6,@3V9F97)I;F<@
M*&EN8VQU9&EN9R`X+C4E(&]F('-H87)E<R!S;VQD('!U<G-U86YT('1O('1H
M92!E>&5R8VES92!O9B!T:&4@;W9E<BUA;&QO=&UE;G0-"F]P=&EO;BDN(%1H
M92!5;F1E<G=R:71E<B!787)R86YT<R!A<F4@97AE<F-I<V%B;&4@870@)#4N
M,C4@<&5R('-H87)E("@Q,#`E(&]F('1H92!P<FEC92!T;R!T:&4@<'5B;&EC
M(&]F('1H92!C;VUM;VX@<W1O8VL@<V]L9`T*:6X@=&AE(%!U8FQI8R!/9F9E
M<FEN9RDL(&-O;6UE;F-I;F<@;VX@=&AE(&-L;W-I;F<@9&%T92!O9B!T:&4@
M4'5B;&EC($]F9F5R:6YG(&%N9"!E>'!I<F4@9FEV92!Y96%R<R!F<F]M('1H
M92!C;&]S:6YG(&1A=&4@;V8@=&AE#0I0=6)L:6,@3V9F97)I;F<N/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($9E8G)U87)Y(&%N9"!-
M87)C:"`R,#$S+"!T:&4@0V]M<&%N>2!M861E#0IP87EM96YT<R!T;W1A;&EN
M9R`D,3DQ(&EN(&-O;FYE8W1I;VX@=VET:"!C86YC96QL960L(&9R86-T:6]N
M86P@<VAA<F4@86UO=6YT<R!O9B!C;VUM;VX@<W1O8VL@*#,U(&-O;6UO;B!S
M=&]C:R!S:&%R92!E<75I=F%L96YT<RD-"FEN(&-O;FYE8W1I;VX@=VET:"!T
M:&4@;VYE+69O<BUF:79E(')E=F5R<V4@<W1O8VL@<W!L:70@969F96-T960@
M1F5B<G5A<GD@-RP@,C`Q,RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^26X@2G5N92`R,#$S+"!T:&4@0V]M<&%N>2!I<W-U960@-#`L,#`P
M('-H87)E<PT*;V8@8V]M;6]N('-T;V-K('1O($UA<FL@0F%U;2P@=&AE($-O
M;7!A;GDF(S$T-CMS($-H:65F($5X96-U=&EV92!/9F9I8V5R(&%N9"!A(&1I
M<F5C=&]R+"!R96QA=&5D('1O('1H92!V97-T:6YG(&]F(%)357,N/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN(%-E<'1E;6)E<B`R,#$S
M+"!T:&4@0V]M<&%N>2!I<W-U960@,BPQ,30-"G)E<W1R:6-T960@<VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:R!T;R!A(&-O;G-U;'1A;G0L('9A;'5E9"!A="`D
M,3`L-S4P+"!I;B!C;VYS:61E<F%T:6]N(&9O<B!C;VYS=6QT:6YG('-E<G9I
M8V5S('!R;W9I9&5D(&1U<FEN9PT*=&AE('EE87(@96YD960@1&5C96UB97(@
M,S$L(#(P,3,N(%1H92!F86ER('9A;'5E(&]F('1H92!S:&%R97,@;V8@8V]M
M;6]N('-T;V-K(&ES<W5E9"!W87,@<F5C;W)D960@87,@<W1O8VLM8F%S960@
M8V]M<&5N<V%T:6]N#0ID=7)I;F<@=&AE('EE87(@96YD960@1&5C96UB97(@
M,S$L(#(P,3,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D1U
M<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,RP@=&AE#0I#
M;VUP86YY(&ES<W5E9"`T,"PP,#`@<F5S=')I8W1E9"!S:&%R97,@;V8@8V]M
M;6]N('-T;V-K('1O($1R+B!2;V)E<G0@2V%M;65R+"!A(&1I<F5C=&]R(&%N
M9"!F;W)M97(@8V]N<W5L=&%N="P@=F%L=65D(&%T("0R.#(L.3DW+`T*:6X@
M8V]N<VED97)A=&EO;B!F;W(@8V]N<W5L=&EN9R!S97)V:6-E<R!P<F]V:61E
M9"!D=7)I;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S(&%N
M9"`R,#$R+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$=7)I
M;F<@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3,L('1H90T*0V]M
M<&%N>2!I<W-U960@82!T;W1A;"!O9B`R,3D@<VAA<F5S(&]F(&-O;6UO;B!S
M=&]C:R!A<R!A(')E<W5L="!O9B!S=&]C:R!O<'1I;VX@97AE<F-I<V5S+B!4
M:&4@0V]M<&%N>2!R96-E:79E9"!N;R!C87-H('!R;V-E961S#0IF;W(@=&AE
M(&ES<W5A;F-E(&]F('-U8V@@<VAA<F5S('5P;VX@=&AE(&5X97)C:7-E('!U
M<G-U86YT('1O(&-A<VAL97-S(&5X97)C:7-E('!R;W9I<VEO;G,@;V8@<W1O
M8VL@;W!T:6]N<R!T;R!P=7)C:&%S92`Q+#`S,"!S:&%R97,-"F]F(&-O;6UO
M;B!S=&]C:R!W:71H(&%N(&5X97)C:7-E('!R:6-E(&]F("0T+C`P('!E<B!S
M:&%R92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^27-S
M=6%N8V5S($1U<FEN9R!T:&4@665A<B!%;F1E9"!$96-E;6)E<@T*,S$L(#(P
M,30\+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($%P
M<FEL(#(P,30L('1H92!#;VUP86YY(&ES<W5E9"`V+#@V."!S:&%R97,-"F]F
M(')E<W1R:6-T960@8V]M;6]N('-T;V-K+"!V86QU960@870@)#4P+#`P,"P@
M:6X@8V]N;F5C=&EO;B!W:71H('1H92!R97-O;'5T:6]N(&]F(&$@8V]N=')A
M8W0@9&ES<'5T92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M26X@3V-T;V)E<B`R,#$T+"!T:&4@0V]M<&%N>2!I<W-U960@-"PP,#`@<VAA
M<F5S#0IO9B!R97-T<FEC=&5D(&-O;6UO;B!S=&]C:R!T;R!A(&-O;G-U;'1A
M;G0L('9A;'5E9"!A="`D,CDL,38P(&EN(&-O;G-I9&5R871I;VX@9F]R(&-O
M;G-U;'1I;F<@<V5R=FEC97,@<')O=FED960N(%1H92!F86ER('9A;'5E#0IO
M9B!T:&4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!I<W-U960@=V%S(')E8V]R
M9&5D(&%S('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!D=7)I;F<@=&AE('EE
M87(@96YD960@1&5C96UB97(@,S$L(#(P,30N/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/D1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q-"P@=&AE#0I#;VUP86YY(&ES<W5E9"!A('1O=&%L(&]F(#(R
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M('=I=&@@97AE<F-I<V4@<')I8V5S(')A;F=I;F<@9G)O;2`D,RXV."!T;R`D
M-"XP,"!A;F0@=&AE($-O;7!A;GD@<F5C96EV960@;F\@8V%S:"!P<F]C965D
M<PT*9F]R('1H92!I<W-U86YC92!O9B`V-BPT,SD@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:R!U<&]N('1H92!E>&5R8VES92!P=7)S=6%N="!T;R!C87-H;&5S
M<R!E>&5R8VES92!P<F]V:7-I;VYS(&]F('-T;V-K(&]P=&EO;G,@=&\-"G!U
M<F-H87-E(#$T-BPV-3(@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!W:71H(&5X
M97)C:7-E('!R:6-E<R!R86YG:6YG(&9R;VT@)#,N-C`@=&\@)#8N,#`@<&5R
M('-H87)E+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$=7)I
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M<W1O8VL@9F]R('!A>7)O;&P@=&%X('=I=&AH;VQD:6YG<R!T;W1A;&EN9R`D
M,3,L,3`Y+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^1'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+`T*
M=&AE($-O;7!A;GD@:7-S=65D(&$@=&]T86P@;V8@-#<L.#(Y('-H87)E<R!O
M9B!C;VUM;VX@<W1O8VL@87,@82!R97-U;'0@;V8@=V%R<F%N="!E>&5R8VES
M97,N($]F('1H97-E+"!T:&4@0V]M<&%N>2!R96-E:79E9"!G<F]S<PT*8V%S
M:"!P<F]C965D<R!O9B`D,S<L.#8W(&9O<B!T:&4@:7-S=6%N8V4@;V8@-BPS
M.3$@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!U<&]N('1H92!E>&5R8VES92!O
M9B!W87)R86YT<R!T;R!P=7)C:&%S92!T:&4@<V%M92!N=6UB97(-"F]F('-H
M87)E<R!O9B!C;VUM;VX@<W1O8VL@=VET:"!A;B!E>&5R8VES92!P<FEC92!O
M9B`D-2XY,C4@86YD('1H92!#;VUP86YY(')E8V5I=F5D(&YO(&-A<V@@<')O
M8V5E9',@9F]R('1H92!I<W-U86YC92!O9B`T,2PT,S@-"G-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@=7!O;B!T:&4@97AE<F-I<V4@<'5R<W5A;G0@=&\@8V%S
M:&QE<W,@97AE<F-I<V4@<')O=FES:6]N<R!O9B!W87)R86YT<R!T;R!P=7)C
M:&%S92`Q,C,L-S$U('-H87)E<R!O9B!C;VUM;VX-"G-T;V-K('=I=&@@86X@
M97AE<F-I<V4@<')I8V4@;V8@)#4N,C4@<&5R('-H87)E+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D1U<FEN9R!T
M:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"P-"C(W+#(Q."!S:&%R
M97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C:R!U;F1E<FQY
M:6YG(%)357,@:7-S=65D('1O(&1I<F5C=&]R<R!V97-T960L(&)U="!T:&4@
M:7-S=6%N8V4@86YD(&1E;&EV97)Y(&]F#0IT:&5S92!S:&%R97,@87)E(&1E
M9F5R<F5D('5N=&EL('1H92!R97-P96-T:79E(&1I<F5C=&]R(')E<VEG;G,N
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^/&(^4')E9F5R<F5D(%-T;V-K(#PO8CX\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!="!$96-E;6)E<B`S,2P@
M,C`Q-"!A;F0@,C`Q,RP@=&AE($-O;7!A;GD-"FAA9"`U+#`P,"PP,#`@<VAA
M<F5S(&]F('!R969E<G)E9"!S=&]C:RP@)#`N,#`Q('!A<B!V86QU92P@875T
M:&]R:7IE9"!A;F0@;F\@<VAA<F5S(&]F('!R969E<G)E9"!S=&]C:R!I<W-U
M960@86YD(&]U='-T86YD:6YG+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z("TP
M+C<U:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^4W1O8VL@3W!T:6]N(%!L86X@
M/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/D]N(%-E<'1E;6)E<B`Q-RP@,C`P-RP@=&AE($-O;7!A;GDF(S$T
M-CMS#0I";V%R9"!O9B!$:7)E8W1O<G,@86YD('-T;V-K:&]L9&5R<R!A9&]P
M=&5D('1H92!#;VUP86YY)B,Q-#8[<R`R,#`W($EN8V5N=&EV92!3=&]C:R!A
M;F0@07=A<F1S(%!L86XL('=H:6-H('=A<R!S=6)S97%U96YT;'D@86UE;F1E
M9`T*;VX@3F]V96UB97(@-2P@,C`P."P@1F5B<G5A<GD@,C8L(#(P,3(L($IU
M;'D@,3@L(#(P,3(L($UA>2`R+"`R,#$S(&%N9"!397!T96UB97(@,C<L(#(P
M,3,@*&%S(&%M96YD960L('1H92`F(S$T-SM0;&%N)B,Q-#@[*2X-"D%S(&]F
M($1E8V5M8F5R(#,Q+"`R,#$T+"!T:&4@4&QA;B!P<F]V:61E<R!F;W(@=&AE
M(&ES<W5A;F-E(&]F(&$@;6%X:6UU;2!O9B`U+#`P,"PP,#`@<VAA<F5S(&]F
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M9&5R('1H92!0;&%N(&%T($1E8V5M8F5R(#,Q+"`R,#$T+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/E-T;V-K
M($]P=&EO;G,\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^02!S=6UM87)Y(&]F('1H92!S=&]C:R!O<'1I;VX@
M86-T:79I='D-"G5N9&5R('1H92!0;&%N(&9O<B!T:&4@>65A<B!E;F1E9"!$
M96-E;6)E<B`S,2P@,C`Q-"!I<R!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@
M8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(^#0H@("`@/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^3G5M8F5R(&]F('-H87)E<SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P
M="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^5V5I9VAT960@079G+B!%>&5R8VES92!0<FEC93PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^5V5I9VAT960@079G+B!296UA:6YI;F<@
M0V]N=')A8W1U86P@3&EF93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!C96YT97([
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^06=G<F5G
M871E($EN=')I;G-I8R!686QU93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[('=I9'1H.B`T-"4[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/<'1I;VYS(&]U='-T86YD
M:6YG("T@2F%N=6%R>2`Q+"`R,#$T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`R)3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PS,C@L-SDP
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[('=I9'1H.B`R)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I
M9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=VED=&@Z(#$P)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+C,Q/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q
M)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`R)3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q)3L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H.B`Q,"4[('1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#(E.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$P)3L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@=&]P.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^3W!T:6]N<R!G<F%N=&5D/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXR-#4L.#@V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV+C,U/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@=&]P.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^3W!T:6]N<R!E>&5R8VES960\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B@S,#<L-#(Y/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXI/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C,N.3`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^3W!T:6]N<R!C86YC96QL960O9F]R9F5I
M=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXH,C,X+#`P-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXV+C8X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*
M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^3W!T:6]N<R!O=71S=&%N9&EN9R`M
M($1E8V5M8F5R(#,Q+"`R,#$T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#`R.2PR-#`\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C4N-S0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV+C`U/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXR+#,U,2PQ-S0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!T;W`[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/<'1I;VYS
M(&5X97)C:7-A8FQE/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXW,C@L-3@U/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXU+C(U/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^-"XY-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,BPP.#`L-3DT/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1B<^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/<'1I;VYS('9E<W1E
M9"!A;F0@97AP96-T960@=&\@=F5S=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^.3DY+#$W-3PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^-2XW,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4N.3@\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C(L,S$Y+#0W-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@86=G<F5G871E(&EN=')I
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M('!R:6-E#0IO;B!$96-E;6)E<B`S,2P@,C`Q-"P@8F%S960@;VX@=&AE(&-L
M;W-I;F<@<')I8V4@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO;B!S=&]C
M:R!O9B`D-RXU,"!O;B!T:&%T(&1A=&4N(%1H92!A9V=R96=A=&4@:6YT<FEN
M<VEC#0IV86QU92!O9B!S=&]C:R!O<'1I;VYS(&5X97)C:7-E9"!D=7)I;F<@
M=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,30@=V%S(&%P<')O>&EM
M871E;'D@)#$L,38Q+#`P,"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
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M<G,@86YD(&-O;G-U;'1A;G1S('1Y<&EC86QL>2!I;F-L=61E9`T*;VYE(&]F
M('1H92!F;VQL;W=I;F<@=F5S=&EN9R!S8VAE9'5L97,Z(#(U)2!O<B`S,R4@
M;V8@=&AE('-H87)E<R!S=6)J96-T('1O('1H92!O<'1I;VX@=F5S="!A;F0@
M8F5C;VUE(&5X97)C:7-A8FQE(&]N('1H92!F:7)S=`T*86YN:79E<G-A<GD@
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M=&5R;'D@;W(@,3`P)2!V97-T:6YG(&%S<V]C:6%T960@=VET:"!T:&4@<')O
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M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
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M(#$L(#(P,3,L('1H92!E>'!E8W1E9`T*=F]L871I;&ET>2!I<R!B87-E9"!O
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M+"!I="!H87,@;&EM:71E9"!R96QE=F%N=`T*:&ES=&]R:6-A;"!D871A(')E
M9V%R9&EN9R!T:&4@=F]L871I;&ET>2!O9B!I=',@<W1O8VL@<')I8V4@;VX@
M=VAI8V@@=&\@8F%S92!A(&UE86YI;F=F=6P@97-T:6UA=&4@;V8@97AP96-T
M960@=F]L871I;&ET>2X@5&AE#0IE>'!E8W1E9"!T97)M(&]F(&]P=&EO;G,@
M9W)A;G1E9"!W87,@9&5T97)M:6YE9"!I;B!A8V-O<F1A;F-E('=I=&@@=&AE
M("8C,30W.W-I;7!L:69I960@87!P<F]A8V@F(S$T.#L@87,@=&AE($-O;7!A
M;GD@:&%S(&QI;6ET960L#0IR96QE=F%N="P@:&ES=&]R:6-A;"!D871A(&]N
M(&5M<&QO>65E(&5X97)C:7-E<R!A;F0@<&]S="UV97-T:6YG(&5M<&QO>6UE
M;G0@=&5R;6EN871I;VX@8F5H879I;W(N(%1H92!E>'!E8W1E9"!R:7-K+69R
M964@:6YT97)E<W0-"G)A=&4@:7,@8F%S960@;VX@=&AE(%4N4RX@5')E87-U
M<GD@>6EE;&0@9F]R(&$@<&5R:6]D(&-O;G-I<W1E;G0@=VET:"!T:&4@97AP
M96-T960@=&5R;2!O9B!T:&4@;W!T:6]N(&EN(&5F9F5C="!A="!T:&4@=&EM
M92!O9@T*=&AE(&=R86YT+B!4:&4@9FEN86YC:6%L('-T871E;65N="!E9F9E
M8W0@;V8@9F]R9F5I='5R97,@:7,@97-T:6UA=&5D(&%T('1H92!T:6UE(&]F
M(&=R86YT(&%N9"!R979I<V5D+"!I9B!N96-E<W-A<GDL(&EF('1H92!A8W1U
M86P-"F5F9F5C="!D:69F97)S(&9R;VT@=&AO<V4@97-T:6UA=&5S+B!&;W(@
M;W!T:6]N(&=R86YT<R!T;R!E;7!L;WEE97,@86YD(&1I<F5C=&]R<RP@=&AE
M($-O;7!A;GD@87-S:6=N<R!A(&9O<F9E:71U<F4@9F%C=&]R(&]F(#$P)2X-
M"E1H97-E(&9A8W1O<G,@8V]U;&0@8VAA;F=E(&EN('1H92!F=71U<F4L('=H
M:6-H('=O=6QD(&%F9F5C="!T:&4@9&5T97)M:6YA=&EO;B!O9B!S=&]C:RUB
M87-E9"!C;VUP96YS871I;VX@97AP96YS92!I;B!F=71U<F4@<&5R:6]D<RX-
M"E5T:6QI>FEN9R!T:&5S92!A<W-U;7!T:6]N<RP@=&AE(&9A:7(@=F%L=64@
M:7,@9&5T97)M:6YE9"!A="!T:&4@9&%T92!O9B!G<F%N="X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@=&%B
M;&4@8F5L;W<@:6QL=7-T<F%T97,@=&AE(&9A:7(-"G9A;'5E('!E<B!S:&%R
M92!D971E<FUI;F5D('5S:6YG('1H92!";&%C:RU38VAO;&5S+4UE<G1O;B!O
M<'1I;VX@<')I8VEN9R!M;V1E;"!W:71H('1H92!F;VQL;W=I;F<@87-S=6UP
M=&EO;G,@=7-E9"!F;W(@=F%L=6EN9PT*;W!T:6]N<R!G<F%N=&5D('1O(&5M
M<&QO>65E<R!A;F0@9&ER96-T;W)S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@
M2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O
M;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CXR
M,#$T/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@-3@E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^5V5I9VAT960M879E<F%G92!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A
M;G1E9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[
M('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^-2XR,CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q."4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-BXP-#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^17AP
M96-T960@=&5R;7,@*&EN('EE87)S*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^-2XX,2`M(#8N.3$\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+C@M-R`\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D5X
M<&5C=&5D('9O;&%T:6QI='D\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/CDV("T@,3`R)3PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$P,B`M(#$R,R4\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY2:7-K+69R
M964@:6YT97)E<W0@<F%T93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,2XS-R`M(#$N-C4E/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XX-B`M(#(N,#4E/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$
M:79I9&5N9"!Y:65L9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B
M;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@
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M9"!T;R!C;VYS=6QT86YT<SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T($-A;&EB<FDL($AE;'9E
M=&EC82P@4V%N<RU397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S
M93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^,C`Q-#PO
M8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB
M/C(P,3,\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#4X)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=E
M:6=H=&5D+6%V97)A9V4@9F%I<B!V86QU92!O9B!O<'1I;VYS(&=R86YT960\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3@E.R!T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C8N,34\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,3@E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4N-C,\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D5X<&5C=&5D
M('1E<FUS("AI;B!Y96%R<RD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C(N-2`M(#$P/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[,BXS,R`M(#$P(#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M17AP96-T960@=F]L871I;&ET>3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^-S@@+2`Y-R4\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(S$V,#LX,"`M(#,V-B4@
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C`N,3`@+2`Q+C8X)3PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B8C,38P.S`N
M,S`@+2`R+C0U)2`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D1I=FED96YD('EI96QD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^+3PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M:6YD96YT.B`M,"XW-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`G/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R
M:7IE<R!I;F9O<FUA=&EO;B!A8F]U="!S=&]C:R!O<'1I;VYS#0IO=71S=&%N
M9&EN9R!A;F0@97AE<F-I<V%B;&4@870@1&5C96UB97(@,S$L(#(P,30Z/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@
M+3`N-S5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T($-A;&EB<FDL
M($AE;'9E=&EC82P@4V%N<RU397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#$P('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY/<'1I;VYS($]U='-T86YD:6YG/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&-O;'-P86X],T0V('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/<'1I;VYS($5X97)C:7-A
M8FQE/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=E
M:6=H=&5D/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D%V97)A9V4\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5V5I
M9VAT960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^5V5I9VAT960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^4F5M86EN:6YG/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D%V97)A9V4\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^079E<F%G93PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY.=6UB
M97(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^0V]N=')A8W1U86P\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^17AE<F-I<V4\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3G5M
M8F5R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/D5X97)C:7-E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M)SX-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY286YG92!O9B!%>&5R8VES92!0<FEC97,\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]U='-T86YD:6YG
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY,:69E
M(&EN(%EE87)S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY0<FEC93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^17AE<F-I<V%B;&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/E!R:6-E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(X)3L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0R+C0P("T@)#,N,C`\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR-3`L,#`P
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^-"XU-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,BXX,#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(U,"PP,#`\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,3$E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C(N.#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD,RXV,"`M("0T+C4Q/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,S,W+#<R,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C0N.34\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0N,S8\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR-S`L,#$U
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXT+C0R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#4N-#D@+2`D-RXW,3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$Y
M,"PU-3<\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXX+C<P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV+C8R/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-C`L,3$P/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXV+C(V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0X+C`V("T@)#$P+C<U/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C0T+#$V
M,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C<N,#,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C@N.3D\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ-#$L-C8P/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXY+C`Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)#(X+C`P("T@)#@P+C`P/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXV+#@P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4N,3,\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C0P+C@V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV+#@P,#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^-#`N.#8\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#`R.2PR-#`\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXV+C`U/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+C<T/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR
M-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^-S(X+#4X-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-2XR-3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!<R!O9B!$96-E;6)E<B`S,2P@,C`Q
M-"P@=&AE<F4@=V%S(&%P<')O>&EM871E;'D-"B0Q+#4W,2PP,#`@;V8@=&]T
M86P@=6YR96-O9VYI>F5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@
M=&\@=6YV97-T960@<W1O8VL@;W!T:6]N<R!G<F%N=&5D('5N9&5R('1H92!0
M;&%N+B!4:&%T(&5X<&5N<V4@:7,-"F5X<&5C=&5D('1O(&)E(')E8V]G;FEZ
M960@;W9E<B!T:&4@=V5I9VAT960M879E<F%G92!R96UA:6YI;F<@=F5S=&EN
M9R!P97)I;V0@;V8@,BXQ('EE87)S+B!4:&4@<W1O8VLM8F%S960@8V]M<&5N
M<V%T:6]N(&9O<B!A;&P-"G-T;V-K(&]P=&EO;G,@=V%S("0Q+#$S-RPV,S0@
M86YD("0Q+#8X.2PW-38@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q-"!A;F0@,C`Q,RP@<F5S<&5C=&EV96QY+CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`G/CQB/E)E<W1R:6-T960@4W1O8VL@56YI=',\+V(^
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^4E-5(&%W87)D<R!A<F4@9W)A
M;G1E9"!S=6)J96-T('1O(&-E<G1A:6X-"G9E<W1I;F<@<F5Q=6ER96UE;G1S
M(&%N9"!O=&AE<B!R97-T<FEC=&EO;G,L(&EN8VQU9&EN9R!P97)F;W)M86YC
M92!A;F0@;6%R:V5T(&)A<V5D('9E<W1I;F<@8W)I=&5R:6$N(%1H92!G<F%N
M="UD871E(&9A:7(@=F%L=64-"F]F('1H92!24U5S+"!W:&EC:"!H87,@8F5E
M;B!D971E<FUI;F5D(&)A<V5D('5P;VX@=&AE(&UA<FME="!V86QU92!O9B!T
M:&4@0V]M<&%N>28C,30V.W,@8V]M;6]N('-T;V-K(&]N('1H92!G<F%N="!D
M871E+"!I<R!E>'!E;G-E9`T*;W9E<B!T:&4@=F5S=&EN9R!P97)I;V0@;V8@
M=&AE(%)357,N(%5N=F5S=&5D('!O<G1I;VYS(&]F(%)357,@:7-S=65D('1O
M(&-O;G-U;'1A;G1S(&%R92!R96UE87-U<F5D(&]N(&%N(&EN=&5R:6T@8F%S
M:7,@=6YT:6P@=F5S=&EN9PT*8W)I=&5R:6$@:7,@;65T+B!/;B!-87D@,BP@
M,C`Q,RP@=&AE($)O87)D(&]F($1I<F5C=&]R<R!O9B!T:&4@0V]M<&%N>2!A
M;65N9&5D(&%N9"!R97-T871E9"!T:&4@4&QA;B!T;R!P<F]V:61E(&9O<B!T
M:&4@:7-S=6%N8V4-"F]F(%)357,@=6YD97(@=&AE(%!L86XN/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&D^1W)A
M;G1S($1U<FEN9R!T:&4@665A<B!%;F1E9"!$96-E;6)E<@T*,S$L(#(P,3,\
M+VD^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^3VX@36%Y(#(L(#(P,3,L('1H92!#;VUP86YY(&=R86YT960-"C$L
M,C4P+#`P,"!24U5S('1O(&ET<R!#:&EE9B!%>&5C=71I=F4@3V9F:6-E<BP@
M36%R:R!"875M+"!P=7)S=6%N="!T;R!T:&4@4&QA;BX@3V8@=&AE<V4@4E-5
M<RP@,C`P+#`P,"!W:6QL('9E<W0@;VX@=&AE('1H:7)D(&%N;FEV97)S87)Y
M#0IO9B!T:&4@4E-5(&=R86YT(&1A=&4L('-U8FIE8W0@=&\@8V]N=&EN=65D
M('-E<G9I8V4@=&\@=&AE($-O;7!A;GD@86YD('1H92!R96UA:6YI;F<@,2PP
M-3`L,#`P(%)357,@=VEL;"!V97-T(&]N('1H92!T:&ER9"!A;FYI=F5R<V%R
M>0T*;V8@=&AE(%)352!G<F%N="!D871E+"!S=6)J96-T('1O('1H92!S871I
M<V9A8W1I;VX@;V8@8V5R=&%I;B!M87)K970M8F%S960@86YD(&-O;G1I;G5E
M9"!S97)V:6-E(&-O;F1I=&EO;G,@*'1H92`F(S$T-SM"875M(%!E<F9O<FUA
M;F-E#0I%<75I='D@07=A<F0F(S$T.#LI+B!4:&4@;6%R:V5T+6)A<V5D('9E
M<W1I;F<@8W)I=&5R:6$@87)E('-E<&%R871E9"!I;G1O(&9I=F4@97%U86P@
M=')A;F-H97,@86YD(')E<75I<F4@=&AA="!T:&4@0V]M<&%N>2!A8VAI979E
M#0IA;F0@;6%I;G1A:6X@8V5R=&%I;B!S=&]C:R!P<FEC92!T87)G971S(')A
M;F=I;F<@9G)O;2`D,3`@<&5R('-H87)E('1O("0S,"!P97(@<VAA<F4@9'5R
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M(&9U<G1H97(@9&5S8W)I8F5D(&)E;&]W.CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E
M<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^
M#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q-B4[(&)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^5')A;F-H93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`V-B4[(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY.=6UB97(@;V8@4VAA<F5S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$V)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/E1A<F=E="!3:&%R92!0<FEC93PO9F]N=#X\+W1D/CPO='(^#0H\='(^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4<F%N8VAE(#$\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ.2XP-24@;V8@=&AE('-H
M87)E<R!S=6)J96-T('1O('1H92!"875M(%!E<F9O<FUA;F-E($5Q=6ET>2!!
M=V%R9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B0Q,"XP,"!O<B!G<F5A=&5R/"]F;VYT/CPO=&0^/"]T<CX-"CQT<CX-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1R86YC:&4@,CPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$Y+C`U)2!O9B!T:&4@<VAA
M<F5S('-U8FIE8W0@=&\@=&AE($)A=6T@4&5R9F]R;6%N8V4@17%U:71Y($%W
M87)D/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#$U+C`P(&]R(&=R96%T97(\+V9O;G0^/"]T9#X\+W1R/@T*/'1R/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^5')A;F-H92`S/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,3DN,#4E(&]F('1H92!S:&%R
M97,@<W5B:F5C="!T;R!T:&4@0F%U;2!097)F;W)M86YC92!%<75I='D@07=A
M<F0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M,C`N,#`@;W(@9W)E871E<CPO9F]N=#X\+W1D/CPO='(^#0H\='(^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY4<F%N8VAE(#0\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ.2XP-24@;V8@=&AE('-H87)E
M<R!S=6)J96-T('1O('1H92!"875M(%!E<F9O<FUA;F-E($5Q=6ET>2!!=V%R
M9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0R
M-2XP,"!O<B!G<F5A=&5R/"]F;VYT/CPO=&0^/"]T<CX-"CQT<CX-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/E1R86YC:&4@-3PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(S+C@P)2!O9B!T:&4@<VAA<F5S
M('-U8FIE8W0@=&\@=&AE($)A=6T@4&5R9F]R;6%N8V4@17%U:71Y($%W87)D
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#,P
M+C`P(&]R(&=R96%T97(\+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY&;W(@96%C
M:"!R97-P96-T:79E('1R86YC:&4@=&\@=F5S=`T*=&AE(&9O;&QO=VEN9R!C
M;VYD:71I;VYS(&UU<W0@8F4@;65T.B`H:2D@=&AE($-O;7!A;GDF(S$T-CMS
M(&-O;6UO;B!S=&]C:R!M=7-T(&AA=F4@86X@;V9F:6-I86P@8VQO<VEN9R!P
M<FEC92!A="!O<B!A8F]V92!T:&4-"E1A<F=E="!3:&%R92!0<FEC92!F;W(@
M=&AE(')E<W!E8W1I=F4@=')A;F-H92`H96%C:"!S=6-H(&1A=&4L(&$@)B,Q
M-#<[5')I9V=E<B!$871E)B,Q-#@[*3L@*&EI*2!D=7)I;F<@=&AE('!E<FEO
M9"!T:&%T(&EN8VQU9&5S#0IT:&4@5')I9V=E<B!$871E(&%N9"!T:&4@:6UM
M961I871E;'D@9F]L;&]W:6YG(#$Y('1R861I;F<@9&%Y<R`H=&AE("8C,30W
M.TUE87-U<F5M96YT(%!E<FEO9"8C,30X.RDL('1H92!A<FET:&UE=&EC(&UE
M86X@;V8@=&AE#0HR,"!C;&]S:6YG('!R:6-E<R!O9B!T:&4@0V]M<&%N>28C
M,30V.W,@8V]M;6]N('-T;V-K(&1U<FEN9R!T:&4@365A<W5R96UE;G0@4&5R
M:6]D(&UU<W0@8F4@870@;W(@86)O=F4@=&AE(%1A<F=E="!3:&%R92!0<FEC
M90T*9F]R('-U8V@@=')A;F-H93L@86YD("AI:6DI('=I=&@@8V5R=&%I;B!L
M:6UI=&5D(&5X8V5P=&EO;G,L($UR+B!"875M(&UU<W0@8F4@:6X@8V]N=&EN
M=6]U<R!S97)V:6-E('=I=&@@=&AE($-O;7!A;GD@=&AR;W5G:"!T:&4-"G1H
M:7)D(&%N;FEV97)S87)Y(&]F('1H92!G<F%N="!D871E+B!!;GD@=6YV97-T
M960@4E-5<R!U;F1E<B!T:&4@0F%U;2!097)F;W)M86YC92!%<75I='D@07=A
M<F0@=VEL;"!B92!F;W)F96ET960@;VX@=&AE('1H:7)D(&%N;FEV97)S87)Y
M#0IO9B!T:&4@9W)A;G0@9&%T92X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@96%R;FEN9R!A;F0@:7-S=6%N
M8V4@;V8@86YY('-H87)E<PT*=6YD97(@=&AE($)A=6T@4&5R9F]R;6%N8V4@
M17%U:71Y($%W87)D('1H870@=V]U;&0@97AC965D('1H92!N=6UB97(@;V8@
M<VAA<F5S(&%V86EL86)L92!F;W(@9W)A;G0@86YD+V]R('1H92!A<'!L:6-A
M8FQE(&%N;G5A;`T*<&5R('!E<G-O;B!G<F%N="!L:6UI="!F;W(@<&5R9F]R
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M86XN($]N($UA>2`R+"`R,#$S+"!T:&4@0F]A<F0@;V8@1&ER96-T;W)S(&%P
M<')O=F5D(&%N(&%M96YD;65N="!T;R!T:&4@4&QA;B!T;R!I;F-R96%S92!T
M:&4@;G5M8F5R(&]F('-H87)E<R!A=F%I;&%B;&4@9F]R#0IG<F%N="!F<F]M
M(#(L-#`P+#`P,"!T;R`U+#`P,"PP,#`@<VAA<F5S(&%N9"!T:&4@87!P;&EC
M86)L92!A;FYU86P@<&5R('!E<G-O;B!G<F%N="!L:6UI="!F<F]M(#8P,"PP
M,#`@=&\@,2PR-3`L,#`P('-H87)E<R!A;F0-"F]N(%-E<'1E;6)E<B`R-RP@
M,C`Q,RP@82!M86IO<FET>2!O9B!T:&4@0V]M<&%N>28C,30V.W,@<W1O8VMH
M;VQD97)S(&%P<')O=F5D('1H92!A;65N9&UE;G0@=&\@=&AE(%!L86XN(%1H
M92`T-3`L,#`P(%)357,@<W5B:F5C=`T*=&\@=&AE($)A=6T@4&5R9F]R;6%N
M8V4@17%U:71Y($%W87)D('1H870@=V5R92!P96YD:6YG('-U8V@@87!P<F]V
M86P@=V5R92!G<F%N=&5D(&]N('1H870@9&%T92X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY#;VYC=7)R96YT('=I
M=&@@=&AE(&ES<W5A;F-E(&]F('1H90T*-#4P+#`P,"!24U5S+"!-<BX@0F%U
M;2!A9W)E960@=&\@8V%N8V5L(#$R,"PP,#`@=6YV97-T960@4E-5<R!P<F5V
M:6]U<VQY(&=R86YT960@=&\@37(N($)A=6T@:6X@2G5L>2`R,#$R+B!!<R!A
M(')E<W5L="P@=&AE($-O;7!A;GD-"FAA<R!T<F5A=&5D('1H92!I<W-U86YC
M92!O9B!T:&4@-#4P+#`P,"!24U5S(&%S(&$@;6]D:69I8V%T:6]N(&]F('1H
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M9B!T:&4@9F%I<B!V86QU92!O9B!T:&4@-#4P+#`P,"!24U5S(&]V97(@=&AE
M(&9A:7(@=F%L=64@;V8@=&AE(&-A;F-E;&5D(#$R,"PP,#`@4E-5<R!O;B!T
M:&4@;6]D:69I8V%T:6]N#0ID871E+"!W:&EC:"!I<R!397!T96UB97(@,C<L
M(#(P,3,N(%1H92!I;FET:6%L(&9A:7(@=F%L=64@;V8@=&AE(#0U,"PP,#`@
M4E-5<R!P=7)S=6%N="!T;R!T:&4@0F%U;2!097)F;W)M86YC92!%<75I='D@
M07=A<F0@9W)A;G1E9`T*=&\@37(N($)A=6T@=V%S("0Q.#DL,#`P+B!.;R!I
M;F-R96UE;G1A;"!C;W-T('=A<R!A<W-O8VEA=&5D('=I=&@@=&AE(&5X8VAA
M;F=E(&]F(%)357,@87,@=&AE(&9A:7(@=F%L=64@<')I;W(@=&\@;6]D:69I
M8V%T:6]N#0IW87,@;6]R92!T:&%N(&%F=&5R('1H92!M;V1I9FEC871I;VXN
M(%1H92`T-3`L,#`P(%)357,@<'5R<W5A;G0@=&\@=&AE($)A=6T@4&5R9F]R
M;6%N8V4@17%U:71Y($%W87)D('=E<F4@=F%L=65D('5S:6YG(&$@36]N=&4-
M"D-A<FQO(%-I;75L871I;VX@=VET:"!A('1H<F5E('EE87(@;&EF92P@-S4E
M('9O;&%T:6QI='D@86YD(&$@<FES:R!F<F5E(&EN=&5R97-T(')A=&4@;V8@
M,"XV-"4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^5&AE(&EN:71I86P@9F%I<B!V86QU92!O9B!T:&4@,C`P+#`P
M,`T*4E-5<R!A;F0@-C`P+#`P,"!24U5S('!U<G-U86YT('1O('1H92!"875M
M(%!E<F9O<FUA;F-E($5Q=6ET>2!!=V%R9"!G<F%N=&5D('1O($UR+B!"875M
M('=A<R`D,RPU,34L,#DP+B!4:&4@-C`P+#`P,"!24U5S('!U<G-U86YT#0IT
M;R!T:&4@0F%U;2!097)F;W)M86YC92!%<75I='D@07=A<F0@=V5R92!V86QU
M960@=7-I;F<@82!-;VYT92!#87)L;R!3:6UU;&%T:6]N('=I=&@@82!T:')E
M92!Y96%R(&QI9F4L(#<U)2!V;VQA=&EL:71Y(&%N9"!A(')I<VL-"F9R964@
M:6YT97)E<W0@<F%T92!O9B`P+C,P)2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY/;B!-87D@,C0L(#(P,3,L('1H
M92!#;VUP86YY(&=R86YT960-"C$P,"PP,#`@4E-5<R!T;R!A(&-O;G-U;'1A
M;G0@=&AA="!W97)E('1O('9E<W0@8F%S960@;VX@=&AE('-A=&ES9F%C=&EO
M;B!O9B!C97)T86EN(&UA<FME="UB87-E9"!C;VYD:71I;VYS('-U8FIE8W0@
M=&\@=&AE(&-O;G-U;'1A;G0F(S$T-CMS#0IC;VYT:6YU960@<V5R=FEC92P@
M86UO;F<@;W1H97(@=&AI;F=S+B!4:&5S92!M87)K970M8F%S960@=F5S=&EN
M9R!C;VYD:71I;VYS(&%R92!F=7)T:&5R(&1E<V-R:6)E9"!B96QO=SH\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B
M;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F
M;VYT.B`Q,'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N<RU397)I9CL@=VED
M=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,S0E.R!B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/E1R86YC:&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,S(E.R!B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3G5M8F5R
M(&]F(%-H87)E<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`S,B4[(&)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY487)G970@
M4VAA<F4@4')I8V4\+V9O;G0^/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5')A;F-H
M92`Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,C`L,#`P('-H87)E<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0Q,"XP,"!O<B!G<F5A=&5R/"]F;VYT/CPO=&0^/"]T<CX-
M"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/E1R86YC:&4@,CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C(P+#`P,"!S:&%R97,\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD,34N,#`@;W(@9W)E871E<CPO
M9F]N=#X\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4<F%N8VAE(#,\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,"PP,#`@<VAA<F5S
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#(P
M+C`P(&]R(&=R96%T97(\+V9O;G0^/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5')A
M;F-H92`T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,C`L,#`P('-H87)E<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B0R-2XP,"!O<B!G<F5A=&5R/"]F;VYT/CPO=&0^/"]T
M<CX-"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/E1R86YC:&4@-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C(P+#`P,"!S:&%R97,\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD,S`N,#`@;W(@9W)E871E
M<CPO9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/D9O<B!E86-H(')E<W!E8W1I=F4@=')A;F-H92!T;R!V97-T#0IT:&4@
M9F]L;&]W:6YG(&-O;F1I=&EO;G,@;75S="!H879E(&)E96X@;65T.B`H:2D@
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M861I;F<@9&%Y<R`H=&AE("8C,30W.TUE87-U<F5M96YT(%!E<FEO9"8C,30X
M.RDL('1H92!A<FET:&UE=&EC#0IM96%N(&]F('1H92`R,"!C;&]S:6YG('!R
M:6-E<R!D=7)I;F<@=&AE($UE87-U<F5M96YT(%!E<FEO9"!H879E(&)E96X@
M870@;W(@86)O=F4@=&AE(%1A<F=E="!3:&%R92!0<FEC92!F;W(@<W5C:"!T
M<F%N8VAE("@H:2D-"F%N9"`H:6DI+"!T:&4@)B,Q-#<[4W1O8VL@4')I8V4@
M0V]N9&ET:6]N<R8C,30X.RD[(&%N9"`H:6EI*2!W:71H(&-E<G1A:6X@;&EM
M:71E9"!E>&-E<'1I;VYS+"`U,"4@;V8@=&AE(%)357,@<W5B:F5C="!T;R!A
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M;FEN9PT*-3`E('=O=6QD('9E<W0@;VX@=&AE('-E8V]N9"!A;FYI=F5R<V%R
M>2!O9B!T:&4@9W)A;G0@9&%T92!I9B`H82D@=&AE(%-T;V-K(%!R:6-E($-O
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M(&%N;FEV97)S87)Y(&]F('1H92!G<F%N="!D871E+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!I;FET:6%L
M('9A;'5E(&]F('1H92`Q,#`L,#`P(%)357,-"G=I=&@@;6%R:V5T+6)A<V5D
M('9E<W1I;F<@8V]N9&ET:6]N<R!G<F%N=&5D('1O('1H92!C;VYS=6QT86YT
M('=A<R`D,C@X+#`P,"P@86YD(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$S('1H
M92!R96UE87-U<F5D(&9A:7(@=F%L=64-"F]F('1H;W-E(%)357,@=V%S("0Q
M,"PP.#`N(%1H92`Q,#`L,#`P(%)357,@=V5R92!V86QU960@=7-I;F<@82!-
M;VYT92!#87)L;R!3:6UU;&%T:6]N('=I=&@@82`R('EE87(@;&EF92`H8F%S
M960@;VX@=&AE(&=R86YT(&1A=&4I+`T*-S4E+3@U)2!V;VQA=&EL:71Y(&%N
M9"!R:7-K(&9R964@:6YT97)E<W0@<F%T97,@;V8@,"XQ,R4M,"XS-B4N($1U
M<FEN9R!-87)C:"`R,#$T+"!T:&4@0V]M<&%N>2!T97)M:6YA=&5D(&ET<R!A
M9W)E96UE;G0@=VET:"!A#0IC;VYS=6QT86YT('1H870@<')O=FED960@9F]R
M('1H92!G<F%N="!O9B`Q,#`L,#`P(%)357,@=&AA="!H860@=F5S=&EN9R!C
M<FET97)I82!B87-E9"!O;B!T:&4@<V%T:7-F86-T:6]N(&]F(&-E<G1A:6X@
M;6%R:V5T+6)A<V5D#0IC;VYD:71I;VYS('-U8FIE8W0@=&\@=&AE(&-O;G-U
M;'1A;G0F(S$T-CMS(&-O;G1I;G5E9"!S97)V:6-E+"!A;6]N9R!O=&AE<B!T
M:&EN9W,N(%5P;VX@=&5R;6EN871I;VX@;V8@=&AE(&%G<F5E;65N="P@86QL
M(#$P,"PP,#`-"E)357,@=V5R92!F;W)F96ET960@86YD(&1E96UE9"!R96-O
M;G9E>65D('1O('1H92!#;VUP86YY+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($IU;F4@,C`Q,RP@=&AE($-O
M;7!A;GD@9W)A;G1E9"!A;@T*86=G<F5G871E(&]F(#,T+#,R-2!24U5S('1O
M(&ET<R!N;VXM96UP;&]Y964@9&ER96-T;W)S+"!V86QU960@870@)#(W,2PX
M-30N(%1H92!24U5S('9E<W0@:6X@9G5L;"`Q,R!M;VYT:',@869T97(@=&AE
M(&1A=&4@;V8@9W)A;G0-"G-U8FIE8W0@=&\@=&AE(&1I<F5C=&]R)B,Q-#8[
M<R!C;VYT:6YU960@<V5R=FEC92P@8G5T('1H92!I<W-U86YC92!A;F0@9&5L
M:79E<GD@;V8@=&AE<V4@<VAA<F5S(&%R92!D969E<G)E9"!U;G1I;"!T:&4@
M9&ER96-T;W(-"G)E<VEG;G,N($EN(%-E<'1E;6)E<B!A;F0@3V-T;V)E<B`R
M,#$S+"!T=V\@9&ER96-T;W)S(')E<VEG;F5D(&%N9"!F;W)F96ET960@86QL
M('-U8V@@4E-5<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY);B!/8W1O8F5R(#(P,3,L('1H92!#;VUP86YY(&ES
M<W5E9`T*."PY-#<@4E-5<R!T;R!A(&9O<FUE<B!D:7)E8W1O<B!F;W(@:&ES
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M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@3F]V96UB97(@
M,C`Q,RP@=&AE($-O;7!A;GD@9W)A;G1E9`T*86X@86=G<F5G871E(&]F(#$P
M+#0Q."!24U5S('1O(&-E<G1A:6X@96UP;&]Y965S+"!V86QU960@870@)#0R
M+#0Y."X@5&AE(%)357,@=VEL;"!V97-T(&EN(&5Q=6%L(&%N;G5A;"!I;G-T
M86QL;65N=',@;W9E<B!A('1H<F5E+7EE87(-"G!E<FEO9"X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\:3Y'<F%N
M=',@1'5R:6YG('1H92!996%R($5N9&5D($1E8V5M8F5R#0HS,2P@,C`Q-#PO
M:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY$=7)I;F<@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,30L
M#0IT:&4@0V]M<&%N>2!G<F%N=&5D(&%N(&%G9W)E9V%T92!O9B`R-BPT.3(@
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M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^02!S
M=6UM87)Y(&]F('1H92!#;VUP86YY)B,Q-#8[<R!24U4-"F%C=&EV:71Y(&%N
M9"!R96QA=&5D(&EN9F]R;6%T:6]N(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E
M;6)E<B`S,2P@,C`Q-"!I<R!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L
M:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R
M9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3G5M8F5R(&]F(%)357,\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=E:6=H=&5D
M($%V97)A9V4@1W)A;G0@1&%T92!&86ER(%9A;'5E/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#0R)3L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/E)357,@=6YV97-T960@+2!*86YU87)Y(#$L
M(#(P,30\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$V)3L@=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#,X.2PY
M-C`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,S8E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C,N,3D\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E)357,@9W)A;G1E
M9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,C8L-#DR/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXW+C4U/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY24U5S('9E<W1E9#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#,P+#8Y
M,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXW+C0Q/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4E-5<R!C86YC
M96QL960O9F]R9F5I=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,3`X+#DT-SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS+C`Q/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY24U5S('5N=F5S
M=&5D(&%T($1E8V5M8F5R(#,Q+"`R,#$T/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXQ+#(W-BPX,34\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,N,C`\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^07,@;V8@1&5C96UB97(@,S$L(#(P,30L('1H
M92!T;W1A;"!U;G)E8V]G;FEZ960-"F-O;7!E;G-A=&EO;B!E>'!E;G-E(')E
M;&%T960@=&\@=6YV97-T960@4E-5<R!W87,@87!P<F]X:6UA=&5L>2`D,2PY
M,C,L,#`P('=H:6-H(&ES(&5X<&5C=&5D('1O(&)E(')E8V]G;FEZ960@;W9E
M<B!A('=E:6=H=&5D+6%V97)A9V4-"G!E<FEO9"!O9B`Q+C,R('EE87)S+"!B
M87-E9"!O;B!E<W1I;6%T960@=F5S=&EN9R!S8VAE9'5L97,N(%1H92!S=&]C
M:RUB87-E9"!C;VUP96YS871I;VX@9F]R(%)3528C,30V.W,@=V%S("0Q+#,S
M,BPQ-S8@86YD("0X,C(L,3,W#0ID=7)I;F<@=&AE('EE87)S(&5N9&5D($1E
M8V5M8F5R(#,Q+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T:79E;'DN/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^
M5V%R<F%N=',\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/CQB
M/B8C,38P.SPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
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M9"!I;B!T:&4@9G5T=7)E+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/CQI/DES<W5A;F-E<R!$=7)I;F<@=&AE(%EE
M87(@16YD960@1&5C96UB97(-"C,Q+"`R,#$S/"]I/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($9E8G)U87)Y
M(#(P,3,L('1H92!#;VUP86YY(&ES<W5E9`T*82!W87)R86YT('1O('!U<F-H
M87-E(#,P+#`P,"!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO
M;B!S=&]C:R!T;R!A(&-O;G-U;'1A;G0@=VET:"!A;B!E>&5R8VES92!P<FEC
M92!O9B`D-2XR-2!P97(@<VAA<F4N#0I4:&4@=V%R<F%N=',@97AP:7)E('1H
M<F5E('EE87)S(&9O;&QO=VEN9R!T:&4@:7-S=6%N8V4@9&%T92P@86YD('9E
M<W0@87,@9F]L;&]W<SH@,3`L,#`P('-H87)E<R!V97-T960@:6UM961I871E
M;'D@=7!O;B!E>&5C=71I;VX-"F]F('1H92!C;VYS=6QT:6YG(&%G<F5E;65N
M="P@86YD('1H92!R96UA:6YI;F<@<VAA<F5S('9E<W1E9"!I;B`T+#`P,"!S
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M1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^26X@2G5L>2`R,#$S+"!T
M:&4@0V]M<&%N>2!I<W-U960@82!W87)R86YT#0IT;R!P=7)C:&%S92`V,"PP
M,#`@<VAA<F5S(&]F('1H92!#;VUP86YY)B,Q-#8[<R!C;VUM;VX@<W1O8VL@
M=&\@82!C;VYS=6QT86YT('=I=&@@86X@97AE<F-I<V4@<')I8V4@;V8@)#@N
M-3`@<&5R('-H87)E+"!I;B!C;VYS:61E<F%T:6]N#0IF;W(@<V5R=FEC97,@
M=&\@8F4@<')O=FED960@;W9E<B!A('-I>"!M;VYT:"!T97)M+B!4:&4@=V%R
M<F%N=',@97AP:7)E(&9I=F4@>65A<G,@9F]L;&]W:6YG('1H92!I<W-U86YC
M92!D871E+"!V97-T960@:6UM961I871E;'DL#0IA<F4@;F]N+69O<F9E:71A
M8FQE+"!A;F0@8F5C86UE(&5X97)C:7-A8FQE(&EN($IA;G5A<GD@,C`Q-"X@
M5&AE($-O;7!A;GD@<F5C;W)D960@86X@:6YI=&EA;"!S=&]C:RUB87-E9"!P
M<F5P86ED(&-O;G-U;'1I;F<@97AP96YS90T*9F]R('1H92!F86ER('9A;'5E
M(&]F('1H92!W87)R86YT<R!T;W1A;&EN9R`D,S$Y+#<X-BP@=VAI8V@@=V%S
M(&)E:6YG(&%M;W)T:7IE9"!O=F5R('1H92!L96YG=&@@;V8@=&AE(&-O;G-U
M;'1I;F<@<V5R=FEC92!T97)M+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQI/DES<W5A;F-E<R!$=7)I;F<@=&AE
M(%EE87(@16YD960@1&5C96UB97(-"C,Q+"`R,#$T/"]I/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#;VUP
M86YY(&1I9"!N;W0@:7-S=64@86YY('=A<G)A;G1S#0ID=7)I;F<@=&AE('EE
M87(@96YD960@1&5C96UB97(@,S$L(#(P,30N/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^02!S=6UM87)Y(&]F('=A
M<G)A;G0@86-T:79I='D@9'5R:6YG#0IT:&4@>65A<B!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q-"!I<R!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R
M:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^3G5M8F5R(&]F(%-H87)E<R!3=6)J
M96-T('1O(%=A<G)A;G1S($]U='-T86YD:6YG/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY796EG:'1E9"!!=F<N/"]F;VYT/CQB
M<B`O/@T*/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^17AE<F-I<V4@4')I8V4\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-30E.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5V%R<F%N=',@;W5T<W1A;F1I
M;F<@+2!*86YU87)Y(#$L(#(P,30\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(P
M)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXX,C$L,#4P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(P)3L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+CDT/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY'<F%N=&5D/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY%>&5R8VES960\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q,S`L,3`V
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4N,C@\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY%>'!I<F5D/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BT\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=A<G)A
M;G1S(&]U='-T86YD:6YG(&%N9"!E>&5R8VES86)L92`M($1E8V5M8F5R(#,Q
M+"`R,#$T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV.3`L.30T/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXV+C`U/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^5V5I9VAT960@879E<F%G92!R96UA:6YI;F<@8V]N
M=')A8W1U86P@;&EF92!O9B!T:&4@;W5T<W1A;F1I;F<@=V%R<F%N=',@:6X@
M>65A<G,@+2!$96-E;6)E<B`S,2P@,C`Q-#PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,"XX-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
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M<W-U960-"G1O(&-O;G-U;'1A;G1S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@
M2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O
M;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/CQB/EEE87(@16YD960\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB
M/D1E8V5M8F5R(#,Q+"`R,#$S/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`W,R4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY796EG:'1E9"UA=F5R86=E(&9A:7(@=F%L=64@;V8@=V%R
M<F%N=',@9W)A;G1E9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`R-"4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^-2XQ,CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^17AP96-T960@=&5R;7,@
M*&EN('EE87)S*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,BXV+34\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/D5X<&5C=&5D('9O;&%T:6QI='D\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C@U)2TS-#8E/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4FES
M:RUF<F5E(&EN=&5R97-T(')A=&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C`N,S(E+3$N,S$E/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$:79I9&5N9"!Y:65L
M9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY!(&QI<W0@;V8@=&AE('=A<G)A;G1S(&]U='-T86YD:6YG(&%S
M#0IO9B!$96-E;6)E<B`S,2P@,C`Q-"!I<R!I;F-L=61E9"!I;B!T:&4@9F]L
M;&]W:6YG('1A8FQE.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@
M,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0Q,"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S
M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^5V%R<F%N=',@3W5T<W1A;F1I;F<\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#8@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=A<G)A;G1S($5X97)C:7-A
M8FQE/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^5V%R<F%N=',\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^17AE<F-I<V4\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5V%R<F%N=',\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^17AP:7)A=&EO;CPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY787)R86YT
M(%-E<FEE<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^27-S=64@1&%T93PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3W5T<W1A;F1I;F<\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E!R:6-E/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY%>&5R8VES
M86)L93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M1&%T93PO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`T,24[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY787)R86YT<R!I<W-U960@=&\@82!F;W)M97(@;6%J
M;W(@<VAA<F5H;VQD97(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#DE.R!T97AT
M+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXT+S(U+S(P,3(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@.24[('1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-#@L,C8R
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C4N.3,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0X+#(V,CPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@.24[('1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0O,C4O,C`Q-3PO9F]N
M=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5V%R<F%N=',@
M:7-S=65D(&EN($%P<FEL(#(P,3(@<')I=F%T92!P;&%C96UE;G0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT+S(U+S(P
M,3(\+V9O;G0^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0Y-BPU,S<\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C4N.3,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXT.38L-3,W/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C0O,C4O,C`Q-3PO9F]N=#X\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY5;F1E<G=R:71E<B!787)R86YT
M<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C(O-R\R,#$S/"]F;VYT/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU-BPQ-#4\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C4N,C4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXU-BPQ-#4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,B\W+S(P,3@\+V9O;G0^/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=A<G)A;G1S(&ES<W5E9"!T
M;R!I;G9E<W1O<B!R96QA=&EO;G,@8V]N<W5L=&%N=#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(O,C@O,C`Q,SPO9F]N
M=#X\+W1D/@T*("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,S`L,#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+C(U/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M,S`L,#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C(O,C@O,C`Q-CPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY787)R86YT<R!I<W-U960@=&\@:6YV97-T;W(@
M<F5L871I;VYS(&-O;G-U;'1A;G0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXW+S$Y+S(P,3,\+V9O;G0^/"]T9#X-"B`@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-C`L,#`P/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXX+C4P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV,"PP,#`\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M-R\Q.2\R,#$X/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L
M93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXV.3`L.30T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV+C`U/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^-CDP+#DT-#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE('-T;V-K+6)A<V5D(&-O;7!E;G-A
M=&EO;B!F;W(@=V%R<F%N=',-"FES<W5E9"!W87,@)#(V+#8T.2!A;F0@)#0V
M."PW-S<@9'5R:6YG('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q
M-"!A;F0@,C`Q,RP@<F5S<&5C=&EV96QY+CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#;VUP86YY(')E8V]R
M9&5D('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;@T**&EN8VQU9&EN9R!T:&4@
M86UO<G1I>F%T:6]N(&]F('-T;V-K+6)A<V5D('!R97!A:60@8V]N<W5L=&EN
M9R!F965S+"!I<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@9F]R('-E<G9I8V5S
M(&%N9"!A8V-R=6%L(&9O<B!S=&]C:RUB87-E9`T*8V]M<&5N<V%T:6]N*2!R
M96QA=&5D('1O(&5Q=6ET>2!I;G-T<G5M96YT<R!G<F%N=&5D('1O(&5M<&QO
M>65E<RP@9&ER96-T;W)S(&%N9"!C;VYS=6QT86YT<R!A<R!F;VQL;W=S.CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT
M86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W
M:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D9O<B!T:&4\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1F]R
M('1H93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/EEE87(@16YD960\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^665A<B!%;F1E9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$96-E;6)E<B`S
M,2P@,C`Q-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^1&5C96UB97(@,S$L(#(P,3,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@-3@E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^16UP;&]Y965S("T@<V5L;&EN9R!A;F0@;6%R:V5T:6YG/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$X)3L@=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXW
M.2PR-S@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,3@E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C@L,CDX/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY%;7!L;WEE
M97,@+2!G96YE<F%L(&%N9"!A9&UI;FES=')A=&EV93PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,BPP.34L,C4T/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PU
M,3(L-#0X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY%;7!L;WEE97,@+2!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BT\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXQ-38L-38X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^1&ER96-T;W)S("T@9V5N97)A;"!A;F0@861M:6YI<W1R871I
M=F4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C$T-BPP.3,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXS.3DL.3@V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY#;VYS=6QT86YT<R`M('-E;&QI;F<@86YD
M(&UA<FME=&EN9SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^.#@L-#`V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/D-O;G-U;'1A;G1S("T@9V5N97)A;"!A;F0@
M861M:6YI<W1R871I=F4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C$T-BPW.3D\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXX-#,L,S`Q/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY#;VYS=6QT86YT<R`M
M(')E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L
M:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXX+#<X.3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C$T+#,W,CPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,'!T.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^5&]T86P\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,BPU-C0L-C$Y/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS+#$S-"PY-S,\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^26YC;VUE(%1A>&5S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487@@1&ES8VQO<W5R92!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN8V]M92!487AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,"<^/&(^3D]412`Q,BX@24Y#3TU%(%1!6$53(#PO8CX\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!I<R!S=6)J96-T('1O
M('1A>&%T:6]N(&EN#0IT:&4@56YI=&5D(%-T871E<R!A;F0@0V%L:69O<FYI
M82X@5&AE('!R;W9I<VEO;B!F;W(@:6YC;VUE('1A>&5S(&9O<B!T:&4@>65A
M<G,@96YD960@1&5C96UB97(@,S$L(#(P,30@86YD(#(P,3,@87)E('-U;6UA
M<FEZ960-"F)E;&]W.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A
M+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C
M;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$96-E;6)E<B`S,2P@
M,C`Q-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M1&5C96UB97(@,S$L(#(P,3,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^0W5R<F5N
M=#H\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M
M;&5F=#H@,3!P=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D9E
M9&5R86P\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^+3PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@-3@E.R!P861D:6YG+6QE9G0Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY3=&%T93PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$X
M)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,BPX
M,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[(&)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BT\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1O=&%L
M(&-U<G)E;G0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR
M+#@P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXM
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/D1E9F5R<F5D.CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT
M9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY&961E<F%L/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$Q+#`X,BPT
M-3D\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C@L,#<U+#,T,CPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.B`Q,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^4W1A=&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C,L,3`P+#8R-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C(L,C,S+#<R-CPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=P
M861D:6YG+6QE9G0Z(#$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY#:&%N9V4@:6X@=F%L=6%T:6]N(&%L;&]W86YC93PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S
M;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXH,30L,3@S+#`X-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXH,3`L,S`Y+#`V.#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*3PO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&]T
M86P@9&5F97)R960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^+3PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU
M<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^26YC;VUE('1A>"!P<F]V:7-I;VX@*&)E;F5F
M:70I/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L
M.#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXM/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN8V]M92!T87AE<R!F
M;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R#0HS,2P@,C`Q-"!A;F0@,C`Q
M,RP@87)E(')E8V]R9&5D(&EN('1H92!G96YE<F%L(&%N9"!A9&UI;FES=')A
M=&EV92!E>'!E;G-E<R!L:6YE(&ET96T@:6X@=&AE(&%C8V]M<&%N>6EN9R!C
M;VYS;VQI9&%T960@<W1A=&5M96YT<PT*;V8@;W!E<F%T:6]N<RX\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!(')E
M8V]N8VEL:6%T:6]N(&]F(&EN8V]M92!T87AE<PT*8V]M<'5T960@8GD@87!P
M;'EI;F<@=&AE('-T871U=&]R>2!5+E,N(&EN8V]M92!T87@@<F%T92!T;R!T
M:&4@0V]M<&%N>28C,30V.W,@;&]S<R!B969O<F4@:6YC;VUE('1A>&5S('1O
M('1H92!I;F-O;64@=&%X#0IP<F]V:7-I;VX@:7,@87,@9F]L;&]W<SH\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B
M;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F
M;VYT.B`Q,'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N<RU397)I9CL@=VED
M=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY$96-E;6)E<B`S,2P@,C`Q-#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$96-E;6)E
M<B`S,2P@,C`Q,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-3@E.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^52Y3+B!F961E<F%L('-T871U=&]R
M>2!T87@@<F%T93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3@E.R!T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,U
M+C`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B4\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$X)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXS-2XP,#PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXE/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY"96YE9FET(&]F(&QO=V5R('1A>"!B<F%C:V5T<SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#$N,#`\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/BDE/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXH,2XP,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*24\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4W1A=&4@=&%X(&)E
M;F5F:70L(&YE=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^*#`N,#,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BDE/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+C`P/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXE/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY297-E87)C:"!A;F0@9&5V96QO<&UE;G0@8W)E9&ET<SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XP,#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,"XT,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)3PO9F]N=#X\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY%;7!L;WEE92!S=&]C
M:R!B87-E9"!C;VUP96YS871I;VX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B@Q+C`S/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI)3PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#0N
M-S(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/BDE/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY,;W-S(&]N(&1E8G0@8V]N=F5R<VEO;CPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XP,#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,"XP,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)3PO9F]N=#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/=&AE<CPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#`N,C$\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/BDE/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXH,"XP.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*24\+V9O
M;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E9A;'5A=&EO
M;B!A;&QO=V%N8V4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#,R+C<V/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXI)3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,CDN-C,\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/BDE/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D5F9F5C=&EV92!I;F-O;64@=&%X(')A=&4\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B@P+C`S/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI)3PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,"XP,#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)3PO9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D1E9F5R<F5D('1A>"!A<W-E=',@
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M87)E(&%S#0IF;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T
M:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E8V5M
M8F5R(#,Q+"`R,#$T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D1E8V5M8F5R(#,Q+"`R,#$S/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$969E<G)E9"!T87@@
M87-S971S("AL:6%B:6QI=&EE<RDZ/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@-3@E.R!P861D:6YG+6QE9G0Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY.3TPF(S$T-CMS/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$X)3L@=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ,"PY
M,C(L.3$T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$X)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXW+#,V-"PP-3@\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY$97!R96-I871I;VX@86YD(&%M;W)T:7IA
M=&EO;CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^*#8L-S@W/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,S0P/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXI/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@
M/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/D]T:&5R/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV-"PX,#8\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ,CDL,3DQ/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/E)E<V5A<F-H("8C,S@[(&1E=F5L;W!M96YT(&-R
M961I=',\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C4U-2PY-#4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXU-C,L-#@U/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE
M9G0Z(#$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$969E
M<G)E9"!S=&]C:R!C;VUP96YS871I;VX\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L-C0V+#(P.#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L,C4R+#8W-#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY5;G)E86QI>F5D(&=A:6X@;W(@;&]S<R!O
M;B!I;G9E<W1M96YT<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z
M(#(P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4;W1A;"!D
M969E<G)E9"!T87@@87-S971S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$T+#$X
M,RPP.#8\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$P+#,P.2PP-C@\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E9A
M;'5A=&EO;B!A;&QO=V%N8V4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#$T+#$X
M,RPP.#8\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*#$P+#,P.2PP-C@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DYE="!D969E<G)E9"!T87@@87-S
M971S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BT\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BT\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O
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M;'D@)#,L.3`P+#`P,"!A;F0@)#,L,#`P+#`P,"!I;@T*,C`Q-"!A;F0@,C`Q
M,RP@<F5S<&5C=&EV96QY+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN
M)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/D%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T+"!T
M:&4@0V]M<&%N>0T*:&%D(&YE="!O<&5R871I;F<@;&]S<R!C87)R>69O<G=A
M<F1S(&9O<B!F961E<F%L(&EN8V]M92!T87@@<'5R<&]S97,@;V8@87!P<F]X
M:6UA=&5L>2`D,C<L.#`P+#`P,"!W:&EC:"!E>'!I<F4@8F5G:6YN:6YG(&EN
M('1H90T*>65A<B`R,#(W(&%N9"!F961E<F%L(')E<V5A<F-H(&%N9"!D979E
M;&]P;65N="!T87@@8W)E9&ET<R!O9B!A<'!R;WAI;6%T96QY("0S-3`L,#`P
M('=H:6-H(&5X<&ER92!B96=I;FYI;F<@:6X@=&AE('EE87(@,C`R-BX@07,-
M"F]F($1E8V5M8F5R(#,Q+"`R,#$T+"!T:&4@0V]M<&%N>2!H860@;F5T(&]P
M97)A=&EN9R!L;W-S(&-A<G)Y9F]R=V%R9',@9F]R('-T871E(&EN8V]M92!T
M87@@<'5R<&]S97,@;V8@87!P<F]X:6UA=&5L>2`D,C0L-C`P+#`P,`T*=VAI
M8V@@97AP:7)E(&)E9VEN;FEN9R!I;B!T:&4@>65A<B`R,#$W(&%N9"!S=&%T
M92!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@=&%X(&-R961I=',@;V8@87!P
M<F]X:6UA=&5L>2`D,S`P+#`P('=H:6-H(&1O(&YO="!E>'!I<F4N/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE
M(&1E9F5R<F5D('1A>"!A<W-E="!A="!$96-E;6)E<B`S,2P-"C(P,30@9&]E
M<R!N;W0@:6YC;'5D92!A<'!R;WAI;6%T96QY("0S,"PP,#`@86YD("0S,"PP
M,#`@;V8@97AC97-S('1A>"!B96YE9FET<R!F<F]M(&5M<&QO>65E('-T;V-K
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M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^571I;&EZ
M871I;VX@;V8@=&AE(&YE="!O<&5R871I;F<@;&]S<V5S#0IM87D@8F4@<W5B
M:F5C="!T;R!S=6)S=&%N=&EA;"!A;FYU86P@;&EM:71A=&EO;B!D=64@=&\@
M9F5D97)A;"!A;F0@<W1A=&4@;W=N97)S:&EP(&-H86YG92!L:6UI=&%T:6]N
M<R!P<F]V:61E9"!B>2!T:&4@26YT97)N86P-"E)E=F5N=64@0V]D92!A;F0@
M<VEM:6QA<B!S=&%T92!P<F]V:7-I;VYS+B!3=6-H(&%N;G5A;"!L:6UI=&%T
M:6]N<R!C;W5L9"!R97-U;'0@:6X@=&AE(&5X<&ER871I;VX@;V8@=&AE(&YE
M="!O<&5R871I;F<@;&]S<V5S#0IA9"!C<F5D:71S(&)E9F]R92!T:&5I<B!U
M=&EL:7IA=&EO;BX@5&AE($-O;7!A;GD@:&%S(&YO="!P97)F;W)M960@86X@
M86YA;'ES:7,@=&\@9&5T97)M:6YE('1H92!L:6UI=&%T:6]N(&]F('1H92!N
M970@;W!E<F%T:6YG#0IL;W-S(&%N9"!R97-E87)C:"!D979E;&]P;65N="!C
M<F5D:70@8V%R<GEF;W)W87)D<RXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#
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M(')A=&4N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3`N-S5I;B<^)B,Q-C`[
M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M83=C9F-B9C5?8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W8V9C8F8U7V)D-&9?-#<Y,%]A-SDY
M7S@U-#%D9#0X9&%A-B]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5,13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%;7!L;WEE92!3879I;F=S
M(%!L86X\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0V]M<&5N<V%T:6]N(&%N9"!2971I<F5M96YT($1I<V-L;W-U
M<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%;7!L;WEE92!3879I;F=S(%!L86X\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\
M+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB
M/DY/5$4@,3,N($5-4$Q/645%(%-!5DE.1U,@4$Q!3CPO8CX\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M
M<&%N>2!H87,@97-T86)L:7-H960@86X@96UP;&]Y964-"G-A=FEN9W,@<&QA
M;B!P=7)S=6%N="!T;R!396-T:6]N(#0P,2AK*2!O9B!T:&4@26YT97)N86P@
M4F5V96YU92!#;V1E+"!E9F9E8W1I=F4@2F%N=6%R>2`Q+"`R,#$T+B!4:&4@
M<&QA;B!A;&QO=W,@<&%R=&EC:7!A=&EN9PT*96UP;&]Y965S('1O(&1E<&]S
M:70@:6YT;R!T87@@9&5F97)R960@:6YV97-T;65N="!A8V-O=6YT<R!U<"!T
M;R`Q,#`E(&]F('1H96ER('-A;&%R>2P@<W5B:F5C="!T;R!A;FYU86P@;&EM
M:71S+B!4:&4@0V]M<&%N>2!M86ME<PT*8V]N=')I8G5T:6]N<R!T;R!T:&4@
M<&QA;B!I;B!A;B!A;6]U;G0@;F]T(&QE<W,@=&AA;B`S)2!O9B!T:&4@<&%R
M=&EC:7!A;G1S)B,Q-#8[(&%N;G5A;"!C87-H(&-O;7!E;G-A=&EO;BP@<W5B
M:F5C="!T;R!A;FYU86P-"FQI;6ET<RX@5&AE($-O;7!A;GD@8V]N=')I8G5T
M960@87!P<F]X:6UA=&5L>2`D-38L,#`P('1O('1H92!P;&%N(&1U<FEN9R!T
M:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"X\+W`^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S($1I<V-L;W-U<F4@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P
M<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/&(^3D]412`Q-"X@0T]-34E4345.5%,@04Y$($-/
M3E1)3D=%3D-)15,\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/&(^0V%P:71A;"!,96%S97,\+V(^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y
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M;&]W<SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P
M/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S
M='EL93TS1"=F;VYT.B`Q,'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N<RU3
M97)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI
M9#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/EEE87(@96YD:6YG
M($1E8V5M8F5R(#,Q+#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`W,R4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXR,#$U/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(T
M)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXR-2PT-S<\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,38\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T
M('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[
M('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,3DL,S(Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY4;W1A;"!M:6YI;75M(&QE87-E('!A>6UE;G1S/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT-"PW
M.3@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY,97-S(&%M;W5N="!R97!R97-E;G1I;F<@:6YT97)E<W0\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^*#$L-S$X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT/CPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E!R97-E;G0@=F%L
M=64@;V8@9G5T=7)E(&UI;FEM=6T@;&5A<V4@<&%Y;65N=',\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0S+#`X,#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DQE<W,@
M8W5R<F5N="!P;W)T:6]N/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@R-"PQ,3(\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^0V%P:71A;"!L96%S92!O8FQI9V%T:6]N<RP@;F5T
M(&]F(&-U<G)E;G0@<&]R=&EO;CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXQ."PY-C@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CPO
M=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE('9A;'5E(&]F('1H92!E
M<75I<&UE;G0@=6YD97(@8V%P:71A;`T*;&5A<V5S(&%S(&]F($1E8V5M8F5R
M(#,Q+"`R,#$T('=A<R`D-3(L-C@W+"!W:71H(')E;&%T960@86-C=6UU;&%T
M960@9&5P<F5C:6%T:6]N(&]F("0X+#8U-BX\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SX\8CY/<&5R871I;F<@
M3&5A<V5S/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($IU;F4@
M,C`Q-"P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O#0IA(&QE87-E(&%G<F5E
M;65N="!F;W(@-RPU-C4@<W%U87)E(&9E970@;V8@;V9F:6-E('-P86-E('1H
M870@8V]M;65N8V5D(&]N(%-E<'1E;6)E<B`Q+"`R,#$T(&%N9"!C;VYT:6YU
M97,@=6YT:6P@3V-T;V)E<B`S,2P@,C`Q."X-"DUO;G1H;'D@<F5N="!B96=A
M;B!O;B!397!T96UB97(@,2P@,C`Q-"!I;B!T:&4@86UO=6YT(&]F("0R,"PT
M,C8L('=I=&@@82`S)2!I;F-R96%S92!I;B!T:&4@8F%S92!R96YT(&%M;W5N
M="!O;B!A;B!A;FYU86P@8F%S:7,N#0I4:&4@;&5A<V4@86=R965M96YT(&%L
M;&]W<R!F;W(@=&AE(&UO;G1H;'D@<F5N="!A;6]U;G0@=&\@8F4@86)A=&5D
M(&9O<B!T=V\@;6]N=&AS(&%T('9A<FEO=7,@=&EM97,@9'5R:6YG('1H92!L
M96%S92!A9W)E96UE;G0N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^26X@07!R:6P@,C`Q,RP@=&AE($-O;7!A;GD@
M96YT97)E9"!I;G1O#0IA(&QE87-E(&%G<F5E;65N="!F;W(@,RPW.#0@<W%U
M87)E(&9E970@;V8@;V9F:6-E('-P86-E('1H870@8V]M;65N8V5D(&]N($UA
M>2`Q+"`R,#$S(&%N9"!C;VYT:6YU97,@=6YT:6P@4V5P=&5M8F5R(#,P+"`R
M,#$V+B!-;VYT:&QY#0IR96YT(&)E9V%N(&]N($UA>2`Q+"`R,#$S(&EN('1H
M92!A;6]U;G0@;V8@)#$P+#0P-BP@=VET:"!A(#,E(&EN8W)E87-E(&EN('1H
M92!B87-E(')E;G0@86UO=6YT(&]N(&%N(&%N;G5A;"!B87-I<RX@5&AE(&QE
M87-E(&%G<F5E;65N=`T*86QL;W=S(&9O<B!T:&4@;6]N=&AL>2!R96YT(&%M
M;W5N="!T;R!B92!A8F%T960@9F]R(&9I=F4@;6]N=&AS(&%T('9A<FEO=7,@
M=&EM97,@9'5R:6YG('1H92!L96%S92!A9W)E96UE;G0N(%1H92!#;VUP86YY
M(&5N=&5R960-"FEN=&\@82!S=6)L96%S92!A9W)E96UE;G0@:6X@1F5B<G5A
M<GD@,C`Q-2!T;R!S=6)L970@,RPX-S0@<W%U87)E(&9E970@;V8@:71S('!R
M979I;W5S;'D@;V-C=7!I960@;V9F:6-E<R!T:')O=6=H('1H92!R96UA:6YI
M;F<-"G1E<FT@;V8@=&AE(&QE87-E+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($IA;G5A<GD@,C`Q,"P@4$,@
M96YT97)E9"!I;G1O(&$@;&5A<V4-"F%G<F5E;65N="!F;W(@,RPQ,S<@<W%U
M87)E(&9E970@;V8@;V9F:6-E(&%N9"!L86)O<F%T;W)Y('-P86-E('1H870@
M8V]M;65N8V5D(&]N($IA;G5A<GD@,2P@,C`Q,"!A;F0@8V]N=&EN=65S('5N
M=&EL($1E8V5M8F5R(#,Q+`T*,C`Q-2X@36]N=&AL>2!R96YT(&)E9V%N(&]N
M($IA;G5A<GD@,2P@,C`Q,"!I;B!T:&4@86UO=6YT(&]F("0S+#4Y-"X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY2
M96YT(&5X<&5N<V4@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<@T*,S$L
M(#(P,30@86YD(#(P,3,@=V%S("0S,#8L-#8U(&%N9"`D,3`S+#$Y,2P@<F5S
M<&5C=&EV96QY+B!4:&4@9F]L;&]W:6YG(')E<')E<V5N=',@9G5T=7)E(&%N
M;G5A;"!M:6YI;75M(&QE87-E('!A>6UE;G1S+"!I;F-L=61I;F<-"FQE87-E
M('!A>6UE;G1S(')E;&%T960@=&\@;&5A<V4@86=R965M96YT<R!E;G1E<F5D
M(&EN=&\@:6X@2F%N=6%R>2!A;F0@1F5B<G5A<GD@,C`Q-2`H<V5E($YO=&4@
M,38I+"!A;F0@;F5T(&]F(&5X<&5C=&5D('-U8FQE87-E#0II;F-O;64L(&%S
M(&]F($1E8V5M8F5R(#,Q+"`R,#$T.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
M"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF
M.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`V
M-24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$U/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#,R)3L@=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT.3(L
M-3`S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXR,#$V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXT-C@L.3DW/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$W/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT.#$L-#0S/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q.#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-#DU+#DS
M.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,C`Q.3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,C4W+#`S.3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/E1H97)E869T97(\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M-#<X+#0W,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%
M1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^5&]T86P\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,BPV-S0L,SDS/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/DQE9V%L/"]B/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN('1H
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M;VYS+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/CQB/DEN9&5M;FET:65S/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN(&%D9&ET:6]N('1O('1H
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M=&\@;6%K92X@2&ES=&]R:6-A;&QY+`T*=&AE($-O;7!A;GD@:&%S(&YO="!B
M965N(&]B;&EG871E9"!N;W(@:6YC=7)R960@86YY('!A>6UE;G1S(&9O<B!T
M:&5S92!O8FQI9V%T:6]N<R!A;F0L('1H97)E9F]R92P@;F\@;&EA8FEL:71I
M97,@:&%V92!B965N(')E8V]R9&5D#0IF;W(@=&AE<V4@:6YD96UN:71I97,@
M:6X@=&AE(&%C8V]M<&%N>6EN9R!C;VYS;VQI9&%T960@8F%L86YC92!S:&5E
M=',N)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P
M.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^/&(^57)I9V5N($QI8V5N<V4\+V(^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4G/D]N($]C=&]B97(-"C(T+"`R,#$T+"`H=&AE("8C
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M8F5T=V5E;B!!<')I;"`R-"P@,C`Q-2!A;F0@3V-T;V)E<B`R-"P@,C`Q-2P@
M=&AE($-O;7!A;GD@=VEL;"!H879E('1H92!R:6=H="P@870@:71S(&]P=&EO
M;BP-"G1O(&-O;G9E<G0@<W5C:"!N;VXM97AC;'5S:79E(&QI8V5N<V4@=&\@
M86X@97AC;'5S:79E(&QI8V5N<V4@9F]R('1H92!R96UA:6YI;F<@=&5R;2!O
M9B!T:&4@57)I9V5N($QI8V5N<V4L('-U8FIE8W0@;VYL>2!T;R!C97)T86EN
M#0IS<&5C:69I960@97AI<W1I;F<@<W5B;&EC96YS97,@*'1H92`F(S$T-SM%
M>&ES=&EN9R!3=6)L:6-E;G-E<R8C,30X.RDN/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET93L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
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M="!O9B!T:&4@9W)E871E<B!O9B`H:2D@)#`N-3`@<&5R(&1O<V4L(&%N9`T*
M*&EI*2`Q-24@+2`R,"4@;V8@:71S(&YE="!S86QE<R!O9B!(3$$L('=I=&@@
M=&AE(')O>6%L='D@86UO=6YT('=I=&AI;B!S=6-H(')A;F=E(&1E<&5N9&EN
M9R!O;B!T:&4@0V]M<&%N>28C,30V.W,@86=G<F5G871E('-A;&5S#0IO9B!(
M3$$@9'5R:6YG('1H92!P97)I;V0@=&\@=VAI8V@@=&AE(')O>6%L='D@<&%Y
M;65N="!A<'!L:65S+B!4:&4@;6EN:6UU;2!A;FYU86P@<F]Y86QT>2!P87EM
M96YT(&-O;G-I<W1S(&]F("AA*2!F;W(@=&AE(#(P,34-"F-A;&5N9&%R('EE
M87(L('1H92!G<F5A=&5R(&]F("AI*2`Q,3`E(&]F('1H92!A9V=R96=A=&4@
M<F]Y86QT:65S('!A:60@=&\@57)I9V5N('5N9&5R('1H92!%>&ES=&EN9R!3
M=6)L:6-E;G-E<R!D=7)I;F<@=&AE('!R96-E9&EN9PT*,3(@;6]N=&AS+"!O
M;B!A('!R;W)A=&5D(&)A<VES+"!A;F0@*&EI*2`D.#`P+#`P,"P@;&5S<R!T
M:&4@86=G<F5G871E(')O>6%L=&EE<R!P86ED('1O(%5R:6=E;B!U;F1E<B!T
M:&4@17AI<W1I;F<@4W5B;&EC96YS97,@9'5R:6YG#0IT:&4@,C`Q-2!C86QE
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M;F<@=VET:"!I=',@9FER<W0@8V]M;65R8VEA;`T*<V%L92!O9B!(3$$@86YD
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M>'!E8W1E9"!T;R!B92!I;F-U<G)E9`T*;W9E<B`Q."TR-"!M;VYT:',@9F]L
M;&]W:6YG('1H92!5<FEG96X@169F96-T:79E($1A=&4N/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
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M96UB97(@,S$L(#(P,30N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^/&(^4$-#02!,:6-E;G-E($%G<F5E;65N="`\
M+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>2<^3VX@075G=7-T(#,P+"`R,#$R+"!T:&4@0V]M<&%N>2!E;G1E<F5D
M#0II;G1O(&$@;&EC96YS92!A9W)E96UE;G0@=VET:"!0<F]F97-S:6]N86P@
M0V]M<&]U;F1I;F<@0V5N=&5R<R!O9B!!;65R:6-A("@F(S$T-SM00T-!)B,Q
M-#@[*2P@<'5R<W5A;G0@=&\@=VAI8V@@4$-#02!H87,@9W)A;G1E9`T*=&\@
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M="!D=7)I;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&]R
M(#(P,3,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>2<^/&(^4$-#02!3=')A=&5G:6,@06QL:6%N8V4@06=R965M96YT
M#0H\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W
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M=&AE($-O;7!A;GD@8GD@4$-#02!E;G1E<B!I;G1O(&$@8V]M;65R8VEA;`T*
M86=R965M96YT(&9O<B!T:&4@;&EC96YS92!O<B!A8W%U:7-I=&EO;B!O9B!T
M:&4@:6YT96QL96-T=6%L('!R;W!E<G1Y(')I9VAT<R!O=VYE9"!B>2!T:&4@
M365M8F5R+T-U<W1O;65R+"!00T-!('=I;&P@8F4@96YT:71L960-"G1O(')E
M8V5I=F4@8V5R=&%I;B!C87-H(&9E97,@=7`@=&\@86X@86=G<F5G871E(&]F
M("0Q,#`L,#`P+"!A<R!W96QL(&%S(&$@8V]M;6ES<VEO;B!B87-E9"!O;B!N
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M8V5M8F5R(#,Q+"`R,#$T(&]R(#(P,3,N/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^07-S970@4'5R8VAA<V4@
M06=R965M96YT<SPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!H87,@86-Q=6ER960@:6YT
M96QL96-T=6%L#0IP<F]P97)T>2!R:6=H=',@<F5L871E9"!T;R!C97)T86EN
M('!R;W!R:65T87)Y(&EN;F]V871I;VYS(&9R;VT@8V5R=&%I;B!I;G9E;G1O
M<G,@*'1H92`F(S$T-SM);G9E;G1O<G,F(S$T.#LI('1H<F]U9V@@;75L=&EP
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M97)C:6%L;'D@<F5A<V]N86)L92!E9F9O<G1S('1O(')E<V5A<F-H+`T*9&5V
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M<F5U;F1E<BX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY);B!C;VYS:61E<F%T:6]N(&9O<B!T:&4@86-Q=6ES:71I
M;VX-"F]F('1H92!I;G1E;&QE8W1U86P@<')O<&5R='D@<FEG:'1S+"!T:&4@
M0V]M<&%N>2!I<R!O8FQI9V%T960@=&\@;6%K92!P87EM96YT<R!T;R!T:&4@
M26YV96YT;W)S(&)A<V5D(&]N('1H92!C;VUP;&5T:6]N(&]F(&-E<G1A:6X-
M"FUI;&5S=&]N97,L(&=E;F5R86QL>2!C;VYS:7-T:6YG(&]F.B`H,2D@82!P
M87EM96YT('!A>6%B;&4@=VET:&EN(#,P(&1A>7,@869T97(@=&AE(&ES<W5A
M;F-E(&]F('1H92!F:7)S="!P871E;G0@:6X@=&AE(%5N:71E9`T*4W1A=&5S
M(&%R:7-I;F<@9G)O;2!T:&4@86-Q=6ER960@:6YT96QL96-T=6%L('!R;W!E
M<G1Y("AI9B!A;GDI.R`H,BD@82!P87EM96YT('!A>6%B;&4@=VET:&EN(#,P
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M<F]M('1H92!A8W%U:7)E9`T*:6YT96QL96-T=6%L('!R;W!E<G1Y("AI9B!A
M;GDI.R!A;F0@*#0I(&-E<G1A:6X@<F]Y86QT>2!P87EM96YT<R!B87-E9"!O
M;B!T:&4@;F5T(')E8V5I<'1S(')E8V5I=F5D(&)Y('1H92!#;VUP86YY(&EN
M(&-O;FYE8W1I;VX-"G=I=&@@=&AE('-A;&4@;W(@;&EC96YS:6YG(&]F(&%N
M>2!P<F]D=6-T(&)A<V5D(&]N('1H92!A8W%U:7)E9"!I;G1E;&QE8W1U86P@
M<')O<&5R='D@*&EF(&%N>2DL(&%F=&5R(&1E9'5C=&EN9R`H86UO;F<@;W1H
M97(@=&AI;F=S*0T*=&AE($-O;7!A;GDF(S$T-CMS(&1E=F5L;W!M96YT(&-O
M<W1S(&%S<V]C:6%T960@=VET:"!S=6-H('!R;V1U8W0N($EF+"!F;VQL;W=I
M;F<@9FEV92!Y96%R<R!A9G1E<B!T:&4@9&%T92!O9B!T:&4@87!P;&EC86)L
M92!A<W-E=`T*<'5R8VAA<V4@86=R965M96YT+"!T:&4@0V]M<&%N>2!E:71H
M97(@*&$I(&9O<B!C97)T86EN(&]F('1H92!);G9E;G1O<G,L(&AA<R!N;W0@
M9FEL960@86X@24Y$(&]R+"!F;W(@=&AE(')E;6%I;FEN9R!);G9E;G1O<G,L
M#0IH87,@;F]T(&EN:71I871E9"!A('-T=61Y('=H97)E(&1A=&$@:7,@9&5R
M:79E9"P@;W(@*&(I(&AA<R!F86EL960@=&\@9V5N97)A=&4@<F]Y86QT>2!P
M87EM96YT<R!T;R!T:&4@26YV96YT;W)S(&9O<B!A;GD@<')O9'5C=`T*8F%S
M960@;VX@=&AE(&%C<75I<F5D(&EN=&5L;&5C='5A;"!P<F]P97)T>2P@=&AE
M($EN=F5N=&]R<R!M87D@=&5R;6EN871E('1H92!A<'!L:6-A8FQE(&%S<V5T
M('!U<F-H87-E(&%G<F5E;65N="!A;F0@<F5Q=65S="!T:&%T#0IT:&4@0V]M
M<&%N>2!R92UA<W-I9VX@=&AE(&%C<75I<F5D('1E8VAN;VQO9WD@=&\@=&AE
M($EN=F5N=&]R<RX@3F\@<F]Y86QT>2!A;6]U;G1S(&AA=F4@8F5E;B!P86ED
M(&]R(&%C8W)U960@=6YD97(@=&AE<V4@86=R965M96YT<PT*9F]R('1H92!Y
M96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"!O<B`R,#$S+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/DYO
M=F5L($1R=6<@86YD($5Y92!#87)E($YO<G1H=V5S=`T*07-S970@4'5R8VAA
M<V4@06=R965M96YT("8C,34P.R!296QA=&5D(%!A<G1Y/"]B/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D]N($%U
M9W5S="`X+"`R,#$S+"!T:&4@0V]M<&%N>2!A8W%U:7)E9`T*:6YT96QL96-T
M=6%L('!R;W!E<G1Y(')I9VAT<R!R96QA=&5D('1O(&-E<G1A:6X@<')O<')I
M971A<GD@:6YN;W9A=&EO;G,@9G)O;2!T:&4@8V]M<&]U;F1I;F<@<&AA<FUA
M8WD@;W!E<F%T:6]N<R!O9B!.;W9E;"!$<G5G#0I3;VQU=&EO;G,L($Q,0R`H
M)B,Q-#<[3D13)B,Q-#@[*2!A;F0@9G)O;2!%>64@0V%R92!.;W)T:'=E<W0L
M($EN8RX@*'1O9V5T:&5R(')E9F5R<F5D('1O(&%S('1H92`F(S$T-SM396QL
M97)S)B,Q-#@[*2!P=7)S=6%N=`T*=&\@86X@87-S970@<'5R8VAA<V4@86=R
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M=&\@<F5S96%R8V@L(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@82!P<F]D
M=6-T#0IB87-E9"!O;B!T:&4@86-Q=6ER960@:6YT96QL96-T=6%L('!R;W!E
M<G1Y+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GDG/DEN(&-O;G-I9&5R871I;VX@9F]R('1H92!A8W%U:7-I=&EO;BP-
M"G1H92!#;VUP86YY(&ES(&]B;&EG871E9"!T;R!M86ME('1H92!F;VQL;W=I
M;F<@<&%Y;65N=',@=&\@=&AE(%-E;&QE<G,Z("@Q*2!A('!A>6UE;G0@<&%Y
M86)L92!W:71H:6X@,S`@9&%Y<R!A9G1E<B!T:&4@:7-S=6%N8V4-"F]F('1H
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M<&%Y;65N="!P87EA8FQE('=I=&AI;B`S,"!D87ES(&%F=&5R('1H92!#;VUP
M86YY(&9I;&5S('1H92!F:7)S="!N97<@9')U9R!A<'!L:6-A=&EO;B!W:71H
M('1H92!&1$$@9F]R('1H92!F:7)S=`T*<')O9'5C="!A<FES:6YG(&9R;VT@
M=&AE(&%C<75I<F5D(&EN=&5L;&5C='5A;"!P<F]P97)T>2`H:68@86YY*3L@
M86YD("@T*2!C97)T86EN(')O>6%L='D@<&%Y;65N=',@8F%S960@;VX@=&AE
M(&YE="!R96-E:7!T<R!R96-E:79E9`T*8GD@=&AE($-O;7!A;GD@:6X@8V]N
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M9`T*=&5C:&YO;&]G>2!T;R!.1%,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3D13(&ES(&]W;F5D(&)Y('1H92!F
M;W)M97(@;W=N97)S(&]F#0I00RX@1'5R:6YG('1H92!Y96%R<R!E;F1E9"!$
M96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q,RP@=&AE($-O;7!A;GD@9&ED(&YO
M="!M86ME(&%N>2!P87EM96YT<R!T;R!.1%,@;W(@=&AE(&]T:&5R(%-E;&QE
M<BP@86YD(&YO#0IA;6]U;G1S('=E<F4@9'5E(&%N9"!P87EA8FQE('1O($Y$
M4R!O<B!T:&4@;W1H97(@4V5L;&5R(&%T($1E8V5M8F5R(#,Q+"`R,#$T(&%N
M9"`R,#$S+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4V5G;65N="!)
M;F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY396=M96YT(%)E<&]R=&EN9R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E9VUE
M;G0@26YF;W)M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$
M)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,"<^/&(^
M3D]412`Q-2X@4T5'345.5"!)3D9/4DU!5$E/3CPO8CX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
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M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/E1H92!#;VUP86YY(&-A=&5G;W)I>F5S(')E=F5N=65S(&)Y
M(&=E;V=R87!H:6,-"F%R96$@8F%S960@;VX@<V5L;&EN9R!L;V-A=&EO;BX@
M06QL(&]P97)A=&EO;G,@87)E(&-U<G)E;G1L>2!L;V-A=&5D(&EN('1H92!5
M;FET960@4W1A=&5S.R!T:&5R969O<F4L('1O=&%L(')E=F5N=65S(&9O<B`R
M,#$T(&%N9`T*,C`Q,R!A<F4@871T<FEB=71E9"!T;R!T:&4@56YI=&5D(%-T
M871E<RX@06QL(&QO;F<M;&EV960@87-S971S(&%T($1E8V5M8F5R(#,Q+"`R
M,#$T(&%R92!L;V-A=&5D(&EN('1H92!5;FET960@4W1A=&5S+CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!S96QL<R!I
M=',@8V]M<&]U;F1E9"!F;W)M=6QA=&EO;G,-"G1O(&$@;&%R9V4@;G5M8F5R
M(&]F(&-U<W1O;65R<RX@3&5S<R!T:&%N(#$P)2!O9B!T:&4@0V]M<&%N>28C
M,30V.W,@=&]T86P@<&AA<FUA8WD@<V%L97,@=V5R92!D97)I=F5D(&9R;VT@
M82!S:6YG;&4@8W5S=&]M97(@9F]R#0IT:&4@>65A<B!E;F1E9"!$96-E;6)E
M<B`S,2P@,C`Q-"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M5&AE($-O;7!A;GD@<F5C96EV97,@:71S(&%C=&EV92!P:&%R;6%C975T:6-A
M;`T*:6YG<F5D:65N=',@9G)O;2!T:')E92!M86EN('-U<'!L:65R<RX@5&AE
M<V4@<W5P<&QI97)S(&-O;&QE8W1I=F5L>2!A8V-O=6YT960@9F]R(#@T)2!O
M9B!D<G5G(&%N9"!C:&5M:6-A;"!P=7)C:&%S97,@9'5R:6YG('1H90T*>65A
M<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"X\+W`^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-V-F8V)F-5]B9#1F7S0W.3!?
M83<Y.5\X-30Q9&0T.&1A838-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO83=C9F-B9C5?8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V+U=O<FMS
M:&5E=',O4VAE970R,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-U8G-E<75E;G0@179E;G1S/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U8G-E<75E;G0@179E
M;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&(^3D]412`Q-BX@4U5"4T51545.5"!%5D5.5%,@/"]B/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!H87,@<&5R9F]R
M;65D(&%N(&5V86QU871I;VX@;V8-"F5V96YT<R!O8V-U<G)I;F<@<W5B<V5Q
M=65N="!T;R!$96-E;6)E<B`S,2P@,C`Q-"!T:')O=6=H('1H92!F:6QI;F<@
M9&%T92!O9B!T:&ES($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q,"U+("AT:&4@
M)B,Q-#<[06YN=6%L#0I297!O<G0F(S$T.#LI+B!"87-E9"!O;B!I=',@979A
M;'5A=&EO;BP@;F]T:&EN9R!O=&AE<B!T:&%N('1H92!E=F5N=',@9&5S8W)I
M8F5D(&)E;&]W(&YE961S('1O(&)E(&1I<V-L;W-E9"X\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
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M=&@@86X@97AE<F-I<V4@<')I8V4@;V8@)#4N.3(U+CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY);B!*86YU87)Y(#(P,34L('1H92!#;VUP
M86YY(&ES<W5E9"`X+#4R,2!S:&%R97,-"F]F(&ET<R!C;VUM;VX@<W1O8VL@
M:6X@8V]N;F5C=&EO;B!W:71H(%)357,@=VAI8V@@:&%D(&)E96X@87=A<F1E
M9"!T;R!A(&YO;BUE;7!L;WEE92!D:7)E8W1O<B!A;F0@=F5S=&5D+"!B=70@
M=V5R92!N;W0@:7-S=65D('5N=&EL#0IT:&4@<F5S:6=N871I;VX@;V8@=&AE
M(&1I<F5C=&]R(&]N($IA;G5A<GD@,2P@,C`Q-2X\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^3VX@2F%N=6%R>2`Q+"`R,#$U+"!T:&4@0V]M
M<&%N>2!C;VUP;&5T960@=&AE#0IA8W%U:7-I=&EO;B!O9B!A;&P@;V8@=&AE
M(&]U='-T86YD:6YG(&-A<&ET86P@<W1O8VL@;V8@4&%R:R!F<F]M('1H92!P
M<F5V:6]U<R!O=VYE<G,@*'1H92`F(S$T-SM087)K(%-E;&QE<G,L)B,Q-#@[
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M*'1H92`F(S$T-SM087)K(%!U<F-H87-E($%G<F5E;65N="8C,30X.RDN#0I0
M87)K(&ES(&$@8V]M<&]U;F1I;F<@<&AA<FUA8WD@86-C<F5D:71E9"!B>2!T
M:&4@4&AA<FUA8WD@0V]M<&]U;F1I;F<@06-C<F5D:71A=&EO;B!";V%R9"!A
M;F0@:7,@;&]C871E9"!I;B!)<G9I;F4L($-A;&EF;W)N:6$N#0I/;B!*86YU
M87)Y(#$L(#(P,34@*'1H92`F(S$T-SM087)K($-L;W-I;F<@1&%T928C,30X
M.RDL(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@8VQO<VEN9R!O9B!T:&4@4&%R
M:R!!8W%U:7-I=&EO;B`H=&AE("8C,30W.U!A<FL-"D-L;W-I;F<F(S$T.#LI
M+"!T:&4@0V]M<&%N>2!P86ED('1O('1H92!087)K(%-E;&QE<G,@86X@86=G
M<F5G871E(&-A<V@@<'5R8VAA<V4@<')I8V4@;V8@)#,L,#`P+#`P,"P@;F5T
M(&]F(&9E97,@86YD(&5X<&5N<V5S+`T*<W5B:F5C="!T;R!A9&IU<W1M96YT
M(&)A<V5D(&]N('1H92!F:6YA;"!C86QC=6QA=&EO;B!O9B!087)K)B,Q-#8[
M<R!W;W)K:6YG(&-A<&ET86P@86YD(&-E<G1A:6X@;W1H97(@9FEN86YC:6%L
M(&EN9F]R;6%T:6]N+"!A;F0-"FES<W5E9"!T;R!T:&4@4&%R:R!396QL97)S
M(#8S+#4R-2!S:&%R97,@;V8@=&AE($-O;7!A;GDF(S$T-CMS(&-O;6UO;B!S
M=&]C:RP@=F%L=65D(&%T("0U,#`L,#`P(&)A<V5D(&]N('1H92!A=F5R86=E
M(&-L;W-I;F<@<')I8V4-"F]F('1H92!C;VUM;VX@<W1O8VL@9F]R('1H92`Q
M,"!T<F%D:6YG(&1A>7,@<')E8V5D:6YG('1H92!087)K($-L;W-I;F<N($EN
M(&%D9&ET:6]N+"!T:&4@0V]M<&%N>2!I<R!O8FQI9V%T960@=&\@;6%K92`Q
M,B!Q=6%R=&5R;'D-"F-A<V@@<&%Y;65N=',@=&\@=&AE(%!A<FL@4V5L;&5R
M<R!C;VQL96-T:79E;'D@;V8@)#4S+#$R-2!E86-H(&]V97(@=&AE('1H<F5E
M('EE87)S(&9O;&QO=VEN9R!T:&4@4&%R:R!#;&]S:6YG+"!T;W1A;&EN9R`D
M-C,W+#4P,"X-"E1H92!087)K(%-E;&QE<G,@:&%V92!T:&4@;W!T:6]N('1O
M(')E8V5I=F4@=&AE(&QA<W0@<VEX(&]F('-U8V@@<75A<G1E<FQY('!A>6UE
M;G1S+"!T;W1A;&EN9R!U<"!T;R!A;B!A9V=R96=A=&4@;V8@)#,Q."PW-3`L
M(&EN#0IT:&4@9F]R;2!O9B`V+#<T.2!S:&%R97,@;V8@=&AE($-O;7!A;GDF
M(S$T-CMS(&-O;6UO;B!S=&]C:R!F;W(@96%C:"!S=6-H('!A>6UE;G0N/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN(&-O;FYE8W1I;VX@
M=VET:"!T:&4@4&%R:R!!8W%U:7-I=&EO;BP@;VYE#0IO9B!T:&4@4&%R:R!3
M96QL97)S+"!$96YN:7,@4V%A9&5H+"!E;G1E<F5D(&EN=&\@86X@96UP;&]Y
M;65N="!A9W)E96UE;G0@=VET:"!T:&4@0V]M<&%N>2P@969F96-T:79E(&%S
M(&]F($IA;G5A<GD@,2P@,C`Q-2P@=&\-"F%C="!A<R!396YI;W(@1&ER96-T
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M(&]F(&%P<')O>&EM871E;'D-"C0L-3`P('-Q=6%R92!F965T(&]F(&QA8B!A
M;F0@;V9F:6-E('-P86-E+B!4:&4@;6]N=&AL>2!R96YT(&%M;W5N="!I<R`D
M.2PW.#@@86YD(&EN8VQU9&5S(&%N;G5A;"!I;F-R96%S97,@;V8@87!P<F]X
M:6UA=&5L>2`S)2X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M26X@1F5B<G5A<GD@,C`Q-2P@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O#0IA
M(&QE87-E(&%G<F5E;65N="!F;W(@87!P<F]X:6UA=&5L>2`X+#8P,B!S<75A
M<F4@9F5E="!O9B!L86(L('=A<F5H;W5S92!A;F0@;V9F:6-E('-P86-E(&EN
M(%)O>&)U<GDL($YE=R!*97)S97DN(%1H92!C=7)R96YT(&QE87-E#0IT97)M
M(&5X<&ER97,@;VX@2G5L>2`S,2P@,C`R,BX@5&AE(&UO;G1H;'D@<F5N="!A
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M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!&96)R=6%R>2`R,#$U
M+"!T:&4@0V]M<&%N>2!A<'!O:6YT960@06YD<F5W#0I2+B!";VQL)B,Q-#8[
M<R!A<R!I=',@0VAI968@1FEN86YC:6%L($]F9FEC97(L(&%N9"!E;G1E<F5D
M(&EN=&\@86X@86UE;F1E9"!A;F0@<F5S=&%T960@96UP;&]Y;65N="!A9W)E
M96UE;G0@*'1H92`F(S$T-SM#1D\@16UP;&]Y;65N=`T*06=R965M96YT)B,Q
M-#@[*2!W:71H($UR+B!";VQL+"!W:&EC:"!A;65N9',L(')E<W1A=&5S(&%N
M9"!S=7!E<G-E9&5S(&EN(&ET<R!E;G1I<F5T>2!-<BX@0F]L;"8C,30V.W,@
M<')I;W(@96UP;&]Y;65N="!A9W)E96UE;G0-"G=I=&@@=&AE($-O;7!A;GD@
M9&%T960@1F5B<G5A<GD@,2P@,C`Q,BX@5&AE($-&3R!%;7!L;WEM96YT($%G
M<F5E;65N="!P<F]V:61E<R!F;W(@=&AE(&9O;&QO=VEN9RP@86UO;F<@;W1H
M97(@=&AI;F=S.B`H:2D@82!T97)M#0IO9B!T:')E92!Y96%R<RP@*&EI*2!A
M;B!A;FYU86P@8F%S92!S86QA<GD@;V8@)#(P,"PP,#`[("AI:6DI(&5L:6=I
M8FEL:71Y('1O(')E8V5I=F4@86X@86YN=6%L(&-A<V@@8F]N=7,@:6X@86X@
M86UO=6YT(&5Q=6%L('1O#0IA="!L96%S="`R,"4@;V8@:&ES('1H96XM8W5R
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M('1H92!S871I<V9A8W1I;VX@;V8@8V5R=&%I;B!C;VYD:71I;VYS+`T*8V]N
M=&EN=65D('!A>6UE;G1S(&]F(&AI<R!T:&5N+6-U<G)E;G0@86YN=6%L(&)A
M<V4@<V%L87)Y(&9O<B!S:7@@;6]N=&AS(&9O;&QO=VEN9R!T:&4@9&%T92!O
M9B!H:7,@=&5R;6EN871I;VX@86YD(&$@;'5M<"US=6T@<&%Y;65N=`T*97%U
M86P@=&\@=&AE('!R;RUR871E9"!P;W)T:6]N(&]F(&AI<R!M:6YI;75M(&%N
M;G5A;"!C87-H(&)O;G5S(&9O<B!T:&4@=&AE;BUC=7)R96YT('EE87([(&%N
M9"`H=BD@:6X@=&AE(&5V96YT(&]F(&$@475A;&EF>6EN9PT*5&5R;6EN871I
M;VX@;V8@37(N($)O;&P@;VX@;W(@=VET:&EN(#$R(&UO;G1H<R!F;VQL;W=I
M;F<@82!C:&%N9V4@;V8@8V]N=')O;"P@37(N($)O;&P@=VEL;"!B92!E;G1I
M=&QE9"!T;R!R96-E:79E+"!S=6)J96-T('1O#0IT:&4@<V%T:7-F86-T:6]N
M(&]F(&-E<G1A:6X@8V]N9&ET:6]N<RP@8V]N=&EN=65D('!A>6UE;G1S(&]F
M(&AI<R!T:&5N+6-U<G)E;G0@86YN=6%L(&)A<V4@<V%L87)Y(&9O<B!S:7@@
M;6]N=&AS(&9O;&QO=VEN9R!T:&4-"F1A=&4@;V8@:&ES('1E<FUI;F%T:6]N
M+"!A(&QU;7`M<W5M('!A>6UE;G0@97%U86P@=&\@=&AE('!R;RUR871E9"!P
M;W)T:6]N(&]F(&AI<R!M:6YI;75M(&%N;G5A;"!C87-H(&)O;G5S(&9O<B!T
M:&4@=&AE;BUC=7)R96YT#0IY96%R+"!A;F0@:6UM961I871E('9E<W1I;F<@
M;V8@86QL(&]F(&AI<R!O=71S=&%N9&EN9R!E<75I='D@87=A<F1S(&%S(&]F
M('1H92!D871E(&]F(&AI<R!T97)M:6YA=&EO;BX@26X@8V]N;F5C=&EO;B!W
M:71H($UR+B!";VQL)B,Q-#8[<PT*87!P;VEN=&UE;G0@87,@=&AE($-O;7!A
M;GDF(S$T-CMS($-H:65F($9I;F%N8VEA;"!/9F9I8V5R+"!T:&4@0V]M<&%N
M>28C,30V.W,@0F]A<F0@;V8@1&ER96-T;W)S(&AA<R!G<F%N=&5D('1H92!F
M;VQL;W=I;F<@97%U:71Y#0IA=V%R9',@=&\@37(N($)O;&PL(&EN(&5A8V@@
M8V%S92!U;F1E<B!T:&4@4&QA;CH@*&DI(&$@<&5R9F]R;6%N8V4M8F%S960@
M<F5S=')I8W1E9"!S=&]C:R!U;FET(&%W87)D(&]F('5P('1O(#$U-RPU,#`@
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M*2!A(%)352!A=V%R9"!O9B!U<"!T;R`S,"PP,#`@<VAA<F5S(&]F('1H90T*
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M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/DEN($9E8G)U87)Y(#(P
M,34L('1H92!#;VUP86YY(&%P<&]I;G1E9"!*;VAN#0I0+B!386AA<F5K(&%S
M(&]F('1H92!#;VUP86YY)B,Q-#8[<R!#:&EE9B!#;VUM97)C:6%L($]F9FEC
M97(L(&5F9F5C=&EV92!A<R!O9B!&96)R=6%R>2`Q+"`R,#$U+"!A;F0@96YT
M97)E9"!I;G1O(&%N(&5M<&QO>6UE;G0-"F%G<F5E;65N="`H=&AE("8C,30W
M.T-#3R!%;7!L;WEM96YT($%G<F5E;65N="8C,30X.RD@=VET:"!-<BX@4V%H
M87)E:RX@5&AE($-#3R!%;7!L;WEM96YT($%G<F5E;65N="!P<F]V:61E<R!F
M;W(@=&AE(&9O;&QO=VEN9RP-"F%M;VYG(&]T:&5R('1H:6YG<SH@*&DI(&$@
M=&5R;2!O9B!T:')E92!Y96%R<RP@*&EI*2!A;B!A;FYU86P@8F%S92!S86QA
M<GD@;V8@)#(R,"PP,#`[("AI:6DI(&5L:6=I8FEL:71Y('1O(')E8V5I=F4@
M86X@86YN=6%L#0IC87-H(&)O;G5S(&EN(&%N(&%M;W5N="!E<75A;"!T;R!A
M('1A<F=E="!O9B`U,"4@;V8@:&ES('1H96XM8W5R<F5N="!A;FYU86P@8F%S
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M('=I=&AI;B`Q,B!M;VYT:',@9F]L;&]W:6YG(&$@8VAA;F=E(&]F(&-O;G1R
M;VPL('1H96X@37(N(%-A:&%R96L@=VEL;"!B92!E;G1I=&QE9"!T;R!R96-E
M:79E+"!S=6)J96-T('1O('1H92!S871I<V9A8W1I;VX-"F]F(&-E<G1A:6X@
M8V]N9&ET:6]N<RP@8V]N=&EN=65D('!A>6UE;G1S(&]F(&AI<R!T:&5N+6-U
M<G)E;G0@86YN=6%L(&)A<V4@<V%L87)Y(&9O<B`Q,B!M;VYT:',@9F]L;&]W
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M4V%H87)E:RP@:6X@96%C:"!C87-E('5N9&5R('1H92!0;&%N.B`H:2D@82!S
M=&]C:R!O<'1I;VX@87=A<F0@;V8@=7`@=&\@.3`L,#`P('-H87)E<R!O9B!T
M:&4@0V]M<&%N>28C,30V.W,-"F-O;6UO;B!S=&]C:RP@=VAI8V@@:&%S(&$@
M=&5R;2!O9B`Q,"!Y96%R<R!A;F0@86X@97AE<F-I<V4@<')I8V4@;V8@)#<N
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M('5P;VX@=&AE(&]C8W5R<F5N8V4@;V8@82!C:&%N9V4@:6X@8V]N=')O;"`H
M87,@9&5F:6YE9"!I;B!T:&4@4&QA;BDL(&%N9"!I<R!S=6)J96-T('1O('1H
M92!#;VUP86YY)B,Q-#8[<PT*<W1A;F1A<F0@9F]R;2!O9B!A=V%R9"!A9W)E
M96UE;G0@9F]R('-T;V-K(&]P=&EO;G,@9W)A;G1E9"!U;F1E<B!T:&4@4&QA
M;BP@86YD("AI:2D@82!24U4@87=A<F0@;V8@=7`@=&\@,S`L,#`P('-H87)E
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M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5TM!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I
M;F<@4&]L:6-I97,@*%!O;&EC:65S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P
M/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY"
M87-I<R!O9B!0<F5S96YT871I;VX\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^3VX@1F5B<G5A<GD@,C@L(#(P
M,3(L('1H92!#;VUP86YY(&5F9F5C=&5D#0IA(&]N92UF;W(M96EG:'0@<F5V
M97)S92!S=&]C:R!S<&QI="!A;F0@;VX@1F5B<G5A<GD@-RP@,C`Q,RP@=&AE
M($-O;7!A;GD@969F96-T960@82!O;F4M9F]R+69I=F4@<F5V97)S92!S=&]C
M:R!S<&QI="X@06QL('-H87)E#0IA;F0@<&5R('-H87)E(&%M;W5N=',@:6X@
M=&AE<V4@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S(&%N9"!N
M;W1E<R!R969L96-T('1H92!E9F9E8W1S(&]F('1H97-E(')E=F5R<V4@<W1O
M8VL@<W!L:71S+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V
M,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/DEM<')I;6ES(&AA<R!P<F5P87)E9"!T:&4@86-C;VUP
M86YY:6YG#0IC;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@:6X@
M86-C;W)D86YC92!W:71H(&%C8V]U;G1I;F<@<')I;F-I<&QE<R!G96YE<F%L
M;'D@86-C97!T960@:6X@=&AE(%5N:71E9"!3=&%T97,@;V8@06UE<FEC80T*
M*"8C,30W.T=!05`F(S$T.#LI+B!4:&4@86-C;VUP86YY:6YG(&-O;G-O;&ED
M871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!I;F-L=61E('1H92!A8V-O=6YT
M<R!O9B!T:&4@0V]M<&%N>2!A;F0@:71S('=H;VQL>2UO=VYE9`T*<W5B<VED
M:6%R>2X@06QL(&EN=&5R8V]M<&%N>2!A8V-O=6YT<R!A;F0@=')A;G-A8W1I
M;VYS(&AA=F4@8F5E;B!E;&EM:6YA=&5D(&EN(&-O;G-O;&ED871I;VXN/"]P
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0G5S:6YE<W,@0V]M8FEN871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\
M<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY"=7-I;F5S
M<R!#;VUB:6YA=&EO;G,\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
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M87)E(&YO="!L:6UI=&5D('1O.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L
M=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S92<^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`R-'!X.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@=VED=&@Z(#(T<'@[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(SDV-SD[/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
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M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXF(SDV-SD[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SYD:7-C;W5N="!R871E<R!U=&EL:7IE9"!I;B!V86QU871I;VX@97-T:6UA
M=&5S+CPO9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E5N86YT:6-I<&%T960@979E
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M=`T*8V]N<VED97)A=&EO;B!O<B!T:&4@;V-C=7)R96YC92!O9B!E=F5N=',@
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M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M<V5A<F-H(&%N9"!$979E;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY297-E87)C:"!A;F0@1&5V
M96QO<&UE;G0\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
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M<W1S(')E;&%T960@=&\@8VQI;FEC86P@=')I86QS+"!C;VYT<F%C=`T*<V5R
M=FEC97,@86YD(&]U='-O=7)C960@8V]N=')A8W1S+CPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5L;&5C
M='5A;"!0<F]P97)T>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y)SX\8CY);G1E;&QE8W1U86P@4')O<&5R='D\+V(^
M/&D^(#PO:3X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-
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M:'1S(&)E9VEN;FEN9R!I;B!T:&4@9FES8V%L('EE87(@,C`Q-2X@0V]S=',@
M;V8@;6%I;G1A:6YI;F<-"FEN=&5L;&5C='5A;"!P<F]P97)T>2!R:6=H=',@
M87)E(&5X<&5N<V5D(&%S(&EN8W5R<F5D+CPO<#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=64@4F5C;V=N
M:71I;VX@86YD($1E9F5R<F5D(%)E=F5N=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-
M"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^4F5V96YU92!296-O
M9VYI=&EO;B!A;F0@1&5F97)R960@4F5V96YU93PO8CX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE($-O;7!A;GD@<F5C;V=N:7IE<R!R
M979E;G5E<R!W:&5N(&%L;"!O9@T*=&AE(&9O;&QO=VEN9R!C<FET97)I82!H
M879E(&)E96X@;65T.B`H,2D@<&5R<W5A<VEV92!E=FED96YC92!O9B!A;B!A
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M<G1E<B!O9B`R,#$T+"!W:&EC:"!I;F-L=61E('-A;&5S(&]F(&-E<G1A:6X@
M;V8@=&AE($-O;7!A;GDF(S$T-CMS('!R;W!R:65T87)Y(&-O;7!O=6YD960@
M9')U9R!F;W)M=6QA=&EO;G,-"F%N9"!C97)T86EN(&YO;BUP<F]P<FEE=&%R
M>2!F;W)M=6QA=&EO;G,N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/CQI/E!R;V1U8W0@4F5V96YU97,\+VD^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P
M+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/D1E=&5R;6EN871I;VX@;V8@8W)I=&5R:6$@*#,I
M(&%N9"`H-"D@:7,@8F%S960-"F]N(&UA;F%G96UE;G0F(S$T-CMS(&IU9&=M
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M(')E<75I<F5D+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\
M:3Y,:6-E;G-E(%)E=F5N=65S/"]I/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
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M="!A<G)A;F=E;65N=',N/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GDG/DYO;BUR969U;F1A8FQE(&9E97,@=&AA="!A<F4@;F]T(&-O;G1I;F=E
M;G0-"F]N(&%N>2!F=71U<F4@<&5R9F]R;6%N8V4@8GD@=&AE($-O;7!A;GD@
M86YD(')E<75I<F4@;F\@8V]N<V5Q=65N=&EA;"!C;VYT:6YU:6YG(&EN=F]L
M=F5M96YT(&]N('1H92!P87)T(&]F('1H92!#;VUP86YY+"!A<F4@<F5C;V=N
M:7IE9`T*87,@<F5V96YU92!W:&5N('1H92!L:6-E;G-E('1E<FT@8V]M;65N
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M;65D(&)Y('1H92!#;VUP86YY+`T*=&AE;B!S=6-H(&YO;BUR969U;F1A8FQE
M(&9E97,@87)E(&1E9F5R<F5D(&%N9"!R96-O9VYI>F5D(&]V97(@=&AE('!E
M<FEO9"!O9B!C;VYT:6YU:6YG(&EN=F]L=F5M96YT+B!'=6%R86YT965D(&UI
M;FEM=6T@86YN=6%L#0IR;WEA;'1I97,@87)E(')E8V]G;FEZ960@;VX@82!S
M=')A:6=H="UL:6YE(&)A<VES(&]V97(@=&AE(&%P<&QI8V%B;&4@=&5R;2X\
M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;W-T(&]F(%-A;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL
M93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/D-O<W0@;V8@4V%L97,\+V(^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M
M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D-O<W0@;V8@<V%L97,@
M:6YC;'5D97,@9&ER96-T(&%N9"!I;F1I<F5C=`T*8V]S=',@=&\@;6%N=69A
M8W1U<F4@9F]R;75L871I;VYS(&%N9"!O=&AE<B!P<F]D=6-T<R!S;VQD+"!I
M;F-L=61I;F<@86-T:79E('!H87)M86-E=71I8V%L(&EN9W)E9&EE;G1S+"!P
M97)S;VYN96P@8V]S=',L('!A8VMA9VEN9RP-"G-T;W)A9V4L(')O>6%L=&EE
M<R`H<V5E($YO=&4@,30I+"!S:&EP<&EN9R!A;F0@:&%N9&QI;F<@8V]S=',@
M86YD('1H92!W<FET92UO9F8@;V8@;V)S;VQE=&4@:6YV96YT;W)Y+CPO<#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DEN8V]M92!487AE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY);F-O;64@5&%X97,\
M+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D%S('!A<G0@
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M871E;65N="!O9B!O<&5R871I;VYS+CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!A8V-O=6YT<R!F;W(@:6YC;VUE('1A
M>&5S('5N9&5R#0IT:&4@<')O=FES:6]N<R!O9B!&:6YA;F-I86P@06-C;W5N
M=&EN9R!3=&%N9&%R9',@0F]A<F0@*"8C,30W.T9!4T(F(S$T.#LI($%C8V]U
M;G1I;F<@4W1A;F1A<F1S($-O9&EF:6-A=&EO;B`H)B,Q-#<[05-#)B,Q-#@[
M*0T*-S0P+"`F(S$T-SM);F-O;64@5&%X97,F(S$T.#LL(&]R($%30R`W-#`N
M($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T+"!T:&5R92!W97)E(&YO('5N<F5C
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M(&]P97)A=&EO;G,@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@
M,C`Q-"!A;F0@,C`Q,RX@5&AE($-O;7!A;GD@:7,@<W5B:F5C="!T;R!T87AA
M=&EO;B!I;B!T:&4@56YI=&5D(%-T871E<PT*86YD($-A;&EF;W)N:6$N(%1H
M92!#;VUP86YY)B,Q-#8[<R!T87@@>65A<G,@<VEN8V4@,C`P,"!A<F4@<W5B
M:F5C="!T;R!E>&%M:6YA=&EO;B!B>2!T:&4@9F5D97)A;"!A;F0@<W1A=&4@
M=&%X(&%U=&AO<FET:65S(&1U90T*=&\@=&AE(&-A<G)Y9F]R=V%R9"!O9B!U
M;G5T:6QI>F5D(&YE="!O<&5R871I;F<@;&]S<V5S+CPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD
M($-A<V@@17%U:79A;&5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE
M/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/D-A<V@@86YD($-A<V@@
M17%U:79A;&5N=',\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG
M/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^0V%S:"!E<75I=F%L96YT<R!I;F-L=61E('-H
M;W)T+71E<FTL#0IH:6=H;'D@;&EQ=6ED(&EN=F5S=&UE;G1S('=I=&@@;6%T
M=7)I=&EE<R!O9B!T:')E92!M;VYT:',@;W(@;&5S<R!A="!T:&4@=&EM92!O
M9B!A8W%U:7-I=&EO;BX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYC96YT<F%T:6]N<R!O9B!#<F5D:70@
M4FES:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4]
M,T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P
M<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>2<^/&(^0V]N8V5N=')A=&EO;G,@;V8@0W)E9&ET(%)I
M<VL\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W
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M('1O("0R-3`L,#`P('!E<B!O=VYE<BX@070@1&5C96UB97(@,S$L(#(P,30L
M('1H92!#;VUP86YY(&AA9"!A<'!R;WAI;6%T96QY("0W+C<-"FUI;&QI;VX@
M:6X@8V%S:"!D97!O<VET<R!I;B!E>&-E<W,@;V8@1D1)0R!L:6UI=',N/"]P
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C;W5N=',@4F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^06-C;W5N=',@
M4F5C96EV86)L93PO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT
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M(&]F($1E8V5M8F5R(#,Q+"`R,#$T+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ
M(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SX\8CY);G9E;G1O<FEE<SPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);G9E;G1O<FEE<R!A<F4@<W1A
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M="!B87-I<R!O9B!I;G9E;G1O<FEE<RX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@0V]M<&%N>2!A;'-O(')E
M9W5L87)L>2!E=F%L=6%T97,-"FET<R!I;G9E;G1O<FEE<R!F;W(@97AC97-S
M('%U86YT:71I97,@86YD(&]B<V]L97-C96YC92`H97AP:7)A=&EO;BDL('1A
M:VEN9R!I;G1O(&%C8V]U;G0@<W5C:"!F86-T;W)S(&%S(&AI<W1O<FEC86P@
M86YD(&%N=&EC:7!A=&5D#0IF=71U<F4@<V%L97,@;W(@=7-E(&EN('!R;V1U
M8W1I;VX@8V]M<&%R960@=&\@<75A;G1I=&EE<R!O;B!H86YD(&%N9"!T:&4@
M<F5M86EN:6YG('-H96QF(&QI9F4@;V8@<')O9'5C=',@86YD(&%C=&EV92!P
M:&%R;6%C975T:6-A;`T*:6YG<F5D:65N=',@;VX@:&%N9"X@5&AE($-O;7!A
M;GD@97-T86)L:7-H97,@<F5S97)V97,@9F]R(&5X8V5S<R!A;F0@;V)S;VQE
M=&4@:6YV96YT;W)I97,@87,@<F5Q=6ER960@8F%S960@;VX@:71S(&%N86QY
M<V5S+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9U<FYI='5R92!A;F0@17%U:7!M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^
M/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\
M8CY&=7)N:71U<F4@86YD($5Q=6EP;65N=#PO8CX\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY&=7)N:71U<F4@86YD
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M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1V]O9'=I;&P@86YD($EN=&%N9VEB;&4@07-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P
M/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SX\8CY'
M;V]D=VEL;"!A;F0@26YT86YG:6)L92!!<W-E=',\+V(^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G
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M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@
M,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`R-'!X.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M('1O<#L@=VED=&@Z(#(T<'@[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(SDV-SD[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SYS:6=N:69I8V%N="!U;F1E<G!E<F9O<FUA;F-E(&]F('1H92!#;VUP
M86YY)B,Q-#8[<R!B=7-I;F5S<R!R96QA=&EV92!T;R!E>'!E8W1E9"!O<&5R
M871I;F<@<F5S=6QT<SL\+V9O;G0^/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@=&]P.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Y
M-C<Y.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^<VEG
M;FEF:6-A;G0@861V97)S92!E8V]N;VUI8R!A;F0@:6YD=7-T<GD@=')E;F1S
M.SPO9F]N=#X\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<CX-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXF(SDV-SD[/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SYS:6=N:69I8V%N="!D96-L:6YE(&EN('1H92!#;VUP86YY)B,Q-#8[
M<R!M87)K970@8V%P:71A;&EZ871I;VX@9F]R(&%N(&5X=&5N9&5D('!E<FEO
M9"!O9B!T:6UE(')E;&%T:79E('1O(&YE="!B;V]K('9A;'5E.R!A;F0\+V9O
M;G0^/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Y-C<Y.SPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^97AP96-T871I;VYS('1H870@82!R97!O
M<G1I;F<@=6YI="!W:6QL(&)E('-O;&0@;W(@;W1H97)W:7-E(&1I<W!O<V5D
M+B`\+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T
M:69Y)SY4:&4@9V]O9'=I;&P@:6UP86ER;65N="!T97-T(&-O;G-I<W1S#0IO
M9B!A('1W;RUS=&5P('!R;V-E<W,@87,@9F]L;&]W<SH\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY3=&5P(#$N(%1H
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M;B!E>&ES=',@=&AA=`T*=&AE(')E<&]R=&EN9R!U;FET)B,Q-#8[<R!G;V]D
M=VEL;"!M87D@8F4@:6UP86ER960@86YD('1H92!#;VUP86YY('1H96X@<&5R
M9F]R;7,@=&AE('-E8V]N9"!S=&5P(&]F('1H92!I;7!A:7)M96YT('1E<W0N
M($EF('1H90T*9F%I<B!V86QU92!O9B!A(')E<&]R=&EN9R!U;FET(&5X8V5E
M9',@:71S(&-A<G)Y:6YG(&%M;W5N="P@;F\@9G5R=&AE<B!A;F%L>7-I<R!I
M<R!R97%U:7)E9"X\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q
M-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY3=&5P(#(N($EF(&9U<G1H97(@86YA;'ES:7,@:7,@
M<F5Q=6ER960L#0IT:&4@0V]M<&%N>2!C;VUP87)E<R!T:&4@:6UP;&EE9"!F
M86ER('9A;'5E(&]F('1H92!R97!O<G1I;F<@=6YI="8C,30V.W,@9V]O9'=I
M;&PL(&1E=&5R;6EN960@8GD@86QL;V-A=&EN9R!T:&4@<F5P;W)T:6YG('5N
M:70F(S$T-CMS#0IF86ER('9A;'5E('1O(&%L;"!O9B!I=',@87-S971S(&%N
M9"!I=',@;&EA8FEL:71I97,@:6X@82!M86YN97(@<VEM:6QA<B!T;R!A('!U
M<F-H87-E('!R:6-E(&%L;&]C871I;VXL('1O(&ET<R!C87)R>6EN9R!A;6]U
M;G0N#0I)9B!T:&4@8V%R<GEI;F<@86UO=6YT(&]F('1H92!R97!O<G1I;F<@
M=6YI="8C,30V.W,@9V]O9'=I;&P@97AC965D<R!I=',@9F%I<B!V86QU92P@
M86X@:6UP86ER;65N="!L;W-S('=I;&P@8F4@<F5C;V=N:7IE9"!I;@T*86X@
M86UO=6YT(&5Q=6%L('1O('1H92!E>&-E<W,N/"]P/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26UP86ER;65N="!O
M9B!,;VYG+4QI=F5D($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA
M<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^26UP86ER;65N="!O
M9B!,;VYG+4QI=F5D($%S<V5T<SPO8CX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY,;VYG+6QI=F5D(&%S<V5T<RP@
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M9"!I<R!M96%S=7)E9`T*8GD@82!C;VUP87)I<V]N(&]F('1H92!C87)R>6EN
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M;W5N=`T*8GD@=VAI8V@@=&AE(&-A<G)Y:6YG(&%M;W5N="!O9B!T:&4@87-S
M970@97AC965D<R!T:&4@9F%I<B!V86QU92!O9B!T:&4@87-S970N($%S<V5T
M<R!T;R!B92!D:7-P;W-E9"!O9B!W;W5L9"!B92!S97!A<F%T96QY('!R97-E
M;G1E9`T*:6X@=&AE(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T(&%N9"!R
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M(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T+"!I9B!M871E<FEA;"X\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY$
M=7)I;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+`T*,C`Q-"!A;F0@
M,C`Q,RP@=&AE($-O;7!A;GD@9&ED(&YO="!R96-O9VYI>F4@86YY(&EM<&%I
M<FUE;G0@;V8@:71S(&QO;F<M;&EV960@87-S971S+CPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D
M(%)E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE
M/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@
M,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/CQB/D1E9F5R<F5D(%)E;G0@/"]B/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#
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M<F5N="X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y&86ER(%9A;'5E($UE87-U<F5M96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^
M/&(^1F%I<B!686QU92!-96%S=7)E;65N=',\+V(^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E
M.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<CX-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@=VED=&@Z(#(T<'@[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXF(SDV-SD[/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY,979E;"`Q.B!!<'!L:65S
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M+CPO9F]N=#X\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!T;W`[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)B,Y-C<Y.SPO9F]N=#X\+W1D/@T*("`@
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M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@=&]P.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Y-C<Y
M.SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J
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M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!="!$96-E;6)E<B`S
M,2P@,C`Q-"!A;F0@,C`Q,RP@=&AE#0I#;VUP86YY(&1I9"!N;W0@:&%V92!A
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M=&EV92!F86ER('9A;'5E<RX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RU"87-E9"!#;VUP96YS871I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$
M)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T
M)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/CQB/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO8CX\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
M)SY!;&P@<W1O8VLM8F%S960@<&%Y;65N=',@=&\@96UP;&]Y965S+`T*9&ER
M96-T;W)S(&%N9"!C;VYS=6QT86YT<RP@:6YC;'5D:6YG(&=R86YT<R!O9B!S
M=&]C:R!O<'1I;VYS+"!W87)R86YT<RP@<F5S=')I8W1E9"!S=&]C:R!U;FET
M<R`H)B,Q-#<[4E-5<R8C,30X.RD@86YD(')E<W1R:6-T960-"G-T;V-K+"!A
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M9B!G<F%N="!A;F0@<F5V:7-E9"P@:68@;F5C97-S87)Y+`T*:68@=&AE(&%C
M='5A;"!E9F9E8W0@9&EF9F5R<R!F<F]M('1H;W-E(&5S=&EM871E<RX\+W`^
M#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4
M:&4@0V]M<&%N>28C,30V.W,@86-C;W5N=&EN9R!P;VQI8WD-"F9O<B!E<75I
M='D@:6YS=')U;65N=',@:7-S=65D('1O(&-O;G-U;'1A;G1S(&%N9"!V96YD
M;W)S(&EN(&5X8VAA;F=E(&9O<B!G;V]D<R!A;F0@<V5R=FEC97,@9F]L;&]W
M<R!T:&4@1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A<F1S#0I";V%R9"`H
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M9&%T92!F;W(@=&AE(&5S=&EM871E9`T*9F%I<B!V86QU92!O9B!T:&4@97%U
M:71Y(&EN<W1R=6UE;G1S(&ES<W5E9"!I<R!T:&4@96%R;&EE<B!O9B`H:2D@
M=&AE(&1A=&4@870@=VAI8V@@82!C;VUM:71M96YT(&9O<B!P97)F;W)M86YC
M92!B>2!T:&4@8V]N<W5L=&%N=`T*;W(@=F5N9&]R(&ES(')E86-H960@;W(@
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M=&5D(&)A;&%N8V4@<VAE971S+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A<VEC(&%N9"!$:6QU=&5D($YE
M="!,;W-S('!E<B!#;VUM;VX@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP
M('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/D)A<VEC(&%N
M9"!$:6QU=&5D($YE="!,;W-S('!E<B!#;VUM;VX-"E-H87)E/"]B/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/D)A
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M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y
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M=V5R92`S+#`R-"PR,3<@86YD(#,L-3,Y+#@P,`T*870@1&5C96UB97(@,S$L
M(#(P,30@86YD(#(P,3,L(')E<W!E8W1I=F5L>2P@86YD(&%R92!E>&-L=61E
M9"!F<F]M('1H92!C86QC=6QA=&EO;B!O9B!D:6QU=&5D(&YE="!L;W-S('!E
M<B!S:&%R92!F;W(@86QL('!E<FEO9',-"G!R97-E;G1E9"!B96-A=7-E('1H
M92!E9F9E8W0@:7,@86YT:2UD:6QU=&EV92X@0V]M;6]N('-T;V-K(&5Q=6EV
M86QE;G1S(&%T($1E8V5M8F5R(#,Q+"`R,#$T(&EN8VQU9&4@,C<L,C$X('-H
M87)E<R!O9B!C;VUM;VX@<W1O8VL-"G5N9&5R;'EI;F<@4E-5<RP@87=A<F1E
M9"!T;R!D:7)E8W1O<G,@=&AA="!H879E('9E<W1E9"P@8G5T('1H92!I<W-U
M86YC92!A;F0@9&5L:79E<GD@;V8@=&AE<V4@<VAA<F5S(&%R92!D969E<G)E
M9"!U;G1I;"!T:&4@9&ER96-T;W(-"G)E<VEG;G,N/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE(&9O;&QO=VEN
M9R!T86)L92!S:&]W<R!T:&4@8V]M<'5T871I;VX-"F]F(&)A<VEC(&%N9"!D
M:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R92!O9B!C;VUM;VX@<W1O8VL@9F]R
M('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q,SH\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS
M1"=F;VYT.B`Q,'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N<RU397)I9CL@
M=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY&;W(@=&AE/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D9O
M<B!T:&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY996%R($5N9&5D
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/EEE87(@16YD960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5C96UB97(@
M,S$L(#(P,30\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/D1E8V5M8F5R(#,Q+"`R,#$S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#4X)3L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/DYU;65R871O<B`F(S$U,#L@;F5T(&QO<W,\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3@E.R!B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q,"PQ,3@L,3`S/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,3@E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B@W+#8T,RPQ,C0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO
M9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5N;VUI
M;F%T;W(@)B,Q-3`[('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F('-H87)E
M<R!O=71S=&%N9&EN9RP@8F%S:6,@86YD(&1I;'5T960\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N
M-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L
M:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^.2PQ,S(L.3@Y/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXX
M+#8U-BPX,C(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/CQB/DYE="!L;W-S('!E<B!S:&%R92P@8F%S:6,@86YD(&1I
M;'5T960\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B@Q+C$Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@P+C@X/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI
M/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E5S92!O9B!%<W1I;6%T97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^
M#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/CQB/E5S
M92!O9B!%<W1I;6%T97,\+V(^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU
M:6XG/B8C,38P.SPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
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M(&%C8V]U;G1S+`T*<F5A;&EZ86)I;&ET>2!O9B!I;G9E;G1O<FEE<RP@=F%L
M=6%T:6]N(&]F(&1E9F5R<F5D('1A>&5S+"!G;V]D=VEL;"!A;F0@:6YT86YG
M:6)L92!A<W-E=',L(')E8V]V97)A8FEL:71Y(&]F(&QO;F<M;&EV960@87-S
M971S#0IA;F0@9V]O9'=I;&PL('9A;'5A=&EO;B!O9B!C;VYT:6YG96YT(&%C
M<75I<VET:6]N(&]B;&EG871I;VYS+"!A;F0@=F%L=6%T:6]N(&]F('-T;V-K
M+6)A<V5D(&-O;7!E;G-A=&EO;B!I<W-U960@=&\@96UP;&]Y965S(&%N9`T*
M;F]N+65M<&QO>65E<RX@06-T=6%L(')E<W5L=',@8V]U;&0@9&EF9F5R(&9R
M;VT@=&AO<V4@97-T:6UA=&5S+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8VQA<W-I9FEC871I;VYS/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G
M:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SX\8CY296-L87-S:69I8V%T:6]N<SPO8CX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY#97)T86EN('!R
M:6]R('!E<FEO9"!I=&5M<R!A;F0@86UO=6YT<PT*:&%V92!B965N(')E8VQA
M<W-I9FEE9"!T;R!C;VYF;W)M('1O('1H92!C;&%S<VEF:6-A=&EO;G,@=7-E
M9"!T;R!P<F5P87)E('1H92!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E
M;65N=',@9F]R('1H92!Y96%R(&5N9&5D#0I$96-E;6)E<B`S,2P@,C`Q-"X@
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M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V5N=&QY($%D;W!T
M960@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-
M"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^/&(^4F5C
M96YT;'D@061O<'1E9"!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]B/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG
M/DEN($IU;F4@,C`Q-"P@=&AE($9!4T(@:7-S=65D(&%N($%C8V]U;G1I;F<-
M"E-T86YD87)D<R!5<&1A=&4@*"8C,30W.T%3528C,30X.RD@3F\N(#(P,30M
M,3`L("8C,30W.T5L:6UI;F%T:6]N(&]F($-E<G1A:6X@1FEN86YC:6%L(%)E
M<&]R=&EN9R!297%U:7)E;65N=',L($EN8VQU9&EN9R!A;@T*06UE;F1M96YT
M('1O(%9A<FEA8FQE($EN=&5R97-T($5N=&ET:65S)B,Q-#@[+B!4:&4@86UE
M;F1M96YT<R!I;B!T:&ES('5P9&%T92!R96UO=F4@=&AE(&1E9FEN:71I;VX@
M;V8@82!D979E;&]P;65N="!S=&%G92!E;G1I='D-"F9R;VT@05-#(%1O<&EC
M(#DQ-2P@)B,Q-#<[1&5V96QO<&UE;G0@4W1A9V4@16YT:71I97,F(S$T.#LL
M('1H97)E8GD@<F5M;W9I;F<@9G)O;2!'04%0('1H92!D:7-T:6YC=&EO;B!B
M971W965N(&1E=F5L;W!M96YT('-T86=E#0IE;G1I=&EE<R!A;F0@;W1H97(@
M<F5P;W)T:6YG(&5N=&ET:65S+B!);B!A9&1I=&EO;BP@=&AE(&%M96YD;65N
M=',@96QI;6EN871E('1H92!R97%U:7)E;65N=',@9F]R(&1E=F5L;W!M96YT
M('-T86=E(&5N=&ET:65S('1O#0HH,2D@<')E<V5N="!I;F-E<'1I;VXM=&\M
M9&%T92!I;F9O<FUA=&EO;B!I;B!T:&4@<W1A=&5M96YT<R!O9B!O<&5R871I
M;VYS+"!C87-H(&9L;W=S+"!A;F0@<W1O8VMH;VQD97(F(S$T-CMS(&5Q=6ET
M>2P@*#(I(&QA8F5L#0IT:&4@9FEN86YC:6%L('-T871E;65N=',@87,@=&AO
M<V4@;V8@82!D979E;&]P;65N="!S=&%G92!E;G1I='DL("@S*2!D:7-C;&]S
M92!A(&1E<V-R:7!T:6]N(&]F('1H92!D979E;&]P;65N="!S=&%G92!A8W1I
M=FET:65S#0II;B!W:&EC:"!T:&4@96YT:71Y(&ES(&5N9V%G960L(&%N9"`H
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M($1E8V5M8F5R(#$U+"`R,#$T+"!W:71H(&5A<FQY(&%P<&QI8V%T:6]N(&]F
M('1H92!A;65N9&UE;G1S('!E<FUI='1E9"X@5&AE($-O;7!A;GDF(S$T-CMS
M('!H87)M86-Y(&]P97)A=&EO;G,@8V]M;65N8V5D#0IO;B!!<')I;"`Q+"`R
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M=',@:6UM961I871E(&%D;W!T:6]N(&]F($%352!.;RX@,C`Q-"TQ,"P@=&AE
M($-O;7!A;GD-"FYO(&QO;F=E<B!P<F5S96YT<R!O<B!D:7-C;&]S97,@86YY
M(&EN9F]R;6%T:6]N(')E<75I<F5D('5N9&5R($%30R!4;W!I8R`Y,34N/"]P
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5C96YT;'D@27-S=65D($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA
M<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\
M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GDG/CQB/E)E8V5N=&QY($ES<W5E9"!!8V-O=6YT:6YG(%!R;VYO
M=6YC96UE;G1S/"]B/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M86QI9VXZ(&IU<W1I9GDG/DEN($%U9W5S="`R,#$T+"!T:&4@1D%30B!I<W-U
M960@;F5W#0IA8V-O=6YT:6YG(&=U:61A;F-E('=H:6-H(&1E9FEN97,@;6%N
M86=E;65N="8C,30V.W,@<F5S<&]N<VEB:6QI='D@=&\@87-S97-S(&%N(&5N
M=&ET>28C,30V.W,@86)I;&ET>2!T;R!C;VYT:6YU92!A<R!A(&=O:6YG#0IC
M;VYC97)N+"!A;F0@=&\@<')O=FED92!R96QA=&5D(&9O;W1N;W1E(&1I<V-L
M;W-U<F5S(&EN(&-E<G1A:6X@8VER8W5M<W1A;F-E<RX@5&AI<R!G=6ED86YC
M92!W:6QL(&)E(&5F9F5C=&EV92!F;W(@86YN=6%L('!E<FEO9',-"F5N9&EN
M9R!A9G1E<B!$96-E;6)E<B`Q-2P@,C`Q-B!A;F0@:6YT97)I;2!P97)I;V1S
M('=I=&AI;B!A;FYU86P@<&5R:6]D<R!B96=I;FYI;F<@869T97(@1&5C96UB
M97(@,34L(#(P,38N($5A<FQY(&%D;W!T:6]N(&ES('!E<FUI='1E9`T*9F]R
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M;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^#0H-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E
M>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY);B!-87D@,C`Q
M-"P@=&AE($9!4T(@:7-S=65D($%352!.;RX-"C(P,30M,#DL("8C,30W.U)E
M=F5N=64@9G)O;2!#;VYT<F%C=',@=VET:"!#=7-T;VUE<G,F(S$T.#L@*"8C
M,30W.T%352`R,#$T+3`Y)B,Q-#@[*2X@5&AE(&]B:F5C=&EV92!O9B!!4U4@
M,C`Q-"TQ.2!I<R!T;R!E<W1A8FQI<V@-"F$@<VEN9VQE(&-O;7!R96AE;G-I
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M4U4@,C`Q-"TP.2!I<PT*=&AA="!A;B!E;G1I='D@<F5C;V=N:7IE<R!R979E
M;G5E('1O(&1E<&EC="!T:&4@=')A;G-F97(@;V8@<')O;6ES960@9V]O9',@
M;W(@<V5R=FEC97,@=&\@8W5S=&]M97)S(&EN(&%N(&%M;W5N="!T:&%T(')E
M9FQE8W1S#0IT:&4@8V]N<VED97)A=&EO;B!T;R!W:&EC:"!T:&4@96YT:71Y
M(&5X<&5C=',@=&\@8F4@96YT:71L960@:6X@97AC:&%N9V4@9F]R('1H;W-E
M(&=O;V1S(&]R('-E<G9I8V5S+B!);B!A<'!L>6EN9R!T:&4@;F5W(&=U:61A
M;F-E+`T*86X@96YT:71Y('=I;&P@*#$I(&ED96YT:69Y('1H92!C;VYT<F%C
M="AS*2!W:71H(&$@8W5S=&]M97([("@R*2!I9&5N=&EF>2!T:&4@<&5R9F]R
M;6%N8V4@;V)L:6=A=&EO;G,@:6X@=&AE(&-O;G1R86-T.R`H,RD@9&5T97)M
M:6YE#0IT:&4@=')A;G-A8W1I;VX@<')I8V4[("@T*2!A;&QO8V%T92!T:&4@
M=')A;G-A8W1I;VX@<')I8V4@=&\@=&AE(&-O;G1R86-T)B,Q-#8[<R!P97)F
M;W)M86YC92!O8FQI9V%T:6]N<SL@86YD("@U*2!R96-O9VYI>F4@<F5V96YU
M90T*=VAE;B`H;W(@87,I('1H92!E;G1I='D@<V%T:7-F:65S(&$@<&5R9F]R
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M8V5M8F5R(#$U+"`R,#$V(&9O<B!P=6)L:6,@8V]M<&%N:65S+B!%87)L>2!A
M9&]P=&EO;B!I<R!N;W0@<&5R;6ET=&5D+B!4:&4@0V]M<&%N>0T*:7,@8W5R
M<F5N=&QY(&5V86QU871I;F<@=&AE(&YE=R!G=6ED86YC92!A;F0@:&%S(&YO
M="!D971E<FUI;F5D('1H92!I;7!A8W0@=&AI<R!S=&%N9&%R9"!M87D@:&%V
M92!O;B!I=',@8V]N<V]L:61A=&5D(&9I;F%N8VEA;`T*<W1A=&5M96YT<RX\
M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14Q%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF
M:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H5&%B;&5S*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!8V-O=6YT
M:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@0F%S:6,@86YD($1I
M;'5T960@16%R;FEN9W,@4&5R($-O;6UO;B!3:&%R93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO
M<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE
M(&9O;&QO=VEN9R!T86)L92!S:&]W<R!T:&4@8V]M<'5T871I;VX-"F]F(&)A
M<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S('!E<B!S:&%R92!O9B!C;VUM;VX@
M<W1O8VL@9F]R('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"!A
M;F0@,C`Q,SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[
M/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,"!S='EL93TS1"=F;VYT.B`Q,'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N
M<RU397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P
M<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY&;W(@=&AE
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/D9O<B!T:&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY9
M96%R($5N9&5D/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/EEE87(@16YD960\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M1&5C96UB97(@,S$L(#(P,30\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@
M<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D1E8V5M8F5R(#,Q+"`R,#$S/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#4X)3L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DYU;65R871O<B`F(S$U,#L@;F5T
M(&QO<W,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3@E.R!B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q,"PQ,3@L,3`S
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,3@E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B@W+#8T,RPQ,C0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^*3PO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^1&5N;VUI;F%T;W(@)B,Q-3`[('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R
M(&]F('-H87)E<R!O=71S=&%N9&EN9RP@8F%S:6,@86YD(&1I;'5T960\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^.2PQ,S(L.3@Y/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU
M<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI
M9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXX+#8U-BPX,C(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/CQB/DYE="!L;W-S('!E<B!S:&%R92P@8F%S
M:6,@86YD(&1I;'5T960\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@
M9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B@Q+C$Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@P+C@X/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXI/"]F;VYT/CPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%14-!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY!8W%U:7-I=&EO;B`M(%!H87)M86-Y($-R96%T:6]N<RP@3$Q#("A486)L
M97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D)U<VEN97-S($-O;6)I;F%T:6]N<R!;06)S=')A8W1=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE
M(&]F($%C<75I<VET:6]N($1A=&4@1F%I<B!686QU92!O9B!#;VYS:61E<F%T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS
M1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P
M="<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y)SY4:&4@=&]T86P@86-Q=6ES:71I;VX@9&%T92!F86ER
M('9A;'5E#0IO9B!T:&4@8V]N<VED97)A=&EO;B!T<F%N<V9E<G)E9"!A;F0@
M=&\@8F4@=')A;G-F97)R960@:7,@97-T:6UA=&5D(&%T(&%P<')O>&EM871E
M;'D@)#$N,2!M:6QL:6]N+"!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L
M:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R
M9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`W.24[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY#87-H('!A>6UE;G0@=&\@=&AE(%!#(%-E;&QE
M<G,@870@8VQO<VEN9SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q."4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^-C`P+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^0V]N=&EN9V5N="!C
M;VUM;VX@<W1O8VL@:7-S=6%N8V4@=&\@=&AE(%!#(%-E;&QE<G,\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0X,RPQ-38\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D-O;G1I;F=E;G0@8V%S:"!C;VYS:61E<F%T:6]N('1O('1H92!00R!396QL
M97)S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,Q+#0V-CPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1O=&%L(&%C<75I<VET
M:6]N(&1A=&4@9F%I<B!V86QU93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXQ+#$Q-"PV,C(\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-
M"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/CPO<#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D
M=6QE(&]F($5S=&EM871E9"!&86ER(%9A;'5E(&]F($%S<V5T<R!!8W%U:7)E
M9"!A;F0@3&EA8FEL:71I97,@07-S=6UE9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G
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M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@,3!P="!#
M86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E.R!B
M;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#<Y)3L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3@E.R!T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C0L.3@R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY!8V-O=6YT<R!R96-E:79A8FQE/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU."PT,C`\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E!R
M97!A:60@97AP96YS97,@86YD(&]T:&5R(&%S<V5T<SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,S`L,C4V/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^26YV96YT;W)Y
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR
M,3,L,3DP/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&
M1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY0<F]P97)T>2!A;F0@97%U:7!M96YT/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT-"PU,3`\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY);G1A;F=I8FQE
M(&%S<V5T<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV-3DL,#`P/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T
M>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/E1O=&%L(&ED96YT:69I86)L92!A<W-E=',@86-Q=6ER
M960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C$L,#$P+#,U.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/D%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@;&EA8FEL
M:71I97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C$R,"PP-#D\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D]T:&5R(&QI86)I;&ET:65S/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P
M="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C$P-RPS,#@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3!P
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1O=&%L(&QI86)I
M;&ET:65S(&%S<W5M960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C(W+#,U-SPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@
M(#QT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY4;W1A;"!I9&5N=&EF:6%B;&4@87-S971S
M(&QE<W,@;&EA8FEL:71I97,@87-S=6UE9#PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^-S@S+#`P,3PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D=O;V1W:6QL/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N
M-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C,S,2PV,C$\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^3F5T(&%S<V5T<R!A8W%U:7)E9#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#$Q-"PV,C(\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(%)E<W5L="!O9B!/<&5R871I;VX@
M9G)O;2!!8W%U:7-I=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^5&AE(&%M;W5N="!O9B!R979E
M;G5E<R!A;F0@;W!E<F%T:6YG#0IL;W-S(&]F(%!#(&EN8VQU9&5D(&EN('1H
M92!#;VUP86YY)B,Q-#8[<R!C;VYS;VQI9&%T960@<W1A=&5M96YT(&]F(&]P
M97)A=&EO;G,@9G)O;2!T:&4@86-Q=6ES:71I;VX@9&%T92!T:')O=6=H('1H
M92!P97)I;V0@96YD960-"D1E8V5M8F5R(#,Q+"`R,#$T(&%R92!A<R!F;VQL
M;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E
M<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`W,R4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4;W1A;"!R
M979E;G5E<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R-"4[(&)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,2PV-3(L,S@V
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY/<&5R871I;F<@;&]S<SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXH-C8R+#DV.3PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*3PO9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!0<F\@1F]R;6$@1FEN86YC:6%L
M($EN9F]R;6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=M
M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@=6YA=61I=&5D('!R;R!F;W)M
M82!R97-U;'1S('!R97-E;G1E9`T*:6YC;'5D92!A;6]R=&EZ871I;VX@8VAA
M<F=E<R!F;W(@:6YT86YG:6)L92!A<W-E=',@86YD(&5L:6UI;F%T:6]N<R!O
M9B!I;G1E<F-O;7!A;GD@=')A;G-A8W1I;VYS+CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L
M:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R
M9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D9O<B!T:&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1F]R('1H93PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/EEE87(@16YD960\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^665A<B!%;F1E
M9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY$96-E;6)E<B`S,2P@,C`Q-#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5C96UB97(@,S$L
M(#(P,3,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@-3@E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&]T86P@
M<F5V96YU97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P
M="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$X)3L@8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,BPR.#(L-C@Q/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[(&)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L.#8V+#4W
M-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^3F5T(&QO<W,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*#$P+#`T."PS.#`\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*#<L,#@T
M+#`Q-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/CPO='(^#0H\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!);G1A;F=I8FQE($%S<V5T<R!!
M8W%U:7-I=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@
M<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R
M9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E
M.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY&86ER(%9A;'5E/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY5<V5F=6P@3&EF93PO9F]N=#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`V,"4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY#=7-T;VUE<B!R96QA=&EO;G-H:7!S/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$X)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU.38L,#`P/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q."4[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$P("T@,34@>65A<G,\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1R861E(&YA;64\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4L,#`P
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M-2!Y96%R<SPO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY.;VXM8V]M<&5T:71I;VX@8V]V96YA;G0\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4P+#`P,#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0@>65A<G,\+V9O
M;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E-T871E('!H
M87)M86-Y(&QI8V5N<V5S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C@L,#`P/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C4@
M>65A<G,\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-C4Y+#`P,#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CPO
M=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/CPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^26YV96YT;W)I97,@*%1A8FQE<RD\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YV96YT
M;W)Y($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!);G9E;G1O<FEE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G
M;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G
M/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG
M;CH@:G5S=&EF>2<^5&AE(&-O;7!O<VET:6]N(&]F(&EN=F5N=&]R:65S(&%S
M(&]F#0I$96-E;6)E<B`S,2P@,C`Q-"!W87,@87,@9F]L;&]W<SH\+W`^#0H-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT
M.B`Q,'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N<RU397)I9CL@=VED=&@Z
M(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N
M-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SX\8CY$96-E;6)E<B`S,2P@,C`Q-#PO8CX\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#<S)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/E)A=R!M871E<FEA;',\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,C0E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$T-BPS,#`\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=O
M<FL@:6X@<')O9W)E<W,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/CDW+#@P,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^1FEN:7-H960@9V]O9',\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@
M<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,3(X+#8S-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/E1O=&%L(&EN=F5N=&]R:65S/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,W,BPW,S4\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/CPO<#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3$4^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4')E<&%I9"!%>'!E;G-E<R!A;F0@3W1H97(@0W5R<F5N
M="!!<W-E=',@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5F97)R960@0V]S=',L($-A<&ET86QI
M>F5D+"!0<F5P86ED+"!A;F0@3W1H97(@07-S971S($1I<V-L;W-U<F4@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y38VAE9'5L92!O9B!0<F5P86ED($5X<&5N<V5S(&%N9"!/=&AE<B!#
M=7)R96YT($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>2<^4')E<&%I9"!E>'!E;G-E<R!A;F0@
M;W1H97(@8W5R<F5N="!A<W-E=',-"F-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W
M:6YG.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E
M<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CY$96-E;6)E<B`S,2P@,C`Q-#PO
M8CX\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB
M/D1E8V5M8F5R(#,Q+"`R,#$S/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`V,B4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY0<F5P86ED('-T;V-K+6)A<V5D(&-O;G-U;'1I;F<@97AP
M96YS97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,38E
M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,38E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(V+#8T.3PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4')E
M<&%I9"!R96YT/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,38L,C@X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY0<F5P86ED(&EN<W5R86YC93PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,3(S+#<W-CPO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C,Y+#$V-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/D]T:&5R('!R97!A:60@97AP96YS97,@86YD(&1E<&]S:71S/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C$Q-BPV,C4\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P
M="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C(R+#DV-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^5&]T86P@<')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H
M97(@8W5R<F5N="!A<W-E=',\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^,C0P+#0P,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B
M;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,3`U+#`V-SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M
M:6YD96YT.B`M,"XW-6EN)SXF(S$V,#L\+W`^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Q%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D9U<FYI='5R92!A;F0@17%U:7!M96YT("A486)L97,I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R
M;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@
M;V8@1G5R;FET=7)E(&%N9"!%<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-
M"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E!R97!A:60@
M97AP96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S#0IC;VYS:7-T960@
M;V8@=&AE(&9O;&QO=VEN9SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T($-A;&EB<FDL($AE;'9E
M=&EC82P@4V%N<RU397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S
M93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^1&5C96UB
M97(@,S$L(#(P,30\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\8CY$96-E;6)E<B`S,2P@,C`Q,SPO8CX\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-C(E.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^4')E<&%I9"!S=&]C:RUB87-E9"!C
M;VYS=6QT:6YG(&5X<&5N<V5S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$V)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$V)3L@=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR-BPV-#D\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/E!R97!A:60@<F5N=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$V+#(X.#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4')E<&%I9"!I;G-U
M<F%N8V4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C$R,RPW-S8\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXS.2PQ-C8\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY/=&AE<B!P<F5P86ED(&5X<&5N<V5S(&%N
M9"!D97!O<VET<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ,38L-C(U/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXR,BPY-C0\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1O=&%L('!R97!A:60@97AP
M96YS97,@86YD(&]T:&5R(&-U<G)E;G0@87-S971S/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(T,"PT,#$\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$P-2PP-C<\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R
M9VEN.B`P.R!T97AT+6EN9&5N=#H@+3`N-S5I;B<^)B,Q-C`[/"]P/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?
M8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V$W8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X
M9&%A-B]7;W)K<VAE971S+U-H965T,S`N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5704%#/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN=&%N9VEB;&4@07-S971S(&%N9"!'
M;V]D=VEL;"`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY';V]D=VEL;"!A;F0@26YT86YG:6)L92!!
M<W-E=',@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($EN=&%N9VEB
M;&4@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S
M='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G
M:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P)SY4
M:&4@0V]M<&%N>28C,30V.W,@:6YT86YG:6)L92!A<W-E=',@870@1&5C96UB
M97(@,S$L(#(P,30-"F-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG.CPO<#X-
M"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z(#`N
M-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L
M=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^06UO
M<G1I>F%T:6]N/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$
M,B!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SYP97)I;V1S/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY!8V-U;75L871E9#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/DYE=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXH:6X@>65A<G,I/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI
M9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^0V]S=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O
M;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T
M('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SYA;6]R=&EZ871I;VX\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^8V%R<GEI;F<@=F%L=64\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#,X)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/D-U<W1O;65R(')E;&%T:6]N<VAI<',\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$S)3L@
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,3`M,34@>65A<G,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,3,E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C4Y-BPP,#`\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3,E.R!T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@S
M-BPW-#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,R4[('1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-34Y+#(V,#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^5')A9&4@;F%M93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^-2!Y96%R<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^-2PP,#`\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH-S4P/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXI/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXT+#(U,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^3F]N+6-O;7!E=&ET:6]N(&-O=F5N86YT/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT('EE87)S/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU,"PP,#`\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXH.2PS-S4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0P+#8R-3PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E-T871E('!H87)M86-Y
M(&QI8V5N<V5S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXR-2!Y96%R<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXX+#`P,#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^*#$L,30Q/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8L.#4Y/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R
M+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C8U.2PP,#`\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@T."PP,#8\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M-C$P+#DY-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^/"]P
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V-H961U;&4@;V8@06UO<G1I>F%T:6]N($5X<&5N<V5S(&9O<B!);G1A
M;F=I8FQE($%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,"<^06UO<G1I>F%T:6]N(&5X<&5N<V4@9F]R(&EN=&%N9VEB;&4@87-S971S
M(&9O<B!T:&4@>65A<B!E;F1E9`T*1&5C96UB97(@,S$L(#(P,30@=V%S(&%S
M(&9O;&QO=W,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@,3!P
M="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E
M.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^1F]R('1H93PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/EEE87(@16YD960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5C96UB
M97(@,S$L(#(P,30\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@-S,E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M0W5S=&]M97(@<F5L871I;VYS:&EP<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`R-"4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,S8L-S0P/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4<F%D
M92!N86UE/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXW-3`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/DYO;BUC;VUP971I=&EO;B!C;W9E;F%N=#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^.2PS-S4\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY3=&%T92!P
M:&%R;6%C>2!L:6-E;G-E<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#$T,3PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-#@L,#`V/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!%<W1I
M;6%T960@1G5T=7)E($%M;W)T:7IA=&EO;B!%>'!E;G-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^
M/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9CL@;6%R9VEN.B`P)SY%<W1I;6%T960@9G5T=7)E(&%M;W)T
M:7IA=&EO;B!E>'!E;G-E(&9O<B!T:&4@0V]M<&%N>28C,30V.W,-"FEN=&%N
M9VEB;&4@87-S971S(&%T($1E8V5M8F5R(#,Q+"`R,#$T(&ES(&%S(&9O;&QO
M=W,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN
M9&5N=#H@+3`N-S5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I
M;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T($-A
M;&EB<FDL($AE;'9E=&EC82P@4V%N<RU397)I9CL@=VED=&@Z(#$P,"4[(&)O
M<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/EEE87)S(&5N9&EN9R!$96-E;6)E<B`S,2P\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-S,E.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q-3PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R-"4[('1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-C<L,#@W/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXR,#$V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXV-RPP.#<\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C(P,3<\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C8W+#`X-SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,3@\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4W+#<Q,CPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q.3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-3,L.#,W
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M5&AE<F5A9G1E<CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR.3@L,3@T/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T
M(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV,3`L.3DT/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!#:&%N9V5S
M(&EN($-A<G)Y:6YG(%9A;'5E(&]F($=O;V1W:6QL/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P
M/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@
M8VAA;F=E<R!I;B!T:&4@8V%R<GEI;F<@=F%L=64@;V8-"G1H92!#;VUP86YY
M)B,Q-#8[<R!G;V]D=VEL;"!D=7)I;F<@=&AE('EE87(@96YD960@1&5C96UB
M97(@,S$L(#(P,30@=V5R92!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L
M:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R
M9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY"86QA;F-E(&%T($IA;G5A<GD@,2P@,C`Q-#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXM
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@-S,E.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^4$,@06-Q=6ES:71I;VX\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R-"4[(&)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,S,2PV,C$\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^0F%L86YC92!A="!$96-E;6)E<B`S,2P@,C`Q-#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS,S$L-C(Q/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%3$4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^06-C;W5N=',@
M4&%Y86)L92!A;F0@06-C<G5E9"!%>'!E;G-E<R`H5&%B;&5S*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY087EA
M8FQE<R!A;F0@06-C<G5A;',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!!8V-O=6YT
M<R!087EA8FQE(&%N9"!!8V-R=65D($5X<&5N<V5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P
M/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!8V-O
M=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S#0IC;VYS:7-T960@
M;V8@=&AE(&9O;&QO=VEN9SH\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T($-A;&EB<FDL($AE;'9E
M=&EC82P@4V%N<RU397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S
M93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^1&5C96UB
M97(@,S$L(#(P,30\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SX\8CY$96-E;6)E<B`S,2P@,C`Q,SPO8CX\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-3@E.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^06-C;W5N=',@<&%Y86)L93PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[('1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-CDX
M+#@P-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q."4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^,C8Q+#DR-#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5F97)R
M960@<F5N=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^-"PY-S4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY"=6EL9&EN9R!L96%S92!L:6%B:6QI='DH,2D\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C<S
M+#4U,CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY/=&AE<B!A8V-R=65D(&5X<&5N<V5S/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P
M="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C,Y+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B@R*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU
M,"PP,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/E1O=&%L(&%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP
M96YS97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C@Q-BPS,S,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXS,3$L.3(T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^3&5S<SH@0W5R<F5N="!P;W)T:6]N/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B@W.#8L-C<U/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S
M;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXH,S$Q+#DR-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY.;VXM8W5R<F5N
M="!T;W1A;"!A8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N
M.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(Y+#8U
M.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^+3PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G
M:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B
M;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F
M;VYT.B`Q,'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N<RU397)I9CL@=VED
M=&@Z(#$P,"4G/@T*/'1R/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,C1P
M>"<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<#L@=VED=&@Z(#(T<'@[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXH,2D\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DEN(%-E<'1E;6)E<B`R,#$T+"!T
M:&4@0V]M<&%N>2!R96QO8V%T960@:71S('!R:6UA<GD@;W!E<F%T:6]N<R!T
M;R!A(#<L-38U('-Q=6%R92!F;V]T(&]F9FEC92!F86-I;&ET>2!I;B!386X@
M1&EE9V\L($-A;&EF;W)N:6$N($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T+"!T
M:&4@0V]M<&%N>2!W87,@;6%R:V5T:6YG(&ET<R!P<F5V:6]U<R!O9F9I8V4@
M<W!A8V4@*#,L.#<T('-Q=6%R92!F965T*2!A<R!A('-U8FQE87-E('1H<F]U
M9V@@:71S(')E;6%I;FEN9R!L96%S92!T97)M+B!4:&4@0V]M<&%N>2!R96-O
M9VYI>F5D(&$@;&]S<R!O9B!A<'!R;WAI;6%T96QY("0Q,3<L,#`P(&1U<FEN
M9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"P@<F5L871E9"!T
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M*'-E92!.;W1E(#$T*2X\+V9O;G0^/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!T;W`[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,BD\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1H92!A;6]U;G0@8V]N
M<VES=',@;V8@82`D,SDL,#`P('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!A
M8V-R=6%L(&%T($1E8V5M8F5R(#,Q+"`R,#$T(&9O<B!S=&]C:R!O<'1I;VYS
M('1O(&)E(&=R86YT960@9F]R('-E<G9I8V5S('!E<F9O<FUE9"X@5&AE('-T
M;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T960@=&\@<F5S
M=')I8W1E9"!C;VUM;VX@<W1O8VL@:7-S=6%N8V5S(&%N9"!A8V-R=6%L<R!W
M87,@)#,Y+#`P,"!A;F0@)#$T,RPU-3,@9'5R:6YG('1H92!Y96%R<R!E;F1E
M9"!$96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q,RP@<F5S<&5C=&EV96QY+CPO
M9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*#0H-"CQP('-T>6QE/3-$)VUA
M<F=I;CH@,'!T)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%]A-V-F8V)F-5]B9#1F7S0W.3!?83<Y.5\X-30Q9&0T.&1A
M838-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83=C9F-B9C5?8F0T
M9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V+U=O<FMS:&5E=',O4VAE970S,BYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14]*04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O
M8VMH;VQD97)S)R!%<75I='D@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(%-T;V-K($]P=&EO
M;B!0;&%N($%C=&EV:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS
M1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY!('-U;6UA<GD@;V8@=&AE('-T
M;V-K(&]P=&EO;B!A8W1I=FET>0T*=6YD97(@=&AE(%!L86X@9F]R('1H92!Y
M96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&ES(&%S(&9O;&QO=W,Z/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A
M8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I
M9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<CX-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY.=6UB97(@;V8@<VAA
M<F5S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY796EG:'1E9"!!=F<N($5X97)C
M:7-E(%!R:6-E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY796EG:'1E9"!!=F<N
M(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T
M97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#L@=VED
M=&@Z(#0T)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]P=&EO
M;G,@;W5T<W1A;F1I;F<@+2!*86YU87)Y(#$L(#(P,30\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED
M=&@Z(#(E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$P)3L@=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXQ+#,R."PW.3`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@=VED=&@Z(#(E.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,3`E.R!T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4N,S$\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED
M=&@Z(#(E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$E
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=VED=&@Z(#$P)3L@=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W
M:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@
M,B4[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,24[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!W:61T:#H@,3`E.R!T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('=I9'1H
M.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT
M<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY/<'1I;VYS(&=R86YT960\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C(T-2PX.#8\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8N
M,S4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY/<'1I;VYS(&5X97)C:7-E9#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*#,P-RPT,CD\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,RXY,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/<'1I;VYS(&-A;F-E
M;&QE9"]F;W)F96ET/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N
M-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B@R,S@L,#`W/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C8N-C@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/<'1I;VYS(&]U
M='-T86YD:6YG("T@1&5C96UB97(@,S$L(#(P,30\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$L,#(Y+#(T
M,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^-2XW-#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8N,#4\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C(L,S4Q+#$W-#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ('1O<#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/D]P=&EO;G,@97AE<F-I<V%B;&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D
M;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C<R."PU.#4\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C4N,C4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT+CDW/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXR+#`X,"PU.30\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=B86-K9W)O=6YD
M+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ('1O<#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]P
M=&EO;G,@=F5S=&5D(&%N9"!E>'!E8W1E9"!T;R!V97-T/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B;W)D97(M8F]T=&]M.B!B;&%C
M:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXY.3DL
M,3<U/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+C<P/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-2XY.#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^,BPS,3DL-#<U/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!&86ER(%9A
M;'5E($%S<W5M<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$
M)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!T86)L92!B96QO=R!I;&QU
M<W1R871E<R!T:&4@9F%I<@T*=F%L=64@<&5R('-H87)E(&1E=&5R;6EN960@
M=7-I;F<@=&AE($)L86-K+5-C:&]L97,M365R=&]N(&]P=&EO;B!P<FEC:6YG
M(&UO9&5L('=I=&@@=&AE(&9O;&QO=VEN9R!A<W-U;7!T:6]N<R!U<V5D(&9O
M<B!V86QU:6YG#0IO<'1I;VYS(&=R86YT960@=&\@96UP;&]Y965S(&%N9"!D
M:7)E8W1O<G,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P
M.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@<W1Y;&4],T0G9F]N=#H@,3!P="!#86QI8G)I+"!(96QV971I8V$L(%-A
M;G,M4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA
M<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/C(P,30\+V(^/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CXR,#$S/"]B
M/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`U
M."4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY796EG:'1E9"UA
M=F5R86=E(&9A:7(@=F%L=64@;V8@;W!T:6]N<R!G<F%N=&5D/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$X)3L@=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+C(R/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$X)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXV+C`T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY%>'!E8W1E9"!T97)M<R`H
M:6X@>65A<G,I/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXU+C@Q("T@-BXY,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C4N."TW(#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^17AP96-T960@=F]L871I
M;&ET>3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^.38@+2`Q,#(E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,3`R("T@,3(S)3PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E)I<VLM9G)E92!I;G1E<F5S="!R
M871E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXQ+C,W("T@,2XV-24\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXP+C@V("T@,BXP-24\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1I=FED96YD('EI96QD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXM
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&4@=&%B;&4@8F5L
M;W<@:6QL=7-T<F%T97,@=&AE(&9A:7(-"G9A;'5E('!E<B!S:&%R92!D971E
M<FUI;F5D('5S:6YG('1H92!";&%C:RU38VAO;&5S+4UE<G1O;B!O<'1I;VX@
M<')I8VEN9R!M;V1E;"!W:71H('1H92!F;VQL;W=I;F<@87-S=6UP=&EO;G,@
M=7-E9"!F;W(@=F%L=6EN9PT*;W!T:6]N<R!G<F%N=&5D('1O(&-O;G-U;'1A
M;G1S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^
M#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E
M<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SX\8CXR,#$T/"]B/CPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^/&(^,C`Q,SPO8CX\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-3@E.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5V5I9VAT960M879E<F%G
M92!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[('1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-BXQ-3PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M."4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^-2XV,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^17AP96-T960@=&5R;7,@*&EN('EE
M87)S*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,BXU("T@,3`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXF(S$V,#LR+C,S("T@,3`@/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY%>'!E8W1E9"!V;VQA
M=&EL:71Y/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXW."`M(#DW)3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B8C,38P.S@P("T@,S8V)2`\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY2:7-K+69R964@:6YT
M97)E<W0@<F%T93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^,"XQ,"`M(#$N-C@E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)B,Q-C`[,"XS,"`M(#(N-#4E(#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M1&EV:61E;F0@>6EE;&0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\+W1A
M8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI;F1E;G0Z
M("TP+C<U:6XG/B8C,38P.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(%-H87)E<R!/=71S
M=&%N9&EN9R!A;F0@17AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP
M('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`G/E1H92!F;VQL;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!I
M;F9O<FUA=&EO;B!A8F]U="!S=&]C:R!O<'1I;VYS#0IO=71S=&%N9&EN9R!A
M;F0@97AE<F-I<V%B;&4@870@1&5C96UB97(@,S$L(#(P,30Z/"]P/@T*#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6EN9&5N=#H@+3`N-S5I
M;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q,'!T($-A;&EB<FDL($AE;'9E
M=&EC82P@4V%N<RU397)I9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S
M93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VTG/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#$P('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED
M.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY/<'1I;VYS($]U='-T86YD:6YG/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0V('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY/<'1I;VYS($5X97)C:7-A8FQE/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=E:6=H=&5D
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P
M86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/D%V97)A9V4\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5V5I9VAT960\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M5V5I9VAT960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^4F5M86EN:6YG/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/D%V97)A9V4\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^079E<F%G93PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D(&-O;'-P86X],T0R
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY.=6UB97(\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^0V]N=')A8W1U86P\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
M;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^17AE<F-I<V4\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3G5M8F5R/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/D5X97)C:7-E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY286YG92!O9B!%>&5R8VES92!0<FEC97,\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]U='-T86YD:6YG/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY,:69E(&EN(%EE
M87)S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY0
M<FEC93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M17AE<F-I<V%B;&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS
M1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[
M('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/E!R:6-E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#(X)3L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B0R+C0P("T@)#,N,C`\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q)3L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR-3`L,#`P/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q,24[('1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-"XU
M-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q,24[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,BXX,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,3$E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(U,"PP,#`\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3$E.R!T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C(N.#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD,RXV,"`M("0T+C4Q/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,S,W+#<R
M,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C0N.34\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0N,S8\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR-S`L,#$U/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXT+C0R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)#4N-#D@+2`D-RXW,3PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$Y,"PU-3<\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXX+C<P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV+C8R/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-C`L,3$P/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXV+C(V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B0X+C`V("T@)#$P+C<U/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C0T+#$V,#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C<N
M,#,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C@N.3D\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ-#$L-C8P/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXY+C`Q/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#
M145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^)#(X+C`P("T@)#@P+C`P/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S
M;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXV+#@P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C4N,3,\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0P+C@V
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV+#@P,#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^-#`N.#8\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ+#`R.2PR-#`\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXV+C`U
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXU+C<T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[
M('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^-S(X+#4X-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-2XR-3PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ
M(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^
M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^36%R:V5T+6)A<V5D(%9E<W1I;F<@0V]N9&ET:6]N<R!F;W(@4F5S
M=')I8W1E9"!3=&]C:R!5;FET<R!'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*
M#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y)SY4:&5S92!M
M87)K970M8F%S960@=F5S=&EN9R!C;VYD:71I;VYS#0IA<F4@9G5R=&AE<B!D
M97-C<FEB960@8F5L;W<Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN
M.B`P.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N
M=#H@,3!P="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H
M.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<CX-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$V)3L@8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY4<F%N8VAE/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q)3L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#8V)3L@8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DYU;6)E<B!O
M9B!3:&%R97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,38E.R!B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&%R9V5T(%-H
M87)E(%!R:6-E/"]F;VYT/CPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/E1R86YC:&4@,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C$Y+C`U)2!O9B!T:&4@<VAA<F5S('-U8FIE
M8W0@=&\@=&AE($)A=6T@4&5R9F]R;6%N8V4@17%U:71Y($%W87)D/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#$P+C`P(&]R
M(&=R96%T97(\+V9O;G0^/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^5')A;F-H92`R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,3DN,#4E(&]F('1H92!S:&%R97,@<W5B:F5C
M="!T;R!T:&4@0F%U;2!097)F;W)M86YC92!%<75I='D@07=A<F0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I
M9GD[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD,34N,#`@;W(@
M9W)E871E<CPO9F]N=#X\+W1D/CPO='(^#0H\='(^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY4<F%N8VAE(#,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXQ.2XP-24@;V8@=&AE('-H87)E<R!S=6)J96-T
M('1O('1H92!"875M(%!E<F9O<FUA;F-E($5Q=6ET>2!!=V%R9#PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF
M>3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0R,"XP,"!O<B!G
M<F5A=&5R/"]F;VYT/CPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/E1R86YC:&4@-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/C$Y+C`U)2!O9B!T:&4@<VAA<F5S('-U8FIE8W0@
M=&\@=&AE($)A=6T@4&5R9F]R;6%N8V4@17%U:71Y($%W87)D/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#(U+C`P(&]R(&=R
M96%T97(\+V9O;G0^/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^5')A;F-H92`U/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,C,N.#`E(&]F('1H92!S:&%R97,@<W5B:F5C="!T
M;R!T:&4@0F%U;2!097)F;W)M86YC92!%<75I='D@07=A<F0\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD,S`N,#`@;W(@9W)E
M871E<CPO9F]N=#X\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"@T*#0H\<"!S='EL93TS1"=M87)G
M:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
M97AT+6%L:6=N.B!J=7-T:69Y)SY4:&5S92!M87)K970M8F%S960@=F5S=&EN
M9R!C;VYD:71I;VYS#0IA<F4@9G5R=&AE<B!D97-C<FEB960@8F5L;W<Z/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A
M8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R:68[('=I
M9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<CX-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#,T)3L@8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY4<F%N8VAE/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#,R)3L@
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DYU;6)E
M<B!O9B!3:&%R97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,S(E.R!B
M;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&%R9V5T
M(%-H87)E(%!R:6-E/"]F;VYT/CPO=&0^/"]T<CX-"CQT<CX-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1R86YC
M:&4@,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C(P+#`P,"!S:&%R97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD,3`N,#`@;W(@9W)E871E<CPO9F]N=#X\+W1D/CPO='(^
M#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY4<F%N8VAE(#(\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXR,"PP,#`@<VAA<F5S/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#$U+C`P(&]R(&=R96%T97(\
M+V9O;G0^/"]T9#X\+W1R/@T*/'1R/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5')A;F-H92`S/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`L,#`P('-H87)E
M<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0R
M,"XP,"!O<B!G<F5A=&5R/"]F;VYT/CPO=&0^/"]T<CX-"CQT<CX-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1R
M86YC:&4@-#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@:G5S=&EF>3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C(P+#`P,"!S:&%R97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXD,C4N,#`@;W(@9W)E871E<CPO9F]N=#X\+W1D/CPO
M='(^#0H\='(^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY4<F%N8VAE(#4\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXR,"PP,#`@<VAA<F5S/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#,P+C`P(&]R(&=R96%T
M97(\+V9O;G0^/"]T9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^/"]P/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U
M;&4@;V8@4F5S=')I8W1E9"!3=&]C:R!5;FET<R!!8W1I=FET>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G;6%R9VEN.B`P
M<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF
M>2<^02!S=6UM87)Y(&]F('1H92!#;VUP86YY)B,Q-#8[<R!24U4-"F%C=&EV
M:71Y(&%N9"!R96QA=&5D(&EN9F]R;6%T:6]N(&9O<B!T:&4@>65A<B!E;F1E
M9"!$96-E;6)E<B`S,2P@,C`Q-"!I<R!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P
M)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^3G5M8F5R(&]F(%)3
M57,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=E
M:6=H=&5D($%V97)A9V4@1W)A;G0@1&%T92!&86ER(%9A;'5E/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#0R)3L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E)357,@=6YV97-T960@+2!*86YU
M87)Y(#$L(#(P,30\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$V)3L@=&5X="UA
M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ
M+#,X.2PY-C`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,S8E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,N,3D\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E)357,@
M9W)A;G1E9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,C8L-#DR/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXW+C4U/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY24U5S('9E<W1E
M9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*#,P+#8Y,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXW+C0Q/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4E-5
M<R!C86YC96QL960O9F]R9F5I=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,3`X
M+#DT-SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXS+C`Q/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY24U5S
M('5N=F5S=&5D(&%T($1E8V5M8F5R(#,Q+"`R,#$T/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U
M<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O
M=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXQ+#(W-BPX,34\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,N,C`\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(%=A<G)A;G1S($%C=&EV:71Y/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G
M:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
M=7-T:69Y)SY!('-U;6UA<GD@;V8@=V%R<F%N="!A8W1I=FET>2!D=7)I;F<-
M"G1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&ES(&%S(&9O;&QO
M=W,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C,38P.SPO<#X-
M"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!#86QI8G)I+"!(96QV971I8V$L(%-A;G,M4V5R
M:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E)SX-
M"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY.=6UB97(@;V8@4VAA<F5S(%-U8FIE8W0@=&\@5V%R<F%N=',@3W5T<W1A
M;F1I;F<\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/E=E:6=H=&5D($%V9RX\+V9O;G0^/&)R("\^#0H\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY%>&5R
M8VES92!0<FEC93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L
M<W!A;CTS1#(@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`U-"4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY787)R86YT<R!O=71S=&%N9&EN9R`M($IA;G5A<GD@,2P@,C`Q-#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,C`E.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C@R,2PP-3`\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M,C`E.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C4N.30\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D=R86YT960\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BT\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&
M)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/D5X97)C:7-E9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^*#$S,"PQ,#8\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BD\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^-2XR.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D5X<&ER960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^+3PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^5V%R<F%N=',@;W5T<W1A;F1I;F<@86YD(&5X
M97)C:7-A8FQE("T@1&5C96UB97(@,S$L(#(P,30\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C8Y,"PY-#0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8N,#4\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY796EG:'1E
M9"!A=F5R86=E(')E;6%I;FEN9R!C;VYT<F%C='5A;"!L:69E(&]F('1H92!O
M=71S=&%N9&EN9R!W87)R86YT<R!I;B!Y96%R<R`M($1E8V5M8F5R(#,Q+"`R
M,#$T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+C@V/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-
M"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/CPO<#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D
M=6QE(&]F(%=A<G)A;G1S($]U='-T86YD:6YG(&%N9"!787)R86YT<R!%>&5R
M8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y
M;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G;6%R9VEN
M.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>2<^02!L:7-T(&]F('1H92!W87)R86YT<R!O=71S
M=&%N9&EN9R!A<PT*;V8@1&5C96UB97(@,S$L(#(P,30@:7,@:6YC;'5D960@
M:6X@=&AE(&9O;&QO=VEN9R!T86)L93H\+W`^#0H-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M.R!M87)G:6XZ(#`[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*
M#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL
M93TS1"=F;VYT.B`Q,'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N<RU397)I
M9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!C;VQS<&%N/3-$,3`@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=A<G)A;G1S($]U='-T86YD:6YG/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0V('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C
M96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY787)R86YT
M<R!%>&5R8VES86)L93PO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X]
M,T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/E=A<G)A;G1S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D5X97)C:7-E/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E=A
M<G)A;G1S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D5X<&ER871I;VX\+V9O;G0^/"]T9#X\+W1R/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^5V%R<F%N="!397)I97,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DES<W5E($1A=&4\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D]U='-T
M86YD:6YG/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY0<FEC93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^17AE<F-I<V%B;&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A
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M0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-#$E.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^5V%R<F%N=',@:7-S=65D('1O(&$@
M9F]R;65R(&UA:F]R('-H87)E:&]L9&5R/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H
M.B`Y)3L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^-"\R-2\R,#$R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#DE.R!T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C0X+#(V,CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU+CDS/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT."PR-C(\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#DE.R!T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT+S(U
M+S(P,34\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/E=A<G)A;G1S(&ES<W5E9"!I;B!!<')I;"`R,#$R('!R:79A=&4@<&QA8V5M
M96YT/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^-"\R-2\R,#$R/"]F;VYT/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT.38L-3,W/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXU+CDS/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^-#DV+#4S-SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI
M;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXT+S(U+S(P,34\+V9O;G0^
M/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^56YD97)W<FET
M97(@5V%R<F%N=',\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXR+S<O,C`Q,SPO9F]N=#X\+W1D/@T*("`@(#QT9#XF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-38L,30U
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXU+C(U/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^-38L,30U/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(O-R\R,#$X/"]F
M;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY787)R86YT
M<R!I<W-U960@=&\@:6YV97-T;W(@<F5L871I;VYS(&-O;G-U;'1A;G0\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR+S(X
M+S(P,3,\+V9O;G0^/"]T9#X-"B`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C,P+#`P,#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^-2XR-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C,P+#`P,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXR+S(X+S(P,38\+V9O;G0^/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5V%R<F%N=',@:7-S=65D('1O
M(&EN=F5S=&]R(')E;&%T:6]N<R!C;VYS=6QT86YT/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-R\Q.2\R,#$S/"]F;VYT
M/CPO=&0^#0H@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8P+#`P,#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^."XU,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M-C`L,#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C<O,3DO,C`Q.#PO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,BXR-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N
M,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^-CDP+#DT-#PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-BXP
M-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C8Y,"PY-#0\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^
M#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!3=&]C:R!"87-E9"!#
M;VUP96YS871I;VX@1W)A;G1E9"!T;R!%;7!L;WEE97,@1&ER96-T;W)S($-O
M;G-U;'1A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S
M='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G
M:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T
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M<F5C=&]R<R!A;F0@8V]N<W5L=&%N=',@87,@9F]L;&]W<SH\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\=&%B;&4@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS1"=F;VYT.B`Q
M,'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N<RU397)I9CL@=VED=&@Z(#$P
M,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C;VQS<&%N
M/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SY&;W(@=&AE/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D9O<B!T:&4\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!C
M;VQS<&%N/3-$,B!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY996%R($5N9&5D/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/EEE
M87(@16YD960\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5C96UB97(@,S$L(#(P,30\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E8V5M
M8F5R(#,Q+"`R,#$S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#4X)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D5M<&QO>65E<R`M('-E;&QI;F<@86YD(&UA<FME=&EN9SPO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[('1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-SDL,C<X/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$X)3L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXX+#(Y.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^16UP;&]Y965S("T@9V5N
M97)A;"!A;F0@861M:6YI<W1R871I=F4\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L,#DU+#(U-#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$L-3$R+#0T.#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M16UP;&]Y965S("T@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,34V+#4V
M.#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D1I<F5C=&]R<R`M(&=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ-#8L,#DS
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^,SDY+#DX-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#
M0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^0V]N<W5L=&%N=',@+2!S96QL:6YG(&%N9"!M87)K971I
M;F<\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C@X+#0P-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY#;VYS=6QT86YT<R`M(&=E;F5R86P@86YD(&%D;6EN:7-T
M<F%T:79E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXQ-#8L-SDY/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^.#0S+#,P,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^0V]N<W5L=&%N=',@+2!R97-E87)C
M:"!A;F0@9&5V96QO<&UE;G0\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^."PW.#D\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(Q-"PS-S(\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$
M)W!A9&1I;F<M;&5F=#H@,C!P=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/E1O=&%L/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE
M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C(L-38T+#8Q.3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P
M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,RPQ,S0L.3<S/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^
M#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X="UI
M;F1E;G0Z(#`N-6EN)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($9A:7(@5F%L
M=64@07-S=6UP=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G
M;6%R9VEN.B`P<'0G/CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@
M,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF
M(S$V,#M4:&4@9F%I<B!V86QU90T*;V8@96%C:"!W87)R86YT(&ES(&5S=&EM
M871E9"!O;B!T:&4@9&%T92!O9B!G<F%N="!U<VEN9R!T:&4@0FQA8VLM4V-H
M;VQE<RU-97)T;VX@;W!T:6]N('!R:6-I;F<@;6]D96PN(%1H92!T86)L92!B
M96QO=R!I;&QU<W1R871E<PT*=&AE(&9A:7(@=F%L=64@<&5R('-H87)E(&1E
M=&5R;6EN960@8GD@=&AE($)L86-K+5-C:&]L97,M365R=&]N(&]P=&EO;B!P
M<FEC:6YG(&UO9&5L('=I=&@@=&AE(&9O;&QO=VEN9R!A<W-U;7!T:6]N<R!U
M<V5D(&9O<B!V86QU:6YG#0IT:&4@=V%R<F%N=',@:7-S=65D('1O(&-O;G-U
M;'1A;G1S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN)SXF(S$V,#L\
M+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@2&5L=F5T:6-A+"!386YS
M+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S
M92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;2<^#0H@
M("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/EEE87(@
M16YD960\+V(^/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M)SX-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/CQB/D1E8V5M8F5R(#,Q+"`R
M,#$S/"]B/CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)W=I
M9'1H.B`W,R4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY796EG
M:'1E9"UA=F5R86=E(&9A:7(@=F%L=64@;V8@=V%R<F%N=',@9W)A;G1E9#PO
M9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`R-"4[('1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M-2XQ,CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^17AP96-T960@=&5R;7,@*&EN('EE87)S*3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,BXV+34\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D5X<&5C=&5D('9O;&%T:6QI='D\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/C@U)2TS-#8E/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^4FES:RUF<F5E(&EN=&5R97-T
M(')A=&4\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C`N,S(E+3$N,S$E/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY$:79I9&5N9"!Y:65L9#PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^+3PO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X\+W1R/@T*/"]T86)L93X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M:6YD96YT.B`P+C5I;B<^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?8F0T9E\T-SDP7V$W.3E?
M.#4T,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W
M8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X9&%A-B]7;W)K<VAE971S
M+U-H965T,S,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5(2#X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY);F-O;64@5&%X97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>"!$:7-C
M;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@4')O=FES:6]N(&9O<B!);F-O
M;64@5&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T
M>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I
M;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E
M>'0M86QI9VXZ(&IU<W1I9GDG/E1H92!#;VUP86YY(&ES('-U8FIE8W0@=&\@
M=&%X871I;VX@:6X-"G1H92!5;FET960@4W1A=&5S(&%N9"!#86QI9F]R;FEA
M+B!4:&4@<')O=FES:6]N(&9O<B!I;F-O;64@=&%X97,@9F]R('1H92!Y96%R
M<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q,R!A<F4@<W5M;6%R
M:7IE9`T*8F5L;W<Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/B8C
M,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@<W1Y;&4],T0G9F]N=#H@,3!P="!#86QI8G)I+"!(96QV971I8V$L
M(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L;&%P<V4Z(&-O
M;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M)SX-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D1E8V5M8F5R(#,Q+"`R
M,#$T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$
M96-E;6)E<B`S,2P@,C`Q,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY#=7)R96YT
M.CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL
M969T.B`Q,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^1F5D
M97)A;#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`U."4[('!A9&1I;F<M;&5F=#H@,3!P=#L@;&EN92UH
M96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E-T871E/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3@E
M.R!B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR+#@P
M,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$X)3L@8F]R9&5R+6)O='1O
M;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^+3PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&]T86P@
M8W5R<F5N=#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(L
M.#`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BT\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^1&5F97)R960Z/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D
M('-T>6QE/3-$)W!A9&1I;F<M;&5F=#H@,3!P=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/D9E9&5R86P\+V9O;G0^/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,3$L,#@R+#0U
M.3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^."PP-S4L,S0R/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6QE9G0Z(#$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY3=&%T93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^,RPQ,#`L-C(W/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,BPR,S,L-S(V/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)W!A
M9&1I;F<M;&5F=#H@,3!P=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/D-H86YG92!I;B!V86QU871I;VX@86QL;W=A;F-E/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q
M+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/B@Q-"PQ.#,L,#@V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N
M-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B@Q,"PS,#DL,#8X/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI
M/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY4;W1A
M;"!D969E<G)E9#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M
M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P
M="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SY);F-O;64@=&%X('!R;W9I<VEO;B`H8F5N969I
M="D\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,BPX
M,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/BT\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6XG/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($EN8V]M92!487@@4F5C
M;VYC:6QI871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP
M('-T>6QE/3-$)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)VUA
M<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[
M('1E>'0M86QI9VXZ(&IU<W1I9GDG/D$@<F5C;VYC:6QI871I;VX@;V8@:6YC
M;VUE('1A>&5S#0IC;VUP=71E9"!B>2!A<'!L>6EN9R!T:&4@<W1A='5T;W)Y
M(%4N4RX@:6YC;VUE('1A>"!R871E('1O('1H92!#;VUP86YY)B,Q-#8[<R!L
M;W-S(&)E9F]R92!I;F-O;64@=&%X97,@=&\@=&AE(&EN8V]M92!T87@-"G!R
M;W9I<VEO;B!I<R!A<R!F;VQL;W=S.CPO<#X-"@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[
M(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN)SXF(S$V,#L\+W`^#0H-"CQT86)L92!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('-T>6QE/3-$)V9O;G0Z(#$P<'0@0V%L:6)R:2P@
M2&5L=F5T:6-A+"!386YS+5-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R+6-O
M;&QA<'-E.B!C;VQL87!S92<^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;2<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@8V]L<W!A;CTS1#(@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M
M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/D1E8V5M8F5R(#,Q+"`R,#$T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@8V]L<W!A;CTS1#(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@4V5R:68G/D1E8V5M8F5R(#,Q+"`R,#$S/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`U."4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY5+E,N(&9E9&5R86P@<W1A='5T;W)Y('1A>"!R871E/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q."4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,S4N,#`\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^)3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W
M:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,3@E.R!T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C,U+C`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M)3L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B4\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D)E;F5F:70@;V8@;&]W
M97(@=&%X(&)R86-K971S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXH,2XP,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*24\+V9O;G0^
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q+C`P/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXI)3PO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY3=&%T92!T87@@8F5N969I="P@;F5T/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH,"XP,SPO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^*24\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/C`N,#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B4\+V9O;G0^/"]T
M9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E)E<V5A<F-H(&%N9"!D
M979E;&]P;65N="!C<F5D:71S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXP+C`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXE/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+C0S/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXE/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@4V5R:68G/D5M<&QO>65E('-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO
M;CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*#$N,#,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/BDE/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXH-"XW,CPO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*24\+V9O;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/DQO
M<W,@;VX@9&5B="!C;VYV97)S:6]N/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXP+C`P/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXE/"]F
M;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXP+C`P
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXE/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/D]T:&5R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXH,"XR,3PO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*24\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@P
M+C`X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXI)3PO9F]N=#X\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^5F%L=6%T:6]N(&%L;&]W86YC93PO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P
M="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXH,S(N-S8\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/BDE/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N
M-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q
M-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@4V5R:68G/B@R.2XV,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*24\+V9O
M;G0^/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^169F96-T
M:79E(&EN8V]M92!T87@@<F%T93PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M*#`N,#,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/BDE/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR-7!T(&1O=6)L93L@
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXP+C`P/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXE/"]F;VYT/CPO=&0^/"]T<CX-
M"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6XG/CPO<#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D
M=6QE(&]F($1E9F5R<F5D(%1A>"!!<W-E=',@86YD($QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G
M:6XZ(#!P="<^/"]P/@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P
M/@T*#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9CL@;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J
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M+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;B<^)B,Q-C`[/"]P/@T*#0H\
M=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL93TS
M1"=F;VYT.B`Q,'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N<RU397)I9CL@
M=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VTG/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@
M("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!C96YT97([(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$96-E;6)E<B`S,2P@,C`Q-#PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^
M)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N
M.B!C96YT97([(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY$96-E
M;6)E<B`S,2P@,C`Q,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^1&5F97)R960@=&%X(&%S<V5T<R`H;&EA8FEL:71I
M97,I.CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y;&4],T0G=VED=&@Z
M(#4X)3L@<&%D9&EN9RUL969T.B`Q,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^3D],)B,Q-#8[<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q."4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,3`L.3(R+#DQ-#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q."4[
M('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^-RPS-C0L,#4X/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.B`Q,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+V9O;G0^/"]T9#X-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@V+#<X-SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^*3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!397)I9B<^*#,T,#PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^*3PO9F]N=#X\+W1D/CPO
M='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=P861D
M:6YG+6QE9G0Z(#$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SY/=&AE<CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^-C0L.#`V/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,3(Y+#$Y,3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=P861D:6YG
M+6QE9G0Z(#$P<'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY2
M97-E87)C:"`F(S,X.R!D979E;&]P;65N="!C<F5D:71S/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXU-34L.30U/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-38S
M+#0X-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-
M"B`@("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^1&5F97)R960@<W1O8VL@8V]M<&5N
M<V%T:6]N/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXR+#8T-BPR,#@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q
M,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L(%-E<FEF)SXR+#(U,BPV-S0\+V9O;G0^/"]T9#X-"B`@("`\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUL969T.B`Q,'!T.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I
M9B<^56YR96%L:7IE9"!G86EN(&]R(&QO<W,@;VX@:6YV97-T;65N=',\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ
M(&)L86-K(#$N-7!T('-O;&ED.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[
M/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@
M,2XU<'0@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED
M.R!L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[('1E>'0M
M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^
M+3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@
M("`\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`R,'!T.R!L:6YE+6AE:6=H
M=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!397)I9B<^5&]T86P@9&5F97)R960@=&%X(&%S<V5T
M<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;3H@8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF
M(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B
M;&%C:R`Q+C5P="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I
M9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXQ-"PQ.#,L,#@V/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA
M8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P
M="!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SXQ,"PS,#DL,#8X/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^
M#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(T-#145&1B<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY686QU871I;VX@86QL;W=A;F-E
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q-"PQ.#,L,#@V/"]F;VYT/CPO=&0^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXI/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q,"PS,#DL,#8X/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SXI/"]F;VYT/CPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SY.970@9&5F97)R960@=&%X(&%S<V5T<SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR
M-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,BXR
M-7!T(&1O=6)L93L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B0\
M+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,BXR-7!T(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M
M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXM/"]F;VYT/CPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO
M='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I;CH@,#L@=&5X
M="UI;F1E;G0Z(#`N-6EN)SX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]A-V-F8V)F-5]B9#1F7S0W.3!?83<Y.5\X-30Q
M9&0T.&1A838-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83=C9F-B
M9C5?8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V+U=O<FMS:&5E=',O4VAE
M970S-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P15I&/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("A486)L97,I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O
M;7!E;G-A=&EO;B!A;F0@4F5T:7)E;65N="!$:7-C;&]S=7)E(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V-H961U;&4@;V8@3&5A<V4@17%U:7!M96YT(%5N9&5R($-A<&ET86P@3&5A
M<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$
M)VUA<F=I;CH@,'!T)SX\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@,'!T
M)SX\+W`^#0H-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF.R!M87)G:6XZ(#`[('1E>'0M86QI
M9VXZ(&IU<W1I9GDG/E1H92!#;VUP86YY(&QE87-E<R!E<75I<&UE;G0@=6YD
M97(@8V%P:71A;`T*;&5A<V5S('=I=&@@86X@:6YT97)E<W0@<F%T92!O9B`T
M+C(U)2!P97(@86YN=6TN($%T($1E8V5M8F5R(#,Q+"`R,#$T+"!F=71U<F4@
M<&%Y;65N=',@=6YD97(@=&AE($-O;7!A;GDF(S$T-CMS(&-A<&ET86P@;&5A
M<V5S#0IW97)E(&%S(&9O;&QO=W,Z/"]P/@T*#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9CL@
M;6%R9VEN.B`P.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@
M,"XU:6XG/B8C,38P.SPO<#X-"@T*/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@<W1Y;&4],T0G9F]N=#H@,3!P="!#86QI8G)I+"!(
M96QV971I8V$L(%-A;G,M4V5R:68[('=I9'1H.B`Q,#`E.R!B;W)D97(M8V]L
M;&%P<V4Z(&-O;&QA<'-E)SX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M)SX-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@
M8FQA8VL@,2XU<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY996%R(&5N9&EN9R!$96-E;6)E<B`S,2P\+V9O;G0^/"]T9#X-"B`@
M("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^
M#0H@("`@/'1D(&-O;'-P86X],T0R('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H
M=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I
M8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G
M/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@-S,E.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^,C`Q-3PO9F]N=#X\+W1D/@T*("`@(#QT9"!S
M='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I9VAT
M.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W=I9'1H.B`R-"4[('1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE
M:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!397)I9B<^,C4L-#<W/"]F;VYT/CPO=&0^#0H@
M("`@/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET92<^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXR,#$V
M/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C
M,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L
M86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG
M:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@4V5R:68G/C$Y+#,R,3PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\
M+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^5&]T86P@;6EN:6UU;2!L
M96%S92!P87EM96YT<SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!397)I9B<^-#0L-SDX/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE
M/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^3&5S<R!A;6]U;G0@<F5P<F5S96YT:6YG(&EN
M=&5R97-T/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI9#L@;&EN92UH96EG:'0Z(#$Q
M-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN
M92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/B@Q+#<Q.#PO9F]N=#X\+W1D
M/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!3
M97)I9B<^*3PO9F]N=#X\+W1D/CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(T-#145&1B<^
M#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SY0<F5S96YT('9A;'5E(&]F(&9U='5R92!M:6YI;75M(&QE87-E('!A
M>6UE;G1S/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E
M<FEF)SXT,RPP.#`\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L(%-E<FEF)SY,97-S(&-U<G)E;G0@<&]R=&EO;CPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3H@8FQA8VL@,2XU
M<'0@<V]L:60[(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI
M9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M(%-E<FEF)SXH,C0L,3$R/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXI/"]F;VYT/CPO=&0^
M/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/D-A<&ET86P@;&5A<V4@
M;V)L:6=A=&EO;G,L(&YE="!O9B!C=7)R96YT('!O<G1I;VX\+V9O;G0^/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K
M(#(N,C5P="!D;W5B;&4[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF
M)SXD/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ(&)L86-K(#(N,C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,3@L.38X/"]F;VYT/CPO
M=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V
M,#L\+W1D/CPO='(^#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68[(&UA<F=I
M;CH@,#L@=&5X="UI;F1E;G0Z(#`N-6EN)SX\+W`^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!&
M=71U<F4@4&%Y;65N=',@56YD97(@3&5A<V5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/@T*
M#0H\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!S='EL
M93TS1"=F;VYT.B`Q,'!T($-A;&EB<FDL($AE;'9E=&EC82P@4V%N<RU397)I
M9CL@=VED=&@Z(#$P,"4[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4G/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@
M-C4E.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q-3PO9F]N
M=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[(&QI;F4M:&5I
M9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T
M:#H@,24[(&QI;F4M:&5I9VAT.B`Q,34E)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SXD/"]F;VYT
M/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W=I9'1H.B`S,B4[('1E>'0M86QI
M9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-#DR
M+#4P,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL93TS1"=W:61T:#H@,24[
M(&QI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!397)I9B<^,C`Q-CPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X-"B`@("`\=&0@
M<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L:6YE+6AE:6=H=#H@
M,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!397)I9B<^-#8X+#DY-SPO9F]N=#X\+W1D/@T*("`@(#QT
M9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-#0T5%1D8G/@T*("`@(#QT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^,C`Q-SPO9F]N=#X\+W1D/@T*
M("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T
M9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P
M.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!L
M:6YE+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^-#@Q+#0T,SPO9F]N=#X\
M+W1D/@T*("`@(#QT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q
M-C`[/"]T9#X\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E)SX-"B`@("`\=&0@<W1Y
M;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C(P,3@\+V9O
M;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G
M/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/C0Y-2PY
M,S@\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%149&)SX-
M"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R
M:68G/C(P,3D\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T>6QE/3-$)VQI
M;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68G/C(U-RPP,SD\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET92<^#0H@("`@/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L(%-E<FEF)SY4:&5R96%F=&5R/"]F;VYT/CPO=&0^#0H@("`@/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q+C5P="!S;VQI
M9#L@;&EN92UH96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^#0H@("`@/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ(&)L86-K(#$N-7!T('-O;&ED.R!T97AT
M+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G
M/C0W."PT-S,\+V9O;G0^/"]T9#X-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$Q-24G/B8C,38P.SPO=&0^/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C0T-%
M149&)SX-"B`@("`\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/E1O=&%L/"]F;VYT/CPO=&0^#0H@("`@/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q,34E)SXF(S$V,#L\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U8FQE.R!L:6YE
M+6AE:6=H=#H@,3$U)2<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!397)I9B<^)#PO9F]N=#X\+W1D/@T*("`@
M(#QT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C(U<'0@9&]U
M8FQE.R!T97AT+6%L:6=N.B!R:6=H=#L@;&EN92UH96EG:'0Z(#$Q-24G/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@4V5R:68G/C(L-C<T+#,Y,SPO9F]N=#X\+W1D/@T*("`@(#QT9"!S='EL
M93TS1"=L:6YE+6AE:6=H=#H@,3$U)2<^)B,Q-C`[/"]T9#X\+W1R/@T*/"]T
M86)L93X-"@T*#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P="<^/"]P/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?
M8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V$W8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X
M9&%A-B]7;W)K<VAE971S+U-H965T,S4N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5:1D%%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-I9VYI9FEC86YT($%C8V]U;G1I;F<@
M4&]L:6-I97,@*$1E=&%I;',@3F%R<F%T:79E*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<&]S:70@8V]V
M97)A9V4@;&EM:71S(&)Y($9$24,L('!E<B!O=VYE<CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`R-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&1E<&]S:71S(&EN
M(&5X8V5S<R!O9B!&1$E#(&QI;6ET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-RPW,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!R96-E:79A8FQE+"!N970@
M;V8@86QL;W=A;F-E(&9O<B!D;W5B=&9U;"!A8V-O=6YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPY-3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEM<&%I<FUE;G0@;V8@;&]N
M9RUL:79E9"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K(&5Q=6EV86QE;G1S+"!D:6QU=&EV92!I
M;G-T<G5M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP
M,C0L,C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPU,SDL.#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<F5S=')I8W1E9"!S=&]C:R!I
M;F-L=61E9"!I;B!C;VUM;VX@<W1O8VL@97%U:79A;&5N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(W+#(Q.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU;2!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#YF=7)N:71U<F4@
M86YD(&5Q=6EP;65N="!D97!R96-I871E9"!U<V5F=6P@;&EF93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#YF=7)N:71U
M<F4@86YD(&5Q=6EP;65N="!D97!R96-I871E9"!U<V5F=6P@;&EF93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?8F0T9E\T
M-SDP7V$W.3E?.#4T,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V$W8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X9&%A-B]7
M;W)K<VAE971S+U-H965T,S8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4Q14%#/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N
M=&EN9R!0;VQI8VEE<R`M(%-C:&5D=6QE(&]F($)A<VEC(&%N9"!$:6QU=&5D
M($5A<FYI;F=S(%!E<B!#;VUM;VX@4VAA<F4@*$1E=&%I;',I("A54T0@)"D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M97)A=&]R("T@
M;F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3`L
M,3$X+#$P,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#<L-C0S+#$R-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E;F]M:6YA=&]R("T@=V5I9VAT960@
M879E<F%G92!N=6UB97(@;V8@<VAA<F5S(&]U='-T86YD:6YG+"!B87-I8R!A
M;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PQ
M,S(L.3@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^."PV-38L.#(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S<R!P97(@<VAA<F4L(&)A<VEC(&%N
M9"!D:6QU=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$N
M,3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XD("@P+C@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?83=C9F-B9C5?8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W8V9C8F8U7V)D-&9?-#<Y
M,%]A-SDY7S@U-#%D9#0X9&%A-B]7;W)K<VAE971S+U-H965T,S<N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-6D%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%C<75I<VET
M:6]N("T@4&AA<FUA8WD@0W)E871I;VYS+"!,3$,@*$1E=&%I;',@3F%R<F%T
M:79E*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<V@@<&%I9"!F;W(@8G5S:6YE<W,@86-Q=6ES:71I;VX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C,V+#,W-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1F%I<B!V86QU92!O9B!L:6%B:6QI='D@9F]R(&5S=&EM871E
M9"!A8W%U:7-I=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3$T+#8R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4&AA<FUA8WD@0W)E871I;VYS+"!,3$,@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!P86ED(&9O<B!B
M=7-I;F5S<R!A8W%U:7-I=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]N=&EN9V5N="!C87-H('!A>6UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@<F5V
M96YU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>'!E8W1E9"!R979E;G5E(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/DUA<B`S,2P-"@D),C`Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!N=6UB97(@;V8@
M8V]M;6]N('-T;V-K(&%P<&QI960@9F]R(&-O;G1I;F=E;G0@<W1O8VL@<&%Y
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$U+#$Y,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]N9&ET:6]N(&9O<B!C;VYT:6YG96YT('-T;V-K('!A>6UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)VUA<F=I;CH@
M,'!T)SYI9B!00R!E87)N<R!R979E;G5E(&]F(&]V97(@)#<L-3`P+#`P,"!D
M=7)I;F<@=&AE(#$R(&UO;G1H('!E<FEO9"!E;F1I;F<@36%R8V@@,S$L(#(P
M,38L(&%L;"`R,34L,3DP('-H87)E<SL\+W`^#0H-"CQP('-T>6QE/3-$)VUA
M<F=I;CH@,'!T)SXF(S$V,#L\+W`^#0H-"CQP('-T>6QE/3-$)VUA<F=I;CH@
M,'!T)SYI9B!00R!E87)N<R!R979E;G5E(&]F(&)E='=E96X@)#,L-3`P+#`P
M,"!A;F0@)#<L-3`P+#`P,"!D=7)I;F<@=&AE(#$R(&UO;G1H('!E<FEO9"!E
M;F1I;F<@36%R8V@@,S$L(#(P,38L#0IA;B!A9V=R96=A=&4@;V8@=&AA="!N
M=6UB97(@;V8@<VAA<F5S(&]F($EM<')I;6ES(&-O;6UO;B!S=&]C:R!E<75A
M;"!T;R!T:&4@86UO=6YT('1H870@<W5C:"!R979E;G5E(&5X8V5E9',@)#,L
M-3`P+#`P,"!D:79I9&5D#0IB>2`Q."XU.#@R+"!R;W5N9&5D(&1O=VX@=&\@
M=&AE(&QO=V5R('=H;VQE(&YU;6)E<B`H;F]T('1O(&5X8V5E9"`R,34L,3DP
M('-H87)E<RDN/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0G5S:6YE<W,@86-Q=6ES:71I;VXL('1O=&%L(&9A
M:7(@=F%L=64@=')A;G-F97)R960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,3$T+#8R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0G5S:6YE<W,@8V]M8FEN871I;VX@<'5R8VAA
M<V4@<')I8V4@86QL;V-A=&EO;B!F;W(@9V]O9"!W:6QL/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,S$L-C(Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0:&%R;6%C>2!#<F5A=&EO
M;G,L($Q,0R!;365M8F5R72!\($UI;FEM=6T@6TUE;6)E<ET@?"!097)I;V0@
M16YD:6YG($UA<F-H(#,Q+"`R,#$V/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X<&5C=&5D(')E=F5N=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@<F5V96YU92!D871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y-87(@,S$L#0H)"3(P
M,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!H87)M86-Y($-R96%T:6]N<RP@3$Q#(%M-96UB97)=('P@36%X:6UU
M;2!;365M8F5R72!\(%!E<FEO9"!%;F1I;F<@36%R8V@@,S$L(#(P,38\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@<F5V96YU
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W+#4P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5X<&5C=&5D(')E=F5N=64@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^36%R(#,Q+`T*"0DR,#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
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M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U,04,^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^06-Q=6ES:71I;VX@+2!0:&%R;6%C>2!#<F5A=&EO;G,L($QL8R`M
M(%-C:&5D=6QE(&]F($%C<75I<VET:6]N($1A=&4@1F%I<B!686QU92!O9B!#
M;VYS:61E<F%T:6]N("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%Y;65N="!T;R!T
M:&4@4$,@4V5L;&5R<R!A="!C;&]S:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#8S-BPS-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!H87)M86-Y($-R
M96%T:6]N<RP@3$Q#(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<V@@<&%Y;65N="!T;R!T:&4@4$,@4V5L;&5R<R!A="!C
M;&]S:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VYT:6YG96YT(&-O;6UO;B!S=&]C:R!I<W-U86YC92!T;R!T:&4@4$,@
M4V5L;&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@S+#$U
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]N=&EN9V5N="!C87-H(&-O;G-I9&5R871I;VX@=&\@=&AE(%!#(%-E
M;&QE<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Q+#0V-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1O=&%L(&%C<75I<VET:6]N(&1A=&4@9F%I<B!V86QU93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#$Q-"PV,C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-$U!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#$^/'-T<F]N9SY!8W%U:7-I=&EO;B`M(%!H87)M86-Y($-R96%T:6]N
M<RP@3&QC("T@4V-H961U;&4@;V8@17-T:6UA=&5D($9A:7(@5F%L=64@;V8@
M07-S971S($%C<75I<F5D(&%N9"!,:6%B:6QI=&EE<R!!<W-U;65D("A$971A
M:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1V]O9'=I;&P\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,S,Q+#8R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&AA<FUA8WD@
M0W)E871I;VYS+"!,3$,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PY.#(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E8V5I
M=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+#0R,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,"PR-38\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=F5N=&]R>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$S+#$Y,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD
M(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L
M-3$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);G1A;F=I8FQE(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C4Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&ED96YT:69I86)L92!A<W-E=',@
M86-Q=6ER960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#$P
M+#,U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C;W5N=',@<&%Y86)L92!A;F0@86-C<G5E9"!L:6%B:6QI=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(P+#`T.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H
M97(@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$P-RPS,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<R!A<W-U;65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,C<L,S4W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!I9&5N=&EF
M:6%B;&4@87-S971S(&QE<W,@;&EA8FEL:71I97,@87-S=6UE9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S@S+#`P,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1V]O9'=I;&P\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S,2PV,C$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@87-S
M971S(&%C<75I<F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$L,3$T+#8R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?83=C9F-B9C5?8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W8V9C8F8U7V)D-&9?-#<Y
M,%]A-SDY7S@U-#%D9#0X9&%A-B]7;W)K<VAE971S+U-H965T-#`N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5/0D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D%C<75I<VET
M:6]N("T@4&AA<FUA8WD@0W)E871I;VYS+"!,;&,@+2!38VAE9'5L92!O9B!2
M97-U;'0@;V8@3W!E<F%T:6]N(&9R;VT@06-Q=6ES:71I;VX@*$1E=&%I;',I
M("A0:&%R;6%C>2!#<F5A=&EO;G,L($Q,0R!;365M8F5R72P@55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0:&%R;6%C
M>2!#<F5A=&EO;G,L($Q,0R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!R979E;G5E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+#8U,BPS.#8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!L;W-S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#8V,BPY-CDI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14A"04,^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^06-Q=6ES:71I;VX@+2!0:&%R;6%C>2!#
M<F5A=&EO;G,L($QL8R`M(%-C:&5D=6QE(&]F(%!R;R!&;W)M82!&:6YA;F-I
M86P@26YF;W)M871I;VX@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY"=7-I;F5S
M<R!#;VUB:6YA=&EO;G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!R979E;G5E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#(X,BPV.#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L.#8V+#4W
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,3`L,#0X+#,X,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#<L,#@T+#`Q-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
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M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%15%!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY!8W%U:7-I=&EO;B`M(%!H87)M86-Y($-R96%T:6]N<RP@3&QC("T@
M4V-H961U;&4@;V8@26YT86YG:6)L92!!<W-E=',@06-Q=6ES:71I;VX@*$1E
M=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-C4Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0W5S=&]M97(@4F5L871I;VYS:&EP<R!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.38L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M=7-T;VUE<B!296QA=&EO;G-H:7!S(%M-96UB97)=('P@36EN:6UU;2!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<V5F=6P@
M3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,3`@>65A<G,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-U<W1O;65R(%)E;&%T:6]N<VAI<',@6TUE;6)E<ET@?"!-87AI;75M(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5S969U
M;"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ-2!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5')A9&4@3F%M92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y&86ER(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^57-E9G5L($QI9F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BU#;VUP971I=&EO;B!#;W9E;F%N
M="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M86ER(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E5S969U;"!,:69E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XT('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=&%T92!0:&%R;6%C>2!,:6-E;G-E<R!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<V5F=6P@
M3&EF93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,C4@>65A<G,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$W8V9C
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M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4D4^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^4F5S=')I8W1E9"!3:&]R="U497)M
M($EN=F5S=&UE;G0@*$1E=&%I;',@3F%R<F%T:79E*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4F5S=')I8W1E9"!3:&]R="UT97)M($EN=F5S=&UE;G0\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V5R=&EF:6-A
M=&4@;V8@9&5P;W-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q-3`L,C8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P13-%04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^26YV96YT;W)I
M97,@+2!38VAE9'5L92!O9B!);G9E;G1O<FEE<R`H1&5T86EL<RD@*%531"`D
M*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^26YV96YT;W)Y($1I<V-L;W-U<F4@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M87<@;6%T97)I86QS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#$T-BPS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=O<FL@:6X@<')O9W)E<W,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDW+#@P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1FEN:7-H960@9V]O9',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$R."PV,S0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!I;G9E;G1O
M<FEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-S(L-S,U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
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M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P13)'04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^4')E<&%I
M9"!%>'!E;G-E<R!A;F0@3W1H97(@0W5R<F5N="!!<W-E=',@+2!38VAE9'5L
M92!O9B!0<F5P86ED($5X<&5N<V5S(&%N9"!/=&AE<B!#=7)R96YT($%S<V5T
M<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5F97)R960@0V]S
M=',L($-A<&ET86QI>F5D+"!0<F5P86ED+"!A;F0@3W1H97(@07-S971S($1I
M<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED('-T;V-K+6)A<V5D(&-O;G-U;'1I
M;F<@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,C8L-C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(')E;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V+#(X.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I
M9"!I;G-U<F%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M,RPW-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS.2PQ-C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D]T:&5R('!R97!A:60@97AP96YS97,@86YD(&1E<&]S
M:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,38L-C(U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(L
M.38T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@<')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N
M="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C0P
M+#0P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3`U+#`V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?83=C9F-B9C5?8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W8V9C8F8U7V)D-&9?
M-#<Y,%]A-SDY7S@U-#%D9#0X9&%A-B]7;W)K<VAE971S+U-H965T-#8N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5&2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY&=7)N:71U
M<F4@86YD($5Q=6EP;65N="`H1&5T86EL<R!.87)R871I=F4I("A54T0@)"D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N(&]F(&9U<FYI='5R92!A;F0@
M97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,W
M+#,T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-2PV-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%,DM!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY&=7)N:71U
M<F4@86YD($5Q=6EP;65N="`M(%-C:&5D=6QE(&]F($9U<FYI='5R92!A;F0@
M17%U:7!M96YT("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P
M97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;06)S=')A8W1=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;7!U=&5R('-O
M9G1W87)E(&%N9"!H87)D=V%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`U,BPU-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(T+#4S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1G5R;FET=7)E(&%N9"!E<75I<&UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$U-"PR,34\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PT
M-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DQA8B!A;F0@<&AA<FUA8WD@97%U:7!M96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV,2PX-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE87-E:&]L
M9"!I;7!R;W9E;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(P+#$W,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U<FYI='5R92!A;F0@97%U:7!M96YT
M+"!G<F]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@X+#@S
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,T+#DX-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C=6UU;&%T960@9&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0U+#0S-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X
M+#`Y,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&=7)N:71U<F4@86YD(&5Q=6EP;65N="P@3F5T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(T,RPS.34\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(V+#@Y,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?
M8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V$W8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X
M9&%A-B]7;W)K<VAE971S+U-H965T-#@N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.-$%%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN=&%N9VEB;&4@07-S971S(&%N9"!'
M;V]D=VEL;"`M(%-C:&5D=6QE(&]F($EN=&%N9VEB;&4@07-S971S("A$971A
M:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@
M-C4Y+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C=6UU;&%T960@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@T."PP,#8I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@0V%R<GEI;F<@=F%L
M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Q,"PY.30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U
M<W1O;65R(%)E;&%T:6]N<VAI<',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3DV+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@86UO<G1I>F%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-BPW-#`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@0V%R
M<GEI;F<@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4U
M.2PR-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-U<W1O;65R(%)E;&%T:6]N<VAI<',@6TUE;6)E<ET@?"!-:6YI
M;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%M;W)T:7IA=&EO;B!P97)I;V1S("AI;B!Y96%R<RD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#=7-T;VUE<B!296QA=&EO
M;G-H:7!S(%M-96UB97)=('P@36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@<&5R:6]D<R`H
M:6X@>65A<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ-2!Y
M96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5')A9&4@3F%M92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@<&5R:6]D<R`H:6X@>65A<G,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU('EE87)S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;W-T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU
M;&%T960@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@W-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@0V%R<GEI;F<@=F%L=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0L,C4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM0V]M<&5T92!#;W9E;F%N="!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]R
M=&EZ871I;VX@<&5R:6]D<R`H:6X@>65A<G,I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XT('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;W-T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&%M;W)T:7IA=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.2PS-S4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M0V%R<GEI;F<@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0P+#8R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1A=&4@4&AA<FUA8WD@3&EC96YS97,@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N('!E
M<FEO9',@*&EN('EE87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^,C4@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-U;75L871E9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,30Q*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($-A<G)Y:6YG('9A
M;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@-BPX-3D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%04I!13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);G1A;F=I8FQE($%S<V5T<R!A;F0@
M1V]O9'=I;&P@+2!38VAE9'5L92!O9B!!;6]R=&EZ871I;VX@17AP96YS97,@
M9F]R($EN=&%N9VEB;&4@07-S971S("A$971A:6QS*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IA
M=&EO;B!O9B!I;G1A;F=I8FQE(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T."PP,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<W1O;65R(%)E
M;&%T:6]N<VAI<',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&EN=&%N9VEB;&4@87-S971S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-BPW-#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R861E($YA
M;64@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06UO<G1I>F%T:6]N(&]F(&EN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;BU#;VUP971I=&EO;B!#;W9E
M;F%N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!;6]R=&EZ871I;VX@;V8@:6YT86YG:6)L92!A<W-E=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,S<U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&%T92!0:&%R;6%C>2!,
M:6-E;G-E<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!;6]R=&EZ871I;VX@;V8@:6YT86YG:6)L92!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PQ-#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6DM!0SX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#$^/'-T<F]N9SY);G1A;F=I8FQE($%S<V5T<R!A;F0@1V]O9'=I;&P@
M+2!38VAE9'5L92!O9B!%<W1I;6%T960@1G5T=7)E($%M;W)T:7IA=&EO;B!%
M>'!E;G-E("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY';V]D=VEL
M;"!A;F0@26YT86YG:6)L92!!<W-E=',@1&ES8VQO<W5R92!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P
M,34\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C<L,#@W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR
M,#$V/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-RPP.#<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P
M,3<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W+#`X-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q
M.#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3<L-S$R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,RPX,S<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1H97)E
M869T97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y."PQ.#0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y);G1A;F=I8FQE(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`V,3`L.3DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P151(/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/DEN=&%N9VEB;&4@07-S971S(&%N9"!';V]D=VEL;"`M(%-C:&5D
M=6QE(&]F($-H86YG97,@:6X@0V%R<GEI;F<@5F%L=64@;V8@1V]O9'=I;&P@
M*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1V]O9'=I;&P@86YD($EN=&%N9VEB;&4@
M07-S971S($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y';V]D=VEL;"P@0F5G:6YN:6YG
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!#($%C<75I<VET:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS,S$L-C(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y';V]D=VEL;"P@16YD:6YG/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#,S,2PV,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
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M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%3D9!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY!8V-O=6YT<R!087EA8FQE(&%N9"!!8V-R=65D($5X<&5N<V5S("A$
M971A:6QS($YA<G)A='9I92D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CYS<69T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CYS<69T/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^
M<W%F=#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P
M+"`R,#$S/&)R/G-Q9G0\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^4&%Y86)L97,@86YD($%C8W)U86QS(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M07)E82!O9B!O9F9I8V4@<W!A8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<L-38U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-RPU-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#@W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^07)E82!O9B!P<F5V:6]U<R!O9F9I
M8V4@<W!A8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.#<T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y296-O9VYI>F5D(&QE87-E(&QO<W-E<R!R96QA=&5D('1O(&5S=&EM871E
M9"!R96UA:6YI;F<@;&5A<V4@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$Q-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&)A<V5D(&-O;7!E;G-A
M=&EO;B!A8V-R=6%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E;&%T
M960@=&\@<F5S=')I8W1E9"!C;VUM;VX@<W1O8VL@:7-S=6%N8V5S(&%N9"!A
M8V-R=6%L<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S.2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$T,RPU-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%0DQ!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY!8V-O=6YT
M<R!087EA8FQE(&%N9"!!8V-R=65D($5X<&5N<V5S("T@4V-H961U;&4@;V8@
M06-C;W5N=',@4&%Y86)L92!A;F0@06-C<G5E9"!%>'!E;G-E<R`H1&5T86EL
M<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,CY$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4&%Y86)L97,@86YD($%C8W)U86QS(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C;W5N=',@<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`V.3@L.#`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R-C$L.3(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E
M<G)E9"!R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#DW
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0G5I;&1I;F<@;&5A<V4@;&EA8FEL:71Y*#$I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RPU-3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\
M+W-U<#X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y/=&AE<B!A8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,ET\+W-U<#X\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&%C8V]U;G1S('!A>6%B;&4@86YD(&%C8W)U
M960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q
M-BPS,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3$L.3(T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,97-S.B!#=7)R96YT('!O
M<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<X-BPV-S4I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S$Q+#DR-"D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM8W5R<F5N="!T;W1A;"!A
M8V-O=6YT<R!P87EA8FQE(&%N9"!A8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(Y+#8U.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1D(&-O;'-P86X],T0U/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$:6YN97)&;V]T;F]T93X-
M"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,5T\+W1D/@T*("`@("`@("`\
M=&0@8V]L<W!A;CTS1#0@=F%L:6=N/3-$=&]P/DEN(%-E<'1E;6)E<B`R,#$T
M+"!T:&4@0V]M<&%N>2!R96QO8V%T960@:71S('!R:6UA<GD@;W!E<F%T:6]N
M<R!T;R!A(#<L-38U('-Q=6%R92!F;V]T(&]F9FEC92!F86-I;&ET>2!I;B!3
M86X@1&EE9V\L($-A;&EF;W)N:6$N($%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T
M+"!T:&4@0V]M<&%N>2!W87,@;6%R:V5T:6YG(&ET<R!P<F5V:6]U<R!O9F9I
M8V4@<W!A8V4@*#,L.#<T('-Q=6%R92!F965T*2!A<R!A('-U8FQE87-E('1H
M<F]U9V@@:71S(')E;6%I;FEN9R!L96%S92!T97)M+B!4:&4@0V]M<&%N>2!R
M96-O9VYI>F5D(&$@;&]S<R!O9B!A<'!R;WAI;6%T96QY("0Q,3<L,#`P(&1U
M<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"P@<F5L871E
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M,30N/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1I;FYE
M<D9O;W1N;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P/ELR73PO=&0^
M#0H@("`@("`@(#QT9"!C;VQS<&%N/3-$-"!V86QI9VX],T1T;W`^5&AE(&%M
M;W5N="!C;VYS:7-T<R!O9B!A("0S.2PP,#`@<W1O8VLM8F%S960@8V]M<&5N
M<V%T:6]N(&%C8W)U86P@870@1&5C96UB97(@,S$L(#(P,30@9F]R('-T;V-K
M(&]P=&EO;G,@=&\@8F4@9W)A;G1E9"!F;W(@<V5R=FEC97,@<&5R9F]R;65D
M+B!4:&4@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@<F5L871E
M9"!T;R!R97-T<FEC=&5D(&-O;6UO;B!S=&]C:R!I<W-U86YC97,@86YD(&%C
M8W)U86QS('=A<R`D,SDL,#`P(&%N9"`D,30S+#4U,R!D=7)I;F<@=&AE('EE
M87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"`R,#$S+"!R97-P96-T
M:79E;'DN/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2T)!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY$96)T("A$971A:6QS($YA<G)A=&EV92D@
M*%!H87)M86-Y($-R96%T:6]N<RP@3$Q#(%M-96UB97)=+"!54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4&AA<FUA8WD@0W)E871I;VYS+"!,3$,@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3&EN92!O9B!C<F5D:71S(&)O<G)O=VEN
M9R!L:6UI="!M87AI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0F]R<F]W960@=&5R;2!L;V%N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%,U,R3SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2`H1&5T86EL<R!.87)R871I=F4I("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#,^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XR($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$.#XQ($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#(W+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA>2`P,BP@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y&96(N(#$S+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA<BX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;"X@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1F5B+B`R."P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y!<'(N(#`R+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA>2`R-"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y.;W8N(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,S`L(#(P,30\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R+B`S,"P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,S$L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`P."P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87!I
M=&%L('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.34L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R
M97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.3`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDP+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@=6YD
M97)W<FET=&5N('!U8FQI8R!O9F9E<FEN9R!C;VUM;VX@<W1O8VL@<VAA<F5S
M(&-L;W-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX-#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VL@<')I8V4@<&5R('-H87)E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#4N,C4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@
M<'5B;&EC(&]F9F5R:6YG<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`X+#$T,"PT,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<VAA<F5S('!U<F-H87-E9"!B
M>2!U;F1E<G=R:71E<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(W-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYE="!C87-H('!R;V-E961S(&9R;VT@=&AE(&5X97)C:7-E
M(&]F('1H92!O=F5R+6%L;&]T;65N="!O<'1I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L,S$V+#$Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@:7-S=65D(&1U<FEN
M9R!P97)I;V0@=F%L=64@:7-S=65D('1O('5N9&5R=W)I=&5R<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<Y+#@V,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W.2PX-C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N9&5R
M=W)I=&EN9R!A9W)E96UE;G0@9&5S8W)I<'1I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
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M:6YG("AI;F-L=61I;F<@."XU)2!O9B!S:&%R97,@<V]L9"!P=7)S=6%N=`T*
M=&\@=&AE(&5X97)C:7-E(&]F('1H92!O=F5R+6%L;&]T;65N="!O<'1I;VXI
M+B!4:&4@56YD97)W<FET97(@5V%R<F%N=',@87)E(&5X97)C:7-A8FQE(&%T
M("0U+C(U('!E<B!S:&%R92`H,3`P)2!O9B!T:&4@<')I8V4@=&\-"G1H92!P
M=6)L:6,@;V8@=&AE(&-O;6UO;B!S=&]C:R!S;VQD(&EN('1H92!0=6)L:6,@
M3V9F97)I;F<I+"!C;VUM96YC:6YG(&]N('1H92!C;&]S:6YG(&1A=&4@;V8@
M=&AE(%!U8FQI8R!/9F9E<FEN9R!A;F0@97AP:7)E(&9I=F4-"GEE87)S(&9R
M;VT@=&AE(&-L;W-I;F<@9&%T92!O9B!T:&4@4'5B;&EC($]F9F5R:6YG+CPO
M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!A>6UE;G0@;6%D92!O;B!C86YC96QL871I;VX@;V8@8V]M;6]N('-T
M;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A>6UE
M;G0@;6%D92!O;B!C86YC96QL871I;VX@;V8@8V]M;6]N('-T;V-K+"!S:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<W1O8VL@:7-S=65D(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,Y+#0T-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M(&ES<W5E9"!S971T;&4@8V%S:&QE<W,@97AE<F-I<V4@<')O=FES:6]N+"!S
M:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#,P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VL@:7-S=65D('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C8L-#,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D('5P;VX@97AE
M<F-I<V4@;V8@<W1O8VL@;W!T:6]N<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,C<L,C$V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@:7-S=65D('5P;VX@
M97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3@S+#@Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!S:&%R97,@:7-S=65D
M('5P;VX@97AE<F-I<V4@;V8@<W1O8VL@;W!T:6]N<RP@<VAA<F5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C`L-S<W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F
M<F]M(&ES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#4R+#@S,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I
M<V4@;V8@8V]M;6]N('-T;V-K(&]P=&EO;B!T;R!P=7)C:&%S92!O9B!C;VUM
M;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-BPV
M-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!U<&]N('9E<W1I;F<@;V8@
M4E-5<R!N970@;V8@=&%X('=I=&AH;VQD:6YG("P@<VAA<F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#DU-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&-O;6UO
M;B!S=&]C:R!H96QD(&9O<B!P87ER;VQL('1A>#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PU,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C
M:R!U<&]N('9E<W1I;F<@;V8@4E-5<R!N970@;V8@=&%X('=I=&AH;VQD:6YG
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,RPQ,#DI/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R
M97,@:7-S=65D('5P;VX@=V%R<F%N=',@97AE<F-I<V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0W+#@R.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES<W5E9"!U<&]N
M(&5X97)C:7-E(&]F('=A<G)A;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,W+#@V-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N=',@86YD('-H87)E<R!I<W-U960@=7!O
M;B!E>&-I<V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV+#,Y,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@=&\@<'5R8VAA<V4@8V]M;6]N
M('-T;V-K(&5X97)C:7-E('!R:6-E('!E<B!S:&%R93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`U+CDR-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I<W-U
M86YC92!O9B!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@=V%R<F%N=',@<VAA<F5S(&ES
M<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$L-#,X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>&5R8VES92!O9B!W87)R86YT('1O('!U<F-H87-E(&]F(&-O;6UO;B!S=&]C
M:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(S+#<Q-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R
M<F%N=',@<VAA<F5S(&5X97)C:7-E('!R:6-E('!E<B!S:&%R93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+C(U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O
M8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<&%R('9A;'5E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F
M97)R960@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&]U='-T
M86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C
M:R!O<'1I;VX@97AE<F-I<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-RXU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);G1R:6YS:6,@=F%L=64@;V8@<W1O8VL@;W!T
M:6]N<R!E>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,38Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N<R!G<F%N=&5D('9E<W1I;F<@=&5R
M;7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$
M)VUA<F=I;CH@,'!T)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L(%-E<FEF)SY697-T:6YG('1E<FUS(&9O<B!O
M<'1I;VYS(&=R86YT960@:6X@9FES8V%L('EE87)S#0HR,#$T(&%N9"`R,#$S
M('1O(&5M<&QO>65E<RP@9&ER96-T;W)S(&%N9"!C;VYS=6QT86YT<R!T>7!I
M8V%L;'D@:6YC;'5D960@;VYE(&]F('1H92!F;VQL;W=I;F<@=F5S=&EN9R!S
M8VAE9'5L97,Z(#(U)2!O<B`S,R4@;V8-"G1H92!S:&%R97,@<W5B:F5C="!T
M;R!T:&4@;W!T:6]N('9E<W0@86YD(&)E8V]M92!E>&5R8VES86)L92!O;B!T
M:&4@9FER<W0@86YN:79E<G-A<GD@;V8@=&AE(&=R86YT(&1A=&4@86YD('1H
M92!R96UA:6YI;F<@-S4E#0IO<B`V-R4L(')E<W!E8W1I=F5L>2P@;V8@=&AE
M('-H87)E<R!S=6)J96-T('1O('1H92!O<'1I;VX@=F5S="!A;F0@8F5C;VUE
M(&5X97)C:7-A8FQE(&EN(&5Q=6%L('%U87)T97)L>2!I;G-T86QL;65N=',@
M=&AE<F5A9G1E<@T*;W9E<B!T=V\@;W(@=&AR964@>65A<G,L(')E<W!E8W1I
M=F5L>3L@<75A<G1E<FQY('9E<W1I;F<@;W9E<B!A('1H<F5E('EE87(@<&5R
M:6]D.R!O<B!M;VYT:&QY+"!Q=6%R=&5R;'D@;W(@,3`P)2!V97-T:6YG(&%S
M<V]C:6%T960-"G=I=&@@=&AE('!R;W9I<VEO;B!O<B!C;VUP;&5T:6]N(&]F
M('-E<G9I8V5S('!R;W9I9&5D('5N9&5R(&-O;G1R86-T<R!W:71H(&-O;G-U
M;'1A;G1S+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E8V]G;FEZ960@8V]M<&5N<V%T:6]N
M(&5X<&5N<V4@<F5L871E9"!T;R!U;G9E<W1E9"!S=&]C:R!O<'1I;VYS(&=R
M86YT960@=6YD97(@=&AE(%!L86X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L-3<Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17AP96YS92!E>'!E8W1E9"!T;R!R96-O9VYI
M>F4@;W9E<B!T:&4@=V5I9VAT960M879E<F%G92!R96UA:6YI;F<@=F5S=&EN
M9R!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(@>65A
M<G,@,2!M;VYT:"`V(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O8VL@=6YI=',@:7-S
M=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(U,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E<W1R:6-T960@<W1O8VL@=F5S="!I;B!F=71U<F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,#4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!S=&]C
M:R!V97-T960@:6UM961I871E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D=R86YT960@<F5S=')I8W1E9"!S=&]C:R!U;FET
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M
M8F5R(&]F(&=R86YT960@<F5S=')I8W1E9"!S=&]C:R!U;FET<R!U;G9E<W1E
M9"!A9W)E960@=&\@8V%N8V5L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(')E<W1R:6-T960@<W1O8VL@
M=6YI=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X.2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,BPV,30L-C$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ,S0L.3<S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!B87-E9"!C
M;VUP96YS871I;VX@;V8@=V%R<F%N=',@:7-S=65D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#`Q."PP-C@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($]P=&EO;G,@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@
M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#$S-RPV,S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#8X.2PW-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!A<W-U
M;7!T:6]N(&]F('9O;&%T:6QI='DL(&UI;FEM=6T\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C@U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!A<W-U;7!T:6]N
M(&]F('9O;&%T:6QI='DL(&UA>&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,T-BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@87-S=6UP=&EO;B!O9B!R
M:7-K(&9R964@:6YT97)E<W0@<F%T97,L(&UI;FEM=6T\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`N,S(E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&%S<W5M<'1I
M;VX@;V8@<FES:R!F<F5E(&EN=&5R97-T(')A=&5S+"!M87AI;75M/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C,Q)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@8F%S960@
M8V]M<&5N<V%T:6]N(&]F('=A<G)A;G1S(&ES<W5E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C8L-C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8X+#<W-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M<R!E>'!I<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C,@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!W87)R86YT<R!V97-T960@:6UM961I=&5L>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@
M<VAA<F5S('9E<W1E9"!I;B!I;G-T86QL;65N=',@9F]R(&5A8V@@9FEV92!M
M;VYT:',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M86ER('9A;'5E(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS,3DL-S@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@:7-S=65D('1O('!U<F-H
M87-E(&YU;6)E<B!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@97AE<F-I<V4@
M<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@."XU/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^(#4N
M,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DUO;G1E($-A<FQO(%-I;75L871I;VX@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@<F5S=')I8W1E
M9"!S=&]C:R!U;FET<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&%S<W5M<'1I;VYS+"!L:69E
M('1E<FT\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(@>65A<G,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D9A:7(@=F%L=64@87-S=6UP=&EO;B!O9B!V;VQA=&EL:71Y+"!M:6YI;75M
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-2XP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@
M=F%L=64@87-S=6UP=&EO;B!O9B!V;VQA=&EL:71Y+"!M87AI;75M/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-2XP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@
M87-S=6UP=&EO;B!O9B!R:7-K(&9R964@:6YT97)E<W0@<F%T97,L(&UI;FEM
M=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,3,E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER
M('9A;'5E(&%S<W5M<'1I;VX@;V8@<FES:R!F<F5E(&EN=&5R97-T(')A=&5S
M+"!M87AI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C,V
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16UP;&]Y965S($%N9"!$:7)E8W1O<G,@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!F;W)F96ET
M=7)E(&9A8W1O<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VYS=6QT86YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O8VL@=6YI=',@:7-S=65D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.#@L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#@P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M<W-U86YC92!O9B!R97-T<FEC=&5D('-T;V-K('5N:71S+"!S:&%R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4&5R8V5N=&%G92!O9B!R97-T<FEC=&5D('-T;V-K('5N:71S('9E
M<W1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M97)C96YT86=E(&]F(')E;6%I;FEN9R!R97-T<FEC=&5D('-T;V-K('5N:71S
M('9E<W1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<W-U86YC92!O9B!R97-T<FEC=&5D('-T;V-K('5N:71S('=E<F4@9F]R
M9F5I=&5D(&%N9"!D965M960L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F]N+45M<&QO>65E($1I<F5C=&]R<R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T
M<FEC=&5D('-T;V-K('5N:71S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C`P+#`Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(W,2PX-30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(')E<W1R
M:6-T960@<W1O8VL@=6YI=',L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C8L-#DR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S0L,S(U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)M97(@1&ER96-T;W)S(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R
M:6-T960@<W1O8VL@=6YI=',@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS.2PX,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(')E<W1R:6-T960@<W1O
M8VL@=6YI=',L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^."PY-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5M<&QO>65E<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D('-T;V-K('5N:71S(&ES<W5E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(L-#DX/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U
M86YC92!O9B!R97-T<FEC=&5D('-T;V-K('5N:71S+"!S:&%R97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#0Q.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!3
M=&]C:R!5;FET<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;VUM;VX@<W1O8VL@<VAA<F5S(&ES<W5E9"!F;W(@<V5R=FEC
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W+#(Q.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!F;W(@<V5R=FEC97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(X,BPY.3<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!F=71U
M<F4@:7-S=6%N8V5S('-H87)E('5N9&5R('1H92!P;&%N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#,V-BPS-CD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N<F5C;V=N:7IE9"!C
M;VUP96YS871I;VX@97AP96YS92!R96QA=&5D('1O('5N=F5S=&5D('-T;V-K
M(&]P=&EO;G,@9W)A;G1E9"!U;F1E<B!T:&4@4&QA;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PY,C,L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E;G-E(&5X<&5C=&5D
M('1O(')E8V]G;FEZ92!O=F5R('1H92!W96EG:'1E9"UA=F5R86=E(')E;6%I
M;FEN9R!V97-T:6YG('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^,2!Y96%R(#,@;6]N=&AS(#(V(&1A>7,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@4W1O
M8VL@56YI=',@6TUE;6)E<ET@?"!.;VXM16UP;&]Y964@1&ER96-T;W)S(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R
M:6-T960@<W1O8VL@=6YI=',@=F5S="!P97)I;V0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/C$@>65A<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C$S(&UO;G1H<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!3
M=&]C:R!5;FET<R!;365M8F5R72!\($9O<FUE<B!$:7)E8W1O<G,@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E
M9"!S=&]C:R!U;FET<R!V97-T('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^,3,@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T<FEC=&5D(%-T;V-K(%5N:71S
M(%M-96UB97)=('P@16UP;&]Y965S(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@<W1O8VL@=6YI=',@=F5S
M="!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C,@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/C(P,#<@26YC96YT:79E(%-T;V-K($%N9"!!=V%R9',@4&QA;B!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M
M(&YU;6)E<B!O9B!C;VUM;VX@<W1O8VL@:7-S=6%N8V4@=6YD97(@=&AE('!L
M86X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F%U;2!097)F;W)M86YC92!%<75I='D@07=A<F0@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!S=&]C:R!U
M;FET<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X
M.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN:71I86P@9F%I<B!V86QU92!O9B!R97-T<FEC=&5D('-T;V-K
M('5N:71S+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D)A=6T@4&5R9F]R;6%N8V4@17%U:71Y($%W87)D(%M-96UB
M97)=('P@36]N=&4@0V%R;&\@4VEM=6QA=&EO;B!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!R97-T<FEC
M=&5D('-T;V-K('5N:71S+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@87-S=6UP=&EO;G,L(&QI
M9F4@=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1F%I<B!V86QU92!A<W-U;7!T:6]N<RP@=F]L871I;&ET>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&%S
M<W5M<'1I;VYS+"!R:7-K(&9R964@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,"XV-"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A=6T@4&5R9F]R;6%N8V4@
M17%U:71Y($%W87)D(%M-96UB97)=('P@36]N=&4@0V%R;&\@4VEM=6QA=&EO
M;B!/;F4@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^27-S=6%N8V4@;V8@<F5S=')I8W1E9"!S=&]C:R!U;FET<RP@<VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER
M('9A;'5E(&%S<W5M<'1I;VYS+"!L:69E('1E<FT\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/C,@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@87-S=6UP=&EO
M;G,L('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1F%I<B!V86QU92!A<W-U;7!T:6]N<RP@<FES:R!F<F5E(&EN
M=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M,S`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y297-T<FEC=&5D(%-T;V-K(%5N:71S($]N92!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!B87-E9"!C;VUP
M96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S,R
M+#$W-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@R,BPQ,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUI;FEM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4W1O8VL@;W!T:6]N('!U<F-H87-E(&]F(&5X
M97)C:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#,N-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:R!E>&5R8VES92!P<FEC92!P97(@<VAA<F4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXV/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT<F%C
M='5A;"!T97)M(&]F('-T;V-K(&]P=&EO;G,@9W)A;G1E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&%R9V5T(')A;F=I;F<@
M<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R
M86YT960@<F5S=')I8W1E9"!S=&]C:R!U;FET<R!P97(@<&5R<V]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N=&5D(')E
M<W1R:6-T960@<W1O8VL@=6YI=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(L-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^36EN:6UU;2!;365M8F5R72!\(%=A<G)A;G0@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I
M<B!V86QU92!A<W-U;7!T:6]N<RP@;&EF92!T97)M/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XR('EE87)S(#<@;6]N=&AS(#8@9&%Y<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X
M:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:R!O<'1I;VX@<'5R8VAA<V4@;V8@97AE<F-I<V4@<')I8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M(&5X97)C:7-E('!R:6-E('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYT<F%C='5A;"!T97)M(&]F('-T;V-K(&]P
M=&EO;G,@9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1A<F=E="!R86YG:6YG('!R:6-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N=&5D(')E<W1R:6-T960@<W1O
M8VL@=6YI=',@<&5R('!E<G-O;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,2PR-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y'<F%N=&5D(')E<W1R:6-T960@<W1O8VL@=6YI
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M36%X:6UU;2!;365M8F5R72!\(%=A<G)A;G0@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!A<W-U;7!T:6]N
M<RP@;&EF92!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XU
M('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y297-T<FEC=&5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!S:&%R97,@:7-S
M=65D(&9O<B!S97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#$Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!F;W(@<V5R=FEC
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y+#$V,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#<U
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!S:&%R97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C8L.#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D('-H
M87)E<R!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-87)K($)A=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!I<W-U960@9F]R(')E;&%T
M960@<&%R='D@=F5S=&EN9R!O9B!24U5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=R86YT960@<F5S=')I8W1E9"!S=&]C:R!U
M;FET<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3G5M8F5R(&]F(&=R86YT960@<F5S=')I8W1E9"!S=&]C:R!U;FET<R!U;G9E
M<W1E9"!A9W)E960@=&\@8V%N8V5L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&-A;F-E;&5D(')E<W1R
M:6-T960@<W1O8VL@=6YI=',@<&QU<R!I;F-R96UE;G1A;"!C;W-T+"!S:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0U,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES
M<W5A;F-E(&]F(')E<W1R:6-T960@<W1O8VL@=6YI=',L('-H87)E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%R:R!"875M
M(%M-96UB97)=('P@0F%U;2!097)F;W)M86YC92!%<75I='D@07=A<F0@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I
M8W1E9"!S=&]C:R!U;FET<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L-3$U+#`Y,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@<F5S=')I8W1E9"!S
M=&]C:R!U;FET<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);FET:6%L(&9A:7(@=F%L=64@;V8@<F5S=')I8W1E
M9"!S=&]C:R!U;FET<RP@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$<BX@4F]B97)T($MA;6UE<B!;365M8F5R72!\
M(%)E<W1R:6-T960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K('-H87)E<R!I<W-U960@9F]R
M('-E<G9I8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S=&]C:R!I<W-U960@9F]R('-E<G9I8V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(X,BPY.3<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3U-!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2`M(%-C:&5D=6QE
M(&]F(%-T;V-K($]P=&EO;B!0;&%N($%C=&EV:71Y("A$971A:6QS*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@<VAA<F5S+"!/<'1I;VYS(&5X97)C:7-E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C(W+#(Q-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E
M<RP@3W5T<W1A;F1I;F<L($5N9&EN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#`R.2PR-#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V9RX@4F5M
M86EN:6YG($-O;G1R86-T=6%L($QI9F4L($]P=&EO;G,@;W5T<W1A;F1I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C8@>65A<G,@,3@@9&%Y
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W1O8VL@3W!T:6]N(%!L86X@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<RP@3W5T<W1A;F1I
M;F<L($)E9VEN;FEN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#,R."PW.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,L($]P=&EO;G,@
M9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0U+#@X
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3G5M8F5R(&]F('-H87)E<RP@3W!T:6]N<R!E>&5R8VES960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,P-RPT,CDI/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@
M<VAA<F5S+"!/<'1I;VYS(&-A;F-E;&QE9"]F;W)F96ET/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R,S@L,#`W*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H87)E
M<RP@3W5T<W1A;F1I;F<L($5N9&EN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#`R.2PR-#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,L
M($]P=&EO;G,@97AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<R."PU.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,L($]P=&EO;G,@=F5S
M=&5D(&%N9"!E>'!E8W1E9"!T;R!V97-T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XY.3DL,3<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F<N($5X97)C:7-E(%!R
M:6-E+"!/=71S=&%N9&EN9RP@0F5G:6YN:6YG(&)A;&%N8V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B`U+C,Q/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F<N($5X
M97)C:7-E(%!R:6-E+"!/<'1I;VYS(&=R86YT960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B`V+C,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F<N($5X97)C:7-E
M(%!R:6-E+"!/<'1I;VYS(&5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^(#,N.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079G+B!%>&5R8VES92!0<FEC
M92P@3W!T:6]N<R!C86YC96QL960O9F]R9F5I=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^(#8N-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V9RX@17AE<F-I<V4@
M4')I8V4L($]U='-T86YD:6YG+"!%;F1I;F<@8F%L86YC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^(#4N-S0\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V9RX@17AE
M<F-I<V4@4')I8V4L($5X97)C:7-A8FQE($5N9&EN9R!"86QA;F-E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@-2XR-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079G
M+B!%>&5R8VES92!0<FEC92P@5F5S=&5D(&%N9"!E>'!E8W1E9"!T;R!V97-T
M("T@96YD(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^(#4N-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960@079G+B!296UA:6YI;F<@0V]N=')A8W1U86P@
M3&EF92P@3W!T:6]N<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^-B!Y96%R<R`Q."!D87ES/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F<N(%)E
M;6%I;FEN9R!#;VYT<F%C='5A;"!,:69E+"!/<'1I;VYS(&5X97)C:7-A8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT('EE87)S(#$Q(&UO
M;G1H<R`Q.2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F<N(%)E;6%I;FEN9R!#;VYT<F%C
M='5A;"!,:69E+"!/<'1I;VYS('9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-2!Y96%R<R`Q,2!M
M;VYT:',@,C,@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!686QU92P@3W!T
M:6]N<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^(#(L,S4Q+#$W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!686QU92P@3W!T
M:6]N<R!E>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPP.#`L-3DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!/<'1I
M;VYS('9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S=#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^(#(L,S$Y+#0W-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?8F0T9E\T-SDP7V$W
M.3E?.#4T,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V$W8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X9&%A-B]7;W)K<VAE
M971S+U-H965T-3<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4T2$)'/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("T@4V-H961U;&4@;V8@
M1F%I<B!686QU92!!<W-U;7!T:6]N("A$971A:6QS*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I
M9VAT960M879E<F%G92!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+C$R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E
M9"!V;VQA=&EL:71Y+"!M:6YI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='DL(&UA>&EM=6T\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,T-BXP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM
M9G)E92!I;G1E<F5S="!R871E+"!M:6YI;75M/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP+C,R)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4FES:RUF<F5E(&EN=&5R97-T(')A=&4L
M(&UA>&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,S$E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$:79I9&5N9"!Y:65L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DUI;FEM=6T@6TUE;6)E<ET@?"!787)R86YT(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E
M<FUS("AI;B!Y96%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C(@>65A<G,@-R!M;VYT:',@-B!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M(%M-96UB97)=('P@
M5V%R<F%N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>'!E8W1E9"!T97)M<R`H:6X@>65A<G,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XU('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($=R86YT960@5&\@
M16UP;&]Y965S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E=E:6=H=&5D+6%V97)A9V4@9F%I<B!V86QU92!O9B!O<'1I;VYS
M(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2XR
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-BXP-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17AP96-T960@=F]L871I;&ET>2P@;6EN:6UU;3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.38N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`R+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T
M960@=F]L871I;&ET>2P@;6%X:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`R+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$R,RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM9G)E92!I;G1E<F5S="!R
M871E+"!M:6YI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+C,W)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N.#8E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2:7-K+69R964@:6YT97)E<W0@<F%T92P@;6%X:6UU;3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XV-24\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+C`U)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&EV
M:61E;F0@>6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]P=&EO;G,@1W)A;G1E9"!4;R!%;7!L;WEE97,@6TUE;6)E
M<ET@?"!-:6YI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X<&5C=&5D('1E<FUS("AI;B!Y96%R<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/C4@>65A<G,@.2!M;VYT:',@,C(@9&%Y
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C4@>65A<G,@.2!M;VYT:',@,3@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W!T:6]N<R!'<F%N=&5D(%1O
M($5M<&QO>65E<R!;365M8F5R72!\($UA>&EM=6T@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=&5R;7,@*&EN
M('EE87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-B!Y96%R
M<R`Q,"!M;VYT:',@,C@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/C<@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@1W)A;G1E9"!4
M;R!#;VYS=6QT86YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"UA=F5R86=E(&9A:7(@=F%L=64@;V8@;W!T
M:6]N<R!G<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#8N,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#4N-C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='DL(&UI;FEM=6T\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<X+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@P+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP
M96-T960@=F]L871I;&ET>2P@;6%X:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.3<N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S8V+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:RUF<F5E(&EN=&5R97-T
M(')A=&4L(&UI;FEM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`N,3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,"XS,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)I<VLM9G)E92!I;G1E<F5S="!R871E+"!M87AI;75M
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C8X)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(N-#4E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M:79I9&5N9"!Y:65L9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3W!T:6]N<R!'<F%N=&5D(%1O($-O;G-U;'1A;G1S(%M-
M96UB97)=('P@36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!T97)M<R`H:6X@>65A<G,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR('EE87)S(#8@;6]N=&AS/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,B!Y
M96%R<R`S(&UO;G1H<R`R.2!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS($=R86YT960@5&\@0V]N
M<W5L=&%N=',@6TUE;6)E<ET@?"!-87AI;75M(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E<FUS("AI;B!Y
M96%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P('EE87)S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%139!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO;&1E
M<G,G($5Q=6ET>2`M(%-C:&5D=6QE(&]F(%-H87)E<R!/=71S=&%N9&EN9R!A
M;F0@17AE<F-I<V%B;&4@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS
M($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#`R.2PR-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T
M=6%L($QI9F4@:6X@665A<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/C8@>65A<G,@,3@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES
M92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+C<T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.=6UB97(@17AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<R."PU.#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V%B;&4@
M17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-2XR-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F%N9V4@3VYE(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)A;F=E(&]F($5X97)C:7-E(%!R:6-E<RP@;6EN
M:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A
M;F=E(&]F($5X97)C:7-E(%!R:6-E<RP@;6%X:6UU;3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`S+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS($]U
M='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A;"!,
M:69E(&EN(%EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XT
M('EE87)S(#8@;6]N=&AS(#(V(&1A>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE
M<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,BXX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.=6UB97(@17AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V%B
M;&4@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,BXX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y286YG92!4=V\@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4F%N9V4@;V8@17AE<F-I<V4@4')I8V5S+"!M
M:6YI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F%N9V4@;V8@17AE<F-I<V4@4')I8V5S+"!M87AI;75M/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#0N-3$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS
M($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M,S<L-S(S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#;VYT<F%C='5A
M;"!,:69E(&EN(%EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XT('EE87)S(#$Q(&UO;G1H<R`Q,B!D87ES/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E
M($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#0N,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DYU;6)E<B!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C<P+#`Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R
M8VES86)L92!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`T+C0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y286YG92!4:')E92!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y286YG92!O9B!%>&5R8VES92!0
M<FEC97,L(&UI;FEM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-2XT.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F%N9V4@;V8@17AE<F-I<V4@4')I8V5S+"!M87AI;75M/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<N-S$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O
M9B!/<'1I;VYS($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ.3`L-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#
M;VYT<F%C='5A;"!,:69E(&EN(%EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XX('EE87)S(#@@;6]N=&AS(#$R(&1A>7,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D
M($%V97)A9V4@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-BXV,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R($5X97)C:7-A8FQE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,"PQ,3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A
M9V4@17AE<F-I<V%B;&4@17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-BXR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F%N9V4@1F]U<B!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y286YG92!O9B!%>&5R
M8VES92!0<FEC97,L(&UI;FEM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@."XP-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F%N9V4@;V8@17AE<F-I<V4@4')I8V5S+"!M87AI
M;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+C<U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@3W!T:6]N<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C0T+#$V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA
M:6YI;F<@0V]N=')A8W1U86P@3&EF92!I;B!996%R<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^-R!Y96%R<R`Q,2!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!
M=F5R86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#@N.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!%>&5R8VES86)L93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,30Q+#8V,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G
M92!%>&5R8VES86)L92!%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Y+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y286YG92!&:79E(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)A;F=E(&]F($5X97)C
M:7-E(%!R:6-E<RP@;6EN:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4F%N9V4@;V8@17AE<F-I<V4@4')I8V5S+"!M87AI;75M
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@3W!T:6]N<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-BPX,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@4F5M86EN:6YG($-O
M;G1R86-T=6%L($QI9F4@:6X@665A<G,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/C4@>65A<G,@,2!M;VYT:"`Q-R!D87ES/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!
M=F5R86=E($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#0P+C@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@17AE<F-I<V%B;&4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8L.#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E
M($5X97)C:7-A8FQE($5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#0P+C@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P135"0D<^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4W1O8VMH;VQD97)S)R!%<75I='D@+2!-87)K970M8F%S960@5F5S=&EN
M9R!#;VYD:71I;VYS(&9O<B!297-T<FEC=&5D(%-T;V-K(%5N:71S($=R86YT
M960@*$1E=&%I;',I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0R/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DUA>2`P,BP@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87D@,C0L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1R86YC:&4@,2!#14\@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!.=6UB97(@;V8@4VAA
M<F5S($=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y
M+C`U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&%R9V5T(%-H87)E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XD,3`N,#`@;W(@9W)E871E<CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5')A;F-H92`R($-%3R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C
M96YT86=E(&]F($YU;6)E<B!O9B!3:&%R97,@1W)A;G1E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3DN,#4E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y487)G970@4VAA<F4@4')I
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B0Q-2XP,"!O<B!G
M<F5A=&5R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4<F%N8VAE(#,@0T5/(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@3G5M8F5R(&]F(%-H
M87)E<R!'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M.2XP-24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1A<F=E="!3:&%R92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)#(P+C`P(&]R(&=R96%T97(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1R86YC:&4@-"!#14\@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R
M8V5N=&%G92!O9B!.=6UB97(@;V8@4VAA<F5S($=R86YT960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y+C`U)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&%R9V5T(%-H87)E(%!R
M:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XD,C4N,#`@;W(@
M9W)E871E<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5')A;F-H92`U($-%3R!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F($YU;6)E<B!O9B!3
M:&%R97,@1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C,N.#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y487)G970@4VAA<F4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B0S,"XP,"!O<B!G<F5A=&5R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYS=6QT86YT(%1R
M86YC:&4@,2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.=6UB97(@;V8@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1A<F=E="!3:&%R92!0<FEC93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)#$P+C`P(&]R(&=R96%T97(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G-U
M;'1A;G0@5')A;F-H92`R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!3:&%R97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&%R9V5T(%-H87)E(%!R:6-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XD,34N,#`@;W(@9W)E871E
M<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]N<W5L=&%N="!4<F%N8VAE(#,@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%-H87)E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y487)G970@4VAA<F4@
M4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B0R,"XP,"!O
M<B!G<F5A=&5R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VYS=6QT86YT(%1R86YC:&4@-"!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@4VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1A<F=E
M="!3:&%R92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)#(U+C`P(&]R(&=R96%T97(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G-U;'1A;G0@5')A;F-H92`U(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O
M9B!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&%R9V5T(%-H87)E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XD,S`N,#`@;W(@9W)E871E<CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?8F0T9E\T-SDP7V$W.3E?
M.#4T,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W
M8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X9&%A-B]7;W)K<VAE971S
M+U-H965T-C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$5*4$%#/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("T@4V-H961U;&4@;V8@4F5S
M=')I8W1E9"!3=&]C:R!5;FET<R!!8W1I=FET>2`H1&5T86EL<RD@*%)E<W1R
M:6-T960@4W1O8VL@56YI=',@6TUE;6)E<ETL(%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S=')I8W1E9"!3=&]C
M:R!5;FET<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.=6UB97(@;V8@4E-5<RP@3W5T<W1A;F1I;F<L($)E9VEN;FEN9R!B
M86QA;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,X.2PY
M-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!24U5S(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(V+#0Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%)357,@=F5S=&5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,"PV.3`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@4E-5<R!C86YC96QL960O9F]R9F5I=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,3`X+#DT-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!24U5S+"!/=71S=&%N
M9&EN9RP@16YD:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,C<V+#@Q-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!'<F%N="!$871E
M($9A:7(@5F%L=64L($)E9VEN;FEN9R!B86QA;F-E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#,N,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@1W)A
M;G0@1&%T92!&86ER(%9A;'5E+"!24U5S(&=R86YT960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-RXU-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!'
M<F%N="!$871E($9A:7(@5F%L=64L(%)357,@=F5S=&5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#<N-#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@
M1W)A;G0@1&%T92!&86ER(%9A;'5E+"!24U5S(&-A;F-E;&QE9"]F;W)F96ET
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,N,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H
M=&5D($%V97)A9V4@1W)A;G0@1&%T92!&86ER(%9A;'5E+"!%;F1I;F<@8F%L
M86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%6$%!13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2`M
M(%-C:&5D=6QE(&]F(%=A<G)A;G1S($%C=&EV:71Y("A$971A:6QS*2`H5V%R
M<F%N="!;365M8F5R72P@55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,L($]U='-T
M86YD:6YG+"!"96=I;FYI;F<@8F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#(Q+#`U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%-H87)E<R!3=6)J96-T
M('1O(%=A<G)A;G1S($]U='-T86YD:6YG+"!'<F%N=&5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!3
M:&%R97,@4W5B:F5C="!T;R!787)R86YT<R!/=71S=&%N9&EN9RP@17AE<F-I
M<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,S`L,3`V*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3G5M8F5R(&]F(%-H87)E<R!3=6)J96-T('1O(%=A<G)A;G1S($]U='-T86YD
M:6YG+"!%>'!I<F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S:&%R97,L($]U='-T86YD:6YG+"!%
M;F1I;F<@8F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-CDP+#DT-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U
M86P@3&EF92!/9B!4:&4@3W5T<W1A;F1I;F<@5V%R<F%N=',@26X@665A<G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C$P(&UO;G1H<R`Q,"!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y796EG:'1E9"!!=F<N($5X97)C:7-E(%!R:6-E+"!/=71S=&%N9&EN
M9RP@0F5G:6YN:6YG(&)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-2XY-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V5I9VAT960@079G+B!%>&5R8VES92!0<FEC92P@
M1W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y796EG:'1E9"!!=F<N($5X97)C:7-E(%!R:6-E+"!%>&5R8VES
M960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-2XR.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I
M9VAT960@079G+B!%>&5R8VES92!0<FEC92P@17AP:7)E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!
M=F<N($5X97)C:7-E(%!R:6-E+"!/=71S=&%N9&EN9RP@16YD:6YG(&)A;&%N
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXP-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?
M8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V$W8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X
M9&%A-B]7;W)K<VAE971S+U-H965T-C(N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4Q4T%'/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("T@
M4V-H961U;&4@;V8@5V%R<F%N=',@3W5T<W1A;F1I;F<@86YD(%=A<G)A;G1S
M($5X97)C:7-A8FQE("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($]U='-T
M86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.3`L.30T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`V+C`U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y787)R86YT<R!%>&5R8VES86)L93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-CDP+#DT-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@27-S=65D(%1O
M($9O<FUE<B!-86IO<B!3:&%R96AO;&1E<B!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U92!$871E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#Y!<'(@,C4L#0H)"3(P,3(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S
M($]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M."PR-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X97)C:7-E(%!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#4N.3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($5X97)C:7-A8FQE/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT."PR-C(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&ER871I;VX@1&%T
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^07!R(#(U+`T*"0DR
M,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y787)R86YT<R!)<W-U960@26X@07!R:6P@,C`Q,B!0<FEV871E(%!L
M86-E;65N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y)<W-U92!$871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#Y!<'(@,C4L#0H)"3(P,3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S($]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.38L-3,W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!0
M<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+CDS/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M87)R86YT<R!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-#DV+#4S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17AP:7)A=&EO;B!$871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y!<'(@,C4L#0H)"3(P,34\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5N9&5R=W)I=&5R
M(%=A<G)A;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DES<W5E($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/D9E8B`W+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!/=71S=&%N9&EN9SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38L,30U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!0
M<FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+C(U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M87)R86YT<R!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-38L,30U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>'!I<F%T:6]N($1A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/D9E8B`W+`T*"0DR,#$X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!)<W-U
M960@5&\@26YV97-T;W(@4F5L871I;VYS($-O;G-U;'1A;G0@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=64@1&%T93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1F5B(#(X+`T*"0DR,#$S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y787)R86YT<R!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!0<FEC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`U+C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!%>&5R8VES86)L
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!I
M<F%T:6]N($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D9E
M8B`R."P-"@D),C`Q-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N=',@27-S=65D(%1O($EN=F5S=&]R(%)E
M;&%T:6]N<R!#;VYS=6QT86YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DES<W5E($1A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/DIU;"`Q.2P-"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@3W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17AE<F-I<V4@4')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@."XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y787)R86YT<R!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!I<F%T:6]N($1A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIU;"`Q.2P-"@D),C`Q.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?
M8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V$W8V9C8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X
M9&%A-B]7;W)K<VAE971S+U-H965T-C,N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,04%'/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y("T@
M4V-H961U;&4@;V8@4W1O8VL@0F%S960@0V]M<&5N<V%T:6]N($=R86YT960@
M=&\@16UP;&]Y965S($1I<F5C=&]R<R!#;VYS=6QT86YT<R`H1&5T86EL<RD@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&]C:R!B87-E9"!C;VUP96YS871I;VX@<F5L871E9"!T;R!E<75I
M='D@:6YS=')U;65N=',@9W)A;G1E9"!T;R!R96QA=&5D('!A<G1I97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPU-C0L-C$Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#$S
M-"PY-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5M<&QO>65E<R!;365M8F5R72!\(%-E;&QI;F<@06YD($UA<FME
M=&EN9R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:R!B87-E9"!C;VUP96YS871I;VX@<F5L871E9"!T;R!E<75I='D@
M:6YS=')U;65N=',@9W)A;G1E9"!T;R!R96QA=&5D('!A<G1I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Y+#(W.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L,CDX/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE
M97,@6TUE;6)E<ET@?"!'96YE<F%L($%N9"!!9&UI;FES=')A=&EV92!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!B
M87-E9"!C;VUP96YS871I;VX@<F5L871E9"!T;R!E<75I='D@:6YS=')U;65N
M=',@9W)A;G1E9"!T;R!R96QA=&5D('!A<G1I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,#DU+#(U-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3$R+#0T.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y965S
M(%M-96UB97)=('P@4F5S96%R8V@@06YD($1E=F5L;W!M96YT(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&)A<V5D
M(&-O;7!E;G-A=&EO;B!R96QA=&5D('1O(&5Q=6ET>2!I;G-T<G5M96YT<R!G
M<F%N=&5D('1O(')E;&%T960@<&%R=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34V+#4V.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&ER96-T;W)S(%M-
M96UB97)=('P@1V5N97)A;"!!;F0@061M:6YI<W1R871I=F4@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@8F%S960@
M8V]M<&5N<V%T:6]N(')E;&%T960@=&\@97%U:71Y(&EN<W1R=6UE;G1S(&=R
M86YT960@=&\@<F5L871E9"!P87)T:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-#8L,#DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,SDY+#DX-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N<W5L=&%N="!;365M8F5R
M72!\(%-E;&QI;F<@06YD($UA<FME=&EN9R!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!B87-E9"!C;VUP96YS871I
M;VX@<F5L871E9"!T;R!E<75I='D@:6YS=')U;65N=',@9W)A;G1E9"!T;R!R
M96QA=&5D('!A<G1I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@X+#0P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N<W5L=&%N="!;365M8F5R72!\($=E
M;F5R86P@06YD($%D;6EN:7-T<F%T:79E(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO
M;B!R96QA=&5D('1O(&5Q=6ET>2!I;G-T<G5M96YT<R!G<F%N=&5D('1O(')E
M;&%T960@<&%R=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,30V+#<Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@T,RPS,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;G-U;'1A;G0@6TUE;6)E<ET@?"!297-E87)C
M:"!!;F0@1&5V96QO<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4W1O8VL@8F%S960@8V]M<&5N<V%T:6]N(')E;&%T
M960@=&\@97%U:71Y(&EN<W1R=6UE;G1S(&=R86YT960@=&\@<F5L871E9"!P
M87)T:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@L-S@Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R,30L,S<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P135!044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A
M>&5S("A$971A:6QS($YA<G)A=&EV92D@*%531"`D*3QB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!4
M87@@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D('1A>"!A<W-E="!V86QU
M871I;VX@86QL;W=A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#,L.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&961E<F%L(&YE="!O<&5R871I
M;F<@;&]S<R!C87)R>69O<G=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-RPX,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y&961E<F%L(&YE="!O<&5R871I;F<@;&]S
M<R!E>'!I<F%T:6]N(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/C(P,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9E9&5R86P@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT('1A
M>"!C<F5D:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y&961E<F%L(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!T87@@8W)E
M9&ET<R!E>'!I<F%T:6]N(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/C(P,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-T871E(&YE="!O<&5R871I;F<@;&]S<R!C87)R>69O
M<G=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PV,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&%T92!N970@;W!E<F%T:6YG(&QO<W,@97AP:7)A=&EO;B!D871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&%T92!R
M97-E87)C:"!A;F0@9&5V96QO<&UE;G0@=&%X(&-R961I=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R97)D('1A>"!A
M<W-E=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M969E<G)E<F0@=&%X(&%S<V5T(&5X8V5S<R!T87@@8F5N969I=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P145.04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S("T@4V-H961U;&4@;V8@4')O
M=FES:6]N(&9O<B!);F-O;64@5&%X97,@*$1E=&%I;',I("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY);F-O;64@5&%X($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&961E<F%L/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#@P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L.#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&961E<F%L
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PP.#(L-#4Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PP
M-S4L,S0R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPQ,#`L-C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPR,S,L-S(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@=F%L=6%T:6]N(&%L;&]W
M86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30L,3@S+#`X
M-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q,"PS,#DL,#8X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&1E9F5R<F5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;F-O;64@=&%X('!R;W9I<VEO;B`H8F5N969I="D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,BPX,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-4]!0SX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W
M<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@5&%X97,@+2!38VAE9'5L92!O9B!)
M;F-O;64@5&%X(%)E8V]N8VEL:6%T:6]N("A$971A:6QS*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M
M92!487@@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E4N4RX@9F5D97)A;"!S=&%T=71O
M<GD@=&%X(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0F5N969I="!O9B!L;W=E<B!T87@@8G)A8VME=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$N,#`E*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$N,#`E*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1A
M=&4@=&%X(&)E;F5F:70L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,"XP,R4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!C
M<F5D:71S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N
M-#,E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%;7!L;WEE92!S=&]C:R!B87-E9"!C;VUP96YS871I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$N,#,E*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0N-S(E*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!O
M;B!D96)T(&-O;G9E<G-I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]T:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@P+C(Q)2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@P+C`X)2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9A;'5A=&EO;B!A;&QO=V%N8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,R+C<V)2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R.2XV,R4I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M9F9E8W1I=F4@:6YC;VUE('1A>"!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@P+C`S)2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?83=C9F-B9C5?8F0T9E\T-SDP7V$W.3E?.#4T
M,61D-#AD86$V#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W8V9C
M8F8U7V)D-&9?-#<Y,%]A-SDY7S@U-#%D9#0X9&%A-B]7;W)K<VAE971S+U-H
M965T-C<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$4Q3T%#/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R
M;VYG/DEN8V]M92!487AE<R`M(%-C:&5D=6QE(&]F($1E9F5R<F5D(%1A>"!!
M<W-E=',@86YD($QI86)I;&ET:65S("A$971A:6QS*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY);F-O;64@5&%X($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.3TPG<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,"PY,C(L.3$T/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W
M+#,V-"PP-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#<X-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-#`I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C0L.#`V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(Y+#$Y,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S96%R8V@@)F%M<#L@9&5V96QO<&UE;G0@8W)E9&ET<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-34U+#DT-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4V,RPT.#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D
M('-T;V-K(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPV-#8L,C`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BPR-3(L-C<T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5;G)E86QI>F5D(&=A:6X@;W(@
M;&]S<R!O;B!I;G9E<W1M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@9&5F97)R
M960@=&%X(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,30L,3@S+#`X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+#,P.2PP-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9A;'5A=&EO;B!A;&QO=V%N8V4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T+#$X,RPP.#8I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`L,S`Y
M+#`V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@9&5F97)R960@=&%X(&%S<V5T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
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M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P13)(/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D5M<&QO>65E(%-A=FEN9W,@4&QA;B`H
M1&5T86EL<R!.87)R871I=F4I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M<&5N<V%T:6]N(&%N
M9"!2971I<F5M96YT($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F
M('-A;&%R>2!D97!O<VET<R!I;B!T87@@9&5F97)R960@:6YV97-T;65N="!A
M8V-O=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y097)C96YT86=E(&]F(&-O;G1R:6)U=&EO;G,@;6%D92!B>2!T:&4@8V]M
M<&%N>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;G1R:6)U=&EO;G,@8GD@=&AE(&-O;7!A;GD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-38L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14):04D^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@*$1E=&%I;',@3F%R
M<F%T:79E*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T
M/&)R/G-Q9G0\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R
M+B`S,"P@,C`Q,SQB<CYS<69T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*86XN(#,Q+"`R,#$P/&)R/G-Q9G0\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`R-"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$T/&)R/G-Q9G0\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`Q."P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5S
M(&5Q=6EP;65N="!U;F1E<B!C87!I=&%L(&QE87-E('=I=&@@:6YT97)E<W0@
M<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"XR-24\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q
M=6EP;65N="!U;F1E<B!C87!I=&%L(&QE87-E<R!N970\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-3(L-C@W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296QA=&5D(&%C8W5M=6QA
M=&5D(&1E<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^."PV-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQE87-E(&%G<F5E;65N="!F;W(@;V9F:6-E('-P86-E("A3
M<75A<F4@9F5E="D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L
M-38U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPX-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW+#4V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG(&QE87-E($5X<&ER>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^3V-T(#,Q+`T*"0DR,#$X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^4V5P(#,P
M+`T*"0DR,#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y/<&5R871I;F<@;&5A<V4L(&UO;G1H;'D@<F5N=&%L/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PT,C8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PT,#8\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P
M97)A=&EN9R!L96%S92P@<F5N="!I;F-R96%S92!P97)C96YT86=E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E
M;G0@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`V
M+#0V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,RPQ.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DUA>&EM=6T@86=G<F5G871E('9A;'5E(&]F(&-A<V@@
M9F5E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y2;WEA;'1I97,@<F%N9V4@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"XU,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F]Y86QT:65S(')A;F=E
M('!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDN
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0:&%R;6%C>2!#<F5A=&EO;G,L($Q,0R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,96%S92!A9W)E96UE;G0@9F]R
M(&]F9FEC92!S<&%C92`H4W%U87)E(&9E970I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#$S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3W!E<F%T:6YG(&QE87-E($5X<&ER>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1&5C(#,Q+`T*"0DR,#$U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y/<&5R871I;F<@;&5A<V4L(&UO;G1H;'D@<F5N=&%L/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#4Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^57)I9V5N(%!H87)M86-E=71I
M8V%L<RP@26YC(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DQI8V5N<V4@86=R965M96YT(&-O;6UI=&UE;G1S(&1E<V-R:7!T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\+W`^#0H-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M4V5R:68[(&UA<F=I;CH@,#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4G/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@4V5R:68G/E1H90T*86YN=6%L('1I
M97)E9"!R;WEA;'1I97,@8V]N<VES="!O9B!T:&4@9W)E871E<B!O9B`H:2D@
M)#`N-3`@<&5R(&1O<V4L(&%N9"`H:6DI(#$U)2`M(#(P)2!O9B!I=',@;F5T
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M96-E9&EN9R`Q,B!M;VYT:',L(&]N(&$@<')O<F%T960@8F%S:7,L(&%N9"`H
M:6DI("0X,#`L,#`P+`T*;&5S<R!T:&4@86=G<F5G871E(')O>6%L=&EE<R!P
M86ED('1O(%5R:6=E;B!U;F1E<B!T:&4@17AI<W1I;F<@4W5B;&EC96YS97,@
M9'5R:6YG('1H92`R,#$U(&-A;&5N9&%R('EE87(L(&%N9"`H8BD@9F]R(&5A
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M86=R965D('1O(&)Y('1H92!P87)T:65S+"!W:&EC:`T*969F;W)T<R!W:6QL
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M;CH@,'!T)SX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DUI;FEM=6T@<F]Y86QT:65S('1O(&)E('!A:60@96%C:"!C
M86QE;F1A<B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y686QU92!O9B!P<F]D=6-T(&1E=F5L;W!M96YT(&EN=F5S=&UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139+
M04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O
M;G1I;F=E;F-I97,@+2!38VAE9'5L92!O9B!,96%S92!%<75I<&UE;G0@56YD
M97(@0V%P:71A;"!,96%S92`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0V]M<&5N<V%T:6]N(&%N9"!2971I<F5M96YT($1I<V-L;W-U<F4@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#XR,#$U/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(U
M+#0W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^,C`Q-CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL
M,S(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@;6EN:6UU;2!L96%S92!P87EM96YT<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L-SDX/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,97-S(&%M;W5N="!R97!R
M97-E;G1I;F<@:6YT97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$L-S$X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R97-E;G0@=F%L=64@;V8@9G5T=7)E(&UI;FEM=6T@
M;&5A<V4@<&%Y;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0S+#`X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&5S<R!C=7)R96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#(T+#$Q,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87!I=&%L
M(&QE87-E(&]B;&EG871I;VXL(&YE="!O9B!C=7)R96YT('!O<G1I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@L.38X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
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M/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4
M>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R
M:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$
M;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-
M"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P
M14Y&04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]M;6ET;65N=',@86YD
M($-O;G1I;F=E;F-I97,@+2!38VAE9'5L92!O9B!&=71U<F4@4&%Y;65N=',@
M56YD97(@3&5A<V5S("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M
M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@1&ES8VQO<W5R92!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/C(P,34\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-#DR+#4P
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^,C`Q-CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8X+#DY
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^,C`Q-SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@Q+#0T
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^,C`Q.#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#DU+#DS
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^,C`Q.3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4W+#`S
M.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&AE<F5A9G1E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#<X+#0W,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#(L-C<T+#,Y,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?83=C9F-B9C5?8F0T9E\T-SDP7V$W.3E?.#4T,61D-#AD86$V
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W8V9C8F8U7V)D-&9?
M-#<Y,%]A-SDY7S@U-#%D9#0X9&%A-B]7;W)K<VAE971S+U-H965T-S(N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5$1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY396=M96YT
M($EN9F]R;6%T:6]N("A$971A:6QS($YA<G)A=&EV92D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4V5G;65N="!2
M97!O<G1I;F<@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M('!E<F-E;G1A9V4@;V8@<V%L97,@
M9&5R:79E9"!F<F]M('-I;F=L92!C=7-T;VUE<CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&1R=6<@86YD
M(&-H96UI8V%L('!U<F-H87-E<R!F<F]M('1H<F5E(&UA:6X@<W5P<&QI97)S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-"XP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4#9"2SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6)S97%U96YT($5V96YT<R`H1&5T86EL
M<R!.87)R871I=F4I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87(N(#$Q+"`R,#$U/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`R."P@,C`Q-3QB<CYS<69T/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,#(L(#(P,34\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1F5B+B`R."P@,C`Q
M-3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S
M(&ES<W5E9"!U<&]N(&5X97)C:7-E(&]F('=A<G)A;G1S+"!S:&%R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W+#@R.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@
M9G)O;2!I<W-U86YC92!O9B!W87)R86YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@:7-S=65D
M('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PR-3@L
M,C,Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^."PY-S`L,S8T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@9F]R(&5A
M8V@@<&%Y;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C8L
M-#,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y296YT(&%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S`V+#0V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P,RPQ.3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&ER871I;VX@;V8@;&5A<V4@=&5R
M;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^3V-T(#,Q+`T*"0DR
M,#$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^4V5P(#,P+`T*"0DR,#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V96YT(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U
M960@=7!O;B!E>&5R8VES92!O9B!W87)R86YT<RP@<VAA<F5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPV-3@\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@
M:7-S=6%N8V4@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<T+#DY.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N=',@<VAA<F5S(&5X97)C:7-E('!R:6-E
M('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U
M+CDR-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W1O8VL@:7-S=65D(&1U<FEN9R!P97)I;V0@<F5S=&EC=&5D(&-O
M;6UO;B!S=&]C:R!I<W-U960L('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^."PU,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-U8G-E<75E;G0@179E;G0@6TUE;6)E<ET@
M?"!,96%S92!!9W)E96UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-Q=6%R92!F965T<R!O9B!L86(@
M86YD(&]F9FEC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PV
M,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XX+#8P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4F5N="!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDL-30X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&%N;G5A;"!R96YT(&EN8W)E
M87-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXW-24\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+C<U
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17AP:7)A=&EO;B!O9B!L96%S92!T97)M/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#Y*=6P@,S$L#0H)"3(P,C(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U8G-E<75E;G0@179E
M;G0@6TUE;6)E<ET@?"!087)K(%-E;&QE<G,@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G<F5G871E(&-A<V@@<'5R8VAA
M<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E9"!S:&%R97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8S+#4R-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K('9A;'5E
M(&)A<V5D(&]N(&%V97)A9V4@8VQO<VEN9R!P<FEC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^475A<G1E<FQY(&-A<V@@<&%Y
M;65N=',@9F]R(&%C<75I<VET:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,RPQ,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%M;W5N="!O9B!C;&]S:6YG('!R:6-E+"!T;W1A
M;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,W+#4P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06=G
M<F5G871E9"!A;6]U;G0@;V8@8VQO<VEN9R!P<FEC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S$X+#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N
M('-T;V-K(&9O<B!E86-H('!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8L-S0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<W%U87)E(&9E971S(&]F(&QA
M8B!A;F0@;V9F:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5N="!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/CDL-S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&%N;G5A;"!R96YT(&EN8W)E87-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RXP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U8G-E
M<75E;G0@179E;G0@6TUE;6)E<ET@?"!!;F1R97<@4BX@0F]L;"=S(%M-96UB
M97)=('P@4E-5(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K(&ES<W5E9"!D=7)I;F<@<&5R:6]D(')E<W1I8W1E9"!C
M;VUM;VX@<W1O8VL@:7-S=65D+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N="!;365M8F5R
M72!\($%N9')E=R!2+B!";VQL)W,@6TUE;6)E<ET@?"!#1D\@16UP;&]Y;65N
M="!!9W)E96UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1O8VL@:7-S=65D(&1U<FEN9R!P97)I;V0@<F5S=&EC=&5D
M(&-O;6UO;B!S=&]C:R!I<W-U960L('-H87)E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,34W+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y;65N="!A9W)E96UE;G0@
M=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06YN=6%L(&)A<V4@<V%L87)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&-U<G)E;G0@86YN=6%L('-A
M;&%R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y097)C96YT86=E(&]F('1A<F=E="!C=7)R96YT(&%N;G5A;"!S86QA
M<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4W5B<V5Q=65N="!%=F5N="!;365M8F5R72!\($IO:&X@4"X@4V%H87)E
M:R!;365M8F5R72!\(%)352!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&]C:R!I<W-U960@9'5R:6YG('!E<FEO9"!R97-T
M:6-T960@8V]M;6]N('-T;V-K(&ES<W5E9"P@<VAA<F5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U8G-E<75E;G0@179E;G0@
M6TUE;6)E<ET@?"!*;VAN(%`N(%-A:&%R96L@6TUE;6)E<ET@?"!#0T\@16UP
M;&]Y;65N="!!9W)E96UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5V%R<F%N=',@<VAA<F5S(&5X97)C:7-E('!R:6-E
M('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W
M+C,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^(#<N,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K(&ES<W5E9"!D=7)I;F<@<&5R:6]D(')E<W1I8W1E
M9"!C;VUM;VX@<W1O8VL@:7-S=65D+"!S:&%R97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDP+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16UP;&]Y;65N="!A9W)E96UE;G0@
M=&5R;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,R!Y96%R<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06YN=6%L(&)A<V4@<V%L87)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#X@,C(P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!C=7)R96YT(&%N;G5A;"!S
M86QA<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&5R;2!O9B!S=&]C:R!O<'1I;VX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P,BYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-"YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,34N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q-RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3@N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Y+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C$N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(R+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R,RYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(U+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-BYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C<N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#(X+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970R.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S`N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,Q+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970S,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,S,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,T
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S-2YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,S8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#,W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S
M."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,SDN:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0P+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970T,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M-#(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0S+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970T-"YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T-#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#0V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T-RYH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#@N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#0Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970U,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-3$N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4R+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970U,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T-30N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#4U+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U-BYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T-3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#4X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970U.2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-C`N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#8Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970V,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-C,N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#8T+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970V-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T-C8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#8W+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970V."YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T-CDN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#<P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970W,2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-S(N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#<S+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM
M/5].97AT4&%R=%]A-V-F8V)F-5]B9#1F7S0W.3!?83<Y.5\X-30Q9&0T.&1A
&838M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ERE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Restricted Short-Term Investment (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_RestrictedShortTermInvestmentDisclosureAbstract', window );"><strong>Restricted Short-term Investment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CertificatesOfDepositAtCarryingValue', window );">Certificate of deposit</a></td>
        <td class="nump"><a title="us-gaap_CertificatesOfDepositAtCarryingValue" onclick="toggleNextSibling(this);">$ 150,264</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CertificatesOfDepositAtCarryingValue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_RestrictedShortTermInvestmentDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_RestrictedShortTermInvestmentDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CertificatesOfDepositAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate.  A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit).  Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties.  Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CertificatesOfDepositAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Furniture and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Furniture and Equipment</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expenses and other current assets
consisted of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2014</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2013</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid stock-based consulting expenses</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">26,649</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid rent</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">16,288</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid insurance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">123,776</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">39,166</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other prepaid expenses and deposits</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">116,625</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">22,964</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total prepaid expenses and other current assets</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">240,401</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">105,067</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expenses and other current assets
consisted of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2014</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2013</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid stock-based consulting expenses</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">26,649</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid rent</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">16,288</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid insurance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">123,776</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">39,166</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other prepaid expenses and deposits</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">116,625</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">22,964</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total prepaid expenses and other current assets</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">240,401</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">105,067</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule Of Prepaid Expenses And Other Current Assets [TableTextBlock].</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock Option Plan Activity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Options exercised</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">227,216</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding, Ending balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">1,029,240</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Avg. Remaining Contractual Life, Options outstanding</a></td>
        <td class="text">6 years 18 days<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember', window );">Stock Option Plan [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding, Beginning balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);">1,328,790</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Options granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);">245,886</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Options exercised</a></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);">(307,429)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Options cancelled/forfeit</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);">(238,007)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding, Ending balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);">1,029,240</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number of shares, Options exercisable</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);">728,585</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares, Options vested and expected to vest</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);">999,175</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Outstanding, Beginning balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);"> 5.31</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Options granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);"> 6.35</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Options exercised</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);"> 3.90</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Options cancelled/forfeit</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);"> 6.68</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Outstanding, Ending balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);"> 5.74</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Avg. Exercise Price, Exercisable Ending Balance</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);"> 5.25</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Avg. Exercise Price, Vested and expected to vest - end of period</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);"> 5.70</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Avg. Remaining Contractual Life, Options outstanding</a></td>
        <td class="text">6 years 18 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Avg. Remaining Contractual Life, Options exercisable</a></td>
        <td class="text">4 years 11 months 19 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Avg. Remaining Contractual Life, Options vested and expected to vest</a></td>
        <td class="text">5 years 11 months 23 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);"> 2,351,174</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Options exercisable</a></td>
        <td class="nump"><a title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);">2,080,594</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Options vested and expected to vest</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue[us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember]" onclick="toggleNextSibling(this);"> 2,319,475</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue<br>/ us-gaap_AwardTypeAxis<br>= IMMY_StockOptionPlanMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_StockOptionPlanMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Inventories - Schedule of Inventories (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
        <td class="nump"><a title="us-gaap_InventoryRawMaterials" onclick="toggleNextSibling(this);">$ 146,300</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryRawMaterials</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in progress</a></td>
        <td class="nump"><a title="us-gaap_InventoryWorkInProcess" onclick="toggleNextSibling(this);">97,801</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryWorkInProcess</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
        <td class="nump"><a title="us-gaap_InventoryFinishedGoods" onclick="toggleNextSibling(this);">128,634</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryFinishedGoods</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">$ 372,735</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWAAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company&#146;s intangible assets at December 31, 2014
consisted of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Amortization</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">periods</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Net</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(in years)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cost</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">amortization</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">carrying value</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 38%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Customer relationships</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10-15 years</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">596,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(36,740</font></td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">559,260</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Trade name</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(750</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,250</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Non-competition covenant</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4 years</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(9,375</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">40,625</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">State pharmacy licenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">25 years</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,141</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6,859</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">659,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(48,006</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">610,994</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Amortization Expenses for Intangible Assets</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Amortization expense for intangible assets for the year ended
December 31, 2014 was as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Customer relationships</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 24%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">36,740</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Trade name</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">750</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Non-competition covenant</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9,375</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">State pharmacy licenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,141</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">48,006</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Estimated future amortization expense for the Company&#146;s
intangible assets at December 31, 2014 is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Years ending December 31,</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 24%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">67,087</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">67,087</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">67,087</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">57,712</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">53,837</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">298,184</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">610,994</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in Carrying Value of Goodwill</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The changes in the carrying value of
the Company&#146;s goodwill during the year ended December 31, 2014 were as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at January 1, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">PC Acquisition</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">331,621</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">331,621</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts payable and accrued expenses
consisted of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2014</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2013</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts payable</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">698,806</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">261,924</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Deferred rent</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,975</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Building lease liability(1)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">73,552</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other accrued expenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">39,000</font></td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(2)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total accounts payable and accrued expenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">816,333</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">311,924</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less: Current portion</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(786,675</font></td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(311,924</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Non-current total accounts payable and accrued expenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">29,658</font></td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1)</font></td>
    <td style="vertical-align: top; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. As of December 31, 2014, the Company was marketing its previous office space (3,874 square feet) as a sublease through its remaining lease term. The Company recognized a loss of approximately $117,000 during the year ended December 31, 2014, related to the estimated remaining lease liability, net of expected sublease income. The obligations were discounted based on current prevailing market rates. This loss is included in rent expense for the year ended December 31, 2014 (see Note 14).</font></td></tr>
<tr>
    <td style="line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; text-align: justify; line-height: 115%">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(2)</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">The amount consists of a $39,000 stock-based compensation accrual at December 31, 2014 for stock options to be granted for services performed. The stock-based compensation expense related to restricted common stock issuances and accruals was $39,000 and $143,553 during the years ended December 31, 2014 and 2013, respectively.</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1. ORGANIZATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Imprimis Pharmaceuticals, Inc. (together with
its subsidiaries, unless the context indicates or otherwise requires, the &#147;Company&#148; or &#147;Imprimis&#148;) is a
pharmaceutical company focused on developing and commercializing innovative and high quality proprietary compounded drug therapies
and making these therapies available to physicians and patients at accessible prices. The Company owns, markets and sells a portfolio
of proprietary combination formulations in ophthalmology and urology that it believes may offer competitive advantages and serve
unmet needs in the marketplace. The Company&#146;s ophthalmology formulation portfolio, led by its Dropless Therapy&#153; and
LessDrops&#153; formulations, serves the multi-billion dollar eye drop market and is designed to address patient compliance issues
and provide other medical and economic benefits to physicians and patients. The Company recently launched its urology business,
headed by its Defeat IC&#153; campaign, which currently includes a patented compounded formulation for patients suffering from
interstitial cystitis. The Company is also developing additional complementary proprietary compounded formulations to add to its
ophthalmology and urology formulation portfolios. The Company makes, dispenses and sells its proprietary compounded formulations,
as well as other non-proprietary products, through its wholly owned compounding pharmacies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 1, 2014, the Company acquired Pharmacy
Creations, LLC (&#147;PC&#148;), a New Jersey based compounding pharmacy and on January 1, 2015, the Company acquired South
Coast Specialty Compounding, Inc. D/B/A Park Compounding (&#147;Park&#148;), a California based compounding pharmacy (see Note
16). Effective with the acquisition of PC, the Company commenced sales and marketing efforts for Imprimis&#146; portfolio of
proprietary and non-proprietary compounded drug formulations.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>46
<FILENAME>0001493152-15-000811-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-15-000811-xbrl.zip
M4$L#!!0````(`&B`;$9*C;@Q@T,!`+%'#P`1`!P`:6UM>2TR,#$T,3(S,2YX
M;6Q55`D``P/Q`54#\0%5=7@+``$$)0X```0Y`0``[%W[<]NVLO[]SMS_@=>G
M/=/.2+:>?B7-&<>/CMLD]K&<WMN?.C`)26CX4`!2MN]??W;!IR12%F5+?`B=
M::*0(+%8?/OM+@`"[__U9)G:E'+!'/N7O?9^:T^CMNX8S![]LO=UT#P;G%]?
M[VG_^O#?_Z7!?^__I]G4KA@UC5/MPM&;U_;0>:=](18]U7ZE-N7$=?@[[0]B
M>GC%N6(FY=JY8TU,ZE*XX==TJO7VN[K6;*[PVC^H;3C\Z]UU]-JQZTY.#PX>
M'Q_W;6=*'AW^3>SKSFJO&S@>UVGTKNO/G__\L7/1:;5[[4ZWK;5;OVM7?VH7
M5U_VGX;0D@OB0BFXW8=2K2[\T>[<MT].NZW3_LF*-;K$]4148^OIN-7JMN`_
M__'W3P_<9*?XIP:=88O3)\%^V4LT\K&[[_#10:?5:A_\W^=/`WU,+=)DMG")
MK=.]\"F3V=_2GFN?G)P<R+MAT8626'E81_<`;S\0$;\9!5Q2?D$2N&NXT0/)
MPOT#_^9,499:]-`ORL*B!ITK)ZB^/W*F!W#C`/NOV6HWN^VP.*?#3)$/#^!N
M6)`)I]=I'RUKGU\B?,!S>6;ADP.X&Q44S1$ADZCPD(@'63"XD2(UW.&.247J
M,_).RD.V8]N>E2Z3X?(#]WE"#Z!0$TI1SO3HN9<?FGT`9,#+Z=+).RG2H85%
M#S!KPIG%Q&1,N$7`:*V#T/3V0E-"^)T*"?([.M0D<D_'LC^993TWPP?VGX2Q
M%]S&RG_9$PQY9D\["%_EFY;NV"Y]<C5F_+)WQ1TKE+'5=AWYN]UIQO5'CU';
M9>YS=#6ZS@R\,V1`;%)*.J/$$)7GU[_O?0`C;W</6YUV[_W!_,-Q=0>I]06U
M3:`#'&-1"C`Y[B([?8B;$[XIOK?P&)!I_)!L=UR],?-(>'U&@/!BH-)L/9^)
MFR'4T:VD;GU"<S_$#8BJ".Z\J9*J"<"$DGJ;5%)@L=V$Q58353,6VUW'8KN;
MM-AL9OPK\%=__2_A'#KV,[4>*"],^[%"Z<BB"9Q%MPP0YFEB,IT%LFH&@Y)^
MC!LTYO3<)`+L+VC3#;]CH[%[]L3$WH>PR$Q[WQ^DOCHIUD&Z7+4D^&RS_.N.
M"A>B!I<:`]?1OWVUF2ON!E_K`9NS1\*->P@W9J&RM,V%0J>T3`."=6+HP._.
M<3V9!A-`BL]??O=`;LR&'1O^*<K*-D'/Y(6,[,*M.R?=$ZYC_27-[F;B@N9O
M36+7`SES9(.IU&EJ0Y5SR@D77X'B5[0X:IS#3\_$H%74%S@O-%E!*#TW:YTT
MNZW(,26LS]=/"*C[1^=^['B"V,:`ZM2^MG74QY3*)\YL0W:)J#<WY5;"MD$W
MD[3*GMUH9A]&Q+4*9\J>.&UK].9E)W-'[!&]L6D]^GTP)IQ^)`)]AS6!NP19
M4%X59YX[=CC[?VI\M0W*YV(4\?'Y\HERG0EZ"TD2E7I)T,:LGI0C6B^6N;0F
MIO-,:?U#F+F6*L!DI-?]1'H-OSLA8,`8=0_=<MJHQ3TP-\"@5U\4Y6A^T6EX
M?YTT'+NZS-#J[S:T^@I:+T?,:@RYX#'D8N9`0QH)$@AQ+81'C7OGRN$6Y9_)
MWPZ7`>?8,2',K`<:[J@)9F3<@@D^(T4(HLLHY^-S\DZ"9/(HI]`$NV#87-MG
M$\[,Q*#$_2,UIYB#3$&OD)GH<EA>P2BWLG8+5C*G?>3,I3Q4VHYB)E,3=05$
M'/'V$A%OK]EM57SU26^=\*^7&##=5&;1:W9.DIE%Y?7<.2E1F)VMYVB*XS.S
MF>59-6&X>*@QO#33OJ*SL`K"@SS5&Q[)]BEX9,#CI-DY#.$!OX\JSM+8G-QZ
MQG9O5,^=9NLHC#KD[S@D_4SXMX^D+F9XSUR3W@RO;8--F>$1,Q%RSK:T4(,,
M^B,?4(*.*VIR2#(<9'7U`,J&YR`C/:DII;5@-N9437:O!+184PIJZT#MRO%J
M,OR[8:3%BE)`6PMH;*HH;26@18I20-O`I'EMEI&M.VU>CO5AY9LX?QMXU29#
M6!=>Y0C]:PNO^F0&:P.L)"%_N2'6Z<80Z_1"B,4?J^R"-\QN;?'`Z737`$ZG
M5QK@U-K/9;=6`>?5P*FW!UO67@6>UX*G/J-5*V&G)&-.]8!.;<:?5H-..4:1
MR@>=U=9)7]M3R$`<+I?OX4J^6,&U"9E?O5YZ%25M&WUE6C>]5$.U":`W":/"
MXNXMPZB:2V%G/FV96=.Z45M3ZROK9P`+?:L61]:F;^6&5NWC2I,;-F`S2EIA
MNTCU#6>9]@$L[<3X^KMTU9-V-[)W5Y5Y?W=@7*?(L)0P+LVG/^6#<?K(@-K"
MJ@I;6!4[>J0^,:C")P9EP$A]YE#K^WU`"7!2G^G2VB[N+P-*:C,S6MN5^5M&
M2;_9ZC;;53L7)J&DH`$;';%+.[$C-*OTP:O:A/]I*>E+;2YZ&4+)SNY(CHUW
MCN?FC\]TETVAK?5`RPO'=B3GA&<;7B#+SAW"L>T-K]/WY]VY\:W<^Q.K8:WB
M1V<S0;LC<PM;!ZV:4E@'M+7D4L5I;PZ/.K&68H]<\)C;2EL=D%9T3+[]=6CJ
MP*'ZCG)U*GGZ<4))G8).90J-XUP2(HT7;H_9I"8;.E]!U.323VR*&WJ#5D?L
MP:1G0E!7?'R6.\1+8YHUGB7Z4)XU+[CN.3'H%V+5Y1BFM1`UKP0%H[PP^N+8
M.LX%N?1LQ*D<AMQE0&6K0T$K+[0^,1W[Q!XI9,%#F=I0P'K#N*J>PU;;C[;4
MH%KI`5ZG@;?J`5P-"^8=*E+9<&FSX8(_9E6I;`E2V8(QH/+0DN:A!>-")9&E
M3"*W?"Q>+W$L7L_?2B/KZ^]ZH"-:$QC,2<FF+?T"O!RA:/[3_GI;..UOV=[[
M:BERN98BER^?B4%TF."@P^KM1S2OY\-UC/5P8\8:1``M!$!LH+=CPBVB/Y]S
MZJ=)GTR]'J:9>V.P;%44Z/Z#[MJH^V\E^%O!H_SPF"&:UCJ$/H>J;4<%\UOP
M+3OY?N=PED<Y*I1X%?*N[;,)9^;]HW,_=CQ!;./^D9I3_`9S"E+=FD2768)"
M8FYE*63F1*;\+/B1,Y?R4.\["KM,32A,O=+/JFVE*[JM]"XAL38[$-5R9^K*
M([%^&:U!V>DG.B+FI92W_"EKO6"3OB8N>D[*<VD;S!Y])EP?WX\96/T5X\)-
MA-(#]N126O&ON38#Q%R4^^JU<GEJ"UN#0$PV=HTN5_:X`7M,+B)3]E@6>\RW
MM$_98QGL,7W[-A5*[<#:D&YB;8C_.SXQ.-QJY`S`QCC5(5?9U4&K);HHE$NZ
MZRP:"?JY*-\^OX5/N/,!-4U<FV4;P.+?J(MT7@NPW3/7I#?#:_!04V9XQ$S#
MU28<YC6N@J318JA/CBZY+;D)0Y;.E8/,N2FC`K4"]4M,7;)-(M=FZE^I33GT
MN&V<&1;DW\+ET`=UV>:WQ,A>KGC%V6_#V0K>"MXU9N\[*B@.DV`F0Z?4=";U
M60-38G`O4[MB[K=A;@5M!>W*LG8XKQ$.+ZF@))I4F%6)"DNJR=T*X`K@>0%>
M*08/D!POXU)C@:?SRE"#@97C;05K!>O=8^N=C$=*@>T2AR-UXFT%<`7P6C/X
MKHX&%@WOT@X'UHF]%;@5N*O!W'VY&45+@CLX.3<:"AQX#X)^]Z#9E]/:P'>N
M4?'V41D%2@">H(_R@6?N&.0-N?UVJ]GIAFX??O>B+^HY&U$[6+A-/9?IQ!1@
MP/4`4?[/ZI>JHV"_*SLQM]_%WMX,NJ(/'JJX$=G,%P(S.XIM\B"K>"=JQ[(<
MNXZ[1::?(!U]?C3?[FW;U+;.YLKH]S/#8$A!Q+PES+BVS\F$N<3<*0PLU<&N
MX4'7/<N3ONB"#K&]%QYG]B@1%H-61S493UH5(+F44E?$K+`(0'F1,NPY7+ZD
M<>Y47`67\@0=&STA=P7*4`%(R0*0:E*)@E')8%0FBE$Q;=5BVHJ2D`):U8"V
M99I:>L*ABH9+0#;EFT[..CM0P:5PRMC2.4^9E*&BWI)%O=6D$@6CDL&H3!2C
M8MJJQ;05)2$%M*H!;>OGH+9.JKZPXV33"SOFEE'+./EF@I[MUB05WQMWV0&.
MJ0VMJT&\O,+8UX28VT.BCAV?WE(U8/DF@$G?)U_!:+UZ7[_3O0)M+M`FMRU7
MH'T[T.;;#EZ!-@VTO^*Q0=2(/WVIOX_.:K*"T-M":.>\]OK`4NZ[R$VC4D][
MJ3D_;O=X%<7&&QJNO*/"Y4P'!<J1AZ\V<\7=X&L],#J'FOCSM25MWL&QEA`+
MP1F0=7:^YR818`A!2V_X'1N-W5ETS&A!>=YR>]X,R-8I82X?9%7:O`)D.XF#
MJ[I07\6F>^;UW%GG(*=N$=0P8PS*^'?:'*,%SHC?XXJ9X,R:7MF`34>&^-UE
MR%GPNULQA2UR5KN3F[.PW9OFK,.$;\`M$L(A`]PN\R.I2^"R;*>DV986S5J'
MZSBWY-X6FP+*20(HN.0B*VVO!V"BQ42!UY--6YJZEP,^)^O`YV0+\,E,FU+5
M&++0!;]SX)_N[\2R*%?0>KMD:ADCIFF]:&"7+)I+;KL5+_-M*5XL(R\&O90/
M/D%W;A@^F9NU8D1R2_G0X1:Q=>JO:96#R/4`4MHLRDMM+AA$95OU_7H01<$^
MOO6<<-,9,+DV&KI*P>QM'"TNG?U"K*0`V>I6"-\4PFN5SA:/ZHHDU+6&=`J+
MW-@U^9BG>(2OR-N1QA7.,S+_?K@OL?^[E[5C>]4AFWLGXOQ;M&\VQ>[GWGLX
MZ-&BF%(AJ$P(*C,'K7IJ1*]_?'C</SX^5%!2XWWYR*B^.;3*8-\"-]T8-W(Q
MBG)B962>H*/R(F@KRXNRINJ_.';XN5IX/G)=%O;GQ5*V*HKV9Z6=U\^/JMU8
ML+]5[+UB:*247Q)4!?WQ[*W\'7OE*X=;E.\ZG:9JH6`LK3&5&_1MJ;"D2/0M
M$5=S_BPOYI,#*^U$])"U?X1">Q+M&]UEHHHX7VO4I[V%.&%%G"L$*_SD&C54
MN7O9<_<RCRGF1Y5RQ"IWKS;ZX^_HCA*(#[X\/(-^GD);@]F\P^[A<;_7JOQL
MW@M;VTH(IVI@V]B9_4[P:`L[2!PEAB^/,C_'KSD`2OG][=$Z8WY'F^:-X##V
M"":I9\Q7'BZSC5IT.*FM+I`L@E[9*%GT$_&2_[NS'`6A;X%@X=N`FB:M2VB^
M*7AL-$1;Z(5"^:V_3EP4H&[3_-9.ND&%;(7L?$3<WO2A`WW<V:!SO!I$/U$B
MZ-F(4QG^*)2^%J42<9$^$RA,4W2Q0$20;#HB@#J.PHA`@5*!<@6_CY#)[?>3
M6-[(:&`_L<U7+BR?7]WX0U]2];.J#LN<V0:GCW<?'=-4@<+FT+ZL*PJ.4181
M4+P9KA%^;\X,UXEME.DITZN"Z141EJWCRJ(I$V4\FTQP5YF-R#%[57/C*;G?
M>G7X>/ZR#_O-&=NW`S(FG-9E&Z12^K`E75&P&2XB0)GAZ\-'97K*]"I@>E4)
M'Q<UM1!8*N.I"((+C&=WRF]ES:V_-`.I#*E"4]:%+F1%<Z30:(8_096U6=-U
MQ6SFTD]L2HUK&]S@B#V8]$P(Z@(5?B9_.USNL3J[2C53&X5"JWRK1)=`*^2E
M<,%OXICS>@#+;\NU;=`G:MP[UT)XE`O?N2T25:8:%*+R;F6N$%5B1)5C3R$/
M.%_"Z>O@8@$5%B7"X_0#$TZOTSXZA3+AR\);LU7@VS+>/\!P6616$2A!%EJ[
M#I#O-J,>N2UHBF[QV2^>13EQG91X/8<.YF5,>VNBT@MJ.Q:S7ZKV9;W,UYOV
MXO#^C!964.@MY3I`_(5>F\#/]7'QW8.V75&:78OG\E/Q?>BN7H=!V>FE-,T[
M.F+"Q47HN&.4%MC`'1TN<\D0WE@3SBPFM%O0O$5TZKE,)Z9H:->VOO_^(*N"
M10'.07^<F)*K?J?/*TN0I-/,MR6KNW!TSPI"_Y5K:;>:O_OO3SZ>]MI;22F7
M/N&L_/ZD$\Q\6[*Z,[AK8(DKDXQ6KF8(74/]&F9>D'SSN<<Y7F8".O)/2GC>
MMC23#<EZVR(`KIA)^3G<&CE\]>X?6`078&IW=.)PE]DC#2-M8C\GT3#SZK1.
M\\7SE7T%U\3*]5_].=MA"V\*J\O(+\4]U/+1!(>[<I7_--UW$TVXSR9$&1;A
M(V:?:JV)N_?/D?L.;QY,Y*]_M+O!'\D'AE#+J=:&\MH]!`Q"^T(?M3O'(G;#
MO]#0!B#]\)T6O?J=AG(UB<E&\,^_(<-CP^>HM@?\\>7F_E)K'^YK@Z\?!Y?_
M_GKYY5Z[_`/^'&A2HH>MRA9<9#8&5E!HO\]L7UYB3=[]HWW8VK*>[L<TQ*4V
M)D*;^+LA4T,CMD:GQ/3D3GR:,Y2"4(D,S=%UL![$M(A`H[F.=D%U/^+KMAL:
M(D-SQ]SQ1F/XFVI#9N(C!IJL,X1+P,YGMNT1,S`2#2K"[3HT)#7M)WPFT$OO
MZ)U?4DKAEPYO';_[>5_[2`3(#,\S$"^6NZ'9#M0#M<)?()<[AF;A>X.&&%3H
MG#W`HP_4=!XUFU)#8$L>*$2M0C<=>.W^[L(#K5W[C8#F@?G\/NUG]:D4);5?
M&[)H"#.&L3[@"]3L0A%XHMUI'/:/-3]&P@NZ8UG0EP+#?0U0232XX9DNWGOT
MOTC3(''@.A-4[&L)$$LA.,`0!T&T$7<$,"818VW"'5UV+KSBAZ->X^3D6`.D
M2\E0(MS_&^\)3Q^'DG@3)T!+4!<"C/CO>R""2:1`[*2#Y5!94$`$(46P/6D'
M^,+T5CTR=RQM+'PUA"N^!#_T]T\Z_1T&W;4=00[QEHJ>XT:_TPYT&P(/37]&
MQ\Q&UV53.1O@:_QN\%5HCV,&G3PF:/44>A0_H89W0F<2X`N[28-T$RC`_W(;
M.LK0IE2XU&AH#YZK/5).D5I"<3SPYCXWH:P@$S0J)$XI?O0FQYZWIQWNZ9L%
M9<QV-O3FQ*0N]LW8MRNB?_>88*%J(<0*->QX+D[]&4A'.IDPY!8?!E``/XC1
MADAF6'3"Z90Y$$LYCS;E8M[3R,+!YS.-V,M($"`]^/T<SS/Y,L\]?Q8+FG!4
M#:0+)!O71YL<T-!N0PJ)YGD;DE$-[8LS]1UJY]!WJ`"_9RD(`9B/(L0%"O,E
MF9'?_Q<^@;?\JTC+@%&H!S`ZI=I/!#WAD-F^HCEE]L^I2ED4-.F$I32R'$/*
MQLYS/+]#)GX2!J+K.J<&P[9!0Z2TX:WS1/FSH)AO0Q\=,%#9!G@Q1*12-6#<
MUWP*,C>T<X`6<+G-B"_#(JQ26W,.WATKPZA_IH]2>`,?UX/R`>#FNSFM#BE.
M4,],%4F43PB3Y#/?=^@>R`@T/9))CO1B80?$WJ+;@$13_@_1B_200TJ%U!9]
MFE`;/&1#B@&AVM_0)`D\`ZT0^P_]F!\X^=[<!JN!-$$/=F`.;2>4_?`=L*?#
MOR6-#&O2*7<)J,V/LO`UML[@'K/EV1J^E4!!*4C`F6DM/NP"K_<3/C.AIZ0,
M29IO:!CN843A@N_T=3';+#*EG(SB#I3*B\,5.NLUPJB@W=+`R`T_O'D6R!HZ
ME?^,Q`YZ=E\#ET4,@\5L$+LKS7D`XI.0A19;Y!N\N:/AF(E+N>D'+'[?$KG6
M0Z0J1G?@;]R(@9K/?I#0;;1!4Y2`)P.2\$6&R`R\UC,DLP*:84)$FR9NPX^\
M\-8/A]VC!NC,MYO[^5K'H#F?7.68*TH6Q%;RJDF$JPGV%,5-4:NBQB3J\B82
M>DE,2_RVCQM'_19:741G"!J\>=@XZIWD0X/L/JD5*5$@QP[[V.MT,IMGKP88
MRXQ-S'J1"VK;@.4!(08=-S1H&[@))&&_2VFT5`EZ-W`-<5V1=Z+#H0]B#.JA
MGD7G[P1>WL42`VHSZ,V+*'8:PJLX9!2(G0M(X4QG(FL*6&K.#A=#K80W1*'E
M$(Q&AIC$2`,-@G*?IG#4@Z/9Q:XJ:1NS*L`V6AC)`^G)3\R2OCQD%%/>P$P@
MH$N@%`M3&#0,^7(,:2:0JCPQ($T:L$,/+503<I@5R5VVUR0/LAT.2`^>0$R(
M3OU,"$S!'8,)<MD;%KA4#%.U'TX:1\?'OA>U==,SI).061K\FZ-H8J%^K?OC
M;IO.%7W@&9E($@`^:H,.CBT`.WY6G\>-PU8GI2\;F-?2,02E=*%;,1ZY<YX>
M/`XFA.WY#?!'G_W>UOUA3+]JGT`ID">X?B9)$VS`PWZ4%M#IO`21?B\_1/:/
M^C\VPA!3BA#H`1V0B-`_9!S<Q1"M7]8O7Y60(!QW(0]HBR@HB#0D.ABG*QUI
MT%2H$J)$RD>.C$(<6[C<\]D-97B@+`B,'SQFRG!'4.Y3#A@]I@D.1%'X;/1R
M?"X,417>,_`.O0X:1YKT/X'PA^+V-?P2(NF-0<^8B9^/&1UJ5U$H>",1S7V@
MS/L/@F/^U(_Q`;:N9.-4IS(79)]?W6CQ.EDI4EINXC/[9^Y+VPA&`&2MH*&@
M1A%D>!,T+\0^"X83P4]P"C`)GT^V%F))##A21)7"S/O`(*^+U.P[IL`L9QL3
M>Q`<O,)IOX0MA<%=PT\$H^%-N"1.M9_8SSB^!D00>_0H,FS`;;QOA[:-L;(F
MB(GR8$36\6/H=U@."E(`"GOP#241`,;/^^-ACNU)C<G>E(Q"O^/=D!Q]BG*A
MN3]B+6C<(+/=#`DL11CIIS47@.OS9'_E1QMQ\(%A.PNH,1`L&-^EJ""9]/Z'
MO7=M;AM)$D6_GXC['Q`^[AMV!,0F`#[;.QVAEN1>[;$M'4F>OOUI`B*+(J9!
M@(V'9,VOOYE954`!!"D^`!*4L+$S(TMD5596OBJ?`!QWTH0@Y52W38&QR1^C
M\/>DK1\BZO&CYDP2`D%IQ1>GVTY]SP0%7N+(!DE/C_DQLP%2^!7^[(2VP#3\
M`A9$FUZN$]+!%4I;H"U<^,'WD87L$!^D^$LR@^4B:!<)797RT/^-\?W\C!+Q
M+OU<_KGJI:=[<N"_`(-D0+G\82/(0M>49R;WB$9...&.$M7T`;G-[33Q.D5K
MR_'P&9>\@]:D$CPU/D*$4LF^>V2P8:K<B-04H*_CV?PDC&=R3Q[C$&0KJ,<_
M">@2*8K'SX"+P4K.#+ZYR`.21S-P(^=Q#](')!4E"$$*54OO@+_$%%!]A:[P
MGP%=/"P!S\B%,]O:",CL@5N9W(#5-[ZXY!VVQN5IU5P<@;#D\O2"F].JN#4"
M`F^.*RT'+/PQ/A3(%2P\0<(#B8NK'DA&F4S<M1R*U\X*>J272_Z95J!N..]R
M1<RU3;A,3BW5OVO+-0H(/F"PA?L%E1OBQ^/0\","YE/U"B1"3_`1WC89:_S]
MY-J>5$[S=.SJ"7?6!$G+4O&2IPP36A[!XNX#H]OGKR'I$\B[0)=[B;C.)Q;`
M^T/QFC%O1H"P1V$$S(#*D=+#A.0Y2-SM)J^?:Z90&\>!HSAC2=>>(-UH/(UK
MB4PBU$K"X.?D!D@B0(L,CI3?5J@"KO8]0=$.K>P!EP>A4/(+<&0$MSPT^S%B
M<\'G)+O(<,`@2OY>+.YVR[AJN/-STVO9'NJ5V.*B?87R1(A05=+ZI!Y&(^8R
M+D9R#!][/!@DSTM.<T[G2<R0Q\B9""M*N<P=H)Z4S1G7N]`*R"4?=>GNSJG3
M`G22S,'+D%XS04J95RC%O20O$Z0)N>)^S:/GQ4</U@SQ"$=+$Z5#BEQ?*H`5
MOU`B@?-NL-QKH%O\1F+99\[R)]%9\2NB\#DD3B+>'TN^N>K](>WJ%6\0;=/W
MA[G1^R/UH*]X@Y3VCM"6O"'D(Z>$=\0*XU`K,`S%%9*91U!(ZBS93%_3TN.(
M*,=,7\]B+D!*!@_;&<W)DV=7=,HG>/G&<]%95F!3W,QA#%F!Q5ULV2)16H(Q
M*Q]]RC&%,9%PUAKVK$@UX'&RG'$T+#"."J`6[^!%XVA**5!2E!IM$>&388S%
M#*)^R^KKJJGK"4&8!NBH4-IU!<UA`-%6#%<"A1NO"R;6XDVN9Y-*+PLC][8(
MSW'[>(FY)3EG-Y-+*]7<XJ'T=4PNE2)RME>R\;&8U:ON_(U;UOEG*\&!3]=E
M=Z[8VO_U\XO)U_DL;12"#LG+\-0;G]$E/``N'!:>\X35.&"'2]W^V<-'O5M^
M!G>GI9U=??UZ>?>5<K=/OYW#O[_=77[[_>+;V>7%[5;)W*5`6^Z+I@($GHE$
M'8I+APVB5N7`NSS(B>8`3RW@O"MRG=+@9I@D\#KT3`,)&P@)VFF9W9]0LY'9
M-FMII]%B8KRN3>((.#6U^U(A423;Q17RO7ED"5-0;6GZA;\<T6U&]KW+P!YV
M78QO@_SZQ[OV._KW'+,WQ+\7'_N8YW<?.+KVW\Q]9%C/!;#:7G@B`'YRQM$4
M/]O^Z1,\!@-`Z`DF3MGSD/VBR9_>I0`A+('<"!0BE8C)<][[4>3/TD^C&*9O
MC.4WQ!;\@_`%UP:):[2Z`&KHN\[XD^:"^CF9,N=ABF<PNC\EG(G'VM2?05_&
M4B6TH2AS42$K0C:NE+!V-%X!^Q+(LG=7O`(@$N[-^\<[\UT)JVVQ`OT8;'2-
M0`]P.0\!)I@B3?C!+]K_/CN[N/C\>=4-"XKJ6S]5<I?H[-GPWB2-+P=H`Z2_
MO-@NIWN_W=',SD]9@1,@4-7@OZMW^OW]W$!)1`MV?<16D6PU9-K;GWC95;B6
MNL=^Z-`8ZI9I5(CB_4G,"K!S1W5B,G3+<\NDV;1WLMQ]A?V05*>C]X>#^I/4
M(>39%Q:&TH\?R%(8M*>D+=\(NPHI\X.A]XV2*',7.#XN!>&HI>4U)V=>%$/E
M0/RAV<C/S>2GI;<'[49^+I6?,C8E,JP:D5FER#0[NF&8C<RLZ%AGJGM-%NSQ
M"*VHJ:PEM9LM$TEQ[,?W+JO%$WX=,/?TI!KHP]Z>[=^?R;&9^55YWM=:NLT3
M(X,"NR\[S7G^P&*;F"?XP_NNJ?<&?9%R$_#.S1@KC&<Q_WG,*`DG2?1X/]![
MW=XFN6O'A?ML&.=JCB%3?*;L/Y!3.^+#'B&QQT0L98NRO+[>[77SA7B9JKMH
M:D<45,=(,]62W[)YQ`E7TBW5OHM`>,B[@&A7H\A7B'O`DY&^JB5W]^P!2]&*
M5A2A:O$ZY>4X>@?;/_"`DV;]E!3CR0]37I!:R^=[V?0Z)TP+O//(R%7I%94&
MJG5Y_(-/OLP\LO&E$5`WC8ANE2=#*_6NR59[8-3C"#@"\9[.`R`5[`>Z%?5:
M>G_0V9!ZO]HRP=0JI-N4%JTV?:S7T@35$B19RE576Z19`VBVO3/-:@7TRI&R
M!<VJA:>;$*W:74I>C\@UH;32$*V:[`TYN91BJD'%CT5P<8/^PL5AKHCL28/M
M'4#ES1TFBX`Q"29MN!4PK$U(R@V2]%H!>,-CA4VD@*"OS_(E^VG)=)ZY#*N_
MA+F0<5S[WJ>^L,]+>2W;=Z!=R&^9X"U"0<V@M&)%D5]PD>4LO3OL--<OKO^&
M:L)X_YM$3O"T25YI++%/X%BJ/B>11@:I!2*L`U8"_A9$&M#%T*!JX;ELQ<*E
M0YI]FWB30^EV$P*MV/NFBSI[R<[9OR8V,%!K3L3DVD\X*8$@K%GA\R%D3/OF
M1TPS>B+[33QJ$3\\<4W(,"'7@)29OLQ6WT.BR6O/*=DM&:'7;9(1]I:,8)E[
M2T;H#$V]V[;V<P5'['T^2#;"T80M>@-].-PTI>7-I!(`[52)FR.GG8&A=SJ;
M"J"W(W6J]"8?.>4,N_K0.H)LDX-)G6%#.TMS,/MZVZH2/T<L=>ZP_,F>P%-O
M[_3SEN+KG?Y`[_2/0/,=,`&S'@38A+Q72%*]U^_HUG#/=/RVHMZX`05=O[`'
MP11[BL$>A^/U4M3H!F/'LVE<4ASPIK?W<0B$%HI^;VK0:V8_8R].E@1E1J[M
MS$+MGL(>$6^_BW7+<QL$I6C1E%M`%^W]`5ZJZ'70A4G=ML5BZ`/&?[IT;^3U
MYU.BJ3M(&((,7E9]1RRK.FLI49@:<J-O=Q[X<_@VM>^;QQ$3?1T"F_]9_I;W
M=:4>*:.DDP$!(C_1TDX]69`=)H`#!EVE*Y1R;/0+.Y'(56II7VW/?N!AC'OF
M\F96=!=QA![=4,ECP@[=HH:,[\(1(H9:N,Y?V-@5EJ<&X+:&G5X#[+O`.]?(
M8O+"(G2/-#</NR7-Q^:^Z)$O&GS&+N]TX?.<!OA2$[G("Q@<$3?S'"3X1LP4
MB!G9Z%L6\#L<7Q.PI.C7U+0(IX[*QAK4T2WM!E!$O5-JCP%ZF\],"[/!^0?F
M`;FZKH@#ASSX$C(02UC[FP=`B=9@')R@X/WZES8%&B?M2M(FT`$/A&?#/P$F
M6P4LVUY]L0T3=E1/X'I.&RLF'=4#N0DLCOWNP/*8LQ&.?$W'1_"@I\,[DSIX
M3]3.`9N2@,T3>.PY3,]`TR=TN*OQ@\`@MF`0K759%+G\`%P)T.0+T5P=H,39
MEKS9]$(+&=ZACW=_#&,G0LC%2"?JX!,X?#1'G#342]?+M72(8E(&V!1:CH%8
MWGFF`%.Z.DM,04L"!"DB[+PQB3'P%V+#GWA$(,L?*6+LA-I?'L4-18;%)+#C
M<>Q2BR,@0I#A]]0EPR75,O4!CY%HM(TS/!YI9E5R2Z"=4+AO@%`5@?SV$]6L
M?%FDXU'0$S?FG45R'T(5GNN-E&<'`99`<C:OPG9#Y0NBPAW3(EPP&'SBM(43
MX)^3#MXBOY!:Z\H^2UQ]9FX%`8C#)&-1?-UA"8LYBM`E3O%)(XH&:+RA.[8)
M<&9R.(U8:F;_H`#OW(\0"8"2?(&_*DFX3K]GB\-!6MI_.R$0'+X'W>=%6PE[
M`2%$-+DJ_;:'_8(E`?"A,F);$?S.YC4C$>F\N0K\G>&8O`PID]ZG+8#\\8'#
M4U[2M10\);D(HQ&'4;9E3^R`>]LE4@VGC$6@Z0^F.NJJS1*=_QU,34#Z%Y`S
MP-.-VL^`M,HE=^7)O$N>2M.1;39RS1$%@B^2#HP+PY^69>-APA"_EN7=Z'/7
MERY+0)'4$A\IG$JL?<@OM71T&!?"8K&DK5FFDY$"L,C'YH*18/G>NFV!C(A(
M1-#X`_H9^UVZ0F#3PVC,IZP(]>VZDMGI^UD845U^O_G=:!LH+DG-*>?Y[R^G
MF</8VA3M)B?M2F>[?^&@(.<_#*T-,,'06DNFB/$LOIF82Y7.5,&\.12XO,E?
M%#`[DB-A0&>2;R9IN>;Z3]A'*N`O4WJ@M;1;.=%-(LL)^1#`'_#8"X%$/DGI
M/R:UK8-<C)Y0-(H<SHX8,89GD+F_\I=9<J)N7,E,)7I5ZIB+B)J,]PD3\MY'
M^8E>06YI9<!)+E5T!5WXO<1,DBFHJ5F"61)-&WWY'G_QJ42BFH(.;].%F4+\
MJPMC\R[D9V[3SV3&P]5%8!R=<#OE[VH@0?Y85G5Q<NV+S<;R5YV1#2C"2&*`
MH2`_*7+50*FCT`O\9]LE!9\,4PMME[L1@)L7ALI)NRO78YTODQHDW/!;MA6=
M,TR,^`?D9SY'%=LLOH>[:E-KI;&/)Y*CFJB!GM']23N1XR60I3#++0-QVII.
M`B7R)T5O4&*V@'H&CIGTCRSW=:1SS&@7@H3OI.83BQ:'&<,YAQ,N=>4DV]7X
MDQBB0WVP/R;L3NE;]-`%8+!MG<8[UQ>@T3`XDLAJ2PZ17H(<2"C((J6H(A;/
MG%6.R"-`DO:D.I^;"V(T$/8@G$!I??A^("<8HKE?*EB)_4PB.H<:`N#^8SHR
M+O-W;AY3\$U?@C*9?ON4OKH4WYP*9P)'EBFSR'-H,(@"0O:1E)\EB)S+23;E
M5`9"AF1^^D2BL4LYCR,2K.`*-3>9QO11<C+5<^$,J<PC1QH,N=:)ZXJ@Q4G-
MU-D4WWZI/,+G60HM)4+C,!-*[V03N*IHP3!)/P[&`S_3:$0>Z`<)(JI`/KL*
MS`(7@8+WR-P5$UG2W<4M"D>S;*,I]R4%+D9C<6F"#H?T,;BT'ZU#;2VE8?(>
M&`-60L32NS:%/A7O<LM$=!$@RCKD!@`5XY*5!)8`ECO07$]>*<=(O2'G@>KY
M"T3AR`E&\0Q[6HY8F'3!3'*`><&$?$-R889M88W!B=DI[C-<:$PWCESQJ+M=
M5(UIZV?>X=T6IB>2VV+$@6A73O\I8"?X?@!J(\B:]_E[+O@>D;$L1Z#FP'2#
M!,HJ]B\*C0CMI/H65K-_#A9EO)%L\,K-FYS8TE21=2]-%IU$7#+!$34-;V0L
MHT4XWC&2T.";Y;,O^@V?!_&#=CI&;1M&XIPYB_;S^6G^#4<B+DP,)AR$]\@;
MS`LN0_"4-Y*.8T;$GY)/.TEKV*R`#Z>V^D`03P+Y0DB[RB>OA'N&@1TYM3QY
M"8SQ1,Y]+&9F(DA9QH6#<0CP%^(LI$ERD+:T;W[.5E)\0ZD+%Y$^&@7Q"MFO
M:KIGT<)0*<-(R@L:\9'W"5V?G9TF6$QG,C3.H8)I\J?Q`_Q"%C":A=X<4>2R
MQ*-#=M-UX$_`$@56`\#4N>1G(O`#7'4*@LD9V:J/`V_J!8\-7:;2BEYR<N9M
MAIHY(];4@3R"QWE,6K";NC$?2NB#-<DB,2A`>DW")'3!1E,/7ID/(IC.7=UV
M9.L+H76RT#*/19Q5BZ>0,*76)TC0],U%Q4N*!2;E=S+[-N<H)QA`,)UPX8,C
M$;@7*>31DGS"`/\KDY91"@5I-_Z*(Y]_IP4/0^S"_U-^-C1??V'R6?XAN_B"
MI?,C$%GUO$A-N1E3$]MQR7J5Q8*J18N%8W8@+`*\AM3$?<X`',KWJ@24DA[X
M.S.DNJV0424CO@"\8LAVD.Q.J!PP)]7SU75IAP=8"`OK&O%>*-YOT0*!M]M(
M.X5W`05+3C,5SXVT+Y#VZ=RD@;Z\EEZ5]V&"9UOB.2_ZX3I:VO<"6M=3X2T%
M(KF#%190':W*]QPY"Q8$$\;N')Q0@,*+6!L^GY??,V(>"E./X,A@XP7X2T;R
M-+'S`X>R<O)6ZU?Z\L]G\HOJW"?R&3\+9T1J(S^AI^->S@I5_I!X4]"21-7Q
M1".01I1\$(H@<%$JE%!/<LY'#J;D[:R8^DH;1IY>`,^..;9;PED*S[G81BJ"
M=0WL7.ZSCV16!*HJ72[(5TN70A6178R;TS'U(RAR-8@H,9]>D5P>U7_+.Y$A
M`5PU=]:\1DT"^),X(&4LH@L9U?,7>^9*&J-#F)WF\/?<0C">0KV))A4:0\[L
M6D@8([V)-@EVC@_]D3+UO@#R_-2353=-<W_HU4@3FO+FC+V`E80'%L)60(=T
MN<2^,O26\U]E"_95#4<*"ZA`Y)LER2"KB/3)2_UW"Y1*L.1G/TFS30XC2W@2
MQY!A!HR8WX(=+1)O(6^,(3R=($6>,)Y&HWWP=`[9FZFO/;&DZ`E)A,/SCZ($
M6((B03,NQ%/K$A$T$NRP^N;N5&F5&S;D>^*Y)MQ%-CPJ9W;$LQ/`'(U(WR<!
M">"U$1K.@)+DF\(P`?N!O+O,X51/\N7!29(4Z;=/(--@261F,<L(7[8!G/L)
M7Z-W6>,C`PS!0)\4#3]L!(&/X>2G65082<%_=[4]I&U@"R6>WL8>VLH>.@W1
M>KV.P1*VU0=ODP2Y<G`)L6T1OW-;/B?RE,X2R7M,>3,ZGN<_"F\>O:'DA]#_
M[%%^8L[HN)1_R%@;HF\-O#\C9^[*7#N\W[F\WS2G40BB97].<K"2UV"RIW1H
M\FQBMCB!RL%4J4CIFR.R'6#)2*2423WR@LSDRCSW'*7MUXQ;R%<>-SJ61S'L
M)(DBT0@O@T=:6.;%9HWA#'W8G`YDQ)(;8`&;Q*!P*%8GEJ#4P65H&*,#5;4X
MLC:6,+\2916J%Y;:S%Q<*G9SVEY%N?SDE4\Y#6'JLQ;AJJRO&KVH,ERJ.J:C
M9)A8(W;3/.I,:D&6#[@1)<GD)4,J2W#Y:"758J3)D'Z.A3-4CDD_;C)`54U)
MF3E@1$28":LKZ=@B)L[GR/VB?3!HPKB@`/A?8D+A-+':VMA^#I6X`%A>L2VF
MR5%6*'^/<!$A??E`U<+.N8W();>05_J"Y/C`K;B/G[0/YD;@)<XC/'HN/L+C
M@8+`83>P?CA?*GE<JH?R\MOYPAC@-4,CR\(B2#&)S2.?<EQR[8`BZV,FEU?<
M3$(N^B("DQ2[]9`H0$7>.<\C+$$+QDF2D<?K'6W%2RD]'B4>=#[F7*A*TFZ&
M&_`E0`^-.6EN>G$LY!MD$J33=,/4\QJ()Y(<MN@];Z-ADD/H`KE@W<(2N.B'
MQ?*#C_GTY4QJO:(Z1CYFM.3?I*K3$U3;1%?"6-3.3\Q!36Y9#K&D<_`+1=8B
MFX+K_06[(N<RXH\3F5>SG/QD&C;2$TUA!<X"'.L%V7?IMY*4!^X$`N'*6]R"
M@(_'P@N#9[!1>()$QGNFB"8FJ>#WT'_,I:E\"BZ2SH)DE3GK`I$$Q`8WKN>6
M6W1[YS%=8+V)NJ^_8QR4A_;30EY[P$[0S?&0`RF)5#PO'&S+)UNVD":32M>\
MV+8;T.D#(PLI"M=\\0RWBJ6$WS`"\<1$5<FR=YU\1'1AJQOQ++FF?(CFO;<T
MP%GH[UY#!6WY_),VF0R#SGGV^K-2OXDR,B4$;BCY;BS"CE^^G*D6Q+?S6]6"
M0*JA?19)1R;&1_X#(]$,KQ06<!>O'!B>KGN+1\Z^064(5GKLT".W3$CAR&![
M1OROYU:^./NFG5ZK=D]+.PW)B\6U@Q.J)G/QQ;S\+N=U83S!C#\!>0DCWN%"
M@KYZC8Z'SEZ2P?Y\"LNX,XKOHON8;BX4>4<@(*G>"YY-)_?VB-?UICGX^&O'
MF[CV;,8[G`H('186IMQ/L+0W.I%[.B-0VL$#H\+O65I*D'N8*JF;'*_Z@CN3
MNR%Y'E3A$S6IE-9RM][[5,;[E3_/7PSMK'Z6+J91K?$T)3>(I#=!).CX4.+@
MXL0;^3VT;7T>W&PIJBTMSQFR(IW3WM9P:13U!F_\Q4+#PO<[/802&SQO<PJR
MW/H!KCH:EC_"M4H?X`3#^N]'-/MW>2X6PRJ*&M37\"X.`P%,H7-@.?!2]NSX
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M^<>[SR`U$;*3M@'_'_GTLV&>6,:[7S-TD%SK/'JWULMWXR^LVU%L0Q?`U=V%
M9A@M[?;NZNS__/?5E_.+FUO%(+_XO]\O[_[<ZD5?)^8L$V5(AS@!"`FJ00P_
MN4/FJK`&0U4H_8EI'!=+)S?PEG?.V\:@FA'9EPZBU"QDLDP+F["IIG;`'M(X
M#S;(X=X0S)<!=:'=GAC"=EAB<UU3U:5V!>L'W#!"@V="O9;NP>QYRG=5($"$
M_N99.J"73LC*0=<"]HL+D2VT$.S49$+.B#,,_PNU1U+.6^00R_8E4[[,IZK`
MB9-25?@3OKJ_G=Z>G_Y?38Z#_,JK8:AXE4`Y20KLQ("BJ\P(K[9L.I%1C8P/
M/N))@%Y,'T6C-(ZF?D#=#L*I':3UPW16`0&'%Y/7NY0VQE/'O!?7*L09+M.6
MRVQB)KUB/D&2631G4)FCK2QB1D3>OB3O(M3FLF%R')'W=>)[EYOBF>1`0Q]T
MZ&X*+Y%@$<0?X7,0KIX^AX7#(R;?X`FTVOMNR^SJPK`604-\7HFN3Z&8H&C`
MGAVKNQC/(V_4$R49\Y1&62B29BNJ/0T3_,B&5-R1I:PB2GW9#W3N"(9P`E'F
M1M4EB4LVDX)B]GL*5B2;9/"?/$L3EVO$SZ^@B<HNL*(5_^L$1XAQ*Y!/,X.=
M-8-W[;!:0%X1S^5,D)7L(,%7)6AV17DBLF7?&[IE]'0#IZGQ/@X@+>:NDL69
MHH@WXI+>Z$SS&1*V7\]_2V33[X$?S[G7YLN7,TZ^+K/'V6L3)G..'JFDD'SZ
M0.>"I(L$N10TN>-)#*2;\@1J]:83BGNR`UXRF6^5HX#YA_A,+E,](8?B7%JC
M/]0'/4D6%"<=M+H_J?>22DC!42%8[M*;M*"VTO:>N$[^6VHMETH'6B$-<"B(
M#CZ*NM>"`VM(EV(A'C]=)-L/.'HH*<`O9G41GTGY`2$68:"BLW[49062TN%"
M$H/J5RBB"')H,]4ID<:(%I?@+\SL,F]8]UPJN@>1R07/H@::V:(B0'E(1]@>
MZ0$DRM`H,L5&:#3#HWB,K7!YKT2T((B(Y/,Z+S<_6-T<X=#'L8SB$1M11"*%
M8XGE]Z+I)DV]!</T;9.`'%UKY5/FR"[(&`&%Z@X$`-JFVF]V/%MJ\IY-'3;1
M+GZP44S9E%>RT2?58\C&EKH:1<25**&,ZX2;V^\;]>5]?1>5&O=+;\L$W=X1
MQ0=8=L\'ZB4&7/[>;(K%Q&YD8_B0YF>/2>S#ZZ'?;>N"LW/1&O$=*H[B?4N3
M?.AQ4=W!$O>=)>85VF!V949W+X%7'!&'(<H^D%1>BG\\X<Y?#/."N9<V+EFO
MSO\M"X#S]3"T&!//RH>UR.T\:`&<]]A*[O_8,RIH2GF?)UYPE_`2JC0')LX3
MTQ4ML#EIONA6MJ3+UFS(8FNRL+F)@%1@&L-E-)$K$^._%`\6:=*&V;8DZ>O1
MSSZ*,LES:A8U!;,$`+*K2VHPJY8TKL?+PI*_)FV[\_"%F4>!H;>ME4I2M#E6
M5Q8U9>\[K78[-;'?,,WMY'3M-$[7["SW3J&!T(-7ZB!'J(KL5FDV(WJ[PMVW
MQ/:&)41^'6]K)D=.R'D3;YBJ+[VT$>NR6^D4V-A+;F6EV68.=3C@YE9;WA)3
MW1;E6&-5=%QZ982RGLKMK*5RS;YN&KT=U>Z5F/V2)=E,'HRWX)HD7^_`T@>&
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M1/2`1S2K$-.%&#!,2^\;W84C*X'5E<=6HS)-DN$V[$<FDBKXUDG6H+"B2T-E
M4`Y+OL46T,FP+)35&/?`5E`96N-M]%R@S.!9R9T-$QL;HQUC65*4%FTH30@2
M9QG\#H[?#*I;[&"7U&11,EO3F70!5:>KLE2S`1R$9VJ/M23?1V&7>8)HX2UX
MWP8ST<`J-/Z(U-5,()Y=N_SK:1K*&.>F88.Q\8;!V2HN[:3=ZM?DVA(*YW1]
MQ9]KURYHB(;&"[*JE%0X"O.V^\N"DP32;[X=X)!#[3PS]3!44JPU>PR/+39>
MIBEP#ZP0Q7)$D-6W26[@*9@`8'S@7<DB/?2;A/%]B$4&-`%5E'K*!$"L7B7@
MNP3[0$^#UF9/]A/^G]A-NH?!/[_:\$<EA*'$"T6@>U51*4*7F9"#D)P2KQ8_
M<#CM)?6`1::5G4RB@W\4"9$U="X'Y(Y23(*YG^:XT/8.-ZM$-R;JB"CQCXZR
MB'LA>=H95?PD>EJ7(Q3YA%SA3L-"PO&C$\K[3UYD!,73%/=/W&>HKZ6C#<@"
MI1XFSM"<2^;AL&'[`6L&0]X,<)+4-</J4V<N>R\"V5)39)YJQA6]0_E6?/8,
MK\8!0.7TT.4S0]72'HJG)4-O13.\M)LH$_28?8:H,ALK>5$J*SC-N!P$++SK
M'G[Z[QA8<?(L*FIOQ>.T8YIISPHX%2:"W&#1;HP;CVG>GW?"O^LD^D#LH7,[
M2TSJ34*,1!CHM.09/8(2;-$EABF#)\]4)R0OMX@86T%[BX(@&X!"?6CJ5@^>
M0KVAZK.U'VW'I<0I9`4Q<#%Y?2MEQ@1N4:W(H;5=;<1WH:YK>NXMFG+`UK.9
M'235YQE7+HD21Q1PYLA/[3*RM+P*64J.60E_.2*D\]X#F(`6SFU,*_S'N_8[
M^O<<4WG%OQ>=4F<`P7W@Z-I_,_>182]/@-7VPA,!\),SCJ;XV?9/G[1[FN>'
M`])<>QZR7S3YT[L4((0E2/Z)Q5OTJ['<&\?J85L$>?3(GW_2<(C.R91AMP'8
MR^C^5'3J:+S!LO=^%/FS+)9'E-*[TVYP8,"O]X]WYKN7=A;(XO^$7[LVT*G1
MZ@+2:33K1K#![GAIFWH5>2%B+DA`Q\,5$KE2!\PV]_C2/?Y!JX'8.GU\:&%B
M(?>17:./K+G3UW"G-TG3LC.138`EW%^<27._1WJ_ITG%!#P$`@<>3B/MGY1O
M4(\+I1]3=<VUM]QT<2;J_SX[N[CX_/G=!I"2?A=61*?S4R58%M:RZD;33K3_
ML3U>8Z9D2^V.<7$4<_E)2N`<:77M91.T[%0ZHJ9/E=R3H5OF0.\/V^7>Q5[0
M=.@+WP7O[TO&]_XHIMNRC(98CD<Z'-GIFGO:^^DVM#C2*>PE^!/*L#'DX,!R
MA%)UU[,?L[XZR6]VNOI@T'O#>*ZQ(;`?$NBUK&YS_P?EX%H?XQA7KBWJ]^0)
MJ%`S)XU-WK#,V(]@_F"U^WK''%:+Z%T@_'BL-/!VM+O5*LT/=(R<6@<94.MC
M'./*M47]L;^ZD^8Z("V""7.BVDN.ET-0A]Q[3W:":0WT=KO?V`FU.O1QV0F]
M5F]PK+=4ZY5KJZQ>_\JU1?WQ>P&R.0`+&9ZUER2%NMMLF:B\QWY\[[)#[[ZO
M7(&V.=3-3O-&?,.ZO]OJUY]CCW'E?9EN[2:`\X;9U]2MKJ$;!^'A8_=X*&VI
M:\]"C<W"[ZYO#O3NH!%Y;UCD89^2YOZ/UF+IM(85>RMKC>0WS[ZFWAZT]>[P
M""R6&OI>>!\@.:6"3QZ(?/IU[9FJL6'X70Z'0[#8&QWVAH5@M]5OO&[':\-T
M6\,F8/:&V=?4+6.H=PXBPPMLF)^I-47F5S7LGU%ITQ)LII/.3G.22F`^`X;W
M-B)(>!</^]ZG>4[S@(5\]M24B3:I\*L3[$K+!TJE8\EXLT^=!@S"+[,--),.
M7'[LCK6I#8O?,^:E34/OGT4#%0)"]O["Z>NN*UNKR-]B,Z!TA""-4YS-V!A'
MJ;O/?%1;^JUP64M/UW^BWBPV[^LTXY,^Z6\$`VQ8T((K,^]<#CM+>H2NT\T2
M6XGV6]TV7\2.:%0:[W94<$$$2C*H)]M\.L7!FGW>J0&:/8>[^N',.+;>&[K1
M,S8=!_JJ644T-)TX(4@B,;1FL5TCP2+;4XF*+&VA9_H(!!HV0$LZFNE*SU)<
M3VF"QFD@NP0-D)2KYPF90."TQ["3E^Q;/8J#`'N1J22])G7J&HT6F/N!,ITR
M9+"B$SD,26X$#//`<-3BWS'(@X1EPV=X>,V0J#FG+PPD1-J#7WH@S.F))E;`
MGGAB%B6=DT\.1-20E)`S+>AX+)CEVJ5'TX`QV87=://;:FG_%)V[^3>P[9*?
MK9U#B;?\@C-=P5?<F!8]SU%=`1_QR9%)*\$$W[R/$\(BNXF'HRD;QRX+?]%,
MG#$)[&DETQWEN,GX_M^PI;Q0(?]P!0+AG@%FLV,CA42:.$'()T_:GH<];T.E
M3U4.O[S+K6SWT>>P]/H_Z4KO6_=9WQ4T@@99@$@4_@M(*R",A:!.W)E4+P'C
MXV=I0&OTY&O4+`NOEVXH"]4G9:&D33M^T5:^@^W[''_\"58B((`6HRF>*/VN
M'U!?J60-.PS]D6,GW"94&V\LK=%`#Z`+)F>N+(Z[XAV_)-4*Y:,R.9<;0BS(
MGF&\5:5LJ(CT:H]&S,5)(MCB4`#G3#B>J$68)AB1CQV)`M_-3-V64S]=VQ,3
MAT4S[<=D-.DDD4XS?^Q,@)`3L:7<+,&6SJ1MM(1B4&6GZ#$;Q)Z*-4[Y(#2Q
MUR3=I.!2.1R5,V0<2MW]&_I<3FY'8.BP\.0KW(Z?T`A*<?P<W!5S6]AR"?G#
M%Z.'DLE@B=/KT7?A/ET2VP0(J9+$?)F"$/8#%%[I)Y_7-6'2D<\36S1K_)S(
MN1Q`O(/[/!WWKFP'N,G84T5`.6G/TKP9A;QH!R3^^"!<8&@<Z2ZFX-@>?C>S
MP9(VM/?,Q4&99(TY$2@>$'-PX<03U">6\]J89G'?XWUAYWE_+B;]A&**WBBF
MUGVR>6@B:)6Y`;I<WW5F#EY3`%S^:`N65,X/7\;O/``92>K(WA."PC$A]'NB
M>'TZ,[:!93:*]DGL)B3(+?,\B3RG73U3IRFH3OQT7G$^D9#!OTHY`Z+*#\;4
M?3:1F6F'V]`!@<E[C)+E"4R2-KS5N$V@M/E,,,/[Q4OTZ%H>-WYJ5*43&`C=
M<S^,3J3,Y)^AUJP<9MZ3])Z!=0$<Q&VNY-"!$_YU,D'](5O!<BC(),_1TO?6
M+7P;M%88@XI]=G"L!TENH79XDUHP=6#K!"\+Z%4D+>I(&I8K[2&X,J:TK.=7
M(*9&I2UFP083T\+YEV%14:`0H[[.R)_LPD+^\#:OC_B0T%''>`Q[UH+=H`N-
MHW'[B],'WP3TQ82E<Y^Q0:_<A81!,M/](9G"D(Y9H9;\:4=@E0!`_P+C(;^D
M9Q!"AN88M7]*.A.'\@\HG/!5F2I$LH2H%6SVW6ESX$D$,Y4<Y-.J:(:6&&9/
M%B-O+\OO5ZCR[\A!_Q$\BFP7AO%,MM&-LDK"R;".N(R,,FC4JZ)>N2L"A+/_
MI#FN"W]%1@P3K"IOXW18NH+@+11KRJFIX:[<*"S).)?CMG+D;EY$+B?VIIWK
MMNU<5WL(5T4@JVDX6'UCP=HT$,0OWY-75R:OWR>.UO5=N\TUE'@-UL&N866&
MP-+0\C:9`T).=`?5-*23;4]/;(`:)P9D'W/^3KV62FV[5:_&?!*:P1X;\)EF
MO?'?7.8F^?B;)C95T>5M?4GU8E9V!4BZ4%^)H?8!GA[D`]VT5'AW<BU70U<I
M(P:&=J+U6L-->W76`4='A.63OE8A@O=G753)M:E?[0AI<4\I?CW@5J-M_G2$
M&#H6'`-Z$<FF5262CUC+WBPX>S7T+QTA1>Z)GEI6'PFJU>LV;%L=FMNM`0I'
ML]6N%,U'K6K/'0R4>V,>=CE"8MP/*9T<(68:W#8IK*\R)*0D`35AH"8,=-3Q
MAR8,5(MK:,)`.Z.S"0,=3^3`V+2<J`D#U?4RNZV>M9_+/&('51,&VKCNL-4E
MO_(1(NA84)Q"9+8LB[#=1(2:B-#.N.H/@):&_<:SO`_6';0!V5:O]],1L&X3
M&JH_9;5;1IN'A@8-`^^#@=LMJTU!HD[W&'BXB1+5F*J:*-%QXK:`-RN-$LGH
MP4F[U=]K2"B)_J0!&!Z5".,9?,CY#Y:Y>1-<E!??WOLQ7I?22($'992^_+Q!
M7%H_;T>+[3+V$*;9#J=''Y,I<+#7+@A0<6C!:-<OMB";*%ZEC+*A_#JN.^C5
M]PHNMNZ]?8#03L/C+YW\*."N(S9VX249VWO5,JRAL08;QXJ-1M6\F:L^`FSL
MHFI.>?9(HVD:_=TP;D-CC>:K.<DTV"@M5"H[B#92NC$H&LYM2*S1?*^68K[%
M&!]K9%*9.#WSDP;G#6++3;X47?(;K#8BH-8X/1"E5JB)7PZG5O$2X8,I)C)V
MRK!)^HB%;X18ZQ/"?B/9`S5$_1=G0HVJ_\0RH0;Y^T4^29L&Z?M%^N'R9-X\
MZ@]![UO8++O5G9=:[FM65,3^WFQUL!S@O=4R-ZU]/.8:Z2T6,_96XFQVVSA6
MK[F.>EQ'I]7MOZ&[V$F<;(FG/?)6:]`P5EWNXLW)N8:WRL%_2<;<M@7"NY>;
M[40(5JM'-ALHIJ9G>77D;%E]O6]NVFRF#O@Y%@QW6L--&S/5`3DU$.[[NA^K
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MS'TFJ-X;>K=O8`$!?CGR(P`E]@(V\A\\YS\,*R!G<^:%-DUV8#_P9Z8%S+7%
M6.W8>V0A_IR9]Y`,W@;;$V#!Z=W7KNVUM+NI'27+.'PN!$OF+/K:/2Z>;.X_
MBB\_$6$H8V(#V?9,P^WQ?^>`*'^,IS!;!A_4B-LQ#MC)O1WF3X-#PVW7)1BR
MT".N`#.&U==[5H>&5<`_>X.AWN_VM'$<R"GFM(W&X)#C1<S3]W!,L`[@AGA&
MYQ'PWMHW=1R68!-I<H\_W,!M!0[=]BVA_+OG1+Q4_C[A[;V,_*@-W][<?M?L
M)SL8`W\"GTK.">/[?P/)T.AZ>-\!M1,XDMP#]G?L`!?`64(B-!_9'`F-\(MD
MK&N.-W+CL>`.&M#BC1A]&N#ZBT4:YPJYYBB`UV'@V)QO")"3,3"Z,I298$!)
M`1\`P&$/>%*.IMH4..:>,4\;,YR6"L)\+!:/Y\!J^'&Q93+;&7]W!OQH>\_B
M!CJ]3R&RZ`R^(1B2?Y5`T1`4.%,HY<>8`R-EQ*(@D$"V@,J$E)K[`6=Q^#/^
M"98+8RYZ1O#KV(UL0FA`(H;981R@'/(`:7P6G3/#<P$0L1<YKMR4()'H0Q!G
M+&II5Y[VU7[63%U(`83G-Q]NF@0UW-XH\H,PAPO-GG%Y@M>$U\DEK9"@""C(
M<!RL1?(+?X]'P(N5=T/GR@G>MR5SEC,;;N#@#[\'=-'GJ2S'IAW:14:4$TQ"
MG',?MK,?(74<R"RB;TG%<F([`F+HHDB1DR:0,,A\[6SJ,&H6-(I1,6I7DXD#
MDDZ'-8._M-_L>*9K\SA`VB8IF!H15\0PH91`9ILO_N2XG"&EV(BF3H!\Y,'R
M06@'SSGIE9$KJKP%7#D>BH60!8\`E-P^85&/<V1JA8`)I1ZQ-%#PSVBNA!.;
MA#H*"Z$.A$`5E@V"M`@W_&;L<('W`9>2@K;_"?&K7:=:@>"Y`)T2/6NGJ(WD
M1P>?/G)]D-DNKS)(8H9L;@<DKD!4^MH$;Q74%-!:!*<;P94)H4:J"\X&MF`&
MK2,@B4<."E=2L`Z>5)Z8*X5Y0%<"],F`C&#E!X1D$O@S3!Y#^:^%4X0'8'AO
MJ;]0++=HBN-%T7Z3"D.9;C;E,*1WTM+^<*)I`H?KS!P\)OLQ8G.A:[\&+2):
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MYFN1O?L/I._KA*;5&K0;ZBUL?K6#[&U"[9\^`^:8/9HJ<5WIXI3N-P($*2QU
M*RI.-^DCG#&`[8/S<:U@&'UI:C]B!`^H>N*,'#C-R/5#"GN15]2.\%;M>Q\A
M$F[,Q4=ZXDDL@/\#'2R,X;^X-]I6O,9W@?/PP`+M''V3J8/X$YP!#J&X5X5/
ME5R\/`K)P@0EZBJ)+]V9S=C8H<P$!6?&$`&C$.;8?E[P8G_E$3J,@B(7PY8*
M5#P@80=.-)VANP^P38A+$&.VL]C+A^*6WH1RT$4(DLO-W856X"Q!*/`N"-WB
M!CX12@"A@-&GC;W.Z"WG80`_#I,XP((+.IH&?OPP35"QAB^ZI9W"%Y-\CUR4
M<;5/FN(A]T1W$T:'6"<NHNS=A-RXY,%`#+,#BCDAF<C8+UX7WBO7<@3+NG=#
M//KDQRZG+!%L]A)WJ%"<]J/MN.1YGY#>P*L!"'X6DL2>SUUG1'^'V\1I2@@#
MAE[@/R'<-O\&T3"MH&0DB.!$D.:&<#:+,3<D%\G6['"1-.5O7@QJ:4^8"J78
M`)01]0A7<_^\+#PO!52!4"`PI[X+`!)4(.E`GX8,8YPI$B5)KT9D,1:UTC"8
M2%\10UTO-X'CA^*+/#&!!)T2C:5HKCCV&H2CQ-4H8&?J'1&]A76Z^`/]0WYU
M8[3@FKUTQ33RG*[(K\,#IIM'/&'+[$LLV,"#__8#I)?EJB!SZPF"",XB#/'H
M:4<-#PL"Y%>RAB$J>!1I=\YHL@O7&`GUTI]DYA")5KL1G!G!>>9[HS@(\&X2
M9:@*3ZD(U7M2U*L-AK)($\)ON)IA\L]E]>$\8(\.*%XW28#`KR2K@'+^GQC^
M!L1F@CH%ZD&6C=THDSM!<&!"543&^;@(UBP]86JG-O/'#MB$MDP3R&86S.PQ
M6P'+'5FNF/VIIDCRM"8_C!93,X6\E/8$9F7Q2#\G9^`AN!'XMR*DTRPR"1['
M98(\-PY)B9$\038B<(0M/;+=4<S33A$UJ`=!6X6)-EA</8.B)$UL!13R3OD7
M1-::@E6"@QO%/.L-3KTH13@R'9"\:)Z_`%8^P66U&%"3:M2[Y/FJ@R&NV]*^
M^0L8Y-F_8>B/',)@P@*`PZF<VR5)*8<E,(U1Q_N+J,!%9S[/Y`#U,(D$BM4/
M%DB_S<Y,HHT@&6LQV>JV]A4$!&?7,SMP?>W6F2%I(.'3R6PUO<-U)G!A_>Y/
MVJ./'W)Q;=0LP'Q.^!?H#,9X;A_FZP3"G&BW>IV?&NFIF)W+*5HD8!$HG(@`
MNU(+;T_FV@*)6WK7`"-AV.945;C%^DIU*65INU,5?]DMH2RKW5!6/H>P\V(2
M83N;0F@K";N*?23<+R+Y6`CQM3+H%/=,SDF8;J28@4(WYC+NP(2<^4!)/!L;
M7K?>0W@<F5BED<NQI6=9G28]JQ`O9ITRC8XD/:M>2*LP/:O)Q-HF(J7Z(E[M
M*:O+JFH2J!JBVWLR5)/WU!#=WG.8FG2EANCVGGK49!DU1'=T&4.U\VB5DQQ$
M>3Y44;]ECM#4'K^4)T1@K,I/V2!/:.<T(0)&I`KQD->!TH0($"552%M,$UJ=
M_Y->W<L90%H^^T?[`%?-+X9G`0GXTL/POAG\VV<)U630O$$"43?-D%1#T]S#
M*F#BP1[*$%%KFO^.[0`D@?N\.F\H6UB[X(O%WQ4?B0,O2"]UZV/1,(=KH5):
M\0C?,]QPS6PH9!^\@^(3+51[$RR(N$6<A`P9^06$.!/M@_UQU<F1>8F".+8<
M&;(3R(#S"A&2(B.-TZT-!Y')_<<\ZC#4LA[B9"K%NCNVM%/7S87,.0Z+<L/6
M6O&('.-[B]!E@G-JW(0S,E[B2[$()0170!WOS<&`<G5XQ*NP\90E>48V42EJ
M(N.+)@XB@@V0#D1L+Q/NV3Q29Z91.B!Q-1:4TLY'G0#I=W\Z&2S&\9;$AD,>
MPC.LGT[:+:OW4TNV$/EJ!R!!DHY;::8EM</A71&PLPPFDLR2-!1;AI$RD2S1
MX66<Z%\.-.R<C8+A9U%4+'1CV#CZ)<'8)`*VV&^B./KUG3H`"30H4C]!A8YM
MN.31TB@RW7HJ%?!2QOB%,>6A@!!Y3@E48+L1!T(<7&)VC\>6QU0!G=S*>(!;
M>!"A::NC6V974[NT>+YW(CI9,&TL\P)UR8U`@._-OJ$/NAW.M_1=THA`89,8
M[]72@"BB::ADB,BD30*&X,@1G-SI!7*[CZ-L=A0G$A<5AM0685+[02U`V(0%
M`76FP_Y-F;T0#O@<(!.H]E+-$,1EK^`SE.?#4?KDI^C0^+<$D2HD"\<GPX*Z
M4#6TF=!F#I>91#+LQT6`#/1AIZ_$^S&+`T/C`NLD'*=.N+1)#R;%R0]G"-8:
MZ@-#I==,YH"@6YYT\!+MY@5E%73+^70U[6H)W9ZJ-)>7H4DSMB(X^1)<1#N9
M_%A0:@WUIM3[#=YSLV+R53-6,"=.E:Y@WG2,04+04@U+Z9H5JAU3[PP'*HTF
M+:7P.Y1K*7*A'2^,0-+P5H"4YR@RE4[0!I)Y^/`R;>YPYRYPW'G>=(%3D'F>
M;8>ZK!NJGCB]%BV1+)^8/2!]<PTK)&.$M&D,O,RURI@AG%N2Q[WP-"TRC>]E
M.X+53;8W%"<Z'</-S&:*/Z#`*PH$P'&+7LOD32?Z%CL>980F78!?HEU,]`9S
M@CNRPB89;]MD/+E1\<"2]--51TI*2/N"(P)&O7^\,Q/TU2;M*\V5(Z?/9C&I
M:M+CWA#V_Q"]RK53T:N<C`P>Q?B,/K!_D@]LO[=2&`I>S8Y;3F04DJ&#B9`5
M8%>4'0L/\HGV/S;8P*`)5/-LJ[30\CKTE;I8+Y>Q6N4((&LPU(<;#VZM/PZK
MH<1-1V_(#.']W:C5,C:=<[PE_DL2+]N.)]M9H,AG^[[3-XYE=!5_DATA>FK`
M]_N:.=_=\\B=_4YTWIG%N<5PA"2\'_KY8+7UWK"D\7^[`/*Q+E?T&F5$YPBF
MOA_,".!]`%PV_ED$3/9.B6]II/$'HTT!OD;BO&*)8[7:1R!Q#FB5))X,.UIT
M.]=#_KSB4:*&;O9[^L!HAHG66H:854ZE+I`A38?3E<-$"\:$BO3!-4>%)AF?
MF7FD.&)S:%I\E)=LK_3";%![83*HDNY`.1<MBZ>"PNF3I$C,EIP15#)Q,AQ-
MV3AVV3HC0S&RJ`0:Q:Q0RS)UH]_CLT('IHG#0PF69EIH>3D;]_C#'W9`61L$
MQ7W"P[5`D80QAZN#0,F+D;`A(E`[SXZ#_RW(MA-IX0*M-&$R#D93.TV<7+,M
M+K6"1):B#%'/CY@FVB3JO`?E$^4GB[Z.?B:K(TRZ0XI$"LQ'P^\@RP8)^XO?
M.#R+;1)'<=#4`"RD-5V*U)-FON6NJ7Z?V7U`\<65F:J@ACCW9)C'RG0>79^'
M,IVM>)4`ZE,6C)R0B?H]6.T]3EE/AQNV"!+47@DG@_+D<Q9EU[(P5XN5I"B)
M3M^>*&92<ETP:U$YA=#@:A4>Y90R/L93-`:4C17Y,:A>0\GU7QB>F5O;TSKI
MEKGL1H^75LJ>CUB02`FZF9(M1X@T\2FU0W`Q2$F]1:[6)<WN4L;N)O)I,=]8
M%C8D[6H)#&ED(!Q-$E>F0L%=SEA:PE0\<5!AK%[%C#5H=96IH;HHA@OA\@,[
MH7$JW%1(X9ZE9"1LT]#YP:F3JE^X:9EG3B+A-7ASD?'T)'<0]:AP62+1<1:[
M9R-[QN3Q*`T,6[Z*=`E*Z2:`)-;1M`[XW.FDD$RU@^<!F]O.6.4@8>,GZ"AN
MKZH8%L#(^+WWEC'4^X.>;*/Z1,/#B2=G.)\[,>_QZR[S'J)I`?\F:?^(VX:K
M2C`!FN3FPK)*R2%CH'XP:KE\HD;%DK2+'GK+WGD-J19E\4K[*4G7Y=A,<L:;
M[-PF._>5Y(?F.UEJMVF9@?1M:%=Q!&8OM?K?P2G;Y._NEK_[T%I`_GV@_9SA
MFZWWN9"&Y^K&G+7)!ZY6`)1+3#4.T!S%B?876!6JJMNI)DDW$:A^*E!??]:X
MV=Y;CO'`-/1VM\D9KS1G?(_WV6T-]\0.)<F80Z2+_=ZDBZ_$S\D18J8&W'[\
ME[,_NZ$"Q$B#O.'KY3F;5ELWVKUR$+0+)$W.9H46@#FHOX@XA-J_H)#-_L7#
M6TH+;TR'&HN&QG38Q,V`45@U_'K29'CO/<.[-VSKP\[^\=P(E?6OJ-4^@LK5
M0]@;221"Y#8K*5.8F138HP@;6U&36Y$?H<J?)/'"\42&22.!]B^!VJU!2>^E
M.HB?2IZD^PMBO.W*CAJ"E"399//&*,E3YH1@&8BLV.!YG5Y!(U;>%YRF_B*S
MG]R.IK[+PI.O(.*QYS0-/*`D/_S<S!\S5XP])^.,QJQJCNL"7+S/=WX,MLP'
MY,D^C#>T3B>AK[UKVD4_3?BSPS">\9$,<!#1^!OWE6=*97F:=8P]1)-\QB;O
MY0!Y+\>::[&G3`K\,I6^I'F'!.=](IZ/-N'A6&^^-EDV"6TLS(TX)A+9+>FA
M;U64])"KB<PIUT27;-?UZ@V$VSM[#+<;F[;5>GOA]HND"!ALKE#[(-^SM0D"
MU2Y09[9Z)T?@5#E4G%>04SKQIR&D9>E=W9].K$[OI_K3TD':1CGA7R>+,Z(:
M:EKJ"[/,GTZ,EF4<`4$=1CB=.UA"Z(VU9X>Y329*32*1;VN"[2G<6!@MU&]F
M8IM)A75A.58RQU4V:DA+6Q&1>_!5-6ZI8W%.&.WZ>2?>7!U6K\9W<)'F4"R]
M@\:]=SQPUQ$;91#JJQ80>\>JS,9NL-K0:MVQ2HG!O#7,GA14W;0T_88=F*SJ
M'.^ZI*8AYYM[AXZ5]6J#^;=BPM<0]8?H;/#FD;[.<ZE!?26H7RG>]^>6EB/X
M*HJJ_Y'-1<L,9Y_9__9%GAQO_;HA"=:^,<#PI[U14^=GL_NSV=X^0:`6"*L4
M^]4%&#H#W>SM*36C%HOM@JPM\VSV=YO=UM!Z0W?9,-91+W8`';,\6:@DL^4@
M]5,Y0\7QM--YX+@8IC0Q*?\1*PCF8"Y2'^@-:;)NP?8:62+[1\2QY"UTACV]
M:Y4T]*P.&-ZGV5!;6Z'&]]-P0(U6>&U*_3`I<M_343+:EO&L-T0,YL_]GY.R
MFD9U[Z`7>KK1:28%UEISFZ_H?AH&J,\*^Y75R]NOO:+'N#(LC@^)I.+WM*#]
M".EL;U1B#AJ57@8F^82V(Z2T1J4?Y?TT#%"?%?8LK)?W@#KJMWBCU<O"9/]G
M8UAOK?Z6VM#V7IE@?'V6`0[I/,+[:9CH""[IZ)1&;3T&1WQM!^E9N5>Q\XJ[
MKC9]GVNOP"ON^]QP4L-)!U8'!;KW;342P?:ZZ@SYD3_#B?'D%:`6MYD!VL*%
M@-/@WYL]O=<9T@B%]YW>0._W^UINP':X=!XT?@M?TKH6L!![?3F/S'UN!F\7
MS#0/V`@ES7CI-1%('W@_%XE]>^:#W?@??HW^)//=><#FMC.6+A_\RH0A?'B[
M.)`>OP`;S."K]#VB@Y`%CPX.J\>KLT>C`/O:TQ_2I0D2%;2/W,/$O4[L[QC'
MACM>&`4Q9G,F[2WIK[.YZS\3'&,'SASY`=]+::#<S!!OFM;4M\3\,S`#\-X.
MEER#U)H@=8LG><,X6]]QKO=XPSO'CM>&?;9P\E99]+SC2*'F`DJ^@$VK%XZN
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M_JV#UJW-:_<M%5T,]/[@&"7`6[HCT^CH5G_3)IAUM`)$CMF)RR8`E`G'KP1A
M=WYDN_40&^NE>N]RV$V#-_7)%3?U;J^C]XQ7(W^:RU[A@-`-JZ,/^U4Z>0K$
MV+XSZ'%+2KO]KY_C\.3!MN>_W&)2,F]O'UY0WO$W/V+G3CAR_3`.V!TL]9L+
MG_GU__E?>/[_DE\\'8U`ND;AM?V,ASCUQJ>8Z\S&7QS['@=1.RPL6`:SE!&\
M&S;YQ[O/@3_#+)N3M@'_'_GTLV&>6,:[7S/(2,XVCW(G69+3O/$7MD=WLOX]
M_O#MZNY"&[:TT[.SJ^_?[FZUZ],_3W_[<J&=?CO'7]Y\OSC7+OZ_ZXMOMQ>W
M!-5]Q?#5-75?$I`VYQ24YLNSL<9^8&H\"T6BO!?"@QE^+<:X)B-8F^3V)KG]
MZ'+<$EE1G&V8RH,F[_#P=V(=[$[VYSRI.!4Q+^@WQ&.3JE9J!>Q`'VP<#VE2
M#^MZGV;/T(?FICEA;R_Y\)Q-6!"`!1DT&4HKFJW#$_@8^Q@<"WZ/(%9ZF%C+
M;['C4DFVR^R0`>JY"^'Y@_'Q",EQ3T4$EM[M5NEWK^\*#;<>4)5>15-X'BTX
M:O9-AV\IQF8-MV@^MS6"=H'T@[E_@?V6**%;=1O"HS8C*+2*HFD-Q_+QZ<T]
MY5P8/=VRFFSG"J6YL<V;_8U8%U]8&/ZBG<4!/M2U.39G\KU&I51(CA_Z@Y[>
MV_C=?Q#SHC$N*J6$4B53-?=\U/;)-]\[&0G1%M785FGRAS9UPP_U7G?3ZL/]
M=%]MJ&'OU+!GQU'M^K#N(=,EG\ZR`KOB6V9G_F-CTL\KE,B?)V#@@M6HX8V=
MWH5@%F8O50#NI0?_F$<\:P*S6'3*T4J[LKK^B#J;.JCF`@<H[%GSYPSKGW"@
M3N1KMM;7N[VN%OX=VP&F=_F1YD\FS@A^!@)R>3=4I`7MW&$/ODZD,O$#S[%;
MVFF(>6$+R319,+`3;U(M*4!ACXX?AW(GI%6F?;#T0;^30,)8]!&;J=I:B!($
M@Q/1%"R)ARFM$;"9[7AIX")BP:REY9O2/GC.?^#\MN;Z(<%JS^>!_P,P$3'W
M67MO&'WTZN2;`B_K":RKO6+QPPPN=T:_R,.3!%)TS6.(4[(I1OC1Y#R.-_)G
MC$/MWP.]B'MY8H"`L1.2@0)?X#UQ?4^3%@PBT':H%I5C5H,K92&NY(3\K/"_
MO-TN7K]'P5=IU5!+W)>.JGT(&=,P(U4S.A];FUF%E2K%0I:K:-E-.'E]?T`!
M%%4B8;]>Y7T)OSO>0AHX1!-9JIS!M??<9Z\M;1DN.T/;40'9)^VB05`F4O*>
M)6V@,WVF093"OV=LS'EXZ8Z2\13I$8#H"!R2!YD^UK+!=::)=<C;F8N#43MS
MHX-!2*N<=N9K,O9>S)V3=JN_RN!)$^BWS(//I].?V>$4_X,Y^(^VBTV_8:G;
MJ1]$=Z!4+FD0'?4"?\6I],N3Q7$#2L*D_/I.2[NYN+V[N3R[NSC7;O_[ZN;N
MY.[BYJMV^>V?\/NO%]_N]II;OVZ.N#Q$CJ(.`F4BOA09$"*YG:`1(R8?$L$1
M*(5B2H@\:H./J@#L*)`L^,\QF_LA6$@Z.I&Q:A9LB9%KAR%\!DVA4)LR=WP2
M^2=@N(#PB)[!CBO8@AMQ*8@$2S&8W&!)A@``P**W/PDW@%)`DMI>(5B73J`!
MN\6LF:@@RS*6WH)RQ02*<LUXY>^-;ELW>QU^#]G+MA.C$7[+(JZHE/5"A6:(
M5@*<@1#P+U,)0T3]$V+`5J#:]0)9G=XG62H2S'TT0[41?!L6&]D!+/(0,#:C
M[;VQM/>Y]9O]DQU'@#:R:5RTW3U`)`,KYUF+GO!-JH&*C*9AJT@1;"'!\TK@
M1A29P_?.TQ+S"ZZWKWW7&3W77^B7*>UOU*K[\US5_:9BLT[\6I+LEJ],Z2G6
M@&Y)V(6*E4=P+.M?@`P&_/1,7`=O-613,"1OEGT\V4F1_<GOY/?QK2>L4C0+
MY=Y<D>3W1QN0K"1=2T>SA+9K!XZP/^^!#R>D3'S*/?*!(Z?,3AWDNIA_DCTW
MR"!X"P,K:Z`\P'S5B7<"V)!K$75.BQ]'H1\'(](5_$/%7+X&BRYR]2/S8G;#
M/0%HBLML9/&7M\;3_-`*/@1[BQ1M\8&&QQ?'&Y$G"6F<,`0FSY1YQ//^A"#)
M%$>""G1`;3JV-K5!==TS^.R,`7`?C(_(GO#$"^'Y!0K.@?/R:48V+(=CK!Z8
MX'9\T7[2X`$.3.LZI`JG(#+\$>=T^)/UD12R:$M&8,P#5+`.V%?.#]3AQ/)H
MKSF>37YX_,V'SD=2[?`(%$XJ_$8`6MG'3SVCJ1`'\E4KL7#/'@!&WD\IXL)%
MX"*>`R'12*<1:.#0228^P;&NSU`D<3"!V<8:NO<B%"438>!PXU`XJU#\<)L$
M;13;\63AZ:+5H8$U"<=E$7HU\;F-448X\SB('_"9/HO%X/!$^,DE/=\[4;^L
M?G@3:_25D3RN[.`/UX$_CD>1%`<\"NJ\;7EP+KE(CBM+6!S94'(5L%$Z90P^
M!WO9G*%5POUW/'[@#Z<`>"I()J)QGO7P6<8DW<N>@\38H?SMG-]0*$6#8'5Z
M*V086[)A-/5#Z2\+6]J%XK>&W3SA;4+QE3J?N,JWQX@&#BY:*K`U2BWN"9.L
M;<\8RC7''TN'%.=J_H0DLX!K?N)N6WDM9F7,DP,2=8SJ2.."ERLL^#"#8_(]
M;7EZ6!V>FB@3/3_B0C9%!P(7HJO]WPP_B0ZW"<@'@@)PX+CP-P00Z("OHX8L
M$ES"R?T9`/-OW_$B$(Q2EBK?D<`@'#D8<!E/[LS/=I\^L!I)$WWZ`D2-CM%&
MTJ3(D3A1K`$,H#VK=C]J,$Y6Y)$EHIY/`O2EN^+K?%[BV(YL,,)M+T2>XK]+
M'B0!<V;W<1!RBV-N/]->.M@>H(O)0)&+4<2>7.%SX&5RA`.#\9^!\;VQM#^D
M'H95(C::>K[K/SRC&YN%H=@>N>(1GA@8`!1/%3[1,1#*?^;`?T>^QP-:+(^*
M$5@AP$8SG`LY=\&(<H470?G0&^:M;QG2()QS8852%P4E/GG@NE`G"2V%(F\2
MD]91+^3^>4$H"MF%4@VI$?X%R\`+3RP:4X37>_3=1WXGPBZ<@\F7,^3T1`OP
M&"TWTA(#F]O7^'E)@N1TQ%`)2Q24\N<Q4;I*=/J"34A#10-;/GM^!H+C*DY(
M[(25'$6OMK1;U!/*1S@S2GMU/GT.Z:4+=BV@`%_38C;ILKV1*UD(]R8QDONL
ML./3S]-9<2#I"*_H1#S;G[EBQ0],G7DH'(4^(&<>T=S3`)3RDQ_\Q=L5`UYL
MSPEG]-08X=<X)Z:<S2\J2OS.*8/;\[F+SD("A@)@B))51\QJ=5+HH;QL:4!Y
M!83J3#2'5*D0)@E1902%&BIWP+*)(\7<4"F`#J<G*CH-W2&B'MDS]Y?`S_^.
M/<()K4?+%$A8@%!8&UH<\6>30)L@0B:H4C!;R/'!?XL"`@4E<<7R)XURS-3C
MRJE4R+DP->DR@K&E70)9C\<.OUMGZ1X"JW3VE%/I`<@-$SU)M%CJNI(>'/'T
MM:7K.'$`\32/](GUE^<_G4S])UH)G4=!Y(2)D9N:3(K2@-M"4>][+KX]TUAK
M3B[I\OGM<;(L(BL$;BR='%R.);DAZ-+BM,_M5V+>(F'6TGZ'IRM&@>%;V$AX
M%L]@,0^8C?OY_&?;)?[/2C84@C;RKXW4>(*A<'PD`,*3K06#(;R4QU+L_GK!
MEY5W?EU2=LF=_8/[QO8=O*S&A<4/I<&IA+'XQMU4IV%&N0++D:4%_^3B6#XM
MEP9M/,IS)[:=P.O6&Z$V#R/XA3`&51-@!CLG.4_"XT/*)DFMMG\DF4_2AXQQ
M)P`)%L3X$,B"L3,!PB4U+AWD<L8W4*/X,P$>,#N:"8D)K^T9USZXB4B.P.<L
MJ8<XF,,#-S$8E2TTOCP*^D0$T`H8#B,("0@%:C5RFN10H6(0K]U[VR4!'4Z9
M#*AE$"0/3(KA+Q!M4]\?IP_&(BCP;4A@W'/)P84AH4,89O!AD@\\9PS!UI,D
MM!^DI=6+NH==02H(RT^L2%X^M``)*K3`*``K#"+Y]B<PZ!SWE-\&NSIP4GRH
M+]TN_5A8O"@]Q[U10($_'RTN\7.$"6OIQQP4E5P0)W)=<V`3T-[R_:RFM0EL
M("9ECHUT24@21MI)<Q[?\,-`I=.D^($[<202T9>+5D>">G+VA&1I`1H_)P+B
M-&6]VPAHT0[&H?:;CQ'?#U+&]#]]/KW]3?YK\.EC\;?._#$/12/!*%\^O3U3
MODL0]3MM74L_D=$%R4=UI"_XL@:?7IVA"EQ%`7.TYSQ%7R,UR<!7AMIPR/>"
MU,Q(`\YO3W[LCLD$2U<%;@.1-.)\P^A'?&#C7F@C9L1(ULF-UCKWZ9,72RS(
M'RK8VXR%D7S.``<($T0UQ5(>`;$=H25>R#E923:UR7<E<^4XG8C=U)T$'&3P
M+<=+6)QLE^:DX4_2DZ=<Q?(#"C97M^0>QD1U91D_D_3Z<I9<%AE93R**8J)6
M`<-W,,=@L5O<.0TVJ'G22^X6D<_!"1U$E4G9??AR2#=C/^S$ZRP,WPD;)R,M
MZ+A<D\3P$@JXVAW'G#Z$@AC!,^$98'E"_@2LQ!Z]7Q#!E)L\EQ$=S!QFQ='7
M9=9D43;=J3?.I6,<Q@2M5_X<HD3CE`$_*,BI8[[<83.A"$,LQ5`:'4SRS[AY
M,(4G%3P/70<^.\ZFI.%#7F2X.3)P$C"91X0RS$4K31AE%`<@UT@2P5R::O0B
M>2_P!'IEO(A+HALG_.N,,J3PI[?)"2H^Z&HX0C3$2,,-JPRWN6OCFX:T+3()
MD7GR<!/*&+X:Q1RW8TRQ(Y=)&HH4&>V`=F0?F:[W-ZAY2@;%[3X+%7,N$@,O
MO3`.2)V?B32_G+7V^?QRP5P3D4(*B3JC),F0WB(`"H?==69XF'B.4+TW>9<5
M?`)H_I/'@E6YJ:JIDJOKZ;?Z_!T#;P:AJ0E=2=:D@TGY\JF,P`M`BIE^.?_F
M6?TZ0&T:/5^#\1.!H$`A02ZS1@-&GS['8`[1:Q;58(*:AN/S&,LBBDE$D1T:
MD75M1^(E`K8QUV.C44Q)+.B.9W.PH9TDTB'3L>D7+63JY7_&/4:V.Q)+Q:'T
M(&4=F#,&UJ9(<Y!>S+08+@[9)':!I2:)BU=D'W_!5S\./<!7/<@'8:I3=HX]
M=[`PGV<'IX=&@SC-)U_<C4<_U1V#PNI`X=;!I&)"))H2*&!0C,28D13ZD^C)
M%DB?@JV<_&.RY#ZX7UE@DV70@:8&2+0)/O+(QB^4+.N*B[R8D:[?,P#S@37F
M]8/29_8&;Z:1*6N[?]324.&/S81QE.<A\E*(QH3,@R'A0.TT9$`D4%,)9/Q7
M?%'RKA,H-6C"W1=FXC(RG8#G#RFEJ\MB*=QL2=V^8.!$3XQYJI-:5`O.;2?-
MEA*_2VM7PD5\H*U@C]#,"C'02U6S/*2'"6"SY`#"1;SP62?,K(^)GDE.%2)Y
MK'9(+A03J]D]+QP^VT[P3ZRL^0IH!Z&5RI-&3H!NQ<(C0H^FX*=YA"\:(4F%
M%FC[%%%"Z8D\.*[SD@)UH>GCF:R=17>H*%''.)4S<N8TUI%<I&@G4,%"X(SX
M7&5N)M#C7-;/M[3?3T^O<R&&J0,R*1A-*7=7,"DH\1!7)%<MAYAB2NDQ!#3P
M3*!<;@0VYD%H_QXCVB+`0@M1T@3*M/Q'8V_QP_?/0G!B`)T;3,*O,$,#K>`+
MC$/*L\BQEA__RH68$G-1@4^/#.@B1U\.,+ZTM(8("VDDAMMK&%CGSE/A&4PS
MUKG%XF*,/VQF^VP[VR?Y9TT:FG#\#7O](4=@_<KXOR#%:<8OVBGF0##>E(0'
M114I@']`6R5)\T%3'/[S=^RCI2*2HS_$'M>L;/R11RR0GB@[JWA)##=R(X3+
M*#`C3C-KTB=R'](2OT;"X&`Q.42':D&'PKLD3$1(E7@3#BEDJOHQE`;T/$DE
MPM);<S?LNU%1UXR]-<C8=^.+8^$<<TO.P01$BKMBA)S7]BUH*?Y[T&6>)MA4
M<)K.4ZW`F,TR(.4&@LITT4(N`N53[@NHJ3GG97-4.<-]TI(430%1\B$%6)$G
M=H_!P"#P[ZD(F5R>RH<$ZV*2:,-3#4^MYBFK!)XJ,A-%,LX$ZW/`B`T8-=D%
MXPNU5)0)#?M/7L:0MN\QR[42\_HS_!.CS'.7Z8+/+0DQ7X<[!,B=Y<-+UA:M
M=D1F$CQQT0\@G7@A/'[!IDQ-<5MM926^HWR,6Z;UZ4-S'(^SHJB(DDXA,U62
M#&QG3'*5RE$IW3])Y2DF[T30"C-%9+'"[<<!O7"$UV4U'(D/IR#Y(84``U9!
M/%,#O8*0$HI28L'ZRVU3]-3!Q2O'D%PX,&MU?=63W\"G`C#UA6^*N\4RF8))
MA5C:=F7!ERV<4Y2%(1U;PN_$G>-8K5.$#:K$82"X9.[*BR=/*]<R`.B+O5<(
M"FYVCF,F4PF55?.Q<T;")(%M:5++&C`&'!F.K/K(]XO17V@8H_TF_0WWJ/'I
M_4H-\&0>*I8P2Q-:'BVI.XF4N^`+9E+JLYA385AT7:8P%;OWU_;$+68,I-W#
M;CC=G6&/A<:!%WVBN=DGG`14/#4>O`4EX;J9GG2)6Q[SRD#?^\]8D$>PC!V0
ME)$?""T.QD7L1C;)H+0U"/7`(W&0Z9`'[$IU*'G93)^)/8PA*)D"-[??0S4I
ME(O6;)<I_&:^0*PHXZ\P95VTRY1-"8!#53;-Y/7%H7C%_X8MBT]N1U/?9>')
M5["'90<#.F)B0LW\,>/:X"MRGG9F!ZZOW3JR?0!A5LV/5U[W$FWB,FS,Q@L3
MEY^(G"J?IRJTC)M5)I"+3E]T'7R!`CR()%,RU/Q@PBA^27U!T]URR4^TH+B0
M1R=D/(?58Y@G80>BTD84%HF8BMB$!UY"GK'.:\WE+ANE7+]J=ERB,-4R!A+O
M!`VJ?+1ZJ/^N8A^!]2]:[*0\RDMJF3?V`YG9,L6R,+(;'GP97$O:[G"O+Z?\
MU3G=!(K(Z\9/+\_M?HB!);T1HY1K]`YP19N0?J[,:6FK3"<4\;2D$YBT0)/,
M6I&Z3,\6D?,?JH)":8F)1@?]#&R4-$]80"OG(27(P5E,6EW93(,L1Q>NEUR3
MPW$,+R1X3%++DP_.QY2'[:0S'A6V.CPB.*$\YX4RW/2^N6`*Q(V+UBVC*:_)
M_N`4[I!=04N^O:SX$+-`?'P28FKZI9"\-@\T\/,FN68K25//98:L@3TB`6I6
M[;B9+LY)Z@=9E$K?';$?O7%E4SE>#CG"L"L=B)+-D&@32M73!S%E?8KN61GF
MH?(3T9&5/WF1)I&J4#AZOB=$:U(C6D`+8`7C(YKWJ,"RK#`IH,^UZL.RV`G"
M@UJ$+R1B:B29L[>5K3O`#+7DU5>(4K6!;6'EU"DA"W[G/N?[B.,?PI4WN1XJ
M!(D@"-(1D%Y=VA4LY,5KSECM;_92A<&2S+VU[.B\^7TA7!K7++B=@AG2F-W1
MI]\HB9/:A3ENC/C_!G3W!7N-8[;F&34Q)I@(98TUGL<D1R`67+@2:;+S\Y1*
M#;G(C:6BP30;Y]$ARSOYEAV!H7P?1_)EJ_:.QK0Z,L+\3$&ST!]/Y"A%22/2
M;[V8O#:\64$"1D@-^5#_2U>%HD[YBJV$`C*'63B%IIZ`:NJW.`7/)-[P)/P-
M0S^FGB-QOC1VD6WSC=])WS$*$H0]D6@;@82&K%6RI@8!2ZF"VPH*9:1II2LN
M4]+C)$,?!5>3H<TS];.*WY!@^)!NC,7%8.\]RU4#M;30F?`.$0$R8V+E"E_U
M1_[,R;V!\5V;(2)>7&CI;;.CFT:?_F;I76NH#]IM^9Y;MT\[=RLB@U%SGK&L
M#N9V&4_7%7TUEE\#U_VN*S/61):^-$CNV<B.0Z94*"(W8U>3$UH3`%F.WN("
M/UFW8_8!!8,E-\I35K#NU"6?'&)2Y^]C;D^FS@G1\>N1)3;8O0B+)%8:;U4A
M&B8FGDNQ<Z81!&\#1K:RV$!D\6`<IWFVJL]6)4^(/]^F\OW(6=I66S[>KR$1
M%KAZL_+,)D-IVPRE93%?/KPK_?3J&"R6P["@[&!W":O"L0'+WC_>F>^VV&&7
MT/%G8:]L']AND%H3I!;F3S2,4]$=_XDY\A<H\!O>>15X;=B'=MALMG"%A+!@
M1KT1/JOM!5C'S9`'G8Q;<,]UF-1[S"?:@CRV'.PMGBS=P4^5\-FW>(:EBF`S
MBH-VX3$GWYX;\IQ\72V'=(/;4!8[DI'.$N+!FB"K(JJZ\<X?C+9N&`/=:&\J
M0E^^SEW@VG1&9D-<=22NOM[K6+IA;FH?'8JV2I+;3U,G8EOH^]TL(L^GMF99
M6;U&,"!U_NN+CL8-+VYWWGO9Q-S''OOACZ%N6*8^'`SWCN7FGC:YIX'>Z_;T
M@6E6>$_[,QFK*$-RY43;A;#$,IF2)C(<7+K43YW72(4;+<,HYYKV:0XVE+)_
M2FFW!H,Z4TJ!A*U%V9N[F&3W0K9</KGN>\BN)G(`6?@F<^F^\T3:!`DY'7,<
M<>W*DP[4>3V8>UM0ZR&2D)&(:.1M],P3?:EEC)AG$N9:7\[LOY3J!%+UZ4`^
M7O>8=NKF-;IL+$?G48]8JICD&3E*,6"2GX[EKF!6Q#++08Y;4D8.9(<D9,LZ
MHN)Z#MD@:Q&>9`ZGG&609,TJZ5%IL;%(_FEIMTJY<HJ/F3UFN7ZA9!C!AO!E
MJL;'LR<M^S%Q`V5WA/WW9'FE+C)IX&;_(T>,4HL:@!3>?%0ZF3:GH0GDZ5`$
M_"-6+5##?]%HR_8>'"K7%+@7(PV4M5T`[\2E*8'\0\E]R+5R6ZH7DW;]5:<+
MR5EERI=6U"W([/>DLBJY#QQ)D_P6$ZVI=(;/I4`!B.GAO(+FI0*:5.AFI6A>
MQMYB.4#LXD=RPIG2]7"$,K=N[U"EO,G$YB:MJ4EK.N;HYJO.P&F06O\P<'/'
M]4R_:?#:L,];S*IITIJ:M*8FK:DY49/6]#*H3>9)K3)/FK2FAKB:M*8FK:E)
M:VK2FII[:M*:FK2F&JCS&JGP)JVIH90FK6G/:4U;QM"7A^)%@\7PFK>>A@5.
M>9OI+VDRR-N-QY^NTYF;0,$F<$Y(+?0FV2E&3?R\B9\?G1L]L=N*`QK;V&C-
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M@\(>'3\.Y4Y(JTS[8.F#?B>!A+'H(XUJU4*4(#9-2P-+XF%*:P1L9CM>&KC`
M0;79B>/*.%N;)VEC0ZGY//!_4"<?]UE[;QA]].JHW9NP?<RR[C'8#(DFFR+J
MLC-:\_`D@12=Z@=QEN\/'#&'T]KE>?AT90ZUT@N)3[/#UE9HH-#T5>R!Y'N:
MM&`0@3:LCF/2";-:0-V+8"4GY&=U0CD1CD;MTM?D#&>U4\[21CD?0L:T;W[$
M-*/SL;6955BI4BQDN8J6W823U_<'%$!1)1+VZU7>E_!#IN&=V321I<H97'O/
M??;:TOYA9.3C"Z!HC"+R1G9:*;#Z/<O,=$[&)XLQWFS,>7CICI+Q%.D1@.@(
M')('F2Y6<KABF+Y';#<D(2H/AG]X;W0P"&GE)=?+C:^RPRXW8NR\N;-IBG-1
MPO?FF=KYK.]U5A!>+?@;/`2E%%4SOD_#JPEB1V1Y:['G\#]\OSU_IXW9",2\
M&Z+U]"L\U>&EGIYEV_VK/$=GC7,,C)YE696?HTS4F[V5J*\0NG40VAL.!NW>
M3M"E?"&K'W"*>BI);E%&7''!=(HL#`;&&ZYC`%-JQHU:7IV@"FZ0G1P_!`O-
MO*7/7+M@RZYE`>%$WE!4/(1-O<.V]0Z'-^6D,[+ZK/JE;M"Z9-M_RY7#[_C<
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M4^L@`VI]C&-<N;:H/_97]PCSXUR7C4%:!!/F;-I5:/^DL(]2MG+"7Q7:":8U
MT-OM?F,GU.K0QV4G]%J]36N]:G-+M5ZYMLKJ]:]<6]0?OQ<@FP.PZQ3#FM@-
MI=>I[K+[OG(%VN90-SO-&_$-Z_YNJU]_CCW&E?=ENK6;`,X;9E]3M[J&;AR$
MAX_=XR&B&5NT<&]LED/9+'USH'<'C<A[PR*O"W37W/_16BR=UK!B;V6MD?SF
MV=?4VX.VWAT>@<520]_+(Z.Y8=AV(.E\$OGTZ]HS56/#B(&]PR%8[(T.>\-"
ML-OJ-UZWX[5ANJUA$S![P^QKZI8QU#L'D>$%-DS]!]!NVW=EG4XNU_;S##O`
M/-G!6%T1BX!IF],PC&?\=V^WJPMVTN(=3.Z9ZS]ICNO"7ZG!'1]!:SL!0?*(
MM=/IY'5MS+`)(!#H6(M#V13K-[2>3N`V?)>%)U^!K'U/=HB9!\Z(>NCY8^9J
M3TXTS<ZXU>ST/F!)T?T+MX4_$@A^MA`(#5PVF[O^,Q,-O,9.`*:O'S3]8YIY
MN6MW,JA-QP+\\CVID69$;DVNH9F*NS,Z99^5$QN@MA^X1M&X-O$GFK]3<6<S
M8[5<!_JF8_::@;EUO<Q>J]U,RWT)21>)JQ1,V5#[X'B\K6LSC'.YC!@8VHG6
M:PTW;0Y2!QP=$99/^EJ%"-Z?=5$EUS[Z+CSDL>W[$=+BGF(*/>!6HVW^=(08
M.A8<`WH1R:95)9*/6,O>..%?)Y.`X0@&4+0LY`,4CI`B]T1/+:N/!-7J=1NV
MK0[-[=8`A:/9:E>*YJ-6M>?.HS-FWEA[=IB[Z>/\[9!2E8.PZKO"\>.V@#=K
M$3-[,6;0A(26AX1P/DWL1O#O)@S4A(&.._[0A(%J<0U-&&AG=#9AH..)'!B;
MYB\U8:"Z7F:WU;/V<YE'[*!JPD`;)SJVNN17/D($'0N*4XC,EF41MIN(4!,1
MVAE7_0'0TK#?>);WP;J#-B#;ZO5^.@+6;4)#]:>L=LMH\]#0H&'@?3!PNV6U
M*4C4Z1X##S=1HAI351,E.D[<%O!FI5$B&3TX:;?ZJ^('JPNJMB]_JD5QU;_$
M[O_ZPP[0)_B5F@D>>\G5&O&ANZGJ&^5!KHG&[-%4>^*HP%'98"DY,QN?/+Y'
M,;,Q3KJ$#Y(#=9OP6TM;$?<C,*(,9,5QO_OG/03]\.,"%R$@(XR;P%\3^-LZ
MXK3O>-*?S`ZT"R`4;BD=253I-=Y\_6*-^::Y;RCPV+<.$GA,]$@3>2R&QNSL
M,5AE[*D`[8A=9DVP:O-@5>]DTXAV/45E$SHY*"$-NC^=6)W>$62+-[[\^E-3
MNV69/YT8+<LX`H)J',LUIJ37Z/S<O(/4[@[/RZ]?_TR6]B?"\QA>I7--3KWQ
M1=H=_.UVC3H%,@;Y#N^GC"].G0!CA])WN3`)!AV8CC=RXS'8'8Z7<_\1=>W!
M@=?XZH[%8V.TZ^>RD<)!4Z3#GETT^[V$7HWOX&*-B0V-S_-XX*XC-LH@U%<M
M(/:.5<'UF[XP&ZPVM'H`6IT[`;U"]J6@ZJ:EZ3?LP&15YR#@)28R:.>;N\R.
ME?5J@_FW8L+7$/77@3-JZ'W/2%_GN=2@OA+4KQ3O6U@`N^5<="I*-?AC,3G/
MQBR^&0NTF?UO7R0.3GT7;F5#$JQ]K?'PI[U14^=GL_NSV=X^:Z(6"*L4^Q4.
MK!OH9J]IF%QI\M'^;K/;&NZI4/Y(%VL8JT:+'4#'+,^@*LEL.43.2MY0<3SM
M=!XX+H8I3:Q4>,2RBCF8BPQCRQO29-TR$&IDB>P?$<>2S-$9]O2NM>DHW#K@
MIP9F0VUMA1K?3\,!-5KAM2GUP^0-?O?&+'@*P)X(M"WC66^(&,R?^S\GM4:-
MZMY!+_1THU-EI4&CN7?6W.8KNI^&`>JSPGYE]?(ITZ_H,1[Y\!Y_9&'D!UK`
M7)MW!$BK_(^0SO9&)>:@4>EE8-)JZ^WV*VISV:CT>M]/PP#U66'/PKKW.M_B
MC58O"Y/]GXUAO;7ZRVDV^]AC3VWR7YE@?'V6P:#5/<;[:9CH""[IZ)1&;3T&
M1WQMJ_GBR`Y6*!),>%P!F8W]^-YEE0F>W"Y[$CW#MC[L=%Z/['E]"KS7:A_C
MT[[AI&.YJ8.K@P+=>\#N*KOU/\ET4?EJ_W!F\>R<S?W0B<Y\WGOQBS-SHG#=
M1BE:[#G\0]]OS]]I8S9RX,@AMMCXU>R"W=@6(*_:+-_,^CKP1XR-0]Q7?(%^
M/HM#X",6E`)=O]_FX*V]ZT+/[:2MS9D_FS,OY!UL\$(>*!7QM^?BSC>BZ8UR
M9]]B:KZB'NLTO)H4'H76#-737'[[_.Y7HVT.S8YRGM+!.^3Y_S6B6_C7#:Y]
MY3'1:OQ%K$@:?/U(N7ORUT6*9?7[IO4FD#(-V-JT8@S;W6[_+:#ELQ\':W-0
MIP,:\4U@Q7E<FU9Z@]<G5:PL3I3^;->N[:W-198YZ`]?'7(ZY2!G_TH:`:6V
M!>/S.("/78/5Z8\Y?&H+/MFI9;RY<;5,<IA]T^@I9]T8E+T=9L=K/;':_8XY
M/(ZCRJ$M0'`SWZ.EUM8%Y=]H>?0OF\B?\J>%W)*Z%Y0@[N`%<;T$+=V6953"
MTJN.5"-,;LA$*S'9[]0?D^$+^_Y.3_)+CW/#VMC<73RMP&RO974WP&QY1SP"
M[$J)^-7QT$>Q"5JM5F_0H/4%M'+7SR9H[;0V,J]KC%:Y>LW$@=7:R$0O]92E
MX_BS'TR8$\5!W;#<*U<Z;'C.0CS?OZQ.[S=6IS=L9H/L]![.`+.!/8IBV[UC
MP<Q<N]_V=>]/8W">P]5^83T>=*VFS`:7V^`RYUC^];KS9^^KV6O0N`4:4U<T
MHM$POAIF@\=M\*AXKW^]'OPY:!"Y'2(5?_>OUWV@R`:+VV`Q]8__>MW]$]BZ
M7T,\;N,ON/@[=J+G2R^,@I@,L:MHRH*[J>VM\X"@/V+3P,^V$_R3AA9NAEUU
M$X0]&9&[F:UI;/+`WQ<J7MD=7<SFKO_,V$97TVV99G,UY5^-=##<,-C9P0EY
M9!%_ARL);VZ_;W)%_5:WX9X=K\A2KL@JCWMZK789/N'F:E9>S6[*I]OJE9%/
MTMQ1[HY$>M]F5V$<C;+9QEQ,5CP-DU%Q<D`J6H5&N<;7$B_VK]=&^\\2C-\7
M3W/\>,L$57Z]-O_L?6T0MZ`+E^*K^^?PJUG*L__UHBS'FKT_C?97LQ07:,UQ
MMK')M9+,RO$:OUZ4Y<BL_P84P/:&XPH%8'TUAV^4T@II:5U3_(T8':OPEC&(
M5Y!8_VLIH9O7AZF<#.N^`7I:85C\9L<S>,#@V!/;&S'^Z*&=LISY%5<]LP/7
MOP7T\88H"0ZM!H?;XE`-N+YQ-*XD,?-PN-G&>;!JIW_Z>#87:.3&CIB0W)4%
M3(`PL7'#@I>DW>IODIE3VD&/#<7+/;;+,3OL-9C=Q1>^#+-&JUV&9^_58W8G
ML=!(A8T<T2L0648\[<@QN9VZ7TM[O1GL\@?+`0R$81FEP!L?]-A0?`QJK(Z8
MK<9`**6J_]5C=@>Q8+5Z>[9NCP7%FUH(5JO38+)""V'?]M<>L'OCA']]#AB[
MQ$Z,+(P.ZT!HMXTR"ODW/.AQ(7@;]P&(E*HLKR/!:Q6V`=+KH"J!^VKPNJ-`
MJ,KZ.F+\;NXX`#16]3XX$CQ69Q2`SGH3-'HPIT';V*CBMZ2#'A>"MS,*>E79
MLT>"UXJ,`K/=X+52H\#L-`@NPRHP2NFQ=,1XK-(JL/;Z,MBC(^;<>73&S!OC
MO@?Q$53LA%'/=R0(W>[M^M;P6)4/H,%CP^"E(W2;1W[M\$:_#4_C:.H'SG_8
MF`;4YUKLA)D&2S<(X!?_B07\)VQFOUO;F;4J_,S6RQUDRSE,W1%7U/-\=;.^
M!G$W^<XR:U:5=H8-ZG*]9-;"W*#5?M&X?B.8*^JOODK.#=90$T>`NN_S^9XU
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M7BO6"KM8KH&/87O8Z1P=0E9IW@I5X\J7^]`J'XTKSWD<R-U:DS;(+DOO[N)P
M>CN8W%%--TC>@U9?&:7K5J#8CPO)+QD!JX=&U9!&MWRJ<^OC:K+X9*_CN[G\
M0QX'9@_PQGX[J*[T/?YVT'BHMWN#X:K?^6\`P]7Y!*I#GLSTN9J#Q1"!"?$%
MTW+@7%]8&#*&$XWAEZ`5;N`_`#.`YH2W\X#9XROOGW;@X*(+I9A9Q*Q7<*GT
M_=D9F+V<SCII=TZL]BL]7>>DW3OHZ8@=;OQGVXT<%A(]"PC`LEV'#;-#=]8Z
M1Z*'E^U;'G"9.3=K`3?<!+;3AX>`/0`ZJ?[X:G)FA]//C(5+"-D\,0;9AXL*
M01MK0!0)OVSQ/&&")/(#GOAWPT:N'8;.Q!GQY\WXWZ"/T-P\9^$H<$@LK9O;
M\^O_ZT:?YEH8/;OL'^]F=O#@>+]H[7GT[O]]B#[A'W^>TT__V[#$?^WTA0F`
M]8MFP.=_]G"*C*O=.3/`Y3?VI-WX,]O3^2]T[18.._FD)3M\TO`\)[;K/,`_
M\<C.Y#G9]!Y_R&,F)'#N#P&8^*4#V@77;;>ZCL>!M6?S3__;Z+4/@ZLS%D2V
MXVESI"=M3@2E@:D]"S5XQ6CVS(_!HB%8IO8CT^X9\[0@P2L;:Y&/M(4C@/#'
M:`H\FD6Z%H?\8R"1YJ!L^6?@#[[KC('2Q]K$\6QOY,"!X+4=T4LIU&!%^N0S
MLP.-`=[&!,4Y&Q%C:Y:A:TBX+>T./H4JW?:>M:D=:@IP<#)8(V3%6XS$X=D/
M-`<`D_#ED+DN2%,Z/>#O+X:R5=>>I@RS:@F$'+K2=?R)V"U9\`F^!4",W'C,
MH;&3W338AA&JM<B)7/BSV%K70):#I'?Y#8QG(&S#""7_(ZY%("R@4#D50.%S
M30$?(.S`9D&>%0!38\WSX8SPKD*\.(#`4:3YA#&)3T&=G=ZG4$'AW`\=7$0G
M6,!\`J,VMZ^N`7Y&(+RTB>L_$6;A^A\=>!V[SP#-W`\`[%9*\ZF:VU2TY44C
ML,/I:(1TB[G1@>_!C_SY'5X#OD;/_+_O@"-^<\'.>ZNB$1`"5W$Z]N=(0"G*
MM"S.&IF91^*EI_U/#+R+M*$3MWP^O?U-<^C9AQR>XI(`ND47HAV`H/@^1V[5
M/DBVZG\ZO?TN_S'X]%'[YK<T3G)M74L_=>$Z(`6(!9#-I-#^G'#D#3$47MX-
M^SMV`GYUNG9)HH?+,X+E%/XPQC^B0):VH29;=&D7`#7:/RE,7+S:\FLA%ZD.
M2'5^%MC*?^0R?<Q`1#@22!O^_<A<?TZ[A62],5S^F0"9`*-II[=GVIT_=T;:
MT.BJ!SY7OGI+7UV$C%`?L/MG#@,>DA;]_?3TFL,#8A-D+P%TSZ(G5%T+,!$P
M3"Q.$M?'986(PD7E'UN`)A#'8R[Z:`<%+4Q<$4=%H-P":;(EN,`](Y]@^&!\
M1!$9XB<`:D:R[23R3PC-#FE83@%<J2T5^;HB=W4Z48C/6>[K504ZHW%]NO;!
M_*BY]CUS$]52J"U!A,,C&73)RLN%Y:R/B/J1BY_%#Z9&*%>0!=\%S>,\\OL5
M&O9IZHRF]&F^+K`7_/0`'Q[S0WWH*-L(E$R<`(B8+(8E2X#&<WVP[8.7Z#.:
MVG@/0M/CDD#Z$6E-LH'$C@MK2(6KD`;:/&PR82/2X$@-MN?%@-R4QJ0E<<]`
M^'A2<-@38$LML7B01;C,>7*BJ08@@?RVYW-7:$>)7F5K6'?F1*AI52M))8+Y
MU`:Z&CTK!`0*<09?'PF+"Q8F[[:F&%R`R=$4WT@2#T#Y<<`D!`7[*,LG]A#G
ME)'_D$H-7[YQX0^/S(M9R(4Z$)^M<4M#5[?(WBE)()3!8>'UCL1W\`I2W"-_
M*9C/'_8/P'5J<V4.O?*8.I!+*$^1.292+_[-`2R/'>1N&Y6PP`!HA*P:4'="
M.-+C"G$1HJTE60%EV'-&7`A9-(8W*`B`K,PM-,`V-:#R!ABJ)VZRH9/BG)&Y
M>!J=V4'P#"O2RW8]GU;!8[G;-GM*R?HZ>^7A(_?)Q8^YPV_J'+Z[;,1N)VUW
MQCU2O\+/O9/V$'Y.@2A:<-M-R3F46)[<482;#H`63M0^J&5NVE;,7?HY=6I?
M"_EP!L\?HNLO[DC.)H5/=_F=50-6%[TG9I_`XC\/$B_/;7P?`F$#45X\)I$U
M"31M</H0,#7J!N":YDF[OS&XIW#TJ\D79-NU?)6W?\<@\C\S5C#Y9J#V6T@7
MWFS+]:]H/:`R4S>V!6K1J[EBRWY7[>F]PY;#TK?<.F?@F^_Q$``?@WSIP:,]
M)JFYD$U83$>K&RHN2Q8QC7:WC$82&X!?%Y25%!UZ9:@334W7K5!9%WD_0N<7
MSW'_\0[V8>^TG_=P$AEV*_TL.4(X,2P0JF44YZ]QEKW@3>JS<%]4L%NZ57*4
M=3.NMA&@J[-P=\X<W_@,-4)=3;+N*D9A^/*^O_,$#H^[G\MH&;()2G=CKC6.
M)T]PL!,NIA,/UB6:LH\GD3MFSB_D7'R&C6>^1[D?'%Z%"HNX!IXD('/6Z(,R
MM#KFT`+V6&^O!0V!G^))1>=QD#1\H;>MDJFRL;I<^=#N#JR!H79UW!2(?9TB
MH3\%I44TF#N?:?:/Z7"GPN]LN]>V,[[TSNRY$]GN&@>%B^P..D=UUM$HIE$F
ML`&;.",GXOLH00&*"10?_B4[-9=%@SDS%SPB^XT5-JXL<@.MSN?HJ+;DROUV
M!J[(7;22[-L=<V_`;>=66@6^U1UV-H2>:Y=BFN6B5^9M[B`_E^5Q]P>FS"W:
M#(22H>\2]MO2DX9J:[4G;8UV2V:O.]C];(K4SJAG6(&^OJGP6)::]N)L@+6@
MJ1;T)8EKJZWN34'?_=TI4E]%YNRC[;@81/[L!V0]KW#4I227JHFLXU:IH+C%
M#(5+#],4G$>N6$Z],4$08E+NVC4`;9%?5_7!,[21TX'E=^[MIT5B17N5W5YQ
MP;2^\\'\N/0BX/;0&2W&=+8T.PVC9Y1S6QL`OOC.NG]YP_LE&PKW6^[I<<-F
MMH/A1<S6#>Q1%-ON'0MFRV)`:\JW7Z^M/]4'U/[@/BJ<903KK]=&NQ9(4VQE
ML<X_&6:L/.!GPTJ2=S$=:C$U:G5.%'U90*9%"!H%T'G$.M0>A+O9\;2)$XYL
MER=+4*@:8:-P-YK.F''$Y.`R71L[`1M%?L"3;D;I""XM>IX[L([[G&8*^%Z2
M6S#Q7==_0E@>!4SA:,K&L<O"7S2S^Q,&PRT+_F>21.U#$J%:&-__&[:4::HB
MY(ZK$`CW;.3/,'<S[0KIJVDEMN>!(@I".WB6L-#9*8&`5N#Y#.+NM7[W)YX_
M$6B]_D\Z9B_,>0Z(^ZS+%;8&#=-6_\8D$HQXP:T0MD(0;2[/_*#<*$H@X4``
MY%KTY&N451LPGE<;9J'ZI"PFD4M?M)7OB%R53[@2&!S1%$^3?@]^"P+\I^3[
M=ACZ(TQRX,DDE+F"1YP'_J,34LY#0(D9+I,9$"$+'D&%A?PSXR1S822X*>3Y
M+PK)\#0&).ALGJ)JGJ[%:7FU*0?MW7*0BI71-Y\*O9@P3DC!J'\_\\/HFQ_]
MR8"!*0OD/VQ).'.=_(=^5C]6!F$=4)%(\!M8%,P:6)CN\CL@*+RY_;[&B]$8
MFM8K0QBW8SYC86&25+2N3@3M9_YI?.V=[P$AA7`>!9;6I#NP)/ZTOIKU0>:N
MQG(V_/%[X(=K!Q#%`RY7.;EVS^M.=U!F=_2"@Y2-*[B*"7,PZS'99S^X.C&M
M0;O=+P]9!2<I1-8.=K)2)ENVD;\2F;]>=_XTC*_&\#R'KOV>I6QT_I-+#V\L
M1Y[>^?BKY5'3JK'<12R;5HE8+N^(I3'^8G8/&MEW4UO&'Q.Y_G*6U[H&S3+G
MJS48#E^>:%K!H6J%S6W-Q*4N[7YO8+PXC^VHL9K5C.7:0R^K^5YG6,;PGPU/
M66IWJY<%4U&/R^IQ>V*U>\.R^H:M?<C]$:ZP4K#9TD%H]\1H#X:=,LRNS8]Z
M`*&;TZ[$4)@=GPQ>+T.[K0S*&66,JBKQP,=R"3OX3G89*OQ:+X.+PB4992_<
M2(E2:64HL//B^-T#8&+OJ@$?L'6\'XMF9]0+#>6$[Q92+ZMXX!?GEV(4[ZO1
M/M\UD+?3$2I(T$TR]^N6A)Q47*J'`P-1.#Q_8QZ;.!&U2WO;K36^7=U=:(;5
MTBZ^7G^Y^O/B0KL]_>?EM]]OM>LOI]^:=AIYQ.7;]X#`!1YTPBEOIB%#Q@1,
M:&.?AU";`YEI\S@(8YNWLKAEO,]#IVU\^.NCC*Y27PN/^F/P,NPS?\QTI1C_
M?VPOQGANII<0+6Z[U+=F;@>1,W+F=M+-(PEAX[9C7G"L.1Y&;NT?6('.@H#"
MX6C)((MK-B^FQI89^!T*CW(`G4`+;1<`T-4(L.@.@`TEHC#;WFAF_R5:)%`P
MU+F/>1!>Q(T)<MYEB'=NTCP_TEP68CP8?FG)C=-S88>7I'Y=;DT-)$8*HQ?`
M1U`4P9A`AO<WGP?^#P>;#+G/VOMN3V^WVQEHQY0OF.OTE/8\2+H\%16J;R**
M,J(Z[>QV-;FE"Q"5XR!U[^P?Y^(2+Y,[%/7PFV<X+6LZ9Z2)>]L"DSG1.>]\
MH!S]3"60WYX%<H(EO?1V.@QO4[@M''D%L_82I90Y]#+!X;7W7BA4#D,6+6D!
MN%94OV=8F?ID6F_]7=;*'6B;'=,T.R_M<AU@%XOH&8\?(5^!X4E9]_DT[PU.
M:/8&JN=OU1:[@K,.*LR.90V[V\'SN^^/GQS7W0`5+]E4JY9<YSB69?1,Y8TA
MU]MBGUT3]->$!#0SF,4.V-J<!@'/%S]$KZH*$+SM=NL@OV>TAVI5PCI[%3/V
M60R"OCB#>DTI8G4Z?2O/WV+9C?=<Y_##=A?N>T&D+-GR&CM`.F-1I`%\1D_8
M<@[?[K9[?96C7]RJ).C6DS?MCNH$V`(ZU/]@90;/FTGAESEC];)KB9^^V;>Z
M*@>D:RY0G3"&L0&A\XB/;?C0YG?_TK$VW6:=8PX,RU1TV*HM\N"D7J34C-N5
MXKOM]E`A^%5;[`K.-IV9-H'GBV/?.RYOA[<E-GK`_FI)I[+DAKNMQ<_MH9EI
MN[)BN]_B$&S*,(37RKUHXIBV[,:1`,Y8]`R3BSR7R`@E[;X.4CH#R^@J25Q;
M;+W@;.)EKE3?=W7O.@^VC!.,2A<96^VU%F<,AKV!\FI]:9\5]+JCR%C!)"]S
MYL[RH0<"8K#)YDLP5;ZVV'RC]92^89@OWONRLY,9S@+I"ZC@T.OOL-;]]@:*
MY;ED\679OS0BA8W+HW3+&O35V0DO;E0*9.O@J6_T+,O<`3)I=US;SVAT8%'D
M:`177";V#&.8\1.LOV7)T*Z%T4&OU^^6`JWR"?C:;=HW-^31M_(</"_M5`9D
MVSF%-H6L3"P91KMO*3JBK-W7,^^[;:.?[Y11PN;F.N_HX;#7L?(M2<K;?,LN
M*;U^WZP>INV;FUB=]M`:6M8>8-RI*4D&Z!,P#+`-1P5T;NUTVX-AOUT]3-O?
M=J<WZ`R-WCY@+/&V+1`J?6M8`1_MU@%I:':KD[1E-"YJM]N]SD(/JBI@+/&V
M.\:@U^VHL867H;YA.,Z!C2_L`+-,PD5XMM6H!<3W\F;E@+>.RBW`UN;@*53_
M4F+J!M(OO^HVNZ[E0,]PX0:[7MO!57"+XQEXZZW"KC.KCK\L7:W=:JNNZC6V
M+`G*C?J?E`JEZ.B2#(%<#X?+NOVU\QUG5NRT(U!K=Z+:)U`T]*X]V#=0O/_4
M3E>'(L#*C!<HWF0'6-:_,1`,IE5,XB7!TA4]V:0>7-E3']CJKUOFNJ#%UFZP
M;77-[NX'>*$-9XFWNZ()YZ90E7C/*Z`26:3AG7\ZHBD?TN?.,.S,QT>*OY32
M%;1G]2SUB;S)_F7#;BFP;^D"K0!].^9/]'("<1<$%P8HMX[Q#KO]11=;9NG"
M!(/+V=QV`CS#&6#D@:W;4&`E,`J"BC?9'I0UJ&H[4!::],&E/=HN7NZYX\:8
MCJKD]I?6@M)"_Y[1+V@2N'+_\J!>C=!E4'>MX:"PM>%:4"<WXKH^C@8:%^?F
MB_2+,BC2[/8Z/;5B;;VMRP-X4[JU#*LSS.0*[1G@%;)3AD3"K`5RR^>CGGKC
MKW(PZQH2M3\T^X-:W4LEQQR8PP.><O/+_)W/N,7@3&;"[3JMN]M#L"L[QW2G
M.YS6Z!IFIW-4=WO#0F8'HRD<5W&A;=>N>Y^WM`G<^=R&;J]F5R0?=>>BSV)Y
M!-GIM8<'5!Q%]UK98:WA<*@VIJK#S8I3G27]#TO1'X-,U_HZ7&I9YZQ.Q&QQ
M.[LQ7G]8+Q.SPM,..I:E>GB/@/.VUA^#_N"X[G7KDYI&QU)3"K8[ZS=X9WO8
M$O>+'Z:-V.]\Y:$H`FZPHC,JXX%W8K0-8V"H.64;0E'!(39]])WT>QW+4)-]
M=CS#K6B]?#61?BER1H6.*)=3_K4D]?=-UHICN6R$73\U.T40[R,]L9U`>\2X
M%>_;S,MU1RK*-!"B7BCJC*GOM*_=L\QO'2JCIKI;^$B4K\,U6H8V<T!]8F6O
M'8J>VN$O1U22'E$7[!'8`.'<'@%A(8'3O^?V>"S_O=CJ_`P@N`\<7?MOYCZ"
MT3"R`59`W(D`^,D91]-?J$C[DW;O!X#TDQ&@QYZ'[!=-_O0N!0AA">1&CSB.
M>F2[\ISW?@3B$A:R1W\]!'[LC7$Q/_A%^]]G9Q<7GS^G"R%?T6)CN9@`I3\$
M2,#282=3:@4!P!G=GW9OZ8ZN8VW._<NR)/OZ3!,Q'J0:'"B.9>\+S;6C\<M@
M&\NASE[NCHOM@H+W6QYM\%.6G`,$JA((>^TVELSOYPKHQV!GTGZ:.A%;1=A5
M$'.B7;!O`:@N6`65BA-BBX@16R3P#5&Z.RGOOL)^2*XSL'2CVZL0/R71V1HB
MM&)*XVTR,JKYX&0F=!9'&Z#/!;QI1JL+APM]UQF7(95?WF,_I&H9>J=W!)1Z
M"(EX]Z)]60O*-%LFDLW8C\&>JX627P?,_9"WH1M&1^^9YGXI_&>RK3._VO\#
MH*#=3XF/S>7OV'3BPB7"Y$P<-N9U^3+-XM13"XG@;_&,C>_HV?Q6W[+I3";^
M+`.4P#<!B32'*'V*$D2I!`IE-RJ;][6Q9:H-/FI=I4K;YDC&-PE]/"?46OL^
M>/-N/?2[E6:&X0\L30AIWJF'>Z=V].%@4S7U]EZI,FU."Y*\N>89N@17W8'>
M,3=U?+R95ZAH(*0Q'B#A0Q1];"(DE&E#5\O>C&W=/`;OQB'D4]*XJ:&>)1@R
M#4LWAHU86BJ6>!]%$D=,-E%LJ&F9U=31N\81$--A9)%LHW@HC?:6/*F][G"+
M.%,]Y9IX2)^X;"(04`G*N(/5$5XB.R74Q(_1R+VECLVVT=:M[J#^]';09^*<
M=S`B;6KS'D:J7ZRAKV7T9;;U=F=8?^HZC)5&S68/2DAO2;4:[;YNM5^#J-NK
M8BWP_S=D6N7+U@0R[?;K3Z;'8`'2R)4Z4/"Q:.S^P(+WAU%_ZCN$/2BG!C3R
MKTJ_L&7H/?,(*'![FW&O<F.?DJ<BL%Z9787=/P[MH6ARP)H<L')RP$I)U,H.
M\%36QJJWJ\G57"2.80Z7DE[VMK.]Q&A!?Z(%?*RBB#YS9(DQB:X?4GK7]9GF
M>#C]B&8B4OJ6&!28CAVDOC&D[*E>*<3>?525`M_WY16$V@106YC_!;\$@?LP
MY5,%^7!XFB-(D"S,$M2P_V!3]53S[#&KFE0J_F:3A+NA4*TJ9>Q(M**`V.RL
M"?*^-&2O:^K68-.<CK>7?G8E);2&TKFQ_>IN^WWH]4Q]V"LICK$+)!^7@G`$
MMN-.QMVR>5K*%ZX#_S.>Y=*;X/^\Z:KVV+/CL8-6W#SP-<('*%M$>`B_82%<
MDS#+A%6(UB3(S/_P\KF1:,P(7\29VMD$$)Y4A".G/6$1@GWHX(COD1@]327P
M-DT"#YNB@&K,NE4Z2\4*3G=F01F&4LFKPK$!R]X_WIGOMMAA%RD*4@*?*!N*
M\P:I-43J%E9@PSA;W_&?S`ZT"WK1-[SS&O#:L,\6L:\*"6'!1_9&^*RV%V#5
MGR%W\^]U!V_=O[=.'/T`WCTJ&JU+4-[4S8&I]P:;AN7W7-O;4,6>J6+0Z^G=
M?K?Q^*X1\F]\O4?AZS4P97V@6X.2BG"J<?<V]%(7>NGK[4%'W]Q4?]71@?62
M2#;TX>=#`)\=#R3Y%^>14DPN8<M)^INT;#&7C!)>VT&4MBXZ\V?WPH_]MK-)
M%GH'H:<?+B&:BLZWL[GO47L7!`D]_DFZ3U&((`S]D4-I)$^.6.+Z+),Q0AUS
M@0$"I45N'+))C#4'CZP)'!P@<-#X"C;Q>&,#K7]NT<+O*+PT=</V=RX:OCB3
MY>C>N_>DUZZHMQ:U]V>!%C"7QUBGSKPN7I0:V'_[;ZS5'?;VUP!ZCXOE,5@A
M!QMM[40SNMHSLU?TXSWB5_Y=8(^9YMFSIIO84C:JN+M%#<R:G="S'^8X3+G[
M-]\[P6<$V+D\R<A_9)[=M"5:3@W;S!RH&WHJY);.ZU4EMUA[H<W%\&I`WHC:
M"];#'_A**T\'#;>MC/;47CGM%>N-I[QVK<UJP&#'7M=9K4]]61*_\H7LG(!T
ME)JQX6S(:Z$ZSP+&'2A?W-$ZLST-H],SS<48Q3H@KG&\Q6I9>Q&=1?6RV&T=
M_G"1MEG/(.0TO)J4AH3.<+`:`R6>HE*<Q7`M7L0_>9.T^JX0<]U!QVQ7A+HE
MA]D;`D6K:S$*%#Y/[<OXWZK#J-4VN[T]8'35Z:I$<=+JN3H4FH9E#"NBR@3\
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M++KT1OZ,X=64@=L3`S3@P!H46%TO[E\JX)MB^J3?'G3@C"7`+47HY^7FX1_D
MO`,I^\@"^X'Q_"),+UJ7K\5>_Z*P_S=[QD+!SK]>=_],S[`+*(<\UA>*.3G>
MP^E#P*@/6'H^\S4<4"99W:@Y5OR(R6>^`ARS>)8<W&B_E8/;/[('/^8;%QKX
M&_IND_R#,Y%^D!RQ4_()J=\-JMX1?$HHAO,X0(Y2TJ#W8D18W7:;GN%KP728
M`Q3S7/(]:B=XX6$R]5<[&$WOIDX0/7]V@C"Z>_+OIGX<VM[XUOD1,>:].I2H
MW%@92OKEH02S%TJC[%_AT]V3M@6?7@(;;+<W<"J@4SQ@KX8'+(WJ-CK@8H_9
MQ,LL'#!ONU*'2G&$I*'.6QPY?+P!_(8@6>RV^F2'3;?5(Z^N>:65-/CE>_RA
MN/_)?<)NU>2-["]QJ>*FNC?VDX:%=($#*KW>I0K[S(%2^^7NJ1=NIZ=;^ZH6
M.>(TUS_\X"]L1SX/_(>`':`_PK&D@@_[^N`8QO(<IK(`7^DA&(O:@^^/FR3I
M:D<Z#O2>55*S@]<FSL0@LM0@KP<I-EG)*\9-]4V];VW:P:C.V;^;#G!9_;C.
M/\J33X.M^56:FBLBZ:NCOYV>I28'%2Z^%`(I]7$LV_8@F`,09P4@9%9?,I\F
MFS08RJS!3&+AV_55".QH3*"'3Z?A"2L<0W*B/(*#HV><$)N`^!-J%Y(T)&E<
M%4T'\<:ET=Q)=7=B'>Q.]NYZZIG5^&2DL`\CT'(G]W;(\Z-PX@3VE)(ZH'%*
MY:'I[<TI=5)OY#<WN7XI;D_O=38=1_3VO(M2)J&IV7@62Y(*=<#,L>#6Z.GF
M8%!_7]EAO+:2/1VP$@+;&S5=DY8[72V]W]]TL&(=\',L&+:&NM&K$L%'K$9Y
MC=&\R)LS9I2)4A,_]VL-N8`:Z9E5NJB;6RK!)L<1H4<0%SN,KN>1L4(94N@1
MKH4\:>)F*\B]T]8[E68D-%==DZLVVEV]W>OO5[3M)41ZTF[U5\5V%F86;Q[P
MRT<OZ?/99<2WBR*8:]4GFJ!WT@#F\@UV`V6M8"K8T&9W&UC$AR[E4W!;9%A#
M`"$%(+_L-MNN%T6VX'VV\;XW.UR[T3,'@X4=;Y;C=MEF2\[W(W1^\1P7'F!!
MS-YI/V="X&+)6W3VDZ__+''U2][8FIQ[/6S?L.XV98"U(08D7C$SX,EQ76J4
MEJT-.W?"D>O#Y;_FR'\VIO;MZNY"&[2TRV]WI]]^O_SMRX5V>GM[<7>KG7X[
MUWZ_NCK_X_++%P+GOF+`=HC?EX46K-,XX]/0Q::=WJ>P:%!*I"U&B`^>#_&6
M4Q_J8*/N*2!^.O,!._^A^J_]6?(%*0)UP'ESHCJ=:`MO1\/4].4Y%6CNT85R
M<%K9QXGV)9%'HW@6NS@,[9A<*X=#V#=696C_%4JAVF3C?7`\WE!^CU-.ZYR=
M>.:'1Y6E4F=<V@<Q;%\W3D=V$#QC+N?C%B,/ZQGH$D]+:_#6IOA9^YSZ=O+B
MS+<WFS*:OX=F?F%SGVM:3U9/[W?*O\]=8-K4D&L(HDP&[PYUL]>TG'@Q$^5P
M0SIK,D2RAG;O7G,]CW4&Z;'@]T._6Q)Z]ZF,WL[]='2SK`MZ?8F*M1E26Y,9
MJF^=68YV!N^Q(/C#4+?Z)26W-_JB$A'1KKC\X(A?$W69TUR7&<!-)<GN2#[6
M.=1OZ8X^&+K1*:GZX;BTUENZY9X^Z&[:9N&H7DI'9I$VQ3_-U/;FJBO3:1VT
M/$HJ@G\%2JVAE15BP6CKP^&>RYWWW39U;]4B:AZ^+([6)GY04"^"O\5J$'R&
M:0Q@'A,T-1CW<2`$-A4K1]L8<D].B\^<93:450?H[-C<\=9W_">*PPL2A\TU
M'^"::Y.E6MQNM];T4,]90O5-7JU5AM<>API5E/'WVD(R!TSP.I:(7FD).O7T
M:NZ"FMKD?QP++948OG]MDJ@NP>&W%+(I,2Y73^'6^-#K[!<MTX7^YMVB%V'D
MX#C3L3:)HSA@FKW,3QH5MMLA@-9KN:,Y!_*6OM2"[G5Z++?62+OZB$+TF6,1
MJTH!^U/(!V^5\6K<$\"TFUJ=C3.BS`!@7V\/-NT)^O:<$4"FQ]BVO\8T5$]I
M5PWI5(F;AG1>L<RI<N;,<1-.MZ_W#;/^A',PF5-EONN1DXZE#ZQ&YA0'7:8L
M8/8D8L'>R><M>3?-X4`W!J]ZRDCCWZRS?[/)^RQW]X*QZ=@Z?#2UO0>&_<+)
MM9EMO:;Y$X*DV.FI/8BV]-HX#O`[V6S1`M?G$T/7ZCZ=GV]RW'I]K+S?;)>&
M7=B1]C^V%]O!L[9=LE1E(GR?PO7XQZSNRVZLV*5[?::=COZ.G=#9HFUG5<[=
M?5B7JO>V+I:F!>JA9VX:23^L@_?@TG37Y-/&H-V[0;L=G=?9H,TE+R^SK1*+
M*ITAM=E`H_PXI'1*6O[+L)Y<.CL<[97.1&J&_]3:$*^[4Z(9_K-_G#<GJM.)
MMK`'&Z:F+S?#?ZHX43/\IYX(:X;_E/$\;(;_'!X?S?"?\G#9#/\I'Z?-\)^-
M.;JV]=/-\)]:)&LWPW^:^VR&_S0$40J#-\-_ZMX;HAG^4XL\C&;X3S/\YRW?
M3S/\YQB:OS3#?VK!+,WPGV;XSQN_H6;X3_W[.S7#?UY/A5<S_*?^=]0,_WD+
MM]P,_WEM*S3)\<WPG^:JF^$_#:WL*!;>0A$X;IFKC]FBPB5?)//9\>"=^L5Y
M9`LE-FH^_@7O;?DFJF7>[/"CUU(S<ZPS2YKQ0\T=EW3'S?BAPUYS;?)DF_%#
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M;.3`L4,TW7[M=8?M=CN?>;)ZWPIA_9=8\U\R7?Y&S9;_2LR_\CS=8:^6YZ$L
MZF\VT-4ZAZCE$;Y0OB78_*</`6,SH/=USC*HU5E&1%;_^N9[9VE2\IG(25[S
M9DHY3M&[_GO()K'[Q9FPG:GKU^ONG^NDDZ5;[@-,0#O/!6<+)/3K=:>&`"\G
M^5^OS3IB>(783#[S%?:=Q;/D($;[6`]B_\@>I+H;"7\/_##,'.(TO)KLI&27
M[U,B7!4IU/W"OK/RW"^X*\3<QKIEOY"7I^)+@5N9'Y9IJK`E&YYT`-+>>EG6
MQ3M7"OO.K'IB]?J=]6[BH.?;B)U/^MTC.-*6+'\RM/K=^I]N.[%P8A@=8T^'
M^\:BK96ST1X..VO!";N4!M/NBKD[-'OKL48E<&_$Q1US32ZN!-0MN;/3[IGK
M<6<E4&_'=;U!=[@MS"KS+?:$*L/=E-/`JS?<'3Q+`<\J!N]'Z/SB.>X_WD5!
MS-YI/U>"DYV9/:?9J\9;:9ZLC/(^)-3;,5-6@QT"_ET=5ED#8[,3;%:%^`U.
M<_>$X?ZO<+3I]H_E?GO0W[84,@_$;D?"0JZ[)_\@)Q%[[WZ`S_#9;4_0M0;6
M3B?`S>41+K]^_?,7)0!]-2$IR,;7=A`]RXA(&5K&LHR>"8R[WHYY%)^S^^C<
M"4>N'\;!JZ]]Q;7N\8=O5W<7L$Q+.[_X[8YVO=]/BM8V>4F5)HA=GVD4VV-C
M;-GH:[;VY`=_8:K7R)X[$>R!X4F"Q9]H(_B<$VFVU"O:DQ--X3L3!T3TR(%/
M.QZL'<7TVH+__VH'HZEF4@2[/=!L;ZR%\7W(_H[AV^ZS%C"//<'>F%>6K@I?
MO&7SB(>_>Q3]MEH$`^:S(4!:$3`VIIS!8G`F.,F]'P3^DQ;/\1_O^S0[C`#`
M_I(A&\5XYOMG@CX((_XK)WI&/``^0@(#EL2MKL_R%=#W,2A8%H:B_KFEK80,
MMX1%9X`FJKRFY#B93U>0=F>G?,RWUPERS\=J[1CT.>79<4#HF&RL:W/;&6M^
MH/EQ%(+`HHI<)6UO#C3ACY<F[FT.4ZLH[+M$H"RD9T;PR\LPC-GXG$"\)NC^
MB2F)0,[TEV5V0R>50O"SU4[LGANXM,`9`89I^<W=D&M!E1'Q2[YQ.[6!@NB/
M5W.R?2]^L&#DA&Q\Y:T;'U`@Y^NIP%]^^PPF6Z_=[_>%[-\*E/R]7`=LPH)`
M8)!_]S2.IG[@_(>-UU.M2X`E7*O87KW7:LA`J5T%U".'WPZ<E1986_E?+X&R
MW6JWC64P+MMU'2SRF]D)@R_@CN^P#BQ7BH2H$"!EF^7IV3R_6\3IOC`[9-?V
M,[U9/OO!&==!].OPM;?G6)W%+22RYA(N--"@SIQT2PP"/9#:FN`1'^&ZV4OU
M68`MI4!T=UIF]R?4!_!7+YZUM-.";#-=]@>9B^L0&RW1#HFU0'L3&$TJ^-MM
M"=)T!&DZ@C0=04K`?U?O])N.(+7L"/*6:F2-H6[M.['Y>++V[WPT?6;<AN4F
M4&(VU:4*JG:5_YV.WA]6V5/CB.79%_(LD:M'"]@<K'<@);2GI"W?"+MJ1T3V
MR^KVL@L<RZ=I';6TO.;DG-0?RX=F(S\WDY^6WAX<02_V@\G/41P$2&=SC-9M
M7`/:B,R-1*;9T8VR6D`U,G-QHHKJ7M/\>X"2Y]3HFL<BBCG5D=J;8M$53ZJ!
M/NSMV?ZM4=.7[3W_^5A"YJ.91>5ZPN*@F,W5Y!N+<G_?-F6D8X$&3H^V.R";
M'^T\9F>"\[<\A-GM]/N;'"+=<BMP+[V[)Y^WC=X28F-HF<:&$*>[;@7TUA32
M@3?NAJ!N#N"E>!5>>B,W'F/"TJZ4;<`#:!.PET.0"9?S%2YD[.H[1I34Q?]P
MHJE<Z@:C56N!?\T"+%`OBN5V,*EYJZT7(I;L`;]WPTC!>@]'F36U4[I4MZ7=
M7OS^]>+;G0;HO;KY>GIW>?6-=M\T>^I`:5,EAV+].<.0:D@QT20AR.=MMN[M
MT`EEWI2M83JNR]"9`^1#T<60$Y2.#Z31%&<E9)>9`#D_,M>?H]]G'OCSP&$1
MME<:!S$EZ01`O;`Y)@;!GQ\="KB%,:R5_C&:@O'Z,"4X0B!N!R<V4":1=R+_
M+88,L9@L8`VK!]#@I=58\.B,F$AO*@K[3ATV$8B@?"/@P!#,SY.9_1<+Y*'.
MZ%,7/]@(]GCD>4M7DPFL'.#Q?8VA+R!!I<0OS@&6B$NW$'AK[>W>:TV#(\#:
M`V7,A$!<C\S#O*G[9^V!^0]``T!:!(P=,!M)DHV1/D/FNHA*$%KTBFAIIYCG
MQE$,CPJ-,FFXCG>?^<<H09"NYSLFQHXURH,)/Q&QL8D?,%V+R`^>@(%#1"BW
M#"B.H,`\/EK;CJ+`N8]QF<A?7)3#X_K>PPGU&U@Y9`376P5A0RA$*'CGH>:0
M2<`9G!(1`ZI%PTOG;0`Q`]2%E9GFQ81G>EKR0@ZX%W*L1%/;`Q!_PK\M20?A
ME)",+PMME_&<19`0`5WI!/1CRMYR"X0HZ4>XJM%@<ZMTJP'@!=#)+]8>H73-
MR7,"!I",*:ED$1+B02\P!IL!PX3Q?.XZ=+NP<LC27U!""J-%00K8HQ'&(SC5
M:(,.73_I(E0H\*J;D?J8Q\%H2OE':>XIP;#F;2HOQ9<MK@53V??0$N1B[,8)
M_Q*FH?W`MN@@M-RN--17WXH]2ZAH\.-@ZXJ&?M\P=ZIH@,U+J"HA6CM870GN
MGGF$_&$'@8UOEC",L=G:>?ZA\7*)DKH$&]_YGT&.LN"K_6^?)X1.?1?DG&S6
M`=\W,54Y>8L405`MB)?>*=B/+KR![Z9^'`+'\LJA:Q#&L/:U"_("F>V@(-.;
M["F`"P[D:@H\UDD;0.H?#(5W_J4'DC;RTX)&8/TP=H$,HRN/Y4$U!_4$%6@@
M"VK_Q!AN"BHPF,,EWCZXIUM(BED8J@9S"PXZ#-BKN6A0R$7[1>4&G-0KY*0:
M@9OEID$A-Q6#*U7:;^+%#R;=/=8'X<<.YENJ(GL]ZT:RX'%W]G^_7]Y>HO=(
M$T9T%[Y__=^G-U]/S_XDJ,YN+LB]=*MK7[Z<;>5D.G02>:5(O?(TDD=:DJZ?
M\9R(AGS\[<]KV/#O:FG8C,@6B_*3K**0%W9I'_"S\CG7S_=2%K\??/K(WQ+_
MT])N1WX4:?_'#GQW-'W^BUX$O['`LX,QP/2(K[^_G@F8Q:5OX6$*<"C+ZM*+
M!>]]^,`]&]DSAI6)H!C<YQ/_R6.\C-`9.^@0RSY#N:]JH5H-ZQUF^$J2[Q&)
M*WCRHK.*8!X[H7!,T(-J#NSJ12=SD<R^X(13G\_T?1^=(7F'VCQ@<UMX5C9Y
MMKYJ^L4[@C>3%^*C%>X(GHQPT<S+/C,Y_:(;,/&+CE(Q22C'FT_+3X&*02Y+
M.I[:\!RF51T1EY`>HB)7)EP/IDSP"LUDQ1"=2#P3"8&1@W%%-65:S(ITQ!_A
M">$UEZU<-DOF#JNLB=C6)K;#;SK)",.[<,;"'<GIA%>7Z8DK4$@XH@'7L>\=
M%U9D5(\;SX23`D@`O8,B?Q++?9GK/]%7DJS*56..[[%J2@+>\.Z"0O\,%Z?]
M4U[:6>;2[M)+:[1W'H.GG.S0R$/%(A185L_JB1]4:BHJ\!;^\E1Q8HF?_?`0
ML`<R=.UPFOC@@/*=$=W-^UZ[C07P+>T2/CT>\QT65@)FP43CR.6.>>%=Y%)8
M?,GF72L`;)%SH-QY/!?!KQ#^'4Z$:$=^9D&$OD;X.%\EU)O*P!(J`U=D"B6U
M2O,?920:YA/D(G^>`+URCUU2I#B`PUY_^&G#/*G"2Z\`PM,,,Q#O\;P'8KHN
M\1QV9G@FLG'(*F%VX"G!.OB@#]C5WEMZES.I)HT,P]1FL/Q4Z=V`XH(WU1"^
M\VYKLXS'2I,`"ZFDW(3JEVYS_53FVF#B#;%(B-T!5![A[5DR*@Q^:QI=W1BV
MM9#Z"*R(,\)K8(8!;5Q6UQQT6R*C^9[[C-Q&CX.DL8E@.6WFN.C.\1C7>#,6
M_=+P4,-#->:A`L61ZHU^HC>4;C_KJ(Z>3OV-LLRV'`7U)H"&%=XT*]RSZ`D=
M/8H5A<_\W9@CIY7((9FFQ:3*Z7(&#ZV9DU5'V*(%'BKBO2:*.6D)\FY*V-F/
M$6/C4`5\[#PZ8]Z<S!BTNH.!J6N!R-@9^T^>7!.[G07D%4VR=3YX/GFB^*HY
MUOZXD:FX[UJ!`[_(W6B*F9+P6<]^X%W;$L\/OS;QB)4YG?2`7_82INZ.]XR>
M[&"71.3?M"FO9JS9Z&<>\>)>)"UQG4L7DSW?X`$]9KR-''R.NR/1`\/=9O1>
M5YU:@1/^)4PGI9Y20PJY9Q0!L,>,>\MYNE:A8RXMTQ0P%COFN(_`([?!/5/_
M@DF@BO,O0C0$_@_Z-UAI[XV6@1:92PZ)QBE0T\FQLL_,L)I.+&?JT[G`Q15)
M7]F&6NGU-Z,Q!GMK1B-\B/NY@D(;ZSBJC\]40:X8!([(JEDD\`U1^H:*W`>6
M;G2K[.U3$IT=J"PXYWS,J>>#D]E;*H&'=T.G=P24>@B)>/>2?5D/RFS*U5>4
MJ^N&T=%[9DD]'FI1L7XDP6+M?9>C/DET>*:.X@$;^0\>-DO.I*:\D&F1?=")
MWCNC)28+E78HMCE/<W+"A82:=`'^$E33K])N%?+3F.1#OGS1@3A-O+D7`]##
M*6-18<%7DX:13\,X=64AW^HTC(2GFER,7'*2@S`Y$X?>\0491@1)4981E;2E
M?$C<,6-V2,,%["1RM<"(22DF_!58,F79E$-#\7V9YBDK*$6J9WY)[LA!OU^X
M?-LL_R]UYO#`0E:6+"9IX=^Q^8PLPTD0Y]$LB?QO)3JEY`K&'$4/8C1)P]<*
M02K3&'BQ>#R#;U*5;^9:<D[`].;7S)*SHV)B.J*[:)QOI3C?$DV/G>4Q8WOS
MWGN-LZU,SX<^'&QJ:[\]5]LISQ8/1:HBO14:7UHQKKH#O6,>0</(@W4EI?Q:
MQDN'U7H.KDP;NEKF^&KKYC&X:`\AG[!RT(O\X+FAGF6M^PT+4Q3J3SZ'$DO8
MEB=Z)G&4#/UIJ&EY4_FN<03$=!A9E'N3U\/I_DK#0;WN<(M@>3WEFGA(G[AL
M(A!0"<IXE&B5+ZZ1>TNC,VVCK5O=9I[&ZF>BK,1!;6J/1@&.9%3\8@U]+:,O
MLZVW.\/Z4]=AK+0K>B<>DI#>DFHUVGW=:K\&4;=7Q5K@_V_(M,J7K0EDVMUT
M>%\]9>;!+4`7PYIUH.!CT=C]@07OCR,8V7<(>_!W$7-NY%^5?F'+T'NO>VCD
M7N7&/B5/O><BU\6N^H8I:@?V4#2)K$TBZY$D-N$&E'IXDW9INTJ&#A!(369B
M+A%,U`T#II*&,128EN,P>&:B'\J6=YLVNDO:VU$_@70"A.@27Y!#*$:*J%WP
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MD"4;R8D)"'EJ89`GI]`!-AK#Y^0A+(:.SR*<V<^:/QK%@7Q%\"I!CKJ"RR<0
MY((I!L5;!-\PR60>;33%Z6*A0&]1[1!SG9GH\$W@47?ZD>S6GO8,/ZJ&S,?T
MF%AE*:E8P2E7+"B[(UL)J\*Q`<O>/]Z9[[;881?=_9F+NPV-B`:I-43J%F^/
MAG&VOF,<U:9=D!^IX9W7@->&?;8(QE9("`M&]QOAL]I>@%5_AMS-J]P=O'6O
M\CJ)'0?P*5,5<UVR1$S=')AZ;[!IGLB>B\T;JM@S50QZ/;W;[S9QAC5R4)H(
MPU%$&`RLH1CHUJ"DJK!J@@P-O=2%7OIZ>]#1-S?5WU!,JBY1%#FB;>R,130`
MO>?8HBEPLITO"::DR42`$X69.M7MM)D?N3S"IY0PGZ8ES$U,3\'55V5^@?<`
M/^*\@6CJ!..3N8V-!+!1F)U0XL0)9C2!*0R=,)+Q'CEFP)9-!2D(M-`\,FDO
MMAC(H6PTFC:HC"Q87(9@P-\NK)`=:"Q;U=$$T)F/<3XJN<,9@WX@/DSC.N.0
MP$L[GXG5`"WN<\@[I$T=G.9-PWF30:\$R9P%%-#R^-1$G!^*`:ED#@3\3C3,
M7/@D#XX5M&*3U2R%:%+X__HL'V;ET\CAE(&<.SYUYGC6P!XSS;-G#,-[W@G&
MQEC$HX4C'Y[%MA?I!#EE]\EYQ,^@I$8D=O*P4C/`PLUXF%6,V5VV%^^""-@<
MQ?PT<2@O&^2@C[.;<>2#/9H6;1SQ2<#B1`5@\Q1'`?J*O49^&.5WRK?10YS#
MO45I?-GW*-J-<<85%R7"S:$/I(*[/CEB"201)5@K4)5IZ0@4.8FQ_.[QN&;(
MOI:09>.EW"36EHST?8W^X;IA^SL7#5^<R7)T[]UOVVM7U&:R6,/4VNUW*#_<
MGCH"#GO[&^BRQ\7R&*R0@XVV=J(979[?5C4/'V1T0V*:[=UC="REUMV*&SW5
MP*S9"3W[88[#='[YMN1-=.3D4"&S;#-#K&[HJ9!;.J]7E=P6>R/J$8EXI4T8
M!@VWK8PSUUXY[17K38RN=ET^:\!@38N#[6*!(O#!N/=<=0/+FIW%@(`Z&(AZ
MT8^H%DE,Z<+Y'!.LH^?C.N``@3V*8ELLJQ5YJ`,6XBI8]D-[M#1ZTA$(^*P+
M<V.C%[WS]P&URX3_D(=>C#OB_NZ"#0%-?[%(U&)EHAI4+10+YP_W]+/@$<R`
ML$7@%'N(<O`E2+EG'ILX$6]5D(0O)%)XI94NRZ7&8H:[XJS7Y?0F._0]H-QG
M$>P`D>[,952&SS4#7#P``OFM\.C1<[8/@S;'3?$H:CAH:<0D.5*83$\3-RGC
M4%C&1<$G>=PQ>P@8/\,8%$\(F("O^3-GI#E`<*-(+2UC/T0TS\&BJGO8:<1:
MVA<91$DQ2LR^,N!R?:9-F3M>@<AC"FKL)TXM^XN1S&WBTRJ.KD3$CY)XTR#9
M/`Y&4QOGU`=`>'S8V7O108Q&AME\R!WG2CDS3$XCM*,H<.YC'K&"OR=,$SY[
M#$`"F.]9],28'%;(BTC3`E-=2\M6[1'.4./1<5&]*D4Z+`TR?(([(P.-`F<N
MZB91^#G48#@"?)_,F3?F4L&'`['(!GDQ#N*'K`24K52R0I++3RR4]#SFIB%8
ME-XS.""(6C_X"Q9"EDXH+2=1LH/@LMA="-_?8Q"5/K[NW#<P;5G@TOC&[`BX
ME;/?,N!BM2A^/^DTDTU^T>AC]W"=`(LRX1)EG1-0?@-()!>$-_S@>2`Y>4VN
M-O-!J$\"]G<,GX'?.1.P;X+(1F'(*V#]@,=[E96"I/"9<A8(!8]2X\@J:`0A
M4>JBDA?_GF`F(4O`-8!.H6^^"^8M@*JB/_+<(-NC*9@QC<T45;%)M73:]8>"
MZ`F@'(0X2'(IG!"3&/Z.[0#`0GG/"W@7<S@<I*LQ$,PWWTMN,8$7_IJP#-#X
M/7Y['(,^PTODE;ITF,C^P?63J(16)/]__1R')P^V/?_E-T%-9\1EM/TYP.GZ
M.!7Q#L3";\#)?_WZ__PO-$K_2WXKF912\%G2C_"/&S;YQ[O/0"]8OW+2-N#_
M(Y]^-LP3RWCW:T9Z)<)H'KU;2P)O_(5*=<BWJ[L+K0OD^.V?%]_NKFXN+V[K
MJ$TDN#FU<A`H"2))2-0D-N!)'H%#5O6$!-P)D/X)<1[CDBT`^>RXJ6,*A#82
M/^R*LW!90(TDQ%]93"]^Y3,RA<>UX5EJDV48QO.YZXA673:WO7/?!PX&H>"@
MO.:V[YW,1Y%3<_%UH)R$1-9BYP12C4U[K:-.+WFEJ22):"@N/4PE1#6.D_UY
M[BKNHG9C/R69Q$VZ1&&#M#TU/^OT=&M?Z1)''.?Y`YXG:(N"C@0E=X#2I&.)
MA0[[^N`86K0?)K3^V?&<<`J6%3Y3FBAAM>-]!GK/*JG.Z+6),S&4(C7&ZT&*
M35ANQ>B!OJGWK4V+A^L<_BI^>>==+ZN<*-+A<OGUZY^_7-O/Z$^ZFN#L]SO_
M#*,<#^CO6L_3\B\>;OG7M7@RGP6,NS2_N*.O9.N_TV+/X<M\OSU_IXW9R(%C
MA_BH^[7;AO_[KY]70I(!]UN,:UY-;F$_%I[2ZWK\V0^23]]&<$*Q5!5GX!NK
MQ[C\]OG=KZ;1-8;R)!L!F7=__6X['GW0@T^.GL]3YW)YQUGM'G.HWHG9@1?*
MYAK28Z*][^MP9QCIUA3OHV%J,X!MJK0!QS]]M8/15+[U>CIZ[C5`%$[YU4+"
MS1:NN/6#%FN>2\8#WEO)T=!;L\M)A:=>LQ_`['T0<3+R$GM$&OA/C@#\Z1+=
M4C,G)"<37'.(U($C?D$XB')0X0:F)<(8MI+PHW>?C4,5^+'SZ,@N[/?/FC%H
M=0<#4]=(?6+XT'_RY+JN_P30/$U]ETG0/F#5*D5.<.7<?7TL]/,N)]D,[TIW
ML.+;OQ;AB&N,1ISRP`[\.@D.J!1_&EY-2A,\EF7T3$/PZ^:`9<Z5'#TZHPLD
M[KX,PQAK`N_\&^X6O*::R[U(U<[`,KH]<;@-H%MV*I#'9Z+LDL`XQ)DL>',7
M'&DU:%E-QP+T<=D/[&H"PGC"'$RE^$QUHT5GL$[:'7D&_K,ISW`QF[O^,P/9
M[HW/G8!1Z>G"(<2&"[JBW3(2G;<"IJ7`GP?Q`VQ\-F4SM)4EJ8;K!D?6@7#0
M*8!PV<9Y%580]PFOX14S6I=67E?\1J)#4_%1QPA.?3*F;#FF%T..25!ZI.)/
MJ#>1@_0?J:!S@6:]:%2@GDF8&B6:B\+_,I^*"YBDWIP'3WF<UPERP?!0YFGE
M9Z2('M/9H+N=J!-TC%%T'H/4#IH#L[1H'W3PS/Z+:2%@RID`PV&23E*`+O(`
MXMD\18>(0N>!T#5*_'(H,$[Y"2(3#+<H*+=/0_Y+\3#GMBL'8QZPDWQ?BPQ2
M6]K%#Z`MEYL[8!OPR%=Z&,>CT#G%OT6$7D:\%U((GE@F$0,#[$GZ@A]0QVKQ
M;P(DT[<Z:41]'_-0/]HZV&2:A[N;H-FV0;-UO//S'V4XRO(>HLB?)T"OW&.G
M`!8!..SUAYO&J0HOO0((!7TGN1M*@BBEU8@HM1;:+GX1X])^`#R`F83$R203
M929.DCJIB^X:BTF5N@AI"\X;PWO$]>?(1FPT]7S7?Y!A;YX(%7ZB/OG+L%?H
M%:S4E59(2.7&"UZZ\/7]H[7!Q.OFHK$3DMVA!:26X@@,A__P$6I)LYQ4;;4V
MH>8F)?[3=T]-J::L.I&^[@2C>!9&^"+EEDPZ=X)<'J34)Q,R6<C`@;]@?HY/
M^>G.V(%7*+I4T#.B&$5ZKFD/)7D&/+--&']B5D5+.P6ER:=[N,_2?_-,J9</
M+!E^4=SWB)L])S+]9ZG1%,;W(4]&3-PZ"Y9:DGS*K2C:7HAPB;!))%(S%[\M
M$*#)[Z$=%0?9MD4`)GODF>?"!18((1]AYB%*=I%P*5*BN'W-N0"=9P!<*#$B
MO&`"&]E<48$I#@L@6$'FIHB4)J6"3)$?2402,-%\2:"(:&9D8P,H.8L$$#YV
M@(("CLL<5@*5:F#?9":+G>1;$`B,TZ`ODX>5\8E)^RA-)F[I6C)2,3=<1<<=
M%0U=B,PLZ4E@U\VS%._M_,O\S`^CJ\DM&@'\`T>465GFDQSQ@(@F3&SU%*^3
MB"X!,Q(A9!_*9U((/(/.+9',S?\A>#'D3`6[Q=AZ#8W/A9H>+E9D@B0&LL?9
M]/H7\B%U9(G0Q^1WZNF%O[!'?]EPF`<NH['^!M[+Z-Q^MEUZXW\(&=.^^1'3
MC,Y'X,&I,Y_3;A[RM#=VN8$;"MV#S/4$+U)VXD\FQ*;W`">+6!+G?2[DN>6<
ME.>Y&S9BSB-J_^/CN0J\8:?2M9/BI?&%%?G"[FV7F@HZ7NH."U*<)2HQC$)E
M*K`(%84+3A(@9]\9,5Y+EFIUG7PAZ&;C!0/"LT-?0>\(327CVV+9QND22)2Z
M"=@"*T&P,LPC7]<3'0.WP-A_A+6/R8&$>DO+'-Y;^K#;7Y;E7,B*RQEL:6E!
MPXB9]/B&`5^J'2!3+BE]I+`I`8+^3%*=@:C6:FFD2IU0K?I%SS%8B$&()]7%
M3S[PW;T-_,N=Q))7&7]I,E$/:@<!%5<EUK):"R"<K3AS\0$T;\#7T[.UP]SI
MG*OJ\>_1RRJ&&R8:FG.C$ZBEPOQ8RN.)/,A*XU0\/Z]<^(/T*,:7PX6JA8`I
MK5L%$*#=X788O46HR`@-!T<:UZ%`3VZIIL:T*%[BAKXD`E>A(>X"IYM-[P*O
M7%0%_AWCDSR2KCIN^X0C>D]]`))Q^(L%[*C(_@O)T/'H[<R])/3<%(UW46(K
M1,'KQ)/7/L$A?)3<Q`08\'W&DX/%Y6<>Z`IH-/M2%)[S0O:9S=L(AU/F3C37
MF1!K)'2\M-I&A`02"U,NG6/!$)TUF'**>@XKT[-82U&EF(FB-D=$<L8I#U+A
MM>@Y7*B_EFFEA<P@D7QPZHW3]M>G%!5I])E2:HW7T_0'WTA^@/'H,/1$`*VJ
M)=6"7\9L`OP&LAV;2Q35]>;K<4EH_P^\#;'<V4A&\6*'';J>IRG.NO5$:2WZ
M7Q1_1\8=*$MUA2Q;=,.A\L-8!HH#3&P@9^$]]@`'+4T'2G0HMS);V@5W$Z$3
M)G6497=5=!7:SMFZ6Z5Z>'5`D7L-9>OI)KS8A!>/-#"BYB!0Q7^NZWWQB/`T
M<X.W<7G,MF1(6Z8(+^WRT]<[*-:$!]\>%RRTWA$^4M@^P.'DS!LW]%P!/>^\
M84/DZQ/YF(UP!_DF+Y#PLD6-/7<B`.X_/#B'YB!:=S\B1BGG2F3+H;YAJ39`
M5^&][__%#;IRDT1J0"L-*[UA5N*63M+BR8X6'RNRMQ'&QI)(_),#BF7LA-A9
M9]S2-N&'?9>>'?X)F[8N2M^?V"E*D\$1Z:>UM>C)/PDC-D_2;H^S7TJE*+U%
M_!A9?YAPRX5)$DR:^9P\[7-TC9G%BT]O-?K+>Y/!!>$_Y"46C84J6M[AMZJX
MV/GT)UN3*5QJ#J22O,4=<=+GONA=+]Y,]>7?/VN438TJTA6M(L7`J&<99Y89
MWKF<=/B+FHV.;Z&"[1+'X939XQ%'6Z(QY;!K/4W;F;%HBF7Q%`E`4-D,O19S
MWG$.B\\`Y#2OO*5=3K*AA33XMB">9'D9WF5Z*YA7)?TRE!'W@X*0*.$2)TUV
M(=5D2!A6.&ID7[3$O9OTV$,GD7AH<MH+T=I&,0XTNM`2C;A>GHX[G%<[BM3#
M+1"JAPW^`D*PI!DD!.G>;:(0JKPP">VK\*4GA%$H5.`6L4:V(#'L93K2<]R9
M8[ZE"^1)!`,;0)48;8I"E6?QGRK?8D`>&<J#LX;.S,'`&WYY>9V'OD0>\K#9
M<GY<DY%6<6G*'C@;.K$W,FE](MU1;IRI/.4AC^*RS[7C$0MQ^`2JJ^"<[!S;
MO9I\\;V'+^A@;F(:28P^O3X@!T30"6&H"6HLP1RAB$<I;%'.))-B03QY5%XI
MR'V,A.[,><#"2QO/JO&-$)-V_RU*I8`]@!'_(SC:IH[1&#81472%U3"\P;!<
MGKT8:5`#"BSM)%JDG#U^)-*;/#6'V!CV09N_A0E5_!\HJ"@A6@@Q'FWGO9L]
M&D-)O7)GS,:^$$FEN"UDLA.FHUY7P8'V2SK;TE,LK\4NY;GT@P?`3T#?NW].
MU+7-FY*O,$_DSJK`4Y*.\[OF):#HK4IJ2<UJ3C.0)"K2YJE+I'(6CB7)X?P\
MI^HER%<=?H8WZ,;''P.LPQ'<YS2'2M#%8J*Q3`L+IXQ%(ID+-40N.V7I!08J
MI"XOJQ3)G"%#;4H&+(6R"`87.`J6&V-78=[@G=O.2XQ:,K3&0J9KV+-GKHU<
M^#"?IXI9`D"')\`P)Y@(D"(AS1Y3T"%T$V%3,6@Y]M6MG]$VY`]M>?"E2-.Q
M$[#,ZVX,.2$YS],F%S0(1>.N.S4%CP"A9J.(>BR+S\YFEC//$^[2\+=.1H>1
M,947TL5I$5L8"9F:><P+Q,;/IYX'I#^"KR1MEJ\#G_^.LO,;2R/Z))&E86L(
M-##2EM199#4VQV*NH'8:/\`O*$65L\3GT]O?0-$0*CWVQ/5;BM*'&`03"B2N
M:"B_(E/]K=KYF(R'OBPAZ/B,=IZ'I*'?(<IXY.WT8\G("JR1AN="4E;DP]:!
MQT4]?`X$*[:,21H83WP_\C"#?IPTC^*&BZC-SA@PJ`U`HZ8G$B\,7BN#/@L>
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M*8LB(1B]H:YH><[@-1)2*J\_9BY/9)2IE?!5D8:I2"?\1%).`,^!9#C#*'L<
M617.K4!B_##&DATFI@K-1%51QM<K5U:G!TD:5QW$,IA^(MVMR:>$\]:GF@/X
M@C-WLVAI#Z6'F$==I)Q,+9.T`QA6!K*Y(TI+X7A>..'F,XC%&;6+I[:C*!CD
MD"(2KLGA22)E6G0%;.+";:4I:]G:1?AV*D0$9/R!))\)]$M7U%S^$*EQ?"8$
MO!X6`:)9%6`A\T$<><F1]",3>]%-?3`^:M)OG1D]]"'\R*_73LX(5&KF/IU)
M``+*>[!SZ=M\,?BF]3&55@E"",_V2#1!@2/`!SL?D]DN6N%GI$]*+JZJO27P
M4$!9^]#]J!BEXN8)%DI$_$`%H!_5ZPCAZ^&$<GJ7+-W*D)LM^OP+)^)21L$7
MXSP2UY@XS/&Y)70;N;E'_IRWW.-UN3Z09X)9$D6GMW*NE*H@<'A'D=9=T&-9
M-B-E1W#D]"R',OG.BWJ6%Q/$@*)1.E"G2/F2>I0*.*,1^;-7T8K:_C4BP5"H
M%45/K&T?%B]UPTO[FIV*OAI7*25_41[9!6WQK(7F7M1#[4?H_.(Y[C_>14',
MWFD_5PG"8G^QU6W<=MA^C8YC-XF+YY+++<=.W--R<<6#K2Q^RKM$?6/1BE/N
MV,[.,``1IKFRAKN,$Y2$J/TCJ#^PVFUC9_R\A!<BQ(L?.-HE9%<3I47BU9SW
M$Y1=[C)_W+S5WI*^L<@.75,PQ.9PY*_W"A4&2"-@=O7<9UR:`C*^^9X0K1L(
MD:*6O5OL6#*P2\2-,X8;@0?L2;M]TLY+GV%9L-^.IFP<NW`;=`]3WP7K+KP`
MHHN>L?C\#SL`ZR4*KX(;S"@*WZ1SZ12>`[,9EH"@MYMCA-=EH8G%N^HF%B'5
MABSZ'/EP(^=8<W7J54>QNLW^%MWT]SAF.+=JG><=?4N:/'.IK]VF040I&+2K
M."*[%'E@^_3%$C#Y]N[G#UH-73F/#XM-O.X#[><,WVR]C]3G&G61WO,M%V8#
M'U(`E$M,=9@-=,PGVH(\=AN*UNU4,RTL$:A^*E"UD[3X5!DT5]MI:9LO9K;W
M-NQL8!IZN[NG86>U6&P7;&T[O&Y_]]EM#??$#B7)F$.,>OH=90I;7HI40Y52
M8#=41T0G1XB9&G#[\5_._NR&"A`C#?*&KY=AZ(-AM76CW2L'0;M`\K$N=_3Z
MY$.W90[J+R(.H?8OL.75`<3#6QHQVI@.-18-C>FPB9N!BDBX34%^_I/%T$4]
M1,EZ(V)+WF4_%-L;MO5A9_]X;H3*^E?4:N]Y`N^QV!M)),+&PJT'M;6E.J),
M-KBDB0>*_'F20LGQ1-%&(X'V+X':K4%)[Z4ZB)]*GJ3["V+48LZ.NUC-M'7"
MR(K,$PPN_X85JY@\R;Q09$6%4>!@K25M]-USHO`4!,7X5"1>W"&"FGR4)0VM
M;FZ_BV(=D:;"*RQY88SC42)PTN.JR5MI\E9>45Y$FK<"7!#N8$HV62F[9:5P
M6Y!B4-HYED-\QI+M?V+)]IYO97]O=B$9.F8U<5FD:"WV'D$[`HI??7Z`T=M;
M/-G0K<%0'_::#(%*,P2L_=VHU3*&^[G,(WZZDT!Y:-($5B+)[.F=H7F$Z*D!
MW^_GAOJM[A'XY@[C\R<6YQ;#$9+PGA(&K+;>&VZJ^YM\@>.2$1VC_C+B8$;`
M"&N179>-`3_!A#G1WBGQ+:4/?##:`WW8Z3<2YQ5+'*O5/@*)<T"K)/%DV%$3
M\=M[Q,_0S7Y/'QA56LZ-#-E9AI@EF:6O*/981L@P'Y$\L\/IJ3?&_\%XYJ/M
M8N^3T^A,M!XEO_6V[0:,;K<_M-I#9?+Z.MN5!N,Z34T&IF%TAN:A0#3706.[
M;75[1G=7&/W9S(FHMPU^UQ?=6D;E-*79<I<E5_32+O_-;#>:PG'95?!@>Z*Q
MLVS?MG&#CP*<][JF->BE*%^YX\[@60IX6R+^BS,"F<#"$I'0'_24CANY#;;8
M?XU3Y@F_O3X`MSB;6/PMW]YF:RKHM<V.0@6Y/;8`84<<O`!`,>%]9=BBW+V-
M>:,SX,OS('X(+WZ@%BF'7=I#<V`-7V*7U8!4=9@2F.OWP`_#Z\"?.*705;?7
M[[3[RC2&=/D-=]Z1G%9L?,M<,*D>`+]?:4X<_%PBP9C6L&T,5,)>NMUN@&V*
MH$%W,-P*K-^I+3XV\SH=SQS/`;/,QF9^)2)MT![T+4,11R_L60*(FZ*O.QQV
MAAG2W@Q$,&>9'8S0NCD'*>?Z-..A5,+K]52MMG+#G:';F#U[\%09F%N"=R6'
M\I[A5`#XBOA<6(Z([QL=HZM0W]+M=H)K4Y3U>\/>H#_<!:Q+;^3/V!<_+`51
M)P9\#@1\$4CI3EL"LREV3OJ]P1+T+(<%#(OR46(,C+:5@I'98V,`MD!#QS+,
M3H7[_TM\^5^GHU$\BRGI])Q-G)$3\?$,"O_>1O8#6Z.18ME@%]Q;)6!O>-T7
M=H!E$^$U"Z23PQFAQ'/<F(8!;D&!UTN:-IX8+4-I3?G"UB5`^B*I+H6TW1H,
MMH949B2*A$2>'BJ<2$K[LIU1O03XH6&9PX$B=K:#I[I3K;Z6):<:]+J]@=KY
MM9Q3G<OY/)B;7H*XM?I61^$]=?E-M][8_NMUA^OM7.S.+,7$ZX'^-10PBK?:
M'J!-D6(95F?8M_8*D&SA6^0?OKG]?N6M(\B!U@VK7QW<1?JH#+@-RS*-?F^_
M@$M%>C&;N_XS8TH'X+6:2EO]GM79+XWL"')O,.QW-\8RV`$!@P^=,_Z_EYYH
MP1YB;W;GD5>OE"`&S&%;$=7K;%L6J"5XG!:WOO1P(*$?Y#WIV[[GNL-NI[L*
M/\J&.T-7"4:N`S:W'31761`P^<X#/<N;0_,A=V6@RC+Z9G\5JM:!I+KS;.YE
M&/8ZU1]'\LJU_4S-W;WQ8K_N4LR=3M=273K;05+=>39^K)K6<-#>PX&DV+_A
M)9*E7XMI=%>2V?+]RX9]8XO-;,.[NRK8Y2@I,(_]T"E'1L&;NV=9JR#.[UH.
MG"4(]F\LPDCV-9]D-_[M^3M8$)=>XJ@2F0PED>5)O]WM=LQ!QC>QYO[E0KZQ
M7.ATK,&PTRD#<A`<%*._\\6T#5@#OA4]7[LVC4^X2.8KEZ%`^R#1%$-Q_=W+
MA7M3C)OMMNK$VA[L)1=U29F`Y9/XT&AW58-E_>W+!7QS-VT6X=O#+:_JLQ_<
ML'DY8V`*#4,UN^GE3<L!<V-[;VCL`B1\3'SG:G+.[B/*/)H[D>U^03VA3'DJ
M)\[4L11PU]^\7+!+T&M`MC1B'%<4+4)D$]-2,-4SC5Y?T6.K]ML5MI+1@8.*
ML?*B#(ZL9-\M\BJZYL`RBV^C<-LU1>UG/MJN;!W1'0X,ZV4CJ&#W<N'>"M&]
MCE$&Y,5IE-<T,S%O#9=C>EK`L(:BF#>!H&SH-W;M=SM6;]@I!W@>#+RS?S!X
MPSH+X^BV3I#)OIIS6VP'Q.;>E4VAB%@`]@S^N91W=PX+Z>J;[ER"T"=)Q\?2
M\W`R)P]*4.:_!COD5H[FK48![`S#QA1@P2M-=>5O`L`^H%\675G#Z6\.S.&P
M7Z.S#=.SP<]6.PEJY,ZX3D"CW>^V:W2TI?&:PJ/)R-EY<./#/Z/_8\]F+#BZ
M*P4F;RL,W][M2LVAT=OU2FF^9VK"42HCEO+@V^+.5RPZ^(ML!8B_]\+8Q5?J
M9R>8X7-+>-65/[#29=[>8=T\%C[L#^04X:H`S6#CAHU<.PQQ"CT]]_`UR.,:
M5Q/X7YDH>(D#C#U&(\MQAC9O[R@_4L4U50;8YDF[/7-@I`.R=X<J<\YT^NWG
M.``HXH"IOK(_'$SR3Q_FI=A`70LE^3;;EPWZ#D:4F+3MN)A#1!O(,,/S!A5;
MZ5!=`X?JEK39BQ-\C1,CGZEK=9-QR<4;Y97).F&NK:8BOV0R[K[Q6AD*PUY7
M>8)OMNF:BI=GLGUC3_2G+=3-DE2X7J^CUONLMWMY,&^5OF<:!X08L-Q)L0P_
M;V#7++N#06]PN`-UE2O@/YO)@6[C^Y#]'6.I`J:%9`W4:SOX"^MJ6!"N?=),
M.OUF)R5YDYH04J0K)H;T?-*H5YE?6VK6<;<U-+M"]&T.2N8D]#&YQA)35C2J
M3D9FE9-4.NCUQ1&V@6$]MVPRJF.?ON!5FQ)E6VU)Y2!KC-54OKI8I3,<+O'8
M+X*3N7:)Q^3/*?GLZ$1?0K*&:?4-2;/K[E[(<WR#?3#9`H^MV'HC05BYHV7)
MD3JYZM^-8"S_A*O27G<\J=DWC765V1Y.NHMC::GU8;SL$]SG`2MQ+QT+(6_O
M9%IQPET/2+)+%I%(&::(5_[%TD1\Q^A@"'"]71?#3^F[-_S"PI"QWVP7-=CM
ME+&()XG^]OS5_K<?G*%'@7)'EV;,Y(,O&SRCNF9OD(FIE0W8SD=?NCC/IU4K
M[Y:4XVS2T::GYN3O!]9"O0]?5NG]^]SW+GYP*Z(*@Z5G#8V<^E\/@@SPHLG(
MZ4/`&)Y:Z6=SSL)1X,R7UX2`'#&M5*:8'2DSOP?.`_.N`929/6(QM:@++[V1
MD"V_IHV?7APNLFOKJ96]-W=IV74W97SXBN?AV*O(80&(JL!_MET9^P^=,)+C
M6P"_0$0TL.*#\U%[WVYUVQH0GC;V0Z;3Y)8/#OS!Z/ZDG>"(=?PDYJ!Z("A"
M[(*"O_CO+Z>ZANY'6I-O]LS!F*$OA?[F>%H8CZ8:D,0#`ZJ9,SZ!"ZYQR2`9
M^P'`>\#A#>I.VI@D.7UI3N)<BWQ$WRBSO2;2CC@8O$M)2P/T:-C_8!;/-(&B
MW.<EAFB[#_;'9$H-OCRT$4;7QW9`,VOT(A0:!D<2_BDY``&17@*ZRA%H3I#`
M4F/&][CXX5!&G09O&E?TV<F<%UB=$=8,4P/&B:9P^8!`&_[B!S1@Y]X&Z)6;
M>S]HMW50BCK!`&@,LZ!I)8!5A!H"X)ZCC]EP-_+O!`>-_$%)QNP)($\O1ILF
MR,=_PH,]JW12"*?XA1`>6<0Y`,<"")P@Y)(.W#E/1V.$!Z`(0;()BNX9L#4-
MER-R1TZ8.$&(5(-V&,AAEXA5TBIB843=MV+\$AS&<1$@@H#AJ%RN9,3)Y[`U
MOH##^/[?;!0A$/AK@7/9*W_IB;/'@6>A!@+.!WR"%*43Q>0<EY"ZG$<Q,\3W
MJ(B*3>"Z8'_XZ)@7G(L3R*\X_V'\7*.1'Q`A"A#A$F?$,K8V=EP$:@3'`>6E
M["YN<&X'B$N=\RS'A-CWR7%=S?%&;CQF7*+X<03'!]E/>-*7B0J'<E&)?P&&
M]\`<L!(BUO$RT'-LR^T2T94`HJR#!X]`O&)'0VQ0#'>OV10<@]-P\47;>2CL
M_T*[R0E`*V.Q\8@)#@2*@DMF(T%0L(+#'<=CS7^$*S0&H)X$(XL95X!3@D2Y
MW8O)!",\CXPFV;06.S+F==9Z`\2$EEY/U:Y*F5652WGJ^(4,HXR=7P1-QIX0
MOC"PJL;Q*%*:*5RF%[XWZ,VV`']=T!;B(N.Q@Y=BNY@S=.D)ZW*9.;=!K\A.
M;]#)QNI?WJL<Z-9Z8@#6>AVU<<3FT,ELJQ*;&16G>BWI#K3&_J54:4K:X9EO
M<M=2CFMVU&9\R[;:!:1-0^<=J]_M;@[2-]_SLWUXRFQQ->BI:%JZUTY`[8BH
MM8%:J+FYG8(&O0.EG^*ZI+J#MM'K+TKVE1N7!NW&*1O%:F@C8&5>!^5S"/D%
M9M98I-1DRWW/G7#D^F$<O.;QH\GZ]_C#MZN["ZW7TJYO+JY/+\^UB__O^N+;
M[<6M=OKM7+NZ^^^+&^WL^\W-Q;<[[?3V]N+NEB"[KQC&'0:#5CJ@55`-F9WT
M3$,SU$<"TF2:A$V41."(MRZ:H_P!DMB@S:35_4]:5;'2S/_<POF5R(SSPGD.
MJ4QH9K(>_DZL@]W)_F:7"`G2JV@BJQ3V(3YT3NYMD6,B4G`3';`A>E__(-`]
MCG8]J3?RFYO<9!!GK],,=5U7)J&I>82S?>HI%>J`F6/!K='3S<%@OV.+CF?T
MF61/!ZR$`",51TB)>Z(CT]+[_=X1XN=8,&P-=:-7)8*/6(V2SP_C_8O>G+'H
M`[9WRGQ+,U(-4",]\QBG$[ZE6S)-?=BK<ECG4>OZ.S^RW6(94N@1KH4\66_F
MZ3Z?FO49FFIVVGJGTK&^S577Y*J-=E=O]TH:T5V+Z:LRLG/2;O57Q7;4N06[
M14;SD5:<_Q!>342!+U8#@*X:/?/_?L7QU.710MR`//"$&@P"`FY#N";*DR.0
M]A1(+2T86"F^KCSM,[L/8CMXULP!A3',3$XBIA92NA]/.]9\X,>)'YP02VH!
M`Y,A9-Q?KX5SU^%IAKZR;)\'1XI7U=(5)Y@/6+!@2SMU72W$?'N1"#ZFA&[Z
MC4BHQ7Q)7)_GE)#%1CFO$]ZL#7-8@0(83Y/`!3P_`LP%;.)25NJ4"8A"$3<.
M"T$)6PW=<+JYG,T#9P8<ACFY9)!A"BCE.H,PHCN6>9\O7PC<'4^_1?<-ST.V
M$Y&&F<[PC3GFRS_PH7_N,_Z=S7%!?N\:E@7"OVYQ4;K#TQF<9603!!]D8FW_
MT^^GI]?R7X-/'WE^L0KR&O0CTGF3TQ+]B70#2=^4*XOYOU,?P#WQGSS!06%\
M'SIC!QB#T[6#T;Z1_)9<C5)U`]L+[1'O)#JU@3GN&?,TALG#GBW.GD(+'VL5
MZ9SU=,3"2$??'V/N,JBD2Q">WH.#G2-(+^7_S5>JOY(I4[M@_IV+H@/K+61E
M4U:[./@#63,_.WN%M%R140+6D,5&OBA`L2F/#!G-47$XESBD_'W4+:'(+X_#
ME,L#,;52>(V2Q&+\^HB%`!7G35R>EQC@3Q,FWH@S!X1(!/I&EL9@4CL6BX,F
M>>`)[7*'1-.HNX@')[PNTZQW+`)RX`B<39^P`"0C"%`^@K+1'+P-9^*@R@-Q
MYP+7>S2P5)O$V/Z'*AED90Y'DI`8'!L\_9Z@3>W&M7;?:F?^$`!]AQ!\\\7]
MP;/:Q\H\^+N0TBLO4RRB""\5=BS)@*5T!&GJQP_3#.0S^YG7IO#:`5_YJC:"
MQ6T2?D5`K00E+7<1)#4!*QL^1^4[6/73TLXDJ<Y@#]Q'*K*5"^/-"/H8JP12
M*),WEJX+E<JC*1O'+A,CX19F(_'JQ-,8$!L@LK]C?8TRA0F+,,/?GC,-#&ZP
MC.T5/QH2692D!&H\SRZ,9_`A0!/>V@07I9H:^QY+=;CUYQ/6>(JAG\[?(YYD
M'(FTE!UI"YE:>T@\7/<E^LJR#`NRQ&J7R59Q?IS1KE^"'!<QH:8,JMS0ZW-<
M=]"K[Q5<I+)ISU>P19RAX?&73GX4<-<1&[OPDIS%^ZIE6$-C#3:.%1N-JGDS
M5WT$V-A%U8AQ[XVF:?1WP[@-C36:K^8DTV"C+`:Z83/A:6^D=&-0-)S;D%BC
M^5XKQ?"6P(U,*A.G9_#AP*;0=(/8,A$K0^0-5AL14&^<'HA2*]3$6Q=^[?02
MH6[._D3&3IE&V3&;%A,=*['6)X3]1K(':HCZ+\X$^_IJ?S([:.A^S\@G:=,@
M?;](/UR>S)M'_2'H?0N;9;=^::4VK#('%76L,EN=MG:BO;=:9GO#&SGF+E];
M+&;LKTE7EX9=--=1C^OHM+J;EC#7'WWU:H"W1]YJ#1K&JLM=O#DYU_!6.?@O
MR9C;MB?6[EU'=B($J]4CFPT4TS&V42GWJ51A9S>KK_=-J\%PA9;5\!B;D]5`
MN._K?JRF=62%^K(/]H_1<$"M.:!C5G@_^W-*U?/.NZW.$"V9?JO?6#(5]F$;
MMO7NQDZ,.N#G6#`\:/4W??K4`3EO1H[W6KTJY7A]5]@3>MNZ830,4&L&,%]Q
MD_(#W_B@U>ZA&6-@+Y;7PP6U$S-FIZ,#/`V&*\-PO]5^10ZOUR?&!ZWAIM.;
M:GP_M2-_HV/HO=<D8%X?!PQ;E?:.?^L>&1-L&0HN#=JMC4.S=6"$MS0YI*</
MCO*.CD4==%M&8PW56!=TVJW!,0:H&AE5_SMJF*A>%M7A7$-'ML(.4XI*WF5/
M;S:];0YUL_.*A$SM#*%>J_V*_)JO3X9W6_TJ!P@VHJHD[ZHYT+N#AI-JS4F5
MSDLM,(8JG5<G\/7BF!B$(S>PHOIY$\LG7%S,YJ[_S!B<ZA&^5@S`J0N+T$]7
MDQLV\A\\FJL'B/#YM+U7/-AB]>0=.5`E8#AABR&E`A9.[A&#VDA!(8'T(1V@
M0^-@9C[8Y/^AOV-/!/6[<@PKCJ"*W4A.VM$U)PQCFN0%7X`-9O!5/D4#A\R$
M_!;Y0!Y[-`IPF`K](5V:(%%!^PC0NS3A)?(U]G?L1,\X[ST*8CZ1ZR&P/?E7
M02T`Q]B!,T=^P/<28-HT7BL40T#"/0SG6)?MLC+B-<[K*!#>QU0RO:>"Z,]\
M%-,.&K%!:DV0NH6[HV&<K>\8VY5H%R!8FU;/KP.O#?MLX;VOD!`61IN]$3ZK
M[05L&I`\NKXIW8I:G<@W9:B=P(O$=>4L/[#=_V+1YBW'WD#I^&!OI>/]H6[V
M!_6^@>8ZUT]3U,WAGFZS)/FT;7BQ+(DDQIQS%\EXYGA.&`4VCNP]0F_QGK+!
M]?:PJYO=8XQ\'`N.#;UKF'JGLRDSU]/"J)B'EXTJ/T+ZW`]UG1PA9HX%MT:W
MIW=[1\"WA]"\YTF8H-&\V]!6IP>Z]Q6EQM8.P]9PJ`^/(2WO,%KW3`GLE?.:
M?SND-1CHG?8Q9DT?"X*KM&J.6.=F>;;1NEMIW7Y3_EFE:.Q8NO6ZRPO+X^#:
MO';?4C7-0.\/CE$"O*4[,HV.;O6/H&W<BU:`R#$[<=D$@#+A^)4@[,Z/-AYA
M=]#D\UT.NVGPIC[9ZZ;>[77TGO%JY$]SV2L<$+IA=?1AOTHG3X$8JS09?M.\
M]Y*ST&6Z^^77KW_^<L/@O>.,(C:FE/E+2L%FXTOOC+*GZ9<7?\?.H^U2NO.:
M&>Q:[#G\0SP]_QU89B,'<!7^X]WEM\_O?C7[IC'XKY^W@2&?KO\9'FT1^P)/
M-O@*6(4/#ES=:1BR*#Q5<L@O?B"NV.DD8@&FE7V&+V2.<QI>30J/\/WV7(6_
M#=`/!\:@D][5#B!D;N,Z8(^.'P,@$[SHN3UBIP&SUP/S]N\84/V9L6@!V]:@
MWQ'(7K)%CB@D_7QA0&=??#A)>,/3X.]\_CO'OG=<3(;?F"(6T6D8_7:[G5##
M^IOG2>$+</W5Y"Q@8R?Z;(_H,U_M'\XLGOWF!X'_!%;$F8T9[#G`LTC]UR@.
M0?#]ZQIH=V:/GF%!NK_PBSOZ2EE0*X_3[])IM@%JH11E"M1SQX+TDV%U<"LP
M%^R;!^W,M4/8_0\[P`J(J^`&96VFRB;Y8RC^&AI%P'=/VM:)8?Q++/ROV_@^
M9'_'P.H7C_!?18!?+Y$JW=;0[*:GV`K$*L]IGIB#U>>45WAV=L7%/CYE3Q\"
MQF8+G_D??^I=W]J(BK\VP5*_9?5+1M)UX,_!WG_&8JOHU!NCN*97^/>036*7
MICJN)R@2]'P%F0HL(@[VZ[7U9PKS&MOM`T+.Q`F$W>T@'#/GEPLO`N[_I^_&
MH#Z"Y\^.RX*UE>VOW_S_^GGI*HO;_,%<]_]X_I-W"\+4]T!GA6',@BVW6[+:
MXK9G<1```F[8'#6B]W`;V5&\_B'_9*&Z;?%JB[M>@[7JC#Z[OAT52\YV[\1J
MKY2+'=1.)-(+EUV4V<AUR@S9HGW-'"TIILX"*R]AXUZ_;[9[/55HYS;>"C)K
M=\@&PW[;ZG7*ABS/?UM`!NIA8%K&!I"=CK%ZCFK][OS3,>AP4*BV>VT[:*#:
M<R>RW26%J6D-*M@OP/\AV(C"AN=VN3!UJ,*Q!#/*[/3`+E6T^)Y@KS?*$G)9
M`LD:AM&A$4MV\:4H;053,J5[T"SJBO^TW9@EMO)94AV;&!#AE;>NFGOA`02/
M:&&PEP;8_HYK*<>UUCGNP!P.^Z_JO&M)T0)=^+INO0SA`+31?:6T<3H:Q;.8
MUCQG$P=>J.=Q`(N>IV$VL+L>6#&:?H3.+Y[C_N-=%,3LG?;S0<79MO1^O!=;
MD2X<&MW>*T7*8:F=FZ(K#R6LU7*%_!)3N=-.?7)E@[]WW&PK$%;@IF+4)`\4
M<HGCDWK,J9%;B<0`Q29F&0:/U38&[=Y`>2=M#$8U!UEUD<)+M8X0Z_4ZP_H=
MKCPSS3RNPVVOCCBA]H[CN.L3:*<WZ/?[99R*A-22KW.AHTHJZ?<=?_;C0H=@
MR4K&-(9"CFX'8GFNAUP0\CL`OIT+HMRWUH$.=F1XW5Y^G-0`R43_9VA$N"XM
M*VDD:^7>@!D:A(S^<CMWG>@SNP]B.WA&A)2A]$^,H2&X<4=H#G"R,FCA=9R_
MNE=,T4ERMNW*H_#/[D&MG%C=%1>Y.<CK*%.ZTL]^P"-#5Y,)"_)QC"WY<MCI
M]KI=8[6B+-Z^<L"WM4\-HU?O\VPO1N"Z.IV$`.MZO.JDQ$I+KE(Z6VID&KWT
MP;X9>"][*K[/?>^?H/[APU>3FS`.]R;E7O30+`%MS0>/,+TK?[TNO[7.BP^@
M53"^?'4+MTWI+K`R+;B5Z%Z>F61V5UW5:E!>U,)[`?S%C;=@EF\LNIK<V3_^
M<*+IU'<70O];QB=/#,MH#S?BC0)(]GJ>[3T]QWC(7:QTRS",(SWUGB,,ZYQA
MN;K:*K';&'97QLS6!^D`Q]M%7U5T\"6*#_2%=(2EZ9EE2$ZK/^CU5YM*A7M7
M#?2V/K1!G<^R@]^[/WC)=7K@HQWN@5$MC2TSQOL#<RU?]IK7PC\L%U'OYI9%
MD4M10Y0O7A38H^C<">=Q5$IJ5[>=>RMM!<E^#[2E<.@?ZS&WEQN=X7!H'>VQ
M*Y8I2PZ1\.V>"'59OO>@-UCCYM:!=L$#X#QX#B`4:Q5&(S_VT$JY]N$YZK"]
MCZ]9MSYTK3$TN/(]_O#MZNY",UO:[?>O7T]O_M2N/FNWE[]_N_Q\>7;Z[4X[
M/3N[^O[M[O+;[P30]=67R[/+BUL"]GZO8.\PI:5B%/YFATZ(DW6NL>>&%_'1
M/0V&/EUYFHP9:.:`VJ.;.@TQDA.0V&3",#I(@-B:[[&3B1^<4'VR%O``!("&
M3!9B"(*:F?C*LGW>=+UX52U=<8)5K04+MK13U]5"E`T<!EA_S@+^&YRU%*.9
MY'BX?DC2C'I5T."CB>/!:\:QX?MPYSQ?B0#T_`@P%[")"V`09!PB(A*^4`$H
M8>OM4LKE;!XX,^"BJ1WR*58!SH["<5>C$;]5X59(T$\0%5X!W!9^*QC3Q*LG
M>$;2O[GTAM4=^,;<!8A%DROW&?_.YGBG_*8U#%3#O[!XBM&MG<[@+"-;^R`P
MU.E_^OWT]%K^:_#I8XL`NEL%<C'%\/%>+#DM41PGE(2BD:J`0K0G>!"[SR?^
MDX=3P^+[T!D[P`:<BAV<'B"VYL0L5\.O@Y[S0E!UF"L":`9VN&?,TY@+>/=L
M<?846OC8&Z;'5+;'H>.Q,,2;N$<\(?H:V9Z=8Y?0&0Z-NY<8&ZD80V#N^<0[
M+&)/AME1+P!8X._8`8[7-5>4L#LXC@Y,N!G^<B2L-)Q+AS_#MYF')I@NQ\CQ
M7U$E([`$"W@PQB;AZP3:Q'8"`N$1@X0A:A#.;3P3!3^+#-K2\%3S.!B!&&(H
M*4!^V$D#"?B%/\*3!8S`#0%/'IC5R,8XYVYF_P4"/349-?1JS4B"4!L]/,X\
M10>';@$(';XV9R@D0"Z1\`KH%[2%DW11$*C3DTU6X&%N/Z?*":3KB;(G@9)!
M:DN[^`%$Y7+!-PH<:E>D'`;D!.*1I!L+(MOQI+A:`"\CQ%"VRYO6@%)F]K/\
M-T$A9.\DCN*`)6+Q/@:M#_\&I:JAK.)#!3<9$G@PSMMV.N`+\&XW''!%4QBQ
MH-F9_]BX<T^^G57DSQ,(TP4+6MV<A,Y_&#^PLNFPUQ]^VK"GS2HA_M*N@MC8
MCSFW&$=V.-4F.(92F\!+#EE^'`/OA;:+-Q#&<ZRKUNPD05U7AVU*006_]8&4
M`XUW)!`UY.(O?,JF8`/1F`]IFHVFGN_Z#XZ0%W-@-MC@$_YC*48*6XT5X*J$
M:]VI*63F7M9OFE;E26I+DV,G)'VJ!21NXP@4XG^X?89RE\OT1!RW-J&-]?HW
MO3)3Y3L8W4`"SIRT)'M,5.'("4;Q#"O<1Z3,N=7LCT8Q3J8$_4P:BIYNTCJ/
M@8F?47G!38#M'3W3"-X8VVRFZIWS>*HPR28/^#!<8<:`3@>9`;HV=5FZS_@]
M#@,8(*".Y6L$S1>Z>B85K:+`3^0<WJ7J/TP:JB``Q39'.F.8;\U-%!*!$F'8
MG6G)MP4"Y'<1;LR33S$`8`.8[!&M(GSZ>GB40`C)"*Z03)DG!UXQ]RRQ$L4C
M#U9C=N!1DQ^!D3FY]"0V4A-(P12'!1"LI<C<#9&<.C@.B$@")D8J"Q01S8SL
MF-[W=+^(\+&#J2M<G>2P$JA4`YO%[I@_S6P-/Q'@2Y&[#H3)*JVUHB?EW.?G
MT-7')0"'#5=L09>PHZ+A"I&9)3T);/,6C#[=J!UUSW,==9OG8.I^X^W<0GPZ
M`5&'4:C."I=]B1-WF]*;&&4(4-TS&?P@DI#%QBWM9DDKXW0GXM,P(EZ4OY/?
M1U(&$H>WZ0SEF]H7F6#([#^*G$=Z?:HB$8P_.Y!FV3WSV,1)33P?#(PIL\?)
MQO)1FCOWR'4\>DA%R-9A^JHE(#(SV/TX"D%2C(0L(KNQ8<#HTZ4789X=UZ"R
MDU26^QS\@6RQGYV&(SD1`E/P]P;2LJ/B<"YQB*!0LU+26*""08<ESM!EG<2E
M/T1E%1>(&%@1?IHP0<TS!YY.D>^QQ`^A$W^#H@&]_[),$'R%LD%E:5!VW!1&
MKR@+V(*K`1T&#MZ&,W$P%N"!/`*=ZM$4`^EE0%T]\16[)A!&!\>&>*TAM#R4
M+`WQ%W??:F?>,!:LPF^^T/1X?V`C^*#A48X(9_;*RQ2+*#Y>%78T2,AF`Y"F
M?OPPS4".!N\]>\"+]Y6O<6"$KZ<8J)6@T)(>AYA;M/#$@<\]XQAK;`'8TLXD
MJ<YL]"(Y7OY\!$-^85N\W3TD5X5`&FF)Y@JWL]7Z06ZY@#F*Q"8^T)@O6?,E
M>7V$\JE"/.Z1.>-/"!*B8=]UJ04H^4C16%=8;L8`N`_&1[0\PM@.D?'9(PH%
M_F)`F8`I3L)[S'Z`]1)^TCZ8'T'VN?#I@(L1\<X8PY^LC\0Z8IJ28`?T4#LA
M\-,/$C0H.0$4C.A0,VK\S8?.1W(*`AO)WK0.'@V[$L*GGND-0G:6B@5@68"1
M1\@B;C<)7,3S1?<Y?QI-M.LSR>$A8!$VQ]Z[^&Z$OV$FA(Y-[4?3Q+E+;C5R
M,V<=R0(*&5[K?0I)IH`1A@T<Z4&-G?+1@1;$#_]_>]_ZVS:2[/O]`/=_(')F
M@02@%8IZ3W8'<)QXCQ=)G!L[NV?OEP$EM6Q.*%+#AQWO7W_KT4TV*4H6];)D
M<S'8R!+975U=75U=7?4KU*,4_Y+YUM$"DTWZ<+337]8??N%Z@DRDK]+%*=5!
M5!M/6-5=KB+2FO(:A)8X+D.UJF`9#3&[AJ7?UZZ#=,'](QG?\&$\A#45CM7=
M%Z]9Z`*M`2GWJE0:+>ST%E@ZH2.E&N12I]-Z;F&K90@[>Y1&+S2,CZE_)!30
MFR_OHU!]L>N+#AUTFG&R5&_:7*%KU%IC,E74TG:FJ=-@3(%F<E6SL>BEM_.\
MNK$9U*GAN*ACR-\SQNW(8,7+&Q8\+!`RG/IT4A<\>5>484=*-F,'$A>AH^L/
M>5$6BDDBSW=X[^^QBPK8(+B=XN4Z\5(YZ_\(P/``Q:ATJ?:.(@;I*-#`D1^R
M9\V7Q:9=K6GB=Y_H<"!J3:,Q1_%$LP;(%:V[-'QR3J)8D?>>A'HV"?$:P9.O
MXVG+1,O>X4`/\CC2=^GI+13N=)B$$5L<V5E,_(2]F`P4U5AV$N0[*%Y@_!D6
M/N'!RO,)[\/02GI]Q<$T422[QU5QYX0(K:^\,!26`PVR>DB/AQ$IAR(K1F"%
MP#*:X@W;S`,CBD,W<P^]X+7U)2<:?.@F9:6NS#-GMMJE4.7),Z@^(<.'.:4H
M=1=J-91&OD-PTR",A(]H=X%WQW,B[<(9F'P%0\Y,=P'-K^^D!C;;U_B\$D%4
MO&CF346Z06D_CTG2=:$SYVQ"CB)SU+'G;7K=(#5VNI1<;5]M&%>X3VB/\&)4
M]NKL]B$B)Q[8M8AW[4KK=7'?N"H%!H6D_O7\L]*.SYZGL49Q"+M,0J$:Y)%\
MX(T5'[AU9Y$IF_(Q;`U/W),0-N7[(/S!+A>!7GPWFK+OAV\%:$;3E<T313?,
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MQ(V5DX/UF-([Y*TO7'J5*[.&\7<XNL(B%P)=F%1S`1KSE2<J#!X<C\/4<IH-
ME:"#Z]=!:3S!>DMX2,``<=6U7&!(+ZJY%[Q[I;XJ]/[A7%RA25`[I#*&L(TD
MMQ_8J&#%CF*E8N@/S5%,,8A^,G%HZ\@Y.K0C7GJ:C`)OK/ON::O!/8ZJY(B$
MX_[@%RS1P[8B>K,"WQ?R7@^^<$8_'!C,#2],,.1".`*#+DZ7QVO4E%\"4(S-
M]AO3P.UKYLIJX+!)C3T.G(KB;)>_Q\/V23"9T/7U$.B$@Q@N3B`B"!_J!8-7
M8;`A"^/:^5FO%^SC-,J9G2I2%_YD0T4Y7>9WR&4A%5D@13[!9`H]IZ$1TA?*
MT<E<?<6(G9_Y4&:._T62H,$9+!+8)3DPA`Q<WE*$BB.D6!'^F0C'>E53:4O`
MTIBR78:=<#!AEMR0A+,@RHY26A<R)`5-H'1SI!9D"+;TEFA4*V>MDT7C\F6/
M]`,-'8],E^A6B#AO`Q*#U(#)9/H!F_YM$(PS5TH9%>@UX5AQWE/93"!VR",+
M/$P[I\L+`,@VE5T&HD&\SWFQ/1<,&7DFDBV2_YO#B8$J/)MH<76I5XS(H'$,
M*0P&>G5AI.C"6MA=]EA4WB@YJOP1.M_I\UC(S\#42'L,4UBDB9):/(8+G8#R
M5YZE=$K@8<D-Y*2Z+E7..B7"^5"@%ZQ#%V8N9$S$6PZTQU/6DQLTHHT4V'B>
M*H@L*Q1SA<`(#<>1\3Z`?_1,H?/3J_=:IE#Y6V?!F/(&2&"TET^OSK1WB:)>
MVS*-[(G<7I`^2L%>\+(!3S>,4R+\@QA14JW1:IKR/B:FV^M[P<?\Q-<L690F
M%>V2DS9Y]LRG8N6T`:^W>PQHH\-)UJJI!U1R;!L:'=A7F*9@E%[_H'G"MUWD
MWY4-<M:3B&)YR)?G1U]:'_HA)5LCH+9C/*.6KIR\)KMUR*L+@A+2.9OD1/:(
M9^:T)VR+$166\"7"G)2Y62`MSFF,;!6Q>M*FHC#(?+?%Z<C'__$!,EWX:<P!
MWKU'AJ`3_6**\LS(^]A1%9.TEB;-80MGL/R@/]]ULNRXDKE%YC,YD8NLLBW+
MXC-UUIGXZ:3W,?)(.!$8F>E)APGMQ+B3)/%M$/*V.TZ$VAQ&<'A^`%KN8;&I
M,W7BI['5/LBL9!)&L5!QS1>L([.#&4:+\E3"!ZW:;&UT2N8(K0IP>JV-94)/
M\'!O&K?NS:WW(&TK>)8<,4+=L9$':HIW@*DS,;X-X<0T!4)O*4380R-*VDQT
M@:7BN?CJO992/"V#VL!`R5AMT5Q6UOCF1C]J2<W;/#//P>,`;58HP"2"Z9F'
M7>(^O!HGS,TQ9CJ1'RZ?[C@D243Q-D;,[3]AAW3C!]XSSJ5V_B`H,-VX\*,D
MI)WP+`CQ!%0T=,X_7,Q9.O+ZF>[9W1&0PFV1&0^D,.V4%8AQ*4C5+W;',G'_
MP"Q^S),.P?@IV7/S!SK<Y9T9]/:3CG3>@_%+K]'C(P"8VW*3(W9)&FCG%3_5
M*1.)EX34"Q*.X\JN_D9W^>14KY<A+4-E#TJ4@H0#0Q27U+5OZO=7-V0*BF(N
MSM2_"]S1G*/;I+Q9M/7X#"^O>_/Q$RK0HF&<EE"B(#%FC&JBC"2.74M/JMC%
M.$B&\23QL@%)BY")QG=^:9F#3@]#-,N.(?6208\>NS?=VJ%78`<?!6(ZVD@[
M"*2/@PK1<:SN+Z'5'^B((M\YW>K*\!UY*3-QPPB':,I/>)-(5S/Y0XY@OXV(
MLG,#G@G2M#%7HXS:#<5-XCFA/.U!>R:'A:7WX12EF:88RZUSB,&),L@I=<GS
MNG%#E?./1V,>EI9%2)O>K8N^=O+0(P\:QK_(:3Z&+2_5'6Z!ARJ;+24"]DB8
M'4%)>4@`[??IB3**U<U5KJD7O%ASKB,O"M34>[K4L&V0+6:Z3(9)EL:"%CE`
M=S)TO1&-*##X-0B)RY;1&S!0G!\R"#Y0FI4O/?&")P@Q!E\7`W(%:XFNTF%*
M-TAJB23L&)3RQH#E66ZJ'M3@T^5,>B43BJF,R8]NA3<!4V<BV+LN)9<=T8]<
M(*D0%&RZL.@TSRGN-R$Z;36N9:S2;H(8)"2]R<Y6G4L$.=Y#?8JG;>0\"7V7
MI`'YB*?X.G%1\BC/&J%80ZZN=,LA78CG<(Y;RN`6\300(EA+FET!)D\8N_^A
M+QIX^%G\,_8!"V0DFTHB=4F5CQZ8BO@VR"(7B(0LXQE6-%I>:CVFH#H-XQ->
M+""`,EX<P#E*`RB3F3TP)+Q[R`8M,<^00CU6HMB;=&9,Z`HCTPS<&GL]R.I$
MC#-B)+I#\""&JSW!=(`HF,3WCF0ZJ(MQ^L=DP7QP4(?DI@JY9@+170+:BR#>
MR(U8+_GXW=^#8$PW1<C&BPR7YY0NVNJ57\SYN7/%/>_=-SKGD-R)BX[M$PQ:
M4H`$19@CNA:`IMQ0I3'#6OR'XQ-&89/2DAW8N"G?#9OE?"*?@0,(!T#+N\_#
M4F"<QR@U1_-(5G0:`^(1DP97($*ERAP^O/H,[J671YJP?!QK&!\9K@!#KC+`
MAGROFJF(A\QL:)(<,#\D*Y:A-!FY/*D:LZG&;-H&/HX.L4;7M+EPT861D"DP
M'4?2W@F^5I*GLNSR1T)W+!Z15V,N/3O,)5VFG#%CLV(&8S!U1VHC@"9!F\>A
M\,>U=&S<^G.4G+$8D<DN72@E2HB=.5EJ/1\$*-'-YX@BO(_7$'GPPD]76.B#
M'0;!#_9';0<<;B\36(OIDXHI;W3R@I1C^(N&HPHLP[C@%)WKWJ4PP@C#"L<-
MHXJL[11L#N][17B0AXKT`*&9S3$&[ZB['3+;.;;L/CB)8C%+`U:=2-K+T5%8
MR[MAXA5RI)EW$$H_978*8@6H7-UTO"K(LTQ,*1Q_](AW#N-TJ?A4.FW<;QXJ
MKJSYW`T#T<$>',=0`(XZGJ@>#4J>277M,'_!\&AG>!=/&,&X[2!,L`2;>5#Y
M4RJ]>\06;>H48N^/'IB,)G!)=ZDG%9&M1LRV=!=22!!F!N''/BH27PX78#)F
MG!2$H5FY\(&&<3')WZYD-X5S:@D]P&+,9_-L5C!43AU&"0^3$#2RZ.*T$9X9
M:$C?AM,E*@_+O%*UO'HE=I1I),\7D0YL0:M6P1[GUWDZNIP,,4>6#6Y.4/T`
MW6&<ER]E1L_<>L%N+M(0-C%Z&8?,U&%:JD9@WCPWCQHI9S0_2V628Q;68V&Y
M+6R`KX.R#O%NAW!E^-(B6Z7XI[Y2*20<N.6C^]2=NIX3TLN+\<K-!1J08S$7
MK\#5&+!T768+`D,I2X`]83A24ZF.!48/9:'\N!N^8`'/P@(R5L+4?`K\FY-/
M!(Y1.W)3"`5D"GEG4U!\!4B[X#8AW235VAEKT/6Y&&?]OD8EL:.K6"&B9+.#
M+EVZ\!"/>U>53Y=M0+5EE6V&/@^)]BF.VU%9+&A;-PC<B_[@#&5\10+OTP7_
MK?!X3V,\/SA_"H?`GDAE26WH1AF`TV-TH+V0W0;YFJ4CKYLU>-E"Q(/$DLI2
M>N4]54$1\=S,]ZRK&PWPM]AK4?\PRB!O"IKRT<.3@)PLH7P!&2F]*1US&[P^
MIE-]$M3I"9^AE`@Z9,ET<;#>L@"KU7(K.-(+]7-)0$SI!(8ZI1X7YY`)HX@X
ME*$<@L7AP6HBE(3TKDVK;%-N1)+5QJ,$%7X3!LG,&'GPL,0_C$@.J0X31B-D
M3,A&KK%#38YF/%*_Z:)573^@+99&_,YE0>281EDH"E/Y!>\K7!APM000(F6^
MNM;8'>?34PA1Q,WM4V2\%-7R"V9[NIUKX(O`J7KW7I*.%^K@KSJLF+1JM70=
M##R(4(\KFYQD/,`0!P7=$.J@1RHR3[ZH`AWR<7?LA(UR@;5J8V`36:-O$>H#
MG_&S-%S0>O&]$`I`D9*&I9:&]9.=/^5W"C>-PYRR_N3=*Y_==3!5OJI`-3=-
M!R!3=N>>E7NB:A]WVA3]C7!BE:QBS_7BC=^=XR;Z3]I$/[,=-:U3H608569?
M3#76R+"=[*"LPR5*>RFM?R!+;M`%"2;S4R0C)4F1O9#&+KHCQH^0!AFF2"F+
MH&%@5;Y"'O:M"XH"[/P'F;TY2V0DH@*Y9HHI\5X[F#,U/^&H_1_I+T@8PR88
M8GRBS$+'QB3,M3__:.+//TQET"2"<_X`,"70C_D7)!PW!XW<.7#T)]O_^C:7
MF*X3GPT9V$79D`7"9--)E-78R!R4[,U3M8@H_C07R"%CKCR$"#H./_6Q1'4<
M>63&)Y0(H_FK<8H01^Q>EF<&;96Z,K0W/72%E&QB_)D$:+=+[-/7B<_;D1B_
MX85+3FZ*="YMDA)J](AYK/VBMTE/%!XRT@RS=`&"J>&2N.AXS=K:HL4N<2%H
M72+L#NL\_;'4'Y"MV*U=U![^)>OQ79"R[-IKRJX>!2#K@LSI<5GMZ!9D4"X4
M*>N9ORJ_!`A\3[IZ2TEY5W@!]S*9+9(#@621?Y?=UTB*TH<T8B40VQ!/TV$8
M#(/49Z,])!</HC#64GWX4MW:@E27F3(258?K7.MW6ZBIXUS@2W#OYXP]9XCI
M5SLQ`<\I;81*F)IRI;44Q=P.GR8I:#R`(Y`C[^15,4A5;(Q#Y5-_IC(7<Q>\
M\VY/MI[JLGR/0G8M1T+1`ZB0$.5VXOIHB&&;HO"4"W2JW%*?M\S60Y`N%!]Y
M0*]`1_$:+Z4`$^;#)%?/6XI.*D,:3@2!,L<@Q.3Y3+$B=&`(LRPY6/MRYCRD
M2*42`RQ$D$^M")7\!IX,`QG-KM!P<B!?*>RYRFPWYW-$BK$*.<>X=$>4<H/@
MI<4L3F%G'AUY!L>>(\#4\_/U"T<)\I*Z9;16B[@:@M1'2MM"K*$5:`R9&2Y[
MX-.<&:("?>LI=EHYT0WCO8JP&.(N2Z<J+O<I(>2P+H<R'-6M:`JF/)^8FKG`
MF6M$B'1O:33,>[DRFFK_+`46!*,?)SPYR&Y83'0FKGT\H+`]1$1$_G!X4.I-
MQ4M!V&V#!P:A)UA2E2`B"[1C2+U#^B"+OKH)'5FBDEHU`E4]]9Z`CHMZDI[!
M:(1(1PWY=O5=`SU[(]5<_BV&T"O@])8!9Y4A/\I8*%7UQ@US2R87HY9$\ASY
MWG.`2U>C6TSM/?D,5J.Z89W)0O)LP$R#L6#-_!DF"AIR0B\PKEP%VZI?MY9<
M..J3X2"P590ZA>;KH<Z'JRD<1FP<6J/ID,%O\WQ(ZY!.4)5/!-VJ4[!-UEL!
MI(@:E!-RYT:"H>!\@:$=3BBAG%U5AY5<X;(3]I?+$MQ<S*10[_A%+L`%VY6.
M_PFB/&(_)]H;LB),SCH!:YM]%MJJY"H-PA\'H<*UX6PT;`@#?B0JO2I2*4-4
M:>96`4,D*E[CTXM!$6\26(3^2!!6(9Z'>9O+WZYGR-FZ[(\T18T2R1<?,C82
M/='2_E-WFA+SCXX)$BPS%QXPSBY)<<NGSP+C_U2]86*M9DKPJM$<W[RHE,V3
M7X]$0FY8<^VET^0RC^%$`H<WNM]_[;[)5JVCH/`IE&/J\M4-(4K,5W;(YMN0
M,(D\X[(:V.B6RWR\=DM[F&M!RLLB/'N7`2LP7Y^PZMDV8>?S_'AY6LI$TRSA
MH+&<>R0"(3P?NMZ#/J]I0C/9<UK,`,/NLE*\"86&L#_"^S$:$*%NH-"FDFIF
M!]"T@&-Q\5"8(8Q+Y:9-$I1)E"I4AW[@2V7*#L?R)0LV*!Y:9?A/%C.!GII<
ME`7BYT\F*DR'V2+O64@7YV<K'U2""&KE[)1SPTW(N*=2R.%38A9\YSWD(P;X
MEC%:.I.EK%@D(DB".GBGTY>I)R=BU&<W.P^5P7/F.?"2-Y;4_'U/,&M4)=+U
M$N31%Y"-3QC#B7AJ,*%3$*BK6\2&JBUBR2Y,R?(4BT;,HNB64+-9"29I'!=&
MS]RY9/VF;SDQ&*O#)%8G/=4";G`(WT"&4)"K6B$U^KW`:`-<^Q(.ST_(B\$5
M:5(R(BHHC3NR4G+:!L<M-M+YS@UF;A2&/@)\?9U1$`E51\+G"/J8>5+D^#+_
M>>X@P9GVZ5E"8X+<X5.?@63"2Q=DJONRDAS(ZW,E!4NF3TG@)"<1)9.1D\8S
M_5D=8?5UVBE/7D@VUX-J-=1QL=T)%_[!.,G,TI3^V3=\N"B<//$TF1,;1L9N
MF9;=-NUFCWYKF9W6P.PC1G'F.B1R2MR'F:N%D.9EG"757!LK:'NVC1@(1I9+
M6C(-M/_"45R%]Z0&`:L8,7*22&[E?)I"9'G8JT^H32!D"7M+T:D5QH/=`Q;T
M%\TH9>)[:>@L<M+D4RG;=*E;P)"%'.]$:@<-Y55`:BEQ!2)9!S?UW<F><_5]
MN+HCV:NR`V0Y"/A+WL^O\]$:?&"Z52<V7L1*U&2`\0KKOSCCU9#$ZSB1JG$B
MBVX=AT$<!]/LZ>4WAIPHN]%%:M4F8$#`/O]OK^Q7CS6WPA7FN;0:UK\TK5GP
M./VE5^&U!-(S_\9HV8^HWUZR$.Z'"UN60ZFV3_A)&$VC,XO+D`0J3\P.6BZ9
M+[E9J$Z&>+'`71GDQUC<X0HS.K=95YS8FKD5F-MZ`N9N:3&MRN-UYF+;;3\-
M#6LP&@Q!$#=,EO/':`P&X:_&?Y^=??QX?KY,H4E3LM,'2[(H(C:*R,H"^B69
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M/#!7`53,TZ-P&M.XQS082KMQSW*VY'URP[C2LKXR?DR=<0'%T:#-%CJ$ERFM
M$,>^O#`<Q_R&@J"/,\PJK:"/J>6AXSVX5B0>?RP49RC483`S<*RT[3D8FG0^
M,BB_7)?ZQ&1E5HU@"-+HR#@!BI?57UH2CJJ"&M,0^70^_,`_2;_%^#F*@9;X
M\]`,1OUQ*'0=";U`1WX3*@22,0]K)0E]G(&=[G">)(<"8Z05',2GD:I!1"H"
M0S!DS`@7@\R"23D&%U5G6C\[S^8T\YV5L5@QET(/&2A$#.0":(HUV",]TI4S
M-Z(%VG`D!Y\J.PP+$Y['":-CF5U*!_][3'2E&IK,*BTP+6LGC3Y)&Z20H#3+
MCT$%5"`YP[\#+4;LQAX!FU'7IH2_DV7:QH@6$E'!XCM1EHI"I.3JN!M9#7?B
M#H$B%6=%5JM70&>$RH5)&POQZ#,64NX?H1PJ!317.][DY/`TTY7C;._<((DH
MT)JWH%HMD5KB'+[3<3##U:#E1GP-`Q\^CVKPH*S6I_&/!-9-5I>9XNSEU@FK
M*^,>49)EEWR?D76DY8.=7GW7LTJ^!`UJ]J1IZ:&!'[%&D9_NWDIA9KDLWU*S
MZ!M;BS*;]2+-7G/8PCR%'\;*A/RG$S)TR`5>S"'D^T=94#&CB56;HUZ3]39=
MK%]-8X&N@CO6I[+TE"32@;_OA!=P/330#3="Y=DC(60AG%Z=&=?!S!T9@V9'
M'_`'[=4K>G6>,I,S_PF?"&@@/"1LE(QFCK##9!BN&ZEPS.9H8DLS5^*2("<*
MX`!82)0R+.`P*<&*\VP1<HJ$-%.S66#3LIP7#'%`-+QNOE&QD:BM!<5XGL3!
M";'9I=U-VFBL'A>I6[,`+SK6HYIU9<I)"Z;QVGYC>,Y0>&F`<;G='DF+;NGD
M0G.M-^KL(.C!:!2Z,R46+"C%=PGQ(SM^P`BS-!YNEU+W_!MX>,R#>MW6NI$L
MH4*Y$BVNO(D,,?01^:035&J4<,R@&]..1?:'['&N#;79::)!$;1T%J,,9BJ>
MXK/I7#C,0-.@?/PTN6>"Q0?3FWE<(JQSZ'`HJ)"KS#'3V:MUC15SW1AWN47)
MX[+ZZ8,F0!0VB4A"*?39*7#!,S1C!V.KTP)P%%COQ/*@N&#GUII/;1%>*93O
MI.C7ZUKQ<?`="!YS0^[T^62=W)R2!I+)1273.Y+O,%RCXOV8SHLIYXN#_1?R
M6@5PYP>]=)@F)?"H>NCZ,!5<N@M<'C-@[#A(%PCL"/EM0!^MS[I"#E>J"X*2
M4$LA8GA335VD]68IY#FO<VOC1S-^+G@#KVV?Y;;/:7*#<&+EUH\/;3MY\T?E
M'TI]S&M4]V85L"QF6'9&.D0D_`]55"Y!Z7&RQ]@-@GAGN/9O`IR^$68)AKZ9
M>C#H`$@`:BFVR"0(8C^(A>;N8@1T:6/ED-"EZLM&)`L%E&IWI=,%IXV0,B<J
MB@J]NPP&M=!8IJ;*-X=NP_C(^X)2*:ZV"R!YTI]$K1*^)'<[OQ?E$);*30+*
MBL!$3^U<Q;LC24/^6.QJ8"%L=4F75)J;=9]QE@OM1M2X!LA)61=\2"0C-)*F
M-0'.$S5!2>)D&>TO6//!&OX,["I?P+GMQQJP!U3#KY#[&5G:9T!5Z&`Y=3)(
MSB0RCV:C%XXZJE7MR,,R$E`%`UQ`<@?DW6]`&>5!!ALJ#0%,JO)X/P_%K0!]
M@0B)A$Y!6`*9::TPN+0,8-[]>1A832`].(SRPU%`0S+#"I=ZE,RPU.*8C0'&
M/Y59W:HL4]F&GV5@9V@BJD#CB:J,I"$*$'91$%*)%)#;F9=GBX5LR8S45#-F
MN>.9W4&XR+#92ZB+T/&C"8>6@"*<(LJ%!$Q`[#Z5D(SJ-!V\1*%D!"4=02U*
MCPNJ^FX*`C)G>7-M!55A@+[T2M//T9B?(XA/7F#H/I3I"@F7DG*!9@I/4ZK,
ME/)6T>2^CM[P]#KI&-_1"2CW=*Y$:^9)UUQ?U-@[/NPH_90RA/CLC%+P%/&.
MCBNRUHTP2I])79>R\450!1H][_@DU'FCH=O+F2=:"(+W-6Y)T1M].M#9'TWH
MP+N@Z49.W!P-C0^8NW"A2/`LGD:4%9Z:4*C=C,ZM(S"2R=:G@W:,MFC*65)%
M8*+R(LAM"7@`7.D4E5]FM+WE7*4I+4AE^LZC.RL#523`HI$\29!38'Z[I0VQ
M_.!%AUL=-&O_>V#!5:OM@W]]FT0G-XXS^U6[4LNLX:\(U@)#OH9MY3T(\H_?
M_L]_X77[7]5;%_):[.%?0?CCPO\J:P2BM,`KW\3D;Z].H\L)JW;[I-5\1?A(
M],/WJP^OL!ZI.W6\"+/6?AOT^E8S(ZF\\2()'^7UU#>V[CYEUY-GS/)3?_P%
MK$+^8UW26@/+LC+2JG5:)/E;BOY$8%X?I6=>)^T<5#4OQ2;\%P?KD5G>T?KD
MM#1R6BN0TVRW.IU657I4!0HL0'$&_[KQV6:3UQ[T.AD1"YLOTD$@$@2TIN.L
MT;?1:0*Z)$3,EN]XQ*;A7)(Z^.J!DO_X4X0CV&J_HI;_AIO=%PKPO)S(7]`'
M>SE3OI=%H_J=]>SOA>8_DY;2ALPTZ:.^^'+^ZK>>W>_TM9'O:4"K\?$4T]?Y
M-/C^(7OD*T.VG6):MFSOGY2##2OJHRS7=!W@5Y=9A"S3LCM&#@:#9N]11FY_
M1*6<'&YI`K7>)%G_DE')IQR4G'OEO=HKWS,D37,+W(:5^G4!QSL-N\CO`QGW
M_J5[&7F[GH6>M4^I7S;2;?-=Z_8";%L7SC,CKIRR%986MB"[U6DV>^WM,7,A
M^:OIC/F.A@LZTO1[OJ,M:8`BHZR^U1D4&;43^O>_DD]O;D(!IRVQ%XEK#MK[
MW;06#$_Q^>+SYW__^A5F`QJ&U<TZY]K%AJZQ!&)\.5%&!?_V=XGG5FZ)=C)+
M%#_;BE4PX2-"D2E8F]\1F/4:FAS=BO8<`R5=<RK0:C0'%G!Q7>(/</"="H.W
M6WWK60W^TA<O>>ZO[X,7/7PL"_4T#,@_H;^]<)QV*QNGW5;C/$NA1Y>(]`*#
MSK;(/_`(07NBNTP6CX+N4B$Z!LK/@R0\3L)A6>^0</Z*'N)S(KOUKH."*J%U
MO4-SY+=?[$[#LO`B!"PI#)&5XZA$X$$-K9,.K64]LZ%E>O>W7YK/;7"9<H;!
M/3>AU#4XK+G#G+O*N__!2F%E>^!@16X-"^'8Y4NS&0YV>ZIN16QW.U(NEC,N
M;42J)O-+E[EW@%3[Q.JO</70L2PK=ZE7WLG<M2A%>E](N%HXO%#[IQS3L<[5
MWB(?<;N1NQA=TNT62+2!,C75\+FUSF5"%1)IJCE(]`-EI'ZEV`'NIR`1Y"O[
M>Q@4[K\E\3#;/<5?^ISY]CX[X8_W3C)=U<!M=_("L1Z1NQMJR:6U&BH.\VL6
M?<)30:WQX%.68*M4:R@K-52S)UQ78KK6\V=)B<14<(P<.H=6VN96'6SSP`>[
M1!Q>U&`WT8)',.Q6-FSX_)SG&$;:U8ZKW9.6I0;[)?!5,-D'57]@U6&WVJU<
ME,3!C;II:2:EI4WQ.:AS$58><'_0[AWT>'43NJG-LIKBE4?:M-K-_N$.=8G2
MVD2@[6Y[8!_NJ#MT:.-1TV>[_[OLY?>K9!B)/Q/AQQ\Q:C5OG)R=7S)/Z$Y=
MU6_+/W/JCT-Q_^U]X'FK2TFGUSEDO;<VP[Y=?=^<.ZW#WA36EZ:SQZ7I'\&M
M__7*0:I^K!SE^$SY-<^+.3%[#L+4U)C31(6\E#DK;+8=N[GM`9\A&LSEY%]<
MN^HR_(;Q?NDE'=:]YR!ZQ_/$^/V#?"Z2#Y:&2K>D*,@IE:^<,KK`PYK3NR&=
M^QFV[D,J'7:[V^KV.VVKN^+Y=^OC)X^J^C$7S:G<;EN8T4<=?X]3L3&]:TW%
M$L+[C8Y5A?`%"1;<.J_:+QBFPE^`]7WM_$24`T0(@;6\Z-#2/K$'N3LVI5(^
MNSZ<2%?V/]GMP@%M73J?;+S.SRKCG?/9'^AX!R=V5XT7/O>J.U</<6`[=+5O
M.EQ:T85&.*[V0B&#>`\K"N>*D3!*CSS6:XY$+K^H[?E7(HX]<>9$MYZ(-%T4
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MWI!!(`:<LI.9:7SZ=,:X+IYPQEEK",LL\6Q9/1A*/Y@*NQL!D+!3"6I2>"R#
M44+$ECL1GB"@14P`:T+*?WG'B$<R$@1JG5:J?HT/9N@PVCP:ZI2C(V,B=)/<
M>(QDID`3$9E$Y1DAU2`^)LA/6F@=Q@NGI[^H`<T5UHG`)%/0$\71OLY0)%0;
M^EM`#:K<6`%+,0H,<T'U5V`20T1(R)NR`<MBVVF.&L[++WANU<H:O\:RO*H#
M!1R23HO$IY`_Y^H?+QGK&U-A_M'L^SEAT`'=2R0"L5U<K//M2GAFQDK,*H4_
MWDP.@V*EQ;NB[XPT1=7+N26F=8F^LE<+,%E.R<Z&LT$LQ?)A]P?/<]2/G@U+
M8#8ZS8XU.$9F++E;+TDA[?</>,I+3I:+1MGN]+O]3K_?72[AEM4_Y-%N%$)0
M,KN]9K_3/MSQKAT\4`:+`R>I`QYI];"!$I`;NSUX/&+@\#32NM(+FJGY>/#+
M:N-=Y""[\,\3`CG>ED>N:766N^14CR5!\@A>@N.:@_W8P%^_Y`JB:>4BXO7>
MMTW<`N?Z$N):*Q)7X##%S,OD7%U*X/_AOVCA"7%;]R#=)0[91VG;[\"J77BD
M-O'F(SM#(\V3`;R3LJ;T-K9VL='4TT:KT;!E\K=X?;&%02VX^2"].G?]L?&M
MT^/'CG7HV#CL`BR.B7#C<@?C846RIJ0NN-.>2>>]L]0AEAF:N3`;V8S*H?K:
M^O?<)76N_3D'+J/*X`79MR*>W[J(AU:WW=4]Y/DNUJ"@,LBAU<K=]VQ.P5PP
MCZ:8ET8Z?07]<`5K7*QD0@UZ_?Z6R09IZ54/T/HDG$@4`MF64]YIKT[YI:HO
M0=U$;%_)C5N]^@6'$E`=K.M[X=T)#+V_71O(M#V`_5##O=R`A'5&\R$1%[YL
MZ]_"":_O@[5'TNT/!KUJ(RGI?BNCP*3:M<<!!\!VQ1DI)6#-D:Q+M]WMM5N#
MZH1O@^&8^;O^"N@,6OW-^(W];V4<B!Z]+O\[/:LUV'`<T/^FXSA%@.I-!]/N
M]=N]#19!CHCBB/ZIBHV>J@*K"F@7K+%3K&MZ1JCO%_[B#-^UX(YU<ZDJ$;L8
M1%7[H54,%MMT$,6GHVR>@R@Z`U/M81*$:"Q&'X(IV)"$;K[>\NCU"\2OT?D&
M]%\AJ/FI/_X4C!QO[4&TB]F?ZU*0L[G/!=9'\/!`HK]-)C)-[P>\'EMQ%?QF
M6W9/&MLK-5RXUH=OMD9(LY=>UC_:;!E'X-@".F1T"US3BOX!KQF->U4'XB,W
M--K)=\5^YUFV%THU0E?J=!V6KB]TW6H\+)_]A>N*O+`;HKNW'EF[>A^/$@0?
MU'<2G3X'ENJ/WPM?3&"@EU3)8D<D5Z-B+MN`QRIG#-J2;<B7UA3:GY'[J^]Z
M?WL5AXEX9;S=0J\K[)0K]IK3PML:<>$N-)<?L4JW6Z-U>WRZ\$>PZ>Z/00OZ
MVYRZ+;!$K3`IL3MD3;-I]>UV9S"_XI?WO3V*J]JD?:O7:;7M;1&<$_D=,KK5
MM*RNW9LG>Q4"MDU\59[;=JO5L[N;$4][M7J1GU6'A?ECQ398?M)L-_LMJZ_L
MA%7[WAK!5=E\@LD%`ZO;7Y/@XNQL5YQ755K[595[VS967)K['?U'58(L[?8;
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MA\6K2#!898%?O+$]ES>VY1`^CWLJ>JUNV^H4W4;KT[&'8:WDG+8&MCW`])A]
MC.OZ5!JF_ZN_\D',0J!)W6Z=3K&Z^W_F0U0KS-9)JVTM&%)E&G8_HI4\K=U>
MO[?M(2V[@M3F5D4[++SU7"E0%L1,#Y2MTN>VZ5V%X=UVWRIQQ^^0W-+#8P4.
M=[JM=K^DU/F*W>Z`ZE7XW.ET!NW=4KW:;3I%U<]52#T+HM+8A-7N=#H8P;F-
MJ_[%Q#T5`U:+7VUW;=T>?Q(&?/=#X7A8)@6W+0''LM,[Q_40;P&DZ<KQ1(9I
M.)_#N'R^5[VQV2XQ&UX?Y8-CUE;HZ4W:\O;7IV(E`R:]@-R0BD<.*-MES.H7
MC!7IVQ++UJ#OBZBB)RN+ZH+FUUP)Z:GC@QLA7DD2BFMH^;V'N"FKQL?E<()2
M])]93%`_&<()8:3P_VWT0H9$]-9'-`MO94"BM/TA?OAR>?W1:-H-X^++V>7G
MC\;UZ?]^O#*H^^&."9'(2*X_%MB$U>BX/A/'P#]=:P^]E^`R(3P/;BN._V"X
MD1$EPS_@=(H01+'SD\UVUT\A=S!;4HP-NA6)"!'G#-H$[>V[#D/]S!0>(0$P
MN21LV!0\KA"9&#1'`"?&Q@<QHJPGH]4T#90P:A07#^$#1<D4QH!;!I$P%+`D
M?]TWGS:8NIB0C3#[-)HY"#B$6HC^GCGCL?I['F\+N3H,7=/X'TR(BMV1`[0Z
M?G0B";YWQ_$M/FO]Y9TQ#,*Q"$]&@><YLTC\:JA/KS*"D)90=70G0FS24^,<
M!G$<3+.G45_0&V/UALZ5$0%SO3,\UQ<GMP)QCX&29N<O93R)Q_MK%88-7/;_
M]LI.62I9PP.$@7H.*+EFHP,LC@+/'>?G^Q$:H!><HJKP:/3RG)S3.+")5._L
MDU7U!+3V/`'T,:RT(&%E`[=NPB#QQ[BZ@_!7X[_/SCY^/#]?ME9WP#P9IOIK
M19YM+J#;%?$0V]G&NGD>+3PY:[:T)NYOP2A9MB+D7GL"YTPI\SM1,3+^ZE`6
MR29#^64#[;A<E#:AZN106%M/SGXG9W^;IS2L.WVPJ_>D-N@P59%YRO[_RS94
MMM;8X^;:]KKKK]3??H37-ON6=2!S4$_H$VBC-?F_+PMF!QRZ#A!&>\26_=XW
MUK7E<I\;YZ$(\SK:Z1!LGWJ27YS]=`AB]PQ.QH?;PI.SYHBW7'6S5_O1#FA@
MSX`U^U/OM2?M>3AKFDW3ZMMFNS,X%![7LS1/5=^T>AVSU;8/WS0\%!_\.LZT
M0Y#I_0A4RVQ:EMFU>T?(H6/AL6W:K9;9L[N'OV@/9\/GC"2LV'6GPN\,1\7?
M'8]S:JM][$=<7S?;9K/?`G-@2P*["3%OZJG>Z51;9LL:F%:W?\A3?<0'?/:I
MC^4QOQ;F(W67UO-SV/.S/_-G!XRY2$.BM5CIUT/.]3F0#=!NV"@PXR`9>N)P
M;VD*9-:7<?5$'Z\&>TNY`KFO#C"A8:>Y*!>K9HL0.7,9(R:EC(1BA"*4EG^^
M`<T:`GGXE#.>NKX;Q9C)?X?5IRGM,B+I,<!<G*J7G-&(<V*PFO,H\&GKI+KE
M$3J8""R%B`@F1I#B-33VS;5#G<A3FH4,<`1K8>NI0$0%<CB1I>"=V<PC7B/S
M(P5@:'QO7#6T%XT0,19E_7&9M*3JIG??P31B,N40DTE%/O-(OI)]1P1DVZ\;
M&0Y*''H<HCJ_:/_Y14^Z01Y3VDK5O*&:L3O*!SK,\XH>OKP#II$^GO#EK*:F
ME6JNR,+##Z!%-N[I9J;3V$$`\B84_:6>S1<QFT?L;E7HYV!=>@BR3(IH*&&6
MCVFCW.L%Y>MF=>'<Q05`5053S]#AS-!1>V`I1H1U!2L0T_#%_E,@CD8:K8:U
M)>NXUA<[F2'K(-3%LS0Q4H@_=!^.L\)_QHA1YFN9/%*9K.>G?0!*_9E:&*KX
M`+R,J&I#Q&XT1AIX8RV62TS?`Y#+VMA8/$/M1F]+`>F'?3AY"G,#@5&-P`=+
M8TB8C[)Z1BV,M951ST]M9>2'18#KM>@M=EO8S:>7O=J26.I8.H1(]&=I2?RS
MSJ/9;W)%RV[T#B&%9O_ZYD5-LSUH=`_[@'K4-DU:'*L8]G<84KU:O/26>ZFO
M>>J9?N&'LCHX/@4/(HWH4&$0NI3R7&?H>E0TAP@)Q<2C"@ZW`J^UZ7%!6C7"
M0)E83&=!Z(0/QMB%;T,!AB$&3<?W0G#L^PAK36$LMC.%_8#?*N^/8O0GK@_&
MI0MC#,4,ZZSY-QQ=G82S())5(BBF7C:7H#,\7QS"4`\WC"L8N#N!+0KOV`*@
MU1>2A@5!W^,ROH30';.C#NJN@[K7LB'KH.[C9^SS".K>":/FE>9K3;._J2'J
M#FA@SX`U^_*D/0%^^Y?+3YH]4G'=[#EJ?I-Q5LWDW7_8?=,R![9M#BIOJ(>?
MN_!2I[1GMKIMT^I4O2=X6CSWPP'6TBMA<PJT5@O[6>_Q&_G"NF:OOR60O(V<
M8?4,+;QN:1^`#^OI0:SVI$;J4(-EW($=JF_M$N_Q<%O8DV%G#\SF8$O1'"]C
MXT\3%WB\K?Z[.GVA`OLZG8XY:'>.D#]'P^%NRVSW=\GA9[8'ISX[3BJHTPE6
MX)EM=MM=T]Y6F%F]D,L!KSO`Y]XN;S&>W?;\W0\%D/L?6,XWCNL;0<CH50A&
MY=^)*&:(L7U+[4L*Y:H19%_N_#R-:6#O2IOD<:>U2[U:@>SR5+IEY/Q:D^SN
M7FBKN/?/+QZ@SA:HJV[44UU7W=B]1;2+``P1'Z[M4R.LOX`36#W)!W.,VVFF
MP,$E!7PC)Y*C,-;+8N%=CH,?BYD@ZHUD!@]/DC@)A2&<T(?S*?3I3@S'?S`I
MRCYVIQ3_S^$BB4\(FZ#9$08+7DK`.@QCQ_4;QND(P?;A84^^ZB_0Q4C"K7,G
MC"&F&4P2SWN`1B?P&\&_EY5]:QC7T&#)#Y@X$`K"U&'H^##XZ4Z=6$";O[3,
M@669EF41^?"G)?]T?2*B4#$@%-&,$\Z\AQJ^7\'W4[[%7)2ZF4O!X!D=TXS+
M$@@@,^3$I`R221#>.^%8)HE(S.B2E`]*+\G/H=W#&BLT:RQUXN?,#5%V@'*4
M5UFF@6C`^A!`GMVC654=A8MPV[!K>?E9TG.KLT*WANJR"PL@+0.QG%W&RJRB
M`A.K,JIM=IE11,5*5#>94=S-NFRB3B67QH'A!['LMEY#<@VA[II7A(83YP0E
M4TGC`#I$/L+,>\E8S+-<4VK\&>9%_!P)D"(-RQ2$*`RFAL@CD`4S4J'BIPA'
MKDK*^G;UW<"K!A;A^!9HH\2I+.]*I5VI585O8981R*GO.@OE.8#S0D&UDBXO
MR=XB\FX##]J/LN^)(/%GXL8/<,;P2.G?NYX'@]24/VU98Y!"V%&BA"1_GANT
M87FQXJ.Z=:GE5,KI]]C5+0BUA^>G5:863IT'G($H&?Y!&88!?@1%XL<N"8>?
MP#\>&`\QMS=.J%J++CVL=H)['^;[UIT9(R[\FKT4<56T,6_N2,X%I@OYCD<D
M?`,=Y2<H2KA$L$%XTW.4VDQ+NF`F84)ZK4`4B&B0>&.43A`+I1M)>:W&!-#C
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M8"F4QS(4GN^^B^7`")X]*M@:K%*SBEWY_/%'RL7-+Q0R"Z)D"F-(%]L0%.A]
MG2>^_SSQ"LG!:P8_;:'58TI[KAJ)54_`EB>@:M[YIJPZZKOGLP3.R/#\$5X&
M/'E:]>&V\.2LV=>%YIX"1L_Y$'THBV2?=UG'?T]53\X!3\[^-L\G`*>@PU1%
MYNT*P&`?43\Z0L&A1`#9>)MU('-03^@3:*.G!:-XBI`L#D@?L66_]XUU;;G<
MY\9Y*,*\CG8Z!-NGGN079S\=@M@]@Y/QX;;PY*PYXBU7I8?7?K0#&M@S8,W^
MU'OM27L>SIIFT[3ZMMGN#`Z%Q_4LS5/5-ZU>QVRUMU3+\27XX-=QIAV"3.]'
MH%IFT[+,KKTEW,1#6/4'QV/;M%LMLV?O,N/\V6WX9QQCZOIEP6_'XYPZRMS7
M.LWYQ4QUG>:\#Y^ZRBFIA?E(W:7U_!SV_.S/_-D!8RZTM,$T5OJUC.$_D`VP
M3I9_(9=Q]40?C`8[B/J)2$<AYV:#/)K%*3EI#=FTG6].++Z)4>"/7(]K8;S<
MG)Q3RN+*.('I8GHF#5&!&<!)G`(L>%0/$M-K,,TRB8/PP?C>N&H4B_129D]Y
MHB^E+,J$R5SBCGPE^XX(R'8O-\*TM[J,8UW&<2TC](#3;FK&OJ@RCGKT[PZ8
M1OI8I=IG:GK-^NF''W^ZOQIDK4[U@MF[K=M6M49Z/9O'.9M'[*V4-CM:EV"X
M@2XG+(,0:'L*:,9CN=][W:PNG+OPGU=5,/4,'<X,';4#DT(L=`0G$^%O:FE<
M)(U6P]J2=5SKBYW,D'40ZN)9FAC?%H$7UL7MCELFZ_EI'X!2?Z86QL<\,N:0
MH"3K8GHKFKX'()>UL;%XAMJ-WI;BN0_[</(4YL8G69]O+(8Q7A@"M5&M+FHK
MHYZ?VLJ8&]9E?"O"6O06NRWL+55SKRV)G3F6#B&0^UE:$G6UO3WG)K3L1N\0
M,E#VKV]>U#3;@T;WL`^H1VW3I'&5Q;"_PY#JU<*-M]Q+?<U3S_0+/Y0=?FQY
M]8#PQ<'E"F8'&CFETG:G_OB3ZPRAG=@5T<N-*_]04GL0+^:\C#E$2"@FGBH7
M@I5M\'$N&T+%36(QG06A$V)Y%/@V%&`<8^!X?(^%`_$EJFM#]0FI-J$LC%+6
M'Y>><WTPL%VJ"0<MIS5TTK)J^!*VJYI+\$(@7U\BK<'6,*Y@X.X$MFF\9TQS
M%E2IGI+`][*:C%1FB]E1![;7@>UKV=%U8/OQ,_9Y!+;OA%'S2O.UIMG?U"AW
M!S2P9\":?7D3GP`"_LOE)\T>J;AN]IPYL,DXJR8#[S_UH&F9`]LV!Y4WU,//
MWWBI4]HS6]VV:76JWI4\+23\X6!S?1"S4(QD)K(L.`^C^$\=B;74']@U>_TM
MX>QMY!"L9VCAE5/[`/QX3X^#M2<U4H=;+.,.[%!]:Y>0D8?;PIX,.WM@-@=;
MBFAY&1M_FKS!XVWUW]4I'!78U^ETS$&[<X3\.1H.=UMFN[]+#C^S/3CUV7%B
M19U2L0+/;+/;[IKVMD+MZH5<CIG=`3[W=GF+\>RVY^]^*(#<_\!ROG%<WPA"
M1O!"0"[_3D0Q[M+[WYY?4CA;#4+[<N?G:4P#>U?:)`]=K5WJU0IDEZ?2+8/O
MUYID=_="6X7.?W[Q`'7&1%VXHY[JNG#'[BVB701@B/AP;9\:I/T%G,#J23Z8
M8]Q.LR6J)D942F90.1$7GS__^]<O"<:Q$FS_-/"OT./[/\(;GP?A5^<A##P/
MFEPU^\%(?)<?NKIU0A&]`FTY<F'XT=]>77PY?_5;L]/L__7MROV6$GJ>Q$DH
M+J(H0>,QHIZ^`[O"KY[CKTCI[Y*#OW\341RZHUB,B8+O0'_T[>K[9PKN?7P\
M=JO;;74'A2$MI3`WIG/'#=$BQK()^*PGQF44??62Z,(?A0)]=8YW%D0Q$U0V
M7/O$ZJGATF<8[BB)8'7^_MD)?[QWDNFJPVMW+/B?'-VFM,YEXN"W[Q&TZ4R[
M8#@-0ZSQAR^_?\@>`9G`KT[OG7"<$@*2GDQG^%:$]260CG\&'C0#0O^`B4&K
M2H-D#[+FJP@GN&)A@!__3*`=ZI(9EK(16SUS0B^X<J>)1W3/L10:POCS.9Y:
MC5Y'6\&[9\+SYONE+UXHZ[^YT8_S4(@+3'*`A7BX`F]9W?:.^%[&A.?,]6KB
M;EFM)^`[[1870)WK>-JF4;99+-[%-N!?Q7VM"J6',L1U-W3;VL;`I<`Y-PM>
M^2=\1U",589\!E*5>+'CQQ4$O*/&LAI)2T8Q=5S?]6\.<CB/TC:G\?!WM#_%
M^$,2PJO0GAN,>2H+S9!4?1$QF*U!.!$NFJZEXMHZL;IJL/2Y9:UM5[(4;HW<
M4HT_?%S5#8NJ#K9Q-Z2'F82*?/@2^`J4](,;@D$0A)%<L*L=.'[[VFQ]+JCL
M;8QCSPQJ6AF#X'.V*F#.IB)\V;QI:KQI:L*C)*<J5UK_/G:F+%&CVUA1N^1/
M[MS_+P<;4DKY8CK%R%?A/2S0(K:F1>P3NY^.2+:SJC9M:GOZ8Z0L\CZHYQ>0
MVM-([>G^DT6D?K_ZH--IO?JMU1ST^MUY7X+J65$V%NZO'X)1@JP_=Z.1X_U;
M..$Y?+.J$85F3A,.'$M:RK'A]$Z$L-.>>4&$>P_(DLBYI<JZ[6C=\F<[Y<E5
M,HS$GPGT^O%.*-XH@?X*6^65\#RAY'@ITSJZO?88G;E!_=_$"<$T]Q[.G.A6
M2G(I`_<UDE;3[LB!E-*6GQ)"\(#1:6-]0N*[K5XGFX82VO+$W]R$X@8.1.,#
M&T:KV>^E)N9R*O,#"H5S.;GZ$Z9-G`L1YX9P&EU.%-F:8EB;[*R;TF.;HKY`
MTCKTYG3N4GH_"=@/3H%?M$=4(;G?M>Q52.9-CK8;U<VU"*<+A,76A&7U49R=
M7Y9TDW_FU!^'XO[;^\#SHIR%L8S*_8_D[/&1_".X];]>.;AE_J@\$F4O7$XF
ML!C"2+<6#F%.EJUR=<9?-H;]CW.]&5LZ3GOU<<X=JL^2,$1*?#]QO"O'0YBJ
M3;7$QG.YV#%@ESD&2L:PW_%N.J<5'2%5QDLW4*"THR.;Z-*!+QM,C@.HPF"+
M06/P<G8H:QA.8)92NW,$SBFB\,;Q)6@`NM`P?HK/:/[X*QQ^D"7D!Y^<*S0X
M*C1')N0',/+!ADG"O>/VK1JGL!+^'K8\I'"CR^N/1K-A7'[[^^F7B_]W>GUQ
M^85(&>Z5J`T`YG;#H(OI+'2G;F1\!3F;.B.14,P8M`$KI6&\CH,;@6GDQKT;
MWQ(M+IQ](I!M=^PZH8N]);XGHHAA"%E$#!@@-!,#<4%H!-C`O1L)(X0%X8;X
M#CZL`'AZ[PH(@?UW^%KVLR(R^_V-`20[#%F8(YPR[*`I8X)G4S'FVB240DOH
MB#Z5-9J"1G`QDP>_<WT_N',(PA=_OG5O;@VP+/'BT9B%`70M8E9UTQE&S4&C
MXS"YP2&$SDPA..*K4^<'-@@_P%C3GPWGSG$]@@>,`V-V^Q"YT+G/&(LSZ)B.
MDTYL.*,1\-'%!V=X<(@:QG4&GV@$]SXP#N;TAT)UC!!MT'`,1'"<P/(.B))@
M4B1[".N;5!A>@LC;K\C`!*;9;7SK>-/`"VX>J,DDY,_P-<QB;`R%YP+[(N@7
M*$#L2<YAC%UFV/C.(<VJ"`KO!!&1^%,X+/A"C*DCG&ZF?.;!7.4&IN-"Y@G2
MR,W&:!H>S,#PP4!!_``#)>&[)FZKMCJM=T@/4?()?L;'(NTWG0\F4\WR"]_&
M[LG0]3SL<XSHBJ$A'@3,>#"3(Z"1NHAA&<%RPNC%`/@`6Q20(:>3>.2Y>-\$
M3T:))B,P-7?N6/"B,-"7A%*+OR#R:C!U1ZK(9[1$7/*2$0K<W[P'PW,2'^.8
MB#=J*H<)'$6!.)-HN!7.6..?F`B8Z(LSC3DC^.C`R$R,"QW=&B/>*:%YUQ]Y
MR5B0R,'B]F-9)$RN"GVZ$"HTE>TH0<'!I3&!;8.U"%YV1C'=FAFC!_I4&!6N
M<"\*<LMW/':Q>;G./0Z,"1>NTYR\\S3A/YA#3RMEH?B72EZ!/ECMJ,G&;H0V
MLM"7)+)V!9)X1IS(N(>W#/B7A<(/_!/];?@\3D8Q:<TP2$`]8?OWMR"=I!6T
M64`F284(FJ?Q<O>U2]\X!09ZA@3K-'4D6M"TM`^-U:[W0-2<@64H5<*G3V?&
MZVP#^GJF;3TFB#^2]@\08/&@U<HK3`!+%`C0/QRP,6$>F93.`E*N@D3NL&>!
M$\7&U0PAH#S8A,ZRMN6V_.'M^[>G!KI^]!]S%,-O!9H1:1:DSW>=932_CH0P
MO@0QJ_%F]TW#R"#NT0A@6&"D.J*UB"B_7\_R@Z(M%I0?K`?'DRN#E2?V)29`
M1LQ`Q,6MO?LN6V_0,N_PVEK`EHKKH[@QZTNL41;KN6W+N&AY?P7B1!@_8(PB
MG##&&'-`"!Y/9U7O$0V[Q/#N-8SS[]^^7%Q___;1./WRP?CX?[]??/W\\<OU
M6C;X]@*!U]%.VT,'/T]@->*M.^__2DI0)"*7`B7D"L"UQ9C8L'YJ5.QC1,6N
M`*9\[(#.Z=HOA\S.5OOJ^05;YEX])P6T[:>8DZ/.O5V@NDVLWE##<!_0P)X!
M:_:5Y2DWU:Z]/QAN/#`DH#E`&T[B>T<N)SB+C/&/BNOH!6`X=_>&X=RQS4[E
M\H`U)/>A3J?=-CNM/4WG_C;V/6FI!9O]L][F-^%7L],V[6:-P[E3<)QV>[!#
M!N_+YMC3"O[D#/G^1+DYZT7\*#YVT^SO%'OI<%MXEA@+Q[T%4]CH;>"-#7>*
M5ZBBAMK<N<EHF<V>?80*X"5-TA$HD771I>I-HVQ1]OMFO[7+H@J'V\)^.-QJ
MFX-C0+A_&K_WZ6B4T.4Z7K8?5)FJEZ3U7[<[9KNR.Z=&H3RV:>Z;UF!+Y7!W
M,\LOR42H000K^YQ;9FMPC&[`>JJK3G77[`]V>58L430[!8W<97CK]@+("D'@
M*`[S9AD'&6NFF2%^4L0R1F[^TNJ9K7:+S+=?.F:W,S#&A!M#\9P/P@DC0U!H
MY5PP#[V#$20F]!W-.$34>RB-N*P2$;ER-.4SCJ%</.5?0S%SW+&:0XZMY;AQ
M&:BOD)21'#V2T*BC")\XBK".8MMPF\&7Z\C"(YF3EQ!9J(=,[8"W2ME3\<`3
ME;5!:'B42"'W@(KLK0-KGM`!7X=('>I,PAFF6SFFXFE#I)ZB<(?226$=//&\
MBF0<"V^;7=/NUT7!'EF>+E@)X9.4!#L:.;);9J]RB/,A\.=8.-P:F,WN+AE\
MQ-OH);EL9F7>G+&8!9%;1S?M=O7#-M*UG\WEQ#.=)=LV!]WG4:-\!]SA"L*E
M.J34(WP0^J2^1EMV8VJ9;>L8H[OJJ:Z<P=$QK6YOOZIM+W7V3K`VU)*[G15N
M!<O+ZV4E^CX3E@SY0Q&5W?5OS@*?H:&B\R1$W9<OT_>2;@BO"7Z.X7:DS_B.
MF81<D%SB2^%0&!-F%Z*9C4)WB-!@P@ON]W`]>/PW@2NZ+]<VV#:R#?#P?[M!
M"O5N+L;4A<EJ?-G3%197>L`K<BX+<:!,6U&8]L2T:UC.(F:.&01TOY!MI4;V
MBMZ)-'I@=VO$V+_!M:\1-@<-J_,7%?P1<?VT*!G^(48Q(B'BMUAMRM`JI!E<
M(LV@8BW/EC._-+&F'^+,WB#LGPB/5GKWGZ)52^]3<^:79N>92.^6PML/<(YJ
MZ5THO?9ST;V[=$W6TGN8G/G%?BZZ=_^W'_L:H=UJ]*U:>LNDM[6![CV"E(O:
M,7<@$W&$WKI6N_;6E?+%/B3'TY%XZPZ+:3OTUM6.N74,%,NT8!N.UI'@XQGE
M[IQLM3^M%KJ]^\9J-U@M='MW:=7>JUKH]NZ)JIU.M=`=G0.IQ$61.B9DT=P-
M0LB*L!1GSLR-L8:H&*LJ!E>RB,'?PR"*RDHCMV28V=):W.U.JYO%R#W6S3;(
M:J]`5L?N]#8@*X50/_7'Y^Y/_!1MQ*:FU6X/,GH6MK\1(:LPIMEIV\U.!4I(
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MG#_;*>57R3`2?R;0X,<[H4;P^PB,LF#Z.U9FO1*>)\)H;F@E*]ZB_VGK:RFE
MN2GY*D+T*#LW8.Z<^G[B>-_@SPM_%*(:*UWQ-))6<_.1R+[G9@ELQY:<I4?(
MV\)0<N*T="BDV$_!H"657FDTO4ZU\:B)?"_+<I]E]=G!`D5#%-["JK3N6(3T
M]2?7&;I8COY,IG.M:\(UVUU;V\W6IZ`XELRL/D_0X/GL^NXTF>+X'4^3V,L9
M->C?$+^C?>9H'-9=Y$XR#%5L?6<W""ZXIM:_:WNF^#1TR[>?C+'VP#8[5E5'
M\<L#J`$Y/490AST)4;=O#@9[3CL\GHQJ/._5LK-(=OI-L]W>Y4W5<6N=8RR6
MM:^MJV,.6C5FTV+9V64MO^.6';O3,ZW6<ZAUN(M+M5L!I\O)LEN87<W^2X*A
M:??Z9KMW!#O?$^+0'(8`UI`C2S2IV>VUS=:V*LJL"SI2-4(_<UAMQ<VD?%<P
MJA^_3H(@]H-8?((_C)_T5?PP`W+@:2I[\$I^&P9(Y&T<SWY]^_;^_K[Q<QAZ
MC2"\>6M;5NLM_OP6'WPEFU<=0(^Y=N%O)PY"U>QMB,ZN_SX',DXLZ\12WWO.
M4'A_>R6__QW>RJZ[BK2?AODNG'"DFH&/CQ`NGW@[<4;QB6I1O3X)@VF!"-E1
MP%_CPR>6_<H@&?_;J^8\E548T%S`@&8Y`ZHUW:S2]'YYVUS,V^8RWJHV<R2&
M(@J2<"2J2&Z1.(U%*1D_IQY\CWY2X9]\OWKUVX4/NF46,^8[^F=-2JO*ZI'0
M?(BQX<:1,0M=6.$/1C"3+N4(T[`<HV=VNATC^C.AE!?HSP@F$W<$GYT1>9P-
MUT=_J_'!%3>!2>[821#ZKM,P3B-,`I@K!9`GX]Z)9,H-YMDP*7QMHGI"?[`P
M7K?,?J^=4B)$_,:`5QW,&O-0C4"KL-7>W%(;H9@ZH'R@1?F;"*<-HUB.Y<;'
M^`AHP\,+5J#5F<W"X"=P(A;>@_%+L]FCB*%"Q95%!5>PS@I7WI,9;!BW,J4O
MBO1XRF%O&KY`GA(ZW`@?3<?C^J-@*ICJ8`B;CYR7>S`IC;$;C<"PP!<X4PEO
MP>3U`S+0@=:A-^:L`5,J(FS)C7BL\"\T[R4X#IA`>DU5G8'I>W2HC;^^S4GX
MDPF^72+XR#!GBMPQ9'T5GESCE]:`(\!R</U3'+;#U7A&HS!Q/,.)2\KI(%_H
M35@DZ0H9"N,&;T&A)?I=A'<@LR#$G+<HQCQ_"WM43-<D!_@4AR[)`CPZA8>X
M5S>*$LR#9`!!26I$"T@-C*H$-=LML]-I;5PGJ'R*"]_BQ@R__/4M3I[[*_X_
M_/G_`5!+`P04````"`!H@&Q&3&RVQ?$:``!==P$`%0`<`&EM;7DM,C`Q-#$R
M,S%?8V%L+GAM;%54"0`#`_$!50/Q`55U>`L``00E#@``!#D!``#M/=ERW#B2
M[QNQ_\#5Q,;,1FQ9E^UN>]H[(>OH58QL*22Y>_JI@V*A)(199#4/'?/U`X!'
M@00()%@D@=*N'RRI"DCD!60"R$S\]+?G9>@]HB3%<?1I9__-WHZ'HB">X^C^
MT\ZWF]G1S?'Y^8Z79GXT]\,X0I]VHGCG;__S[__FD7\__<=LYIUA%,X_>B=Q
M,#N/%O%?O:_^$GWT?D812OPL3O[J_>*'.?TD/L,A2KSC>+D*48;(%\7`'[VW
M;PX#;S8#@/T%1?,X^79]7H-]R++5Q]W=IZ>G-U'\Z#_%R??T31##P-W$>1*@
M&M;YER^__>?!R<'>_MO]@\-];W_O[][9;][)V=<WSPM"R8F?D5;DZW>DU=XA
M^6__X';_P\?#O8_O/@!'S/PL3^L1]YY_W-L[W"/_BNX_A3CZ_I'^=^>GR"/B
MB=*/SRG^M,/1^73X)D[N=P_V]O9W__'EXB9X0$M_AB,JI@#M5+TH%%F__0\?
M/NRR;ZNF0LOGNR2LQCC<K="I(9-OL:(]ATF*/Z8,O8LX\#.F9=IAO,X6]*]9
MU6Q&/YKM'\P.]]\\I_.=BOF,@TD<HFNT\.A/HBWUJ'BY2O`2IZL'/UGZ1$^6
MN[3)+A%3OD11=A3-3Z,,9R]49J0%19F0P6`^)&CQ:0<OER^S2D/HP'^"],U>
M5F3NI)BJ_HZWNQ&NG_V0<O?F`:$LU2$G;3P:-E=^0ACQ@#(<^*$1:M*>0^)Y
M'$=I'.(YF<)S.@D1%5EZN;A<T76*B$K+2CB$(?'F1[K)XN#[0QS.R<)Y^D=.
M5$V',ZSW=/@:*4@/4&-1<NRG#V=A_*15$F6G(;&[3.[]"/\3M$+)V@[*J7RY
M]),7(B5\'^$%$0A9#8,@SLER&-U?D4D38*1GG1&4(?$_"HA&I9BR9W;%O@M>
MCA-43.J+,-!A#NT_),[7*,T2'-"UZ"%.LEF&DN5Y]$@^I=JGPQC6>TA\*?2(
M^(,`19`T'1*3JP2M?#P_?5ZA*$4I,=N79!E)CO.$+BA':0HPJR8PAL3]+$\B
MG.4)HLX&4;H51-C*3L/*F/A]]_@N1`4'R'@_Q_'\"8?:M1[0==@9S]85XG:\
M^'3,:$X^27)42U0_Y8$`AL3Z!-UIA<VW&=8:FOL>4_@;YV2_ND2W_C-D71&:
M#HG)*0$2OR!TXS\2>Y5>$>]6AY&BR["^[W*)V<I.YQ7Q8ZE!)1M]P%H,Z#JH
MEJ%[.I;![JN[Q[`>SEV*_LC)0*?4-@%\&7G[Z;VN8;VO,;TP&`:W=+D=B)HF
MK"D]2A@59E!&\M9@J'9VF-IS@Z%K#FET+PZ&.*#K1!X=5"^``";U[J#3SPC,
MN-X6<-W3]!O)\X+J0D>'B7P=&)9@`(/*6V6F3E#FXS#]ZB?TG/$1:96@#[#I
M+?F,7ES,\Q!=+C[[*0X(MT]PF&=D?OEDD:/^,%F1B33BZ(8,@$K,AS']&PX^
MI:]@*OZ^\*:DB6,_UY3>KYWY.&&78Y<+>N".Y^7A.E#ZHP]LB4NG:8:7].:!
M0[.TJ!1(@N9$@R^P?X=#`H]X-&F:+]%\>*X-@X@E+EZC-`\S[LKF+(F7O!X,
MSB[#$2WQY2J)S^CV^0Q'/K%T?LAMIX?GB<%HEO@A>*UCJ@A\L.GN#TQM3C]H
M(^U8&[RM/P4*SA3.U/O;QCS2-P=2/?[(H^^?3576",CHV'/,52'6BRA#V!.=
M'RA60/!4'0#X]-0>+<D*6=[&5S.(V,-1F=!OS.EYL_8N<Z:E(MJ#LL5XN.DY
M<OQ`&J'T/#HF:](+V9B6/G?5=%!^&`XVZ9E=8VE^Q(!M<$^`DU+5V(_"$-Z8
M\`W&'/HVV]1HJ_J,>_YJ?`@'AC`NWIRPV9>7*[JZT9OFHX!@L<;+G"!CT)-1
M6I]-L-.'E<&^;4.PT\F2'DJFEWG&8O/)2DT=NF>4!#BE$WD0F1H-,3+E7_SD
M.\IF-/![_@O95A)TCF."%=M/$T^&VX#2SM^(EYO^G/A1!CX#&W70R?1"AM*0
M$]T`_F0T_TI7U&A8.C4P)Z>M.0VK3P>>\7T'F]:"?:;3D681$0>%N>KEE+N-
MJW"J]`0G*,CB)*4G^7F84?0',W/#C#_23:RIFP+H.A*FS0/A1TQ3P=B6M(V0
M`0G&,,>GK?[T&@5Q%.`0FYRJ;P)S?-I.T`(E"=%\_[G>57)7/QO1:`9[Y#A.
MTUEE`&*BV`=3"GJ`FH@23D<N$%F*ZV/,;Q%9LX_]%<[\D'T#U+\QQIJ>%\4)
M%MG'LX8,/X88=!8..\JX,<'&>W$PA#%CAHVQ!O97X1SX89"'C.0+\G>C!WK.
M$!'@O()#D1XD499\3"'M%?_VO9E7]>)_)?ZE5X#P&C!&)D">$-O`^("@6>?Q
MD=_YQ$^O[.^5`$ID*W3#.&B@&-*TYSAIBKK$D.4V+_STCB4XY^GLWO=7NU0%
M=E&8I=4G3"EF>_MEGO.?RH]_+ZQB>>56#1#Z=RADP_Y>MFLUV[6',$V'I$L+
M^4'7T4<_9(M-UCAK[B8$V+U-(*=`1TG@Q0E9LC[M[%?C^$G04!LQZ;QLL9O2
MN#)VGX^)9E3]%TF\5/&[Y&W<AQ1>+@2+'>\)X?N'C&%O48[-R]_J[A>HCJ#.
M,!D>6)6A`1><D^#Z$&<=HZ$7G;H73&:'5F4&H=LY8557-&2OA\A2<1>BKRC3
M+_O*7C!AO;4J+`C=S@FKBA-Z(;AV"Z?9"B:,=U:%(:/+.>8WTZZ[7"%77(0N
MM=\*"W*5Q"N49"_T9"/C8XF4>J_NY8;5[S3W>H*=DU([Z(/@>OH<A#D]V&]G
MU\M6*4AO-^Q^Y[(%9X!STM-+R%0*8QOT#BDXSVGN7%GK6,G:6D2].FF^1B$]
MGC"A!-#5MJ7L)J>E8F`V.*=[G1%8)J(T`F+;SH*%VH,USHGW.$^S>(F2$[2*
M4PS897=VL&UHP6+3D.R>B+AKG,N[$-\723IZ26GZV;;)<(&!&#"@W"1WP%^^
M_/;[YSS%$4KY!*CZ'BJKL@LY!#D")5*B(#>":'M?KI??QB0Z.B/5@A79XY2C
MTC')MLEFR=>#KW$4]%P3^:X.N1]FZZ%(OW.2JQ:#XWAYAR._N1@TLMHK+KQT
MR[(7,(>\E`[I;L`CY^0-\9`AT]84CD.NS09[ARV8T-TU%$4ARMK:M")%\12*
ME.YF7VAIVYPK2E?&&M0=5:1K&CP4K:O;D-F0+W-V6'*"%CC`RHM??5_;5ATL
M,3@CG)/AT;Q(/?'#*Q_/:9(F\U,X'52L\("^MFTW6(9P1C@G0[XR3C0W6=[U
M/6VOFE#:NG=&9F*SN',PH4]7![F+S)]VVU1>D+\GC(Z4O[#0")4\A(=*>G]I
MP/NOT2,]#=[K:-#TMD53DZ@U)"]>>!PLBTZB'Z+T&CVB*$?*^W>AH=6%,&`)
MYB4ZJG6OU=#V,M?!;F%5D]+GG$'Z7^2'V<,QF9K\*R%:J6BZV5ZJ83("T>Z<
MQ'Y.XC2]2N*%RF=O-+(]8R08MVUDA[Q<X[U<8[Z@.35I-_EJ%1;.P4F2WZ=E
M;+#I)-)!LSVW]-+<A$L2D<_LRKRT\33W/V7)4>TG/D3!*KK8#?M&A+$T]>"$
M3+4P9@%L6BW5=+.]N&C%(P:!Z[G@W,)S@\*P2,<OBE*0W[6"4_6QO8B82DU/
MOW,B*YY`#>G1\WR)(YQF1=Z>5F[:CK8/:DR%!^2$<Q*LZ2Q2U"^(W0.L^7QC
M9Q9'D8*VC"16W<E3&#A)>C5USM?X&D=QDS[M:J'H8C?T'"4HU7L70D/;4T8K
M`C'&7$:I>[JUSGDKR*H05\FFJX?M1<!<2&K:G3,]9!,,,3JM9M;GC@SKKE59
MTM))@P,A2J^/SAWU`Y^&;AR-OU,=]S=/QGF0?_;:5U16:`+<9[S?C,#)[SC4
MSTTW2/L!3AJ%Y!6@K*Z`%`]6QXNPY?/+MY3F;=?+1UF93QDC:@+C_Q=[\W71
M4$#M15.ZL+IFB4_0*D$!]OD*-Z)LFJT<,%F;B49&M'.2X<NUBW7^%;$PFGZV
MCU<VEAZ,,<[)DQ4<%JIK*LXW.]K;CD[=6'YJ1C@G-[*()T4-O.+G>236[E!M
M,B&];2?C;"Q3$R:Y>';0QIY[$<E$MHUN,*&^WR:A2MBR#=(LJUE515>E5:U,
MQ`R#!Y/_#]LD?Q-&;H-B0/(H^JSM:G@PQ?AQFQ3#A)%;8.&["RZ8:(,*"DP'
M/FR3#NB9M@62;Z?WF\A;[`L\Q-C;)C%W<<@YX7;07ER6;';$)H5ALV!96;+Z
M-BYSXCL+>G63:@+#T<,YA6C;!<^,&>:>.R/04.7^(EH)K#@QKTHD&(A="<71
MH[\-!`]@VA:(GKU+?-MXEEBQJ@&[.WI2N(&P56QR3\H=])</BV]DP*0P[%;<
M#!":I_3]^/)%IO)!)A5QZEZ.&BF%^,2JG%JF..=U\4B?IVE.<^3(L@K)X@5T
M==3^]).IDCWN";9<3-G+@*L\"1YH`1F@9`%]';4V!J(%,\@]4T,0+K&G;U/=
M9>S]!FF=H&XAF\!P]!(++FQSAKDG=/E#'5<HP?&\O>_O%KL9%-M&N0_-8F"'
MJ5OJ9.3?>*Q03:,-6#'>VC\>*U0G;<X%3?+YC/(PNQ_I&U<X#<(XS1-$_FAV
M&3L>D$HS>;E<W.#[""]P0,]JBIL'PN&K.,0!S]\&YA_:F)?`6+#C&IRWAN>M
M`8Y,%U?=<G;%O@M>CHFR,?MQ$092BO;WVA1Q8,A?%2"OAO3?WL7%\>C$<&\H
MT]WV+&MLM^6D[+=)60/Q"BATT^[Q8$:F0G;3W4#YH(VR].Y_).R:SS.EU05L
M67JS=0_;0/NPC78)RJM@L9?K&#2O!.>U+[1'(NHL3R),'V"4'K\VJ'C;IJ+N
M6SR\)YY4CZ8FS>@S@KKP'D`#\W>BVE002CXS"L2W#T9;>CHN;H5LL@89[\6U
MIX#CE8`8%24H3\P/'XD:ZHG+$?ZAC7#1=/0`=E#FP;Y@5JWD%W!/%<O1%&QH
MT<,KNXR,GN3982F:!X)AK'IZ95>OZ#MZA:;.-V?E>`M6D(/`YE,+QMC**[PK
M*T=;L(1EQTD?/FT_)RM'5;!^ZVY>U<\)'U;IRQX(Y@_NRWI_J7Z;('T'1.HM
M-1<=A`K6TH30`O#X9.J\=Q6!$CL*\.&GHXUS:E5D"-:5ZS<=LA"O6$6%8(7!
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M=G_E)](ZZQ2$$03;-[5]Q,4_'=:#7>,_`L<AY:</37H,):CK;_MZ>4#YP5CE
M;,24>P':X]VD;R+U84.T+=^E&YCTTS3#2ZK.G#$OM\8EF<1;Y)]G((O8DC[H
MHC#QPK:_CXFO$6O9]G*[76''_$<./Z]$T%6K?XV"F#C)_T3S\SE1-.(M^^O#
M"!7'=9G"8XSEUGM[O<DI(VRXZ)IIV"@;UT'/9B"5U#\&.((`G;.[@Y+-'QZO
M:UE,I;V=HSOHW6V!#FN$^7]'DYM7)=!*&);0<="GW3)=AXC[52M_=1]I]B#P
M$,/9SG382N45Q/6JE;-'LOY$P]NN2[:5RMNGE,#K4>;S:(X6.")BO<"/]$]H
MW<I)D;!=FVTK%1LHVE>MWJ!24*,-^$J86/JF_!?-&)I)MR`J-%[349&L(-?H
M^P^]C%_U<O$UC@*!$6SS-8V*J\9_34=(T^JV7JJO1:FK:$HY&U2O,8\VX/8Q
M<3+FP9FV)78,JGYCSG6'W^MMIQI*'EL4\@BW;+7OJ0%"$N8VQP=<HS0/L\M%
M64L@CFCQ(#X.4!$(\+9/EK@0"%!@0'^K<?"HA!O`W(D/Y7AWE<1G-`FM+$GA
MAUQ2FI)ODL!\<[Z1T3TVO%>/SV?%N<DR(3\#J&E"\'\?CHE)'7943%W%`!2`
M_%;(*]!5-;`2>\RE:C64H/Y4*70A^X#/_&J+ELL)<R`RJ+YD4+IBS5:6'[AD
MB%S[3U]\HH]D,5&6IY8VM^T(RI@N><VRDU#G?+`:VS/Z]/-#X;%`Y-)J;]L_
M,Q&,E%1W)?-KG'RG;U?$`5(]0-?5WG;X@8EDI*2ZY_Q",G4;3IR^N=)*"8ED
M\,S>MD,'S@AVP,*IPCY*=!5QYY#.0^9&E`.R/(V[XGFPB&X[<'3?+D;3RHH`
M];1M^0R$P:=!&'#%N16XQ/T:HF?7!@$'XUG!'D*2D>&V/,Z)`B4T"THK%*ZE
M;2NXL60$JIT3#Z.H2:=VE5;UL1UZUE]D>DZXY]-(*W/`#@J$?.[.&AT6S@>D
M=''.F8IN.;E"8G87N4W?2\<4NYY61\S7SXGRT6M=/ZO5H5DY:WH\3]]IS<E&
M_"9>9$]^@C1$Z7O:]\4@XFHM2E"&.&=7^!EZAI_I;ZE&A(HN]EVT'K+3LF#\
MU.\+_XX,7IV":Q<(VD?=Q;Y'9B((/3V.SAY6SY^6,#HG!C)^1"PW63-]5'WL
M>V4]YH^>"<[)K9-.Y7&_NI>S=JO[:!`H;M>D=Q0$^3)G11Y.T"I!`2ZO;%<A
M8NR.YD?+.,G*TO,]4BB&&\%9B]BM%4.S5_.XB8W]F*+,H.*R6[EQ$>HF:4H0
MZJZVI[O.AC&#%WEUN'@6)T8\DM2(-N`1C\'ZD'T1)UO`O749CYQYFB(S58Q[
M9UK?LK-4!QM=RDDGMLIM9I)%ZO0Y"/,YCN[U`6VPWC8W6]T),A*-^$KT\?8)
MA8_H2QQE#ZH=V89P;;LN)F)O;]X&8:ES+HX96;\A/[E]BH=2D!J<;>=E,KUH
M,?`UJ`,97G&'TQN@[8.%:56"9^(K4(JS.%?D%O6%9_O08E*5X%GX&C2"NW<:
M1",8/-NE`:;5"/[J;KLUXFB1H61HM6@!M9U=/YEN2)GIWM4T;/]Z_$`:H?0\
M.O:3Y(6PJBQ%6355[EZ%=`FCW6LYM(<CKQI\76UR_:+#A-D2FB<=&O?ZCUA^
MK_].DA$!>MRA><M/P#M`<:,$.8P[<J8(61$PIK2+CYLPTN9Q1R>SN'2V*I`U
MXC*+E0?7/2':/<_GD=Z(8AAQ4Q]P;"IH\80>RC#G/)(BSFM#-3<"8OL48V#A
M]V#@^`$,GW,<4@^*W0576'45JN]J;/ML82A!J6AT=%:>H*+N.@U1/B8_<::-
M+E5TL7TB,/",TS+'.7%"&#"4.[%M=M;4NIIKSS9J@W:Z&P'9!I,[I!ZXN[VG
M3UF#`LW?"=G:M*N=5].$=P5A%(A/PDE?&'2"(F[+S+Z\7+%8FM"/C@*"TYIF
M.:GB*V\R4IO[8M;$*P9BKUQ[U5`3GIXH.5&_<<)JN*QT527>"<D"`"YPKY6L
M1W&%`>PQO?0RS]+,CZC[2..IGE$2X)0N04IF@-Z);ZL$&\_C!BSR)]9#VN7,
M%S_YCK(9RVW\!:4TL?$X)GBR$B%G<<)5XJ"=OT681I[Z4:9^`>>=$(C4P2M^
M?*]$P%MCP(*/^,(=;(8Q++P2#5<T2\8IR$KS7@@]`JA5!TM<6VY^I08@`O)!
M.,0&\*$:P%G*FRM-]2EPQ7D/>]&W@R7M-:?^PIG%IV6A/Q<)UDMZ?LP&+F?X
M;7RZ7(7Q"T+I"4Y00)SXM,S#IO0H.2B<=X/-.,/&X]&I5YPL]FJ,O!HEC\-I
MTO#(^IEED!/W7E(TB']PV4H1I)J$9O&P1YR205@0;)M(.6V"@]J@32@/5L`O
M(UPE3+!Y=5%N?&K*RWN5SRA""ZS81NKZV4QJ+%`[0_0]PM"<INZ.MH]%8,)J
MIS3"V.'<:4>)]TWF9W3/?D%&ZB%,77?;)QR;B!3&&N<$6QW#&J\YVHX.$%5.
ML]ZTZ?K;7H*`PNLX>8=QQUF-;4RXWB*&0;&],&TF:!-.C7^KV:2E"$0ZC^CA
M4<'/,(R?.FKET/[P[K9O/@V%9D:<HY/3>!XZN[;V<@(&F5S3)X3T650V(M5.
M3*9LQUE_2FNC1P$.J[Q<Q8Y3N"=0[#C77WG-$>P<%W"45X(DG]=!JMPEG)(#
MPAV!@@/5.(P'7&0J_WZY"YMO@1^:DA-=[<>PE?48])>R4/]7E)6UX:/["S(R
M$5\91T$#>L_BY,E/I'5Q>4.S"6#;*[1:8#*SNCD;IW./*EQOCYX+?/[!X\/7
M$&B5#@!*O`=<VX:JO\![,]$Y!TNFRIR^+DK2-"]>F4%QQ9%6R[T7:=LMY6N4
M(H+UP\:"7@.R'64XAJS;;-H*<5>?5=4XN4LILE:5WG;*8@V$2[3C.`4<?0P[
MFNWTQ(T59RB&NZ]=WZ($%645J<.#TLOHZ)%XW_1RF$R9&S]$-RC($^::FSK!
M/6#;3E[<3'-Z,]-]/5'6;9.W=FY/T%V12R-VYZ4#.C'MHK7_>>F$[KV![(R.
M2&T72JL"26[\1[+I3&G4*"R,0XA&K"!Y):@B`M5&/`>QADO,WM1B.^@XHOMI
M%`48&J(B1`]R$-EY40.F:S1RYVHL.:FNU_>-C)*4A8S9-ZISM1^$N$`U$YH'
M;0P\5Z:;#>V58Y??NG#0QG,C+8JG?<$17N;+*_^%D7J2*]8R8'?[A;S5&&IS
M0\R@V#:\1D*5U_DVXI=S]AE$Q'ET^Q33\A7Z8NYP0+;M]NBB%[FVA=*_2E!*
M?I8E/HAKT_I^$X70PW9_>8#RIX\";;':G$<9(IRA-\MA/J?7KD,HC`JJ^\O)
M:*JB9[9F-V%9A2[O0GS/6`Q*1`9T=6G=4%)G+&NP$KF\9G`L,?(G9?U<FO=]
M1=W-#_?B46"[R4)W*Z5D6[I"J97[2"&ORF0?6=:SKL8L]Y'%J$YL(-?W]3VW
MD&``-DOZ`'"DE9>OXY",?0^K:;T14-NVP%#L[0H_F_/3.5,`Y,AY5!*E+6G=
M&Z!MXS&^;BCX^#KT0EW;>@.0ML-'+.B&TR6N^U"D+G+='Z+M<)/I=</I6M>]
M"%*6->X/T79`B075<+GHM2E!P++7&X*U'3LRK9)L2?7K&W2_9,DPBSA9\ND4
MZBO@'\32%P4@CX-DI])4?I>B/W*"RNDC6I>?T)`CUJ&HP7@%G&YB2K'1_VB=
M'/+)OP!02P,$%`````@`:(!L1D"B-:82.@``!!,$`!4`'`!I;6UY+3(P,30Q
M,C,Q7V1E9BYX;6Q55`D``P/Q`54#\0%5=7@+``$$)0X```0Y`0``[7UM<]PX
MDN;WB[C_P//&Q>Q&G-J2;?FE=_HV9,GJU:ULZ:1R]\VG"HJ%DCAFD1J0E*7Y
M]0>`9!591.*%!1*@Q(Z.;EO"2V8^22"1F4C\]3\>5Y'W@'`:)O%OKPY^V7_E
MH3A(%F%\^]NK[]=[1]?'9V>OO#3SXX4?)3'Z[56<O/J/__W?_YM'_OGK_]C;
M\TY#%"U^]4Z28.\L7B;_[GWS5^A7[W<4(^QG"?YW[P\_RNE/DM,P0M@[3E;W
M$<H0^44Q\:_>NU_>!M[>GL*P?Z!XD>#O5V?K8>^R[/[7UZ]__OSY2YP\^#\3
M_"/])4C4AKM.<AR@]5AG7[_^[7^^.7FS?_#NX,W;`^]@_[^\T[]Y)Z???GE<
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MG(79$X67M*`D$S;8F'<8+7][%:Y63WN5,M&)_T6E;_9T3SZS-*1?R2OO]4ZT
M?O8C*MWK.X2R5$8<MW%OU%SZF`CB#F5AX$=:I'%[FJ3S.(G3)`H7Y&M?T.\5
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M8`L[F<68V'VWX4V$"@F0^7Y/DL7/,)*N]0I=S7[Q;%TA9L>33^>,%^0G.$=K
M1.6?O.(`)JD^03=2L.MMS.Z&^K;'$/;&&3G:KM#,?U195UI-35+RA0R2/"%T
M[3^0_2J])-:MC")!%[.V[VH5LI6=?E?$CJ4;*HI5-F6%KD:U#-W2N31.7W`/
MLQ;.38K^D9.)OM"]2<&6X;<?WNHR:WWU:86I43"CRZTA;IIC#6E1JG&A-TI/
MUIH:J6"'H2TW-7+U1^K=BE,C7*'K0!:=JEXH#C"H=:?Z^6D-TZ^UI;CN2?KU
M9'FIZ@+082!;1XU*Y0&,XBW:IDY0YH=1^LW'U,_X@*1*T&6PX7?R/1KC6.01
MNEA^]M,P(-(^":,\(]^73Q8Y:@^3%9F@D<379`)44FYFZ]]Q\B%M!5WXNXXW
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M%W^08R4AYS@A5+'S-+%D:@=0VOD[L7+3W[$?9\H^L%XG'4PO>"29_-`UQA^,
MYS_IBAJ;Y5,RYN"\-3_#ZJ>&O_BNDPV[@WVFGR.]<$0,%&:JEY_<+*G2J=*3
M$*,@2W!*/?EYE%'RC6US9N;O*1*K:Z8H=.V)TJ9#^"&DM\;8D72;(`T6M,?L
MG[?U3Z]0D,1!&(4Z7O5=QNR?MQ.T1!@3S?<?UZ?*6NAG)Q[UQNXYCU/WJ](8
M8J#<!UT..@PU$"<U'3E'9"E>NS&_QV3-/O;OP\R/V&\4]:^/N8:71>'!(N=X
MUI#1QPA3_0K-SM)O3K#V65QYA#YSAK6I5NPOHMG'044VKW&=`.#6;77YEUZW
M/61TW9$A<)#?H+U%2,2:LI3K<J*Z7-:CA''VFC1]7;9YS1V@?[K7D^TMDI4?
M:A+=[CT`Q6RFO15:W2"L26ZS:_^T^O2BC@Z%K$/_=,5)=J1+6M5G4)U$2Y^<
M%#HK9=6]23/Y<1@S?\4Y^6N#;O28(;)^+RK*Z8!&[LF3'].1]HM_#KP]K^I5
M_R,Y7GK%$%YCC'[IYU^';Q#\AE"YOL5+_ER_]NV5_;UJ@`&IY=]W;I#^5IUT
M[U\;X_U;WZQH7)YOL/1NBZ4F3YN1O&3IU<?JEQO%:_4-3@Y%X#09J0_Y%Z\<
MM&2H8BE*@@8?$2VPD6#N.L36CZ6?WK!%)$_W;GW__C4U-EZC*$NKGS#S8V__
MH*RH\2_EC^=KXHCPT!GYXQJKR+]!$9M[7C;FM7WM`.DL=5N![++=-LD;!3K"
M%?'E(JRXTQ4K_Z_DO)X1E?L2L=G([E&8IA5E2YRLI/(L99<(.:@+F!#RRDLP
M4:??7AWL;VB)DA0M?GN5X9S#L@V4"E6GOK4D9B>1QU!%U_C=C&+(M5EEF#6A
M`/`2\<R!SRI06[2>E)8P!!#0W"@P;;M<AHI0X(D*`Q`X;_9'C\[\@,.#*8`J
M&W77M7!7!!F3$(AO[8)8WCFA%L#7\O`&`=AJ.C>.7?,4">`B_DH2.<UN+G9'
MBR+2ZT>7?KB@.5',W2=#1=BMA\_+.$1R!D"\+`,6D+-E'ODL_+X,@S`[R7$8
MWYZ@!Q0ES&]+EI!;)$50:YPY;]5W#5)]CL`]SB[&\&F+9Q]NMYT?VL%*PXKG
MD@R"81>+[00A`13;3=U'@DLQ:#38_RC.TC0GGS?[KB\1#I,%2U6K9>95&1P;
M9P?PS>@,Y3Z0G3B"@'[G(M"%KII!6C#66*&6L01A?6C9_/Q[7ER?2V<)8),Q
MSEKY2'5.KU!QF1!=(_P0!JB0",T;N2U0$QFR@Q#@O%8-*0=(%=]W5$5.MLW7
MKW^;TV^$!@/H5??U>>PH7M0)9@OD%6)&XRPI$]EH1N`M1J7O.^9Y5.D$QL9W
M5SG,LPEA_V%X[(L54TAU:1_MI`(ZTXQ?$[2YA13BHUF%T#:03I.<=WJF@W4:
MRVUHN[,$X?=I$/P$5H\^@)+!1HF@"D^B*)I)#(_IXA%%S'RHEH_FSG&%Z),>
MA<9=WT=A=HIN<.[C)S+86P#,'4=U&U43S!EW9&K`N[4="(DMVFJ@K#_X^,#N
MR".(>5=G6H=M]33!E_E-%`87RR7"?,^9;.]IC>$V@OJL@$!U=;9UV3]W1`H8
M9)10B7@!L>KJ+],YO'R_3^+R>N;%\BK-TV\HNUC._,<_P^R..M-AV#J/YS:"
MN[$%@MG5(68:3.%VN..HSQ18E0W0L),)6$;(`E+9V9L;IWJK*G<(MX'3Y@1$
MR;`[2+;8[XJ58*!1(B;C!\2MJ]?&=C2!=^/?2E2A$R'NZIA%>8`Z:M@SI;9;
M&=C-G\_6K;!/6\XR%?I#N8K:,=N`.Y:[&._&$@BV`^E6H.O4#-JBP<8*MY0G
M$.\^O%`%-165=>/S&F59D7[-JIYGV`^RDS"]SS,HKM=]0'>Q-,`7B&<?SBJ`
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MO0!=I_)-:SNL>GIE5Z_HVW<9%_EST`VR6WM?;03V*6V-T;/BPH]%-ZAN[7]E
MQR%+%8%/2#<H;>UYFVY>U<\%HU5HO+YI;7KJQBLY`I5_ZO_TT^51Z0:?K3U2
MA\]BX-ZYU'QTNL$?9_=4L-D'8PU^I+K!16M/K?4;C-8.+U0WF&CMO<K&\&`L
MJKQEW>"IM5,#MO&`"J7ZNG6=C[>MO5QL*@_XZ>L]>-U@JK73*UG.@_$F?1F[
MP4S;`.!ZWRK:'2B==3[59IMJL_6`TG'DI^DZQ^D"7X6W=YFX+IN@B]LUV:2\
MNE:BB$NPK.Z7L).=VFQRP2L`Y7AU-M-8N5RIS2">+M=J*^F5U9-J-+-5`4SE
MDTDD9(.+H.4DI>:39<(R#-5[3FP;F!&=_DP(^R$P/G8>>\Y34I>"[898A)3#
M<K8BA[GR^8JCGSYNE6I@'&^>]TMWT9/N\XQ29W9DUTT+2_IQL/2AHSR[2W#X
M3[1@3Z)LO8:9?GZJ+@M<XC!`5_2171-KS\YSCU+/>A`!:#(:3MY;<U.\+`D\
M+)ECZI63KCPLLZW[B.YB;X(QT&)T>C7AOJY)UU/39HOF1.[J2H_\0BIDN01@
M\S'*AD?S6Y*A]1N>A86?ZBF+WI!C4HL.G$$*8/@:=$5D`KR_6GMW56M/T![/
M73AW9PO"LNN=9],?\SH/I+BWQU_%CB)&"_D3?8B9W>DC-D^1QWZ<I)H?N^$I
MW=6>03B'%*QV77OX_/1:[I,HVM5*(JEG0`T6H1/D%HF(;^6."#.,AHLWBG)$
MP*<<&YRULT5D*2+EN-YZX"DT.84FGVUHDAWDQ:'(6A.W0X\M7EQSA#$"99&.
M1B,[H<2V(#F";O+A7*A05]8NAP(U\'`YU/>5R'*5KV2@-)K9LHAY*IY(R`3%
M;G?5^>H_*HF]WFS^SEFQM\@$?4R&"Y"6,Y^@^R0-L^/D`6'_%IT3PQ6LYR3J
M,G_OZEE/B7(W=]A+G`0(+=)3PG5)._OS<9YFY#2&!6:.M*N[@&EQ8#I.8^S=
M,9;H>H4"%#Y0(^\;RF"PN,V=!PBFVLU0"U$H8J)G3S0"F-43S+^G:)E'Y^%2
M<*Y3Z.P\8*H\N!GF8&GP9ZM[/\24YN,[']]RBX15ZLEM[SQ(`K('BC[4BI%1
M#7GP(^HX.PFCG/J/SN*4'/-7""[[J-S?72STV3`=30"PV8I:GL5!E"\0K0O(
MI19`2',4MW'JPHR3KGFURX1[FZ#%9S\-`[*.,YU$BR\^CMF-881+UFD4HW0`
M\_W)K=MY&K</2>.2$MJ:T<*<ZR4U7D6.=TGODS&"/$;1VBEM_>*BFM.]=?E/
M\0KCY'J?7.]C<[VG*/CE-GEXO4!A`1#YPS8NY$?S<W3K1U_(BI`]`>YVTJK5
MR%&'.X_4/AT"JD(NZ`$OA)`FS18#N]<%8DL`"GOUKO<C5B<]Z=JB[\>1#ABI
MO*T6]-?2'G"'^<"6)Z2QB2JQ;CH27UA<U*[S;XJ+NBMK)U?S*2YJZPJD;EQ4
M>.71[JK3*2[*^WK=$'N+3'`!LBOVR@HX(3N7I`9"JZ7;^RS$F6MAG9-BV3T-
M8S\.0C_:5!*FE,N^![7>EFH@0`@D'5AP=`/O'SV7MWR#"`][PF,Y[U_818NO
M9**[V5V(LZ?3$*?9[&<RNTORU(\7U^%CAE`L/OMU&,J6N:#UI24&>`1M#<N1
M].)>-WV>BKK",?J<IV&,TA05#PW2\NWE;Q;PQZLSBKLAJ*[,F'840%]J05=!
MP"QA-Q]N:TO2]M<(-'=7_E*J33L)`$'3\G4T"$D?G8YS5#S]4XL4`0*7=7-;
M\$K4FS8;%0'PP:=M."W')>:*8$BRAI]8_I93'LJ+U.G1_7T4(OH"TOH[8S'V
M\B,$9*XUAMMHZ+,"X=0U<<?,+OX[D<CF)MS3"4H#'-X#:U79">[C+F9JI$,8
MV;T.7%D1Q\GJAEB=E%KZ;$Y(2&-_F6$_3I<($ZOB`$9-9Q3G<=1F!D+6\+/)
M%5VU[>\R)[:^7Q:9V=P>WGXU8VNIU!_(7<QVX`>"S>ZKR7SM*Q:5K*&'YZ%_
M$T9A]E36TM;]/%7&=!=X,ZQ!.E![E7CX/#U95EDM0Z_6E!IMIWZ(V;.O[#W!
M#>_"'+U6V7:%]+,HV$K/J_>AE'B4%(_1PMY;JU-3R\]S(.FKI6%3OMJ4KS;E
MJTWY:E.^VI2O9LA'.N6K.9:O9B'`8"D5HI\`@RAAPG"`H6[.K^_;T#>U_3A`
ML^0*1?1]WTL?;YX$;-T74Q[!792Z,#)09*)&%M&1IJ]$$Q]Q_]&@H\"&Z:#%
M:-V!SF+:E1F%H(G3/H4O:1:NJ++6O`GE6V/E\G\4+RIO2HA25F,=+80^AM8S
M:EU\#&O"MIP+Y?ME%77LDF"-/J\D<'([3&Z'R>TPN1TFM\/D=IC<#I/;P0WS
M>E/G^6Q!="Q<AO[F;5>1O<7.XT6-';@8!VS#&IQWC":\:?9?@+[5GX'>E.0:
M2NN`V5^6[HF$8-K9X[@&-A\KK]XJ+WYG025%Y+Q<'95*931>L,[R.(L?2/L$
M\YR?/8A_/=V+4KHFUPH.N)$K%5AH<1@E`Z=_44HGE@*DA'93LLU^="6RZ#Q\
MH'_-_/@V7/<=:KT3$O&B%%)%%I!:.I>%WED*0VK?"U0R!5WJFO?NGBZ5QFS]
M%V5-ZDO_21P%&92,%Z6!:M*`E//3LU'.;TD<M$3!#EC#:"4\_XM21XD81+'#
M9Z*(M9\,HWFUG[PH5=OF&]2MY^-U%CYK87BB%Z5+%;^@#MGU&PNN,%;7;:N[
M?*ZCUB`4%/<H/9X5:X-]NK()G5>&/OD&=6LLF8=7*,VC[&)Y<5_F5M+GF.I7
M'`4IAN_V3:08%A30/ZUI\"C8C<&F/,(ICW#*(YSR"*<\0C#G8,HCG/((ISS"
M(<WU:W3O$X,%14\;>Y)=3?$#QE59VBLE%B0M5)1N6FD9Z=VG&:-IOB.WST9Y
MR@0>RN=Y0F^$]J0]@GF>H_K(V`6WUY&<YRYQ<IJ0!NMZMF?QDOY=>I8[,'&6
M([-[;'IO/;]7(\"=5^)J$MN.V:L>?M^8$-AF\L:5NNG4.YUZQW7J[8[2*9P^
M\_GIJ__W!!]'?IJ*'V+0&L31,W075MPT=P0L;!CXYJ\0>(*4RX(_D)U'';I`
MI@RZ2&+./?U@"WDG70RVM,/EEZ2.\S1+5@BSXAS4*KH+[U/9DR""3D-[-W;\
M7A,=OMQ<W,EI:H$H:U+8MEO.>;HW&K"XW(!?F>&*3-]H!935/<K"HAC*`R+'
MJTSH$11UF;\;)1)*;$&0O+/[V9R'`=U/XMNC6XR*!V9DWP_897XX2OB4V(+@
M.YQ>6YU>6VUQ,;VV.KVVV@D/EVWDZ;55.V*?7ENUYS*(>$9%E8HGJ'NHTGO^
MT?$XEC(3;IX(*QH%YN&?*+R]R]#BZ`%A_Q9]3]$RC\[#I<`KO\NHSB.^,W-.
MQBFO4)KAD+YJ=GV7X&PO0WA%ZP2D&95)&<SZYF.:Y?FPL4X;8;6WVV&US:!>
M,>J,C.IMAEU'R;SUR+V'%ZOB!R%*&Y'$]4^%D<-WVRS6.K;B@YO?#!8\;980
M2:L:(HTR(XV0L[RY4!Z'V_(H1_2J(5EY43:H5XY:14NWP\^J_0:3Y6F.R7"$
MK7JU`K4OX?VV6-9C,;[6H]GX`+ALU71"Q#:?VP^JW#8AE\ED@*5@:\..US<'
M!$D&0E&T7@=J9PE09JMII"D%4QK!E$8PI1%,:013&L&41C"E$4QI!%,:P91&
M8'UQWR&-P)+/M:<T`J%KUBY&M,X*B[4C]:`UW&?<Z1\2OL!U\AEE'8PS:42)
M+0@^RTDC4]:!PY'P*>M@RCIXZ5D'SD:_MZET<\GIE'+@;J9'BTSPZ.%"R@'/
MHE`)3*OTGA]80DDSYT"%"S?/CP*K\'><I-V<O*SGF+&K<^#FDB>@_2@(\E7.
M'FT]6B4X"__)W!F=D`3&&C6V0IY`J\)5M(6UZL3]1HWBFG[PS&DSA4<MG%U7
MORK9XC3!6E'NUONT6E'N.@6;?(]E@J?X=V^D3_'O*?X]Q;^=@'2*?T_Q[RG^
M/<6_I_CW"XQ_6SK\]!3_%KJ8'+]&/\Y,!"6VP)WQ&06T1YV0(&8+W+<L7Q6K
M'=O;6?$PAN)^\_>.NX,4R%?8I5SU!GU)LW!%O9*G.;ORT78.B1Q!AZU7!+0<
M0>O)O6)VKF?(M>L@QW<TF):>Q<<^QD_D&_[#CW+R\ZJI4%ZM2IU:\BJG]L+8
MJR;WV.STE^L^`Q;J;+PC1\1%?H)SM+Y.UK@K]1#R[TH=<HIQ%N-ZY<!,).70
M&W_AULTI,KQ]ANMN5D7A\&72NDFI)I,M/ZN6''N7W@FZ4;L]=]BZ9$F[<J_*
M.>!9G9S"DU,81FEZ461Z461Z461Z461Z4>19O2A"-QYR%,!H$6:G?D`?F'LJ
M4^@^)Q@G/XEI?NS?D]]D3R+OAOHHSC_HH,V,F\BR.B6T3,F::)%AUV[L/$X0
MS>!68M.)<9TEP8^[)"*4I+1`!%E'E$X0K;(D]8'^XA5#32>*Z40QOA/%#F$K
M^HE0%^8B?`@7N1^)$TJ`YHZ>.<1$N[G7M(C],\SNZI'062*QK2&N90/921(1
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MZYPI,7Y5<MFXL:5N+EM*6\?([P2F].KZN^:9N=EM?F`KRZ+/M4)X_.8)`#04
M.E_T`OSOLY_)["[)4S]>7*,`Q6<Q^0_-ERC<.G'!74KY$CKGM<>9'UARW0\!
M]`X2`9'O_-0J@#P-^%PBO$SPRB>D%8DSC"8AT+)N\S>6XF!#X:HF`-!(,!U`
M`Q:3BQAV*]!^LF[S=Y9.M$/!J"8`\-1@^:C,0HV4?9P]S8AH4C]@D<?/3_7?
M2#RF&F.X?=33EP8GNNH,GC+3F]?6D@=67^XP<(X?KW9#R.6C30\H#IJK\V5U
M'R5/B+UQ>!)B%)".</D!VD708WY@Z=:ZX%-(-"@'S<?WANV.8Z(A1.MDA3JV
MF\W??'!9OGQRP27I@_E**!7":IH,=YB_M?4(MI*@982#BX?I`_`IL>,15I,V
MM^W\K:5POYJ@!32#,NX<[9>MT&JK<D7C.%;B.K6@1#NOOF:,E^HX)#X0-%NY
M;?+S.&K+_;T34I>9BVX$5+@2Y0O=<5.]F]Q=-M&UL1DV69YR<^SC*+D.625T
MPK(X<1[L,']C:3.5.XQD1(,?P[NNJ<$:XI:Y^X1]YF\L[;3=A+Y%-RCW]X[D
MRQ<>8NK-3&+JOU3,F>=W<WM75N*Y#=4'JT!MT2K;-8#FEC/HA0)/5!AP=#,W
M@8[+6[LQ!%W.%/B3WL(7>(K*=HUF\W>6'!CB[R.140R&C$Q[+LJYCX(L?*`5
M.43[/[?M_)VE4*V2A"5D@V*V7$NUO(114GZ!K\+;NTR\Y0NZN+W=2WEMP_/1
M/7`4KV?Q.]G9]N6"5P#*\8W?-%8N&P$&\7Q^9H"EPZG*-R,T!D2'TW>6'<(7
M]U1V9_$"/:+%+#E+TWQ=ATE^#T"MM]M[EXX$VOA]<AH]V2JIVM_.YJ:%C!ZH
MCF]YP^#J\D;8._8N;X]52)$E)!;LR+9*L,O\W4<[VZ;F)YCHL`/NIA\MG_G\
M^S#S(Y9#>I1G=PD._[DIA\BQ4KGMYX>NOY\JHAO"QC(RR6J5Q$R=6-*P&CQP
MIQ%@)",>W/L,IS+EE)^+Y7>R$N"?.,PR%%_F-U$87"R7"-.2L=N4'K-RBE"F
M4]?Q'(;,`%_@5N:`TYZN_?2*Q"7"C/"C%7VT0N:[Y_=R&$5EZL'MRVZV!$X"
MA!;I*>&\HOZ,"M6/FGHH2*10'<)]%#59@2#M>IL`6$S9Q\],J<5)3F<GZA4F
MBV(Y*'X^2]8K"+&W@$54>QR'`=N!'P@UR^EB-=6K&<#IET>$@Y"_,W*TEMO5
M81SU6("@ZYI"H/?!L2>Y=O_>P&$<AJD[.Z9#00!DZXGKCR^>H#3`(=,D`")9
M-\<A42/?33<F4Z<K=)_CX(Y>YCR*%U<H"S%'NT3Y4LJ#.`QE5V;`4[?E6B1*
M?!3;]*[0%J,\%VSKW(#@6GY'161T;5VK9G>ROZ'L8GF:X"4*Z5N@,L1W&7HD
M:K`[BZ!NV$YZE1KDA)5KA!_"H+,BM,89.>H`/R#$=GT[<B-P%X3YPXP68!$[
M(+Y=_4'@3=VU_["@Y!IE682._?0N0NGZ@$4.8`\A#>*!VW)Q0;;+8`[CMRM3
M((IV"TH(%YQOZ"?[5=<%>-W?85P[\`%":=<O)%I:NB/9[#Y:('EL@#C:O6<B
M5$5-AY_^6*-%6,H3"+?=7&.1PII!&QYJM&#+6`*Q[NK)ZA)PX=)W$?.<5-(@
M!326PPCNR!.8?S#6\KDEI[_3W-_T+"XD\2>BZ<)H<?2`L'^+-B8DL?\%'_IP
M1#BL8+:$`6JFY>(=G)#TQ;)V9M$+S#>ZNJ\%BBR`V!E.:ZK4ID%"H6^SY++T
M[<K08?5CM`=R&*M=&`*1Z^KFDKM!&M]^E:DC=WAPNSF.BAKY(`:&75'<#_C[
M?1+_@5(:P;Q87J5YRCS>,_^1OJE('_8FOQ#ZI'8<U7$$C7`'`FPX4:G*9JR1
M^I\HHKY/LC\3T42$1$F"IZBKXU"ILP#BT=759/J#,_VI.8[<CGR!<`Z3EE1\
MZ>7U0Z%#07IV:PWB.'!=F`'1,IR1Q&BK:`!\'>5SC4J8:0XU!N0ZL03B9]@)
M5!%W%#<"M719^/+8,G4!Y/0&<1RS+LQ`:)FN0E?1MCEL=+3X]0<:"6JZ#('(
MN>@/J9C4=894_1S&4(-^$+*>;G=5L[<BZ!(C'^SG,`P:](,P&/9I;'PN)4%=
M?5#B[HZ#HL<&B(UA7T>E(L5&V64#$O1T'!%E#D`P[&;/7)*Q$,9E&J;ZS6%Q
M/X=!TZ`?A,SV[:DZZ9<^OL",[>(@(?CBN*Q#_<<&H9@/$$J[B3(\+02M"H'F
M.F]1*-(.PF0WP85']D6>I9D?`QY$`;^UCN,$K,4`B)KE2U>RJ#H45*],WW)7
M>/##B);7.DTPB[/OD-30<4;W]:1?SB$%XU70-W'6.\WI_9/JY%G8=NSZ(2WC
M+CGO"?LZ#*0F#R`DADO_;B5705E%M"VOJ>,"ATD&Y6OYUE/7[WR+TW6NTBS)
M_.@LSG`8IV$@NP$[P.P.:\S@4@"5T+!SAY%[(^?H1I3^AK;SWJX0%3LK*T1X
M\X,L]Z,9PJL#*/(T+!4.*YHU:8`*9]AC5<_;+0DMP]^4F%1>2T%]`-=AUF0$
M1,AP>@U9F>@C\D1EZE>"3_V@-L`6)J(NCJ,@)QV4NUU?U+J,97'?D[\U?4OB
M!Z)3J'BW/&7;3?WWQTF:?4NROZ'L"@7);2SV//8VI<,Z,@SKH(Y9?K6H+ZX+
MZX=\;^6/:#N><="W]+ETO&!M%,@#5%%W;\#Q*EW\CI.TXT56<#CW%68'MD#<
M#2=";9%!3:&SN'"'`%:'H(?#B"A1#@G]T+#;;>;C6_+]DX,%U0F!AZ?=T'$1
M0P2#DC7L/>-`C!9GJQ5:A(3\Z$E=IQO=')>Z&OD@!H83B+:H827%RY-6?14D
M_R7_IN")4W>8<6&DR`Z(F=U"05O,U..:+)&^^`$Q:)H9]0(+H.N(#J-NA#-0
M`4Q7$J*!CZA\A7?)4]:ZE@*?K-X@#D/7E1D0+;LY3]O[`ZO$L*V'73]5I=$<
MQGIGKD#0#5_X.O5#7%Z=*'03+7A:>1GEZ5D<8,8U/7NFF?"*Y:[#.@RM.?9`
MC!VN.V3N'"X9SV$-,,`7"+UE#TS7<-7Z@S@B\EA5$=)[1`4`10OK@=A>YAR!
M"O7,.ZAF(\TI$[']1T+-JBC,GJZ(]'M(?U"??"2*-X00(`WD/=(Z5@V\"M,?
MIQBA,W+N)DM_-J#^\:9^8=H'BP#4/</^P?*]GYI1R#,&Q25)-(9P&-]NK(`X
M&?8AUO,#>#05+DZ%O`BXL^/8Z#`!HF(X;:U)4YG8M",\TE%&A9,B-R!@=M^+
M&\#4^$KDL\I75FV^D@:'%<N2+$"UM%SP?``Q^(_VU;*@85++;5F`:FFY>'O?
MIO&P:Z6`@A>FDE))@`IIV1O<NQ`&724%%$P*J;A".IDE"+O=RU3PSL\C",<<
M@=+LR!NH!@[XD+NXSHEM$&+6&$P[V-4[OSW%")3$+*N0SGSHZ:KQ28@1O>5!
MU#F\C=E;B:*OOGY+5]358=ST6`#QL/PR)'<_T[4$'$9)@6X0&KM7E(\C/TW7
M!;(N\!6]@+@N,X""G#XAC-)C/XK0XO-35<"I;"C(!MAQ8/?!-L(@J!6&G:_;
M%6]URHV-N=!8AQ)C'WJJ]\9V4&:;0:M?D_!&Z]&(FT,U*.B>:LQ7Q-0SV07I
M^[)NCHM>C7P0`\-IALT"-24M\5F<9F099&_S2%"`.XX$!QD#(!*&2\+7XK*"
M$KA;28XC*'HKI!@4KI.NC$V:L(YMK#V6PV#NR!,(=\UE\=?76^P28GY4O^/\
MJC$H>LQ0O-B<+1O2"5?W.%R%Z3VA<.7_$B2KUTPXC!N:Y8UP^N4?>9@][5T'
M=VB11U7=^J*"!"T/=11DX0-I<8(R/XPV\@DS.M$^^^?PO;?GG81I$"5ICA'Y
M2WV&OWC%'/3'Y2Q>LBR:>,5$'IW)JZ;R_K6<[-]>V?PB(-7@:7R[K=6/N21G
M1DNO*9!=MC/Z`9(]A<Q,?KO(?@V2.".*^B5BL_WV*D6W]`\F/DL>IYQ'-O<W
MM!`=18O?7F4XY[`\($K,:34CLQP]A@+=VFIF%*,[,BP.\ANT1WY*%J[:L@YC
MTA1U(B(6A,-!7X_*ZXP;]N(%7;&^^2MTPC::'6)&G68SNU=6X.\M&LRT=(`/
MKZFW+^72Y3R<XGCRKO.J-#=O>6VT"2W]/,HZ;P.VU&T^Y.,O6^;6UX;!"E<I
MV[2=6S*=^_S.^07-FCR/='.1%'.L%6,NSNL]9"-`4\UYJZE3I[!>.'Z>BM1\
M0EIV,=+\9,]>F2">05/%10=/X0OD/GO?,4>%.Y;[RM"-)=!(&/72L:E8N5;O
M_I8.SF3N:TM//$/JY.*UB>+3V#RQP^K);QEKS>`F+9N%JB!$^1OJ2RB%HJMB
MQ@D8J=KU(P=(%4>:DUZR5@2]R+EC?4,]H3\:T.A6I6"DRMB3(,`PRJBUL<;K
M5EEUV?,8YL]#(@*>O2[JR`%210=RD#MY8[BGF9[4T1P1XU=)P[(01;[&K)>M
MQTTLJ:86'<]?._7%`2JHXVXVF20X9SE+*JI)R?-7TBX"`=74@7>Z6K=B.A[]
M:N9.*2F16#ZCVS"F51\^^Q&M,*A=0,T.E>-0;Y>$!:J^B^XGDP=-.X>OW>@:
MAWK;%0^HT`[4^^ARPU%Z6H5>8WNCNV3W2LPX5->"3$!]=<#-M8,X:A[F'5YT
M-(1-!V*>O;YVE0FHKR,M'=QUY[&@QN9H?/;:;5A4H-([[@!6=X$/]7HS..4X
M5+(WSL$$(@<\969VF2;3P^SV6W..0\?Z8QU4,@?\7+V>&H]N;S&Z)2`,M<QU
M)FD<*FI-,J`&UY+O'+M:R2E^)KQ6^:'#M4HZA\<F\3:S3#<JIQN5TXU*_K6B
MZ4;E=`UNNE$YW:B<;E3V+!-(XTS?J*P.0.5S]JGP2B6_\3._4PDS;7I_$4-4
M/A!\3/Y(M)KFNZE@!?6:\Q3I^:$F9!_\QNP:""Q'06R5U9JX;9&U>''MJA\C
M$/R0ZEQ4C>S8/FU!<@3=Y,,Y<T57UBX;!QIX]+.?FX&D?,I`!DJC60^P*&T=
M/!5/)&2"6[3=5:<LV"\5>[V9+0^G@MA;9#KJ,.?6^!7OM((N;N^\4EY=NXC-
M)5AV)A5VLK-3RP6O`)3CC@?36+F\TQO$TV5+H*17MB4UFLT/+.U)*M],(J,;
MM@T<=Q!#)^0BQ$5K%..<':4OLCN$9W=^K')-COWRA.PLZ\!;#V%>TR3.#W@O
M4C^+N&\_HG(X)M(E?T/TBF!?6872.4>BE#WR[J:OI_.G.,XG;<>AA0/*PLUS
MSQ!2<.A%VTDKMV0!:>5(+Q*.[T';EZ614DE`^NC`/<!>9>#,>[:3/BJMCR,M
MKB;:)4["AW"!X@65P<";=7WJ%Z:!L`@@U:M=,74L:;JHB%!/"J<)X^O+#<($
MZH]=WJ5A\WFU"3WR/Z\VY91-/653/_]L:OZ"I%2?Y/-3NT*).";9RV1N1S-[
ME*^3OM!NK+89[9;3N^-D=N*N?:I(CZ6%'8_TCET;78XLCUIC!\U2+\IVQ7#R
M(&W5;.145KJ9M2$1\6IZ,Q,A,?N9R)%8-[)V-7=`*)K,@FMY+V"0)@H?1JW9
M_-T+`&2+7=#+W@<DITF.Y8AL6LUM^5L&!&2+6]"KUPL>X8/"%[)I-?_X`O!H
M<@OA\?$9'8;.DY\(%W\*5V$VD!VZ->O\P-;-*RLOIW"Y?P$'[^_W]Q9T;6O6
M%Z9K7.Z?62J2"R]?CE2K=F;9X?RAEUPA=QSJ:$,HSRRUJ"V.(O7Y+`XP(HU/
M4/%_Z^]#Z9,U$B6V*Q[3F4G`D;%8\FLA;.#0V&KG,(@">DWGUT!/MYNT]-KO
M,(JTA[=?L=?2+9+DN*[8%\U8<F^^^O@'RO;8WDT+,A:;\8)-2A_5N2(_(VP1
M9EGG[X2<JBJ),!OGDV(V3GU^KR3`VU#@+1/L;6@H1O$8%5Y)QI2A,V7H//\,
MG:G>H:OFOO-%ZJ9ZATXGHXQ)E5Q.1WD1]0Z)J1GD6?B`>';9C+`1W$D33;3&
M<"H/Q7R=/6U9#)2GHD*7+(U%:PQ;5;%<`KHI#!!I&U!+DV0T1W$KJ<D2W%OB
M&"KM286V=SN#_>YE%$K5%06X45L`^7!GD`]=S(BS`W)=%&#@R##(F[J\BJ87
MW&%^^+PAE'`.QD;Z1DQF1,$=W,IZ'`"Q)N=@W*5WQ*2VD*C+_,-+0VV+=S`P
MT3=NTJQB00^W,EH'0&V+=0BTSNFMRJ#)4H\%/>:?7AIH3=8AT#X9!NT2X8!P
MX-^B(L`Y"^GK:C,?WZ+L8EF$S:NK]67,#`"SPTCS`UN.`Z5`<&>.!O+S-"FH
M4R?,VN!U<!P)&>'@Z=NLP(LI&1%%A!]%/GN-<.MHP90!P$!K#,=AZ<`+>(1V
M++5A4U:$=VP\"LB!DC0393&\W^]04P3(5JCFF](5IG2%*5UA2E>88LQ3NL*4
MKC"E*SR/=`5#+VQQ[+2KZ^_2-[=$W9YQ`H,J^R/=J3J_+/`MB1_8<_.]W2W4
M)<%:N-W^,P\\2;PTA6P^=6%#'YL4O&!UY`AB(,_3KC?0_F!?$2N(6CY8D=`?
MM2[[\MX,@>_$]#"_N]HUO!@4?&7/:J4[3?`2A40J-A>[%A'N:J0E68`),L]4
M+==&B)./AJE3]X(565-(8)K#,]7P9_@VWLO5]2Z2`E-$GJG"%W:8TPJO2>(+
M5O@ND@+3:YZIPI>67([1=OT!-[1=A[X7K.K:8A*%?1W-MRA?*U;+L3CHD&-1
M33!E54Q9%2\HJT+ZEKOBJ_5CR+:0OUOO6/A`X5%W17CLYD'(!:\`E..I#::Q
M<CG1P"">+N<.E/3*<@4:S2SE!JA\,8F8:C>7P,Y6\[>D-(_;YO,`E8(U9G^^
M!Q==(;P8#82OS/0G\NHJR@O4MCKKIB/SSNI854%R6"U;S_H2]:S)_#.+TXO8
MO@\Q&T;[A4Y3\[Y,;6NR;SH`+\HYNI%S<@-RDM:JWRI6;Q<F(`U.C+O:9EDF
MD`H.4CA;YV,2/"`@JXV_4\*7-@$C4+7AY&`Z'MU5O<`\^PU;PG"[$14S2L3(
MU<R\+$Q'@GM4M8IXV]JF1<?S5SA]<:A$9=U1NK7Q:5WMM"AY"8JG+Q!0]0Z<
M3PBH&1!'\:+Z:<V"%68*O-DE4Z`VM4?^M_E%;?8IBV#*(GC^601EB9=+'V=/
MM')52DZ&=`'Z_%3_C3BM0&<,M_,,]*7A6LRC3J<LALUK:R?-H(/<8>`<3S?8
M#2&7DPMZ0''0]Q0J*^`L37-ZE>\TP2N$O_I_3S`SW0KC0E@!46<(2PD'@D\E
MZ<Z(Z=50":*S^(C8G]'L9S*[2_*46'*SGRAZH.;Q`^'Q,O(#IKH:D.D-:>M,
MT@7##IR!*ZAA5-G;>S]QF"%<T2R$#&QOJ_:Y&AYBLL$H4*^?T"PY8U?IZ.-^
M47'VW)0RE54P[S*4K4K9W98]98[``(H]]&35S+L,9:OVLG'TFAR!\0D'LXBG
M%&\W,G^F%.\IQ=O%4]B4X@TG2Q_LCS/)F]$-NQ5[M#'\.$#T&J*"#5$UG1\X
M':F!21[H#+MKT:'!BCQQRABY#6U?#)LV0/I7#%'<<`!U$4[_<I1(00S@[CJ$
M:K&?ID=Y=I?@\)]HP1P4+(Y:\$(KCJ8-JJ^H$*K7&VK!TI)W/=4R/_TH5:LO
M,8`.I7ZLA4WV@H*]T&SL.&PBHB$A'SJ;?L%^V5+"\J;-+/FRNH^2)X32DQ"C
M@"A!S6F2"C,RWG;(R"@>Q6#4>'5RO)(>+TN\-47>FB2O1M.4IS'E:3S_/(T9
M_=0NEF?$KG@(%[D?B=V`0'.W78!"'EU+M&@1^V>8W:T=S7?A/5E*XRR4Q_BU
M![+C)A2#(P%233;.N0UM8>RR>[%'/1@TV6-M58C?W6ZVLI2RT?5[2H2,N+FN
M5C:>S+';;&<KJKPC,C`O0\63-X:TXLNN=N/`!KX$+BN.!H#/8G*F0QL#E\Y$
MQ2NT_82=W+8`%?AU+0P,D"RS""3=[-AX*N)7`LQQNZX/S%RVV0SC.JB==HVB
MJ+@A]-7'/U!&_BS<J<#VEFPWM2\D461@H$C4[RA&F)CV\>)HL2(22C/J]Y2\
M_B[N9"M55EO^"FR`*!B&X0JEB(Q_1V@Y00\H2NZEV<RB+K:R8[4AD#(!AC;L
MV@)'$1L<+?B!'OI(4)P*7*QJ_><''UR-EG3@0^$4.GP`I=#8F?^(JI#'-QH#
MHLL`/_;Q;COV48S@L2'6$0IO/<J_U;CKFX-:[.<2)P\A-2E.$]SFD<_:H9"U
M9CAG/;ZW3#!?!I8X7__T"A'K*0BCL%B#1)R_U^!\\RNO.8-MQD_0$F&,%N3G
M1VF*LI0LJN>A?T/HRT()]!\T!%#-PT10S,2N5M?F&DX4E;?KVG\@YE-*(^AJ
MW_'';8ZKD;QR*(^.9>.#)@OH*LQ8)0&"("WB1,A!1,]4EZA/VZS51F1(-<;D
MLNA`D+*U]4SQU2F^.MV#G^[!3_?@IWOPCKC;QGX/_I*9'L'3,49%7.4\"H1.
M![C#_-#E^X(2NB%Y'YJ^_HQ#8G65Q*`\"P,_2HFI+;X#+>PT_^2RW!5HAV3_
MR?*V0C-O)5;`IHGCF_PV+ZZ%UAB!LCR`1B-+NW9+D!Q!-_EP;S?6E+73^Z\Z
M'B[?</Q*9+G*5S)0&LVLW7#DZ7@BHQ,^(-I=Y;_ZCTJ2KS>;'YC_(DQ)ODTG
M*/D#P[;-.?)3Q"XAL!@.N]MR[-^'F1^Q7]'\G3/R>6.49E?PO1'=8>8'EF)=
M:C=*NK$#@6;Y;GV-[O0<I2E"G_V(WJR]OD,H*US!GY]8Z:CB'C1]!/42)\2<
MR9ZH.S4[BA=K67Q#&?S%F9_+847IF6<W_3;:W(*,,C$<!4&^RMF9Y`3=8Q04
M01F#&M9I_F>H=3O(P<W3QQ%&_L7RW(\%[S!MVKB/Z#:MH-5K5>I,X9H7+7F7
MBLOFO-;N(P%3#6'2]<JN&4PNR(?MT]!@L1I<$1;+%`[A9BWLYCY*"N2##D*7
MX"+?/%N^U^'=C++B1^EG/PW3:[(8^XN+^`\?A]17!-C@?)GH#STZV+NR"*E&
MUP>5S*A&6:XB/:4U\6+!M[O5T'W8N`1#('PP?,8-`[HL'-UBQ&BM)5:<H#3`
MX3U@<[*CH%)GAP'090("I>M;4.:_C.3)CVB^DMKG4;5V&"(IU6"TQ>R'\H<?
MY446XB(/LEIJ;U&H<\5?DFA7A9X.RU^+`]@I:CBYO%(!YD"\1#B@&]LMY(&#
MFCLN=C'9L!O4K*R/;LG*>$OH+;7@V$_O3A%WA:'MH>:.RUI,-BCKVC%_^$QO
M05IE+8FV.+&![EI1$NV'?;V\RV96+1O>6\_LL:F]<N[RMX-EU:K)ZC3/")_5
M7L,(+DQIH90.=I%2,:57S5E*J9AU./%<%V')LWB9D)_7LLO%B;D?VB]9%0-Y
MM9%L9!Q?YS<I^D=.S[T/:%/\2<)-NPK4>ABO&&=*+9Y2BU]2:O'6=S0C\XDS
MB,`.;N<32?AT+=+$(5>6ABKH8B?S2"9R*4".YPB;Q,CEC"5#.+J<S;1%M"RW
MAMO<TA5^^7<CQ,?UBDO3U1?35U\LI\U.5U\<W]:FJR_.7GWQ\0]:@`5A<5W`
M5KLYCQ)G+ESPR06%:KB,R5&\P.CGU><DBL12;3><6RIUH296@%XP[&BXJ/__
M2>[BRVN?UMCX(91KNZ&]/'$EP4($P\=^PZ)=1S(!LZ=P=S?:.&K6<"@%O_N>
M9`AN<0W:+)D?L'QX`NS-L#`I0R<-A"YR'G3K9^&"-0'"]937=/";KB*]W+YJ
MP*,5DNNAX=W_^/2B**+"@%>2KZC+X!:!HIRE-(-6@6EY'^O+6]!E>$M!5>!2
MHF%KP>X!?;UA%T^BT-)H2<RBJN*P@+B;H_:'&O$05'83G[=HE1W5@>:60@-*
M`D]4&'#4BV("'2=-)=,(#FI&75U_%Q<HK7YOJT2%6,D3B%)(?I\,;]_L1:SB
M`?.3'(?Q[27"85)4TDPW+Y$5K\'QKB:Q&L):@SB>5M:%&3<C+9<X"1!:I*=$
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M(E<@'O96NVL*?T,_V:^ZFK[K_@[CUX$/$$K3UPI929?K?Y`%$YTB;BT.IGU;
MS1P6-DPN*%.[#H*IHD*!@N'<D<U%W8OE41SG?G3%KM8%F%WJ`Q1=TLMAF2M3
M#P)@]]@\E6WB@M+U9"Q\L[H1[YXAO`*^!J"UPX*64@T*VFY9G8OEDIAQ.*T_
M<@9K/Z^UPZ!(J09!,7SNK:^/QSG&5$78,GGM1SY^4M@3.+T<%KPR]2``AH_%
M=6+6VU(W)$3=1P2)G`T0&\-G:KI&$J.9'E(N1.6F6NT<ES9`+Q@MK/$"%1,I
M?T[_<T.P(S_Y_U!+`P04````"`!H@&Q&@&;:V_N*``#,.`@`%0`<`&EM;7DM
M,C`Q-#$R,S%?;&%B+GAM;%54"0`#`_$!50/Q`55U>`L``00E#@``!#D!``#M
MO7MS)#>2)_C_F=UWP&EWK[O-6))*:O6,>F9V+?E2<YO%Y)`L:=K:UF3!2"09
MK<B(['B03'WZPR/>@6=D).!)W=G>=(GI[N$._``X`(?[O_^OMTV,7G"61VGR
M'U]\_/+K+Q!.PG05)4__\<7G^P^+^[.KJR]07@3)*HC3!/_'%TGZQ?_ZG__W
M_X7(__?O_\^'#^@RPO'JS^@\#3]<)>OTW]!-L,%_1C_@!&=!D6;_AGX,XI+^
M);V,8IRALW2SC7&!R0_\PW]&?_SRVQ!]^&`@]D><K-+L\]U5(_:Y*+9__NJK
MU]?7+Y/T)7A-LU_R+\/43-Q]6F8A;F1=??KTM__QS?DW7W_\X\=OOOV(/G[]
M5W3Y-W1^>?/EVYI8<AX4A(K\_!VA^OI;\G\^?O/P\?L_?_OUG[_[WO"+15"4
M>?/%K]_^]>NOO_V:_'^<_=_C*/GES_3_/`8Y1J1[DOS/;WGT'U]T['S]]LLT
M>_KJFZ^__OC5?WVZO@^?\2;X$"6TFT+\1<U%I8CX/G[__?=?L5]KTA'EVV,6
MU]_X]JM:G48R^352T'<TR:,_YTR]ZS0,"H8R[6>0E(+^UX>:[`/]TX>/WWSX
M]N.7;_GJB[KQ60MF:8SO\!HQ,_]<[+8$N7E$@?=%];?G#*_%RL19]A7E_RK!
M3Z3#5_1#W],/??P3_=!_J_Y\'3SB^`M$*0D>I79]WY-5,7WE6ME;G$7IZB*9
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M3,D`!FLF6@[QUO(@QH08%["I;/$:9*L'\A7%]#6@<0DGH7I=^/0(P,!%I-40
M'HP&42)0\P_=:^,-3HJ+?Y91L:,'#VE"_C-7`$3#XQ(P1NIW`:1D``,H$RV'
M`..DJ*6="6?19K/[4!_W,.S0(Z"?V1RWW-+SBENBAW#!4A&Z0(E>40H-.95W
M/&A5&X*`KSR<&%'JV=8?"0SXI_(?J(>%5V?DGV5<D'_G<D!H69Q!PU#Y!B0:
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MO6X&/F'#>.BUE@`Q+.E2+SJ*>R`*A<_XCW*L6+$[`]`$HQI46?#"@)J]PD/\
M543HC^CL8@D!<-_M![CO0`+NNST`]]VQ`>X[(\!]YP)PU;54?I7G)0U@N$RS
M#<X^!?](,[:R/Z<Q6<_EB+/C=P:Y*68UF+-AA@&Z"1I++KUSQ&70999+04P,
MZL@!M@NZPS&+'`JR8D?'3AZ$S&,XW75_46QN;`2XO=:T-:Q_QVG*[1W#DU4>
MWWXR,L3H#KMCZ`^YJV2QS:*X<\[T\(KC%[K=>2$:D4U0R&Y23"=26WF>)M9I
M9DLF6CMAWD$[EP6ZB?@J04PJC6;^!E6B4"/KT`X"V\^_9E&!LUHS.8@5Q,X0
MJE6X@9^4$@:V=.H-@=.A1PV(8"W5GZ(DVI0;95S1@,;E@BM4K[NF]@B\HT2E
MU1`<%0TP/.B.G3T=%BN/>.$=S.J.4^<\/YUI'@C>]/-`G\;I/"!2KS</=`G`
MX$"DU6@>X#2']AH^!=DOIX&DAX44SOP#L6J-4]#_V7O?RG4:]VSV"Z)4P.;X
MAZB(\7)]E:RBEVA5!K%BOI?0NAS[2G6[<X"0T#M>3+0;'3A26AJCWE(?=N_,
M%B2R2]*$,'0HW(8PC%3KAS`T/WOO;;E.8A^`4#D)3WD@)+H`E1Z-X_X=JS?H
MX98`4A^/M)+T,J5STL^7Q$)--W=)W/;R6+E^)[>_`^KCD5+B+J9D;GHX>M$-
MY"Z)XQX>*3?HX>9W2#T\5$K2PS3`$,!MLS+2T%(`J!MG>9RB%3<,9$U167;O
M_!%*H(/20[04``IZ<O_2BOMXH*?S3FOH?0,&>FH'UEH$+/@IW%]+_B."H-9Y
MKD'XK0L0ML]:3-99%;4S:.E5;E`D)X4!&*U^HV?\#0-JETG7$%&NARIJ?Q"1
MKW1R4J`0T:UA`HA\XQXBZG5+3>\1)HH5244,%2K:M48`EF^=@T5]>J,D]P<5
MQ:F.@A8H4+2G/0*<_-$]3I1G0$IRCSB1GPTI:*'B1'=F),#)=ZY#QZ^2%^)^
MIQD+PJ1AFZU22N=VFAQOH>0V9DI#RDV$P,#B'IH;A)C7TE`CKO/@'Q"`E:[W
M-#D0`2QWUZ<(<0K@%YP]IDU.R'DZZ4AP+,D3ILX1H.5Q=Y5CJ'Y[MZ-A@#%Q
M&FIIF,!MSN0#ZNEP$1;12U3LM//=D-#UA"96=#AC]:D@3DE"#8\D)VE))KT-
M;B?1YV@K?AY@Q.$T+ZE>]5YF4CFY]^G&7,?1MJ'B0#T68""[C,@,B*_)%FAU
ME9#U]"EZC/$BSW&1G^[8XT269%415F@EP24()YC6!:4%.QB0VNL\!"V7\(&)
M0*T,Q(6@QUWU8I6GWH44]DZVYBM,JTNHY\@QF=,`6(F2O=C7`0T8=$D4$USU
MK3"K\P%LKKLA_4.3ZQ1X\91A]L!/C145@TO4Z!7OXD=.#09)6A6'F"(,'\XX
M!]G[O>`$GKMV'84XR:/DR1!<"GJ7V-*JW866E!@,LG0:CK.IL@>_ST&V"<(=
MXNPSYCXZ2`IY):XDM!Y3QLOQ)"0$@R65=MJ3!5@`:K)-5R46>&I.@_S?8WHO
MN;]E:@OS?@^)P0!*IZ&TOD4%J4,^&ZJGP+,,\\WJ=1S*3ZE4U,Z.JO0J-^=5
M<E+OX##3;PB-9L5J.$[0]?790::='(=?/J4O7ZUPQ&<<\H_A1$/^]/,U?@KB
MBZ2(A`F!A!0NL*)0C>)#\+-W3,AU&N*`42%.=N`)HJY^1YRK3Z0]GA^>HZS8
M74997G130$=O!<:*'-[3Y+B;5/8PLYUN)@CQ#KI]-1]-44P4XK(0$X:^_7A"
M4^W\"8975,^=M*"IJMC7B,SI6;I$R=X!^H#&.Y8TBHV]YVV:%:RP[&$GL2:Y
M[2)9G4<9#@FC(N62DMS=LP.]TNT3`SFM=U`8*CA*6-TD)*;%`!J>@[]DT:>K
M]I>G6I>@&F1F:K.4U,[R3]_C.*8'1<F*9O?`!5WQI%VM('97YDBG<%OJ2$8)
M`P@Z]4:'=)R>C?^&`]@)RQ4]T<;-#K\N]*UP*Y0<+CT,`]6[SH:"W#N\S'4<
M8HQSH(8%U3R'=4A^P`G.@IA6R5EMHB3*BRPHE"'A.@YGTY&9ZLV<I";WCAQS
M'8?(J9AXJ:(>FX/81$RW5=25PB\X3K?J-+AJ>I<QB5JUN_&(4F(8H#'04'!;
MP%BX1]LR`5O3:E];>=\T)'*Y<HD5["Y6?0KO@%&J-42)LZU.&TUM\A+)X_,C
M[9LC(-VLTDKQN@C6Z+\O'W/\SY*6J'V1+2L:6J=WA2IU>_>$(D+OD#'1;K0O
M:F@1(X8-H(>=LB:YE-HCB(8J*V!4DT(%TD`_+90H_6&W/I^SZ`DGU44F+HLH
M#.*<;,/D:Y".PUT:?"/5VUSX2G+OB#'7<905GS&A`=<)K>(*;"XZ2S>;--%'
M3PGHG%[VR-3LW?8,B;PC2*?9V.>A="`CI1:K542/?8+X-HA65\E9L(V*(%:"
M1L/C$D!&ZG?!I&0``RP3+8<@:WD09?IPE:"*#1KDPK#<E*RXTCE>1V%4G)=9
ME#QU#@;NB^!)?"8X58A34$XRL(=2*PEP8#M%[1&.6R&HDG+H`X'S["XEXHN_
M!IN-JD"AF,Z9&Z92LW&^1$3>`:+3;'04E'V).#'BU(=&`*UU<(NS=4H<.]()
M%_\L:1S::Y"MY&C0\SA#AJGZ#4IT##`08ZCE$#VL<$6'#W%&Q#@/7JTD30I\
M%F1Q>A^Q:8PLR7(,J:C=53'1JMQ6-)&2PD",5K]1I1/*@!@':EF`>4RT[CU]
M8*@X3NJ3N/1V1,IU?9GN[]Y!HE!J%,])_JMZUGG(8R$18I795C0,7F<->9X5
M);5W6!BK:#A].,BP<I,F=>B8062GBMH98O0J-W"1D\+`BE8_T8O>FL-=4">O
MNFV`#PFA,V@H%6U0(:2"`0B5:J.D$[P6NC,4W`;9+S2F$*L0("!R]PA%IF#[
MPF1(`:/796J-?`E:3Z\B/'1O7^,@;_,,R#M<3.>LSU5J-MTN(H+1\PK-QF_6
M""EJ:`_=_\V'!+L%$8&S'A<JUG1U[U<8?2Q2:71:V7;K(7<)9Y=+[CTP=?2#
M6TWO+I3)0.TVK$E!#`,0!AJ.KOXNEZCE<3@+)*L,O]Z=IG&L6/1%5.[F`ZF*
M[:0P(H$!!*E>H^F!$:*[+Q&E_=W!%_^[^\^*>.CV1W?!ST.%VDCG^A<873I4
M9Q3#?/_YX'&I9Y:3O)+>W21OH'8[R2N(80#!0,/1)'_F9Y+_W^ES<GL?/`<9
M%H?Y2*F<@4.N8@.),0D,($CU&G8_)42W7Z**UL')'\\-Q\(]ZO1PRK,_!;W+
MTS^MVMWS/RDQ#'08:"C/ZL=XH&;VJX\I6;C:<BN]P#2@=WD/I56[>RDE)?8.
M+E,-QYG]:'`A)X26SX]K=96L\!LKET!+'60YOY77A,F;L;K$F8TQ7<B9\(%!
MGX6R0R!R5E3QHB+EI2TRLOGA_"<.@NW/T[!D_ENRXLFBKA(6#<)>13_2!ZMA
M(9K5S?C<17Q9F-%&@!DP>0>:K::C"+&*E3TIK?*!=;A]Y(/C6MSA)_8@.BEH
M[,#`:CF9J\QP*B7K]'`B&N^`T2@V2JO"(='2LE`.?[`X(UC-@IC-BG_%.ZEQ
M(SJWP)"HV4?&@`@0-,2:2;!1$?.5"A%R'^BHYS&Z)`K,ZO_L"@LBI6H(='\#
MT?,"A:2+!:7QV<M-ND&:^DUARX#.=;\+U1P"H$<$"@DBS:20:-,VLGQ\/M"Q
M((JLJ#*7<?`DL&OPNRLT"-6J4=#[$43OBS0:7<?4-(@2^?,&?DSC,BF";'<9
MT9`0Z7HVHG/K#4C4['L#`R(06%!I)O$&&F+$J?V!XR<<QW]-TM?D'@=YFN`5
MWS]+S932NP6+1NT^:"3$@,"CUE`"(LKTH<=5'7YXW'B4648F/)YR-DJ>:,:W
M4C[CR,@=;T.42@]V(T):0$A2*BC;FW`>U#`ASN4#1Y4NEU$>!O'?<)#)_5<Y
MJ2O\Z)2ML2.C`X$;C7+CRHL<+)P>40:O_BS',%M&SX@*3VDF/^\84+F=9H0J
M]F>7'@D(<,CUDLPEC!35M/X`<5L^QE%X&:?!\.A=0N,6#`+U^E#H$``"PE@K
M"0PX(6*4'MV1-F7*/8V6R)=ED1<!*YH@7T&53(Y=$P,#!@Z*@@,0D`S4E#DK
MG?0V)X@SHPZWSQ,WOB;R0YY+\C>1YZN@=7WR)E5W>/HV(@2!))UVTE.XRG6I
M#N,8BW_44$?*##,=2C^(&:DJQDM#!A`M0]UT6&%N[NQ(F:'FX')]&25!$D9D
M!*1YI`@YL&/U4HG0P!AA44(%GW?L35!66$>5H3%=HX89U=SH[S4_D`@L7L]<
M`\,AD=.<64(%>SFQ>A1@0"14:W3O<']_\7`/"0K5F8$1(D:T[H$A47>,CP$A
M,)B(M9.=YP2,!P9JSH*<9ORG_T.C^%Z"F&B8+XJS(,MVQ,?_,8C+X8F@):_3
MQ*,VYO22D9HP@D&=C;8C%!(F1#9P**3_P"T[#$"V%:BODA?R;U;[O!HYDM90
ML_BI&"Y77EPX?$P/!FP&2BK*B.?/:59\*'"V05'+#@-KBS!,2Z+-'0XQ&06/
M,;[!A1IK:A;'V4BUR@]RCTKIP6#-0$E!7E'&@K*&YP0E>-:ST'WJJ=$T]&FV
M(W9(;.Z3N*V8-E:N7R*M_1T,1`1*C8N@<9((`YEH;C.\#:+5Q=L6)SDF*_>R
M>,99SW>46&O$Z30MH+DIO6R!>C8P"#/7=90/B',BS%ESYF>EE!N%`)U_$P!Z
MA)H65/[@4Z1%$%^;[@LE:'F@0D`"XRHIB*(164JY'62JO7@+XY+>^OR0IJO7
M*)9/SR:L;E<Y<V/ZJY^>#\R<9:'L>+6L62L,`G*?-&#S`R@5:,`!0]/Y]<\P
MNOLV2[<X*W8T1R][/?C/,F+E!>3>LYK%K6>D5[[O$LGIP<#'0,E1&LPR2Z*B
MS##S?G#-`&A6X5.D<N7VX>G(71R(OHW,J5D^+*X1I(N1ZRAXC.*H(+M!`F`6
MS?*<QJOFW;OFKL2<W25B;(WJ8LJ4%\PD9*GP*%'GU>+TZOKJX>KB'BUNSM']
MP_+LKW]97I]?W-W_#EW\Y^>KA[^!@ZK919Z*P1,<#:[TY-00(6=WN1>WC#`P
M59^/W@8[>C9*B\*'85;BU=A$S:&LD00?1^`6IHE.Q`W8P>#27F?I>?F6BV!>
M6L"%-`=7,*!;YTJZPZQLF#%@#?A\9+#2FB'*9"5E`@-)4TT%0&28(S@DWX@9
M#C,N`]XL>E;F14HK`>`MC073`%!*[3060JUR+_I!3`H&8FK]QDLQIT:KBOQ0
MQ>7*/$IPGB]"XH7F5;[`A+[JH^X"_6.&5\O'.'IBN8ORSL@8V+F_.'<EZ?8W
MNJU6-UV6=VC.9(#,C63/0].$AJ&&C42R3#??06DK%L@4R:O2LK(('9LU,Z6&
MR6WPF(D!_:@Q%8=WC%JI:8+$JNYPS"I?@`.@L7_HVR$T\P`]NWS:8T!C1Z]_
MSPG/M1./CAO2CU.FKBX?@-EK;(;!!-8R09_#1IJ.PUTE<Q:[CV"S6G^B@P%*
MDWV^%J&V0J"=W:BQ:R<!#)`GJ2W;.]?G-;#!7+O)9^GF,4J"OIM,_I5'*YRQ
M/]=M,$PLL9<DE[#>P]0NMB>(`0/PZ;J/YNXCV?G(-_9""D^NIL;'!.M<*B^:
M.W=[,+!`DR9$_)$#?:%3(SB48T/)X=2#U*O>\QWEY&#F(KV.XSFGX>"OI+H\
M,"!F'<(`)6C!+DSA"`(3K$,1X(8>=-+$*-]\CLA<SU`B)8?34I<&#%@DBHDF
M(.+DY#SKSG__^LNOO_Z(MD&&7BC3"?K^ZY.OOV;_/\IY2IZ@+)[3+/H5K\BO
M)]]\]Z\GWWS[D4U>_WKR_;]\??+MG_Y8DT8T:^6*/TMH$_F@H$#G.&2E9="W
M'T\0Q0@C(O_X]@01SBT.B^@%Q[/F&=MC>[Q:,5\PB&^#:'655+O\3A/+=E\&
MC$ZWP<:&]+:^6BXPJ#=6=;3%;1@1?5/S(4KJ\V<8$+S#14#V.:N+($O(&,K)
MEKS<E.SZ^AROHS"2/U?6,[I]M&QJ2/_ILHX+#`2-516<LM2$:,4I86!O['<8
M.RB^/3XS3P_69E2JGWA/"M?)TP72ZC?C$C9(H<^:<PXA#RR\&6JK/1$!'NW<
M\0%N@VR9L>1;*^8;W^*,Y9O4N])R3D\;$YTIDKV*C`W,*FJNJWI'TVQEP(&0
M9SA=-+LI?4.,.3R!3J:Z!&Q#<H@@D^BH!M=H1PP49*QZA#'`:FJOX.JKK`06
M)X4+JIY^1H#BYR9`P21/M6W&XA56DC3;)O1P`:9/L2U$67J8W-K[Y($(TPUN
MDJ)JKAFDU&ZS/2A5[B=X$)*"@95:OW$:!TJ-V@RVT'+5WN$7G)18EZUV3.;V
M,$RL9/_HJT\#!C`2Q<;9^3C9GV'@XB\XB(OG,S(#+K.G((E^9:$=E9(22S4\
M+A%CI'X7/DH&,%@RT7)TNQG$&%+VF.LH9-%Q:BR-J-P>9@E5[)]=]4C`($2L
MU^CQ/:="637IP$`&0VJEN#RWS(C*Z=&Y6,7>N7F?!-8AIE@Y\=L`6.`03WV?
M\"H*@_B^W&YC?C![GI5/>94ET&H6U8GROWR9&:M?U=1RW`#V>P[8!#^QY\G6
M:YZ1#>/]7<[BL7,Z"F#`^H<LS?/;+%U+;Z9[%$XSJHU5ZR55:W^&-<>-%1OE
M5Z,4:,M(8,!@N671U\D3A2A%<P5DW;[,@,\E9(S-Z`))RP3&N3+5=(BWAJ]Y
M&@)DEW>/8R+SB5CR*<A^P51%]=*I8G#JAVD5[[ED4FHPT-*J.-K6<086$+BI
M66"@Z@><$+S']!'5:A,E$1T;-$Y1#2TME].US\R$WGJH9@&#-#,]1TLFY^)Y
MB7I\,#!WAW-,&I068#DG^Y8X9>DMU8C3\#BN4:)7?U"D1,X`!FLF6@K*E#`>
M!K55RP4#9U(7P-9E`.*863EDL/Q\G9KB4XUTY(L!`Q:_,KHF.Q2=W5U*+V`:
MJRJ$44L&%$`C!4?GI72_2!NAA@^85ZXW:9+VS:@K9*@WC@9\+B%E;$878%HF
M,.N@J::CC2.K4A+Q2^3?5Q/6'X!L'J^2`I.&TCA9(RK'529$*@X*2G1)H)U^
MBM435(M@5/6:!@4@=6DYCOE:2ZFI,G+7Y;=42@]+<8EHP<P[&@6E,.(S#@P4
M2>=.V[D6R(IFM9+!<IAT:DH\[LXB!B@.X0876E=[0.,4/R+U>ICI$@##B4"U
M(38(#8K)SS#`4+]"K!]-G`9Y%-)3BR@N"VE,N);+:4)K,Q-ZZ:S5+&"6,3,]
MAPAC5/P4B=.Q=%PQN_HC$Q(+[^6I7-NH7QAH_`E'3\]$X<4+F6R?\$U)<P`L
MU\SV3A2S&4BG"G.)W?T,[D)ZFB0P2-]+_>$`J(6A@$M#"1/'(B"JV/8^^KNQ
M[B?H<3A^8`R.)I;Z@6;JDUVG#8C</J\6*=A_6MVE``,^H5JC>\<VE)V1`8EC
M;]2ZCA)\1?XI<^E$A%[0,5)4B)"&"AY*AJHID$))$:-5PN6@S3XQY\$W3AN>
M."91NB(MEQ7*,$ZYGF,OB/QG"&0O;_HTSO-[.*-'<'Y?OID"Q?#E6X62ZM$;
M$+!0D/-7H>=E1G2_93:SQ^WLM^667<1<O.$LC'*I`SQ!CO-L+%/,'$U<-D(`
M+2?3-!\BN/Z=>;?<F=WV4XH7P1MZC8IG.F^"B962F,_'[0PH5PH"`',#0PUP
MKI`"'>AZU?=&>OV4&0;B%ZM_E/Q.(G]()8GHZE,>O#I+-_2$F5VY=QOI#O/4
MT_@>9R]1B'ECWN$P?4J81$DO./NZVWR%3INTG_30R:?!C&*W]HZW5$3&AT<J
MFA[<-+(/5$N-SE;4+5RN.\D4ZN17E2ELH:ZJ##ZD-)-\&=/[H<53AMGN+U\F
MPU.:N84[J[,V>X,T5==FD^Q]I!S$G-%-=25_=()9UZHL4IHDO)*(@D:DQY'"
M5WJEP=5V;?J`L?L&J'$SI7FLAH_-!XYG%$VP:K;!-)=C*1E4UEO#2]+THG:<
M*,C9\-C+T&8,3)("`^C[J&Z\/7*+4L6^SA*F6DF^<6IHJ@ZH&C&@D6JFN\5.
M_J`3ZQF=[>.8[4]ZU0^:982FB,AR/O;NMW%47.+'K`RR':T](&J7O44Z`_%,
MQC=HWE,>#%C/8\2XS&,EM>]6!`7Z[]]]^<UWG3"<CJ>1\0]5M#G]U`FJ/\9J
M7S@<%0/O2MD(G-:T=:=(]CI&IC>%<JC8BX4[8B;;XFC@>/37+]/LMGR,HW"Y
M7N-L?/,[18!OOT=MF)%?/N*&`>XI*@\QS(F(:\.I1IO+,9C;>JGT02?]QW__
M[OL_G7SSKQ]/4)2T4*8A:9_8$^$#K@9*1V\?-$LE^(:SQC0S]_VX`*W6V1>B
M#SQ-"T^5/F_3Y$><TP.>Y?HN+_,;7"S7#\';3^T]HO$1E9DPOZ>/-@:KCQE-
M),$8!?NJ;WQP6!*9Z(4+I3_>W7_.#Q2&,3?(Y5[\WB+A`U[BM^\I[\C!K_34
MYQ@"R(]?3I:]^@!JN?XIR+(@*83`M^/W[<8HS=(Y,4)F&/B=H+'JO/&U(O7D
M/N^%/*44W_@S,-'8E3XR+.KU-D'D;-.A[WBU.S+[9U%88'YA^SF)"@]Q:Q.U
M.([XM;V:>)XXMDDJ>!_&?NW>RXORNF/8=WL`="^PE^-_?%[^?"X]K+5*&4<A
M',5VP>I*00!>$Q@8:OQJ1BC%*<A?</:8YECYOFNJ!:XBBUV\DID!V&I)`)!M
M8JKY0QG_V)[^4F8.5+LX<.E6M3PON_OU>UP4,8N@I*M4PA(`GD?YMBR$<;_[
M2'.[&=[+Y/ZF>)(H[PB>1W]56<JJZ"F]/<H;0=Q3X:+0BLOR`.UF^S\CP,UD
M@H"YC?E&8#<1"!_R%E;,`GR3N?V`Z[=EWC:WZ254JZY8KREIVP[M'4U)X^$V
MSI)G9[A(E*E=%5I.2.)QR$:?E@[#1^8479-+E3R.A!A50IWE>HP=3;YO0UXO
MF9!,S!$F1U(Q@IE7;;25IU`B"UV7^W>(\\]83]KF6'04,76;\=->-L",S^5T
M8OP>DIH9J3XK5<OPCM$]%3<^.5VG&=H.HN>V5&`;*N<PJ%\+5@,FKZ'X:B!J
M.6#`SE1-P]CXF>$T^XI]%N3/EW'ZJJOHJ&;QM#Y+E9<LRR-Z[Y"S4%*Y"%,F
MQ+AF7'IG2VA.M;O-TI=HA5>GN\\Y7ETE396;15A$+U$1:8N*3A'D.#7Z1$,'
M^W!+*6!`/%GUT5RZN/\+NKQ>_G2/+N^6G]#R]N)N\7!U\P-:G#U<_7CU<'5Q
M#P/<O3@%&E"0A%&,>V<6#^D\\#_,I[S%T\S<6-*@F9F^`V:0'="XX3#L?(H_
MY*L^UB:L)W^E_P[IZE/F_!BTK607-!\"4AKJ'&^)$9'J(K9/XG)TB)3KHKK[
M.Q@T"I0:HJA+PNNT;M*LB'[E?R"^R[K,DJ@H,\Q^I:%:@`IK+CK*+M=724%,
MBQYCO,AS/`H.-F5R.ND:&=";/I4<8*!GI.9H2AM@+VK84,#X8*#.+G8$0GB(
M>00(\""/.>(XV$2V#7:SI':;J^A=F&&BZ#GF_]OU!QCP-=ZG!;_;LGB69O7K
MY!DR@T&GK<:CC=4S^2^<4S>-3W<,J7$4/$8Q<]2:E\%XO<9A4567#4(>/TUS
M``%QY<8ML0C#M$QHL'>(HQ=%$18S5K\HEANC!O"8#U[E4&.=1XMW14AW(A4E
M5##2"I<)^5HDK<"NX?$+/X'Z:MQU&.`#;JSLN.)H0P$58;<9W@;1ZARO<9;A
MNLC\(EFQXLS*[<E487XQ:6.P&JPFDN"CV,**4<80SEJ79>9>`*^'&I9$6%*`
MV@W)EXS;8$=7`6(T^4M6DB9L71GK]4<M#(8_8&*PF8>@D@3M.<E>5DB]B"WG
MY6=2G+L9$5"!?['9QND.U_D/I\!=)<(OR/7&J:$MYX</:*WN`A@SQ!(4DZ_&
M#,5UUKW.A@XJD,_*O$@W.#O'VY3L+,WA.V;T"UJ9(6JH#KG@`U2B\>B$H2)#
MJXH.!@#-KZ;WOMN&&G2P7[`!N$KN=GJ/W@M</"`69?#Y_N(<7=T`#C&0V$JW
MJ/D<\3-*00"@;&"H`:054L"<[DY671<_<W7SX\4]2'#?5I<D#^F"GC%G^/XY
MS8H'G&VXU>Q'27,9\KJ$L)4Y7=0:,4([D[!1>IRT-`N?`YYA*6M2MJ"<2OA0
M$!$H:F4`Q>IIF4<)SLEVD:7GHV.W^D56#=-.A%?D&ABG!+""'SR.];JKX'S[
M'&2;(-RA,^(Z5W4SKJ_/VJ2[-%J*'3JL7FC0.%1XDW6(^%/%[I986BR2U44=
MF6/:C`H!7J&M-4P);"DW>%CK-)>!.@<?I67N.>WM>D'UB??SA8]B>R?76[N]
M@^L!2VR]C!*R-LRPO5,*`@!E`T,-(*V0`GU[IU==M[V[O+I9W)Q!!'>]!%VF
MV1W>5LM)[T&G9NU2,?KP(?2&B'P'.1=4GT&KL=GS1Q@H))949BW7Y_B1NCY5
M"M%K>K:]?(RC)^ZH2UK%1H!+5-H;UD6G.3<TE%IK/O)L*W9$@!IR3A1CMG]K
M>6&`ERP7(<:K_)+T?)6UNLY.+3T84[(XG38-E.]-F`IZ,.NX@9*B]$3;BHV'
MU&)1AG&ZL\J[!3?A05"8E<&@H21\OL"H-$.&2"$32%BJ-!T'@W5Q&<ER95!L
M-D"EB3/H,59SIM6DSV`5I6#`UMS?WMMAA[J3VF\'=12'`G*]I8<"MW?+'Z_.
M+\[1Z=\`[YW8J3-U;/)G>E#W$L348^')"X?A&9(FLQ/A$L)3C.N"V(8?%HPG
M:"X$\E\6-S]<T*,M!NG%S3G_Q\5_?K[Z<7%]<?.@A+'SKEV0P9ME.S).61)P
M\SX=,'I)WW=?!%EAWZDRU87G.:(>/$&/^"E*DBJQ/U?F?78KP$28=HI;="JF
MT?8FW>GPP7&YW?+<M4%<)R"Z2HB;MV%[85UR*%-NIT^2[4SJO5$V8P7C^MOI
M.WK%_/GV]OKB$\'FXAJ=7]V?72_O/]]=H.4E:DZ:R4)SN;S[M'BX6M[`>0&:
M;O!#\(9S6A:(N(?R6-81H>.888FB@QCA`148>$E5&Q\"Y\^(O2RB&\2(L=&J
MDE!"'*Z2`M-@(VJ%U-8NB5N8C)7K`Z3]'1`T1DKI0,$98`#BAG0+4:^]6$Y6
MS7[RJL`;[9VK.;_3`P);LWKG`Z;,8$!HJ['A`GA/5\";Y<T'M@IV(@B(4R<Z
M-MA[7=2F.J;/W)J<7`]IYVR/_%*7M*1_3_(RIBUQ&64;5D>>/_CL_(!UU>+F
M_I:'I,F':2Y!9N5Y/^1]7+FP3I6CF<=&UE^D2>;D)]'LQUH^6M,O\[3.U1/G
M[H_X8)65[G`8!WD>K:.PRD=5/\NN\U2?T7/QJX2T18)#2D(+;?-DZ36)J!=F
M$NQL\,W:$,U(FT4JC&$UIRG#,3243<?2JI(^N*&A&8#"Y@NLZCN+Z2QV#2$,
M#TU529#_F97P865=9?<XEC(`E-53FV=:*W(DP/L0V$=KJZS^G6D_K\30_6A<
MKGB2TL!%$@#)8G';A%5=UC'5W6#LG\A8[$:SB&81:Q'.%H")QC53O26_=T3O
MH;3J#8DDVIY/U$$_9@G&1+W,GH*DRJQ)/;XTCE;\]#%9$4<PIX>3?,&K]F9!
MW&2PUVVS9Y+M<F*?M3FZ$_XL@KT/FT-8,QQ/7=DGJ">=C:JN?#KFFB^@]A/@
MJBGLU6#G41[&:4ZFE0?\5IS&\M"M^3]S-(-/T4BSC4/!-]['D)0;IAJ=,(96
ME1B*>J/$YM"@(H."P6F*;ZWBO?3>4FHP$-2J*,GI1=W]F@/<S'T?/25L:YX4
M8_MT\[$IL].]JY5!O4VK$2<8.%JI.[I<*#>;(-NQ2HFM'"1`+`R8UF_?S]+-
M(YG?61BZ9AY4L[B$I(GR72"JZ,'`ST#)49G8B@5U><#-B`+#S#U44V;/\#/T
M)LTX(4/2W/-;M-GDT0=9MHR#7=34J68$N6I:$R03WC01#B]?)AG7N6:QXO>.
MQCV4'E^=-"F([ML41*T@&!,F#:49AJ,F(KNU_N0D2:X?"$PT=1A\;"G&.ZSW
MUUV+[@>(Z*Z3[N^T\[`1A]O8/:WJ_5`^*3D8].EUE!5-V*&6!9S/*3!+-U>J
M63S#3#G[J>CA91S6Z@J^2D<=RL%".*H;O^A7O*H"H?JU&8QGN;VENJUB.4L3
M]`M?[B42S(PZCQWC\II5@`\3>X(Z@D]0)?J$W7<QZ8B+ASQ%3VPGW32^O]@C
M&$?*Y6!?F<<^DG3K25T6YZ);%H>/FK.J+,X"4%D<:3I'S7IBP.<X+8>9&8.T
M'&HF,%@UU520EH/QD4F<<C(L-KS@YFRIE>;SLYT($`@UG'=M^.'CUGP^O>P%
ML34"8"#VAS1=O49Q3$P;UHXV]LPM9;C$["3SNJ"U$@`&M5.T'L*VEL%0VTHY
M`L_9R'K=/&PK!!RJE7.QG83CPK7^O&2(98KP6C0,"%<%_?*ZHE\0ZZ(/E!R.
M<\3J5!\DAY61@X&=7D=!9DW&P:!5\X";*$W*1YK/F).E>0@2G&JR((+05A08
M5.^GO[2>Z&WG*5%=G?$"5#U1FBO7XMA93.SV%$RE</]L2T0)!G)*]<9'NH\%
M9#>S;XS^W%5"[0](FE-2(2E0*.EF)TH-`S7\";-FTAD2N<2(6,$N-/H48!`A
M5&L(!$X$;BYA+X&?TWB%LYRK>),6V'QVL>!W_J[;QJS1FVX39C`(M-5X%"3?
MX?\=XA)@X+/)?681E*3@\))WSC0H24H.!F=Z'<=G'BP)'6&![%$)[-)'):E8
M/.-,$Y4DIX>,-/WQ6@TU*/N]LW1#MY_UZ\T[7$09-HITGR3!:7RPO6F]N&!S
M=C"0M-=YE(JQ(X$=4[0R(,^.`\,O-MLXW6%\BA.\C@IZ0:F/=[<2X1'(1L8I
MD*SDAPIE$Z5'^YF*!]T'+U'RE+,P"3!XW40\,I_F#T_9,T^<A+UC1?W$:R/#
M,6+MS1M`UEP`),Q::RV8@&L9;/[M20$^!>N--YB$K82``[5N(K:0<%RPUDW&
M2ES#0/`]?J+ZW>%MFK$DP9J2!E)RI\=(&J5[IT826C!(TR@X.A/BY*BA!S<I
M#@VR.+4TX?0)--.32CT;6/A9G$Y62.R4U``"P/(QQ_\LB6X7+P9I].3D;NNR
MJ)7N%V(1T\(!E5K!<3*8FAQQ>GASVL`@[4PFI_<)*O6L)2,&"RM]DJ$!KF"`
MZ33(HWRY'B1-VO'_JTWP8LCL-,&+E4&]!"]&G&``:*7N*/L09:8)K[KI`H$@
M4I!+B1LE:P@%@^_,5GW%=7FM.#4<A.E4-,II!0-5=P3FI!EIM<!S_(+CE+US
MJ6+_E/`RXG2),PM3NH`S8`.#/'-=!7E4&"<[X^CPPD"AXHW`\+^5F)P@!\@;
M$+69AL]`Q$+`H'>JYH+'(#B.<5B408SJQWXP@'Q'1E92XCL<ID\)RQ-7/_BN
M?I$.;"V?VZG4T(S^1*IA`@-$4TW'DRC[%748J_FT2F11$<#`(DTQL%S?!S'.
MS;8M*@:W%QHZQ?N7%S)J,'C3JCB^E,@+EG:7LL!`4Q-59(8E.;F7^"X#',EH
MX66;4NIY!*%=PN+DAE.4&:_K=(_&YNBKRX.=PRRT%=;199>K]!\==B"`I)V<
M%!G;E]]%^2]G9"V/"OHOZ82NX'"[5&I5[Z^54G(X0-/J.%XM.QSL](ZS(,H#
M`V+$8\0$](_&OIB*P>U.0*=X?PL@HP8#+ZV*TD>R+2<,3#5I)TT],AFYESR@
M1AZ9F!:>1Z;4$WSN3VF^)#-@F;.#R'QE`#Q37FA`M-3[O22],H.IC0`@A\(&
M4#7G!K,"6ZMLE^4*!ERO-ML@RNCP66;G4;Y-\R!>KJ_3Y.DZ>L$K&^!.$^5T
M4=_#V-Z"/T$.&%COH?S(0VA$T<T,%?&!R0"%\":3[7.0/9EN:W1,7O(4*PT0
M9B$6<H!!HI&:TF3<=V"6_$LR"%A=]4\XH,&NK2=C!C8+?I>XLS:K"T%C9C!H
MM-5XY)42?L0$H(X$()-@]S7@'8Z#HLKL;7KA9LCMZU6G@4FR!YT*5C#0M--7
MF/GCPVF0LPH&K208R+P(R&8N><IO<79/U@%LAD@ME].L1F8F]-(<J5G`(,],
M3U%T:L@C#J*XI#6Q;G!!_,,\1UN:Z3_=;-($,8$P0/@YQ\OU15Y$&S*V<DE;
M#(E<0DRL8!=1?0HP`!*J-<0+(:(;B(8,!BANLRC-"/"C='6'PSC(<U99F#VH
M7_VCK,H?XCS,HBW]H_2PRU:,V^/':4;VCR'M9(`!YT3%Q^%6?5X@^+W!KYW'
M!5F:D'^&W"FUV9W8BW&)WZE&=O%K*P,,?B<J+L`O88EW:+%*MW2U[E9.[TD]
M6,E@KL`BX=]:J:V2(79/60Z+".]G;J>:\#1!W@$\A_92%%_E>7E($,_T"C1\
MQJLRIM[1P,=FWC-].<%]YP=ZDZ]](SI5FM,7I/N9W'M?.DV4=^#/H_]HAU])
MHT[T>.]5?P'=@MQ[M4U1/S_K5*_/3W>=_VIRGA3D7WFTPCR4RGQPS/`%/P-F
MMJ81#Z*]Q0,<6'/9I!IL'6GHG.Q<4><0F(;W=>5"&VW5XY!?\>IJ1=J`[%[J
MRS]F589ID<=.N0;R6[FQ7HYF^HJ?43=K$XE'WBR?`#CZYK1+-0+K,Z/58.A5
MU9?JC[$%L?,Y5'WO0!N:;COD95PLU\MM-0U<$JQUI@WE<-I3EK,-S;[F-AN:
MJ8*\#X`YM%?!G`ND_VI$(MH!W14(Q@(C6';)]NN29G7J)'?29B:QE>(C482E
MB:+L$88BO.-[/[U5R";LB/&CRR@)DC`*8GA9P(AJ48%Y?!2-!ESA=?N787!@
ML\#EMT%6M(YH)ZF&D1-UZ(\ZC25QTH"]`)2#?A',@'1BIFK\CBM>@EN2VG6Y
M>0%1%9NWW,SHV/WL4LR,$F\_U+Q@4&ZIL!JOL[UJT3K_MQG>!M&JKE!(!NBR
M>,99I3H?+C8;@"GR/&P"IILMV`C8"_..VKDL4+M-3&A3_9)M<)E<5`D&%80M
M??$S^=$6M.=:TQYJP0&MM:HJ=()^H=5=3`;^4;*JW^Q8>P;&DGPY"9:FROP%
M0S%@\#Q==RNO%P:T+Q6^_X;FY/Z5.?G5HF&["YT@TM,><[+QDAVDM3PP\)_!
M".4%6$=&ZXNLTPSJ"*F53]>*EKDLZ=HU=<3,^PD?R\6<C2-:1^:0#V:$'<`H
MPPLO)E,X!&&-M>6Z66>-'2H!AQ_'2:JZV$$:D8/#J5Q'%>S.GLDO9&J/$G06
M9-F.AM4UEZVU0&BPJU/BW`8[.LR(PT?^DI6X>_%LZ>A/$>D'N-.-%R/;7AY`
MZ$\V0AT%5&5>JJ2R36\EMW&*H(V-.MB0/B5LWP2RMX)+]M@A7X1%]!(5.\L1
M,EVPGW&R;T.(1\M4J0#'S)ZFJ$8.$X*X%%9=%-6BX`X7,LCI6=;B-<A6W4:@
MJR%_.D1#B_C?)@^=?3[B>QCMWT"Z(37]"Z"'U]YF*8]DV_"X5@S<4=:;:NA?
M\T59/*<9C2C\G*QPUFD@5LSX='?QAK,PRO%M%H7XCKJK>R]:,WS8]V@\3$-:
M+7I[?Q7TJ#V(J<I%DWT$+<LB+XBG27=B[):%"YTC[Z?V8OM3D/V"BT=J_H\X
MIU'T9RG1A,U,EV5&KR%M[K4GB/-PK3W9:,&MMK4L[T-@)@.&P.9R/C!!J)*$
M6E'L*/F._)F,%'KFQ1W&STE$=EL_9$%2[!_"[68-:VU@)C`+V$(_ZR[+^BN0
M5J>)362S%%E^PON@.ZQ=FH!ST9@#NSVC.CZG,5EN<QIN4.QNT@+_%&1TCLB7
MV5WT]&Q0:76Z/$\#:9K9DB%C)PSBX)AD@6H8U+RS`5_C6J7K1MO6O:-1.*US
M9^Y831#FW*V:;/#(J;*6Y!W`LZAOA-[A7J'Y8<9-P^QI$3;;.-UA?(^S%[)-
M$B]\BYCI0O[5?7+(4_JP%'D6B1/F_IZGU`J':39)\H5Y/^9]1+JR4'\F/D[7
M6.]W4)&B6JL<G4<9#LE8S-EC\S(N`H`93J@9:4)SK]`HO*HL6'4Q=HH3O(YL
M7V),D.AG.$XV73S@K,4!'%)3;="\(GR)<O8JEL6>0:LEUYE0UFM,?4G<F'X7
M%*S$9Q)&<63^/'`_D9X6I\G&2]8?:WD`Q\-D(]0!RO400'U)T,9#G<^=:-J$
M94\/S[&4YF<43#)9/`"L1`'$_A3]5;!OJ@-0X%?O40>I/Z`-`![&^2E*HDVY
MN<;$[ZON@?/+-#L+ME$1Q.S/MF-ANF`_PV+?AA"/D*E2`0Z6/4U1C1O&UC[4
M0NSB$E4R^:^@QPTM!A+$G>:HTJ0D3_L/'5O9`$;/M.8P&$!V@J&/H4G6J-\]
MLI#\6F(UC+BP`YT<?PK>J"GG>)OF47&6OA`+GO!UM(F*82)[`WIGY[\F:C='
MO"IB[Q@SU7!<R(C1HK`B1C&C1H\[='E^=7;"2B6DKPG.8,R\9(L=8KS*:2JK
M2G?V[[,R+\A6(Y.533#@<_R`V\R,P?MM-9-W%-IJ*BQ]OJH8Z"L/_!;BG!6I
MIFBLP`D#B76\?5OH^`87DO:0T+I$G%+=+LJ$A&"0I=).6HLZ:XA/4()9`KL@
MCM/7@+0:.ZI;I>5CL2YC%%0L,"`FS8+P.<=$V^MHC>4#4,\)(F/%V!2CE!4M
M&QAHFNLZ!.JZEZ@"-_L?,A,2Z$;LG67)A)`9<`UD#\3.-=K:FU7Y1-FPE1`[
MG0&5"O>F0"$E&*`IU5-71XUI==2854<-9GD/+]D/\`3O[!*1#H.7(*8[$98+
MGATQYT56LLV)R(VU8':V4[`VJ-DV&'-ZQ]<D=4<N'$_MG[/[8]Q*.$&K2@;Q
MZQHA!ROETHM$O$K"N%S1]_!BZT3M8"W"8>&62<9UZK58\<.`Y32EA^"\*3>/
M=#^[)BYA$UG*H1I5$NFN(Y1@&,;"2QQ>?J]&2QDN7H(H9@=$::<EJNA#5H5#
MLHA82W%;3VN2B?UR6E8BO*-\/[T%0*=GB&1K\X'M>&(B3(7>`_;E3YC&N^+5
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M0,90RR%T:C:RRV%\CC`3%,/C:#F9-V1TE)2"@=#`[/]6,5V7HQ6A/5"_]QS6
M?+'=QA%>T>"?>D9CNY1JNA.992G`&58F&=:@R(H;!KZFJ#Q^.\^"#CK[C-[Q
M2<"%,A<G;)<T_N-,:]H\YRH_!%%;C3'<"<K-#YQ`%8/+TQ*]XEV/6T[M'9/&
M*@I\)9ZJX0A@)BAWTZ_\F05)SN.'/TK:QTZ$CZ)D-L:)*I*9\(.!ZP2EAP`^
M%6S^3E"1TKC7-<V9]<)R9A6MI`.M[:>"TFJDK9Z#*D]0^\BP3K<J6E>F2'&V
MRD\WL5GJ[45X!^M^>DOQ&K:81]M*%-I262S$)@R:6?F)2$1P\O.*!ZVH%'/]
M:J,N]F0U"Y@)]#]%VQBNG[!-I'D?$;.9,!P<E^V$34,N:B8V"G"3.-WPF.^]
MG-U^"^TT?I+VDB-<)HD^B2^>,;H]0_<XCG%&5O,"A7%*Q#X=+,ZF!6IS/WB5
MYR4-;7Q([W!,L4;K+.[$P1X6[`YC;:R-ZD3;&/-ZGX`F*JPZ*.[NO*-*R!B7
MAP<C&19]%]@&BCIF'T`T,T@$0S4G.!`:J:N[JPB[$NSP]UXVIV[O*ME.4;7:
M3=)]V,T/;#_:<5S8*7-G@PK6M6_SX5RM"$JC=12,ZQ'W'GVS]-1XQ;P`'LLM
M#A9T]5'/6X0#-*!F:,WX16BNIQ-KA:XJ#1AA,S2XJ,99VZ1;U+9]*>1DZ$H_
M?;0#6-.8!QO&DN]Z]Y@\&&OPLNV=C^)^^>JZ>C7_S77_J'5Y%^/<I+F=#'R5
M(N]_)C"P?C@UU"79<;<D>\I*LL_SX@O>1'&5O!#Z-!N>*QSX6\<ZT$?-=:B!
MW'SH70[4H76CAY?U[^]OP$E?.CMH=L6WCW5`:IOS4`-4^N%W.6!UUHY74D[?
M?Y3__D;S5;+":WG1:"=3J4:#8QW9ADU[N`58^?EW.<K-;!XOUC79N_62G8WF
M8Q^T;L:FAR$XY9)H'OO$%TE11V(U[/CET@SAC?#&7[6Q[_[0+P/N[G!!I<.Q
MCEKCYCWPL95<@7>YW)I:+3W!WG:JU0=5M?JXE?;^YH$;,BY&C<;.]1QTE^KC
MQSKR]0UZJ"$O__*['.M:<X>#G/WVOD=SYR\.>J#WM6,=KX(F.]0`[?SE_7K:
M8R/%[G9G'%)OF[*^O_$HS\$[^U>.=?Q)\O[._(GWN0)*<PW+=[0Q?2;UWL9>
M_3S,S1C4?^T(QJ)ID\TP)G6?>A=KH:&1HF1:QW+6=(^W0184.-ZU#<("M8.0
M_IQ7:4%HN2KZ9#YOJ<R;>I]O>!YU^S>/9JQ-_P#DU6]OJ\1K7Y5X!NX>3V=W
M%67%BK^E]!G@(8:3\B/`QY-!`^TYH!1?..81I3=K=')2EX#29FYU/Z0ZR0/R
MVRR]3+--4,T9FB93<OH`OX$I(D0KV*`^-=&K?$RSNLB:7N+D":TQX(<"1Z%9
MIJ#L,1\3-$6*R]+BPH#F)8LYB44Q)_6.19;.R8S5)2!MC.EBT80/S$)NH:PP
MP\>/<%Z\UOI>R@.?!DG'M16D]A/IMK+9_L;W"Z!-EP<&W#,8,00])T#7F@I4
M!^CI8060YS0K'G"VH2'V>4&C<L^CG"9:*3.\>"1DQ._N]NP4?CCIX_?2?MB)
MK1S$!'THB"34BD+GN`BB.$<W049W("]`9K@SG-%C0"(?Y[1@.RL1N2C.B)8[
MLDUB<[%D*)BQNIRQ;(SISDPF?&!F(`ME1T_56U::0:LJ"`H#B,VSGKO@]1-1
M,(N"6+;=D-"ZA)I2W2ZVA(1@P*32;C3%!:]H4],``\U/:?;+5<+*XTHWJ3)B
M+[`1*BS$38\2'G!$Z@V10VEH_:]MECX11:"!A_IR^3._^=*"9T#L!3Q"A87@
MZ5'"`X](O=&>L*)AB4Y]I;AJ-)9<*'=_AY:B2JB;),ZB(ITAI%!6(H<_HV?9
M^!Z#'*]HMJPRID?R]6F^R$TW8G-7.,?<B+:&CI['^_BT5%26(H&E2?S`>%G&
M.L[<9$Z`,?M7RM[)7U?W*-S6]!ZIUJ_=W?SL'3%RG63@R,"\]:TTNB(`S6@^
M3[5I'3(/6!@I*0!$0P,-%4/%9-"(:CH8^&!1]OU,,>I,Y2H&EYC1*]Y%CYP:
M#(ZT*HH?2&Q%*7NJ0P]?CJ0J\Y"BDPS8H+F=-BJ+O5%A__&42]5[&5"/RL^"
M;434IM$G9^EF6Q8XNT_7Q6N0X1\R^=VYGLWI$:JA$;WC4PT/F'G$4-%Q%F9.
MB_**F`'Q.<A6]#]@@.^RS)*HH#<5R>HR>J/_RE6H4]`[O1#7J=V[!9<1@P&8
M3L/1V49-/V\N',G>F\S61*];`MQ-$.Z:-#TBF!C0.]MMFZC=;+-5Q-YA8JKA
M$":$A0%D6S%!RYITC<E>_SF-5U>;;9:^8%;_0S7[J!A<3C]ZQ;OSCYS:.[*,
M51Q!JV9`48<#!JRDB<54T-(QN=V\FQC0]_-5'-`<?`-=#5>\$_24@0DY7(1A
MN2E9<8YS3#8A8<2BT<F_8TS_06Q=;-*LB'YE?[?-VCB?>+?18/,V2C\R;![9
M;L;']WQ\)/B)*JP:(3/;)<CU4HNGQQJ-?)[SI2/8VUF'Q![))9J*'M[IAH&N
MQI,?88(Q]<G#&K6!K6:L[J.MS8P91UNK^<!X?!;*CN:/SA2!")JC=)6CWT<)
MVN$@R_\`'9'J\PTM&PPD*DX[-#Q'@$#ESN,LS<%/>GEGB>V.%ON6D`H"`D.-
MH8;`E$@Y!JBJ55>Y7J:>%@A`RW.(Z)B``%7B.ZHYC@&`ZM0:=7@WI'J`JM'4
M&1/5#>`-?BL>7G'\@C^E2?$\8>$V$@H$IA8-8#JWZB4>`\S-S1@.`X+"[XX1
M^'\CWO3#:SI+4S6RX,)\8.YT=%>"CA34?>T%6/[3T6*9?-[^$$`C#3B>NR;O
MB6@JZI@QW=%?@.I_.5947Y)VG:V1N##8F.X:O!^DJ:0C1G1'?0&@__5H`4UH
MYVLC)@PXH#L&[PEH0GO,@&[5%P#Z^V,$]&)=X&Q65`\DPH6VT/3I^.Z).U*0
MBVP8A1`_XPP'E-#;D\'1^<[%6QB7JRAYJG.LBKK3A`_:;:B5SGO5"#M@AZDZ
MQ5/#\TNY^R+("E7S:YNX)CA!I_@I2A+2+0>*,>TD'5NN[S`[(;\EZN^&K=L-
MB31@<A9M:FQ`$W*JY?`^RUJI.7J==88ZK)#'YK<>QN9%HHP`&NDF'YE$T@S#
M<J8(.+)T+M?702++T-LE<!J%-E*L%T?6_.I]R$E5&MTD$@*:C"==KZ,0HWP;
M[/_^4?[V_B5*RWS)/G5/OT2_+IHLI*0NW]BKE.V^JQ?1>0>`@7(R*&PK+A>8
M:#,FLTCP.HTR6QT>4OZWJ@K`3F2A';\S]$PQJY/1SIP9!LXF:#Q.8%>+0#&E
M9RE@<8XR+@45*<)Y$6W8?V1X$T0)2Z/-:6OA,):OB\TV3G<85RW0*6-1/3Q=
M))VB:Y*9VU:(RV5PFH'=I=).@G>4[Z7V$.HLM0FJ\Y-LZ)%"%3=-ZV0&,0P0
M=S)34GVKHP])N\B(78)2K7`7?&)*,"!3JB<$TP<!F*I7Z]T)-&N3A!+2#2%B
MJ7)0E.<ES7N1M]5:P:38&Y2=M9A`C3@=/V$Q-67P.D7'!@:ZYKKJ"@?#0-\Y
M7F.B-4LL=$;^-RK4*5@4]"Z1IE6[BR\I,1A4Z30<8JFFGR79DV3C<EI&,3TP
MT6]19)3.-B-J59MMAYC,.PCTN@V[OR8>;@Y^_Q'(FQ*>B88719^V.;"2X#SW
MDYUIHV109NS>@3E=9W&ZJ("+`):G<+"BTR>C^P!WNCB/GIJUT0KWS5@6K!O6
M/:T0)]@*!CY?N_TP'`8P(+!GK[NZT[5Z-VZM_#BQ1Y[_&554:$MC*+S=WIG8
ML_\@[H`>6'C$1.U'[X#2Y$.=^*Z89P`[S!$4)7BYYKN'RR!D#N&GX"W:E)O3
M-,O25^(PG@5;\LO(BY\FPFD>H0G&]3(+6?"#\;LF*#V:I(@(>N,5,B$Y>JSY
MR*9A$Q5HP\7!0'!3(*BQ3O:&34CI$H\*5;NP$Y"!09=<M]%VDQ'0$U9:<BE.
M`R"O<*MLDY\3@NQ%61![%"6/9<0><G]*%!9D_!Q0@L&.4KU1'@).S(_B3U#^
M'&3T(+YA.]#YU4VY><39<OTY6>'L-8N*`B>WY6,<A<OU&F=T[F17!.Q^X9XI
M=1:G^0A`^PIS=@JVM\'-0=ED2=X!.HOZ([>0R:/+:-F1B+9,)(TA83+[-TX5
MRD,F%\9T23,H%;NKZBKL%F?,],6&.KBRVV`EB],+>0/E>]?O"GKO*+504I`J
MN079-J/12UN:./D93*)D5JD*K_)+TG^U:5=DH8B"N#\()8UBP>\XU:2=68/$
M:V;,8*!IJ_&XY`3G1[05AU/EH6H?L0F=:HM7YR7]T"T/[V=S,?_[0]JL"C@3
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M#E]M)#@]V+8WK7?@;<[N':G3=1YM=H(=`^HF6)&%.B%+.FGG..9ARO3VI;-I
M/R8$<_=ZKV:K1<##<-\X>Q!S_B-#<4_I?6!<G^,#@K-L>SAX;;!X#;(5<;R7
MZ\LT6V.6+EZ)\?WD.@?^',TP&@W["(4U1&:P1'X_4)TI5![P.LV:QRE;F@@`
MO=`7?L2W(:1W]Y^/8?#POY,VN,?92Q1.&RD"(6"&A=1`XS$PDG`<@)>IK;QQ
M&`,\K[@]1;[I-[73NE8LP''<VPO.'M,<JR+?IJFO[&/+SMUC\]ZYAN6ZWN.B
MB/%9D#_'.&].SVZS]"7*B1,B]$?WDN1LH[^?J<WV?YH8[Q/2_KJ;(#9G\MB!
M*A78'J%N:Y%'Y+7>X%?VTZ0%M\,,9J$=&62\P#:<WG$\25TCZ,*')5M2)J)R
MR`L`E&)S3#V#HX&D4%MS1.JK8?B:3HQO$>VE'(V79V+#Z/JFY\&76Y9(H;UJ
MY!C@MXNYR7+I:>3NV_UR(4?3^P8F[-/Y/F)TA-8LD^$MRCZ"?-\RFQEJ%J\C
MD^)]4=I;=7W<SFP3F,OW+4274WHX?];)8[/(,F(I+PM^NFMIJM-X=A!9-=0/
MA++(KQ+>D#_AZ.F95E,C4TCPA-O]4Q1*KQU=:N#V/8[SINV_\W'V>>]CVY_-
MXD@4/M2;.#XZ!W0V_I$ZL:/C@.'ENG,(8AHHW&."YYV8JZR.$:YS=,U]82[Q
M0VJ`]53ER'Q(;RLP"?NKN\9-D>+,`YEN8N-^V(OP/C_MI_<0HQ<=UZ+WP*>:
M=HJT-_,X`&Y'Y]XD63\?T1R]2GA\'(0KU1<=>0L98`#.4$OER4M_V9KO78_F
M@61'];_@F-X7D<6:6!L_!&\B4\WXG#][-#%C],)1Q00#6!::RN,2>C/7,V%G
MMWM;+@`5P9N/S?Y/0<8\0-E3ADD28&SOI::9[>M'[#"@.$EG@R.HUXJUF0`/
MB<9:3\EYVG+=F\/EF+26XQ:9$\WLX]-2"""43M/<\KBTPNV!T%J;L$AZ`3N?
MM[1*U\BW%;6$K01G")UF6H--.W88J)RD\Q"/M1"6A4IX#BK:JAP8G^U^:LK.
M9(H4YSBU-W&$57,1L/!JK;<4L]V=<NABVW.X=`;+=6V5U9E8R^0[<<'8`/TA
M9,WA'9]6:IJ?.=9>Z(%WV[5^HV@XU>9/P>1\GZTU8+3)EG)XAY*5FO+M=;.!
MZ:W)!S^XKA2>=%RMX_5P2&UFCN!H6LT(`V26VJJ.H2NT>3AZKD<(]V"M?3PE
MFW.GSL"(D1>GX($!,W-%I7Y:-8=!]\JJ"AALT'!KM2D@=4QNO3(3`_I>F8K#
M._RLU!Q[975!$S9]'2!)Y"%@=QMDR^R^H._[V*F29`ZT9?8'0YU!<CC*.('"
M4J.N%I[;(--'1ON=#86;"A,&W[/@>#.AIP8*,X&*IC/?/%N(P\%K619Y$;"*
MVA9-T>/R#32!"3JT=5A`0VZLIRGNTI83!OBT88:R*,-Z6U^Y("]!%-,*#I=I
MQ@(/):UYN,^!"H?=L]&L8E\G?@O,`#NP@<.1655X0(DX>J,YLF3)U5AJP&V\
M?T9^S:GE94D38-2GK'Q[R;)UW9)OJP[5-(S.3R^-#!F=8"JYO`/56E7Y2>::
M<7?JY;)EP0W6!J]!1.\8%'3.D*12LP&.B`@&3A2:*>/KS6/JC\`W&#1"\PB!
M56V[2HHL2O(H5";P<_+IH_`9)C3F+/Z#Q7>]#ST/Q@Y'<T-4I6D=OI5K1OBA
M+JZ888]ZVQ]5[X7P\*'0'=X$4<)J>A`#@[`H@YA6-?HHC`USK8*[H#\_C=O&
M"[K]OO<![='H\1N"AHQ7Z!J-["?^G4.&U?8M^I'GN:-:YYIDS#;<;D-HK4SJ
M!\X:L0+!L*V^*B^Q@5J3Z9`"\E`A-60%#,F((D.FFZ7QD@R%5D#75#6],W"9
MJ-W`244,`T`&&HX.'QL6MN=LF-":<<'87%QLMG&ZP[A*GB?VW&[2A"*=S-UT
M6L^9-];]_2S-BYNT^!LN[G"8/B6*V^D#?L]IH:Y#-UNORM>A/N9]:+FR<)R"
M/VM(Z,%C(Z.N=MQDM&7U'?AGQ>Y&Y]3H=H93(^"CFF_'R`18_8G2#?<@OI1X
M%^-?V<!.)@6A!N]_IE"9/8Y3Y),$G2S":I9H)A16PXC-!Z_5CN=#P+<\A*;:
M\S2.(R\I`V/24"7@$N4-_R%+\RD9$A6RH&1,U)IKFGM-*@C,@-I'^^&X:.FK
MM;*DI9,/&R@^T)'NZJX2?CTD\N.5Y,XV1P9*-WLC!:UW$!DJJ,4)G0Y1E%07
M<P="RD.0/9$9GRA"42Z[=Q-1.<.%7,4&#F,2&"B0ZC7L?$Z(,DXYST6;^=R`
M5U>;#5Y%Q+F/=X9H'O#XG"6$ZJNFBAX##*08:FDT:9#_B%I.-S#Z3!>UZA"Q
MNV22_TO^7RX^`+:7X0MFQN;)8*<5`!*&IEH/85FQ$-]>Z/O0%R5;Q@_#R1]8
MW8W=976`^!_(-N@A>/LI*IZ?TYA&2<K\_.GB7+KZ^QK=]?:GRO(.^ID,L,/_
MH;+#=6JV+=>BD=P=PJ+1;RO!7>:X2::U>>2LV+V#<KK.\NB^)_6,W!SGLM*K
M[.R&EP`$.4'S].?#,3II<C84Y7%BMC)6,2D;R?&._1F4'PZ"RR#*VL`GIU,R
M_725=8J/9[P2C>3;N,RODC!C@2/T5#8ON*VBB6%_F<ZF[;G,;R;R?05ZA_><
M5JAQ'E:2I3XXD8ZB5CP*B7Q@2?-520=G.GS7"@-P^FYH\%Z56X_B_-U,_5'T
M:R?3CW@P`(/]U-#"9EY9$(LW==0POXT3Q<6Z^*#S,/:#-MPH>/T@7X,S#`]M
MHF()"UK.$Q1':\SB"0&-T"FA_*IV^3&EF[TX*G9W03'[VQ.;+Q_%TQ/[IISE
MY8GY9V&-8B>VF@[GEX;Y'8[GNRC_Y3+#^"HA$Q9Q-UR-9O%WCW8LJYKQ8"-9
M]-'W.8X5EIJ.XHR(0&LB@VPCN1"4$2D'.DJYHM%G0=S9.XOVS/)C$SM^9T<D
M4\QJCD-LF+W#>*K&X\>,3`1:&QSKS;6Q,WB%(K*#W^*+VL&4T\O+%+TIPC<J
M<C88V+/25?UN17*FQN]0G("MBIG=!W4&(CS!S]@X"0ZU_!`!::JT#IEU-/5!
M,0K0[Q;O3#Z1QMB4&W];HT:!H_7$C1K6\>:Z^KKW<>S-9",GG4X([5[[!&VX
MB-_.X.?YM#SV6:W`>QO\_89U/?CYUW]3@[]G\K3!ST6\P\$O.LMPN.XK/W^T
M`]^@49T>P[WK%5]OL/&0EYS*Y>]Y]1<VG[NU7_GY]S4!.%KW%=_^#4T`T]9\
MQ00`R@.P#?&I$LQ(DZCL(Q!TD-?(\+T"O1II<`;2OB;8!WRA5TQ3#M5R6%'-
M%2:C=O5.0L'(+B+*&+'PM<<!Y!]%H)>L66:)ZQH*AS/`9K;(,,,!>[\^3RX/
M38KR\RC#-'L8421Z2O!JD4A7"PL^YPG*3<P8Y2=7,7E'H*VF\O=+JXJ93NB,
MF\W9S0RN`IASA]O</?[Y&Z==](*SQS3'U]9>;:.G.`,DFSAZ*<-@+)]G,7&-
MF[*+R^R.IAYJ2C/@D'@;183SLR".\>IT5]?!JPAE+PGVENIRJ9RI";I0WE.D
M]TEI7CLDQ13KXNS=2IWBLAX'+MAI7:H32I%.N_*<1U"8<U))SGEK+VBQ0OP]
MM@OKK6-B8P:D'O`A5%:`C!X=-$R(E%.@@9([*E/>S4$C2PRDY_%6I%RFOK1&
M^9`!!E(,M32H4-Y+#73`S$#]VE>5OLE5DA=D):5[2V%\K@F7<RSI31BA2<X"
M"T]:/>6(XB=D#9X2\O]:;KHG0S@(G]$Z>L&(N#G%LX/G]?7P$)DL)//Q"'ZH
MI.A=>TT#`RURQ=2OS^M)Q]>^7)&_TV+/;BW%\7Y^PJFZB?*FF_S>Z@*I:NWD
MJ[FJ&$:GABJ?]>:^`I1_YRBNBW7--&>-K]%'G(XP?GQ]7P1987]JMK^1NC7X
M!'4X3]`I?HH2%OS]&,3T!NQ]#$>63:TI>Z9,\G&(+QW3D%0TU9R#4O`9.`O?
MP6PS&(WF5;=\11ATBS[5)U+VD05"*3]_ZQ0$!<XT=QG3+3#OZME*)\*8:]LR
M3LT0.-`X$W[IF.9:15/-.=<*/O-NYEJY;>8#D"<ZB_'JJ^HV&-1=,'AOVNV.
ME?O3%\G*K3<MV]EJ_.D+]K_'X$SS-6U1%L]I1@OWL++OG26.5N'J7T#1H@2X
M/@RL?@D>8URUH577'.#K_A>"@S6I?CS/_NEC&>.',MS:G:,B((]W\\F0G_`O
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M_E,#^.T<?78!/_H!G9E@M8[=Y-6Y@:KGKE-P<]=!C^`]G"_OJQ0H']U)![B]
MCP+COP.YI9K=K?]1?G^%/B!,_IRN9\K$XCFOD=8#;?*HGZ5)D05A408QK3CV
MC=6*<V!-_#M$3IIZEJQ*T]6`=33@Q7;U--)PHPX[NH[6G9."M/WV^Y@Z.AZ:
M86/.7C9S'TV.:>K8HZGGG#HFJ/%NIH[IMN\_=<`,I=NC,:T].]<SRIP*'M-$
M,W_'S#G_S*?=NYF69F^2_6>KWU(,X!5IA"C)HY!E`SC\+<'P>\=TX*)MM@-=
M*O4_]OZ.272F#D?TXNDIPT]!@5%#CAC];V.OTF\C!UN2T0>/R2'0-]R!-AB#
MKP$=MH>T=<*XA;E1..@1<-,J3I;B/?0YIJ5Z[V9W>RTB40;HG.&Q*29,*>_7
MF[_X9QD5.YJO+RM96-FR>,;9PW.0F`2=LQ_/2=,UB=WF[O/Y]3N**>A0W3++
ME#2W<K#.(0"UB.P8XD/`&0=%ZU,8Z8*FNH2J\I7SGZ9IOP;T`=%A;1TB[J)9
M[0A9CGX?)6B'@RS_P[%%^!Y;)6J8X'-KNQ2,ED6HCQR/((HC_R;Q.+#=#(_Z
MJHC'@D>H-7O?-Q9-+!^53",\'\9%.M_5[`BU@.QO$(V:>5&.1E`58P^Q@)Q'
M+]$*)RO:3"X7KOYWC^*(P[89#^[X=#]Z_$<2EI8.QW!-@G81CB&%>8_:8N)S
MGNOT%6?\7]$F*JR:?ZY/^A^G\S;>P5(1#KX'?'3.:N1H<:4$]+2O_VHC-_+U
MCG2L?MYN78_5T2>/=JQ*&N]@8W7PO?<Y5L5&6HS5XSPE\)M;VFT]@(-X95K;
MY%DFZ[OHI5E8&L0;GN-_`P9SL^^I$111TOQZ4AXH3<O\_8U>)$'V5B:-9W[#
M>Y6$&2;$YYC_K]\TJ5-T\N_O.&[^`ZU=]@J]QU5N<BMHYYB^:W70&K2=8-5!
MB\F('%>8%2@X*"C;H?`.,Z5:$C_H8K[87DE7S[I-&%<04$%^F%0`@#[.``RA
MV9NQXE,9&,,20`N8SOP\.9*+58`L8B%9XLBW>4,\1#3V^"'(GG"Q7/<K8?_`
M8_!$;3M)C+.!N(>1S?B9(`,&[*<K/D1K*XGNW=M=/.=%/^A#-/=V5VI%NT;(
MEV`QM6,'1J7RP),1D<(`D58_^1D/9SD0*K@.[!-\;L9QP%Y/W.&\('\@_V9S
M.<.FR#!+`<ZP,\FP!DY6W#`0-D7E(>BX#(ZX>59-Z"]9;M*$O^,Y3(4J^^\?
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MG[.`X7<>U"5O,/$K"Q<?//*1+7BY<?BO';]+:VJB+L(?W9>/_\!A08L(_!1D
M[/"P/X9G>B`"=N36#[8<CMW.)X]\](X:[\#CM_G>>Q[!0R/W'\.-Q'<\BK=1
MQL3D+CNJ\]&C'\FC!CSX6&Z^^+Y'\]#,.<8SD>FWKL9[W=^]IU.?*79;[O#F
M/<Q1A?4_ZAO@4=H`^Y1L'X5I>]#$;<"_MZ;N1_\[5\/[,N3?]GTRJ2W7Z.$9
M=^>'=OFZFBG+VMP/?]HVD^>?4^5(<_YU^$]_)C?I_F]_K#\-Z3C7C^GJ`O/]
M;#:'/MV=.KAS?:,HP^+V'^`S:P!GD!^D:<T'^JR?![2\N[;9;I0?-B?0'`U0
M:^QU1%LJ<52#>E(#SSJNK31X/T-[BMEVHWNVP^"#CN_FT,SO"+=4X\C&^*1&
MGGF46^GPGL;Y%,-M1[J/8^+?T.X1T&&Q+]/WV#\Z.3NN3Z"N\KRDGSD?U\-3
MT#F;SU5J-L@6$<&8$16:#0%"23"+"H5V%B@KB7*0;#]'G=;'0?Z>]YJHQS@C
MC^CF%_Z(4:T9AQY'FF\?X^@R:LY#C#GEA]_=2#2Q=EQSW4&B=[&-/$S$.OM]
MG0YZG`7?8F0>XMO'6=O!H#D/4\=!\6'((_-@UDI7SL/7:*D_U>[F=?N+(:7S
M'898U=$>HT\&`U=*W<;S<TTTRV9CGLC71<R$XY5XB-#DC4DN>YQMRNPR$M7.
MH&XTGQFG=^!-4G>(13;+(1:P@\(.%\IXOGP:Z8E9C!Z*VB"].JT*_;4FW`99
M$>U?F&$>--,'G=SI(HWSRO;]>(VS#*\>@K=%GN/B[)E.X5?)8I.6HU(.T\6X
M1/A4([M8MY4!!O43%1_BOV9"1?"&`LJ&7FK)**A%PP#UT,!\N<5T'4F>KM,\
M/R-+T&Z=9G0?D9^G&YP742AIO$F27$)[#U.[Z)X@!@S`I^L^Q/@E)NYL$*.$
M@#NMA:"82$%A5\R!/-'J\S>XZ%F@=TP-&9WYJ5:&-&ZK$9=WU%FK:@$RW/J[
MJ\,=KE<*W.$<D[9[7B2K<_R"XW1+/18RB,[(6(J*X1LL.U;74#,U9@@V'1\H
MN!DJ*P-<5K&C(%FA52N`K>@A%^$7<L8SG:T@:'`TFPGMI!P55*UF2A/@SCUW
M.G=$[PNB-6FN:Z+-#)[.0!Q0EU1H]$2_M"?+^V"8R8#Q*01-Q>3)/V4?M_=.
MC=C<W1^8&]$>_>MYO`/.4E%C8+GQ2=GGIWBDAHQNX67MC1IQ`8+81$^4@\R%
M'WJ@Y?N'C$[:)?F;]"14P^-U(1:IKUQMNPS>X6>CI>3T,NL<7P*%&/E'_;?J
M0J(7&I&L3G&"UU&5_M&TB6RE>H7IM"90`ME.)%RH3[+#8#"093[$9+6G?WBL
M1,`8(-6XKO:"Q/[*[LI02<-IN5P"W-"$+H`U+&``:J:G9&,/"F"]W9<ES'2\
M'L!F9HX`<FI&:,`STE;HAH("WU42IAMLB3HIDP>X:0P0X$S"X11@15H$\;4>
M96I=A_!ZH%)1R%EAP*SV&:J)UPYNILP^?$8S@T2NH9H36K$I*ZU!+[>U);V9
M>QH@S43X@*6-<2)PFO!#A:B%[@=9F"4GC+5Z7*,ZY&D<'"4Z\S+G=7;.:&M.
M<]1HRNC=TYNB[1!0G`%%"?Q8M6E3(*A9;\)$!V%NTWJ!9LJ*W<!5Q0L#;'8@
M`P$N"U`=!9CL0,2IV;'<-DM?HIS.8+^O3NC^``-4%^LU#HOH!3>FW;$K(MJY
M41SQB;H^(J)+?$D4V?6()6TUBV278)VQ*;K`GD&L]^5\?EN&8^7SE_=?HG45
M,Y37G&SL9(?S*RM[PH%!U;!>KJ_35YR1/YYF0?@+%E]BV\MPYF=.-:_Q-VT%
M>`?J/EH/(5G1T]3;,>7@]RL5S_',WN(M'9:5:=A/)+3Y6F>\[40MD^<=^#,:
M(0[\Z%PNGM!0H^,9`&UD2QWYLD?;B81!`[W<8%NXCR4=%="EZ@\A?B>+:@(5
MT61B\CE>E2%/<+?9QND.8_["_S7!6?X<;>DC__/H)5KA9+7/$F#Y'6A#9%(S
MV8X>JX\<U<":8MDH/T#%2;Q]\>/LP_K\`_MHK.V2V/58G-%*O!G=JRM\2R-N
MUWZ^A4E##]^`U3M`I^D[A!TE130>FA`3N-74QS/#L^"PQ>H?95ZP+`5[#..Q
M*&CSM,Q8VZEX*,<[F&=0?HAL1G8\.*[O@T9ADMIKO8-]!1KZ)S21[<"P^,11
MC1E[NX;#Z4>HEXYB\VDUJ"@IH^2I>C\DK\1I(\#_D%`9ID>[B!LXD!4JCWSH
M6@"*VKNF`YZ7BT+:%^$_2YKE?/AR;9&L^.:;O9.\K%XWJN($]I'J/'9C_R88
M175,%^D=T?/:,:J!N;S^W:'>Q0Z5?EA49T;_U57L'&\S'$;U0XW%)LV*Z%?V
MGR8M,4&H-T!/;@`IGJTEPH3S5#/&+WA:#G;@&'1X8+@8HI'<&:[U4W7;5VQR
M$;Z?K.F,T[U/D_%#C?.TT!WP-M/0&LVUC[44@&!57?18BO`^^>ZGM_1JY_\-
M-MM_@WNY,_VUJ#@AZEF:&[]RG^53OD?%7(TUSU-D^7=`CZ^9C)/F'^5W/7/>
M\AQH]'U.,AS$-$TZW:W@?)DL7H(HIJG,R<1S'\3X'H=E%M%DP"R%@6DC3Q#L
M=61-;@CE.+*6"G?43#5E%`'9R$%/092@-.,Y?,@F(4I><'7V#W2X6`T!"+`V
MAZI[^!F_:1#JJ'[*T&:-@`HEX^L?<%<Z$Z]IP%R]?,_AE^`GFNK>"H#'?ZLR
M,ND&&_O/C-0KTCK**J%%Z(!/9:V&HU-@7!QB&I.<"]]B8FI2!$]XN2:+>)#M
MSO$VS2-:]KWC*%\U2_,B#`4U%O:4Y>P4>%]SF\/?J8*\.WAS:#^$;"N.OB+(
MF4""82Z1OFRE,&XPW;IY*.!B#W?G$26XWL[18#UZYYA%CR6[;#S=5;%Y6:N_
MY(#<7HS+>XVI1G9O,FQEP,#Q=,75$`Z[4M`F6&'TN$/%,V9[^B#9@5G,S<R7
MKTJF_(Z7?3NS!KZ`&;-W!$_5>)1`H`?6>7$JF5FO<9#C_.*?9<2.F%F)O;-@
M&U$OB/[T4U0\7R4%)DU5"-[.3I3A;$Z=:EXSH=H*\([%?;0>A1XS,:S0&+^`
M**D@%'))**8_HU<BBW@"7-@LL3PS)3OKV)M?8^)ZXU->./[^&>.".^^GNT_!
M/]+L+":N.;LGO,UH1NIB1P=OL4A631O*=U>'^)#3I&H':ZA>(K;9O^)]J!W<
MM%'TG&H@YG`>.5HWB+0M>"1Y&):;DI4S[(:BS-4;$S\.>HCNU:![#=M)7S[>
MH;R/N>.;?UZR,VBYZ-Z[85,-[@.";Y'A8+F^#I*5""#MKS]_`RUX2*";T,5!
MP5.&605XM$XSLFU<1R%&^38@__?W]_\L@PRC->E^("EPF,[].AO#>NQJ4I=3
METK9+HY$=&"F!85RHVBSMJ`)@Q;C`G+*T`8TL_GMC@"^BIN0>[<:'I=0,E*_
MBRDE`QAPF6BI0=D)VJ1)\1SO$,T"#"7YZL`P,A.S!94_%WDBBMXQ9?/3((_R
M>[+.!:ME\F.0130409&H:P:Y'F$[O1D4T+87"A7^DRW1#A$Z-.BSHXS-R]OF
MF!C&8+D-=BQ>YC+-[N3U?D94+H$L4;$+RP$)&)")]1H[X`FM3<+FWD.=MQ+/
MDDA?U`[G6;K91#Q2ZASG819M94]T3#G=G:U:F=*>J!JQ>4>.O:ZCK05G[FPN
MPI:=;.P:?G@34+H+8AK^9S":6E)?4]%06=E\5--YAY:!<D,L?8J2:%-N4%;3
MH2)%CV05"Z(5PD'XC,(@QLDJR-`.!WN_=I%,7C06"B_7MUE*L^ET:O&UX06B
M463$YFS:LC"BF;,,>+RCRE)149P;NS'?<M[>PY,VT.-`R&KP?T>S(*BC..2T
MSC"D4[<!CHP0!EHTVHW<HV;RR5BB^_E<:`DJ%D]DZ:2QG16LSX+\^1*/EB4-
MK3-4Z-1M4"$CA($*C7:CI2EX8TM34+.QZ@<\^(9PTH-3()';O</]R[(H,URM
MJ_5*?%YB=;U5.Q'>KH@,C9->]&CXH9WS3]!]B&("F>^."*57R<-K^C?BZ<E<
M=&LIX+`Z-M$:KJV(HT3L2'T!:/]T1*#=IRT``G0R+&$]:+!16?Q4:U-M3OF%
MU[;B.A9@UG%P5TD8ERL:*E__,KG!5")AP5AOO!VZY?*@O0B;P99Q+$&>T]PX
M)=DQ9S1N(\?L#J.)CCR6(7'+5:_\_QM<#'Z?W*1ZP;"&AVE#V`T2G=1C6Q\,
M[1D]U.!L[79QS81/6$X<863Y&$=//+VAX49JS.$J2&K:1*C05SC9566'T9;F
M`_,6H":QX(9P6G=3R^0XG,UJ'*H5'CTKZ<7KIPTO*XO"SFG,N]%;](APYKG!
M;\5=&I-O/SV\XO@%?Z)A,++U:2^)'B-&IIBNB!6Q$0=MW[R_*7`/?DQL8Z<"
ME7'T9.#A-=VCI832H`%=8;(MR`6BCA'@<C/@'A!-LHLH8!@#:",//,"[9N\-
M<2KL78"\8X@`YO]RO#"_)$T\8T-Q<=!!WC5Z7XQ36>\!XAT[!`C_UR-&>/0R
MYSS.Q8%'>,?HO1%.9+T+A+=V"!#^_7$B?+$N<#8SS`<R(6-=:/X^@.\)/';4
MBXP9W:(]XPP'E/"H!L!^+002U'O`%]9AH9W2PFM=&%@\HWV;%/S=Y5V4_])&
M*<K>O*I9G%XP&2C?.Y-6T'N/#;104A8BN!UFE\/T'41&9L85HBV'<H+8&*.P
MS(MTL_]T:)`I\3PKGVAIGV>\B<(@OB4M]4Q'C"@PTHS/2P9$G1G";(<R)N]0
ML]54G0)N19A9V9JP8D?;FI^CKJ!'"VA#<UCGY78;1SAS?=U8!=Y6#X46;Y$H
M:+CS*YQ<"PK=!.G-\C(N@J1`#UF0D.Y`']'?*<O_\='<K`+T59Z7>'5>9F3F
M(;")TA6K%9#_%&1$Q2*_>"-8BG*\&O6''3NP#INH_+!'.3V*F"!4;M,$X8J)
MCKS72M`)RADA$)>"I6!:5U8NL[OHZ;FH;;W-HA`W/^;5K[G4UY@FRZD3LH^Y
M/>]DBB`HJ)_#B"'Z:[H*W2WTMU0.]7;X+Y["(I1C_`[G!=&RP"M&MJ"5B:0E
M!J9)@C/ES63':/9CM6&JR6_%!-).)Q(1C?9CLMB;7S(MYAU:6--AYQ7J;89?
MHK3,60W,/%(D6=,Q>7H+K#!`\BI8P.'=_;52<PC*YO46?WU5N[I\3O(5H,7&
M`!LN?*SQ,2C>`@M)X<TE.D7'SN]H'IAI&I`]GB1&D!W069S2776UM'6T%OKQ
M6AYWCRD-U6_W1QH&[\/:1DLE>GC`[",M9T:++05<)`JY3/U(WP-4_UD&68&S
M>$<?A4K"P56$SN"C5+3!C)`*!E!4J@W1T=!6<WY%S9(9!NV*<:B)AKUX("CN
M8%H(?2&=NPE%H68[B0B(8.!!H=G(!>!/4&A@;W=*.$'%'.?ZNK?Z*V,\:#C<
MO]M7JCY^O2\D!X(6$QVEKN.J?L4TA!#$G>P-?F4_V>]<&TYXWJ6EWL.>I#_3
MI,6\`DK'=:`K`DL75*T1AYH,6.)=GCGW$H]RBTIHW`UXB7KM$!\0`!G48JU&
M9<?*S2/.V`U;F[HXI_]-A+&+$)[@V--@GI!%$-SPE"DH3"C(YU('=YF+)"F#
MF'[SJLIRJ;W&%+)XN<%4*"^\O!30PQBE9DJJKRP#QM?/6.KK!>1>";S!C5RE
MEJ-Z&PT=FSW9\SFRS]H<:"SSZE#L&K6^3WT@7Q.!3$KJ;.QJE&W&K(0.QEA5
M*S>"0T/=R>DY!QYF"MMCJWJ6=TO<2T:!F-1I0)Y"V5[TG8#..W8,E!OMK?B,
M3@_MJK*:#AR"Z@TW_S:O#JI;L80L7AP"A?)"AT!`[QTH%DIJREA6+[0KQ\`9
M@AJW90*4U+Q>,&5BCA!<*D9X*#/05@VW(LB><.$4=73=)9M;>DJQE.9`%Q`Y
MPY%4P08P(PH8R)"I-8KZ)G3LU("=%*7:U.0'.YUI;RR6ZZHFUFV0%;L?TG3U
M&L7QJ.&U'#^OTM!91Y!OE=0U%#E@5NJ.?(B6#RW7J"X7QEA1S?NEG\C5?3/?
MPNH@M9;RD`N>1)OT#>5`EYK,M\=QGP&S9U2Z*NXUJJLQVD/5O09C]#1HS,.]
M@77"6+5QF]<;9'\!WM-O?&$UMP72(<$[667X]>XTC>/\$Z97$N.V'Y$`:WF9
M?N/=/25$7]XA1HO^SJG]H-[Z<@M6FXNU&[4X(:,XKZIS4DH_*)\]3`U6;YAI
M.^J=*B2M-PNQ:8E?1C->+_UU&I0;LM==I]F&7I#3<KW%CL5Z2^8H'0.L_C+4
M=MA?E`UU^!!G1(S3ZVQV6D;QJG['?!T%CU%,%!OWDI`,6-^H=!SU2$6,>('B
MAMS/H"G)*,9Y-_J\+<_(_ICA52<G9:UM)-@![B$+6G?N:\BXS[E$U-WHMS)1
M+11UI**.6"C8J)_GLEE_$;-30/)GZ?&-O0CP2##3WP@`M:AJ$6V%^3WR.3M;
M"FY/)8NHBAA67QIH.HK-/UNBSM5P9^?K<=T\N[3I'@4QL.[1:SKJGDN(W4.]
MK#@.ZC/@WM/#STE$L[.T89_C#K-B!]:%4W0?I[1NA?"S\%H,WUL@)@AQ28B+
M\MC/>-79,[%YG*C$@GEE72OG`-F;6G4E'4CZJ[LEK-8XPHL8LY^536!2_428
MW;@\I'>8;'!SS'_:$N_K$C]F99#MOOGZX[><UJAC[<7"[_W)-AE"I,HY4=]^
M/:2H^D3]._T(JK^"Z&<J'C!H8M=$9BUD!",+>?#Q8V_,X8#C!S%M6]!CF!=:
MV)DLBE%<%M$+ODK(2E>*GS,:<P)#@:7:DL>QO!<[$E`M`G5D>._2;JX1N1>@
M88#;@0IME8^:9<E3?/<7?X1UCXLBQO16/R;[\];(](5LTPFE9,F?)`9LW]K;
M8)0$@<GC+Y>IQ"X2*IE5H@1/4*B3ELDVSP,":-TGU$Z>FLUO&U=YX6BR7&US
MCVBAMKQ,48/\>)3'[T'%R`K24L9=T]!"[YJAHB9=0WA@=<TR,1XT#2GPCAGJ
M:=`OA`56M[#*):8=TR$&WC5C30TZAS$!ZY[7U+AS:E+H73/0TZ1C7E/?W5)=
M<U+/DBH8K3!_>TD/`=H8:5$OF7&"ZS0KM05]6-\+,]<Y[$I`18H*TJL9E[.E
M<GQYS[65_7T$/:(Q[U@=+]BN-51<U;G#+1.+SZGZ]YX><V5^-D;G>(VSC);%
M)BKBLV>B/[Y*Z.D=:QAZ3_U*=1WUJRDCK$ZUU'K8HS4[XOR("R#_A1H1J)'A
MM3\?@K=%3C;E#XNW,_*?4?%?09;M+M.,QH+EY[2N>1AQFQ,:A9\5T:^CY[OS
M2(2)@'W-D4*#"$9,,OL7ETTF=R(<U=)15SPB\E'W`R!PD]-_5)%*-[AH*Y&D
M>4YS^#.SSKI-I@6.O4C8R)ELCQXZ.?]G'2E&I*-&/*+R&6@J;)WUL.4+/5&"
M5Z<X(?\H;HEU=.W+HL>2A;>=[GCH!L[:!ZHBN-C*`(>/B09H7HUWI:!-L,+H
M<<<<![(&;8/$CT]XGMVE9)M1_#78;+#L+$E$!*S3Y!J.AFF&."WBQ%YW6A?K
M-0Z+**0W:]05(?/%'?%'*_`MU]?I*\[('T^S(/P%"VX9;07`ZK:)VH]RP31B
M:H^.SKM4$JI$T;`D)HS]4HOS,N(J90<FT]5@F9SC1[)-2>A%N,B',V<%V<WF
M>DLZ6-"_;!5=)HB*0:T</SW+%P9,W89SLN*'19K)7MLI:('UG591<68FPL&\
MFX;'[SQ;ZZ3K#M!=8-CL_AMZ>B8R@`TO4U*1D:R-:Z;T?B:C-QRR>!M14&]U
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MPV"$?J&,<5^8<`'K'0N51_W%>5&""^)<UD$5<<K>+#650KRMAI5Z9![!A.69
M7IZ0!2!.M^P0.:B"E00CRHP/9#\:*BWKR9J=7QNU`CH!6%['H\X\L_%I)^4H
M^]EJ_)KT.NK4_CGW-J+3;(,SW;VND`I8+RI4'/42HP5RB?L#3BAD:"#G:A,E
M$?&C@D+^.%%-#JM/C'0==D[%Q"-/>VQ>N^F*^+-1$'=<+Y$W+=E9V###ZL()
MFH\JA7(1:-W;.4@V#!ZW!O7S"5I3CP#V'V5>L!4@[1PAD5]J)YK^G;UQ(A[:
M991M:*7&VPQO@VC5^4%4H>!0'P*&G,-:*:U'2_8Y?.JHOTC3L/3R=]"?Z\_R
M'VOYB'V9ABNCZMN]'[%W9/;;KG.@G0]R(K5J-U$;%<DR&7MQ<W\`*A)GM4Z%
MP!'>^+^JCPGR!'5@UGZQIB/?!(N[?BXE4;M-!9R1Y.-#FHU9>T",'_IH$08*
M6G3*+Q_C*%RNUSBKL\%+,QA-D'$$<#$RP*H:^Y:)HR6YF3P0Z8^$IG_>ILF/
MQ"\D2A(_,R]S>H:V)EOFGZ+B^3EEV<K-4&`BZ0BP8&&&\51!9:)**,MK2L3R
M1UQK=CK1$7U<R)#MO?:3]TY0HMZAS8`5GPDPS5IE+WP<+QAF['F/7?R_T^?D
M]CZ@"OPB.1D;D\#J+JE^PTZAA.C+6U31>CWVN@X>B6]Y2Q39!.&.9KYDY]@_
M9&D^'DHJ8EA]8:#IL%<("W.S:R;4<"'&YF58L-(MNMS[(B)@W2'7<-0-K%@-
MC!3[3)>\P<'G9(6SLV`;%4',?J++XU528'K6>2>Z/;,5`+#7[+47]FC>&4Y,
M$*HD5=6)J"Q4"V./)/V,-[)S2CI0I6MFQ$X9\W.<AUDD+MMLQ@:L=VUT'O4I
M9T9!,T[#EAVM6GXOO?@IR'ZA]<@D\V7_9UB](M1MV/J4"+&":SYGQT_!6[0I
M-^=XF^81@0\OV'<=;401(BIB:#V@U73<'XR%X)[QD+%0%2^,&9>?,9"2R?0L
MR.+TGNC&RYS(QH.4%%C/Z/0<]0ME0(P#M2Q^!XW`!OD#.R4U_,[1/:"3](_O
MYW(W:5(_2]<%SLA)8?6.5L]AUQ`&5',`":2Y*>FGJ]<<P6,\=K='%,`Z0:+>
MJ.T9'>H0^FONWMG37W"\HM<7P8Y(B!^"-TD/J)D@=HJ1QI)^&E[)/!-V?B_#
M!:`B>//B`M2FU</W#N?14X)7BX2:M\91@<=UX4R88/:@@<;R'EQ5S#1NB7&C
M(&&]R/F]]M]E6909KH]R^8$OVT/3-&_2#E1RP>Q!$Y7E7;AFW$V"VRK6#)7L
MM(%FK-L21J\=R<_7%]MM'&&*39:CEZ;HY37O`I:&1=JA1MPP.]9&=4D'+]=U
MM$PEAD5Q-8+JXG]<%(!>?HAH^,=#D#UA79=V22'WGT!/;6=1'AJ=PKD`]`N]
M\Z(IF&D]KR".Q570]"R0^TFAKWSVK/J+\Z(H05UNK_W&5H#7+"H*G/0C9T8E
M(\_B-%?X--:28/;R5#/DG5]V)(["B7K.+8_?1B&3ZQ46=83OJ+J8M/NE'#"[
M6:>NO#M?Z^#GJK=XF300O57-39L-?2*%XW')!AT#[+Z2:&O052_5Q-NP>NFN
M*KI4EWA23`:K:Y0Z#CNDCJI]HIU!NJ%($:X9??9#MQ2FM!>Z1##[0*"AK`?Z
M13Q]#H(?.!;:2D>:T2"C!]DE&F4-QD?8LOKHI-L@^Z6J72/IEA$%K(Z0J3?*
MQT\O>RM"K^?OU=Z:IAO)G]G+!K[U%C2\F!!:^RNU''<#3Y)+`REIL2S^XH*S
M>)FEVCH-Q(0RRVB^WR0I@_@^B(-L[%AIZ(%UCI&RBM(5M)LX'^*,B'-Z[ZKS
MK'RB!5J>\28*@[A.9#8^@S!A@MMI&HW514=6A)F=OX<5>Y.L+4>T65'!DFQN
M@HAL2TMV'.BI@EG7Y.JRH<SP94"O$I0].B2&VY,23=4]N&Z8T)IQ>>\=E@.+
M(LAVKE0QPNTU`ZW5LV<C`.@\>H?I\(^2)U&^`KX-5W:K`3_<WC577CU,LUJ.
M+%T#/Y4`T-D3^_@8NW;/'H7<CWSNJ$(K\ZOD(7AKBV)2'5G5BC!,2]&V8J(@
MN'T]P0IU[^=,8!V'2C,STN`3\M]5C;^HD8H"+M8S),87B\MU_S*K.JA0H,%8
M!E0@V!J@P(#PUI4NYZ.+V4JDK_Z/TM5%0M^5?B),SP_/45;L+J,L+QY>TX?G
MM,R)^W\?O148RZ*6IP@!AX"I%@@@0$0A+@LQ8>C;CR?HFZ\__LGOH5'UFNZ,
M.)/L"/$Z#F4=*B4%UFTZ/4>=4[\H;#@086FZQ<\0Y.F/F(_Q2-S\3A(FFOPY
M$9Y(Z'F`]92QPJ,NJ[)#\:@BQMM-L%)S^^JZEXA,#<OU.@KQ_38(\8(`2]1=
M(CIP7:104M`MC!IQ<L3H$67PTQ--%8++,DO8<<<B634/'>F;QNY[R7$/V?$#
MZ[E)RH]ZM*["0#R31@Y[A]V^%V5O0WO/1;WT]G^605;@+-[1\__J.F`\20JI
M8/6<2L5A_S2T_-:CIO;2`7?WGR6N0_,+K(8>JC5L7/([X@1^VI/H@B_EJ6@'
MOP-K6Z%RHQ:F5&C-DLMN_'G!7%G2",J6;GZ'V-)#Y20M3<B:EO8':OF+RO[/
M`!M:]V:2MW.:8`#-K*H9."0`V-3ZJG^\L?EM(X#FEA;MZ_\,L:DU9?>JAJ8U
M];PV,Z8':?%ND21I24A7U>$KR]*8\K\Q_^<VC:-P]X#?BM-85&AMJB!@7;>?
M%:-.KL2A1AYJ!:*^1/3W@4QO@(B#/(_(;I._:%_7!_1MR'U.C^[/TB3!(25Y
M);L5NG<I=C6)"!W[2P4'E=E,$N"F)YON%6OIJ.9%E7S4^P#B'VBH/&$H?4JB
M7_&*[5UIK:!.)FK^MRAXC&*BJ`@JQLS@$&&KN:#C*Q$H9EFB8B8$95768QJE
MG1?1)N"EZNJ[[(JV%NYIXA!5FY$MWPIB:)VJU73<B9)2.3ZO)0:W[%=)&)<K
M>NO:>6Q#IXZ7(!:>\ECR@^O$"<K+W[",8@ZB2B*]?^Z]'L.M5%^C<A1<45V$
M\M*8_!Z-_%_R_W)!HC=;`:`[WE1[P8@65<:N)"$N"E57DN1_$)<&I</O[C\K
MS@<T#/`[5*"M80?2X\AN[B4(0Y2&/ETE/#&$KK.ZM*#[2:"HMHLH#R+N+>>"
MTC7U6\=`^)93QP"^DT3:&O44^8\.IY_>2G=!7$3$YZ9G*VV,T+B7)(3`>D>M
MY:A7:G+$CY9:!A]]<1\^XU49X^6:IN[$!0LHJ+*OD_WJBM7BSB_+K'C&V0/-
M^"4_6MI#%JP>W=^08:?7$ND!04=FD^>^E8HJL>CO3#"BDA$_9_*+CRKPI`XP
M(7NF)=6SCN(GV]\B-P:(O3"H")ELB0HB=9!/+97M4)G<]LT#DURAQ/-99-L:
M9,DIXV*YKNI/I\DEH5J$9'.5,W@;`\1.$%1P3+)""@RRH>4"Z;\:D?S=64>H
M8.;PBHJTR4&Q+(N\"%@D*`W(:;-(&L+"6A),7$PU0P6,)EM'VHID#Q5Q*Q3*
MDH+CF!O,5T(:8RS>\DHI@?6K1LU1OW%Z-JDW'%X/'5GD_2F/0]W0)8?9NJ"0
M>F*W7J>[EJ2*M%H0R*UNTJ1*P-"!\D\X>GHF&XT%SS6N3A7B[M/`0./:[A$*
M60[*TRJ`N%4!=71`ISO4I:M3#3!%$,W$7*??Z.B":F50I4V=+YCL=:@^1P7P
M<5/ST^6/\P%9^HEW`EB=?4-@-@62.QQ'CAG5\#PHDI0??K?X,K%ZB+KCGZ/X
MZ1[S([<X9'?9]$\.IB[C+[\OQ-F:/80<YP<)M5SO?=0#)K]*^(7:O&[?W!H<
M&?0.9/X4)S`W]P(;E>A]4'7->HS>H%'K;R-^`.-S`%CI\!Z'P)0&./@@:)1Z
M_\.`A5;X&P'FGW]_X+>V_<"XY_H<(^2K(A!E\9QF-*:3I3%G5^;<-EKDHY\J
MEEW==LYKJS90=<(WA@/`C3+',!R<ML3H%$("7G:"_LZ`7*=T&;><Z5YQ_@^_
M8X#JK98>B7FNO,8,?M3OF!^UNQ9JP6!8-JGC:/;:+`B+,H@?<+:18-"Y&@`1
MZ:L-A)[$H]*1:/R(1[,]))MG1Y-PHQCJ:(:H:D<U'/JISMV/@VG??R<#8"_C
MQ3ZT(?21"/L]]QD+O&8YYC_ZB>L@?8)O<%%%H"1/]`%5N^D])[^.D:KG`88N
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M\?$.TYUK[WUE3]I$5`"[4:*BL)N&M)Y;O[[9J=[6TXN2_!SG819MNR:+ND3#
M"K:?S/06C['A_5.=DH`)01TI_D95]TC@O.P>_=[CHHC9)=MR7=^.G4?YMA3>
M04T5!;#?][%#C(/*66ZFW,'A>"N65;"M!*-*,CAL-*>&<R'$1.#QX,3"&FNT
M=,Y9H8*FWA%*G)7EFF<:5&^Z+84`!,<T"X0A$,TA:[E-DSKI0#<S@9?.YE7F
M:-`=2PPMBD(?D\#J**E^PVZH*NI5E/XB4[D>#!0\Y+%.K#O(8L;\#4EW&')#
M["D[U26=R*.%_'4A<?VJP;\4^\PC"F!=(5%OU-R$CE6>['C"?B:J3E%%FHO^
M*J$YX:(7OF]>)"L6*Y8K-I;6$H#UV$3UASU*/ODOJ&&N.I9&\'!^1`5X3;72
M.?RJEU])CTHI8?6<3LUA#W7HVY-YKXE=&XUH$I^G##.'575BH&,`VD%J;:7]
MQ%(5U7S=`P$O?95%3SBIZI;BLHC"(,[)>)>-(24YL'XRT7742XP)#;CH#.AU
MEJOV#[=9NBK)AK*-GFRKAX_ZRH`'5H>9*SS*_,".L,GF:,MYT:H37]J60O<R
M&U9S\B(D"VA4["0#2T@%JWM4*DH>6'EL;YHYM'M8\YGLHR_>>(ACI_J!K",,
MV4'VD)WNTK=Q--MA+CJ+J$\BN@4??`ZM_I/`6YPQXZ4]*Z2&V9$J575O&JO]
M+BO+P/@\=Y'R/8N8#&JG&+Q:Z?1&\TKEW-<KE9[F[&`R$/KA$CK`W3!24MT/
M_.X[\.5L=\^'`T*J'`I=(I@](-!0VOPUK?]!P-?$JV2QS:*X<TSR\(KC%SK3
MOA`-;^.`ER=4NVN3A,'MS(F6*#N=UL=($).*B%A4RT5<,*HDHT:TUWU6OS4>
MTLLTV^#L4_"/E*^]SVE,=O%&H%`S0P:!D>:Z3G]($9>"F!C4D0.JA_G>,LW8
M[0(-W#@C_W\9%X1&7CMJBA#8/6YA@4'/U])0(PZU\GJ5IX!#0%Z(>8J0HX6`
MKJBS-03H2@`!`GR;;+=_5/#`[&"]PM+^K/;_3?S!EFTIMV0.S[UO*1_26])D
MST&.N]4LK;K27`3,GK767]K118JVE:A!(4](7=_6]EJN%TE2!O$=.QX.,UH(
M>!S[KZ&'U:EFR@Y[L.6B1W(!XT,9/_>N.+UTU4V:L/PM!:NA<Y:^X"20;J=4
MQ+`ZR4#34?G<-$$='E0S@5@`W?M`W_X</\;..K1G_][>3ZV[;!JU$79L=U&P
M^DVBG*1C^M2.6[[,/SP%P?9G7F&NJC?7;70AP<_?>&]OM5[#IN94)W5!/:^-
M+&]=<,VJ:4]/S7@=!8]1'-&RJ@K`CJD`-:]"N6%3=TA]X[>CBJ;%83:U21M[
M:EJV.>(GD/G%/TNR'(A:>$SU\Q_!-+1".>&SDHKT=X@3HT519-%C6;!DH&3+
M=QO`@#H-6##J'1T/S$&A5E4Q4E@,!B?W-6B"&.=WF.Q82IJ^43AB^B2`ND"F
MV;BP.R,Y083(4SO_!0=Q\7Q&QN,R>PJ2Z%>V;_B$5S3^\+[<;F..H_.L?,JK
M,L:BSI@B!U"/[:7^L%NY,$2EH:ZX$U0)1+5$-LZ8S+I$M"<8_)"E>7Z;I>M(
M.-0Z/P/J-)%6P[Y@-(@3>6K;)O7L69JS&+FZ&KBHI:7$@-I=K^.P%QH.Q%CX
M\E(Q^>Z5JR1,-YBF!5;V1TL&L2<$VLG[@!.CWU/R/WAJ_JNDP*0U"L62,B`!
MU.PRS89-7M-YGMQOTB3M`T71ZE)B0.VOUU%P%IZ.\%\Q^1H"_'JT4V52Z.0.
MB0"<A^IU$S\M/_%8";@=NOQRZASS_[U*%F&8EDE!_/401R]TARJ>C/1\@$:(
ME;KC:8LSH=_7[']`48)J":@5`:83Z<5'4J29Y/A*R0"ZVT1Z&O97AQ5,/]UF
M>!M$JW.\QEF&:\>1N)#+XAEG\D/T:9)`]ZR5`89=7LFL_0WF9S-QR.NIOGPV
MN@UV=!ZA[\+#,"OQ2G,./4T2:!Q8&6`[55="&1`JL<C_B?BX$2XVVSC=X3K7
MAC4*Y/R@^]Y`;<,>KR6A2A3(7CXK\X)XWMDYWJ9Y9#K3#[E`]ZA46<-^K/E1
M+<#7GA$79T'^?)NE+]$*KTYWGW/Z2J,Y1*@B&R0#U)P;4&=.4'JTS<0%HC)0
M+00][M#OJ1S2MW]`[1%,*\M3_U:UR_*'=!'^LXPR?/^<9@7-H],^>A=VK1$C
MH%ZUTW<4Y5AQTTO+BA\Q`1\*FG*H(P)*/Q+D$905.YH@IZ!GL^2OVV&>!GMN
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MZD<C-<='#A43:KG0WRD?8HRN'P1U3E'2#7X(WF[3.`IWFOX1TX+J&XV*@J,@
M>A]-.,@`8CSH[]7_0NB<"C1&G2.F!=4Y&A6E@P9@WT@WO@9]9<H+J.^L51[M
M)_I;_/X.'V#_GI9YE.`\)YN=1^(Z47_X#H?I4Q+]2CRS%<V-O([8I1&[W:M.
M,E:D:;I!X'E>;O"J6OD[J[4(%8?](B`L.3)TB,#ZLZCSW1/4?AEU/UU=VM8G
M5"N&UVZ4?O7]$]1X9!T=W@%FY?$`\W_EG6)3$T=P(#QZC3:8L_DT%]$'^M0[
MQ:+)]?:!`.G_-GQB0_Z0IJO7*(Z%#2IY&'6@3QT_*HTMG!65)ZC^[HD<H/Y>
M@-6V,75SEBJ$/JJA2?2"ZH&:"F0*-H"`,=%6VOD=YA-ZPLD2#0:HX@?8?014
MZM<MQLQ'TI5BG6T[E)YB0W@C(]WOLD=M5IMZQ@&H$PT5M=S`,V9?"4#"L-R4
M+/;N'&\S'$8\53?>QIC^@\9U;M*LJ-Z"6H5IS"4;$`!F-VF4QJ3]`.I^X00U
MW^!1L9VOG,`,`C&)$*ZRAY#?;HA`1:Z?B;)@06<_$P10@1PMS1Y/G08Y7K%L
M;DG.L,J?5"W*XCG-J`O*RCP-RGCW<V_2BI+XIJ29J);KZA=J;E4X6H061Y\&
M!"[7%@M?RGUXI`J@K@8G=3G>5@E44BUZ-0_9K)6?#$MQ,&7('H.I0\,N.@K5
M=<-!@7M!LZ<]L;3LI[N6I(H'8B4`*[5IE7-VW$"?O(2L3"?]4^>A(;?:'-WS
M?QL\O`]HLBF^44<'&C32I:OTX*4?3VK`GB"N3)-,@*I#`SKIGWM/36OD'RG$
M.Y;\A*.G9]H!+S@+GG!OQCD$P@T_#>U-LD.+#XGO'H1K;5"ESF".]XGMQYF6
MRXZ]51NHNN`4/T5)0FA/@YA6>/DH'0!`](.V#$!K%I>N4$?G=KP!'F('7;)=
MKRK[:01M&/EO"!@^UOL</1T3KY(BBY(\"EG5UP.[6_V/O2/,ZVUTYE(UWT=,
M`5`NU+A!'R4-VMG+]QO4PB&:XVO0,'I8(P\)TL[G08'TH"O=XNDIPT]!@0\_
MS4Y6!AK$O;8!#*^CT?+8!PK/MGR5Y$56\A=V-&_/PW.05*URD[)GJWAU@`--
MVX^_AP.?R38?`/A5FO2.,E7:IH*HTPZ+1J-C/=$T;_/!QN<'6DV%EO"]#*)L
M_H5A1KU^6T/#O#E`C)K1'I4IS&I#(ZKR<2X=Q$!N[+C?#GH-9O'=]S`JIIA[
M`-03-3Y41YSC`0#AWHN5R]J_E:?<>SG^-(`*+;XL%@+;B0J^$@;P(*+F<6^5
M8O,4)UA2-$'-`6@O::CH*`T`9T/M\^4F[^CO*UY?D;-U4M5+O"(`BBTZS8P3
M4.=9*CSLQ)H=5?R0>_.^('X:?;N1AI/ZU(0?8,]:J2WM7R:%OS^A<B#W\X2N
M/9[>G-R!`#O,HJ/@=Y!MQP#LCQHK1"?^!HW\XXS\=U2<!5FV6Z<9];CX;EXU
MFDSX`?7<)+6EXXQV:%U3EOZ;2T(]42?\H`%*-TO?`XDI(7>=^OV/L)-\OOH9
MZ4\/D/C6)X[35QK@9-0O8S;(G:30UJC'&G[4"(#2?Y(GU2(ZR#VD>LPL[!+Z
MYC%=`^J9;E[)_+(LR@Q_BI)H4V[JK*#G)5;4B+;A!]23D]0>)^CK)-,DG<OE
MH$I0?:"8HW->>_2M0`^O.'XA%&E2//M+R6A@^E7R\)K^#0>9<+VS%'%L_2[0
M?(^NI^4&B#S$!$+N\\D]?6S].T>O@NW(NA@BV3?%Y8INA.M?IO6O7-Y1=;N!
M&1/1P&+'>/W)6CBK$57]#!8HMT1E\K_L*G:Y)H[)X/=I<-%)/2K0&!LS&3K5
M%_B%./4,J8,X)/-=NE?10M2KN4MCPOW$?1ONVHBPLX<X0*"9PPIYR6`M7I@7
M6<D&X4V:M`=SJ2JEJ1=$O*&I`!&(.C)PJ"S8`QB5HUE#@TJF7N<QH>(YPT(?
M=+*P8T=&SX:YL4&%'Q$Z+DEWS`4.*NO(L=$S869H4-G'A(SH9;9I@\HZ=F1T
M39@;&43VD2!CL29[LCGAT1-XQ!@1VS$?4`(J_UC@L@<PC@\"^W>VSX.O.,CS
MY?JG@(8Z%LOLCD8N]@(6FQ_SZM=<^#)SDB!`G;V?_J.#"BJ-GCM4+(A6@*,\
MHXP.+4W>$(DVG=T_79-_D3_7?R+_AX9:D[_\?U!+`P04````"`!H@&Q&:X0W
MGM-6``#!%P8`%0`<`&EM;7DM,C`Q-#$R,S%?<')E+GAM;%54"0`#`_$!50/Q
M`55U>`L``00E#@``!#D!``#M?6USY#:2YO>+N/]0YXV+W8VX=K_98[=WYBZJ
M)957-^HNG:2V=SXY*!:JA&D660.2>IE??P!(5O$-0((D"+"Z)B9L60*2R'P2
M0"*1F?CS_WG>!K-'1&(<A7_Y[NWW;[Z;H="/5CC<_.6[+[>OYK=GEY??S>+$
M"U=>$(7H+]^%T7?_YW__]_\VH__[\_]X]6JVP"A8_3([C_Q7E^$Z^H_99V^+
M?IG]BD)$O"0B_S'[S0M2]IMH@0-$9F?1=A>@!-$_9!_^9?;#]^_]V:M7`+*_
MH7`5D2\WEWNR#TFR^^7UZZ>GI^_#Z-%[BLC7^'L_@I&[C5+BHSVMRT^?_O8_
MWYV_>_/VA[?OWK^=O7WSU]GB;[/SQ>?OG]>4DW,OH:WHGW^DK=Z\I_]X^^[N
M[8=?WK_YY<</P"\F7I+&^R^^>?[YS9OW;^C_LNY_#G#X]1?VCWLO1C,*3QC_
M\ASCOWQ7XO/I_?<1V;Q^]^;-V]?_]>GJUG]`6^\5#AE,/OJNZ,6HM/5[^^'#
MA]?\KT731LOG>Q(4WWC_NAC.GC+]*Y:T+XTDQK_$?'A7D>\E7,N4GYD)6[#_
M>E4T>\5^]>KMNU?OWW[_'*^^*X3/)4BB`-V@]8S]FVK+_JMXNR-XB^/=@T>V
M'M63[6O6Y#6%*=VB,)F'JXLPP<D+PXRV8$.F;'":#P2M__(=WFY?7A4:PC[\
M+Y"^R<N.SIT8,]7_;O:ZUU@_>@&3[NT#0DFL&EQK8V.CN?8(%<0#2K#O!5I#
M:^TYY#C/HC".`KRB4WC%)B%BD,7+]7+'UBD*E5*4<`I#CKO\I=LD\K\^1,&*
M+IP7_TBIJJG&#.L]WGBU%*0#*5.<G'GQPR*(GI1*(NTTY.B69..%^)^@%:JM
M[:"22K=;C[Q0E/`FQ&L*"%T-?3]*Z7(8;J[II/$Q4HM.B\J0XY_[5*-BS,3S
MZIK_S7\Y(RB;U%>!KQHYM/^08[Y!<4*PS]:BAX@DKQ)$MI?A(_TMTS[5B&&]
MAQPOHQY2>Q"@""U-AQS)-4$[#Z\NGG<HC%%,M^TE74;(64K8@C*/8\"VJD-C
MR+$O4A+B)"6(&1M4Z780L*6=AL68VGT;?!^@3`+T>[]&T>H)!\JU'M!UV!G/
MUQ5J=KQX[)OABOZ&I&B/J'K*`PD,.>IS=*\$N]QFV-U0W_88P]ZXI.?5+;KS
MGB'K2J/ID".YH$2B%X1NO4>Z7\77U+I5C4C295C;=[O%?&5G\XK:L6Q#I0=]
MP%H,Z#JHEJ$-^Y;&Z4O<8U@+YSY&_TCIAR[8W@2P9=K;CV]U#6M]F;3"8".X
M8\OM0-Q4:8UI4<*XT*-BR%J##57886S+#39<?4K&K3C8P`%=1[+HH'H!)#"J
M=0>=?EIDS%I;P'5/T<^0Y075!4&'D6P=V"C!!`;%6[9-G:/$PT'\V2/,S_B(
ME$K0A=CX._DK=G&Q2@.T7'_T8NQ3:9_C($WH_/+H(L?L8;HB4S2B\)9^`.4C
M'V;K[_GQ,6T%7?B[TAN3IY+X2TW9_=K"PX1?CBW7S.&.5[ES'8B^\0];DM)%
MG.`MNWDH#3/?41D1@E94@Z^P=X\#2H]:-'&<;M%J>*D-,Q!+4KQ!<1HDI2N;
M!8FV93T87%R:7[0DEVL2+=CQ>8%#C^YT7E`Z3@\O$XVO69)'PVHUJ2+PCXUW
M?Z"[YW2C9NC$6I'M_K=`X'3IC'V^K<PC=7,@U^:_;/S\K*NR6D2,C[XD7-G`
M.C&E27LD_X%D!01/U0&(C\_M?$M7R/PVOIA!=#\T*H1NWQQ?-@?K,N5:VASV
MH&+1_MSX$CE[H(U0?!F>T37IA1Y,<YN[:#JH/#0_-JK/KK(T/V+`,;@CP5&Y
MJIQ'80/NS7B/;PY]FZV[:<OZF/6_:COAP!3,CKL$-O_C<L=6-W;3//?I*`[C
MTF=(F_1HG.Y]$]S[L-,XM_4D.QZ6S"D9+].$Q^;3E9H9=,^(^#AF$WD03+4^
M89CS3Q[YBI)7+/![]1L]5M+AG$5T5/P\32V9T@&4=?Y"K=SX5^*%"=@'9O2C
MH^E%VY"&G.@:]$?C^7>VHH;#\JF@.3IOU6E8_';@&=_U8^/N8!_9=&191-1`
MX:9Z/N7NHB*<*C['!/E)1&+FR4^#A`U_L&UNF.\;NHG5-5,`70V-M.H0?L0L
M%8P?2>L#TF!!FZ9YWO:_O4%^%/HXP#I>]3XTS?-VCM:($*KYWO/^5%FZ^NG%
MHQYMPW&<NK-*@\1(L0^Z''0@-1(G)1VY0G0IWKLQOX1TS3[S=CCQ`OX7H/Z9
M^-;XLL@\6/0<SQOR\?&!06?AL%\Q&Q.L?18'4S`9,ZP]:F!_V9AW]`1'^W*>
MK^@O*EW0<X(H@JN"$!OU()FR]->,TIOL?V]GKV9%K_*/U,"<921F91KY^`L.
M@LBO##I@B<0146XJGS[][0_96.?W]"#C^?M<B<"[1P$G_P?K"^OZNLM@<P'S
MU.88^=]OHL?7*X1?L_&S'S@CK]Z\S1.;_X7^ZH]L##=H@]FGPX0ED[>,G#9M
M;UD?:%DOYL2?183.9(I80=,C?D4;FKG8>8O7.YZ&^<I_P,%>D=8DVNJ*,A=;
MI&"D+%TZA-$A.*.,$!:QL$+/?T4O,@P:38$@O'4/!0'7-F`H^+BC9-NE7VT!
M%/H[EX3>QJ--65\C@B/*P8K%R<F%7FL*E/Y[%Z7?RK4-&.9T-"LVHD7@;=K%
M7VL"%/L/+HF]E4M["_UO49!2B9$77K4FEBWTC:9`\?_HDOBE7-N#X7<4!'\-
MHZ?PEAXSHA"M+N,X140&A[`+$)8_N0>+0@H6S:$LXNL&[5CD1+C)RAM)K2)!
M#R`X/[D'CEP&-K#)1[3`L>\%?T,>D6[=XM9`3'YV"1,5[_;F"E]2S^A0-A&1
M'AQJ#8$H?'`)!0G']@"X3N\#["^"R&L[]>]'76D&/K.Y)_T6=BUN%%DJ%;L_
M:\052+<+:3\H.BX>J0$"L7GFRQ;0[`RTH+\3;.J2YE!PG#QZ"]FWCPG;U,"(
ME!I#\7#R,"Y@O06-/[]N<'=%?V'8+=Y>9['B!W\W>S7;EX>C/Y?K"<[R_K.<
M0%_-6GOQ/4<IC5]M/&^7J1<*DKCX35W/\E__L1_A<KW/S[J.LG0DB<\\[P[K
MW7OB=&<OOTM6,E)O9\N!KB77ZNP1<#+\,M87C2)M"`A*H[DUO[I<PFTP"%AU
M`PU6KY+=_=)_L8ON1R]@UX[SI)(,($8'V-V:0QX$1-2%)9=`/`1H'O(O"V[%
MV,E[6?/B=X`,PK\;2!6Y%S?(1U2U[@/T&25*I.2]K#G^.R`%X=\-I(KLWQ<Z
M0#$RU5;6[@`Z(-'&GQN2KR8:%WG&%=[$@(`Z6[L4Z("3AC3<@`\(5#=(AK\*
MZ+*(*81/QY[%L5YE7`M'R(>71"R>D+6TO-Y5DT7ILG#Q[`<I\TW5J_*VK8.0
MWM;N%G2,=AU!N#'CU/!H0S#\Q8(.!&Z*^9I$.T22%Q;9G91K*4@M!'DO>U<-
M.GA`.'<#HVH5=M&N8_,20=]_<"P[3+E`6+AJYERI?4%P"O;\WOV==[IR<F/F
ME48-]NW)^D`1-':LU89!B*+3#D!A-8@F`VH'!8@(%%ECQV0`-.U>"PT9N0%N
MD9-V@P)VXZ0#*:`K%$ACYVAM(,'R<`.^LS1.HBTBYVC'M@XU:,(.4*B,G:^U
MH5+PWA<@0?;0QS3&(8K+]1CW:7%)4>QT>1_@35[5\<!6"RJ,9"^*4-B,G9CA
ML/7FU:F)5\KR+(U7/?\4_:!X&CM^ZT]#D"3<0$UG>^NQG[TS=AC71@>T@4WR
ML"C0N\]1Z'><A.6N4*2-'?]['B[`TG%C8D+L9PBRNG2@,!N+.^@)<S>YN8%Y
M80N<1=M[''I56Z!2;+]@IBT^/J?6B1@4?6,^H)[H]Y"@&RH@-XZ;0H)#-@&G
MS]%LQ.K'`%NV8%DG*,ACN`TZ;;[0YQ%MS[\N+O8!G.KOQCB-=@%N*J[T4IJ(
M*ORRT1**D;$39J?IU,:M&UC,5UGI3R^X]O"*%<GFEG=IT!)S%=`7'&;I#%YP
MB;B!X`TKH10>WOBB)G2Z3;G_]QRML8^E(;+JOE`$C9TEM1&$2\0-!,6/2D/V
M+SA"QHZ!`^Q4QV).JK;P[I?_<)Q=/?!!93.H#CB0.G?-9?N`$NQ[AYBO2A[=
M>W@>W>S?*O3^_917-X*=2D6^)'S`*V[$72/",YQ!IJNX\W0S\#1DX\8FV\A-
MGZ?)0T3P/P\S6PIBLY/M%+UAT!,)PU'4>)$@'<2*#K93](9$JRH$1Y&2%\,0
ML=:E%(:+08X=2V'8L5;*UL:>Y[CTP*L@^_^'FM52-5L.E&;1>E:B93,)A)5E
MWP],;:,(.U@]\#^B,$6`A/]F2\L&AT+^C7-\.Z-N+'C_B;P@>3BC;"_)Q@OS
M)_;R,8LQ472S;50(91[I<.$23E?8YZ^^*9%I-+1M,@"Q$##HAO1OO6`_,FD>
M4:.A[<T?*'T!@U/W8[5/\$]HQ7P.M^EN%V1>G'.2;N(\>5=WT5-1LYWXK[=;
M]9&8OK9\R+0E1!L>Z&U=7WXE41Q?DV@MNVZH-+)=3$`/W1;^IC[%<XN<O?\7
M\ZO^_=/G2L,2T-5VPKL>O&!9.+*KHB#('K++GG.D/RO78%D?VXGK</%'8)Y<
MPNM7%%(&`Q;@N-KBD+_^P9Z[48*F[&@[W[TK<D")N`'?#94I'0,KFW5.+;T@
MXLGA2O`4W:SGQG?%#B0.-Y`3LMAA;W,@J[XK8DHQ'(TMDVW[5]18`R!<;FRO
MLF\_@Z7)\-2Q_!R%496[HCB4TBX%=+6>=Z^',U@8;JRWEV&"J$#5>V.CH?6L
M>;BD&_64VEB>_I'^4&LR$T?!J`Q440_KJ?3=T94+P8UI)^2NPU+I0#)]5["4
M8IC\UH@2B(%3:V8]RUYSRVMC<NK(%;'(17#41R_&/CM`X2!-9`$MRH[6L[KU
MT`4*PHUU]7>$-P]T5/-'NJILT.=T>X_(<LT'7@KH`(/9E9[U?&X]C/N)S9FP
MF'(HC"1:N1(2\Z,LD+<:$5,F^:^SG*@3P;S=$NM`W:VF6>0CO&/)Y@!.\G:J
MR=?06B,S4`N>1KI%E:.R9]$%0.AT19?T1XE)T];6,6`J:B5"H#3\\L;L`@J9
M*IU%VUT4\N3?9PP!I+W;%+%IYZ04<673?JR.[3S:>CB46(WMS1U#1:9Q=;.Q
MG:%2"(@;L<^?$+-UQ,"T-+4=\M<%#B'';MCM@AQ>%3B*;K;C`;L`!9*$(Z`U
MTG3/4T*/":4[1BJ!#5*BJ$G'=J!A)U@[R<H-G$=*=S8_#1MFJ_DLYQU_O)..
M@"3V?5H:>3XN)_<H803D[TP91::E6499MH9D#\3R5$[^M^6.I^U</"/BXUCF
MWNI`RG:,K]YD[B(FAQ;=YO`SW1X&9BDMV]&^?7$&",H-H.>KOZ?Y"X%WD<#Z
M*QSO:,6,#13&'(8R<S<HJW",;A%YQ#[*A'"#_&@3<HHR(WJD`=A^Y0RL4B-#
M8JAT.)L3K`S%<ETZ_!5U//(Q\M4P+SY_%S'?=QJPR]CYAJ#<DQZV>5[9!P:D
M;SOV7*T9`S-L'?AL>90.-#>C>N&O]QG;4>W#J4$7\1K2!FT[:!&E;8=U1JPC
M+=LQ[S!<>PEJ7/`DQHT^>DIBUN/>>^$'E)4A`,_82A$$W$JH5)7<KPTL%97$
MF8;=[@*<+-`]23WR0HF]%R#9FZKUP'@8I`-);T1L:PN_='A96PV(NQ"W'B;?
M'>GNLK2PE2XB<IW>!]A?KM>(M/O65+M,"PUWW@WLO'<*)6-CS^P)DY"(]2R%
M`?;(L8%J-:2_[*+P-Q0S6WFYOHE3]MSQ<GWG/?^.DP?FFQ=CUH.>]62&'D</
M'8FYAJ1T"^Q-U7H2@V%4;6YZ=+$H[.CE^G>/$"]L?>=8LNH(2%C/9NBUE$KE
M8FG'ZPN4E)#U9(5A=CYSH-F^)KBAJPC!/B\5R!:6$"=VK@LZ#L3Z&X4CW!OT
MPLCJIC[`#JZY79M+C!ERNQYV;QXA<J!5+SN&#@AH6<^*&29X0"JISC$FCXC<
M1S%R-KXD]Z,.HR9R8M:?21PH^`"J*(/;@N6JT^=IV3:]14D2Y&DI[*4PEH1R
MCN-=FHBN^?H0M/[BH89MV$MF%L#<6Z[#0@HC:_U=Q/[`ZLC/C>W;:#+Y._N1
M7*H\<MM[8N<0Z#_>.?#(9(\H:#;^GM9-%D%[$3I0)J5/%+0.DA;]4[+A&P+2
MQ8QOP#M.?^J7_NWFVTZNI8/K.!@:EU#7)/-]B)YO$A[)593<><L)GA_>F=G1
M`R$@L`'Z.9-KJ8L26"9.5L\X\^*'11`]"=Z1^0F^:C)*LXR4$VOCGC.M);&E
ME]V#`!O0-8D>,47YX\N7&*TNPWV)R;F?X,?LV49U!<8.M-Q9.85H-H\6'27F
MQOG#;!TQ8V7ANDM],B?#RIT/NYP)?1R@RH#OHL%FJYFOV4[0'4Q/3(+AAKJ=
M(PJ.CQ5>]VHKVXF[1E&))(R[!-Q\&Y$D?V-FN;ZDX@\W^#Y`\SA&K?$8A?`4
M_6SGXXX(+DR$;L"M?4_6[RK,F/-V1'C-7I<-]AXE072(YRC[=YE/KH6@%RJA
M)&PGS`ZV+VN+S56TY[X?I2&+S?$1?I27)83UMIWZJ@^-"EJQC(ZAQ'J=6U9O
M/*1?P[(G2A3=;.>]#J\#+5(Y1O"O"=IYF%5TXNP41<_#U3)Y0$1EVG6E9SN=
M=GAUT9'C,>I1L61>>R]LO62/;/D^2>E@L7>/`[[%=MEHY/2LY_6:VWL@@IQ^
MI%Z3_XOM+HA>4)$?VU%]9%2L9PX/KS1JH1VCJIS1<QT]P9%SM(MBK+=/-?M:
M3S,>7BU$`IJ^,L#/=4/<&SF0Q#SD182FY*;^#HJ`X^R9I6'N&J6TW,G,[7W;
M")"9&WX/:CT524S^/U),T.U#1)([1+:'U[4D2P.PN_7LW!XP15T8/I;S2X/=
MCVF,0T1WV2Q)F0DU_XND**4>%>M)P>:4!2"](]09*DBZ:28OUX$7)NR!6_I;
M7@9;0V,D-*QG)9O3%Z7DIJ\M<.$-86PXD&(\F+;H2^Y(#=0%#KW0'\9`E=)R
M)ZFUMX$*D)E;!NHB(C=HEQ+_P8NK\=#J7436UWH":@^`VG</M:2FOVM0!G-N
ME^MS=,_VQKSHPA7SZ"SO`[SA$$IV#1T:UK-;!],2?<E-7UNHU'R$5O&"2C4O
M^5+4@)&=;:6]K*?%#K=N`*3CR%Y0&FEK:@P,3$%7Z]FS1A"5RLD-6.%\#V'.
M.9"?.QC0^I*;^A&`NTS8EA4_L,/PHQ>PK2Q+\Z_?ZXBU18\*5%_,ESV#F_U=
MY'2<NC&G4X20%SH;>$D?7:5H=(=J@_D:97VU02"9XW@Z:PQET"@1\-Y\);.!
MU>'(*D&DNUU6^<4+"C%=ANN(;#.DU!FB4`)0A3!?T0JN$)K2<<-LS-(2[KQG
M%+.RB]06DL:U--I"@3)7L4I3ZHTH%@'[KL"3("K1A`U.!DRY%102<[6F>D+2
M9-D-,#Y'H4_9.=P-A*O](8&7E0$XS.$DH#":+X"DX2?7E9#Q4JPLHG6?DL4>
MEBJ_0%54+BX_.+7`9,LK^V<AUJ4_($#9UJ$_!U4"<]?XVHBV5EXQ`X,A[;E!
M?N#%,5YC/\^=+`+MBV(Q9U&<Q)<A'56(?-;D"2</68T3Q3L9`]&&ZH6YZ_H^
M>C&H@-W8&V0%<+-?\\J)O#"UQ`.G20:J!N;NX;NJ03=^C4[[Z_UMWR(E(4Y2
M@LK1(NP=B?(ECV"":U,!)Z0[AV$G=H40VBGBM"0;+\QSY/>#J]1N^GGV:G:.
M8S^(8LH<_8]*%WLK3GD8AWI23&G"U75)3A29#$TO.%2:4ENJ`Y&WN"3WXN"`
M^!W5JX^!]%YL^"]9KA@UJ&[5EGQ3L#BSI-RFVZU'J)URBS<AMW'"),^S8QL<
MY=<OWR55%IL/]<4F)\;K:1[(S0[T9GN"%FNU-+@#5&:2]+%IQ\DP`RP%T/Z6
M)[@:L;JAIB479^8B#P&.^>LOKZ[YW_R7,X*RV)RKP&^=A6_?U&=AB0S]KX+0
M;$_I?\VNKLXL3L`B))Z>J^_IHLG'I)Z"\EX6)V'+P+3V8VA_RY,0@EIM&NI)
MQIEI6'JNB67ZO$HJJ3[MD_!M?1(>B,PR*BQA:%8B,Z@+J#+@:FK28522.9;Y
M.32I6+[JK=]EAFWCANR"G8C9FHV=D!)>"7>4H3-3M:T2365>OJO/RW(/FS=E
MV2A>0+-S?]<DZ63UVJ\Q+L"LD_>RO-D!\&E<!*J%,'!M`3M3+K_CR*OXQ$49
MG[.4,+G6JOE4YN+[^ES,2<T*6C,O7,TXM5E.;I;3LUF2-<.)^_ASYR#^)UKE
M8Z]6,=*9S;T)6ZU3VVGL@%6A/V7+*\=`^M*H?#N,P)W9N%O][^W+Q@_U96/?
MEZ\7A]Y6LQ3:DW;5RP"@J]WTB_;1:4UJ/2J6)S`8RV8&AK:HG)F.]7++=/R_
M1M'J"0?M+RN]_;%I5Q<4\CV;3\X]$7LJ7`R!LE3G4F>[UB1C<<Z"1@J8M;IT
M+,_;3CC7YG`WT3DSBX7U$0L#NWTN_ZGI0,[HS')"?"KGI/;&NLWM-AM67##H
M!0#_L;23S:<#`$4MM>9M9X*V-UXUJO4G`_J)SIEYRY*RVZ?F3_6IR9O://C=
MPQS*^W-+>WNK9]=[/>M5V,'Z25.&1>,`*>7:F:D@?HJW.C$:<4YM[W=:G"C0
MASD'>8%SP*#0BN@_1PG2FBH:)"Q/'OD3C_KL.#:-2IE"[?.G$;J3]9AE71S(
M\-*[&)%T<B%=3?-B1-;+^L6($A]1TMH4YDU1+/S6>\3A)F:^G-;Y\ZX1=%/T
MG.5=9[ROQ1ORTBM+U#"^00DF"!P/4%P1ZQ"Q&0Y0'6>!Q4<4HC5.&!*@.``M
M*I8G8@=\Z_?_'83FS$1E.5DXBTY@:>T1C_!#H3!6]5TC0*=$@?LWJC2LZK*(
M,\VIJT/&[N15CQ0V?;7HV)_`^C@WIW`'T3DSB6_1AHV]E&W=/G<;03QYQUFY
MI\6#4S::&[1C+UB&&T!E"6$/F^>_VJ#T3GZ0SK9?%E?@5#_]P>7ASHQ*[V/T
MCY02O6#A2(*]L!&(<^@VR_O9+-M290%2IT74PVKUF>J@('-(W,7VS%%@TJ@M
MH^#=H?D"R7Z29D&]:\2GP+.@9O]6_/3OIX2H07(QO!C'RW5M="_9/R&Y&,#^
M4TN(TI.+&T4*VA).L@%+\)/T`3^(Z`QH2@&X`=0-E2,=`ZLO=XX>41#QL*<\
M3D"%&*@SM`"C,]!IB,0-#"61+_7_5B':@12XHJ(K^'86EQMHWU"=#%-T@_R(
MVB<\+R\/,,[_(INORJ[@&B&NH`D6AQOHL2!P:K%Z06Z90@P;61\@7L:*H&OC
MI1:`&T#MK[[`,(E[`$$R5E]/&R05\]-_:%50<!L\)6'=@<`;JZFG/SMUQ.+&
M1#V+0I\.DG"AWN#XZQE51IRPGV1+JJ03$#5C%>\ZK*E*$;B!%=VE$56J>YW=
M3]8'B)2QHG0=K!65`-P`:I\1J['[B7J`S^[.H*3B?OK;GS#A"8PWG`(4?W><
M-[K2F;X^2,[$8(W0H0'5"7>\0OH2<F0EW^X\3'AQ;7*.XUT4>\%R?16%FRO\
MB%::&'>C!D7;'1]1'ZFY@?L^Z_S!(QL-<TO5#XJE.QXBF"3<0&U!M8Z7)/Z$
M/'8C>=ATP`!JD(!BZ8[W2%L^;L!:#M>\00%[9I-7@]!P`0()0"%UQ]>D*1LW
M`+WP2,B#S!&YI<L*`@.I[`@%T!V?$5`6;@#WA140OX@3O*6*)BF/7V\'A<4=
MIU`[IVZ@<$UP1+("_/47&@Z/=YRCV"=X5PXM;3N&ZE*"(NF.TZBKM-S`^C-Z
M*G%,HI#^Z&<UMC4M&WU*X-@#9[#N*BUS#]303P<O\S`;R$H^.!F(^7,L'<E!
MD73`B=2/42&<+@=9WG&/]G[PE1#+1K4AG1#+C/`IP'*8L&;_`:W2@)D%-9.-
MA1CZ+-X)!RFUO[G4(4'/70E.+02SI^2<F<VJ(O6R>=Q2:0A0JMZ%*7QD->L/
MRE@,L81$_/&E]%_[K+*$O7^"Z:3B?&A-[0$^,KWJ]P9D[(8U?F`LCYC[)UI=
MKNC@Z39<^+4Y<P2QRJ2E8DST;^FVR]XPT(=LAX#WTJ)!A6W(UB^/ECV!N5PO
M=[DR+Z@P2BJOU`%&KSLYVQ'C.DCWX]2EE:%EH:-'E07+T2VEZFJ\B0(F9#N"
MO,?K*)K"<@/I!0YQ@K*+3':;O4+KPV\:U62+]2F^]DARV`]+PH)N"::_:SMV
MO8,>C0.%,^>/T@,>LJ-&HW)BJ9\+!XJC>@'DL'OM1Y@_X*!OZJDH6"^`I?LR
MB*YPG)EID)<^9%.P4:,1_-Z'"Q/TR![^4!KL8+3A1GL7DM:+J@[Z?$=_>3BV
M)K2^VR%;!!J%)@6O=[@PY;^]9SSZ!&F[,VD'?[+#W?DG>:A#,@O?-\I5RI_K
M<&$R?G/O=I3M1#G(FO8TF-@1O.#10XC..58:'&Q9(;+L+?K<ANC@-NE`U;;;
M?`C%&$*N;FA(H>+16L+3(N5&6G>-&?8KMMWQ0RXM0\K=+8U:KO<KI,X.T]+)
MMCM^V*U$*!5GS$+ERT\RX[!1&AGT_I,+-N)1/01UT#?(NT;ZAF`7JK8/=MI/
M0@TA1&=F=?/]$=DT;E9);GD2QX59.\FW<;P$[5U=DME6:Z>:/PV%,S*-@(_=
M5(=>+JG@@N3IE$*7]$=)PDU;6S<0:-<?$0*EX9>S"VPF'[*,D>7Z=X\0C^4S
MW^#-0S)_QA(P)%TFA(F$B]*IUS5DSJ.MAR493]).;J"CU#@(4`5+!S/%(E+Y
MT#ZA[3TB8FQJS6R?G`'Z54.BE4_7#KI%X#V[Z3OD#G.+:;G+HF[\!#\6)I>6
MH=V=MNTR[\*]5FAE]Y6CNWI!SPW\"NG)(ZLR/ZQT0`8(BZ_-?M='1_I\Q[9C
MMI?"]!>PN\I3F0SLM_$\31XBPD()OM!S("DQS%_:^OAR\8R(CV-T3;"/;KQP
M,\BB,\"W;>]`PZU*@P%A/'K^DT>^HN2><?`;BEENR%D4KK+,D45*6-2(9BQ.
M!XJVG;AJX'NS.*5UY(;R1%4R0=EJ^27$2<P7SZ$M%>T/V0Z:'FR%Z"ABY_2G
M]=WBW"Z/<QL>]")1=Y*VBXIWT8EN8C.\&43K_0C2)$X\NJ*%&Q:LE&U37"%U
MMH(.]&S7'M?;"#H+S+5IO'^,&)%':HJT+UGS@(^%_E3.$,PJO?`@5KT<_*$_
M:;MZ>8=EP)#8G;E5*KT-+[M.:CP26'XAWH5KI*-Z*OZ@?DS+HI#5=6$Q;/EH
M\TOW_&UF?4.O`U'K>3:Z#\T/($+G=H#U&C'+$^VYN*'+&5MO0A\'6"MSLA]5
MVYZF/NK078JNZ4.1G4)9V`>U]HH)T21HVQ741PLZR<Z935ORTK=L$V^\32I]
M]=Z%7;UB9(6K&Y3@K$2OSBZO1<2)F9W%C7["(=ZFVRM$S<W</1XO(I+GH?%?
M=YCDW6E;M@$ZZ()P^O<5L&M;086?&P9*4&(H+QX2;@;1&5WRMHT%8WK33<[.
M;"+2^HOG*/%P$']FOA-F++5O*,U*C*KRBSG=V9[PJ1+C*22Q0_G$4WCB*3Q1
M^"8<NZ65AR.6FDQ(YJ51NQ%NR`>D"F&K-')#V@T-:1-T,60GP@5SDT,EZUHS
MVU>Q+?I1DW0K7VY8UY^\9Y#(J\ULWW0"1-[&EZ%KR_Q;YV@7Q3@YBQZI@;Q!
M5]0<3=I69]9'WL7V80)V^0AAVPTEOR:1C]`J9F4E\^'RG\_2.(FVB$CV4$!7
MVQY"\'T?6`QNH%9DLQT>?_V,U&>6>G/W([KDXW<)$6'QF"\Q6J?!%5Y+#F6@
MSK;W<IVY!!6%&]CQ"X##^XSYJWZ2Z21H;WOKA\\G*<.&3`%VUY#G`I0>@N>O
M'/#+.'K>3[DC36`7:/2?1H22MD",O<A3"7.\#/T@7;%:%NT#%,"C3<7]6*!.
M;+GFY`6]MO.J]#I!]?F1TNLD.<<L`"KWXK8[A1O/>F@\ST,;YR-AK?E8^,5D
M/II9,9S9-:L2R@<TXR/:>Y9/_N2!WEA+LNOUJRB.YX]4LOPR(RJI?1X;RT$2
M\Z=-:&HO^724E!NFS^^(13&CU3P[H7Y.F4\@CX<OQ<O6%@4QVEWIV3[6:Z/>
M3W`E\"FG623*529,(3^<&?JU^RA&O*U3S]6"-439T;;/H/=KM>-@[N9S7[!K
MXT8U?N##7TY='A_;&V"3OD#N\I32Z0KYV*^08^1_OXD>7Z\0S@"@/]3E3G_U
MQQ7:>,$%7?.3%\&U,6W5:#0%2;>->\BK8ZB$L^\+"]'0)M46EF7;)K:&8*LC
M[GE++/#-M.VQP@M)UD/6P9J1W1!6T\^B9M2-`],W%%OR[A1;<HHMZ1U;8NR<
M=HHM&?W"UE)LR4"I)/G.<DX70T6MPD9+-U866(G"QN!+6F%1_.=H[:5!LJ"G
ML]#'7K!G)F8C54T$6&\W8!(I6@TH&$N&S$J>F7[!792?*',/=P^8)"\+3.+D
M[BFZ>XC2V`M7M_@Y02B4&YR=2-G>/'2TL6*F]A"<&\M@D:YR%^6/?Q:N$Q1_
M1LER?>;%#\6SH)*(%2TJMKW[\-"5#L(Q="N?#R7[)KM-H@<H]B2\:!H*F]N>
M:K![=A6[AJ3,R@"PR_T;](C"%)VGA%6'.7BC!=)6=[-MJL&D#F5_).G3(0,%
MSENZ'Q$G'+I1L58N(^/Y;A=@M&)YK<6DXI?2^8P3"%R3AONA;QV8<FG;_M7#
MX2$[_^4<Q3[!.\$2E7>2]7$_1`[`A$L`M=Q`T6''>,53@J/PCGAAG-WZOM6Z
M'I10<3^$KA-;1A?'8BBE7>XZI8:\EY=X/93R*MYY$JR070@!`?O9[C+9740N
M3\5L!4DJ>E=4?"F>8->=F#":0-0_.#I-=03G3-RK*E"E%/%::LJ,LX6'"2LZ
MSBN'E5B6QKPV'K<'1+0$?BW<M=R'C63&AC+C8V%_KHS&B7C74PC,*03&)`Z-
M]>H4`G,*@3F%P)Q"8$XA,*<;A*.\01@]&T"8K'DP^_=I+)=QG'JAC^ZB&Q10
M>:RN/9*\"&:A%H5IW%%T$(JQ7-K]2*@^55TIFN"H^D_C(D-;(&XLI0X[#>W7
M$>CI--1;2I.(5?R<0HI-R7-Q$2=XRU2[Y+/(JQGG6TRUJC%_0@VMI)Z,#T-X
M,O8#J[DPLL'-BM'QU-[2^&;Y`$_.C9-SX^3<.#DW3LZ-DW/CY-PX.3?L[OJ'
M!YTN5U0(>(W93`386?RLG]6_$M?.$6]P@WYW,@Z4<0"8?@&&0>647>)F+0]%
M]L925^'7W7<+C2J.HUTGRQQ?$[3S\"I_GXNV7[*7>K._6=!'^7#<=X[9E<^Q
M:NQE^$C;1Z3-OVI`XJ7/3=E[-YRXCT^CA$53Q]$PR>?=#^T>5Q['JH&7X0JM
M<8@3=(4?V7\F7KC!^[YCK72*04PF;MT"-,>GDV.JGJ:&.1E4/Y"@![U%F[@*
MYM9N^0]Y-?IK[T5^E3+R,*8<9FX>GN-;'#]'H=_@GA^_QE%)V??![L:C4D8U
M(L>GA:7?C*-VE0]"]>RX_-HM,C]MV:5I*'L+9_`/057PN+S4SCW`(\G6S)MH
MIV&^M>^WG4R")421"F9&F[3J#T(U8;+^5*C,OZW`R1L4IT&R7.</=D<A>^NM
MG`<JB9#\X<T0$9+9"-A/^S',F')4B)W"(`=GYQ0&>0J#/(5!GL(@S4CX%`:I
M$.HI#'*R89"WB')/)V'P<K`[>0H.W7L8)WE]LYA:FJQF4WQHI64F]/G,E(,<
M^XMWLIJ3!P\QUM@;:LB4ZDB_,^58PP$$/,7"/=<D6D2TP;Z*[V6X9O^M/,&]
M'>($1[\^XY^?[;\_*PW@='@SQTX)KKA0@GQ]5',E[6SY\<D.YSL-F1Q/T'L;
MLY5W.+NI08V$;7-B8&UH%=`W\2IA:<^HQTY!G7[OAM@R#A^O9$*?O'TG;]_)
MVW?R]IE&82$.(?WX\LG[>T3.`H_N'=+'<;2(3`@W+;Z&]"T:P?,PX,_>%@D=
MDFK>VPFY@6L'?8:#WLZX$^^UG:5Q0LTXPNL:L4WA`>]BU0M*TDZV+=V.FEQ_
M^DHM%S=\9'?$6R'&CA*U9DO;"6##0"62@*D7,5CIJ.T.)=S2/HOHL=@+$^D-
M@[R+[:2HGBBH&71INEQA'X4Q>YEF0U#V2I=JWDBZV,X@&F8"*67B!G2GYW)'
ME?3IN=P1)'UZ+G=\D9^>R[5SN`S:MJDBME12DA36V_:Q`WSGJB,,-^`KAB6Q
M-GY'>/.0H-7\$1%O@[[$:)T&5W@M\9/VHVI["03#/83PG+E0OT%Q0C![@?#V
M(2+)JP21+2NH$2=,%/F=PV>/L"#DQ\/P*[<?[^NW'P>BLXSJ':4Z.Y#=7V;,
M]I2[76L(#G0UINZJ/.U'*KFZ8&2TJ=AT^B#"(OPI?10OU^=H%\4XF2=G5+PO
M]!C`2^Q*O#^@WK9NOSMAT>X"TI"2,S.T*&^#45RYJ=S_5GHS^4-];I8Z-NX?
M#W]QX;9Q7]<'-&/S7M).%B?H?EPWWM,GJG\$>X'DV"MH;CD`!8!(;<9)V7;#
M%MH/\?>(?+T,KTGD(UF(B*B];7.U!SBMG#N&#K.VXH<L90V"3JV];>NR!SJM
MG#N&CC0_L]K*]KF[!Q+'E1%9+<X8%]49*P4<*_&TZN924^3'NBF24YP5)/F#
M#YSH+*=:!$+58VNA_5PP8\YS[3B+XB0^\W:8XL]BJW,NJD4Q=4R=WH0'S=')
M/LH?/;KW8C:JD.6P4K.Z@$EPS`+UM&SX#(1A)=<'+C`WUOI\P#=(5G6RTLBV
M130P:FTL.@C0)54CPMX<4Z)4:FG;/#(*54,B;N#%.:KNJLJ'QF5];!M69C!4
M2\D--&6EKI6P@CK;CNTQ.D<A<CL"FWN1DA`G3"JEJL$P+_N?ZN;SGA:W?_?4
M!G.N#S4O!+62U08NH*O%"7^.J'KXF"N'S$@OM[)LQH*QJ,W1-E:=\8^W3JG2
MN54VY=IGVD_0F58]EJKFXVD6FKCX.NQ#+%XQ31"YC=;)$YT.OQ)IJI^ZYT1G
M*U0D;MA-Y>FYP,_LIUB!G*2+[2-G5\R44C`4^DR-(OK%(C]Q/UH1`*R/O(OM
M@Z0V`&J67)HM5\B+T4,4K"[I;A@]9J&]BNDBZV/[S-AUOJCEX`9>0OX4F*GZ
MV3X+=L4-)H^IERN>^WZZ3?FS\F73F?X<((Y0N)IO(Y+@?_+?=WC=9[@OV,Y5
MZ:I)0\M87^<^9#H7H@T;A'VM$[(HO9R5][*=#C/X.G-<5[B-<.-P7])74M5"
M>OC]N1DP5B]+P8ZWQ6>4-2Q<./V6RAPW9*%QX:I)QH6*"I.L;-$)KE.I"\=R
MX$ZE+DZE+NSC>2IU<2IU<2IU\0V7NC#FNG*[U,4P^+`GRW@5"`0OKB#K8]MM
M-0QF:JFX@9Z5RABN%C51,^@2=*?*&*-*^E098^J5,8Q99*?*&"X6(W&],D;;
M-@4IH0#K;7M.:%;&@`G#=?B442G*GK;GU0"PN7C'+AEMZ9*P?!G8"40A+=L'
MT2%@50C*>:"E5YRJ?K9/I4,`*']QU^7;R;*^%9EOBXAH75I^Z'5I61[!(:ET
M'9'3=>;I.O-TG7FZSCQ=9YZN,]W`\W2=>;K./%UG?L/7F<:<`VY?9SI6N=_5
M2^53Y7Y[I_AOZGZR?&1N!AB+\5/UL[UAP8L`@P0P,5?,19S@+?,!+E*>B]CT
MS,B\,#^^Z>6%V7]\EGV]U2US\K\X=B!IT9'/5$/OGE#PB#Y%8?+0[<P)HFLY
M07L(Q\XPHG5C4]#CY6_((W=/T5#:L2=G>PL97RMJDIRL,M#/=[H:5Q"T?;*R
MI!!E:4Y5)191*CD,=*5G^Y!G1R'*LIRL/I2J8PVB#YR>[9.C)7TH5QJ;H#[,
MUPDB0RM%C:CMF.?Q-:-5JFZH1TO(P\6S'Z0K'&X*08GU`-;;=K[[$(#KR.F;
MR8$_>V!!I?%E6'GL9;DNFDH=&V][.3;R3\]P."L^/N-?9W_<]SDY-BPRK.;E
M*)P-@\W^'2(X6MTF'DGZU#T1W.KP!]9BG+E6^:4?6EW33[U(X&(=`?TF[1P`
M\NC2G@V?8'^\.XZ3>IF?06;915BO+61GGYW[?I2&27SMO;!P&U9?R?=)BO8O
M@E3*&#_B]C+&/[ZK[Z4%W5E.F&^E.>E#-&:MJ#$E;[6<:C;4N!""%\2`0JJR
M3C;O\@CRENLK*G;)O5VIC>VRJ&K9U^_J&@P:"D>X)N@11VF\7*^QCVYWGH_8
MMP7;E;"U[4U*0\)2/HS*^@;YT29D16YY+<BKB"[3<;XAWD79[[!WCP.<O`@`
MT"-A>W/21*6+?-RP&2ZVNR!Z02@?;#%*C(KW`*@$6`J^ZE$%73JVW<+Z"ULW
M2;F!<NE%5_8$4K[1B]$4M;?MO-5'3<ZY,R$C2GNOG,,#M`W;3<+&^]$PD["6
MQ*-E1IZ,Q^%*W9:1UUNA09VG9V["1>+&4EP\[,.>-#NC_\:)\L$B29<)6:]J
M9HR:L!]3R@<.-R!C5=1X8F:IG&<WYD/V`E6V=72V/K6(3,_T["`C-\`5FBJ=
MD>Y.<7JV:U_I'4%E?RC_@RB,_1`$HSK272U<*[X/87JHQ:3#$F*N0+\1]3"\
M<-@Y4)^C>]A3CS_^4#\0LZZ.O>O(N=%ZK;R]O0O5"R995D(.P*E^A&-U"(S7
MCXB1__TF>GR]0C@#@/Y0ESO]U1]7=,L,+D*ZXKP(*D+05HU&4Y!TV[B'K.@`
ME7#V?6%Q!MJDVL*R;-O$UA!L=<0]RR6(KD_S!_C.",KR_*\"7YK++>M@S0W5
M$%;+C:F243?.RFRI6JXSE]C"\[FK)B^]^3$B)'K"X>;,V]&_M+JM<C)Z5&R[
M#\$9P%V$XP:LMP\12>X0.8Q3MNVV-;;M=`2#)&'5F8LV?@O(WK)$)&;OE-&5
M`W1*^+%^2B@3^M=91LJQ4T,V*/5IH=[.!1MUDJ>$=H&?3@>NV*QCG0YZ%#5B
MBPXK<;'"CWB5>H&\CIR@^82P$'#@1FVXQN!^Q\E#N3#67:0X?HBX5!%R`T&I
M-JJ`5+%HYECSR2-?/WJ2*ORL5;V1[:NACGI6/N6T\VWH+OV<W$3T*\E?O>T6
M$:FHVYO:=J0/('"9#!PY>13K+R^&M5QSBU6^GTBZN+$BZ>WO32[<>`:G/"[5
MUM'6UC$L1/I5KRS9PHD3I4!K,:+*]XG:F]N^.Q8KE3PDUL6EZQMZD>O]Z46N
MTXM<I8%W?)'K]"37Z$]RO3V]R=4:G//DD=4=_8I\_:XU<V-5`:WAM9&7#H=6
MKQDH?Q^]&*UX/>(PSB5'F"KQRK8?7PYMKKT7]CO.R8&=<'4=>"&DUKV9K[FA
M`ZWZV[CI,,&_$]M4S3K\$N(DOKG]HFD4U[M!EU1S[W89G!]R^[I=@H8\,W=/
MT=U#E,9>N+I%/@HO0_H/=@^5'<["C)N8\2%UVW2@`X78F%-G#(@[RL8HYLSM
M=XW(.B);CPXEOX1B8Y!"K.X&O7@V]U;;2(A")6@LN[YUP5B&XH-9EG2NZ@;U
M:YN+[Q@)0*@$W;"0RY6$[J@H8L_G?N>/+^6_*-P?&C3<L*M@_A$-MDH.-4?`
M5)G-;6W=`$=?)27`F;WA*^HPL"R(<TR03SN*GS)A7:0]H&;+3\8.^T(%*J]P
M`*X-[4YG5`W2(%$]]=-L!C4??K8K61%_AL3Y.0H++&':*^L`364U=JR"B5C-
MLR%A+ZA%APA,SH*V4!$;N]>!B5C*J2'I[M<DV.JK*U%75EP73<C"))8;B=56
M;E@:(#.P.O!2-(@#(E<9>6YZ-=L41B!TPP%:49B@,X\$T2W>IEG$C3Q82](!
M:F*82]A6'DW5_!I:G=L^K'(I*/I`Q6ULY>XF;D?=`/N5,/,W,0])%#*?"#!&
MJ[V;&\N-7IQ6.R>Y-OUD=]FOC4VU^@N:.X:*3./J90_;&7+BKNIWEF4C.9?F
M[6K-H%Y18X<FJ4K5Q-_*HJ$=(__6W$_P(\NOD^T4@K90V1J[,@#)5L)`0\!Z
M!3`>$;F/8F2_1$H>#9ASN20W>/.0R#<621?'EB_9IB+A(E>^GYT(_JT.$!@%
MW-[)#724&@<!:O+;B\;+"C\8,Y,!*B;;9EI?4[!9(G#')'<9KM`S*Z=]&<?I
M/GM7'6@&Z^W&'`*M<#"&<B7[8'<*J<:J6O>@_=V`3T=1-4%U:F$L7*/\LCT;
MN6J1E'2!+I<?3"V7>DHJ*`LOE(4;:^B9M\.)%_#(B'F:/$2$O58@,3@$[2=3
M,43.L".@1-MM%'+-X5$P,&1DG293*P3`NJD+V)3-SN7Z"YWOY(G@)$'A=7H?
M8'^YIB<]5DBF/K:S@)[IVB#AEYO=Z=FN1*Q&JR>#+DVV;#UGBSN+\;M&A`]U
MOF7U,57^/%$OVXGCX.D&8=X-F*Y)Y".TBA>4UV*\EW01QUY053K)#1R<A.VD
M33"`VF(QM'KR2<XMI-5YRKYWG;U.R:=]]ON[:+]24#-*L&IVH&.[:`!LM>PL
M(/>F7\FDC2^>$?%Q^R[8HJ*"KD`(C3E&.DTWJ1C&G6;\)>/^LTQ"!HB0L9B]
M7I-,*1Y#:.T_14<RWQ#$&3A'L4\P5QL!.NIN0#2,G8QA:$#9=V.%X[IS@W8I
M\1]8UL$\7-V@!),659)=PFL0`9^9K2]['60S)5"S3;@OJ@45ZZGY`\-:E8Y#
MN(JLJ5K6#T\9^HR2Y7H1D37"2:H&NQ]IZX4"]#1@"#E.0"VRW].QWR+RB/W.
M.M!"QWX:\R"`"R7D-+HEZZX/N"(R4&SM.W,ZR<=F2(LPLVCO-LR&?8N2)$!G
M7OP0H'A_UJ)GL4<<4Q2$VW>6QM.-&!1VBRZ@/NQ-8%YG0_V,GOB?NJ[6I?[V
M*Q$,LDHW).(TBGSUZ0YBO;OUM,Q!5N-I09BIG:;7KPLM*+@6O4P]N+._WYJ?
MZ,,HB8P45$<L^KZZ,V=?1;I<[[0RLPS;W&3*FQ`Q+7`(@Y,N:)BD'-D&.E=G
MR5G[E<6,QI=AQOKOB(69HM6<JJ>W00>3E!Y#)$O#F(.`ZI8#+KOQL7%#*=LN
MNI?KTO%'[]Z_UA6J`/8]=F`Y.+B+%.I5&6^FEW?1=>Z%5H'*<_`[$()";#FJ
MJKN,C-5YV7^ILCP4P4)JOXN@F_TR<KH>%BG_AL3?.L>_[*+P-Q2SB]7E^B9.
M8^Z6O_.>V7L5[/$Q^@>I5ZPW5>L9]C#P!I*>X9#3TMC^$P7,2TLW;BJ*@(Y)
M`""L*Q0ER[%1.G)P;9H-/<$<J*9@>&K9"9'*)G2>SR;U32A/<2U$K-<T&^!P
M*I2-2:"*CPK\)/F[)2"XM$E!0;,<1M5'3F8K`K"B@^6;8S;[+YX;UJL`-%TB
MX*P(NW!UDXUAH`Y'AX[F?!="4,`L>E6ZLN:^9Z3@2M<M<N@'A<]5GTA=`H:-
M^.)SC1MYA04OZ6>]C*>>^:Z4@*EZDWN723Z"KLXD57<H'I8]%KKR,+SW9+M@
ME\U&VM-Z`5:]W04@!5>VD]Q9K)E_K.H'Q<M^]`U,`BZB=>V1)>%\9L<"R3QK
MY57<WWIQWH[HJ23B(HKE8X/>?-,U'.P'TJ@Y=Q>A99K$B1<*O(`2!BL=H5C9
M#V@!RL`-P)07Y:)[\L*:S=?]1P\'K.C2(B+\ZKQ'Q$+G+X++"5A7$=-2-WR&
M6Z0LJ:4X0F8V&\]B9`6&%><X15_[;RYIG>5`DC"$1BU`2A0HQ-JV-X7*VJ+G
M0CSXHUA$:ZSMXXWNHL0++L.$X##&OBJ9=I2O6R_[:WYQ[8"&J3L?-KY[-0OW
MLN@U5`];NT&L$!LO.$29\?PD]8([1+9O1==%8X_">OECX$V3'71,WB]61Y9?
M3;.OQ^HZ##H$H`A;]D;IR\00.'0!8J^C4O4HIQ,O/+]$H`:'O`L4`,NA+A"^
MW=C[]P4LLX31]LWG<Q0^4OU!^=NV?$,I__TLBI//4?(WE-P@/]J$<A>BP4]:
MK[T,+\EF6NY'KEZ9:4/G5OXKUJ[-$#`M;L$XH(IHWS5G!R$WM%.6N]56%N-7
M$L4=DULEY*Q70!XDUTTI+T,F1NV[S,ZY##._AL#"D/8`EX2T:V``N#8D[SN/
M;.@TIV<%AK_$:=/6$"I=R^XQ,8_C*3%:76ZW:(7I>(,7N";7ND$%;ME'!N5_
M'/'SJN'YN:F\SM%_TO_'PI.D/ADH/)9#?[K*QXU=OC;Z\NTCCUO/?D$-E6H`
MNV2C[TX1"KC],D-]I68J3XU=5`3YRX[K-L4L:Z1@HNH2@:)FNTI0)]DX.4FS
M\@EUG>LZ08'4H##;CUWJ(RU#$W/A89(G*61ZB%9M&G@=I/%EZ!/.)CM$QHDT
MA;$_62BJEA.MAI*?&]-9N^)DMZ.UDAX4?/M^F'X2<P3UKC=+>^6?4P%LBWO,
M'6(<BZ[XRM>EAKX)U1X'/#/&)>^0AG6Y')?Q^5O$;*8`)R\W5-P&(A5T/@Y^
MY\(-G1L'BR-4OAL<?UT0A"[I*9I"G(RH>NV?ABK>!*HC#86#J2H$V<L])8NO
MS=*35_;0(@&%UK(7L(M<1@A<:!M$YJ$$A##(.D-AL>S]TY/%*(#DH48]D0%0
M@4)D.:2KHW2.<%MMMR,^48%LTZU5TVX_!JA.V7]V;GQDOAV-])[M:V0Q!JA&
MVG=\CH_,$6IDF\D[[@HI'0%4&^T'\8V-RK>BBZ.NC=(10'71`?_QR*@XHHNZ
M7O,\&KOSFP8*FE!]<<!CW%MRCFA`5\\WW?TQX8V%L0)]G>O-3X"?P+6O'T/+
MU7!2[SDFB*574-7%FY"_<BB;Z^4L6'E7*&2.I/1"Y.#0S&WL6+J[/AP@^Q7,
MY!Q/_\V8L\"+XWT]JB6Y81F"^YQ_Y*?LE6`4GWE!@%8?7XJB27E#R?5_;\)0
M';&?_CN0#`U7^^I2YZM?A:^?++M809P;E_HN?[97M%161UIK#96T([74!-R.
M5."Q'(,N"<%7=X-*W9'J["K^#8L_.W_D'P\OPSBA"QU_\48!@*PC%`++(8!P
M&9B/X904EJU%*VJ7DOW)<GET"9>.&,:R)^5TC>8.M*`X.NO$`$BJ!>D_OVYP
M2[__M?AKZQ\KU-!S@L+5X9A5$0G>[@C>XGA'A[7UOO>C;6:\<Q98C#8B\<4_
M4IR\O+KU']`J#8IR[UDA!U:1:>XG^)&V.$>)AX.#4'#"/O2&_^_'/\U>S<YQ
M[`=1G!)$_Z/\A7^=9=]@O\Z_,HO669-9]J$9^]*L^-3LW_*/_?MW%K/(^9CG
M]S$O+")6]GH[JW,X5^$[5N!,-C^K[51SKZ&]1B9@N\`;DZ\Z].)-3N:[<D'R
MC<5#(OU26S<0:-<?$0*EX9<?R+2(`G<%WM&OS)^Q!(!:LPG)OC;RO?([Z%*#
MO!MY8"=<L0W@L[=%YQ&+).IQ#=?I:V[H0*O^#O9*IXS_7).Z*I*Z3!;[X"?$
MCAH"XU[0%F@6FO.#&U1N0?6LIJ@<.2'TK!%8JN>;'3H-W+6+/V5=D<8JQ2@4
M<V=7_RZ[I$T\DMAW]_<53_618E4&H(F/0=\&F[PF2D3MR(JF_:!ZQP`.`2WP
MLV/6-:&SH#HO.@DB+MPN]IT#AT*,^XE@;KEI_1BXPKMU)3,G:D>6FPD;4'^\
MTRA3-G5-:N5^$"/J(ERYNJ9EB_GA,2)>DK]V+*E>1+-:9:BX/\K_PIP7N11U
MM=/``,!YS6YJK#%(CE>+X9,\N^JDA_-]Y8&(_6K$118^`G`$IYMZ;`Z4DR)7
M=JM:>7S5,R?#;Y?R`0#5V($KWG$A^48\,T)7::N_P)`N#SD(L$_1?84>'IOI
M1Q;W%EKC51Q+.JTY#JA:3\!7;@2AB7@35+RW^$LLZ:?V2*`:.@$?NB&4)J*C
M1V+::GC'WCK@S1]/*$=V2FND)G;TT)0DF,M4)LB/:(-#5ESGHQ>P*JW:A2EM
MC1(Z)1RY>W!&;D<V:XSZ@^SL"WW'!9T9T[]+&0;!HYD+79+;E=NNZ!G,=[H;
MA>'!0+7>$3^V':P<LMQ["*!T]]3C1=V!T.@T&*BR.E*%QPY6QZ&LVGN4!1T>
M<HQ0U7;D(L81J3FG\<,<X=L?:3?J2JE_$AH1.P&'<U^YGPS=RGY4%=(X)D+C
MFU#U=,3;;%3R1Z.?1H^T\\V&H`T%;:S%M<>0H-H]?;]U;]P&5WX'L_];*G-*
M,_]_ZI#YS[XQXQ^9';YR2OH_)?T+TT].2?^GI/]3TO\IZ?^4].]\TG]QE-CN
M@N@%H5B:]2]J;#U;>Z2T?[FP#%5<*X=T,@;#.`T2%MX)@4K<RWJBX;B8J<3G
MAJ.0!R3(=\92$S=61-"N6!IU*6'>MJ2%,Z@\:NB$&4?:#0UI$W0QY)Y;QC"2
MSA\H4<FZULQVV846_:A)NI4O-Y:1_!T.I<BKS6S7-P"(O(TO-T3>6I-;OI)+
MNKBQUH!6=@D7)85Q#1G5$4;:R0UTE!H'`6J@P\4P2.5#4RU;M6;6([D!"E:#
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M(U,$`S<JT$%MP.;3BC)5:=O<V)CL#LFZ(PBD)B[`YG)\R">/?$7)*[Z]LVIF
MV7Z]PIR[141NZ.\H,Y1%WOE+B).B=($T8N0#,&*D_/U9/H#9802S=41FAS%D
M5&9\%+-\&*<HDE,4R2F*Q-7H`7>C2$Z%OYP\,IT*?WVCA;^H[>2G"7Y$;2;'
M'1VQ_Z",I]"D8?V>8Z224YU$:^@<!1F+*EI#DX;U>P:'8!XKV`,T%F4LB#85
MZS<`+D$]6B@)9#0_]`;Z!TV0)U\IL(-8+0+\8V^`?W0[X,L.P#^.`O"A#"70
MTI)UL.Y`'@D^M=#&0DME,,DZ6/?CVD)K+%.H^6&EW2/O`D3,W,MRUA`;S:)I
M?%H9*"OMX6:@Y@B(C19!V_RR*II6V@/L&3@^Q`:/LQ4@=HV(ST2Z0=EMW!UF
M+^K<>62#DN4ZN]XMLI;SJQX!DITH6??]@*XO>PC):&!!\<WR>*01!NT=K'MF
M-$(-9"P;DG7V$?[9[!(:!1Y_=ZIV7N#("\2O2<.Z`P6$2"?!N'P-?RC3T'84
MG/OTD$B;R6[<__2F0XT&P<UZ\;W3U?KI:OUTM>[H]>[I:OUTM7ZZ6C]=K0^O
M2&TFR,WM%^7C-/)NU@]<(YRH89(8YLS@>GG]SU'XR%_,-98(IC\$ZSIHOSR^
M`);.R3C9V\24,9),."%'\U4!&\I<'X'[OI/116+4&=,W6TC]?'@V(]M>:A!G
M,ACY_C2<0*,#<NP[]B(B:X2I(&PN<RV#L![O8W^E$T)S[#KIGA7Y!SSW;<(I
MKEVD,H@E>1&NCMF.W(O-R??&=$9G/6[(H3G0Y96QTS'K]";?..%:]B=*_S?Y
MOK4*(4J19J<7IV>*]A"MA\G9GRD=83WV8T!^_DFI0CBIZGKCLQ]=:%_1NR!Z
M[%I^+(<#C2/RVV_BK@4D,4/'9P=CW/+GQF%Q;6\[Q+45'SA%LITBV4Z1;!81
MF'HDVUG@Q?%^P5J2&[:.RZ/:)%TFA(F$"S>BW5H'J`I:DW9R`QVEQD&`<BJ<
M+!^:*GRLULQVJ`Y`OVI(M/(Y\2,+M6`S6[9IZXY0Z5OKZ[85QOQYHP,8W_A]
M@UABXHQ"<RCIYAY..'0++/BC71^+4K#CJECIJ^X'<8TBAJ-7LQTFG(SV&Z;#
M???X`[2T`#A:97/,YOLV(K$T!>)"$)8L@OI>+8)[H0CB4@5VX',CTG!J"X.Q
M7AP+'EMM#2K7(O@/3(F?NU&]S=(K8KW#`-R/.AI;(FZ<B+OJIC`[\2`):935
M(/HY\"#<C_>Q(16[:R"`F6*\ME5-<QP3B+JQ))D):-S^D&5=YS1',H$X&&NR
M.5E[PPQ`)][*<BVU<87R[854E80S#U?%;TMG,6FLU;L^L5:E3\_HOPY_*'W]
M%(=UBL,ZQ6&-C\#4X[#R`H_7]/#]P@K5QE2/V%[P\:7\%WE@E@Z-":&FPY8;
MH5OE<:DBMMK:N@&.ODI*@#/[M%:Q$U_&<<K*7"PBLD7DD_?WB'!C*]O@I=6R
M]4C8CL41:UC9%NTB%D.'E>I0+L,Y-0&#NZ?H[B%*8VI,W3VAX)'9M8^4K^O`
M\_FRH(&8+DG;T0-=$.PF-D.(\B>%GPA.$"E&*85+TM[V'2<,"R7#HTR=N^B2
MY]RPEXN#S!=Q*'&O>M2F&RG;A1"Z+78Z8K*/G.J!FVZD;-\_#(Z<[$F;B6;0
MGS(PA!D8[TX9&";0.65@Z!GQQYZ"`=B]O-!'+)\7L#L=FMH^),$<]C(V7;NY
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M`0=N7,$W!O<[3A[V#N4'O*/[7IA@]?V\-B$W$)1JHPI(%8MF+O'WN[[T(J31
MRK:7J:.FE8U,`>=NI-D6)IC*N5IO9_O6L"<N`JZ,GJL.-B[P87=7[OD&F`,B
MWMV8!)<A/6JA@_7!OL1D*]WBI9W<V"9`&[V4#S>NZ@1#5&WNBFYN8`30/1A@
M9K?O6Q0$65#^)X]\10G]6;J*2=K;WM)!VE3QZZEX-[1A_(I"1*AM%Z[FJRT.
M,3N])OA1'@2DZF3;0:\M?9@4#$%P0X5#B3[0KY^C1Q1$.V7@HKR+;;^HMO@A
M$G!C%Y\'G#A:M?OAV3-Y82QQ=$'[VUZ_P#5;]`3BC+<[4]$[[QD5_NG/S$W/
MYGR[H_J'NJ,ZHS#C)/;NY-F>BLWDK3USAP&K,[FDG2S..%;[/5-[JFE//+PB
M#]*C8YW',4K.'MA=UF4XWT9I*.%0GQ)P%II=1Z4XUF9C5V&YL;C6QQHO=XC-
MIG!S%<7Q&9U:+^N(L"ORF.XE*$ZP+T:[$S';RZX^XCUD9LB<6:`5LZ4^HZ0R
M%-!-+["O[0`B#9@TN!H#E79+BW)R1G4()VVNB!('ZMYN6/ZZR$"E8A<;G1FD
M2\MV\(L9W,S,L-$W.VZ,4Q[902H89,>K473CP&AHVVN5GJE@.?:M3CL?J*?M
MPHB:LU1#&B;QZ+CG`?O:OJ3J@LE8^YVAE?)7PN9X2IAT-);#:C?;Q1\'6//:
MY.`H9(S/_'>Y2Z@2%!VN/J(0K7'^/IP&J+J$;=]S#@![-UFZZ'HK19A>D^@1
MQ_0CBX@TG7/M/KD?I3ZY:M#HGOZ,V@7MSKN3RVZHK,=L2<J-=#J^7$USO10S
MI.PX.8<<4!1NK-KY8"L&LSYZJN[3\[%IR<4I*/>\:F(H[#<ASQN0HP9J>D4`
MDBCQ`OLE``J#(%]HM'&']I^0GTB3LYYZX$PQB(+?RFK561]@5*;K/]*1DDW=
M$/@W"C:RD1=W>\U;0(&+`]Y]8IXG7;FXL6E71]UAMO:=H"XXJ:`L'<>^K0UU
M7X@=\F>-":U+KH[];V^0'X4^#G#F#I>Y.OZDX>HX_&E6_<+)TS$T,Q?K-?)9
MN-<!4^Y>+TM]7IS^F:V1TH&\5!J+F1Z$^.0\)@.*U-"E4CY"OS;$?/E:KJ^B
M)T3H+S]2+K\BX?V2/ID)>4ZZ,>B2,0;1P_;3`Y(D]/2C.CWORQ!2G(X^'&Y0
MBQO6?IK01F]"$58].9T:^N?4`LOJFQ?9N%D%GJ<0$9;!R(KPG+/L1FI(]EPB
M-#\U/:^=,7F;M0EJXV7Q+DLZSOOD+`H?Z:CH8.76`(C`A-QMNJQ-;<[S*_;Y
MZN]IG/#2,/VF=9/:A/QNO?B<&NZ%2[$1G`'RO6J(2NM#TW/S&9*URXK$7G3&
M88K#31X723<P71UIIS$]%Z"^A!P/8VKH*#O78.^>ZG*"%>%,/VGX^(KO<"]?
M]B7^H%SI6R=OG])J:PNMF_O_2#']73UNF0*9G5!X</DB#RY77*SU(3P=S]U0
M'!NUT.L#O)OG)\[_*@_B'%$Q^[B(I)QO(Y+@?_+_!$+=@>[$_'J#2=*-7;I-
M<TOJ6:21=`A,%E.9GB.OBY2.)YA&P;7:VZ=-:'INOHZR<G<1@`79M]>].(MB
MG=240;XV/2^?2:D[JE=?0H*\@-5H9Y80BI?A_)$:Z:QV&ITAMUZ`;I&?$F[!
M\_P>#2WJ0'M"KL0!N79:0W11UT/2(4^AG/.I1W;U\@P>J;>OFP</"/^'#/X0
M;5@Y*@<5@!Z#-1#GK:?GT9-Q?001??N;1N\1AYN87S&"ZH?]7'?N%91F.:D9
MH^58(;&:\76#$DQX53@=;YX6D2$]/M>(^`S]#7O`Q`L\\G*.=E%,K<?+L&1H
M9F^%\M>7?%]008S1ZT[.LB>O`XIE=T]?,9KSY^$0%0<"-GG8M0'!]RF_+_CX
MDD\P<AB_V(.G3\FVSZXGJ#VDYXS9#&-`NN5"2=CVU_5`6Y]9QR[:*.];G,4)
ML(L#?C>X0:&/H:4[/]2WWA)%?FE6H>G>%BSD7F\3UB'CPE-$TWHRJIN<6Z?J
MZ8THV\\5./Q&5/G)L3OBT3W!SQ?P\E_DKTKHT)@0:CILN?'$5.7].,5#$VUM
MW0!'7R4EP)E]8>*:VQ;^RQE!65C15>!+"^W+.MCVN(JUIW)\4[)LZ(#VA6"Z
M\^6?1]3,]+V`'AGE\E9U`A^[[`H=QKL;)RG^$K!BPS@T<6/)@>T'AU&[\<00
M'Y#J$;1*(S>DW="0-D$70^ZY<`\CZ4\XQ-MTJY)UK1ET<3'FU&E1D)JH6QES
M8QWYY#V#9%YM!I6Y,=<*0.9MC!G:-*^0%R/^_C8OR<K?<3_S=IC=?[`_L5?Q
M+L,$42DE@NQQ1D>?C&4?->PI]:[2<6."E$<:7Z$X1NBC%[!+S]L'A)+LNNSC
MRR?O[Q$Y"[PX"Z:[)M$.46.#N>R2>;C:<R^]3C3Q+=LN;_";1.8$/5%%$K*6
M)6+Y?KI-N5E;#MH=4+DZ?M^VU]V<PO4"Q`TEG-/SY')]Y84KL:*4V]@.:(6_
M:-9@;/IQS%PSJY7WWXIA:V]M.[P4#*",63?FSB$;AJ\8-Y2I/-Q5NJDKNMF.
MY00#!&+?2:3HNL!7]_W%3L(&[P7Q1R_&\2V5N+=:AK]Y!#._A+R\TP"D;7L@
MNR+>78QN:,6U]\*O^!8180,78]QH:#MF$XR8@$53QU[LL^D_WQ#$1U>Z1CU'
ML4_P3I*!!^UL.Y@2>,;5$H5[\R%Z\0(6:@^;%(?6MA_FZ#0SZLP:FAXL3#I[
M(X-5O"D]V7,(NA/,#5!/ZY<JL)FA(05#..SQYDY#96"AN+EU3S-,XBI^#8EY
MOJ&+'XOBSQ$_\^*'!6I=4EA[<7/KSF68F%7\3B$4KU0#(SM_"9VTLAH8/[W1
MB]6K%L7@Y&?[+\_XIV?YM_._NE`48R)A]0:<E8LTH>/*+[&*C?0\1<K'W/2H
M3#?@OA.[Q^*E`G%]&=X]17]#'I%8F-J$;%]MC*0Q3=E](TK34U7L7T6,I""]
MU<*1Y%LUL\4U\67H!^F*I2\5?^FC*S*JMB]`QE`AM52GG]>KEL)UAFQNS7]&
M2>WO?31,3=OV/<T8>@:5\#&M8\O[`&^R$%XM<[FMG^VKHF%U1"R9XUIM2GQ^
MCD*_HQ*4N]J^0#*F!TWY'$'Q`9C[)5LPBY60^T"RE53J>'G;Q_&2?7)6?#-W
MO&1?=<7C\FUE4=8N7%LWT<]4"6^B@'Y[<_>$@D?TB3+T(+%.>A&U[Y/IG9@Y
M@%"G?]Z&"(&[&G(I,'?#W5/43ZM:"3K@M!E%I232_$;5B0X`'EBC0](!-X\=
ME2I+]-M4JD642K)6NE-TP.UC1:7*\OQ&-:I4D60@C>(4'7#PV-&H<H67;TZC
MYNL$D>'5JD;6`<?0Z+K5*MEO1L%ZJY(37J2QE.:(O$FW:),%SZTC^GN>*0$I
MI_73N[JG*"<T*U%RK(A6/L(;M&./4-`9K_3TB'O8]`5'(0O`R]):;G#\]1"1
M)\GFD?>RG?>K0*;N[05(P%!08KD,YCE)-VRE>4!;5MGC.B7^`ULU!`&*L*ZV
MW1E0*.`<"?&PM."E]S'Z1TJ)7CSRY1RTW+UO+'=[,K.,CFN+78U-P&(G[.%"
MN;E)U@%4@7`J^3<B%A,O^5?3I3OZ/7FY)F&'*>$AXL&-RGTMPU,5\)-T<007
MN9ZI`1JH=I\1A%1EB03-K1ME*CV3H^)BG:A3!=,A*YC:+FEWJF`J8LU0!5./
M?+U%08!(+"]<VFQG^]X`6*]4Q*"I9,-P1=#3S<<H".02;6MH.Z4<)E(QBX9D
M^G^CA_#ZUF-O]'V5RK2MH?7<6)A0Q3P:RXK-*P((ML8LD[32QHW55;[UM0R[
M="5N1(#"C:HR%D>VJ!;Y2`1H=O/A=R/[;TEG=GM3:S=%K4)JRE'&H*%I?;98
M9D^O<'Q!LI5WL;8G`64,8=B4K,_T92WM8F^O@@H;P+$;Q\+]+L'R]Y,7EAD0
MA=QU*O=UR;M-80>$<5*RSBVB5!N;ZL@G:.X8*C*-JX$D8,C,=GMS^T6Z-I7^
M;KV$CU0Q*C5EZDP96NMOD\C_>AG'*5J=IP2'FVM$<+3B#X?'O[.+.HKTQ3,B
M/HX/%XDU">L2L>XN!-6;Z2::Z4=$79/(1V@5+ZC8&/NL0.]R73`L7L54_6Q'
MC<-+EX$$X(8]D!7F+@:W)#=X\Y`42GE-<'GD^5]C611,-W*VH[?A):C[B&OZ
M4UNZI-V@.*$22-"*-YL_>615>6N^S:SL1L^VCQ6L+_T$-GV%*55QO";H$4=I
M//>I#1-C>>U[53_;`=1=REA*!.#(7A!MMU'(=3%3T$QQ):N]J(/M4&7X>BYG
MV>8$%+E7*6EO@\Z"*&;+2;;EE-@0^5N5W=ROF0SCP^AQY_^E'DD0"5Y8\4A)
MH1G66-#6]F463,Y21DU=O6S9@_84SA*X(G5N;>I^<6/QV`U?:N6E3U<Z,E9T
MLNX,T2S[*N7=C1U8:BY^1D_\3UWMZ5)_ZY>_PQC0#8FXN%_S=VYN_T'74[1`
MK>^.<"UM-)M*564!?VY,*.-/2+RU[Y-0OR'AREPHY[/,PS#U`C;@R]`G")C7
MT]H+"I5%=P"(#Y<FSHA/6;VU?TH'OF7ERCQJN6N^0V0KF#_"UE!\+![3I>-W
M:;XLUVMJ39*X7&I//%_:6T/QL/]LD8S;$1)#\_*3V2)ZZP4>>0'L':V]H#*W
M?!P'<C^"[/?[53<0Y-VA:%@^P>O*PQ`L;!6DIC<[(2UE+W>UM`/?I=H5M)!#
MK6SG_"_L'_<4*?J;_P]02P,$%`````@`:(!L1B$?;K"4&@``9BL!`!$`'`!I
M;6UY+3(P,30Q,C,Q+GAS9%54"0`#`_$!50/Q`55U>`L``00E#@``!#D!``#M
M/6MSXSARGY.J_`?&5:E<JB++LL>[.W,S=V5+HSUG[9%B:_;QZ0HF(0D[%*$!
M2%O:7Q\\"!)\"`1I>\B-.1]V9:*[T8UN--"-U_N_[S:^\P`)13CX<#0Z/CER
M8.!B#P6K#T>?[P87=^.KJR/G[W_[MW]UV+_W_SX8.%,$?>^=,\'NX"I8XK\Z
MG\`&OG-^A`$D(,3DK\[/P(_X%SQ%/B3.&&^V/@PA*Y`UO7/>')^YSF!@0?9G
M&'B8?+Z]2LBNPW#[;CA\?'P\#O`#>,3D"SUVL1VY.QP1%R:TKFYN?ON/T\GI
MR>C-Z/1LY(Q.?G*FOSF3Z:?CW9)),@$A@V+%YPSJY(S]9W2Z&+U]=W;R[ORM
M98TA"".:U'BR^^'DY.R$_;-#OT'439"'`&_I][M;].L*!C]$<Q#L;GX!=__X
M>C_S=N>7YW?PR_KAE]O3>Q"`8/_F]_W(HXO]3Y=@LOCQ$?XPEU6^I^X:;H##
M=!_0#T=:>SZ>'6.R&IZ>G(R&O]Y<WPFX(PGX;N>CX$L9^.CMV[=#4:I`"Y"[
M>^(KTF=#7GP/*$PHLU)D@$<!#4'@9N"],$'0@<^'LC`#BDI!OY.@2(%Z,`='
MH7N\P@]#5C#D%C(X&0W.1@H\HH,5`-L$90GHO2`=%Y2C$.Q#6HHC2DJ0`AP$
MT::\=;R0#,/]%@X9T(!!08+<!*\:*8O`>."?R[D3)27<\0Z4(*#-EJ`-HMLU
M(!O`^N1FJ'H6\RL^W,`@G&*RF<`EB'RFP*\1\-$20>_("0%9P9#;/-T"%UK1
M5-T'!`%FO8QYEO@+_[;=(M:-V(=_><_M[1UOWP63PN$_F#\QU<!!AJPG1ISC
MB\#[&(0HW/-NR2!X/4<.\CX<&2%XS8P/4;<'ERA`@L$3^6_D#!R%KO\$@>=(
M6HY&[/TP3T8C'E'HS8*_B=];`BDC(Y"NV8<8,08Y@.0"WXW\>C@I*Z4H\0?5
MYD_0PB7P>=>_6T,84MGLV4_F=CYEC<L],(P;>HP#BGWDL2^>$Q-R)*6^D64[
MS`%ATJUAB!C/)2V>+3<W_YE]\SM_R1#^KU>L#KV5DM:CL^5LRV=8K/ZX(UC`
MF=7S)J>>K'Y2D@Y>.BG15ZP9O97O0NQ^66/?8Y/:CU\CYK*E5BI@S!HY-W68
MK$)TVO_I2.J]:@XT>XE3JX-@5MIW3U-:[_E*E3@&=#WU\2,MJBLM,BOF>WO%
M<)*.H/F*FW]&5B!`?VA3W,P7<V/_P.>Q+%KU,8T(9'_HN*^X4>^BS0:0/7,R
M:!6P:,<%+&)P71RQ:7ZPFC-[=!%41FX':U;$V[PB8JK"_Z1TG92PHRB_8C5=
MN,P94U'38"[*W/V80#GEN?9=J:!***-J1B=YU6CTV%^*HI.0_&_G^GK\BK5R
M"VE(D,LGN&M,PD$(R>8J>&!?N>>6.JF`,6MDE-=(2LV1Y!:,G)/2>\7*X(T0
MA)@D[DK_8&[FTWPS:ZBON$7G!&X!\C[NMC"@D%X$WHQ-`\DX(GQ">$%IDO2P
M@C3KX"RO@YBFHXB*[),@Z\1T'4GX%6MH&A%6#VLOGN1COGJ;^IWR(K,.WN1U
MD!"1J3]%YA6W^!63)EBA>Q]*XV.M^R/&WB/R?>5U#@.86_^\Z(44J=C2A184
MM5>LA'AN2.=@#WA#!Q[[0B*8."`U':H",RODN^)\2!)T8HI"'S'-Q$^]8KU,
MX'WL?<0O<^M^GV]=CO.*&^]PQJY>EFY4"'7[7%S.A;.?<`%VZ40Q_6!NVD+P
M*E$=@?N*F_3C9NOC/81WX($%['3N@SA#4U9@;.+30A"J2#@Q#8<3><5M/<:;
M#1+!'I];C+'(D<`@3=.8`,QM7P@W-5)BK,L0>\4ZN(,KWBB%-?>2[^86+T2>
M,85^?3W.3MY3^#5B0GWD`7F2A\Q]-;=Q(;),\1U)X%6WL$U.MTD>V"X??%J(
M.>WSP<Y?U*]7O2IEI8T%CU=JZ2_&,&NO$+/6T9ZLX37KKBIAKVO-$M:LKY*0
MUB+%WZLJDU[6M5+\;%9`(>K5"/3-;)=SUMN_!KQ9,86HV3K_W*OM0"):UY,)
MP*R80LQ]("G=J\&8G<XZK2HPHTK."C&Z.5/=:\8B99T=ZNV`S5HJ1/-6Z>M>
M666IV,ST^5"I61W%4+]TMUW?^EHZ-NNT\I_-[5T(^_5<;=_.QD2BWN[58&8]
M%`)\8U*Q5PQS/Z:P?`)#@'SZ"1"^X?T!QCZI%HI98<68OBJ0CRMPDAI>M?:L
MLBL#?GS1BWPX6UX"BES6M2;(CT(VQ@,VO>5K)2R*83T%!W>L`A@W<9T$3M,J
MS-91R"#4R/@PX)@E#BV8$AX@9LM1?#ES>3"7<>8(UA(3>\V&594`*O<,M;',
MZB_D+RP32+V+J*%)K>=JH/RX]Q0@(HY;SY;\N`#RXF-/&??P<N3-ME%(H5C8
MAN_FO(*.PUER.$_RB+DX":&SU;N%>L;TD89HPX^7:'J.,P"<"($>&R.N$;A'
M/J,'*2N+-M!K:EQ/K,YL;(6T4!-C2SC,65F<Q%!LBD%*8]2).>WMKY[]W4(:
M^:%V!'1*\$9W00T-S9:NT:+>-#G^4+`HR4KF2*JS9-QDB/5F4\MLY@3SBQG`
M%`6`!8G`US9'-#49&YIF<RE)K]4W%\:&(_AP$D;TK1^]I=2SE$)B^^F^Q8*D
MV4X*>;\F=E),L/?^I,Y9K/+8J":.6<^%?&/56:T^*#JTP)[I?LG73`^VAC8K
MK9"<U)?C\UU06ZCO.YS52GUFP*T&SVCX!>F;;:*0_[3?"9`?W*UW$/3V5+Z%
MH-QOVX&:M5S(8Q[<5M![Z2HM:=W0I!J#\FPIF'5:2$X>TFFVGU9I_C7KV[!5
MQ#!)S@W53R%AUG@AY5BQ$Z5J5MVKW%;E%QLVI8WO3U$#'(MDG\$2:E(V&TC)
MB:T:!J*SD@[C+#SO3><)II/FA2/AYXOZ;F`U]D2-!G->=V_;P82R8*/4@GI3
ML3:5\9H!07H5C-GD:X^"5;R,H$`;&(HM2;.9%+)_M<PDYL%!@:.X2!<?TFV3
MO9E4[YO,3/L?$+3<05E`,ZN[)(EGM9<R&SNP>GI=&I2269BV4Z"ENIM0-EM$
M(=UG9Q'YQ>XZ5O2:;8=?#E&>#"@M,>NND/7C-/I`OV(/](&=A]5P9F44MQN6
M[HONE6-4CN;@1.%LR]G@5R5<N*RU4K4<TIH]`;,ZB_L#R]29=8,"Q)$UBNL=
M'%5G[_NJM)WLK1%[4K:%I<ZFR&8M%S)M%EK6MMBDU?4*KNS.?`,LG44A?V:$
MOWW#\Z([2%Q$^92A1K>V(V16O-7E0OGN+2IVM)IEHC6MN[>"<BNX`>0+#`?\
M.1KO9TCY;NHQ9BTH]@E,,=$6L#GR9\8G_9&`(,QMVGL9TF9+*5[T6VXI.B-.
MS(F3LB*R;?I2NA@K!#M.S$]O/54^I$R9]><%-E2,-O%=(;EFX3T.Z+Z?(=@J
M_Q<^8PZ:*/P0IEG)A=28A9)53;U::ZLU.Z"KKXUF"+5)F@W![L3K`4/(SQ:2
M@G[:4#<6O.1#*W_G$`94"!&/FPNL[M:C$T2@&V)"^?F*R`]Y2]<,&)]8B]F4
MBG=XV4:5@BU'YRN9-H0XN5R0.@EOCL9<;V#9\]CE*2`3@%FM)=OO]#/:?<ZG
M7`W9?>P/B#];*E;(\WHHZ,<>TZRXDKNJ-<45]KC+BN*%\Q(-]WK-:R?Y>@M=
M'+C(1\7C#HTPS7HM9.\,>DV+G&Q5O5H/JG4"EY`0-BB"7;)&K1TLLU"O)06S
MFDMN(3NH9E6A4+2VM*V?A^L57GH'<OEP:0-H5E\A"5=Z1W(_?MI>=U*NISH(
M9GT54F$55Z#T>K/3F^86KR&;YR=;=S\'+"X8@RT*@2]*,H[U62D:-?]](>%E
MUGS6\XIZM/W(@@<G9B(N[3VOK87(#7ESL!>`HBU%$](&ME%)RVP5]>Y9+^Q6
M%QL+5>6Q5<CJ>W,HO9S]P,Z%:CBS&FTN;^^=N?%"]P.:J8(RZZ7ZPO?_WUKA
M_^'+:;=PZ>S$EY"5?SBB3"L^:V+Y;4W@\L,1VFSV@].3T9O1Z=GHGTRTX]W&
M5R"<=*+2Q\?'X]T]\8\Q60U/3T[.I$;SK1%7K$@`XA:H/)X)&J.W;]\.!10C
M@K>0\%!BJ)A7!$(4<O2Y5HW#ZV'^>O@<(OO@OJ[(#`7Z+RCK-:?_K$(RZZLK
M9,Y@7TC4<5K+LPK,NDY=@;.][87DG225Z.(ZXM_[(=AN$1LZXB_L[R#`TN35
M)R8X)J$3@`VD6^":A$(!7S]Q&0>4S1XVX!J[@I0!A?\U4'@#_FDP.AV<C8YW
MU$LYK<-$V@SUF%!X#9C0J9V+O[S0NGJ%P.L]KU4CA>[Q"C\P,T)#;H:#DQ%C
M^F#%I3C\QR!%MJU_">B]$""B@Q4`6^OZ2Q&'T`^I^O)$;GAWI<_$CJ#5@)^,
MBKV0##FA88"#01!M($&NG7'HF)\D(C>2M]PX1]\]D9EFC%1Q`7WYM+Q()M[<
M_/9/%4;@`RN]VM*JN(5U`7?AI8_=+T="%#8Q>P(!Y/O\TX>CD$3<+3)YT#OF
M+A'V%L*K>Y&\+^G(D5Z>-303\5VH:%R%<,,A63.Q^1QSJ)%<9<31]L.1)(<8
MB*D!;L`.;:+-!&XQ1>$8/T`"5O":S53YVT)2Q@J8&F+(LGO@<W?*"N`]"I5P
MLFR#`S8/)?MG$(W9Y#TDF@*4/&4%M74A(:C8R/<,S(H=@84%8[E/\"(*UYB@
M/Z`G(MO<9F2U"P'.F>G#6WZ,2A--PM%?(%JM0^A=2-UE4$X36VZ7A_K=@?4%
M5BX8?#$57/!>O1*@E_L4)$XV7#P"XL7R:1U?6MC(W+!/I%S97'+:$GY3@VTD
MD\DP7J(-J^JKV[+?Q`X;=D-I+[-EL3M6M.R+U->RS=[B/?!Y,")8G3,.>0"]
M2@8&0WE#F^`$GH'QB]6*P!4(H;J*%M#U%,)DA#:4VS/^30?GQMWY$P[J]>@G
M.Y`F-7;2A6BRTFIAQ9XP>A7,!=?/TL+/76OG9PP6`BN9OGE+UZVX]<;F8\\5
MI1'T)A'AM_J+NN4XE=N1"[VDI>IBM1T(Q,\/<+8S&IC'+:D$LX!K6V,Y0\M8
M\(&RMED6=.ZK!XG[`[/,>"-MKBO=P@U`@3Q/%!+@AA'P^=67V2G8-ZVVH9FK
MK\_5G[/\QV>=.(]T`JE+T%:RH/5E6XRF_3CD3J(#\1&73%P'SR\]<,6N<?[I
MY8+,.A6V[20;]Y?"\,?%^&:]]:FU=Z#3/LO$8XLD0RW,>>I6W?:`E`:AL^4=
M"\W(/D[#,@$68*>VHJ9W*,<7J*A6>P)^4]&?*>85"X/0NX0!^Q'R=(/H$>A>
MD&+*CK=XDF(<WPRU97GU"=W7"#T`7VSTX`]!H0=XQ>)%$@DS+YL!5B&T[K"M
M7Z8P+[,TP._"*HL:4F_A`PPB*",1C6DEI@5<\]46E_7S%\SHY'D'(3PDEBQJ
M.IHQ[&>U2.L'LPU6V8A&%RPS9EQXD7A*(\[Z,;M3PB1#B15H1_.-6B?B/L3G
M-U+.`0GWZF[!))5J`=C9/FC,=NCA4Y+QF`7PR"958D!N>VR1&WT/[TO_!87K
M*Q8LLMK"6\TK-<!K=Q5`I:NXCK@YZ2[V0%F[/C;-KZEI=QG+A=)VF8XC![F(
MLL!BX_D*:C/JP^7=W@FA[CNZV&Y]!+TI)@GOHG?'@F5W2=@CM>T&+B/*)OU4
M?XYH'A%W#>)@[L+WXUU$>9??"+.CXUQR3B+4P@/E%!98']#2.*(.2F?'/DT,
MUC$SKV)6REV)T%FI]?B>=<XE%,\V3`&_N*$L!U`"TW+<JW,W(1'?-#=>PPUR
M@:]Z(2V3Q`#;LD2WD!/R]Q=!@"-F!)[V$C7!\IL(S,4ST/M"6/$$_"Z$%"7N
M-.UJZ@'1V;V/5C(3IQV;-GCD&B0:N^87CY#EO)D_)9PX6CFG7F!EOYG"-(!N
M@-GV@*R&D-F2WRCM_1[)!".?,B5L:I<IB:E4'$].$=GP*_?BD%,KT#:]O"#]
MKD[DF&?P`:7B17D9H:H$[FS)_B]6#2A/[3*)`NARD$<6Q<C+@!2(YF:>A5AW
MQ\:D8Y2^H,3C.SW>2P:9VFA=-9?+"/E\X4[PJ7SD/G6R!TJ[ZC_3GJQ49+M9
MHA%FVTL_@CD]KL_F9>*M?AD1LMM>ZN-VMBNG`V`LE/6`60G?]C"IM"3C;"LS
M-H.V;;<J<:"XS465J9':`'9%.VP$D*TN.?N\Y8\H%:9D>4598[4MYC4SH8#"
MBQ6!HD2[?J%D(XXU=-N;<&(_QZ(F+W+#"7R`/M[**P[4>K>2R0ZTJR-][B+B
MJ\#U(X\OZY<O$J=3P+IH;1LJF[$_(!Q1-O]D1GC'CQ)>$`BT-:H#Q4U2]XQG
M\#RS=KP*^"$*.=7"E$(:)Y@6N'QR5A.GJW:9QFC9H$Q?3A(]+Q$MC<42]T*U
M1:KG)-C9V8Z-D')<,4H9/V]0K_%JTFW;']1?M)SBB!PU7O*,L=L6>\S5Z/MB
M+YQ29-;L^5X+0J$HN=LR-S&%]R1B]GEZ,CI+4N!/)M/9/E0F6LZVC;))6%-#
M-:+6MN$<L'BA=)X0B^Y]Y.8S1761.FL4QOY>5_S#6&TKN=3/\^`CWBX_6][2
MB&8MO"9.)T4LZ*(TBFZ&VG947>:!R@\&60"V+8R=L7V"X6RY`#N><>47VVM=
M\BD$.NN=&@O5I">;R+3=N0\X7-9'"WD]6N&D#^%TU@BJ!IO:+6#&[(2J]1S9
M)-)U=P?#4*)P:Y8'8B:(;J-T&]F3*'3;#`Y(E6CTB:UC2:=M$TDW?4B&%XA/
MMQ>`K+@+RVY3BX\%%O>+U$%M>?M(EBV=Y?*M>3F(MM4E&1&LR6M!T@`IDVP4
M[:TDJHO4=F(Y?W+<N%S3>*'F92^)R#6M//]YM=DPO\;:WM=2D95P;=M<8>5(
M>C2^K\^'5%-`_.Y*+KAOBMVVV,H/B*WKCP2%(0RR44PA73'V,2VNP#4AT+;P
MQNF._+[`B6"0V,V3#B!V5%B1@6D@JPFOLU.BA$\]&5VR.FD!U_;P4>)2KP)Y
MC;W!ZVH@;=NC'*_Y-5DJ59(=R7,E;><;3$_W:MUB+DX$T]24&N"UK9DX_1/O
MZ"L30.<\ES2RQVI;S,SA(:$-H/N`P\7MWZ$PA?R8@<\3,/(,<[#BR[OEAZ1L
M@1N*M?H-`O(LXQ-CPTXB.]"6Y8F;G74$1L]=7P2>MB-D`79C,=31G)8LP#L[
MN@JUV,IK"]Q9:2T59NR3M9%;MNGTK@_^LMUXS>]-N0KX5%#>I.+[^%%>CY_<
MHF$+W]7M)Q]9%..&R.778:@W()DNXHM!9LMK_`@)^WA)@/L%IO;=`*_EI%',
M<8YA[EIGP03>AV,<\.5I;8BLA='^73#9)Q[YC_@84'XHX6?"1`<<LSG`?HH)
MOP*(YHWZ290Z>O8S+]OB(G9%O^K\3^"60%>^2\H/SFPP"=$?F=G3<Q#J:!NI
MC(>6U_@']/E"P1SL"?9])G,^.U(!V_946+$I@T.U^B>7ZD4LS"]`RLM4!=RV
M4%.`2'*9,8]-^.TQQ:AD[D>4^2\BL('/#RQE<WO/0*?MIKCBS^,`7Y.D3(+<
M&G`]G+9%U,_UEC$J<\YEIX"-T!TZV9Q<ZU=7/!NTCBQ8J:!;7R'0%Q(LX-HV
M1*W#Y)?7RXNZ.O.-KS/DV7J5ARL]J6(!UU41_S<")(3$W_.%&O7XIY+K4&%7
MA6&SIT@LOVN*2'147M994=1C!)Y1J"JHSHI'()@M[[XR`X-3F"[*EWQO\<R)
MO.&2?TN60/@MLDGP=["X_?RH/OZI"_2"(`*^O+^T;)@L!VOWMBZ=/S&UY)>3
M6,I3`=^N8-Q0XK/#L\S"6UE!^^:47M)X`\@7&(JK"^.MD&,<>.)V$3J-"+^P
ML>J>QR8DNG`GRS6X9R'Z?,W?'G;WR5T&C`9-ALP*F(X']#*6B:>4`;_]%OA^
M9DI@!=GV!%3W`K+7WXHSJ+$_*',6Y6#M^HC<0U$WD#=]9E-"26'3CN)A'B0]
M`]?9MP7BHV]\HI_EOQJL=4D6CWBQQA$%@7?';Y-BEL'*T0-41_[$Q>BTJ)LF
MB*U+*Y[KF@4P*TKA:^M\JL.$\O9Q6&Y6Q=+6^?ZX@ZZX5+PL"[%@W8"-CV^R
MPM1#^5-(>%Y?PO/N2)B]#&:!IYAL(+D!OV.YRX:?`6%_9T2LB=,Q&:^"BRU!
MON;1%H_0?^#;<!]8W,E<F+Q&SR1S;1JMMX&VFT^)DA70!-`Z]WQ^?0FB39;E
MPM?6^11C"[.*DA%'_]H1/M<LQ"_C-/.]&[SR\_4EK&8^=X13YOK+.-4_M\ZI
MS2!5F#C51?I32%GHK'61_AQ2%KMZ?;36)4U#JD,F:H3H'O\%XS-"=)#_HEE5
MP'1/AN+(8@;IH`2%$<<,TKH$^?A!7J6&B3C=QV/=E/]"#V^(^V>2N>`5&N*V
M+G/9R')[][F8D:F&:UV66`<7?&LD"O>E"BH4MLZURMJ/"8QO1/?=+.M&B/;Y
M%W5]%,^,WO!-U8LU(N%^B@@-]90DVH40YE*6#7%;ESE)]/$-Y(A`_AQ#+E8W
M@W1'@@-<=X?3.^C[_#A@X,D5/&XJV34)`T#KW/\(`W[@0%QSOT$!8EX4A(7)
M0"54ZW*4GY@HC!$FF-9E2(?@0U.Q[O#ZF?"'FF+/#QF^"WR^S367$*R":EV.
M";G%C)7P)[#9Y'/4!\I:YYGG*]G(M,2L50,7RE<3Q.)9EG\+N-9EN<%!",>`
M^/@.;2(Y%\UE:$T0G>2_,#FM`FI=BD\X4"/K@>F"$:)U_N7JT0'6#Q6VSO6<
M30?XY`#F.2XK:)U;<3%TLJ4OR_"!LM9Y'D]G)=L1<Z.K&:9U&=ALA<#'VTOL
M^SDS*2UIG5\6=>>F7=J'UKD;CRTLP@S3N@S_@]?!_`[P9?(O6<Y+2UKG]Q-_
M8FVS99$/1QWC!Q@4YK@5,*W+,,&N>/&>/]<4,`K[JT#,JSBABWLJ[K5+YHU6
ML"#^I61J_>88TX4^3:\[KT3N[#%^+:&XQD1L84^?ZY@@ZOJ8\N>[<KJOC=8Y
M,U![6=6$B4F$5@'TF#7'+WP6+_FJ@.W23FT9!?&MN41T4K77,OLNZX29$?)I
M7KM/)M,Y;2?#V\4.)5N`<Q^_,=->^,Y#K'8:J]Z*_8EP]`4!U.>GB]!\0'D_
MI,QL-H#]_#]02P$"'@,4````"`!H@&Q&2HVX,8-#`0"Q1P\`$0`8```````!
M````I($`````:6UM>2TR,#$T,3(S,2YX;6Q55`4``P/Q`55U>`L``00E#@``
M!#D!``!02P$"'@,4````"`!H@&Q&3&RVQ?$:``!==P$`%0`8```````!````
MI('.0P$`:6UM>2TR,#$T,3(S,5]C86PN>&UL550%``,#\0%5=7@+``$$)0X`
M``0Y`0``4$L!`AX#%`````@`:(!L1D"B-:82.@``!!,$`!4`&````````0``
M`*2!#E\!`&EM;7DM,C`Q-#$R,S%?9&5F+GAM;%54!0`#`_$!575X"P`!!"4.
M```$.0$``%!+`0(>`Q0````(`&B`;$:`9MK;^XH``,PX"``5`!@```````$`
M``"D@6^9`0!I;6UY+3(P,30Q,C,Q7VQA8BYX;6Q55`4``P/Q`55U>`L``00E
M#@``!#D!``!02P$"'@,4````"`!H@&Q&:X0WGM-6``#!%P8`%0`8```````!
M````I(&Y)`(`:6UM>2TR,#$T,3(S,5]P<F4N>&UL550%``,#\0%5=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`:(!L1B$?;K"4&@``9BL!`!$`&```````
M`0```*2!VWL"`&EM;7DM,C`Q-#$R,S$N>'-D550%``,#\0%5=7@+``$$)0X`
<``0Y`0``4$L%!@`````&``8`&@(``+J6`@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Plan Activity</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the stock option activity
under the Plan for the year ended December 31, 2014 is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of shares</font></td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Avg. Exercise Price</font></td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Avg. Remaining Contractual Life</font></td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate Intrinsic Value</font></td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 44%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding - January 1, 2014</font></td>
    <td style="vertical-align: bottom; width: 2%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,328,790</font></td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.31</font></td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options granted</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">245,886</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.35</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options exercised</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(307,429</font></td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.90</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options cancelled/forfeit</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(238,007</font></td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.68</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding - December 31, 2014</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,029,240</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.74</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.05</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,351,174</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options exercisable</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">728,585</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.25</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.97</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,080,594</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options vested and expected to vest</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">999,175</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.70</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.98</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,319,475</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumption</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below illustrates the fair
value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing
options granted to employees and directors:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2014</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted-average fair value of options granted</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.22</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.04</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected terms (in years)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.81 - 6.91</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.8-7 </font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">96 - 102%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">102 - 123%</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.37 - 1.65%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.86 - 2.05%</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below illustrates the fair
value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing
options granted to consultants:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2014</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted-average fair value of options granted</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.15</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.63</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected terms (in years)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.5 - 10</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;2.33 - 10 </font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">78 - 97%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;80 - 366% </font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.10 - 1.68%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;0.30 - 2.45% </font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&#160;</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Shares Outstanding and Exercisable</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following table summarizes information about stock options
outstanding and exercisable at December 31, 2014:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options Outstanding</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options Exercisable</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Contractual</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Range of Exercise Prices</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Life in Years</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 28%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$2.40 - $3.20</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.57</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.80</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.80</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$3.60 - $4.51</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">337,723</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.95</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.36</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">270,015</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.42</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$5.49 - $7.71</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">190,557</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8.70</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.62</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">60,110</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.26</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$8.06 - $10.75</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">244,160</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7.03</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8.99</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">141,660</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9.01</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$28.00 - $80.00</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6,800</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.13</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">40.86</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6,800</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">40.86</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,029,240</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.05</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.74</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">728,585</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.25</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock', window );">Market-based Vesting Conditions for Restricted Stock Units Granted</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These market-based vesting conditions
are further described below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 16%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche</font></td>
    <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td>
    <td style="width: 66%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of Shares</font></td>
    <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Target Share Price</font></td></tr>
<tr>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 1</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">19.05% of the shares subject to the Baum Performance Equity Award</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$10.00 or greater</font></td></tr>
<tr>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 2</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">19.05% of the shares subject to the Baum Performance Equity Award</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$15.00 or greater</font></td></tr>
<tr>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 3</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">19.05% of the shares subject to the Baum Performance Equity Award</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$20.00 or greater</font></td></tr>
<tr>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 4</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">19.05% of the shares subject to the Baum Performance Equity Award</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$25.00 or greater</font></td></tr>
<tr>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 5</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">23.80% of the shares subject to the Baum Performance Equity Award</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$30.00 or greater</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>



<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">These market-based vesting conditions
are further described below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 34%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche</font></td>
    <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td>
    <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of Shares</font></td>
    <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td>
    <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Target Share Price</font></td></tr>
<tr>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 1</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20,000 shares</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$10.00 or greater</font></td></tr>
<tr>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 2</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20,000 shares</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$15.00 or greater</font></td></tr>
<tr>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 3</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20,000 shares</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$20.00 or greater</font></td></tr>
<tr>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 4</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20,000 shares</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$25.00 or greater</font></td></tr>
<tr>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 5</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20,000 shares</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$30.00 or greater</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company&#146;s RSU
activity and related information for the year ended December 31, 2014 is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of RSUs</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average Grant Date Fair Value</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 42%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">RSUs unvested - January 1, 2014</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,389,960</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 36%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.19</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">RSUs granted</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">26,492</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7.55</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">RSUs vested</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(30,690</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7.41</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">RSUs cancelled/forfeit</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(108,947</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.01</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">RSUs unvested at December 31, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,276,815</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.20</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Activity</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of warrant activity during
the year ended December 31, 2014 is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of Shares Subject to Warrants Outstanding</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Avg.</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Exercise Price</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding - January 1, 2014</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 20%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">821,050</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 20%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.94</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(130,106</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.28</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding and exercisable - December 31, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">690,944</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.05</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average remaining contractual life of the outstanding warrants in years - December 31, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.86</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock', window );">Schedule of Warrants Outstanding and Warrants Exercisable</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A list of the warrants outstanding as
of December 31, 2014 is included in the following table:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants Outstanding</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants Exercisable</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expiration</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrant Series</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Issue Date</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Date</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 41%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants issued to a former major shareholder</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 9%; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4/25/2012</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">48,262</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.93</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">48,262</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 9%; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4/25/2015</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants issued in April 2012 private placement</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4/25/2012</font></td>
    <td>&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">496,537</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.93</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">496,537</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4/25/2015</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Underwriter Warrants</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2/7/2013</font></td>
    <td>&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">56,145</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.25</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">56,145</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2/7/2018</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants issued to investor relations consultant</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2/28/2013</font></td>
    <td>&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">30,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.25</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">30,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2/28/2016</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants issued to investor relations consultant</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7/19/2013</font></td>
    <td>&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">60,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8.50</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">60,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7/19/2018</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">690,944</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.05</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">690,944</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock Based Compensation Granted to Employees Directors Consultants</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded stock-based compensation
(including the amortization of stock-based prepaid consulting fees, issuance of common stock for services and accrual for stock-based
compensation) related to equity instruments granted to employees, directors and consultants as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2013</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Employees - selling and marketing</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">79,278</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8,298</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Employees - general and administrative</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,095,254</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,512,448</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Employees - research and development</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">156,568</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Directors - general and administrative</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">146,093</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">399,986</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Consultants - selling and marketing</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">88,406</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Consultants - general and administrative</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">146,799</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">843,301</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Consultants - research and development</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8,789</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">214,372</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,564,619</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3,134,973</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumption</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;The fair value
of each warrant is estimated on the date of grant using the Black-Scholes-Merton option pricing model. The table below illustrates
the fair value per share determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing
the warrants issued to consultants:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Year Ended</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2013</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted-average fair value of warrants granted</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 24%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.12</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected terms (in years)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.6-5</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">85%-346%</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.32%-1.31%</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule Of Marketbased Vesting Conditions Further [Table Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ScheduleOfMarketbasedVestingConditionsFurtherTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule of warrants outstanding and exercisable [Table Text Block]</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ScheduleofWarrantsOutstandingAndExercisableTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition - Pharmacy Creations, Llc - Schedule of Result of Operation from Acquisition (Details) (Pharmacy Creations, LLC [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Pharmacy Creations, LLC [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized', window );">Total revenues</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">$ 1,652,386</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Operating loss</a></td>
        <td class="num"><a title="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">$ (662,969)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The revenues and gains recognized recorded for each transaction with the acquiree that is recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrentAndNoncurrent" onclick="toggleNextSibling(this);">$ 698,806</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrentAndNoncurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrentAndNoncurrent" onclick="toggleNextSibling(this);">$ 261,924</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrentAndNoncurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
        <td class="nump"><a title="us-gaap_DeferredRentCreditCurrent" onclick="toggleNextSibling(this);">4,975</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredRentCreditCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_BuildingLeaseLiability', window );">Building lease liability(1)</a></td>
        <td class="nump"><a title="IMMY_BuildingLeaseLiability" onclick="toggleNextSibling(this);">73,552</a><span style="display:none;white-space:normal;text-align:left;">IMMY_BuildingLeaseLiability</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" onclick="toggleNextSibling(this);">39,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Total accounts payable and accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" onclick="toggleNextSibling(this);">816,333</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" onclick="toggleNextSibling(this);">311,924</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Less: Current portion</a></td>
        <td class="num"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">(786,675)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">(311,924)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Non-current total accounts payable and accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">$ 29,658</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</span><span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. As of December 31, 2014, the Company was marketing its previous office space (3,874 square feet) as a sublease through its remaining lease term. The Company recognized a loss of approximately $117,000 during the year ended December 31, 2014, related to the estimated remaining lease liability, net of expected sublease income. The obligations were discounted based on current prevailing market rates. This loss is included in rent expense for the year ended December 31, 2014.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">The amount consists of a $39,000 stock-based compensation accrual at December 31, 2014 for stock options to be granted for services performed. The stock-based compensation expense related to restricted common stock issuances and accruals was $39,000 and $143,553 during the years ended December 31, 2014 and 2013, respectively.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_BuildingLeaseLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Building Lease Liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_BuildingLeaseLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(1),(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 1, 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 24<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EDG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Segment Information (Details Narrative)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Maximum percentage of sales derived from single customer</a></td>
        <td class="nump"><a title="us-gaap_ConcentrationRiskPercentage1" onclick="toggleNextSibling(this);">10.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ConcentrationRiskPercentage1</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageOfDrugAndChemicalPurchases', window );">Percentage of drug and chemical purchases from three main suppliers</a></td>
        <td class="nump"><a title="IMMY_PercentageOfDrugAndChemicalPurchases" onclick="toggleNextSibling(this);">84.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfDrugAndChemicalPurchases</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_PercentageOfDrugAndChemicalPurchases">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of drug and chemical purchases from three main suppliers.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_PercentageOfDrugAndChemicalPurchases</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EQGAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 8,211,492</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 15,579,309</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsCurrent', window );">Restricted short-term investments</a></td>
        <td class="nump"><a title="us-gaap_RestrictedInvestmentsCurrent" onclick="toggleNextSibling(this);">150,264</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedInvestmentsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_RestrictedInvestmentsCurrent" onclick="toggleNextSibling(this);">50,097</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RestrictedInvestmentsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNetCurrent" onclick="toggleNextSibling(this);">81,322</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNetCurrent</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
        <td class="nump"><a title="us-gaap_InventoryNet" onclick="toggleNextSibling(this);">372,735</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InventoryNet</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">240,401</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">105,067</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">9,056,214</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">15,734,473</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
        <td class="nump"><a title="us-gaap_IntangibleAssetsNetExcludingGoodwill" onclick="toggleNextSibling(this);">610,994</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IntangibleAssetsNetExcludingGoodwill</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
        <td class="nump"><a title="us-gaap_Goodwill" onclick="toggleNextSibling(this);">331,621</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Goodwill</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furniture and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">243,395</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">26,892</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">10,242,224</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">15,761,365</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">786,675</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">311,924</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related liabilities</a></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">716,332</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">338,703</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerDepositsCurrent', window );">Customer deposits</a></td>
        <td class="nump"><a title="us-gaap_CustomerDepositsCurrent" onclick="toggleNextSibling(this);">1,683</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CustomerDepositsCurrent</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities', window );">Current portion of contingent acquisition obligations</a></td>
        <td class="nump"><a title="IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities" onclick="toggleNextSibling(this);">31,466</a><span style="display:none;white-space:normal;text-align:left;">IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Current portion of capital lease obligations</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeaseObligationsCurrent" onclick="toggleNextSibling(this);">24,112</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsCurrent</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">1,560,268</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">650,627</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital lease obligations, net of current portion</a></td>
        <td class="nump"><a title="us-gaap_CapitalLeaseObligationsNoncurrent" onclick="toggleNextSibling(this);">18,968</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeaseObligationsNoncurrent</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent', window );">Accrued expenses, net of current portion</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent" onclick="toggleNextSibling(this);">29,658</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent acquisition obligations</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationContingentConsiderationLiability" onclick="toggleNextSibling(this);">483,156</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationContingentConsiderationLiability</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">2,092,050</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">650,627</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 90,000,000 shares authorized, 9,258,231 and 8,970,364 shares issued and outstanding at December 31, 2014 and 2013, respectively</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">9,258</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">8,970</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">50,006,411</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapitalCommonStock" onclick="toggleNextSibling(this);">46,849,160</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapitalCommonStock</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(41,865,495)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(31,747,392)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">8,150,174</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">15,110,738</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 10,242,224</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 15,761,365</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Business Acquisition Contingent Acquired Obligations Liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_BusinessAcquisitionContingentAcquiredObligationsLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liability recognized arising from contingent consideration in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 805<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph b<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455314&amp;loc=d3e45023-112735<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerDepositsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current portion of money or property received from customers which is either to be returned upon satisfactory contract completion or applied to customer receivables in accordance with the terms of the contract or the understandings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CustomerDepositsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Goodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph ((a)(1),(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386567&amp;loc=d3e3927-108312<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Liabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the current portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2GAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PrepaidStockbasedConsultingExpenses', window );">Prepaid stock-based consulting expenses</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="IMMY_PrepaidStockbasedConsultingExpenses" onclick="toggleNextSibling(this);">$ 26,649</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PrepaidStockbasedConsultingExpenses</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidRent" onclick="toggleNextSibling(this);">16,288</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidRent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
        <td class="nump"><a title="us-gaap_PrepaidInsurance" onclick="toggleNextSibling(this);">123,776</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidInsurance</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidInsurance" onclick="toggleNextSibling(this);">39,166</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidInsurance</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses and deposits</a></td>
        <td class="nump"><a title="us-gaap_OtherPrepaidExpenseCurrent" onclick="toggleNextSibling(this);">116,625</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherPrepaidExpenseCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherPrepaidExpenseCurrent" onclick="toggleNextSibling(this);">22,964</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherPrepaidExpenseCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">$ 240,401</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">$ 105,067</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_PrepaidStockbasedConsultingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Prepaid Stock based Consulting Expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_PrepaidStockbasedConsultingExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5865-108316<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5865-108316<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare', window );">Issuance of common stock for public offering price per share</a></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare" onclick="toggleNextSibling(this);">$ 5.25</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_CancelledCommonStockPricePerShare', window );">Cancelled common stock price per share</a></td>
        <td class="nump"><a title="IMMY_CancelledCommonStockPricePerShare" onclick="toggleNextSibling(this);">$ 5.25</a><span style="display:none;white-space:normal;text-align:left;">IMMY_CancelledCommonStockPricePerShare</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_CancelledCommonStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cancelled Common Stock Price Per Share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_CancelledCommonStockPricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common stock for public offering price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_IssuanceOfCommonStockForPublicOfferingPricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5BBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Market-based Vesting Conditions for Restricted Stock Units Granted (Details)<br></strong></div>
        </th>
        <th class="th" colspan="2">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>May 02, 2013</div>
        </th>
        <th class="th">
          <div>May 24, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember', window );">Tranche 1 CEO [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted', window );">Percentage of Number of Shares Granted</a></td>
        <td class="nump"><a title="IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted[us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember]" onclick="toggleNextSibling(this);">19.05%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted<br>/ us-gaap_AwardTypeAxis<br>= IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_TargetSharePriceRelatedToRestrictedStockGrant', window );">Target Share Price</a></td>
        <td class="text">$10.00 or greater<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember', window );">Tranche 2 CEO [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted', window );">Percentage of Number of Shares Granted</a></td>
        <td class="nump"><a title="IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted[us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember]" onclick="toggleNextSibling(this);">19.05%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted<br>/ us-gaap_AwardTypeAxis<br>= IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_TargetSharePriceRelatedToRestrictedStockGrant', window );">Target Share Price</a></td>
        <td class="text">$15.00 or greater<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember', window );">Tranche 3 CEO [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted', window );">Percentage of Number of Shares Granted</a></td>
        <td class="nump"><a title="IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted[us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember]" onclick="toggleNextSibling(this);">19.05%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted<br>/ us-gaap_AwardTypeAxis<br>= IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_TargetSharePriceRelatedToRestrictedStockGrant', window );">Target Share Price</a></td>
        <td class="text">$20.00 or greater<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTranche4Member', window );">Tranche 4 CEO [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted', window );">Percentage of Number of Shares Granted</a></td>
        <td class="nump"><a title="IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted[us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTranche4Member]" onclick="toggleNextSibling(this);">19.05%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted<br>/ us-gaap_AwardTypeAxis<br>= IMMY_ExecutiveRestrictedStockUnitsTranche4Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_TargetSharePriceRelatedToRestrictedStockGrant', window );">Target Share Price</a></td>
        <td class="text">$25.00 or greater<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTranche5Member', window );">Tranche 5 CEO [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted', window );">Percentage of Number of Shares Granted</a></td>
        <td class="nump"><a title="IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted[us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTranche5Member]" onclick="toggleNextSibling(this);">23.80%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted<br>/ us-gaap_AwardTypeAxis<br>= IMMY_ExecutiveRestrictedStockUnitsTranche5Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_TargetSharePriceRelatedToRestrictedStockGrant', window );">Target Share Price</a></td>
        <td class="text">$30.00 or greater<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheOneMember', window );">Consultant Tranche 1 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberOfSharesTiedToTarget', window );">Number of Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_NumberOfSharesTiedToTarget[us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheOneMember]" onclick="toggleNextSibling(this);">20,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberOfSharesTiedToTarget<br>/ us-gaap_AwardTypeAxis<br>= IMMY_ConsultantTrancheOneMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_TargetSharePriceRelatedToRestrictedStockGrant', window );">Target Share Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">$10.00 or greater<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheTwoMember', window );">Consultant Tranche 2 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberOfSharesTiedToTarget', window );">Number of Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_NumberOfSharesTiedToTarget[us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheTwoMember]" onclick="toggleNextSibling(this);">20,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberOfSharesTiedToTarget<br>/ us-gaap_AwardTypeAxis<br>= IMMY_ConsultantTrancheTwoMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_TargetSharePriceRelatedToRestrictedStockGrant', window );">Target Share Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">$15.00 or greater<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheThreeMember', window );">Consultant Tranche 3 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberOfSharesTiedToTarget', window );">Number of Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_NumberOfSharesTiedToTarget[us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheThreeMember]" onclick="toggleNextSibling(this);">20,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberOfSharesTiedToTarget<br>/ us-gaap_AwardTypeAxis<br>= IMMY_ConsultantTrancheThreeMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_TargetSharePriceRelatedToRestrictedStockGrant', window );">Target Share Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">$20.00 or greater<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheFourMember', window );">Consultant Tranche 4 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberOfSharesTiedToTarget', window );">Number of Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_NumberOfSharesTiedToTarget[us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheFourMember]" onclick="toggleNextSibling(this);">20,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberOfSharesTiedToTarget<br>/ us-gaap_AwardTypeAxis<br>= IMMY_ConsultantTrancheFourMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_TargetSharePriceRelatedToRestrictedStockGrant', window );">Target Share Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">$25.00 or greater<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheFiveMember', window );">Consultant Tranche 5 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberOfSharesTiedToTarget', window );">Number of Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_NumberOfSharesTiedToTarget[us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheFiveMember]" onclick="toggleNextSibling(this);">20,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberOfSharesTiedToTarget<br>/ us-gaap_AwardTypeAxis<br>= IMMY_ConsultantTrancheFiveMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_TargetSharePriceRelatedToRestrictedStockGrant', window );">Target Share Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">$30.00 or greater<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_NumberOfSharesTiedToTarget">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number Of Shares Tied To Target.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_NumberOfSharesTiedToTarget</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage Shares Tied To Target Of Number Of Shares Granted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_PercentageSharesTiedToTargetOfNumberOfSharesGranted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_TargetSharePriceRelatedToRestrictedStockGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Target Share Price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_TargetSharePriceRelatedToRestrictedStockGrant</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheFiveMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheFiveMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheFourMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheFourMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheOneMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheOneMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheThreeMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheThreeMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheTwoMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_ConsultantTrancheTwoMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTranche4Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTranche4Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTranche5Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTranche5Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTrancheOneMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTrancheThreeMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=IMMY_ExecutiveRestrictedStockUnitsTrancheTwoMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Significant Accounting Policies (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_MaximumDepositCoverageLimits', window );">Deposit coverage limits by FDIC, per owner</a></td>
        <td class="nump"><a title="IMMY_MaximumDepositCoverageLimits" onclick="toggleNextSibling(this);">$ 250,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_MaximumDepositCoverageLimits</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDepositsFromCustomers', window );">Cash deposits in excess of FDIC limits</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromDepositsFromCustomers" onclick="toggleNextSibling(this);">7,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromDepositsFromCustomers</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net of allowance for doubtful accounts</a></td>
        <td class="nump"><a title="us-gaap_AccountsReceivableNet" onclick="toggleNextSibling(this);">3,957</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsReceivableNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
        <td class="nump"><a title="us-gaap_AssetImpairmentCharges" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetImpairmentCharges</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetImpairmentCharges" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetImpairmentCharges</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_CommonStockEquivalentsDilutiveInstruments', window );">Common stock equivalents, dilutive instruments</a></td>
        <td class="nump"><a title="IMMY_CommonStockEquivalentsDilutiveInstruments" onclick="toggleNextSibling(this);">3,024,217</a><span style="display:none;white-space:normal;text-align:left;">IMMY_CommonStockEquivalentsDilutiveInstruments</span><span></span></td>
        <td class="nump"><a title="IMMY_CommonStockEquivalentsDilutiveInstruments" onclick="toggleNextSibling(this);">3,539,800</a><span style="display:none;white-space:normal;text-align:left;">IMMY_CommonStockEquivalentsDilutiveInstruments</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_RestrictedStockIncludedInCommonStockEquivalents', window );">Number of restricted stock included in common stock equivalents</a></td>
        <td class="nump"><a title="IMMY_RestrictedStockIncludedInCommonStockEquivalents" onclick="toggleNextSibling(this);">27,218</a><span style="display:none;white-space:normal;text-align:left;">IMMY_RestrictedStockIncludedInCommonStockEquivalents</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">furniture and equipment depreciated useful life</a></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">furniture and equipment depreciated useful life</a></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_CommonStockEquivalentsDilutiveInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common Stock Equivalents Dilutive Instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_CommonStockEquivalentsDilutiveInstruments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_MaximumDepositCoverageLimits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum deposit coverage limits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_MaximumDepositCoverageLimits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_RestrictedStockIncludedInCommonStockEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of restricted stock included in common stock equivalents.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_RestrictedStockIncludedInCommonStockEquivalents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.5)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2420-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDepositsFromCustomers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from customers for deposits on goods or services during the period; excludes deposits with other institutions and time deposits, which pertain to financial services entities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromDepositsFromCustomers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EENAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Schedule of Provision for Income Taxes (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
        <td class="nump"><a title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" onclick="toggleNextSibling(this);">2,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
        <td class="nump"><a title="us-gaap_CurrentIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">2,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
        <td class="nump"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">11,082,459</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">8,075,342</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
        <td class="nump"><a title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">3,100,627</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">2,233,726</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_DeferredIncomeChangeInValuationAllowance', window );">Change in valuation allowance</a></td>
        <td class="num"><a title="IMMY_DeferredIncomeChangeInValuationAllowance" onclick="toggleNextSibling(this);">(14,183,086)</a><span style="display:none;white-space:normal;text-align:left;">IMMY_DeferredIncomeChangeInValuationAllowance</span><span></span></td>
        <td class="num"><a title="IMMY_DeferredIncomeChangeInValuationAllowance" onclick="toggleNextSibling(this);">(10,309,068)</a><span style="display:none;white-space:normal;text-align:left;">IMMY_DeferredIncomeChangeInValuationAllowance</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ 2,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_DeferredIncomeChangeInValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred Income Change In Valuation Allowance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_DeferredIncomeChangeInValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Paragraph Question 1-7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Segment Information<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 15. SEGMENT INFORMATION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company operates the business on the basis
of a single reportable segment, which is the business of developing proprietary drug therapies and providing such therapies through
sterile and non-sterile pharmaceutical compounding services. The Company&#146;s chief operating decision-maker is the Chief Executive
Officer, who evaluates the Company as a single operating segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company categorizes revenues by geographic
area based on selling location. All operations are currently located in the United States; therefore, total revenues for 2014 and
2013 are attributed to the United States. All long-lived assets at December 31, 2014 are located in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company sells its compounded formulations
to a large number of customers. Less than 10% of the Company&#146;s total pharmacy sales were derived from a single customer for
the year ended December 31, 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company receives its active pharmaceutical
ingredients from three main suppliers. These suppliers collectively accounted for 84% of drug and chemical purchases during the
year ended December 31, 2014.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 29<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8864-108599<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 32<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8933-108599<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8844-108599<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8538-108599<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8380-108599<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 34<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8981-108599<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 35<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8984-108599<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 41<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9038-108599<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 30<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8906-108599<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 42<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9054-108599<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 31<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8924-108599<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 40<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e9031-108599<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 33<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8971-108599<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 280<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6534315&amp;loc=d3e8595-108599<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1EAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Common Share (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Numerator - net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (10,118,103)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" onclick="toggleNextSibling(this);">$ (7,643,124)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Denominator - weighted average number of shares outstanding, basic and diluted</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">9,132,989</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">8,656,822</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (1.11)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.88)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWKAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basis of Presentation</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 28, 2012, the Company effected
a one-for-eight reverse stock split and on February 7, 2013, the Company effected a one-for-five reverse stock split. All share
and per share amounts in these consolidated financial statements and notes reflect the effects of these reverse stock splits.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Imprimis has prepared the accompanying
consolidated financial statements in accordance with accounting principles generally accepted in the United States of America
(&#147;GAAP&#148;). The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned
subsidiary. All intercompany accounts and transactions have been eliminated in consolidation.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Business Combinations</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for business combinations
by recognizing the assets acquired, liabilities assumed, contractual contingencies, and contingent consideration at their fair
values on the acquisition date. The purchase price allocation process requires management to make significant estimates and assumptions
at the acquisition date, especially with respect to intangible assets, estimated contingent consideration payments and pre-acquisition
contingencies. Examples of critical estimates in valuing certain of the intangible assets we the Company has acquired or may acquire
in the future include but are not limited to:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 24px; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 24px; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">future expected cash flows from product sales, support agreements, consulting contracts, other customer contracts, and acquired developed technologies and patents; and</font></td></tr>
<tr>
    <td style="line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr>
    <td style="line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">discount rates utilized in valuation estimates.</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Unanticipated events and circumstances
may occur that may affect the accuracy or validity of such assumptions, and estimates compared to actual results. Additionally,
any change in the fair value of the acquisition-related contingent consideration subsequent to the acquisition date, including
changes from events after the acquisition date, such as changes in our estimates of relevant revenue or other targets, will be
recognized in earnings in the period of the estimated fair value change. A change in fair value of the acquisition-related contingent
consideration or the occurrence of events that cause results to differ from our estimates or assumptions could have a material
effect on the consolidated financial position, statements of operations, or cash flows in the period of the change in the estimate.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company expenses all costs related to
research and development as they are incurred. Research and development expenses consist of expenses incurred in performing research
and development activities, including salaries and benefits, other overhead expenses, and costs related to clinical trials, contract
services and outsourced contracts.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intellectual Property</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Intellectual Property</b><i> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The costs of acquiring intellectual property
rights to be used in the research and development process, including licensing fees and milestone payments, are charged to research
and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired
rights, and are capitalized in situations where the Company has identified an alternative future use for the acquired rights.
No costs associated with acquiring intellectual property rights have been capitalized to date, although the Company may begin
to capitalize certain costs associated with intellectual property rights beginning in the fiscal year 2015. Costs of maintaining
intellectual property rights are expensed as incurred.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionDeferredRevenue', window );">Revenue Recognition and Deferred Revenue</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Revenue Recognition and Deferred Revenue</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenues when all of
the following criteria have been met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling
price is fixed and determinable; and (4) collectability is reasonably assured. The Company began generating revenues upon the acquisition
of PC in the second quarter of 2014, which include sales of certain of the Company&#146;s proprietary compounded drug formulations
and certain non-proprietary formulations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Product Revenues</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Determination of criteria (3) and (4) is based
on management&#146;s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability
of those amounts. Estimated returns and allowances and other adjustments are provided for in the same period during which the related
sales are recorded. The Company will defer any revenue received for a product that has not been delivered or is subject to refund
until such time that the Company and the customer jointly determine that the product has been delivered and no refund will be required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>License Revenues</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">License arrangements may consist of non-refundable
upfront license fees, data transfer fees, research reimbursement payments, exclusive license rights to patented or patent pending
compounds, technology access fees, and various performance or sales milestones. These arrangements can be multiple element arrangements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Non-refundable fees that are not contingent
on any future performance by the Company and require no consequential continuing involvement on the part of the Company, are recognized
as revenue when the license term commences and the licensed data, technology, compounded drug preparation and/or other deliverable
is delivered. Such deliverables may include physical quantities of compounded drug preparations, design of the compounded drug
preparations and structure-activity relationships, the conceptual framework and mechanism of action, and rights to the patents
or patent applications for such compounded drug preparations. The Company defers recognition of non-refundable fees if it has
continuing performance obligations without which the technology, right, product or service conveyed in conjunction with the non-refundable
fee has no utility to the licensee and that are separate and independent of the Company&#146;s performance under the other elements
of the arrangement. In addition, if the Company&#146;s continued involvement is required, through research and development services
that are related to its proprietary know-how and expertise of the delivered technology or can only be performed by the Company,
then such non-refundable fees are deferred and recognized over the period of continuing involvement. Guaranteed minimum annual
royalties are recognized on a straight-line basis over the applicable term.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cost of Sales</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of sales includes direct and indirect
costs to manufacture formulations and other products sold, including active pharmaceutical ingredients, personnel costs, packaging,
storage, royalties (see Note 14), shipping and handling costs and the write-off of obsolete inventory.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Income Taxes</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of the process of preparing the Company&#146;s
consolidated financial statements, the Company must estimate the actual current tax liabilities and assess temporary differences
resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and
liabilities, which are included within the balance sheet. The Company must assess the likelihood that the deferred tax assets will
be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, a valuation allowance
must be established. To the extent the Company establishes a valuation allowance or increase or decrease this allowance in a period,
the impact will be included in income tax expense in the statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes under
the provisions of Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;)
740, &#147;Income Taxes&#148;, or ASC 740. As of December 31, 2014, there were no unrecognized tax benefits included in the
consolidated balance sheet that would, if recognized, affect the effective tax rate. The Company&#146;s practice is to recognize
interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties
in its consolidated balance sheets at December 31, 2014 and 2013, and has not recognized interest and/or penalties in the consolidated
statements of operations for the years ended December 31, 2014 and 2013. The Company is subject to taxation in the United States
and California. The Company&#146;s tax years since 2000 are subject to examination by the federal and state tax authorities due
to the carryforward of unutilized net operating losses.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Cash and Cash Equivalents</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash equivalents include short-term,
highly liquid investments with maturities of three months or less at the time of acquisition.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Concentrations of Credit Risk</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company places its cash with financial
institutions deemed by management to be of high credit quality. The Federal Deposit Insurance Corporation (&#147;FDIC&#148;)
provides basic deposit coverage with limits up to $250,000 per owner. At December 31, 2014, the Company had approximately $7.7
million in cash deposits in excess of FDIC limits.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Accounts Receivable</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The balance in accounts receivable
consists of revenue amounts the Company has invoiced and recognized, but for which payment has not been received. Accounts receivable
are presented net of an allowance for doubtful accounts in the amount of $3,957 as of December 31, 2014.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Inventories</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower
of cost or market. Cost is determined on a first-in, first-out basis. The Company evaluates the carrying value of inventories on
a regular basis, based on the price expected to be obtained for products in their respective markets compared with historical cost.
Write-downs of inventories are considered to be permanent reductions in the cost basis of inventories.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also regularly evaluates
its inventories for excess quantities and obsolescence (expiration), taking into account such factors as historical and anticipated
future sales or use in production compared to quantities on hand and the remaining shelf life of products and active pharmaceutical
ingredients on hand. The Company establishes reserves for excess and obsolete inventories as required based on its analyses.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Furniture and Equipment</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Furniture and Equipment</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Furniture and equipment is stated at
cost less accumulated depreciation and amortization. Depreciation and amortization is calculated using the straight-line method
over the estimated useful life of the asset. Leasehold improvements and capital lease equipment are amortized over the estimated
useful life or remaining lease term, whichever is shorter. Computer software and hardware and furniture and equipment are depreciated
over three to five years.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Goodwill and Intangible Assets</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reviews its goodwill and
indefinite-lived intangible assets for impairment as of January 1 of each year and when an event or a change in circumstances indicates
the fair value of a reporting unit may be below its carrying amount. Events or changes in circumstances considered as impairment
indicators include but are not limited to the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 24px; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 24px; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">significant underperformance of the Company&#146;s business relative to expected operating results;</font></td></tr>
<tr>
    <td style="line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr>
    <td style="line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">significant adverse economic and industry trends;</font></td></tr>
<tr>
    <td style="line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr>
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">significant decline in the Company&#146;s market capitalization for an extended period of time relative to net book value; and</font></td></tr>
<tr>
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr>
    <td style="text-align: justify; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">expectations that a reporting unit will be sold or otherwise disposed. </font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The goodwill impairment test consists
of a two-step process as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Step 1. The Company compares the fair
value of each reporting unit to its carrying amount, including the existing goodwill. The fair value of each reporting unit is
determined using a discounted cash flow valuation analysis. The carrying value of each reporting unit is determined by specifically
identifying and allocating the assets and liabilities to each reporting unit based on headcount, relative revenues, or other methods
as deemed appropriate by management. If the carrying amount of a reporting unit exceeds its fair value, an indication exists that
the reporting unit&#146;s goodwill may be impaired and the Company then performs the second step of the impairment test. If the
fair value of a reporting unit exceeds its carrying amount, no further analysis is required.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Step 2. If further analysis is required,
the Company compares the implied fair value of the reporting unit&#146;s goodwill, determined by allocating the reporting unit&#146;s
fair value to all of its assets and its liabilities in a manner similar to a purchase price allocation, to its carrying amount.
If the carrying amount of the reporting unit&#146;s goodwill exceeds its fair value, an impairment loss will be recognized in
an amount equal to the excess.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Impairment of Long-Lived Assets</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets, such as furniture
and equipment and purchased intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured
by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the
asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized in the amount
by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented
in the consolidated balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no
longer depreciated. The assets and liabilities of a disposal group classified as held-for-sale would be presented separately in
the appropriate asset and liability sections of the consolidated balance sheet, if material.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended December 31,
2014 and 2013, the Company did not recognize any impairment of its long-lived assets.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Rent</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Deferred Rent </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for rent expense
related to its operating leases by determining total minimum rent payments on the leases over their respective periods and recognizing
the rent expense on a straight-line basis. The difference between the actual amount paid and the amount recorded as rent expense
in each fiscal year and interim periods within each fiscal year is recorded as an adjustment to deferred rent.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value Measurements</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value measurements are determined
based on the assumptions that market participants would use in pricing an asset or liability. GAAP establishes a hierarchy for
inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by
requiring that the most observable inputs be used when available. The established fair value hierarchy prioritizes the use of inputs
used in valuation methodologies into the following three levels:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 24px; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 1: Applies to assets or liabilities for which there are quoted prices (unadjusted) for identical assets or liabilities in active markets. A quoted price in an active market provides the most reliable evidence of fair value and must be used to measure fair value whenever available.</font></td></tr>
<tr>
    <td style="vertical-align: top; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2: Applies to assets or liabilities for which there are significant other observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</font></td></tr>
<tr>
    <td style="vertical-align: top; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3: Applies to assets or liabilities for which there are significant unobservable inputs that reflect a reporting entity&#146;s own assumptions about the assumptions that market participants would use in pricing an asset or liability. For example, Level 3 inputs would relate to forecasts of future earnings and cash flows used in a discounted future cash flows method.</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2014 and 2013, the
Company did not have any financial assets or liabilities that are measured on a recurring basis. At December 31, 2014 and 2013,
the Company&#146;s financial instruments included cash and cash equivalents, restricted short-term investments, accounts receivable,
accounts payable and accrued expenses, accrued payroll and related liabilities, customer deposits, and capital leases. The carrying
amount of these financial instruments, except for the restricted short-term investments and the capital leases, approximates fair
value due to the short-term maturities of these instruments. The Company&#146;s restricted short-term investments are carried
at amortized cost, which approximates fair value. Based on borrowing rates currently available to the Company, the carrying values
of the capital leases approximate their respective fair values.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock-Based Compensation</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">All stock-based payments to employees,
directors and consultants, including grants of stock options, warrants, restricted stock units (&#147;RSUs&#148;) and restricted
stock, are recognized in the consolidated financial statements based upon their fair values. The Company uses the Black-Scholes-Merton
option pricing model and Monte Carlo Simulation to estimate the fair value of stock-based awards. The estimated fair value is determined
at the date of grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary,
if the actual effect differs from those estimates.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#146;s accounting policy
for equity instruments issued to consultants and vendors in exchange for goods and services follows the Financial Accounting Standards
Board (the &#147;FASB&#148;) guidance. As such, the value of the applicable stock-based compensation is periodically remeasured
and income or expense is recognized during the vesting terms of the equity instrument. The measurement date for the estimated
fair value of the equity instruments issued is the earlier of (i) the date at which a commitment for performance by the consultant
or vendor is reached or (ii) the date at which the consultant or vendor&#146;s performance is complete. In the case of equity
instruments issued to consultants, the estimated fair value of the equity instrument is primarily recognized over the term of
the consulting agreement. In accordance with FASB guidance, an asset acquired in exchange for the issuance of fully vested, nonforfeitable
equity instruments should not be presented or classified as an offset to equity on the grantor&#146;s balance sheet once the
equity instrument is granted for accounting purposes. Accordingly, the Company records the estimated fair value of nonforfeitable
equity instruments issued for future consulting services as prepaid expenses in its consolidated balance sheets.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss per Common Share</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Basic and Diluted Net Loss per Common
Share</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is computed
by dividing net loss attributable to common stockholders for the period by the weighted average number of common shares outstanding
during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the
period by the weighted average number of common and common equivalent shares, such as stock options and warrants, outstanding during
the period.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic and diluted net loss per share
is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents
(using the treasury stock or, &#147;if converted&#148; method) from stock options, RSUs and warrants were 3,024,217 and 3,539,800
at December 31, 2014 and 2013, respectively, and are excluded from the calculation of diluted net loss per share for all periods
presented because the effect is anti-dilutive. Common stock equivalents at December 31, 2014 include 27,218 shares of common stock
underlying RSUs, awarded to directors that have vested, but the issuance and delivery of these shares are deferred until the director
resigns.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the computation
of basic and diluted net loss per share of common stock for the years ended December 31, 2014 and 2013:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2013</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Numerator &#150; net loss</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(10,118,103</font></td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(7,643,124</font></td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Denominator &#150; weighted average number of shares outstanding, basic and diluted</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9,132,989</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8,656,822</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Net loss per share, basic and diluted</b></font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1.11</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.88</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements
in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and
expenses during the reporting periods. Significant estimates made by management are, among others, allowance for doubtful accounts,
realizability of inventories, valuation of deferred taxes, goodwill and intangible assets, recoverability of long-lived assets
and goodwill, valuation of contingent acquisition obligations, and valuation of stock-based compensation issued to employees and
non-employees. Actual results could differ from those estimates.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reclassifications</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain prior period items and amounts
have been reclassified to conform to the classifications used to prepare the consolidated financial statements for the year ended
December 31, 2014. The Company has classified in these financial statements certain expenses as selling and marketing, whereas
in prior periods certain of these expenses were included in an expense line item titled selling, general and administrative in
the consolidated statements of operations. These reclassifications had no material impact on the Company&#146;s financial position,
results of operations, or cash flows as previously reported.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recently Adopted Accounting Pronouncements</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2014, the FASB issued an Accounting
Standards Update (&#147;ASU&#148;) No. 2014-10, &#147;Elimination of Certain Financial Reporting Requirements, Including an
Amendment to Variable Interest Entities&#148;. The amendments in this update remove the definition of a development stage entity
from ASC Topic 915, &#147;Development Stage Entities&#148;, thereby removing from GAAP the distinction between development stage
entities and other reporting entities. In addition, the amendments eliminate the requirements for development stage entities to
(1) present inception-to-date information in the statements of operations, cash flows, and stockholder&#146;s equity, (2) label
the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities
in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer a development stage entity
that in prior years it had been in the development stage. These amendments are effective for annual reporting periods beginning
after December 15, 2014, with early application of the amendments permitted. The Company&#146;s pharmacy operations commenced
on April 1, 2014. This change in the nature of the Company&#146;s operations included the recognition of operating revenues;
as a result, the Company is no longer defined as a development stage company for reporting dates beginning April 1, 2014. With
the change in the Company&#146;s operations, its revenue recognition and its immediate adoption of ASU No. 2014-10, the Company
no longer presents or discloses any information required under ASC Topic 915.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2014, the FASB issued new
accounting guidance which defines management&#146;s responsibility to assess an entity&#146;s ability to continue as a going
concern, and to provide related footnote disclosures in certain circumstances. This guidance will be effective for annual periods
ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted
for annual or interim reporting periods for which the financial statements have not previously been issued. The Company is currently
evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial statements.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the FASB issued ASU No.
2014-09, &#147;Revenue from Contracts with Customers&#148; (&#147;ASU 2014-09&#148;). The objective of ASU 2014-19 is to establish
a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede
most of the existing revenue recognition guidance, including industry-specific guidance. The core principle of ASU 2014-09 is
that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects
the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the new guidance,
an entity will (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine
the transaction price; (4) allocate the transaction price to the contract&#146;s performance obligations; and (5) recognize revenue
when (or as) the entity satisfies a performance obligation. ASU 2014-09 applies to all contracts with customers except those that
are within the scope of other topics in the FASB ASC. The new guidance is effective for annual reporting periods, including interim
periods within those periods, beginning after December 15, 2016 for public companies. Early adoption is not permitted. The Company
is currently evaluating the new guidance and has not determined the impact this standard may have on its consolidated financial
statements.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Recently Announced Accounting Pronouncements [PolicyTextBlock].</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_RecentlyAnnouncedAccountingPronouncementsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -Subparagraph (a)-(d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognition of costs in the period which correspond to the sales and revenue categories presented in the statement of operations. The accounting policy may include the amount and nature of costs incurred, provisions associated with inventories, purchase discounts, freight and other costs included in cost of sales incurred and recorded in the period. This disclosure also includes the nature of costs of sales incurred and recorded in the statement of operations for the period relating to transactions with related parties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 50<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6408645&amp;loc=d3e63676-111659<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390181&amp;loc=d3e202-110218<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 330<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 206<br><br> -Paragraph b<br><br> -Subparagraph i, ii<br><br> -Chapter 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3-5<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35738203&amp;loc=d3e4975-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionDeferredRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2H">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Savings Plan (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount', window );">Percentage of salary deposits in tax deferred investment account</a></td>
        <td class="nump"><a title="IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_DefinedBenefitPlanContributionsByEmployerPercentage', window );">Percentage of contributions made by the company</a></td>
        <td class="nump"><a title="IMMY_DefinedBenefitPlanContributionsByEmployerPercentage" onclick="toggleNextSibling(this);">3.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_DefinedBenefitPlanContributionsByEmployerPercentage</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Contributions by the company</a></td>
        <td class="nump"><a title="us-gaap_DefinedBenefitPlanContributionsByEmployer" onclick="toggleNextSibling(this);">$ 56,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DefinedBenefitPlanContributionsByEmployer</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_DefinedBenefitPlanContributionsByEmployerPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of contributions made by the company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_DefinedBenefitPlanContributionsByEmployerPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of salary deposits in tax deferred investment account.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_PercentageOfSalaryDepositsInTaxDeferredInvestmentAccount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase in the fair value of plan assets from contributions made by the employer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35743120&amp;loc=d3e1928-114920<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELSAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (10,118,103)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (7,643,124)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization of furniture and equipment</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">37,343</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">5,659</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets" onclick="toggleNextSibling(this);">48,006</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation and payments</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">2,614,619</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">3,134,973</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisitions:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">(22,902)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInInventories" onclick="toggleNextSibling(this);">(159,545)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInInventories</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(131,727)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(16,964)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">345,360</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" onclick="toggleNextSibling(this);">(239,800)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll and related liabilities</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" onclick="toggleNextSibling(this);">342,154</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" onclick="toggleNextSibling(this);">320,312</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCustomerDeposits', window );">Customer deposits</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInCustomerDeposits" onclick="toggleNextSibling(this);">(10,633)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInCustomerDeposits</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED IN OPERATING ACTIVITIES</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(7,055,428)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(4,438,944)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of restricted short-term investments</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireShortTermInvestments" onclick="toggleNextSibling(this);">(100,167)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireShortTermInvestments</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireShortTermInvestments" onclick="toggleNextSibling(this);">(50,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireShortTermInvestments</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Purchase of Pharmacy Creations, LLC, net of cash and advances</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" onclick="toggleNextSibling(this);">(636,374)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of furniture and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(173,986)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(20,003)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">(910,527)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">(70,003)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Cancelled common stock</a></td>
        <td class="num"><a title="us-gaap_PaymentsForRepurchaseOfCommonStock" onclick="toggleNextSibling(this);">(13,109)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRepurchaseOfCommonStock</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsForRepurchaseOfCommonStock" onclick="toggleNextSibling(this);">(191)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRepurchaseOfCommonStock</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payments on capital lease obligations</a></td>
        <td class="num"><a title="us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" onclick="toggleNextSibling(this);">(10,431)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from exercise of warrants and stock options</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromWarrantExercises" onclick="toggleNextSibling(this);">621,678</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromWarrantExercises</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants for cash, net of offering costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock" onclick="toggleNextSibling(this);">10,052,832</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">598,138</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">10,052,641</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET CHANGE IN CASH AND CASH EQUIVALENTS</a></td>
        <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(7,367,817)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">5,543,694</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, beginning of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">15,579,309</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">10,035,615</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, end of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">8,211,492</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">15,579,309</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxesPaidNet" onclick="toggleNextSibling(this);">800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxesPaidNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxesPaidNet" onclick="toggleNextSibling(this);">1,600</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxesPaidNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">3,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees', window );">Issuance of and adjustment to common stock and warrants to consulting firms for prepaid consulting fees</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees" onclick="toggleNextSibling(this);">319,786</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering', window );">Reclassification of deferred offering costs in connection with equity offering</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering" onclick="toggleNextSibling(this);">596,281</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for consulting services included in accounts payable and accrued expenses</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" onclick="toggleNextSibling(this);">139,444</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease', window );">Purchase of furniture and equipment with a capital lease</a></td>
        <td class="nump"><a title="IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease" onclick="toggleNextSibling(this);">$ 35,350</a><span style="display:none;white-space:normal;text-align:left;">IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of And Adjustment To Common Stock And Warrants To Consulting Firms For Prepaid Consulting Fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_IssuanceOfAndAdjustmentToCommonStockAndWarrantsToConsultingFirmsForPrepaidConsultingFees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase Of Furniture And Equipment With Capital Lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_PurchaseOfFurnitureAndEquipmentWithCapitalLease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reclassification Of Deferred Offering CostsIn Connectionwit Equity Offering</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ReclassificationOfDeferredOfferingCostsInConnectionwithEquityOffering</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInCustomerDeposits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInCustomerDeposits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to reacquire common stock during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt and payment of capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EYIAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">90,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">90,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">9,258,231</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">8,970,364</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">9,258,231</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">8,970,364</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Debt<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 10. DEBT</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">PC entered into a working capital line
of credit agreement with a financial institution on March 21, 2008 and subsequently renewed the agreement on September 6, 2013.
The line of credit agreement allowed PC to borrow up to $75,000 and was secured by a first security interest on all of PC&#146;s
business assets. The line of credit agreement was terminated following the Company&#146;s acquisition of PC, and no amounts were
borrowed, paid or outstanding during the period ended December 31, 2014 following the Company&#146;s acquisition of PC.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EVRAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 11, 2015</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">Imprimis Pharmaceuticals, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001360214<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,  2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-KnownSeasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityPublicFloat" onclick="toggleNextSibling(this);">$ 47,000,000</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityPublicFloat</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">9,342,935</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityPublicFloat</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_DocumentAndEntityInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 11. STOCKHOLDERS&#146; EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Issuances During the Year Ended December
31, 2013</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 7, 2013, after the effectiveness
of the registration statement on Form S-1 filed in connection with the Public Offering (as defined below), the Company effected
a one-for-five reverse stock split of its common stock and on February 8, 2013, the Company&#146;s common stock began trading
on The NASDAQ Capital Market on a split-adjusted basis. On September 10, 2014, the Company decreased the number of authorized shares
of its capital stock to 95,000,000, and the number of authorized shares of its common stock to 90,000,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 13, 2013, the Company closed a
public offering of its common stock (the &#147;Public Offering&#148;) and issued an aggregate of 1,840,000 shares of its common
stock at a per share price to the public of $5.25, and received net proceeds of $8,140,435, after deducting underwriter fees and
commissions and other offering expenses. The underwriters also exercised their option to purchase an additional 276,000 shares
of common stock from the Company at $5.25 per share to cover over-allotments on March 14, 2013. Net cash proceeds from the exercise
of the over-allotment option were $1,316,116. As contemplated by the underwriting agreement entered into with MDB Capital Group,
LLC, the lead underwriter for the Public Offering, at the closing of the Public Offering and the over-allotment exercise, the lead
underwriters received warrants (the &#147;Underwriter Warrants&#148;) to purchase up to an aggregate of 179,860 shares, or 8.5%
of the number of shares sold in the Public Offering (including 8.5% of shares sold pursuant to the exercise of the over-allotment
option). The Underwriter Warrants are exercisable at $5.25 per share (100% of the price to the public of the common stock sold
in the Public Offering), commencing on the closing date of the Public Offering and expire five years from the closing date of the
Public Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February and March 2013, the Company made
payments totaling $191 in connection with cancelled, fractional share amounts of common stock (35 common stock share equivalents)
in connection with the one-for-five reverse stock split effected February 7, 2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2013, the Company issued 40,000 shares
of common stock to Mark Baum, the Company&#146;s Chief Executive Officer and a director, related to the vesting of RSUs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2013, the Company issued 2,114
restricted shares of common stock to a consultant, valued at $10,750, in consideration for consulting services provided during
the year ended December 31, 2013. The fair value of the shares of common stock issued was recorded as stock-based compensation
during the year ended December 31, 2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2013, the
Company issued 40,000 restricted shares of common stock to Dr. Robert Kammer, a director and former consultant, valued at $282,997,
in consideration for consulting services provided during the years ended December 31, 2013 and 2012.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2013, the
Company issued a total of 219 shares of common stock as a result of stock option exercises. The Company received no cash proceeds
for the issuance of such shares upon the exercise pursuant to cashless exercise provisions of stock options to purchase 1,030 shares
of common stock with an exercise price of $4.00 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Issuances During the Year Ended December
31, 2014</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2014, the Company issued 6,868 shares
of restricted common stock, valued at $50,000, in connection with the resolution of a contract dispute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2014, the Company issued 4,000 shares
of restricted common stock to a consultant, valued at $29,160 in consideration for consulting services provided. The fair value
of the shares of common stock issued was recorded as stock-based compensation during the year ended December 31, 2014.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2014, the
Company issued a total of 227,216 shares of common stock as a result of stock option exercises. Of these, the Company received
net cash proceeds of $583,811 for the issuance of 160,777 shares of common stock upon the exercise of stock options to purchase
the same number of shares of common stock with exercise prices ranging from $3.68 to $4.00 and the Company received no cash proceeds
for the issuance of 66,439 shares of common stock upon the exercise pursuant to cashless exercise provisions of stock options to
purchase 146,652 shares of common stock with exercise prices ranging from $3.60 to $6.00 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2014, the
Company issued 1,954 shares of common stock to employees related to the vesting of RSUs. In connection with these common stock
issuances, the Company withheld 1,518 shares of common stock for payroll tax withholdings totaling $13,109.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2014,
the Company issued a total of 47,829 shares of common stock as a result of warrant exercises. Of these, the Company received gross
cash proceeds of $37,867 for the issuance of 6,391 shares of common stock upon the exercise of warrants to purchase the same number
of shares of common stock with an exercise price of $5.925 and the Company received no cash proceeds for the issuance of 41,438
shares of common stock upon the exercise pursuant to cashless exercise provisions of warrants to purchase 123,715 shares of common
stock with an exercise price of $5.25 per share.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2014,
27,218 shares of the Company&#146;s common stock underlying RSUs issued to directors vested, but the issuance and delivery of
these shares are deferred until the respective director resigns.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Preferred Stock </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2014 and 2013, the Company
had 5,000,000 shares of preferred stock, $0.001 par value, authorized and no shares of preferred stock issued and outstanding.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.75in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock Option Plan </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 17, 2007, the Company&#146;s
Board of Directors and stockholders adopted the Company&#146;s 2007 Incentive Stock and Awards Plan, which was subsequently amended
on November 5, 2008, February 26, 2012, July 18, 2012, May 2, 2013 and September 27, 2013 (as amended, the &#147;Plan&#148;).
As of December 31, 2014, the Plan provides for the issuance of a maximum of 5,000,000 shares of the Company&#146;s common stock.
The purpose of the Plan is to provide an incentive to attract and retain directors, officers, consultants, advisors and employees
whose services are considered valuable, to encourage a sense of proprietorship and to stimulate an active interest of such persons
in the Company&#146;s development and financial success. Under the Plan, the Company is authorized to issue incentive stock options
intended to qualify under Section 422 of the Internal Revenue Code, non-qualified stock options, RSUs and restricted stock. The
Plan is administered by the Compensation Committee of the Company&#146;s Board of Directors. The Company had 2,366,369 shares
available for future issuances under the Plan at December 31, 2014.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock Options</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the stock option activity
under the Plan for the year ended December 31, 2014 is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of shares</font></td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Avg. Exercise Price</font></td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Avg. Remaining Contractual Life</font></td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Aggregate Intrinsic Value</font></td>
    <td style="vertical-align: bottom; text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 44%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding - January 1, 2014</font></td>
    <td style="vertical-align: bottom; width: 2%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,328,790</font></td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.31</font></td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 2%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 10%; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options granted</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">245,886</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.35</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options exercised</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(307,429</font></td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.90</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options cancelled/forfeit</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(238,007</font></td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.68</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options outstanding - December 31, 2014</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,029,240</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.74</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.05</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,351,174</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td></tr>
<tr style="background-color: white">
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options exercisable</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">728,585</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.25</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.97</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,080,594</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td></tr>
<tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options vested and expected to vest</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">999,175</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.70</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.98</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td>
    <td style="vertical-align: bottom; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="vertical-align: bottom; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,319,475</font></td>
    <td style="vertical-align: bottom; line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value in the
table above represents the total pre-tax amount of the proceeds, net of exercise price, which would have been received by option
holders if all option holders had exercised and immediately sold all options with an exercise price lower than the market price
on December 31, 2014, based on the closing price of the Company&#146;s common stock of $7.50 on that date. The aggregate intrinsic
value of stock options exercised during the year ended December 31, 2014 was approximately $1,161,000.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal years 2014 and 2013, the
Company granted stock options to certain employees, directors and consultants. The stock options were granted with an exercise
price equal to the current market price of the Company&#146;s common stock, as reported by the securities exchange or quotation
system on which the common stock was then listed or quoted, at the grant date and have contractual terms ranging from three to
10 years. Vesting terms for options granted in fiscal years 2014 and 2013 to employees, directors and consultants typically included
one of the following vesting schedules: 25% or 33% of the shares subject to the option vest and become exercisable on the first
anniversary of the grant date and the remaining 75% or 67%, respectively, of the shares subject to the option vest and become exercisable
in equal quarterly installments thereafter over two or three years, respectively; quarterly vesting over a three year period; or
monthly, quarterly or 100% vesting associated with the provision or completion of services provided under contracts with consultants.
Certain option awards provide for accelerated vesting if there is a change in control (as defined in the Plan) and in the event
of certain modifications to the option award agreement.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option award
is estimated on the date of grant using the Black-Scholes-Merton option pricing model. Prior to April 1, 2013, expected volatilities
were based on historical volatility of the Company&#146;s common stock and other factors. Following April 1, 2013, the expected
volatility is based on the historical volatilities of the common stock of comparable publicly traded companies based on the Company&#146;s
belief that it has significantly changed its business operations and focus as of such date and as a result, it has limited relevant
historical data regarding the volatility of its stock price on which to base a meaningful estimate of expected volatility. The
expected term of options granted was determined in accordance with the &#147;simplified approach&#148; as the Company has limited,
relevant, historical data on employee exercises and post-vesting employment termination behavior. The expected risk-free interest
rate is based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of
the grant. The financial statement effect of forfeitures is estimated at the time of grant and revised, if necessary, if the actual
effect differs from those estimates. For option grants to employees and directors, the Company assigns a forfeiture factor of 10%.
These factors could change in the future, which would affect the determination of stock-based compensation expense in future periods.
Utilizing these assumptions, the fair value is determined at the date of grant.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below illustrates the fair
value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing
options granted to employees and directors:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2014</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted-average fair value of options granted</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.22</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.04</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected terms (in years)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.81 - 6.91</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.8-7 </font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">96 - 102%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">102 - 123%</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1.37 - 1.65%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.86 - 2.05%</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below illustrates the fair
value per share determined using the Black-Scholes-Merton option pricing model with the following assumptions used for valuing
options granted to consultants:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2014</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2013</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted-average fair value of options granted</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.15</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.63</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected terms (in years)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.5 - 10</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;2.33 - 10 </font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">78 - 97%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;80 - 366% </font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.10 - 1.68%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#160;0.30 - 2.45% </font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following table summarizes information about stock options
outstanding and exercisable at December 31, 2014:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options Outstanding</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Options Exercisable</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Average</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Contractual</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Range of Exercise Prices</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Life in Years</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 28%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$2.40 - $3.20</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.57</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.80</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 11%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.80</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$3.60 - $4.51</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">337,723</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.95</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.36</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">270,015</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4.42</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$5.49 - $7.71</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">190,557</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8.70</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.62</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">60,110</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.26</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$8.06 - $10.75</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">244,160</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7.03</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8.99</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">141,660</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9.01</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$28.00 - $80.00</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6,800</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.13</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">40.86</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6,800</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">40.86</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,029,240</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.05</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.74</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">728,585</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.25</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2014, there was approximately
$1,571,000 of total unrecognized compensation expense related to unvested stock options granted under the Plan. That expense is
expected to be recognized over the weighted-average remaining vesting period of 2.1 years. The stock-based compensation for all
stock options was $1,137,634 and $1,689,756 during the years ended December 31, 2014 and 2013, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Restricted Stock Units</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">RSU awards are granted subject to certain
vesting requirements and other restrictions, including performance and market based vesting criteria. The grant-date fair value
of the RSUs, which has been determined based upon the market value of the Company&#146;s common stock on the grant date, is expensed
over the vesting period of the RSUs. Unvested portions of RSUs issued to consultants are remeasured on an interim basis until vesting
criteria is met. On May 2, 2013, the Board of Directors of the Company amended and restated the Plan to provide for the issuance
of RSUs under the Plan.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Grants During the Year Ended December
31, 2013</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 2, 2013, the Company granted
1,250,000 RSUs to its Chief Executive Officer, Mark Baum, pursuant to the Plan. Of these RSUs, 200,000 will vest on the third anniversary
of the RSU grant date, subject to continued service to the Company and the remaining 1,050,000 RSUs will vest on the third anniversary
of the RSU grant date, subject to the satisfaction of certain market-based and continued service conditions (the &#147;Baum Performance
Equity Award&#148;). The market-based vesting criteria are separated into five equal tranches and require that the Company achieve
and maintain certain stock price targets ranging from $10 per share to $30 per share during the three year period following the
grant date. With certain limited exceptions, Mr. Baum must be employed with the Company on the third anniversary of the grant date
in order for the Baum Performance Equity Award to vest. These market-based vesting conditions are further described below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 16%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche</font></td>
    <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td>
    <td style="width: 66%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of Shares</font></td>
    <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td>
    <td style="width: 16%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Target Share Price</font></td></tr>
<tr>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 1</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">19.05% of the shares subject to the Baum Performance Equity Award</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$10.00 or greater</font></td></tr>
<tr>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 2</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">19.05% of the shares subject to the Baum Performance Equity Award</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$15.00 or greater</font></td></tr>
<tr>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 3</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">19.05% of the shares subject to the Baum Performance Equity Award</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$20.00 or greater</font></td></tr>
<tr>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 4</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">19.05% of the shares subject to the Baum Performance Equity Award</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$25.00 or greater</font></td></tr>
<tr>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 5</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">23.80% of the shares subject to the Baum Performance Equity Award</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$30.00 or greater</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For each respective tranche to vest
the following conditions must be met: (i) the Company&#146;s common stock must have an official closing price at or above the
Target Share Price for the respective tranche (each such date, a &#147;Trigger Date&#148;); (ii) during the period that includes
the Trigger Date and the immediately following 19 trading days (the &#147;Measurement Period&#148;), the arithmetic mean of the
20 closing prices of the Company&#146;s common stock during the Measurement Period must be at or above the Target Share Price
for such tranche; and (iii) with certain limited exceptions, Mr. Baum must be in continuous service with the Company through the
third anniversary of the grant date. Any unvested RSUs under the Baum Performance Equity Award will be forfeited on the third anniversary
of the grant date.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The earning and issuance of any shares
under the Baum Performance Equity Award that would exceed the number of shares available for grant and/or the applicable annual
per person grant limit for performance-based restricted stock units under the Plan as of the grant date of the Baum Performance
Equity Award were subject to approval by the Board of Directors and the Company&#146;s stockholders of increases tothe number
of shares available for grant and the applicable annual per person grant limit for performance-based restricted stock units under
the Plan. On May 2, 2013, the Board of Directors approved an amendment to the Plan to increase the number of shares available for
grant from 2,400,000 to 5,000,000 shares and the applicable annual per person grant limit from 600,000 to 1,250,000 shares and
on September 27, 2013, a majority of the Company&#146;s stockholders approved the amendment to the Plan. The 450,000 RSUs subject
to the Baum Performance Equity Award that were pending such approval were granted on that date.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Concurrent with the issuance of the
450,000 RSUs, Mr. Baum agreed to cancel 120,000 unvested RSUs previously granted to Mr. Baum in July 2012. As a result, the Company
has treated the issuance of the 450,000 RSUs as a modification of the RSU grant made to Mr. Baum in July 2012. The total compensation
cost to be recognized by the Company is equal to the original grant date fair value of the canceled RSUs plus any incremental cost
calculated as the excess of the fair value of the 450,000 RSUs over the fair value of the canceled 120,000 RSUs on the modification
date, which is September 27, 2013. The initial fair value of the 450,000 RSUs pursuant to the Baum Performance Equity Award granted
to Mr. Baum was $189,000. No incremental cost was associated with the exchange of RSUs as the fair value prior to modification
was more than after the modification. The 450,000 RSUs pursuant to the Baum Performance Equity Award were valued using a Monte
Carlo Simulation with a three year life, 75% volatility and a risk free interest rate of 0.64%.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The initial fair value of the 200,000
RSUs and 600,000 RSUs pursuant to the Baum Performance Equity Award granted to Mr. Baum was $3,515,090. The 600,000 RSUs pursuant
to the Baum Performance Equity Award were valued using a Monte Carlo Simulation with a three year life, 75% volatility and a risk
free interest rate of 0.30%.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 24, 2013, the Company granted
100,000 RSUs to a consultant that were to vest based on the satisfaction of certain market-based conditions subject to the consultant&#146;s
continued service, among other things. These market-based vesting conditions are further described below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 34%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche</font></td>
    <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td>
    <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of Shares</font></td>
    <td style="width: 1%; text-align: center; line-height: 115%">&#160;</td>
    <td style="width: 32%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Target Share Price</font></td></tr>
<tr>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 1</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20,000 shares</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$10.00 or greater</font></td></tr>
<tr>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 2</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20,000 shares</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$15.00 or greater</font></td></tr>
<tr>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 3</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20,000 shares</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$20.00 or greater</font></td></tr>
<tr>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 4</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20,000 shares</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$25.00 or greater</font></td></tr>
<tr>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Tranche 5</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20,000 shares</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$30.00 or greater</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For each respective tranche to vest
the following conditions must have been met: (i) the Company&#146;s common stock must have had an official closing price at or
above the Target Share Price for the respective tranche (each such date a &#147;Trigger Date&#148;); (ii) during the period that
included the Trigger Date and the immediately following 19 trading days (the &#147;Measurement Period&#148;), the arithmetic
mean of the 20 closing prices during the Measurement Period have been at or above the Target Share Price for such tranche ((i)
and (ii), the &#147;Stock Price Conditions&#148;); and (iii) with certain limited exceptions, 50% of the RSUs subject to a tranche
would vest on the quarterly anniversary of the grant date following the satisfaction of the Stock Price Conditions with respect
to that tranche, subject to the consultant being in continuous service with the Company on such quarterly anniversary and the remaining
50% would vest on the second anniversary of the grant date if (a) the Stock Price Conditions had been satisfied with respect to
that tranche prior to the second anniversary of the grant date and (b) the consultant was in continuous service with the Company
on the second anniversary of the grant date. All unvested RSUs would be forfeited on the second anniversary of the grant date.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The initial value of the 100,000 RSUs
with market-based vesting conditions granted to the consultant was $288,000, and as of December 31, 2013 the remeasured fair value
of those RSUs was $10,080. The 100,000 RSUs were valued using a Monte Carlo Simulation with a 2 year life (based on the grant date),
75%-85% volatility and risk free interest rates of 0.13%-0.36%. During March 2014, the Company terminated its agreement with a
consultant that provided for the grant of 100,000 RSUs that had vesting criteria based on the satisfaction of certain market-based
conditions subject to the consultant&#146;s continued service, among other things. Upon termination of the agreement, all 100,000
RSUs were forfeited and deemed reconveyed to the Company.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2013, the Company granted an
aggregate of 34,325 RSUs to its non-employee directors, valued at $271,854. The RSUs vest in full 13 months after the date of grant
subject to the director&#146;s continued service, but the issuance and delivery of these shares are deferred until the director
resigns. In September and October 2013, two directors resigned and forfeited all such RSUs.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2013, the Company issued
8,947 RSUs to a former director for his service to the Company as a director, valued at $39,814. The RSUs were to vest in full
13 months after the date of grant subject to the director&#146;s continued service, but the issuance and delivery of these shares
are deferred until the director resigns. All such RSUs were forfeited upon the director&#146;s resignation in September 2014.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2013, the Company granted
an aggregate of 10,418 RSUs to certain employees, valued at $42,498. The RSUs will vest in equal annual installments over a three-year
period.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Grants During the Year Ended December
31, 2014</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December 31, 2014,
the Company granted an aggregate of 26,492 RSUs to its non-employee directors valued at $200,015. These RSUs vest in equal quarterly
installments over a one year period subject to the director&#146;s continued service, but the issuance and delivery of these shares
are deferred until the director resigns.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of the Company&#146;s RSU
activity and related information for the year ended December 31, 2014 is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of RSUs</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Average Grant Date Fair Value</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 42%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">RSUs unvested - January 1, 2014</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,389,960</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 36%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.19</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">RSUs granted</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">26,492</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7.55</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">RSUs vested</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(30,690</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7.41</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">RSUs cancelled/forfeit</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(108,947</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.01</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">RSUs unvested at December 31, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,276,815</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3.20</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2014, the total unrecognized
compensation expense related to unvested RSUs was approximately $1,923,000 which is expected to be recognized over a weighted-average
period of 1.32 years, based on estimated vesting schedules. The stock-based compensation for RSU&#146;s was $1,332,176 and $822,137
during the years ended December 31, 2014 and 2013, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Warrants</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, the Company issues
warrants to purchase shares of the Company&#146;s common stock to investors, note holders, underwriters and to non-employees for
services rendered or to be rendered in the future.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Issuances During the Year Ended December
31, 2013</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2013, the Company issued
a warrant to purchase 30,000 shares of the Company&#146;s common stock to a consultant with an exercise price of $5.25 per share.
The warrants expire three years following the issuance date, and vest as follows: 10,000 shares vested immediately upon execution
of the consulting agreement, and the remaining shares vested in 4,000 share installments on each of the five monthly anniversaries
of the date of the consulting agreement, provided the consultant continued to provide services to the Company as of the applicable
vesting dates.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2013, the Company issued a warrant
to purchase 60,000 shares of the Company&#146;s common stock to a consultant with an exercise price of $8.50 per share, in consideration
for services to be provided over a six month term. The warrants expire five years following the issuance date, vested immediately,
are non-forfeitable, and became exercisable in January 2014. The Company recorded an initial stock-based prepaid consulting expense
for the fair value of the warrants totaling $319,786, which was being amortized over the length of the consulting service term.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Issuances During the Year Ended December
31, 2014</i></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company did not issue any warrants
during the year ended December 31, 2014.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A summary of warrant activity during
the year ended December 31, 2014 is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Number of Shares Subject to Warrants Outstanding</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted Avg.</font><br />
<font style="font: 10pt Times New Roman, Times, Serif">Exercise Price</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 54%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding - January 1, 2014</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 20%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">821,050</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 20%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.94</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Granted</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercised</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(130,106</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.28</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expired</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants outstanding and exercisable - December 31, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">690,944</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.05</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average remaining contractual life of the outstanding warrants in years - December 31, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.86</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each warrant is estimated
on the date of grant using the Black-Scholes-Merton option pricing model. The table below illustrates the fair value per share
determined by the Black-Scholes-Merton option pricing model with the following assumptions used for valuing the warrants issued
to consultants:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Year Ended</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2013</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Weighted-average fair value of warrants granted</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 24%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.12</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected terms (in years)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2.6-5</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expected volatility</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">85%-346%</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.32%-1.31%</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A list of the warrants outstanding as
of December 31, 2014 is included in the following table:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants Outstanding</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants Exercisable</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Expiration</font></td></tr>
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrant Series</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Issue Date</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Price</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Date</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 41%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants issued to a former major shareholder</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 9%; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4/25/2012</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">48,262</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.93</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 9%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">48,262</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 9%; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4/25/2015</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants issued in April 2012 private placement</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4/25/2012</font></td>
    <td>&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">496,537</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.93</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">496,537</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4/25/2015</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Underwriter Warrants</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2/7/2013</font></td>
    <td>&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">56,145</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.25</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">56,145</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2/7/2018</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants issued to investor relations consultant</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2/28/2013</font></td>
    <td>&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">30,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5.25</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">30,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2/28/2016</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Warrants issued to investor relations consultant</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7/19/2013</font></td>
    <td>&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">60,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8.50</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">60,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7/19/2018</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">690,944</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6.05</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">690,944</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The stock-based compensation for warrants
issued was $26,649 and $468,777 during the years ended December 31, 2014 and 2013, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded stock-based compensation
(including the amortization of stock-based prepaid consulting fees, issuance of common stock for services and accrual for stock-based
compensation) related to equity instruments granted to employees, directors and consultants as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2013</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Employees - selling and marketing</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">79,278</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8,298</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Employees - general and administrative</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,095,254</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,512,448</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Employees - research and development</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">156,568</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Directors - general and administrative</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">146,093</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">399,986</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Consultants - selling and marketing</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">88,406</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Consultants - general and administrative</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">146,799</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">843,301</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Consultants - research and development</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8,789</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">214,372</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,564,619</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3,134,973</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EOSAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenue', window );">Sales, net</a></td>
        <td class="nump"><a title="us-gaap_HealthCareOrganizationRevenue" onclick="toggleNextSibling(this);">$ 1,652,386</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_HealthCareOrganizationRevenue</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License revenues</a></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue" onclick="toggleNextSibling(this);">7,860</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_LicensesRevenue" onclick="toggleNextSibling(this);">10,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LicensesRevenue</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">1,660,246</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueNet" onclick="toggleNextSibling(this);">10,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense', window );">Cost of sales</a></td>
        <td class="num"><a title="us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense" onclick="toggleNextSibling(this);">(1,092,839)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">567,407</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="nump"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">10,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
        <td class="nump"><a title="us-gaap_SellingAndMarketingExpense" onclick="toggleNextSibling(this);">2,390,180</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SellingAndMarketingExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_SellingAndMarketingExpense" onclick="toggleNextSibling(this);">85,890</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SellingAndMarketingExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">8,087,316</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">5,994,907</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">236,660</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">1,616,082</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating expenses</a></td>
        <td class="nump"><a title="us-gaap_OperatingCostsAndExpenses" onclick="toggleNextSibling(this);">10,714,156</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingCostsAndExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingCostsAndExpenses" onclick="toggleNextSibling(this);">7,696,879</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingCostsAndExpenses</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(10,146,749)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(7,686,879)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(3,800)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump"><a title="us-gaap_InvestmentIncomeInterest" onclick="toggleNextSibling(this);">32,446</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentIncomeInterest</span><span></span></td>
        <td class="nump"><a title="us-gaap_InvestmentIncomeInterest" onclick="toggleNextSibling(this);">43,755</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InvestmentIncomeInterest</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
        <td class="nump"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">28,646</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">43,755</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (10,118,103)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (7,643,124)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share of common stock</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (1.11)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.88)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares of common stock outstanding, basic and diluted</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">9,132,989</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">8,656,822</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GrossProfit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of medical supplies consumed, for example, but not limited to, bandages, syringes and drugs, for patient care.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_HealthCareOrganizationMedicalSuppliesAndDrugsExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenues recognized by the entity from providing services to in-patients, outpatients, residents in facilities owned or operated by the entity, from insurance premiums, or from goods provided or services performed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventories<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5. INVENTORIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are comprised of over-the-counter
retail pharmacy products, commercial pharmaceutical products, related laboratory supplies and active pharmaceutical ingredients.
The composition of inventories as of December 31, 2014 was as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2014</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Raw materials</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 24%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">146,300</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Work in progress</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">97,801</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Finished goods</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">128,634</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total inventories</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">372,735</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.6)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 6<br><br> -Subparagraph a, b, c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Restricted Short-Term Investment<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_RestrictedShortTermInvestmentDisclosureAbstract', window );"><strong>Restricted Short-term Investment</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Restricted Short-Term Investment</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4. RESTRICTED SHORT-TERM INVESTMENTS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The restricted short-term investments
at December 31, 2014 consist of certificate of deposits, which are classified as held-to-maturity. At December 31, 2014, the restricted
short-term investments were recorded at amortized cost which approximates fair value.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2014, the certificate
of deposits of $150,264 were classified as a current asset. The certificates of deposit are required as collateral under the Company&#146;s
corporate credit card agreement and office lease agreement and automatically renew every twelve months.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_RestrictedShortTermInvestmentDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_RestrictedShortTermInvestmentDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 16. SUBSEQUENT EVENTS </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has performed an evaluation of
events occurring subsequent to December 31, 2014 through the filing date of this Annual Report on Form 10-K (the &#147;Annual
Report&#148;). Based on its evaluation, nothing other than the events described below needs to be disclosed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From January 1, 2015 through the filing date
of this Annual Report, the Company issued a total of 12,658 shares of common stock as a result of warrant exercises. The Company
received gross cash proceeds of $74,998 for the issuance of such shares upon the exercise on a cash basis to purchase the same
number of shares of common stock with an exercise price of $5.925.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2015, the Company issued 8,521 shares
of its common stock in connection with RSUs which had been awarded to a non-employee director and vested, but were not issued until
the resignation of the director on January 1, 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 1, 2015, the Company completed the
acquisition of all of the outstanding capital stock of Park from the previous owners (the &#147;Park Sellers,&#148; and such
transaction, the &#147;Park Acquisition&#148;), pursuant to a Stock Purchase Agreement, dated November 26, 2014, by and among
the Company, the Park Sellers, Park and the Seller Representative (as defined therein) (the &#147;Park Purchase Agreement&#148;).
Park is a compounding pharmacy accredited by the Pharmacy Compounding Accreditation Board and is located in Irvine, California.
On January 1, 2015 (the &#147;Park Closing Date&#148;), in connection with the closing of the Park Acquisition (the &#147;Park
Closing&#148;), the Company paid to the Park Sellers an aggregate cash purchase price of $3,000,000, net of fees and expenses,
subject to adjustment based on the final calculation of Park&#146;s working capital and certain other financial information, and
issued to the Park Sellers 63,525 shares of the Company&#146;s common stock, valued at $500,000 based on the average closing price
of the common stock for the 10 trading days preceding the Park Closing. In addition, the Company is obligated to make 12 quarterly
cash payments to the Park Sellers collectively of $53,125 each over the three years following the Park Closing, totaling $637,500.
The Park Sellers have the option to receive the last six of such quarterly payments, totaling up to an aggregate of $318,750, in
the form of 6,749 shares of the Company&#146;s common stock for each such payment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Park Acquisition, one
of the Park Sellers, Dennis Saadeh, entered into an employment agreement with the Company, effective as of January 1, 2015, to
act as Senior Director of Corporate Development of Park. In addition, on January 1, 2015, Park and an entity affiliated with and
controlled by the Park Sellers entered into a Commercial Lease Agreement, for the lease of certain premises to Park of approximately
4,500 square feet of lab and office space. The monthly rent amount is $9,788 and includes annual increases of approximately 3%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2015, the Company entered into
a lease agreement for approximately 8,602 square feet of lab, warehouse and office space in Roxbury, New Jersey. The current lease
term expires on July 31, 2022. The monthly rent amount is $9,548 and includes annual increases of approximately 3.75%, and the
lease allows for the first five months of rent amounts to be abated. This facility is currently undergoing construction and being
built to serve as an outsourcing facility and pharmacy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2015, the Company appointed Andrew
R. Boll&#146;s as its Chief Financial Officer, and entered into an amended and restated employment agreement (the &#147;CFO Employment
Agreement&#148;) with Mr. Boll, which amends, restates and supersedes in its entirety Mr. Boll&#146;s prior employment agreement
with the Company dated February 1, 2012. The CFO Employment Agreement provides for the following, among other things: (i) a term
of three years, (ii) an annual base salary of $200,000; (iii) eligibility to receive an annual cash bonus in an amount equal to
at least 20% of his then-current annual base salary and a target of 50% of his then-current annual base salary, with the precise
amount to be determined at the discretion of the Company&#146;s Board of Directors; (iv) if Mr. Boll is terminated other than
for cause, by death or by disability or if he terminates his employment with the Company for good reason (any such termination,
a &#147;Qualifying Termination&#148;), then Mr. Boll will be entitled to receive, subject to the satisfaction of certain conditions,
continued payments of his then-current annual base salary for six months following the date of his termination and a lump-sum payment
equal to the pro-rated portion of his minimum annual cash bonus for the then-current year; and (v) in the event of a Qualifying
Termination of Mr. Boll on or within 12 months following a change of control, Mr. Boll will be entitled to receive, subject to
the satisfaction of certain conditions, continued payments of his then-current annual base salary for six months following the
date of his termination, a lump-sum payment equal to the pro-rated portion of his minimum annual cash bonus for the then-current
year, and immediate vesting of all of his outstanding equity awards as of the date of his termination. In connection with Mr. Boll&#146;s
appointment as the Company&#146;s Chief Financial Officer, the Company&#146;s Board of Directors has granted the following equity
awards to Mr. Boll, in each case under the Plan: (i) a performance-based restricted stock unit award of up to 157,500 shares of
the Company&#146;s common stock, which will vest if the Company achieves and maintains certain stock price vesting targets during
the three-year period following the date of grant of the award and subject to Mr. Boll&#146;s continued employment with the Company
on the third anniversary of the date of grant, subject to certain exceptions, and (ii) a RSU award of up to 30,000 shares of the
Company&#146;s common stock, which will vest on the third anniversary of the date of grant, subject to Mr. Boll&#146;s continued
employment with the Company on such date and accelerated vesting of all unvested shares thereunder upon the occurrence of a change
in control (as defined in the Plan), and is subject to the Company&#146;s standard form of award agreement for RSUs granted under
the Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2015, the Company appointed John
P. Saharek as of the Company&#146;s Chief Commercial Officer, effective as of February 1, 2015, and entered into an employment
agreement (the &#147;CCO Employment Agreement&#148;) with Mr. Saharek. The CCO Employment Agreement provides for the following,
among other things: (i) a term of three years, (ii) an annual base salary of $220,000; (iii) eligibility to receive an annual
cash bonus in an amount equal to a target of 50% of his then-current annual base salary, with the precise amount to be determined
at the discretion of the Company&#146;s Board of Directors; (iv) in the event of a Qualifying Termination of Mr. Saharek, Mr.
Saharek will be entitled to receive, subject to the satisfaction of certain conditions, continued payments of his then-current
annual base salary for six months following the date of his termination; and (v) in the event of a Qualifying Termination of Mr.
Saharek on or within 12 months following a change of control, then Mr. Saharek will be entitled to receive, subject to the satisfaction
of certain conditions, continued payments of his then-current annual base salary for 12 months following the date of his termination
and immediate vesting of all of his outstanding equity awards as of the date of his termination. In connection with Mr. Saharek&#146;s
appointment as the Company&#146;s Chief Commercial Officer, the Company&#146;s Board of Directors has granted the following
equity awards to Mr. Saharek, in each case under the Plan: (i) a stock option award of up to 90,000 shares of the Company&#146;s
common stock, which has a term of 10 years and an exercise price of $7.37, will vest in equal quarterly installments over a three-year
period, subject to Mr. Saharek&#146;s continued employment with the Company at the end of such period and accelerated vesting
of all unvested shares thereunder upon the occurrence of a change in control (as defined in the Plan), and is subject to the Company&#146;s
standard form of award agreement for stock options granted under the Plan, and (ii) a RSU award of up to 30,000 shares of the
Company&#146;s common stock, which will vest on the third anniversary of the date of grant, subject to Mr. Saharek&#146;s continued
employment with the Company on such date and accelerated vesting of all unvested shares thereunder upon the occurrence of a change
in control (as defined in the Plan), and is subject to the Company&#146;s standard form of award agreement for restricted stock
units granted under the Plan.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 12. INCOME TAXES </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to taxation in
the United States and California. The provision for income taxes for the years ended December 31, 2014 and 2013 are summarized
below:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2013</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Current:</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Federal</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">State</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,800</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total current</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,800</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Deferred:</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Federal</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">11,082,459</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8,075,342</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">State</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">3,100,627</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,233,726</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Change in valuation allowance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(14,183,086</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(10,309,068</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total deferred</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Income tax provision (benefit)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,800</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Income taxes for the years ended December
31, 2014 and 2013, are recorded in the general and administrative expenses line item in the accompanying consolidated statements
of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of income taxes
computed by applying the statutory U.S. income tax rate to the Company&#146;s loss before income taxes to the income tax
provision is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2013</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">U.S. federal statutory tax rate</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">35.00</font></td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">35.00</font></td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Benefit of lower tax brackets</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">State tax benefit, net</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.03</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Research and development credits</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.43</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Employee stock based compensation</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1.03</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(4.72</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Loss on debt conversion</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.21</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.08</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(32.76</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(29.63</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Effective income tax rate</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(0.03</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)%</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">0.00</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">%</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities
reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. Significant components of the Company&#146;s deferred tax assets are as
follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2013</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Deferred tax assets (liabilities):</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 58%; padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">NOL&#146;s</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,922,914</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">7,364,058</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation and amortization</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(6,787</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(340</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">64,806</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">129,191</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Research &#38; development credits</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">555,945</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">563,485</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Deferred stock compensation</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,646,208</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,252,674</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Unrealized gain or loss on investments</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 20pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total deferred tax assets</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">14,183,086</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,309,068</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Valuation allowance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(14,183,086</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(10,309,068</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Net deferred tax assets</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Realization of deferred tax assets is
dependent upon future earnings, if any, the timing and amount of which are uncertain. Accordingly, the net deferred tax assets
have been fully offset by a valuation allowance. The valuation allowance increased by approximately $3,900,000 and $3,000,000 in
2014 and 2013, respectively.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2014, the Company
had net operating loss carryforwards for federal income tax purposes of approximately $27,800,000 which expire beginning in the
year 2027 and federal research and development tax credits of approximately $350,000 which expire beginning in the year 2026. As
of December 31, 2014, the Company had net operating loss carryforwards for state income tax purposes of approximately $24,600,000
which expire beginning in the year 2017 and state research and development tax credits of approximately $300,00 which do not expire.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The deferred tax asset at December 31,
2014 does not include approximately $30,000 and $30,000 of excess tax benefits from employee stock option exercises and RSU vests
that are a component of the federal and California net operating loss carryover, respectively. The Company&#146;s stockholders&#146;
equity balance will be increased if and when such excess tax benefits are ultimately realized.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Utilization of the net operating losses
may be subject to substantial annual limitation due to federal and state ownership change limitations provided by the Internal
Revenue Code and similar state provisions. Such annual limitations could result in the expiration of the net operating losses
ad credits before their utilization. The Company has not performed an analysis to determine the limitation of the net operating
loss and research development credit carryforwards.&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company did not have any unrecognized
tax benefits of as of December 31, 2014 and 2013, all of which is offset by a full valuation allowance. These unrecognized tax
benefits, if recognized, would not affect the effective tax rate.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.75in">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 8. INTANGIBLE ASSETS AND GOODWILL</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company&#146;s intangible assets at December 31, 2014
consisted of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Amortization</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">periods</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Net</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(in years)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cost</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">amortization</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">carrying value</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 38%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Customer relationships</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 13%; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10-15 years</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">596,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(36,740</font></td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 13%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">559,260</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Trade name</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(750</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,250</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Non-competition covenant</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4 years</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(9,375</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">40,625</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">State pharmacy licenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">25 years</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,141</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">6,859</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">659,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(48,006</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">610,994</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Amortization expense for intangible assets for the year ended
December 31, 2014 was as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Customer relationships</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 24%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">36,740</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Trade name</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">750</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Non-competition covenant</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">9,375</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">State pharmacy licenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,141</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">48,006</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Estimated future amortization expense for the Company&#146;s
intangible assets at December 31, 2014 is as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Years ending December 31,</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 24%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">67,087</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">67,087</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">67,087</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">57,712</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">53,837</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">298,184</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">610,994</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The changes in the carrying value of
the Company&#146;s goodwill during the year ended December 31, 2014 were as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at January 1, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">PC Acquisition</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="width: 24%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">331,621</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2014</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">331,621</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EJPAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Restricted Stock Units Activity (Details) (Restricted Stock Units [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Restricted Stock Units [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Outstanding, Beginning balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">1,389,960</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">26,492</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1', window );">Number of RSUs vested</a></td>
        <td class="num"><a title="IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">(30,690)</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs cancelled/forfeit</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">(108,947)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Outstanding, Ending balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">1,276,815</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 3.19</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, RSUs granted</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 7.55</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, RSUs vested</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 7.41</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, RSUs cancelled/forfeit</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 3.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending balance</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue[us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember]" onclick="toggleNextSibling(this);">$ 3.20</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_RestrictedStockUnitsRSUMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Vested</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(2)(iii)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 6. PREPAID EXPENSES AND OTHER CURRENT ASSETS</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expenses and other current assets
consisted of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2014</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2013</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid stock-based consulting expenses</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">26,649</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid rent</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">16,288</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid insurance</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">123,776</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">39,166</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other prepaid expenses and deposits</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">116,625</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">22,964</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total prepaid expenses and other current assets</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">240,401</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">105,067</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Furniture and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Furniture and Equipment</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 7. FURNITURE AND EQUIPMENT</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Furniture and equipment consisted of
the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2014</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2013</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Furniture and equipment, net:</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 62%; padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Computer software and hardware</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">52,576</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 16%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">24,536</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Furniture and equipment</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">154,215</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10,449</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Lab and pharmacy equipment</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">61,868</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Leasehold improvements</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">20,172</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">288,831</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">34,985</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Accumulated depreciation and amortization</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(45,436</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(8,093</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">243,395</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">26,892</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded depreciation and
amortization expense of $37,343 and $5,659 during the years ended December 31, 2014 and 2013, respectively.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>NOTE 9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts payable and accrued expenses
consisted of the following:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2014</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2013</b></font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts payable</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">698,806</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">261,924</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Deferred rent</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,975</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Building lease liability(1)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">73,552</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other accrued expenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">39,000</font></td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(2)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total accounts payable and accrued expenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">816,333</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">311,924</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less: Current portion</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(786,675</font></td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(311,924</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Non-current total accounts payable and accrued expenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">29,658</font></td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%">
<tr>
    <td style="width: 24px">&#160;</td>
    <td style="vertical-align: top; width: 24px; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1)</font></td>
    <td style="vertical-align: top; text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">In September 2014, the Company relocated its primary operations to a 7,565 square foot office facility in San Diego, California. As of December 31, 2014, the Company was marketing its previous office space (3,874 square feet) as a sublease through its remaining lease term. The Company recognized a loss of approximately $117,000 during the year ended December 31, 2014, related to the estimated remaining lease liability, net of expected sublease income. The obligations were discounted based on current prevailing market rates. This loss is included in rent expense for the year ended December 31, 2014 (see Note 14).</font></td></tr>
<tr>
    <td style="line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; text-align: justify; line-height: 115%">&#160;</td></tr>
<tr>
    <td>&#160;</td>
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(2)</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">The amount consists of a $39,000 stock-based compensation accrual at December 31, 2014 for stock options to be granted for services performed. The stock-based compensation expense related to restricted common stock issuances and accruals was $39,000 and $143,553 during the years ended December 31, 2014 and 2013, respectively.</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: -0.75in">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a),20,24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 24<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax asset valuation allowance</a></td>
        <td class="nump"><a title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" onclick="toggleNextSibling(this);">$ 3,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" onclick="toggleNextSibling(this);">$ 3,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" onclick="toggleNextSibling(this);">27,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_FederalNetOperatingLossExpirationDate', window );">Federal net operating loss expiration date</a></td>
        <td class="text">2027<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_FederalResearchAndDevelopmentTaxCredits', window );">Federal research and development tax credits</a></td>
        <td class="nump"><a title="IMMY_FederalResearchAndDevelopmentTaxCredits" onclick="toggleNextSibling(this);">350,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_FederalResearchAndDevelopmentTaxCredits</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_FederalResearchAndDevelopmentTaxCreditsExpirationDate', window );">Federal research and development tax credits expiration date</a></td>
        <td class="text">2026<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" onclick="toggleNextSibling(this);">24,600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StateNetOperatingLossExpirationDate', window );">State net operating loss expiration date</a></td>
        <td class="text">2017<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StateResearchAndDevelopmentTaxCredits', window );">State research and development tax credits</a></td>
        <td class="nump"><a title="IMMY_StateResearchAndDevelopmentTaxCredits" onclick="toggleNextSibling(this);">30,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StateResearchAndDevelopmentTaxCredits</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossCurrent', window );">Deferrerd tax asset</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsGrossCurrent" onclick="toggleNextSibling(this);">30,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsGrossCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther', window );">Deferrerd tax asset excess tax benefits</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther" onclick="toggleNextSibling(this);">$ 30,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_FederalNetOperatingLossExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Federal net operating loss expiration date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_FederalNetOperatingLossExpirationDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_FederalResearchAndDevelopmentTaxCredits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Federal Research And Development Tax Credits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_FederalResearchAndDevelopmentTaxCredits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_FederalResearchAndDevelopmentTaxCreditsExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Federal Research And Development Tax Credits Expiration Date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_FederalResearchAndDevelopmentTaxCreditsExpirationDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StateNetOperatingLossExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State net operating loss expiration date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StateNetOperatingLossExpirationDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StateResearchAndDevelopmentTaxCredits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State Research And Development Tax Credits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StateResearchAndDevelopmentTaxCredits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31938-109318<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Asset<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from other compensation and benefits not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32123-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5OAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Reconciliation (Details)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory tax rate</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">35.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" onclick="toggleNextSibling(this);">35.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets', window );">Benefit of lower tax brackets</a></td>
        <td class="num"><a title="IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets" onclick="toggleNextSibling(this);">(1.00%)</a><span style="display:none;white-space:normal;text-align:left;">IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets</span><span></span></td>
        <td class="num"><a title="IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets" onclick="toggleNextSibling(this);">(1.00%)</a><span style="display:none;white-space:normal;text-align:left;">IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax benefit, net</a></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">(0.03%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" onclick="toggleNextSibling(this);">0.43%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends', window );">Employee stock based compensation</a></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" onclick="toggleNextSibling(this);">(1.03%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends</span><span></span></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" onclick="toggleNextSibling(this);">(4.72%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_EffectiveIncomeTaxRateLossOnDebtConversion', window );">Loss on debt conversion</a></td>
        <td class="nump"><a title="IMMY_EffectiveIncomeTaxRateLossOnDebtConversion" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_EffectiveIncomeTaxRateLossOnDebtConversion</span><span></span></td>
        <td class="nump"><a title="IMMY_EffectiveIncomeTaxRateLossOnDebtConversion" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_EffectiveIncomeTaxRateLossOnDebtConversion</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" onclick="toggleNextSibling(this);">(0.21%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</span><span></span></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" onclick="toggleNextSibling(this);">(0.08%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(32.76%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(29.63%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
        <td class="num"><a title="us-gaap_EffectiveIncomeTaxRateContinuingOperations" onclick="toggleNextSibling(this);">(0.03%)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</span><span></span></td>
        <td class="nump"><a title="us-gaap_EffectiveIncomeTaxRateContinuingOperations" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effecticve Income Tax Rate Benefit Of Lower Tax Brackets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_EffecticveIncomeTaxRateBenefitOfLowerTaxBrackets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_EffectiveIncomeTaxRateLossOnDebtConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective Income Tax Rate Loss On Debt Conversion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_EffectiveIncomeTaxRateLossOnDebtConversion</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for dividend paid to employee stock ownership plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock Based Compensation Granted to Employees Directors Consultants (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation related to equity instruments granted to related parties</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 2,564,619</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 3,134,973</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=IMMY_EmployeesMember', window );">Employees [Member] | Selling And Marketing [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation related to equity instruments granted to related parties</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=IMMY_SellingAndMarketingMember;us-gaap_TitleOfIndividualAxis=IMMY_EmployeesMember]" onclick="toggleNextSibling(this);">79,278</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= IMMY_SellingAndMarketingMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_EmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=IMMY_SellingAndMarketingMember;us-gaap_TitleOfIndividualAxis=IMMY_EmployeesMember]" onclick="toggleNextSibling(this);">8,298</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= IMMY_SellingAndMarketingMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_EmployeesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=IMMY_EmployeesMember', window );">Employees [Member] | General And Administrative [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation related to equity instruments granted to related parties</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=IMMY_GeneralAndAdministrativeMember;us-gaap_TitleOfIndividualAxis=IMMY_EmployeesMember]" onclick="toggleNextSibling(this);">2,095,254</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= IMMY_GeneralAndAdministrativeMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_EmployeesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=IMMY_GeneralAndAdministrativeMember;us-gaap_TitleOfIndividualAxis=IMMY_EmployeesMember]" onclick="toggleNextSibling(this);">1,512,448</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= IMMY_GeneralAndAdministrativeMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_EmployeesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=IMMY_EmployeesMember', window );">Employees [Member] | Research And Development [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation related to equity instruments granted to related parties</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=IMMY_ResearchAndDevelopmentMember;us-gaap_TitleOfIndividualAxis=IMMY_EmployeesMember]" onclick="toggleNextSibling(this);">156,568</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= IMMY_ResearchAndDevelopmentMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_EmployeesMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Directors [Member] | General And Administrative [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation related to equity instruments granted to related parties</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=IMMY_GeneralAndAdministrativeMember;us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember]" onclick="toggleNextSibling(this);">146,093</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= IMMY_GeneralAndAdministrativeMember<br>/ us-gaap_TitleOfIndividualAxis<br>= us-gaap_DirectorMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=IMMY_GeneralAndAdministrativeMember;us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember]" onclick="toggleNextSibling(this);">399,986</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= IMMY_GeneralAndAdministrativeMember<br>/ us-gaap_TitleOfIndividualAxis<br>= us-gaap_DirectorMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=IMMY_ConsultantMember', window );">Consultant [Member] | Selling And Marketing [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation related to equity instruments granted to related parties</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=IMMY_SellingAndMarketingMember;us-gaap_TitleOfIndividualAxis=IMMY_ConsultantMember]" onclick="toggleNextSibling(this);">88,406</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= IMMY_SellingAndMarketingMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_ConsultantMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=IMMY_ConsultantMember', window );">Consultant [Member] | General And Administrative [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation related to equity instruments granted to related parties</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=IMMY_GeneralAndAdministrativeMember;us-gaap_TitleOfIndividualAxis=IMMY_ConsultantMember]" onclick="toggleNextSibling(this);">146,799</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= IMMY_GeneralAndAdministrativeMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_ConsultantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=IMMY_GeneralAndAdministrativeMember;us-gaap_TitleOfIndividualAxis=IMMY_ConsultantMember]" onclick="toggleNextSibling(this);">843,301</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= IMMY_GeneralAndAdministrativeMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_ConsultantMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=IMMY_ConsultantMember', window );">Consultant [Member] | Research And Development [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation related to equity instruments granted to related parties</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=IMMY_ResearchAndDevelopmentMember;us-gaap_TitleOfIndividualAxis=IMMY_ConsultantMember]" onclick="toggleNextSibling(this);">$ 8,789</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= IMMY_ResearchAndDevelopmentMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_ConsultantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=IMMY_ResearchAndDevelopmentMember;us-gaap_TitleOfIndividualAxis=IMMY_ConsultantMember]" onclick="toggleNextSibling(this);">$ 214,372</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= IMMY_ResearchAndDevelopmentMember<br>/ us-gaap_TitleOfIndividualAxis<br>= IMMY_ConsultantMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=IMMY_ConsultantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=IMMY_ConsultantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=IMMY_EmployeesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=IMMY_EmployeesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZF">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Schedule of Lease Equipment Under Capital Lease</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases equipment under capital
leases with an interest rate of 4.25% per annum. At December 31, 2014, future payments under the Company&#146;s capital leases
were as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year ending December 31,</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 24%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">25,477</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">19,321</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">44,798</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less amount representing interest</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,718</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Present value of future minimum lease payments</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">43,080</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less current portion</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(24,112</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Capital lease obligations, net of current portion</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">18,968</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Payments Under Leases</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 65%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 32%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">492,503</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">468,997</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">481,443</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">495,938</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">257,039</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">478,473</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,674,393</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6455398&amp;loc=d3e45280-112737<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ETH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets and Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_AcquisitionOfRelatedPartyGoodwill', window );">PC Acquisition</a></td>
        <td class="nump"><a title="IMMY_AcquisitionOfRelatedPartyGoodwill" onclick="toggleNextSibling(this);">331,621</a><span style="display:none;white-space:normal;text-align:left;">IMMY_AcquisitionOfRelatedPartyGoodwill</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending</a></td>
        <td class="nump"><a title="us-gaap_Goodwill" onclick="toggleNextSibling(this);">$ 331,621</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Goodwill</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_AcquisitionOfRelatedPartyGoodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Acquisition Of Related Party Goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_AcquisitionOfRelatedPartyGoodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Goodwill</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 14. COMMITMENTS AND CONTINGENCIES</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Capital Leases</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company leases equipment under capital
leases with an interest rate of 4.25% per annum. At December 31, 2014, future payments under the Company&#146;s capital leases
were as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year ending December 31,</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 24%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">25,477</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">19,321</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">44,798</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less amount representing interest</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(1,718</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Present value of future minimum lease payments</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">43,080</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Less current portion</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(24,112</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Capital lease obligations, net of current portion</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">18,968</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The value of the equipment under capital
leases as of December 31, 2014 was $52,687, with related accumulated depreciation of $8,656.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><b>Operating Leases</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2014, the Company entered into
a lease agreement for 7,565 square feet of office space that commenced on September 1, 2014 and continues until October 31, 2018.
Monthly rent began on September 1, 2014 in the amount of $20,426, with a 3% increase in the base rent amount on an annual basis.
The lease agreement allows for the monthly rent amount to be abated for two months at various times during the lease agreement.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2013, the Company entered into
a lease agreement for 3,784 square feet of office space that commenced on May 1, 2013 and continues until September 30, 2016. Monthly
rent began on May 1, 2013 in the amount of $10,406, with a 3% increase in the base rent amount on an annual basis. The lease agreement
allows for the monthly rent amount to be abated for five months at various times during the lease agreement. The Company entered
into a sublease agreement in February 2015 to sublet 3,874 square feet of its previously occupied offices through the remaining
term of the lease.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2010, PC entered into a lease
agreement for 3,137 square feet of office and laboratory space that commenced on January 1, 2010 and continues until December 31,
2015. Monthly rent began on January 1, 2010 in the amount of $3,594.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Rent expense for the years ended December
31, 2014 and 2013 was $306,465 and $103,191, respectively. The following represents future annual minimum lease payments, including
lease payments related to lease agreements entered into in January and February 2015 (see Note 16), and net of expected sublease
income, as of December 31, 2014:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 65%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 32%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">492,503</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2016</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">468,997</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2017</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">481,443</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2018</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">495,938</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2019</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">257,039</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Thereafter</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">478,473</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,674,393</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Legal</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In the ordinary course of business,
the Company may face various claims brought by third parties and the Company may, from time to time, make claims or take legal
actions to assert the Company&#146;s rights, including intellectual property disputes, contractual disputes and other commercial
disputes. Any of these claims could subject the Company to litigation. Management believes the outcomes of currently pending claims
are not likely to have a material effect on the Company&#146;s consolidated financial position and results of operations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Indemnities</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the indemnification provisions
contained in the Company&#146;s charter documents, the Company generally enters into separate indemnification agreements with
each of the Company&#146;s directors and officers. These agreements require the Company, among other things, to indemnify the
director or officer against specified expenses and liabilities, such as attorneys&#146; fees, judgments, fines and settlements,
paid by the individual in connection with any action, suit or proceeding arising out of the individual&#146;s status or service
as the Company&#146;s director or officer, other than liabilities arising from willful misconduct or conduct that is knowingly
fraudulent or deliberately dishonest, and to advance expenses incurred by the individual in connection with any proceeding against
the individual with respect to which the individual may be entitled to indemnification by the Company. The Company also indemnifies
its lessors in connection with its facility leases for certain claims arising from the use of the facilities. These indemnities
do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically,
the Company has not been obligated nor incurred any payments for these obligations and, therefore, no liabilities have been recorded
for these indemnities in the accompanying consolidated balance sheets.&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Urigen License</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On October
24, 2014, (the &#147;Urigen Effective Date&#148;), the Company entered into a license agreement (the &#147;Urigen License&#148;)
with Urigen Pharmaceuticals, Inc. (&#147;Urigen&#148;), pursuant to which Urigen granted to the Company a license under certain
U.S. patents and patent applications to develop and sell in the U.S. Urigen&#146;s URG101 product (&#147;HLA&#148;), a heparin
and alkalinized lidocaine compounded formulation, for the prevention or treatment of disorders of the lower urinary tract. Such
license is non-exclusive; provided that, between April 24, 2015 and October 24, 2015, the Company will have the right, at its option,
to convert such non-exclusive license to an exclusive license for the remaining term of the Urigen License, subject only to certain
specified existing sublicenses (the &#147;Existing Sublicenses&#148;).</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As consideration
for the license granted under the Urigen License, the Company agreed to pay Urigen annual tiered royalties based on sales of HLA,
subject to certain minimum annual royalty payments. The annual tiered royalties consist of the greater of (i) $0.50 per dose, and
(ii) 15% - 20% of its net sales of HLA, with the royalty amount within such range depending on the Company&#146;s aggregate sales
of HLA during the period to which the royalty payment applies. The minimum annual royalty payment consists of (a) for the 2015
calendar year, the greater of (i) 110% of the aggregate royalties paid to Urigen under the Existing Sublicenses during the preceding
12 months, on a prorated basis, and (ii) $800,000, less the aggregate royalties paid to Urigen under the Existing Sublicenses during
the 2015 calendar year, and (b) for each calendar year thereafter, 110% of the aggregate amount owed by the Company to Urigen under
the Urigen License during the prior calendar year. The Company is obligated to pay such royalties beginning with its first commercial
sale of HLA and continuing until the expiration of the patents subject to the license granted under the Urigen License. The Company
has also agreed to use commercially reasonable efforts to develop and commercialize HLA according to the terms of a diligence plan
agreed to by the parties, which efforts will include, without limitation, the Company&#146;s investment of $2 million in commercialization
efforts of HLA, which investment and timeline can be adjusted dependent on market circumstances, and is expected to be incurred
over 18-24 months following the Urigen Effective Date.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to certain conditions and each
party&#146;s right to terminate the Urigen License earlier under certain circumstances, the Urigen License will continue in effect
until the expiration of the Company&#146;s royalty obligations under the Urigen License. The Urigen License terminates upon the
first commercial sale of HLA by Urigen, its affiliates, or a third party after the U.S. Food and Drug Administration (the &#147;FDA&#148;)
grants Urigen approval to market HLA in the U.S., if market approval is granted. The Company shall have the option, at its discretion,
to become a non-exclusive distributor of HLA following the FDA granting Urigen such market approval. No royalty amounts have been
paid or accrued under the Urigen License during the year ended December 31, 2014.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>PCCA License Agreement </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 30, 2012, the Company entered
into a license agreement with Professional Compounding Centers of America (&#147;PCCA&#148;), pursuant to which PCCA has granted
to the Company and its affiliates certain exclusive rights under PCCA&#146;s proprietary formulations, other technologies and
data, and the Company has agreed to pay to PCCA certain royalties on net sales relating to the sale of certain potential future
FDA-approved products that the Company may produce, which royalties will range from 4.5% to 9% for each such product, subject to
certain minimum royalty payments. PCCA may terminate the license agreement if the Company fails to commence efforts to research
and develop any such products within certain time periods, as set forth in the license agreement. No royalty amounts have been
paid or accrued under this agreement during the years ended December 31, 2014 or 2013.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>PCCA Strategic Alliance Agreement
</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 18, 2013, the Company entered
into a strategic alliance agreement with PCCA. Under this agreement, PCCA has agreed that, during the term of the agreement, it
will not introduce any of PCCA&#146;s members or customers meeting certain criteria (the &#147;Member/Customers&#148;) to any
third party whereby such third party licenses or otherwise acquires the intellectual property rights of such Member/Customer, without
first presenting such an opportunity to the Company. PCCA may, but is not required to, present such opportunities to the Company,
use reasonable efforts to facilitate an introductory meeting between the Member/Customer and the Company, and to further provide
certain key technical assistance with respect to any potential development project the Company may pursue associated with the Member/Customer&#146;s
intellectual property rights. In the event the Company and a Member/Customer introduced to the Company by PCCA enter into a commercial
agreement for the license or acquisition of the intellectual property rights owned by the Member/Customer, PCCA will be entitled
to receive certain cash fees up to an aggregate of $100,000, as well as a commission based on net sales, if any, generated by the
Company as a result of the acquired intellectual property rights. The agreement has a term of one year and is automatically extended
for successive one year periods unless either party gives the other written notice of non-renewal. This agreement automatically
renewed for a one-year term on February 18, 2014 and 2015. No royalty amounts have been paid or accrued under this agreement during
the years ended December 31, 2014 or 2013.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Asset Purchase Agreements</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has acquired intellectual
property rights related to certain proprietary innovations from certain inventors (the &#147;Inventors&#148;) through multiple
asset purchase agreements. The asset purchase agreements provide that the Inventors will cooperate with the Company in obtaining
patent protection for the acquired intellectual property and that the Company will use commercially reasonable efforts to research,
develop and commercialize a product based on the acquired intellectual property. In addition, the Company has acquired a right
of first refusal on additional intellectual property and drug development opportunities presented by these Inventors during the
term of the respective agreements, which remains in effect until expiration of all payment obligations thereunder.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for the acquisition
of the intellectual property rights, the Company is obligated to make payments to the Inventors based on the completion of certain
milestones, generally consisting of: (1) a payment payable within 30 days after the issuance of the first patent in the United
States arising from the acquired intellectual property (if any); (2) a payment payable within 30 days after the Company files the
first investigational new drug application (&#147;IND&#148;) with the U.S. Food and Drug Administration (&#147;FDA&#148;) for
the first product arising from the acquired intellectual property (if any); (3) for certain of the Inventors, a payment payable
within 30 days after the Company files the first New Drug application with the FDA for the first product arising from the acquired
intellectual property (if any); and (4) certain royalty payments based on the net receipts received by the Company in connection
with the sale or licensing of any product based on the acquired intellectual property (if any), after deducting (among other things)
the Company&#146;s development costs associated with such product. If, following five years after the date of the applicable asset
purchase agreement, the Company either (a) for certain of the Inventors, has not filed an IND or, for the remaining Inventors,
has not initiated a study where data is derived, or (b) has failed to generate royalty payments to the Inventors for any product
based on the acquired intellectual property, the Inventors may terminate the applicable asset purchase agreement and request that
the Company re-assign the acquired technology to the Inventors. No royalty amounts have been paid or accrued under these agreements
for the years ended December 31, 2014 or 2013.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Novel Drug and Eye Care Northwest
Asset Purchase Agreement &#150; Related Party</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 8, 2013, the Company acquired
intellectual property rights related to certain proprietary innovations from the compounding pharmacy operations of Novel Drug
Solutions, LLC (&#147;NDS&#148;) and from Eye Care Northwest, Inc. (together referred to as the &#147;Sellers&#148;) pursuant
to an asset purchase agreement (as amended, the &#147;ECN APA&#148;). As part of this acquisition, the Company acquired intellectual
property rights that include a provisional patent application related to injectable ophthalmological compositions having anti-bacterial
and anti-inflammatory properties for the prevention of post-ophthalmic surgery complications. In addition, under the ECN APA, the
Company has a right of first refusal on any of the Sellers&#146; additional intellectual property and drug development opportunities
during the term of the agreement, which remains in effect until the expiration of all payment obligations thereunder. The ECN APA
provides that the Sellers will cooperate with the Company in obtaining patent protection for the acquired intellectual property,
among other things, and that the Company will use commercially reasonable efforts to research, develop and commercialize a product
based on the acquired intellectual property.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In consideration for the acquisition,
the Company is obligated to make the following payments to the Sellers: (1) a payment payable within 30 days after the issuance
of the first patent in the United States arising from the acquired intellectual property (if any); (2) a payment payable within
30 days after the Company files the first IND with the FDA for the first product arising from the acquired intellectual property
(if any); (3) a payment payable within 30 days after the Company files the first new drug application with the FDA for the first
product arising from the acquired intellectual property (if any); and (4) certain royalty payments based on the net receipts received
by the Company in connection with the sale or licensing of any product based on the acquired intellectual property (if any), after
deducting (among other things) the Company&#146;s development costs associated with such product. If, following five years of
the date of the ECN APA, the Company either has not filed an IND or has failed to generate royalty payments to NDS for any product
based on the acquired intellectual property, NDS may terminate the ECN APA and request that the Company re-assign the acquired
technology to NDS.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">NDS is owned by the former owners of
PC. During the years ended December 31, 2014 and 2013, the Company did not make any payments to NDS or the other Seller, and no
amounts were due and payable to NDS or the other Seller at December 31, 2014 and 2013.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EECAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition - Pharmacy Creations, LLC (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Acquisition Date Fair Value of Consideration</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The total acquisition date fair value
of the consideration transferred and to be transferred is estimated at approximately $1.1 million, as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cash payment to the PC Sellers at closing</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">600,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Contingent common stock issuance to the PC Sellers</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">483,156</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Contingent cash consideration to the PC Sellers</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">31,466</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total acquisition date fair value</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,114,622</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the estimated
fair values of the assets acquired and liabilities assumed at the acquisition date.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,982</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">58,420</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and other assets</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">30,256</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Inventory</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">213,190</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">44,510</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Intangible assets</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">659,000</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total identifiable assets acquired</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,010,358</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts payable and accrued liabilities</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">120,049</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other liabilities</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">107,308</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total liabilities assumed</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">227,357</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total identifiable assets less liabilities assumed</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">783,001</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Goodwill</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">331,621</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Net assets acquired</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,114,622</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ScheduleOfResultOfOperationFromAcquisitionTableTextBlock', window );">Schedule of Result of Operation from Acquisition</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The amount of revenues and operating
loss of PC included in the Company&#146;s consolidated statement of operations from the acquisition date through the period ended
December 31, 2014 are as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total revenues</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 24%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,652,386</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Operating loss</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(662,969</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Pro Forma Financial Information</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited pro forma results presented
include amortization charges for intangible assets and eliminations of intercompany transactions.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2013</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total revenues</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,282,681</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,866,575</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Net loss</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(10,048,380</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(7,084,014</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock', window );">Schedule of Intangible Assets Acquisition</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the components
of identified intangible assets associated with the PC acquisition and their estimated useful lives.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Fair Value</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Useful Life</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 60%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Customer relationships</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">596,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 18%; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10 - 15 years</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Trade name</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Non-competition covenant</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4 years</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">State pharmacy licenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">25 years</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">659,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ScheduleOfResultOfOperationFromAcquisitionTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule of Result of Operation from Acquisition [Table Text Block].</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ScheduleOfResultOfOperationFromAcquisitionTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)-(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAJAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Intangible Assets and Goodwill - Schedule of Amortization Expenses for Intangible Assets (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets" onclick="toggleNextSibling(this);">$ 48,006</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer Relationships [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember]" onclick="toggleNextSibling(this);">36,740</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_CustomerRelationshipsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Name [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember]" onclick="toggleNextSibling(this);">750</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_TradeNamesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=IMMY_NonCompetitionCovenantMember', window );">Non-Competition Covenant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=IMMY_NonCompetitionCovenantMember]" onclick="toggleNextSibling(this);">9,375</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= IMMY_NonCompetitionCovenantMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">State Pharmacy Licenses [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfIntangibleAssets[us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember]" onclick="toggleNextSibling(this);">$ 1,141</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfIntangibleAssets<br>/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis<br>= us-gaap_LicensingAgreementsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=IMMY_NonCompetitionCovenantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=IMMY_NonCompetitionCovenantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition - Pharmacy Creations, Llc - Schedule of Pro Forma Financial Information (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Total revenues</a></td>
        <td class="nump"><a title="us-gaap_BusinessAcquisitionsProFormaRevenue" onclick="toggleNextSibling(this);">$ 2,282,681</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessAcquisitionsProFormaRevenue</span><span></span></td>
        <td class="nump"><a title="us-gaap_BusinessAcquisitionsProFormaRevenue" onclick="toggleNextSibling(this);">$ 2,866,575</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessAcquisitionsProFormaRevenue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" onclick="toggleNextSibling(this);">$ (10,048,380)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" onclick="toggleNextSibling(this);">$ (7,084,014)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)-(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(2)-(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ES4AI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-In Capital [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit [Member]</div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2012</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 6,772</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 34,093,933</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">$ (24,104,268)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 9,996,437</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, share at Dec. 31, 2012</a></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">6,772,066</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne', window );">Issuance of common stock related to consulting agreements</a></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">40</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">282,957</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne" onclick="toggleNextSibling(this);">282,997</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne', window );">Issuance of common stock related to consulting agreements, shares</a></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">40,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour', window );">Exercise of stock options, shares</a></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">219</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013', window );">Cancelled common stock at $5.25 per share related to reverse stock split, February 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">(191)</a><span style="display:none;white-space:normal;text-align:left;">IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num"><a title="IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013" onclick="toggleNextSibling(this);">(191)</a><span style="display:none;white-space:normal;text-align:left;">IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares', window );">Cancelled common stock at $5.25 per share related to reverse stock split, February 2013, shares</a></td>
        <td class="num"><a title="IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">(35)</a><span style="display:none;white-space:normal;text-align:left;">IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockIssuedDuringPeriodValueForPublicOffering', window );">Public offering of common stock at $5.25 per share, net of costs of $596,281, in February and March 2013</a></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodValueForPublicOffering[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2,116</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodValueForPublicOffering<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodValueForPublicOffering[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">9,454,435</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodValueForPublicOffering<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodValueForPublicOffering" onclick="toggleNextSibling(this);">9,456,551</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodValueForPublicOffering</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockIssuedDuringPeriodSharesForPublicOffering', window );">Public offering of common stock at $5.25 per share, net of costs of $596,281, in February and March 2013, shares</a></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodSharesForPublicOffering[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2,116,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodSharesForPublicOffering<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Issuance of common stock upon vesting of RSUs</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">40</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="num"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">(40)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_IssuanceOfCommonStockUponVestingOfRsusShares', window );">Issuance of common stock upon vesting of RSUs, shares</a></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockUponVestingOfRsusShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">40,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockUponVestingOfRsusShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">3,018,066</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" onclick="toggleNextSibling(this);">3,018,068</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2,114</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">(7,643,124)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(7,643,124)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">8,970</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">46,849,160</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">(31,747,392)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">15,110,738</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, share at Dec. 31, 2013</a></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">8,970,364</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net of tax withholding</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">227</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">583,584</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" onclick="toggleNextSibling(this);">583,811</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, net of tax withholding, shares</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">227,216</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">227,216</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">2,469,810</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" onclick="toggleNextSibling(this);">2,469,810</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne', window );">Issuance of common stock related to consulting agreements</a></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">4</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">29,156</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne" onclick="toggleNextSibling(this);">29,160</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne', window );">Issuance of common stock related to consulting agreements, shares</a></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">4,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding', window );">Issuance of common stock upon vesting of RSUs net of tax withholding</a></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="num"><a title="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">(13,111)</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num"><a title="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding" onclick="toggleNextSibling(this);">(13,109)</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares', window );">Issuance of common stock upon vesting of RSUs net of tax withholding , shares</a></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,954</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares" onclick="toggleNextSibling(this);">1,954</a><span style="display:none;white-space:normal;text-align:left;">IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockIssuedDuringPeriodForExerciseOfWarrants', window );">Exercise of warrants</a></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodForExerciseOfWarrants[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">48</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodForExerciseOfWarrants<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodForExerciseOfWarrants[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">37,819</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodForExerciseOfWarrants<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodForExerciseOfWarrants" onclick="toggleNextSibling(this);">37,867</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodForExerciseOfWarrants</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants', window );">Exercise of warrants , shares</a></td>
        <td class="nump"><a title="IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">47,829</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute', window );">Common stock issued in settlement of contract dispute</a></td>
        <td class="nump"><a title="IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">7</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">49,993</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute" onclick="toggleNextSibling(this);">50,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute', window );">Common stock issued in settlement of contract dispute, shares</a></td>
        <td class="nump"><a title="IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">6,868</a><span style="display:none;white-space:normal;text-align:left;">IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">(10,118,103)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(10,118,103)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 9,258</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 50,006,411</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDeficitDuringDevelopmentStageMember]" onclick="toggleNextSibling(this);">$ (41,865,495)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AccumulatedDeficitDuringDevelopmentStageMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 8,150,174</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, share at Dec. 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">9,258,231</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cancelled Common Stock Shares Related To Reverse Stock Split February 2013 Shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_CancelledCommonStockSharesRelatedToReverseStockSplitFebruary2013Shares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cancelled Common Stock Shares Related To Reverse Stock Split February 2013.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_CancelledCommonStockValueRelatedToReverseStockSplitFebruary2013</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock And Stock Options Shares Related To Consulting Agreements Shares One.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_IssuanceOfCommonStockAndStockOptionsSharesRelatedToConsultingAgreementsSharesOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock And Stock Options Value Related To Consulting Agreements One.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_IssuanceOfCommonStockAndStockOptionsValueRelatedToConsultingAgreementsOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock Upon Vesting Of Rsus Net Of Tax Withholding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock Upon Vesting Of Rsus Net Of Tax Withholding Shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_IssuanceOfCommonStockUponVestingOfRsusNetOfTaxWithholdingShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_IssuanceOfCommonStockUponVestingOfRsusShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock Upon Vesting Of Rsus Shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_IssuanceOfCommonStockUponVestingOfRsusShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockIssuedDuringPeriodForExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period For Exercise Of Warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockIssuedDuringPeriodForExerciseOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period Shares For Exercise Of Warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockIssuedDuringPeriodSharesForExerciseOfWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockIssuedDuringPeriodSharesForPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period Shares For Public Offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockIssuedDuringPeriodSharesForPublicOffering</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period Shares Stock Options Exercised Four.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockIssuedDuringPeriodSharesStockOptionsExercisedFour</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockIssuedDuringPeriodValueForPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period Value For Public Offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockIssuedDuringPeriodValueForPublicOffering</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Shares Issued Duing Period For Settlement Of Contract Dispute.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockSharesIssuedDuingPeriodForSettlementOfContractDispute</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Shares Issued Duing Period Shares For Settlement Of Contract Dispute.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_StockSharesIssuedDuingPeriodSharesForSettlementOfContractDispute</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of equity-based compensation, related to restricted stock units or restricted stock awards, recognized as expense or an asset, if compensation is capitalized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued as a result of the exercise of stock options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition - Pharmacy Creations, LLC<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition - Pharmacy Creations, LLC</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3. ACQUISITION &#150; PHARMACY
CREATIONS, LLC</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 1, 2014, the Company acquired
all of the outstanding membership interests of PC (the &#147;PC Acquisition&#148;) from J. Scott Karolchyk and Bernard Covalesky
(the &#147;PC Sellers&#148;), such that PC became a wholly-owned subsidiary of the Company. The acquisition of PC permits the
Company to make and distribute its patent-pending proprietary drug formulations and other pharmaceutical preparations.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The transaction has been accounted for
as a business combination and the financial results of PC have been included in the Company&#146;s consolidated financial statements
for the period subsequent to its acquisition.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated acquisition date fair
value of consideration transferred, assets acquired and liabilities assumed for PC are presented below and represent the Company&#146;s
best estimates.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value of Consideration Transferred</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At the closing of the PC Acquisition,
the Company paid to the PC Sellers an aggregate cash purchase price of $600,000. In addition, the PC Sellers are entitled to receive
additional contingent consideration upon the satisfaction of certain conditions, as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="width: 24px; line-height: 115%">&#160;</td>
    <td style="vertical-align: top; width: 24px; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">A contingent cash payment of $50,000, payable if PC earns revenues of over $3,500,000 for the 12 month period ending March 31, 2015.</font></td></tr>
<tr>
    <td style="line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr>
    <td style="line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">A contingent stock payment of up to an aggregate of 215,190 shares of the Company&#146;s common stock, issuable only if the following revenue milestones are met:</font></td></tr>
<tr>
    <td style="line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr>
    <td style="line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">if PC earns revenue of over $7,500,000 during the 12 month period ending March 31, 2016, all 215,190 shares;</font></td></tr>
<tr>
    <td style="line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%">&#160;</td>
    <td style="text-align: justify; line-height: 115%">&#160;</td></tr>
<tr>
    <td style="line-height: 115%">&#160;</td>
    <td style="vertical-align: top; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">&#9679;</font></td>
    <td style="text-align: justify; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">if PC earns revenue of between $3,500,000 and $7,500,000 during the 12 month period ending March 31, 2016, an aggregate of that number of shares of Imprimis common stock equal to the amount that such revenue exceeds $3,500,000 divided by 18.5882, rounded down to the lower whole number (not to exceed 215,190 shares).</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Although management estimates that certain
of the contingent consideration will be paid, it has applied a discount rate to the contingent consideration amounts in determining
fair value to represent the risk of these payments not being made. The total acquisition date fair value of the consideration transferred
and to be transferred is estimated at approximately $1.1 million, as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cash payment to the PC Sellers at closing</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">600,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Contingent common stock issuance to the PC Sellers</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">483,156</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Contingent cash consideration to the PC Sellers</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">31,466</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total acquisition date fair value</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,114,622</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">A $514,622 liability was recognized
for the estimated acquisition date fair value of the future contingent common stock and cash payments and is included in the contingent
acquisition obligations in the accompanying consolidated balance sheet at December 31, 2014.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Allocation of Consideration Transferred
</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The identifiable assets acquired and
liabilities assumed were recognized and measured as of the acquisition date based on their estimated fair values as of April 1,
2014, the acquisition date. The excess of the acquisition date fair value of consideration transferred over the estimated fair
value of the net tangible assets and intangible assets acquired was recorded as goodwill.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the estimated
fair values of the assets acquired and liabilities assumed at the acquisition date.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Cash and cash equivalents</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4,982</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts receivable</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">58,420</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and other assets</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">30,256</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Inventory</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">213,190</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Property and equipment</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">44,510</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Intangible assets</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">659,000</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total identifiable assets acquired</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,010,358</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Accounts payable and accrued liabilities</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">120,049</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Other liabilities</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">107,308</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total liabilities assumed</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">227,357</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total identifiable assets less liabilities assumed</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">783,001</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Goodwill</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">331,621</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-left: 10pt; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Net assets acquired</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,114,622</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Results of Operations</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The amount of revenues and operating
loss of PC included in the Company&#146;s consolidated statement of operations from the acquisition date through the period ended
December 31, 2014 are as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total revenues</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 24%; border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">1,652,386</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Operating loss</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(662,969</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Pro Forma Financial Information</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the Company&#146;s
unaudited pro forma results (including PC) for the years ended December 31, 2014 and 2013 as though the companies had been combined
as of the beginning of each of the periods presented. The pro forma information is presented for informational purposes only and
is not indicative of the results of operations that would have been achieved if the acquisition had taken place at the beginning
of each period presented, nor is it indicative of results of operations which may occur in the future. The unaudited pro forma
results presented include amortization charges for intangible assets and eliminations of intercompany transactions.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">For the</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Year Ended</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2014</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">December 31, 2013</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 58%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total revenues</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,282,681</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">2,866,575</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Net loss</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(10,048,380</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">(7,084,014</font></td>
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company did not incur material acquisition
expenses related to the PC Acquisition.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Intangible Assets</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Management engaged a third-party valuation
firm to assist in the determination of the fair value of the acquired intangible assets of PC. In determining the fair value of
the intangible assets, the Company considered, among other factors, the best use of acquired assets, analyses of historical financial
performance of PC and estimates of future performance of PC. The fair values of the identified intangible assets related to PC&#146;s
customer relationships, trade name, non-competition covenant, and state pharmacy licenses. The fair value of customer relationships
and the non-competition covenant were calculated using the income approach. The fair value of the trade name and state pharmacy
licenses were calculated using the cost approach. The following table sets forth the components of identified intangible assets
associated with the PC acquisition and their estimated useful lives.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Fair Value</font></td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Useful Life</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 60%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Customer relationships</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 18%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">596,000</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 18%; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">10 - 15 years</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Trade name</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">5 years</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Non-competition covenant</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">4 years</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">State pharmacy licenses</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">8,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">25 years</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">659,000</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: center; line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determined the useful lives
of intangible assets based on the expected future cash flows and contractual lives associated with the respective asset. Trade
names represent the fair value of the brand and name recognition associated with the marketing of PC&#146;s formulations and services.
Customer relationships represent the expected benefit from customer contracts that, at the date of acquisition, were reasonably
anticipated to continue given the history and operating practices of PC. The non-competition covenant represents the contractual
period and expected degree of adverse economic impact that would exist in its absence. Licenses represent eight state pharmacy
licenses PC held at the date of acquisition.</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Goodwill </b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Of the total estimated purchase price,
$331,621 was allocated to goodwill and is attributable to expected synergies between the combined companies, including access
for the Company to fulfill prescriptions with its patent-pending proprietary drug formulations through PC&#146;s market channels
and assembled workforce. Goodwill represents the excess of the purchase price of the acquired business over the estimated fair
value of the underlying net tangible and intangible assets acquired. Goodwill resulting from the PC Acquisition will be tested
for impairment at least annually and more frequently if certain indicators of impairment are present. In the event the Company
determines that the value of goodwill has become impaired, it will incur an accounting charge for the amount of the impairment
during the fiscal quarter in which the determination is made. None of the goodwill is expected to be deductible for income tax
purposes.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1383-128463<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6996-128479<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4922-128472<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4934-128472<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4926-128472<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7000-128479<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1392-128463<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1486-128463<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1497-128463<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1490-128463<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=39739317&amp;loc=d3e4845-128472<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1500-128463<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25497992&amp;loc=d3e1524-128463<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EE6AG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Shares Outstanding and Exercisable (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">1,029,240</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
        <td class="text">6 years 18 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 5.74</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberExercisable', window );">Number Exercisable</a></td>
        <td class="nump"><a title="IMMY_NumberExercisable" onclick="toggleNextSibling(this);">728,585</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberExercisable</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2', window );">Weighted Average Exercisable Exercise Price</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2" onclick="toggleNextSibling(this);">$ 5.25</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeOneMember', window );">Range One [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeOneMember]" onclick="toggleNextSibling(this);">$ 2.40</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeOneMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeOneMember]" onclick="toggleNextSibling(this);">$ 3.20</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeOneMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeOneMember]" onclick="toggleNextSibling(this);">250,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeOneMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
        <td class="text">4 years 6 months 26 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeOneMember]" onclick="toggleNextSibling(this);">$ 2.80</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeOneMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberExercisable', window );">Number Exercisable</a></td>
        <td class="nump"><a title="IMMY_NumberExercisable[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeOneMember]" onclick="toggleNextSibling(this);">250,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberExercisable<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeOneMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2', window );">Weighted Average Exercisable Exercise Price</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeOneMember]" onclick="toggleNextSibling(this);">$ 2.80</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeOneMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeTwoMember', window );">Range Two [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeTwoMember]" onclick="toggleNextSibling(this);">$ 3.60</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeTwoMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeTwoMember]" onclick="toggleNextSibling(this);">$ 4.51</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeTwoMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeTwoMember]" onclick="toggleNextSibling(this);">337,723</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeTwoMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
        <td class="text">4 years 11 months 12 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeTwoMember]" onclick="toggleNextSibling(this);">$ 4.36</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeTwoMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberExercisable', window );">Number Exercisable</a></td>
        <td class="nump"><a title="IMMY_NumberExercisable[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeTwoMember]" onclick="toggleNextSibling(this);">270,015</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberExercisable<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeTwoMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2', window );">Weighted Average Exercisable Exercise Price</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeTwoMember]" onclick="toggleNextSibling(this);">$ 4.42</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeTwoMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeThreeMember', window );">Range Three [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeThreeMember]" onclick="toggleNextSibling(this);">$ 5.49</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeThreeMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeThreeMember]" onclick="toggleNextSibling(this);">$ 7.71</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeThreeMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeThreeMember]" onclick="toggleNextSibling(this);">190,557</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeThreeMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
        <td class="text">8 years 8 months 12 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeThreeMember]" onclick="toggleNextSibling(this);">$ 6.62</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeThreeMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberExercisable', window );">Number Exercisable</a></td>
        <td class="nump"><a title="IMMY_NumberExercisable[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeThreeMember]" onclick="toggleNextSibling(this);">60,110</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberExercisable<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeThreeMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2', window );">Weighted Average Exercisable Exercise Price</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeThreeMember]" onclick="toggleNextSibling(this);">$ 6.26</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeThreeMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFourMember', window );">Range Four [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFourMember]" onclick="toggleNextSibling(this);">$ 8.06</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeFourMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFourMember]" onclick="toggleNextSibling(this);">$ 10.75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeFourMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFourMember]" onclick="toggleNextSibling(this);">244,160</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeFourMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
        <td class="text">7 years 11 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFourMember]" onclick="toggleNextSibling(this);">$ 8.99</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeFourMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberExercisable', window );">Number Exercisable</a></td>
        <td class="nump"><a title="IMMY_NumberExercisable[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFourMember]" onclick="toggleNextSibling(this);">141,660</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberExercisable<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeFourMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2', window );">Weighted Average Exercisable Exercise Price</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFourMember]" onclick="toggleNextSibling(this);">$ 9.01</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeFourMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFiveMember', window );">Range Five [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Prices, minimum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFiveMember]" onclick="toggleNextSibling(this);">$ 28.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeFiveMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Prices, maximum</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFiveMember]" onclick="toggleNextSibling(this);">$ 80.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeFiveMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFiveMember]" onclick="toggleNextSibling(this);">6,800</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeFiveMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life in Years</a></td>
        <td class="text">5 years 1 month 17 days<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted Average Exercise Price</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFiveMember]" onclick="toggleNextSibling(this);">$ 40.86</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeFiveMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_NumberExercisable', window );">Number Exercisable</a></td>
        <td class="nump"><a title="IMMY_NumberExercisable[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFiveMember]" onclick="toggleNextSibling(this);">6,800</a><span style="display:none;white-space:normal;text-align:left;">IMMY_NumberExercisable<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeFiveMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2', window );">Weighted Average Exercisable Exercise Price</a></td>
        <td class="nump"><a title="IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2[us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFiveMember]" onclick="toggleNextSibling(this);">$ 40.86</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2<br>/ us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis<br>= IMMY_RangeFiveMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_NumberExercisable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number Exercisable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_NumberExercisable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted Average Exercisable Exercise Price</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in the weighted average exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFiveMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFiveMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFourMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeFourMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeOneMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeOneMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeThreeMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeThreeMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeTwoMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=IMMY_RangeTwoMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBZAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2013

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2010

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Oct. 24, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>sqft</div>
        </th>
        <th class="th">
          <div>Feb. 18, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate', window );">Leases equipment under capital lease with interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate" onclick="toggleNextSibling(this);">4.25%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet', window );">Equipment under capital leases net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">$ 52,687</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation', window );">Related accumulated depreciation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation" onclick="toggleNextSibling(this);">8,656</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Lease agreement for office space (Square feet)</a></td>
        <td class="nump"><a title="us-gaap_AreaOfLand" onclick="toggleNextSibling(this);">7,565</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AreaOfLand</span><span></span></td>
        <td class="nump"><a title="us-gaap_AreaOfLand" onclick="toggleNextSibling(this);">3,874</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AreaOfLand</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AreaOfLand" onclick="toggleNextSibling(this);">7,565</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AreaOfLand</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease Expiry</a></td>
        <td class="text">Oct. 31,  2018<span></span></td>
        <td class="text">Sep. 30,  2016<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating lease, monthly rental</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">20,426</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">10,406</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate', window );">Operating lease, rent increase percentage</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate" onclick="toggleNextSibling(this);">3.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate" onclick="toggleNextSibling(this);">3.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate" onclick="toggleNextSibling(this);">3.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsForRent" onclick="toggleNextSibling(this);">306,465</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsForRent" onclick="toggleNextSibling(this);">103,191</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_AggregateValueOfCashFees', window );">Maximum aggregate value of cash fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_AggregateValueOfCashFees" onclick="toggleNextSibling(this);">100,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_AggregateValueOfCashFees</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_RoyaltiesRangePercentage', window );">Royalties range percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_RoyaltiesRangePercentage[us-gaap_RangeAxis=us-gaap_MinimumMember]" onclick="toggleNextSibling(this);">4.50%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_RoyaltiesRangePercentage<br>/ us-gaap_RangeAxis<br>= us-gaap_MinimumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_RoyaltiesRangePercentage', window );">Royalties range percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_RoyaltiesRangePercentage[us-gaap_RangeAxis=us-gaap_MaximumMember]" onclick="toggleNextSibling(this);">9.00%</a><span style="display:none;white-space:normal;text-align:left;">IMMY_RoyaltiesRangePercentage<br>/ us-gaap_RangeAxis<br>= us-gaap_MaximumMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_PharmacyCreationsLlcMember', window );">Pharmacy Creations, LLC [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Lease agreement for office space (Square feet)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AreaOfLand[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">3,137</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AreaOfLand<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease Expiry</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Dec. 31,  2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating lease, monthly rental</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">3,594</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_UrigenPharmaceuticalsIncMember', window );">Urigen Pharmaceuticals, Inc [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_LicenseAgreementCommitmentsDescription', window );">License agreement commitments description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><font style="font: 10pt Times New Roman, Times, Serif">The
annual tiered royalties consist of the greater of (i) $0.50 per dose, and (ii) 15% - 20% of its net sales of HLA, with the royalty
amount within such range depending on the Company&#146;s aggregate sales of HLA during the period to which the royalty payment
applies. The minimum annual royalty payment consists of (a) for the 2015 calendar year, the greater of (i) 110% of the aggregate
royalties paid to Urigen under the Existing Sublicenses during the preceding 12 months, on a prorated basis, and (ii) $800,000,
less the aggregate royalties paid to Urigen under the Existing Sublicenses during the 2015 calendar year, and (b) for each calendar
year thereafter, 110% of the aggregate amount owed by the Company to Urigen under the Urigen License during the prior calendar
year. The Company is obligated to pay such royalties beginning with its first commercial sale of HLA and continuing until the
expiration of the patents subject to the license granted under the Urigen License. The Company has also agreed to use commercially
reasonable efforts to develop and commercialize HLA according to the terms of a diligence plan agreed to by the parties, which
efforts will include, without limitation, the Company&#146;s investment of $2 million in commercialization efforts of HLA, which
investment and timeline can be adjusted dependent on market circumstances, and is expected to be incurred over 18-24 months following
the Urigen Effective Date.</font></p>



<p style="margin: 0pt"><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Minimum royalties to be paid each calendar year</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsForRoyalties[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_UrigenPharmaceuticalsIncMember]" onclick="toggleNextSibling(this);">800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsForRoyalties<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_UrigenPharmaceuticalsIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ValueOfProductDevelopmentInvestment', window );">Value of product development investment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="IMMY_ValueOfProductDevelopmentInvestment[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_UrigenPharmaceuticalsIncMember]" onclick="toggleNextSibling(this);">$ 2,000,000</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ValueOfProductDevelopmentInvestment<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= IMMY_UrigenPharmaceuticalsIncMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_AggregateValueOfCashFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate Value Of Cash Fees</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_AggregateValueOfCashFees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Leases Equipment Under Capital Lease With Interest Rate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_LeasesEquipmentUnderCapitalLeaseWithInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_LicenseAgreementCommitmentsDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License agreement commitments description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_LicenseAgreementCommitmentsDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_RoyaltiesRangePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalties Range Percentage</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_RoyaltiesRangePercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ValueOfProductDevelopmentInvestment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of product development investment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ValueOfProductDevelopmentInvestment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Area of land held.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:areaItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of long-lived depreciable assets not included within other defined categories that are subject to a lease meeting the criteria for capitalization.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassOtherPropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of depreciation for the use of long-lived depreciable assets subject to a lease meeting the criteria for capitalization not included within the other defined categories in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CapitalLeasesLesseeBalanceSheetAssetsByMajorClassPropertyPlantAndEquipmentOtherAccumulatedDepreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage points added to the reference rate to compute the variable rate on the lessee's operating lease.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash payments to lessor's for use of assets under operating leases.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for royalties during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_PharmacyCreationsLlcMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_PharmacyCreationsLlcMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_UrigenPharmaceuticalsIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=IMMY_UrigenPharmaceuticalsIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The composition of inventories as of
December 31, 2014 was as follows:</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif"><b>December 31, 2014</b></font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 73%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Raw materials</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td>
    <td style="width: 1%; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="width: 24%; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">146,300</font></td>
    <td style="width: 1%; line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Work in progress</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="line-height: 115%">&#160;</td>
    <td style="text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">97,801</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Finished goods</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; line-height: 115%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">128,634</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">Total inventories</font></td>
    <td style="line-height: 115%">&#160;</td>
    <td style="border-bottom: black 2.25pt double; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 115%"><font style="font: 10pt Times New Roman, Times, Serif">372,735</font></td>
    <td style="line-height: 115%">&#160;</td></tr>
</table>
<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 2<br><br> -Paragraph 6<br><br> -Subparagraph a,b,c<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>171</ContextCount>
  <ElementCount>442</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>69</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement -  Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Acquisition - Pharmacy Creations, LLC</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc</Role>
      <ShortName>Acquisition - Pharmacy Creations, LLC</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Restricted Short-Term Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/RestrictedShort-termInvestment</Role>
      <ShortName>Restricted Short-Term Investment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Furniture and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/FurnitureAndEquipment</Role>
      <ShortName>Furniture and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Employee Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/EmployeeSavingsPlan</Role>
      <ShortName>Employee Savings Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Acquisition - Pharmacy Creations, LLC (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcTables</Role>
      <ShortName>Acquisition - Pharmacy Creations, LLC (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Furniture and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/FurnitureAndEquipmentTables</Role>
      <ShortName>Furniture and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Significant Accounting Policies (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfBasicAndDilutedEarningsPerCommonShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Basic and Diluted Earnings Per Common Share (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Acquisition - Pharmacy Creations, LLC (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlcDetailsNarrative</Role>
      <ShortName>Acquisition - Pharmacy Creations, LLC (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Acquisition Date Fair Value of Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfAcquisitionDateFairValueOfConsiderationDetails</Role>
      <ShortName>Acquisition - Pharmacy Creations, Llc - Schedule of Acquisition Date Fair Value of Consideration (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfEstimatedFairValueOfAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisition - Pharmacy Creations, Llc - Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Result of Operation from Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfResultOfOperationFromAcquisitionDetails</Role>
      <ShortName>Acquisition - Pharmacy Creations, Llc - Schedule of Result of Operation from Acquisition (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Pro Forma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfProFormaFinancialInformationDetails</Role>
      <ShortName>Acquisition - Pharmacy Creations, Llc - Schedule of Pro Forma Financial Information (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Acquisition - Pharmacy Creations, Llc - Schedule of Intangible Assets Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/Acquisition-PharmacyCreationsLlc-ScheduleOfIntangibleAssetsAcquisitionDetails</Role>
      <ShortName>Acquisition - Pharmacy Creations, Llc - Schedule of Intangible Assets Acquisition (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Restricted Short-Term Investment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/RestrictedShort-termInvestmentDetailsNarrative</Role>
      <ShortName>Restricted Short-Term Investment (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Inventories - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/Inventories-ScheduleOfInventoriesDetails</Role>
      <ShortName>Inventories - Schedule of Inventories (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/PrepaidExpensesAndOtherCurrentAssets-ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Furniture and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/FurnitureAndEquipmentDetailsNarrative</Role>
      <ShortName>Furniture and Equipment (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Furniture and Equipment - Schedule of Furniture and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/FurnitureAndEquipment-ScheduleOfFurnitureAndEquipmentDetails</Role>
      <ShortName>Furniture and Equipment - Schedule of Furniture and Equipment (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Schedule of Intangible Assets (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Intangible Assets and Goodwill - Schedule of Amortization Expenses for Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfAmortizationExpensesForIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Schedule of Amortization Expenses for Intangible Assets (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Schedule of Estimated Future Amortization Expense (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Intangible Assets and Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/IntangibleAssetsAndGoodwill-ScheduleOfChangesInCarryingValueOfGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Schedule of Changes in Carrying Value of Goodwill (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Accounts Payable and Accrued Expenses (Details Narratvie)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/AccountsPayableAndAccruedExpensesDetailsNarratvie</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details Narratvie)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/AccountsPayableAndAccruedExpenses-ScheduleOfAccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Debt (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/DebtDetailsNarrative</Role>
      <ShortName>Debt (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Stockholders' Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders' Equity (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Stockholders' Equity - Schedule of Stock Option Plan Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockOptionPlanActivityDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock Option Plan Activity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Stockholders' Equity - Schedule of Fair Value Assumption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StockholdersEquity-ScheduleOfFairValueAssumptionDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Fair Value Assumption (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Stockholders' Equity - Schedule of Shares Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StockholdersEquity-ScheduleOfSharesOutstandingAndExercisableDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Shares Outstanding and Exercisable (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Stockholders' Equity - Market-based Vesting Conditions for Restricted Stock Units Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StockholdersEquity-Market-basedVestingConditionsForRestrictedStockUnitsGrantedDetails</Role>
      <ShortName>Stockholders' Equity - Market-based Vesting Conditions for Restricted Stock Units Granted (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StockholdersEquity-ScheduleOfRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Restricted Stock Units Activity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - Stockholders' Equity - Schedule of Warrants Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsActivityDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Warrants Activity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Stockholders' Equity - Schedule of Warrants Outstanding and Warrants Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StockholdersEquity-ScheduleOfWarrantsOutstandingAndWarrantsExercisableDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Warrants Outstanding and Warrants Exercisable (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - Stockholders' Equity - Schedule of Stock Based Compensation Granted to Employees Directors Consultants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/StockholdersEquity-ScheduleOfStockBasedCompensationGrantedToEmployeesDirectorsConsultantsDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock Based Compensation Granted to Employees Directors Consultants (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/IncomeTaxes-ScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision for Income Taxes (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - Income Taxes - Schedule of Income Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/IncomeTaxes-ScheduleOfIncomeTaxReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Reconciliation (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/IncomeTaxes-ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - Employee Savings Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/EmployeeSavingsPlanDetailsNarrative</Role>
      <ShortName>Employee Savings Plan (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - Commitments and Contingencies - Schedule of Lease Equipment Under Capital Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfLeaseEquipmentUnderCapitalLeaseDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Lease Equipment Under Capital Lease (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - Commitments and Contingencies - Schedule of Future Payments Under Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/CommitmentsAndContingencies-ScheduleOfFuturePaymentsUnderLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Payments Under Leases (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - Segment Information (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/SegmentInformationDetailsNarrative</Role>
      <ShortName>Segment Information (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>00000073 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://imprimispharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 00000002 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">Process Flow-Through: 00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Feb. 08, 2013'</Log>
    <Log type="Info">Process Flow-Through: 00000004 - Statement -  Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 00000006 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 00000007 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>immy-20141231.xml</File>
    <File>immy-20141231.xsd</File>
    <File>immy-20141231_cal.xml</File>
    <File>immy-20141231_def.xml</File>
    <File>immy-20141231_lab.xml</File>
    <File>immy-20141231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EMLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Acquisition - Pharmacy Creations, Llc - Schedule of Acquisition Date Fair Value of Consideration (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payment to the PC Sellers at closing</a></td>
        <td class="nump"><a title="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" onclick="toggleNextSibling(this);">$ 636,374</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember', window );">Pharmacy Creations, LLC [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payment to the PC Sellers at closing</a></td>
        <td class="nump"><a title="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ContingentCommonStockIssuanceToRelatedParty', window );">Contingent common stock issuance to the PC Sellers</a></td>
        <td class="nump"><a title="IMMY_ContingentCommonStockIssuanceToRelatedParty[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">483,156</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ContingentCommonStockIssuanceToRelatedParty<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_IMMY_ContingentCashConsiderationToRelatedParty', window );">Contingent cash consideration to the PC Sellers</a></td>
        <td class="nump"><a title="IMMY_ContingentCashConsiderationToRelatedParty[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">31,466</a><span style="display:none;white-space:normal;text-align:left;">IMMY_ContingentCashConsiderationToRelatedParty<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total acquisition date fair value</a></td>
        <td class="nump"><a title="us-gaap_BusinessCombinationConsiderationTransferred1[dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember]" onclick="toggleNextSibling(this);">$ 1,114,622</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_BusinessCombinationConsiderationTransferred1<br>/ dei_LegalEntityAxis<br>= IMMY_PharmacyCreationsLlcMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ContingentCashConsiderationToRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent cash consideration to the relatedparty.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ContingentCashConsiderationToRelatedParty</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_IMMY_ContingentCommonStockIssuanceToRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent common stock issuance to the Sellers.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">IMMY_ContingentCommonStockIssuanceToRelatedParty</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>IMMY_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 30<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=IMMY_PharmacyCreationsLlcMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Savings Plan<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Savings Plan</a></td>
        <td class="text"><p style="margin: 0pt"></p>

<p style="margin: 0pt"></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 13. EMPLOYEE SAVINGS PLAN</b></p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has established an employee
savings plan pursuant to Section 401(k) of the Internal Revenue Code, effective January 1, 2014. The plan allows participating
employees to deposit into tax deferred investment accounts up to 100% of their salary, subject to annual limits. The Company makes
contributions to the plan in an amount not less than 3% of the participants&#146; annual cash compensation, subject to annual
limits. The Company contributed approximately $56,000 to the plan during the year ended December 31, 2014.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
